Programme

Ve Conférence internationale sur le

SIDA

Le défi scientifique et social

4-9 juin 1989
Montréal
Québec, Canada
June 4-9 1989

V International Conference on

AIDS

The Scientific and Social Challenge

La V^e^ Conférence internationale sur le SIDA remercie les organismes suivants pour leur généreuse contribution:

The V International Conference on AIDS thanks the following organizations for their generous contributions:

Santé et Bien-être social Canada
Health and Welfare Canada

L'Agence canadienne de développement international
Canadian International Development Agency

Le Centre de recherches pour le développement international
International Development Research Centre

L'Organisation mondiale de la santé/World Health Organization

Le Gouvernement du Québec – Ministère de la Santé et des Services sociaux

Le Secrétariat d'État du Canada/Secretary of State of Canada

Sandoz

Australian International Development Agency

La Société canadienne de la Croix Rouge
The Canadian Red Cross Society

La Commission des Communautés européennes
Commission of the European Communities

Overseas Development Administration—Britain

L'Industrie des assurances de personnes au Canada
The Life and Health Insurance Companies in Canada

Organon-Teknika

Le Gouvernement du Québec – Ministère du Tourisme

Admiral Travel Agencies Ltd.

Voyageur Travel Services

The Upjohn Company

Schering Canada, Inc.

Genentech Inc.

Syntex



SECTION A

SECTION B

SECTION C

SECTION D

SECTION E

SECTION F

SECTION G

SECTION H

SECTION I

Médias
Media

Retransmission
Overflow

Affiches
Posters

Ve Conférence internationale sur le

SIDA

Le défi scientifique et social

Montréal (Québec) Canada
du 4 au 9 juin 1989

Parrainée par le

Centre de recherches pour le développement international, Santé et Bien-être social Canada, et l'Organisation mondiale de la santé

En association avec:

La Société internationale sur le SIDA

V International Conference on

AIDS

The Scientific and Social Challenge

Montréal, Québec, Canada
June 4 – 9, 1989

Sponsored by the

International Development Research Centre, Health and Welfare Canada, and the World Health Organization

In association with:

The International AIDS Society

Table des matières

MESSAGES 7

Message du Ministre de Santé et Bien-être social Canada 8

Message du Président du Centre de recherches pour le développement international 10

Message du directeur général de l'organisation mondiale de la santé 12

COMITÉS ET PERSONNEL DE LA CONFÉRENCE 15

RENSEIGNEMENTS GÉNÉRAUX 23

Emplacement des services de la conférence 24

Accréditation par une université 24

Aires de repos pour P.A.S. ET P.A.V.I.H. 25

Assurances 25

Autobus navette 25

Bureau d'information 25

Bureau de change et services bancaires 26

Bureau de poste 26

Cassettes audio 26

Cassettes vidéo 26

Centre de diffusion 26

Centre des médias 26

Excursions touristiques 27

Exposition 27

Hébergement 27

Information après la conférence 27

Inscription 27

Insignes d'identification 27

Interprétation simultanée 28

Journaux de la Conférence 28

Messages (Bell Canada) 28

Pictogrammes 29

Premiers soins 30

Présentations d'affiches 30

Rafraîchissements et repas 30

Réglementation de l'usage du tabac 30

Restaurants 30

Service de réservation de restaurants 31

Réservations de vols 31

Retransmission vidéo 31

Service de secrétariat aux délégués (Sandoz) 31

Stationnement 31

Téléphones publics 32

Transport en commun 32

ACTIVITÉS SOCIALES 41

CARTES 45
Hôtels et centre-ville 46
Coupe du Palais 48
1er étage : inscription 50
1er étage : affiches, retransmission, exposition 52
1er étage : exposition 54
4e étage : étage des congrès 56
6e étage : caféterias et retransmission 58
Guy-Favreau : programme audiovisuel 60
SIDART 62

INSTRUCTIONS GÉNÉRALES 65
Auteurs d'affiches 66
Auteurs de films et de vidéos 67
Conférenciers 67
Services offerts 67
Présidents d'assemblées 68

PROGRAMME 73
Sommaire du programme 74
Système de numérotation 93
Cérémonie d'ouverture 94
Lundi 97
Mardi 239
Mercredi 377
Jeudi 519
Vendredi 659
Cérémonie de clôture 662
Index des présentateurs 664
Index vidéo 692

Table of Contents

MESSAGES 7

A Message From the Minister of Health and Welfare Canada 9

A Message From The President of the International Research Centre 11

A Message From the Director General of the Workd Health Organization 13

COMMITTEES AND CONFERENCE PERSONNEL 15

GENERAL INFORMATION 23

Location of Conference Services 33

Airline Reservations 33

Audio Tapes 33

Broadcast Centre 33

Conference News 33

Exhibits 34

First Aid 34

Foreign Exchange and Banking Facilities 34

Housing 34

Information Desk 34

Insurance 35

Local Tours Desk 35

Media Centre 35

Messages (Bell Canada) 35

Name Badges 35

Parking 35

Pictograms 36

Post-Conference Enquiries 37

Post Office 37

Poster Presentation 37

Public Telephones 37

Public Transportation 37

Refreshments/Meals 38

Registration Desk 38

Rest Areas for People with HIV/AIDS 38

Restaurants 38

Restaurant Reservation Service 39

Secretarial Services for Delegates 39

Shuttle Buses 39

Simultaneous Interpretation 39

Smoking Policy 39

University Accreditation 40

Video Overflow 40

Video Tapes 40

SOCIAL ACTIVITIES 41

MAPS 45
Hotels and Downtown 46
Cross section of Palais 48
1st floor: Registration 50
1st floor: Posters, overflow, exhibition 52
1st floor: Exhibition 54
4th floor: Convention floor 56
6th floor: Cafeterias and overflow 58
Guy-Favreau: Audiovisual programme 60
SIDART 62

GENERAL INSTRUCTIONS 65
Chairpersons 69
Poster Presenters 69
Speakers 70
Services Provided 71
Videotape Presenters 71

PROGRAMME 73
Programme Summary 75
Key to Numbering 93
Opening Ceremonies 95
Monday 97
Tuesday 239
Wednesday 377
Thursday 519
Friday 659
Closing Ceremonies 663
Presenting Authors Index 664
Video Index 692

Messages

Message du Ministre de Santé et Bien-être social Canada

La *V^e Conférence internationale sur le SIDA* est un événement déterminant de la réponse de l'humanité au problème du SIDA. Jamais autant de scientifiques, d'artistes, d'éducateurs, d'écrivains, de décideurs et d'organismes communautaires s'intéressant au SIDA, venus des quatre coins du monde, ne s'étaient réunis.

Comme le combat contre le SIDA, il s'agit d'un effort international. La planification s'est déroulée dans le monde entier. Ensemble, nous allons nous attaquer au SIDA. Le besoin urgent de réponses nous donnera des forces.

Au nom du gouvernement du Canada, je vous souhaite la bienvenue à la *V^e Conférence internationale sur le SIDA*. Chacun d'entre nous rentrera dans sa collectivité et sa famille avec un nouveau bagage de connaissances. Dans un esprit universel de collaboration et de compassion, nous sommes prêts à écouter, à apprendre et à lutter ensemble contre le SIDA.

Perrin Beatty

A Message From the Minister of Health and Welfare Canada

The *V International Conference on AIDS* is a milestone in humanity's response to AIDS. An unprecedented number of scientists, artists, educators, writers, policy makers and community-based AIDS organizations from around the world are taking part in this Conference.

Like the fight against AIDS itself, this Conference is an international effort. Planning has taken place in every region of the world. Together we will face the challenge of AIDS. Our efforts will be strengthened by the urgent need for answers.

On behalf of the Canadian government, I welcome all of you to the *V International Conference on AIDS*. The knowledge we share and gain here will return with each and every one of us to our respective communities and families. In the spirit of universal cooperation and compassion, we are ready to listen, to learn, and to work together in the fight against AIDS.

Perrin Beatty

Message du président du Centre de recherches pour le developpement international

Je vous remercie d'avoir accepté notre invitation à la *V^e Conférence internationale sur le SIDA* et vous souhaite la bienvenue à cette tribune d'une envergure sans précédent.

En tant que président du Comité directeur de la Conférence, je me considère comme un témoin privilégié de l'immense somme d'énergie qui se déploie à l'échelle planétaire pour affronter ce problème qui nous concerne tous. Depuis que je suis président du Centre de recherches pour le développement international, j'ai eu l'occasion de constater que la mise en commun de nos capacités intellectuelles et créatrices va de pair avec l'une des aptitudes humaines les plus précieuses : la conviction de pouvoir redresser le cours des événements et façonner l'avenir.

Je ne puis m'empêcher de voir un parallèle instructif entre le mandat du CRDI et le mandat qui unit ici tous les participants à cette *V^e Conférence internationale sur le SIDA*. L'objectif est le même : combattre l'ignorance, ou plutôt multiplier la connaissance en la partageant. La menace du SIDA a déclenché l'état d'urgence et notre action doit être partagée entre ces deux priorités : combattre le virus causant le SIDA et combattre l'ignorance.

Quand on considère tous les éléments essentiels à la qualité de la vie, la nourriture, l'éducation, l'habitat, l'environnement social et par-dessus tout la santé, c'est d'abord en mettant nos connaissances en commun que nous trouvons les solutions qui les rendent accessibles à tous.

Dans tous les grands fléaux qui ont frappé l'humanité, on a vu à la fois ressortir le pire et le meilleur. Et la pandémie du SIDA n'y échappe pas : chaque jour les médias reflètent la peur, l'intolérance, l'ostracisme, l'ignorance et la bureaucratisation de la détresse humaine. Quant au meilleur, il procède de l'ampleur même de la tragédie du SIDA : compassion, solidarité, tolérance, sensibilisation, conscience collective et partage des connaissances.

Cette conférence est une gageure sur la volonté de communication et de collaboration, non seulement entre les pays du globe, mais aussi entre gens de tous milieux et de toutes disciplines. Comme vous le savez, le thème de la V^e Conférence est "Le SIDA, défi scientifique et social", et ce défi s'adresse à tous : aussi bien aux spécialistes des sciences bio-médicales et sociales qu'aux décideurs du secteur public et aux organismes communautaires. Mais il y a également un défi à ce défi : ne jamais perdre de vue la personne seule, démunie, angoissée qui vit au jour le jour avec le SIDA.

Ivan L. Head

A Message From the President of the International Research Centre

I welcome you warmly to this extraordinary gathering, and express the thanks of the Steering Group for your participation in the *V International Conference on AIDS*.

In preparing for this event, my associates and I have been privileged witnesses to the immense energies deployed by men and women in all parts of the world as they seek to understand and to come to grips with this pandemic of planetary proportions. The commitment to work and to share is a critical component of success. But it is more. My lengthy involvement with the International Develpment Research Centre has convinced me that the sharing of intellectual and creative effort is a reflection of one of the most precious of human traits the conviction that, working together, we are able to overcome adversity and to shape our future.

The involvement of IDRC in this enterprise flows naturally from one of the Centre's key objectives, one which is remarkably similar to a major goal of this Conference: the overcoming of ignorance. More accurately, the broadening of knowledge through exchange and cooperation. The urgency of the AIDS tragedy demands a twofold reponse: the first, a campaign to counter the virus, and the second, an undertaking to sweep away the misinformation surrounding it.

Such a response is not unprecendented. In each of the sectors essential to human wellbeing food, shelter, education, a wholesome environment, as well as in health problems are solved and standards of living raised only through the wise applications of knowledge broadly shared and disseminated. It is to that end that this Conference is dedicated.

Through history, the great scourges have stimulated the best and the worst of human qualities. The AIDS pandemic is no exception. Daily, the media reflects the fear, the ignorance, the intolerance, and the resulting ostracism and regimentation of human distress that continue, sadly, to be present in so many communities. Yet coincidentally one finds increasing evidence of one compassion, sensitivity, understanding, and a collective commitment to humanitarian responses and to scientific research.

This Conference is a testament to the willingness of human beings to communicate and cooperate at all levels of society, in all regions of the world. The V Conference theme takes the form of a challenge, one addressed to scientists in the biomedical and the other disciplines; one addressed to community organizations; one addressed to governments. That challenge reflects as well, we must never forget, one other: the struggle faced daily by those solitary, anguished individuals living with AIDS.

Ivan L. Head

Message du directeur général de l'organisation mondiale de la santé

En sa qualité d'institution spécialisée des Nations Unies chargée d'orienter et de coordonner l'action internationale dans le domaine de la santé, l'Organisation mondiale de la Santé est heureuse, une fois encore, de coparrainer la présente Conférence.

Chaque année, la Conférence internationale sur le SIDA constitue un événement d'importance majeure dans le cadre des efforts qui se déploient dans le monde pour connaître, prévenir et maîtriser le SIDA. Chacune à sa façon, les quatre conférences antérieures sont devenues des jalons du réseau de communication que la communauté scientifique internationale est en train de construire au-delà des frontières géographiques et au travers de disciplines aussi diverses que celles qui touchent au comportement, aux sciences cliniques et biomédicales et aux domaines social, économique et politique.

A l'ouverture de sa première réunion en mars 1989, la Commission mondiale du SIDA a dénoncé le danger de relâchement. Elle a exprimé son inquiétude de voir que, dans certaines régions, les milieux officiels et les individus étaient devenus moins sensibles à la nécessité de s'attaquer d'urgence au SIDA. Tous, nous devons continuer à combattre les attitudes de rejet, car il ne faut pas que diminue notre volonté de prévenir l'infection à VIH, d'en atténuer l'impact personnel et social et d'unifier les efforts déployés à l'échelon national et international pour lutter contre le SIDA. En même temps, nous devons mettre à profit l'occasion qui s'offre de réexaminer quelques-uns des problèmes complexes, déjà anciens et préexistants que le SIDA a mis en relief au sein de nos systèmes sanitaires et sociaux.

Au moment où s'ouvre la Ve Conférence internationale sur le SIDA, vous avez à affronter le défi du passé aussi bien que l'avenir chargé d'inconnu de la prévention et de la lutte contre le SIDA. Notre tâche aujourd'hui consiste à miser sur nos ressources et notre expérience, à identifier les lacunes les plus graves, à partager sans réserve nos succès et nos échecs avec la certitude que nous pouvons tous apprendre les uns des autres et, de cette façon, renforcer notre propre contribution à l'effort mondial contre le SIDA.

Dr. Hiroshi Nakajima

A Message From the Director General of the World Health Organization

As the specialized agency of the United Nations responsible for directing and coordinating international health work, the World Health Organization is pleased, once again, to co-sponsor this Conference.

Each year, the International Conference on AIDS represents a key event in the global effort to understand, and to prevent and control, AIDS. The past four conferences have become landmarks -each in its own say - as the international scientific community forges new lines of communication across geographical boundaries and across disciplines - behavioural, clinical, biomedical, social, economic and political.

We have also seen that, as knowledge of AIDS has grown, the issues and concerns it generates become increasingly complex, far exceeding the level usually seen in health programmes.

The danger of complacency was voiced by the Global Commission on AIDS at its inaugural meeting in Geneva in March 1989. The Commission was concerned that, in some areas, there had been a decline in official and individual appreciation of the urgency of AIDS. We must all continue to fight denial, for we must not diminish our commitment to preventing HIV infection, reducing its personal and social impact, and unifying national and international efforts against AIDS. At the same time we must utilize the opportunity to re-examine some of the complex,long-standing and pre-existing problems that AIDS has highlighted in our health and social systems.

As you commence the V International Conference on AIDS, you are challenged by the past, and by the uncharted future of global AIDS prevention and control. Our challenge now is to build on existing strengths and experience, to identify critical gaps, and to share openly our successes and failures with the confidence that we can all learn from each other and thereby strengthen our own contribution to the global effort against AIDS.

Dr. Hiroshi Nakajima

Comités et personnel

Committees and Personnel

La V^e Conférence internationale sur le SIDA remercie chaleureusement tous ceux qui ont contribué de leur temps et de leurs énergies à la réalisation de cet événement

The V International Conference on AIDS wishes to express its gratitude to all those who have contributed to this event's success.

Groupe directeur
Steering Group

Président/Chairman
Ivan L. Head

Marie Berlinguet
Manuel Carballo
Alastair J. Clayton
Joel Finlay
Lars Olof Kallings
Jonathan M. Mann
Richard A. Morisset
Martin T. Schechter

Directeur général
Executive Director
Claude Paul Boivin

Comité de programme
Programme Committee

Président/Chairman
Richard A. Morisset

A.

Épidémiologie et santé publique
Epidemiology and Public Health

Coordonnateur
Coordinator
Robert S. Remis

Michel Alary
Randall A. Coates
Richard Lessard
Francis A. Plummer
Michael Rekart

B.

Aspects cliniques
Clinical Aspects

Coordonnateur
Coordinator
Michel G. Bergeron

Mary M. Fanning
Norbert J. Gilmore
Sabih R. Khan
Diane Lalande
Normand Lapointe
Julio S.G. Montaner
John R. Ruedy
Emil Toma
Christos M. Tsoukas

C.

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Coordonnateur
Coordinator
Mark A. Wainberg

Paul Jolicoeur
Jean Latreille
Michael V. O'Shaughnessy
Louis F. Qualtière
Stanley E. Read

D.

Le SIDA et l'individu
AIDS and the Individual

Coordonnateurs
Coordinators
Catherine Hankins
Michel R. Morissette

Alix Adrien
Barbara Jones
Bryce Larke
Jaime Smith
Margaret A. Somerville

E.

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Coordonnateur
Coordinator
Pierre Dionne

David Bennett
Gilles Bibeau
Richard Burzynski
Elaine Carey-Bélanger
Guy R. Descary
Donald De Gagné
Miriam Green
Jean Robert
Sorin Sonea
Anne Usher
Anne V. Whyte

F.

Droit et éthique
Ethics and Law

Coordonnateurs
Coordinators
David J. Roy
Bernard Dickens

Jean-Louis Baudouin
Harry Grantham
Horace Krever
T. David Marshall
Manon Pomerleau

G.

Implications internationales
International Issues

Coordonnateurs
Coordinators
Allan R. Ronald
Pierre Viens

Iona V. Campagnolo
Stephen Simon
Richard Wilson

H.

Répercussions économiques du SIDA
The Economic Impact of AIDS

Coordonnateurs
Coordinators
Margaret Duckett
André-Pierre Contandriopoulos

Rod Fraser
Steven Grover
Gilles Paquet
Jacques Ross

I.

Présentations audiovisuelles
Audiovisual Presentations

Coordonnateur
Coordinator
Ken Morrison

Andy Fabo
John Greyson
Colette Lachance
René Lavoie
Guy Lonergan
James Miller
Georges Tarjan
Tom Waugh

Comité du programme Membres internationaux
Programme Committee International Members

Président/Chairman
Dr. Richard A. Morisset

SECTION A
Roy M. Anderson (United Kingdom)
June Balthazar (Philippines)
C. Bartholomew (Trinidad and Tobago)
Jean-Baptiste Brunet (France)
John Chipanghwe (Malawi)
James Chin (WHO)
James Curran (USA)
Donald Francis (USA)
Neal Halsey (USA)
Harold W. Jaffe (USA)
Richard A. Kaslow (USA)
Mads Melbye (Denmark)
Gary R. Noble (USA)
S.I. Okware (Uganda)
June Osborn (USA)
Jean Pape (Haiti)
George Papaevangelou (Greece)
Praphan Phanupak (Thailand)
Peter Piot (Belgium)
Alain Pompidou (France)
Valentin Pokrovsky (USSR)
Jaime Sepulveda (Mexico)
Werasit Sittitrai (Thailand)
Bertino Somaini (Switzerland)

SECTION B
Robert E. Allen (USA)
Nathan Clumeck (Belgium)
David Cooper (Australia)
J.P. Coulaud (France)
Peter Eriki (Sweden)
J. Goudsmit (The Netherlands)
H. Husrev Hatemi (Turkey)
Martin S. Hirsch (USA)
King K. Holmes (USA)
Leteiev Jemni
Helen I. Joller-Jemelka (Switzerland)
Bila M. Kapita (Zaire)
Marcy Kaplan (USA)
Victor Lorian (USA)
André Lefesvre (France)
David Miller (United Kingdom)
Yves Mouton (France)
Abraham Morag (Israel)
Rafael Najera (Spain)
B. Oberg (Sweden)
Jean-Claude Pechère (Switzerland)
Roger A. Pradinaud (Guyanne Française)
Paul Racz (West Germany)
Willy Rozenbaum (France)
Ethan Rubinstein (Israel)
Merle Sande (USA)
Gary Slutkin (WHO)
Giuseppe Visco (Italy)
Paul A. Volberding (USA)
Hetty Waskin (USA)
Constance Wofsy (USA)
Fernando Zacharias (WHO)

SECTION C
Françoise Barré-Sinoussi (France)
Dani Bolognesi (USA)
Françoise Brun-Vézinet (France)
Jean-Claude Chermann (France)
Angus Dalgleish (United Kingdom)
Freidrich Deinhardt (FRG)
V.V. Delektorsky (USSR)
Guy De The (France)
Peter Ebbensen (Denmark)
José Esparza (WHO)
Myron Essex (USA)
Anthony S. Fauci (USA)
Eva-Maria Fenyo (Sweden)
Robert C. Gallo (USA)
Bernardo Galvao de Castro (Brazil)
Gaetano Giraldo (Italy)
Jean-Claude Gluckman (France)
Ian D. Gust (Australia)
William A. Haseltine (USA)
Yorio Hinuma (Japan)
Takashi Kitamura (Japan)
David Klatzmann (France)
George Klein (Sweden)
Kai Krohn (USA)
Jay A. Levy (USA)
Souleymane M'Boup (Senegal)
Fred Mhalu (Tanzania)
Luc Montagnier (France)
James Mullins (USA)
Akira Oya (Japan)
Gerald V. Quinnan (USA)
Giovanni B. Rossi (Italy)

Geoffrey C. Schild (United Kingdom)
Pei-zhen Tao (People Republic of China)
Simon Wain-Hobson (France)
Robin A. Weiss (United Kingdom)
Flossie Wong-Staal (USA)
Daniel Zagury (France)

SECTION D

Lawrence Adeookun (Nigeria)
Ernst Buning (USA)
Manuel Carballo (WHO)
Judith B. Cohen (USA)
Roel Coutinho (The Netherlands)
Robert G. Covell (United Kingdom)
William Darrow (USA)
Daniel Defert (France)
Don C. Des Jarlais (USA)
Michiko Fakazawa (Japan)
Timothy W. Harding (WHO)
Fathia Mahmoud (Sudan)
Leonardo Mata (Costa Rica)
Amir Mehryar (Iran)
David Miller (New Zealand)
Janet Mitchell (USA)
Jan-Olaf Morfeldt (Sweden)
Eustace Muhondwa (Tanzania)
David Nabarro (United Kingdom)
Elizabeth Ngugi (Kenya)
D.S. Obikeze (Nigeria)
Willie Pasini (Switzerland)
Peter Selwyn (USA)
Fritz Van Dam (Holland)
Françoise Weil-Halpern (France)

SECTION E

Donald Abrams (USA)
Maxine Ankrah (Uganda)
Jacqueline Bonneau (France)
Doreen Boyd (Switzerland)
Jeffrey L. Carples (USA)
Maria Da Penha Silva R. Franco (Brazil)
Iris L. Davis (USA)
Fodé Diouf (Senegal)
William Hartley (New South Wales)
Aart Hendriks (Denmark)
Paul Kawata (USA)
André Rauget (France)
Caitlin C. Ryan (USA)
Renée Sabatier (United Kingdom)
Inon Schenker (Israel)
Kathleen Toomey (USA)
Edouard Vincke (Belgium)
Akiko Yagi (Japan)

SECTION F

John Arras (USA)
Ronald Bayer (USA)
Vera Boltho-Massarelli (France)
Edouard Boné (Belgium)
Susan S. Connor (USA)
Robert Delizee (Belgium)
Netherlands)
Cécile De Sweener (Senegal)
Sev S. Fluss (WHO)
Raanan Gillon (United Kingdom)
Kevin Gordon (USA)
Larry Gostin (USA)
Albert R. Jonsen (USA)
Ian M. Kennedy (United Kingdom)
Rihito Kimura (Japan)
Michael Kirby (Australia)
Nancy Lee Jones (USA)
Robert Levine (USA)
Ruth Macklin (USA)
Wendy K. Mariner (USA)
Vivienne H. Nathanson (United Kingdom)
Henriette D.C. Roscam Abbing (The Netherlands)
Earl E. Shelp (USA)
Manfred Steinbach (Federal Republic of Germany)
Père Paul Sye (Korea)

SECTION G

G. P. Acharya (Nepal)
Kazem Behbehani (Kuwait)
Ngaly Bosenge (Zaire)
Christophe Bouramoue (Congo)
Pedro Cahn (Argentina)
Geoffrey Carliner (USA)
M. Chakravarty (India)
C. S. Chutani (India)
Vincent Dan (Benin)

Gloria Echeverria de Perez (Venezuela)
Oscar Fay (Argentina)
A. J. Georges (Central Africa Republic)
Lair Guerra de Macedo Rodriguez (Brazil)
Ali Guindo (Mali)
Indira Kapoor (India)
Lazare Kaptue (Cameroun)
Ong Kok Hai (Malaysia)
Yamil H. Kouri (USA)
A. S. Lalif (Zimbabwe)
Francisco A. Machado Ramirez (Cuba)
A. N. Malaviya (India)
Mguemby C. Mbina (Gabon)
Ofelia Monzon (Philippines)
Mutama Mugambi (Kenya)
M. Mukunyandela (Zambia)
L. Muyenbe-Tamfum (Zaire)
Bernardin Niragira (Burundi)
Didace Nzaramba (Rwanda)
Patricia O'Connor (Costa Rica)
A. O. Osoba (Saudi Arabia)
A. Outtara (Cote d'Ivoire)
Khyrhed Pavri (India)
Nihal Perera (Sri Lanka)
Arletty Pinel (Brazil)
Femi Soyinka (Nigeria)
Ronald St. John (USA)
Sundararaman Swaminathan (India)
Daniel Tarantola (WHO)
Amnuay Traisupa (Thailand)
J. L. Valdespino (Mexico)
Jack Wirima (Malawi)
Ong Yong Wan (Singapore)

SECTION H
Dennis Andrulis (USA)
Jacques Baudouy (USA)
Gabriel Bez (France)
Geoffrey Carliner (USA)
Nick Drager (WHO)
Anne Johnson (United Kingdom)
Kenneth Kizer (USA)
Guiseppe Marasca (Italy)
Mary Pittman-Lindeman (USA)

SECTION I
Christa Brunswicher (Switzerland)
Jan Zita Grover (USA)
Len Hilgermann (USA)
Manfred Sahlsberg (FRG)
Wieland Speck (West Germany)
Jacques Vandembourghe (France)
Simon Watney (United Kingdom)

Comité des communications
Communications Committee

Président/Chairman
David Nostbakken

Jon Baggaley
Claude Paul Boivin
Bernard Dagenais
Tom Elmslie
Anne Kern
Carole Peacock
Jean Robert
Serge Turgeon

Directrice des communications
Director of Communications
Lyne Champoux

Comité Opérationnel
Operations Group

Président/Chairman
Joel Finlay

Claude Paul Boivin
Antoine Hawara
Nora Ritchie

Directrice générale adjointe
Deputy Director General
Lyse Lavictoire

Équipe de gestion
Management Team

Directeur général
Executive Director
Claude Paul Boivin

Directrice générale adjointe
Deputy Director
Lyse Lavictoire

Directrice des communications
Director of Communications
Lyne Champoux

Personnel de la conférence
Conference Personnel

Secrétariat général
Executive Office

CLÉROUX, Chantal
GOLTZ, Diane
LEMIEUX, Patrick
MORAND, Hélène
WARING, Bruce

Secrétariat des communications
Communications Secretariat

ARGUIN, Maurice
BOIVIN, Élise
CHEVALIER, Carmen
KLUSACEK, Allan
LALIBERTÉ, François
LUSSIER, Sophie

Coordonnateur du SIDART
SIDART Coordinator:
MORRISON, Ken

Secrétariat des médias
Media Secretariat

DURDIN, Martha
GOSSAGE, Patrick
IMRIE, Anne
MERCER, Alison
SHANNON, Kristin
SWITOCZ, Alice

Coordonnatrice
Coordinator:
FOX, Marie-Hélène

Secrétariat de la conférence
Conference Secretariat

BETTANY, Caroline
CHARBONNEAU, Denise
CRISTEL, Robert
FUKUSHIMA, Kuniko
GENDREAU, Louise
GUILLET, Valérie
HARDY, Joanne
KARVOUNIARIS, Tassy
LA RICCA, Lise
LEMME, Corie
LEVIN, Nurit
LIPOWSKI, Lisa
MACKIE, Isobel
MICHAUD, Véra
TAKAHATAKE, Masako
WOLOSCHUK, William
YAP, Yenny

Vice-présidente/Vice-President
Kenness Canada:
POLLACK, Danielle

Secrétariat du programme
Programme Secretariat

BARRON, Craig
CAMPBELL, Sally
CORNEAU, Francine
DELLI COLLI, Sylvia
GUILLEMET, Nicole
HATCHWELL, Patrick
LAJOIE, Yoshiko
PALMER, Robert
STERN, Gary

Coordonnatrice
Coordinator:
FELICISSIMO, Lucy

ARA NO'VO DESIGN INC.; CENTRE FÉDÉRAL SUR LE SIDA FEDERAL CENTER FOR AIDS; CORPAV; C.R.D.I./I.D.R.C.: Bureau du trésorier/Office of the Treasurer, Service de l'administration Administration Services, Division des communications/Communications Division, Bureau du conseiller juridique/Office of the General Counsel; *Diffuseur-hote*, SOCIÉTÉ RADIO CANADA/*Host Broadcaster*, CANADIAN BROADCASTING CORPORATION; GENDARMERIE ROYALE DU CANADA/ROYAL CANADIAN MOUNTED POLICE; GLOBAL VILLAGE PRODUCTIONS; LE GROUPE EXPOSITIONS INC.; MULTICOM INTERNATIONAL MONTREAL; OFFICE DU TOURISME DU GRAND MONTRÉAL GREATER MONTREAL CONVENTION AND TOURISM BUREAU; SERVICE DE TRADUCTION SIMULTANÉE INTERNATIONAL/INTERNATIONAL SIMULTANEOUS TRANSLATION SERVICE; PALAIS DES CONGRES; PIXART; SCRIPTUM; SPACEBRIDGE BROADCASTING INC.; TELAV

BAKER Ted, BRUNEAU Daniel, DE VARENNES Lise-Anne, GILBERT Sylvie, JUTRAS Michel, N'SELE KIBALABAL Paulin, LEROUX Jean, MARTIN Gilles, McKAGUE Ormond, NETTER Tom, RIVEST Jacques, SCHILLER Denis, TRUDEL, Jocelyne, YOUNG Tom, ZARYN Barbara

Renseignements généraux

General Information

Emplacement des services de la conférence (Palais des Congrès)

Accréditation :	Le hall d'accueil
Aire de repos pour personnes atteintes du VIH/SIDA :	Hôtel Méridien
Bureau de change :	Le hall d'accueil
Bureau d'information :	Le hall d'accueil
Bureau d'inscription :	Le hall d'accueil
Bureau de poste :	Le foyer, 4e étage
Centre de diffusion :	Tente sur l'esplanade
Centre des médias :	Pièce 100-A, 1er étage
Ecouteurs :	le foyer, 4e étage
Excursions touristiques :	Le hall d'accueil
Exposition :	Pièce 100-B, 1er étage
Hébergement :	Le hall d'accueil
Messages (Bell Canada) :	Le foyer, 4e étage
Photocopieur (Sandoz) :	Le foyer, 4e étage
Premiers soins :	Pièce 314 (3e étage)
Secrétariat de la conférence (Kenness Canada Inc.) :	Pièce 402-C (4e étage)
Services aux conférenciers :	Pièce 402-A (4e étage)
Service de secrétariat aux délégués (Sandoz) :	Le foyer, 4e étage
Visionnement préliminaire des diapositives :	Pièce 402-A (4e étage)

Accréditation par une Université

Les Services de l'enseignement médical permanent de l'Université McGill et de l'Université de Montréal accordent à cette activité d'éducation permanente un minimum de 24 crédits d'étude et 24 heures de crédits de catégorie I du Physicians Recognition Award de l'American Medical Association. Pour obtenir votre certificat de participation, prière de vous adresser au comptoir de renseignements de la conférence dans le hall d'accueil.

Les Services de l'éducation permanente en médecine de l'Université McGill et de l'Université de Montréal sont entièrement accrédités par la Corporation professionnelle des Médecins du Québec, le Comité d'agrément des écoles de médecine du Canada (CAEMC) et le Conseil d'accréditation correspondant (ACCME) des États-Unis, en matière d'éducation permanente à l'intention des médecins.

Aires de repos pour personnes atteintes du VIH ou du SIDA

Le Salon d'accueil pour personnes atteintes du VIH ou du SIDA est situé dans la salle Anjou de l'hôtel Méridien alors qu'une aire de repos se trouve dans la pièce adjacente, salon Lorraine. Les deux salles se trouvent à l'extrémité sud du Basiliaire 2, côté ouest du Complexe Desjardins.

Un service de navette entre le Palais des Congrès (à partir de la rue Viger, niveau 0) et de l'hôtel Méridien (l'entrée pour voitures, rue Jeanne-Mance) est offert aux personnes atteintes durant les heures de la Conférence.

La Société canadienne de la Croix rouge en collaboration avec le Comité des personnes atteintes du VIH (CPAVIH) du Comité SIDA-Aide Montréal (CSAM) et le Vancouver Persons with AIDS Society sont responsables du fonctionnement des deux aires de repos.

Assurances

La V^{e} Conférence internationale sur le SIDA n'est responsable d'aucune blessure subie à la suite d'un accident survenu pendant la Conférence ou à la suite de celle-ci. Nous vous recommandons de souscrire à une assurance-voyage et assurance-maladie appropriée.

Autobus navette

Un service de navette quotidien est offert aux clients des hôtels situés sur Côte de Liesse, Dorval, Longueuil et Laval. Pour obtenir l'horaire veuillez vous informer auprès des coordonnateurs de ce service dans le hall d'accueil du Palais des Congrès.

Bureau d'information

On peut obtenir des renseignements sur la ville de Montréal, les restaurants, les boutiques, les églises, le transport en commun, les théâtres et les activités sportives auprès du bureau d'informations touristiques qui se trouvent au kiosque circulaire du hall d'accueil.

Bureau de change et services bancaires (Bank of America)

Un bureau de change est situé dans le hall d'accueil. Il sera ouvert du lundi au vendredi.

De nombreuses banques sont situées à proximité du Palais des Congrès et la plupart sont dotées de guichets automatiques, multiservice (System Plus et Interac).

Banque de Commerce	Complexe Guy-Favreau
Banque de Montréal (Service Cirrus)	355, rue Ste-Catherine
Banque de Nouvelle-Écosse	437, rue St-Jacques
Banque Nationale du Canada	Complexe Desjardins un guichet est aussi situé à la sortie métro du Palais des Congrès
Banque Royale	Complexe Desjardins
Banque Toronto-Dominion	305, rue Ste-Catherine
Caisse Populaire Desjardins	Complexe Desjardins

Bureau de poste

Le Palais des Congrès offre le service d'un bureau de poste situé au 4^{e} étage.

Cassettes audio

Les sessions du programme sont enregistrées sur bandes audio et les cassettes sont vendues dans le foyer du quatrième étage au prix de 10,00 $ CAN l'unité.

Cassettes vidéo

Les sessions de la Conférence ayant lieu dans les salles 407A, B et C sont filmées et les cassettes vidéo sont mises en vente dans le foyer du quatrième étage.

Centre de diffusion

La Conférence offre des services de diffusion aux médias électroniques. Ceux-ci sont situés dans la tente sur l'esplanade du Palais des Congrès. Seuls les journalistes portant l'insigne vert y auront accès.

Centre des médias

Le Centre des médias est situé à l'arrière de la pièce 100-A. Seuls les journalistes portant leur insigne vert y auront accès.

Excursions touristiques

La vente des billets (encore disponibles) pour les diverses excursions touristiques est assurée par le Bureau des Tours Maestro Plus située dans le hall d'accueil.

Exposition

La salle d'exposition est située au 1er étage du Palais des Congrès. Nous encourageons les participants à visiter l'exposition qui présente les plus récents équipements, produits ou publications sur le sida.

Les heures d'ouverture sont les suivantes : du lundi au mercredi, de 9h à 18h et le jeudi, de 9h à 17h.

On peut trouver dans la section "Cartes" une liste complète des exposants avec un plan de l'exposition.

Hébergement

Le Bureau d'hébergement de la Conférence est situé dans le hall d'accueil. Le service d'hébergement est fourni par l'Office des congrès et du tourisme du Grand Montréal.

Information après la conférence

Pour tout renseignement, veuillez vous adresser au :

Centre de recherche pour le développement international
Bureau des conférences
C.P. 8500
Ottawa (Ontario)
K1G 3H9

Inscription

Samedi 3 juin et dimanche 4 juin, le bureau d'inscription est situé à la salle 100-A. Pour tout le reste de la semaine, le bureau sera situé dans le hall d'accueil.

Heures d'ouverture

le samedi 3 juin	–	de 13h00 à 20h00
le dimanche 4 juin	–	de 10h00 à 20h00
le lundi 5 juin	–	de 07h00 à 20h00
le mardi 6 juin	–	de 08h00 à 17h00
le mercredi 7 juin	–	de 08h00 à 17h00
le jeudi 8 juin	–	de 08h00 à 17h00

Insignes d'identification

Tous les participants sont tenus de porter leur insigne d'identification pour avoir accès aux séances scientifiques, à l'exposition et aux activités sociales.

Noir : membres des comités de la Conférence
Bleu : délégués
Vert : journalistes
Orange : exposants
Jaune : personnel de la Conférence

Toutes les personnes portant un insigne ***noir*** sont membres de l'un des comités organisateurs de la Conférence; ces personnes répondront avec empressement aux questions des participants.

Chaque délégué porte un insique ***bleu*** qui lui donne accès aux séances scientifiques, à la salle d'exposition et aux activités sociales.

Les journalistes doivent porter un insigne ***vert.*** Seul l'insigne vert donne accès au Centre des médias, au Centre de diffusion et aux conférences de presse.

Le personnel de l'exposition est tenu de porter un insigne ***orange.*** Cet insigne donne accès aux séances plénières seulement. Les autres séances scientifiques peuvent être suivies sur des moniteurs de télévision installés à la salle 100 A et dans les deux cafétérias du Palais des Congrès.

Tous les employés de la Conférence portent un insigne ***jaune.*** Ils se feront un plaisir de répondre à toutes les demandes des participants.

Interprétation simultanée

Toutes les plénières sont interprétées en français, anglais et espagnol, tandis que les sessions sont interprétées en français et en anglais.

Les écouteurs pour l'interprétation simultanée sont distribués au 4^{e} étage. Une pièce d'identité valide telle qu'une carte de crédit, un permis de conduire ou un passeport, sera requise en dépôt.

Les écouteurs doivent être retournés à la fin de chaque jour afin qu'ils puissent être rechargés.

Journaux de la conférence

Un journal, "DIMENSIONS", est produit et distribué chaque jour de la Conférence. Il contient les principales informations ayant trait au fonctionnement de la Conférence et résume le contenu des séances scientifiques. Veuillez le consulter pour tout changement d'horaire ou de salles.

Un journal télévisé est aussi produit chaque jour de la Conférence et est retransmis, le matin avant les sessions plénières, dans le Palais des Congrès (aires de retransmission) et à la télévision montréalaise, au canal 23 (câble).

Messages (Bell Canada)

Pendant la Conférence, vous pouvez laisser des messages au Centre de message Bell Canada, qui est situé dans le foyer, au 4^{e} étage du Palais des Congrès ou en téléphonant au (514) 397-0583.

Pictogrammes

Les neufs modules du programme ainsi que certaines activités de la Conférence sont identifiés dans les publications et l'affichage au Palais par des pictogrammes. En voici la description :



Épidémiologie et santé publique

Aspects cliniques

Recherche fondamentale (biomédicale)



Le SIDA et l'individu



Le SIDA, la société et le comportement

Droit et éthique

Implications internationales

Répercussions économiques du SIDA



Audiovisuel

Affiches

Médias



Retransmission

SIDART

Premiers soins

La Société canadienne de la Croix-Rouge est responsable des services de premiers soins. L'infirmerie est située dans la salle 314, au 3e étage du Palais des Congrès. Elle est ouverte du dimanche au vendredi pendant les heures de la conférence.

Un dossard blanc avec emblème Croix-Rouge identifiera les secouristes en devoir.

Présentation d'affiches

Vous trouverez dans le programme ci-après les titres et noms des auteurs d'abrégés sélectionnés pour ces présentations d'affiches. Les auteurs qui présentent sont identifiés par un astérisque dans le coin droit en haut de leur nom.



Les séances d'affichage auront lieu dans la salle d'exposition du Congrès (voir le plan d'étage dans la section "Cartes")

Chaque domaine de spécialité sera identifié par un pictogramme.

Afin de garantir suffisament de temps à tous les participants pour visionner et discuter des présentations d'affiche, chaque affiche reste en place pendant une journée.

Rafraîchissements et repas

Du café et d'autres boissons ainsi que des goûters sont disponibles dans plusieurs casse-croutes au Palais des Congrès. Il y a aussi un restaurant et un bar sur les terrasses au niveau du 6e étage.

Réglementation de l'usage du tabac

La Ve Conférence internationale sur le SIDA reconnaît les effets potentiellement nocifs du tabagisme. Aussi, sera-t-il interdit de fumer tant à l'intérieur du Palais des Congrès que dans la tente du Centre de diffusion pendant toute la durée de la Conférence.

Restaurants

Plusieurs restaurants et casse-croûtes sont situés à quelques minutes de marche du Palais des Congrès, dans le quartier chinois, au Complexe Guy-Favreau, au Complexe Desjardins et à l'hôtel Méridien au nord du Palais des Congrès.

Service de réservations de restaurant
Montréal détient le titre de capitale gastronomique d'Amérique du Nord. Afin de vous aider à choisir les restaurants qui correspondent le mieux à vos goûts et à votre budget, nous avons prévu un service d'assistance et de réservations au Palais des Congrès. Ce service gratuit, situé à l'étage des congrès, est ouvert toute la semaine durant les heures de la Conférence et permet aux délégués de consulter les menus d'un grand choix de restaurants, représentant les différentes cuisines offertes à Montréal.

Réservations de vols

Air Canada et les Voyages Parthenon offrent leurs services aux voyageurs qui désirent faire des changements à leurs réservations. Leurs bureaux sont situés dans le hall d'accueil.

Vous pouvez également consulté le Guide du délégué pour les numéros de téléphone de compagnies aériennes afin de confirmer directement votre billet de retour.

Retransmission vidéo

Les sessions de la Conférence sont filmées et retransmises en direct dans la salle 100-A et les deux cafétérias au 6^{e} étage du Palais. Pour connaître l'endroit précis de diffusion des sessions, veuillez consulter le journal quotidien de la Conférence.

Service de secrétariat aux délégués (Sandoz)

Un service de secrétariat aux délégués sera offert dans le foyer du 4^{e} étage du Palais des Congrès. Le service sera ouvert durant les heures de la Conférence. Nous vous invitons à visiter et à prendre avantage des services suivants :

- dactylographie : révision de manuscrits, communiqués de la Conférence, affiches
- photocopies : en quantité limitée
- reproduction de diapositives : en 24 heures
- service postal : vente de timbres
- interprètes : service offert en plusieurs langues
- recherche littéraire

Stationnement

Le Palais des Congrès dispose de deux aires de stationnement dont une est située sous le Palais. Le tarif est de 8,50 $ par jour. L'autre aire de stationnement est située sur la rue Bleury, entre les rues Ste-Antoine et Viger. Le tarif est de 1,50 $ par demi-heure, maximum 5 $ par jour.

Téléphones publics

Des téléphones publics sont disponibles à divers emplacements au Palais des Congrès. Pour effectuer un appel local, déposer 25 cents et composer le numéro voulu. Pour établir une communication interurbaine, il serait peut-être plus simple d'établir une communication à frais virés. On peut également faire porter ses appels sur une carte d'appel approuvée. Pour de plus amples renseignements, consulter les premières pages de l'annuaire téléphonique.

Transport en commun

Vous pouvez acheter une carte d'accès au réseau métro autobus valable pour cinq jours au coût de 10,00 $ CAN dans le hall d'accueil. Le service de transport en commun de Montréal propre, silencieux et sécuritaire est exploité par la STCUM (la Société de transport de la communauté urbaine de Montréal).

Les stations de métro pour le Palais des Congrès, et pour la plupart des hôtels ainsi que les résidences, sont les suivantes :

Place d'Armes	Palais des Congrès et l'hôtel Méridien
Place Bonaventure	L'hôtel Grand, Le Reine Elizabeth et le Château Champlain
Place des Arts	Le Holiday Inn Crowne Plaza
McGill	Le Baccarat et les résidences de l'université McGill
Sherbrooke	Le Holiday Inn Richelieu
Berri-de-Montigny	Le Holiday Inn Place Dupuis
Vendôme	Les résidences de l'Université Concordia
Univ. de Montréal ou Vincent d'Indy	Les résidences de l'Université de Montréal

Location of Conference Services (Convention Centre)

Broadcast Centre:	Tent, front terrace
Conference Secretariat (Kenness Canada Inc.):	4th Floor, 402-C
Currency Exchange:	Main Entrance Hall
Earphones:	Lobby, 4th Floor
Exhibits:	Main Floor
First Aid:	Third Floor, 314
Housing Desk:	Main Entrance Hall
Information Desk:	Main Entrance Hall
Local Tours Desk:	Main Entrance Hall
Media Centre:	Main floor, 100-A
Message Centre (Bell Canada):	Lobby, 4th Floor
Photocopier (Sandoz):	Lobby, 4th Floor
Post Office:	Lobby, 4th Floor
Registration Desk:	Main Entrance Hall
Rest areas for people with HIV/AIDS:	Méridien Hotel
Secretarial Services for delegates (Sandoz):	Lobby, 4th Floor
Slide Preview:	4th Floor, 402-A
Speakers Centre:	4th Floor, 402-A
University Accreditation:	Main Entrance Hall

Airline Reservations

Air Canada and Parthenon Travel will assist passengers who need to make changes in their reservations. Their desk is located in the Main Entrance Hall. You may also refer to your Delegate guide for the phone numbers of various airlines in order to reconfirm directly your onward flights.

Audio Tapes

Conference sessions will be taped on audio cassettes which will be sold on the 4th floor, lobby area, for the price of $10.00 CAN.

Broadcast Centre

The Conference is providing broadcast services to electronic media in a tent situated in front of the Palais on the terrace. Only accredited media wearing green badges will be allowed access.

Conference News

A Daily newspaper, "DIMENSIONS", is produced throughout the week of the Conference. It contains information pertaining to the schedule of sessions and Conference activities as well as summaries of scientific presentations.

A televised news show will also be produced every day of the Conference. It will be broadcasted in the mornings before the plenary sessions throughout the Palais (overflow areas) and on the Montreal cable television network (Channel 23).

Exhibits

Exhibits are located in the Exhibit Hall on the main floor of the Palais des Congrès. Participants are encouraged to visit these exhibits and see the latest equipment, supplies, products and publications covering the subject of the Conference.

Exhibits will be open during the following hours:

Monday, June 5 to Wednesday, June 7 – 9:00 to 18:30
Thursday, June 8 – 9:00 to 17:00

A list of exhibitors and the floor plan are included in this publication (see Maps).

First Aid

The Canadian Red Cross Society is responsible for all first aid services. The infirmary is located on the 3rd Floor of the Palais des Congrès in room 314. It is open from Sunday to Friday during Conference hours. First aid personnel on duty will be identified by a red cross on a white background on their fronts and backs.

Foreign Exchange and Banking Facilities (Bank of America)

Foreign exchange service is available in the Entrance Hall of the Convention Centre.

There are several banks located near the Convention Centre. Most have automatic tellers and province interbanking service (Plus System and Interac) including the following:

Bank of Commerce	Guy-Favreau Complex
Bank of Montreal (Cirrus service)	355 Ste-Catherine St.
Bank of Nova Scotia	437 St-Jacques St.
Caisse Populaire Desjardins	Complexe Desjardins
National Bank of Canada	Complexe Desjardins an automatic teller is also situated at the metro entrance to the Palais des Congrès
Royal Bank	Complexe Desjardins
Toronto-Dominion Bank	305 Ste-Catherine St.

Housing

The Housing Desk of the Conference is located in the Main Entrance Hall. Housing is managed by the Greater Montreal Tourist and Convention Bureau.

Information Desk

Information on the city, restaurants, shopping, churches, public transportation, theatre and sporting activities is available at the information desk situated in the Entrance Hall.

Insurance

The V International Conference on AIDS cannot accept liability for injuries arising from accidents which may occur during or arising from the Conference. We recommend that you take out appropriate travel and health insurance.

Local Tours Desk

Tickets for the various touristic activities, which are still available, can be purchased from the Maestro Plus Tours Desk, located in the Main Entrance Hall.

Media Centre

The media centre is located at the back of room 100-A. Only accredited media wearing green badges will be admitted.

Message Centre (Bell Canada)

During the Conference, messages can be telephoned to the Bell Canada Message Centre, located on the 4th floor lobby of the Palais des Congrès. Telephone number is (514) 397-0583.

Name Badges

All Conference registrants are required to wear their name badge in order to gain entry to the scientific sessions, the exhibits and the social functions.

Black: Committee members
Blue: Delegates
Green: Media
Orange: Exhibitors
Yellow: Staff

All those wearing ***black badges*** participated in the organization of the Conference; they welcome any questions from delegates.

All delegates are required to wear a ***blue badge*** which allows them access to sessions, exhibits and social functions.

Access to Media Centre, Broadcast Centre and news conferences are limited to accredited media representatives wearing the official ***green badge.***

Exhibitors, wearing an ***orange badge***, have access only to plenaries because of the limited number of places in the scientific sessions. It will be possible however to follow the sessions on closed circuit TV in overflow areas located on the first and sixth floors of the Palais des Congrès.

All Conference staff will be identified by a ***yellow badge.*** Questions regarding the Conference services should be directed to them.

Parking

The Palais des Congrès has two parking areas, one of which is situated under the Centre. The rate is $8.50 per day. The other parking area is located on Bleury Street between St-Antoine and Viger Streets. The rate is $1.50 per half hour, maximum of $5.00 per day.

Pictograms

The nine programme sections, as well as a few conference activities, are illustrated throughout the Palais and in the publications by pictograms. Here is a complete description:



Epidemiology and Public Health

Clinical Aspects

Basic Research (Biomedical)



AIDS and the Individual



AIDS, Society and Behaviour

Ethics and Law

International Issues

The Economic Impact of AIDS



Audiovisual



Posters

Media



Overflow

SIDART

Post Conference Enquiries

Any post-conference enquiries can be addressed to:

International Development Research Centre
c/o Conference Section
P.O. Box 8500
Ottawa, Ontario
CANADA
K1G 3H9

Post Office

The Convention Centre has a post office situated in the lobby on the 4th floor.

Poster Presentation

The title and the name of the abstracts accepted for poster display are listed in this programme. The presenting authors are marked with an asterisk* at the upper right corner of the name.



The poster sessions are held in the Exhibit Hall of the Palais des Congrès (see Floor Plan).

Each section is identified by a sign post baring the sections's pictogram (as described under Pictograms).

Public Telephones

Public telephones are located throughout the Palais des Congrès. To make a local call deposit 25 cents and dial the desired number. To make a long distance telephone call, it may be simpler to place a collect call. Approved telephone credit cards may also be used to charge calls. For more information, please consult the telephone book.

Public Transportation

You may purchase a five-day pass at a cost of $10.00 CAN for the subway/bus system in the Main Entrance Hall. Clean, quiet and safe, Montreal's public transit system is operated by S.T.C.U.M. (Societé de Transport de la Communauté Urbaine de Montréal).

The subway stations for the Palais des Congrès and for most hotels and the residences are as follows:

Place d'Armes	Palais des Congrès, Méridien Hotel
Place Bonaventure	Grand Hotel, Queen Elizabeth Hotel and Château Champlain
Place des Arts	Holiday Inn Crowne Plaza
McGill	Le Baccarat Hotel and McGill University residences
Sherbrooke	Holiday Inn Richelieu
Berri-de-Montigny	Holiday Inn Place Dupuis
Vendôme	Concordia University residences
Univ. de Montréal or Vincent d'Indy	Université de Montréal residences

Refreshments/Meals

Coffee and other beverages, as well as snacks, are served in snack bars throughout the Palais des Congrès. There is also a restaurant and a bar on the 6th floor of the Palais.

Registration Desk

On Saturday and Sunday, the Registration Desk will be in Room 100-A. For the rest of the week it will be situated in the Entrance Hall of the Palais.

Business Hours

Saturday, June 3:	13:00 to 20:00
Sunday, June 4:	10:00 to 20:00
Monday, June 5:	07:00 to 20:00
Tuesday, June 6:	08:00 to 17:00
Wednesday, June 7:	08:00 to 17:00
Thursday, June 8:	08:00 to 17:00

Rest Areas for People with HIV/AIDS

The Welcome Centre for people with AIDS and people with HIV is located in the Anjou meeting room at the Méridien hotel. A rest area is located next door, in the Lorraine room. Both rooms are located at the south end of Basilaire 2 on the west side of Complexe Desjardins.

A shuttle service for PWAs and PWHIVs operates during the Conference hours between the Palais des Congrès (Viger Street entrance on the lowest level) and the Méridien Hotel (drive-through entrance on Jeanne Mance Street).

The Welcome Centre and the Rest Centre are being operated by the Canadian Red Cross Society with the collaboration of the Comité des personnes atteintes du VIH du Comité SIDA-Aide Montréal and the Vancouver People with AIDS Society.

Restaurants

Restaurants and fast food outlets are situated within short walking distance from the Palais des Congrès. Several are located in China Town, Complexe Guy-Favreau, Complexe Desjardins and the Méridien Hotel, north of the Palais.

Restaurant Reservation Service
Montreal is widely known as the gastronomic capital of North America. To assist you in finding a restaurant to suit your tastes and budget, a complimentary restaurant recommendation and reservation service will be offered during the conference. Located on the Conference (4th floor) level of the Palais des Congrès, the service will operate during the official Conference hours.

The recommendation and reservation service will allow delegates and accompanying persons to study menus from a wide selection of establishments featuring a full variety of cuisines and budget levels available in Montreal.

Secretarial Services for Delegates

Secretarial services for delegates are provided by Sandoz in the lobby area of the 4th floor at the Palais des Congrès and will be available during Conference hours. You are invited to take advantage of their services:

- Typing: Manuscript revisions, Conference communications, Posters
- Photocopying: Facilities are available for making limited quantities
- Slide duplication: Slides returned within 24-hours
- Postal Service: Sale of stamps
- Interpreters: Assistance available in several languages
- Literature Search

Shuttle Buses

Delegates residing in hotels outside the centre core will be shuttled to/from the Palais des Congrès. To obtain a schedule, please consult the Shuttle Desk in the Main Entrance Hall of the Palais.

Simultaneous Interpretation

All plenary sessions will be interpreted into French, English and Spanish. All specialized sessions will offer simultaneous interpretation in French and English.

Receivers for simultaneous interpretation will be distributed on the 4th floor. A valid identification card will be required as deposit: either a credit card, a driver's licence, or a passport will be accepted.

Receivers must be returned at the end of each day in order to be recharged overnight.

Smoking Policy

The V International Conference on AIDS recognizes the probable negative health implications of smoking. Its policy, therefore, is that there will be no smoking inside the Palais des Congrès and the Broadcast Centre.

University Accreditation

The continuing Medical Education units at McGill University and l'Université de Montréal grant, for participation at the Conference, a minimum of 24 study credits or the equivalent of 24 credit hours, Category 1 from the Physicians Recognition Award of the American Medical Association. To get your participation certificate enquire at the Information Desk in the Main Entrance Hall.

The continuing Medical Education services of McGill University and l'Université de Montréal are fully accredited by La Corporation professionnelle des Médecins du Québec, The Accreditation Committee of the Canadian Association of Medical Colleges and the corresponding accreditation organization from the United States (ACCME).

Video Overflow

Conference sessions will be taped and retransmitted live in Room 100-A and the two cafeterias on the 6th floor. To know where specific sessions will be shown please consult the daily newspaper "DIMENSIONS".

Video Tapes

Conference sessions in rooms 407A, B and C will be filmed and the videotapes will be on sale on the fourth level, lobby area.

Activités sociales

Social Activities

Activités sociales

Pour vous procurer des billets pour le gala ou le concert, vous adresser au kiosque d'information situés dans le hall d'accueil.

LE DIMANCHE 4 JUIN 1989 (16h30)
Cérémonie d'ouverture — Palais des Congrès

Cérémonie d'ouverture suivie d'une réception pour tous les participants inscrits.

Inclus dans les droits d'inscription.

LE LUNDI 5 JUIN 1989 (17h00)
Réception — Musée d'art contemporain

Réception offerte par le Gouvernement du Québec (sur invitation seulement).

LE MARDI 6 JUIN 1989 (18h30)
Concert à la basilique Notre-Dame

Soirée de musique classique avec le groupe I Musici de Montréal dans l'historique basilique Notre-Dame au coeur du Vieux Montréal.

Coût : 15 $/personne.

LE MERCREDI 7 JUIN 1989 (19h00)
Soirée de gala — Palais de la civilisation

Spectacle et buffet gastronomique au milieu de scènes reconstituées de grands films (exposition).

Coût : 85 $/personne.

LE JEUDI 8 JUIN 1989 (18h00)
Réception au Jardin Botanique de Montréal

Santé et Bien-être Social Canada sera l'hôte d'une réception au Jardin botanique de Montréal pour tous les participants inscrits à la conférence. Le transport à partir du Palais sera fourni.

Inclus dans les droits d'inscription.

Social Activities

Ask the General Information Desk (Main Entrance Hall) where you can purchase tickets to the gala or concert.

SUNDAY, JUNE 4, 1989 (16:30 hours)
Opening Ceremony — Palais des Congrès

Opening Ceremonies followed by a reception for all registered participants.

Included in the registration fees.

MONDAY, JUNE 5 1989 (17:00 hours)
Reception — Contemporary Art Museum

Reception hosted by the Government of Québec (invitations only).

TUESDAY, JUNE 6 1989 (18:30 hours)
Concert at Notre-Dame Basilica

An evening of classical music performed by I Musici de Montréal in historic Notre-Dame Basilica in the heart of Old Montreal.

Cost: $15.00/person.

WEDNESDAY, JUNE 7 1989 (19:00 hours)
Gala Evening — Palais de la civilisation

Entertainment and gourmet buffet amidst reconstituted film sets (exhibit).

Cost: $85.00/person.

THURSDAY, JUNE 8 1989 (18:00 hours)
Reception at Montreal's Botanical Garden

Health and Welfare Canada will host a reception at Montreal's Botanical Garden for all registered participants. Transportation from the Palais will be available for all participants.

Included in the registration fees.

Cartes
Maps


Georges-Vanier
Sussex
Guy
10
Guy-Concordia
15
8
Lucien-L'Allier
Saint-Jacques
Saint-Antoine
Boul. René Lévesque
Sainte-Catherine
de Maisonneuve
Sherbrooke
18
Avenue des Pins
1
20
Peel
Peel
Bonaventure
2
14
11
De La Gauchetière
17
University
4
McGill
Square-Victoria
5
3
9
16
19
Viger
Bleury
Avenue du Parc
21
22
23
24
Place-des-Arts
13
Jeanne-Mance
Saint-Urbain
Place-d'Armes
Saint-Laurent
Saint-Laurent
Champ-de-Mars
Saint-Denis
Berri-UQAM
Sherbrooke
12
6
Berri
7
Amherst

1. Centre Sheraton
2. Château Champlain
3. Delta Hotel
4. Grand Hotel
5. Holiday Inn Crowne Plaza
6. Holiday Inn Dupuis
7. Holiday Inn Richelieu
8. Hôtel Maritime
9. La Citadelle
10. Le Nouvel Hôtel
11. Le Shangri-La
12. Lord Berri
13. Hôtel Méridien
14. Quatre Saisons
15. Ramada Inn Centreville
16. Ramada Renaissance du Parc
17. Hôtel Reine Elizabeth
18. Ritz Carlton
19. McGill University
20. Y.M.C.A.
21. Palais des Congrès
22. Complexe Guy-Favreau
23. Complexe Desjardins
24. Place des Arts

Coupe du Palais des Congrès

Cross-Section of the Palais des Congrès



1 Autoroute Ville-Marie
Ville-Marie Highway

2 (1er étage)
Étage des expositions (exposition d'affiches et aires de visionnement
(1st Floor)
Exhibition Floor, Exhibition Posters & Overflow Areas

3 (4e étage)
Étage des Congrès
(4th Floor)
Convention Floor

4 Métro
Metro

5 Stationnement souterrain
Underground Parking

6 Avenue Viger
Viger Street

7 Hall d'accueil
Main Entrance Hall

8 Toilettes
Rest Rooms

9 Cafétéria, bar et restaurant, aires de visionnement
Cafeteria, Bar & Restaurant, Overflow Areas



1er étage : Inscription (3 et 4 juin) ***1st Floor: Registration (June 3 and 4)***



1 Centre de diffusion
Broadcast Service Centre

2 Hall d'accueil (information)
Main Entrance Hall (Information)

3 • Bureau de service pour la navette
Shuttle Service Desk
• Visites guidées
Tours
• Air Canada
• Bureau de change
Currency Exchange

4 • Guichet hébergement
Housing Desk
• Guichet vente de billets d'événements spéciaux
Special Events Ticket Sales Office

5 Croix-Rouge (urgence)
Red-Cross (Emergency)

6 Inscription exposants
Exhibitors' Registration

7 Inscription médias
Media Registration

8 Pré-inscription, délégués
Pre-Registration, delegates

9 Correction des insignes
Badge Correction

10 Inscription sur le site, délégués
On-Site Registration, delegates

11 Renseignements
Enquiries

12 • Accreditation C.M.E.
C.M.E. Accreditation
• Société internationale sur le SIDA
International AIDS Society

13 Distribution des porte-documents
Satchel Distribution

14 Centre des médias
Media Centre

15, 16, 17 Casse-croûte
Snack Bar

1er étage : Affiches, retransmission, exposition

1st Floor: Posters, Overflow, Exhibition



1 Centre de diffusion
Broadcast Services Centre

2 Hall d'accueil
Main Entrance Hall

3 • Bureau de service pour la navette
Shuttle Service Desk
• Visites guidées
Tours
• Air Canada
• Bureau de change
Currency Exchange

4 • Pré-inscription
Pre-Registration
• Inscription sur le site
On-Site Registration
• Caisse
Cashier
• Événements spéciaux, cahiers d'abrégés
Social Events, Abstract Books

5 Exposition
Exhibition

6 Séances d'affiches, module C
Poster Sessions, Section C

7 Comptoir de service pour affiches, module C
Poster Service Desk, Section C

8 Séances d'affiches, module A
Poster Sessions, Section A

9 Comptoir de service pour affiches, module A
Poster Service Desk, Section A

10 Croix-Rouge (urgence)
Red-Cross (Emergency)

11 Séances d'affiches, modules B-D-E-F-G-H
Poster Sessions, Sections B-D-E-F-G-H

12 Comptoir de service pour affiches, modules D-E
Poster Service Desk, Sections D-E

13 Comptoir de service pour affiches, module B
Poster Service Desk, Section B

14 Comptoir de service pour affiches, modules F-G-H
Poster Service Desk, Sections F-G-H

15 Aire de visionnement # 1 (retransmission)
Overflow Area #1

16 Aire de visionnement # 2 (retransmission)
Overflow Area #2

17 Aire de visionnement # 3 (retransmission)
Overflow Area #3

18 Aire de visionnement # 4 (retransmission)
Overflow Area #4

19 Aire de visionnement # 5 (retransmission)
Overflow Area #5

20 Centre des médias
Media Centre

21, 22, 23 Casse-croûtes
Snack Bars

24 Douanes Milgram
Milgram Customs Office

1er étage : Exposition

1st Floor: Exhibition



001 C.R.D.I./*I.D.R.C.*, CANADA
005 O.M.S./*W.H.O*, SUISSE
008 MICROGENESYS, U.S.A.
009 INCSTAR, U.S.A.
011 GOV. OF BRITISH COLUMBIA, CANADA
014 GOV. OF ALBERTA, CANADA
015 ASSOCIATION CANADIENNE DE SANTÉ PUBLIQUE, *CANADIAN PUBLIC HEALTH ASS.*, CANADA
016 SOCIÉTÉ CANADIENNE D'HÉMOPHILIE, *CANADIAN HEMOPHILIA SOCIETY*, CANADA
017 SOCIÉTÉ CANADIENNE DU SIDA, *CANADIAN AIDS SOCIETY*, CANADA
018 HIGHWAY BOOKSHOP, CANADA
019 INSTITUT VIRION, SUISSE
022 MARQUEST MEDICAL PRODUCTS, U.S.A.
023 RAVEN PRESS, U.S.A.
024 PFIZER INTERNATIONAL, U.S.A.
025 AMFAR, U.S.A.
026 MEDICAL PUBLISHING GROUP, U.S.A.
027 RHONE POULENC PHARMA INC., CANADA
028 AMERICAN SOCIAL HEALTH ASS., U.S.A.
029 M.A. LIEBERT PUBLISHING,, U.S.A.
030 AMERICAN ASS. ADV. SCIENCE, U.S.A.
031 BIOSCIENCES INFORMATION SER., U.S.A.
032 CURRENT SCIENCE, U.S.A.
034 FORMA, U.S.A.
036 N.A.B.I., U.S.A.
037 FAMILY HEALTH INTERNATIONAL, U.S.A.
038 FISONS CORPORATION, U.S.A.
039 NEW ZEALAND HEALTH DEPT, NEW ZEALAND
040 PHYSICIANS ASS. FOR AIDS CARE, U.S.A.
041 PANOS INSTITUTE, ENGLAND
044 CALYPTE BIOMEDICAL, U.S.A.
045 BAXTER HEALTHCARE CORP. PANDEX, U.S.A.
047 CAREMARK HOMECARE, U.S.A.
049 DEUTSCH AIDS-HILFE E.V., WEST GERMANY
050 IMRÉ CORPORATION, U.S.A.
052 CHANNING L.BETE, U.S.A.
054 MARCEL DEKKER, U.S.A.
056 LYPHOMED INC., U.S.A.
100 SANTÉ ET BIEN-ÉTRE SOCIAL, CANADA *HEALTH & WELFARE CANADA, CANADA*
110 IAF BIOCHEM CANADA, CANADA
111 VIRX, U.S.A.
112 CITY OF TORONTO, CANADA
113 ASS. NURSES IN AIDS CARE, U.S.A.
114 LABMEDICA. U.S.A.
115 ACADEMY EDUC. DEVELOPMENT, U.S.A.
116 NATURE, U.S.A.
117 W.G.B.H. BOSTON, U.S.A.
118 MUREX CORPORATION, U.S.A.
119 BECKMAN INSTRUMENTS INC., CANADA
200 BURROUGHS WELCOME, CANADA
211 CELLULAR PRODUCTS, U.S.A.
212 STATE OF HAWAI, U.S.A.
213 MIAMI UNIVERSITY, U.S.A.
214 CANADIAN CABINETS CO., CANADA
215 CAMBRIDGE RESEARCH, U.S.A.
217 GENE TRAK SYSTEMS, U.S.A.
218 CITY OF SAN FRANCISCO, U.S.A.
219 ORTHO BIOTECH, U.S.A.
300 GOUVERNEMENT DU QUÉBEC, CANADA
303 AUSTRALIA HEALTH DEPT, AUSTRALIA
305 ORGANON TEKNIKA, BELGIQUE
310 MINISTERIO DE SANIDAD-ESPANA, ESPANA
311 EPITOPE, U.S.A.
312 CAMBRIDGE BIOSCIENCE, U.S.A.
313 TRITON BIOSCIENCES INC., U.S.A.
314 CARTER WALLACE INC., U.S.A.
316 PAN DATA SYSTEMS, U.S.A.
317 BYOSIN, U.S.A.
318 BIO-RAD, CANADA
319 AMGEN, U.S.A.
400 BEHRINGWERKE, WEST GERMANY
401 GAY MEN HEALTH CRISIS, U.S.A.
402 BECTON DICKINSON, CANADA
405 ADVANCED TECHNOLOGIES, U.S.A.
407 PENINSULA LABORATORIES, U.S.A.
408 AM. EUROPEAN CLINICAL LAB., U.S.A.
409 GOV. OF ONTARIO, CANADA
410 COULTER CORPORATION, U.S.A.
500 INSTITUT MÉRIEUX, FRANCE
501 MARYLAND MEDICAL LAB., U.S.A.
502 N.I.A.I.D., U.S.A.
503 OLYMPUS CORPORATION, U.S.A.
504 ANGEWANDIE COMPUTER SOFTWARE, WEST GERMANY
507 DUPONT COMPANY, U.S.A.
510 SYNTEX INTERNATIONAL, U.S.A.
511 SYVA, U.S.A.
600 JULIUS SCHMID, CANADA
601 IMMUNODIAGNOSTICS INC., U.S.A.
603 GENETIC SYSTEMS, U.S.A.
604 SWETS & ZEITLINGER, HOLLAND
606 PORTON INTERNATIONAL INC., U.S.A.
608 BRITISH HEALTH DEPT, ENGLAND
609 ORTHO DIAGNOSTICS SYSTEMS, U.S.A.
610 ABBOTT LABORATORIES, U.S.A.
613 NAIC, U.S.A.
619 PHARMACIA E.N.I., CANADA
700 FUJIREBIO, U.S.A.
701 ANSELL INTERNATIONAL, U.S.A.
710 COMITÉ FRANCE SIDA, FRANCE
800 ICN PHAMACEUTICALS, U.S.A.
810 HOFFMANN LAROCHE, U.S.A.
900 OKAMOTO U.S.A. INC., U.S.A.
901 COMMUNITY RESEARCH INITIATIVE, U.S.A.
902 DISEASE DETECTION INTERNATIONAL, U.S.A.
903 IN TOUCH COMMUNICATIONS, CANADA

4e étage : Étage des congrès

4th Floor: Convention Floor



1 Comptoir de vente des cassettes vidéo
Video Cassette Sales Counter

2 Comptoir de vente des cassettes audio
Audio Cassette Sales Counter

3 Centre de messages Bell
Bell Message Centre

4 Réservation de restaurants
Restaurant Reservation

5 Sandoz

6 Écouteurs d'interprétation simultanée
Simultaneous Interpretation Headsets

7 Secrétariat Kenness
Kenness Secretariat

8 Salle de visionnement de diapositives pour conférenciers
Speakers' Audiovisual Preview Room

9 Centre des conférenciers
Speakers' Centre

6e Étage: Caféterias et retransmission

6th Floor: Cafeterias and Overflow



1 Aire de visionnement # 9 (retransmission)
Overflow Area #9

2 Aire de visionnement # 8 (retransmission)
Overflow Area #8

3 Aire de visionnement # 7 (retransmission)
Overflow Area #7

4 Aire de visionnement # 6 (retransmission)
Overflow Area #6

5 Bar & Restaurant

6 Cafétéria
Cafeteria

7 Aire de visionnement # 12 (retransmission)
Overflow Area #12

8 Aire de visionnement # 11 (retransmission)
Overflow Area #11

9 Aire de visionnement # 10 (retransmission)
Overflow Area #10

Complexe Guy-Favreau :
Programme audiovisuel

Guy-Favreau Complexe:
Audiovisual Programme



1 Passage du métro
Metro Passage

2 Complexe Guy-Favreau
Guy-Favreau Complexe

3 Cinéma de l'ONF
présentation audiovisuelle, section I
NFB Cinema
Audiovisual Presentation, Section I

4 Centre de ressources audiovisuelles:
Salle des érables
Audiovisual Centre:
Des Érables Room

5 • C.R.D.I
I.D.R.C.
• Santé Bien-être Social Canada
Health and Welfare Canada
• O.M.S.
W.H.O.


Rue Ste-Catherine
1
2
3
4
5
6
7
8
Boul. René Lévesque
10
11
9
Rue Jeanne-Mance
Rue St-Urbain
Rue De La Gauchetière
Rue Viger
12

Place des Arts

1 Café de la place
- Pièce de théâtre
Play

Hôtel Méridien

2 Amphithéâtre Méridien
- Pièces de théâtre
Plays

3 Salon Alfred Rouleau
- Tables rondes
Round Table Discussions

Complexe Desjardins

4 Kiosques d'information
Information Kiosks

5 Expositions-dessins d'enfants, tableaux et bandes dessinées
Exhibitions—Children's Drawings, Paintings, Comics

6 Amphithéâtre du Complexe
- Animation le midi
Complexe Amphitheatre
- Noon Hour Shows

7 Plafond
- Courtepointe commémorative
Ceiling
- Names Project—Quilt

Corridor

8 Affiches d'artistes montréalais
Posters By Montreal Artists

Complexe Guy-Favreau

En bas/*Lower Level*

9 Exposition d'affiches (art et éducation)
Poster Exhibitions (Art and Education)

10 Cinéma ONF — Films et vidéos
NFB Cinema—Films and Videos

En haut/*Upper Level*

11 Exposition de photos
Photo Exhibit

Palais des Congrès

Foyer/*Lobby*

12 Exposition du concours international de logotype de l'O.M.S.
International Logotype Contest Exhibition by the W.H.O.

Instructions générales

General Instructions

Instructions générales

Auteurs d'affiche

Les auteurs d'affiches recevront une carte d'inscription leur indiquant le numéro de leur tableau d'affichage et le pictogramme de leur section.

Les séances d'affichage seront tenues dans la salle d'exposition du Palais des Congrès (Voir le plan d'étage)

Chaque domaine de spécialité (section) sera identifié par un pictogramme comme ci-dessous:



Épidémiologie et santé publique

Aspects cliniques

Recherche fondamentale (biomédicale)



Le SIDA et l'individu



Le SIDA, la société et le comportement

Droit et éthique

Implications internationales

Répercussions économiques du SIDA

Afin de garantir suffisamment de temps à tous les participants pour visionner et discuter des présentations d'affiche, chaque affiche restera en place pendant une journée.

Les auteurs sont priés de respecter l'horaire suivant pour le montage et démontage de leur affiche:

Horaire Jour	Heure du montage	Heure de la séance	Heure du démontage
5 juin lun.	7h30-8h30	13h00-14h00	18h00-18h30
6 juin mar.	7h30-8h30	13h00-14h00	18h00-18h30
7 juin mer.	7h30-8h30	13h00-14h00	18h00-18h30
8 juin jeu.	7h30-8h30	13h00-14h00	18h00-18h30

Les auteurs doivent présenter leur affiche entre 13h et 14h le jour de la présentation. Le pictogramme du panneau de l'affiche identifie la section; les affiches sont numérotées de façon consécutive à l'intérieur de chaque section. Les aires réservées à chaque section sont clairement identifiées.

Le personnel de la Conférence sera disponible en tout temps sur les lieux pout porter assistance en cas de besoin.

À noter
La Conférence n'accepte aucune responsabilité pour les affiches qui ne sont pas démontées à temps.

Auteurs de films et de vidéos

Les personnes qui présentent des films ou des vidéos ou les conférenciers du module audiovisuel sont priés de contacter François Laliberté dès leur arrivée au Complexe Guy-Favreau, salle des Érables.

Conférenciers

Le Centre des conférenciers situé au 402-A est ouvert:
du dimanche 4 juin au vendredi 9 juin de 8:00 à 19:00

Services offerts

- Transposition des diapositives dans les carrousels utilisés par la Conférence
- Équipement de visionnement des diapositives
- Scellage et identification des carrousels qui seront entreposés puis transportés aux salles appropriées par le personnel de la Conférence. La projection des diapositives durant les présentations est prise en charge par les techniciens de la Conférence
- Retour des carrousels au Centre pour conférenciers à la fin de chaque session

Nous prions les conférenciers de bien vouloir suivre les procédures suivantes:

1) Vous rapporter au Centre au moins 24 heures avant le début de votre présentation et remettre vos diapositives.

À noter
les conférenciers du lundi sont priés de se présenter au Centre le dimanche après leur inscription.

Assurez-vous que chaque diapositive porte une marque dans le coin gauche inférieur afin d'assurer leur position adéquate dans les carrousels.

2) Signer le formulaire de décharge afin de permettre au personnel de la Conférence d'enregistrer votre session.

3) Rencontrer le président de session dans la salle de conférence appropriée 15 minutes avant le début de la session.

4) Pour la durée de la présentation, prière de se conformer à l'horaire prévu et au temps alloué.

Présidents d'assemblées

Tous les présidents d'assemblées sont invités à une réunion d'information, dimanche à 19h30, au Grand Salon "A" de l'Hôtel Méridien. Les présidents des sessions quotidiennes doivent se rencontrer le jour-même de leur session à 07h45 heures au Palais des Congrès, salle 401ABC (4^{e} étage).

Les présidents de sessions sont également priés de se rendre à leur salle 15 minutes avant le début de la session afin d'y rencontrer les conférenciers.

Chairpersons

All *chairpersons* are invited to a brief meeting on Sunday evening at the Meridien Hotel (Grand Salon "A") at 19:30 hours. Chairpersons for each day's sessions meet on the morning of their session at 07:45 hours in Room 401ABC at the Palais des Congrès.

Chairpersons are requested to meet with their speakers in the session hall 15 minutes before the session starts.

Poster Presenters

The poster sessions will be on the Exhibit Floor, lower level of the Palais des Congrès (see Floor Plan).

Each section will be identified by a sign post showing the section pictogram such as:



Epidemiology and Public Health

Clinical Aspects

Basic Research (Biomedical)



AIDS and the Individual



AIDS, Society and Behavior

Ethics and Law

International Issues



The Economic Impact of AIDS

In order to provide ample time for all participants to view and discuss poster presentations, each poster will be on display for one day.

Authors are requested to adhere to the following schedule in mounting and removing their posters on their assigned boards:

Schedule

Day	Mounting Time	Session Time	Removal Time
June 5 Mon.	07:30 - 08:30	13:00 - 14:00	18:00 - 18:30
June 6 Tue.	07:30 - 08:30	13:00 - 14:00	18:00 - 18:30
June 7 Wed.	07:30 - 08:30	13:00 - 14:00	18:00 - 18:30
June 8 Thu.	07:30 - 08:30	13:00 - 14:00	18:00 - 18:30

Authors must be present at their poster from 13:00 to 14:00 on the day of presentation. The poster board pictogram identifies the section; posters are numbered consecutively within each section. Each specialty area will be identified by a sign.

Conference personnel will be on the floor at all times should assistance be required.

The Conference accepts no responsibility for posters not removed on time.

Speakers

The Speakers Centre situated in Room 402-A is open: Sunday, June 4 through Friday, June 9 08:00 - 19:00.

Services provided

- Transfer of slides to conference-standard slide trays
- Projection equipment for viewing slides
- Sealing and identification of slide trays to be stored by conference staff, ready to be taken at the proper time and place to the speaker's presentation. (Projection during the presentation is provided by Conference staff.)

Slide trays will be returned to the Speakers' Centre and speakers can collect them at the conclusion of each session.

We kindly ask speakers to observe the following *procedures*:

1) Report to the Speakers' Centre at least 24 hours prior to the scheduled time of the presentation and drop your slides at that time.

Note
Speakers scheduled for Monday should report at the Centre on Sunday after registration.

Make sure that each slide is marked at the bottom left hand corner to ensure proper loading in the slide trays.

2) Sign Discharge forms to allow Conference staff to tape sessions.

3) Meet with the Session Chairperson in the session hall 15 minutes prior to the beginning of the session.

4) During the presentation, please conform to the instructions regarding the length of the oral presentation.

Videotape Presenters

All people presenting films or videos as well as speakers for the Audiovisual sections are asked to contact François Laliberté upon their arrival at the Complexe Guy Favreau, room des Érables.

Programme

Sommaire du programme

Le samedi 3 juin

13 h à 20 h		
Inscription	Palais des Congrès	100A

Le dimanche 4 juin

10 h à 19 h		
Inscription	Palais des Congrès	100A

16 h 30 à 19 h	
Cérémonie d'ouverture	Palais des Congrès

20 h à 21 h 30	
Réception d'ouverture	Complexe Desjardins

Program Summary

Saturday June 3

13:00 to 20:00		
Registration	Palais des Congrès	100A

Sunday June 4

10:00 to 19:00		
Registration	Palais des Congrès	100A

16:30 to 19:00	
Opening Ceremonies	Palais des Congrès

20:00 to 21:30	
Opening Reception	Complexe Desjardins

Le lundi 5 juin

8 h 30 à 10 h 30

« Nouvelles prespectives »
—Plénière — Palais des Congrès — 407 ABC

11 h à 17 h 30

Présentations audiovisuelles — Centre de conférences Guy-Favreau

11 h à 12 h 30

A.	**Épidémiologie et santé publique**	
	Études séro-épidémiologiques : États-Unis	407 A
	SIDA/VIH : le sang et les produits sanguins	408 A
	Autres rétrovirus : VIH-2 et HTLV-1/II	408 BC
B.	**Apects cliniques**	
	Le VIH chez les enfants	401 ABC
	(Table ronde) Coordination des soins : le point de vue du personnel	403 ABC
	(Colloque) Infections à *Pneumocystis carinii*	407 B
C.	**Recherche fondamentale (biomédicale)**	
	(Colloque) Mécanismes de pathogenèse du VIH	407 C
	Biologie moléculaire (partie 1) : Diversité génomique et ses liens aux aspects cliniques	410 ABC
D.	**Le SIDA et l'individu**	
	Recherches sur le comportement (partie 1)	409 ABC
E.	**Le SIDA, la société et le comportement**	
	(Colloque) Vivre avec le SIDA : le point de vue de personnes atteintes	411 A
	(Atelier) Éducation-SIDA : Leçons à tirer des pays en voie de développement	411 B
F.	**Droit et éthique**	
	(Colloque) Vue d'ensemble de la législation sur le SIDA	411 C
G.	**Implications internationales**	
	Le sérodiagnostic	406 A
	(Colloque) Aspects culturels et sociaux de la sexualité	406 BC
H.	**Répercussions économiques du SIDA**	
	Aperçu et coûts de la prévention et de l'éducation	404 AB

13 h à 14 h

Présentation d'affiches par les auteurs — 100A/100B
(Affiches exposées toute la journée)

14 h à 15 h 30

A.	**Épidémiologie et santé publique**	
	(Table ronde) L'évolution de la politique en matière de santé publique	407 A
	Tests de dépistage du VIH dans les cliniques de MTS	408 A
	Incidence et prévalence du VIH	408 BC

B.	**Aspects cliniques**	
	Manifestations buccales du SIDA	401 ABC
	Nouvelle technique de diagnostic rapide et améliorée	403 ABC
	(Colloque) Traitement des infections associées à l'immunodéficience causée par le VIH	407 B
C.	**Recherche fondamentale (biomédicale)**	
	(Colloque) Les bases moléculaire et cellulaire des immunodéficiences provoquées par les rétrovirus	407 C
	Pathogenèse (partie 1)	410 ABC
D.	**Le SIDA et l'individu**	
	Les adolescents (partie 1)	409 ABC
E.	**Le SIDA, la société et le comportement**	
	Les proches et la famille	411 A
	(Colloque) Stratégies innovatrices pour l'éducation des minorités au sujet du SIDA	411 B
F.	**Droit et éthique**	
	(Table ronde) Points de controverse dans les rapports sur les politiques relatives au SIDA	411 C
G.	**Implications internationales**	
	Information et comportement sexuel	406 A
	(Colloque) Les nourrissons à risque : Le point de vue africain	406 BC
H.	**Répercussions économiques du SIDA**	
	Coûts en milieu hospitalier	404 AB

16 h à 17 h 30

A.	**Épidémiologie et santé publique**	
	La transmission sexuelle du VIH (partie 1)	407 A
	Infection par le VIH chez les détenus	408 A
	Histoire clinique de l'infection au VIH : Cofacteurs et progression	408 BC
B.	**Aspects cliniques**	
	Infections concomitantes du SIDA	401 ABC
	Pédiatrie : développement neurologique des enfants infectés par le VIH	403 ABC
	Traitement : essais de l'AZT	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Biologie moléculaire (partie 1)	407 C
	Pathogenèse (partie 2)	410 ABC
D.	**Le SIDA et l'individu**	
	Travailleurs de la santé	409 ABC
E.	**Le SIDA, la société et le comportement**	
	(Table ronde) L'entraide : Une stratégie d'adaptation	411A
	Les facteurs culturels déterminants dans les attitudes à l'égard du SIDA	411 B
F.	**Droit et éthique**	
	(Colloque) Éthique et injustice sur le plan international	411 C
G.	**Implications internationales**	
	Prévalence (partie 1)	406 A
	(Atelier) Atelier régional : Afrique orientale	406 BC
H.	**Répercussions économiques du SIDA**	
	Coûts en dehors du milieu hospitalier	404 AB

Monday June 5

8:30 - 10:30

"New Perspectives" — Plenary session	Palais des Congrès	407 ABC

11:00 - 17:30

Audiovisual Presentations	Guy-Favreau Conference Centre

11:00 - 12:30

A.	**Epidemiology and Public Health**	
	Seroepidemiologic studies: United States	407 A
	AIDS/HIV: Blood and blood products	408 A
	Other retroviruses: HIV-2 and HTLV-I/II	408 BC
B.	**Clinical Aspects of AIDS**	
	HIV in children	401 ABC
	(Round table) Coordinating care: A nurse's perspective	403 ABC
	(Symposium) Natural History and Diagnosis of HIV infection	407 B
C.	**Basic Research Biomedical**	
	(Symposium) Mechanisms of pathogenesis of HIV	407 C
	Molecular Biology (part 1): Genomic diversity and relationship to clinical aspects	410 ABC
D.	**AIDS and the Individual**	
	Behavioural research (part 1)	409 ABC
E.	**AIDS, Society and Behaviour**	
	(Symposium) Living with AIDS: A person with AIDS perspective	411 A
	(Workshop) AIDS education: Lessons from developing countries	411 B
F.	**Ethics and Law**	
	(Symposium) Global survey of AIDS legislation	411 C
G.	**International Issues**	
	Serodiagnosis	406 A
	(Symposium) Cultural and social perspectives of sexuality	406 BC
H.	**The Economic Impact of AIDS**	
	Overview plus costs of prevention and education	404 AB

13:00 - 14:00

Poster Presentations by Authors
(Posters on display throughout the day)

14:00 - 15:30

A.	**Epidemiology and Public Health**	
	(Round table) Analysis of Public Health Policy	407 A
	HIV testing in STD clinics	408 A
	HIV incidence and prevalence	408 BC

B.	**Clinical Aspects of AIDS**	
	Oral manifestations of AIDS	401 ABC
	New improved rapid diagnosis	403 ABC
	(Symposium) Management of infections associated with HIV immunodeficiency	407 B
C.	**Basic Research Biomedical**	
	(Symposium) Molecular and cellular bases of retrovirus induced immunodeficiencies	407 C
	Pathogenesis (part 1)	410 ABC
D.	**AIDS and the Individual**	
	Adolescents (part 1)	409 ABC
E.	**AIDS, Society and Behaviour**	
	Close friends and family	411 A
	(Symposium) Innovative strategies for AIDS education with minorities	411 B
F.	**Ethics and Law**	
	(Round table) Points of controversy between policy reports on AIDS	411 C
G.	**International Issues**	
	Knowledge and sexual behaviour	406 A
	(Symposium) Infants at risk: An African perspective	406 BC
H.	**The Economic Impact of AIDS**	
	Hospital-based costs	404 AB

16:00 - 17:30

A.	**Epidemiology and Public Health**	
	Sexual Transmission of HIV (part 1)	407 A
	HIV infection in prisoners	408 A
	Natural History of HIV infection: Co-factors for progression	408 BC
B.	**Clinical Aspects of AIDS**	
	Concomitant infections in AIDS	401 ABC
	Pediatric: Neuro-development in HIV-infected children	403 ABC
	Therapy: AZT trials	407 B
C.	**Basic Research Biomedical**	
	Molecular biology (part 1)	407 C
	Pathogenesis (part 2)	410 ABC
D.	**AIDS and the Individual**	
	Health care workers	409 ABC
E.	**AIDS, Society and Behaviour**	
	(Round table) Self-help: A coping strategy	411 A
	Cultural determinants in responding to AIDS	411 B
F.	**Ethics and Law**	
	(Symposium) Ethics and international inequity	411 C
G.	**International Issues**	
	Prevalence (part 1)	406 A
	(Workshop) Regional workshop: East Africa	406 BC
H.	**The Economic Impact of AIDS**	
	Out-of-hospital costs	404 AB

Le mardi 6 juin

8 h 30 à 10 h 30

« État de la question »
—Plénière — Palais des Congrès 407 ABC

11 h à 17 h 30

Présentations audiovisuelles — Centre de conférences Guy-Favreau

11 h à 12 h 30

A.	**Épidémiologie et santé publique**	
	(Table ronde) L'annonce aux partenaires et la prévention de l'infection par le VIH	407 A
	Surveillance du SIDA	408 A
	Infections par le VIH chez les consommateurs de drogues par voie intraveineuse	408 BC
B.	**Aspects cliniques**	
	(Atelier) Prophilaxie de la PCP	401 ABC
	Le SIDA dans les pays en voie de développement	406 A
	(Colloque) Traitement des infections par le VIH	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Virologie (partie 1)	403 ABC
	(Colloque) Mécanismes de pathogenèse des rétrovirus humains	407 C
	Biologie moléculaire : les différents niveaux d'expression du provirus VIH-1	410 ABC
D.	**Le SIDA et l'individu**	
	(Colloque) Détenus : contraintes et défis	409 ABC
	Recherches sur le comportement (partie 2)	411 A
E.	**Le SIDA, la société et le comportement**	
	(Table ronde) Services sociaux : expériences et évaluations	411 B
F.	**Droit et éthique**	
	(Colloque) La confidentialité et ses limites	411 C
G.	**Implications internationales**	
	(Colloque) Sérodiagnostics rentables	406 BC
H.	**Répercussions économiques du SIDA**	
	Planification et gestion	404 AB

13 h à 14 h

Présentation d'affiches par les auteurs — 100A/100B
(Affiches exposées toute la journée)

14 h à 15 h 30

A.	**Épidémiologie et santé publique**	
	Transmission sexuelle du VIH (partie 2)	407 A
	(Table ronde) Efficacité et évaluation des programmes	408 A
	(Table ronde) Déclaration du VIH	408 BC

B.	**Aspects cliniques**	
	(Table ronde) Transmission périnatale du VIH	401 ABC
	(Colloque) Diagnostic et histoire clinique de l'infection par le VIH	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Pathogenèse (partie 3)	403 ABC
	(Colloque) Origines des rétrovirus humains et des modèles animaux	407 C
	Biologie moléculaire : les mécanismes de régulation de type *tat* des gènes viraux	410 ABC
D.	**Le SIDA et l'individu**	
	Minorités	409 ABC
	Psychologie et sexologie	411 A
E.	**Le SIDA, la société et le comportement**	
	(Atelier) Empowerment : Réappropriation de la santé, les expériences des personnes atteintes	411 B
F.	**Droit et éthique**	
	(Colloque) Éthique clinique	411 C
G.	**Implications internationales**	
	Risques et prévention	406 A
	(Colloque) Compassion et soins communautaires dans les pays en voie de développement	406 BC
H.	**Répercussions économiques du SIDA**	
	Coûts dans les pays en voie de développement	404 AB

16 h à 17 h 30

A.	**Épidémiologie et santé publique**	
	Histoire clinique de l'infection à VIH : manifestations précoces et progression	407 A
	Modèles mathématiques	408 A
	(Colloque) Évaluation de l'efficacité des programmes de prévention	408 BC
B.	**Aspects cliniques**	
	Traitement de la PCP	401 ABC
	(Colloque) Problèmes de laboratoire dans le diagnostic du SIDA	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Virologie (partie 2)	403 ABC
	Modèles animaux (partie 1)	407 C
	Biologie moléculaire : les gènes régulateurs et leurs produits	410 ABC
D.	**Le SIDA et l'individu**	
	Les adolescents (partie 2)	409 ABC
	Counseling	411 A
E.	**Le SIDA, la société et le comportement**	
	Problèmes de la communauté gaie	411 B
F.	**Droit et éthique**	
	(Colloque) Infection par le VIH, reproduction et fonction parentale	411 C
G.	**Implications internationales**	
	Prévalence (partie 2)	406 A
	(Atelier) Atelier régional : Asie	406 BC
H.	**Répercussions économiques du SIDA**	
	Impact macroéconomique dans les pays en voie de développement	404 AB

Tuesday June, 6

8:30 - 10:30

"State-Of-The-Art"
Plenary session — Palais des Congrès — 407 ABC

11:00 - 17:30

Audiovisual Presentations — Guy-Favreau Conference Centre

11:00 - 12:30

A.	**Epidemiology and Public Health**	
	(Round table) Partner notification in HIV prevention	407 A
	AIDS surveillance	408 A
	HIV infection in IVDUs	408 BC
B.	**Clinical Aspects of AIDS**	
	(Workshop) PCP Prophylaxis	401 ABC
	AIDS in the developing world	406 A
	(Symposium) HIV therapy	407 B
C.	**Basic Research Biomedical**	
	Virology	403 ABC
	(Symposium) Mechanisms of pathogenesis of human retroviruses	407 C
	Molecular biology; different level of expression of HIV-1 provirus	410 ABC
D.	**AIDS and the Individual**	
	(Symposium) Prisoners: constraints and challenges	409 ABC
	Behavioral research (part 2)	411 A
E.	**AIDS, Society and Behaviour**	
	(Round table) Social Services: Experiences and evaluations	411 B
F.	**Ethics and Law**	
	(Symposium) Confidentiality and its limits	411 C
G.	**International Issues**	
	(Symposium) Cost-effective serodiagnosis	406 BC
H.	**The Economic Impact of AIDS**	
	Planning/Management	404 AB

13:00 - 14:00

Poster Presentations by Authors
(Posters on display throughout the day)

14:00 - 15:30

A.	**Epidemiology and Public Health**	
	Sexual transmission of HIV (part 2)	407 A
	Programme effectiveness and evaluation	408 A
	(Round table) HIV reporting	408 BC
B.	**Clinical Aspects of AIDS**	
	(Round table) Perinatal transmission of HIV	401 ABC
	(Symposium) Pneumocystis Carinii infections	407 B

C.	**Basic Research Biomedical**	
	Pathogenesis (part 3)	403 ABC
	(Symposium) Origins of human retroviruses and animal models	407 C
	Molecular biology: TAT-mediated regulation of viral genes	410 ABC
D.	**AIDS and the Individual**	
	Minorities	409 ABC
	Psychology and sexology	411 A
E.	**AIDS, Society and Behaviour**	
	(Workshop) Empowerment: Reappropriation of health and experience of persons with AIDS	411 B
F.	**Ethics and Law**	
	(Symposium) Clinical ethics	411 C
G.	**International Issues**	
	Risks and prevention	406 A
	(Symposium) Community compassion and care in the developing world	406 BC
H.	**The Economic Impact of AIDS**	
	Costs in developing countries	404 AB

Tuesday, June, 6

16:00 - 17:30

A.	**Epidemiology and Public Health**	
	Natural history of HIV infection: Early manifestation and progression	407 A
	Mathematical models	408 A
	(Symposium) Evaluation of programme effectiveness	408 BC
B.	**Clinical Aspects of AIDS**	
	PCP Treatment	401 ABC
	(Symposium) Laboratory issues in the diagnosis of AIDS	407 B
C.	**Basic Research Biomedical**	
	Virology	403 ABC
	Animal models (part 1)	407 C
	Molecular biology: Regulatory genes and their products	410 ABC
D.	**AIDS and the Individual**	
	Adolescents (part 2)	409 ABC
	Counselling	411 A
E.	**AIDS, Society and Behaviour**	
	The gay community issues	411 B
F.	**Ethics and Law**	
	(Symposium) HIV infection, reproduction and parenthood	411 C
G.	**International Issues**	
	Prevalence (part 2)	406 A
	(Workshop) Regional workshop: Asia	406 BC
H.	**The Economic Impact of AIDS**	
	Macroeconomic impact in developing countries	404 AB

Le mercredi 7 juin

8 h 30 à 10 h 30

« État de la question »
—Plénière — Palais des Congrès — 407 ABC

11 h à 17 h 30

Présentations audiovisuelles — Centre de conférences Guy-Favreau

11 h à 12 h 30

A.	**Épidémiologie et santé publique**	
	Transmission du VIH dans le milieu des soins de la santé	407 A
	(Table ronde) Transmission hétérosexuelle	408 BC
B.	**Aspects cliniques**	
	Pharmacologie et toxicité de l'AZT	401 ABC
	Traitement : thrombocytopénie	403 ABC
	(Colloque) Qualité des soins offerts aux personnes atteintes du SIDA	407 B
C.	**Recherche fondamentale (biomédicale)**	
	(Colloque) Gènes régulateurs et diversité génomique virale	407 C
	Éléments de base en immunologie (partie 1)	408 A
	Biologie moléculaire (partie 2)	410 ABC
D.	**Le SIDA et l'individu**	
	Les femmes	409 ABC
E.	**Le SIDA, la société et le comportement**	
	Rôle des ONG dans la lutte mondiale contre le SIDA	411 A
	La lutte communautaire contre le SIDA dans les années 1990	411 B
F.	**Droit et éthique**	
	(Colloque) Recherche de traitements et de vaccins	411 C
G.	**Implications internationales**	
	Le VIH en pédiatrie	406 A
	(Colloque) Infections parasitaires tropicales : impact du VIH	406 BC
H.	**Répercussions économiques**	
	Rôle des assurances	404 AB

13 h à 14 h

Présentation d'affiches par les auteurs — 100A/100B
(Affiches exposées toute la journée)

14 h à 15 h 30

A.	**Épidémiologie et santé publique**	
	Études séro-épidémiologiques des femmes enceintes	407 A
	Incidence et mortalité du SIDA	408 BC
B.	**Aspects cliniques**	
	Manifestations cliniques	401 ABC
	Hémophilie : histoire clinique et études de cohortes 403 ABC	
	(Colloque) Infection par le VIH : atteintes à certains organes	407 B

C.	**Recherche fondamentale (biomédicale)**	
	(Colloque) Mise au point de vaccins contre le SIDA	407 C
	Mise au point des médicaments : nouvelle approche pour l'étude des médicaments antiviraux	408 A
	Modèles animaux (partie 2)	410 ABC
D.	**Le SIDA et l'individu**	
	(Colloque) Consommateurs de drogues par voie intraveineuse : réalités changeantes et mythes persistants	409 ABC
E.	**Le SIDA, la société et le comportement**	
	Le SIDA en milieu de travail	411 A
	Le SIDA dans les médias	411 B
F.	**Droit et éthique**	
	(Colloque) Prévenir la transmission du VIH : les conflits religieux en matière de santé publique	411 C
G.	**Implications internationales**	
	Perspectives mondiales	406 A
	Transmission hétérosexuelle et rôle des MTS	406 BC
H.	**Répercussions économiques du SIDA**	
	Financement et assurances	404 AB

16 h à 17 h 30

A.	**Épidémiologie et santé publique**	
	L'annonce aux partenaires	407 A
	Test de dépistage du VIH/Questions en matière de politiques et de programmes	408 BC
B.	**Aspects cliniques**	
	Infections associées au SIDA	401 ABC
	Atteintes neuropsychiatriques	403 ABC
	(Colloque) Essais cliniques : points de vue des « acteurs »	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Virologie (partie 3)	407 C
	Éléments de base en immunologie	408 A
	Modèles animaux (partie 3)	410 ABC
D.	**Le SIDA et l'individu**	
	(Colloque) Les femmes dans les pays industrialisés : Questions et options	409 ABC
E.	**Le SIDA, la société et le comportement**	
	Services de pastorale	411 B
F.	**Droit et éthique**	
	(Colloque) Coercition ou volontarisme? Analyse critique internationale	411 C
G.	**Implications internationales**	
	Prévalence (partie 3)	406 A
	(Atelier) Atelier régional : Afrique occidentale	406 BC
	(Colloque) Déplacements internationaux et SIDA	411 A
H.	**Répercussions économiques du SIDA**	
	Méthodologie des analyses de coûts	404 AB

Wednesday June 7

8:30 - 10:30

"State-Of-The-Art"
Plenary session — Palais des Congrès — 407 ABC

11:00 - 17:30

Audiovisual Presentations — Guy-Favreau Conference Centre

11:00 - 12:30

A.	**Epidemiology and Public Health**	
	HIV transmission in the health care setting	407 A
	(Round table) Heterosexual transmission	408 BC
B.	**Clinical Aspects of AIDS**	
	AZT Pharmacology and toxicity	401 ABC
	Therapy: Thrombocytopenia	403 ABC
	(Symposium) Quality of care for patients with AIDS	407 B
C.	**Basic Research Biomedical**	
	(Symposium) Regulatory genes and viral genomic diversity	407 C
	Basic immunology	408 A
	Molecular biology (part 2)	410 ABC
D.	**AIDS and the Individual**	
	Women	409 ABC
E.	**AIDS, Society and Behaviour**	
	The role of NGO in the global response to AIDS	411 A
	The community-based response to AIDS into the 1990s	411 B
F.	**Ethics and Law**	
	(Symposium) Research for treatments and vaccines	411 C
G.	**International Issues**	
	HIV in pediatrics	406 A
	(Symposium) Tropical diseases: the impact of HIV	406 BC
H.	**The Economic Impact of AIDS**	
	The role of insurance	404 AB

13:00 - 14:00

Poster Presentations by Authors
(Posters on display throughout the day)

14:00 - 15:30

A.	**Epidemiology and Public Health**	
	Seroepidemiologic studies: Neonatal	407 A
	AIDS incidence and mortality	408 BC
B.	**Clinical Aspects of AIDS**	
	Clinical manifestations	401 ABC
	Hemophilia: Natural history/cohort studies	403 ABC
	(Symposium) HIV Infection: Organ specific involvement	407 B
C.	**Basic Research Biomedical**	
	(Symposium) Vaccine developments in AIDS	407 C
	Drug development: Novel study approach to anti-viral drugs	408 A

	Animal models (part 2)	410 ABC
D.	**AIDS and the Individual**	
	(Symposium) Injection drug users: Changing realities and persisting myths	409 ABC
E.	**AIDS, Society and Behaviour**	
	AIDS in the workplace	411 A
	AIDS in the media	411 B
F.	**Ethics and Law**	
	(Symposium) Preventing HIV transmission: Religious conflicts in public health	411 C
G.	**International Issues**	
	Global Perspectives	406 A
	Heterosexual transmission and the role of STDs	406 BC
H.	**The Economic Impact of AIDS**	
	Financing and Insurance	404 AB

16:00 - 17:30

A.	**Epidemiology and Public Health**	
	Partner notification	407 A
	HIV testing/policy and programme issues	408 BC
B.	**Clinical Aspects of AIDS**	
	AIDS-related infection	401 ABC
	Neuropsychiatric involvement	403 ABC
	(Symposium) Clinical trials: The "actors'" perspective	407 B
C.	**Basic Research Biomedical**	
	Virology	407 C
	Basic Immunology	408 A
	Animal models (part 3)	410 ABC
D.	**AIDS and the Individual**	
	(Symposium) Women in developed countries: Issues and options	409 ABC
E.	**AIDS, Society and Behaviour**	
	Pastoral care	411 B
F.	**Ethics and Law**	
	(Symposium) Coercion or voluntarism: An international critical review	411 C
G.	**International Issues**	
	Prevalence (part 3)	406 A
	(Workshop) Regional workshop: West Africa	406 BC
	(Symposium) International travel and AIDS: A perspective	411 A
H.	**The Economic Impact of AIDS**	
	Methodology of cost studies	404 AB

Le jeudi 8 juin

8 h 30 à 10 h 30

« Synthèse des plénières » Palais des Congrès 407 ABC

11 h à 17 h 30

Présentations audiovisuelles Centre de conférences Guy-Favreau

11 h à 12 h 30

A.	**Épidémiologie et santé publique**	
	(Table ronde) Contrôle de l'épidémie de VIH	407 A
	(Colloque) Modélisation mathématique	408 A
	Transmission périnatale	408 BC
B.	**Aspects cliniques**	
	Thérapie : la ribavirine et les autres médicaments	401 ABC
	Test de dépistage par réaction en chaîne des polymérases	404 AB
	(Colloque) Infections respiratoires chez les consommateurs de drogues par voie intraveineuse	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Éléments de base en immunologie (partie 3)	403 ABC
	(Colloque) Aspects pathologiques de l'infection par le VIH	407 C
	Mise au point de médicaments : utilisation des molécules CD4 dans le traitement du SIDA	410 ABC
D.	**Le SIDA et l'individu**	
	Consommateurs de drogues par voie intraveineuse (partie 1)	409 ABC
	Prostitution	411 A
E.	**Le SIDA, la société et le comportement**	
	(Atelier) Innovations en matière de prévention et d'éducation au sujet du SIDA	411 B
G.	**Implications internationales**	
	SIDA et tuberculose	406 A
	(Colloque) Recherches sur la sexualité humaine	406 BC
H.	**Répercussions économiques du SIDA**	
	Affectation des ressources et processus décisionnels	411 C

13 h à 14 h

Présentation d'affiches par les auteurs 100A/100B
(Affiches exposées toute la journée)

14 h à 15 h 30

A.	**Épidémiologie et santé publique**	
	(Table ronde) Rôle du dépistage et du counseling dans la prévention du SIDA	407 A
	Questions de méthodologie	408 A
	Transmission sexuelle du VIH (partie 3)	408 BC

B.	**Aspects cliniques**	
	Neurologie	401 ABC
	Les lymphokines	404 AB
	(Colloque) Les problèmes associés au VIH en hémophilie : aujourd'hui et demain	407 B
C.	**Recherche fondamentale (biomédicale)**	
	Mise au point des médicaments : utilisation de l'AZT et d'autres oligonucléotides dans le traitement du SIDA	403 ABC
	Virologie (partie 4)	407 C
	Vaccins : étude de l'immunisation à l'aide des glycoprotéines du VIH	410 ABC
D.	**Le SIDA et l'individu**	
	Consommateurs de drogues par voie intraveineuse (partie 2)	409 ABC
	(Colloque) Les femmes des pays en voie de développement	411 A
E.	**Le SIDA, la société et le comportement**	
	Politiques sociales : expériences et critiques	411 B
G.	**Implications internationales**	
	(Colloque) Les femmes à risque	406 A
	(Colloque) Défis posés par la gestion de programmes	406 BC
	MTS et facteurs de risque	411 C

16 h à 17 h 30

A.	**Épidémiologie et santé publique**	
	Histoire clinique de l'infection par le VIH : progression vers l'infection	407 A
	(Colloque) Infection par le VIH et travailleurs de la santé : questions actuelles	408 BC
	Autres rétrovirus : le HTLV-I	409 ABC
B.	**Aspects cliniques**	
	SIDA et nutrition	401 ABC
	Immunomodulateurs	404 AB
	(Colloque) Pharmacologie des médicaments anti-SIDA	407 B
	VIH-2 et autres rétrovirus	408 A
C.	**Recherche fondamentale (biomédicale)**	
	Oncologie	403 ABC
	(Colloque) Le rôle des macrophages et des lymphocytes comme réservoirs du VIH-1	407 C
	Vaccins : utilisation d'un modèle animal pour l'étude des vaccins anti-VIH	410 ABC
E.	**Le SIDA, la société et le comportement**	
	Dimensions sociales du SIDA	411 B
F.	**Droit et éthique**	
	(Colloque) Discrimination et droit de la personne	411 C
G.	**Implications internationales**	
	Aspects cliniques	406 A
	(Atelier) Atelier régional : Antilles	406 B
	(Atelier) Atelier régional : Amérique latine	406 C
	Le SIDA chez l'enfant	411 A

Thursday June 8

8:30 - 10:30

"Synthesis" Plenary speakers	Palais des Congrès	407 ABC

11:00 - 17:30

Audiovisual Presentations	Guy Favreau Conference Centre

11:00 - 12:30

A.	**Epidemiology and Public Health**	
	(Round table) Monitoring the HIV epidemic	407 A
	(Symposium) Mathematical modelling	408 A
	Perinatal transmission	408 BC
B.	**Clinical Aspects of AIDS**	
	Therapy: Ribavirin and other anti-HIV drugs	401 ABC
	PCR diagnostic test	404 AB
	(Symposium) Respiratory infection in IV drug users	407 B
C.	**Basic Research Biomedical**	
	Basic immunology	403 ABC
	(Symposium) Pathological aspects of HIV infection	407 C
	Drug development: Use of CD-4 molecules in AIDS therapy	410 ABC
D.	**AIDS and the Individual**	
	Injection drug users (part 1)	409 ABC
	Prostitution	411 A
E.	**AIDS, Society and Behaviour**	
	(Workshop) Innovations in AIDS education and prevention	411 B
G.	**International Issues**	
	AIDS and tuberculosis	406 A
	(Symposium) Human sexuality research	406 BC
H.	**The Economic Impact of AIDS**	
	Resource allocation and decision-making	411 C

13:00 - 14:00

Poster Presentations by Authors
(Posters on display throughout the day)

14:00 - 15:30

A.	**Epidemiology and Public Health**	
	(Round table) The role of HIV testing and counselling in AIDS prevention	407 A
	Methodologic issues	408 A
	Sexual transmission of HIV (part 3)	408 BC
B.	**Clinical Aspects of AIDS**	
	Neurology	401 ABC
	Lymphokines	404 AB
	(Symposium) HIV related issues in hemophilia: today and tomorrow	407 B

C.	**Basic Research Biomedical**	
	Drug development: Use of AZT and other oligonucleotides in AIDS therapy	403 ABC
	Virology	407 C
	Vaccines: Immunization study using HIV glycoproteins	410 ABC
D.	**AIDS and the Individual**	
	Injection drug users (part 2)	409 ABC
	(Symposium) Women in developing countries	411 A
E.	**AIDS, Society and Behaviour**	
	Public policy: Experiences and critiques	411 B
G.	**International Issues**	
	(Symposium) Women at risk	406 A
	(Symposium) Challenge of programme management	406 BC
	STD and risk factors	411 C

Thursday, June 8

16:00 - 17:30

A.	**Epidemiology and Public Health**	
	Natural history of HIV infection: Progression to disease	407 A
	(Symposium) HIV infection and the healthcare worker: contemporary issues	408 BC
	Other retroviruses: HTLV-I	409 ABC
B.	**Clinical Aspects of AIDS**	
	Nutrition and AIDS	401 ABC
	Immunomodulators	404 AB
	(Symposium) Pharmacology of anti-AIDS drugs	407 B
	HIV-II and other retroviruses	408 A
C.	**Basic Research Biomedical**	
	Oncology	403 ABC
	(Symposium) Role of macrophages and lymphocytes as reservoirs of HIV-1	407 C
	Vaccines: Use of animal model to study anti-HIV vaccines	410 ABC
E.	**AIDS, Society and Behaviour**	
	Social dimensions of AIDS	411 B
F.	**Ethics and Law**	
	(Symposium) Discrimination and human rights	411 C
G.	**International Issues**	
	Clinical	406 A
	(Workshop) Regional workshop: Caribbean	406 B
	(Workshop) Regional workshop: Latin America	406 C
	Pediatric AIDS	411 A

Le vendredi 9 juin

8 h 30 à 12 h

« Perspectives d'avenir »
—Plénière — Palais des Congrès — 407 ABC

Cérémonie de clôture

Friday June 9

8:30 - 12:00

"Future Prospects"
Plenary session — Palais des Congrès — 407 ABC

Closing Ceremonies

Système de Numérotation

Les présentations de ce programme sont groupées par jour et par section. La numérotation des abrégés indique le jour et la nature des présentations.

Ces numéros renvoient aussi aux abrégés réunis dans le Cahier des abrégés.

Exemple : M.A.O.37

M.	**A.**	**O.**	**37**
Jour de la présentation : M : Lundi T : Mardi W : Mercredi Th : Jeudi F : Vendredi	*Numéro de section :* A, B, C, D, E, F, G, H	Nature de la présentation : O : Exposé P : Affiche	*Numéro de la présentation :* Renvoi au 37 exposé orale de la Section A

Key to Numbering System

The presentations in this program are grouped by day, by section. The numbering system utilized for the abstracts serves to identify the day, type of presentation.

These numbers also refer to the abstracts in the Abstract Volume.

Example : M.A.O.37

M.	**A.**	**O.**	**37**
Day of the presentation: M: Monday T: Tuesday W: Wednesday Th: Thursday F: Friday	*Section number:* A, B, C, D, E, F, G, H	*Type of presentation:* O: Oral P: Poster	*Presentation number:* Refers to the 37th oral presentation in the Section A

Cérémonie d'ouverture

le dimanche 4 juin

Président:

Ivan Head
Président de la Conférence
Président, Centre de recherches pour le développement international

Monsieur Robert Bourassa
Le Premier Ministre du Québec

Dame Nita Barrow
Représentante permanente de la Barbade aux Nations Unies

Kevin Brown
Président émérite
Vancouver Persons with AIDS Society
Canada

Jonathan Mann
Directeur, Programme mondial de lutte contre le SIDA, OMS

Armand Frappier
Fondateur, Institut Armand Frappier
Montréal, Québec
Canada

Le Très Honorable Brian Mulroney
Premier Ministre du Canada

CONFÉRENCIER PRINCIPAL:
Son Excellence Kenneth Kaunda
Président de la République de la Zambie

Opening Ceremony

Sunday June 4

Chairman:

Ivan Head
Conference Chairman
President—International Development Research Centre

Mr. Robert Bourassa
Premier of Quebec

Dame Nita Barrow
Permanent Representative of Barbados at the United Nations

Kevin Brown
Chairman Emeritus
Vancouver Persons with AIDS Society
Canada

Jonathan Mann
Director
Global Programme on AIDS
World Health Organization

Armand Frappier
Founder, Institut Armand Frappier
Montreal, Quebec
Canada

The Right Honourable Brian Mulroney
Prime Minister of Canada

KEYNOTE ADDRESS:
His Excellency Kenneth Kaunda
President of the Republic of Zambia

Lundi
Monday

le lundi 5 juin

Nouvelles Perspectives

Présidents:

Maureen Law
Sous-Ministre
Santé et bien-être social Canada

Donald deGagné
Directeur, Vancouver Persons with AIDS Society
Canada

Conférenciers:

June Callwood
Journaliste
Globe & Mail
Canada

Albert Jacquard
Professeur à l'Université de Genève
Chef du service de génétique
Institut national d'études démographiques
France

Mechai Viravaidya
Fondateur
Population and Community Development Association
Thaïlande

Stephen Joseph
Commissaire de la santé
Ville de New York
Etats-Unis

David Suzuki
Scientifique/Journaliste
Département de zoologie
University of British Columbia
Canada

New Perspectives

Chairpersons:

Maureen Law
Deputy Minister
Health and Welfare Canada

Donald deGagné
Director
Vancouver Persons with AIDS Society
Canada

Plenary speakers:

June Callwood
Columnist
Globe & Mail
Canada

Albert Jacquard
Professor, University of Geneva
Chief, Genetic Services
Institut national d'études
démographiques
France

Mechai Viravaidya
Founder
Population and Community
Development Association
Thailand

Stephen Joseph
Commissioner of Health
New York City
U.S.A.

David Suzuki
Scientist/Broadcaster
Department of Zoology
University of British Columbia
Canada

11:00 - 12:30

Salle / Room **407A**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique **Études séro-épidémiologiques: États-Unis**

Specialty Session **Seroepidemiologic Studies: United States**

Présidents / Chairpersons
J. Borgano (Chile)
Gary Noble (U.S.A.)
Stan Vermund (U.S.A.)

11:00 **M.A.O.1** HIV Seroconversion Rate in a Serially-tested Population of Young Adults in the United States (1987-1988). *John G. McNeil*, Z. F. Wann**, D. S. Burke*, J. F. Brundage*, *Walter Reed Army Institute of Research, Washington, DC; **SRA Technologies, Alexandria, VA, U.S.A.*

11:15 **M.A.O.2** Sentinel Hospital Surveillance for HIV Infection in the United States: Early Cross-Sectional Findings. *Michael E. St. Louis, K. J. Rauch, C. R. White, J. E. Anderson, T. J. Dondero, the Sentinel Hospital Investigation Group, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:30 **M.A.O.3** Epidemiology of HIV Infection in Active Duty Army Men at No Identified Risk (NIR). *Philip O. Renzullo*, J. G. McNeil*, J. R. Bunin**, J. F. Brundage*, *Walter Reed Army Institute of Research, Washington, DC; **AIDS Program, NIAID, Rockville, MD, U.S.A.*

11:45 **M.A.O.4** Evaluation of the Estimated Number of HIV Infections Using a Spreadsheet Model and Empirical Data. *Timothy J. Dondero, M. St. Louis, J. Anderson, L. Petersen, M. Pappaioanou, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

12:00 **M.A.O.5** Measuring Levels and Trends of HIV Infection in the General Population by Monitoring HIV Seroprevalence in Primary Care Outpatients. *Lyle R. Petersen*, T. J. Dondero*, R. Engel**, N. Herring**, *Centers for Disease Control, Atlanta, GA; **Damon Clinical Laboratories, Needham Heights, MA, U.S.A.*

12:15 **M.A.O.6** Prevalence and Estimated Incidence Rates of HIV Infection among Civilian Applicants for US Military Service: Current Status and Trends. *John F. Brundage*, L. Gardner*, D. Burke*, J. McNeil*, R. Visintine**, M. Goldenbaum*, et al., *Walter Reed Army Institute of Research, Washington, DC; **U.S. Military Entrance Processing Command, North Chicago, IL, U.S.A.*

11:00 - 12:30

Salle / Room **408A**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **SIDA/VIH : le sang et les produits sanguins / AIDS/HIV: Blood and Blood Products**

Présidents / Chairpersons: Pier M. Manucci (Italy); Cladd E. Stevens (U.S.A.); V. I. Pokrovsky (USSR)

11:00 **M.A.O.7** Transfusion-associated AIDS Cases in Europe. *Angela M. Downs*, R. A. Ancelle-Park*, J. B. Brunet*, and national surveillance correspondents of 31 countries, *WHO Collaborating Centre on AIDS, Paris, France.*

11:15 **M.A.O.8** The Epidemiology of Transfusion-associated (TA) AIDS in the United States. *John W. Ward*, R. Reisler**, J. Karon**, *AIDS Program, Centers for Disease Control, Atlanta, GA; **Columbia School of Public Health, New York, NY, U.S.A.*

11:30 **M.A.O.9** Blood and Plasma Donations among a Cohort of IV Drug Users. *Kenrad E. Nelson, D. Vlahov, J. Margolick, M. Bernal, The ALIVE Study, Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A.*

11:45 **M.A.O.10** Prospective Evaluation of Contemporary Screened Blood Donors for Occult HIV Infection. *Michael P. Busch*/**, B. Eble*, P. Ulrich*, Z. ElAmad**, H. Perkins*/**, G. Vyas*, *University of California at San Francisco; **Irwin Memorial Blood Centers, San Francisco, CA, U.S.A.*

12:00 **M.A.O.11** Routine 6-Month Monitoring for Blood Transmitted HIV Infection. *Anna Giovanetti, F. Mozzi, A. Bellobuono, L. Vianello, A. Zanella, G. Sirchia, et al., Centro Transfusionale e di Immunologia dei Trapianti, Ospedale Policlinico, Milan, Italy.*

12:15 **M.A.O.12** No Late Seroconverters among HIV-negative Patients at Bonn Hemophiliac Center. *Bernd S. Kamps*, D. Niese*, H. H. Brackmann**, P. Euler**, B. van Loo**, T. Kamradt***, *Universitätsklinik Bonn; **Institut für experimentelle Hämatologie, Bonn, Federal Republic of Germany; ***Massachusetts Institutes of Technology, Cambridge, MA, U.S.A.*

11:00 - 12:30

Salle / Room **408BC**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Autres rétrovirus : VIH-2 et HTLV-I/II** / **Other retroviruses: HIV-2 and HTLV I/II**

Présidents / Chairpersons: C. Attende (Gabon); Roy W. Stevens (U.S.A.); Gaetano Giraldo (Italy)

11:00 **M.A.O.13** Observations on the Natural History of HIV-2. *Richard G. Marlink*, I. Thior**, T. Siby**, I. Ndoye**, P. Kanki*, I. Romieu*, et al., *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.; **University of Dakar and the National Center for STD, Dakar, Senegal.*

11:15 **M.A.O.14** HTLV-I, HIV-1 and HIV-2 Seroprevalences in Guadeloupe, French West Indies. *Gérard Agius*, V. Vaillant*, G. Dindinaud*, M. Bazillou*, J. F. Zagury**, M. Castets*, *CHU La Milétrie, Poitiers; **Université Curie, Paris, France.*

11:30 **M.A.O.15** Epidemiology of HIV-2 in Female Prostitutes in Senegal. *Phyllis J. Kanki*, S. M'Boup**, I. Romieu*, R. Marlink*, T. Siby**, M. Essex*, et al., *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.; **University of Dakar, Dakar, Senegal.*

11:45 **M.A.O.16** Séroprévalence du virus HTLV-I dans la population générale de 6 pays d'Afrique centrale. *Eric Delaporte*, M. P. Peeters*, J. P. Durand**, P. Porte***, J. Audoin***, R. Josse****, *Centre International de recherches médicales, Franceville, Gabon; **Centre Pasteur, Cameroon; ***Hôpitaux Elf Pointe Noire, Congo, Elf Luanda, Angola; ****OCEAC Yaoundé, Cameroon.*

12:00 **M.A.O.17** HIV 1 and HTLV-I Antibody Prevalence in a U.S. Population Survey: NHANES-II. *Carl Saxinger, G. McQuillan, W. Haddon, R. Murphy, A. Bodner, R. Gallo, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

12:15 **M.A.O.18** Human Immunodeficiency (HIV) and Human T-Lymphotropic (HTLV-I/II) Viruses in Childbearing Women: Tests of 24,569 Consecutive Newborns. *Roy W. Stevens, J. A. Wethers, D. S. Berns, K. G. Pass, New York State Department of Health, Albany, NY, U.S.A.*

11:00 - 12:30

Salle
Room **401ABC**

Section
B

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Le VIH chez les enfants**
Specialty Session **HIV in Children**

Présidents
Chairpersons
Claude Griscelli (France)
E. Mworosi (Uganda)
Gwendolyn Scott (U.S.A.)

11:00 **M.B.O.1** HIV-related Symptoms in Children Born to HIV-positive Mothers: Results from the European Collaborative Study. *Catherine Peckham, European Collaborative Study, Department of Paediatric Epidemiology, Institute of Child Health, London, U.K.*

11:15 **M.B.O.2** Natural History of Infants Born to HIV-positive Women. *Anne Willoughby*, H. Mendez**, J. Goedert*, M. Berthaud**, G. Moroso**, A. Sunderland**, et al., *PAMA Branch, CRMC, NICHD, Bethesda, MD; **State University of New York at Brooklyn Health Science Center, Brooklyn NY, U.S.A.*

11:30 **M.B.O.3** Prospective Study of Infants Born to Mothers Seropositive to HIV-1: French HIV in Newborn Study Group. *S. Blanche*, F. Verber, M. J. Mayaux, C. Rouzioux, A. M. Duliège, M. L. Moscato, et al., France.*

11:45 **M.B.O.4** Prospective Evaluation of Immune Function in Infants Born to HIV-seropositive Mothers. *Martha F. Rogers, NYC Perinatal HIV Transmission Collaborative Study Group, Centers for Disease Control, CID/AIDS Program, Atlanta, GA, U.S.A.*

12:00 **M.B.O.5** Predictive Value of Beta 2 Microglobulin Level in Serum from Children Born to HIV Infected Mothers. *Hugo Di Maria*, M. E. Toubert****, M. H. Schlageter****, D. Dormont**/***, G. Lasfargues*, C. Courpotin*, *Hôpital Trousseau; **CRSSA, Fontenay aux Roses; ***Institut Pasteur; ****Hôpital Saint Louis, Paris, France.*

12:15 **M.B.O.6** HIV-1 DNA Detection by PCR for Studies on Perinatal HIV Transmission in Africa. *Patricia Paterlini*, S. Lallemant-Lecoeur**, M. Lallemant***, P. M'Pelé*****, B. Larouze**, C. Bréchot*/**** and Research Group on Perinatal HIV-1 Infection in Congo,*INSERM U75, CHU Necker, Paris; U13/IMEA Claude Bernard, Paris, France; ***ORSTOM, Bondy; ****Hybridotest, Institut Pasteur, Paris, France; *****Programme National de lutte contre le SIDA (PNLS), Congo.*

11:00 - 12:30

Salle / Room **403ABC**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Table ronde / Round Table

Coordination des soins : le point de vue du personnel infirmier
Coordinating Care: Nurses' Perspectives

Présidents / Chairpersons: Joan Bennett (U.S.A.), Diane Lalande (Canada)

11:00 **M.B.O.7** An Interdisciplinary Approach to AIDS Care: St. Paul's Experience. *Irene Goldstone, St. Paul's Hospital, Vancouver, BC, Canada.*

11:15 **M.B.O.8** The Impact of AIDS on Families of Hemophiliacs in Wales. *Jackie Beese, School of Nursing Studies, Cardiff, U.K.*

11:30 **M.B.O.9** The Challenge Facing Nursing in Central Africa. *Olive Kopolo, University Teaching Hospital, Lusaka, Zambia.*

11:45 **M.B.O.10** A Comparison of the Projected Nursing Care Needs of Hospitalized AIDS and Non-AIDS Patients. *Lidia Ivanus, Royal Victoria Hospital, Montreal, QC, Canada.*

12:00 **M.B.O.11** Home Needs (Care for AIDS Patients). *Pat Maynard, St. Elizabeth Nursing Home, Don Mills, ON, Canada.*

11:00 - 12:30

Salle / Room **407B**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Colloque / Symposium

Les infections à *Pneumocystis carinii*
Pneumocystis Carinii Infections

Présidents / Chairpersons: John Mill (U.S.A.)
Richard A. Morisset (Canada)

11:00 **M.B.O.12** Changing Pattern of *Pneumocystis Carinii* Infections. *Phil Hopewell, San Francisco General Hospital, San Francisco, CA, U.S.A.*

11:15 **M.B.O.13** Animal Models of *Pneumocystis Carinii* Pneumonia. *Sherry F. Queener, Indiana University School of Medicine, IN, U.S.A.*

11:30 **M.B.O.14** Treatment of *Pneumocystis Carinii* Infections: Antimicrobials. *Emil Toma, Hôtel-Dieu de Montréal and Université de Montréal, Montreal, QC, U.S.A.*

11:45 **M.B.O.15** New Developments in the Treatment and Prophylaxis of PCP. *Julio Montaner, St Paul's Hospital, Vancouver, BC, Canada.*

11:00 - 12:30

Salle / Room **407C**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium **Mécanismes de la Pathogenèse du VIH**
Mechanisms of Pathogenesis of HIV

Présidents / Chairpersons Ten Feizi (U.K.)
Jay A. Levy (U.S.A.)

11:00 **M.C.O.1** Viral and Host Factors Influencing the Progression to AIDS. *Jay A. Levy*, C. Cheng-Mayer, C. Walker, J. Homsy, *University of California at San Francisco, Department of Medicine, San Francisco, CA, U.K.*

11:15 **M.C.O.2** Immune Responses to HIV. *John Sullivan, University of Massachusetts, Department of Pediatrics, Boston, MA, U.S.A.*

11:30 **M.C.O.3** Role of N-Linked Glycosylations in HIV Infection. *Jean-Claude Gluckman*, E. Fenouillet*, L. Gattegno**, B. Clerget-Raslain*, L. Montagnier***, E. Bahroui***, *CERVI, Hôpital de la Pitié-Salpêtrière, Paris; **Laboratoire de Biologie Cellulaire, Faculté de Médecine Paris-Nord; ***Unité d'Oncologie Virale, Institut Pasteur, Paris, France.*

11:45 **M.C.O.4** New Approach to the Study of Oligosaccharides as Determinants of the Tissue Tropisms of HIV-1. *Ten Feizi*, *MRC Clinical Research Centre, Harrow, U.K.*

11:00 - 12:30

Salle / Room **410ABC**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (Biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Biologie moléculaire (partie 1) : diversité génomique et ses liens aux aspects cliniques / Molecular Biology: Genomic diversity and Relationship to Clinical Aspects**

Présidents / Chairpersons: M. Hayami (Japan), Louis F. Qualtière (Canada), Pierre Sonigo (France)

11:00 **M.C.O.5** Genetic Analysis of SIV Derived from Mandrill (SIV-MND). *Masanori Hayami*, H. Tsujimoto**, A. Hasegawa***, R. W. Cooper****, M. Fukasawa**, T. Miura*, et al., *Institute for Virus Research, Kyoto University, Kyoto; **Institute of Medical Science, University of Tokyo, Tokyo; ***Toa Nenryo Kogyo K. K., Japan; ****Centre International de recherches médicales de Franceville, Gabon.*

11:15 **M.C.O.6** Genomic Diversity of SIVAGM Group of Virus. *Yoshihiro Ohta*, M. Fukasawa*, J. Sakuragi**, K. Miki***, M. Isahakia****, M. Hayami**, et al., *Institute of Medical Science, University of Tokyo, Tokyo; **Institute for Virus Research, Kyoto University, Kyoto; ***Toa Nenryo Kogyo, Japan; ****Institute of Primate Research, National Museums of Kenya, Kenya.*

11:30 **M.C.O.7** Prospective Clinical, Immunological, and Virologic Follow-up of an Infected Lab Worker (LW). *W. Blattner*, P. Nara*, G. Shaw**, B. Hahn**, L. Kong**, T. Matthews***, D. Bolognesi***, D. Waters****, R. Gallo*, *National Cancer Institute, Bethesda, MD; **University of Alabama, Birmingham, AL; ***Duke University, Durham, NC; ****PRI, Frederick, MD, U.S.A.*

→

11:45 **M.C.O.8** Evolution of the Biological Phenotype of Sequential Human Immunodeficiency Virus (HIV) Isolates in Seroconverting Homosexual Men. *Matthijs Tersmette*, R. E. Y. De Goede*, F. De Wolf**, J. Goudsmit**, J. G. Huisman*, F. Miedema*, *Central Laboratory Netherlands Red Cross Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, University of Amsterdam; **Academic Medical Centre, Amsterdam, Netherlands.*

12:00 **M.C.O.9** Replicative Capacity of Sequential Virus Isolates from HIV-1 Infected Subjects and Relationship to Clinical Progression. *Eva M. Fenyö*, J. Albert**, L. Morfeldt-Manson*, B. Asjo*, *Karolinska Institute, Department of Virology; **National Bacteriological Laboratory, Stockholm, Sweden.*

12:15 **M.C.O.10** CD4+ T Lymphocytes from the Peripheral Blood Mononuclear Cells (PBMC) of Healthy Seropositive Individuals Harbor the HIV-1 Proviral Sequences. *Miltiades Psallidopoulos*, S. Schnittman**, M. Baseler***, A. S. Fauci**, C. H. Lane**, N. P. Salzman*; *School of Medicine, Georgetown University, Washington, DC; **NIAID, National Institutes of Health, MD; ***PRI, Frederick, MD, U.S.A.*

11:00 - 12:30

Salle / Room **409ABC**



Section **D**

Lundi 5 juin
Monday, June 5

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Recherches sur le comportement (partie 1)**

Specialty Session **Behavioural Research (Part 1)**

Présidents / Chairpersons: Michel Careal (Switzerland), M. Kobue (Botswana), Sheena Lee (Canada)

11:00 **M.D.O.1** Population Prevalence of AIDS High Risk Behaviors in France, the United Kingdom and the United States. *James A. Wells*, G. R. Wilensky*, A.-J. Valleron**, G. Bond***, R. L. Sell*, P. De Filippes*, *Project HOPE Center for Health Affairs, Washington, DC, U.S.A.; **Université Paris, Paris, France; Central Office of Information, London, U.K.*

11:15 **M.D.O.2** Behavioral Determinants of Blood Donations among HIV-Seropositive Persons: A Multi-Center Study. *Lynda S. Doll*, HIV Blood Donor Study Group**, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.; **Investigators from 20 blood donation sites throughout the U.S.A.*

11:30 **M.D.O.3** Sexual Behavior and Behavior Changes in Kinshasa: Implications for AIDS Counselling. *Melinda Moore*/**, A. Doppagne***, S. E. Hassig*/**, L. Piripiri*, W. E. Bertrand*/**, T. D. Kashala*, *Zaire School of Public Health, Kinshasa, Zaire; **Tulane SPHTM, New Orleans, LA, U.S.A.; ***Banque Commerciale Zaïre, Kinshasa, Zaire.*

11:45 **M.D.O.4** An Ethnographic Survey of Nonpenetrative Sexual Behaviour. *Glen E. Margo*, B. Porter**, C. M. Cassidy**, D. Feldman**, *Academy for Educational Development, AIDSCOM, Washington, DC; Porter Novelli, Washington, DC, U.S.A.*

12:00 **M.D.O.5** Compliance with AIDS Prevention Measures among Intravenous Drug Users: Health Beliefs or Social/Environmental Factors? *Karen H. C. Huang*/**/***, J. Watters**/***, P. Case***, *Stanford University, Palo Alto; **University of California at San Francisco; ***Urban Health Study, San Francisco, CA, U.S.A.*

12:15 **M.D.O.6** The National Survey of Health and Sexual Behavior: The Pretest Experience. *Marcie L. Cynamon, National Center for Health Statistics, Department of Health and Human Services, Hyattsville, MD, U.S.A.*

11:00 - 12:30

Salle
Room **411A**



Section
E

Lundi 5 juin
Monday, June 5

Le SIDA, la societé et le comportement
AIDS, Society and Behaviour

Colloque / Symposium

Vivre avec le SIDA: les points de vue de personnes atteintes
Living with AIDS: A Person with AIDS Perspective

Présidents / Chairpersons: Michel Callen (U.S.A.), Pierre Luc Delorme (Canada)

11:00	**M.E.O.1**	Women's Issues. *Amanda Heggs, Positive Women's Group, Copenhagen, Denmark.*
11:10	**M.E.O.2**	Children's Issues. *Barbara Chimness, Childkind, U.S.A.*
11:20	**M.E.O.3**	Women's Issues. *Belinda Maison, National Association of PWAs, United States.*
11:30	**M.E.O.4**	Hemophilia. *Rogerio Fiaro Guimares, Brazilian Interdisciplinary AIDS Association, Brazil.*
11:40	**M.E.O.5**	AIDS in the Caribbean. *Godfrey Sealy, Community Action Resource, Trinidad and Tobago.*
11:50	**M.E.O.6**	Homophobia and Africa. *Peter Ssebbenja, Uganda.*
12:00	**M.E.O.6a**	Isolation of PWAs/Media Relations. *Hassan Bangura, National AIDS Committee, Sierra Leone.*

11:00 - 12:30

Salle / Room **411B**



Section **E**

Lundi 5 juin
Monday, June 5

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Atelier / Workshop

Éducation-SIDA : leçons à tirer des pays en voie de développement
AIDS Education: Lessons from Developing Countries

Présidents / Chairpersons
Ousmane Diouf (Senegal)
Lair Rodrigues (Argentina)
Sheldon Shaeffer (Canada)

11:00 **M.E.O.7** Planification d'un programme d'information et d'éducation pour la prévention du risque d'infection VIH à partir d'une enquête C.A.P. *Ousmane Diouf, I. Ndoye, A. Petitgirard, Centre National d'éducation pour la santé, Dakar, Senegal.*

11:15 **M.E.O.8** The Role of Health Education in Prevention of AIDS (Uganda's Experience). *Jonathan K. Gaifuba, A. B. Amana, Ministry of Health, Uganda.*

11:30 **M.E.O.9** Street Teenagers and an AIDS Prevention Program in Brazil. *Flavio Braune Wiik*, A. Filguerias**, M. L. Castro***, *Brazilian Interdiscplinary AIDS Association (ABIA); **S.O.S. Child; ***Street kids' educator, Rio de Janeiro, Brazil.*

11:45 **M.E.O.10** AIDS Education for Young People in a Multilingual Society. *Soulemayne M'Boup*, A. Sow**, P. G. Sow**, M. M'Diaye**, M. M'Diaye***, et al., *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A., Université de Dakar; **Association Jeunesse Anti-SIDA et MST; ***Ministry of Health, Dakar, Senegal.*

12:00 **M.E.O.11** The Gaga Baptism of the Condom: Folklore and Religion as Adjuncts of AIDS Prevalence among Haitian Migrant Agricultural Workers in the Dominion Republic. *Nelson Didiez, M. Arbaje, S. Rosario, E. Guerrero, R. A. De Moya, I. Troncoso, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

12:15 **M.E.O.12** Lessons Learned from Family Planning Communication Programs. *Phyllis T. Piotrow, P. Coleman, L. Liskin, Center for Community Programs, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

11:00 - 12:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Lundi 5 juin
Monday, June 5

Colloque / Symposium: **Vue d'ensemble de la législation sur le SIDA** / **Global Survey of AIDS Legislation**

Présidents / Chairpersons: Sev Fluss (Switzerland), Manon Pomerleau (Canada)

11:00 **M.F.O.1** The Human Rights Context of AIDS Law. *Justice Michael Kirby, Court of Appeal, Supreme Court of Australia, Sydney, Australia.*

11:15 **M.F.O.2** Implementing HIV/AIDS Legislative Policy Focusing on Ethical Issues in a National Health Care System. *Marvelu R. Peterson, S. H. Mather, E. Shelp, L. N. Stout, S. K. Sverha, R. A. Allen, Department of Veterans Affairs, Washington, DC, U.S.A.*

11:25 **M.F.O.3** State AIDS Legislative and Policy Trends: 1983-1988. *Mona J. Rowe, D. M. Merritt, C. C. Ryan, B. Bridgeham, I. Bowleg, AIDS Policy Center, Intergovernmental Health Policy Project, Washington, DC, U.S.A.*

11:35 **M.F.O.4** The Limits and Prospects of AIDS Legislation in Anglophone Africa. *Akwasi Aidoo, IDRC Fann, Dakar, Senegal.*

11:45 **M.F.O.5** AIDS in Court: Important Quebec Developments. *Louis Letellier de St-Just, Maison Chaboillez, Longueuil, QC, Canada.*

12:00 **M.F.O.6** A Global Survey of AIDS Legislation. *Larry Gostin, Harvard School of Public Health, Boston, MA, U.S.A.*

12:15 **M.F.O.7** A Global Survey of AIDS Legislation. *William Curran, Harvard School of Public Health, Boston, MA, U.S.A.*

11:00 - 12:30

Salle / Room **406A**

Section **G**

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Séance thématique **Le sérodiagnostic**
Speciality Session **Serodiagnosis**

Présidents / Chairpersons: Jeckonia O. Ndinya-Achola (Kenya)
Don E. Savigny (Canada)
Gary Slutkin (Switzerland)

11:00 **M.G.O.1** Evaluation of the Program of Prevention and Control of Blood Transmission of HIV in Mexico. *Jaime Sepulveda*, M. L. Garcia*, J. L. Dominguez**, J. L. Valdespino*, *Directorate of Epidemiology, Ministry of Health; **National Center of Blood Transfusion, Mexico City, Mexico.*

11:15 **M.G.O.2** A Regional Perspective of HIV Antibody Testing in the Americas. *Michael V. O'Shaughnessy*, J. Finlay*, A. Meltzer*, R. St-John**, F. Zacarias**, N. Ritchie*, *Federal Centre for AIDS; **Health and Welfare Canada, Ottawa, ON, Canada.*

11:30 **M.G.O.3** Determination of HIV-1 Sero-prevalence in a Cohort of 8000 Individuals in Kinshasa, Zaire Using Pooled Sera Compared to Testing of Individual Sera. *Frieda Behets*, M. Kasai*, M. Ndilu*, C. Brown*, R. Ryder*, T. C. Quinn**, *Projet SIDA, Kinshasa, Zaire; **National Institutes of Health, NIAID, Bethesda, MD, U.S.A.*

11:45 **M.G.O.4** A Simple, Rapid, Practical HIV Screening Assay for Developing Country Manufacturing and Use. *Barbara A. Schaeffler, M. Herrick, M. Coulter, F. Spielberg, M. Tam, Program for Appropriate Technology in Health (PATH), Seattle, WA, U.S.A.*

12:00 **M.G.O.5** The Use of Dilution Techniques in Screening for HIV-1 and -2 Antibodies in West Africa. *Andrew S. B. Hughes*, R. Njie*, K. Manneh*, B. Oelman**, M. K. Cham***, R. S. Tedder****, *Royal Victoria Hospital; **Epidemiology and Statistics Unit; ***Medical and Health Department, Banjul, The Gambia; ****Middlesex Hospital, London, U.K.*

12:15 **M.G.O.6** Pooling of Sera to Reduce Costs of HIV-Antibody Screening in Blood Bank Donors from Bogota, Colombia, South America. *Jorge Boshell*, M. Garcia**, L. S. Jaramillo*, M. V. Florez**, M. Guzman*, *Virus Laboratory, Instituto Nacional de Salud; **Red Cross National Bank, Bogota, Colombia.*

11:00 - 12:30

Salle / Room **406BC**

Section **G**

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Colloque / Symposium **Aspects culturels et sociaux de la sexualité / Cultural and Social Perspectives of Sexuality**

Présidents / Chairpersons: Iona Campagnolo (Canada), Elizabeth Ngugi (Kenya)

11:00 **M.G.O.7** Culture, Sex and Science: Anthropological Perspectives for AIDS Prevention and Care. *Barbara O. de Zalduondo, Harvard School of Public Health, Boston, MA, U.S.A.*

11:10 **M.G.O.8** Cultural, Sexual and Social Perspectives of AIDS in Brazil. *Arletty Pinel, Centro de Referência e Treinamento AIDS, Sao Paulo, Brazil.*

11:20 **M.G.O.9** Adolescent Sexuality in Europe. *L. Slikkerveer, Institute of Culture and Social Studies, University of Leiden, Leiden, The Netherlands.*

11:30 **M.G.O.10** AIDS and the South African Culture. *Musa Zazayokwe, South African Institute for Medical Research, Johannesburg, South Africa.*

11:40 **M.G.O.11** Sexuality in Africa: The Role of Cultural Beliefs and Behaviour. *V. N. Kimani, Department of Community Health, University of Nairobi, Nairobi, Kenya.*

11:50 **M.G.O.12** Cultural Determinants of Sexuality in the Sudan. *L. Asma, University of Khartoum, Faculty of Medicine, Khartoum, Sudan.*

12:00 **M.G.O.12a** Summation. *Iona Campagnolo, McMaster Centre for International Health, Hamilton, ON, Canada.*

11:00 - 12:30

Salle / Room **404AB**

Section **H**

Lundi 5 juin
Monday, June 5

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique **Aperçu et coûts de la prévention et de l'éducation**

Speciality Session **Overview Plus Costs of Prevention and Education**

Présidents / Chairpersons: Nick Drager (Switzerland), Margaret Duckett (Canada)

11:00 **M.H.O.1** Overview. *Margaret Duckett, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

11:15 **M.H.O.2** Cost of Medium-Term AIDS Prevention and Control Programmes in Sub-Saharan Africa. *Nick Drager*, L. Collis**, D. Tarantola*, J. L. Lamboray**, U. Camen***, M. Phillips****, et al., *World Health Organization, Geneva, Switzerland; **World Bank, Washington, DC, U.S.A.; ***University of Geneva, Geneva, Switzerland, ****London School of Hygiene and Tropical Medicine, London, U.K.*

11:30 **M.H.O.3** Costs of AIDS Education. *Harvey Fineberg, Harvard School of Public Health, Boston, MA, U.S.A.*

11:45 **M.H.O.4** HIV Screening among Potential Immigrants: A Cost/Benefit Analysis. *Hanna Zowall*, N. Gilmore*, R. D. Fraser**, A. Deutsch*, S. A. Grover*, *Division of Clinical Epidemiology, Montreal General Hospital, Montreal, QC; **Queen's University, Kingston, ON, Canada.*

12:00 **M.H.O.5** Cost-effectiveness of HIV Screening among Pregnant Women in Paris Hospitals. *Catherine Le Galès*, J. P. Moatti*, Collectif Paris-Tours d'étude de la transmission HIV périnatale ("Paris-Tours" Study Group on Perinatal Transmission HIV); *INSERM Research U240, Fontenay-aux-Roses, France.*

12:15 **M.H.O.6** The Role of Community Based Organizations in Containing the Costs of the AIDS Epidemic. *M. Smith, Hospital of the University of Pennsylvania, Pittsburg, PA, U.S.A.*

11:00 - 12:30

Cinéma de l'ONF, Complexe Guy Favreau
NFB Cinema, Complexe Guy



Section
I

Session vidéo
Video session

Le Counseling
Counselling

Lundi 5 juin
Monday, June 5

11:00 Introduction: *Ken Morrison*

11:10 **M.I.V.1** ***"TALKING ABOUT AIDS"***

Vidéo de/Video by:
British Medical Association
Foundation for AIDS
Année/Year: 1988

11:33 **M.I.V.2** ***"PRE AND POST HIV TEST"***
(en français, Rwanda), (in French, Rwanda)

Vidéo de/Video by:
Suzan Muska
Norwegian Red Cross
Année/Year: 1989

Le counseling est devenu un élément capital dans les traitements médicaux ou le dépistage d'anticorps reliés au SIDA. L'intervenant doit aider les personnes atteintes à comprendre l'infection par le VIH, ses modes de transmission et ses possibilités de traitement; il doit aussi les aider à faire face à leur situation tout en abordant les problèmes de la confidentialité, des droits, des responsabilités et du consentement éclairé. Ces deux films vidéo destinés à la formation de consultants (le premier en anglais, le deuxième en français) ont été choisis parmi plusieurs autres propositions sur le sujet.

Counselling has become a vital element in AIDS-related medical treatment or antibody testing. As well as helping people understand HIV infection, transmission routes and treatment possibilities, the care provider must help people to cope with their situation while addressing issues such as confidentiality, rights, responsibilities and informed consent. These two videos for counsellor training (the first in English, the second in French) were chosen from many submissions on the subject.

12:45 - 13:45

Salle / Room **409ABC**



Section I

Lundi 5 juin
Monday, June 5

Aspects audio-visuels
Audio-Visual Aspects

Sessions du midi / Noon Hour Sessions

L'histoire : Qu'avons-nous appris? / History Teaches: What have we learned?

Présidents / Chairpersons: Myron Eckenberg (Canada), Sorin Sonea (Canada)

12:45 Introduction.
M. Eckenberg, Canada

12:50 L'histoire d'une année de peste en Italie (1630): imaginaire et comportements sociaux/History of a plague year in Italy (1630): imaginary and social behaviours. *Guila Calvi, Université de Sienne, Florence, Italie/Sienna University, Florence, Italy.*

13:00 L'aspect culturel de la tuberculose et son impact sur les efforts pour contrôler la maladie en Afrique du Sud./Cultural construction of tuberculosis and its impact on efforts to control it within South Africa. *Randal M. Packard, Université de Tufts, États-Unis/Tufts University, U.S.A.*

13:10 La peur devant l'autre, condamné et damné: Leçons de l'histoire./Fear in the face of the other, condemned and damned: Lessons from history. *Mikael Elbaz, Université Laval, Québec, Canada/Laval University, Quebec, Canada* and *Ruth Murbach, Université du Québec à Montréal, Canada/University of Quebec, Montreal, Canada.(D*

13:20 L'expansion biologique de l'Europe: quelques réflexions./The biological expansion of Europe: Some reflections. *Alfred Crosby, Jr., Université du Texas, Austin, Texas, États-Unis/University of Texas, Austin, Texas, U.S.A.*

13:30 Le SIDA comme maladie post-moderne: Entre la biologie et la société, entre le passé et le présent./AIDS as a postmodern illness: Between biology and society, between past and present. *Mirko D. Grmek, Ecole Pratique des Hautes Études, Paris, France.*

Suite à la lecture de quelques pages de leur oeuvres récentes, des auteurs reconnus de l'histoire de la médecine parleront de leur, travaux ainsi que des leçons qu'on peut en tirer en relation avec le SIDA.

Following dramatic readings from recent works by several internationally-respected authors of medical history, the authors talk about their works, what it has taught us, and applications to our contemporary dilemma around AIDS.

14:00 - 15:30

Salle
Room **407A**



Section
A

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde

Évolution des politiques préventives en matière de santé publique : Où nous sommes-nous mépris? Où allons-nous?

Round Table

Analysis of Public Health Policy for the Prevention of AIDS: Where Have We Gone Wrong? Where Do We Go from Here?

Présidents
Chairpersons

Donald P. Francis (U.S.A.)
Bertino Somaini (Switzerland)

14:00 **M.A.O.19**

Program Content:

- Public health decision-making in a difficult political environment
- Are currently HIV prevention policies rational? clear?
- Policies that have failed
- Policies that have succeeded
- Lessons for future policy development

Panelists:

Randy Shilts, San Francisco, CA, U.S.A.
Ronald Bayer, New York, NY, U.S.A.
John K. Watters, San Francisco, CA, U.S.A.
Additional speaker, to be announced

14:00 - 15:30

Salle / Room **408A**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique **Tests de dépistage du VIH dans les cliniques de MTS**

Specialty Session **HIV Testing in STD Clinics**

Présidents / Chairpersons: N. N. Agata (Kenya), Ronald St-John (U.S.A.), Henrick Zoffman (Denmark)

14:00 **M.A.O.20** Seroprevalence of HIV among Clients Attending Sexually Transmitted Disease (STD) Clinics in the U.S. *Eugene McCray, I. M. Onorato, P. A. Sweeney, AIDS Program, HIV Seroepidemiology Branch (MS-G29), Centers for Disease Control, Atlanta, GA, U.S.A.*

14:15 **M.A.O.21** Surveillance of HIV Infection Using a Network of Sentinel Physicians: A Pilot Project in the Province of Quebec. *Michel Alary, J. Castel, Hôpital du Saint-Sacrement, Département de Santé Communautaire, Québec, QC, Canada.*

14:30 **M.A.O.22** HIV-infected STD Clients Who Decline HIV Counseling and Testing. *David W. Fleming*, D. Bennett*, R. Klockner*, J. Gould*, D. Cassidy**, L. Foster*, *Oregon Health Division; **Multnomah County Health Division, Portland, OR, U.S.A.*

14:45 **M.A.O.23** HIV-1 Seroprevalence in Sexually Transmitted Disease (STD) Clinic Patients in Central North Carolina. *Suzanne E. Landis*, V. J. Schoenbach*, D. J. Weber*, M. Mittal*, G. G. Koch*, P. H. Levine**, *University of North Carolina, School of Public Health, Department of Epidemiology, Chapel Hill, NC; **National Cancer Institute, Bethesda, MD, U.S.A.*

15:00 **M.A.O.24** Centre de dépistage anonyme et gratuit français : Bilan de deux centres parisiens, Ville de Paris. *Annick Cavelier*, H. Helal*, S. Pretet*, J. Loygue*, R. Poinsard*, R. Ancelle-Park**, et al., *Direction des Affaires sociales, de l'Enfance et de la Santé; **Centre collaborateur O.M.S., Europe SIDA, Paris, France.*

15:15 **M.A.O.25** HIV Seroprevalence in Sexually Transmitted Disease (STD) Clinic Patients. *John Moye, P. Bracci, R. Kappes, L. Kunches, J. Day, R. Timperi, et al., Massachusetts Department of Public Health, Boston, MA, U.S.A.*

14:00 - 15:30

Salle / Room **408BC**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Incidence et prévalence du VIH / HIV Incidence and Prevalence**

Présidents / Chairpersons: Margareta Bottiger (Sweden); Marc Dionne (Canada); James Hospudales (Trinidad and Tobago)

14:00 **M.A.O.26** Incidence of Seroconversion and Risk Factors in a Cohort of Homosexual Men: Results at 6 Years. *Phil Sestak*, M. T. Schechter*, B. Willoughby*, K. J. P. Craib*, M. Maynard*, M. V. O'Shaughnessy**, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC; **Federal Centre for AIDS, Ottawa, ON, Canada.*

14:15 **M.A.O.27** Incidence and Prevalence of HIV Infection among Homosexual and Bisexual Men, 1978-1988. *Nancy A. Hessol*, A. R. Lifson*, R. Kohn*, J. S. Harrison**, L. S. Doll**, G. W. Rutherford*, et al., *San Francisco Department of Public Health, AIDS Office, San Francisco, CA; **AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:30 **M.A.O.28** HIV Seropositivity in a Clinic for the Homeless. *Pedro Greer, Jr.*, G. Dickinson**, F. Parra***, F. Eqea***, L. Jordahl***, R. Holmes**, *University of Miami, School of Medicine; **Miami VA Medical Center; ***State of Florida Department of Health and Rehabilitation Service, Miami, FL, U.S.A.*

14:45 **M.A.O.29** Prévalence de l'infection HIV et de la tuberculose pulmonaire dans une population asymptomatique en Haïti. *Alix Lassegue*, R. Elie**, R. Hippolithe*, D. César**, M. César**, *Hôpital de l'Université d'État d'Haïti, Centre Médical de Port-Au-Prince; Laboratoire d'Investigations biologiques, Port-au-Prince, Haiti.*

15:00 **M.A.O.30** Epidemiology of Kaposi's Sarcoma in AIDS Patients: United States. *Thomas A. Peterman, V. Beral, R. L. Berkelman, S. D. Holmberg, H. W. Jaffe, Centers for Disease Control, Atlanta. GA, U.S.A.*

15:15 **M.A.O.31** Epidemiology of HIV Encephalopathy in the United States. *Robert S. Janssen, J. Stehr-Green, T. Starcher, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:00 - 15:30

Salle / Room **401ABC**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Manifestations buccales du SIDA / Oral Manifestations of AIDS**

Présidents / Chairpersons: Silvio Gomez (Canada), J. J. Pindborg (Denmark), Drasco P. Pekovik

14:00 **M.B.O.16** Oral Pathology in 105 HIV-Reactive Patients in Buenos Aires. Zulema Casariego*, *P. Cahn*, H. Prez*, A. Casiro*, N. Grinberg*, G. Muchinik**, et al., *Infectología, Hospital Fernández; **IIEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

14:15 **M.B.O.17** Oral Manifestations of HIV Infection in African Patients. Joseph H. Perriens*, *Z. Mugaruka**, B. N'Galy***, E. Baende*, M. Kahotwa*, B. Kapita**, *Projet SIDA; **Mama Yemo Hospital; ***National AIDS Control Programme, Kinshasa, Zaire.*

14:30 **M.B.O.18** Demonstration of EBV-DNA Prior to the Occurrence of OHL and Its Correlation with the Clinical Status. Helmut Näher*, *U. K. Freese**, L. Gissmann**, C. Von Knebel Doeberitz**, D. Petzoldt*, J. S. Greenspan***, et al., *Ruprecht-Karls University, Heidelberg; **Deutches Krebsforschungszentrum, Heidelberg, Federal Republic of Germany; ***University of California at San Francisco, San Francisco, CA, U.S.A.*

14:45 **M.B.O.19** Sexual Practices as Risk Factors for Candidiasis and Hairy Leukoplakia: The Oral AIDS Epidemiology Project. David Feigal*, *D. Greenspan**, G. Overby**, A. Moss*, G. Rutherford***, J. S. Greenspan**, University of California at San Francisco, Schools of *Medicine and **Dentistry, The Oral AIDS Center, ***Department of Public Health, San Francisco, CA, U.S.A.*

15:00 **M.B.O.20** Risk Factors for Rapid Progression from Hairy Leukoplakia (HL) to AIDS. Deborah Greenspan*, *J. S. Greenspan*, G. Overby*, C. Borowsky**, H. Hollander**, D. W. Feigal**, University of California at San Francisco, Schools of *Dentistry and **Medicine, Oral AIDS Center, San Francisco, CA, U.S.A.*

15:15 **M.B.O.21** Oral Kaposi's Sarcoma in AIDS: Management with Intralesional Chemotherapy. Joel B. Epstein*, *F. Lozada-Nur**, W. A. McLeod***, J. Spinelli****, *Cancer Control Agency of British Columbia, Vancouver, BC, Canada; **University of California at San Francisco, San Francisco, CA, U.S.A.; ***St. Paul's Hospital; ****Cancer Control Agency of British Columbia, Vancouver, BC, Canada.*

14:00 - 15:30

Salle / Room **403ABC**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Nouvelle techique de diagnostic rapide / New Rapid Diagnosis Approach**

Présidents / Chairpersons
G. Charlier (Haiti)
Thomas Quinn (U.S.A.)
Rachelle Weiss (U.S.A.)

14:00 **M.B.O.22** Immunological Characterization of Recombinant HIV Envelope Proteins. *James A. Lautenberger*, G. C. Dubois**, K. P. Samuel**, S. D. Showalter**, M. Zweig**, T. S. Papas*, *Laboratory of Molecular Oncology, National Cancer Institute; **Program Resources Incorporated, Frederick Research Facility, Frederick, MD, U.S.A.*

14:15 **M.B.O.23** Antibody Responses to Accessory Gene Products in HIV-1 Infection. *Joep M. A. Lange*, P. Reiss*, A. De Ronde*, F. De Wolf*, C. Debouck**, J. Goudsmit*, et al., *Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; **Department of Molecular Genetics, Smith Kline and French Laboratories, PA, U.S.A.*

14:30 **M.B.O.24** Seroreactivity to HIV-1 vif, tat, and nef Proteins. *Ulrike Wieland*, C. Jassoy*, K. Tenscher*, V. Wolber**, J. E. Kuehn*, R. W. Braun*, *Institute for Medical Virology, University of Heidelberg; **Max-Planck Institute for Medical Research, Heidelberg, Federal Republic of Germany.*

14:45 **M.B.O.25** A Rapid and Simple Procedure for Field Testing of HIV-1 Antibodies. *Falk Fish, M. Ritterband, M. Herzberg, ORGENICS Ltd., Yavne, Israel.*

15:00 **M.B.O.26** A Rapid Whole Blood Application for HIV Antibody Testing Using Liposome-based Technology. *Charles F. Hilberg, D. Duschl, J. Blackwell, J. Huff, J. Britz, J. Smialek, *Becton Dickinson and Company, Sparks; **Office of the Medical Examiner, Baltimore, MD, U.S.A.*

15:15 **M.B.O.27** A Multistate Study of a Particle Agglutination Test for Detection of HIV Antibodies. *Robert Schiff*, R. Piccirilli**, M. Busch***, F. Peetoom****, G. Tegtmeier*****, *Schiff & Company Inc., North Caldwell; **NE Pennsylvania Region ARC, Wilkes Barre, PA; ***Irwin Memorial Blood Bank, San Francisco, CA; ****ARC Blood Services, Portland, OR; *****Community Blood Center of Greater Kansas City, Kansas City, KS, U.S.A.*

14:00 - 15:30

Salle / Room **407B**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Colloque / Symposium

Traitement des infections associées à l'immunodéficience causée par le VIH

Management of Infections Associated with HIV Immunodeficiency

Présidents / Chairpersons: S. J. G. Semple (U.K.), Émil Toma (Canada)

14:00 **M.B.O.28** New Perspectives in the Management of Toxoplasmosis. *Jean-Claude Pechère, Hôpital Cantonal de Genève, Geneva, Switzerland.*

14:15 **M.B.O.29** Cryptococcosis. *Merle Sande, San Francisco General Hospital, San Francisco, CA, U.S.A.*

14:30 **M.B.O.30** Tuberculosis (TB) and Atypical Mycobacteria in Patients with HIV Infection. *Richard Chiasson, John Hopkins Hospital, Division of Infectious Diseases, Los Angeles, CA, U.S.A.*

14:45 **M.B.O.31** Human Cytomegalovirus (HCMV) Infections in AIDS: Diagnosis and Antiviral Treatment. *Giuseppe Gerna, University of Pavia, IRCCS San Matteo Hospital, Pavia, Italy.*

15:00 **M.B.O.32** Cryptosporidiosis, Isosporiasis and Microsporidiosis. *Pearl Ma, St. Vincent's Hospital and Medical Center of New York, NY, U.S.A.*

14:00 - 15:30

Salle / Room **407C**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque — **Bases moléculaires et cellulaires des immunodéficiences provoquées par les rétrovirus**

Symposium — **Molecular and Cellular Bases of Retrovirus Induced Immunodeficiencies**

Présidents / Chairpersons — Paul Jolicoeur (Canada), Luc Montagnier (France)

14:00 **M.C.O.11** The Murine Acquired Immunodeficiency Syndrome (MAIDS) is Caused by a Defective Retrovirus. *Ming Huang*, Z. Hanna*, D. Azziz*, C. Simard*, P. Jolicoeur*/**, Institut de recherches cliniques, Montreal, QC, Canada, **Université de Montréal, Montréal, QC, Canada.*

14:15 **M.C.O.12** Induction of Immunodeficiency Disease by FeLV and Relevance to SIV- and HIV- Disease. *J. Mullins, E. A. Hoover, M. Murphey-Corb, P. R. Donahue, J. Overbaugh, et al., Harvard University of Public Health, Boston, MA, U.S.A.*

14:30 **M.C.O.13** Role of Antibodies, Cytokines, and Virus Variation in SIV/SMM Induced Disease. *Patricia Fultz, R. Stricker, L. Montagnier, P. Sonigo, H. McClure, et al., Emory University, Yerkes Regional Primate Research Centre, Atlanta, GA, U.S.A.*

14:45 **M.C.O.14** New Concepts in Human AIDS Pathogenesis. *Luc Montagnier, Institut Pasteur, Unité d'oncologie virale, Paris, France.*

14:00 - 15:30

Salle / Room **410ABC**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Pathogenèse (partie 1) / Pathogenesis (Part 1)**

Présidents / Chairpersons: Dominique Dormont (France), David Ho (U.S.A.), Edward Podorowski (Canada)

14:00 **M.C.O.15** Effect of Soluble Recombinant Human CD4 (sCD4) on Infectivity of Six Monocytotropic Strains of HIV (MO-HIV). *Peter John Gomatos*, H. Gendelman**, N. Stamatos*, A. Fowler***, D. Burke*, et al., *Walter Reed Army Institute of Research; **Henry M. Jackson Foundation; ***SRA Tech., Inc., Washington, DC, U.S.A.*

14:15 **M.C.O.16** HIV Persistence in Monocytes Involves Negative Regulation of Viral Replication and Escape from Immune Surveillance. *Judy A. Mikovits*, M. Razuiddin*, M. Gonda**, F. Ruscetti***, *BCDP, Program Resources Inc.; **Laboratory Cell Molecular Structure, PRI; ***Laboratory Molecular Immunoregulation, BRMP, NCI-FCRF, Frederick, MD, U.S.A.*

14:30 **M.C.O.17** HIV-1 Infected Monocytes as a Target for ADCC. *Samuel D. Stanley*, N. Miller**, K. Stine*, D. Tyler*, D. Bolognesi*, K. Weinhold*, *Duke University Medical Center, Durham, NC; **National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A.*

14:45 **M.C.O.18** Antiviral Effects of Amino Sugars: Potency of N-Butyldeoxynojirimycin (Bu-DNJ). *Abraham Karpas*, R. A. Dwek**, G. W. J. Fleet***, G. S. Jacob**, T. W. Rademacher**, *University of Cambridge Clinical School of Medicine, Department of Haematology, Cambridge; **University of Oxford, Glycobiology Unit, Department of Biochemistry; ***University of Oxford, Dyson Perrins Lab, Department of Organic Chemistry, Oxford, U.K.*

15:00 **M.C.O.19** Novel Mode of HIV Replication in Persistently Infected Monocytoid Cells: Accumulation of Self-Integrated, Extrachromosomal Proviruses Leads to the Production of Defective Virions. *C. David Pauza, The Salk Institute for Biological Studies, San Diego, CA, U.S.A.*

15:15 **M.C.O.20** Biologic, Biochemical and Molecular Analyses of Monocytotropic Human Immunodeficiency Virus. *Howard E. Gendelman*, L. Baca*, M. Leader*, P. Kriebel**, A. Fowler**, et al., *Walter Reed Army Institute of Research, H. M. Jackson Foundation; **SRA Tech, Washington, DC, U.S.A.*

14:00 - 15:30

Salle / Room **409ABC**



Section **D**

Lundi 5 juin
Monday, June 5

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Les adolescents (partie 1)**
Specialty Session **Adolescents (Part 1)**

Présidents / Chairpersons: Christine Charmasson (France), Angus Dalgleish (U.K.), Daniel S. Obikeze (Nigeria)

14:00 **M.D.O.7** Epidemiology of AIDS in Adolescents, U.S.A. *Helene D. Gayle, S. Manoff, M. Rogers, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:15 **M.D.O.8** Adolescents at Risk of HIV Infection. *Joyce L. Radford, W. K. Warren, A. J. C. King, Social Program Evaluation Group, Queen's University, Kingston, ON, Canada.*

14:30 **M.D.O.9** The Significance of the AIDS Pandemic for Homeless Adolescents. *Cajetan G. Luna*, R. C. Brown*, E. Eisenstein**, *Mount Zion Hospital and Medical Center, University of California at San Francisco, San Francisco, CA, U.S.A.; **Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil.*

14:45 **M.D.O.10** Infection with HIV and HBV in Adolescents Lodged in Security Institutes of Buenos Aires City: IVDA as a Risk Factor of Infection. *Mercedes C. Weissenbacher*, E. Casanueva**, R. Hosokawa***, M. Boxaca*, M. Calello*, O. Libonatti*, *Departamento de Microbiologia, Facultad de Medicina, Universidad de Buenos Aires; **National Direction for the Protection of Youth and Family; ***National Institute of Microbiology, Buenos Aires, Argentina.*

15:00 **M.D.O.11** Sex, Drugs and AIDS: Two Innovative Approaches to HIV/AIDS Prevention Education and Outreach for Minority Adolescents. *Adewale Troutman*, J. Y. Hall**, *Newark Department of Health and Human Services, Newark, NJ; **New York City Health and Hospitals Corporation, New York, NY and Greater Brownsville Youth Council, Inc., Brooklyn, NY, U.S.A.*

15:15 **M.D.O.12** The Development of a Street Based Outreach Programme to Reach Young Male, Female and Transsexual, Street Based Prostitutes in Sydney, Australia. *Julian Gold, L. Griggs, M. Toomey, D. L. Alan, P. Turbitt, M. Anns, et al., Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

14:00 - 15:30

Salle / Room **411A**



Section **E**

Lundi 5 juin
Monday, June 5

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique / Specialty Session **Les proches et la famille / Close Friends and Family**

Présidents / Chairpersons
Stéphane Mantion (France)
Aubert Ouellet (Canada)
Gilles Poirier (Canada)

14:00 **M.E.O.13** AIDS and the Family. *Robert Bor, R. Miller, E. Goldman, M. Johnson, C. Lee, P. Kernoff, AIDS Counselling Unit, Royal Free Hospital and School of Medicine, London, U.K.*

14:15 **M.E.O.14** Gay Men with AIDS: Family of Choice vs. Family of Origin. *John T. Patten, G. Walker, New York Hospital, Cornell Medical School, AIDS Project, Ackerman Institute of Family Therapy, New York, NY, U.S.A.*

14:30 **M.E.O.15** The Developmental and Family Services Unit: A Model AIDS Project Serving Developmentally Disabled Children and Their Families. *Karen Hopkins, J. Grosz, Albert Einstein College of Medicine, Rose F. Kennedy Center, Bronx, NY, U.S.A.*

14:45 **M.E.O.16** Effectiveness of a Support Group with Families of HIV-infected Children: A One-year Follow-up. *Sheila Crandles*, A. Sussman**, M. Berthaud**, A. Sunderland**, F. Cancellieri*, *Kings County Hospital Center, AIDS Team; State University of New York, Health Science Center, Brooklyn, NY, U.S.A.*

15:00 **M.E.O.17** Multiprofessional Experience with HIV-infected Patient's Family Members Group in Rio de Janeiro, Brazil. *Lahire D. Carvalho Neto, E. M. M. Moura, J. L. L. Hanan, P. H. P. Longo, M. C. Rachid de Lacerda, C. A. Morais de Sá, Gaffrée and Guinle University Hospital, University of Rio de Janeiro (UNI-RIO), Rio de Janeiro, Brazil.*

15:15 **M.E.O.18** Discussant. *Steven Scribailo, PWA Coalition, Vancouver, BC, U.S.A.*

14:00 - 15:30

Salle / Room **411B**



Section **E**

Lundi 5 juin
Monday, June 5

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Colloque / Symposium

Stratégies innovatrices pour l'éducation des minorités au sujet du SIDA

Innovative Strategies for AIDS Education with Minorities

Président / Chairperson: Jean Merveille (Canada) / Stephen Sroka (U.S.A.)

14:00 **M.E.O.19** SAMM: Stopping AIDS is My Mission; A Minority Adolescent AIDS Education. *V. A. Cargill, University Hospitals of Cleveland, Cleveland, OH, U.S.A.*

14:15 **M.E.O.20** Triple Jeopardies - Reaching Ethnic and Racial Minority Youth Who are Gay-Identified and/or IV Drug Users. *Jacob A. Gayle, Kent State University and American School Health Association, Kent, OH, U.S.A.*

14:30 **M.E.O.21** AIDS Education in Communities of Color: How to Make a Difference. *Rashidah Hassan, BEBASHI, Philadelphia, PA, U.S.A.*

14:45 **M.E.O.22** Integrating HIV/AIDS Information into School Health Education for Minority Students. *Rueben C. Warren, Centers for Disease Control, Bethesda, MD, U.S.A.*

15:00 **M.E.O.23** AIDS and Minorities: Strategies for Prevention. *James R. Dumpson, Black Leadership Commission on AIDS, New York, NY, U.S.A.*

14:00 - 15:30

Salle
Room **411C**

Section
F

Droit et éthique
Ethics and Law

Lundi 5 juin
Monday, June 5

Table Ronde — **Points de controverse dans les rapports sur les politiques relatives au SIDA**

Round Table — **Points of Controversy between Policy Reports on AIDS**

Président — Michel Chrétien (Canada)
Chairperson — Thomas Hemrick (U.S.A.)

14:00	**M.F.O.8**	Introduction. *Michel Chrétien, Montreal, QC, Canada.*
14:10	**M.F.O.9**	*Alain Pompidou, France.*
14:20	**M.F.O.10**	*June Osborn, Detroit, MI, U.S.A.*
14:30	**M.F.O.11**	*Vivienne Nathanson, U.K.*
14:40	**M.F.O.12**	*WHO Representative. Geneva, Switzerland.*
14:50	**M.F.O.13**	*Jean Martin, Lausanne, France.*
15:00	**M.F.O.13a**	*Norbert Gilmore, Montreal, QC, Canada.*

14:00 - 15:30

Salle / Room **406A**

Section **G**

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Séance thématique / Specialty Session **Information et comportement sexuel / Knowledge and Sexual Behaviour**

Présidents / Chairpersons
Laura Caldiz (Argentina)
José Garcia Suarez (Cuba)
Clément Olivier (Canada)

14:00 **M.G.O.13** Knowledge about AIDS in Rural Uganda. *Joseph K. Konde-Lule, E. A. Rwakaikara, Makerere University, Institute of Public Health, Kampala, Uganda.*

14:15 **M.G.O.14** An Assessment of AIDS Related Knowledge, Attitudes, and Practices (KAP) in Rakai District, Uganda. *David Serwadda*, M. J. Wawer**, S. Musgrave**, J. Konde-Lule*, J. Ndumu***, W. Naamara****, *Makerere University, Department of Medicine, Mulago Hospital/AIDS Control Programme, Kampala, Uganda; **Columbia University, New York, NY, U.S.A.; ***Uganda Virus Research Institute; ****AIDS Control Programme, Entebbe, Uganda.*

14:30 **M.G.O.15** Impact of AIDS on Rural and Urban Behaviour in Uganda. *E. Maxine Ankrah, S. O. Ouma, Department of Social Work and Social Administration, Makerere University, Kampala, Uganda.*

14:45 **M.G.O.16** Knowledge and Behavior Related to AIDS: A Study of 3500 Zairian Health Workers. *Melinda Moore*/**, N. Lusakulira*, S. E. Hassig*/**, W. E. Bertrand*/**, T. D. Kashala*, *Zaire School of Public Health, Kinshasa, Zaire; **Tulane University, New Orleans, LA, U.S.A.*

15:00 **M.G.O.17** An HIV Serosurvey in the General Population of Kinshasa Appears Feasible. *Munkolenkole M. Kamenga*/**, R. W. Ryder**/***, B. N'Galy*, T. Ngoy**, A. Liambi***, K. Ngandu****, et al., *National AIDS Program, Kinshasa; **Projet SIDA, United States Embassy, Kinshasa, Zaire; ***Centers for Disease Control, Atlanta, GA, U.S.A.; ****Ministry of Public Health, Kinshasa, Zaire.*

15:15 **M.G.O.18** Knowledge of HIV/AIDS and Sexual Practices in Sri Lanka. *L. A. Adeokun*, J. Weeramunda**, M. Carballo*, O. Tawil*, *Social and Behavioral Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland; **Department of Sociology, University of Colombo, Colombo, Sri Lanka.*

14:00 - 15:30

Salle / Room **406BC**

Section **G**

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Colloque / Symposium: **Nourrissons à risque : le point de vue africain** / **Infants at Risk: An African Perspective**

Présidents / Chairpersons: Joan Kreiss (U.S.A.), Allan R. Ronald (Canada)

14:00 **M.G.O.19** Infant Morbidity and Mortality in Uganda. *E. A. Mworozi, Makerere University, Department of Pediatrics, Kampala, Uganda.*

14:15 **M.G.O.20** Infant Morbidity and Mortality in Nairobi. *Pratibha Datta, University of Nairobi, Nairobi, Kenya.*

14:30 **M.G.O.21** Risk Factors for Maternal-Infant Transmission in Zaire. *Robert W. Ryder, Projet SIDA, Kinshasa, Zaire.*

14:45 **M.G.O.22** Breast Milk as a Risk Factor for HIV-1 Transmission. *Subhash Hira, University Teaching Hospital, Lusaka, Zambia.*

15:00 **M.G.O.23** Safety and Efficacy of Immunizations with Live Vaccines. *Joanne Embree, University of Manitoba, Winnipeg, MB, Canada.*

14:00 - 15:30

Salle / Room **404AB**

Section **H**

Lundi 5 juin
Monday, June 5

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique / Specialty Session **Coûts en milieu hospitalier / Hospital-based Costs**

Présidents / Chairpersons
Dennis P. Andrulis (U.S.A.)
Gabriel Bez (France)
Steven Grover (Canada)

14:00 **M.H.O.7** Hospital Care for AIDS Patients: Clinical Problems and Associated Daily Costs. *Steven A. Grover*, N. Gilmore**, J. Falutz*, C. Tsoukas*, L. Coupal*, R. Fakhry*, McGill University, *Montreal General Hospital, Division of Clinical Epidemiology; **Royal Victoria Hospital, Montreal, QC, Canada.*

14:15 **M.H.O.8** Pediatric HIV-Related Discharges in a Sample of U.S. Hospitals: Demographics, Diagnoses, and Resource Use. *Judy K. Ball, S. J. Thaul, USDHHS, National Center for Health Services Research, Rockville, MD, U.S.A.*

15:30 **M.H.O.9** Longitudinal Hospital Use and Charges of Scatter Bed and AIDS Cluster Unit Inpatients. *Marianne Fahs*, J. Strain*, G. Fulop*, H. Sacks*, R. Papgug**, J. Eisenhandler**, *Mount Sinai Medical Center; **Empire Blue Cross and Blue Shield, New York, NY, U.S.A.*

14:45 **M.H.O.10** The $147,000 Misunderstanding: Overstating the Cost of AIDS. *Jesse Green*, M. Leigh*, G. Oppenheimer**, *New York University Medical Center, Department of Health Policy Research, New York; **Brooklyn College, Brooklyn, NY, U.S.A.*

15:00 **M.H.O.11** New York Medicaid AIDS Patients: Trends in Hospital Use and Mortality Rates. *Barbara J. Turner*, T. Fanning**, M. Keyes***, *Jefferson Medical College, Philadelphia, PA; **Department of Social Services, Albany, NY; ***SysteMetrics, Washington, DC, U.S.A.*

15:15 **M.H.O.12** Un système d'information hospitalier pour les infections par le VIH. *Fabrice Boulay, J. Salin, P. Buchet, F. Petit, H. Logerot, G. Bez, Direction des Hôpitaux, Ministère de la Solidarité, de la Santé et de la Protection sociale, Paris, France.*

14:00 - 15:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

Lundi 5 juin
Monday, June 5

La Sexualité, la politique et l'histoire
Sex, Politics and History

14:00		Introduction: *Andy Fabo*
14:04	**M.I.V.3**	***"ARE WE GOING BACKWARD"***
		Vidéo de/Video by: *David Tuff* Année/Year: 1987
14:14	**M.I.V.4**	***"PROSTITUTES RISK & AIDS"***
		Vidéo de/Video by: *GMHC* Année/Year: 1988
14:39	**M.I.V.5**	***"THEY ARE LOST TO VISION ALTOGETHER"***
		Vidéo de/Video by: *Tom Kalin* Année/Year: 1989
14:52	**M.I.V.6**	***"REFRAMING AIDS"***
		Vidéo de/Video by: *Pretibhe Parmar* Année/Year: 1988

➜

La vidéo offre toute une panoplie de méthodes pour poser un regard historique et analytique sur le sujet. Ce groupe éclectique d'artistes et de militants du monde des arts aborde les problèmes de la sexualité, de l'orientation sexuelle, du racisme, du sexisme, de la politique de la santé, de diverses phobies reliées au SIDA, des stéréotypes et de la considération du SIDA comme une catastrophe idéologique. Ces films vont de l'analyse visuelle à l'analyse textuelle en essayant de comprendre comment s'articule le discours sur le SIDA.

Video offers the use of a myriad of historical and analytical methods. This diverse grouping of artists and aesthetic activists touches on issues of sexuality, sexual orientation, racism, sexism, politics of health, various AIDS-related phobias, stereotyping and confronting AIDS as an ideological catastrophe. It ranges from visual to textual analysis attempting to understand the construction of AIDS discourse.

Notes

16:00 - 17:30

Salle / Room **407A**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Transmission sexuelle du VIH (partie 1) / Sexual Transmission of HIV (Part 1)**

Présidents / Chairpersons
Rand L. Stoneburne (U.S.A.)
Shu-Tao-Msu (China)
Subbash K. Hira (Zambia)

16:00 **M.A.O.32** Serum Antibody to Haemophilus Ducreyi as a Risk Factor for HIV Infection in Africa, but not in Europe. *Peter Piot*, E. Van Dyck*, R. Ryder**, N. Nzila**, M. Laga*, et al., *Institute of Tropical Medicine, Antwerp, Belgium; **Projet SIDA, Kinshasa, Zaire.*

16:15 **M.A.O.33** Assessment by PCR of Transmission of HIV from Infected Hemophiliacs to Their Sex Partners and Children. *Indira K. Hewlett*, J. Epstein*, Y. Laurian**, J. P. Allain***, *Center for Biologics Evaluation and Research, Bethesda, MD; **IHTC, Bicêtre, France; ***Abbott Laboratories, North Chicago, IL, U.S.A.*

16:30 **M.A.O.34** A Prospective Cohort Study of HIV-1 Seroconversion in Patients with Genital Ulcer Disease in New York City. *Edward E. Telzak* **, M. A. Chiasson*, R. L. Stoneburner*, J. Rivera*, H. Jaffe***, S. Schultz*, *New York City Department of Health; **Memorial Sloan-Kettering Cancer Center, New York, NY; ***Centers for Disease Control, Atlanta, GA, U.S.A.*

16:45 **M.A.O.35** Extramarital/Prostitute Sex and Genital Ulcer Disease (GUD) Are Important Risk Factors in 7068 Male Kinshasa Factory Workers and Their 4548 Wives. *Robert W. Ryder*/**, S. Hassig*, M. Ndilu*, F. Behets*, K. Nanlele*, Malele*, et al., *Projet SIDA, Kinshasa, Zaire; **Centers for Disease Control, Atlanta, GA, U.S.A.*

17:00 **M.A.O.36** Efficacy of Nonoxynol-9 in Preventing HIV Transmission. *Joan Kreiss*, I. Ruminjo**, E. Ngugi**, P. Roberts*, J. Ndinya-Achola**, F. Plummer***, *University of Washington, Seattle, WA, U.S.A.; **University of Nairobi, Nairobi, Kenya; ***University of Manitoba, Winnipeg, MB, Canada.*

17:15 **M.A.O.37** Anti-HIV Efficacy of Barrier Contraceptives in HIV-discordant Couples. *Paul J. Feldblum*, S. K. Hira**, J. Kamanga**, G. Tembo**, *Family Health International, Research Triangle Park, NC, U.S.A.; **University Teaching Hospital, Lusaka, Zambia.*

16:00 - 17:30

Salle / Room **408A**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Infection par le VIH chez les détenus / HIV Infection in Prisoners**

Présidents / Chairpersons: Jane Balthazar (Philippines), Harold W. Jaffe (U.S.A.), D. Serraino (Italy)

16:00 **M.A.O.38** HIV Infection Spread in Northern Italian Prisons. *Diego Serraino*, S. Franceschi*, E. Vaccher**, P. Bullian**, D. Gerdol*, V. Tirelli**, *Epidemiology Unit; **Medical Oncology, Aviano Cancer Centre, CRO, Aviano, Italy.*

16:15 **M.A.O.39** Retrovirus Seroprevalence in the Short-term Incarcerated: The Philadelphia Prison Seroprevalence Study. *Bruce L. Davidson*, A. DeMeis*, D. A. Paul**, R. Kline***, T. C. Quinn***, *Philadelphia Department of Health, Philadelphia, PA; **Abbott Laboratories, North Chicago, IL; ***Johns Hopkins University, School of Medicine and National Institutes of Health, Baltimore and Bethesda, MD, U.S.A.*

16:30 **M.A.O.40** Étude des risques de contamination par les virus de l'hépatite B, du VIH1 en milieu carcéral. *Pierre Espinoza*, P. Balian*, I. Bouchard*, Direction Générale de la Santé, Bureau de la Toxicomanie, *Hôpital de Fresnes (EHPNF), Fresnes, France.*

16:45 **M.A.O.41** Prevalence and Risk Factors for HIV Infection among Adolescent Inmates in Madrid. *Concepcion Colomo-Gomez*, M. V. Zunzunegui**, P. Estebanez*, J. Sastre*, M. Rua*, F. Babin*, *Ayuntamiento de Madrid, Centro de Salud de Centro, Madrid; **EASP, Granada, Spain.*

17:00 **M.A.O.42** Sexual Practices and HIV Infection in Some Zambian Prisons. *Mwendaweli N. Maboshe*, O. O. Simooya*, S. K. Hira*, E. Chimfwembe*, P. L. Perine**, M. L. Sandala**, M. Mukunyandela*, *Tropical Diseases Research Centre, Ndola; **University Teaching Hospital, Lusaka, Zambia.*

17:15 **M.A.O.43** Corrections AIDS Prevention Program (C.A.P.P.) in New York City. *Ellen Rautenberg, R. Hayes-Cozier, J. M. Vowels, L. C. Kayser, I. Solis, New York City Department of Health, New York, NY, U.S.A.*

16:00 - 17:30

Salle / Room **408BC**



Section **A**

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique **Histoire clinique de l'infection au VIH : cofacteurs et progression**

Specialty Session **Natural History of HIV Infection: Co-Factors for Progression**

Présidents / Chairpersons: Mads Melbye (Denmark), Khorshed M. Parvi (India), Alfred J. Saah (U.S.A.)

16:00 **M.A.O.44** Incidence of AIDS in Homosexual Men Developing HIV-1 Specific Antibody. *John P. Phair, A. Muoz, L. Kingsley, R. Fox, R. Kaslow, B. Visscher, et al., Multicenter AIDS Cohort Study, Chicago, IL, U.S.A.*

16:15 **M.A.O.45** Immunologic Markers Model the Risk of AIDS. *Alexander Krämer*, P. S. Rosenberg*, D. Fuchs**, R. J. Biggar*, W. A. Blattner*, J. J. Goedert*, *National Cancer Institute, Bethesda, MD, U.S.A.; **University Innsbruck, Innsbruck, Austria.*

16:30 **M.A.O.46** Human Herpes Virus 6 (HHV6) in a Cohort of Homosexual Men. *Scott D. Holmberg*, C. A. Lopez**, R. H. Byers*, G. W. Rutherford***, H. W. Jaffe*, *AIDS Program and **Division of Viral Diseases, Centers for Disease Control, Atlanta, GA; ***San Francisco Department of Health, San Francisco, CA, U.S.A.*

16:45 **M.A.O.47** HIV-1 p24 Antigenaemia and Loss of Anti-Core Antibodies Are Correlates of Rapid Disease Progression and not of Disease Progression Per Se. *Frank De Wolf*, J. Lange*, J. Houweling**, R. Coutinho*, J. Van der Noordaa*, J. Goudsmit*, et al., *University of Amsterdam, Department of Virology; **Municipal Health Service, Amsterdam, Netherlands.*

17:00 **M.A.O.48** Psychosocial Co-factors in Illness Onset among HIV-positive Men. *Ronald C. Kessler*, J. Joseph*, D. Ostrow*, J. Phair*, J. Chmiel**, C. Rusk**, *The University of Michigan, Institute for Social Research, Ann Arbor, MI; **Northwestern University, Chicago, IL, U.S.A.*

17:15 **M.A.O.49** Psychosocial Predictors as Co-Factors for Disease Progression in Men Infected with HIV: The San Francisco Men's Health Study. *Thomas J. Coates*, R. D. Stall*, M. Ekstrand*, G. F. Solomon**, *University of California at San Francisco, San Francisco; **University of California at Los Angeles, Los Angeles, CA, U.S.A.*

16:00 - 17:30

Salle / Room **401ABC**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Infections concomitantes et SIDA / Concomitant Infections in AIDS**

Président / Chairperson: Donald Armstrong (U.S.A.), Pierre Dellamonica (France), Sunity Soleman (India)

16:00 **M.B.O.33** The Spectrum of Neurosyphilis in HIV-Infected Individuals. Stewart Reid, *H. Umedaly, D. Forrest, W. A. McLeod, R. Chan, J. Ruedy, et al., St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.*

16:15 **M.B.O.34** Concomitant Syphilitic and HIV Infection. Helene Douville*, *W. Calderon*, M. Nigro*, G. Bono**, P. Grossi*, *University of Pavia, IRCCS San Matteo Hospital, Department of Infectious Diseases, Pavia; **IRCCS C. Mondino-University of Pavia, Pavia, Italy.*

16:30 **M.B.O.35** Effect of Previous Syphilis Infection on CSF Abnormalities in HIV-1 Infected Individuals. Julie H. McArthur, *K. Alwood, R. Fox, C. Herman, E. Hook, J. C. McArthur, et al., Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

16:45 **M.B.O.36** Traitement de la toxoplasmose cérébrale par la clindamycine et le 5-fluorouracile. Muriel Eliaszewicz*, *M. Kirstetter, M.-C. Meyohas, J. Frottier, *Hôpital Saint-Antoine, Paris, France.*

17:00 **M.B.O.37** Central Nervous System Toxoplasmosis in AIDS Patients. Efficacy of an Intermittent Maintenance Therapy. José M. Gatell, *E. Pedrol, J. M. Gonzalez-Clemente, J. Mallolas, J. M. Miro, E. Soriano, Infectious Disease Unit/Hospital Clinic, Univerity of Barcelona, Barcelona, Spain.*

17:15 **M.B.O.38** Mortality, Treatment Results and Relapse Rates of Pulmonary Tuberculosis in African HIV(+) and HIV(-) Patients. Joseph H. Perriens*, *C. Karahunga*, J. C. Willame**, M. Kaboto***, P. Pauwels**, R. Colebunders*, *Projet SIDA; **Bureau National de Tuberculose; ***Centre de Dépistage de la tuberculose, Kinshasa, Zaire.*

16:00 - 17:30

Salle / Room **403ABC**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Pediatric: Neuro-Development In HIV Infected Children**

Specialty Session **Pediatric: Neuro-Development In HIV Infected Children**

Présidents / Chairpersons
G. Delage (Canada)
Sir Mohamed K. Hashim (Sudan)
Ann Willoughby (U.S.A.)

16:00 **M.B.O.39** Neurological Involvement and Prognostic Factors after Materno-Fetal Infection. *Marc Tardieu*, S. Blanche, A. M. Duliège, C. Rouzioux, C. Griscelli, *INSERM U56, Université de Paris Sud, Le Kremlin-Bicêtre, France.*

16:15 **M.B.O.40** A Prospective Study of Neurological Development in Infants at Risk for Human Immunodeficiency Virus (HIV-1) Infection. *Gwendolyn B. Scott*, D. Cohen, R. Curless, A. Naguiat, R. Morgan, W. P. Parks, *University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.S.A.*

16:30 **M.B.O.41** The Course of Neurodevelopmental Functioning in the Infants of IVDA and HIV-seropositive Parents. *Molly Nozyce*, G. Diamond*, A. Belman**, T. Cabot***, H. Cohen*, A. Rubinstein***, et al., *Albert Einstein College of Medicine, Department of Pediatrics, Bronx; **State University of New York at Stony Brook, Stony Brook; ***Rose F. Kennedy Center, Bronx, NY, U.S.A.*

16:45 **M.B.O.42** Prospective Neurodevelopmental Outcome of Infants with Perinatally Acquired HIV Infection and Their Controls. *Joan Hittelman*, A. Willoughby**, H. Mendez*, J. Kehe*, J. Goedert**, S. Landesman*, et al., *State University of New York at Brooklyn, Health Science Center, Brooklyn, NY; **National Institutes of Health, Bethesda, MD, U.S.A.*

17:00 **M.B.O.43** The Adaptive Behavior of Children with Symptomatic HIV Infection and the Effects of AZT Therapy. *Pamela L. Wolters, H. Moss, P. Brouwers, J. Eddy, P. Pizzo, National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A.*

17:15 **M.B.O.44** Neurologic Disease in Pediatric HIV Infection. *Ram Kairam, A. Kaul, M. Bamji, A. Gupta, S. Bakshi, J. Pitt, St. Luke's-Roosevelt Hospital Center, Columbia University Presbyterian Medical Center and New York Medical College, New York, NY, U.S.A.*

16:00 - 17:30

Salle / Room **407B**

Section **B**

Lundi 5 juin
Monday, June 5

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session: **Traitement : essais de l'AZT / Therapy: AZT Trials**

Présidents / Chairpersons: Michel Poisson (Canada), Stephano Vella (Italy), Hetty A. Waskin (U.S.A.)

16:00 **M.B.O.45** Validation of the Survival Experience among a Large Cohort of AIDS Patients Treated with Zidovudine. *Terri H. Creagh-Kirk*, P. Doi, E. Andrews, H. Tilson, *Burroughs Wellcome Co., Research Triangle Park, NC, U.S.A.*

16:15 **M.B.O.46** Survival Patterns of Zidovudine-Treated AIDS Patients Compared to Untreated Controls. *Stefano Vella, F. Menniti Ippolito, M. G. Agresti, P. Pezzotti, D. Greco, National Institute of Health, Rome, Italy.*

16:30 **M.B.O.47** Nature, Time Course and Dose Dependency of Zidovudine Related Side Effects. Results from the Multicentre Canadian Azidothymidine Trial (MCAT). *John Ruedy, J. S. G. Montaner, K. Gelmon, M. Fanning, J. R. M. Smith, J. Falutz, et al., Multicentre Canadian Azidothymidine Trial, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.*

16:45 **M.B.O.48** Double-Blind Placebo Controlled Study of Recombinant Human Erythropoietin in AIDS Patients with Anemia Caused by HIV Infection and Zidovudine. *Mark U. Rarick, E. Wilson, M. Bernstein-Singer, P. S. Gill, F. Muggia, A. M. Levine, University of Southern California, Los Angeles, CA, U.S.A.*

17:00 **M.B.O.49** Toxicity of Combined AZT/Ganciclovir (DHPG) Therapy in AIDS Patients. *Joseph Nussbaum, D. Antoniskis, D. Causey, J. M. Leedom, Los Angeles County/University of Southern California Medical Center, Los Angeles, CA, U.S.A.*

17:15 **M.B.O.50** One Year Follow-up of Zidovudine Plus Acyclovir in Asymptomatic HIV-seropositives. *Harry Hollander*, M. Moore**, S. Nisinoff-Lehrmann**, J. Barnhart***, A. Lifson***, *AIDS Clinic, University of California at San Francisco, San Francisco, CA; **Burroughs-Wellcome Company, Research Triangle Park, NC; ***AIDS Office, Department of Public Health, San Francisco, CA, U.S.A.*

16:00 - 17:30

Salle / Room **407C**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Biologie moléculaire (partie 1) / Molecular Biology (Part 1)**

Présidents / Chairpersons
William A. Haseltine (U.S.A.)
Yoshiro Ohta (Japan)
Michael O'Shaughnessy (Canada)

16:00 **M.C.O.21** The Immunodominant Neutralization Loop of HIV-1: Biological and Immunological Significance. *David J. Looney, L. Ivanoff, J. R. Rusche, J. Hoxie, R. Redfield, F. Wong-Staal, Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S.A.*

16:15 **M.C.O.22** Molecular Analysis of Single Cell Lysis by HIV-1. *Joseph G. Sodroski, M. Kowalski, T. Dorfman, L. Bergeron, M. Wojtkowsky, W. Haseltine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, U.S.A.*

16:30 **M.C.O.23** Three-Dimensional Structure of the HIV-1 Protease and Its Role in Virus Maturation. *Manuel A. Navia, P. M. D. Fitzgerald, B. M. McKeever, I. S. Sigal, P. L. Darke, J. P. Springer, et al., Merck, Sharp & Dohme Laboratories, Rahway, NJ, U.S.A.*

16:45 **M.C.O.24** Structural Patterns in Regulatory Sequences of HIV. *Gerald Myers, C. S. Tung, C. R. Linder, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, U.S.A.*

17:00 **M.C.O.25** Construction of an Infectious Molecular Clone of SIVagm and Genetic Complementation with a Replication-Defective env Mutant of HIV-1 and Pol Mutant of SIVagm. *Masanori Hayami, T. Miura, A. Adachi, R. Shibata, M. Fukasawa, Kyoto University, Institute for Virus Research, Kyoto, Japan.*

17:15 **M.C.O.26** Experience with Eight HIV-Vaccine Trials in Chimpanzees. *Jorg W. Eichberg, Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A.*

16:00 - 17:30

Salle / Room **410ABC**

Section **C**

Lundi 5 juin
Monday, June 5

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session: **Pathogenèse (partie 2) / Pathogenesis (Part 2)**

Présidents / Chairpersons: Roberto Cauda (Italy), Francine Décary (Canada), John L. Martin (U.S.A.)

16:00 **M.C.O.27** Intestinal HIV Infection in AIDS and ARC: Correlation with Tissue Content of p24 and of Interleukin-1 Beta. *Safak Reka*, A. Borcich*, W. Cronin**, D. P. Kotler*, *St. Luke's-Roosevelt Hospital Center, New York; **Lenox Hill Hospital, New York, NY, U.S.A.*

16:15 **M.C.O.28** Activated Astrocyte-Conditioned Medium Stimulates HIV-1 Expression in a Chronically Infected Promonocyte Clone. *Ljubisa Vitkovic, T. Kalebic, A. S. Fauci, LIR, NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

16:30 **M.C.O.29** Sperm-Mediated Transfer of HIV into Target Cells: Role in AIDS Transmission. *Veronica E. Miller, V. L. Scofield, University of California at Los Angeles, School of Medicine, Deptartment of Microbiology and Immunology, Los Angeles, CA, U.S.A.*

16:45 **M.C.O.30** Investigation of the Susceptibility of Thymic Precursor T Cells to Infection by HIV-1. *Rosemarie Pereira*, M. T. Nugeyre*, C. Aubert*, J. London*/**, J. Ozden*, F. Barre-Sinoussi*, *Institut Pasteur; **Université Paris, Paris, France.*

17:00 **M.C.O.31** Transient Expression of the HIV-1 Genome during Infection of the Developing Human Nervous System. *Charles Kunsch, B. Wigdahl, The Pennsylvania State University College of Medicine, Department of Microbiology and Immunology, Hershey, PA, U.S.A.*

17:15 **M.C.O.32** HIV gp41 Synthetic Peptides Inhibit LAK Activity. *Roberto Cauda*, M. Tumbarello*, L. Ortona*, P. Kanda*, R. Kennedy**, T. Chanh*, *Catholic University of Rome, Department of Infectious Diseases, Rome, Italy; **Southwest Foundation, Department of Virology and Immunology, San Antonio, TX, U.S.A.*

16:00 - 17:30

Salle / Room **409ABC**



Section **D**

Lundi 5 juin
Monday, June 5

Le SIDA et l'individu
AIDS and the Individual

Séance thématique / Specialty Session **Travailleurs de la santé / Health Care Workers**

Présidents / Chairpersons: E. Muhonowa (Tanzania), Constance Wofsy (U.S.A.), Catherine Taylor (Canada)

16:00 **M.D.O.13** The Impact of AIDS on Acute Care Hospitals: A Survey of Infectious Disease Teaching Hospitals in the United States. *Joseph R. Thurn*/**, S. Campbell*, K. Henry*/**, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul; **University of Minnesota Medical School, Minneapolis, MN, U.S.A.*

16:15 **M.D.O.14** Predictors of Intraoperative Blood Exposures. *Julie Louise Gerberding, C. Littell, A. Brown, A. Tarkington, W. Schecter, University of California at San Francisco; San Francisco General Hospital, San Francisco, CA, U.S.A.*

16:30 **M.D.O.15** Improving the Care of AIDS Patients: Roles of Provider Gender and Specificity of Training. *Joseph M. Merrill*, L. Laux, S. Wente, J. Thornby, *Baylor College of Medicine, Department of Community Medicine, Houston, TX, U.S.A.*

16:45 **M.D.O.16** AIDS-Related Knowledge, Attitudes, and Behaviour of Nurses and Physicians: A Comparative Analysis. *Scott Campbell*, M. Maki**, K. Henry***, Department of *Medicine and **Infection Control, St. Paul-Ramsey Medical Center, Section of Infectious Diseases; ***University of Minnesota Medical School, St. Paul, MN, U.S.A.*

17:00 **M.D.O.17** Sexual Behavior and Perceived AIDS Risk among 3,500 Zairian Health Workers. *Melinda Moore*/**, S. E. Hassig*/**, N. Lusakulira*, W. E. Bertrand*/**, T. D. Kashala*, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A.*

17:15 **M.D.O.18** Preventing HIV Infection in England and Wales: What Has Primary Care to Offer? *Tim J. Rhodes, S. Bond, M. Gallagher, C. Foy, P. Philips, J. Bond, Health Care Research Unit, University of Newcastle upon Tyne, Newcastle upon Tyne, U.K.*

16:00 - 17:30

Salle
Room **411A**



Section
E

Lundi 5 juin
Monday, June 5

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Table Ronde
Round Table

L'entraide : une stratégie d'adaptation
Self-Help: A Coping Strategy

Présidents
Chairpersons

Hector Balthazar (Canada)
Martin Hazel (U.S.A.)

16:00 **M.E.O.24** Self-Help Groups and the AIDS Patient. *J. Hector Balthazar, Canadian Council on Social Development, Ottawa, ON, Canada.*

16:05 **M.E.O.25** Self-Help: A Personal Perspective. *Alex Kowalski, Vancouver Person's with AIDS Society, Vancouver, BC, Canada.*

16:10 **M.E.O.26** The AIDS Prevention Concept of the Deutsche AIDS-Hilfe Co-operative Model. *Ian Schäffer, N. Specht, Deutsche AIDS-Hilfe, Berlin, Federal Republic of Germany.*

16:15 **M.E.O.27** The Difficulties of PWA Coalitions in Providing Services to Active Drug Misusers. *John Mordaunt, London Lighthouse, London, U.K.*

16:20 **M.E.O.28** Physicians Self-Support Group. *Michel Chateauvert, Royal Victoria Hospital, Montreal, QC, Canada.*

16:30 **M.E.O.29** Self Help Experience in Africa. *Nicolas Anumudu, Ministry of social Development, Youth and Sports, Social Welfare Division, Owerri, Uganda.*

16:00 - 17:30

Salle / Room **411B**



Section **E**

Lundi 5 juin
Monday, June 5

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique / Specialty Session: **Facteurs culturels déterminants dans les attitudes envers le SIDA** / **Cultural Determinants in Responding to AIDS**

Président / Chairperson: Carol La Fabor (USA); J. M. Lema (Kenya); Inon Shenker (Israel)

16:00 **M.E.O.31** Worldviews and Sexual Practices in Sri Lanka: The Role of Anthropological Approaches in a Global Programme. *J. Weeramunda*, M. Carballo**, A. Mehryar**, *Department of Sociology, University of Colombo, Sri Lanka; **Social and Behavioural Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland.*

16:15 **M.E.O.32** Comportements sexuels et contexte culturel. Une approche méthodologique de la prévention du SIDA. *Moussa Seck, P. Engelhard, ENDA-TM, Dakar, Senegal.*

16:30 **M.E.O.33** La réaction de la société zaïroise envers le SIDA. *Wa Nkera Rukarangira, Brooke, Ngirabakunzi, Kitembo, Bihini, Projet CONNAISIDA, Kinshasa, Zaire.*

16:45 **M.E.O.34** Cross-Cultural Training for AIDS Providers Serving Culturally Different Patients. *Noel A. Day*, A. Houston-Hamilton*, P. Evans**, *Polaris Research and Development; **Department of Public Health, San Francisco, CA, U.S.A.*

17:00 **M.E.O.35** Is There a Unique Role for Anthropology in the Study of AIDS? *Douglas A. Feldman, Department of Epidemiology, University of Miami, School of Medicine, Miami, FL, U.S.A.*

17:15 **M.E.O.36** Les Enquêtes CAP sur le SIDA. Expérimentation d'une technique d'enquête par discussions de groupe sur un échantillon d'étudiants zaïrois. *Ronald Verbeke*, A. Katangaza-Lahaye**, *Université de Mons; **Université catholique de Louvain, Belgium.*

16:00 - 17:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Lundi 5 juin
Monday, June 5

Colloque / Symposium

Éthique et injustice sur le plan international
Ethics and International Inequity

Présidents / Chairpersons: Bernard Kouchner (France), Renée Sabbatier (U.S.A.)

16:00 **M.F.O.14** Overview. *Bernard Kouchner, Action Humanitaire, Paris, France.*

16:15 **M.F.O.15** The Reach of International Codes of Ethics. *George Annas, Boston University Schools of Medicine and Public Health, Boston, MA, U.S.A.*

16:25 **M.F.O.16** Limited Resources for AIDS. *Bosenge N'Galy, Project SIDA, Kinshasa, Zaire.*

16:35 **M.F.O.17** The Dearth of Therapeutic Agents in Developing Countries. *Cécile De Sweemer, International Development Research Centre, Dakar.*

16:45 **M.F.O.18** Overcoming the NIMBY Syndrome for Facilities to Care for HIV Infected People. *Robert E. Stein, Washington, DC, U.S.A.*

16:55 **M.F.O.19** A Focus on Latin America. *Susan S. Connor, Washington, DC, U.S.A.*

17:10 **M.F.O.19a** Ethics and Inequity. *René Sabbatier, London, U.K.*

16:00 - 17:30

Salle / Room **406A**

Section **G**

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Séance thématique **Prévalence (partie 1)**
Speciality Session **Prevalence (Part 1)**

Présidents / Chairpersons: C. Bartholomew (Trinidad & Tobago)
Jean Robert (Canada)
Fernando Zacarias (U.S.A.)

16:00 **M.G.O.25** The Wave-like Progression of AIDS in the Dominican Republic. *Ivelisse Garris, E. A. De Moya, E. Guerrero, C. Pena, L. Dominguez, M. Belliard, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

16:15 **M.G.O.26** Trend Analysis of AIDS Cases Reported in Brazil, 1982-1988. *Pedro Chequer, L. Rodrigues, E. Castilho, D. Bergamaschi, Ministry of Health, National Division of STD/AIDS, Brasilia; Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil.*

16:30 **M.G.O.27** HIV Epidemiological Patterns and Trends in Mexico. An Update. *Jose-Luis Valdespino, J. Sepulveda, J. A. Izazola, M. L. Garcia, M. Palacios, E. Bravo, General Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico.*

16:45 **M.G.O.28** HIV Infection in Ecuador. *Roy A. Ringenberg*, G. Leoro**, M. L. Merino**, H. Jurado*, A. Racines*, J. Rumbea*, et al.,*Ministry of Public Health; **Ecuadorian Red Cross, Quito, Ecuador.*

17:00 **M.G.O.29** HIV Infection in Voluntary Blood Donors in Argentina. *Oscar Fay*, G. Muchinik**, J. Rey***, S. Sileoni****, D. Koffmann*****, H. Gatti*, *Universidad Nacional de Rosario, Centro de Tecnologia en Salud Publica, Rosario; **IIHEMA, Academia Nacional de Medicina; ***Hospital de Clinicas, Universidad de Buenos Aires, Buenos Aires; ****Facultad de Ciencias Medicas, Universidad Nacional de Cordoba, Cordoba; *****Hospital Juan A. Fernandez, Buenos Aires, Argentina.*

17:15 **M.G.O.30** A Critique of the Cumulative Rate of AIDS in the Caribbean. *Courtenay Bartholomew*, F. Cleghorn**, P. Imperato***, *Faculty of Medical Sciences, The University of the West Indies; **The Caribbean Epidemiology Centre, Port of Spain, Trinidad; ***State University of New York, Health Science Centre, Brooklyn, NY, U.S.A.*

16:00 - 17:30

Salle
Room **406BC**

Section
G

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Atelier Workshop	**Atelier régional : Afrique orientale** **Regional Workshop: East Africa**
Présidents Chairpersons	Steven Moses (Canada) Didace Nzaramba (Rwanda)

16:00 **M.G.O.31** Impact on the Health Care System. *Mead Over, World Bank, Washington, DC, U.S.A.*

16:15 **M.G.O.32** Social Economic Impact of AIDS in a Home. *Elizabeth N. Ngugi, University of Nairobi, Department of Community Health, Nairobi, Kenya.*

16:30 **M.G.O.33** The Impact of HIV on the Laboratory in Developing Countries. *John Shao, Muhimbili Medical Centre, Dar-es-Salaam, Tanzania.*

16:45 **M.G.O.34** AIDS and Community Based Care. *Noerine Kaleeba, TASO, Actionaid Uganda, Kampala, Uganda.*

16:00 - 17:30

Salle / Room **404AB**

Section **H**

Lundi 5 juin
Monday, June 5

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique **Coûts en dehors du milieu hospitalier**
Speciality Session **Out of Hospital Costs**

Présidents / Chairpersons: Joel Finlay (Canada); Joao Santos Lucas (Portugal); Paula Van Ness (U.S.A.)

16:00 **M.H.O.13** Medical Cost of HIV Infection of Patients Followed in General Practice in France. *Véronique Massari*, R. Landman**, F. Fagnani***, A.-J. Valleron*, *INSERM U263, Université Paris; **Service des Maladies Infectieuses, Hôpital Bichat; ***INSERM U240, Paris, France.*

16:15 **M.H.O.14** Trends in Utilization and Cost of Treating AIDS in an H.M.O. *Kathryn L. Coltin, J. Goldberg, L. Kuvin, Harvard Community Health Plan, Boston, MA, U.S.A.*

16:30 **M.H.O.15** Place of Death Measures Effectiveness of AIDS-Specific Community-Based Services. *Sharon G. Hopkins, A. Kruzich, R. Wood, Seattle-King County Department of Public Health, Seattle, WA, U.S.A.*

16:45 **M.H.O.16** Post Discharge Needs of Hospitalized Persons with AIDS and HIV-Related Illnesses in New York City. *Nicholas Rango*, E. J. Anderson*, I. Feldman*, B. Collins**, J. Green***, *New York State Department of Health/AIDS Institute; **New York State Department of Social Services, Albany; ***New York University Hospital, New York, NY, U.S.A.*

17:00 **M.H.O.17** Resource Use and Costs of Care for AIDS Patients in Los Angeles. *Charles L. Bennett, A. Pascal, R. L. Bennett, M. Cvitanic, RAND/UCLA Center for Health Policy Study, Santa Monica, CA, U.S.A.*

17:15 **M.H.O.18** Impact of Degree of Immune Deficiency on Planning of Publicly Funded Outpatient Services for HIV. *David E. Dassey, C. Braithwaite, AIDS Program Office, Department of Health Services, Los Angeles, CA, U.S.A.*

16:00 - 17:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Lundi 5 juin
Monday, June 5

Session vidéo
Video session

Les Femmes et le sida
Women and AIDS

16:00		Introduction: *Colette Lachance*
16:14	**M.I.V.7**	***"SAFE SEX SLUT"***
		Vidéo de/Video by: *Scarlot Harlot* Année/Year: 1988
16:17	**M.I.V.8**	***"CORI: A STRUGGLE FOR LIFE"***
		Vidéo de/Video by: *Nina Sobell* Année/Year: 1989
16:35	**M.I.V.9**	***"DOCTORS, LIARS & WOMEN"***
		Vidéo de/Video by: *Carlomusto, Maggenti* Année/Year: 1988
16:58	**M.I.V.10**	***"JULIE"***
		Vidéo de/Video by: *Seth Levin* Année/Year: 1989
17:08	**M.I.V.11**	***"LE SIDA ET LE MILIEU DU TRAVAIL"***
		Vidéo de/Video by: *Kate Wardrop, ACSP, CTC.* Année/Year: 1988

➜

Mères, filles, amantes, travailleuses, lesbiennes, malades, militantes, prostituées, soignantes : les femmes sont vues de multiples manières à travers le prisme du SIDA. Ces films s'attaquent à la marginalisation des femmes sous divers angles. Chacun dépeint les luttes particulières des femmes face au SIDA et à l'infection par le VIH.

Mothers, daughters, lovers, workers, lesbians, patients, activists, prostitutes and caregivers: women are depicted in many ways in relationship to AIDS. From various viewpoints, these videos challenge the marginalization of women. Each depicts the special struggles which women face in relation to AIDS and HIV infection.

Notes



Section
A

Lundi 5 juin
Monday, June 5

Épidémiologie et santé publique
Epidemiology and Public Health

Session d'affichage
Poster Session

Études séro-épidémologiques sur la prévalence du VIH
Seroepidemiologic HIV Prevalence Studies

M.A.P.1 Prevalence of HIV Infection among U.S. Army Reserve Component Personnel. *David N. Cowan*, J. F. Brundage, R. N. Miller, M. Goldenbaum, R. Pomerantz, F. Wann, *Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

M.A.P.2 HIV Prevalence among Military Women: An Examination of Military Applicant, Active Duty, and Reserve Testing Data. *Jacqueline A. Horton*, L. Alexander, J. Brundage, *Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

M.A.P.3 HIV Prevalence Rates and Trends in Endemic and Non-Endemic Metropolitan Areas in the United States, 1985-1988. *Lytt I. Gardner*, J. Brundage, D. Burke, R. Miller, *Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

M.A.P.4 Surveillance for HIV Infection in the Active Duty U.S. Army: Overall Seropositivity and Trends from 1985 to 1988. *Patrick W. Kelley*, R. Pomerantz, F. Wann, J. Brundage, D. Burke, R. Miller, et al., *Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

M.A.P.5 Prevalence of HIV Infection in Heterosexual Persons in the United States, 1988-89. *Ida M. Onorato*, L. Peterson, M. Pappaioanou, T. Dondero, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

M.A.P.6 Prevalence of HIV Antibodies in Childbearing Women in Florida. *Marlene LaLota*, D. G. Withum, D. Holtzman, E. E. Buff, M. S. Chan, S. Lieb, et al., *AIDS Program, Department of Health and Rehabilitative Services, Tallahassee, FL, U.S.A.*

M.A.P.7 Seroprevalence of Antibodies to the Human Immunodeficiency Virus (HIV) in Applicants for Marriage Licenses in Alabama. *Donald E. Williamson*, L. A. Foss, J. B. Parker, W. J. Callan, R. C. Moody, *State of Alabama Public Health Department, Montgomery, AL, U.S.A.*

M.A.P.8 Anonymous HIV Testing on Newborns in 63 Italian Hospitals: An Estimate of Prevalence of Infection among Women in Reproductive Age. *Giuseppe Ippolito*, P. Angeloni, M. Stegagno, E. Mannella, U. Angeloni, F. Costa, et al., *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy.*

M.A.P.9 HIV Seroprevalence on University Campuses, U.S.A. *Helene D. Gayle*, R. Keeling, M. Garcia-Tunon, B. Kilbourne, J. Narkunas, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.A.P.10 HIV Seroprevalence at the Bronx Lebanon Hospital Center, CDC Sentinel Hospital. *Jerome A. Ernst*, S. Bauer, L. Amaral, M. St. Louis, I. Falco, *Bronx Lebanon Hospital Center, Bronx, NY, U.S.A.*

M.A.P.11 Incidence of HIV Seroconversion in U.S. Navy Personnel: Results of Total Navy Screening. *Frank C. Garland*, D. Mayers, T. Hickey, M. Miller, L. Bigbee, *Navy Retroviral Study Group, Naval Health Research Center and University of California at San Diego, San Diego, CA, U.S.A.*

M.A.P.12 HIV Seroprevalence among Parturients in Los Angeles County, 1988. *Deirdre A. Hill*, P. R. Kerndt, L. M. Frenkel, R. Settlage, M. Lee, M. L. Yonekura, et al., *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A.*

M.A.P.13 Demographics of HIV Infection in the United States Air Force (USAF) Personnel. *Robert A. Zajac*, D. R. Lucey, G. P. Melcher, D. Weisenfeld, S. Abbadessa, R. N. Boswell, et al., *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A.*

M.A.P.14 Trends in Newborn HIV Rates Reveal the True Proportion Seen Clinically. *Lynne M. Mofenson*, R. Hoff, G. F. Grady, *Massachusetts Department of Public Health, Boston, MA, U.S.A.*

M.A.P.15 A Prospective Study of HIV in 30,525 Pregnant Women Screened in the Paris Metropolitan Area Between February 1987 and July 1988. *Alain M. Goudeau*, Y. Brossard, M. Larsen , J. Huchet, F. Barin, R. Henrion, et al., *CHRU Bretonneau, Tours, France.*

M.A.P.16 Sentinel Hospital Surveillance for HIV-1 Antibody Versus Clinical Laboratory Submissions in a University Hospital. *Joseph M. Lombardo*, P. Kloser, B. Pawel, R. Trost, R. Kapila, M. St. Louis, *University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A.*

M.A.P.17 Epidemiology of HIV Infection among Young Adults in the US: Regional Variations and Trends. *Erica S. Sharp*, D. Cowan, M. Goldenbaum, J. Brundage, J. McNeil, Walter Reed Retroviral Research Group, *Henry M. Jackson Foundation, Rockville, MD, U.S.A.*

Le VIH chez les détenus
HIV in Prisoners

M.A.P.18 Seroepidemiological Survey of AIDS, Hepatitis and Syphilis in Portuguese Prisoners. *Antonio Meliço-Silvestre*, V. Pombo, A. Pereira, R. Lopses, R. Côrte-Real, Infectious Diseases Clinic, University Hospital of Coimbra, Coimbra, Portugal.*

M.A.P.19 HIV-1 et HIV-2 en milieu carcéral : Dakar (Sénégal). *Souleymane M'Boup*, N. D. Samb, C. S. Boye, G. Diouf, G. Siby, A. Sow, *Hôpital Le Dantec, Laboratoire de Bactériologie, Dakar, Senegal.*

M.A.P.20 ARRIVE: AIDS Prevention Training for Intravenous Drug Users Paroled from Prison. *Stephen Magura*, H. K. Wexler, H. Josepher, R. Bixler, M. Beardsley, *Narcotic and Drug Research Inc., New York, NY, U.S.A.*

M.A.P.21 Occurrence of Serological Markers of Different Infections in HIV Seropositive and Seronegative Inmates from a Penitentiary Population. *Raúl Ortiz de Lejarazu*, J. M. Eiros, E. Perlado, A. Ordua, M. A. Bratos, A. Rodriguez-Torres, *University Hospital, Faculty of Medicine, Department of Microbiology, Valladolid, Spain.*

M.A.P.22 HIV Seroprevalence and the Efficacy of Voluntary HIV Testing among Male Prison Inmates in Wisconsin. *Jeffrey P. Davis*, J. M. Vergeront, H. F. Frisby, N. J. Hoxie, R. Golubjatnikov, J. Pfister, *Wisconsin Division of Health, Section of Acute and Communicable Disease Epidemiology, Madison, WI, U.S.A.*

M.A.P.23 Risk Factors Associated with HIV Infection among Women Incarcerated in a Medium Security Prison. *Catherine A. Hankins*, S. Gendron, S. St-Pierre, C. Richard, M. O'Shaughnessy, M. Benoit, *DSC, Hôpital Général de Montréal and McGill University, Montreal, QC, Canada.*

M.A.P.24 Fréquentation hospitalière et infection par le VIH en milieu carcéral. *Isabelle Bouchard*, P. Espinoza, S. Stein, J. Polo de Voto, P. D'Halliville, R. Benamouzig, *Hôpital de Fresnes (EHPNF), Fresnes, France.*

M.A.P.25 Épidémiologie du SIDA en milieu carcéral. *Pierre Espinoza*, I. Bouchard, J. Polo de Voto, P. Atkhen, *Hôpital de Fresnes (EHPNF), Fresnes, France.*

M.A.P.26 Updated Temporal Trends of HIV-1 Infection among Inmates Entering Maryland Prisons (USA) 1985-88. *David Vlahov*, A. Muñoz, C. Taylor, E. Taylor, F. Brewer, B. F. Polk, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

M.A.P.27 Increasing Tuberculosis in Association with AIDS/HIV among New York State Prison Inmates. *Dale L. Morse*, B. Truman, M. Braun, G. DiFerdinando, B. Maguire, R. Broaddus, *New York State Department of Health, Albany, NY, U.S.A.*

M.A.P.28 Incidence and Prevalence of HIV Infection during 44 Months of Testing Prostitutes/IVDUs in the Women's Jail, Orange County, California. *Peter G. Burrell*, T. J. Prendergast, R. Maxwell, J. R. Greenwood, C. Swatzel, *County of Orange Health Care Agency, Santa Ana, CA, U.S.A.*

Donneurs et receveurs de sang et de produits sanguins
Recipients and Donors of Blood and Blood Products

M.A.P.29 Frequency of HIV Seroconversion among Blood Donors: Relationship to Risk of HIV Transmission. *Roger Y. Dodd*, J. Nardolillo, *American Red Cross, Jerome Holland Laboratory, Rockville, MD, U.S.A.*

M.A.P.30 Blood Center, Health Department Collaboration: A Method for Detecting Infected Previous Donors. *Susan Samson*, M. Busch, P. Holland, J. Ward, J. Garner, H. Perkins, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A.*

M.A.P.31 Blood Donations by Individuals Who Later Develop AIDS. *David W. Feigal*, H. Hollander, J. Ziegler, M. Clement, P. A. Volberding, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.A.P.32 Surveillance for Unusual Modes of Transmission in the USA: A 5-Year Multicenter Study of Blood Donors. *Lyle R. Petersen, Centers for Disease Control, Atlanta, GA, U.S.A.*

M.A.P.33 Séropositivité HIV chez les donneurs de sang et estimation du risque résiduel en transfusion. *Anne-Marie Couroucé, Groupe de Travail Rétrovirus de la S.N.T.S , Fondation nationale de Transfusion sanguine, Paris, France.*

M.A.P.34 The Risk of HIV-1 Transmission by Transfusion of Screened Blood. *Kenrad E. Nelson*, N. Cohen, A. Muñoz, O. Frazier, D. Yawn, B. F. Polk, et al., *Johns Hopkins University, Department of Epidemiology, Baltimore, MD, U.S.A.*

M.A.P.35 The Epidemiology of Transfusion-associated (TA) AIDS in Children in the United States, 1981 to 1988. *Donna S. Jones*, R. Byers, T. Bush, M. Rogers, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S A.*

M.A.P.36 Seroprevalence of HIV Infection among Blood Donors in Rome. *Emilio Mannella*, G. Ippolito, M. Miceli, P. Angeloni, *National Center for Blood Transfusion, Italian Red Cross, Rome, Italy.*

M.A.P.37 Thirty-six Post-Transfusional (P-TRF) HIV Infection in a Regional City Hospital Since 1980. *Pierre Dellamonica*, J. F. Quaranta, E. Cassuto-Viguier, F. Sanderson, M. Vivinus, J. P. Cassuto, *Service des maladies infectieuses et tropicales, Hôpital de l'Archet, Nice, France.*

M.A.P.38 Blood Sale and Donation Behaviour of IVDUs. *Dale D. Chitwood*, M. Comerford, C. B. McCoy, E. J. Trapido, *University of Miami Medical School, Miami, FL, U.S.A.*

M.A.P.39 Impact of an Auto-designation Form on Blood Donor Selection. *Yves Landry*, C. Hankins, B. Jean, J. C. Soto, F. Décary, *La Société canadienne de la Croix Rouge, Montreal, QC, Canada.*

M.A.P.40 Prevalence of HIV-Antibodies in Blood Donors in the FRG. *Dorothee Glück*, D. Koerner, B. Kubanek, G. Caspari, G. Elbert, W. Grässmann, et al., *University of Ulm, German Red Cross Blood Bank, Ulm, Federal Republic of Germany.*

M.A.P.41 A Follow-up Study of Children of Anti-HIV Positive Haemophiliacs. *Christine Ann Lee*, P. B. A. Kernoff, E. Goldman, J. Morris-Smith, P. D. Griffiths, R. S. Trompeter, *Haemophilia Centre, Royal Free Hospital, London, U.K.*

M.A.P.42 Hemophiliacs Doubly Infected by HIV-1 and HTLV-I. *Masafumi Akao*, H. Yorifuji, K. Koike, M. Hada, S. Ikematsu, M. Fujimaki, *Tokyo Medical College, Department of Clinical Pathology, Shinjuku-ku, Tokyo, Japan.*

M.A.P.43 Anti-HIV Seroprevalence in Blood Donations from July '85 until December '88 in Switzerland. *Johann J. Burckhardt*, E. Bütler-Brunner, L. H. Perrin, P. Bachmann, *Central Laboratory, Blood Transfusion Service, Swiss Red Cross, Bern, Switzerland.*

M.A.P.44 Different Epidemiology of HIV Infection in Hemophiliacs (H) from Three European Countries. *Pier Mannucci*, A. Gringeri, A. Bianchi, *Bonomi Hemophilia and Thrombosis Center, University of Milan, Milan, Italy.*

M.A.P.45 Hepatitis B and HIV Coinfection in Hemophiliacs. *Paul R. Becherer*, G. White, C. McMillan, S. M. Lemon, *University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, NC, U.S.A.*

Le VIH chez les prostitué(e)s et les sans-abri
HIV in Prostitutes and Homeless Populations

M.A.P.46 HIV Spread in Prostitute Population in Toulouse (France). *J. M. L. Puel*, C. Gayet-Mengelle, S. Averous, J. Bazex, *Centre Hospitalier universitaire Toulouse-Purpan, Toulouse, France.*

M.A.P.47 Clients of Prostitutes: A Review. *Catherine M. Bisset*, A. Kynaston, S. M. Burns, R. P. Brettle, *HIV Counselling Clinic, City Hospital, Edinburgh, U.K.*

M.A.P.48 HIV Seropositivity and Risk Behaviours of Italian Prostitutes. *Alberto Saracco*, U. Tirelli, R. De Mercato, F. Caprilli, M. Giuliani, G. Rezza, *Istituto Malattie Infettive, Ospedale "Sacco", Milan, Italy.*

M.A.P.49 Female Prostitutes in Antwerp: A Risk Group for HIV Infection. *Christ'l Praats*, M. Laga, P. Van Royen, M. Peeters, C. Hendrickx, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium.*

M.A.P.50 Risk of HIV Infection among Homeless IV Drug Users (IVDUs) in Chicago. *Wayne W. Wiebel*, T. Lampinen, D. Chene, D. Jimenez, W. Johnson, L. Ouellet, et al., *University of Illinois at Chicago, Chicago, IL, U.S.A.*

M.A.P.51 HIV Infection among Homeless Men in a New York City Shelter. *Ramon A. Torres*, S. Mani, J. Altholz, P. W. Brickner, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A.*

M.A.P.52 Prevalence and Risk Factors/or HIV-1 and HTLV-I Infection in Prostitutes in Southern Catalonia. *Jordi Casabona*, R. Salinas, E. Sanchez, C. Lacasa, P. Veranni, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain.*

M.A.P.53 Social and Seroepidemiologic Survey for Antibodies to Human Immunodeficiency Virus and Other Sexual Diseases in Prostitutes in Rio de Janeiro. *Maria-José Andrada-Serpa*, C. De Meis, A. C. Vasconcellos, D. Linhares, *Basic Research Centre, National Cancer Institute, Rio de Janeiro, Brazil.*

Le VIH chez les clients des cliniques de MTS et des centres de dépistage
HIV among Clients of STD Clinics and Testing Centres

M.A.P.54 HIV Seroprevalence in Heterosexual Men and Women, Denver Metro STD Clinic, 1985-1988. *Franklyn N. Judson*, D. L. Cohn, J. M. Douglas, *Denver Public Health, University of Colorado, Denver, CO, U.S.A.*

M.A.P.55 Comparison of Race/Ethnicity, Transmission Category in Persons Electing HIV Counselling and Testing Services. *Kathy Cahill*, G. S. Bowen, C. Kirby, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.A.P.56 HIV Seroprevalence in Patients with PID. *Rhoda S. Sperling*, F. Friedman, *Mount Sinai Medical Center, Department of Obstetrics and Gynecology, New York, NY, U.S.A.*

M.A.P.57 Risk Factors for HIV-1 Infection in a British Population. *Colin Kenny*, E. J. Beck, C. Donegan, C. S. Cohen, V. W. Moss, P. Terry, et al., * St. Mary's Hospital Medical School, Virology Division, Paddington, U.K.*

M.A.P.58 Heterosexual Transmission of HIV Is Rare amongst Attenders at an STD Clinic in London. *David Barlow*, J. E. Banatvala, C. S. Bradbeer, R. N. Thin, I. Christie, S. Palmer, *St. Thomas' Hospital, London, U.K.*

M.A.P.59 HIV Prevalence in an AIDS Counselling Center in Israel. *Zeev T. Handzel*, R. Burstein, M. Meyer, R. Levinstein, R. Nave, Z. H. Bentwich, *Hebrew University Medical School, Kaplan Hospital, Rehovot, Israel.*

M.A.P.60 Trends in HIV Seroprevalence among Self-Identified Risk Groups Utilizing Anonymous Test Sites in San Francisco. *John B. Greenhalgh*, M. J. Wilson, B. H. Nguyen, G. F. Lemp, R. E. Evans, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

M.A.P.61 Trends in HIV Seroprevalence in an Urban Sexually Transmitted Disease Clinic, 1986-1989. *H. Hunter Handsfield*, E. Sohlberg, S. Hopkins, P. D. Swenson, N. Harris, *Seattle-King County Department of Public Health, University of Washington, Seattle, WA, U.S.A.*

M.A.P.62 Effectiveness of Voluntary HIV Antibody Testing Provided at a Clinic Treating Sexually Transmitted Diseases. *Michele M. Ginsberg, County of San Diego Department of Health Services, San Diego, CA, U.S.A.*

M.A.P.63 Epidemiological Observations of a Territorial HIV Screening Centre in Milan. *Clara Schiantarelli*, M. Rastrelli, M. C. Moioli, M. Meini, M. Orso, M. R. Villa, *Niguarda Ca' Granda Hospital, Milan, Italy.*

M.A.P.64 HIV Seroprevalence Surveys in the San Francisco Bay Area. *Mary J. Wilson*, J. B. Greenhalgh, G. F. Lemp, C. I. Perkins, K. W. Kizer, G. W. Rutherford, et al., *California Department of Health Services, San Francisco, CA, U.S.A.*

M.A.P.65 Heterosexual Transmission of HIV: Prevalence and Risk Factors. *James Guinan*, C. Stone, A. Morlet, J. Gold, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

M.A.P.66 Prevalence of HIV-infection among STD-Patients in Antwerp, Belgium. *Dirk Avonts*, M. Van Den Bruaene, C. Goliav, G. Vercauteren, M. Laga, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium.*

M.A.P.67 HIV-1 Infection in New York City STD Clinic Patients: Evidence for Stable Seroprevalence, 1987-1988. *Isaac B. Weisfuse*, M. A. Chiasson, S. Back, L. Ramirez, B. Greenberg, W. Ewing, et al., *New York City Department of Health, New York, NY, U.S.A.*

M.A.P.68 Characterization of HIV-infected STD Clinic Clients Identified through Routine Voluntary Screening: Implications for Future Health Care Needs. *Beth Erickson*, D. Glasser, J. N. Wasserheit, A. M. Rompalo, W. Brathwaite, E. W. Hook, *Baltimore City Health Department, Baltimore, MD, U.S.A.*

M.A.P.69 Frequency of HIV Infection among Patients of STD Out-patient Clinic. *Lidia Babiuch*, A. Stapinski, W. Mazurkiewicz, U. Wójtowicz, T. Napiórkowska, *Warsaw Medical Academy, Warsaw, Poland.*

M.A.P.70 Analysis of Trends over Time in Client Characteristics at Minnesota (MN) HIV-1 Antibody Counselling and Testing Sites. *Richard N. Danila*, J. Shultz, M. Osterholm, K. Henry, M. Simpson, K. MacDonald, *Minnesota Department of Health, Minneapolis, MN, U.S.A.*

M.A.P.71 Blind HIV-AB and Syphilis-AB Seroprevalence Survey in New York State STD Clinics. *George T. Diferdinando Jr.*, K. Arthur, S. Hipp, D. Murphy, *New York State Department of Health, Albany, NY, U.S.A.*

M.A.P.72 HIV-1 Infection in Persons Attending Sexually Transmitted Disease (STD) Clinics in Minnesota (MN). *Richard N. Danila*, K. Henry, M. Simpson, M. Osterholm, K. MacDonald, *Minnesota Department of Health, Minneapolis, MN, U.S.A.*

M.A.P.73 HIV Seroprevalence of STD Clinics in Houston, Texas, U.S.A. *Robert L. Falletti*, M. Enochs, K. Sullivan, D. Sanchez, D. Penaloza, H. Honeycutt, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A.*

M.A.P.74 HIV Seroprevalence in Sexually Transmitted Disease Clinics in Los Angeles County. *Wesley L. Ford*, T. Rose, P. Kerndt, I. Onorato, S. Waterman, *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A.*

M.A.P.75 Development and Funding of Public HIV Counselling and Testing Services in the United States. *Kathy Cahill*, G. S. Bowen, C. Kirby, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.A.P.76 Incidence of HIV Infection in Gay and Bisexual Men Attending a Counselling and Testing Site or an AIDS Prevention Program. *David L. Cohn*, J. Koleis, S. Cooper, V. Cole, F. Judson, *Denver Disease Control Service, Denver, CO, U.S.A.*

Autres rétrovirus : le VIH-2
Other Retroviruses: HIV-2

M.A.P.77 HIV-2 Infection. Some Clinical and Epidemiological Aspects in Portugal. *Julio Botas*, L. Tavares, C. Carvalho, H. Feliciano, F. Antunes, *Department of Infectious Disease, Hospital Santa Maria, Lisbon, Portugal.*

M.A.P.78 HIV-2 in Italy: No Evidence, Yet. *Giampiero Carosi*, G. P. Cadeo, L. Corda, G. Pizzocolo, A. Albertini, *Clinica di Malattie Infettive e Tropicali, Università di Brescia, Brescia, Italy.*

M.A.P.79 Human Immunodeficiency Virus Type 2 (HIV-2) Screening of a High Risk Population in Addis Ababa, Ethiopia. *Seyoum Ayehunie*, D. Zewdie, J. Woody, N. Constantine, B. Gebrehiwot, T. Messele, et al., *National Research Institute of Health, Addis Ababa, Ethiopia.*

M.A.P.80 Detection of Antibodies against HIV-2 Proteins in HIV-1 Seropositive Subjects from France and Greece. *Vassilis Georgoulias*, P. Fountouli, A. Carvela, A. M. Beroli, E. Malliaraki-Pinetidou, A. Ammar, et al., *School of Medicine, University of Crete and AIDS Reference Center of Crete, Iraklion, Greece.*

M.A.P.81 HIV-2 in Drug Abusers of Spain. *Vincent Soriano*, J. Tor, A. Ribera, R. Muga, *Hospital "Germans Trias I Pujol", Badalona, Barcelona, Spain.*

M.A.P.82 Epidemiology of AIDS in Portugal. *Laura Ayres*, A. Pista, A. Benito-Garcia, C. Furtado, F. Avillez, *Instituto Nacional da Saude, Lisbon, Portugal.*

M.A.P.83 AIDS Caused by HIV-2 in Southern Africa. *Susan F. Lyons*, G. M. McGillivray, B. D. Schoub, A. N. Smith, L. Clausen, *National Institute for Virology, Sandringham, South Africa.*

M.A.P.84 HIV-2 Infection in Female and Male Brazilian Prostitute Groups. *Maria Odette Santos-Ferreira*, C. Mazza, M. H. Lourenço, R. Focaccia, R. Veronesi, *University of Lisbon, Faculty of Pharmacology, Lisbon, Portugal.*

M.A.P.85 Efficacité dans le dépistage des sérums HIV-2. *Anne-Marie Couroucé, Groupe de Travail Rétrovirus de la SNTS, Fondation nationale de Transfusion sanguine, Paris, France.*

M.A.P.86 Prevalence of HIV-1 and HIV-2 Antibodies in Individuals Attending a Clinic for S.T.D. A Two Year Follow-up. *Laura Ayres*, J. Cardoso, F. Avillez, I. Santo, A. Pista, *National Institute of Health, Lisbon, Portugal.*

Progression : marqueurs de laboratoire et cofacteurs
Progression: Laboratory Markers and Cofactors

M.A.P.87 The Level of Epstein-Barr Virus Excretion is a Predictor of Disease Progression in HIV Infection. *Francisco Díaz-Mitoma*, A. Ruiz, S. Houston, B. Romanowski, J. Preiksaitis, D. L. J. Tyrrell, *University of Alberta, Edmonton, AB, Canada.*

M.A.P.88 Prognostic Value of Anemia in Asymptomatic HIV-Positive Men. *Manuel M. Battegay*, B. Ledergerber, J. Brühwiler, W. Siegenthaler, R. Lüthy, *University Hospital Zurich, Department of Internal Medicine, Zurich, Switzerland.*

M.A.P.89 Age at Time of HIV Infection as Cofactor of Progression to Advanced Immune Dysfunction and AIDS. *Angelo Hatzakis*, T. Mandalaki, K. Katsouyanni, A. Karafoulidou, H. Polychronaki, A. Gialeraki, et al., *Athens University Medical School, Athens, Greece.*

M.A.P.90 History of Syphilis as a Cofactor for the Expression of HIV Infection. *Joseph R. Berger*, M. McCarthy, L. Resnick, M. A. Fleetcher, N. Klimas, L. Pall, et al., *University of Miami School of Medicine, Department of Neurology, Miami, FL, U.S.A.*

M.A.P.91 Effect of Previous Knowledge of HIV Positivity on Survival of AIDS Patients in Norway. *Anne Eskild*, P. Magnus, Nilsen, *National Institute of Public Health, Oslo, Norway.*

M.A.P.92 Continued Injecting Drug Use as a Cofactor for Progression of HIV. *Peter J. Flegg*, M. E. Jones, L. R. MacCallum, A. G. Bird, J. M. Whitelaw, R. P. Brettle, *City Hospital, Infectious Diseases Unit, Edinburgh, U.K.*

M.A.P.93 Co-factors and Cohort Effects in Progression to AIDS among HIV-1 Infected Homosexual Men. *Cladd E. Stevens*, P. E. Taylor, T. R. Holford, P. Rubinstein, *Laboratory of Epidemiology, The New York Blood Center, New York, NY, U.S.A.*

M.A.P.94 Progression of ARC to AIDS in a Population of Drug Abusers and Correlation with CD4 Decrease and Rise of HIV1 Antigenaemia. *Enzo Raise*, V. Vannini, S. Sabbatani, G. Raise, M. L. Schiattone, L. Pulsatelli, et al., *C.A. Pizzardi Hospital, Department of Infectious Disease and Immunopathology Unit, Bologna, Italy.*

M.A.P.95 Predictors of Progression of HIV Infection. *Marco Rizzi*, C. Arici, M. G. Finazzi, E. Minola, *Ospedali Riuniti di Bergamo, Department of Infectious Diseases, Bergamo, Italy.*

M.A.P.96 Use of Serial T4 Lymphocyte Counts to Predict Time to Develop AIDS in Anti-HIV Positive Haemophiliacs. *Christine Ann Lee*, A. N. Phillips, J. Elford, G. Janossy, P. D. Griffiths, P. B. A. Kernoff, *Haemophilia Centre, Royal Free Hospital, London, U.K.*

M.A.P.97 Laboratory Markers of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with HIV Disease. *Randall A. Coates*, V. Farewell, J. Raboud, S. E. Read, D. MacFadden, L. Calzavara, et al., *Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

M.A.P.98 T Cell Subsets in a Cohort of Intravenous Drug Users (IVDUs): Initial Levels and Stability Over Time. *Joseph B. Margolick*, A. Muñoz, S. Cohn, D. Vlahov, *Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

M.A.P.99 Presence of HIV p24 Antigen Strongly Predicts Development of AIDS. *William Lang*, R. Anderson, S. Shiboski, H. Sheppard, M. Ascher, W. Winkelstein, *Children's Hospital, San Francisco Men's Health Study, San Francisco, CA, U.S.A.*

M.A.P.100 A Comparison of the Prognostic Value of B2 Microglobulin, Neopterin, and Soluble CD8 in HIV-2 Infection. *Dennis Osmond*, P. Bacchetti, W. Krampf, E. Ross, E. Winger, A. R. Moss, *University of California, San Francisco General Hospital, San Francisco, CA, U.S.A.*

M.A.P.101 Is HLA Associated with Progression of HIV-1-Induced Immunodeficiency? *Richard A. Kaslow*, R. Duquesnoy, M. J. Van Raden, M. Marrari, L. Kingsley, R. Detels, et al., *National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, U.S.A.*

M.A.P.102 Evolutive Process towards AIDS in the Majority of Symptomless HIV-infected Subjects. *Jean-Jacques Lefrère*, P. Lambin, C. Doinel, A. M. Couroucé, *Institut national de Transfusion sanguine, Paris, France.*

M.A.P.103 Different Courses of HIV Infection in PGL/ARC Patients of Frankfurt University, Out-patient Clinic, Infectiology. *Hans-Reinhard Brodt*, G. Kindervater, S. Staszewski, B. S. Kamps, E. B. Helm, *Universitätsklinik Frankfurt, Zentrum der inneren Medizin/Infektiologie, Frankfurt, Federal Republic of Germany.*

M.A.P.104 Lack of Antibodies against p17 as Predictive Value for AIDS. *José Barrera*, C. Sanchez, J. Mallolas, I. Planas, J. M. Miro, J. M. Gatell, et al., *Blood Transmitted Diseases Unit, Barcelona Hospital Clinic, Barcelona, Spain.*

M.A.P.105 Prospective Evaluation of HIV Progression in Edinburgh Injection Drug Users. *Peter J. Flegg*, F. M. Cowan, M. E. Jones, L. R. MacCallum, J. M. Whitelaw, R. P. Brettle, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K.*

M.A.P.106 Signifiance of Increase of CD8 Lymphocytes in Asymptomatic HIV Infection. *Christian Doinel*, H. Roquin, J. J. Lefrère, P. Lambin, P. Rouger, *Institut national de transfusion sanguine, Paris, France.*

M.A.P.107 Clinical and Laboratory Progression of HIV Infection in Blood Recipients and Their Spouses. *Jane Garner*, M. Busch, S. Samson, H. Perkins, J. Ward, *Irwin Memorial Blood Bank, San Francisco, CA, U.S.A.*

M.A.P.108 Prediction of HIV-related Clinical Outcomes by Using Beta-2 Microglobulin (B2), p24 Antibody (Ab), and Antigen (Ag) in a Cohort of Initially Asymptomatic Gay Men. *Kenneth H. Mayer*, A. Stoddard, L. Falk, S. Saltzman, G. Dawson, J. McCusker, et al., *Memorial Hospital/Brown University, Pawtucket, RI, U.S.A.*

M.A.P.109 Evaluation of Group Specific Component as Determinant of HIV Susceptibility and Progression. *Angelos Hatzakis*, T. Mandalaki, R. Butler, R. Pflugshaupt, C. Tsoukala, K. Katsouyanni, et al., *Athens University Medical School, Athens, Greece.*

M.A.P.110 Factors Associated with HIV Progression in Nairobi Prostitutes. *Donna Holton*, D. W. Cameron, J. N. Simonsen, J. O. Ndinya-Achola, E. Ngugi, F. A. Plummer, *University of Manitoba, Winnipeg, MB, Canada.*

M.A.P.111 The Natural History of HIV Infection in a Cohort of Homosexual and Bisexual Men: Cofactors for Disease Progression 1978-1979. *Nancy A. Hessol*, A. R. Lifson, S. P. Buchbinder, L. S. Doll, G. W. Rutherford, J. L. Barnhart, *San Francisco Department of Public Health, AIDS Office, San Francisco, CA, U.S.A.*

M.A.P.112 No Evidence for Risk Factors for Progression of HIV Infection among Homosexual Men. *Godfried J. P. Van Griensven*, E. M. M. De Vroome, F. De Wolf, J. Goudsmit, M. Roos, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

M.A.P.113 Cofactors of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with HIV Disease. *Randall A. Coates*, V. Farewell, S. E. Read, D. MacFadden, L. M. Calzavara, J. K. Johnson, et al., *Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

Prévention : politiques et évaluation des programmes
Prevention: Policy Issues, Program Evaluation

M.A.P.114 Virus Leakage through Natural Membrane Condoms. *W. Howard Cyr*, L. E. Bockstahler, C. D. Lytle, P. G. Carney, S. Vohra, Division of Life Sciences, Center for Devices and Radiological Health, Rockville, MD, U.S.A.*

M.A.P.115 AIDS Street Nurses. *Michael L. Rekart*, M. McCarthy, C. Farrow, *STD Control, Ministry of Health, Vancouver, BC, Canada.*

M.A.P.116

M.A.P.117 Surveillance-Éducation sanitaire des prostituées au Sénégal. *Tidiane Siby*, I. Thior, J.-L. Sankalé, A. Gueye, I. Ndoye, S. M'Boup, *Université de Dakar, Département de Bactério-Virologie, Dakar, Senegal.*

M.A.P.118 Contrôle de qualité des trousses anti-HIV commercialisée en France. *Marie-Louise North*, L. Mouillot, A.-M. Couroucé, Groupe Rétrovirus, *Société Nationale de Transfusion Sanguine, Strasbourg, France.*

M.A.P.119 Évaluation de l'intérêt d'un test utilisant des peptides synthétiques (Immunocomb) pour le diagnostic sérologique de l'infection à VIH. *Michel Rosenheim*, M. Ritterband, D. Kerouedan, Y. Schwartz, P. M'Pelé, M. Gentilini, *Hôpital Salpêtrière, Département de Médecine tropicale, Unité INSERM 313, Paris, France.*

M.A.P.120 Safer Sex Behavior Reinforcement in Public Parks. *Charles E. Haley*, M. Lerro. A. C. Freeman, J. A. Valentine, *Dallas County Health Department, Dallas, TX, U.S.A.*

Notes

Section
B
Clinical Aspects of AIDS
Aspects cliniques

Lundi 5 juin
Monday, June 5

Session d'affichage
Poster Session

Grossesse et obstétrique
Pregnancy/Obstetrics

M.B.P.1 In Utero HIV-1 Transmission Identified through PCR. *Valérie Courgnaud*, F. Laure, F. Barin, A. Goudeau, A. Brossard, C. Brechot, *CHU Necker, Paris, France.*

M.B.P.2 Antigenemia p24 and CD4 Cell Counts in HIV Pregnant Women. *Jean-François Delfraissy*, D. Séréni, J. C. Pons, D. Meyer, V. Chambrin, P. Engelman, et al., *Hôpital Antoine-Béclère, Clamart, France.*

M.B.P.3 Disease Progression following Pregnancy in HIV Seropositive Women. *Frances M. Cowan*, L. MacCallum, J. Whitelaw, S. M. Burns, R. P. Brettle, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K.*

M.B.P.4 Pregnancy Arising in HIV Infected Women While Being Repetitively Counselled about "Safe Sex". *Mark H. Kaplan*, B. F. Farber, W. W. Hall, C. Mallow, C. O'Keefe, R. G. Harper, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A.*

M.B.P.5 Failure of Targeted Screening to Identify HIV+ Pregnant Women. *Marguerite Barbacci*, T. Quinn, R. Kline, J. Repke, R. Chaisson, *Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.*

M.B.P.6 Pregnancy and Acceleration of HIV-related Illness. *Marie-Marcelle Deschamps*, J. W. Pape, S. Madhavan, W. D. Johnson, *GHESKIO, Cornell University Medical College, Division of International Medicine, New York, NY, U.S.A.*

M.B.P.7 Factors Influencing Maternal Decision-making Regarding Pregnancy Outcome in HIV Infected Women. *Arye Rubinstein*, A. Wiznia, C. Bueti, C. Douglas, T. Cabat, *Albert Einstein College of Medicine, New York, NY, U.S.A.*

M.B.P.8 The Effect of Pregnancy on Progression of HIV-related Disease. *Katherine Davenny*, E. E. Schoenbaum, P. A. Selwyn, D. Hartel, M. Rogers, *Montefiore Medical Center/Albert Einstein College of Medicine, AIDS Research, Bronx, NY, U.S.A.*

M.B.P.9 Pharmacokinetics (PK) of Zidovudine (ZDV) in HIV+ Pregnant Women. *Heather Watts*, Z. Brown, T. Tartaglione, K. Coombs, R. Opheim, S. Burchett, *University of Washington, Department of Obstetrics and Gynecology, Seattle, WA, U.S.A.*

M.B.P.10 Knowledge of HIV Serostatus and Pregnancy Decisions. *Marguerite Barbacci*, R. Chaisson, J. Anderson, J. Horn, *Johns Hopkins University, Baltimore, MD, U.S.A.*

M.B.P.11 Immunohistochemical Detection of HIV-associated Antigens in Formalin-Fixed Neonatal Placentas. *Florian Eitelback*, E. Jimenez, Z. Huang, M. Unger, G. Wagner, I. Grosch-Wörner, et al., *Universitätsklinikum Rudolf Virchow, Charlottenburg Pathologie, Berlin, Federal Republic of Germany.*

M.B.P.12 HIV Seroprevalence in an Inner City Obstetric Population. *L. Alger*, S. Watkins, S. Hines, D. Richardson, J. P. Johnson, *University of Maryland School of Medicine, Baltimore, MD, U.S.A.*

M.B.P.13 Transplacental Transfer of Zidovudine. *Jashvant D. Unadkat*, A. Lopez-Anaya, L. A. Schumann, *University of Washington, Department of Pharmaceutics, Seattle, WA, U.S.A.*

M.B.P.14 A Prospective Study of HIV in Pregnant Women. *Carlo Giaquinto*, L. Di Lenardo, D. Truscia, P. V. Grella, *Department of Pediatrics, University of Padua, Padua, Italy.*

M.B.P.15 Pharmacokinetics of Zidovudine in the Newborn Macaques. *Jashvant D. Unadkat*, A. Lopez-Anaya, L. A. Schumann, A. L. Smith, *University of Washington, Department of Pharmaceutics, Seattle, WA, U.S.A.*

M.B.P.16 Pregnancy and HIV Infection: An Experience about 15 Cases. *Giampiero Carosi*, F. Castelli, A. Chiodera, M. Tarantini, E. Prati, U. Bianchi, *Clinica di Malattie Infettive e Tropicali, Università di Brescia, Brescia, Italy.*

M.B.P.17 Ultrasonic Assessment of Fetal Growth and Morphology in HIV-1 Positive Pregnant Women. *Marc Boucher*, J. Samson, G. Delage, C. Hankins, M. Fauvel, N. Lapointe, *Hôpital Sainte-Justine, Université de Montréal, Montreal, QC, Canada.*

M.B.P.18 HIV-Antigens Can Be Demonstrated Immunohistochemically in Formalin-Fixed Material from Therapeutic Abortions of HIV-Exposed Pregnancies. *Florian Eitelback*, M. Unger, Z. Huang, E. Jimenez, G. Wagner, A. Schäfer, *Universitätsklinikum Rudolf Virchow, Charlottenburg Pathologie, Berlin, Federal Republic of Germany.*

M.B.P.19 Seroprevalence of HIV-1 and HTLV-I among Pregnant Women in Newark, N. J. *Thomas N. Denny*, E. Connor, L. Goode, P. Niven, M. Oxtoby, J. Oleske, et al.,* University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A.*

M.B.P.20 Pathology and HIV Expression in Term Placentas from Seropositive Women. *Sulachni Chandwani*, M. Greco, K. Mittal, K. Krasinski, W. Borkowsky, *New York University Medical Center and Bellevue Hospital Center, New York, NY, U.S.A.*

M.B.P.21 Differences in Immunosuppression during Pregnancy in HIV-infected Women. *Axel Schäfer*, W. Friedmann, B. Schwartländer, *Free University of Berlin, Department of Obstetrics and Gynecology, Berlin, Federal Republic of Germany.*

M.B.P.22 Effect of Pregnancy on the Pharmacokinetics of Zidovudine. *Jashvant D. Unadkat*, A. Lopez-Anaya, L. A. Schumann, *University of Washington, Department of Pharmaceutics, Seattle, WA, U.S.A.*

M.B.P.23 Seroprevalence in a Pregnant Multiethnic Population. *Mary J. O'Sullivan*, A. Fajardo, P. Ferron, J. Efantis, C. Senk, M. Duthely, *University of Miami, Department of Obstetrics and Gynecology, Miami, FL, U.S.A.*

M.B.P.24 A Prospective Study of the Mental and Motor Development of Infants Born to HIV Infected Intravenous Drug Using Mothers. *Ron Kletter*, R. J. Jeremy, C. Rumsey, P. Weintrub, M. Cowan, *BAART/FACET, San Francisco, CA, U.S.A.*

M.B.P.25 Influence of Gestation on HIV Infection. *Alain Berrebi*, J. Puel, J. Tricoire, H. Herne, G. Pontonnier, *CHU La Grave, Service de Gynécologie-Obstétrique, Toulouse, France.*

M.B.P.26 Effects of HIV Infection on Pregnancy. *Alain Berrebi*, W. E. Kobuch, J. Puel, J. Tricoire, P. Herne, A. Fournie, *CHU La Grave, Service de Gynécologie-Obstétrique, Toulouse, France.*

M.B.P.27 Pregnancy Outcome in Women: HIV Infection in Puerto Rico in a Population of Predominant Heterosexual Transmission. *J. Romaguera, C. Zorrilla, C. Díaz, R. Moscoso, A. De La Vega, J. Carrodeguas, San Juan, Puerto Rico.*

M.B.P.28 Comparison of Lifestyles and High Risk Sexual Behavior between HIV Seropositive and HIV Seronegative Pregnant Women. *Carmen D. Zorrilla*, J. Romaguera, J. Torres, L. Morales, K. Adamsons, *University of Puerto Rico School of Medicine, San Juan, Puerto Rico,*

M.B.P.29 Reproductive History (Hx) of HIV Antibody Positive (HIV AB+) Women Followed in a Prospective Study in Newark, N.J., U.S.A. *Mary Shneck*, L. Goode, E. Connor, B. Holland, M. Oxtoby, J. Oleske, *University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A.*

M.B.P.30 Drug Abuse and Pregnancy: Concomitant Risk Factors for HIV Infection. *Susan M. Weiner*, K. A. Kaltenbach, L. P. Finnegan, *Family Center, Thomas Jefferson University Hospital, Philadelphia, PA, U.S.A.*

M.B.P.31 Equally Poor Response to Tetanus Vaccine in HIV Seropositive and Seronegative Mothers in Zaire. *Robert W. Ryder*, E. Baende, N. Halsey, A. Donnenbeurg, T. Quinn, *Projet SIDA, Kinshasa, Zaire.*

M.B.P.32 Caractères épidémiologiques et évolution clinique de 45 patientes enceintes séropositives pour le VIH. *Muriel Eliaszewicz*, F. Parnet-Mathieu, M. G. Meyohas, O. Vincenti, J. Barrat, Y. Brossard, *Hôpital St-Antoine, Service des maladies infectieuses, Paris, France.*

M.B.P.33 HIV-1 Seroprevalence and Risk Behavior Are Increased in Pregnant Women Receiving no Prenatal Care. *Bonnie J. Dattel*, L. B. Hauer, W. Crombleholme, D. V. Landers, R. Edison, R. L. Sweet, et al., * University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

M.B.P.34 Does Pregnancy Influence Disease Progression in HIV Positive Women? *Jean-François Delfraissy*, J. C. Pons, D. Séréni, V. Chambrin, D. Meyer, P. Engelman, et al., *Hôpital Antoine-Béclère, Clamart, France.*

Infections opportunistes diverses
Miscellaneous Opportunistic Infections

M.B.P.35 Quantification of Glomerular and Tubular Marker Proteins in Urine of Hemophiliacs with Positive HIV Antibody Test. *Dirk Schmidt*, H. Pohlmann, W. Hofmann, W. Schramm, J. Eigler, W. Guder, *Institut Klin. Chemie Städtisches-Krankenhaus München-Bogenhausen, Munich, Federal Republic of Germany.*

M.B.P.36 Isolation of a Bacterium from Epithelioid Angiomatosis. *Alvin E. Friedman-Kien*, C. J. Cockerell, D. Zucker-Franklin, P. M. Tierno, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.37 AZT's Effect on Responses to Pneumococcal Vaccine (PV). *Jordon B. Glaser*, S. Volpe, G. Schiffman, *The Staten Island Hospital, Staten Island, NY, U.S.A.*

M.B.P.38 Growth of the Cat Scratch Disease Bacillus from Skin Lesions and Blood in Two HIV Positive Men. *Pearl Ma*, J. Nord, J. Oliver, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A.*

M.B.P.39 Empiric Antibiotherapy of Febrile Episodes in HIV Carriers. *Michaël Finaud*, J. Rossi, J.-C. Mayordome, P. Casanova, *Hôpital Conception, maladies infectieuses, Marseille, France.*

M.B.P.40 Comparative Study of Clinical Laboratory and Pathological Diagnosis in 35 Patients with AIDS. *Rosana Del Bianco*, J. Sullemmann, M. F. Araujo, P. S. Prado, D. Carnaúba, R. L. Mecelis, et al., *Centro de Referência e Treinamento em AIDS, Sao Paulo, Brazil.*

M.B.P.41 Apport de la tomodensitométrie au diagnostic des complications pulmonaires du SIDA de l'adulte. *Pierre M. Trotot*, C. Sandoz-Tronca, M. Marichez, R. Levillain, *Institut Pasteur, Paris, France.*

M.B.P.42 Evolution of Lung HIV-Specific CTL Activity and Clinical Correlations. *Brigitte Autran*, J.-M. Guillon, P. Joly, F. Plata, P. Debre, C. Mayaud, et al., *Hôpital Pitié-Salpêtrière, Paris, France.*

M.B.P.43 The Value of Gallium-67 Scan in the Diagnosis of Lymphadenopathy in Symptomatic HIV-infected Patients. *Daniel Podzamczer*, I. Ricart, F. Bolao, D. Bonin, V. Romagosa, F. Gudiol, *Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.*

M.B.P.44 Lymphadenopathy and Human Immunodeficiency Virus (HIV) Infection in Sao Paulo, Brazil. *Ricardo L. Chaves*, M. F. A. Nascimento, L. Batista, A. Albano, *Hospital Emilio Ribas, Sao Paulo, Brazil.*

M.B.P.45 Seronegative Disseminated Coccidioidomycosis in Patients with HIV Infection. *Diana Antoniskis*, M. U. Rarick, B. Akil, R. A. Larsen, J. M. Leedom, *Los Angeles County, University of Southern California, Pasadena, CA, U.S.A.*

M.B.P.46 Coccidioidomycosis among Patients Infected with HIV: A Prospective Epidemiologic Study. *Neil M. Ampel*, C. L. Dols, J. N. Gagliani, *Tucson Veterans Administration Medical Center, University of Arizona College of Medicine, Tucson, AZ, U.S.A.*

M.B.P.47 Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus II with Foscarnet in a Person with AIDS. *Renslow Sherer*, K. Muller, S. Blair, S. Kathpalia, R. Muldoon, E. Hill, et al., *Cook County Hospital, Chicago, IL, U.S.A.*

M.B.P.48 Foscarnet Treatment of Acyclovir (ACV)-resistant Herpes Simplex Virus (HSV) Infection in 26 AIDS Patients. *Sharon Safrin*, T. Assaykeen, S. Follansbee, J. Mills, *San Francisco General Hospital, Division of Infectious Diseases, San Francisco, CA, U.S.A.*

M.B.P.49 Successful Therapy of Progressive Acyclovir-Resistant Orofacial Herpes Simplex with Intravenous Foscarnet in an AIDS Patient. *Richard K. Sall*, C. L. Kauffman, C. S. Levy, *Washington Hospital Center, Washington, DC, U.S.A.*

M.B.P.50 Ulcerative Herpes Simplex (UHS) in AIDS Patients. *Guido Carminati*, R. Zerboni, M. Mansi, M. Cusini, S. Muratori, E. Alessi, *1st Clinic of Dermatology, University of Milan, Milan, Italy.*

M.B.P.51 Successful Treatment of Severe Acyclovir-resistant Herpes Simplex Virus Type 2 Proctitis in Two Patients with AIDS: Use of Continuous Infusion Acyclovir. *Jeffrey P. Engel*, J. Englund, C. Fletcher, *East Carolina University School of Medicine, Greenville, MS, U.S.A.*

M.B.P.52 Acyclovir Therapy of Acute Retinal Necrosis Syndrome (ARN) in AIDS Patients. *Eva-Maria Fabricius, Augenklinik Krankenhaus München-Harlaching, Munich, Federal Republic of Germany.*

M.B.P.53 HIV, Human Papillomavirus, and Cervical Dysplasia in Nairobi Prostitutes. *Joan Kreiss*, N. Kiviat, F. Plummer, E. Ngugi, P. Waiyaki, K. Holmes, *University of Washington, Seattle, WA, U.S.A.*

M.B.P.54 Prevalence and Risk Factors for HIV-1 Infection in Patients with Acute Pelvic Inflammatory Disease (PID). *Sharon Safrin*, B. J. Dattel, L. B. Hauer, R. Edison, W. Crombleholme, R. L. Sweet, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

M.B.P.55 Diagnostic et traitement des lésions cervico-vaginales et vulvaires à papillomavirus chez les femmes séropositives pour le virus VIH. *Patrick Caubel*, H. Foulques, J. Blondon, J. P. Lefranc, *Service de chirurgie gynécologique, Hôpital de la Salpêtrière, Paris, France.*

M.B.P.56 Human Immunodeficiency Virus and Human Papilloma Virus in the Development of Cervical Intraepithelial Neoplasia (CIN) in Past Intravenous Drug Abusers (PIVDA) Women. *Maria-Luisa Muggiasca*, E. Conti, L. Ravasi, D. Imperiale, A. Agarossi, M. Conti, *VII Clinica Ostetrico Ginecologica dell'Università di Milano, Milan, Italy.*

M.B.P.57 Genital Ulcers (GU) and HIV Infection in an Urban Sexually Transmitted Disease (STD) Clinic. *Keith Chirgwin*, S. Dillon, J. Dehovitz, S. H. Landesman, W. McCormack, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

M.B.P.58 The Risk of Progression of Cervical Dysplasia in Women with HIV. *Caroline S. Bradbeer*, E. Heyderman, *St. Thomas' Hospital, London, U.K.*

M.B.P.59 Cervical Intraepithelial Neoplasia in HIV Infected Women. *Diana J. Sojo*, A. Fresneda, F. Babin, A. Lazaro, S. Abad, *Centro de Promoción de la Salud, Distrito Centro, Madrid Council, Madrid, Spain.*

M.B.P.60 High Rates of Cervical Dysplasias, Cervical Intraepithelial Neoplasias (CIN) and Human Papilloma Virus Infections in HIV-infected Female Patients. *Klaus F. Hiller*, R. Lutz, S. Baur, M. Stauber, *University of Munich, University Women's Hospital, Munich, Federal Republic of Germany.*

M.B.P.61 Infection in HIV Seropositive Individuals with the EBNA 2B Epstein-Barr Virus Subtype: Correlation with T4 Lymphocyte Numbers. *Jean-Marie Seigneurin*, M. Buisson, D. Eme, O. Genoulaz, K. Beldjord, J. M. Andrieu, et al., *Faculté de médecine de Grenoble, La Tronche, France.*

M.B.P.62 Association of Epstein-Barr Virus in Epithelioid Angiomatosis of AIDS Patients. *Jeannette Guarner*, E. R. Unger, *Emory University, Department of Anatomic Pathology, Atlanta, GA, U.S.A.*

M.B.P.63 Effects of rhG-CSF on Secondary Infections in AIDS. *Satoshi Kimura*, H. Mohri, H. Sugiyama, A. Nakagawa, K. Mitamura, K. Shimada, et al., *Institute of Medical Science, the University of Tokyo, Tokyo, Japan.*

M.B.P.64 Prevalence and Clinical Significance of Coomb's Test and Cold Agglutinins in AIDS Patients. *Johannes R. Bogner*, B. Gathof, B. Heinrich, A. Matuschke, U. Bäcker, F.-D. Goebel, *University of Munich, Medizinische Poliklinik, Munich, Federal Republic of Germany.*

M.B.P.65 Increase of Factor VIII Activity in HIV Infected Patients. *Sergio Gafà*, P. Rivasi, A. Artioli, F. Vezzani, A. Tuzza, *Divisione Malattie Infettive, Arcispedale S. Maria Nuova, Modena, Italy.*

M.B.P.66 Therapy of Salmonella Infections in AIDS Patients. *Kenneth V. I. Rolston*, S. J. Rodriguez, P. Mansell, *The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.*

M.B.P.67 Salmonella Bacteremia and HIV Infection. *Inmaculada Ocaña*, A. De Luis, A. Planes, A. Pahissa, E. Serra, J. M. Martínez-Vázquez, *Autonomous University of Barcelona, Barcelona, Spain.*

M.B.P.68 Shigella Enteritis among AIDS Cases in Los Angeles. *Loren E. Lieb*, M. P. Tormey, D. P. Ewert, P. K. Wakamarsu, G. H. F. Y. Run, P. R. Kerndt, *Los Angeles County Health Services, Los Angeles, CA, U.S.A.*

M.B.P.69 Clinical Presentation and Quinolone (Q) Therapy of Salmonella in HIV Infection. *Nigahus Karabulut*, R. Porwancher, C. Cherney, A. Ricketti, R. Friedland, *Saint Francis Medical Center, Trenton, NJ, U.S.A.*

M.B.P.70 Nosocomial Infection (NI) in Patients with HIV Infection. *Christopher P. Kales*, R. S. Holzman, K. Krasinski, R. LaCouture, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.71 Bacteremic Pneumococcal Disease as the First Manifestation of Human Immunodeficiency Virus (HIV) Infection in Adults. *Jay F. Dobkin*, W. Mandell, N. Sethi, *Presbyterian Hospital, Columbia University, New York, NY, U.S.A.*

M.B.P.72 Staphylococcus Aureus Nasal Carriage Rate in Patients with AIDS or ARC. *Mario C. Raviglione*, P. Mariuz, A. Pablos-Mendez, P. Ottuso, A. Taranta, S. Scimeca, *Department of Medicine, Cabrini Medical Center, New York, NY, U.S.A.*

M.B.P.73 Prevalence of Significant Lower Respiratory Bacterial Infections in HIV Positive Persons Undergoing Bronchoscopy with Semi-Quantitative BAL Culture. *Kenneth J. Skahan*, R. P. Baughman, P. T. Frame, *University of Cincinnati Medical Center, Department of Medicine, Cincinnati, OH, U.S.A.*

M.B.P.74 AIDS-Associated Urinary Tract Infection (UTI). *Luiz Paulo José Marques*, O. Santos, G. S. Lopes, M. C. De Lacerda, G. B. Teixeira, M. M. Fernandes, *Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.75 Severe Bacterial Infections in AIDS Patients. *Piero Marone*, P. Sacchi, P. Grossi, G. Gatti, *University of Pavia, IRCCS San Matteo Hospital, Pavia, Italy.*

M.B.P.76 Bacterial Infections in AIDS. *Pramod M. Shah*, A. Bolz, E. B. Helm, W. Stille, *University Hospital, Center for Internal Medicine, Frankfurt, Federal Republic of Germany.*

M.B.P.77 Listeriosis in Patients with HIV Infection. *Christopher P. Kales*, R. S. Holzman, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.78 AIDS Related Histoplasmosis. *James M. Parks*, S. D. Nightingale, S. M. Pounders, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.*

M.B.P.79 Disseminated Histoplasmosis in a Danish AIDS Patient. *Else Smith*, M. Franzman, L. Mathiesen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

M.B.P.80 Chronic Suppression of Disseminated Histoplasmosis in HIV Disease with Oral Ketoconazole. *Robert E. Neihart*, J. Brewer, *St. Luke's Hospital, Kansas City, MO, U.S.A.*

M.B.P.81 Histoplasmosis in an AIDS Patient Treated with Itraconazole. *Mike Youle*, J. Midgley, D. Shanson, C. Campbell, B. Gazzard, *St. Stephen's Hospital, London, U.K.*

M.B.P.82 Histoplasmose africaine disséminée chez un enfant noir de Guinée Bissau, séropositif pour HIV-2. *M. J. Matos Almeida, Serviço Dermatologia, Hospital Sta. Maria, Lisbon, Portugal.*

M.B.P.83 Rhodotorula Rubrum Septicemia in an AIDS Patient with an Indwelling Hickman Catheter. *Dennis M. Causey*, J. M. Leedom, C. Olsen, *University of Southern California, Los Angeles, CA, U.S.A.*

M.B.P.84 Sepsis from Implanted Catheters in Patients with AIDS. *Jonathan H. Rosenthal*, C. Langley, M. Lederman, *Case Western Reserve University, Cleveland, OH, U.S.A.*

M.B.P.85 Experience with Central Venous Catheters (CVCs) in Patients with AIDS. *Joseph R. Thurn*, C. Miller, S. Johnson, F. Rhame, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

M.B.P.86 Indwelling Right Atrial Catheter (IAC) Infections in AIDS Patients. *Athanasios Skoutelis*, J. Phair, C. Sterkel, J. Von Roenn, R. Murphy, K. MacDonell, *Northwestern University Medical School, Section of Infectious Diseases, Chicago, IL, U.S.A.*

M.B.P.87 Infections and Complications of Indwelling Central Venous Catheters (CVC): Comparisons between Patients (PTS) with AIDS Vs. Other Illnesses (Non-AIDS). *Brian R. Saltzman*, D. C. Perlman, D. I. Levey, D. Sturm, L. Kelly, *Beth Israel Medical Center, New York, NY, U.S.A.*

M.B.P.88 Pharmacocinétique (sang-liquide rachidien) de fortes doses d'acyclovir IV chez les patients HIV+. *Pascal Chavanet*, M. Buisson, P. Lokiec, S. Aho, P. Bielefeld, A. Waldner, et al., *Service des Maladies infectieuses et tropicales, Hôpital du Bocage, Dijon, France.*

M.B.P.89 Hickman Catheter Infections in AIDS. *Mario C. Raviglione*, R. Rattan, A. Pablos-Mendez, P. Aceves-Casillas, M. P. Mullen, A. Taranta, *Department of Medicine, Cabrini Medical Center, New York, NY, U.S.A.*

M.B.P.90 Invasive Aspergillosis (IA) in AIDS: Clinical Manifestations and Predisposing Factors. *David C. Perlman*, N. Salomon, B. R. Saltzman, A. Klapholz, W. Talavera, *Beth Israel Medical Center, New York, NY, U.S.A.*

M.B.P.91 Cryptococcose, histoplasmose africaine et SIDA au Congo. *Bernard Carme*, A. Mbitsi, A. Ngolet, A. Itoua-Ngaporo, B. Ebikili, G. M. Aya, et al., *Centre hospitalier et universitaire de Brazzaville, Brazzaville, Congo.*

M.B.P.92 A Multicenter Trial on the Efficacy and Safety of Fluconazole in the Treatment of Opportunistic Fungal Infections, Sponsored by the Italian Institute of Health. *S. Vella*, D. Greco, M. G. Agresti, A. Cassone, G. De Crescenzo, M. P. Ruffilli, *National Institute of Health, Rome, Italy.*

M.B.P.93 Paracoccidioidomycosis and HIV Infection. *Rogerio J. Pedro*, F. H. Aoki, M. L. Branchini, J. N. Lima, W. B. Abreu, M. B. S. Dias, *Hospital de Clinicas, UNICAMP, Grupo de AIDS, Campinas, Brazil.*

M.B.P.94 Disseminated Infection Due to Penicillium Marneffei in an HIV Positive Patient. *Massimo Coen*, M. A. Viviani, G. Rizzardini, A. M. Tortorano, C. Bonaccorso, T. Quirino, *Ospedale "L.Sacco", 1 Divisione Malattie Infettive, Milan, Italy.*

M.B.P.95 Invasive Aspergillosis: An AIDS Typical Opportunistic Infection? *Juan Artigas*, G. Grosse, F. Staib, M. Steibold, W. Heise, *Auguste-Viktoria Hospital, Department of Pathology, Berlin, Federal Republic of Germany.*

M.B.P.96 Fluconazole Treatment for Fungal Infection in ARC and AIDS. *Francesco M. Gritti*, E. Raise, V. Vannini, G. Di Giandomenico, G. Lanzoni, *Ospedale Maggiore, Bologna, Italy.*

M.B.P.97 Visceral Leishmaniasis as HIV-associated Infection: Report of 5 Cases. *Ana Salas*, J. Altes, M. Riera, J. Balanzat, C. Villalonga, *Hospital Son Dureta, Mallorca, Baleares, Spain.*

M.B.P.98 Unusual Diagnosis of Leishmaniasis in AIDS. *Inmaculada Ocaña*, A. De Luis, D. Irreguible, T. Vallespi, M. Torrebadella, J. M. Martínez-Vázquez, *Autonomous University of Barcelona, Barcelona, Spain.*

M.B.P.99 HIV Serology and Visceral Leishmaniasis in Cameroon. *Lazare N. Kaptue*, E. Fomekong, L. Zekeng, *Ministry of Public Health, Yaounde, Cameroon.*

M.B.P.100 Tropical Diseases of HIV Patients in Non-endemic Countries: A Case of Visceral Leishmaniasis and a Case of Tropical Pyomyositis. *C. Elsing*, J. F. Erckenbrecht, F. Borchard, G. Strohmeyer, *Department of Medicine, University of Düsseldorf, Düsseldorf, Federal Republic of Germany.*

M.B.P.101 Detection of HIV-1 in Cerebrospinal Fluid (CSF): Correlation with Presence and Severity of the AIDS Dementia Complex. *Morris O. Paul*, B. J. Brew, R. W. Price, A. Khan, M. Gallardo, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

M.B.P.102 Cerebral Abcess Caused by Trypanosoma Cruzi in a Patient with AIDS. *Matias Kronfeld*, E. Sprinz, A. Cavalcanti, A. Carneiro, L. Severo, *Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

M.B.P.103 Role of Pulmonary Function Tests (PFT) and CD4 Lymphocyte Count for Diagnosing Lung Complications in AIDS. *Bonaventura Clotet*, O. Parra, H. Sala, J. Ruis, J. Morera, *Pneumology and Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain.*

M.B.P.104 The Efficacy of Screening Tests for Infectious Diseases in Persons with Symptomatic ARC. *Fred M. Gordin*, P. M. Hartigan, C. Oster, *VA Medical Center, Washington, DC, U.S.A.*

M.B.P.105 Elevation of Lactate Dehydrogenase in Asymptomatic AIDS Patients. *A. Regeniter*, W. H. Siede, H. D. Brede, H. Rübsamen-Waigmann, U. M. E. Unkelbach, U. B. Seiffert, *Zentrallabor, Klinikum der J. W. Goethe Universität, Frankfurt, Federal Republic of Germany.*

M.B.P.106 67 Gallium Scintigraphy of Chest in AIDS Patients. Analysis of 152 Cases. *Giuseppe Visco*, P. Narciso, F. M. Pau, F. Pigorini, M. A. Rosci, P. Sette, * Hospital "L. Spallanzani", Department of Infectious Diseases, Rome, Italy.*

M.B.P.107 Adenosine Deaminase (ADA) Levels in Sera of Patients with HIV-1 Infection. *Javier Ena*, V. Valls, I. Figueredo, V. Roca, R. E. De Salamanca, *Hospital Clinico San Carlos, Madrid, Spain.*

M.B.P.108 Clinical Manifestations of AIDS in Women from Sao Paulo, Brazil. *Ana-Carolina Ferreira*, J. L. Grandi, M. E. Fernandes, *Reference and Training Center for AIDS, Sao Paulo, Brazil.*

M.B.P.109 Opportunistic Infections in AIDS Patients: A Comparison of Clinical and Postmortem Findings in Rio de Janeiro, Brazil. *Carla Ismael*, D. J. H. Signorini, D. P. Oliveira, M. C. R. Lacerda, C. A. Basílio de Oliveira, C. A. Morais de Sá, *Gaffrée and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.110 A Serologic Study of Cryptosporidium Infection in HIV Positive Men and the Relationship to T-Cell Subsets. *Charles T. Leach*, T. Kuhls, D. Mosier, P. English, J. Giorgi, J. Cherry, et al., *University of California at Los Angeles School of Medicine, Los Angeles, CA, U.S.A.*

M.B.P.111 CD4+ T-Lymphocytes and the Manifestation of Opportunistic Mucocutaneous Infections in HIV Infection. *Helmut Schöfer*, F. R. Ochsendorf, R. Milbradt, *Klinikum der J. W. Goethe-Universität, Department of Dermatology, Frankfurt, Federal Republic of Germany.*

M.B.P.112 Prevalence of Hepatitis B and Delta Virus Infection in Hemophiliacs with AIDS. *Carlos Eduardo Brandao-Mello*, A. L. Gonzaga, J. P. Simonetti, S. R. R. Simonetti, *Centro de Hematologia Santa Catarina, Hospital Gaffrée e Guinle, Rio de Janeiro, Brazil.*

M.B.P.113 Chronic Acute Hepatitis (CAH) in Two Groups of IVDAs (HBcAb Positive) with and without HIV Infection. *Franco Fedeli*, G. Gardini, S. Gafà, M. G. Giudici, A. Tuzza, E. Nigrisoli, *Surgical Pathology Department, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.*

CMV
CMV

M.B.P.114 Human Cytomegalovirus Antigenemia for Monitoring Systemic Infections and Ganciclovir Treatment in AIDS Patients. *Lorenzo Minoli*, M. G. Revello, E. Percivalle, M. Zavattoni, P. Grossi, G. Gerna, *Institute of Infectious Diseases, University of Pavia, Pavia, Italy.*

M.B.P.115 The Significance of Detecting Cytomegalovirus in Bronchoalveolar Lavage Samples from AIDS Patients with Respiratory Disease. *Simon E. Barton*, D. A. Hawkins, B. G. Gazzard, *Kobler Centre, St. Stephen's Hospital, London, U.K.*

M.B.P.116 Cytomegalovirus Colitis in AIDS: Presentation in 33 Patients. *Douglas T. Dieterich*, M. Rahmin, H. Rotterdam, D. Dolitsky, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.117 Prophylaxis of CMV Retinitis Relapse : Evaluation of Foscarnet in Maintenance Therapy. *Christine Katlama*, E. Dohin, I. Massin-Cochereau, D. Fassin, P. Le Hoang, M. Gentilini, *Département de santé publique, Parasitologie, Médicine tropicale, Hôpital Salpêtrière, Paris, France.*

M.B.P.118 CMV Meningoencephalomyelitis AIDS: A Case Report. *Ennio Ricchi*, P. Costigliola, A. Casadei, F. Giangasparo, F. Chiodo, *Università di Bologna, Istituto di Malattie Infettive, Bologna, Italy.*

M.B.P.119 Treatment of CMV Retinitis in AIDS: Experience with 59 Courses of Foscarnet (PFA). *Christine Katlama*, E. Dohin, B. Girard, M. Gentilini, M. Rosenheim, P. Le Hoang, et al., *Département de santé publique, Parasitologie, Médicine tropicale, Hôpital Salpêtrière, Paris, France.*

M.B.P.120 Ganciclovir Therapy in Gastrointestinal Cytomegalovirus Lesions in AIDS. *Walter Heise*, P. Mostertz, K. Arasteh, G. Grosse, M. L'Age, H. Timm, *Auguste-Viktoria Hospital, II Department Internal Medicine, Berlin, Federal Republic of Germany.*

M.B.P.121 Ganciclovir Therapy for Cytomegalovirus Related Polyradiculo(myelo)pathy in Patients with AIDS. *Jan De Gans*, G. Tiessens, P. Portegies, D. Troost, S. A. Danner, *Academisch Medisch Centrum, Department of Neurology, Amsterdam, Netherlands.*

M.B.P.122 An Open Comparative Study of Foscarnet and Ganciclovir in the Treatment of CMV Retinitis. *Mark E. Newell*, M. Harris, G. Moyle, D. Smith, J. Clarbour, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

M.B.P.123 Tolerance and Efficacy of Daily Intravenous (IV) Maintenance Foscarnet (PFA) Therapy for Cytomegalovirus (CMV) Retinitis in AIDS Patients (ACTG Protocol 015). *Mark A. Jacobson*, D. Causey, D. Hardy, B. Polsky, J. Mills, J. Feinberg, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.B.P.124 Cytomegalovirus Cultures during Maintenance DHPG Therapy for CMV Retinitis in AIDS. *Jennifer F. Hoy*, I. D. Jennens, C. R. Lucas, A. M. Sandland, H. MacLean, K. Hayes, *Fairfield Infectious Diseases Hospital, Fairfield, Australia.*

M.B.P.125 Pulmonary CMV Infection in AIDS Patients: A Clinicopathologic Study. *Heinz Krystossek*, B. Ruf, G. Jautzke, H. Timm, H.-D. Pohle, *Rudolf Virchow University Hospital, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

M.B.P.126 Possible Usefulness of High Dose Acyclovir as Prophylaxis for CMV. *Craig E. Metroka*, H. Josefberg, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

M.B.P.127 Diagnosis and Grading of CMV Colitis: Comparison of H & E Stains, DNA In-situ Hybridization, and Immunoperoxidase Stains for Early and Late Antigens. *Heidrun Rotterdam*, Y. J. She, D. Dieterich, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.128 A Randomized Controlled Clinical Trial of Foscarnet for the Treatment of Cytomegalovirus Retinitis in Patients with Acquired Immunodeficiency Syndrome . *Michael A. Polis*, R. T. Davey, H. Lane, J. Manischewitz, H. Masur, A. Palestine et al., *National Institutes of Health, Clinical Center, Bethesda, MD, U.S.A.*

M.B.P.129 Therapy of Cytomegalovirus (CMV) Infections with Ganciclovir. *Kenneth V. I. Rolston*, S. J. Rodriguez, F. Carvajal, J. Nelson, G. P. Bodey, P. Mansell, et al., *University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.*

M.B.P.130 Treatment with Ganciclovir (D.H.P.G.) in HIV Carriers with CMV in the Bronchoalveolar Lavage. *Michaël Finaud*, C. Tamalet, P. Casanova, *Hôpital Conception, Département des maladies infectieuses, Marseille, France.*

M.B.P.131 In Vitro Secretion of CMV Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. *Jean-Pierre Vendrell*, M. Segondy, J. Ducos, J. Reynes, M.-F. Huguet, A. Cannat, et al., *Université Montpellier I, Hôpital Lapeyronie, Montpellier, France.*

M.B.P.132 Efficacy and Toxicity of Ganciclovir Maintenance Treatment in AIDS-related CMV Retinitis. *Willy Rozenbaum*, S. Gharakhanian, L. Zazoun, M. Vaseghi, R. De Sahb, M. Thomson, *Unité de maladies infectieuses, Hôpital Rothschild, Paris, France.*

M.B.P.133 Foscarnet Continuous Infusion in HSV Infection with AIDS. *Alberto Volonterio*, I. Schlacht, F. Genova, M. R. Villa, I. Errante, L. Caggese, *Niguarda Ca' Granda Hospital, Milan, Italy.*

M.B.P.134 Predominance of Polymorphonuclear Leukocytes in Cerobrospinal Fluid of AIDS Patients with Cytomegalovirus Related Polyradicul(myelo)pathy. *Jan De Gans*, G. Tiessens, P. Portegies, D. Troost, *Academisch Medisch Centrum, Department of Neurology, Amsterdam, Netherlands.*

M.B.P.135 Intestinal HIV Expression in AIDS Patients with Cytomegalovirus Colitis. *Donald P. Kotler*, S. Reka, W. Cronin, A. Borcich, A. Tierney, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

M.B.P.136 Electron Microscopy of AIDS Related Cytomegalovirus (CMV) Infection of the Lung. *Pierre G. Bauer*, C. A. Basilio, F. Fialho, H. A. Valle, F. S. Sion, C. A. M. Sá, *Department of Virology, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.*

Transfusions
Transfusions

M.B.P.137 Demographic and Epidemiological Characteristics of HIV Positive Blood Donors in Catalonia. *Jordi Casabona*, G. Barba, A. Segura, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain.*

M.B.P.138 A Safer Test Tube for HIV and Other Viral Marker Tests. *Habib A. Sioufi*, M. S. Jacobson, M. A. Renaud, S. V. Kevy, *Medcon Research and Development Inc., Brookline, MA, U.S.A.*

M.B.P.139 HIV Screening of Commercially Available Blood Products in India. *Srikanth Prasad Tripathy*, K. Chaudhuri, Y. N. Singh, P. Seth, T. Varghese, A. N. Malaviya, *All India Institute of Medical Sciences, New Delhi, India.*

M.B.P.140 Detection of HIV Markers Prior to IgG Antibody Seropositivity in Plasma Donors. *Susan L. Stramer*, J. S. Heller, R. W. Coombs, R. V. Parry, D. D. Ho, J. L. Stewart, et al., *Abbott Laboratories, Diagnostics Division, Abbott Park, IL, U.S.A.*

M.B.P.141 Risk Factors for HIV among New York Blood Donors in 1988. *Suzanne M. Gaynor*, D. Kessler, P. Berge, S. Andrews, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A.*

M.B.P.142 Self-Exclusion by HIV Antibody Positive Blood Donors. *Suzanne M. Gaynor*, D. Kessler, S. Andrews, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A.*

M.B.P.143 Changing Profile of HIV-Seropositive Blood Donors. *Penny J. Ballem*, N. A. Buskard, M. Elliot, S. Lord, M. Sinclair, *Canadian Red Cross Blood Transfusion Service, Vancouver, BC, Canada.*

M.B.P.144 Immunophenotypes of Anti-HTLV-I Positive (+) Blood Donors. *Mary A. Fletcher*, Transfusion Safety Study, *University of Miami School of Medicine, Department of Medicine, Miami, FL, U.S.A.*

M.B.P.145 Clotting Factor Treatment and CD4 Counts in Anti-HIV+ Hemophiliacs. *George F. Gierset*, Transfusion Safety Study, *Puget Sound Blood Center, University of Washington, Seattle, WA, U.S.A.*

M.B.P.146 Serological Evidence of Prior Sexually Transmitted Diseases in HIV-1 Seropositive Blood Donors. *Alan E. Williams*, K. W. Creedon, T. Grandinetti, M. T. Sullivan, *American Red Cross, Jerome H. Holland Laboratory, Rockville, MD, U.S.A.*

M.B.P.147 Photoinactivation of HIV-1 with Merocyanine 540. *James C. Sunstrum*, R. L. Harvey, L. L. Sensenbrenner, *Wayne State University, Detroit, MI, U.S.A.*

M.B.P.148 P24 HIV Antigen Screening of Blood Donors. *Josef Eberle*, B. Gathof, U. Bäcker, E. Gossrau, R. Stute, K. Baumgarten, et al., *Max von Pettenkofer Institute, University of Munich, Munich, Federal Republic of Germany.*

M.B.P.149 HIV Seroprevalences amongst Health Blood Donors in 31 Hospitals in Zambia. *Nkandu P. Luo*, A. B. C. Dallas, L. Chipuka, R. Nshimbi, R. Tedder, J. Siyambango, *University Teaching Hospital, Lusaka, Zambia.*

M.B.P.150 Risk of HIV-1 Transmission by Blood Transfusions in San Francisco prior to Anti-HIV-1 Screening. *Michael Busch*, S. Samson, M. Young, J. Ward, H. Perkins, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A.*

M.B.P.151 Transmission du VIH-1 par transfusion: décroissance du risque. *Anne-Marie Jullien*, A. M. Couroucé, D. Richard, M. Girard, M. H. Elghouzzi, B. Habibi, *Fondation Nationale de Transfusion Sanguine, Hôpital Saint-Antoine, Paris, France.*

M.B.P.152 Experience with Notification and Follow-up of Western Blot Indeterminate Donors. *Suzanne M. Gaynor*, B. Hosein, C. Del Valle, C. Bianco, *The New York Blood Center, New York, NY, U.S.A.*

M.B.P.153 Donor Showing only Core Positive HIV Antibody: A 3-Year Follow-up. *Prakash C. Das*, A. H. DeVries, R. L. McShine, C. T. Smit Sibinga, *Red Cross Blood Bank Groningen-Drenthe, Groningen, Netherlands.*

M.B.P.154 Antigénémie HIV: Dépistage systématique des donneurs de sang de la région parisienne. *Dominique Vignon, Médico-chirurgical Foch, Suresnes, France.*

M.B.P.155 The Value of HIV Counselling Consultation Meetings at the North London Blood Transfusion Centre (1986-1989). *Riva Miller*, P. Hewitt, C. Moore, J. Barbara, M. Contreras, S. O'Brien, *Haemophilia Centre, Royal Free Hospital, London, U.K.*

M.B.P.156 Changes in the Prevalence of HIVs among Nigerian Blood Donors in Ibadan, Nigeria. *Etim M. Essien*, I. Saliu, *University College Hospital, Ibadan, Nigeria.*

M.B.P.157 Anti-HIV Screening of Blood Donors in Canada (November 1985 to December 1988). *Sadanand Mankikar*, A. Adatia, N. B. Whittemore, *The Canadian Red Cross Society, Ottawa, ON, Canada.*

M.B.P.158 HIV-2 Seroprevalence in Different Groups Tested in University College Hospital, Ibadan, Nigeria. *Etim Essien*, I. Saliu, *Department of Hematology, University College Hospital, Ibadan, Nigeria.*

M.B.P.159 Transfusion and HIV, Finnish National Look Back Program. *Jukka Koistinen, Finnish Red Cross Blood Transfusion Service, Helsinki, Finland.*

M.B.P.160 Absence of HIV Seropositivity in Children with Sickle Cell Anaemia at Kenyatta National Hospital, Nairobi, Kenya. *Samuel E. N. Waweru*, J. S. Meme, D. M. W. Kinuthia, G. W. Kitonyi, *Department of Paediatrics, University of Nairobi, Nairobi, Kenya.*

M.B.P.161 Risk of Transmission of HTLV-I by Transfusion. *James G. Donahue*, N. Cohen, A. Munoz, B. Reitz, O. Frazier, B. F. Polk, et al., *The Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

M.B.P.162 Prevalence of HTLV-I Antibodies in Blood Donors in the Netherlands. *Cees L. van der Poel*, N. Lelie, H. Reesink, P. Ehlers, E. Bakker, H. Huisman, *Red Cross Bloodbank, Amsterdam, Netherlands.*

Transfusions/Dépistage
Transfusions/Tests

M.B.P.163 Comparison of Immunoassays for Early Detection of HIV-1 Seroconverters. *James R. George*, W. Velleca, S. Phillips, G. Schochetman, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.B.P.164 Comparison of Nine HIV-1 Seroconversion Donors on Six HIV-1 Antibody Assays. *Susan L. Stramer*, J. Gibes, E. Zemel, K. Sachs, M. Mathieu, J. S. Heller, *Abbott Laboratories, HIV Technical Product Development, Chicago, IL, U.S.A.*

M.B.P.165 Progressive Changes with Time in Expression of Carbohydrates Antigen in PBL of HIV Infected Patients. *M. John Gill*, C. Schiozawa, N. Kashiwagi, D. Church, M. Ohnishi, M. C. Poon, et al., *University of Calgary, Departments of Microbiology, Infectious Diseases and Medicine, Calgary, AB, Canada.*

M.B.P.166 Packed Red Blood Cell (PRBC) Transfusion Therapy for Anemia in Patients with AIDS and ARC: Incidence, Associated Factors. *Mark A. Jacobson*, L. Peiperl, P. A. Volberding, D. Porteus, P. T. C. Y. Toy, D. Feigal, *San Francisco General Hospital, University of California, San Francisco, CA, U.S.A.*

M.B.P.167 Screening of Blood Donation with EIA Combined Test (COMBI IgG EIA) by Using Synthetic Peptides to Detect Anti-HIV1/Anti-HIV-2. *Nelson Hamerschlak*, M. B. Carvalho, H. Mizawa, K. Cavagnoli, C. C. C. Guerra, L. Szterling, *Hospital Israelita Albert Einstein, Centro de Hematologia de Sao Paulo, Sao Paulo, Brazil.*

M.B.P.168 Detection of Antibodies to Human Immunodeficiency Virus in Venous and Capillary Whole Blood by Latex Agglutination. *Céleste Chenet-Monte*, C. H. Riggin, K. Mayer, *Cambridge Bioscience Corporation, Worcester, MA, U.S.A.*

M.B.P.169 Impact of Leukocyte Filtration of Donor Blood on Reduction of Human Immunodeficiency Virus-infected Cells. *Bhupat Rawal*, M. Busch, R. Endow, H. Perkins, R. Schwadron, G. Vyas, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A.*

M.B.P.170 The Adaptation and Evaluation of High Performance ELISA Assays for Detection of HIV Antibodies in Dry Blood Spots. *John W. D. Kay*, T. S. Flowers, J. V. Roman, F. V. Crout, *Organon Teknika Corporation, Durham, NC, U.S.A.*

M.B.P.171 Do Autoantibodies to Red Blood Cells in Patients with Positive Anti-HIV Serology Really Exist? *Roberto Luzzati*, S. Ciaffoni, C. Roata, O. Antonello, G. Aprili, M. Malena, *Institute of Infectious Diseases, University of Verona, Civil Hospital, Verona, Italy.*

M.B.P.172 Evaluation of Serodia Particle Agglutination Assay for Antibody to HIV. *Michael P. Busch*, C. Bueno, R. Cordell, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A.*

M.B.P.173 Sensitivity and Selectivity of HTLV-I Immunoassays. *Steven K. H. Foung*, J. Lipka, J. Parker, *Stanford University, Department of Pathology, Palo Alto, CA, U.S.A.*

M.B.P.174 Use of Three Recombinant Assays to Test Blood Donor Samples with Western Blot (WB) Indeterminate Patterns. *Vito Scalia*, B. K. Buchner, J. P. Reeves, L. Sabourin, P. Gill, *Canadian Red Cross Society, Ottawa, ON, Canada.*

La peau
Skin

M.B.P.175 Recurrence Rate for Buccal Candidosis and Its Relationship to T4 Count and p24 Antigen. *Don E. Smith*, M. Allan, J. Migley, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

M.B.P.176 Probability of Developing AIDS in HIV-Infected Patients with Mucocutaneous Lesions. *Daniel Podzamczer*, F. Bolao, X. Pagerols, R. Pallares, F. Gudiol, *Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.*

M.B.P.177 Mycobacterial Skin Infection in AIDS. *Stylianos Lomvardias*, K. Vaidya, *Woodhull Medical and Mental Health Center, Brooklyn, NY, U.S.A.*

M.B.P.178 Hyperkeratotic Disseminated Herpes Zoster in Preterminal AIDS. *Alan M. Solinger*, W. B. Hoppenjans, R. Orme, M. Bibler, *University of Cincinnati College of Medicine, Cincinnati, OH, U.S.A.*

M.B.P.179 Varicelle et infection à HIV. *Christian M. Perronne*, M. Lazanas, C. Leport, D. Salmon, F. Bricaire, J. L. Vildé, *Service des maladies infectieuses, Hôpital Claude-Bernard, Paris, France.*

M.B.P.180 Non-Infectious Dermatoses: Correlation with CD4+ T-Lymphocytes and Stage of HIV Infection. *Falk R. Ochsendorf*, H. Schöfer, R. Milbradt, *Klinikum der J. W. Goethe-Universität, Frankfurt, Federal Republic of Germany.*

M.B.P.181 Manifestations cutanées et vénérologiques chez les malades infectés par le VIH en Guyane Française. *Roger A. Pradinaud*, D. Sainte-Marie, *Centre Hospitalier de Cayenne, Cayenne, French Guyana.*

M.B.P.182 Dermatological Manifestations and HIV Infection. *Eleonora P. Quinhoes*, E. A. V. Abreu, M. C. Rachid de Lacerda, M. S. Serra, F. S. Sion, C. A. Morais de Sá, *Gaffrée & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.183 Manifestations cutanéo-muqueuses du SIDA africain. *A. M. Coll*, M. D. Ball, E. Benga, C. Faty-Ndieye, M. A. Faye-Ndao, E. Feller-Dansokho, et al., *Hôpital de Fann, Université Cheikh Anta Diop de Dakar, Dakar, Senegal.*

M.B.P.184 Primary HIV-1 Infection with Virus Demonstrated in Histocytes of Skin Rash. *Joyce I. Wallace*, J. Oliver, S. Beatrice, *St. Vincent's Hospital and Medical Center, New York, NY, U.S.A.*

M.B.P.185 Dermatological Manifestations Related to AIDS in Central Africa. *M. Dieudonné Vohito*, R. Koyada, L. Belec, B. Di Costanzo, A. J. Georges, J. Testa, *Centre National Hospitalier Universitaire, Bangui, Central African Republic.*

M.B.P.186 Basal Cell Carcinoma in HIV Disease. *Ian Gilson*, J. Barnett, S. Snow, *Internal Medicine Specialties, Milwaukee, WI, U.S.A.*

M.B.P.187 Psoriasis in HIV Infection: Clinic, Histology and HLA Tissue Typing. *Monika Fröschl*, D. Stallmann, M. Landthaler, O. Braun-Falco, *Dermatological Department of Ludwig-Maximilians University, Munich, Federal Republic of Germany.*

M.B.P.188 Les manifestations cutanées de l'infection au HIV au Rwanda. *Fidele Harelimana*, G. Bugingo, *Université nationale du Rwanda, Hôpital universitaire, Butare, Rwanda.*

M.B.P.189 Nail Dyschromia in Zidovudine Treated AIDS/ARC Patients. *Frederick P. Duncanson*, P. C. Don, F. Fusco, P. Fried, A. Batterman, T. H. Lenox, et al., *New York Medical College, Metropolitan Hospital, New York, NY, U.S.A.*

M.B.P.190 Liposome Encapsulation Facilitates Enhanced Killing Effect of Amikacin on Mycobacterium Avium Complex (MAC) in Beige Mice and Macrophages. *Pattisapu R. J. Gangadharam*, L. Kesavalu, J. Goldstein, R. J. Debs, N. Duzgunes, *National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, U.S.A.*

M.B.P.191 Human Papilloma Virus (HPV) in Anal Bowen's Disease of Homosexual Men. *Gregory Y. Lauwers*, W. Cronin, H. L. Ioachim, *Department of Pathology, Lenox Hill Hospital, New York, NY, U.S.A.*

M.B.P.192 Peripheral CD4 Lymphocyte Counts Are Predictive of CMV, MAI, and Pneumocystis in HIV. *Craig E. Metroka*, D. Jacobus, N. Lewis, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

M.B.P.193 A High Incidence of Allergic Disorders in Patients with HIV Infection. *David N. Chernoff*, S. Sample, G. Lenahan, M. Serwonska, H. Hollander, E. Goetzl, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.B.P.194 Acute HIV Infection: Clinical and Biological Study of Twelve Patients. *Alessandro Sinicco*, G. Palestro, P. Caramello, D. Giacobbi, G. Giuliani, G. Paggi, et al., *Institute of Infectious Diseases, "Amadeo di Savoia" Hospital, University of Turin, Turin, Italy.*

M.B.P.195 Aspects cliniques HIV-1 et HIV-2 et classifications de Bangui. *A. M. Coll*, A. Sow, M. A. Faye-Ndao, G. Diouf, E. Feller-Dansokho, B. M. Diop, et al., *Hôpital de Fann, Université Cheikh Anta Diop, Dakar, Senegal.*

M.B.P.196 Suivi par IRM depuis octobre 1986 d'une cohorte de 50 patients HIV+, initialement asymptomatiques. *Pierre M. Trotot*, E. A. Cabanis, R. Lavayssière, A. E. Cabée, M. Thibierge, J. M. Bigot, et al., *Institut Pasteur, Paris, France.*

M.B.P.197 Étude de la protéine S au cours de l'infection par le VIH. *Marc Pulik*, D. Lebret-Lerolle, L. Jari, F. Teillet-Thiebaud, F. Teillet, G. Canneson, *Hôpital V. Dupouy, Argenteuil, France.*

M.B.P.198 The Implications of Human Immunodeficiency Virus (HIV) Infection and Accidental Falls (AF) among Young Patients in a City Hospital. *Tony W. Cheung*, I. Weg, *Queens Hospital Center, Long Island Jewish Medical Center, Jamaica, NY, U.S.A.*

M.B.P.199 HIV Infection Natural History: "Persistent" and "Active" Forms Do Exist and They Are Clinically Distinguishable. *Francesco Montella*, F. Di Sora, A. F. Propersi, O. Recchia, P. A. Preite, G. Macchia, et al., *Centro per lo Studio dell'AIDS e delle Sindromi Correlate, Rome, Italy.*

M.B.P.200 HIV-2 in New England. *Richard Marlink*, K. Mayer, M. Essex, J. Ayanian, J. Macguire, P. Kanki, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.*

M.B.P.201 Clinical and Autopsy Findings in HIV-1 Seropositive Patients. *Bekele Afessa*, W. Green, L. Olopoenia, S. Barnes, C. Saxinger, W. Frederick, *Howard University Hospital, Washington, DC, U.S.A.*

M.B.P.202 Pain in Patients with AIDS. *Mathew Lefkowitz*, A. H. Lebovits, *State University of New York, Department of Anesthesia, Brooklyn, NY, U.S.A.*

M.B.P.203 Recurrent Maxillary Sinusitis in AIDS Patients. *Roel J. Hadderingh, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.*

Manifestations pulmonaires
Pulmonary Manifestations

M.B.P.204 Nocardia Asteroides Infections in Patients with the Acquired Immunodeficiency Syndrome (AIDS). *Lawrence A. Cone*, G. R. Polkinghorn, D. R. Woodard, A. Berk, M. Fiala, J. Lynch, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A.*

M.B.P.205 Prolonged Healing of Spontaneous Pneumothorax and Sclerotherapy in AIDS Patients. *Susan J. Jacobson*, K. McGowan, R. Scheib, S. Schwaitzberg, C. Quinn, *Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, MA, U.S.A.*

M.B.P.206 Role of HIV Infection in Alteration of Pulmonary Function in Intravenous Heroin Addicts. *Valeriano Foresti*, A. Villa, G. Guareschi, E. Parisio, N. Scolari, A. M. Pediconi, *Fatebenefratelli Hospital, Milan, Italy.*

M.B.P.207 Pneumothoraces in Patients with AIDS. *Kent Sepkowitz*, E. E. Telzak, M. Carrow, M. Dickmeyer, E. Bernard, J. M. W. Gold, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

M.B.P.208 Spontaneous Pneumothorax in AIDS Patients on Prophylactic Aerosolized Pentamidine. *Glenn S. Newsome*, D. J. Ward, P. F. Pierce, *Georgetown University Hospital, Washington, DC, U.S.A.*

M.B.P.209 Fatal Adverse Reaction with Induced Sputum in Patients with Pleural Effusions. *Mark R. Nelson*, D. E. Smith, D. Hawkins, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

M.B.P.210 Cell Differentials in Bronchoalveolar Lavage (BAL) and Transbronchial Lung Biopsy (TBLB) from Patients with Advanced HIV Infection and Diffuse Pulmonary Infiltrates. *Michael G. Rust*, M. Schneider, H. Kronenberger, S. Falk, E. B. Helm, J. Meier-Sydow, *Frankfurt University Hospital, Division of Pneumology, Department of Internal Medicine, Frankfurt, Federal Republic of Germany.*

M.B.P.211 Spectrum of Pulmonary Diseases Associated with the Acquired Immunodeficiency Syndrome. *Thomas Weinke*, W. Scherer, C. Ortmann, H.-D. Pohle, *Universitätsklinikum Rudolf Virchow, Berlin, Federal Republic of Germany.*

M.B.P.212 Fiberoptic Bronchoscopic Diagnosis of Pulmonary Disease in 171 HIV-infected Patients. *Francisco J. Aspa Marco*, M. B. Padilla Ortega, I. Garcia Polo, M. P. Sanz, N. Baena Mendo, M. L. Jimenez Gonzalo-Anleo, *Hospital de la Princesa, Madrid, Spain.*

M.B.P.213 Early Detection of Pulmonary Complications in AIDS Patients: Value of Lung Function Tests (LFT) and Nuclear Medicine Procedures (NMP). *Christine Armbruster*, N. Vetter, H. Köhn, *2nd Medical Department, Pulmogisches Zentrum, Vienna, Austria.*

M.B.P.214 Valuation of the Cellular Populations in the Bronchalveolar Lavage (BAL) from HIV-Infected Patients with Pneumonitis by Various Ethiology. *Francisco J. Aspa Marco*, C. Jimenez, C. Lopez Elzaurdia, M. B. Padilla Ortega, A. Noguerado, M. L. Jimenez Gonzales-Adleo, *Hospital de la Princesa, Madrid, Spain.*

G.I., foie/hépatite et autres manifestations
G.I., Liver/Hepatitis and Other Manifestations

M.B.P.215 Chronic HBsAg Positive Hepatitis in HIV Infection. *Antonietta Cargnel*, P. Viganò, G. Gubertini, P. Meraviglia, M. A. Mezzenzana, N. Zanchetta, *2nd Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy.*

M.B.P.216 Chronic Hepatitis in HIV Infected Patients. *Francesco Caredda*, A. d'Arminio Monforte, S. Antinori, G. Gaiera, L. Vago, C. Parravicini, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

M.B.P.217 Reactivation of Acute Hepatitis B in AIDS. *Roberto Luzzati*, G. Di Perri, M. Malena, E. Rossi, P. Iuzzolino, D. Bassetti, *Institute of Infectious Diseases, University of Verona, Civil Hospital, Verona, Italy.*

M.B.P.218 HIV Infection and Delta Hepatitis in Intravenous Drug Addicts. *G. Lake-Bakaar*, K. Bhat, S. Govindarajan, *SUNY Health Science Center, Brooklyn, NY, U.S.A.*

M.B.P.219 Correlation between HIV and HBV Infections. *Alessandro Sinicco*, M. Valle, A. Santoro, C. Scolfaro, G. Cariti, *Institute of Infectious Diseases, "Amadeo di Savoia" Hospital, University of Turin, Italy.*

M.B.P.220 Modulation of Viral Hepatitis in HIV-1 Infection. *Siegbert Rossol*, R. Voth, K. H. Meyer zum Büschenfelde, G. Hess, *University of Mainz, 1st Medical Clinic, Mainz, Federal Republic of Germany.*

M.B.P.221 Influence of HIV Infection in Hepatitis Delta Chronic Carriers. *Inmaculada Castillo*, J. Bartolomé, M. F. Martínez, A. Madejón, J. C. Porres, V. Carreño, *Hepatology Unit, Fundacion Jiménez Díaz, Madrid, Spain.*

M.B.P.222 The Effect of HIV on Chronic Hepatitis B: A Study of 150 Homosexual Men. *Neil J. Bodsworth*, B. J. Donovan, *Department of Public Health, University of Sydney, Sydney, Australia.*

M.B.P.223 Liver Disease in Patients with AIDS. *Carlos Eduardo Brandao-Mello*, M. A. Silva, M. B. Correa Lima, C. A. Basilio de Oliveira, A. L. Gonzaga, *Hospital Gaffrée e Guinle, Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.224 The Interaction of HIV and Hepatitis B Vaccination in a Cohort of Homosexual and Bisexual Men. *Susan P. Buchbinder*, N. A. Hessol, A. R. Lifson, P. M. O'Malley, G. W. Rutherford, S. C. Hadler et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

M.B.P.225 Toxoplasmose oculaire au cours du SIDA. *Sophie Matheron*, S. Fégueux, L. Zazoun, P. De Truchis, J. P. Coulaud, A. G. Saimot, *Hôpital Bichat Claude Bernard, Paris, France.*

M.B.P.226 Toxoplasmose oculaire au cours du SIDA. *Mohamed Chakroun*, M. C. Meyohas, B. Pelosse, L. Zazoun, B. Vacherot, C. Leport, *Hôpital Claude Bernard, Paris, France.*

M.B.P.227 Ocular Involvement in Children with HIV Infection. *Mirella Blini*, G. Bertoni, M. Chiama, M. Massironi, A. Plebani, A. d'Arminio Monforte, *2nd Ophthalmology Clinic, University of Milan, Milan, Italy*

M.B.P.228 Vitrious Fluorophotometry in HIV Infection. *Mauro Cellini*, A. Baldi, P. Costigliola, E. Ricchi, F. Chiodo, R. Caramazza, *Cattedra Clinica Oculistica II, Policlinico S. Orsola, Bologna, Italy.*

M.B.P.229 Retinal Manifestations in HIV Patients. *Andrea Antinori*, A. Minnella, E. Pizzigallo, G. Federico, E. Tamburrini, L. Ortona, *Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.*

M.B.P.230 A Study of Retinal Cotton Wool Spots in HIV Patients. *Enrica Tamburrini*, A. Minnella, A. Antinori, A. Bagolini, *Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.*

M.B.P.231 The Liver in AIDS: A Clinical and Histologic Study. *Dirce Bonfim de Lima*, R. Lana Braga Costa, O. Fernandes da Silva, E. Jurado da Silva, P. Moreira, *Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.232 Gastrointestinal Lymphoid Hyperplasia in AIDS. *Daniel Scevola*, G. Barbarini, A. Zambelli, G. Bottari, M. Paulli, R. Fiocca, *University of Pavia, Institute of Infectious Diseases, Pavia, Italy.*

M.B.P.233 Pancreatitis Associated with HIV-1 Infection. *Scott E. Dowell*, E. A. Holt, F. K. Murphy, *Johns Hopkins University, School of Public Health, Baltimore, MD, U.S.A.*

M.B.P.234 The Value of Gastrointestinal Endoscopy for Strategy and Control of Therapy in Epidemic KS. *Andreas Plettenberg*, A. Stoehr, F. Begemann, W. Meigel, *Allgemeines Krankenhaus St-Georg, Dermatologie, Hamburg, Federal Republic of Germany.*

M.B.P.235 Acute Pancreatitis in Patients with AIDS. *Antonio Bernal*, G. Del Junco, D. Piot, E. Stool, R. Conklin, J. Conklin, *Park Plaza Hospital, Houston, TX, U.S.A.*

M.B.P.236 HIV Enteropathy in Lusaka, Zambia: A Clinical, Microbiological, Histological and Functional Study. *Christopher P. Conlon*, S. B. Lucas, N. P. Luo, A. H. Moody, A. J. Pinching, *St. Mary's Hospital Medical School, London, U.K.*

M.B.P.237 Acute Diarrhea in HIV+ Patients Associated with B. Hominis. *Scott K. Morris*, S. Shaunak, E. G. Estevez, J. A. Bartlett, H. Waskin, *Duke University Medical Center, Durham, NC, U.S.A.*

M.B.P.238 Endolimax Nana and Blastocystis Hominis Infections in HIV-1 Seropositive Patients. *Sahid Sanusi*, L. Olopoenia, M. Grigsby, S. Barnes, B. Afessa, W. Frederick, *Howard University Hospital, Washington, DC, U.S.A.*

M.B.P.239 Zidovudine Myopathy: A Prospective Study. *Barry S. Peters*, G. Wilson, A. J. Pinching, *St. Mary's Hospital, London, U.K.*

M.B.P.240 Candida Esophagitis (CE) in Patients Infected by Human Immunodeficiency Virus (HIV). *Bonaventura Clotet*, G. Sirera, J. Boix, M. Dominguez, A. Jou, J. Tor, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain.*

M.B.P.241 Gastrointestinal (GI) Structure and Mucosal Function in HIV Positive Patients. *M. John Gill*, D. Church, L. Sutherland, W. Huang, J. Kelly, *University of Calgary, Departments of Microbiology, Infectious Diseases and Medicine, Calgary, AB, Canada.*

M.B.P.242 Relation between HIV Infection and Non-A, Non-B Hepatitis. *Inmaculada Castillo*, M. G. Martínez, C. García-Reinoso, J. C. Porres, V. Carreño, *Hepatology Unit, Fundacion Jiménez Díaz, Madrid, Spain.*

M.B.P.243 Hemophagocytic Histiocytosis in the Liver of an HIV-infected Former Drug User. *David M. Novick*, R. Tempesta, R. J. Stenger, *Beth Israel Medical Center, New York, NY, U.S.A.*

M.B.P.244 Ulcerating Pharyngo-Oesophageal Leukoplakia in Advanced HIV Disease. *Valerie S. Kitchen*, M. Helbert, N. Francis, R. Logan, F. Lewis, A. J. Pinching, et al., *Praed Street Clinic, St. Mary's Hospital, London, U.K.*

M.B.P.245 Spontaneous Resolution of Candida Esophagitis (CE) in a Seroconverting Patient for HIV Antibodies. *Bonaventura Clotet*, G. Sirera, J. Boix, A. Jou, A. Ribera, C. Tural, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain.*

M.B.P.246 Detection of Hepatitis B Virus DNA in Peripheral Blood Mononuclear Cells from Asymptomatic Anti-HIV Carriers. *Inmaculada Castillo*, J. Bartolomé, G. Moraleda, M. G. Martínez, J. C. Porres, V. Carreño, *Hepatology Unit, Fundacion Jiménez Díaz, Madrid, Spain.*

M.B.P.247 Aphthous Ulcerations of the Gastrointestinal Tract in Patients with AIDS. *Michael C. Bach*, D. A. Howell, A. J. Valenti, T. Smith, R. H. Dretler, D. L. Winslow, *Maine Medical Centre, Portland, ME, U.S.A.*

Manifestations hématologiques
Hematologic

M.B.P.248 Haematologic Abnormalities in HIV Infection. *Salvatrice Mancuso*, V. Accurso, M. Spina, V. Abbadessa, R. Perricone, A. Cajozzo, *Istituto di Clinica Medica e Malattie Cardiovascolari, Universita' degli Studi, Palermo, Sicily, Italy.*

M.B.P.249 Microangiopathie thrombotique et infection HIV. *Sophie Matheron*, M. A. Khuong, P. Detruchis, E. Oksenhendler, P. Dosquet, J. P. Clauvel, et al., *Hôpital Bichat Claude Bernard, Paris, France.*

M.B.P.250 Étude prospective des anomalies de la coagulation chez 156 patients consécutifs séropositifs pour le VIH. *Bruno Taillan*, C. Roul, J. G. Fuzibet, H. Vinti, A. Pesce, J. Bayle, et al., *Médecine interne 1, Nice, France.*

M.B.P.251 Bone Marrow in AIDS Patients. *Bonaventura Clotet*, A. Casals, E. Abella, F. Milla, G. Sirera, J. Junca, *Hospital de Badalona "Germans Trias I Pujol", Badalona, Barcelona, Spain.*

M.B.P.252 Circulating Anticoagulant and Human Immunodeficiency Virus Infection. *Evelyne Bernard*, J. Durant, C. Roul, M. Carles, V. Mondain, P. Dellamonica, *Archet Hospital, Infectious Diseases Department, Nice, France.*

M.B.P.253 Lupus-like Anticoagulant and Anticardiolipin Antibodies in Non Hospitalized HIV Infected Patients. *Nathan Clumeck*, P. Capel, W. Feremans, M. Gérard, A. Janssens, D. Vandevelde, et al., *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

M.B.P.254 Les lymphadénopathies chroniques sont-elles le témoin d'une aggravation de l'immunodéficience liée au VIH? Étude d'une cohorte de 264 sujets séropositifs, Bordeaux, France. *Philippe Morlat*, D. Lacoste, P. Msellati, M. Dupon, J. L. Pellegrin, G.E.C.S.A., *Centre hospitalo-universitaire, Hôpital Pellegrin, Bordeaux, France.*

M.B.P.255 Abdominal Lymphadenopathy in 200 HIV Positive Patients. Ultrasound and Clinical Study. *J. P. Cassuto*, A. Geoffray, P. Dujardin, A. Coussement, *Service de médecine interne II, Hôpital de Cimiez, Nice, France.*

M.B.P.256 Kikuchi's Lymphadenitis in HIV Infection: A Case Report. *Stefano Pileri*, P. Baglioni, E. Ricchi, F. Tumietto, P. Costigliola, F. Chiodo, *Sezione de Emolinfopatologia, Istituto "L. e A. Seragnoli", Bologna, Italy.*

M.B.P.257 Bone Marrow Findings in HIV-Infected Patients at Gaffrée and Guinle University Hospital - University of Rio de Janeiro (UNI-RIO). *Carlos Alberto Morais de Sá*, L. C. Brito Lyra, M. Campos de Magalhaes, C. A. Basílio de Oliveira, W. Eyer-Silva, F. S. Sion, *Gaffrée & Guinle Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.258 Bone Marrow Findings in 33 Multistaged HIV-Infected Patients. *Lorenzo Minoli*, A. Malfitano, P. Sacchi, G. Poma, A. Castello, G. Castelli, *University of Pavia, IRCCS San Matteo Hospital, Pavia, Italy.*

Manifestations endocriniennes, cardiaques, rénales, musculo-squelettiques
Endocrine/Cardiac/Kidney/Musculoskeletal

M.B.P.259 Echocardiography in AIDS Patients: A Prospective Study in 24 Patients. *Thyge Lynghi Nielsen*, R. Videbæk, K. Lindvig, C. Pedersen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

M.B.P.260 Neuromuscular Involvement in HIV Infection. *Inmaculada Ocaña*, A. De Luis, J. Montalbán, J. M. Fernández, C. Cervera, J. M. Martínez Vázquez, *Autonomous University of Barcelona, Barcelona, Spain.*

M.B.P.261 Rheumatic Symptomatology in Patients Infected with the Human Immunodeficiency Virus (HIV): Prevalence and Relationship to Clinical and Laboratory Variables. *Leonard H. Calabrese*, A. Myers, D. Kelley, *Cleveland Clinic Foundation, Cleveland, OH, U.S.A.*

M.B.P.262 Joint, Bone and Muscle Lesions and HIV Infection. *Ian F. Rowe*, S. M. Forster, M. S. Youle, D. A. Hawkins, A. G. Lawrence, M. H. Seifert, et al., *Department of Rheumatology, Westminster Hospital, London, U.K.*

M.B.P.263 Reduced Cortisol Production and Adrenal Necrosis in Patients with AIDS. *David Salomao Lewi*, C. A. Accetturi, H. Sader, R. S. Dias, C. E. Kater, P. R. Motta, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

M.B.P.264 Diabetes Insipidus as a Complication of Cerebral Toxoplasmosis in an AIDS Patient. *Drago Stambuk*, S. Singh, B. Gazzard, *St. Stephen's Hospital, London, U.K.*

M.B.P.265 Deficiency of Glucocorticoids in AIDS. *Albrecht Falkenbach*, S. Klaucke, B. Michels, P. Hunold, E. Schifferdecker, P. H. Althoff, et al., *University Hospital Frankfurt, Department of Internal Medicine, Frankfurt, Federal Republic of Germany.*

M.B.P.266 Gonadal Hormone Levels and Testicular Histology in AIDS. *Conceiçao A. Accetturi*, D. S. Lewi, E. N. Arruda, A. Cedenho, J. G. Vieira, I. T. N. Verreschi, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

M.B.P.267 HIV Induces Glucocorticoid Resistance in Mononuclear Cells. *Claudia Balotta*, T. Vago, M. Bevilacqua, M. Galli, G. Norbiato, M. Moroni, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

M.B.P.268 Assessment of Adrenal Function in AIDS Patients with Documented CMV Infection. *Mary A. Young*, T. Taylor, P. Pierce, *Georgetown University Hospital, Division of Infectious Diseases, Washington, DC, U.S.A.*

M.B.P.269 Modifications in Circadian Rhythms of Plasma Levels of Cortisol, ACTH, Testosterone and Adrenal Androgens (DHEA and DHEA-S) in HIV-Infected Male Patients. *Jean-Marie Villette*, P. Bourin, C. Doinel, I. Mansour, P. Boudou, J. Fiet, *Laboratoire de Biochimie hormonale, Hôpital Saint-Louis, Paris, France.*

M.B.P.270 Disorders of Lipid Metabolism in AIDS. *Albrecht Falkenbach*, S. Klauke, U. Unkelbach, W. März, H. Förster, P. H. Althoff, et al., *University Hospital Frankfurt, Department of Internal Medicine, Frankfurt, Federal Republic of Germany.*

M.B.P.271 Hyporeninemic Hypoaldosteronism Associated with HIV-1 Positivity. *Nathan Clumeck*, D. Bosson, T. Bril, S. Harnie, S. De Wit, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

M.B.P.272 Comparison of Thyroid Biochemical Abnormalities (TBA) in Acquired Immunodeficiency Syndrome (AIDS) and Other Illnesses. *Nathan Clumeck*, P. Bourdoux, M. Bonnyns, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

M.B.P.273 Myocarditis in Intravenous Drug Abusers with and without Acquired Immunodeficiency Syndrome: An Autopsy Study. *James W. Roberts*, C. Francis, C. Navarro, J. Brown, W. El-Sadr, *Harlem Hospital Center, College of Physicians and Surgeons, Columbia University, New York, NY, U.S.A.*

M.B.P.274 The Pathology of the Male Genital Tract in AIDS. *William J. Cronin*, M. Shevchuk, M. Da Silva, N. Armenakas, J. Fracchia, M. Tannenbaum, *Lenox Hill Hospital, Department of Pathology, New York, NY, U.S.A.*

M.B.P.275 Genitoanal Ulcers in HIV Infection. *Falk R. Ochsendorf*, H. Schöfer, R. Milbradt, *Klinikum der J. W. Goethe-Universität, Department of Dermatology, Frankfurt, Federal Republic of Germany.*

M.B.P.276 Need for Gynecologic Protocols in AIDS Primary Care Clinics. *Carola Marte*, D. Ribble, C. Keyes, J. Wolbert, P. Rodgers, J. Kelly, *Bellevue Hospital Center, Community Health Project, New York, NY, U.S.A.*

M.B.P.277 Outcome of Patients with Human Immunodeficiency Virus (HIV) on Chronic Dialysis (D). *M.D. Gurbindo Gutierrez*, R. Perez García, J. Luño, J. M. Lopez Gomez, A. Franco, F. Valderrabano, *Hospital General Gregorio Marañon, Madrid, Spain.*

M.B.P.278 Henoch-Schonlein Purpura and IgA Glomerulonephritis Associated with HIV Infection. *Ian L. Thompson*, D. Cooper, E. Savdie, J. Gold, R. Melville, *St. Vincent's Hospital, Sydney, Australia.*

M.B.P.279 Outcome of Kidney Transplanted Patients with HIV. *Miguel Neto Cendoroglo*, C. A. P. Pereira, C. Stabile, A. Pacheco, E. Silva, C. A. Acetturi, Z. Peixinho, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

M.B.P.280 Lack of Clinical Evidence for a Glomerulopathy (GP) in 203 Patients with HIV Infection. *Ulrike Brunkhorst*, R. Brunkhorst, B. Tschechne, G. Eisenbach, I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany.*

M.B.P.281 Nephropathy as the Initial Sign of AIDS. *Luiz Paolo José Marques*, O. Santos, G. S. Lopes, A. V. Oliveira, F. Fialho, E. P. Madeira, *Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.282 The Treatment of Infectious Causes of AIDS-associated Heart Disease. *Evlin L. Kinney*, J.-J. Monsuez, *The Reed Institute, Miami, FL, U.S.A.*

M.B.P.283 Echocardiographic Abnormalities in AIDS. *Sven A. Danner*, S. Reichert, C. Visser, A. Dunning, *Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.*

M.B.P.284 Characteristics of Patients with AIDS-associated Heart Disease but no Demonstrable Cardiac Pathogen. *Evlin L. Kinney*, J.-J. Monsuez, M. Toussaint, *The Reed Institute, Miami, FL, U.S.A.*

M.B.P.285 Left Ventricular Dysfunction in AIDS Patients with Severe Pneumocystis Carinii Infection. *Robert D. Wood*, B. Akil, J. Tuchschmidt, R. S. Swinney, C. T. Boylen, *Los Angeles County, University of Southern California, Medical Center, Pulmonary Medicine, Los Angeles, CA, U.S.A.*

M.B.P.286 Electrographic Changes in Patients Receiving Pentamidine for the Treatment of Pneumocystosis. *Bisher Akil*, A. Gonzalez, A. Bhandari, P. Sager, C. Leon, S. H. Rahimtoola, *University of Southern California, West Hollywood, CA, U.S.A.*

M.B.P.287 Staphylococcus Aureus Endocarditis in HIV+ and HIV- Intravenous Drug Abusers. *Rita Poblete*, C. Sone, M. Fischl, *University of Miami School of Medicine, Miami, FL, U.S.A.*

Néoplasme
Neoplasm

M.B.P.288 Polyclonal and Monoclonal B-Cell Lymphoma in AIDS. *Lawrence D. Kaplan*, T. Meeker, E. Feigal, B. Herndier, F. Khayam-Bashi, M. S. McGrath, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.B.P.289 Kaposi's Sarcoma in Patients with HIV Infection. *Ahmed S. Latif*, S. Houston, P. Neill, M. Bassett, C. Thornton, J. Sitima, *Medical School, University of Zimbabwe, Harare, Zimbabwe.*

M.B.P.290 Lymphomas in Patients with HIV Infection. *Carlos Del Rio*, J. Guarner, D. Carr, L. E. Hendrix, *Emory University School of Medicine, Crawford W. Long Hospital, Atlanta, GA, U.S.A.*

M.B.P.291 Kaposi's Sarcoma, Clinical Distribution, Opportunistic Infections and Survival. *Carla Ismael*, R. G. Pacheco, M. G. Dias, W. A. Eyer-Silva, L. A. Miguez, C. A. Morais de Sá, *Gaffrée & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

M.B.P.292 Lower Genital Tract Neoplasia. Its Incidence in HIV Infected Women and the Role of Human Papilloma Virus (HPV) and Other Risk Factors. *James R. Smith*, M. Byrne, M. Botcherby, P. Munday, D. Taylor-Robinson, S. M. Forster, *St. Mary's Hospital, The Praed Street Clinic, London, U.K.*

M.B.P.293 Malignant Neoplasms in Surgical Specimens of Different AIDS Risk Groups. *Heidrun Rotterdam*, M. Vasquez, G. Sidhu, *New York University Medical Center, New York, NY, U.S.A.*

M.B.P.294 B-ALL in HIV-Positive 27 Y.O. Man. *Pierluigi Oreste*, A. M. Nosari, F. De Cataldo, L. Gargantini, G. Landonio, H. Mura, *Department of Pathology, Cà Granda Niguarda Hospital, Milan, Italy.*

M.B.P.295 Unusual Presentation and Clinico-pathological Correlations in Non-Hodgkin's Lymphomas (NHL) Association with HIV Infection. *Eric Oksenhendler*, J. P. Farcet, G. Gisselbrecht, J. P. Clauvel, A. Thyss, M. Raphael, *Hôpital Saint-Louis, Paris, France.*

M.B.P.296 Absence of HLA DR5 and Kaposi's Sarcoma in Trinidad and Tobago. *Courtenay Bartholomew*, V. Wilson, F. Cleghorn, *Faculty of Medical Sciences, The University of the West Indies, Port of Spain, Trinidad.*

M.B.P.297 Kaposi's Sarcoma (KS) in Women with Acquired Immunodeficiency Syndrome (AIDS). *Tony W. Cheung*, F. Siegal, *Queens Hospital Center, Long Island Jewish Hospital Affiliation, Jamaica, NY, U.S.A.*

M.B.P.298 Lymphoblastic Leukemia in HIV-infected Patients. *Lorenzo Minoli*, R. Maserati, A. Pan, A. Malfitano, P. Sacchi, G. Pagnucco, *Infectious Disease Department, IRCCS San Matteo, Pavia, Italy.*

M.B.P.299 Predictors of Shortened Survival in Patients with Kaposi's Sarcoma and HIV-1 Infection. *Barbara Tschechne*, U. Brunkhorst, I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany.*

M.B.P.300 Treatment of Disseminated Mycobacterium Avium (MAI) with Ciprofloxacin (CPF), Ethambutol (ETH), Rifampin (RIF) and Amicacin (AMK). *Joseph Chiu*, J. Nussbaum, S. Bozzette, L. Young, P. Hesseltine, J. A. McCutchan, et al., VCIMC, Orange, CA, U.S.A.*

Programmes de soins infirmiers : éducation
Nursing Health Care Programmes: Education

M.B.P.301 Patient Compliance and Termination in Community-based Clinical Trials of AIDS Treatment. *Stephen P. Holzemer*, J. D. Seaman, *Community Research Initiative, New York, NY, U.S.A.*

M.B.P.302 Clinical Impact of Case Management by an Inpatient AIDS Clinical Nurse Specialist on Costs and Quality of Patient Care. *Diane E. Schull, Parkland Memorial Hospital, Dallas, TX, U.S.A.*

M.B.P.303 The Role of Nursing in Managing Community-Based Research. *Stephen P. Holzemer*, M. Tomita, J. Forrest, J. A. Bennett, P. B. Scherer, *Community Research Initiative, New York, NY, U.S.A.*

M.B.P.304 Nursing in the Community for People with HIV: Description of a Training/Implementation Programme. *Gorm D. Kirsch*, H. Moore, R. Mayon-White, I. Klimes, *Oxford Regional Health Authority, Oxford, U.K.*

M.B.P.305 Projective Report about Self, Family, Environment and Discomfort Associated with Symptomatic Human Immunodeficiency Virus Infection in Children. *Susan R. Carter*, P. Schwartz, T. Raburn, I. Hanson, *Clinical Research Center, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, U.S.A.*

M.B.P.306 Infection Control Nurse Role: Powerful Change Agent in Psychiatric Systems in the Era of AIDS. *Sheila H. Dollard-Pavlis*, J. B. Gordon, *Connecticut Medical Health Center, Yale-New Haven Mental Center, New Haven, CT, U.S.A.*

M.B.P.307 HIV Self-assessment and Care Program. *Tom E. Emanuele, Parkland Memorial Hospital AIDS Clinic, Dallas, TX, U.S.A.*

M.B.P.308 Outbreak of Norwegian Scabies among Health-Care Workers. *Ann Kelly*, C. Fry, *St. Stephen's Hospital, London, U.K.*

M.B.P.309 Developing Community Nurses' Skills in HIV/AIDS Programmes. *Thomas H. Snee*, B. Robottom, R. Pratt, C. Wills, J. Kuykendall, J. Newbury, *Department of Health, London, U.K.*

M.B.P.310 Total Home Health Care for Patients with HIV Disease. *Susan E. Carr*, A. J. Esposito, *Windsor Home Care Inc., New York, NY, U.S.A.*

M.B.P.311 Interdisciplinary HIV Case Management Team. *Tom E. Emanuele*, K. Joy, L. McMurtry, *Parkland Memorial Hospital AIDS Clinic, Dallas, TX, U.S.A.*

M.B.P.312 A Description of NYC's Gay Population as a Legitimate Community, and Its Response to HIV Disease. *Donald G. Smith*, M. Lyden, K. May, *Mount Sinai Medical Center, New York, NY, U.S.A.*

M.B.P.313 Los Angeles Pediatric AIDS Network (LAPAN): A County-Wide Model to Maximize Service Delivery for Children Diagnosed with HIV and Their Families. *Marcy E. Kaplan*, D. C. Garell, *Los Angeles Pediatric AIDS Network, Children's Hospital of Los Angeles, Los Angeles, CA, U.S.A.*

M.B.P.314 The Development of a Prenatal-Pediatric AIDS Liaison Service at a Municipal Hospital. *Peter A. Laqueur*, L. Watts, L. Urcuyo, J. Tropnes, P. Grier, B. Abisogun, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.S.A.*

M.B.P.315 Comprehensive Care Program for Children with HIV-related Problems and Their Care Givers. *Stanley E. Read*, S. M. King, C. Arneson, S. Palmer, R. Goldie, L. Szewczyk, et al., *Hospital for Sick Children, Toronto, ON, Canada.*

M.B.P.316 Les soins infirmiers face à l'épidémie. *Claudie Schneeberger, Assistance publique Villejuif, Villejuif, France.*

M.B.P.317 The Effectiveness and Feasibility of Hospital-based Support Group Intervention for Parents of HIV-Infected Children. *Marcy E. Kaplan*, J. A. Church, K. T. Mitsuhata, *Los Angeles Pediatric AIDS Network, Children's Hospital of Los Angeles, Los Angeles, CA, U.S.A.*

M.B.P.318 HIV and Maternal Child Health: Expanding the Expertise among Providers. *Marcia J. Quackenbush*, C. Pies, E. Melia, A. Horton, M. Schuyler, A. Mayes, *University of California AIDS Health Project, San Francisco, CA, U.S.A.*

M.B.P.319 A Comparison of Health Care Delivered to People with AIDS and ARC by a Nurse Practitioner and a Physician: A Case Matched Retrospective Study. *Jerry Wolbert*, P. Rodgers, C. Keyes, C. Marte, K. Smothers, *Bellevue Hospital Center, Community Health Project, AIDS Assessment Program, New York, NY, U.S.A.*

M.B.P.320 Survey of Tennessee Nurses' Attitudes toward AIDS. *Regina L. Monnig*, V. Harris, *Meharry Medical College, Nashville, TE, U.S.A.*

M.B.P.321 Gay Grief in the Context of AIDS. *Hildur Helgadottir, University of Calgary, Calgary, AB, Canada.*

M.B.P.322 Provider Education: The Effect of AIDS Inservice Training on Nursing Staff in a Psychiatric Setting. *Jonathan Jacobs*, P. Reid, *New York Hospital, Center for Special Studies, New York, NY, U.S.A.*

Thérapie et évaluation clinique : pharmacologie
Therapy and Clinical Evaluation: Pharmacology

M.B.P.323 Pharmacokinetics of Zidovudine in AIDS Patients: Influence of Age and Hepatic Disorders. *Hélène Sauvageon-Martre*, F. Bannie, I. Tabah, B. Rio, J. Monsuez, E. Oksenhendler, et al., *Hôtel-Dieu, Pharmacie, Laboratoire de pharmacologie, Paris, France.*

M.B.P.324 Evaluation of Less Frequent Dosing in Children with Symptomatic HIV Infection. *Carlo Giaquinto*, A. Terragna, A. Plebani, P. Tovo, A. De Rossi, P. Dowd, et al., *Department of Pediatrics, University of Padua, Padua, Italy.*

M.B.P.325 Cyanocobalamin (Vitamin B12) Supplementation Does not Prevent the Hematologic Toxicity of Azidothymidine (AZT). *J. Allen McCutchan*, C. Ballard, B. Freeman, A. Bartok, D. Richman, *University of California, San Diego Medical Center, San Diego, CA, U.S.A.*

M.B.P.326 Investigation of HIV Positive Patients with Gastrointestinal Symptomatology. *Barry S. Peters*, N. Francis, A. W. Boylston, J. R. W. Harris, A. J. Pinching, *St. Mary's Hospital, London, U.K.*

M.B.P.327 Non Conclusive Results in HIV Western Blot Analysis of Mozambican Sera. *Cesar A. D. Palha de Sousa*, J. A. X. Barreto, F. V. De La Cruz, L. Barquet, *Immunology Laboratory, National Health Institute, Maputo, Mozambique.*

M.B.P.328 A Study of the Safety and Efficacy of Recombinant Human Erythropoietin (r-HuEPO) in AIDS Patients with Anemia Induced by Zidovudine (Retrovir, AZT). *Jennifer E. Thompkins*, R. Abels, J. E. Galpin, T. J. Turpen, *Porton Medical Group of Sherman Oaks, Sherman Oaks, CA, U.S.A.*

M.B.P.329 Myopathy Associated with Long-Term Zidovudine Therapy. *Margaret A. Fischl*, S. Gagnon, R. Uttamchandani, J. Patrone-Reese, L. Dearmas, S. Tarras, et al., *University of Miami School of Medicine, Miami, FL, U.S.A.*

M.B.P.330 HIV Associated Myopathy: Features in 21 Patients and Role of AZT. *David M. Simpson*, D. Wolfe, J. Farraye, A. Bender, *Mount Sinai Medical Center, New York, NY, U.S.A.*

M.B.P.331 Serum Level and Serum Kinetic of Zidovudine: Investigation with a Radioimmunoassay (RIA). *Stefan Köppen*, B. Ruf, J. Pannhorst, H.-D. Pohle, *2nd Department of Internal Medicine, Rudolf Virchow University Hospital, Berlin, Federal Republic of Germany.*

M.B.P.332 Pharmacokinetics (PK) of Zidovudine (ZDV) in Adult Patients with HIV Infection and Hepatic Disease (HD). *Teresa Tartaglione*, K. Opheim, C. Van der Horst, R. Raasch, S. Cheeseman, K. High, et al., *Harborview Medical Center, Seattle, WA, U.S.A.*

M.B.P.333 Assessment by PCR of HIV-1 Activity in AIDS-KS Patients Treated with Recombinant Interferon Alpha (r-IFNa). *Jay Epstein*, I. K. Hewlett, J. Metcalfe, C. Hawthorne, H. C. Lane, *Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, U.S.A.*

M.B.P.334 Bayesian Estimation of the Pharmacokinetic Parameters of Chronic Zidovudine (ZDV) Therapy in HIV Infected Patients. *Janice Y. Tam*, B. J. Guglielmo, H. Hollander, H. K. Mohammad, *University of California at San Francisco, Division of Clinical Pharmacy, San Francisco, CA, U.S.A.*

M.B.P.335 Effect of Zidovudine with Phase I and II Metabolism in the Liver. *N. H. Brockmeyer*, L. Mertins, M. Goos, *Department of Dermatology, University of Essen, Essen, Federal Republic of Germany.*

M.B.P.336 Zidovudine Levels in AIDS and ARC: Virologic and Haematologic Effects. *Adriano Lazzarin*, C. Uberti Foppa, P. Ronchi, P. Cinque, M. T. Reale, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

M.B.P.337 A Preliminary Study of Serum AZT Levels in HIV-Infected Individuals. *Erika Steffe*, N. M. Flynn, J. King, K. Batra, T. Tonjes, A. Winship, et al., *University of California at Davis, Sacramento, CA, U.S.A.*

M.B.P.338 Interactive Pharmacokinetics of Zidovudine and Acetaminophen. *George J. Pazin*, R. J. Ptachcinski, M. Sheehan, M. Ho, *University of Pittsburgh, School of Medicine and Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

M.B.P.339 A Sensitive and Specific HPLC Method for the Determination of Zidovudine and Zidovudine Glucuronide in Plasma and Urine. *Mohsen A. Hedaya*, R. J. Sawchuk, *University of Minnesota, Department of Pharmaceutics, Minneapolis, MN, U.S.A.*

M.B.P.340 Pharmacokinetics of AZT among HIV-infected Patients Treated by Itraconazole. *P. Henrivaux*, Y. Fairon, G. Fillet, *CHU Sart Tilman, State University of Liège, Liège, Belgium.*

M.B.P.341 Molecular Interaction of Recombinant ß Interferon and Zidovudine (AZT): Alterations of AZT Phamacokinetics in HIV-infected Patients. *Mostafa A. Nokta*, J. P. Loh, S. M. Douidar, E. A. Ahmed, R. B. Pollard, W. R. Snodgrass, *The University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX, U.S.A.*

M.B.P.342 Intravenous and Oral Pharmacokinetics of Zidovudine in Hemophilia Patients with Human Immunodeficiency Virus Infection. *Gene D. Morse*, J. Olson, A. Portmore, C. Taylor, C. Plank, R. Reichman, *State University of New York at Buffalo, Department of Pharmacy, Buffalo, NY, U.S.A.*

M.B.P.343 Pharmacokinetics of Zidovudine and p24 Ag Time Course in 48 ARC Patients Under Steady-State Conditions. *Bertrand Diquet*, F. Simon, L. Ory-Lavollée, F. Brun-Vézinet, J. N. Colin, Groupe Vigie, et al., *Hôpital de la Salpêtrière, Paris, France.*

M.B.P.344 Pharmacokinetics of Zidovudine (AZT) and Its Glucuronide (G. AZT) in Healthy Subjects and in Uremic Patients: Influence of Hemodialysis. *Eric Singlas*, J. C. Pioger, A. M. Taburet, J. N. Colin, J. P. Fillastre, *Pharmacie Clinique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.*

M.B.P.345 Comparison of Radioimmunoassay (RIA) and High Performance Liquid Chromatography (HPLC) Methods for Serum Zidovudine (AZT) Level Measurements. *K. K. Batra*, M. DeSouza, E. Stephy, N. Blynn, T. Tonjas, *University of California at Davis Medical Center, Department of Pathology, Sacramento, CA, U.S.A.*

Thérapie et évaluation clinique : marqueurs de l'évolution en cours de thérapie
Therapy and Clinical Evaluation: Markers of Evolution during Therapy

M.B.P.346 The Enumeration of Peripheral Blood HIV-antibody Secreting Cells as a Monitor of the Activity of Antiviral Drugs. *André J. Nahmias*, F. Lee, S. Nesheim, S. Lowery, A. Smith, S. Thompson, *Emory University School of Medicine, Atlanta, GA, U.S.A.*

M.B.P.347 Évaluation des lymphocytes activés et des sous-populations "Natural Killer" au cours du traitment par la zidovudine de patients présentant un ARC. *Maryse Levacher*, E. Dournon, S. Tallet, B. Rouveix, J. J. Pocidalo, Comité AZT, *INSERM U13, Paris, France.*

M.B.P.348 Relevance of Antigenemia in AIDS Patients Treated with AZT. *Marie-Christine Dazza*, E. Dournon, S. Matheron, W. Rozenbaum, C. Gaudebout, F. Brun-Vézinet, et al., *Hôpital Bichat Claude Bernard, Paris, France.*

M.B.P.349 Clinical and Laboratory Effects of AZT in HIV Positive Men Compared to a Concurrent Control Group. *Mary M. Fanning*, K. Johnson, J. Osachoff, J. Montaner, R. Coates, J. Ruedy et al., *Toronto General Hospital, Toronto, ON, Canada.*

M.B.P.350 Chez le patient, une fraction seulement de l'infection rétrovirale paraît sensible à l'AZT. *Dominique Mathez*, J. Leibowitch, D. Cesari, C. Belilovsky, I. Gorin, J. Deleuze, et al., *Hôpital Raymond-Poincaré, Garches, France.*

M.B.P.351 Persisting of HIV-Viremia in p24 Antigen Negative Subjects Receiving Zidovudine. *Adriano Lazzarin*, P. Cinque, O. Varnier, T. Bini, R. Terzi, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

M.B.P.352 Disease Progression despite Antigen Decline during Zidovudine Treatment of Asymptomatic HIV-infected Subjects: Need for Placebo Controlled Trials. *Joep M. A. Lange*, J. Mulder, F. De Wolf, R. Coutinho, J. Goudsmit, *Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.*

M.B.P.353 Follow-up of In-vitro Immunologic Parameters and Interferon Production during Long-term Zidovudine Treatment in HIV-positive Patients. *Alberto Biglino*, A. Pugliese, B. Forno, A. M. Pollono, M. Busso, M. Sciandra, et al., *University of Turin, Institute of Infectious Diseases, Turin, Italy.*

M.B.P.354 AZT Treatment Induces a Decrease of Soluble Interleukin 2 Receptor (SIL-2R) but not of Soluble CD8 Antigen (SCD8) Serum Levels in HIV Infected Patients. *Massimo Galli*, C. Balotta, A. L. Ridolfo, F. Cocchi, C. Uberti-Foppa, M. Moroni, *L. Sacco Hospital, Milan, Italy.*

M.B.P.355 AZT Therapy is Associated with an Increased Capacity of PHA-stimulated Cells to Express IL-2 Receptors (IL-2R). *Deborah McMahon*, A. Winkelstein, H. Hawk, J. A. Armstrong, G. J. Pazin, M. Ho, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.*

M.B.P.356 Predictive Value of CD8 Cell Count in Morbidity and Mortality among AIDS and ARC Patients (P) Treated with Zidovudine (AZT). *Stéphane De Wit*, M. Gérard, B. Sommereijns, N. Clumeck, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

M.B.P.357 Quantitative Dosage of Core Antibodies is a Better Prognostic Marker than HIV Antigen Assay. *Corinne A. Liesnard*, S. Przedborski, C. M. Farber, *Hôpital Érasme, Cliniques universitaires de Bruxelles, Brussels, Belgium.*

M.B.P.358 Erythrocyte Adenosine Deaminase (ADA) Expression in AZT-treated AIDS Patients. *Claudio Casoli*, G. Magnani, F. Fiaccadori, E. Barchi, R. Starcich, U. Bertazzoni, et al., *Istituto di Patologia Medica, Università di Parma, Parma, Italy.*

M.B.P.359 Effect of AZT Cessation on Levels of Antibodies Participant in Antibody-Dependent Cell Cytotoxicty (ADCC) Reactions. *André Dascal*, F. Zeira, C. Tsoukas, M. A. Wainberg, *McGill University, SMBD-Jewish General Hospital, Montreal, QC, Canada.*

M.B.P.360 Effect of Azidothymidine (AZT) on Neopterin, Beta-2-Microglobulin, Soluble CD8, Soluble Interleukin-2 Receptor, Tumor Necrosis Factor and HIV p24 Antigen Levels in Patients with AIDS Related Complex and AIDS. *Mohan M. Reddy*, G. McKinley, A. Englard, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

M.B.P.361 Serologic HIV Ag Levels and AZT Therapy in Drug Addicts. *Antonietta Cargnel*, P. Meraviglia, L. Valsecchi, G. Gubertini, M. A. Mezzenzana, N. Zanchetta, *2nd Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy.*

M.B.P.362 Effect of Zidovudine on Hepatitis B Virus (HBV) Replication in Patients with Chronic HIV and HBV Infections. *Gilles Pialoux*, M. Girard, P. Marcellin, M. Martinot, M. C. Dazza, J. P. Benhamou, *Service d'hépatologie, Hôpital Beaujon, Clichy, France.*

M.B.P.363 Effect of Zidovudine on HIV Related Arthritis. *Sergio Gafà*, F. Vezzani, M. G. Giudici, A. Tuzza, *Divisione Malattie Infettive, Arcispedale S. Maria Nuova, Modena, Italy.*

M.B.P.364 HIV-associated Alopecia in a Woman and Regrowth of Hair after Zidovudine Therapy (A Case Report). *Pietro L. Vernazza*, R. L. Galeazzi, *Med. Klinik A, Kantonsspital, St-Gallen, St-Gallen, Switzerland.*

M.B.P.365 Dermatological Manifestations during Zidovudine Treatment. *Monika Frõschl*, D. Stallmann, H. Holzmann, M. Landthaler, O. Braun-Falco, *Dermatological Department of Ludwig-Maximilians University, Munich, Federal Republic of Germany.*

M.B.P.366 Treatment of Advanced AIDS-Related Kaposi's Sarcoma (KS): Experience with 112 Patients from One Institution. *Parkash S. Gill*, A. M. Levine, M. Bernstein-Singer, B. Espina, M. Rarick, *University of Southern California at Los Angeles, Los Angeles, U.S.A.*

M.B.P.367 Bone Marrow Changes in HIV-1 Positive Asymptomatic Patients on Zidovudine. *Mary M. Fanning*, K. Gelmon, J. Falutz, J. Montaner, C. Tsoukas, J. Ruedy, et al., *Toronto General Hospital, Toronto, ON, Canada.*

M.B.P.368 Evaluation of the Association of Zidovudine (Z) and Vinblastine (V) in the Treatment of AIDS-Related Kaposi's Sarcoma. *Shahin Gharakhanian*, R. De Sahb, M. Vaseghi, B. Cardon, W. Rozenbaum, *Unité des maladies infectieuses, Hôpital Rothschild, Paris, France.*

M.B.P.369 Results after 18 Months of Treatment with Zidovudine. *Maria-José Mellado*, M. J. Cilleruelo, J. Villota, G. Barreiro, M. L. Pérez, P. Fontelos, *Instituto de Salud Carlos III, Servicio de Pediatria, Madrid, Spain.*

M.B.P.370 Viral Antigen (HIV-Ag) Evolution in AIDS and ARC Patients with Zidovudine Treatment. *Maria-Eulalia Valencia*, R. M. Zapico, V. Pintado, J. M. L. Dupla, M. P. Lavilla, A. Gil, *Hospital La Paz, Madrid, Spain.*

Additionnels
Additional

M.B.P.371 Bacteremia in Patients with Human Immunodeficiency Virus. *Jean Chow*, I. Luten, G. Thomas, N. Garcia, C. Ugokwe, A. Gupta, *Lincoln Hospital, New York Medical College, Department of Pediatrics, Bronx, NY, U.S.A*

M.B.P.372 Pulmonary Tuberculosis and HIV Disease in Infants and Children. *Adel N. A. Malek*, K. Mukelabai, N. P. Luo, *University Teaching Hospital, Lusaka, Zambia.*

M.B.P.373 HIV Infection and Tuberculosis in Mozambique. *Jorge A. X. Barreto*, C. Palha de Sousa, M. Djedje, L. Parkkali, L. Barquet, F. De La Cruz, F. Neves, et. al., *National Health Institute, Immunology Laboratory, Tuberculosis Control Programme, Maputo, Mozambique.*

M.B.P.374 High Case Rate of Extrapulmonary and Pulmonary Tuberculosis in HIV-Infected in Upper Austria. *R. Simader*, W. Pfeifer, M. Geit, *AKH Linz, Linz, Austria.*

M.B.P.375 Predictors of Mortality in Patients with AIDS and Pneumocystis Carinii Pneumonia (PCP). *Paul M. Sullam*, H. M. Krumholz, I. B. Tager, *VA Medical Center, University of California at San Francisco, San Francisco, CA. U.S.A.*

M.B.P.376 Results of a Consensus Panel on Process of Care for Patients with Pneumocystis Carinii Pneumonia (PCP). *Charles L. Bennett*, W. C. Mathews, J. Kosecoff, D. Kanouse, *RAND Corp., University of California at Los Angeles, Center for Health Policy Study, Santa Monica, CA, U.S.A.*

M.B.P.377 Splenic Pneumocystosis. *Didier F. Piot*, J. Gathe, Jr., G. W. Del Junco, E. W. Stool, J. R. Trujillo, *Park Plaza Hospital, Houston, TX, U.S.A.*

M.B.P.378 Disseminated Granulomatous Pneumocystosis in a Patient Receiving Aerosolized Pentamidine Prophylaxis. *Douglas J. Ward, George Washington University Hospital, Washington, DC, U.S.A.*

M.B.P.379 Pneumocystis Carinii Choroiditis. *Dennis M. Causey*, N. A. Rao, P. L. Zimmerman, *University of Southern California, Los Angeles, CA, U.S.A.*

M.B.P.380 Incidence of Pneumocystis Carinii Pneumonia (PCP) in Men Infected with Human Immunodeficiency Virus-1 (HIV-1). *John P. Phair*, A. Munoz, R. Detels, C. Rinaldo, A. Saah, *Northwestern University Medical School, Chicago, IL, U.S.A.*

M.B.P.381 Psychiatric Morbidity in HIV Infected Individuals in India. *K. S. Jacob*, H. Moses, J. K. John, T. J. John, *Department of Psychiatry, Christian Medical College, Vellore, India.*

M.B.P.382 Prevalence and Course of Psychiatric Disturbances Associated with HIV Infection (CDC Categories II-IV). *Frans M. van den Boom*, H. Sno, J. Storosum, *Netherlands Institute of Mental Health, Utrecht, Netherlands.*

M.B.P.383 Diagnosis of Depression in HIV-Infected Individuals. *Barry A. Hong*, J. Rice, D. Brookshire, P. Guedet, *Washington University School of Medicine, St. Louis, MO, U.S.A.*

M.B.P.384 Prévalence des troubles psychiatriques parmi les patients hospitalisés pour SIDA. *Marco Zamperetti*, D. Ferrazzi, I. Schlacht, M. Cusini, S. Muratori, R. Zerboni, *Ospedale Cà Granda Niguarda, Servizio Psichiatrico, Milan, Italy.*

Notes

Section
C

Lundi 5 juin
Monday, June 5

Recherche fondamentalebiomédicale)
Basic Research (Biomedical)

Session d'affichage
Poster Session

Mise au point de médicaments et vaccins
Drug Development and Vaccines

M.C.P.1 Differential Viral Gene Expressions and Their Effect on the Biological Properties of Clones of an HIV-1 Infected Cell Line. *V. S. Kalyanaraman*, V. Rodriguez, S. Joseph, R. C. Gallo, M. G. Sarnagadharan, *Bionetics Research, Inc., Rockville, MD, U.S.A.*

M.C.P.2 Protective Vaccine against Feline Leukemia Virus Using a Recombinant Antigen. *Charlotte R. Kensil*, G. A. Beltz, C.-H. Hung, A. Aubert, D. J. Marciani, *Cambridge Bioscience Corp., Worcester, MA, U.S.A.*

M.C.P.3 Clinical Evaluation of Experimental AIDS Vaccines. *Wayne C. Koff*, S. L. Wescott, J. Novak, D. Stablein, B. Fernie, J. Gerin, *Vaccine Research and Development Branch, AIDS Program, NIAID, National Institutes of Health, Rockville, MD, U.S.A.*

M.C.P.4 Humoral and Cellular Immune Response to Recombinant HIV-Hepatitis B Surface Antigen Particles. *Maryline Mancini*, M. L. Michel, G. Vogt, Y. Hénin, Y. Rivière, D. Dormont, et al., *UREG, Institut Pasteur, Paris, France.*

M.C.P.5 Production and Characterization of a Human-Mouse Chimeric Monoclonal Antibody (Cß1) Against HIV. *Shuzo Matsushita*, H. Maeda, Y. Maeda, S. Tokiyoshi, Y. Hattori, K. Takatsuki, et al., *Kumamoto University Medical School, Second Division of Internal Medicine, Kumamoto, Japan.*

M.C.P.6 Mapping the Neutralizing Epitope of HIV-1 Envelope Protein. *Kashi Javaherian*, K. Ross, A. Profy, A. Langlois, T. Matthews, S. Putney, et al., *Repligen Corp., Cambridge, MA, U.S.A.*

M.C.P.7 In Vivo Immunization against HIV Proteins Using gag Synthetic Peptides: Preliminary Results. *Bruno Vaslin*, J. M. Claverie, F. C. Barré-Sinoussi, P. Kourilsky, D. Dormont, *Commissariat à l'Énergie atomique (DPS/SPE/SSA), Fontenay-aux-Roses, France.*

M.C.P.8 HIV-1 Recombinant gp160 Vaccine Recipients Demonstrate gp160-Specific Lymphocyte Proliferation Prior to Western Blot Reactivity. *Michael C. Keefer*, W. Bonnez, J. Roberts, R. Dolin, R. C. Reichman, *University of Rochester School of Medicine, Infectious Diseases Unit, Rochester, NY, U.S.A.*

M.C.P.9

M.C.P.10 Gp160ISCOMS: A Candidate HIV Vaccine. *Lennart S. Akerblom*, M. Villacres, K. Lundin, K. Ljunggren, B. Morein, *Swedish University of Agriculture Science, Department of Microbiology, Section of Virology, Uppsala, Sweden.*

M.C.P.11 Clinical and Virologic Response to a Recombinant Vaccinia HIV-1 gp160 Vaccine (HIVAC-1e). *Ann C. Collier*, S. L. Hu, R. Coombs, D. Arditti, L. Corey, *University of Washington, Harborview Medical Center, Seattle, WA, U.S.A.*

M.C.P.12 Kinetics, Magnitude and Duration of Antibody Responses in HIV-1 rgp160 Vaccinees. *Leslie Garrison*, K. Midthun, B. Clayman, G. Smith, R. Viscidi, NIAID, AIDS Vaccine Evaluation Group, *Johns Hopkins University, Baltimore, MD, U.S.A.*

M.C.P.13 Evaluation of a Synthetic HIV-1 p17-Based Candidate AIDS Vaccine, HGP-30. *Allan L. Goldstein*, P. H. Naylor, J. E. Kirkley, C. W. Naylor, C. J. Gibbs, P. S. Sarin, *George Washington University, Washington, DC, U.S.A.*

M.C.P.14 Cellular Immunity in HIV-1 rgp160 Vaccinees. *Karen Midthun*, L. Garrison, K. Gershman, M. L. Clements, G. Smith, W. Adler, *Johns Hopkins University, Baltimore, MD, U.S.A.*

M.C.P.15 Expression of Recombinant Particles which Display an HIV/p24 T-Cell Epitope Fused to the HBV/HBc Antigen. *Juli S. McGee*, D. J. Leturcq, G. B. Thornton, A. M. Moriarty, D. Milich, *R. W. Johnson Pharmaceutical Research Institute, San Diego, CA, U.S.A.*

M.C.P.16 Recombinant Vaccinia Viruses that Coexpress HIV or SIV env and gag-Encoded Proteins Produce Retroviral Particles. *Dennis L. Panicali*, N. King, G. Mazzara, N. Cormier, R. Desrosiers, J. MacKey, et al., *Applied bioTechnology Inc., Cambridge, MA, U.S.A.*

M.C.P.17 Type-Specific Neutralizing Antibodies to HIV-1 in Rabbits Immunized with Vaccinia/HIV-1 Recombinant Viruses. *Ruthann M. Hesselton*, R. Koup, D. Panicali, G. Mazzara, E. Day, J. Sullivan, *University of Massachusetts Medical School, Department of Pediatrics, Worcester, MA, U.S.A.*

M.C.P.18 Hypericin: Efficacy of a New Agent against HIV In Vitro. *Fred Valentine*, D. Meruelo, V. Itri, G. Lavie, *Department of Medicine, New York University Medical Center, New York, U.S.A.*

M.C.P.19 Functional Antibody Response in Persons Immunized with Baculovirus-Derived gp160. *Barney S. Graham*, J. Rowland, E. Robinson, D. Montefiori, W. Mitchell, P. Wright, et al., *Vanderbilt University, Division of Infectious Diseases, Nashville, TN, U.S.A.*

M.C.P.20 HLA-DR Peptide Inhibits HIV-1 Induced Syncytia. *Dorothy E. Lewis*, R. Ulrich, H. Atassi, M. Z. Atassi, *Baylor College of Medicine, Houston, TX, U.S.A.*

M.C.P.21 Recombinant Adenovirus Induces Antibody Response to HIV gag in Mice. *Kenneth L. Rosenthal*, F. L. Graham, L. A. Prevec, *McMaster University Health Sciences Centre, Hamilton, ON, Canada.*

M.C.P.22 Human T-Cell Clones Define Distinct Epitopes within the V3 Region of HIV-1 gp120. *Kent J. Weinhold*, S. D. Stanley, K. Javaherian, C. Scott, S. Putney, D. P. Bolognesi, *Duke University Medical Center, Durham, NC, U.S.A.*

M.C.P.23 Plaque Reduction Assay to Detect HIV Neutralizing Antibodies in Sera from Human Vaccinees. *Terry W. Fenger*, R. Belshe, T. Seaman, *Marshall University School of Medicine, Huntington, OH, U.S.A.*

M.C.P.24 Quantitative Assessment of Sera Inhibition of HIV/Receptor Binding. *Janis V. Giorgi*, P. G. Nishanin, D. D. Ho, I. Schmid, *University of California at Los Angeles, School of Medicine, Department of Microbiology and Immunology, Los Angeles, CA, U.S.A.*

M.C.P.25 Cross Reactivity of Goat Sera Generated against Five HIV-Derived gp120 Recombinants and Synthetic Peptides. *Yair Devash*, A. T. Profy, K. Javaherian, J. Rusche, *E. I. Dupont de Nemours & Co. Inc., Medical Products Department, Wilmington, DE, U.S.A.*

M.C.P.26 Immunogenicity of HIV-env Glycoproteins Is Dependent on Properties of the Glycoconjugate. *Lena Hammar*, K. Malm, S. Eriksson, T. Friberger, L. Akerblom, B. Morein, *Department of Virology, National Veterinary Institute, Uppsala, Sweden.*

M.C.P.27 SIV Vaccine Development Surveillance. *Alan M. Schultz*, M. Glass, *Vaccine Research and Development Branch, AIDS Program, NIAID, National Institutes of Health, Rockville, MD, U.S.A.*

M.C.P.28 Zairian HIV-1 Variable and Hypervariable Envelope Fragments. *Gérard Agius*, R. S. Snart, V. Kolesnitchenko, J. F. Zagury, D. Zagury, *Université Pierre et Marie Curie, Physiologie cellulaire, Paris, France.*

M.C.P.29 Comparison of Immune Responses in Mice Immunized with Native HIV-2 Envelope Glycoprotein or Corresponding Immunosome. *Lise Thibodeau*, L. Flamand, D. Oth, L. Lachapelle, L. Montagnier, *Institut Armand-Frappier, Université du Québec à Montréal, Virologie, Laval, QC, Canada.*

M.C.P.30 An Immunodominant Epitope of the HIV gp160 Envelope Glycoprotein Recognized by Class I, MHC Immunized Humans. *Ammar Achour*, I. Fossati, C. Margaritte, J. A. Berzofsky, R. C. Gallo, D. Zagury, *Université Pierre et Marie Curie, Paris, France.*

M.C.P.31 Mapping of T- and B-Cell Epitopes of HIV-1 NEF Protein in Immunized Chimpanzees. *Jean-Claude Gluckman*, M. Yagello, J. M. Sabatier, B. Guy, M. Girard, E. Bahraoui, et al., *Hôpital de la Pitié-Salpêtrière, CERVI, Paris, France.*

M.C.P.32 Demographic Characteristics and Frequency of Exclusionary Criteria in a Population Volunteering for HIV Immunization. *T. Ulf Westblom*, R. B. Belshe, G. J. Gorse, E. L. Anderson, C. F. Berry, NIAID, AIDS Vaccine Program, *Marshall University School of Medicine, Department of Medicine, Huntington, OH, U.S.A.*

M.C.P.33 An Automated Microtiter Test System for the Detection of HIV-1 and HIV-2 Neutralizing Antibodies. *Volker Erfle*, W. Mellert, A. Kleinschmidt, *GSF-Abteilung für Molekulare Zellpathologie, Neuherberg/Munich, Federal Republic of Germany.*

M.C.P.34 Novel Approach to Purification of HIV p24 Protein by Cleavage from Hybrid Ty Virus-like Particles. *Jacqueline E. M. Gilmour*, N. R. Burns, S. M. Kingsman, A. J. Kingsman, S. E. Adams, *British Bio-Technology Limited, Oxford, U.K.*

M.C.P.35 HIV Vaccine Design: Exploitation of Ty Virus-like Particles. *Mark Richardson*, S. E. Adams, J. M. Griffiths, N. R. Burns, J. M. Senior, A. J. Kingsman, *British Bio-Technology Limited, Oxford, U.K.*

M.C.P.36 Rhesus Monkeys Immunized with Recombinant Vaccinia Viruses Containing HIV-1 Envelope Genes Develop Antibodies Reactive with Envelope of Divergent HIV-1 Strains. *Alec E. Wittek*, M. A. Wells, R. M. Hendry, E. W. Carrow, B. Moss, G. V. Quinnan, Jr. et al., *Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A.*

M.C.P.37 Salivary Antibodies to HIV in an AIDS Vaccine Trial. *David W. Archibald*, C. Amrheim, D. Sun, C. Tacket, *University of Maryland at Baltimore, Baltimore, MD, U.S.A.*

M.C.P.38 Retention of Purified HIV-1 gp120 by Alhydrogel. *Julian W. Bess, Jr.*, S. W. Pyle, J. E. Drummond, L. O. Arthur, *NCI, Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A.*

M.C.P.39 Replication of HIV under Single Growth Cycle Conditions: A Model for Studying the Effect of Antiviral Drugs. *Ferdinando Dianzani*, G. Antonelli, M. R. Capobianchi, P. Amicucci, P. Di Marco, O. Turriziani, *La Sapienza University, Institute of Virology, Rome, Italy.*

M.C.P.40 Induction of Antibody to HIV-1 Envelope Proteins by p24 Core T Epitopes. *Anthony R. M. Coates*, D. Y. Sia, P. Mascagni, G. K. Toth, L. R. Haaheim, W. A. Gibbons, *London Hospital Medical College, Department of Medical Microbiology, London, U.K.*

M.C.P.41 T Cell Epitopes in a Chemically Synthesized 104-MER Core Protein (p24) of Human Immunodeficiency Virus (HIV-1). *Dwo Yuan Sia*, P. Mascagni, G. K. Toth, W. A. Gibbons, A. R. M. Coates, *London Hospital Medical College, Department of Medical Microbiology, London, U.K.*

M.C.P.42

M.C.P.43 Low Response Rates to Hepatitis B Vaccine in Inactive Drug Addicts. *Mariagrazia Rumi*, R. Romeo, S. Sampietro, D. Mari, E. Tanzi, M. Colombo, *Institute of Internal Medicine, Milan, Italy.*

M.C.P.44 Immune Response of Rabbits and Chimpanzees to Inactivated Whole Virus Concentrates of HIV-1. *Jens-Peter Gregersen*, P. N. Fultz, J. F. Lemp, J. Hilfenhaus, *Behringwerke AG, Marburg, Federal Republic of Germany.*

M.C.P.45 Study Design Issues in SIV Vaccine Trials. *Susan S. Ellenberg*, D. R. Spriggs, *Biostatistics Research Branch, AIDS Program, Rockville, MD, U.S.A.*

M.C.P.46 Clindamycin Plus Primaquine Is Effective for Prophylaxis of Pneumocystis Carinii Pneumonia in Rats. *James W. Smith*, M. S. Bartlett, M. M. Durkin, T. P. Glancy, S. F. Queener, *Indiana University, Indianapolis, IN, U.S.A.*

M.C.P.47 Generation and Analysis of Recombinant Vaccinia Viruses that Express SIV Polypeptides. *Dennis L. Panicali*, V. Stallard, G. P. Mazzara, M. D. Daniel, R. Desrosiers, A. Destree, et al., *Applied bioTechnology Inc., Cambridge, MA, U.S.A.*

M.C.P.48 The Search for a Candidate Vaccine against AIDS: Progress Report III. *Daniel Zagury*, O. Picard, J. Bernard, J. J. Salaün, Z. Lurhuma, R. C. Gallo, *Université Pierre et Marie Curie, Paris, France.*

M.C.P.49 Inhibition of De Novo HIV Infection in Monocyte/Macrophages by Agents which Block the Binding of HIV-1 gp120 to CD4. *Carlo-Federico Perno*, R. Yarchoan, S. Broder, *National Cancer Institute, Bethesda, MD, U.S.A.*

M.C.P.50 Use of Nucleic Acid Hybridization for HIV Susceptibility Testing. *Stuart H. Cohen*, D. R. Scholl, V. Bolton, M. Loeffelhoelz, M. Jennings, J. R. Carlson, *University of California at Davis, Sacramento, CA, U.S.A.*

M.C.P.51 HeLa Cells Stably Expressing HIV env and tat as Tools for Studying Structure, Function and Candidate Inhibitors of These Key HIV Gene Products. *Ruth M. Ruprecht*, M. A. Gama-Sosa, R. DeGasperi, F. Fazely, *Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

M.C.P.52 Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythtopoietin (r-HuePO) May Abrogate the Neutropenia and Anemia of AIDS and May Allow for Resumption of Zidovudine (AZT) in Patients with AIDS. *Steven A. Miles*, R. T. Mitsuyasu, S. McCarthy, K. Alton, L. Souza, J. Glaspy, et al., *University of California at Los Angeles, AIDS Center, CHS, Los Angeles, CA, U.S.A.*

M.C.P.53 Use of AZT as a Chemopreventive Agent: Efficacy and Toxicity in Murine Retrovirus Infections. *John A. Bilello*, C. MacAuley, R. A. Yetter, J. L. Eiseman, T. Frederickson, S. Shapiro, et al., *VA Medical Center Research Service, Baltimore, MD, U.S.A.*

M.C.P.54 Phosphorylation of 3'-Azido-2'3'-Dideoxyuridine, 3'-Azido-3'-Deoxythymidine, and Thymidine in Uninfected and HIV-1 Infected CEM Cells. *Bertil F. H. Eriksson*, B. J. Oswald, J. P. Sommadossi, C. K. Chu, G. Williams, R. F. Schinazi, *Veterans Administration Medical Center, Medical Research, Decatur, GA, U.S.A.*

M.C.P.55 Effect of Dehydroepiandrosterone (DHEA) in Lymphocytes and Macrophages Infected with HIV-1. *Raymond F. Schinazi*, B. F. H. Erikson, B. Arnold, P. Lekas, M. S. McGrath, *Veterans Administration Medical Center, Medical Research, Decatur, GA, U.S.A.*

M.C.P.56 Role of Fc Receptors in the Binding of HIV to Monocytes. *Guerrero Loyda Meléndez*, J. Nicholson, S. McDougal, C. Dawson, *Emory University, Pathology Department, Atlanta, GA, U.S.A.*

M.C.P.57 Ocular Diffusion of DHPG After Systematic Administration: Animal Study and Application to a Clinical Case. *Hélène Sauvageon-Martre*, F. Chast, F. Fauvele, S. Callaert, O. Carton, *Hôtel-Dieu, Pharmacie, Laboratoire de Pharmacologie, Paris, France.*

M.C.P.58 Potential of Autocatalytic Self-Cleaving RNAs as Anti-HIV Agents. *Margaret I. Johnston*, N. Sarver, J. McGowen, *AIDS Program, National Institute of Allergy and Infectious Diseases, Rockville, MD, U.S.A.*

M.C.P.59 Impact on AIDS Clinical Trials of the Use of Non Approved Therapies. *Bernard Bihari*, *SUNY/Health Science Center at Brooklyn, Kings County Addictive Disease Hospital, Brooklyn, NY, U.S.A.*

M.C.P.60 Preliminary Results from an On-going Prospective Evaluation of Foscarnet in the Treatment of AIDS-Associated Cytomegalovirus Retinitis. *Fred M. Ussery, III*, C. N. Karol, R. H. Conklin, J. C. Gathe, Jr., E. W. Stool, K. L. Redding, *Foscarnet Research Project, Park Plaza Hospital, Houston, TX, U.S.A.*

M.C.P.61 Shortening the Research and Development Time for New AIDS Drugs: The Pre-IND Program and Proactive Clinical Guidance at FDA's Division of Antiviral Drugs. *Ellen C. Cooper*, P. C. Hoyle, *U.S.A. Food and Drug Administration, Rockville, MD, U.S.A.*

M.C.P.62 Low Dose Naltrexone in the Treatment of AIDS: Long Term Follow-up Results. *Bernard Bihari*, F. Drury, V. Ragone, G. Ottomanelli, G. Cannon, E. Klein, *State University of New York, Health Science Center at Brooklyn, King's County Addictive Disease Hospital, Brooklyn, NY, U.S.A.*

M.C.P.63 Anti-HIV-1 Activity, Toxicity and Pharmacokinetics of Totally Novel Nucleoside Analogs. *Mark A. Wainberg*, M. D. Stern, R. Martel, B. Belleau, H. Soudeyns, *Jewish General Hospital, Montreal, QC, Canada.*

M.C.P.64 Isoleucine Ester of Zidovudine (IAZT) as a Pro-Drug with Enhanced Efficacy against HIV-1. *Krishna C. Agrawal*, S. K. Aggarwal, S. R. Gogu, R. H. Lupia, J. J. L. Lertora, S. R. S. Rangan, *Tulane University School of Medicine, Department of Pharmacology, New Orleans, LA, U.S.A.*

M.C.P.65 The Carbocyclic Analogue of Oxetanocin G Inhibits the Replication of Cytomegalovirus and Herpes Simplex Viruses In Vitro. *Daniel Norbeck*, W. Rosenbrook, J. Plattner, J. Erickson, G. Arnett, W. Shannon, *Abbott Laboratories, Abbott Park, IL, U.S.A.*

M.C.P.66 Inhibition of Human Immunodeficiency Virus Infectivity by Chloroquine. *Stephen Oroszlan*, W.-P. Tsai, P. L. Nara, H.-S. Kung, *NCI, Frederick Cancer Research Facility, Frederick, MD, U.S.A.*

M.C.P.67 Neutralization of HIV-1 by Anti-Idiotypic Antibodies. *Didier J. Leturcq*, B. J. Winslow, P. Johnson, G. B. Thornton, *R. W. Johnson Pharmaceutical Research Institute, San Diego, CA, U.S.A.*

M.C.P.68 Phosphonoformate Inhibits Feline Retrovirus Infection in Cats. *Cheryl L. Swenson*, S. E. Weisbrode, R. Sams, L. Nagode, K. Hayes, L. E. Mathes, et al., *The Ohio State University, Columbus, OH, U.S.A.*

M.C.P.69 Pharmacokinetics, Toxicity and Prophylactic Antiviral Activity of Pmea in Feline Retrovirus Infected Cats. *Lawrence E. Mathes*, C. L. Swenson, P. A. Polas, R. Sams, K. Hayes, G. Kociba, *The Ohio State University, Columbus, OH, U.S.A.*

M.C.P.70 Phosphate Triester Derivatives of AZT as Inhibitors of HIV. *Chris Mc Guigan*, K. Devine, T. O'Connor, S. Galpin, J. D. Williamson, D. J. Jeffries, *University College, London, U.K.*

M.C.P.71 Fluconazole Treatment of Esophageal Candidiasis in AIDS Patients. *Antonio Gil Aguado*, P. Lavilla, A. Gonzalez, M. E. Valencia, J. M. L. Dupla, J. J. Vasquez, *Hospital La Paz, Madrid, Spain.*

M.C.P.72 Recombinant Soluble CD4 as a Vehicle to Deliver Ricin to HIV-Envelope Expressing Cells. *Nancy A. Cochran*, A. R. Collinson, T. Liu, W. Meier, M. D. Rosa, V. S. Goldmacher, *ImmunoGen Inc., Cambridge, MA, U.S.A.*

M.C.P.73 Effects of Dideoxynucleosides on the Cell Cycle. *Camilla M. Smith*, J. F. Henderson, *Cancer Research Group, University of Alberta, Edmonton, AB, Canada.*

M.C.P.74 In Vivo Anti-Retrovirus and Anti-Cytomegalovirus Activity of 9-((2-Phosphonylmethoxy)Ethyl)Adenine (PMEA). *Joanne J. Bronson*, I. Ghazzouli, M. J. M. Hitchcock, E. R. Kern, J. C. Martin, *Bristol-Meyers Company, Wallingford, CO, U.S.A.*

M.C.P.75 Comparative Inhibitory Effects of Sulfated Polysaccharides on Giant Cell Formation Induced by Co-Cultivation of CD4-Positive Cells with Persistently HIV-1 Infected Cells. *Masanori Baba*, D. Schols, R. Pauwels, H. Nakashima, J. Balzarini, E. De Clercq, *Rega Institute for Medical Research, Leuven, Belgium.*

M.C.P.76 Antiretrovirus Activity and Intracellular Metabolism of 2', 3'-didehydro-2', 3'-dideoxythymidine (D4T). *Jan M. Balzarini*, P. Herdewijn, E. De Clercq, *Rega Institute for Medical Research, Leuven, Belgium.*

M.C.P.77 Inhibition of HIV Replication in Cell Culture by Anti-Sense RNA Expressed from Recombinant Murine Retroviruses. *William S. James*, A. R. Rhodes, *University of Oxford, Sir William Dunn School of Pathology, Oxford, U.K.*

M.C.P.78 Megakaryocytes of HIV-Seropositive Individuals Express Viral RNA. *Dorothea Zucker-Franklin*, Y. Z. Cao, Y. Z. Kouri, *New York University Medical Center, New York, NY, U.S.A.*

M.C.P.79 Inhibitory Effect of Sulfated Amphotericin B on the Proliferation of HIV In Vitro. *Toru Otake*, K. Miyano, H. Shimonaka, M. Kanai, N. Ueba, N. Kunita, et al., *Osaka Prefectural Institute of Public Health, Osaka, Japan.*

M.C.P.80 Inhibition of Human Immunodeficiency Virus (HIV-1) Replication by Synthetic Oligo-DNA Derivatives. *Sudhir Agrawal*, D. K. Sun, P. S. Sarin, P. C. Zamecnik, *Worcester Foundation for Experimental Biology, Shrewsbury, MA, U.S.A.*

M.C.P.81 Assessment of the Therapeutic Activity of Phosphonylmethoxyethyl Adenine (PMEA) Azidothymidine (AZT) in a Murine Model of Acquired Immunodeficiency Disease. *J. David Gangemi*, R. M. Cozens, A. Matter, H. Hochkeppel, *University of South Carolina, School of Medicine, Department of Microbiology and Immunology, Columbia, SC, U.S.A.*

M.C.P.82 Inhibition of HIV Replication by Alpha Interferon. *Marilyn S. Smith*, E. L. Brian, R. Thresher, J. S. Pagano, *University of North Carolina, Chapel Hill, NC, U.S.A.*

M.C.P.83 Experimental Azidothymidine (AZT) Pulse Therapy Leads to Adequate and Prolonged Levels of Intracellular AZT-Triphosphate (AZT-TP). *Markus W. Vogt*, W. Siegenthaler, H. Kuster, V. Nadai, B. Joos, R. Lüthy, *University Hospital, Division of Infectious Diseases, Zurich, Switzerland.*

M.C.P.84 Expression of Authentic and Enzymatically Active HIV-1 and HIV-2 Proteases in Saccharomyces Cerevisiae. *Sergio Pichuantes*, L. Babe, P. Barr, C. Craik, *University of California at San Francisco, Department of Pharmaceutical Chemistry, San Francisco, CA, U.S.A.*

M.C.P.85 Immunologic Effect After Single Dose Atvogen (Ampligen) in Healthy Volunteers. *Craig W. Hendrix*, P. S. Lietman, P. O. P. T'So, J. B. Margolick, H. Farzadegan, B. G. Petty, *Johns Hopkins University, Division of Clinical Pharmacology, Baltimore, MD, U.S.A.*

M.C.P.86 Studies of Anti-HIV Activity and Metabolism of 2', 3'-Dideoxyguanosine (ddG). *Lionel Resnick*, M. E. Busso, M. A. Mian, *Mount Sinai Medical Center of Greater Miami, Miami Beach, FL, U.S.A.*

M.C.P.87 The Antiviral Effect of Dextran Sulfate (DXS) Is HIV-Strain Dependent. *Lionel Resnick*, M. E. Busso, *Mount Sinai Medical Center of Greater Miami, Miami Beach, FL, U.S.A.*

M.C.P.88 In Vitro Activity of Ribavirin in Acute and Cocultivated HIV Infection of Human Peripheral Blood Mononuclear Cells. *Richard B. Roberts*, *Cornell University Medical College, New York, NY, U.S.A.*

M.C.P.89 Expression and Characterization of Chimeric Proteins Containing Human CD4 Linked to Human Immunoglobulin Heavy Chain Constant Regions. *Tamio Mizukami*, C. D. Smith, E. A. Berger, B. Moss, *LVD, NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.90 Analogs of 3'Amino-3'-Deoxyadenosine Inhibit HIV-1 Replication. *Lee Ratner*, N. Vander Heyden, C. Rodi, *Washington University, St-Louis, MO, U.S.A.*

M.C.P.91 Sulfated Sugars Inhibit HIV. *Myra O. McClure*, D. Whitby, R. Chensong-Popov, J. Weber, D. Davies, R. A. Weiss, *Chester Beatty Laboratories, Institute for Cancer Research, London, U.K.*

M.C.P.92 CSF from Patients with Early HIV Infection Produces Neuronal Cell Killing In Vitro: Prevention by Peptide T. *Candace B. Pert*, J. M. Buzy, D. E. Brenneman, A. Salazar, A. Martin, M. R. Ruff, *National Institute of Mental Health, Bethesda, MD, U.S.A.*

M.C.P.93 Synthesis of New Sugar-Fluorinated Guanosine Analogues as Potential Anti-HIV Agents. *Roger Guedj*, F. Puech, G. Gosselin, J. L. Imbach, E. De Clercq, *Université de Nice, UER IMSP, Laboratoire de Chimie Bio-Organique, Nice, France.*

M.C.P.94 Population Phamacokinetic Behavior of Zidovudine (AZT) in Patients with ARC. *George L. Drusano*, S. R. Gitterman, M. J. Egorin, H. C. Standiford, *University of Maryland, Division of Infectious Diseases, Baltimore, MD, U.S.A.*

M.C.P.95 Anti-Retroviral Activity of an Aqueous Extract of Hydrocotyle Asiatica. *Arnold B. Rabson*, U. Flatov, H. Krutzsch, A. Kinter, M. D. Hoggan, *NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.96 Activation of the Anti-HIV Agent 2'-3'-Dideoxy-2'-3'-Didehydrothymidine (D4T) by Human Peripheral Blood Mononuclear Cells (PBMC) in Culture. *Hsu-Tso Ho*, H. Yang, M. J. M. Hitchcock, *Bristol-Meyers Pharmaceutical Research and Development Division, Wallingford, CO, U.S.A.*

M.C.P.97 Three Drug Synergistic Inhibition of HIV-1 Replication by Recombinant Soluble CD4 (rsT4), Zidovudine (AZT), and Recombinant Interferon-Alpha-A (rIFN-A) *Victoria Anne Johnson*, M. A. Barlow, T. C. Chou, D. P. Merrill, M. S. Hirsch, *Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A.*

M.C.P.98 Comparative Pharmacokinetics of 3'-Azido-2', 3'-Dideoxyuridine (AZddU) and 3'-Azido-3'-Deoxythymidine (AZT) in Monkeys. *Douglas F. Boudinot*, R. F. Schinazi, J. M. Gallo, H. McClure, D. Anderson, C. K. Chu, *University of Georgia, College of Pharmacy, Athens, GA, U.S.A.*

M.C.P.99 Differential Sensitivity of Bone Marrow DNA Polymerases Alpha and Delta to Inhibition by Dideoxynucleotides. *John J. Byrnes, University of Miami, Miami, FL, U.S.A.*

M.C.P.100 Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) Increases Neutrophil Number and Function but Does not Alter HIV Expression in Patients with AIDS. *Steven A. Miles*, J. Glaspy, Y. Chung, K. Lee, L. Souza, G. Baldwin, *University of California, Los Angeles, AIDS Center, Los Angeles, CA, U.S.A.*

M.C.P.101 Randomized Phase II Trial of Recombinant Tumor Necrosis Factor (rTNF) and Recombinant Interferon-Gamma (rIFN-Gamma) in Patients with ARC. *Jan M. Agosti*, R. Coombs, P. G. Kidd, M. Paradise, S. Sherwin, L. Corey, *University of Washington, Harborview Medical Center, Seattle, WA, U.S.A.*

M.C.P.102 A Long-Lived CD4 Carrier in Circulation: Red Blood Cells with CD4 Receptors Inserted in Their Membrane. *Claude Nicolau*, T. Arvinte, A. Cudd, B. Schulz, *Biophor Corporation and Baylor College of Medicine, College Station, TX, U.S.A.*

M.C.P.103 Treatment of AIDS Associated Tumors with Recombinant DNA Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). *Umberto Tirelli*, S. Sarracchini, A. Lazzarin, R. Sorio, P. Mazzanti, S. Monfardini, *Centro di Riferimento Oncologico, Aviano, Italy.*

M.C.P.104 In Vitro Inhibition of HIV Replication by Glucosyl Phospholipid Derivatives of Nucleoside Analogs. *Olivier Schwartz*, Y. Hénin, L. Montagnier, *Institut Pasteur, Unité Oncologie Virale, Paris, France.*

M.C.P.105 Role of HIV Anti-Sense RNA in HIV Replication. *Maurizio Federico*, F. Carlini, B. M. R. Taddeo, I. Saggio, A. M. di Rienzo, G. B. Rossi, *Istituto Superiore di Sanità, Rome, Italy.*

M.C.P.106 Organic Gold Compounds Are Effective against HIV-1 Reverse Transcriptase. Herbert Blough*, *M. Ricchetti, L. Montagnier, H. Buc, *Institut Pasteur, Paris, France.*

M.C.P.107 Acid-Stable 2', 3'-Dideoxypurine Nucleosides with the Potential for Improved Anti-AIDS Activity in the Central Nervous System. John S. Driscoll*, *V. E. Marquez, J. J. Barchi, H. Ford, D. A. Cooney, H. Mitsuya, et al., *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.108 A Novel Compound that Inhibits Reverse Transcriptase. Hideki Ohnota*, *S. Morikawa, D. Momose, H. Ushijima, Y. Kurashina, T. Kitamura, *Creative Products Research Laboratories, Kissei Pharmaceutical Co. Ltd., Matsumoto, Japan.*

M.C.P.109 Chronically Infected Monocyte-Macrophages (M) Are Markedly Less Sensitive to Zidovudine (AZT), Foscarnet (FOS) and Alpha Interferon (IFN) When Compared to Acutely Affected M. Suzanne M. Crowe*, *M. S. McGrath, T. Elbeik, J. Kirihara, N. McManus, J. Mills, *Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Fairfield, Australia.*

M.C.P.110 Computerized Quantification of Synergism/Antagonism of Anti-HIV Agents. Ting-Chao Chou*, *J. Chou, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

M.C.P.111 Possible Protective Effect of Dehydroepiandrosterone (DHEA) and/or DHEA-Sulfate (DHEA-S) in HIV Infection. Mark A. Jacobson*, *P. Lekas, M. S. McGrath, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.C.P.112 A Very Effective Anti-Diarrhea Agent Inhibits HIV-1 Replication in a Human Monocytic Cell Line. Louis Mercure*, *D. Phaneuf, R. Morisset, M. A. Wainberg, *Université de Montréal, Lady Davis Medical Research Institute, Montreal, QC, Canada.*

M.C.P.113 Analysis of the Effect of Acetaminophen on Zidovudine Pharmacokinetics in HIV Infected Patients. Erika M. Steffe*, *J. Inciardi, J. King, N. Flynn, E. Goldstein, T. Tanjes, *University of California, Davis School of Medicine, U.C. Davis Medical Center, Sacramento, CA, U.S.A.*

M.C.P.114 Comparative Evaluation of Three Thymidine Analogs (D4T, FDDT and AZT) Active against HIV. Roman Z. Sterzycki, *Bristol-Myers Company, Pharmaceutical Research Development Division, Wallingford, CO, U.S.A.*

M.C.P.115 Anti-HIV Activities of Anthraquinone Derivatives In Vitro. C. K. Chu*, *R. F. Schinazi, M. Nasr, *University of Georgia, Athens, GA, U.S.A.*

M.C.P.116 Azidothymidine (AZT)-Alpha-Interferon (IFN) Combination Therapy Reduces p24 Antigenemia. Brian R. Edlin*, *S. M. Whaling, R. A. Weinstein, J. D. Bitran, *Michael Reese Hospital, Division of Infectious Diseases, Chicago, IL, U.S.A.*

M.C.P.117 Castanospermine Analogs as Potent Inhibitors of Human Immunodeficiency Virus (HIV). Prasad S. Sunkara*, *P. Taylor, M. Kang, P. Liu, T. Bowlin, A. Tyms, et al., *Merrell Dow Research Institute, Cincinnati, OH, U.S.A.*

M.C.P.118 Anti-HIV Reverse Transcriptase and Anti-HIV Activities of PC6. *Patrick K. Lai*, H. Takayama, Y. T. Wu, M. Nonoyama, *Showa University Research Institute, St. Petersburg, FL, U.S.A.*

M.C.P.119 Effect of Chloroquine on HIV-1 Infection of Monocytes. *Isabelle Desportes*, M. Fouchard, C. K. Pyne, B. Réveil, *Université Paris VI, Paris, France.*

M.C.P.120 Cellular Pharmacology of Anti-HIV Agents Azidothymidine (AZT) and 2',3'-Didehydrothymidine (D4T) in Human T Cells. *Arnold Fridland*, M. Connelly, R. Ashmun, *St. Jude Children's Research Hospital, Memphis, TN, U.S.A.*

M.C.P.121 Anti-HIV Activities of a Novel Nucleoside Oxetanocin and Its Derivatives. *Jun-ichi Seki*, T. Takeuchi, N. Shimida, K. Takahashi, T. Takita, H. Hoshino, *Department of Hygiene, Gunma University School of Medecine, Gunma, Japan.*

M.C.P.122 Computer-Assisted Structure Activity Correlations of Anti-HIV Drugs. *Charles Litterst*, M. Nasr, P. Johnston, J. McGowan, *AIDS Program, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.123 Discovery and Development of Therapies for AIDS and Its Sequela. *Margaret I. Johnston*, C. Litterst, J. McGowan, *AIDS Program, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.124 Inhibitory Effects of Unsaturated Phospholipids on HIV Production In Vitro. *Dorothy E. Lewis*, A. J. Baran, V. Knight, M. Jett, *Baylor College of Medicine, Houston, TX, U.S.A.*

M.C.P.125 Further Studies on the Potent Antiviral Synergism of Carbovir and AZT against Human Immunodeficiency Virus (HIV) In Vitro. *William M. Shannon*, G. C. Lavelle, K. J. Qualls, E. L. White, J. M. Johnson, R. Vince, *Southern Research Institute, Birmingham, AL, U.S.A.*

M.C.P.126 Quantitative Analysis of HIV-1 Expression Using Magnetic Particle RNA-RNA Hybridization: Application to Anti-HIV Drug Screening. *Scott R. Decker*, K. A. Logan, J. M. Lawrie, M. G. Pelligrino, G. Li, D. J. Volsky, *Gene-Trak Systems, Framingham, MA, U.S.A.*

M.C.P.127 Pharmacokinetics of Recombinant Soluble CD4 (sT4) in Cynomolgus Monkeys Following Intravenous Administration. *Carl Crysler*, K. L. L. Fong, K. E. Boyle, *Smith Kline & French Laboratories, King of Prussia, PA, U.S.A.*

M.C.P.128 Strong Synergistic Anti-HIV Activity of a Purine and a Pyrimidine Nucleoside Analog ddI and d4T. *Vera Brankovan*, K. Tarantini, R. Datema, T. C. Chou, *Oncogen, Seattle, WA, U.S.A.*

M.C.P.129 The Construction and Characterization of Immunotoxins Specific for HIV-Infected Cells. *Victor Ghetie*, M. A. Till, D. Capon, E. Patzer, J. W. Uhr, E. S. Vitetta, *University of Texas Southern Medical Center, Department of Microbiology, Dallas, TX, U.S.A.*

M.C.P.130 Phase I Study of 2'3' Dideoxyinosine (ddI) Administered Twice Daily to Patients with AIDS/AIDS-Related Complex. *John S. Lambert*, R. Dolin, M. Seidlin, C. Knupp, C. McLaren, R. C. Reichman, *University of Rochester, School of Medicine, Rochester, NY, U.S.A.*

M.C.P.131 Development of an In Vitro Human Monocyte-Derived Macrophage (MDM)-Based System for Drug Screening against HIV-1. *Bruce Polsky*, P. A. Baron, H. E. Gendelman, J. W. M. Gold, T. C. Chou, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

M.C.P.132 Polyvinyl Alcohol Membrane Permeability Characteristics of Zidovudine. *Andrew P. Pearson*, D. L. Blandford, M. L. Maliszewski, T. J. Smith, *University of Kentucky, Department of Ophthalmology, Lexington, KY, U.S.A.*

M.C.P.133 Effect of Organic Arsenicals on Productive Infection of HIV. *Phalguni Gupta*, S. O'Marro, C. R. Rinaldo, M. Ho, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

M.C.P.134 Novel Glucosidase Inhibitors as Anti-HIV Agents. *Hiroyuki Shimizu*, S. Morikawa, H. Yamamoto, H. Ushijima, T. Kitamura, *National Institute of Health, Tokyo, Japan.*

M.C.P.135 Carbocyclic Oxetanocin Analogues that Inhibit De Novo Replication of Human Immunodeficiency Virus in T-Cells and Monocytes/Macrophages In Vitro. *Hiroaki Mitsuya*, S. Hayashi, D. W. Norbeck, J. Plattner, S. Broder, *The Clinical Oncology Program, NCI, National Institutes of Health, Bethesda, MD, U.S.A.*

M.C.P.136 New Analogues of 2', 5'-Oligoadenylate with Improved Anti-HIV-1 Activity In Vitro. *David C. Montefiori*, R. J. Suhadolnik, R. W. Sobol, Jr., N. L. Reichenbach, R. Charubala, W. Pfleiderer, et al., *Vanderbilt University, Department of Pathology, Nashville, TN, U.S.A.*

M.C.P.137 Phase I Study of the Administration of Recombinant Soluble CD4 (rCD4) by Continuous Infusion to Patients with AIDS or ARC. *Robert Yarchoan*, R. V. Thomas, J. M. Pluda, C. F. Perno, S. A. Sherwin, S.y Broder, et al., *National Cancer Institute, Bethesda, MD, U.S.A.*

M.C.P.138 Metronidazole (M) Trichomoniasis (T) Eradication as Possible Potent Immunity-restoring Procedure in AIDS. *Sukrija Krvavac*, A. Rustembegovic, *University and Medical Center, Women's Health Institute, Sarajevo, Yugoslavia.*

M.C.P.139 A Useful Immunotherapy in AIDS. *Bernard J. Marichal*, M. C. Jenaer, Brussels, Belgium.*

Additionnels
Additional

M.C.P.140 A Model of AIDS-Virus Disinfection. *Luben G. Angeloff*, *Angel's Biomedical Laboratories, Ltd., Montreal, QC, Canada.*

M.C.P.141 Concentration Dependent Dual Effects of the Monolauryl Ester of Sucrose (L.S.) on the Antifungal Activity and Absorption Spectra of Amphotericin B (AmB). *Janina M. Brajtburg*, I. Gruda, G. Medoff, *Washington University, School of Medicine, St. Louis, MO, U.S.A.*

M.C.P.142 Serologic and Immunologic Parameters in a Randomized, Double-Blind, Placebo-Controlled Trial of Ampligen Administered to Subjects with HIV Infection. *Kenneth R. Ong*, G. F. McKinley, M. M. Reddy, Y. Inada, J. I. O'Connor, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, Columbia University, New York, NY, U.S.A.*

M.C.P.143 Treatment of Therapy-Resistant Oro-Pharyngeal Candidiasis with Fluconazole in HIV-1-Infected Patients. *Barbara Tschechne*, U. Brunkhorst, J. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany.*

M.C.P.144 Inhibition of HIV Reverse Transcriptase by a Kampo Medicine, Sho-Saiko-To. *Katsuhiko Ono*, H. Nakane, M. Fukushima, J.-C. Chermann, F. Barré-Sinoussi, *Aichi Cancer Center Research Institute, Nagoya, Japan.*

M.C.P.145 Viral Inhibition Therapy against AIDS (VITA). *Sadhna Joshi*, A. Van Brunschot, I. Robson, A. Bernstein, *University of Toronto, Faculty of Medicine, Department of Microbiology, Toronto, ON, Canada.*

M.C.P.146 Effect of Pepsin Treatment on the HIV Envelope and Core Antigens. *Eszter Ujhelyi*, G. Füst, G. Illei, S. Allam, J. Szelényi, S. R. Hollán, *National Institute of Hematology and Blood Transfusion, Budapest, Hungary.*

M.C.P.147 Menaquinone (Bacterial Vitamin K) Inhibits HIV-1 Induced Syncytia Formation but not HIV-1 Replication. *Louis F. Qualtiere*, A. Zbitnew, J. M. Heise-Qualtiere, J. Conly, *University of Saskatchewan, Department of Microbiology, Saskatoon, SK, Canada.*

M.C.P.148 The Effects of Traditional Medicine (Sho-Saiko-To: SST) on Peripheral Mononuclear Cell (PMC) from AIDS and ARC Patients. *Kazuhito Watanabe*, Y. Inada, H. Ikegami, M. Lange, W. Clark, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

M.C.P.149 AIDS: Is a Safe Vaccine Readily Available? *Norman J. Godin, Geneva University Hospital, Geneva, Switzerland.*

M.C.P.150 African Traditional Medicine and AIDS. *Chief S. O. Ajisefinni, Ijero-Ekiti, Nigeria.*

Notes



Section
D

Lundi 5 juin
Monday, June 5

Le SIDA et l'individu
AIDS and the Individual

Session d'affichage
Poster Session

Adolescents (partie 1)
Adolescents (Part 1)

M.D.P.1 HIV Infection in Disadvantaged Adolescents in the U.S.: Findings from the Job Corps Screening Program. *Michael E. St-Louis*, C. L. Hayman, C. Miller, J. E. Anderson, L. R. Petersen, T. J. Dondero, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.D.P.2 Young People's Lay Beliefs about HIV Infection and AIDS. *Ian Warwick*, P. J. Aggleton, *Bristol Polytechnic, Department of Education, Bristol, U.K.*

M.D.P.3 AIDS Risk Behavior among Sexually Active Hispanic and Caucasian Adolescent Females. *Susan M. Kegeles*, R. Greenblatt, J. Catania, C. Cardenas, J. Gottlieb, T. Coates, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

M.D.P.4 Predictors of Condom Use and Multiple Partnered Sex among Highly Sexually Active Adolescent Women. *Joseph A. Catania*, T. Coates, R. Greenblatt, P. Dolcini, S. Kegeles, M. Corman, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

M.D.P.5 Behavioral Survey among High Risk Adolescents. *Susan Huscroft*, R. Morris, J. Roseman, E. Aslanivatan, C. Baker, O. Ré, *LAC, University of Southern California, Medical Center, Clinical Instructor of Pediatrics, Los Angeles, CA, U.S.A.*

M.D.P.6 AIDS Prevention in Junior High School Students in an AIDS Epicenter: Results of a Baseline Survey. *Meg A. Durbin*, D. Siegel, L. Lazarus, F. Krasnovsky, M. Chesney, D. Kakimoto, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.7 Sexual Abuse in Children and HIV Infection. *Patricia Estela Uribe*, H. G. Ornelas, G. J. L. Valdespino, M. M. *Palacios, AIDS Information Center of Mexico City, D.G.E Ministry of Health, Mexico City, Mexico.*

M.D.P.8 Influence of Percieved Referent-Group Normative Behavior on Adolescents' Use of Condoms. *Ralph J. Diclemente*, R. DuNah, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.9 Differential Effects of AIDS Knowledge and Perceived Susceptibility on the Reduction of High-Risk Sexual Behaviors among College Adolescents. *Ralph J. Diclemente*, K. Forrest, S. Mickler, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.10 HIV Infection in Adolescents: Can We Predict Who Is at Risk. *Lawrence J. D'Angelo, P. Getson, N. Luban, E. Stallings, H. Gayle, Children's Hospital National Medical Center, Washington, DC, U.S.A.*

Comportement (partie 1)
Behaviour (Part 1)

M.D.P.11 Prédiction de l'intention d'utiliser un condom comme moyen de prévention de M.T.S. *Michel Lavoie*, G. Godin, *D.S.C. Hôpital du Saint-Sacrement, Canada.*

M.D.P.12 Knowledge of Risk Factors and the Avoidance of AIDS in the Gambia, West Africa. *Bruce J. Oelman, K. O. Jaiteh, M. K. Cham, A. B. H. Njie, H. A. Wilkins, S. Baldeh, Epidemology and Statistics Unit, Medical and Health Department, Banjul, Gambia.*

M.D.P.13 Knowledge Regarding AIDS among Employees and Spouses at a Bank in Kinshasa, Zaire. *Melinda Moore, A. Doppagne, S. E. Hassig, N. Lusakulira, T. D. Kashala, Zaire School of Public Health/Tulane University, New Orleans, LA, U.S.A.*

M.D.P.14 AIDS-Related Knowledge, Attitudes and Behaviors among a Population-Based Sample of California Residents. *Melinda K. Moore*, M. Jang, N. Day, *URSA Institute, San Francisco, CA, U.S.A.*

M.D.P.15 High Risk Sexual Behaviour and Condom Use in a Sample of Homosexual Men in England. *Mary Boulton*, R. Fitzpatrick, G. Hart, J. Dawson, J. McClean, *St. Mary's Hospital Medical School, London, U.K.*

M.D.P.16 Appropriate AIDS Knowledge but Negative Attitudes of College Students. *Harold P. Katner*, M. V. Smith, K. W. Couch, J. N. Tripp, E. H. Young, *Mercer University School of Medicine, Macon, GA, U.S.A.*

M.D.P.17 HIV Associated Health Beliefs of Army Basic Trainees. *Linda L. Alexander*, H. Overton, *Division of Preventitive Medicine,, Washington D.C., U.S.A.*

M.D.P.18 Les pratiques et moeurs sexuelles au Sénégal (contribution à la conaissance du SIDA). *Y. Mb. Guisse*, L. D'Almeida, E. Bienvenu, *IFAM CH. A. DIOP, Dakar, Sénégal.*

M.D.P.19 Demographic and Sexual Practices of Male Bar Workers in Bangkok. *Werasit Sittitrai*, P. Phanupahak, N. Satirakorn, E. Wee Ekweera, R. E. Roddy, *Institute of Population Studies, Chulalongkorn University, Bangkok, Thailand.*

M.D.P.20 Peer and Partner Influence and Self-Confidence as Correlates of AIDS Preventive Behavior (APB) in a Low Prevalence State. *Suzanne E. Landis*, J. A. Earp, University of North Georgia, School of Public Health, Department of Epidemiology, Chapel Hill, NC, U.S.A.*

M.D.P.21 The Impact of Community-Based Behavioral Group Intervention to Help Persons Reduce High-Risk Sexual Behaviors. *Kelly A. Jeffrey*, J. S. St. Lawrence, T. L. Brasfield, M. V. Hood, R. Betts, *University of Mississippi Medical Center, Jackson, MS, U.S.A.*

M.D.P.22 Psychological and Demographic Characteristics of Gay Men Who Do or Do Not Engage in Unsafe Sex. *Jeffrey A. Kelly*, J. S. St. Lawrence, T. L. Brasfield, J. E. Smith, H. V. Hood, A. L. Lemke, et al., *University of Mississippi Medical Center, Jackson, MS, U.S.A.*

M.D.P.23 Persistence of High-Risk Sexual Behavior in Homosexual/Bisexual Men: A Multi-Center Study. *Lynda Doll*, R. Byers, G. Bolan, J. Douglas, P. Moss, P. Weller, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

M.D.P.24 Condom Use Can Occur Despite Use of Alcohol and Drugs. *Janet S. Harrison*, L. S. Doll, P. Weller, B. Bartholow, D. Joy, P. Moss, *The U.S. Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

M.D.P.25 Casual Sexual Contacts of Swiss Tourists in Tropical Africa, the Far East, and Latin America. *Robert Steffen*, M. Stricker, A. Eichmann, F. Gutzwiller, *Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland.*

M.D.P.26 Changes in AIDS Knowledge, Attitudes, and Behaviors in San Francisco's Latino Communities: 1987 to 1988. *Susan F. Payne*, G. F. Lemp, G. Bregman, G. Sandlin, F. Sabogal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, U.S.A*

M.D.P.27 Cognitive Differences between Boys and Girls Relating to the Use of Condoms. *Joanne Otis*, G. Godin, J. Lambert, R. Pronovost, *DSC de l'Hôpital Charles LeMoyne, Greenfield Park, Canada.*

M.D.P.28 Predictors of Higher Risk Sexual Behaviors among Gay and Bisexual Men Attending an STD Clinic. *Dan M. Joy*, G. Bolan, J. Harrison, L. Doll, C. Goeghegan, V. Lore, *Division of STD Control, Department of Public Health, San Francisco, CA, U.S.A.*

M.D.P.29 Factors Affecting Retention in a Longitudinal AIDS Risk Reduction Study of Gay Men. *Charles E. Haley*, A. Freeman, B. A. Petty, D. W. Diehl, *Dallas County Health Department, Dallas, TX, U.S.A.*

M.D.P.30 AIDS knowledge and Unsafe Sexual Practices at an STD Clinic. *Robert Kohn*, P. M. Gibson, G. Bolan, *Division of STD Control, Department of Public Health, San Francisco, U.S.A*

M.D.P.31 Prevalence and Change of AIDS High Risk Sexual Behavior among Bisexual Men in San Francisco The San Francisco Men's Health Study. *Maria L. Ekstrand*, T. J. Coates, S. Lang, J. Guydish, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

M.D.P.32 Intentions to Change Behavior, Perceived Change and Reported Change: Do they Correlate? *Donna L. Higgins*, C. Galavotti, K. R. O'Reilly, J. Sheridan, *AIDS Community Demonstration Projects , Centers for Disease Control, Atlanta, GA, U.S.A.*

M.D.P.33 Changes in Hatian Immigrants' Knowledge, Attitudes and Practices about AIDS in Montreal, Canada. *Alix Adrien*, Y. Tousignant, C. A. Hankins, J. F. Boivin, *Département de santé communautaire de l'Hôpital Général de Montréal, QC, Canada*

M.D.P.34 Safe and Unsafe Sex among Homosexual Men in the Netherlands. *Roberta A.P. Tielman*, S. Polter, *University of Utrecht, Utrecht, The Netherlands.*

M.D.P.35 Predicting HIV Risk Behaviors among Gay Men. *Robert W. Wood, L. Krueger, P. Diehr, K. O'Reilly, Seattle-King County Department of Public Health AIDS Prevention Project, Seattle, WA, U.S.A.*

M.D.P.36 Knowledge, Beliefs, Attitudes and Behaviour about AIDS in the 14 to 20 Age Group. Evaluation of an Educational Program. *Yann Seyrer*, W. Böhm, W. Heckmann, S. Michel, *World Health Organization-Centre Paris, Hôpital Claude Bernard, Paris, France*

M.D.P.37 Sexual Behaviour and HIV Related Knowledge among a Random Sample of Young Population of Italy. *Giuseppe Marasca*, E. D'Arcangelo, D. De Candido, G. Della Guista, B. Liseo, P. Pezzotti, *Instituto Superiore di Santi, Rome, Italy*

M.D.P.38 Peer Norms for Safer Sex as a Predictor of Sexual Risk Behaviours in a Cohort of Gay Men. *Theresa M. Exner*, H. F. L. Meyer-Bahlburg, R. S. Gruen, A. A. Ehrhardt, J. M. Gorman, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

M.D.P.39 Gay Identification Influences the Effects of Alcohol Use on AIDS Risk Behavior. *Peggy L. Peterson*, D.J. Mckirnan, *University of Alabama, School of Public Health, Department of Health Behavior, NY, U.S.A.*

M.D.P.40 Knowledge, Attitude and Practice Relating to AIDS among a Random Sample of Students at a Paris University. *Juan Menares*, P. Echevarria, V. Massari, F. Lepont, J. Chwalow, S. Lesieur, et al., *Université Paris, Laboratoire Biostatistique INSERM U263, Paris, France.*

Travailleurs de la santé
Health Care Workers

M.D.P.41 Decentralized Services: Global Network Type Approach. *Andre Bouchard*, M. R. Morissette, *Équipe de prévention et de dépistage, région 03 (DSC du CHUL), Ste-Foy, Canada.*

M.D.P.42 Overestimations of Risk for Occupational HIV Transmission as a Factor within AIDS-HIV Education and Care. *Margaret M. Grade*, H. S. Bartnof, T. J. Ficarrotto, J. S. Mandel, L. S. Zegans, J. L. Ziegler, *AIDS Professional Education Project, School of Medicine, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.43 Job-Related Stress among HIV-Antibody Test Counsellors. *Susan Lloyd Schulz*, D. Rugg, R. Fagan, F. Rhodes, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.D.P.44 Primary Care Physicians' Knowledge, Attitudes, and Willingness to Treat AIDS Patients. *James E. Fordyce*, R. Stoneburner, D. Gemson, J. Colombotos, J. Elinson, *New York City Department of Health, AIDS Research Unit, New York, NY, U.S.A.*

M.D.P.45 Collaborative Evaluation Study of AIDS Training Programs for Women's Health Providers. *Sharen I. Duke*, E. Drucker, P. Gillette, H. Sacks, *New York City Department of Health, AIDS Program Services, New York, NY, U.S.A.*

M.D.P.46 The Needs of Persons Living with AIDS. *Nena M. Nera*, Degner L., *Federal Centre for AIDS, Ottawa, Canada.*

M.D.P.47 The Knowledge and Understanding of Human Immunodeficiency Viral (HIV) Infection among Health Care Workers in Teaching and Non-Teaching Hospitals in Jamaica. *Fitzroy A. Orrett*, P. Prabhakar, *University of the West Indies, Department of Microbiology, Kingston, Jamaica.*

M.D.P.48 Impact of AIDS Workshop of Knowledge and Attitudes in Health Care Workers. *Grania M. Christie*, Zazayokwe M., R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa.*

M.D.P.49 Experience with AIDS among 3,500 Zairian Health Workers, 1987-1988. *Melinda Moore*, E. E. Hassig, N. Lusakulira, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Tulane University, New Orleans, LA, U.S.A.*

M.D.P.50 A KAP Survey of Healthcare Workers is Bankok about AIDS. *Praphan Phanuphak*, V. Sittitrai, B. Veerasukont, *Chulalongkorn University Hospital, Bangkok, Thailand.*

M.D.P.51 General Practitioners and Management of HIV Infection. *Véronique Massari*, R. Landman, F. Fagnani, A. J. Valleron, *INSERM U263, Université Paris, Paris, France.*

M.D.P.52 Would Patients Switch Physicians if Their Doctor Were HIV Positive? *Barbara Gerbert*, B. Maguire, S. Hulley, T. Coates, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.53 Access to Dental Care in the San Francisco AIDS Behavioral Research Cohort. *Barbara Gerbert*, B. Maguire, J. Sumser, T. Coates, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.54 Fear of Contagion in Home Health Aides: A Community Survey. *Janice Bell Meisenhelder, New England Deaconess Hospital, Boston, MA, U.S.A.*

M.D.P.55 Health Workers and AIDS: Knowledge, Attitudes and Experiences as Determinants of Anxiety. *Jan Fouchard*, A. Krasnik, T. Bayer, N. Keiding, *University of Copenhagen, Institute of Social Medicine, Copenhagen North, Denmark.*

M.D.P.56 Knowledge of HIV Transmission and Attitudes about AIDS among 629 Registered Nurses at a Minnesota Hospital. *Scott Campbell*, M. Maki, K. Willenbring, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

M.D.P.57 The AIDS-Related Knowledge, Attitudes and Behaviour of Internists and Surgeons: A Comparative Analysis. *Keith Henry*, S. Campbell, S. Eyer, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

M.D.P.58 Knowledge, Attitude and Concerns of Hospital Staff about AIDS. *Ruth M. Gallop*, G. Taerk, W. J. Lancee, R. Coates, M. Fanning, M. Keatings, *University of Toronto, Toronto, ON, Canada.*

M.D.P.59 Knowledge and Attitudes of Rural Georgia Physicians Concerning AIDS. *Harold P. Katner*, M. U. Smith, R. E. Godeau, *Mercer University School of Medicine, Macon, GA, U.S.A.*

M.D.P.60 Staff Discomfort in Working with HIV Spectrum Patients. *Michael D. Knox*, M. G. Dow, *University of South Florida, Tampa, FL, U.S.A.*

M.D.P.61 Analysis of Nurse-AIDS Patient Verbal Interaction by the SAVI. *Elucir Gir*, T. M. Moriya, E. C. Carvalho, *University of Sao Paulo, School of Nursing of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.*

M.D.P.62 Counselling Professionals with HIV Needle Stick Injuries. *Pascal J. De Caprariis*, S. Dansky, G. Rodriguez, L. Laviena, I. Madera, E. Visconti, et al., *Lutheran Medical Center, Brooklyn, NY, U.S.A.*

M.D.P.63 Assessment of Nursing Home Preparation for Long-Term Care of Persons with HIV Infection. *Nathan L. Linsk*, E. J. Wright, G. Youngman, R. Miller, P. Hefron, L. Chen, *University of Illinois at Chicago, Chicago, IL, U.S.A.*

M.D.P.64 AIDS Mini-Survey on Attitudes, Beliefs and Knowledge among Dental Professionals in Metropolitan Montreal. *Julio C. Soto*, M. Levy, R. Allard, E. Pérèz, *Department de santé communautaire de L'hôpital Saint-Luc, Montréal, QC, Canada.*

M.D.P.65 Measuring Attitudes about AIDS among Public Health Personnel Using the Semantic Differential Technique. *Yves Tousignant*, A. Adrien, L. Ste-Marie, *Université de Montréal, Faculté des Sciences de l'Éducation, Québec, QC, Canada.*

M.D.P.66 HIV Patients' Perceptions of their General Practitioners. *Michael M. Kochen*, J. Hasford, *Biometric Center for Theraputic Studies, Munich, Federal Republic of Germany.*

M.D.P.67 HIV-Related Problems Facing General Practitioners (G.P.) in Belgium. *Dirk Avonts*, F. Buntinx, P. Sweetlove, *Institute of Tropical Medicine, Antwerp, Belgium.*

M.D.P.68 Evaluation de quatre dispositifs de récuperation des aiguilles usagées pour la prévention de l'infection HIV chez les Personnels de Santé et Proposition de Critères de Choix. *Alain Fisch*, F. Vincent-Ballereau, J. E. Malkin, G. Haroche, *Centre Hospitalier, Villeneuve St. Georges, France.*

M.D.P.69 Myths and Stigmas about AIDS in Health Personnel in a Latin American Country. *Lourdes Garcia*, J. A. Izazola, J. L. Valdespino, L. Alanís, M. L. Cravioto, J. Sepulveda, *General Directorate of Epidemiology, Mexico, Mexico.*

M.D.P.70 HIV-1 Knowledge, Attitudes and Risk Perception in Biomedical Research Facility Employees. *Robyn R. M. Gershon*, B. A. Curbow, D. Vlahov, Johns Hopkins University School of Health, Department of Environmental Health Sciences, Kellogg Program, Baltimore, MD, U.S.A.*

M.D.P.71 Medical Students' Knowledge and Concerns about HIV Infection. *Lee Strunin*, A. Culbert, *Boston University School of Public Health, Boston, MA, U.S.A.*

M.D.P.72 Risk of Occupational Exposure to HIV Infected Dody Fluids and Transmission of HIV I among Health Care Workers:A Multicentre Study. *Giuseppe Ippolito*, P. Cadrobbi, G. Carosi, P. Espiscopo, G. Finzi, V. Puro, *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy.*

M.D.P.73 Adverse Exposures to Blood and Body Fluids among Practicing Midwives in the United States. *David K. Henderson*, M. Willy, G. Dhillon, N. Loewen, R. Wesley, National *Institutes of Health, The Clinical Center, Office of the Director, Bethesda, MD, U.S.A.*

M.D.P.74 The Impact of AIDS on Health Care Providers: An Annotated Bibliography and International Survey. *Merrijoy Kelner*, K. M. Taylor, J. M. Eakin, *University of Toronto, Department of Behavioural Science, Toronto, ON, Canada.*

M.D.P.75 The Role of the Homemaker/Home Support Services in AIDS Care in Canada. *Kathleen L. Jacobson*, Fietz M., *Canadian Counsil on Homaker Services, Toronto, ON, Canada.*

M.D.P.76 The Doctor-Patient Relationship: Is It Working for People with HIV Infection? *Michelle E. Roland*, L. Temoshok, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.D.P.77 AIDS/HIV Infection: Knowledge, Attitudes and Beliefs of Dental health Faculty and Students. *Diana M. Shin*, A. Y. Wong, *Center for Interdisciplinary Research in Immunology and Disease (CIRIC) at UCLA, Los Angeles, CA, U.S.A.*

M.D.P.78 Physician perception of Personal Risk from AIDS (HIV Virus). *Kathryn M. Taylor*, H. A. Skinner, J. E. Eakin, M. J. Kelner, M. Shapiro, *University of Toronto, Department of Behavioural Science, Toronto, ON, Canada.*

M.D.P.79 Practices and Attitudes of Health Care Workers (HCW) towards HIV-Infected Patients in a Large Acute Care Hospital. *Walter F. Schlech*, S. Mac Donald, C. Fanning, S. *Lefort-Jost, Dalhousie University and Victoria General Hospital, Halifax, Canada.*

M.D.P.80 AIDS and Dental Health Professionals: Knowledge, Attitudes and Infection Control Practices. *Francisco S. Sy*, N. Steplight, J. Kronenfeld, J. Daniel, K. Jackson, *University of South Carolina, School of Public Health, Columbia, SC, U.S.A.*

M.D.P.81 A Method for Implementation of Universal Precautions. *Christopher LaCharite*, S. Marino, S. Nottebart-Finn, J. Sniffen, R. Platt, *Brigham and Women's Hospital, Boston, MA, U.S.A.*

M.D.P.82 A Survey of Knowledge and Attitudes Concerning HIV Infection and AIDS among Faculty and Students at 3 U.S. Dental Schools. *James A. Cottone*, S. B. Dove, R. Bebermeyer, J. A. Molinari, *University of Texas Dental School at San Antonio, San Antonio, TX, U.S.A.*

M.D.P.83 HIV-Related Risk, Worry, and Behaviour Changes among Emergency Medical Workers: Personal and Job-Related Factors. *Rick S. Zimmerman*, T. Bolon, M. Rodriguez, J. Patrone-Reese, *University of Miami Department of Sociology, Coral Gables, FL, U.S.A.*

M.D.P.84 Attitudes and Practices of General Internists Regarding Care of People with HIV Infection. *Harvey J. Makadon*, R. S. Phillips, Beth Israel Hospital, Harvard University, Boston, MA, U.S.A.*

M.D.P.85 Evidence for the Benefits and Need for Ongoing AIDS/HIV Curiculum Revision for Medical, Nursing, Pharmacy and Dentistry Students at the University of California at San Francisco, School of Medicine. *Harvey S. Barntof*, M. A. Papadakis, M. M. Grade, B. A. Koenig, L. S. Zegans, J. L. Ziegler, *University of California at San Francisco, AIDS Professional Education Project, School of Medicine, San Francisco, CA, U.S.A.*

M.D.P.86 The Attitudes of PWAs to Their Primary Care Physician. *Surinder Singh*, S. J. Mansfield, *St. Stephen's Hospital, London, U.K.*

M.D.P.87 Verbal Interaction between the Nursing Team and the AIDS Patients. *Elucir Gir*, T. M. Moriya, *University of Sao Paulo, School of Nursing of Ribeirao Preto, Ribeirao, Preto, Sao Paolo, Brazil.*

M.D.P.88 Assesment of Risk for Occupational/Nosocomial Transmission of Human Immunodeficiency Virus-1 in Health Care Workers. *David K. Henderson*, B. J. Fahey, J. M. Schmitt, A. J. Saah, H. C. Lane, *National Institute of Health, The Clinical Center, Bethesda, MD, U.S.A.*

M.D.P.89 The AIDS-Related Knowledge, Attitudes, and Behavior of Internists and Family Physicians: A Comparative Analysis. *Keith Henry*, S. Campbell, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*



Section
E

Lundi 5 juin
Monday, June 5

Le SIDA, la societé et le comportement
AIDS, Society and Behaviour

Session d'affichage
Poster Session

Information
Information

M.E.P.1 A Structured Educational Support Group for HIV Infected Individuals. *Nancy L. Van Devanter*, C. Tendler, R. Shipton-Levy, M. Steilen, A. Stuart, *Columbia University School of Public Health, New York, NY, U.S.A.*

M.E.P.2 Report From a Public Health Psychosocial Clinic for Gay and Bisexual Men with HIV-Related Problems. *M. G. Claes Von Zeipel*, H. G. Westman, *Landstingets psykhälsa, Stockholm, Sweden.*

M.E.P.3 AIDS-Stigma and Anti-Gay Prejudice: Public Reactions to AIDS-Related Policies to Gay Men in the U.S.A. *Gregory M. Herek*, E.K. Glunt, Graduate Center, *City University of New York, New York, NY, U.S.A.*

M.E.P.4 Communicating AIDS Information to Hispanics: The Importance of Language and Media Preference. *Dale J. Hu*, R. Keller, D. Fleming, *Johns Hopkins University Preventive Medicine Residency, Baltimore, MD, U.S.A.*

M.E.P.5 AIDS: A Proactive Approach to Mental Handicap. *Gillian James, Royal College of Nursing, London, U.K.*

M.E.P.6 Evaluation of Aids Education Programs for Offenders. *Jan R. Godes*, K.J. Bell, V.M. Thelen, R.D. Miller, R. E. Sherman, J.L. Craig, *Hennepin County Community Health Department, Minneapolis, MN, U.S.A.*

M.E.P.7 An Application of Social Marketing to the Development of AIDS Educational Materials. *Peter G. Burrell*, J.R. Magana, J.R. Greenwood, T.J. Prendergast, R. Montoya, *County of Orange, California, Santa Ana, CA, U.S.A.*

M.E.P.8 Using National and Regional Minority Organizations to Provide Culturally Relevant HIV Information and Education in the the United States. *M. Isabel Fernandez*, W. Duncan, B. Lindsey, A. Kwarmoogi, *Centers for Disease Control, National AIDS Information and Education Program, Atlanta, GA, U.S.A.*

M.E.P.9 AIDS in the Inner City: How a Black Community Organization Has Responded to the AIDS Epidemic. *Mindy Fullilove*, M. Weinstein, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

M.E.P.10 AIDS Education Program for Haitian Immigrants in Montreal. *Alix Adrien*, J. Merveille, A. Alcindor, M. L. Ambroise, R. Duperval, J. Dreyfuss, et al., *Département de santé communautaire de l'Hôpital Général de Montréal, Montréal, QC, Canada.*

M.E.P.11 AIDS Education in Communties of Color: A Private-Public Partnership Model. *Catlin P. Fullwood*, K. Hartfield, *People of Color against AIDS Network, Seattle, WA, U.S.A.*

M.E.P.12 Implementing a Culturally Sensitive AIDS Prevention Program for Haitian Immigrants in New York City. *Arnaud Bastien*, P. Freedman, Y. Norat, J. DeHovitz, *State University of New York- Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

M.E.P.13 AIDS Knowledge, Language Use and Response to Spanish and Englsih Radio Messages of Low-Income Mexican-American Women in South Texas. *Marc Weiner*, C., Jr. Martinez, T. Prihoda, A. Rogan, M. Reyes, *University of Texas Health Science Center, Department of Medicine, San Antonio, TX, U.S.A.*

Médias
Media

M.E.P.14 Aids: The Language, Media, and Public Response. *Josee C. Duffhues, Waterloo Regional Health Unit, AIDS Program Supervisor, Kitchener, ON, Canada.*

M.E.P.15 Utilizing the Mass Media to Provide Culturally Relevant HIV Education to Hispanic Americans. *M. Isabel Fernandez*, R. Lepicier, L. Montealegre, *Centers for Diseases Control, National AIDS Information and Education Program, Atlanta, GA, U.S.A.*

M.E.P.16 The Development of a Large Scale AIDS Media Campaign by Combining Public and Private Sector Resources. *Claudia L. Webster*, D. Fleming, R. McAlister, G. Tycer, R. Schmidt, *Oregon Health Division, Portland, OR, U.S.A.*

M.E.P.17 The Impact of Media Events on Public Interest in AIDS. *Robert W. Wood*, K. A. Hartfield, L. Ray-Keil, *Seattle-King County Department of Public Health, Seattle, WA, U.S.A.*

M.E.P.18 Perceived Risk of HIV Transmission from a Promiscuous Bisexual Patient with AIDS among Lay People and Public Health Specialists. *Gen Ohi, Teikyo University, School of Medicine, Tokyo, Japan.*

M.E.P.19 The Metaphors of AIDS: Reporting of an Epidemic in Puerto Rico. *Ineke Cunningham*, E. L. Cunningham, *University of Puerto Rico, Department of Sociology, Rio Piedras, PR, U.S.A.*

M.E.P.20 AIDS Information Center in Lima, Peru. *Manuel E. Lujan*, P. G. Goicochea, L. R. Varela, P. Coleman, *Ministry of Health/AIDS Project, Lima, Peru.*

M.E.P.21 AIDS Media and Anti-Discrimination: A Critical Presentation. *Catherine G. Saalfield*, R. Navarro, *Whitney Museum Independent Study Program, New York, NY, U.S.A.*

M.E.P.22 AIDS Makes Newspapers Sell. *Carmen Arredondo Miguel*, F. Conde, A. Coronado, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spain.*

Milieu de travail
Workplace

M.E.P.23 Employment and the Social Challenges of AIDS. *Linda J. Laubenstein*, J. B. Greene, J. R. Campbell, M. S. Weisberg, *New York University Medical Center, New York, NY, U.S.A.*

M.E.P.24 Healthcare Workers and AIDS: Risk Prevention and Education. *Genevieve M. Clavreul, World Immunological Network Project Foundation, Los Angles, CA, U.S.A.*

M.E.P.25 The Metro Toronto AIDS Education Program: A Model for Low-Budget Municipal Training. *Diane M. Riley*, W. A. Davey, S. Varley, J. Sloggett, *Municipality of Metropolitan Toronto, Toronto, ON, Canada.*

M.E.P.26 Effecting Behavior Change through Policy and Training. *Julie Louise Gerberding, San Francisco General Hospital, San Francisco, CA, U.S.A.*

M.E.P.27 An Employer-based Approach to AIDS Prevention, Education and Management. *William L. Beery*, R. D. Vance, N. S. Sofian, E. S. Anderson, *Center for Health Promotion, Group Health Cooperative of Puget Sound, Seattle, Washington, DC, U.S.A.*

M.E.P.28 An AIDS Education Intervention in a Multinational Hotel Industry. *Grania M. Christie*, M. Zazayokwe, R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa.*

M.E.P.29 Responding to AIDS: Ten Principles for the Workplace. *Carol Levine, Executive Director, Citizens Commission on AIDS for N.Y. City and Northern N.J., New York, NY, U.S.A.*

M.E.P.30 Workplace AIDS Education: An Evaluation of Centers for Disease control Employees. *Deborah L. Rugg*, S. Kidd, D. Brownell, D. Schnell, *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.E.P.31 Educational Strategies on AIDS at Workplaces. *Joao Luis Grandi*, M.E. Fernandes, N. Abbud, V.M. Adao, R. Kakihara, *Centro de Referência e Treinamento AIDS, Sao Paulo, Brazil.*

M.E.P.32 Rules for Adequate Care after Accidental Skin Lesions with Risk of Exposure for Blood-borne Infection. *Lars Hambraeus*, Y. Greitz, *National Bacteriological Laboratory, Department of Epidemiology, Stockholm, Sweden.*

M.E.P.33 Results on the Effectiveness of an AIDS in the Workplace Education Pilot Program. *Susan M. Blake*, D. Najjar, A. George, R. Makinodan, *American Red Cross, National Headquarters, Washington, DC, U.S.A.*

Famille
Family

M.E.P.34 Family Treatment Approach for HIV Infected Children. *Anita Septimus*, A. Rubinstein, *Albert Einstein College of Medicine, D.S.S., Bronx, NY, U.S.A.*

M.E.P.35 Multi-Family Support Group for Transfusion Related HIV Infection. *Ann Stuart*, M. Steinlen, S. Campbell, *Columbia University, New York, NY, U.S.A.*

M.E.P.36 Bisexual Men and their Partners Workshop Session. *William A. Palmer*, *Gay and Married Men's Association / Dental Hospital, Melbourne, North Balwyn, Victoria, Australia*

M.E.P.37 AIDS and Hemophilia: A Coordinated Education, Support and Personal Care Program. Evaluative Report From a Two-Year Pilot Project. *John R. McDonald*, G. Dowdle, *Faculty of Social Welfare, University of Calgary and Calgary Region Canadian Hemophilia Society, Calgary, AB, Canada.*

M.E.P.38 The HIV-Endangered/Infected Child in the Foster-Family. *Gabriele Schwarz*, A. Hemme, *Arbeitskreis zur Förderung von Pflegekindern e.V., Frankfurt, Federal Republic of Germany.*

M.E.P.39 Who Speaks for the Abandoned Child Born with HIV? A Foster Parent and Adoptive Parent Respond. *Barbara A. Chamness*, T. McCarroll, *Childkind, Inc., Norcross, U.S.A.*

M.E.P.40 AIDS Orphans in New York City: Projected Numbers and Policy Demands. *Chris Norwood, Women and AIDS Studies, New York, NY, U.S.A.*

M.E.P.41 Expérience Québécoise d'intervention auprès de familles à l'occasion de l'hospitalisation de leur proche homosexuel... . *Pierre Berthelot*, G. Poirier, *Centre des services sociaux de Québec, Services sociaux hospitaliers, Québec, Canada.*

M.E.P.42 Providing Comprehensive Services for Developmentally Disabled Children with AIDS: Services and Issues. *Phyllis L. Susser*, T. Anthony, *The Herbert G. Birch Community Services, Inc., Springfield Gardens, U.S.A.*

M.E.P.43 Accessing, Educating and Researching Married Homosexual and Bisexual Men. *William A. Palmer, Gay and Married Men's Association/ Dental Hospital, Melbourne, North Balwyn, Victoria, Australia*

La communauté (partie 1)
Community (Part 1)

M.E.P.44 The Genesis and the Rapid Development of the AIDS Activist Movement. *Henry J. Yeager, The Dwight Foundation, New York, NY, U.S.A.*

M.E.P.45 Des professionnels de la santé et la création d'un groupe d'entraide à Québec: réalisation probante de la Complémentarité des ressources. *Colette Lachance*, R. Raymond, *Hôpital du Saint-Sacrement, Département de santé communautaire, Québec, QC, Canada.*

M.E.P.46 A Comparative Study of Local AIDS Programmes in the United Kingdom. *Mukesh Kapila*, M. Pye, G. Buckley, D. Cuningham, *Health Education Authority, London, U.K.*

M.E.P.47 The Establishment and Administration of Casey House Hospice, Toronto. *Miriam Mayhew*, D. Ley, *Casey House Hospice, Toronto, ON, Canada.*

M.E.P.48 Homelessness and AIDS: A Video. *Barbara Blakeney*, J.R. McMahon, *Long Island Shelter: Department of Health and Hospitals, Boston, MA, U.S.A.*

M.E.P.49 Community Coalition Building As a Means of Improving Service Systems for People with HIV Infection. *C. Hostetter*, S. Matheny, D. McMenamin, *Department of Health and Human Services, Rockville, MD, U.S.A.*

M.E.P.50 A Community-Based AIDS Education, Counselling and Information Service in Zimbabwe: A Model for Africa? *Geoff Foster, Mutare Provincial Hospital, Mutare, Zimbabwe.*

Services sociaux
Social Services

M.E.P.51 An Assessment of the Psychosocial Needs of the HIV Antibody Positive Population Using the Montreal Health and Social Service Network. *Elizabeth Clark*, V. Atkinson, N. Grayson, *Comité SIDA AIDE Montréal, Montréal, QC, Canada.*

M.E.P.52 Hospitalized AIDS/ARC Patients Presenting Disposition Problems: No Simple Solutions. *Rachel A. Pousson, King's County Hospital Aids Team, Brooklyn, NY, U.S.A.*

M.E.P.53 Developing the Skills of Home Care Staff in Caring for People Living with AIDS. *Terry M. Cotton*, D. Platt, *London Borough of Hammersmith and Fulham, Social Services Department, London, U.K.*

M.E.P.54 Estimating Numbers of People Living with AIDS/HIV Infection in a Small Urban Area for Social Services Planning Purposes. *Nicholas P. Manning, London Borough of Hammersmith and Fulham, London, U.K.*

M.E.P.55 Establishing Quality Control Targets for the Provision of Personal Social Services to People Living with AIDS and HIV Infection. *Nicholas P. Manning, London Borough of Hammersmith and Fulham, London, U.K.*

M.E.P.56 Local Government Provision of Social Care to People Living with AIDS/HIV Infection. *Denise Platt*, T.M. Cotton, *London Borough of Hammersmith and Fulham, Social Services, London, U.K.*

M.E.P.57 Political Attack, Medical Comfort, Psychological Deficiencies: Facets and Effects of AIDS policies in Bavaria, West Germany. *Walter Satzinger*, H. Jaeger, G. Hammel, U, Weber, *GSF-Institute for Medical Informatics (MEDIS), Neuherberg, Bavaria, Federal Republic of Germany.*

M.E.P.58 HIV Infection, Aids and Mental Health: The Canadian National Working Group's Experience. *Stephen Woo*, J. De Montigny, *Department of Psychiatry, Mount Sinai Hospital, Toronto, ON, Canada.*

M.E.P.59 "We Haven't Dealt with Much of That Here": Helping Mental Health Providers Prepare to Work with HIV Related Clients. *Marcia J. Quackenbush*, D. Deitch, R. Martin, M. Schuyler, *University of California at San Francisco, AIDS Health Project, San Francisco, CA, U.S.A.*

M.E.P.60 Sources of Delayed Hospital Discharge for AIDS Patients. *Mindy Widman*, D.W. Light, J J. Platt, *University of Medicine and dentistry of New-Jersey, School of Osteopathic Medicine, Camdem, NJ, U.S.A.*

M.E.P.61 Post-Discharge Housing of HIV Infected Patients in Rome. *Giuseppe Ippolito*, O. Armignacco, G. Antonucci, G. Bove, *Ospedale Lazzaro Spallanzani, Rome, Italy.*

M.E.P.62 Developing Comprehensive Services for HIV Infected Intravenous Drug Users: A Guide for Case Managers. *Diane Pincus Strom, Bronx-Lebanon Hospital, Bronx, NY, U.S.A.*

M.E.P.63 Needs, Assessment of Persons with AIDS and HIV Illness: Implications for Community-Based Service Planning in a Low Incidence Community. *Richard V. Carrick*, D. A. Coleman, D. Zelinski, *United Way of Franklin County, Columbus, U.S.A.*

M.E.P.64 Comprehensive Volunteer Program for People with AIDS. *Jonathan Jacobs*, S. Miller, N. Streeter, *Center for Special Studies, New York Hospital- Cornell Medical Center, New York, NY, U.S.A.*

M.E.P.65 Hospital Liaison and Visitation Programs Provide Emotional Support, Advocacy and Linkage to Community Based Organizations for Hospitalized PWA/PWARCs. *Michael Hedderman*, S. Jue, D Bergman, S. Stroup, *AIDS Project Los Angeles, Los Angeles, CA, U.S.A.*

M.E.P.66 The Importance of the Social Service Experience at a University Hospital in Rio de Janeiro, Brazil. *Eleonora P. Hanan*, E. M. M. Moura, E. R. Oliveira, C. A. Morais de Sá, *Gaffrée and Guinle University Hospital/University of Rio de Janeiro (UNI-RIO), Rio de Janeiro, Brazil.*

M.E.P.67 Northern Manhattan Women and Children HIV Demonstration Project: Social Service Issues. *Ester Chachkes*, R. Andrew, C. Healton, V. Walter, J. Johnson, *Presbyterian Hospital, New York, NY, U.S.A.*

M.E.P.68 Group Residence and Scattered Site Apartments as Housing for Homeless Persons with AIDS. *Douglas H. Dornan*, K. Wampler, G. Hough, *AIDS Resource Center, New York, NY, U.S.A.*

M.E.P.69 Social Service Needs for People with AIDS: Perceptions of Need and Unmet Need. *John A. Fleishman*, J. Piette, V. Mor, *Center for Gerontology and Health Care Research, Brown University, Providence, U.S.A.*

M.E.P.70 Step Down Care Acceptability in Hospitalized AIDS Patients. *Wayne C. McCormick*, T. S. Inui, R. A. Deyo, C. DeGroff, R. Wood, *University of Washington, Robert Wood Johnson Clinical Scholars Program, Seattle, WA, U.S.A.*

M.E.P.71 A Multi-Disciplinary Model for Decision-Making and Case Planning for HIV-Infected Children and Youth in Child Welfare and Child Protective Services Systems. *Burt J. Annin*, L. J. Emery, K. Ponts, *Child Welfare League of America, Washington, DC, U.S.A.*

M.E.P.72 Community-Based Care for People with HIV Disease. *Howard C. Rubin*, H. S. Sacks, *Mount Sinai School of Medicine, New York, NY, U.S.A.*

M.E.P.73 The Challenge of AIDS in an Area of Scattered Population and Low Prevalence. *Pat Tyson, Regional Joint AIDS Community Support Center, Newcastle-Upon-Tyne, U.K.*

M.E.P.74 Comprehensive Social Service HIV Retrovirus Program at Walter Reed Army Medical Center. *Robert H. Gemmill, Walter Reed Army Medical Center, Washington, DC, U.S.A.*

Notes

Section
F
Droit et éthique
Ethics and Law

Lundi 5 juin
Monday, June 5

Session d'affichage
Poster Session

Vue d'ensemble de la l'égislation
Global Survey of AIDS Legislation

M.F.P.1 Legal Protections against HIV-Related Discrimination in the U.S.A.: A Fifty-State Analysis. *Benjamin H. Schatz, AIDS Civil Rights Project, National Gay Rights Advocates, San Francisco, CA, U.S.A.*

M.F.P.2 Legal Authority for HIV Testing of Adolescents. *Richard L. North, University of Maryland School of Law, Baltimore, MD, U.S.A.*

M.F.P.3 Impact of the Sanitary Legislation on HIV Transmission in Blood Donations in Guadalajara, Mexico. *Eduardo Vázquez-Valls*, B. Torres-Mendoza, M. L. Jauregui-Ríos, E. Soto-Sánchez, *Instituto de Patología Infecciosa y Experimental de la Universidad de Guadalajara, Guadalajara, Mexico.*

M.F.P.4 AIDS in U.S. and Canadian Correctional Facilities: Epidemiology and Policy Responses. *Theodore M. Hammett*, S. Moini, L. Harrold, M. Weissberg, *Abt Associates Inc., Cambridge, MA, U.S.A.*

M.F.P.5 Current Issues in Drug Regulation in the U.S.A. *Stephen C. Smith, Human Rights Campaign Fund, Washington, DC, U.S.A.*

M.F.P.6 Trends in AIDS Litigation in the United States--1983 to 1988. *Gene W. Matthews*, V. S. Neslund, *Office of the General Counsel, Centers for Disease Control, Atlanta, GA, U.S.A.*

M.F.P.7 AIDS and the Courts: Compelling and Protecting the Disclosure of AIDS Status. *H. Patrick Glenn*, Y.-M. Morissette, N. Gilmore, M. Somerville, *McGill Center for Medicine, Ethics and Law, Montreal, Canada.*

M.F.P.8 The Consequences of the Legislation of Prostitution in Victoria. *Cheryl M. Overs, Prostitutes Collective of Victoria, Melbourne, Australia.*

M.F.P.9 SIDA: Problèmes éthiques posés par la protection des dons de sang. *Catherine Manuel*, D. Reviron, M. P. Larher, J. Charrel, P. Enel, J. L. San Marco, *Laboratoire de Santé Publique, Faculté de Médecine, Marseille, France.*

M.F.P.10 Compulsory HIV/AIDS Case-Reporting: Does It Promote or Inhibit Public Health? *Julie C. Hamblin, McGill Centre for Medicine, Ethics and Law, Montréal, QC, Canada.*

Notes

Section
G

Lundi 5 juin
Monday, June 5

Implications internationales
International Issues

Session d'affichage
Poster Session

Épidémiologie
Epidemiology

M.G.P.1 Patterns and Trends of Heterosexual Transmission of HIV among Brazilian AIDS Cases. *Euclides Castilho*, P. Chequer, D. Bergamaschi, L. Rodrigues, *Oswaldo Cruz Foundation, Ministry of Health, Rio de Janeiro, Brazil.*

M.G.P.2 HIV-1 and HIV-2 Serological Survey in Lunda Norte, Northeastern Province of Republica Popular de Angola. *Manuel José M. Almeida*, M. O. Santos-Ferreira, M. H. Lourenco, T. Cohen, J. M. Azevedo Pereira, *S. Dermatologia, Hospital Santa Maria, Lisbon, Portugal.*

M.G.P.3 The Seroprevalence of HTLV-I and HIV-1 Co-Infection in Haiti. *Michael Giordano*, J. Pape, W. Blattner, W. D. Johnson, Jr., *Cornell University Medical College, Division of International Medicine, New York, NY, U.S.A.*

M.G.P.4 Estimate of HIV Infection Prevalence in Brazil. *Claudio Struchiner*, E. A. Castilho, M. D. C. Guimaraes, *Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.*

M.G.P.5 HIV and Hepatitis B. Transmission in Sudan. *Michael C. McCarthy*, K. C. Hyams, M. El-Dabi, J. Woody, *United States Naval Medical Research Unit No. 3, New York, NY, U.S.A.*

M.G.P.6 Empirical Extrapolation Projections of AIDS Incidence in Brazil. *Euclides A. Castilho*, C. Struchiner, M. D. C. Guimaraes, *Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.*

M.G.P.7 Prévalence des infections par les virus HIV-1, HIV-2 et HTLV-I dans la region de Tananarive Madagascar. *Philippe Chevallier*, J. Ritter, E. Andriamampihantona, M. Septjan, *Laboratoire de santé publique FAC médecine Lyon Nord, Lyon, France.*

M.G.P.8 HIV-1 Infection in Pregnant Women from Santos, Brazil. *Nelson Mendes*, P. Giraldes, A. Porto, Z. Peixinho, I. Longo, M. Souza, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

M.G.P.9 HIV Infection in Some Urban and Rural Areas of Cameroon. *Giuseppe Ippolito*, V. Angeloni, F. Costa, M. L. Aebischer, G. Spedini, M. C. Martorana, et al., *L. Spallanzam Hospital for Infectious Diseases, Rome, Italy.*

M.G.P.10 Prevalence of Anti-HIV Antibodies in a Sample of the General Population. *Blanca Torres-Mendoza*, E. Vazquez-Valls, M. L. Jauregui-Rios, *Instituto de Patologí Infecciosa y Experimental de la Universidad de Guadalajara, Guadalajara, Mexico.*

M.G.P.11 Geographic and Risk-Group Patterns of HIV Infection in Africa. *Peter O. Way*, V.-P. Sneller, W. H. Lyerly, *Center for International Research, Washington, DC, U.S.A.*

M.G.P.12 Study of HIV-1, HIV-2, and HTLV-I in Homosexuals in Brazil. *Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, D. D. Ho, *Faculdade de Medicina, UFRJ, Departamento de Clinica Medica, Hospital Universitario, Rio de Janeiro, Brazil.*

M.G.P.13 Study of HIV-1, HIV-2, and HTLV-I in Female Prostitutes in Brazil. *Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, D. D. Ho, *Faculdade de Medicina, UFRJ, Departamento de Clinica Medica, Hospital Universitari, Rio de Janeiro, Brazil.*

M.G.P.14 Seroprevalence of HIV-1, HIV-2, and HTLV-I in Brazilian Bisexual Males. *Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, D. Ho, *Faculdade de Medicina, UFRJ, Departamento de Clinica Medica, Hospital Universitario, Rio de Janeiro, Brazil.*

M.G.P.15 Seroprevalence of HIV-1 in Emergency Room Patients in Brazil. *Eduardo J. B. Cortes*, R. Lourenço, M. Lima, L. Huang, R. Vianna, C. Nogueira,*Faculdade de Medicina, UFRJ, Departamento de Clinica Medica, Hospital Universitario, Rio de Janeiro, Brazil.*

M.G.P.16 HIV-2 Infection in Prenatal Women in Guinea-Bissau. *Per-Ake Andreasson*, F. Dias, J. M. Teixeira Goudiaby, A. Nauclér, G. Biberfeld, *Laboratorio Nacional de Saúde Pública, Embaixada da Suecia, Bissau, Guinea-Bissau, Guinea.*

M.G.P.17

M.G.P.18 HIV Seroprevalence in Rural Zaire. *Iain R. Hardy*, S. R. Green, W. A. M. Cutting, M. Cranefield, *University of Edinburgh, Edinburgh, U.K.*

M.G.P.19 Anti-HIV Testing in Blood Banks in Ecuador. *Galo Leoro-Monroy*, M. L. Merino, M. Sanchez, C. Herrera, R. Chiribosa, F. Weilbauer,*Ecuadorian Red Cross, Quito, Ecuador.*

M.G.P.20 Seroprevalence of HIV-1, HIV-2, and HTLV-I in Male Prostitutes in Rio de Janeiro, Brazil. *Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, D. Ho, *Faculdade de Medicina- UFRJ/ Departamento de Clinica Medica, Rio de Janeiro, Brazil.*

M.G.P.21 Dynamique de l'infection à VIH-1 en Guyane Française de 1978 à 1987. *Hervé J. A. Fleury*, R. Pradinaud, M. Levadoux, *Université de Bordeaux II, Bordeaux, France.*

M.G.P.22 HIV Seroprevalance in Egypt: A-Two-and-a-Half-Year Surveillance. *Douglas M. Watts*, N. Constantine, F. Sheba, H. Amer, S. Khashaba, R. Danahy, et al, *United States Naval Medical Research Unit No. 3, New York, NY, U.S.A.*

M.G.P.23 An Epidemiological Review of HIV in Zambia. *George S. Tembo*, S. Hira, *University Teaching Hospital, Department of Community Medicine, Lusaka, Zambia.*

Prévalence : VIH et autres maladies
Prevalence: HIV and Other Diseases

M.G.P.24 HIV-1, HIV-2 and Tuberculosis (TB) in Abidjan, Côte d'Ivoire. *M. Miles Braun*, T. Mamadou, G. Damet, K. De Cock, J. Krebs, R. Bretton, et al., *Centers for Disease Control, Atlanta, GA, U.S.A.*

M.G.P.25 HIV-1 et HIV-2 parmi les tuberculeux du Centre antituberculeux et du service de pneumophysiologie du C.H.U. de Cocody. *Guy-Michel Gershy-Damet*, M. Traore, S. Ouattara, B. N. Soro, A. Assoa, K. Koffi, *Institut Pasteur de Côte d'Ivoire, Abidjan, Ivory Coast.*

M.G.P.26 Tuberculose et infection à VIH à Bobo-Dioulasso (Burkina Faso). *Jean-Elie Malkin*, T. Prazuck, F. Simonnet, E. Traoré, H. Tiendrebeogo, A. Dublanchet et al., *Groupe d'Études Épidemiologiques et Prophylactiques (GEEP), Villeneuve St-Georges, France.*

M.G.P.27 Early Infant Measles: Association with Maternal HIV Infection. *Joanne E. Embree*, P. Datta, L. Sekla, M. Braddick, J. Kreiss, F. Plummer, *University of Washington, Department of Infectious Diseases, Seattle, WA, U.S.A.*

M.G.P.28 Specific Antibody Response to Plasmodium Falciparum Schizonts in Zambian Children with HIV-1 Infection and Their Hospital Controls. *Rosemary M. Mwendapole, Tropical Diseases Research Centre, Ndola, Copperbelt, Zambia.*

Notes

Section
H

Lundi 5 juin
Monday, June 5

Répercussions économiques du SIDA
The Economic Impact of AIDS

Session d'affichage
Poster Session

Coûts des traitements médicaux
Medical Treatment Costs

M.H.P.1 The Impact of Zidovudine on AIDS-Related Hospital Admissions: How Long Does the Honeymoon Last? *Timothy Ng*, J. S. G. Montaner, M. Schechter, A. McLeod, B. Willoughby, J. Beardsell, et al., *University of British Columbia, St-Paul's Hospital, AIDS Research Programs, Vancouver, BC, Canada.*

M.H.P.2 Effects of the Use of AZT on the Medical Care Costs of Persons with AIDS in the First 12 Months. *Anne A. Scitovsky*, M. Cline, D. I. Abrams, *Palo Alto Medical Foundation, Research Institute, Palo Alto, CA, U.S.A.*

M.H.P.3 Role of a Dedicated HIV/AIDS Ward in a Central London Teaching Hospital. *Surinder Singh*, G. M. Connolly, D. A. Hawkins, B. Gazzard, *Kobler Centre, St. Stephen's Hospital AIDS Unit, London, U.K.*

M.H.P.4 Digestive Infections during AIDS, Diagnostic Strategy and Cost. *E. René*, A. Durrbach, R. Bouali, T. Chevalier, L. Geoffroy, C. Roze, et al., *Hôpital Bichat, Paris, France.*

M.H.P.5 Hospital Use by PWA's in New York, Los Angeles and San Francisco. *Jesse Green*, M. Leigh, N. Wintfeld, *New York University Medical Center, Department of Health Policy Research, New York, U.S.A.*

M.H.P.6 Costs and Characteristics of Out-of-Hospital Programs for Persons with AIDS in San Francisco, 1985-1988. *Adam C. Stern*, J. Amory, M. Bala, S. Hernandez, G. Rutherford, *Department of Public Health, San Francisco, CA, U.S.A.*

M.H.P.7 The Contribution of PCP to Trends in AIDS Hospital Discharges and Average Lengths of Stay. *Sandra R. Hernandez*, F. Strachaz, G. Rutherford, L. Baskett, A. Stern, *AIDS Office, San Francisco Department of Public Health, San Francisco, U.S.A.*

M.H.P.8 Costs of Hospital Care for Patients with HIV Infections. *Jan C. C. Borleffs*, J. C. Jager, R. M. A. Geels, J. T. L. Jong, C. K. Musch, M. J. J. C. Poos, et al., *University Hospital Utrecht, Department of Internal Medicine, Utrecht, Netherlands.*

M.H.P.9 Hospital Use by a Population-Based Cohort of AIDS Patients. *David W. Fleming*, S. Modesitt, R. Klockner, D. Bennett, S. Hulman, *Oregon Health Division, Portland, OR, U.S.A.*

M.H.P.10 Outpatient Treatment of AIDS: A Viable Alternative that Demonstrates Significant Cost Savings. *Richard J. Liekweg*, P. Dideriksen, T. Adinolfi, J. A. Bartlett, *Duke University Medical Center, Durham, U.S.A.*

M.H.P.11 La Fréquentation hospitalière liée au virus de l'immunodéficience humaine. *Christine M. Jestin*, J. M. Nadal, G. Vidal-Trecan, B. Morel, O. Choquet, J. Chevalier, *Ministere de la Solidarité, de la Santé, Protection Sociale, Paris, France.*

M.H.P.12 Medical Charges and Health Care Utilization for Privately Insured Patients with HIV Disease in California. *Meg A. Durbin*, B. Bowen, S. Maerki, E. Hudes, *University of California at San Francisco, San Francisco, CA, U.S.A.*

M.H.P.13 Implications of Prophylactic Aerolsolized Pentamidine for the Direct Medical Care Costs of AIDS. *Michael E. Gluck*, R. Chaisson, *School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD, U.S.A.*

M.H.P.14 The Costs of Treating AIDS in a Rural Setting. *Leo E. Waivers*, J. T. Busher, R. L. Rumley, H. G. Adams, *East Carolina University School of Medicine, Section of General Internal Medicine, Greenville, NC, U.S.A.*

M.H.P.15 L'Hôpital et la consommation médicale des patients infectés par le VIH. *Gabriel Bez*, F. Petit, *Ministère de la Santé- Direction des Hôpitaux, Paris, France.*

M.H.P.16 Health Care Costs for AIDS Patients in Saskatchewan. *John M. Conly*, S. Shafran, K. Browne, *University Hospital, University of Saskatchewan, Saskatoon, SK, Canada.*

M.H.P.17 Resource Use, Charges, and Mortality for AIDS Patients with PCP. *Charles L. Bennett*, J. Garfinkle, S. Greenfield, D. Draper, W. Rogers, W. C. Mathews,*RAND/UCLA Center for Health Policy Study, Santa Monica, CA, U.S.A.*

M.H.P.18 AIDS Health Care in the United States: Characteristics of the Patients and the Hospitals Who Treat Them. *Dennis P. Andrulis*, V. Weslowski, E. Hintz, *National Public Health and Hospital Institute, Washington, DC, U.S.A.*

M.H.P.19 Coût par pathologies dues au VIH et traitées à l'hôpital. *Fabrice Boulay*, D. Gauthier, F. Petit, H. Logerot, G. Bez, J. Salin, *Ministère de la Solidarité, de la Santé et de la Protection Sociale, Paris, France.*

Prévention
Prevention

M.H.P.20 Potential Impact of HIV in the Labor Force of the Future. *Antonia Novella*, A. Wright, *National Institute of Child Health and Human Development, Bethesda, MD, U.S.A.*

Mardi
Tuesday

le mardi 6 juin

Etat de la Question

Président: *James O. Mason*
Secrétaire adjoint de la santé des Etats-Unis

Conférenciers:

Progrès en gestion clinique du SIDA et de l'infection par le VIH dans le monde industrialisé

Ian Weller
Directeur d'études
Faculté de médecine génito-urinaire
University College & Middlesex School of Medicine
Angleterre

Difficultés et obstacles à la gestion optimale du SIDA et de l'infection par le VIH dans le monde en développement

N'Galy Bosenge
Directeur
Comité national du programme de lutte contre le SIDA au Zaïre

La perspective communautaire - questions auxquelles font face les personnes ayant le SIDA et infectées par le VIH dans le monde en développement

Daniel Defert
Président
AIDES Fédération nationale
France

Humanité: les mesures pour une éthique sur le SIDA

David J. Roy
Directeur, Centre de bioéthique
Institut de recherche clinique de Montréal, Québec
Canada

La dynamique de la transmission du VIH: le rôle des modèles dans l'interprétation, la prédiction et l'évaluation des paramètres

Roy M. Anderson
Professeur
Imperial College of Science and Technology
Angleterre

State-of-the Art

Tuesday June 6

Chairperson:

James O. Mason
Assistant Secretary for Health of the United States

Plenary speakers:

Advances in Clinical Management in AIDS and HIV Infection in the Developed World

Ian Weller
Reader in Genito-Urinary Medicine
Academic Department of Genito-Urinary Medicine
University College & Middlesex School of Medicine
England

Difficulties and obstacles for optimal management of AIDS and HIV infection in the developing world

N'Galy Bosenge
Director
National AIDS Control Programme in Zaire

The community perspective - issues confronting persons with AIDS and HIV infection and the community

Daniel Defert
Président
AIDES Fédération nationale
France

Humanity: the measure of an ethics for AIDS

David J. Roy
Director
Centre for Bioethics Clinical Research Institute of Montreal, Quebec
Canada

The transmission dynamics of HIV: the role of models in interpretation, prediction and parameter estimation

Roy M. Anderson
Professor
Imperial College of Science and Technology
England

11:00 - 12:30

Salle
Room **407A**



Section
A

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde
Round Table

L'annonce aux partenaires et la prévention de l'infection par le VIH
Partner Notification in HIV Prevention

Présidents
Chairpersons

Nathan Clumeck (Belgium)
Robert Remis (Canada)

11:00 **T.A.O.1**

Program Content:

- Rationale for partner notification
- Overviews of policies and programs in different countries
- Legal and ethical issues
- Operation of a partner notification program
- Evaluation of efficacy and cost-effectiveness

Panelists:

John Gallwey, Oxford, U.K.
Jan Amil Kristoffersen, Skarer, Norway.
Kathleen Toomey, Atlanta, GA, U.S.A.
Fred Wolf, Denver, CO, U.S.A.

11:00 - 12:30

Salle / Room **408A**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique **Surveillance du SIDA**
Specialty Session **AIDS Surveillance**

Présidents / Chairpersons
Jean-Baptiste Brunet (France)
Arletty Pinel (Brazil)
Brian Willoughby (Canada)

11:00 **T.A.O.2** The Impact of the Revised Definition on AIDS Cases Diagnosed in Massachusetts: A Preliminary Analysis. *Beverly Heinze-Lacey*, J. Day**, G. Seage*, S. Oddleifson*, L. Makarewicz**, *Boston and **Massachusetts AIDS Surveillance Programs (BMASP), Boston, MA, U.S.A.*

11:15 **T.A.O.3** L'impact de la nouvelle définition de SIDA à Barcelone: le rôle de la tuberculose. *Joan-Arthur Caylá, A. Plasencia, J. Batalla, J. M. Jansá, N. Parellada, Instituto Municipal de la Salud, Barcelona, Spain.*

11:30 **T.A.O.4** Impact of the 1987 Revision of the AIDS Case Definition in the United States. *Richard M. Selik, J. W. Buehler, J. M. Karon, R. L. Berkelman, AIDS Program, Surveillance Branch, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:45 **T.A.O.5** Marked Underreporting of CDC Defined AIDS Due to Poor Utilization of the HIV Antibody Test. *Andrew Masterson, A. Oppermann, S. Landesman, Kings County Hospital Center, Brooklyn, NY, U.S.A.*

12:00 **T.A.O.6** Evaluation of AIDS Surveillance in Switzerland: Estimation of Underreporting and Impact of Active Surveillance. *Robert R. Engel*, C. Minder*, T. Spuhler**, H. Paradis*, M. Samuel*, B. Somaini*, et al., Federal Offices *of Public Health, **of Statistics, Medical Division, Bern, Switzerland.*

12:15 **T.A.O.7** Underreporting of Minority AIDS Deaths in the San Francisco Bay Area, 1985-1986. *Norman G. Hearst*, G. Chu*, A. I. Trachtenberg**, N. Riordan*, J. Creeger**, J. Sorensen*, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco; **California Department of Health Services, Office of AIDS, Sacramento, CA, U.S.A.*

11:00 - 12:30

Salle / Room **408BC**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Infections par le VIH chez les consommateurs de drogues par voie intraveineuse / HIV Infection in IVDUs**

Présidents / Chairpersons: Graham Hart (U.K.), Harry Haverkos (U.S.A.), J. L. Valdespino (Mexico)

11:00 **T.A.O.8** Trends in HIV Seroprevalence and Risk Behavior among Drug Treatment Program Entrants. *James L. Hadler*, T. Farley**, L. Peterson**, M. Cartter*, *Connecticut Department of Health Services, Hartford, CT; **CDC, Atlanta, GA, U.S.A.*

11:15 **T.A.O.9** Needle Exchange in Central London: One Year Follow-up. *Graham J. Hart*, A. Carvell*, N. Woodward**, A. M. Johnson*, J. Parry***, M. W. Adler*, *Academic Department of Genito Urinary Medicine, Middlesex Hospital; **Bloomsbury Health Authority; ***PHLS, London, U.K.*

11:30 **T.A.O.10** Seroprevalence of Human Immunodeficiency Virus (HIV) Infection among Intravenous Drug Users (IVDUs) in the U.S. *David M. Allen, I. Onorato, P. Sweeney, T. Jones, *enters for Disease Control, Atlanta, GA, U.S.A.*

11:45 **T.A.O.11** Seroconversion for HIV in Intravenous Drug Users in San Francisco. *Andrew R. Moss, P. Bacchetti, D. Osmond, R. Meakin, A. Keffelew, R. Gorter, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

12:00 **T.A.O.12** Risk Factors for HIV-1 Infection among Street-Recruited Intravenous Drug Users in New York City. *Samuel R. Friedman*, A. Rosenblum*, D. Goldsmith*, D. C. Des Jarlais**, M. Sufian*, et al., *Narcotic and Drug Research, Inc.; **New York State Division of Substance Abuse Services, New York, NY, U.S.A.*

12:15 **T.A.O.13** Heterosexual Behavior of Intravenous Drug Users. *Anneke Van den Hoek, H. J. A. Van Haastrecht, R. A. Coutinho, Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

11:00 - 12:30

Salle / Room **401ABC**

Section **B**

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Atelier / Workshop: **Prophylaxie de la PCP / PCP Prophylaxis**

Présidents / Chairpersons: Françoise Camus (France), John E. Conte (U.S.A.), Jemni Leteiv (Tunisia)

11:00 **T.B.O.1** Follow-up Study of Patients Receiving Pentamidine Aerosol for Prophylaxis of PCP. *Michael J. Scolaro*, P. Kennedy*, B. Kahn**, T. Magee*, F. Eggerding*, *Los Angeles Oncologic Institute; **Chief, Pulmonary Medicine, St. Vincent Medical Center, Los Angeles, CA, U.S.A.*

11:15 **T.B.O.2** Effets des aérosols prophylactiques de pentamidine sur la fonction respiratoire à moyen terme. *Françoise Camus, C. De Piccioto, A. Leprêtre, R. Landman, P. M. Girard, A. G. Saimot, Hôpital Bichat-Claude Bernard, Explorations fonctionnelles, Paris, France.*

11:30 **T.B.O.3** Aerosol Pentamidine for *Pneumocystis carinii* Pneumonia Prophylaxis: A 3-Arm Randomized Trial. *Gifford S. Leoung*, A. B. Montgomery**, D. I. Abrams*, L. Wardlaw*, K. Corkery*, D. Busch***, D. W. Feigal*, S. Gordon****, the San Francisco County Community Consortium, *San Francisco General Hospital, Department of Medicine, AIDS Activities, University of California at San Francisco, San Francisco, CA; **State University of New York, Stony Brook, NY; ***Childrens' Hospital; ****Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A.*

11:45 **T.B.O.4** Successful Chemoprophylaxis for Pneumocystis with Dapsone or Bactrim. *Craig E. Metroka*, D. Jacobus**, N. Lewis**, *St. Luke's-Roosevelt Hospital Center, New York, NY; **Jacobus Pharmaceutical, Princeton, NJ, U.S.A.*

12:00 **T.B.O.5** Low Dose Dapsone (D) Prophylaxis (PX) of *Pneumocystis carinii* Pneumonia (PCP). *Onnie S. Lang, J. M. Kessinger, R. M. Tucker, S. I. Greene, S. C. Deresinski, D. A. Stevens, Santa Clara Valley Medical Center, San Jose, CA, U.S.A.*

12:15 **T.B.O.6** Trimethoprim-Sulfamethoxazole for Secondary Prophylaxis of *Pneumocystis carinii* Pneumonia in AIDS. *Gerald Pierone, J. Masci, P. Nicholas, Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.S.A.*

11:00 - 12:30

Salle / Room **406A**

Sections
B & G

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Implications internationales
Clinical Aspects of Aids
International Issues

Séance thématique — **Le SIDA dans les pays en voie de développement**

Specialty Session — **AIDS in the Developing World**

Présidents / Chairpersons — Raphael Bittera (Burundi)
Richard McLean (Canada)
Diana Menwa ( )

11:00 **T.B.O.7** Evaluation of Definitions for AIDS Case Surveillance. *Celso F. Ramos Filho*, L. G. M. Rodrigues**, C. A. Morais de Sá***, B. G. Weniger****, A. B. Sereno*, J. W. Krebs****, et al., *Hospital Universitário, Universidade Federal do Rio de Janeiro; **Ministry of Health (MH); ***Hospital Gaffrée e Guinle, Universidade do Rio de Janeiro, Rio de Janeiro, Brazil; ****Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **T.B.O.8** HIV-1 and HIV-2 Infection Prevalence in the Mortuary-Abidjan. *Emmanuel Gnaore*, K. De Cock*, L. Diaby*, A. Porter*, A. Dago**, G. Lafontant**, et al., *Projet RETRO-CI, Abidjan, Ivory Coast/Centers for Disease Control, Atlanta, GA, U.S.A.; **University of Abidjan, Abidjan, Ivory Coast.*

11:30 **T.B.O.9** Étude comparée des prévalences HIV-1, HIV-2 et HTLV-I chez les lépreux de 4 pays : Côte d'Ivoire, Congo, Sénégal, Yemen. *Mireille Verdier*, A. Sangaré**, E. Sassou-Guesseau**, A. Gaye**, Y. Al-Qubati**, F. Denis*, et al., *Laboratoire de Virologie et de Neurologie CHU Dupuytren, Limoges, France; **Divers Instituts de Côte d'Ivoire, du Congo, du Sénégal et du Yemen.*

11:45 **T.B.O.10** Clinical Manifestations of HIV-1 and HIV-2 Infections in Abidjan, Côte d'Ivoire. *Koudou Odehouri*, K. De Cock*, R. Colebunders**, A. Porter*, G. Adjorlolo*, W. Heyward**, et al., *Projet RETRO-CI, Abidjan, Ivory Coast; **AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

12:00 **T.B.O.11** 2 Years Experience from an AIDS Clinic in Uganda. *E. T. Katabira, Department of Medicine, Makerere University, Kampala, Uganda.*

12:15 **T.B.O.12** Epidemiological Approach of Tuberculosis in AIDS Patients: Brazil, 1982-1988. *Pedro Chequer*, L. Loures*, E. Castilho**, L. Rodrigues*, D. Bergamaschi*, *Ministry of Health, National Division of STD/AIDS, Anexo-Terreo, Brasília; **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil.*

11:00 - 12:30

Salle / Room **407B**

Section **B**

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Colloque / Symposium

Traitement des infections par le VIH
Management of Infections Associated with HIV Immunodeficiency

Présidents / Chairpersons: Michel G. Bergeron (Canada), Martin S. Hirsch (U.S.A.)

11:00 **T.B.O.13** AZT Update. *Margaret A. Fischl, University of Miami School of Medicine, Miami, FL, U.S.A.*

11:20 **T.B.O.14** New Anti-HIV Drugs: Hope for the Future. *Tom Merigan, Stanford University School of Medicine, Stanford, CA, U.S.A.*

11:40 **T.B.O.15** Les Immunomodulateurs : therapeutique alternative ou associée de l'infection par le VIH. *Alain Pompidou, Faculté de médicine Cochin, Paris, France.*

12:00 **T.B.O.16** Restistance to Anti-HIV Drugs. *Douglas Richman, University of California, CA, U.S.A.*

11:00 - 12:30

Salle / Room **403ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique **Virologie (partie 1)**
Specialty Session **Virology (Part 1)**

Présidents / Chairpersons
Donald Jeffries (U.K.)
A. G. B. R. Sourde (Africa)
Michael D. Weaver (Canada)

11:00 **T.C.O.1** Design and Activity of a Novel Class of Nucleoside Analogs Effective against HIV-1. *Bernard Belleau*, D. Dixit*, N. Nguyen-Ba**, J. L. Kraus*, *Université du Québec, Institut Armand-Frappier; **IAF BioChem International Inc., Laval, QC, Canada.*

11:15 **T.C.O.2** Differential Sensitivity of Wild Type and Recombinant HIV-Reverse Transcriptase to Inhibition by Foscarnet. *Marilyn M. Lightfoote, J. M. Bailey, Biochemistry Department, Washington University Medical School, Washington, DC, U.S.A.*

11:30 **T.C.O.3** Inhibition of HIV-1 Induced Syncytia Formation by Monoclonal Antibodies to the Membrane Adhesion. *Antonio Valentin*, M. Patarroyo**, B. Åsjö*, *Department of Virology and **Department of Immunology, Karolinska Institute, Stockholm, Sweden.*

11:45 **T.C.O.4** Structure and Function of HIV-1 Reverse Transcriptase (RT). *Dorothy J. Purifoy, D. Lowe, D. Stammers, B. A. Larder, G. K. Darby, M. Tisdale, et al., Wellcome Research Laboratories, Beckenham, U.K.*

12:00 **T.C.O.5** Identification of Several Species of HIV-1 Major Core Protein: Production and Cell-Surface Expression. *Ara G. Hovanessian, A. G. Laurent, B. Krust, M. A. Rey, L. Montagnier, Institut Pasteur, Unité d'Oncologie virale, Paris, France.*

12:15 **T.C.O.6** GAG and GAG-POL Protein Precursors Made from a SV40 Late Replacement Vector Are Properly Processed and Assembled into Particles. *Alan Smith*, M. L. Hammarskjöld**, D. Rekosh***, State University of New York at Buffalo, Departments of *Microbiology, **Biochemistry and ***Oral Biology, Buffalo, NY, U.S.A.*

11:00 - 12:30

Salle / Room **407C**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium

Mécanismes de pathogenèse des rétrovirus humains
Mechanisms of Pathogenesis of Human Retroviruses

Présidents / Chairpersons: Robert C. Gallo (U.S.A.), David Klatzman (France)

11:00 **T.C.O.7** Variants of HIV Resistant to Zidovudine (AZT). *Brendan A. Larder, G. Darby, D. D. Richman, Wellcome Research Laboratories, Beckenham, U.K.*

11:15 **T.C.O.8** Surface Structures Involved in HIV Recognition. *Paul Maddon, Columbia University, New York, NY, U.S.A.*

11:30 **T.C.O.9** Trans-Regulation of HIV-1 Gene Expression. *Bryan R. Cullen, Duke University Medical Centre, Durham, NC, U.S.A.*

11:45 **T.C.O.10** Current Developments in Pathogenesis. *Robert C. Gallo, Laboratory of Tumour Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

11:00 - 12:30

Salle / Room **410ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session

Biologie Moléculaire : les différents niveaux d'expression du provirus VIH-1

Molecular Biology: Different Level of Expression of HIV-1 Provirus

Présidents / Chairpersons
Christine C. Debouck (U.S.A.)
Freidrich Deinhardt (Federal Republic of Germany)
Serge Montplaisir (Canada)

11:00 **T.C.O.11** Expression, Purification, Structure, Activity and Substrate Specifity of the HIV-1 Retroviral Protease. *Christine M. Debouck, I. Deckman, J. Malinowski, T. Meek, M. Moore, J. Strickler, et al., Smith Kline & French Laboratories, King of Prussia, PA, U.S.A.*

11:15 **T.C.O.12** Tumor Necrosis Factor- Activates HIV Expression in a Chronically Infected T Cell Clone through Induction of Nuclear Factor Binding to NF-KB Sequences. *Arnold B. Rabson*, E. Duh*, W. J. Maury*, T. Folks**, A. S. Fausi*, *NIAID, National Institutes of Health, Bethesda, MD; **Centers for Disease Control, Atlanta, GA, U.S.A.*

11:30 **T.C.O.13** RNA Splicing Events Detected in Early In Vitro HIV Infection Using Polymerase Chain Reaction (PCR). *Mary E. Klotman, A. DeRossi, A. Buchbinder, F. Wong-Staal, Laboratory of Tumor Cell Biology, NCI, National Institutes of Health, Bethesda, MD, U.S.A.*

11:45 **T.C.O.14** Potential Biological Signifiance of a Secondary RNA Start Site within the HIV-LTR. *Joseph D. Mosca*, D. P. Bednarik**, *Henry M. Jackson Foundation for Advancement of Military Medicine, Rockville; **The Johns Hopkins Oncology Center and Department of Immunology and Infectious Diseases, Baltimore, MD, U.S.A.*

12:00 **T.C.O.15** Regulatory Elements in the LTR (HIV-1) Responsive to Glucocorticoid Stimulation. *Ronald S. Snart*, V. Heisig**, J. F. Zagury*, D. Zagury*, *Université Pierre et Marie Curie, Physiologie cellulaire, Paris, France; **University of Hamburg, Hamburg, Federal Republic of Germany.*

12:15 **T.C.O.16** Mechanism of HIV-1 Infection of Mononuclear Phagocytes. *William A. O'Brien, Y. Koyanagi, I. S. Y. Chen, University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.*

11:00 - 12:30

Salle / Room **409ABC**

Section **D**

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Colloque / Symposium **Détenus : contraintes et défis / Prisoners: Constraints and Challenges**

Présidents / Chairpersons Michel R. Morissette (Canada)
Kathleen Kay (Switzerland)

11:00 **T.D.O.1** HIV in Prison: A Test Case for Human Rights. *Timothy Harding, University Institute of Legal Medicine, Geneva, Switzerland.*

11:15 **T.D.O.2** Risk Behaviour in Prison: Sexual Activity. *Bruno Gravier, Service Médico-psychologique régional, Paris, France.*

11:30 **T.D.O.3** AIDS and Intravenous Drug Users: The Challenge for the Jail Administrator. *Steven Thomas, Department of Correction, New York, NY, U.S.A.*

11:45 **T.D.O.4** Constraints to the Implementation of Preventive Measures in Prison. *Patrick Hynes, Prison Medical Services, London, U.K.*

12:00 **T.D.O.5** Approaches to the Seropositive Prisoner. *Elizabeth Kantor, San Francisco County Jails; University of California, San Francisco, CA, U.S.A.*

11:00 - 12:30

Salle / Room **411A**



Section **D**

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Recherches sur le comportement (partie 2)**

Specialty Session **Behavioural Research (Part 2)**

Présidents / Chairpersons: L. Adeorin (Nigeria), Jean Barry (Thailand), Pierre Dionne (Canada)

11:00 **T.D.O.6** Perceived Need for Behavioural Change: Distinguishing between Groups at Risk of HIV Infection in a Longitudinal Cohort of Gay and Bisexual Men. *David L. Cohn*, B. Bartholow*, K. O'Reilly**, F. Judson*, *Denver Disease Control Service, Denver, CO; **Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **T.D.O.7** Situational Factors Associated with, and Rationalizations Employed to Justify Unprotected Intercourse in Gay Men. *Peter J. Grant*, R. Gold**, M. Skinner*, D. Plummer***, *Victorian AIDS Council, Melbourne; **Deakin University, Victoria; ***Monash University, Melbourne, Australia.*

11:30 **T.D.O.8** Risky Sex Relapse, the Next Challenge for AIDS Prevention Programs: The AIDS Behavioral Research Project. *Maria L. Ekstrand, R. D. Stall, T. J. Coates, L. McKusick, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

11:45 **T.D.O.9** Psychological Status and Risk Behavior in Men Seeking HIV Testing. *John W. Bobo, B. Fishman, S. Perry, L. Jacobsberg, J. Ryan, Cornell University Medical College, New York, NY, U.S.A.*

12:00 **T.D.O.10** Tension Reduction Expectancies Underlie the Effects of Alcohol Use on AIDS: Risk Behavior among Homosexual Males. *David J. McKirnan*, P. L. Peterson**, *University of Illinois at Chicago, Chicago, IL; **University of Alabama at Birmingham, AL, U.S.A.*

12:15 **T.D.O.11** HIV Risk Behavior Screening: Concordance between Assessments through Interviews and Questionnaires. *Sevgi O. Aral, L. S. Magder, G. S. Bowen, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:00 - 12:30

Salle
Room **411B**



Section
E

Mardi 6 juin
Tuesday, June 6

Le SIDA, la societé et le comportement
AIDS, Society and Behaviour

Table ronde / Round Table

Les services sociaux : expériences et évaluations
Social Services: Experiences and Evaluations

Présidents / Chairpersons
Marie Berlinguet (Canada)
Ralph Garber (Canada)
Gayle Chris James (Canada)

11:00 **T.E.O.1** New York State's Response to AIDS: A Road Map for Human Services. *Cesar A. Perales, B. J. Sabol, J. L. Carples, N. A. Rango, D. P. Whalen, New York State Department of Social Services, Albany, NY, U.S.A.*

11:15 **T.E.O.2** Compte rendu et évaluation d'une expérience de formation des travailleurs sociaux sur le SIDA. *Catherine Tourette-Turgis, J. Bonneau, Université et Direction de l'Action sociale (Ministère de la Santé), Paris, France.*

11:30 **T.E.O.3** Evaluation of the Social Service Needs of HIV+ Women Enrolled in a Cohort Study in Kigali, Rwanda. *Pauline M. Keogh, C. Almedal, S. Allen, C. Muhawenimana, J. Tice, S. Hulley, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

11:45 **T.E.O.4** Obstacles to Use of Public Social Services and Workers in AIDS Prevention and Control Programmes. *Gary A. Lloyd, Tulane University School of Social Work, New Orleans, LA, U.S.A.*

12:00 **T.E.O.5** The Social Impact of AIDS in Brazil. *Daniel Herbert, Associacao Braseleira Interdisciplinas de AIDS, Rio di Janeiro, Brazil.*

12:15 **T.E.O.6** Social Services Response to AIDS in Quebec. *Miriam Green, Ville Marie Social Services, Montreal, QC, Canada.*

11:00 - 12:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Mardi 6 juin
Tuesday, June 6

Colloque / Symposium **La confidentialité et ses limites / Confidentiality and its Limits**

Présidents / Chairpersons Michael L. Closen (U.S.A.)
Justice T. David Marshall (Canada)

11:00	**T.F.O.1**	Overview of the Issues *Michael L. Closen, Chicago, IL, U.S.A.*
11:10	**T.F.O.2**	X v. Y (1988); When is Confidentiality a Legal Right? *Dai Harris, The Terrence Higgins Trust Legal Centre, London, U.K.*
11:20	**T.F.O.3**	The Stigma of AIDS on the Death Certificate. *Michael B. King, Institute of Psychiatry, London, U.K.*
11:30	**T.F.O.4**	AIDS and Privacy: Retaining, Restructuring or Abandoning Medical Confidentiality? *H. Patrick Glenn, Y.-M. Morissette, N. Gilmore, M. Somerville, McGill University, Centre fOR Medicine, Ethics and Law, Montreal, QC, Canada.*
11:40	**T.F.O.5**	AIDS and the Canadian Privacy Act. *John W. Grace, Office of the Privacy Commissioner of Canada, Ottawa, ON, Canada.*
11:50	**T.F.O.6**	Medical Privacy for the HIV -- Infected Individual. *Clint Hockenberry, AIDS Legal Referral Panel, San Francisco, CA, U.S.A.*
12:00	**T.F.O.7**	SIDA: Le secret médical bousculé. *Patricia Enel, M. P. Larher, J. Charrel, C. Manuel, J. L. San Marco, Laboratoire de Santé publique, Faculté de médecine, Marseille, France.*
12:10	**T.F.O.8**	First Discussant. *Martin Hébert, Clarkson, Tétrault, Montréal, QC, Canada.*
12:20		Commentary. *David T. Marshall, University of Ottawa, Ottawa, ON, Canada.*

11:00 - 12:30

Salle / Room **406BC**

Section **G**

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Colloque / Symposium

Sérodiagnostics rentables
Cost Effective Serodiagnosis

Présidents / Chairpersons: Souleymane M'Boup (Senegal), Richard Wilson (Canada)

11:00 **T.G.O.1** HIV-2 Testing. *Francis Bariu, Université de Tours, Laboratoire de virologie, Tours, France.*

11:15 **T.G.O.2** Evaluation of HIV Testing. *Peter Piot, Département de microbiologie, WHO Collaborating Centre on AIDS, Institut de médecine tropicale, Belgium.*

11:30 **T.G.O.3** Considerations for Retroviral Serodiagnosis. *Phyllis Kanki, Harvard School of Public Health, Boston, MA, U.S.A.*

11:45 **T.G.O.4** HIV Testing in Africa. *J.-L. Sankale, Université de Dakar, Dakar, Senegal.*

12:00 **T.G.O.5** HIV Testing Criteria for Africa. *Hartmut Hampl, Federal Republic of West Germany.*

11:00 - 12:30

Salle
Room **404AB**

Section
H

Mardi 6 juin
Tuesday, June 6

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique **Planification et gestion**
Specialty Session **Planning/Management**

Présidents
Chairpersons

Anne M. Johnson (U.K.)
Kenneth Kizer (U.S.A.)
André Dicaire (Canada)

11:00 **T.H.O.1** Work Disability among AIDS Clinic Patients. *Edward Yelin, R. M. Greenblatt, H. Hollander, J. McMaster, S. Kidd, M. Filson, University of California at San Francisco, San Francisco, CA, U.S.A.*

11:15 **T.H.O.2** Five -- Year AIDS Planning Process at a Health Maintenance Organization. *Elizabeth S. Anderson, R. L. Thompson, W. L. Beery, Group Health Cooperative of Puget Sound, Center for Health Promotion, Seattle, WA, U.S.A.*

11:30 **T.H.O.3** Utilization of Community-Based and Hospital Care for Persons with AIDS in San Francisco, 1988-89. *Adam C. Stern, R. Chen, L. Udall, Y. Frazier, A. Lifson, G. Rutherford, et al., Department of Public Health, San Francisco, CA, U.S.A.*

11:45 **T.H.O.4** Patient Preference and Satisfaction with AIDS Services. *Mary A. Pittman-Lindeman, D. Miller, S. Hernandez, A. Moss, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

12:00 **T.H.O.5** Publicly-Funded Costs of Community-Based Education Programs by Risk Category in San Francisco. *Patricia E. Evans, M. Herring, G. W. Rutherford, J. W. Amory, D. Werdegar, B. Nguyen, San Francisco Department of Public Health-AIDS Office, San Francisco, CA, U.S.A.*

12:15 **T.H.O.6** Community-Based Research in AIDS: CRI as Model. *Tom Hannen, New York Community Research Initiative, New York, NY, U.S.A.*

11:00 - 12:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Mardi 6 juin
Tuesday, June 6

Session vidéo
Video session

L'autodétermination des personnes atteintes
PWA Power

11:00		Introduction: *Une Personne Atteinte/A PWA*
11:04	**T.I.V.1**	***"MEREDITH A YOUNG MOTHER WITH AIDS"***
		Vidéo de/Video by: *Edan Programs* Année/Year: 1988
11:24	**T.I.V.2**	***"Robert Marshall"***
		Vidéo de/Video by: *Stuart Marshall* Année/Year: 1989
11:34	**T.I.V.3**	***"LIVING WITH HIV"***
		Vidéo de/Video by: *Nicke Johanssen* Année/Year:
11:54	**T.I.V.4**	***"SURVIVAL OF THE DELIRIOUS"***
		Vidéo de/Video by: *Michael Balser, Andy Fabo* Année/Year: 1988
12:08	**T.I.V.5**	***"WORK YOUR BODY"***
		Vidéo de/Video by: *GMHC* Année/Year: 1988

→

La prise en charge de soi-même est devenue essentielle pour vivre avec le SIDA. Ces films scrutent la vie d'hommes et de femmes porteurs du VIH et examinent d'autres moyens de faire face aux dangers de l'affaiblissement du système immunitaire et à une société hostile. Films des États-Unis, de Suède, de Grande-Bretagne et du Canada.

Self empowerment has become the key to living with AIDS. These videos investigate the lives of those affected by HIV infection and examine alternative means of coping with the hazards of a weakened immune system and a hostile society. Presentations from the United States, Sweden, Britain and Canada.

12:45 - 13:45

Salle / Room **409ABC**



Section I

Aspects audio-visuels
Audio-Visual Aspects

Mardi 6 juin
Tuesday, June 6

Sessions du midi / Noon Hour Sessions

VIH et les idées—le théâtre et la transmission : exemples internationaux de théâtre comme moyen d'éducation

HIV and Ideas—Theatre and Transmission: International Examples of Theatre as an Educational Tool

Présidents / Chairpersons: Len Hilgemmann (Etats-Unis/U.S.A.), Herbert Daniel (Brésil/Brazil)

12:45 Live Wire, Plays for Living, New York. (anglais/English). *Anne Downer, consultante en éducation de la santé/Health education consultant, Seattle, WA, U.S.A.*

12:55 Inconnue dans notre bande, collectif théâtral de la ville de Québec. (français/French). *Pierre Berthelot, équipe de prévention et de dépistage/Prevention and Detection Team, Québec, QC, Canada.*

13:05 Face to Face, Trinity Theatre, Toronto. (anglais/English). *Alan Richardson, directeur/director, Trinity Theatre, Toronto, ON, Canada.*

13:15 Puppets against AIDS, AREPP. *Gary Friedman and Mike Mvelase, Recherche Africaine et Programme Éducatif de marionnettes/African Research and Education Puppetry Programme, Johannesburg, South Africa.*

13:25 De quoi souffre-t-elle? *Mutombo Buitshi, Directeur, La Troupe Malaika/Director, Malaika Group, Zaire.*

13:35 Discussion

Cette session regroupe des extraits de pièces présentées dans le cadre de SIDART lors de la Ve Conférence internationale sur le SIDA, ainsi que de courtes présentations suivies d'une discussion tant sur leurs succès et que sur leurs échecs.

This dynamic session will combine performance of extracts of plays being presented in the SIDART portion of the V International Conference on AIDS along with a short presentation on it's reception in various circumstances and discussion of the successes and failures of it's production.

14:00 - 15:30

Salle / Room **407A**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Transmission sexuelle du VIH (partie 2) / Sexual Transmission of HIV (Part 2)**

Présidents / Chairpersons: King K. Holmes (U.S.A.), A. S. Latif (Zimbabwe), George Papaevangelou (Greece)

14:00 **T.A.O.14** Transmission of HIV in Edinburgh amongst Heterosexual Injection Drug Users (IDU). *Susan J. Davidson*/**, J. R. Robertson**, R. P. Brettle*, *Department of Infectious Diseases, City Hospital; **Muirhouse Surgery, Edinburgh, U.K.*

14:15 **T.A.O.15** Co-Factors in the Heterosexual Transmission of HIV in West Germany. *Schlomo Staszewski, S. Rehmet, E. B. Helm, W. Stille, Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

14:30 **T.A.O.16** Heterogeneous Male-to-Female Transmission of Human Immunodeficiency Virus. *Nancy S. Padian, S. Shiboski, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:45 **T.A.O.17** Risk Factors for HIV Transmission in Steady Heterosexual Couples. *Mindell Seidlin, T. Dugan, M. Vogler, D. Bebenroth, K. Krasinski, R. Holzman, New York University Medical School/Bellevue Hospital, New York, NY, U.S.A.*

15:00 **T.A.O.18** Smoking as a Risk Factor for Heterosexual Transmission of HIV-1 in Haitian Women. *Neal A. Halsey*, R. Boulos**, E. Holt*, T. C. Quinn*, J. R. Brutus**, A. Ruff*, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.; **Centers for Health and Development, Port-au-Prince, Haiti.*

15:15 **T.A.O.19** Risk Factors in Heterosexual Transmission. *Paolo Costigliola*, E. Ricchi*, G. Marinacci*, V. Colangeli*, M. C. Re**, F. Chiodo*, *Istituto Malattie Infettive; **Istituto di Microbiologia, Università di Bologna, Bologna, Italy.*

14:00 - 15:30

Salle / Room **408A**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde / Round Table

Efficacité et évaluation des programmes
Programme Effectiveness and Evaluation

Présidents / Chairpersons
Richard Lessard (Canada)
Patricia O'Connor (Costa Rica)
Daniel Zulaica (Spain)

14:00 **T.A.O.20** Safer Injection among Participants in the First North American Syringe Exchange Program. *Don C. Des Jarlais**, H. Hagan**, D. Purchase***, T. Reid**, S. R. Friedman****, *New York State Division of Substance Abuse Services, New York, NY; **Tacoma-Pierce City Health Department, Tacoma, WA; ***Point Defiance AIDS Project, Tacoma, WA; ****Narcotic and Drug Research Inc., New York, NY, U.S.A.*

14:15 **T.A.O.21** Evaluation of the Needle Exchange Program in Amsterdam. *Christina Hartgers, E. C. Buning, R. A. Coutinho, *Municipal Health Service of Amsterdam, Amsterdam, Netherlands.*

14:30 **T.A.O.22** Brief Counseling to Reduce AIDS Risk in IV Drug Users: Update. *David R. Gibson, J. Lovelle-Drache, S. Derby, M. Garcia-Soto, J. Sorenson, I. Melese-d'Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:45 **T.A.O.23** Plan for the Prevention and Control of AIDS In Basque Country. *D. Zulacia, B. Elizalde, A. Garcia Gurutxarri, I. Zubia, A. Urcelay, Servicio Vasco de Salud, Osakidetza, San Sebastian, Spain.*

15:00 **T.A.O.24** Increasing Condom Sales Following AIDS Education, USA. *John S. Moran**, H. R. Janes**, T. A. Peterman*, K. M. Stone*, *Center for Prevention Services, Division of Sexual Transmissions, Centers for Disease Control, Atlanta, GA; **Nielson Marketing Research, Northbrook, IL, U.S.A.*

15:15 **T.A.O.25** Effectiveness of Condom Promotion in a Nairobi Community of Prostitutes. *Francis A. Plummer**/***, J. Scarth***, E. N. Ngugi*, P. Waiyaki**, J. O. Ndinya-Achola*, A. R. Ronald***, et al., *University of Nairobi; **Kenya Medical Research Institute, Nairobi, Kenya; ***University of Manitoba, Winnipeg, MB, Canada.*

14:00 - 15:30

Salle / Room **408BC**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde / Round Table: **Signalement du VIH / HIV Reporting**

Présidents / Chairpersons: Ruth L. Berkelman (U.S.A.), Joel DeKoven (Canada)

14:00 **T.A.O.26** Surveillance for HIV Infection in Minnesota: Results from the First Three Years of Operation. *Kristine L. MacDonald, R. Danila, D. Reir, J. Heier, D. Stiepan, M. Osterholm, Minnesota Department of Health, Minneapolis, MN, U.S.A.*

14:30 **T.A.O.27** HIV Infection Reporting in the United States. *Jeanette K. Stehr-Green, R. Berkelman, H. Van Patten, J. Curran, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

15:00 **T.A.O.28** The Role of HIV Infection Reporting in Public Health. *Ruth Berkelman, Centers for Disease Control, Bethesda, MD, U.S.A.*

Program Content:

- Objectives/rationale of HIV reporting
- Does HIV notifiability discourage testing?
- Nominal versus non-nominal reporting
- Confidentiality issues
- Review of HIV reporting in different countries
- Mechanisms for reporting

Panelists:

Molly Coye, Trenton, NJ, U.S.A.
O. Noel Gill, London, U.K.
Fred Wolf, Denver, CO, U.S.A.

14:00 - 15:30

Salle
Room **401ABC**

Section
B

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Table ronde
Round Table

Transmission périnatale du VIH
Perinatal Transmission of HIV

Présidents
Chairpersons

Normand Lapointe (Canada)
Wade Parks (U.S.A.)

14:00 **T.B.O.17** Perinatal Transmission in Industrialized Countres. *Catherine Peckham, Institute of Child Health, University of London, London, U.K.*

14:15 **T.B.O.18** Estimates and Projections of Perinatal Transmission of HIV. *James Chin, World Health Organization, Global Program on AIDS, Geneva, Switzerland.*

14:30 **T.B.O.19** Modes, Rate, and Risk Factors for Perinatal Transmission of HIV. *Martha Rogers, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:45 **T.B.O.20** Diagnosis of HIV in Infants. *Claude Griscelli, Hôpital des enfants malades, Paris, France.*

15:00 **T.B.O.21** Natural History of HIV Infections in Children. *Gwendolyn Scott, University of Miami, School of Medicine, Department of Pediatrics, Miami, FL, U.S.A.*

14:00 - 15:30

Salle
Room **407B**

Section
B

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Colloque — **Diagnostic et histoire clinique de l'infection par le VIH**

Symposium — **Natural History and Staging of HIV Infection**

Présidents — J. P. Coulaud (France)
Chairpersons — Alastair McLeod (Canada)

14:00 **T.B.O.22** Natural History and Staging of HIV Infection. *Robert Redfield, Walter Reed Army Institute of Research, Bethesda, MD U.S.A.*

14:15 **T.B.O.23** Clinical Diagnosis of AIDS and Related Disorders. *Henry Masur, Clinical Center, National Institutes of Health, Bethesda, MD, U.S.A.*

14:30 **T.B.O.24** Clinical Diagnosis of HIV Infection in the Developing World. *Fernando Zacharias, Pan-American Health Organization, U.S.A.*

14:45 **T.B.O.25** Prognosis Factor. *Willy Rozenbaum, Unité des maladies infectieuses, Hôpital Rothschild, Paris, France.*

14:00 - 15:30

Salle / Room **403ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session: **Pathogenèse (partie 3) / Pathogenesis (Part 3)**

Présidents / Chairpersons: Djordjie Adjukovic (Canada), F. Barré-Sinoussi (France), Issidore Zohoun (Benin)

14:00 **T.C.O.17** The Role of the VPX and VPR Genes in Simian Immunodeficiency Virus Life Cycle. *Xiao-Fang Yu, M. Essex, T. H. Lee, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

14:15 **T.C.O.18** Effect of Recombinant Soluble CD4 (rCD4) on Infection of Non-Lymphoid Cells by HIV-1. *Kenji Ikeuchi, R. A. Byrn, D. Scadden, S. Goldring, J. E. Groopman, New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

14:30 **T.C.O.19** Genetic Analysis of Sequential HIV-1 Isolates from an Infected Lab Worker. *Lilly I. Kong*, M. E. Taylor*, D. Waters**, W. A. Blattner***, B. H. Hahn*, G. M. Shaw*, *University of Alabama at Birmingham, Birmingham, AL; **Program Resources Inc., Frederick; ***National Cancer Institute, Bethesda, MD, U.S.A.*

14:45 **T.C.O.20** Molecular Characterization and Complete Nucleotide Sequence Analysis of an Attenuated Isolate of HIV-2. *Beatrice H. Hahn*, P. Kumar*, H. Hui*, J. C. Kappes*, J. A. Hoxie**, G. M. Shaw*, *University of Alabama at Birmingham, Birmingham, AL; **University of Pennsylvania, Philadelphia, PA, U.S.A.*

15:00 **T.C.O.21** Antibody Mediated Enhancement of HIV Infectivity: Mechanisms and Significance. *Jacques Homsy*, M. Meyer*, M. Tateno*, S. Clarkson**, J. A. Levy*, *University of California at San Francisco, School of Medicine, Cancer Research Institute; **San Francisco General Hospital, Rosalind Russell Rheumatology Laboratory, San Francisco, CA, U.S.A.*

15:15 **T.C.O.22** Serological and Molecular Analysis of the Immunodominant Loop (IL) (296-331 a.a.) from Neutralization Resistant Variants Derived from HIV-I Inoculated Chimpanzees. *Peter L. Nara*, N. Dunlop*, D. Waters**, J. Smit***, J. Goudsmit***, R. Gallo*, *National Cancer Institute-Frederick Cancer Research Facility; **Program Resources Inc., Frederick, MD, U.S.A.; ***Academic Medical Centre, Amsterdam, Netherlands.*

14:00 - 15:30

Salle / Room **407C**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium

Origines des rétrovirus humains et modèles animaux
Origins of Human Retroviruses and Animal Models

Présidents / Chairpersons: Myron Essex (U.S.A.), Kenneth Rosenthal (Canada)

14:00 **T.C.O.23** The Origins of Human Retroviruses. *Myron Essex, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

14:15 **T.C.O.24** Transgenic Constructs Involving HIV-1 Genes. *Malcolm Martin, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, U.S.A.*

14:30 **T.C.O.25** Relationship Among Primate Retroviruses. *Masanori Hayami, Institute for Virus Research, Kyoto University, Japan.*

14:45 **T.C.O.26** Primates for the Study of AIDS-Related Disorders. *Jorg W. Eichberg, Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A.*

14:00 - 15:30

Salle / Room **410ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherches fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session: **Biologie moléculaire : mécanismes de régulation de type tat des gènes viraux / Molecular Biology: tat-mediated Regulation of Viral Genes**

Présidents / Chairpersons: Paul Maddon (U.S.A.), Nahum Sonnenberg (Canada), Simon Wain-Hobson (France)

14:00 **T.C.O.27** The tar Region of HIV-1 Binds and Activates. *Sophie Roy*, I. Edery*, N. Parkin*, R. Petryshyn**, M. Katze***, N. Sonenberg*, *McGill University, Montréal, QC, Canada; **State University of New York, Syracuse, NY, U.S.A.; ***Washington University, Seattle, WA, U.S.A.*

14:15 **T.C.O.28** Progressive Genetic Changes in HIV-1 tat Gene Coincident with Disease. *Andreas Meyerhans*, R. Cheynier*, S. Kwok**, J. Sninsky**, B. Åsjö***, S. Wain-Hobson*, et al., *Institut Pasteur, Paris, France; **Cetus Corporation, Emeryville, U.S.A.; ***Karolinska Institute, Stockholm, Sweden.*

14:30 **T.C.O.29** Binding of the HIV-1 tat Protein to tar Sequences In Vitro. *Michael A. Skinner, C. Dingwall, I. Ernberg, S. Heaphy, M. J. Gait, J. Karn, MRC Laboratory of Molecular Biology, Cambridge, U.K.*

14:45 **T.C.O.30** SIVmac (BK28) Has the Capacity to Encode Isoforms of the TAT and REV Proteins through Alternative mRNA Splicing. *Gregory A. Viglianti, J. I. Mullins, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

15:00 **T.C.O.31** Binding of HIV-1 tat to the 5'Region of mRNA. *Jay F. Rappaport, S. Josephs, C. Y. Kang, S. Daefler, J. Rusche, F. Wong-Staal, National Cancer Institute, Laboratory of Tumor Cell Biology, Bethesda, MD, U.S.A.*

15:15 **T.C.O.32** CD8+ Lymphocytes Can Control Acute HIV Infection of CD4+ T Cells. *Christopher M. Walker, University of California, School of Medicine, Cancer Research Insititute, San Francisco, CA, U.S.A.*

14:00 - 15:30

Salle / Room **409ABC**



Section **D**

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Les minorités**
Specialty Session **Minorities**

Présidents / Chairpersons: Martha Grieg (Canada), Nzilambi N'Zila (Africa), Elizabeth Parker (Australia)

14:00 **T.D.O.12** Identification, Recruitment and Retention of Black and Latin Community Leaders in AIDS Prevention Research. *Edward S. Morales*, M. Fullilove**, *Center for AIDS Prevention Studies; **Multicultural Inquiry and Research on AIDS, Bayview Hunters Point Foundation, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:15 **T.D.O.13** American Indians/Alaska Natives: Are They at Higher Risk of HIV Infection? *Ronald M. Rowell, T. Tafoya, L. Beaulieu, A. Green Rush, National Native American AIDS Prevention Centre, Oakland, CA, U.S.A.*

14:30 **T.D.O.14** Involvement of Native Health Care Providers in Developing an AIDS Prevention Strategy for Native Peoples. *Jay Wortman*, M. Rekart**, D. Mearns**, *Division of STD Control, Province of British Columbia; **Vancouver Indian Center Society, Vancouver, BC, Canada.*

14:45 **T.D.O.15** A Video AIDS Prevention Training Program for People Who Are Mentally Retarded/Developmentally Disabled. *Raymond M. Jacobs, P. Samowitz, P. Levy, J. Levy, R. Jacobs, Young Adults Institute, New York, N.Y., U.S.A.*

15:00 **T.D.O.16** Deaf Outreach Project on AIDS. *Kim Upton*, G. Kerr**, Y. Perreault***, *Ontario Association of the Deaf; **Canadian Hearing Society;***AIDS Committee of Toronto, Toronto, ON, Canada.*

15:15 **T.D.O.17** An AIDS Education Program for Black and Latina Women. *Jacquelyn H. Flaskerud, A. M. Nyamathi, University of California at Los Angeles, Los Angeles, CA, U.S.A.*

14:00 - 15:30

Salle
Room **411A**

Section
D

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Psychologie et sexologie**
Specialty Session **Psychology and Sexology**

Présidents
Chairpersons

Ramon Bayes (Spain)
Joseph A. Catania (U.S.A.)
Leonardo Mata (U.S.A.)

14:00 **T.D.O.18** The Worried Well: Identification by Simple Checklist. *Barbara Hedge*, T. Acton**, D. Miller**, et al.**, *St. Mary's Hospital, Department of Psychology; **Middlesex Hospital, London, U.K.*

14:15 **T.D.O.19** Social Support, HIV Symptoms and Depression among Gay Men. *Robert Hays, H. Turner, J. Catania, J. Mandel, T. Coates, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:30 **T.D.O.20** Modifications of Sexual Behavior Due to AIDS in French Heterosexual "At Risk" Population. *Jean-Paul Moatti*, J. Taveres**, J. P. Durbec**, N. Bajos**, C. Ménard**, C. Serrand**, *ISERM U.240, Paris; **French Committee for Health Education (CFES); ***INSERM U.31, Marseille, France.*

14:45 **T.D.O.21** The Prevalence of AIDS-Risk-Related Sexual Behaviours among White, Middle-Class, Urban American Adults: A Survey of Research from Kinsey to the Present. *Stephanie A. Sanders, J. M. Reinisch, M. Ziemba-Davis, The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A.*

15:00 **T.D.O.22** HIV-Positve Gay Men: Sexual Dysfunctions. *Heino F. L. Meyer-Bahlburg, A. A. Ehrhardt, J. M. Gorman, R. R. Goetz Jr., New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

15:15 **T.D.O.23** Changes in Lymphocyte Phenotype and Function in HIV Seropositive Homosexual Men Following the Death of a Partner. *Margaret E. Kemeny*, R. Durran**, H. Weiner*, S. E. Taylor**, B. Visscher*, J. L. Fahey*, *University of California at Los Angeles, School of Medicine, Department of Microbiology and Immunology; **University of California at Los Angeles, Los Angeles, CA, U.S.A.*

14:00 - 15:30

Salle / Room **411B**



Section **E**

Mardi 6 juin
Tuesday, June 6

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Atelier / Workshop

Empowerment : la réappropriation de la santé, les expériences des personnes atteintes

Empowerment: Reappropriation of Health and Experience of Persons with AIDS

Présidents / Chairpersons: Bernard Lapointe (Canada), Dame Nita Barrow (U.S.A.)

14:00 **T.E.O.7** Introduction. *Bernard Lapointe, Canada*

14:15 **T.E.O.8** PLUSS, an Organization of Body Positives in Norway Encompassing All Groups. *Arne N. Husdal, S. Kalbakk, HIV+ leader of the organization Pluss, Oslo, Norway.*

14:25 **T.E.O.9** La place, les responsabilités, l'implication dans les associations des personnes séropositives ou atteintes par la maladie. *Michel Gaïto, AIDES, Fédération Nationale, Paris, France.*

14:45 **T.E.O.10** The Role of AIDS Service Organizations in Developing Public Health Policy and Services for HIV Disease. *James P. Hymes, Philadelphia Department of Public Health, AIDS Activities Office, Philadelphia, PA, U.S.A.*

15:00 **T.E.O.11** *Martin Delaney, Project Inform, San Francisco, CA, U.S.A.*

15:15 **T.E.O.12** The Learning about AIDS Project: A Participatory Approach to Health Education about HIV Infection and AIDS. *Peter J. Aggleton, Bristol Polytechnic, Department of Education, Bristol, U.K.*

14:00 - 15:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Mardi 6 juin
Tuesday, June 6

Colloque / Symposium: **Éthique clinique / Clinical Ethics**

Présidents / Chairpersons: David J. Roy (Canada), Albert R. Jonsen (U.S.A.)

14:00 **T.F.O.10** Clinical Ethics: The Issues. *David J. Roy, Centre de bioéthique, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.*

14:15 **T.F.O.11** "Physicians, Ethics and AIDS": A Framework for Ethical Analysis of HIV/AIDS. *Margaret A. Somerville*, N. Gilmore*, **Canadian Medical Association, *McGill University, McGill Centre for Medicine, Ethics and Law, Montreal, QC; **Ottawa, ON, Canada.*

14:30 **T.F.O.12** The Ethical Duty of Health Professionals to Care for Persons with AIDS and HIV Infections. *Albert Jonsen, University of Washington, Department of Medical History and Ethics, Washington, DC, U.S.A.*

14:45 **T.F.O.13** HIV Screening for Early Therapeutic Intervention: An Ethical Analysis. *Carol Levine*, R. Bayer**, *Citizens Commission on AIDS for New York City and Northern New Jersey; **Columbia University, School of Public Health, New York, NY, U.S.A.*

15:00 **T.F.O.15** Le Médicin difficile. *Jean Robert, Hôpital St-Luc, Département de santé communautaire, Montréal, Québec, Canada.*

15:15 **T.F.O.16** Le patient difficile. *Clément Olivier, Clinique l'Actuel, Montréal, QC, Canada.*

14:00 - 15:30

Salle / Room **406A**

Section **G**

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Séance thématique **Risques et prévention**
Specialty Session **Risks and Prevention**

Présidents / Chairpersons: Paul Cappon (Canada), Oscar Fay (Argentina), Jonathan Mann (Switzerland)

14:00 **T.G.O.7** Some Correlates of Perceived Vulnerability to HIV Infection in Sri Lanka. *A. H. Mehryar*, M. Carballo*, O. Tawil*, J. Weeramunda**, *Social and Behavioural Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland; **University of Colombo, Department of Sociology, Colombo, Sri Lanka.*

14:15 **T.G.O.8** The Challenge of Modifying Risky Practices in Well-informed Gay Men. *Jose-Antonio Izazola*, J. Sepulveda*, J. L. Valdespino*, M. Ramah**, M. Ramos*, *Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico, **AIDSCOM, Washington, DC, U.S.A.*

14:30 **T.G.O.9** Massive Campaign for AIDS Education, Achievements and Problems. *Jaime Sepulveda*, J. A. Izazola*, J. L. Valdespino*, M. Mondragon*, J. Townsend**, *Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico, **Population Council.*

14:45 **T.G.O.10** An Internationally Adaptable AIDS Prevention Program for Youth. *Wendy Arnold*, S. Mantion**, R. Velly**, L. Renaud***, *Adolescent Alliance, Los Angeles, CA, U.S.A.; **Association Jeunes Contre le SIDA (JCS); ***Association des Artistes contre le SIDA, Paris, France.*

15:00 **T.G.O.11** Adoption of Safer Sexual Behaviour by an HIV High Risk Group of Bar and Restaurant Workers in Dar es Salaam, Tanzania. *Fred S. Mhalu*, C. Akim**, P. Senge**, J. Shao*, U. Bredberg Raden***, G. Biberfeld***, et al., *Muhimbili Medical Centre, University of Dar es Salaam; **Dar es Salaam City Council, Dar es Salaam, Tanzania; ***National Bacteriology Laboratory, Stockholm, Sweden.*

15:15 **T.G.O.12** Theory and Practice in Procurement of Safe Blood in Kampala, Uganda. *E. J. Watson-Williams, P. Dataaha, S. Coutinho, P. Ssenyonga, E. D. F. Nakasero Blood Bank Project, Ministry of Health, Kampala, Uganda.*

14:00 - 15:30

Salle / Room **406BC**

Section **G**

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Colloque — **Compassion et soins communautaires dans les pays en voie de développement**

Symposium — **Community Compassion and Care in the Developing World**

Présidents / Chairpersons — Gloria Ornelas Hall (Mexico), Stephen Simon (Canada)

14:00 **T.G.O.13** TASO's Counselling Experience. *Peter Ssebbenjae, TASO, Actionaid Uganda, Kampala, Uganda.*

14:15 **T.G.O.14** Counselling and Education in the Townships. *Alfred Machela, Township AIDS Project, Soweto, South Africa.*

14:30 **T.G.O.15** AIDS Messages and Help to Women in the Thai Sex Industry. *Chantawipa Apisook, EMPOWER, Bangkok, Thailand.*

14:45 **T.G.O.16** Counselling in Mexico City. *Rosalina Plascencia, CONASIDA, Mexico City, Mexico.*

15:00 **T.G.O.17** Counselling in Bogota. *Manuel Velandia, The Panos Insitute, London, U.K.*

14:00 - 15:30

Salle / Room **404AB**

Section **H**

Mardi 6 juin
Tuesday, June 6

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique **Les coûts dans les pays en voie de développement**

Specialty Session **Costs in Developing Countries**

Présidents / Chairpersons: Yamil H. Kouri (U.S.A.), N. Mapoza (Zaire), Mead Over (U.S.A.)

14:00 **T.H.O.7** Cost Effectiveness Analysis of Blood Screening Tests. *Holly Wong, M. Makinen, ABT Associates Inc., Washington, DC, U.S.A.*

14:15 **T.H.O.8** Prospective Quantification of the Economic and Morbid Impact of Perinatal HIV Infection (PI) in a Cohort of 245 Zairian Infants Born to HIV(+) Mothers. *Ntumbanzondo Mposo, B. Engele, S. Bertozzi, S. Hassig, R. Ryder, Projet SIDA, Kinshasa, Zaire.*

14:30 **T.H.O.9** The Economic Impact of HIV Infection in Adult Admissions to Internal Medicine (IM) at Mama Yemo Hospital. *Susan E. Hassig*/**, J. Perriens*, E. Baende*, K. Bishagara*, R. W. Ryder*/***, B. Kapita****, *Projet SIDA, Kinshasa, Zaire; **Tulane University, New Orleans, LA; ***Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.; ****Mama Yemo Hospital, Kinshasa, Zaire.*

14:45 **T.H.O.10** Comparative Study of a Comprehensive Versus a Traditional System of AIDS Health Care in San Juan, Puerto Rico. *Yamil Kouri*, J. D. Balling*, J. Garib**, F. Borras***, J. Rullan****, *Harvard Institute for International Development, Cambridge, MA, U.S.A.; **San Juan AIDS Institute; ***San Juan Department of Health; ****Department of Health of the Commonwealth of Puerto Rico, San Juan, Puerto Rico, U.S.A.*

15:00 **T.H.O.11** An Analysis of Direct and Indirect Costs of AIDS and ARC in Mexico. *Roberto C. Tapia, A. Martin, J. Lipscomb, J. Bratt, Ministry of Health, Col. Del Valle, Mexico City, Mexico.*

15:15 **T.H.O.12** Costs of AIDS in a Developing Area: Indirect and Direct Costs of AIDS in San Juan, Puerto Rico. *Donald S. Shepard*, Y. Kouri*, S. Borras**, J. Garib***, J. Balling*, *Harvard Institute for International Development, Cambridge, MA; **City of San Juan Health Department; ***San Juan AIDS Institute, San Juan, Puerto Rico, U.S.A.*

14:00 - 15:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

Mardi 6 juin
Tuesday, June 6

La discrimination
Discrimination

14:00 Introduction: *Tom Waugh*

14:05 **T.I.V.6** ***"ONE OF OUR OWN"***

Vidéo de/Video by:
G.T. Rogers
Année/Year: 1987

14:35 **T.I.V.7** ***"WHEN THE FAMILY GETS AIDS"***

Vidéo de/Video by:
Slawomir Grunberg
Année/Year: 1988

15:03 **T.I.V.8** ***"THE 2nd EPIDEMIC"***

Vidéo de/Video by:
Amber Hollibaugh
Année/Year: 1988

Trois films, trois situations, trois techniques visuelles : illustration du SIDA au travail et des dilemmes qui en découlent, un regard personnel sur une famille aux prises avec une infection par le VIH et une analyse documentaire des effets négatifs de la réaction de la société au SIDA. Ces documents offrent une vision éclairante des problèmes inhérents à un monde dominé par la peur et les préjugés et présentent les diverses manières dont des personnes atteintes font face à ces difficultés.

Three videos, three situations and three visual techniques: 2 dramatizations of AIDS in the workplace and resulting dilemmas, a personal look at a family dealing with HIV infection, and a documentary analysis of the negative effects of society's response to AIDS. Each gives an insightful look at the problems inherent in a world of fear and prejudice and the various ways by which PWAs cope with these difficulties.

16:00 - 17:30

Salle / Room **407A**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Histoire clinique de l'infection à VIH : manifestations précoces et progression / Natural History of HIV Infection: Early Manifestation and Progression**

Présidents / Chairpersons: Randall A. Coates (Canada) Bila M. Kapita (U.S.A.)RI. B. Kemp (Federal Republic of Germany)

16:00 **T.A.O.29** Prognostic Indicators for Developing AIDS within 24 Months. *Alfred J. Saah, A. Munoz, R. Fox, R. A. Kaslow, C. Rinaldo, R. Detels, et al., Johns Hopkins School of Hygiene and Public Health and the Multicenter AIDS Cohort Study (MACS), Baltimore, MD, U.S.A.*

16:15 **T.A.O.30** Clinical Course of Primary HIV Infection: Consequences for the Subsequent Course of the Infection. *Court Pedersen, B. Lindhardt, B. L. Jensen, E. Lauritzen, J. Gerstoft, E. Dickmeiss, et al., University of Copenhagen, Copenhagen, Denmark.*

16:30 **T.A.O.31** Progression to AIDS in the San Francisco General Hospital Cohort Study. *Andrew R. Moss, P. Bacchetti, D. Osmond, B. Brodie, E. Ross, W. Krampf, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

16:45 **T.A.O.32** The Natural History of HIV Infection in a Cohort of Homosexual and Bisexual Men: Clinical Manifestations, 1978-1989. *George W. Rutherford*, A. R. Lifson*, N. A. Hessol*, S. P. Buchbinder*, L. S. Doll**, H. W. Jaffe**, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA; **AIDS Program, Center for Disease Control, Atlanta, GA, U.S.A.*

17:00 **T.A.O.33** The Probability of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with HIV Disease. *Vernon Farewell*, C. Struthers*, R. A. Coates**, *University of Waterloo, Department of Health Studies, Waterloo; **University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

17:15 **T.A.O.34** Risk of AIDS Progression Appears Early in HIV Infection. *Bruce Douglas, M. T. Schechter, B. Willoughby, W. A. McLeod, P. Constance, M. S. Weaver, et al., The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*

16:00 - 17:30

Salle / Room **408A**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Modèles mathématiques / Mathematical Models**

Présidents / Chairpersons: Parvis Gaudirian (Canada), Alain Valleron (France), George Wells (Canada)

16:00 **T.A.O.35** Simplified Backcalculations for the AIDS Epidemic. *Philip S. Rosenberg, M. H. Gail, R. J. Biggar, J. J. Goedert, National Cancer Institute, Bethesda, MD, U.S.A.*

16:15 **T.A.O.36** Statistical Analysis of the Stages of HIV Infection Using a Markov Model. *Ira M. Jr Longini*, W. S. Clark*, C. R. Horsburgh**, G. F. Lemp***, R. H. Byers**, W. W. Darrow**, et al., *Emory University, Altanta, GA; **AIDS Program, Center for Disease Control, Atlanta, GA; ***AIDS Office, Department of Health, San Francisco, CA, U.S.A.*

16:30 **T.A.O.37** Extrapolating Recent Trends to Make AIDS Case Projections. *John M. Karon, O. J. Devine, *Centers for Disease Control, Atlanta, GA, U.S.A.*

16:45 **T.A.O.38** Model-Based Optimization of Infectivity Parameters. *David J. Ahlgren*, M. K. Gorny**, A. C. Stein*, *Trinity College, Department of Engineering and Computer Science, Hartford, CT; **New York University Medical Center, New York, NY, U.S.A.*

17:00 **T.A.O.39** A Risk Behavior Based Model of the Cubic Growth of AIDS in the United States. *Stirling A. Colgate*, E. A. Stanley**, J. M. Hyman*, S. P. Layne*, C. Qualls**, *Los Alamos National Laboratory, Los Alamos; **University of New Mexico, Albaquerque, NM, U.S.A.*

17:15 **T.A.O.40** Drugs, Sex and HIV: A Mathematical Model for New York City. *Sally M. Blower*, J. M. Courval**, Z. A. Stein**, R. M. May***, R. M. Anderson*, *London University, Imperial College of Science and Technology, London, U.K.; **Columbia University and Columbia Presbyterian Medical Center, HIV Center for Clinical and Behavioural Studies, New York State Psychiatric Institute, New York, U.S.A.; ***Oxford University, Oxford, U.K.*

16:00 - 17:30

Salle / Room **408BC**



Section **A**

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde / Round Table

Évaluation de l'efficacité des programmes de prévention
Evaluation of Preventive Programme Effectiveness

Présidents / Chairperson: Richard Biritwum (Switzerland), David Heymann (Switzerland)

16:00 **T.A.O.41**

Program Content:

- Surveillance
- Serosurveillance
- Indicators of process and programme effectiveness
- Methods of collecting indicator information
- Evaluation in the development of programme interventions

Panelists:

Richard Biritwum, Geneva, Switzerland.
Jean-Baptiste Brunet, Paris, France.
Therese Mulandi, Nairobi, Kenya.
Ron Waldman, Atlanta, GA, U.S.A.

16:00 - 17:30

Salle / Room **401ABC**

Section **B**

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Traitement de la PCP / PCP Treatment**

Présidents / Chairpersons: John R. Black (U.S.A.), Michael J. Davis (Canada), Willy Rosenbaum (France)

16:00 **T.B.O.26** Aerosolized Pentamidine *vs.* Trimethroprim-Sulfamethoxazole (TMP-SMX) for Acute *Pneumocystis carinii* Pneumonia (PCP): A Randomized Double Blind Trial. *A. Bruce Montgomery*, R. J. Edison**, P. Hopewell**, F. R. Sattler***, J. Feinberg****, D. W. Feigal**, et al., *Department of Pulmonary Medicine, State University of New York, Stony Brook, NY; **University of California at San Francisco, San Francisco; ***University of Southern California, Los Angeles, CA; ****NIAID, Rockville, MD, U.S.A.*

16:15 **T.B.O.27** The Improving Survival Rate after Intensive Care for *P. carinii* Pneumonia and Respiratory Failure. *Robert M. Wachter*, M. B. Russi**, P. C. Hopewell**, J. M. Luce**, *Robert Wood Johnson Clinical Scholars Program, Stanford University, Stanford; **San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

16:30 **T.B.O.28** Trimetrexate (TMTX) Salvage Therapy of PCP in AIDS Patients without any Therapeutic Options: Interim Results of the 1st AIDS "Treatment IND" Protocol. *Judith Feinberg, D. Katz, C. McDermott, M. Myers, D. Hoth, AIDS Program, NIAID, Rockville, MD, U.S.A.*

16:45 **T.B.O.29** Oral Corticosteroids Prevent Acute Respiratory Failure in AIDS-Related *Pneumocystis carinii* Pneumonia. *Julio S. G. Montaner, L. Lawson, N. Levitt, A. Belzberg, M. Schechter, J. Ruedy, AIDS Research Program, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.*

17:00 **T.B.O.30** Eflornithine in PCP Cases Resistant to Conventional Therapy. *Don E. Smith, S. Owen, M. Nelson, B. G. Gazzard, St. Stephen's Hospital, London, U.K.*

17:15 **T.B.O.31** Clindamycin/Primaquine for *P. carinii* Pneumonia in AIDS. *Emil Toma, S. Fournier, M. Poisson, R. Morisset, D. Phaneuf, C. Vega, Hôtel-Dieu de Montréal and Université de Montréal, Montréal, QC, Canada.*

16:00 - 17:30

Salle / Room **407B**

Section **B**

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Colloque / Symposium

Problèmes de laboratoire dans le diagnostic du SIDA

Laboratory Issues in the Diagnosis of AIDS

Présidents / Chairpersons: Françoise Brun-Vézinet (France); Micheline Fauvel (Canada)

16:00 **T.B.O.32** Les antigenes HIV-1 circulants. *Christine Rouzioux, Hôpital Necker pour enfants malades, Paris, France.*

16:15 **T.B.O.33** Serology Tests for the Diagnosis of AIDS. *Michael O'Shaughnessy, Federal Centre for AIDS, Ottawa, ON, Canada.*

16:30 **T.B.O.34** Immunological Markers. *Jeffrey Lawrence, Cornell University Medical School, New York, NY, U.S.A.*

16:45 **T.B.O.35a** Viral Culture as an Adjunct to Clinical Trials: Isolation of AZT-Resistant Variants of HIV-1. *Mark A. Wainberg, Jewish General Hospital and McGill University, Montreal, QC, Canada.*

17:00 **T.B.O.35** New Technologies of the Diagnosis of AIDS. *Gerald Schochetman, AIDS Program, Centers for Disease Control, Bethesda, MD, U.S.A.*

16:00 - 17:30

Salle / Room **403ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Virologie (partie 2) / Virology (Part 2)**

Présidents / Chairpersons: Gregory Hammond (Canada); Francisco A. Machado Ramirez (Cuba); G. M. Shaw (U.S.A.)

16:00 **T.C.O.33** Identification of Sites within gp41 Which Serve as Targets for ADCC Using Human Monoclonal Antibodies. *Douglas S. Tyler*, S. Zolla-Pazner**/***, M. Gorny**, S. D. Stanley*, D. P. Bolognesi*, K. J. Weinhold*, *Duke University Medical Center, Department of Surgery, Durham, NC; **New York University Medical Center; New York VA Medical Center, New York, NY, U.S.A.*

16:15 **T.C.O.34** Functional Domains on the HIV-1 Envelope Protein. *Patricia L. Earl, B. Moss, National Institutes of Health, Bethesda, MD, U.S.A.*

16:30 **T.C.O.35** Putative Interaction Site between HIV gp120 and gp41: Antiviral Action of Synthetic Peptides. *Dale A. McPhee*, N. Pavuk*, S. Cumming*, D. Stapleton**, R. Doherty*, B. Kemp**, *Fairfield Hospital, NHMRC Special Unit for AIDS Virology, Fairfield; **St. Vincent's Institute, Melbourne, Australia.*

16:45 **T.C.O.36** Characterization of the HIV-2 Envelope Glycoproteins: The Transmembrane Glycoprotein is a Homodimer. *Marie-Anne Rey, A. G. Laurent, B. Krust, L. Montagnier, A. G. Hovanessian, Institut Pasteur, Unité d'Oncologie virale, Paris, France.*

17:00 **T.C.O.37** Definition of Epitopes Along an Immuno-Dominant Region of the HIV-1 gp41 and the Effect of Conservative and Non-Conservative Amino Acid Substitutions Corresponding to Various HIV-1 Isolates. *Peter Horal*, B. Svennerholm*, S. Jeansson*, L. Rymo**, A. Vahlne*, University of Göteborg, Departments of *Clinical Virology and **Medical Biochemistry, Göteborg, Sweden.*

17:15 **T.C.O.38** Gp160 Is Endoproteolytically Cleaved in a Prefucosyltransferase Containing Compartment of the Golgi Complex. *Barry S. Stein*, K. S. Steimer**, E. G. Engleman*, *Stanford University School of Medicine, Blood Center, Palo Alto; **Chiron Corporation, Emeryville, CA, U.S.A.*

16:00 - 17:30

Salle / Room **407C**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session: **Modèles animaux (partie 1) / Animal Models (Part 1)**

Présidents / Chairpersons: Patricia Fultz (U.S.A.), Alain J. Georges (South Africa), Oliviero Varnieri (Italy)

16:00 **T.C.O.39** Prevention of Simian AIDS by Passive Protection. *Malcom R. MacKenzie, C. Zaiss, P. Marx, D. Maul, N. Lerche, University of California at Davis, Sacramento, CA, U.S.A.*

16:15 **T.C.O.40** Genetic Characterization of an Acutely Lethal Variant of SIV/SMN. *Pierre Sonigo*, F. Laure***, V. Courgnaud***, P. W. Fultz**, L. Montagnier*, C. Brechot*/***, *INSERM U.75, Institut Pasteur, Unité de Recombinaison et Expression génétique, Paris, France; **Emory University and Yerkes Primate Center, Atlanta, GA, U.S.A.; ***INSERM U.75, CHU Necker, Paris, France.*

16:30 **T.C.O.41** Characteristics of SIV AGM Isolated from Wild Caught Animals in Central African Republic (CAR). *Françoise Barré-Sinoussi*, M. C. Georges-Courbot**, M. C. Lang*, P. Sonigo*, M. Jennings***, A. J. Georges**, *Institut Pasteur, Paris, France; **Institut Pasteur, Bangui, Central African Republic; ***University of California at Davis, Davis, CA, U.S.A.*

16:45 **T.C.O.42** Prophylactic Effects of AZT Following Exposure of Macaques to an Acutely Lethal Variant of SIV (SIV/SMM/PBj-14). *Harold M. McClure*, D. C. Anderson*, P. Fultz*, A. Ansari*, A. Brodie*, S. Lehrman**, *Emory University, Atlanta, GA; **Burroughs Wellcome Company, Department of Virology, Research Triangle Park, NC, U.S.A.*

17:00 **T.C.O.43** SIV from Sooty Mangabey Monkeys: An African Primate Lentivirus Closely Related to HIV-2. *Vanessa M. Hirsch*, M. Murphey-Corb**, P. R. Johnson*, *Georgetown University - National Institute of Health/Twinbrook II, Rockville; **Delta Regional Primate Research Center, Covington, LA, U.S.A.*

17:15 **T.C.O.44** HIV-1 Infection of Human PBL-Reconstituted SCID Mice. *Donald E. Mosier*, R. J. Gulizia*, S. A. Spector**, D. H. Spector**, S. M. Baird**, D. B. Wilson*, *Medical Biology Institute, La Jolla; **University of California at San Diego, San Diego, CA, U.S.A.*

16:00 - 17:30

Salle / Room **410ABC**

Section **C**

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Biologie moléculaire : les gènes régulateurs et leurs produits / Molecular Biology: Regulatory Genes and Their Products**

Présidents / Chairpersons
Bryan Cullen (U.S.A.)
John Hiscott (Canada)
Mario Pazzella (Italy)

16:00 **T.C.O.45** Localization of the VPR Gene Product in SIVmac Infected Cells. *Sabine Lang, G. Jaenel, M. Weeger, B. Fleckenstein, Universität Erlangen-Nürnberg, Institut für klinische und molekulare Virologie, Erlangen, Federal Republic of Germany.*

16:15 **T.C.O.46** Viral Protein R (CPR) of HIV-1 and HIV-2 Is Dispensable for Replication and Cytopathicity. *Douglas Dedera, W. Hu, N. Vander Heyden, L. Ratner, Washington University, Departments of Medicine and Microbiology and Immunology, St-Louis, MO, U.S.A.*

16:30 **T.C.O.47** Functional Characterization of the HIV-1 vpu Gene Product: Not Just Another Protein. *Klaus Strebel, T. Klimkait, F. Maldarelli, M. A. Martin, NIAID, National Institutes of Health, Laboratory of Microbiology, Bethesda, MD, U.S.A.*

16:45 **T.C.O.48** Analysis of a Functional HIV-2 REV Gene. *Sylvie Paulous, M. Emermen, A. Cordonnier, Institut Pasteur, Paris, France.*

17:00 **T.C.O.49** Analysis of a Potential HIV-1 Coding Sequence. *Eric A. Cohen, Y. Jalinoos, E. Terwilliger, Y. C. Lu, W. Haseltine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, U.S.A.*

17:15 **T.C.O.50** Identification of Novel HIV-1 mRNAs by S1 Nuclease Analysis and PCR Amplification. *Barbara K. Felber*, S. Schwartz**, C. M. Drysdale*, E. M. Fenyo**, G. N. Pavlakis*, *National Cancer Institute-FCRF, BRI-Basic Program, Frederick, MD, U.S.A.; **Karolinska Institute, Stockholm, Sweden.*

16:00 - 17:30

Salle / Room **409ABC**

Section **D**

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Les adolescents (partie 2)**
Specialty Session **Adolescents (Part 2)**

Présidents / Chairpersons
Anna Giovanetti (Italy)
Alan J. C. King (Canada)
M. T. Lesbehari (Tanzania)

16:00 **T.D.O.24** Do Health Belief Models about HIV and Condoms Predict Condom Use? *Ralph W. Hingson, L. Strunin, Boston University School of Public Health, Boston, MA, U.S.A.*

16:15 **T.D.O.25** Predictors of Condom Use and STDs in a Group of Sexually Active Adolescent Women. *Ruth M. Greenblatt*, J. Catania*, S. Kegeles*, J. Schachter*, J. Miller**, T. Coates*, et al., *University of California at San Francisco, San Francisco; **Planned Parenthood of Santa Cruz, Santa Cruz, CA, U.S.A.*

16:30 **T.D.O.26** Peer Education Program Reaches High Risk Adolescents with AIDS Information and Prevention. *Wendy Arnold, F. Barnes, Adolescent Alliance, Los Angeles, CA, U.S.A.*

16:45 **T.D.O.27** An Evaluation of an AIDS Risk Reduction Education and Skills Training (ARREST) Program for Adolescents. *Michele D. Kipke, C. Boyer, K. Hein, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, U.S.A.*

17:00 **T.D.O.28** Steps in Developing a Sex Education, STD and AIDS Program for Adolescents in Brasil. *L. G. M. Rodrigues, R. Cavalcante, B. Silveira, Divisao Nacional de Doenças Sexualmente Transmissiveis/AIDS-Ministerio da Saúde, Brasilia, Brazil.*

17:15 **T.D.O.29** Youth at High Risk for HIV: Knowledge, Sexual Practices and Intentions to Inform Sexual Partners of HIV Status. *Lydia Temoshok*, R. M. Ellmer*, J. M. Moulton*, M. Baxter**, J. Shalwitz**, *University of California at San Francisco, School of Medicine; **San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

16:00 - 17:30

Salle / Room **411A**



Section **D**

Mardi 6 juin
Tuesday, June 6

Le SIDA et l'individu
AIDS and the Individual

Séance thématique / Specialty Session **Counseling**

Présidents / Chairpersons
Daniel Defert (France)
Maria Eugene Fernandez (Brazil)
David G. Ostrow (U.S.A.)

16:00 **T.D.O.30** Training Inmates as HIV Peer Support Counsellors in Gaol. *Kim Begley*, S. Lyons**, L. McCallum**, L. Conolly***, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney; **Bathurst Gaol; ***NSW Department of Corrective Services, Australia.*

16:15 **T.D.O.31** Optimizing Inner City Prenatal AIDS Counselling. *Theresa C. Mendez*, H. W. Lischner*, S. A. Raphael*, M. M. Olson*, A. W. Cohen**, F. Steinberg*** et al., *St. Christopher's Hospital for Children; **University of Pennsylvania; ***Episcopal Hospital, Philadelphia, PA, U.S.A.*

16:30 **T.D.O.32** Problems with Counselling Undereducated People Regarding HIV-1 Serologic Results. *Jean-Robert Brutus*, M. Adrien*, R. Boulos*, N. Halsey**, M. Abellard*, P. Kissinger*, *Centers for Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A.*

16:45 **T.D.O.33** Are Patients Getting the AIDS Education They Want from Their Physicians? *Barbara Gerbert, B. Maguire, T. Coates, University of California at San Francisco, San Francisco, CA, U.S.A.*

17:00 **T.D.O.34** Special Problems Involved in Counselling of HIV-Infected Homosexuals and Hemophiliacs. *Günter Reisbeck, M. Ermann, G. Hutner, M. M. Schneider, O. Seidl, W. Schramm, University of Munich, Department of Psychotherapy and Psychosomatics of the Psychiatric Clinic, Federal Republic of Germany.*

17:15 **T.D.O.35** Condom Use and Associated HIV Seroconversion Following Intensive HIV Counselling of 122 Married Couples in Zaire with Discordant HIV Serology. *Munkolenkole Kamenga*, K. Jingu*, S. Hassig*, C. Brown*/**, F. Behets, R. Ryder*/***, *Projet SIDA, Kinshasa, Zaire; **National Institutes of Health, Bethesda, MD, U.S.A.; ***Centers for Disease Control, Atlanta, GA, U.S.A.*

16:00 - 17:30

Salle
Room **411B**



Section
E

Mardi 6 juin
Tuesday, June 6

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique **Problèmes de la communauté gaie**
Specialty Session **The Gay Community Issues**

Présidents
Chairpersons

J. K. Gaifuba (Uganda)
Michael Pollak (France)
Michael Sobota (Canada)

16:00 **T.E.O.13** Les homosexuels et le SIDA. *Michael Pollak, Author, Paris, France.*

16:15 **T.E.O.14** Coverage of Selected Drugs Under State Medical Assistance (Medicaid) Programs in the U.S.A.. *Benjamin H. Schatz, AIDS Civil Rights Project, National Gay Rights Advocates, San Francisco, CA, U.S.A.*

16:30 **T.E.O.15** Networking: A Prevention and Care Strategy for the Gay Minority in South Africa. *John V. Pegge, G. Isaacs, S. D. Miller, Gasa/6010 Counselling Service, Woodstock, Cape Town, South Africa.*

16:45 **T.E.O.16** Homophobia in the Development of Public Policy on AIDS in the United States of America. *Eric Rosenthal, A. Ziegler, Human Rights Campaign Fund, Washington, DC, U.S.A.*

17:00 **T.E.O.17** Organizational Preconditions for Community Action. *Melinda A. Cuthbert, Yale University, New Haven, CT, U.S.A.*

16:00 - 17:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Mardi 6 juin
Tuesday, June 6

Colloque / Symposium

Infection par le VIH, reproduction et fonction parentale
HIV Infection, Reproduction and Parenthood

Présidents / Chairpersons: Bernard Dickens (Canada), Ruth Macklin (U.S.A.)

16:00 **T.F.O.17** Overview of the Issues. *Bernard Dickens, Faculty of Law, University of Toronto, ON, Canada.*

16:20 **T.F.O.18** Ethical Dilemmas in Pediatric and Maternal AIDS. *Anne D. Willoughby, A. Wright, A. Novello, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, U.S.A.*

16:30 **T.F.O.19** Should HIV Positive Women Have Children? An Ethical Perspective. *John D. Arras, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

16:40 **T.F.O.20** Uninfected Children of Infected Women: The Hidden Pediatric Epidemic. *Sheldon Landesman, State University of New York, Health Science Centre, New York, NY, U.S.A.*

16:50 **T.F.0.21** Ethical Implications of HIV/AIDS Among Mothers and Children in Kenya. *Philista Onyango, Nairobi, Kenya.*

15:00 **T.F.O.22** AIDS and Reproductive Health in the African Setting. *Dorothy Temu, Tanzania.*

15:10 **T.F.O.22a** Commentary. *Ruth Macklin, Albert Einstein College of Medicine, New York, NY, U.S.A.*

16:00 - 17:30

Salle
Room **406A**

Section
G

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Séance thématique **Prévalence (Partie 2)**
Specialty Session **Prevalence (Part 2)**

Présidents
Chairpersons

Alix Adrien (Canada)
Giuseppe Ippolito (Italy)
Jean W. Pape (Haiti)

16:00 **T.G.O.19** Progressive Increase in HIV-1 Seroprevalence in Pregnant Haitian Women: 1986 through 1988. *Reginald Boulos*, N. Halsey**, E. Holt**, T. Quinn**, A. Ruff**, J. R. Brutus*, et al., *Centers for Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A.*

16:15 **T.G.O.20** HIV-1 in Hospitalized Haitian Pediatric and Adult Patients. *Mario Adrien*, R. Boulos*, A. Louis*, F. Joseph*, P. Kissinger*, N. Halsey**, et al., *Centers for Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A.*

16:30 **T.G.O.21** Prevalence of HIV-1 and HTLV-I in Gonaives, Haiti. *Judith A. Fortney*, M. G. Bonhomme*, T. C. Quinn***, F. Lebrun**, N. Halsey***, et al., *Family Health International, Research Triangle Park, NC, U.S.A.; **Centre pour le Développement et la Santé, Port-au-Prince, Haiti; ***Johns Hopkins University, Baltimore, MD, U.S.A.*

16:45 **T.G.O.22** Rising Prevalence of Antibodies against Human Immunodeficiency Virus (HIV-1) in Western Maharashtra, India. *Kaylan Banerjee, National Institute of Virology, Pune, Maharashtra, India.*

17:00 **T.G.O.23** Second Seroprevalence Survey among Bangkok's Intravenous Drug Addicts (IVDA). *Suphak Vanichseni*, W. Sonchai*, K. Plangsringarm*, P. Akarasewi**, N. H. Wright**, K. Choopanya*, *Bangkok Metropolitan Administration; **Division of Epidemiology, Ministry of Public Health, Bangkok, Thailand.*

17:15 **T.G.O.24** AIDS in Papua New Guinea: Heterosexual Transmission and Some Important Local Considerations. *Clement Malau, B. Currie, P. Mondia, T. Pyakalyia, Department of Health, Boroko, Papua, New Guinea.*

16:00 - 17:30

Salle / Room **406BC**

Section **G**

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Atelier / Workshop — **Atelier régional : Asie / Regional Workshop: Asia**

Présidents / Chairpersons — Khorshed M. Pavri (India), Thelma Tupasi (Philippines)

16:00 **T.G.O.25** HIV Transmission Among Intravenous Drug Abusers. *Praphan Phanuphak, V. Poshyachinda, T. Un-eklabh, W. Rojanapithayakorn, Chulalongkorn University, Department of Medicine, Bangkok, Thailand.*

16:15 **T.G.O.26** HIV Transmission Through Blood/Blood Products in India: Difficulties in Control and Suggested Strategies. *Khorshed M. Pavri, ICMR Centre for AIDS Research and Control, Pune, India.*

16:30 **T.G.O.27** Health Education Strategies in Control. *Shankar Choudhury, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.*

16:45 **T.G.O.28** Strategies for Regional and International Cooperation. *S. Pattanayak, World Health Organization, New Delhi, India.*

16:00 - 17:30

Salle / Room **404AB**

Section **H**

Mardi 6 juin
Tuesday, June 6

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique / Specialty Session: **Impact macroéconomique dans les pays en voie de développement / Macroeconomic Impact in Developing Countries**

Présidents / Chairpersons: Gerald M. Desmond (U.S.A.), N. Hiza (Tanzania), A. Masters (Switzerland)

16:00 **T.H.O.13** Policy Challenges of the Socio-Economic Impacts of the AIDS Pandemic: A Co-Ordinated Response by the United Nations System. *Gerald M. Desmond, Department of International Economic and Social Affairs, United Nations, New York, NY, U.S.A.*

16:15 **T.H.O.14** The Migrant labour System and its Implications for HIV Transmission. *Eddie Webster, National Union of Mineworkers, South Africa.*

16:30 **T.H.O.15** A Production Function Approach to Estimating the Aggregate Macroeconomic Impact of AIDS on Central African Economies. *Mead Over, The World Bank, New York, NY, U.S.A.*

16:45 **T.H.O.16** Some Economic Implications of Introducing Control Measures to Reduce the Spread of HIV Infection in Sub-Saharan Africa. *Jane T. F. Rowley, T. W. Ng, R. M. Anderson, Imperial College, Pure and Applied Biology, London, U.K.*

17:00 **T.H.O.17** A Medium-Run Model for the Analysis of the Economic Impact of AIDS in Sub-Saharan Africa. *Gerard Kambou, Ivory Coast.*

16:00 - 17:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

Mardi 6 juin
Tuesday, June 6

Programmation française
French Programming

16:00		Introduction: *Colette Lachance*
16:04	**T.I.V.9**	***"O'U EST PASSÉ STÉPHANE"*** Vidéo de/Video by: *Dr. Didier Jayle, Mutualité Française* Année/Year: 1987
16:08	**T.I.V.10**	***"UNE VIE INCURABLE" (EXTRAIT)*** Vidéo de/Video by: *Robert Blais* Année/Year: 1988
16:18	**T.I.V.11**	***"REPORTAGE SUR JACQUES UNE PERSONNE ATTEINTE DU SIDA"*** Vidéo de/Video by: Année/Year: 1988
16:27	**T.I.V.12**	***"UN MONDE UNI CONTRE LE SIDA"*** Vidéo de/Video by: *OMS/WHO* Année/Year: 1988
16:48	**T.I.V.13**	***"VIRUS, QUEL VIRUS?"*** Vidéo de/Video by: *Fabrice Rouleau* Année/Year: 1987
17:05	**T.I.V.14**	***"FAITS DIVERS"*** Vidéo de/Video by: *Quentin Van De Velde* Année/Year:

➜

Les films de France, de Belgique, de Suisse et du Québec traitent de multiples aspects du SIDA, des campagnes d'information pour les jeunes au contexte international du SIDA, avec des reportages très personnels.

Presentations from France, Belgium, Switzerland and Quebec, these videos address many aspects of AIDS ranging from general information for youth, the international context of AIDS, to very personal accounts.

Notes



Section
A

Mardi 6 juin
Tuesday, June 6

Épidémiologie et santé publique
Epidemiology and Public Health

Session d'affichage
Poster Session

Prévalence régionale du VIH
Regional HIV Prevalence

T.A.P.1 Virus HIV-1 chez des enfants drépanocytaires polytransfusés à Yaoundé (Cameroun). *Ekoe Tetanye*, E. Nyouma, P. Ndumbe, L. Kaptue-Noche, *Centre universitaire des sciences de la santé, Yaounde, Cameroon.*

T.A.P.2 Epidemiology of HIV Infection in Greater Tel Aviv. *Michael Burke*, N. Vardinon, A. Hasner, M. Hoffman, I. Yust, *Tel Aviv Medical Center, Tel Aviv, Israel.*

T.A.P.3 Prevalence of STD and HIV-1 in Risk Groups and Control Populations in Various Regions in Senegal. *Fred Van der Veen*, I. Ndoye, S. M'Boup, N. Samb, L. Fransen, L. Van de Velde, *Bureau National MST, Ministère de la Santé, Dakar, Senegal.*

T.A.P.4 The Extent of Heterosexual HIV Transmission in England and Wales: Evidence from Surveillance Data. *O. Noel Gill*, J. D. H. Porter, G. A. Ellam, S. E. Clarke, K. Porter, E. Miller, et al., *PHLS Communicable Disease Surveillance Centre, Colindale, U.K.*

T.A.P.5 Temporal Trends of HIV Infection by Risk Indicator in the Latium Region, Italy. *Carlo A. Perucci*, M. Arcà, D. Abeni, P. Chierchini, N. Orchi, T. Spadea, *Regional Epidemiology Unit of Latium Region, Rome, Italy.*

T.A.P.6 HIV Serology in Ontario, 1985-1988. *Bernadette McLaughlin*, C. J. Major, V. Bond, B. Gregory, G. Strunc, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada.*

T.A.P.7 HIV Infection Surveillance in Poland. *Jacek R. Juszczyk*, D. Naruszewicz-Lesiuk, A. Stapinski, H. Seyfried, B. Kalinowska, *Medical Academy, Clinic of Infectious Diseases, Poznan, Poland.*

T.A.P.8 Apparent High HIV Seroprevalence among Heterosexual Men of Mexico City. *Carlos L. Magis*, M. L. Garcia, E. Bravo, E. Uribe, J. L. Valdespino, G. Ornelas, et al., *Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.*

T.A.P.9 The Epidemiological Situation of HIV in the Federal Republic of Germany. Results Based on Mandatory Reports of Laboratories. *Horst-Günter Maxeiner*, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany.*

T.A.P.10 Seroepidemiology of HIV-Infection in Frankfurt/FRG. *H. W. Doerr*, R. Enzensberger, S. Staszewski, *Department of Medical Virology, University Clinic of Frankfurt, Frankfurt, Federal Republic of Germany.*

T.A.P.11 Anti-HIV Seroprevalence in Adult Rural Populations of Uganda and Its Implications for Preventive Strategies. *Jane Frances Kengeya-Kayondo*, A. Amaana, J. R. Ndumu, W. Naamara, *Uganda Virus Research Institute, Entebbe, Uganda.*

T.A.P.12 4 Year Follow-up Study of the HIV Infection in High Risk and Control Groups in Martinique (FWI). *Roger Chout*, D. Cales-Quist, M. Verdier, R. Helenon, R. Demeuleemester, F. Denis, *Association de Recherche et d'Étude en Microbiologie (AREM), Hôpital du Lamentin, Le Lamentin, Martinique.*

T.A.P.13 Are Missionaries at Risk of AIDS? *W. Robert Lange*, E. M. Dax, R. Kovacs, D. Kreider, J. D. Frame, *Johns Hopkins Medical Institutions, Medical Advisors Office, Baltimore, MD, U.S.A.*

T.A.P.14 High-Risk Heterosexuals: Differences between Private and Commerical Partners in Sexual Behavior and Condom Use. *Christa Hooykaas*, J. Van der Pligt, G. J. J. Van Doornum, M. M. D. Van der Linden, R. A. Coutinho, *Municipal Health Service of Amsterdam, Amsterdam, Netherlands.*

T.A.P.15 Seroprevalence of HIV Infection among Migrant Farmworkers. *John P. Narkunas*, K. L. Castro, S. Reig, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.16 Prevalence of HIV-1 Infection among College Students. *Karen L. Kotloff*, C. Tacket, M. Bridwell, J. Cowan, S. Wasserman, T. Quinn, *University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, U.S.A.*

T.A.P.17 HIV Seroprevalence in Transvestites of the City of Sao Paulo. *Galvao Ayroza*, J. Suleiman, G. Suleiman, *Faculdade de Ciências Médicas, Hospital Emilio Ribas, Sao Paulo, Brazil.*

T.A.P.18 Do Homosexual Men Evade HIV Testing? *Sirkka-Liisa Valle*, S. Sarna, *University Central Hospital: Department of STDs, Helsinki, Finland.*

T.A.P.19 Diffusion des précautions sexuelles et évolution de la séropositivité dans la population homosexuelle française: 1985-1988. *Michael Pollak*, M. A. Schiltz, P. Boisson, *CNRS-GSPM, Paris, France.*

T.A.P.20 Changes in Sexual Behavior Connected to Strong Decline in HIV Incidence among Homosexual Men. *Godfried J. P. Van Griensven*, E. M. M. De Vroome, J. Goudsmit, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

T.A.P.21 Incidence of HIV-1 Infections among Homosexual Men in Dallas, Texas, 1987-88. *Charles E. Haley*, A. Freeman, P. Anderson, A. Petty, K. O'Reilly, *Dallas County Health Department, Dallas, TX, U.S.A.*

T.A.P.22 Prevalence and Seroconversion for HIV Infection in Homosexual and Bisexual Men in Madrid. *Francisco Bru*, F. Babin, C. Colomo, I. Pascual, M. Rua-Figueroa, A. Garcia-Saez, *Ayuntamiento de Madrid, CPS Centro, Madrid, Spain.*

T.A.P.23 Trends in HIV Antibody Positive Admissions to a Connecticut Community Hospital. *Gayle M. Madden*, C. A. Smith, *St. Francis Hospital and Medical Center, Hartford, CT, U.S.A.*

T.A.P.24 HIV Screening in an Urban Hospital Outpatient Population. *Michael Marmor*, K. Krasinski, M. Sanchez, H. Cohen, N. Dubin, L. Weiss, et al., *New York University Medical Center, New York, NY, U.S.A.*

T.A.P.25 Surveillance hospitalière de l'infection par le VIH à Bordeaux, France: Tendances épidémiologiques, 1985-1988. *Philippe Morlat*, A. Chaslerie, M. Dupon, D. Lacoste, J.-L. Pellegrin, Groupe d'épidémiologie clinique du SIDA en Aquitaine (GECSA), *Hôpital Pellegrin, Clinique des Maladies Infectieuses, CHRU Bordeaux, Bordeaux, France.*

T.A.P.26 Increase in the Reported Number of HIV-infected Patients in U.S. Dialysis Centers from 1985-1987. *Martin S. Favero*, M. J. Alter, *Centers for Disease Control, Hospital Infections Program, Atlanta, GA, U.S.A.*

T.A.P.27 HIV Antibody in Chronic Hemodialysis Patients, United States. *Ruthanne Marcus, Cooperative Dialysis Study Group, Centers for Disease Control, Atlanta, GA, U.S.A.*

Le VIH chez les consommateurs de drogues par voie intraveineuse
HIV in Intravenous Drug Users

T.A.P.28 Prevention of HIV-Infection in Parenteral Drug Abusers (PDAs): About Evaluation and Efficacy of Opiate-Substitution Treatment. *Reinhard Bornemann*, G. Grimm, B. Wolf, F. Bschor, *Institut für Rechtsmedizin, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

T.A.P.29 HIV and Hepatitis B Infection Associated with Different Risk Behaviors. *Beryl A. Koblin*, J. McCusker, B. Lewis, J. Sullivan, B. Patashnik, F. Birch, *University of Massachusetts at Amherst, Amherst, MA, U.S.A.*

T.A.P.30 Report on an Extremely Low Rate of Seropositivity among I.V. Drug Users (IVDU) in a Local Health District of (LHD) North East Italy. *Paolo Mezzelani*, F. Lugoboni, L. Venturini, R. Bricolo, *Istituto di Patologia Medica, Università di Verona, Verona, Italy.*

T.A.P.31 Long-term Follow-up and Assessment of Human Immunodeficiency Serostatus and Risk-Taking in a Cohort of 203 Intravenous Drug Users. *Carol A. Skidmore*, J. R. Robertson, *Edinburgh Drug Addiction Study, Muirhouse Medical Group, Edinburgh, U.K.*

T.A.P.32 Prevalence of Syphilis (S), HTLV-I (I), HTLV-II (II) and HIV-1 among Crack (C) and Other Drug Users (DUs). *Jordan B. Glaser*, J. Monnier, K. D'Angelo, A. Drakatos, B. Poiesz, G. Ehrlich, et al., *The Staten Island Hospital, Staten Island, NY, U.S.A.*

T.A.P.33 Needle Sharing Practices among Intravenous Drug Users in a State Allowing the Purchase of Injection Equipment. *William L. Atkinson*, D. Lawrence, A. Lauro, *Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, U.S.A.*

T.A.P.34 The AIDS Problem and Drug-Rehabilitation in Therapeutic Communities (TC). *Marco Olgiati, Zurich University Hospital, Department of Social Psychiatry, Zürich, Switzerland.*

T.A.P.35 Coordinated Community Program for HIV Surveillance among IVDU. *Benjamin F. Lewis*, J. Sullivan, F. Birch, J. McCusker, B. Koblin, S. Noone, et al., *Spectrum House Inc., Westboro, MA, U.S.A.*

T.A.P.36 No Trend in Yearly HIV-seroprevalence Rates among IVDU in Amsterdam: 1986-1988. *Harry J. A. Van Haastrecht*, J. A. R. Van Den Hoek, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

T.A.P.37 Epidemiology of AIDS Associated with Intravenous Drug Use, United States, 1979-1988. *Nicholas Crofts*, L. Petersen, R. Selik, J. Buehler, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.38 Second National Survey on HIV Infection, At-Risk Behaviours and Behavioural Change among Italian Drug Users. *Stefania Salmaso*, H. Sasse, S. Conti, *Istituto Superiore di Sanità, Rome, Italy.*

T.A.P.39 Introduction of HIV Infection among Intravenous Drug Abusers (IVDAs) in Low Prevalence Cities. *Robert J. Battjes*, R. W. Pickens, *National Institute on Drug Abuse, Rockville, MD, U.S.A.*

T.A.P.40 Heterosexual Transmission of HIV among Intravenous Drug Abusers (IVDAs). *Robert J. Battjes*, Z. Amsel, R. W. Pickens, P. Sholinsky, L. Ritz, L. S. Brown, *National Institute on Drug Abuse, Rockville, MD, U.S.A.*

T.A.P.41 Incidence and Risk Factors of HIV Infection in a Cohort of Italian Drug Addicts (NISDA Study). *Alfredo Nicolosi, NISDA, National Research Council, Department of Epidemiology, ITBA, Milan, Italy.*

T.A.P.42 HIV Serostatus and Risk Behaviors of Street IVDUs. *Nancy H. Corby*, F. Rhodes, R. J. Wolitski, *Long Beach Health Department, Long Beach, CA, U.S.A.*

T.A.P.43 A Comparison of HIV-1 Infection Rates in Minnesota (MN) IV Drug Users between 1987 and 1988. *Kristine L. MacDonald*, J. Thomas, R. Danila, M. Osterholm, J. Shultz, C. Falkowski, et al., *Minnesota Department of Health, Minneapolis, MN, U.S.A.*

T.A.P.44 Is Condom Use an Independent Risk for HIV in IV Drug Users? *David D. Celentano*, D. Vlahov, J. C. Anthony, M. Bernal, *Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

T.A.P.45 Risk Factors for HIV-1 Infection among Intravenous Drug Users (IVDU) (1978-1987). *David Vlahov*, A. Muñoz, D. D. Celentano, S. Cohn, M. Shapiro, J. C. Anthony, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

T.A.P.46 Association between Former Place of Residence and Serostatus of IVDUs in South Florida. *Mary Comerford*, D. D. Chitwood, C. B. McCoy, E. J. Trapido, *University of Miami Medical School, Miami, FL, U.S.A.*

T.A.P.47 HIV Infection in Female Intravenous Drug Users in San Francisco. *Andrew R. Moss*, A. Keffelew, P. Bacchetti, R. Meakin, B. Brodie, A. R. Moss, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.A.P.48 Drug Abuse Patterns and Ethnicity in IVDA during the Early Years of the HIV Epidemic. *David M. Novick*, H. L. Trigg, D. C. Des Jarlais, S. R. Friedman, D. Vlahov, M. J. Kreek, et al., *Beth Israel Medical Center, New York, NY, U.S.A.*

T.A.P.49 Demographic and Behavioral Features of HIV Infection in Intravenous Drug Users (IVDUs) in New York City Drug Treatment Programs: 1985-1988. *Lawrence S. Brown*, R. Phillips, D. Ajuluchukwu, R. Battjes, B. J. Primm, T. Nemoto, *Addiction Research and Treatment Corporation, Brooklyn, NY, U.S.A.*

T.A.P.50 Intravenous Drug Use as a Risk Factor for AIDS and HIV Infection in Louisiana, 1981-1988. *William Atkinson*, S. Troxler, M. Dal Corso, L. McFarland, *Louisiana Department of Health and Hospitals, New Orleans, LA, U.S.A.*

T.A.P.51 Transmission of HIV by Mobility in Injection Drug Users (IDU). *Raymond P. Brettle*, G. Jones, J. Davidson, C. Bisset, S. M. Burns, J. M. Inglis, *Department of Infectious Diseases, City Hospital, Edinburgh, U.K.*

T.A.P.52 Comparative HIV Seroprevalence in IV Drug Users (IVDU) from Four Different Testing and Treatment Programs. *David L. Cohn*, J. Douglas, J. Koleis, F. Feeney, F. Judson, *Denver Disease Control Service, Denver, CO, U.S.A.*

T.A.P.53 Human Immunodeficiency (HIV) and Human T-lymphotropic (HTLV-I/II) Virus Infections Associated with Intravenous Drug Abuse (IVDA). *Roy W. Stevens*, J. A. Wethers, C. Samsonoff, D. Berns, *New York State Department of Health, Albany, NY, U.S.A.*

T.A.P.54 HIV Infection among Intravenous Drug Users (IVDUs) in NYC. *Benedict I. Truman*, J. S. Lehman, L. S. Brown, N. Peyser, N. Peters, D. Des Jarlais, et al., *New York State Department of Health, Albany, NY, U.S.A.*

T.A.P.55 HIV Seroprevalence in Injecting Drug Users in South London, 1985-88. *Sheena Sutherland*, T. J. McManus, *Dulwich Hospital, London, U.K.*

T.A.P.56 HIV Seroconversion in a Group of IVDAs (1985-1988). *Giorgio Barbarini*, S. Edo, T. Gola, S. Guerini, S. Lopez, P. Sanbartolomeo, *Institute of Infectious Diseases, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy.*

T.A.P.57 HIV Prevalence among Different Groups of Intravenous Drug Users in Seattle, Washington. *Robert W. Wood*, J. P. McGough, N. Harris, J. Kleyn, M. Carlisle, *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A.*

T.A.P.58 Sexually Transmitted Diseases (STDs) and HIV Seroprevalence in a Cohort of IV Drug Users. *Kenrad E. Nelson*, D. Vlahov, L. Solomon, N. Chowdhury, *Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A.*

T.A.P.59 Sero-Epidemiology of HIV-1 Infection among Drug Users Seeking Medical Help in Montreal: 1985-1988. *Julie Bruneau*, F. Lamothe, J. Soto, M. Brabant, J. Vincelette, M. Fauvel, *Hôpital Saint-Luc, Montreal, QC, Canada.*

T.A.P.60 Comparative Monitoring of HIV-Spread in the IVDU Population of Berlin and Hamburg. *Friedrich Bschor, R. Bornemann, K. Pueschel, R. Rex, W. Platz, R. Lueth, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

Surveillance du SIDA et marqueurs de l'infection
Surveillance of AIDS and Marker Infections

T.A.P.61 Underreporting of AIDS Cases, South Carolina, 1986-1987. *George A. Conway*, B. L. Niemeyer, P. Rion, C. Pursley, C. Cruz, C. W. Heath, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.62 Using Death Certificates to Estimate the Completeness of AIDS Case Reporting in Ontario. *B. Lily Montano*, R. J. Johnson, E. M. Wallace, *Public Health Branch, Ontario Ministry of Health, Toronto, ON, Canada.*

T.A.P.63 Risk Group Differences in Reporting Deaths in AIDS Patients. *Owen J. Devine*, R. L. Berkelman, J. M. Karon, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.64 High Percentage of Non-Reported Cases of AIDS in Hemophiliacs of the Federal Republic of Germany. *Gert G. Frösner, Max von Pettenkofer-Institut, University of Munich, Munich, Federal Republic of Germany.*

T.A.P.65 Active Surveillance for Pediatric HIV Infection in Los Angeles County. *Laurene Mascola*, M. Evans, T. Frederick, J. Church, Y. Bryson, A. Kovacs, et al., *County of Los Angeles, Department of Health Services, Los Angeles, CA, U.S.A.*

T.A.P.66 Medical School Subcontract Ensures State-wide Active AIDS Surveillance in New Jersey. *D. Jean Schneider*, M. A. Lavenhar, *University of Dentistry and Medicine of New Jersey, New Jersey Medical School, Newark, NJ, U.S.A.*

T.A.P.67 Evaluating Racial Classification among Native American Indians with AIDS in Los Angeles County, California. *Loren E. Lieb*, P. R. Kerndt, M. Hedderman, E. Chase, J. S. Yao, G. A. Conway, *Los Angeles County Health Services, Los Angeles, CA, U.S.A.*

T.A.P.68 Use of Automated Secondary Data Sets for AIDS Surveillance. *Cyrus Hamidi*, J. Hidalgo, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A.*

T.A.P.69 A Record Linkage Study to Determine the Degree of Under-Reporting of AIDS Cases in Canada. *Liviana Calzavara*, K. Craib, R. A. Coates, M. T. Schechter, K. Elmslie, University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

T.A.P.70 Evaluating Completeness of New York's Case Registry. *Rita H. Hindin*, P. Thomas, A. Nicholas, N. Miller, S. Schultz, New York City Department of Health, AIDS Surveillance Unit, *New York City Department of Health, AIDS Surveillance Unit, Englewood, NJ, U.S.A.*

T.A.P.71 Linkage of Records of Persons in the New York City (NYC) AIDS Case Registry with Death Certificates Filed in NYC. *Rita H. Hindin*, T. P. Singh, P. Thomas, S. Blum, E. Rautenberg, New York City Department of Health, AIDS Surveillance Unit, New York City Department of Health, AIDS Surveillance Unit, Englewood, NJ, U.S.A.*

T.A.P.72 Trends in the Outpatient Diagnosis of AIDS: Implications for Epidemiologic Analysis and Surveillance. *Sharon G. Hopkins*, W. Lafferty, J. Honey, M. Hurlich, *Seattle-King County Department of Public Health, Seattle, WA, U.S.A.*

T.A.P.73 Hospital-based AIDS Reporting in a High Incidence Area, Houston, Texas, U.S.A. *Robert L. Falletti*, N. Cole, A. Phelps, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A.*

T.A.P.74 Evaluation of AIDS Case Reporting in Massachusetts. *Stephanie Oddleifson*, B. Heinze-Lacey, L. Makarewicz, J. Day, G. Seage, *Boston Department of Health and Hospitals, Boston, MA, U.S.A.*

T.A.P.75 DMAC: A Software for Cooperative Epidemiology of HIV Infection. *A. J. Valleron*, O. Retel, S. Lesieur, D. Longinovic, *Centre Coopérateur de Données sur l'Épidémiologie de l'Immunodéficience Humaine, INSERM SC4, Université Paris 7, Paris, France.*

T.A.P.76 Temporal Trends for Past Sexually Transmitted Disease in Men with AIDS and ARC In San Francisco. *David W. Feigal*, H. Hollander, J. Ziegler, M. Clement, P. A. Volberding, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.A.P.77 Impact of the Revision of the CDC AIDS Case Definition on Case Reporting. *Cyrus Hamidi*, J. Hidalgo, A. Rogers, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A.*

T.A.P.78 Effect of the CDC Revised Definition on AIDS Case Reports in New Jersey. *Christine M. Grant*, S. Costa, J. Beil, J. Massey, J. Ryan, L. Robeson, *New Jersey State Department of Health, Trenton, NJ, U.S.A.*

T.A.P.79 Retrospective Review of Non-AIDS Reports in New Jersey Based on CDC Revised Surveillance Definition of 1987. *Molly J. Coye*, S. Costa, D. Yeager, J. Ryan, J. Massey, J. Beil, *New Jersey State Department of Health, Trenton, NJ, U.S.A.*

T.A.P.80 The Effect of the Revised AIDS 1987 Case Definition on the Characteristics of Cases Reported in Upstate New York. *Perry F. Smith*, F. Coles, J. Caouette, D. Putnam, L. Chiarello, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.S.A.*

T.A.P.81 Can the Infection Rate of HBV Serve as a Predictor of HIV Infection? *Edna Ben-Porath*, A. Etzioni, Y. Satinger, N. Rimon, S. Pollack, *Rambam Medical Center, Virology Unit, Haifa, Israel.*

T.A.P.82 Declining Incidence of Acute Hepatitis B among Drug Users in Amsterdam may Indicate a Change in Risk Behavior. *Ernst C. Buning*, C. Bardoux, A. Leentvaar-Kuijpers, A. Verster, R. A. Coutinho, *Municipal Health Service, Amsterdam, Netherlands.*

T.A.P.83 Fear of AIDS and Incidences of Gonorrhea, Syphilis, and Hepatitis B, 1982-88. *Franklyn N. Judson*, D. L. Cohn, J. M. Douglas, *Denver Public Health, Denver, CO, U.S.A.*

T.A.P.84 Changing Sexual Behavior in the 1980's. *Michael L. Rekart, STD Control, Ministry of Health, Vancouver, BC, Canada.*

Transmission hétérosexuelle (partie 1)
Heterosexual Transmission (Part 1)

T.A.P.85 AIDS Patients with No Identified Risk: Lack of Evidence for New Modes of Transmission. *Lois J. Conley*, T. J. Bush, M. E. Chamberland, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.86 The Relationship Between Male Circumcision and HIV Infection in African Populations. *Priscilla Reining*, J. Bongaarts, P. Way, F. P. Conant, *American Association for the Advancement of Science, Washington, DC, U.S.A.*

T.A.P.87 HIV-1 Infection in Sexually Exposed Women: Risk Factors for Prevalent and Incident Infections. *Francis A. Plummer*, J. Pepin, G. Maitha, G. Moss, J. O. Ndinya-Achola, L. D'Costa, *University of Nairobi, Nairobi, Kenya.*

T.A.P.88 HIV Transmission in Stable Sexual Partnerships in Kenya. *Gregory B. Moss*, L. J. D'Costa, J. O. Ndinya-Achola, F. A. Plummer, J. K. Kreiss, D. W. Cameron, *University of Washington, Department of Medicine, Seattle, WA, U.S.A.*

T.A.P.89 HIV Infection and Circumcision Status. *Ilona W. Surick*, M. McLaughlin, M. Chiasson, *New York City Department of Health, New York, NY, U.S.A.*

T.A.P.90 HIV Risk Factors in Steady Male Sex Partners of Kinshasa Prostitutes. *Nzilambi Nzila*, M. Laga, M. Kivuvu, A. T. Manoka, G. Mwungura, R. Ryder, *Projet SIDA, Kinshasa, Zaire.*

T.A.P.91 Serologic Concordance and Incidence of HIV in Regular Sexual Partners in Nairobi, Kenya. *D. William Cameron*, M. L. Kosseim, D. Oduor, L. J. D'Costa, G. M. Maitha, G. M. Irungu, et al., *Ottawa General Hospital, Ottawa, ON, Canada.*

T.A.P.92 Potential Role of Spermatozoa in the Transmission of HIV. *Elisabeth Dussaix*, D. Guétard, A. Ellrodt, M. De Almeida, M. Hadchouel, M. Auroux, *Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.*

T.A.P.93 Ethnic Differences in the Heterosexual Transmission of HIV in California. *Nancy S. Padian*, A. Moreno, S. Glass, S. Shiboski, G. Maisonet, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.A.P.94 Heterosexual Transmission of HIV from Intravenous Drug Users to Their Sexual Partners. *Nancy S. Padian*, H. Petersen, R. Meakin, B. Brodie, C. Wofsy, A. Moss, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.A.P.95 Statistical Analysis of Infectivity Based on Partner Studies. *Stephen C. Shiboski*, N. Jewell, *University of California at Berkeley, Berkeley, CA, U.S.A.*

T.A.P.96 Comparison of Risk for HIV Infection among Self-Referred and Provider-Referred Heterosexuals in a Study of HIV Transmission. *Kenneth H. Mayer*, D. Laufer, L. Feingold, S. Zierler, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A.*

T.A.P.97 Heterosexual Behavior and HIV Status in a Cohort of Persons at Increased Risk for HIV Infection. *Kenneth H. Mayer*, S. Zierler, L. Feingold, D. Laufer, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A.*

T.A.P.98 Heterosexual Transmission of HIV: A European Study. I: Male-to-Female Transmission. *Isabelle De Vincenzi*, R. Ancelle-Park, *Centre collaborateur OMS-SIDA Europe, IMET, Hôpital Claude Bernard, Paris, France.*

T.A.P.99 Risk Factors for Heterosexual Transmission of HIV Infection. *Alberto Saracco, University of Milan, Infectious Diseases Clinic, Milan, Italy.*

T.A.P.100 Behavior Modification in Couples Enrolled in a Study of Heterosexual Transmission. *Heidi M. Petersen*, N. Padian, S. Glass, A. Moreno, I. Ajaniku, C. Wofsy, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.A.P.101 Changes in Sexual and Reproductive Behavior in Heterosexual Couples after HIV Testing. *Mary A. Vogler*, T. Dugan, M. Seidlin, *New York University School of Medicine, New York, NY, U.S.A.*

T.A.P.102 High Prevalence of HIV-1 Antibodies in STD Patients with Genital Ulcers. *Debrework Zewdie*, M. Abdurahman, S. Ayhunie, G. Adal, M. Tadesse, T. Yemaneberhan, et al., *National Research Institute of Health, Addis Ababa, Ethiopia.*

Transmission hétérosexuelle (partie 2)
Heterosexual Transmission (Part 2)

T.A.P.103 HIV-1 Transmission in Heterosexual Couples. *Giuseppe Luzi*, C. Papetti, A. M. Pesce, I. Mezzaroma, E. Pinter, G. D'Offizi, et al., *Department of Allergy and Clinical Immunology, University of Rome "La Sapienza", Rome, Italy.*

T.A.P.104 Preliminary Analysis of Factors Associated with Seroconversion in a Study of Heterosexual Sexual Transmission of HIV in Monogamous Couples. *Margaret Nichols*, P. Paroski, G. Sampson, J. Leibel, M. J. Kennedy, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.S.A.*

T.A.P.105 The Risks for Heterosexual Transmission from Infected Blood Transfusion Recipients. *John W. Ward*, H. Perkins, E. Donegan, C.-Y. Ou, S. Laussecq, S. Gaynor, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

T.A.P.106 Risk of Heterosexual Transmission of HIV-1 from Recipients of Blood and Blood Products. *Elizabeth A. Donegan*, Transfusion Safety Study Group, *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.A.P.107 No More Seroconversions among Spouses of Patients of the Bonn Hemophiliac Cohort Study. *Bernd S. Kamps*, D. Niese, H. H. Brackmann, P. Euler, B. Van Loo, T. Kamradt, *Medizinische Universitätsklinik, Bonn, Federal Republic of Germany.*

T.A.P.108 Real Value of Seronegativity in Long-term Exposed Sexual Partners of HIV-Infected Hemophiliacs. *María Belén Bouzas*, G. Picchio, I. Mathov, G. Muchinik, R. Pérez Bianco, A. Anselmo, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

T.A.P.109 Results of HIV Antibody Testing in Sexual Partners of Seropositive Hemophiliacs over a 5-Year Period. *Ann D. Forsberg*, J. L. Sullivan, D. L. Willitts, E. Kraus, D. B. Brettler, *Worcester Memorial Hospital, Hematology Clinic, Worcester, MA, U.S.A.*

T.A.P.110 Heterosexual Transmission of HIV Infection from Hemophiliacs to Their Spouses. *Detlef Niese*, T. G. A. Kamradt, B. S. Kamps, K. E. Schneweis, P. Euler, H. H. Brackmann, *Department of Internal Medicine, University of Bonn, Bonn, Federal Republic of Germany.*

T.A.P.111 Transmission hétérosexuelle de l'infection VIH chez les partenaires de toxicomanes VIH-séropositifs (VIH+). *Isabella Errante*, M. Orso, M. Meini, L. Caggese, D. Ferrazzi, I. Schlacht, *Hôpital Niguarda Ca' Granda, Milan, Italy.*

T.A.P.112 Risk Factors for HIV-1 Infection in STD Clinic Patients: Evidence for Crack-related Heterosexual Transmission. *Mary Ann Chiasson*, R. L. Stoneburner, E. Telzak, D. Hildebrandt, S. Schultz, H. Jaffe, *New York City Department of Health, New York, NY, U.S.A.*

T.A.P.113 Transmission of HIV Infection in Heterosexual Partners of HIV+ Drug Addicts. *Luigi Perroni*, L. Le Foche, G. De Stefano, P. De Longis, F. Albertoni, F. Soscia, *Ospedale S. Maria Goretti, Latina, Italy.*

T.A.P.114 Increasing Importance of Heterosexual Transmission of HIV Due to IVDU in Catalonia. *Jordi Casabona*, R. Salinas, J. Tor, T. Garcia, M. Campillo, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain.*

T.A.P.115 Transmission of HIV Infection in Heterosexual Partners of HIV Infected Drug Abusers. *Pietro Tullio Cataldo*, A. Chirianni, M. D'Abbraccio, S. Noce, L. Picciotto, M. Piazza, *University of Naples, Clinic of Infectious Diseases, Naples, Italy.*

T.A.P.116 Absence of HIV Transmission Through Casual Contacts in Former Drug Users. *Alessandro Zanetti*, A. Gringeri, G. Zehender, F. Tradati, A. Boschini, M. Colombo, *University of Milan, Institute of Virology, Milan, Italy.*

T.A.P.117 Anal Intercourse: A Risk Factor for HIV Infection in Female Partners of Bisexual Men, Rio de Janeiro, Brazil. *Fernando S. Sion*, C. A. Morais de Sá, M. C. Rachid de Lacerda, N. P. M. Rubini, E. P. Quinhoes, E. A. Castilho, *Gaffrée & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

T.A.P.118 HIV-1 in Patients with Genital Lesions Attending a North American STD Clinic: Assessment of Risk Factors. *W. L. Whittington*, B. Jacobs, J. Lewis, F. Lee, T. Edwards, A. J. Nahmias, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.A.P.119 Gential Herpes as a Possible Risk Factor for HIV Transmission. *André J. Nahmias*, L. Corey, F. Lee, N. Clumeck, R. Cannon, S. Holmberg, et al., *Emory University School of Medicine, Atlanta, GA, U.S.A.*

T.A.P.120 Epidemiology of HIV Infection in Hong Kong. *E. K. Yeoh*, P. C. K. Li, W. L. Lim, Y. Y. Chan, S. H. Lee, *Queen Elizabeth Hospital, Medical and Health Department, Hong Kong.*

Notes

Section
B

Mardi 6 juin
Tuesday, June 6

Aspects cliniques
Clinical Aspects of AIDS

Session d'affichage
Poster Session

Traitement de la PCP : Pentamidine et autres médicaments (diagnostic clinique)
PCP Treatment: Pentamidine and Other Drugs (Clinical Diagnosis)

T.B.P.1 Évaluation quantitative du parasitisme au cours de la pneumocystose (PNC.P) chez les patients atteints de SIDA ou d'autres immunodépressions. *Patricia Roux*, A. Parrot, C. Mayaud, M. Denis, F. Parquin, F. Lancastre, *Hôpital Tenon, Paris, France.*

T.B.P.2 Final Diagnosis in Patients with Negative Bronchoalveolar Lavage for Pneumocystis. *Jihad Slim*, G. Perez, C. Forrester, A. Shafii, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.S.A.*

T.B.P.3 A Pathologic Basis for Bronchoalveolar Lavage Neutrophilia in *Pneumocystis Carinii* Pneumonia. *Gregory R. Mason*, L. L. Foutty, P. S. Dickman, *Harbor-UCLA Medical Center, Torrance, CA, U.S.A.*

T.B.P.4 Intérêt et limites des expectorations induites dans le diagnostic de la pneumocystose du SIDA. *Patricia Roux*, T. Delacour, F. Camus, M. Fay, M. Denis, P. M. Girard, *Hôpital Tenon, Paris, France.*

T.B.P.5 Antibodies to *Pneumocystis Carinii*. Reduced Levels in HIV Infected Patients during Pneumocystis Infection and Evaluation of Passive Immunisation. *Sheila M. Burns*, J. A. Read, P. L. Yap, R. P. Brettle, *Regional Virus Laboratory, City Hospital, Edinburgh, U.K.*

T.B.P.6 Purification and Characterization of a Major Human *Pneumocystis Carinii* Surface Antigen. *Bettina Lundgren*, G. Lipschik, J. A. Kovacs, *National Institutes of Health, Critical Care Department, Clinical Center, Bethesda, MD, U.S.A.*

T.B.P.7 The Diagnosis of *Pneumocystis Carinii* Pneumonia in High Risk Patients by Induced Sputum Using a Direct Immunofluorescent Antibody Test. *Margo E. Heath-Chiozzi*, M. Mitchell, J. Rosol-Donoghue, D. Cotton, P. Holme, P. Hanff, *Beth Israel Hospital, Harvard Medical School, Boston, MA, U.S.A.*

T.B.P.8 Bronchoalveolar Lavage (BAL) CMV Culture Positivity (CMV+) Is Associated with Better Outcome of *Pneumocystis Carinii* Pneumonia in Men with AIDS. *Samuel A. Bozzette*, J. Arcia, A. Bartok, J. A. McCutchan, D. Richman, S. Spector, et al., *University of California at San Diego Medical Center, San Diego, CA, U.S.A.*

T.B.P.9 A Measure of *Pneumocystis Carinii* Pulmonary Burden. *Robert P. Baughman*, P. T. Frame, *University of Cincinnati Medical Center, Cincinnati, OH, U.S.A.*

T.B.P.10 Defective Peripheral Oxygen Utilization in AIDS Patients with Respiratory Failure Due to *Pneumocystis Carinii*. *Robert D. Wood*, B. Akil, J. Tuchschmidt, R. S. Swinney, C. T. Boylen, *LAC-USC Medical Center, Department of Pulmonary Medicine, Los Angeles, CA, U.S.A.*

T.B.P.11 Rapid Diagnosis of *Pneumocystis Carinii* Pneumonia (PCP) in Patients with AIDS Using a Direct Fluorescent Monoclonal Antibody (DFA) Assay. *Nzeera A. Virani*, V. L. Ng, R. E. Chaisson, W. K. Hadley, D. Yajko, P. C. Hopewell, et al., *Johns Hopkins Hospital, AIDS Service, Baltimore, MD, U.S.A.*

T.B.P.12 Frequent Inability to Confirm the Diagnosis of Presumptive *Pneumocystis Carinii* Pneumonia (PPCP). *Samuel A. Bozzette*, F. Sattler, J. Chiu, D. Gluckstein, J. Coffman, C. Newlett, et al., *University of California at San Diego, San Diego Medical Center, San Diego, CA, U.S.A.*

T.B.P.13 A New Method for the Diagnosis of *Pneumocystis Carinii* in Bronchoalveolar Lavage. *Annick Datry*, I. Hilmarsdottir, P. Deletoille, C. Katlama, M. Danis, M. Gentilini, *Département de santé publique, Parasitologie, Médicine tropicale, Hôpital Salpêtrière, Paris, France.*

T.B.P.14 *Pneumocystis Carinii*: Diagnosis in Non-Induced Sputum by Immunofluorescence. *Günter Weber*, B. Tschechne, U. Brunkhorst, R. Gerdelmann, I. Schedel, H. Deicher, et al., *Public Health Laboratories, Hannover, Federal Republic of Germany.*

T.B.P.15 Predictive Data for Positive Bronchoalveolar Lavage Results in Pneumocystis Pneumonia. *Jihad Slim*, A. DeLuca, G. Perez, C. Forrester, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.S.A.*

T.B.P.16 Unusual Pathologic Manifestations of *Pneumocystis Carinii* Pneumonia (PCP) in AIDS. *William D. Travis*, S. Pittaluga, G. Y. Lipschik, F. P. Ognibene, A. F. Suffredini, H. Masur, et al., *Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

T.B.P.17 How Predictive Are LDH-Elevations for the Severity of *Pneumocystis Carinii* Pneumonia in AIDS Patients? *Chistoph Elsing*, J. F. Erckenbrecht, H. Worth, G. Strohmeyer, *University of Düsseldorf, Düsseldorf, Federal Republic of Germany.*

T.B.P.18 Comparison of First Episode of PCP in Community Patients and Inmates. *Victoria L. Sharp*, A. Andrews, R. Heyman, R. Weiss, *Albany Medical Center, AIDS Treatment Center, Albany, NY, U.S.A.*

T.B.P.19 Pneumocystose et SIDA à Brazzaville, Congo. *Bernard Carme*, J. Mboussa, P. Mpelé, A. Datry, G. Mouanga-Yidika, A. Itoua-Ngaporo, et al., *Centre hospitalier et universitaire de Brazzaville, Brazzaville, Congo.*

T.B.P.20 Non-Obvious AIDS: *Pneumocystis Carinii* Pneumonia in the Elderly. *Henri Vinti*, A. Pesce, B. Taillan, P. Dujardin, J. P. Cassuto, *Service de médecine interne II, Hôpital de Cimiez, Nice, France.*

Traitement de la PCP : Pentamidine et autres médicaments (traitement clinique)
PCP Treatment: Pentamidine and Other Drugs (Clinical Treatment)

T.B.P.21 Primary and Secondary Prophylaxis against *Pneumocystis Carinii* Pneumonia with Fansidar. *Bernhard Ruf*, H.-D. Pohle, D. Schürmann, *2nd Department of Internal Medicine, Rudolf Virchow University Hospital, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

T.B.P.22 A Quantitative Scoring System for Evaluating the Response to Therapy of *Pneumocystis Carinii* Pneumonia (PCP). *Larry C. Nichols*, J. Black, F. Sattler, J. Feinberg, *Research Triangle Institute, Research Triangle Park, NC, U.S.A.*

T.B.P.23 Aerosolized Pentamidine (AP) in the Treatment of PCP Episodes: An Open Multinational Trial, Preliminary Results on 70 Patients. *Pierre-Marie Girard*, T. Lecompte, A. Lazzarin, *Hôpital Bichat-Claude Bernard, Paris, France.*

T.B.P.24 Survival Rate and Prognosis for AIDS Patients with Severe *Pneumocystis Carinii* Pneumonia (PCP) Requiring Mechanical Ventilation. *Thyge Lynghi Nielsen*, H. Guldager, C. Pedersen, L. Mathiesen, J. O. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

T.B.P.25 Reduced Dose of Aerosolized Pentamidine Treatment for *Pneumocystis Carinii* Pneumonia (PCP): 3-6 Month Follow-up. *John E. Conte*, D. Chernoff, H. Hollander, D. Feigal, J. Golden, *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.26 Penetration of Trimethoprim (TMP) Compared with That of Sulfamethoxazole (SMX) into Bronchoalveolar Lavage Fluid (BALF) during *Pneumocystis Carinii* Pneumonia (PCP). *Jean M. Decazes*, S. Durand, M. D. Kitzis, J. Mohler, A. Hirsch, *Saint-Louis Hospital, Paris, France.*

T.B.P.27 Traitement de la pneumocystose du SIDA par le DFMO. *Jean-Pierre Coulaud*, P. M. Girard, A. Garou, W. Rozenbaum, C. Perronne, M. Wolff, *Hôpital Bichat-Claude Bernard, Paris, France.*

T.B.P.28 Aerosol Therapy with Pentamidine Isethionate in Acute Moderate Cases of *Pneumocystis Carinii* Pneumonia (PCP). *Keikawus Arastéh*, C. Schneider, K. Nehm, U. Schaefer, W. Heise, M. L'Age, *Auguste-Viktoria-Krankenhaus, Berlin, Federal Republic of Germany.*

T.B.P.29 Eflornithine in the Treatment of *Pneumocystis Carinii* Pneumonia (PCP). *Glenn S. Hammer*, E. P. Neibart, F. Dembitzer, R. Dembitzer, H. S. Sacks, S. Z. Hirschman, *Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY, U.S.A.*

T.B.P.30 Clindamycin Plus Primaquine as Primary Therapy for *Pneumocystis Carinii* Pneumonia in AIDS Patients. *John R. Black*, J. Feinberg, R. J. Fass, J. F. Plouffe, R. Murphy, G. Leoung, et al., *Indiana University Medical Center, Indianapolis, IN, U.S.A.*

T.B.P.31 Correlation between ICU Survival and Required CPAP/PEEP in AIDS Patients with *Pneumocystis Carinii* Pneumonia. *Athanasios Skoutelis*, W. Peruzzi, D. Currie, R. Murphy, R. Cane, B. Shapiro, *Northwestern University Medical School, Chicago, IL, U.S.A.*

T.B.P.32 Treatment and Outcome of Pneumocystis Carinii Pneumonia in AIDS Patients. *Jens D. Lundgren*, C. Pedersen, T. Nielsen, *National Institutes of Health, Bethesda, MD, U.S.A.*

T.B.P.33 Prospective Randomized Study of TMP/SMX (T/S) Versus Pentamidine Aerosol (P) in *Pneumocystis Carinii* Pneumonia (PCP). *Pierre Dellamonica*, J. Durant, P. M. Roger, E. Bernard, V. Mondain, Y. Le Fichoux, *Archet Hospital, Infectious Diseases Department, Nice, France.*

T.B.P.34 The Bioavailability of Co-Trimoxazole in Patients with AIDS Receiving Treatment for *Pneumocystis Carinii* Pneumonia. *Carole J. Wells*, M. Kapembwa, L. O. White, C. J. Cairns, M. H. Wansbrough-Jones, *Clinical Pharmacy Practice Unit, St. George's Hospital, London, U.K.*

T.B.P.35 The Use of Steroids in the Therapy of Respiratory Failure Complicating *Pneumocystis* (PCP). *Mark H. Kaplan*, M. J. Schiff, B. F. F. Farber, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A.*

T.B.P.36 Diagnosis and Treatment of *Pneumocystis* Pneumonia: A Survey of Oregon and Vancouver, Washington Physicians. *James M. Sampson*, C. J. Spence, *Good Samaritan Hospital and Medical Center, Portland, OR, U.S.A.*

T.B.P.37 Prospective Randomized Treatment for *Pneumocystis Carinii* Pneumonia (PCP) in AIDS Patients. *Frederick P. Duncanson*, N. C. Klein, T. H. Lenox, O. Kawwaff, A. Pitta-Alvarez, G. P. Wormser, et al., *New York Medical College, Metropolitan Hospital, New York, NY, U.S.A.*

T.B.P.38 Pentamidine Use in a Tertiary Care Hospital: 1984-1988. *Lilly J. Miedzinski*, G. Taylor, S. Nazarali, *University of Alberta Hospitals, Edmonton, AB, Canada.*

T.B.P.39 Erythromycin in the Treatment of PCP in AIDS Patients. *Alois Dörlemann*, E. Reisinger, S. Schwander, A. Meyer, M. Dietrich, *Bernhard-Nocht Institute for Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany.*

T.B.P.40 Treatment of AIDS-related PCP by Pentamidine Inhalation. *Andreas Meyer*, M. Dietrich, *Bernhard-Nocht Institute for Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany.*

T.B.P.41 Traitement de la pneumocystose par le cotrimoxazole. *Bougary Traore*, D. Eckert, M. Rosenheim, M. Gentilini, *Département de santé publique et médecine tropicale, Hôpital Pitié-Salpêtrière, Paris, France.*

T.B.P.42 *Pneumocystis Carinii* Pneumonia in the Acquired Immune Deficiency Syndrome (AIDS). *David A. Haase*, W. Ghesquiere, B. L. Johnston, W. F. Schlech, T. J. Marrie, J. Whelan, *Victoria General Hospital, Halifax, NS, Canada.*

T.B.P.43 High Rates of Recurrence of *Pneumocystis* Pneumonia and Toxicity in AIDS Patients Taking Pyrimethamine-Sulfadoxine Prophylaxis. *Laurel A. Miller*, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A.*

T.B.P.44 Primary Versus Secondary PCP Prophylaxis. *Anne M. Mijch*, M. Slavin, J. Hoy, C. R. Lucas, *Fairfield Infectious Diseases Hospital, Fairfield, Australia.*

T.B.P.45 Secondary Prophylaxis of *Pneumocystis Carinii* Pneumonia with Systemic Pentamidine. *Dean L. Winslow*, A. Bincsik, P. Lincoln, H. Smolka, W. Holloway, *Medical Center of Delaware, Infectious Disease Research Laboratory, Wilmington, DE, U.S.A.*

T.B.P.46 Clinical and Pharmacokinetic Interactions of Combined Zidovudine (ZDV) Therapy and Sulfadoxine-Pyrimethamine (FANSIDAR) Prophylaxis in Post-PCP AIDS Patients (ACTG 021). *W. David Hardy*, R. S. Holzman, V. Avramis, R. Bawdon, H. Fall, J. Feinberg, *University of California at Los Angeles, AIDS Clinical Research Center, Los Angeles, CA, U.S.A.*

T.B.P.47 Utilisation du Fansidar pour la prophylaxie de la pneumocystose et de la toxoplasmose. *Jean-Michel Livrozet*, K. Mounilaila, J. P. Garin, M. Mojon, J. L. Garnier, J. L. Touraine, *Hôpital Édouard-Herriot, Lyon, France.*

T.B.P.48 Pyrimethamine-Sulfadiazine in the Prophylaxis of *Pneumocystis Carinii* Pneumonia in AIDS Patients with Cerebral Toxoplasmosis. *Gerald Pierone*, G. Turett, J. Masci, P. Nicholas, *Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.S.A.*

Prophylaxie par la pentamidine
Prophylaxis with Pentamidine

T.B.P.49 Prévention des rechutes de pneumocystose par les aérosols de pentamidine: Étude prospective randomisée chez les patients SIDA traités par AZT. *Pierre-Marie Girard*, R. Landman, C. Gaudebout, A. Leprêtre, C. Michon, A. G. Saimot, *INSERM U13, Hôpital Bichat-Claude Bernard, Paris, France.*

T.B.P.50 Compliance and Laboratory Data Predict Relapse Rate of *Pneumocystis Carinii* Pneumonia (PCP) During Prophylaxis with Aerosol Pentamidine. *Milos Opravil*, R. Weber, B. Ledergerber, W. Siegenthaler, R. Lüthy, R. Speich, *University Hospital, Department of Internal Medicine, Medical Polyclinic, Zurich, Switzerland.*

T.B.P.51 Successful Chemoprophylaxis of PCP by Postural Inhalation and Low Dose Aerosolized Pentamidine. *Craig W. Keyes*, P. Rodgers, C. Marte, J. Wolbert, J. Kelly, D. Ribble, *Bellevue Hospital Center, Community Health Project, New York, NY, U.S.A.*

T.B.P.52 Home Aerosolized Pentamidine Prophylaxis in an Inner City Population. *Jonathan E. Samuels*, M. Hilton, J. Hendrix, C. B. Small, *North Central Bronx Hospital, Bronx, NY, U.S.A.*

T.B.P.53 Long Term Safety and Effectiveness of Aerosol Pentamidine for Prevention of *Pneumocystis Carinii* Pneumonia. *Edward M. Bernard*, M. Dickmeyer, H. J. Schmitt, M. Seltzer, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

T.B.P.54 Aerosolized Pentamidine for the Secondary Prophylaxis of *Pneumocystis Carinii* Pneumonia in AIDS: A Progress Report from the Canadian Cooperative Trial. *Julio S.G. Montaner*, L. Lawson, J. Falutz, R. Hyland, A. Rachlis, A. Gervais, et al., *St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.*

T.B.P.55 Prophylactic Inhalation Pentamidine in Patients with HIV Disease. *Jerome A. Ernst*, L. DiPasquale, E. R. Sy, D. Rubinstein, *Bronx Lebanon Hospital Center, Bronx, NY, U.S.A.*

T.B.P.56 A Clinical Experience with Aerosolized Pentamidine (AP). *Stephen D. Nightingale*, R. S. Ferguson, S. M. Pounders, J. D. Jockusch, K. J. Robertson, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.*

T.B.P.57 Absolute Pulmonary Deposition of Nebulized Pentamidine Isethionate. *Simon H. L. Thomas*, M. O'Doherty, C. Page, T. Nunan, N. T. Bateman, *St. Thomas' Hospital, London, U.K.*

T.B.P.58 Aerosol Pentamidine for Treatment and Secondary Prophylaxis of PCP. *Leo Flamholc*, S. Haidl, E. Westin, T. Prellner, *Malmö General Hospital, Department of Infectious Diseases, University of Lund, Sweden.*

T.B.P.59 Prophylactic Treatment with Aerosol Pentamidine to Prevent Relapse of PCP. *Brigitte Nybo Jensen*, T. L. Nielsen, B. Lerche, V. Backer, L. Mathiesen, P. Skinhoj, *Department of Infectious Diseases, State University Hospital, Copenhagen, Denmark.*

T.B.P.60 Efficacy of Monthly Intramuscular Pentamidine in the Prophylaxis of Recurrent *Pneumocystis Carinii* Pneumonia. *Steven D. Miller*, D. Sifris, *Johannesburg Hospital, HIV Clinic, Johannesburg, South Africa.*

T.B.P.61 Pharmacokinetics of Aerosolized Pentamidine in AIDS Patients Being Treated for Acute *Pneumocystis Carinii* Pneumonia. *Yana J. Paulson*, R. J. Ko, R. T. Koda, C. T. Boylen, T. M. Gilman, *University of Southern California at Los Angeles, School of Pharmacy, Los Angeles, CA, U.S.A.*

T.B.P.62 Community Study of the Efficacy of Inhaled Pentamidine on the Prevention of *Pneumocystis Carinii* Pneumonia: Continuing Experience. *Joel D. Weisman*, T. M. Gilman, P. Rothman, A. Scarsella, L. Eppolito, E. Rogolsky, et al., *Sherman Oaks Community Hospital, Sherman Oaks, CA, U.S.A.*

T.B.P.63 Inhaled Pentamidine as Primary Prophylaxis in a High Risk Group: Continuing Experience. *Joel D. Weisman*, T. T. Gilman, E. Rogolsky, P. Rothman, A. Scarsella, L. Eppolito, et al., *Sherman Oaks Community Hospital, Sherman Oaks, CA, U.S.A.*

T.B.P.64 Comparison of Nebuliser Efficiency for Aerosolising Pentamidine. *Don Smith*, D. Erskine, J. Steele, D. Hills, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

T.B.P.65 Effect of Aerosol Characteristics on Pulmonary Deposition of Pentamidine. *Anita Simonds*, S. Newman, M. Johnson, N. Talaee, C. Lee, S. Clarke, *Royal Free Hospital, London, U.K.*

T.B.P.66 Low PCP Relapse Rate Using High Dose (300mgs) Nebulized Pentamidine Prophylaxis but Poor Long Term Survival. *Don E. Smith*, D. Herd, D. Hawkins, B. G. Gazzard, *St. Stephens Hospital, London, U.K.*

T.B.P.67 The Effect of Initial Pentamidine Solution Volume on Total Pulmonary Deposition. *Michael O'Doherty*, S. Thomas, C. Page, T. Nunan, N. Bateman, *St. Thomas' Hospital, London, U.K.*

T.B.P.68 Prophylaxis for *Pneumocystis Carinii* Pneumonia (PCP): A Cost-Effectiveness Analysis. *Kenneth A. Freedberg*, C. J. Cohen, D. J. Cotton, A. N. A. Tosteson, *Harvard Medical School, Beth Israel Hospital, Boston, MA, U.S.A.*

T.B.P.69 Aerosolized Pentamidine as Chronic Suppressive Therapy for *Pneumocystis Carinii* Pneumonia in a Heterogeneous AIDS Population. *Kassandra Rodriguez*, M. Fischl, P. Deziel, *University of Miami School of Medicine, Miami, FL, U.S.A.*

T.B.P.70 Aerosolized Pentamidine (AP) Prophylaxis for *Pneumocystis Carinii* Pneumonia (PCP) in a Boston Community Health Center. *Martha W. Moon*, S. Harris, R. Feldman, K. H. Mayer, *Fenway Community Health Center, Boston, MA, U.S.A.*

T.B.P.71 Prophylaxie secondaire de la pneumocystose pulmonaire par la pentamidine en aérosol. *Muriel Eliaszewicz*, F. Lacassin, J. Lebas, M.-C. Meyohas, M. Perrin, O. Picard, *Hôpital Saint-Antoine, Paris, France.*

T.B.P.72 Single and Multiple Dose Pharmacokinetics (PK) of Reduced Dose (3MG/KG) Intravenous Pentamidine. *John E. Conte, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.73 Nebulized Pentamidine in the Primary and Secondary Prophylaxis of PCP. *Schlomo Staszewski*, R. Müller, K.-H. Stimmel, S. Rehmet, E. B. Helm, W. Stille, et al., *Klinikum der J.W.-Goethe-Universität, Frankfurt, Federal Republic of Germany.*

T.B.P.74 Efficacité et sécurité de la prophylaxie avec pentamidine par aérosol dans des toxicomanes i.v. italiens atteints de SIDA en thérapie avec Zidovudine. *Sergio Gafà*, M. G. Giudici, F. Vezzani, A. Tuzza, G. F. Calonghi, *Divisione Malattie Infettive, Arcispedale S. Maria Nuova, Modena, Italy.*

T.B.P.75 Prophylaxis for *Pneumocystis Carinii* Pneumonia (PCP) with Aerosol Pentamidine (AP) or Oral Dapsone (OD) in Patients with AIDS or with Severe ARC. *Ramon A. Torres*, S. Palermo, G. Gregory, S. Carlo, M. Harismides, E. Chanin, et al., *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A.*

T.B.P.76 Pneumothorax in Patients Receiving Aerosol Pentamidine for *Pneumocystis Carinii* Pneumonia Prophylaxis. *Gifford S. Leoung*, L. Wardlaw, A. B. Montgomery, D. I. Abrams, D. W. Feigal, San Francisco County Community Consortium, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A.*

T.B.P.77 AZT-Aerosol Pentamidine vs. AZT Alone in Long Term AIDS Survivors: A Retrospective Case-Control Survival Analysis. *Stephen D. Nightingale*, S. M. Pounders, R. S. Ferguson, J. D. Jockusch, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.*

T.B.P.78 Double-Blinded Randomized Trial of Aerosol Pentamidine for Secondary Prophylaxis of *Pneumocystis Carinii* Pneumonia. *Gifford S. Leoung*, A. B. Montgomery, E. McGinty, D. W. Feigal, LyphoMed Consortium Investigation, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A.*

T.B.P.79 Is Upper Lung Deposition of Nebulized Pentamidine Improved by Inhalation Lying Down? *Michael J. O'Doherty*, S. Thomas, C. Page, C. Bradbeer, T. Nunan, N. Bateman, *St. Thomas' Hospital, London, U.K.*

Diagnositic : Analyse de flux cytométrique et RCP
Diagnosis: Flow Cytometric Analysis and PCR

T.B.P.80 Quantitation of HIV-1 PCR Products by Solution Hybridization with 125I-DNA Probes. *Matthew J. Bankowski*, M. Kuhns, A. McNamara, H. Kessler, A. Landay, L. Falk, et al., *Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, U.S.A.*

T.B.P.81 Detection of HIV-1 by Polymerase Chain Reaction in Relation to Results of Virus Culture. *Anders B. Sönnerborg*, B. Johansson, Ö. Strannegard, *Central Microbiological Laboratory, Department of Virology, Stockholm, Sweden.*

T.B.P.82 Failure of the Polymerase Chain Reaction (PCR) to Detect Viral HIV-1 DNA by Amplification of a gag Segment in Hemophiliacs with HIV Antibodies. *Elaine M. Eyster*, J. Goedert, R. Kumar, *Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, U.S.A.*

T.B.P.83 Multiparametric Flow Cytometric Analysis (Lymphocyte p24-FCA) Allows Rapid Quantitation of Active HIV-1 Infection in Peripheral Blood Cells. *Betsy M. Ohlsson-Wilhelm*, J. M. Cory, H. A. Kessler, M. E. Eyster, F. Rapp, A. Landay, et al., *The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A.*

T.B.P.84 Use of Flow Cytometric Analysis (Lymphocyte p24-FCA) to Evaluate Active Infection in Female Sexual Partners at High Risk for HIV-1 Infection. *Joan M. Cory*, B. M. Ohlsson-Wilhelm, F. Rapp, E. M. Eyster, *Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A.*

T.B.P.85 Monitoring the Accuracy of the Total Lymphocyte Count to Improve the Absolute CD-4 Count. *Robert E. Anderson*, D. Hirschkorn, S. Edmondson, *ViRx, Inc., San Francisco, CA, U.S.A.*

T.B.P.86 Where Lies the Truth? Methodological Influence on the Determination of CD4 and CD8 Lymphocyte Subpopulations. *Walter Fierz*, M. Vogt, R. Lüthy, P. Grob, *University Hospital, Section of Clinical Immunology, Zurich, Switzerland.*

T.B.P.87 Flow Cytometric Methods for HIV Serology and Antigen Quantitation Using Recombinant HIV Envelope (eNv-9) Protein. *Jon R. Gentsch*, D. Campbell, T. Papadopoulos, K. Janney, S. Rifat, S. D. Douglas, *E. I. Du Pont de Nemours & Company, Medical Products Department, Wilmington, DE, U.S.A.*

T.B.P.88 Identification and Quantitation of HIV Infected Cells in Peripheral Blood from AIDS Patients by Flow Cytometry. *James J. McSharry*, R. Echols, R. Stevens, J. Lehman, *Albany Medical Center, Albany, NY, U.S.A.*

T.B.P.89 Statistical Analysis of Flow Cytometric Data: A Non-Parametric Approach. *Yves Lacouture*, T. Cardno, C. Tsoukas, *Montreal General Hospital, Montreal, QC, Canada.*

Diagnostic : Détection des antigènes
Diagnosis: Antigen Detection

T.B.P.90 Antigénémie VIH au cours de la primoinfection. *Jacqueline M. L. Puel*, D. Schiavini, S. Averous, J. Bazex, *Centre hospitalier universitaire Toulouse-Purpan, Toulouse, France.*

T.B.P.91 Production and Characterization of Human Immunodeficiency Virus Antigenic Determinants and their Use in Diagnostics of AIDS. *Sergey G. Arsenian*, O. N. Voloshin, A. F. Shevalier, M. V. Michailov, I. A. Nikolaeva, V. M. Rostapshov, et al., *Shemyakin Institute of Bioorganic Chemistry, USSR Academy of Sciences, Moscow, U.S.S.R.*

T.B.P.92 Sensitivity of Five Commercial HIV-Antigen Detection Methods. *Concepcion Casado*, J. M. Varela, E. Vallhonrat, A. Garcia Saiz, R. Najera, *Instituto de Salud Carlos III, Madrid, Spain.*

T.B.P.93 Use of Triton-X in the HIV Antigen Assay to Assess the Presence of Infective HIV. *James L. Stewart*, S. Ketchum, R. W. Coombs, J.-P. Allain, *Abbott Laboratories, Abbott Park, IL, U.S.A.*

T.B.P.94 Evaluation of Two HIV Antigen Enzyme Immuno Assays on European and African Sera. *Gaby Vercauteren*, G. Van der Groen, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium.*

T.B.P.95 Lack of Correlation of p24 Antigenemia with Clinical Status or Peripheral Blood T4 Lymphocytes (PBT4) in Women with HIV Infection. *Charles C. J. Carpenter*, K. H. Mayer, L. McCrow, S. Danforth, *Brown University, The Miriam Hospital, Providence, RI, U.S.A.*

T.B.P.96 Correlation of HIV Core Antigen, Antibody and Immune Complex Levels in Sera of HIV-Infected Individuals. *Eszter Ujhelyi*, J. Lange, J. Goudsmit, V. Salavecz, G. Füst, S. R. Hollán, et al., *National Institute of Haematology and Blood Transfusion, Budapest, Hungary.*

T.B.P.97 Detection of HIV-1 p24 Antigen in Serum with a New Monoclonal EIA. *André Dascal*, P. René, B. Spira, J. Chan-Thim, J. Mendelson, M. Wainberg, et al., *McGill University, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada.*

T.B.P.98 Specificity of HIV-1 p24 Antigen Capture Assay as Viral Growth Determinant in Tissue Culture Fluids (TCF). *Homayoon Farzadegan*, K. Qatsha, P. Gupta, C. Grovit, C. Rinaldo, A. Saah, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

T.B.P.99 Specificity of HIV Antigen Capture Assays. *Jairo Ivo-Dos-Santos*, J. C. Couto-Fernandez, B. Galvao-Castro, *WHO Collaborating Centre on AIDS, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil.*

T.B.P.100 HIV-Antigens: Prevalence and Correlation with Clinical Evolution in an HIV-Infected Florentine Group. *Massimo Di Pietro*, P. Paci, F. Mazzotta, D. Milo, D. Bartolozzi, E. De Majo, et al., *Divisione Malattie Infettive, Ospedale Careggi, Florence, Italy.*

T.B.P.101 Comparison of Assays for Detection of HIV-I Antigen. *Amy R. Atkinson*, W. A. Meyer, L. Kahl, D. E. Senn, *Maryland Medical Laboratory, Baltimore, MD, U.S.A.*

T.B.P.102 Comparison of the Organon Teknika Corporation HIV Antigen Assay with Six Commercially Available HIV Antigen Test Kits. *Don E. Lockwood*, P. Youngbar, J. Hyman, T. Holody, B. Butman, S. Tondreau, *Organon Teknika Corporation, Durham, NC, U.S.A.*

T.B.P.103 Prognostic Significance of HIV-Antigenaemia in AIDS. *Lars L. S. Teglbjærg*, C. Pedersen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

Diagnostic : Infection par le VIH-2
Diagnosis: HIV-2 Infection

T.B.P.104 Evaluation of a Synthetic Peptide EIA for Detection of Antibodies to HIV-1 and HIV-2. *Rigmor Thorstensson*, F. Mhalu, P. A. Andreasson, T. Buck, S. Brust, G. Biberfeld, et al., *National Bacteriological Laboratory, Department of Immunology, Stockholm, Sweden.*

T.B.P.105 Aptitude d'un test rapide pour HIV et de tests d'agglutination à détecter des anticorps anti-HIV 2 au Sénégal. *Souleymane M'Boup*, J.-L. Sankalé, C. M. Kabeya, L. Diakhate, D. Thiam, S. Mitchell, *Bactériologie-Virologie, Université Cheikh Anta Diop, Dakar, Senegal.*

T.B.P.106 HIV-2 Infection in Canada. *Michael V. O'Shaughnessy*, P. Neumann, D. Lepine, I. D'Souza, C. Major, B. McLaughlin, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, QC, Canada.*

T.B.P.107 HTLV-I Antibody Prevalence in Patient Populations in Zaire: Analysis of Western Blot (WB) Patterns. *Christopher Brown*, N. Nzila, L. Atikala, F. Behets, R. Ryder, T. C. Quinn, et al., *Projet SIDA, Kinshasa, Zaire.*

T.B.P.108 HIV-1 and HTLV-I Prevalence in African and European Populations: A Comparison of 3 HTLV-I Antibody Assays. *Gaby Vercauteren*, R. Colebunders, R. Ryder, M. Laga, P. Piot, G. Van der Groen, *Institute of Tropical Medicine, Antwerp, Belgium.*

T.B.P.109 HIV-2 Infection in 2 European Hemophiliac Patients. *François Simon*, J. Puel, R. Hammek, V. Courgnaud, P. Kirpach, F. Brun-Vézinet, et al., *Hôpital Claude-Bernard, Laboratoire de virologie, Paris, France.*

T.B.P.110 Detection of HIV-1 in Cultured Peripheral Blood Lymphocytes from HIV-Seropositive Hemophiliacs. *Susan Knight*, E. E. Sheid, K. E. Laurie, K. L. Rosenthal, D. G. Harnish, *McMaster University, Department of Pathology, Hamilton, ON, Canada.*

T.B.P.111 The Effects of Phorbol Ester (TPA) and Iodo-Deoxyuridine (IUDR) on the Isolation and Detection of HIV from Seropositive Individuals. *Louis F. Qualtiere*, A. Zbitnew, J. Conly, *University of Saskatchewan, Department of Microbiology, Saskatoon, SK, Canada.*

T.B.P.112 T-Cells Versus Macrophage for Isolation of HIV from Blood. *Arnold K. Fowler*, R. R. Redfield, H. Gendelman, M. Meltzer, C. Oster, D. S. Burke, et al., *SRA Technologies Inc., Rockville, MD, U.S.A.*

T.B.P.113 Fréquence d'isolement du virus HIV dans le sang et les sécrétions vaginales de femmes séropositives. *T. D. Ly*, S. Hoffmeister-Barcellos, G. Henrion, J. P. Coulaud, F. Catalan, *Institut Alfred Fournier, Paris, France.*

T.B.P.114 Development of a Sensitive Microassay for the Measurement of Relative Number of Lymphocytes Infected with HIV. *Phalguni Gupta*, M. Ho, A. Enrico, M. Doerr, C. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

T.B.P.115 Réflexions sur l'isolement du VIH dans une unité de virologie hospitalière. *Hervé J. A. Fleury*, B. Delord, B. Masquelier, *Université de Bordeaux II, Bordeaux, France.*

T.B.P.116 Dual Serologic Reactivity for HIV-1 and HIV-2 in Abidjan. *Stephanie L. Lee*, A. Porter, K. De Cock, R. Colebunders, G. Damet, M. Rayfield, et al., *Centers for Disease Control, AIDS Program, International Activity, Atlanta, GA, U.S.A.*

T.B.P.117 Standardization of HIV Coculture Isolation Techniques in Multicenter Clinical Trials. *F. Blaine Hollinger*, J. W. Bremer, S. M. Rao, *Baylor College of Medicine, Houston, TX, U.S.A.*

T.B.P.118 Tissue Culture and p24 Methods of HIV Detection Compared and Correlated with Demographic Data in Symptomatic ARC Patients. *John Hamilton*, C. Compton, K. Weinhold, M. Simberkoff, P. Hartigan, *Veterans Administration Medical Center, Durham, NC, U.S.A.*

T.B.P.119 Sensitivity of U.S. FDA Licensed HIV-1 Enzyme Immunoassays for Detection of HIV-2 Antibodies. *James R. George*, M. Rayfield, G. Schochetman, W. Heyward, K. Odehouri, R. Soudrey, et al., *Centers for Disease Control, Atlanta, GA, U.S.A.*

Diagnostic : Contrôle de la qualité et techniques rapides
Diagnosis: Quality Control and Rapid Techniques

T.B.P.120 Évaluation d'un test de détection rapide des sujets séropositifs pour HIV-1 et HIV-2. *F. Catalan*, A. Milovanovic, T. D. Ly, *Institut Alfred Fournier, Paris, France.*

T.B.P.121 Proficiency in Performing HIV p24 Antigen EIAs and Comparability of Results in a Multicenter Quality Assurance Program. *James W. Bremer*, F. B. Hollinger, M. D. Haywood, L. E. Myers, *Baylor College of Medicine, Houston, TX, U.S.A.*

T.B.P.122 Is a Virology Quality Assurance (QA) Program Essential for Multicenter Clinical Trials? *F. Blaine Hollinger*, J. W. Bremer, *Baylor College of Medicine, Houston, TX, U.S.A.*

T.B.P.123 Western Blots: Indeterminate Results and Lot-to-Lot Variability in Adults at Low Risk for HIV-1 Infection. *Leslie Garrison*, K. Midthun, B. Fernie, H. Farzadegan, Clements, NIAID AIDS Vaccine Evaluation Group, *Johns Hopkins University, Baltimore, MD, U.S.A.*

T.B.P.124 Detection of Antibodies to HIV-1 by a Rapid, Peptide-Based Immunoassay. *Larry H. Gosting*, J. P. Montana, N. Monji, C. A. Cole, P. Coleman, *Genetic Systems Corporation, Seattle, WA, U.S.A.*

T.B.P.125 A Simplified 5-Minute Staining Procedure for HIV Western Blots Using Protein-A Colloidal Gold. *Peter K. Chun*, A. E. Chu, *E-Y Laboratories, Inc., San Mateo, CA. U.S.A.*

T.B.P.126 Utility of a Rapid Antibody Assay for Detection of HIV-1 Infection in Patients Attending an Emergency Department. *Richard L. Kline*, G. D. Kelen, T. A. Brothers, T. C. Quinn, *National Institutes of Health, Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

T.B.P.127 Evaluation of a Recombinant HIV-1 Enzyme Immunoassay (EIA) in Patients Attending an Emergency Room and a Sexually Transmitted Disease Clinic. *Richard L. Kline*, G. D. Kelen, E. W. Hook, T. A. Brothers, S. M. O'Sullivan, T. C. Quinn, *National Institutes of Health, Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

T.B.P.128 Detection of Anti-HIV Antibodies with Synthetic Peptides Using a 3-Minute Rapid Test. *Stéphane Bettinger*, J. Martin, A. Herranen, P. K. Tsai, C. Richardson, G. Sommé, *CLONATEC, Paris, France.*

T.B.P.129 Use of a Peptide-Based, Rapid Immunoassay for the Detection of Antibody to HIV-1. *Monica S. Krieger*, R. L. Stout, S. S. Fotopoulos, B. Kyle, M. Hosseini, C. Ferrera, *Genetic Systems Corp., Seattle, WA, U.S.A.*

T.B.P.130 Comparison of Serum and Paper-Absorbed Fingerstick Blood Samples for Diagnosis of HIV Infection in Intravenous Drug Users. *Rodney Hoff*, K. Steger, G. Deutsch, B. Weiblen, B. Comella, D. Craven, *Massachusetts Department of Public Health, Center for Disease Control, Jamaica Plain, MA, U.S.A.*

T.B.P.131 Anti-HIV Testing by Quick Tests and a Comparison with a Standard Enzyme Method. *Prakash C. Das*, A. H. De Vries, R. L. McShine, C. T. Smit Sibinga, *Red Cross Blood Bank Groningen-Drenthe, Groningen, Netherlands.*

T.B.P.132 A Simultaneous Unidot Quick Test for Detection of HIV-Antibody and HBs Ag for Blood Screening. *Augusta K. Takeda*, J. Hardy, A. J. Wilson, M. R. Schmal, F. T. Yamada, M. M. Provesana, *Akita Co., Emilio Ribas Hospital, Sao Paulo, Brazil.*

T.B.P.133 Field Evaluation for Immunobinding and Agglutination Tests for HIV. *Sheila W. Mitchell*, P. M. Tukei, S. M'Boup, J. Mingle, P. R. Lamptey, *Family Health International, AIDSTECH Division, Durham, NC, U.S.A.*

T.B.P.134 Use of Agglutination Assays as Supplemental Tests for Antibody to HIV. *Peter M. Tukei*, S. Mitchell, J. Nyamongo, *Virus Research Center, Nairobi, Kenya.*

T.B.P.135 Confirmation of HIV Infection with a Line Immune Assay (INNO-LIA) Using Whole Blood Impregnated Filter Paper Discs. *Luc Kestens*, D. E. Poller, P. L. Gigase, M. Vandenbruaene, D. Peeters, G. Van Der Groen, *Institute of Tropical Medicine, Department of Immunopathology, Antwerp, Belgium.*

T.B.P.136 A Rapid Colorimetric EIA for Detection of Antibody to HIV-1. *Robert K. Shockley*, T. Maitski, M. White, B. Davis, C. Abel, *Murex Corporation, Norcross, GA, U.S.A.*

T.B.P.137 Rapid, Manual Screening Test (HIV/CHEK (TM)) for Antibodies against HIV-1 and HIV-2. *William R. Pagels*, J. P. Galvin, J. Tirado, D. Reed, P. K. Chun, A. E. Chu, *E. I. du Pont de Nemours & Co., Inc., Wilmington, DE, U.S.A.*

T.B.P.138 Multiple Use of Single HIV/CHEK (TM) Device for Screening for HIV-1 Antibodies. *William R. Pagels*, J. P. Galvin, J. Tirado, C. M. Mitten, P. K. Chun, A. E. Chu, *E. I. du Pont de Nemours and Co, Inc., Wilmington, DE, U.S.A.*

T.B.P.139 A Particle-Agglutination Assay for Anti-HIV-1 in Developing Countries. *Ema Rickard*, G. Muchinik, M. Manca, R. Pérez Bianco, H. Pérez, P. Cahn, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

T.B.P.140 Evaluation of a New Rapid Screening Assay for HIV Antibodies. *Guillermo Muchinik*, E. Rickard, G. Picchio, M. Manca, P. Cahn, R. Pérez Bianco, et al., *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

T.B.P.141 Evaluation of Laboratory Performance of Enzyme Immunoassay Tests for HIV-1 Antibody. *Thomas L. Hearn*, W. Schalla, R. Taylor, H. Muir, C. Griffin, R. Wood, et al., *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.B.P.142 Results of CDC's Model Performance Evaluation Program for HIV-1 Antibody Testing. *Roger N. Taylor*, T. L. Hearn, C. W. Griffin, W. O. Schalla, H. Muir, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.B.P.143 Centers for Disease Control Model Performance Evaluation Program: Results of the Western Blot and Indirect Immunofluorescnece Tests for Detection of HIV-1 Antibodies. *William O. Schalla*, T. L. Hearn, R. N. Taylor, C. W. Griffin, H. W. Muir, R. O. Valdiserri, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.B.P.144 Quality Control in Anti-HIV Testing. The Experience of Zambia. *Evelyn C. Chimfwembe*, C. Stahli, M. Mukunyandela, *Tropical Diseases Research Centre, Ndola, Zambia.*

T.B.P.145 Problems Encountered in HIV Serology. *Carol J. Major*, B. McLaughlin, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada.*

T.B.P.146 Enhanced Cardiac Function in Pediatric HIV Infection. *Steven E. Lipshultz*, P. Sanders, D. Colan, K. McIntosh, *Department of Cardiology, The Children's Hospital, Boston, MA, U.S.A.*

T.B.P.147 Mortality in Children with AIDS: Age at Diagnosis as Risk Factor. *Silvia Iosub*, M. Bamji, R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.S.A.*

T.B.P.148 Isolation of Human Immunodeficiency Virus (HIV) from Cerebral Tissue and Characterization of Its Biological Properties. *F. Blaine Hollinger*, D. H. Dimitrov, F. Gyorkey, I. Hanson, J. L. Melnick, W. Shearer, *Baylor College of Medicine, Houston, TX, U.S.A.*

T.B.P.149 Cutaneous Manifestations of Pediatric Human Immunodeficiency Virus Infection. *Neil S. Prose, State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

T.B.P.150 Clinical Spectrum of Human Immunodeficiency Infection in Children Less than 4 Months of Age. *Ellen R. Cooper*, M. D. LeMay, T. Schwartz, S. I. Pelton, A. Fine, *Boston University School of Medicine, Boston City Hospital, Boston, MA, U.S.A.*

T.B.P.151 HIV Activation by Cofactors: p24 Antigenemia after Injections of Soluble Antigens in Children with AIDS. *Johanne Samson*, J. Charest, C. Pâquet, N. Lapointe, *Hôpital Ste-Justine, Université de Montréal, Montreal, QC, Canada.*

T.B.P.152 Natural History of Lymphoid Interstitial Pneumonia in Perinatal HIV-1 Infection. *Graciela Gray*, G. Scott, A. Castro, B. B. Bradford, M. T. Mastrucci, W. P. Parks, *University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.S.A.*

T.B.P.153 *Pneumocystis Carinii* Pneumonitis (PCP) in Children with Human Immunodeficiency Virus (HIV-1) Infection. *Gwendolyn B. Scott*, J. Reyes, M. Mastrucci, L. Smith, W. P. Parks, *University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.S.A.*

T.B.P.154 Adrenal Dysfunction in Perinatal HIV Infection. *Eileen Sacharski*, S. Iosub, M. Bamji, R. Stone, D. Pincus, R. Noto, *New York Medical College, Valhalla, NY, U.S.A.*

T.B.P.155 Broncho-Alveolar Lavage to Evaluate Pulmonary Status in the HIV Infected Child. *Liliane A. Boccon-Gibod*, A. Sardet, A. Grimfeld, J. Costil, C. Courpotin, *Hôpital Trousseau, Paris, France.*

T.B.P.156 Unusual Mortality from *Pneumocystis Carinii* Pneumonitis (PCP) During Early Infancy: Primary, Not Reactivation of Infection? *Jean Chow*, K. Shah, K. Li, A. Gupta, V. Chablani, A. Kaul, et al., *Lincoln Hospital, New York Medical College, Department of Pediatrics, Bronx, NY, U.S.A.*

T.B.P.157 Seroprevalence of HIV Infection in an Urban Pediatric Population. *Naomi L. C. Luban*, S. J. Josephs, P. Getson, H. Gayle, *Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC, U.S.A.*

T.B.P.158 HIV Infection and Pediatric AIDS in Semi-Rural Dabou Protestant Hospital (Ivory Coast). *Guy de Thé*, L. Schuerman, V. Seynhaeve, A. Ouattara, *CNRS Laboratory of Epidemiology and Immunovirology of Tumors, Alexis Carrel Faculty of Medicine, Lyon, France.*

T.B.P.159 Maternal Drug Abuse and Perinatal HIV Seropositivity. *Andrew Wiznia*, T. Checola, L. Hand, M. Kim, L. M. Noble, J. J. Yoon, *Bronx-Lebanon Hospital Center, Bronx, NY, U.S.A.*

T.B.P.160 Difficulties Encountered in Informing the Parents of Newborns of HIV Testing Results in an Urban Community. *Andrew Wiznia*, B. Caffrey, R. Checola, A. Thorpe, T. Daley, W. Caspe, *Bronx-Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Pédiatrie : Histoire clinique
Pediatrics: Natural History

T.B.P.161 Clinical and Immunologic Features Associated with Pediatric HIV Infection in Los Angeles County, California. *Toni Frederick*, L. Mascola, M. Evans, J. Church, Y. Bryson, A. Kovacs, et al., *County of Los Angeles, Department of Health Services, Los Angeles, CA, U.S.A.*

T.B.P.162 Newark Perinatal Cohort Natural History Progress Report. *Edward M. Conner*, M. Schneck, T. Denny, M. Oxtoby, C. Y. Ou, J. Oleske, et al., *Children's Hospital of New Jersey, Newark, NJ, U.S.A.*

T.B.P.163 Forty-four HIV-Exposed Newborns: Clinical, Virological, and Immunological Follow-up. *Carla Rosendahl*, U. Wintergerst, R. Lutz, B. H. Belohradsky, *Immunodeficiency Clinic, University Hospitals for Sick Children, Munich, Federal Republic of Germany.*

T.B.P.164 Evolution of a Series of 23 Children Who Are Seropositive to HIV. *Pablo Fontelos*, M. J. Cilleruelo, M. J. Mellado, J. Villota, M. García, G. Barreiro, *Instituto de Salud Carlos III, Servicio de Pediatria, Madrid, Spain.*

T.B.P.165 Natural History of Pediatric HIV Infection. *Carlo Giaquinto*, A. De Rossi, S. Girotto, S. Cozzani, R. D'Elia, L. Chieco Bianchi, et al., *Department of Pediatrics, University of Padua, Padua, Italy.*

T.B.P.166 Human Immunodeficiency Virus-1 (HIV-1) Infected Infants: Association of Laboratory Parameters and Clinical Outcome. *Gwendolyn B. Scott*, C. Hutto, S. Lai, M. T. Mastrucci, W. P. Parks, *University of Miami School of Medicine, Deparment of Pediatrics, Miami, FL, U.S.A.*

T.B.P.167 Seven Year Follow-up of HIV Infection in Neonatal Transfusion Recipients. *Thomas M. Mundy*, L. Lieb, J. Ward, F. Allen, M. Oxtoby, J. Faust, et al., *Cedars-Sinai Medical Center, Department of Pediatrics, Los Angeles, CA, U.S.A.*

T.B.P.168 Clinical Characteristics of Pediatric AIDS below and above One Year of Age. *Silvia Iosub*, M. Bamji, R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.S.A.*

T.B.P.169 Natural History of Pediatric AIDS, 1988. *Lawrence D. Frenkel*, S. Gaur, H. Kesarwala, R. Scudder, *University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, U.S.A.*

T.B.P.170 HIV Infection in Children: Prognostic Factors for the Progression of the Disease. *Anne-Marie S. Duliège*, S. Blanche, M. Tardieu, C. Rouzioux, A. Messiah, C. Griscelli, *Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.*

T.B.P.171

T.B.P.172 Longitudinal Evaluation of Immunologic and Viral Markers of HIV Infection in Children: Clinical Correlation. *Teresa Hernandez-Sampelayo*, L. Perez Alvarez, M. D. Gurbindo Gutierrez, L. Muñoz, J. Fermosel, C. Casado, et al., *Hospital General Gregorio Marañon, Madrid, Spain.*

T.B.P.173 Long Term Follow-up of Infants Born to Intravenous Drug Users of Known HIV Serostatus in the Bronx, N.Y.: Clinical and Lab Parameters. *Marguerite M. Mayers*, K. Davenny, E. E. Schoenbaum, A. Feingold, P. Selwyn, M. Rogers, et al., *Montefiore Medical Center, North Central Bronx Hospital, Bronx, NY, U.S.A.*

Pédiatrie : Développement neurologique
Pediatrics: Neuro-Development

T.B.P.174 Early CNS Signs in Infants with Perinatally-acquired HIV Infection. *Anita L. Belman*, Y. Park, G. Diamond, M. Notcze, C. Douglas, T. Cabot, et al., *State University of New York at Stony Brook, Stony Brook, NY, U.S.A.*

T.B.P.175 Behavioral Changes in Children with Human Immunodeficiency Virus (HIV) Infection. *Marta Lifschitz*, C. Hanson, G. Wilson, W. T. Shearer, *Baylor College of Medicine, Houston, TX. U.S.A.*

T.B.P.176 Neurologic Symptoms as the Initial Presentation of HIV Infection in Pediatric Patients. *Judy Vincent*, M. Bash, D. Shanks, D. Daigh, R. Moriarty, G. Fischer, *Walter Reed Army Medical Center, Department of Pediatrics, Washington, DC, U.S.A.*

T.B.P.177 AIDS-Related Peripheral Neuropathy in Children and Young Adult Hemophiliacs. *Thomas K. Koch*, A. Wesley, E. Lewis, D. Bredesen, M. Koerper, P. Weintraub, et al., *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.178 Psychic Development of Children Born to HIV-Infected Italian Mothers. *A. M. Laverda*, A. Condini, C. Cattelan, F. Viero, S. Casella, M. Zampiron, *University of Padua, Neuropsychiatric Service, Department of Pediatrics, Padua, Italy.*

T.B.P.179 Neuropsychological Profile of Children with Symptomatic HIV Infection Prior to Anti-Retroviral Treatment. *Pim Brouwers*, H. Moss, P. Wolters, J. Eddy, P. Pizzo, *National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A.*

T.B.P.180 Neurodevelopmental Assessment of Children with Symptomatic HIV Infection. *Joan Hittelman*, S. Fikrig, H. Mendez, F. Skovera, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

T.B.P.181 Developmental Abnormalities May Occur Before Other Clinical Manifestations of Perinatally-acquired HIV Infection: A Cohort Study of 119 Zairian Children Born to Seropositive Mothers. *Robert Ryder*, K. Breden, M. Binyingo, S. Elonga, U. Kabagabo, *Projet SIDA, Kinshasa, Zaire.*

T.B.P.182 Neurocognitive Functioning among Infants Exposed Perinatally to HIV. *Thomas P. Swales*, G. B. Scott, D. S. Cohen, R. G. Curless, A. D. Falk, W. P. Parks, *Division of Behavioural Sciences, Department of Pediatrics, University of Miami, Miami, FL, U.S.A.*

T.B.P.183 Neurodevelopment in Children with HIV Infection Acquired from Neonatal Blood Transfusion. *Sarale Cohen*, T. Mundy, B. Karassik, J. Ward, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.*

T.B.P.184 Divergence of Onset of Neurologic and Immunologic Impairment in Infants Born to HIV Seropositive Mothers. *Theresa A. Calvelli*, A. Belman, C. Bueti, M. Golodner, A. Rubinstein, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

T.B.P.185 Pattern of Neurological Abnormalities in Infants at Risk of Developing AIDS. *Joseph C. Marcus*, C. A. Butler, H. Mendez, J. J. Goedert, A. Willoughby, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

T.B.P.186 Neurological Manifestations in Perinatally HIV-Infected Children. A Prospective Study. *Anna Maria Laverda*, P. Cogo, A. Del Mistro, M. Pampazzo, E. Ruga, F. Zacchello, et al., *Department of Pediatrics, University of Padua, Padua, Italy.*

T.B.P.187 Expression neurologique grave et précoce chez un nouveau-né infecté par le virus VIH. *Joëlle Tricoire*, M.-R. Rolland, A. Robert, M. B. Delisle, J. Puel, A. Berrebi, *Hôpital Purpan, Toulouse, France.*

Pédiatrie : transmission verticale et infection par le VIH dans les pays en voie de développement
Pediatrics: Vertical Transmission and HIV Infection in Developing Countries

T.B.P.188 Incidence of Opportunistic Infections in 196 Children with Symptomatic AIDS in Kinshasa. *Farzin Davachi*, N. Mayemba, L. Kabongo, K. Ndoko, K. Ngoie, B. N'Galy, *Department of Pediatrics, Mama Yemo Hospital, Kinshasa, Zaire.*

T.B.P.189 Perinatal Transmission of HIV Infection in Uganda: 0 to 34 Months Follow-up. *Edison A. Mworozi*, C. M. Ndugwa, P. K. Kataaha, S. Kiguli, *Makerere University, Kampala, Uganda.*

T.B.P.190 Pediatric HIV Infection at Gaffrée & Guinle University Hospital. Epidemiologic, Clinical and Survival Characteristics. *Norma P. M. Rubini*, D. J. H. P. Signorini, M. H. P. Graça, F. S. Sion, C. A. Morais de Sá, M. D. C. Guimaraes, *Gaffrée & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

T.B.P.191 Kaposi's Sarcoma in 4 African Pediatric Cases. *Alain J. Georges*, J. C. Bouquety, M. R. Siopathis, C. Lanckriet, P. Ravisse, N. Lagarde, *Institut Pasteur, Bangui, Central African Republic.*

T.B.P.192 Standardized Assessment of Psychopathology in an HIV Sample. *Robert H. Remien*, J. B. W. Williams, J. G. Rabkin, R. L. Spitzer, J. Gorman, A. A. Ehrhardt, *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A.*

T.B.P.193 Clinical Behaviour of 13 Mexican Pediatric Patients Infected by the Human Immunodeficiency Virus. *Gustavo Perez Rguez*, H. L. Alvarez, R. M. C. Gorbea, G. F. Torres, L. V. M. Peredo, *Hospital de Infectología, Centro Médico La Raza, Mexico City, Mexico.*

T.B.P.194 Pediatric AIDS: Risk Factor Distribution at Hospital Emilio Ribas, Sao Paulo, Brazil. *Marinella Della Negra de Paula*, C. Rodriguez, M. Janini, G. Suleiman, W. Queiroz, C. Soraggi, et al., *Emilio Ribas Hospital, 3rd Inpatient Unit, Sao Paulo, Brazil.*

T.B.P.195 Valeur prédictive du statut clinique et biologique de mères HIV+ sur celui de leurs enfants. *Sophie Matheron*, H. Di Maria, C. Courpotin, F. Brun-Vézinet, D. Dormont, H. Balloul, *Hôpital Bichat-Claude Bernard, Paris, France.*

T.B.P.196 Cryptosporidium SP and Isospora Belli Infections in Pediatric Patients. *Marinella Della Negra de Paula*, W. Queiroz, M. Janini, C. Soraggi, V. Hughes, C. Rodriguez, et al., *Hospital Emilio Ribas, 3rd Inpatient Unit, Sao Paulo, Brazil.*

T.B.P.197 Diseases Indicative of AIDS in Children of African Origin Seen in Belgium: Evidence for Two Patterns. *Tijl Jonckheer*, J. Levy, J. Ninane, *Institute for Tropical Medicine, Antwerp, Belgium.*

T.B.P.198 Perinatal Transmission of HIV-1: Is a Decreased CD4 Cell Count Predictive? *Bonnie J. Dattel*, L. B. Hauer, C. B. Wofsy, W. Crombleholme, P. Weintrub, R. L. Sweet, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

T.B.P.199 Pulmonary Infectious Complications in Pediatric AIDS Patients. *Marinella Della Negra de Paula*, M. Janini, W. Queiroz, V. Hughes, C. Rodriguez, R. Lorenço, et al., *Hospital Emilio Ribas, 3rd Inpatient Unit, Sao Paulo, Brazil.*

T.B.P.200 Perinatal and Heterosexual Transmission through HIV-Positive Women. *Sybille Rehmet*, S. Staszewski, B. Wegerich, W. Kreuz, W. Stille, *Univeritätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

T.B.P.201 Immunological, Serological and Clinical Evaluation of HIV Positive Pregnant Women in Relation to Vertical Transmission of HIV. *Maria-Luisa Muggiasca*, M. Conti, N. Zanchetta, L. Salvaggio, R. Novati, E. Massironi, *VII Clinica Ostetrico-Ginecologica dell'Università di Milano, Milan, Italy.*

T.B.P.202 Clinical and Serologic Prospective Study in Infants Born from HIV Seropositive Mothers. *Claudia Fortuny*, C. Sanchez, J. M. Barrera, M. G. Ercilla, D. Navio, R. Jimenez, et al., *Department of Pediatrics, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain.*

T.B.P.203 Ophthalmic Manifestations of HIV Infection in an African Pediatric Population. *Philippe G. Kestelyn*, P. Lepage, A. M. Stevens, P. Van de Perre, *Department of Ophthalmology, Centre hospitalier de Kigali, Kigali, Rwanda.*

T.B.P.204 Anthropometric Measures in a Cohort of Children Born to HIV+ Women in Kinshasa, Zaire. *Susan E. Hassig*, T. Manzila, W. Nsa, M. Kashamuka, R. Ryder, *Projet SIDA, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A.*

T.B.P.205 High HIV-Associated Infant Mortality Correlates with Poor Post-Partum Maternal Health: 18 Months Follow-Up of 477 Children (CH) Born to HIV (+) Mothers (MO) in Zaire. *Nsanga Badi*, R. Ryder, M. Nsuami, B. Matela, W. Nsa, *Projet SIDA, Kinshasa, Zaire.*

Pédiatrie : Immunologie
Pediatrics: Immunology

T.B.P.206 Perinatal Immune Function in Offspring of HIV Seronegative Women at Risk for AIDS. *Kenneth C. Rich*, A. Landay, I. Chasnoff, *University of Illinois at Chicago, College of Medicine, Department of Pediatrics, Chicago, IL, U.S.A.*

T.B.P.207 ADCC in HIV-1 Infected Children. *Emmanuel B. Walter*, R. E. McKinney, C. Wilfert, D. S. Tyler, D. P. Bolognesi, K. J. Weinhold, *Duke University Medical Center, Durham, NC, U.S.A.*

T.B.P.208 Long Term Follow-up of Immunologic Parameters in HIV-Exposed Infants. *Uwe Wintergest*, C. Rosendahl, R. Lutz, E. Fahrenheim, B. H. Belohradsky, *Immundefekt-Ambulanz der Universitäts-Kinderkliniken, Munich, Federal Republic of Germany.*

T.B.P.209 HIV-Specific Immune Response in Congenital HIV Infection. *Katherine F. Luzuriaga*, R. A. Koup, D. Panicali, J. L. Sullivan, *University of Massachusetts Medical School, Worcester, MA, U.S.A.*

T.B.P.210 HIV Infection in Infants: Natural History and Outcome. *John P. Johnson*, P. Nair, M. Advani, K. O'Neil, S. Seiden, S. Hines, *University of Maryland School of Medicine, Baltimore, MD, U.S.A.*

T.B.P.211 Perinatal Transmission of HIV: Indicators of Infection. *Jacqueline Y. Q. Mok*, R. A. Hague, F. D. Hargreaves, J. Whitelaw, P. L. Yap, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K.*

T.B.P.212 Serum Interleukin-2 Receptor (SIL-2R) Levels in Neonates Born of HIV Infected Mothers: Preliminary Results. *Massimo Galli*, A. L. Ridolfo, M. Galli, F. d'Arminio Monforte, F. Cocchi, R. Novati, et al., *L. Sacco Hospital, Infectious Diseases Clinic, University of Milan, Milan, Italy.*

T.B.P.213 Serum Neutrophil Antibodies in Children with HIV Infection. *Joseph A. Church*, L. Beyer, T. Coates, *Children's Hospital of Los Angeles, Division of Allergy and Clinical Immunology, Los Angeles, CA, U.S.A.*

T.B.P.214 Immunological Abnormalities in HIV Infection by Vertical Transmission. *Teresa Español*, N. Curell, T. Figuera, J. Quer, X. Garcia, I. Caragol, *Immunology and Pediatric Infectious Disease Units, R. S. Valle Hebrón, Barcelona, Spain.*

T.B.P.215 Immunoglobulin E (IgE) in Children with Aquired Immunodeficiency Syndrome (AIDS). *M. D. Gurbindo Gutierrez*, P. Tornero, A. Del Moral, J. Fermosel, T. Hernandez Sampelayo, *Hospital General Gregorio Marañon, Madrid, Spain.*

Pédiatrie : Marqueurs
Pediatrics: Markers

T.B.P.216 Early Detection of HIV Infection in Childhood. *Inmaculada Castillo*, M. Ruiz-Moreno, F. Omeñaca, F. Varas, L. Zamora, V. Carreño, *Fundación Jiménez Díaz, Hepatology Unit, Madrid, Spain.*

T.B.P.217 Detection of Specific IgM Antibody by Radioimmunoprecipitation Assay for Early Diagnosis of HIV Infection in Infants. *Micheline Fauvel*, J. Lecomte, C. Claessens, J. Samson, N. Lapointe, *Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, QC, Canada.*

T.B.P.218 IgG Subclass Concentration and Antibody Levels to Bacterial Toxids in Children with Human Immune Deficiency Virus (HIV). *W. Kreuz*, S. Enenkel, S. Zielen, T. Güngör, S. Haas, B. Wegerich, et al., Klinikum der J. W. Goethe Universität, Frankfurt, Federal Republic of Germany.*

T.B.P.219 Western-Blot quantitatif: suivi des nouveaux-nés VIH séropositifs. *Jacqueline M. L. Puel*, D. Schiavini, A. Rousseau, C. Gayet-Mengelle, *Centre hospitalier Universitaire Toulouse-Purpan, Toulouse, France.*

T.B.P.220 Serologic Response to HIV Infection in Infants. *John P. Johnson*, E. Davis, R. Shinaberry, P. Nair, *University of Maryland School of Medicine, Baltimore, MD, U.S.A.*

T.B.P.221 The Use of Anti-HIV IgM Immunoblot in the Diagnosis of Neonatal HIV Infection: A Report of 5 Cases. *Wattana Panmoung*, S. Sirivichayakul, S. Chumdermpadetsuk, S. Likitnukul, P. Phanuphak, *Chulalongkorn University Hospital, Department of Microbiology, Bangkok, Thailand.*

T.B.P.222 Is the IgM Antibodies Status a Useful Marker to Assess the Neonates Contamination by HIV-1? *Jacqueline M. L. Puel*, C. Gayet-Mengelle, J. Tricoire, A. Rousseau, *Centre hospitalier universitaire Toulouse-Purpan, Toulouse, France.*

T.B.P.223 Enumeration of Peripheral Blood Antibody-Secreting Cells as a Diagnostic Aid for HIV Infection in Children. *André J. Nahmias*, F. Lee, S. Nesheim, C. O'Neill, J. Muther, B. Slade, *Emory University School of Medicine, Atlanta, GA, U.S.A.*

T.B.P.224 Recovery of HIV from Lymphocytes and Monocytes of Symptomatic HIV-Infected Children. *Alan L. Landay*, E. G. Chadwick, S. Kucik, R. Yogev, *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A.*

T.B.P.225 Neopterin: Potential Early Marker of Perinatal HIV Infection. *Harold W. Lischner*, O. Bagasra, S. A. Raphael, C. S. Treston, L. Shandilya, *Temple University School of Medicine, St. Christopher's Hospital for Children, Philadelphia, PA, U.S.A.*

T.B.P.226 High Prevalence of HIV-specific IgA and IgG-specific IgM Antibodies in Neonates of HIV-Positive Mothers. *Jörg Schupbach*, W. Wunderli, C. Kind, R. Kernen, A. Baumgartner, Z. Tomasik, *Swiss National Center of Retroviruses, University of Zurich, Zurich, Switzerland.*

T.B.P.227 Prospective Study of Polymerase Chain Reaction for Early Detection of HIV Infection in Infants Born to HIV Antibody Positive Women. *Morton J. Cowan*, P. Weintrub, P. Ulrich, J. Edwards, C. Rumsey, G. Vyas, et al., *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.228 The HIV p24 Antigen Assay as a Diagnostic/Prognostic Test in Pediatric HIV Infection. *Warren A. Andiman*, T. J. Silva, B. Olson, B. J. Simpson, *Yale University School of Medicine, Department of Pediatrics, New Haven, CT, U.S.A.*

T.B.P.229 Sequential in Parallel Study of HIV Infected Mothers and Their Children since the Neonatal Period Age. *Alvarez Lucia Perez*, M. D. Gurbindo Gutierrez, L. Muñoz, T. Hernandez-Sampelayo, A. Garcia Saiz, J. M. Varela, et al., *Instituto de Salud Carlos III, Unidad de SIDA, Madrid, Spain.*

T.B.P.230 Comparison of the Ortho HIV Recombinant Antigen Neutralization Assay and Dupont Western Blot for Confirmation of ELISA Reactive Sera from Children. *Andra R. Frost*, C. Mohla, N. Luban, J. Campos, *George Washington University Hospital, Department of Pathology, Washington, DC, U.S.A.*

T.B.P.231 A Novel HIV-1 EIA Detects IgG and IgM Antibodies in Adults and Neonates. *Sylvie Blanc*, M. Baccard-Longere, O. Genoulaz, M. Giroud, J. M. Seigneurin, *Wellcome Laboratoires, Paris, France.*

T.B.P.232 IgM May Be Directed to Conformational Epitopes Early in Seroconversion to HIV. *Robert A. Gregg*, G. Smith, R. Mayner, L. Pollock, J. S. Epstein, *Federal Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A.*

T.B.P.233 Hypergammaglobulinemia and Hypogammaglobulinemia as Manifestations of HIV Disease in Perinatally Infected Children. *Theresa A. Calvelli*, E. Steinhauer, R. Pathak, V. Davydov, L. Bernstein, A. Rubinstein, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

T.B.P.234 Association between Plasma Human Immunodeficiency Virus Type-1 (HIV) Viremia and Clinical Class of Pediatric HIV Infection. *Sandra K. Burchett*, R. Coombs, K. Chaloupka, J. Stamateou, C. Wilson, L. Corey, et al., *University of Washington, Children's Hospital and Medical Center, Seattle, WA, U.S.A.*

T.B.P.235 Detection of HIV Sequences in Children Born to Seropositive Mothers. *Vanni Borghi*, L. Selleri, G. Lami, G. Frigieri, B. De Rienzo, G. Torelli, *Department of Infectious Diseases, University of Modena, Modena, Italy.*

T.B.P.236 Lymphokine Production and Immunoglobulin Production In Vitro in Neonates and Infants with Human Immunodeficiency Virus (HIV) Infection. *Cecilia Prieto*, I. C. Hanson, T. N. Hansen, W. T. Shearer, *Baylor College of Medicine, Texas Children's Hospital, Houston, TX, U.S.A.*

T.B.P.237 Early Detection of HIV-1 Seroconversion in Infants of Seropositive Mothers Using Serial Dilutions in Western Blotting. *Sandra E. Barnes*, S. Alexander, M. Young, L. Olopoenia, M. Manak, W. Frederick, *Howard University Hospital, Washington, DC, U.S.A.*

T.B.P.238 Detection of Secretory Antibodies to HIV in Neonates. *David W. Archibald*, P. Nair, S. Hines, E. Davis, J. Johnson, *University of Maryland at Baltimore, Baltimore, MD, U.S.A.*

T.B.P.239 Anemia and Hypergammaglobulinemia in Infants with Perinatal HIV Infection. *Gregory M. Welsh*, N. Hutton, J. F. Modlin, *Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.*

T.B.P.240 ELISA (E) and Western Blot (WB) Patterns and a Possible Marker of Seroreversion (SR) in Infants Born to Seropositive (SP) Women. *Hermann Mendez*, S. Holman, R. Stevens, J. Wethers, H. Minkoff, S. Landesman, et al., *State University of New York, Department of Pediatrics, Brooklyn, NY, U.S.A.*

T.B.P.241 Sequential Western Blot Patterns in Confirmed HIV Seropositive Infants. *Naomi L. C. Luban*, V. C. Criss, S. Josephs, C. Mohla, J. M. Campos, *Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC, U.S.A.*

T.B.P.242 Evaluation of the Western-Blot IgM Technique Specificity. *Jacqueline M. L. Puel*, C. Gayet-Mengelle, A. Rousseau, *Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France.*

T.B.P.243 Monitoring of HIV Antibody Profiles by RIPA as a Means of Diagnosing Infection in Infants. *Micheline Fauvel*, J. Samson, G. Delage, M. Boucher, N. Lapointe, *Laboratoire de santé publique du Québec, Ste-Anne de Bellevue, QC, Canada.*

T.B.P.244 Early Diagnosis of HIV Infection in Children Born to Seropositive Mothers: Critical Evaluation of New Diagnostic Approaches. *Anita De Rossi*, A. Amadori, C. Giaquinto, A. Del Mistro, F. Mammano, F. Zacchelo, et al., *Institute of Oncology, University of Padua, Padua, Italy.*

T.B.P.245 Intérêt de la mise en culture systématique du VIH chez les enfants nés de mères infectées. *Hervé J. A. Fleury*, B. Delord, D. Douard, Y. Perel, M. Micheau, B. Contraires, *Université de Bordeaux, Bordeaux, France.*

Pédiatrie : Traitement du SIDA chez les enfants
Pediatrics: AIDS Treatment in Children

T.B.P.246 Infusion of Anti p24 Antibody Rich Plasma in Two Children with Persistent HIV Antigenaemia: A Pilot Study. *Rosemary A. Hague*, P. L. Yap, J. Y. Q. Mok, G. G. Jackson, F. D. Hargreaves, N. A. Coutts, *City Hospital, Infectious Diseases Unit, Edinburgh, U. K.*

T.B.P.247 Dideoxycytidine (ddC) Alone and in Combination with AZT for Children with Symptomatic HIV Infection. A Phase I Evaluation. *Philip A. Pizzo*, M. Einloth, K. Butler, J. Eddy, J. Meer, J. Falloon, *Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

T.B.P.248 The Effects of Encephalopathy and AZT Treatment on the Social and Emotional Behavior of Pediatric AIDS Patients. *Howard A. Moss*, P. Wolters, P. Brouwers, J. Eddy, L. Weiner, P. Pizzo, *Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

T.B.P.249 Elevated Hepatic Transaminases Are not Associated with Increased Zidovudine Toxicity in Children with Congenitally Acquired HIV-1 Infection. *Steven R. Martin*, M. D. LeMay, K. McIntosh, H. S. Winter, *Children's Hospital, Harvard Medical School, Boston, MA, U.S.A.*

T.B.P.250 Long-term Treatment of Symptomatic HIV Infection in Children with Zidovudine. *Mechthild Vocks-Hauck*, U. Wintergerst, S. Sauer, W. Kreuz, V. Wahn, C. Rosendahl, et al., *Free University Berlin, Kinderklinik, Berlin, Federal Republic of Germany.*

T.B.P.251 Chorioretinitis Responding to AZT Therapy in an Infant with AIDS. *Tijl Jonkheer*, C. Pierre, A. De Selijs, E. Moens, H. Taelman, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium.*

T.B.P.252 AZT Therapy in HIV-Infected Children. *Andrea De Maria*, A. Terragna, B. Ciravegna, A. Loy, F. Forni, A. Ferrazin, *University of Genoa, Ist Clinic of Infectious Diseases, G. Gaslini Institute, Genoa, Italy.*

T.B.P.253 Zidovudine Treatment in Adolescent Hemophiliac Children with HIV Infection. *Alan P. Knutsen*, J. D. Bouhasin, K. Gioia, K. B. Mueller, *St. Louis University Medical Center, St. Louis, MO, U.S.A.*

T.B.P.254 Disease Progression and Effect of Zidovudine (AZT) in Pediatric AIDS. *Anil Gupta*, M. Ravipati, H. Slade, C. Leombruno, M. Marecki, S. Pahwa, *North Shore University Hospital, Manhasset, NY, U.S.A.*

T.B.P.255 Our Experience in Treatment with Zidovudine in Children. *Maria José Mellado*, M. J. Cilleruelo, M. García, J. Villota, M. L. Pérez, P. Fontelos, *Instituto de Salud Carlos III, Servicio de Pediatria, Madrid, Spain.*

T.B.P.256 Selenium Deficiency and Cardiomyopathy in Malnourished Pediatric AIDS Patients. *Andrea J. Ruff*, A. Kavanaugh-McHugh, S. Rowe, Y. Benjamin, N. Hutton, J. Modlin, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.*

T.B.P.257 Clinical and Immunological Course of HIV Infection in Hemophiliac and Perinatally Infected Children Prophylactically Treated with Immunoglobulines Containing High Titers of Anti-CMV, Anti-EBV and Anti-HIV and Timing of Azidothymidine Indication. A Prospective Longitudinal Study of 61 Children. *Wolfhart Kreuz*, U. Ebener, B. Wegerich, T. Güngör, S. Haas, S. Enekel, et al., *Universitätsklinik Frankfurt, Zentrum der Kinderheitkunde, Frankfurt, Federal Republic of Germany.*

T.B.P.258 Experience with Central Venous Catheters in Pediatric AIDS. *Donna Futterman*, E. Connor, M. Boland, J. Oleske, *Children's Hospital AIDS Program, University of Medicine and Dentistry of New Jersey, Newark, NJ, U.S.A.*

T.B.P.259 Neoplastic Diseases in Children with AIDS. *Vijay V. Joshi*, E. M. Connor, F. DiCarlo, L. Epstein, J. M. Oleske, *East Carolina University School of Medicine, Greenville, NC, U.S.A.*

T.B.P.260 Safety and Efficacy of Central Venous Catheters in Pediatric AIDS Patients. *Deborah Gleason-Morgan*, J. Church, H. Bagnall, J. Atkinson, *Childrens Hospital of Los Angeles, AIDS Program, Los Angeles, CA, U.S.A.*

T.B.P.261 HIV Infection (HIV) in Patients (PTS) Treated for Leukemia or Solid Tumor, a Pediatric Oncology Group (POG) Study. *Sylvain S. Baruchel*, L. Clavel, S. Toledano, *McGill University, Montreal Children's Hospital, Montreal, QC, Canada.*

T.B.P.262 Very Late Onset of Group B Streptococcal Sepsis in Infants with HIV Infection. *David Di John*, J. P. Johnson, R. Lawrence, L. S. Schieken, M. B. Rennels, *New York University Medical Center, New York, NY, U.S.A.*

T.B.P.263 Diarrhea and Its Consequences in HIV-Infected Children. *Karen L. Kotloff*, J. P. Johnson, P. Nair, G. A. Losonsky, A. Young, J. G. Morris, *University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, U.S.A.*

T.B.P.264 Burkitt Lymphoma in an HIV-Infected Child. *Maurizio Arico*, D. Caselli, A. Deicas, G. Michelone, A. Maccabruni, P. Lanzarini, *Department of Pediatrics, University of Pavia, Pavia, Italy.*

T.B.P.265 Chronic Mucocutaneous Candidiasis in Pediatric AIDS. *Silvia Iosub*, M. Bamji, R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.S.A.*

T.B.P.266 Opportunistic Infections and Mortality in an Urban Pediatric Population Infected with Human Immunodeficiency Virus (HIV). *I. Celine Hanson*, H. M. Rosenblatt, W. T. Shearer, *Texas Children's Hospital, Baylor College of Medicine, Houston, TX, U.S.A.*

T.B.P.267 Spectrum of Infections Identified at Autopsy in Pediatric AIDS. *Lawrence A. Ross*, V. K. Wong, E. D. Gomperts, A. L. Ricalde, J. A. Church, *Childrens Hospital of Los Angeles, Division of Infectious Diseases, Los Angeles, CA, U.S.A.*

AZT SK/thrombocytopénie et autres traitements
AZT KS/Thrombocytopenia and Other Rx

T.B.P.268 Hematologic Effects and Outcome of Zidovudine (AZT) Therapy. *Walter F. Schlech*, G. Marrier, B. Johnston, *Dalhousie University and Victoria General Hospital, Halifax, NS, Canada.*

T.B.P.269 Thrombocytopenia in HIV Infection. *Giuseppe Sacchi*, F. Zorzi, M. Bonetti, M. Falchetti, R. Stellini, A. Scalzini, *Ospedali Civili, University of Brescia, Brescia, Italy.*

T.B.P.270 Platelet Production in HIV Infection: Evidence for a Compensated Thrombolytic State Enhanced by AZT. *Penny J. Ballem*, A. Belzberg, H. Chambers, B. Spruston, *Canadian Red Cross Society Blood Transfusion Service, Vancouver, BC, Canada.*

T.B.P.271 Effects of Long Term Zidovudine on Platelet Count. *Peter J. Flegg*, M. E. Jones, L. R. MacCallum, K. G. Williams, M. K. Cook, R. P. Brettle, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K.*

T.B.P.272 Response to Splenectomy for Severe HIV-related Thrombocytopenia in 10 Drug Abusers and Pathological Features of the Spleen. *Giuseppe Landonio*, F. De Cataldo, L. Gargantini, A. Nosari, M. Costantini, M. Gambacorta, *Niguarda Ca Granda Hospital, Milan, Italy.*

T.B.P.273 HIV-Related Immune Thrombocytopenia: Follow-up and Treatment of 132 Patients. *Eric Oksenhendler*, M. Seligmann, M. P. Archambault, J. F. Delfraissy, P. Bierling, J. Peynet, *Hôpital Saint-Louis, Paris, France.*

T.B.P.274 HIV-Associated Thrombocytopenia (HTP), Platelet-Associated Immunoglobulin (PAI) and Zidovudine. *V. Cárcaba*, J. A. Carton, P. Vicente, J. A. Maradona, F. San Roman, R. Llorente, et al., *Hospital Universitario de Oviedo, Oviedo, Spain.*

T.B.P.275 Therapy of HIV-Associated Thrombocytopenia. *Seng Gee Lim*, C. A. Lee, P. B. A. Kernoff, *Haemophilia Control and Haemostasis Unit, Academic Department of Haematology, Royal Free Hospital, London, U.K.*

T.B.P.276 Lack of Efficiency of On-Line Column-A-Adsorption in Treatment of HIV-Associated ITP. *Michael J. Scolaro*, P. Kennedy, *Los Angeles Oncologic Institute, St. Vincent Medical Center, University of Southern California School of Medicine, Los Angeles, CA, U.S.A.*

T.B.P.277 Efficacité de la zidovudine à faible dose dans le traitement des thrombopénies liées au virus HIV. *J.-P. Routy*, C. Garabedian, A. P. Blanc, C. Maurice, M. David, Y. Jolio, *Hôpital Cézanne, Aix en Provence, France.*

T.B.P.278 Combined Steroid-Zidovudine Treatment of Severe Thrombocytopenia Associated with HIV Infection. *J. Arrizabalaga*, J. A. Iribarren, J. M. Santamaría, Z. Zubero, C. Garde, D. Zulaica, *Hospital Nuestra Señora de Aránzazu, Hospital Civil de Basurto, San Sebastian, Spain.*

Thérapie et évaluation clinique : Sarcome de Kaposi et autres
Therapy and Clinical Evaluation: Kaposi's Sarcoma and Others

T.B.P.279 Phase II Study of Alpha-2A Interferon (INF) Associated with AZT Patients (PTS) with AIDS-related Kaposi's Sarcoma. *Gustavo Gonzalez-Canali*, E. Navarro-Carola, A. De Gramont, B. Demuynck, C. Louvet, M. Krulik, *Hôpital Saint-Antoine, Paris, France.*

T.B.P.280 Treatment of Lymphomas (NHL) Associated with Human Immunodeficiency Virus (HIV). *Christian Gisselbrecht*, E. Oksenhendler, J. P. Farcet, H. Dombret, B. Coiffier, N. Raphael, *Institut d'hématologie, Hôpital Saint-Louis, Paris, France.*

T.B.P.281 Correlation of Effects of Interferon-Alpha in AIDS-Associated Kaposi's Sarcoma with Serum Levels and Dose. *Leigh A. Sawyer*, E. Boone, K. Zoon, J. Metcalf, C. Lane, G. Quinnan, et al., *Laboratory of Retrovirology Research, DV, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, U.S.A.*

T.B.P.282 Efficacy of High Dose (50 MU/M2) Intravenous Recombinant Interferon Alfa-2-b (HD/IV/rIFN2b) in AIDS Related Kaposi's Sarcoma. *Gilles Beaucaire*, C. Chidiac, J. P. Brion, J. Y. Lacut, P. Massip, Study Group, et al., *Service régional des maladies infectieuses, Centre hospitalier de Tourcoing, Tourcoing, France.*

T.B.P.283 HIV-Antigenemia in Patients with AIDS-related Kaposi's Sarcoma (KS) Treated with Recombinant Alpha-2a Interferon (IFN). *Willy Rozenbaum*, S. Gharakhanian, C. Rouzioux, R. De Sahb, M. Bugard, B. Cardon, *Hôpital Rothschild, Unité de maladies infectieuses, Paris, France.*

T.B.P.284 Chemotherapy with or without Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF) in Patients with AIDS-Associated Non-Hodgkin's Lymphoma. *Lawrence D. Kaplan*, J. O. Kahn, H. Grossberg, P. A. Volberding, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.285 Adoptive Transfer of Immunity to Recall Antigens Following Allogeneic Bone Marrow Transplantation (BMT) in an AIDS Patient with Non-Hodgkin's Lymphoma (NHL). *Albert D. Donnenberg*, H. K. Holland, W. H. Burns, G. H. Santos, R. Saral, *The Johns Hopkins University Oncology Center, Baltimore, MD, U.S.A.*

T.B.P.286 Carbon Monoxide Diffusing Capacity (DLco) as a Predictor of Lung Function in Patients Receiving Bleomycin for Treatment of Kaposi's Sarcoma. *Bisher Akil*, A. Ireland-Gill, B. E. Espinar, P. Gill, *University of Southern California, West Hollywood, CA, U.S.A.*

T.B.P.287 Regresssion of Kaposi's Sarcoma (KS) Following Prosorba Column Treatments. *David E. Reed*, H. W. Synder, J. P. Balint, F. R. Jones, *IMRE Corp., Seattle, WA, U.S.A.*

T.B.P.288 Adverse Reactions with High Dose (50 MU/M2) Intravenous Recombinant Interferon Alfa-2b (HD.IV.rIFN2b) in AIDS-Related Kaposi's Sarcoma. *Gilles Beaucaire*, Y. Mouton, F. Biron, G. Lepeu, J. Reynes, Study Group, *Service régional des maladies infectieuses, Centre hospitalier Tourcoing, Tourcoing, France.*

T.B.P.289 High Doses of Interferon Alfa-2b in Kaposi's Sarcoma. *Inmaculada Ocaña*, A. De Luis, I. Ruiz, E. Bejarano, L. De Buen, J. M. Martínez-Vázquez, *Autonomous University of Barcelona, Barcelona, Spain.*

T.B.P.290 Intralesional Vinblastine (VELBAN) Treatment of Lesions of Kaposi's Sarcoma. *Marcus A. Conant*, G. Galzagorry, M. L. Illeman, *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.291 Remission of Kaposi-Sarcoma by a Combined Therapy with Interferon-Beta + AZT in an AIDS Patient. *Heribert Knechten*, F. Braeck, *Hematology-Oncology Institute, Aachen, Federal Republic of Germany.*

T.B.P.292 Interferon Administered Intralesionally in Skin, Conjunctiva and Oral Cavity Lesions in Patients with AIDS-Related Kaposi's Sarcoma. *Efisio Sulis*, C. Floris, M. L. Sulis, A. Tedde, R. Turno, L. Contu, *Divisione Medicina, I Ospedale Oncologico A. Businco, Universidad Autonoma de Madrid, Cagliari, Italy.*

T.B.P.293 Assessment of the Management of Kaposi's Sarcoma (KS) in AIDS Patients. *Iluminada García-Polo*, I. Santos Gil, C. Del Arco Galan, J. Fraga, J. Fernández, A. Noguerado Asensio, *Medicina Interna-Infecciosas, Hospital de la Princesa, Universidad Autonoma de Madrid, Madrid, Spain.*

Thérapie et évaluation clinique : Ribavarine et autres médicaments
Therapy and Clinical Evaluation: Ribavirin and Other Drugs

T.B.P.294 Comparison of Ribavirin versus Placebo for Preventing the Progression of HIV Infected Subjects from CDC Stage III to Stage IV. *J. M. Gatell*, E. Bouza, X. Carne, R. Cisterna, B. Clotet, J. Cosin, et al., *Spanish Ribavirin Study Group, Barcelona, Spain.*

T.B.P.295 Dextran Sulfate Is Poorly Absorbed after Oral Administration. *Kevin J. Lorentsen*, C. W. Hendrix, J. M. Collins, R. H. Eckel, B. G. Petty, P. S. Lietman, et al., *Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.*

T.B.P.296 Ribavirin Dose Escalating Phase I Trial in Patients with AIDS and ARC. *Clyde S. Crumpacker*, D. Cotton, G. Pearlstein, F. Valentine, J. Mills, S. Spector, *Beth Israel Hospital, Harvard University School of Medicine, Boston, MA, U.S.A.*

T.B.P.297 Phase I Study of 2', 3' Dideoxyinosine (ddI) Given Once Daily to Patients with AIDS or ARC. *Timothy P. Cooley*, C. A. Saunders, C. J. Perkins, R. P. McCaffrey, C. McLaren, H. A. Liebman, *Boston University School of Medicine, Boston, MA, U.S.A.*

T.B.P.298 Evaluation of Megestrol Acetate Treatment in AIDS. *Julian Gold*, C. Oliver, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

T.B.P.299 Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Lack of Neurological Toxicity. *Bruce J. Brew*, J. G. Keilp, A. E. Sadler, S. E. Krown, J. Sidtis, R. W. Price, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

T.B.P.300 Operational Therapy for People with AIDS. *Jonathan Jacobs*, V. Lebowitz, *Center for Special Studies, New York, NY, U.S.A.*

T.B.P.301 Supervised Physical Exercise Leads to Psychological and Immunological Improvement in Pre-AIDS Patients. *Celia A. Schlenzig*, H. Jäger, H. Rieder, G. Hammel, M. Popesco, *AIDS Study Group, Schwabinger Krankenhaus, Munich, Federal Republic of Germany.*

T.B.P.302 Long Term Ribavirin Treatment. *Dénes Bánhegyi*, J. Lendvay, E. Ujhelyi, I. Mihály, G. Y. Füst, F. Várnai, *Institute for Infectious and Tropical Diseases, Postgraduate Medical School, Budapest, Hungary.*

T.B.P.303 A Phase I Study of the Safety and Pharmacokinetics of the Soluble Recombinant CD4 (rCD4) in Patients with AIDS or ARC. *J. Davis Allan*, J. Kahn, T. Hodges, S. Sherwin, P. Volberding, J. Groopman, *New England Deaconess Hospital, Boston, MA, U.S.A.*

T.B.P.304 Essai randomisé contre placebo de fortes doses d'acyclovir (ACV) chez les patients HIV+. *Pascal Chavanet*, S. Aho, J. Mallet, A. Waldner, M. Buisson, P. Bielefeld, et al., *Service des maladies infectieuses et tropicales, Hôpital du Bocage, Dijon, France.*

Thérapie et évaluation clinique : Toxicité des médicaments
Therapy and Clinical Evaluation : Toxicity of Drugs in AIDS

T.B.P.305 Crise d'épilepsie generalisée après l'absorption de zidovudine à dose toxique (à propos d'une observation). *J.-P. Routy*, E. Prajs, A. P. Blanc, S. Drony, M. Moriceau, C. Sarrazin, *Hôpital Cézanne, Aix en Provence, France.*

T.B.P.306 Effective Doses of AZT in HIV-ITP Is Associated with Erythroid Hypoplasia. *Lothar Huebsch*, G. Garber, D. W. Cameron, M. T. Aye, *Ottawa General Hospital, Ottawa, ON, Canada.*

T.B.P.307 Vitamin B12 Supplements in Patients Treated with Zidovudine. *Maria-Soledad Navarette*, S. Gharakhanian, B. Cardon, W. Rozenbaum, *Hôpital Rothschild, Unité de maladies infectieuses, Paris, France.*

T.B.P.308 Toxicity of Zidovudine (AZT) in Patients with AIDS. *Bonaventura Clotet*, J. M. Gimeno, A. Jou, G. Sirera, J. Tor, M. Dominguez, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain.*

T.B.P.309 Corticothérapie prolongée d'une dermatopolymyosite à VIH. *René Roué*, T. Debord, D. Dormont, R. Vazeux, B. Tisne, *Hôpital militaire Bégin, Saint-Mandé, France.*

T.B.P.310 Successful Re-introduction of Zidovudine (AZT) after an Allergic Cutaneous Reaction to AZT. *Anne Mathieu-Boué*, P. Malfon, P. Lebras, R. Caquet, *Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.*

T.B.P.311 Role of p24 AG Testing in Patients on Zidovudine. *Jennifer F. Hoy*, J. Chua, A. M. Mijch, M. Dimitrikakis, I. D. Gust, C. R. Lucas, *Fairfield Infectious Diseases Hospital, Fairfield, Australia.*

T.B.P.312 Change in Beta-2 Microglobulin (B2M) during Zidovudine (ZDV) Therapy (Rx) Predicts Clinical Outcome. *Mark A. Jacobson*, D. Abrams, P. Bacchetti, K. Kocurek, J. Wilber, A. R. Moss, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.B.P.313 Use of Multiparametric Flow Cytometry (Lymphocyte p24-FCA) to Evaluate Azidothymidine Therapy. *Betsy M. Ohlsson-Wilhelm*, J. M. Cory, H. A. Kessler, M. E. Eyster, F. Rapp, A. Landay, et al., *The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A.*

T.B.P.314 The Inhibitory Effects of AZT on HIV Replication as Determined by p24 Antigen Capture Assays. *Michael V. O'Shaughnessy*, D. Lepine, J. Wainberg, J. Ruedy, C. Tsoukas, M. Fanning, et al., *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

T.B.P.315 The Effect of Treatment with Zidovudine on Immune System Defects Early in the Course of HIV Infection. *William M. Reiter*, P. J. Cimoch, *Center for Special Immunology, Inc., Fort Lauderdale, FL, U.S.A.*

T.B.P.316 Cutaneous Reactions to Trimethoprim-Sulfamethoxazole (TMP-SMZ) in the Treatment of *Pneumocystis Carinii* Pneumonia (PCP). *Helmut Schöfer*, F. R. Ochsendorf, H. Bauer, R. Milbradt, W. Stille, *Klinikum der J. W. Goethe-Universität, Department of Dermatology, Frankfurt, Federal Republic of Germany.*

T.B.P.317 Preliminary Observations about the Adverse Effects of Pefloxacin in the Treatment of Salmonella Bacteremia in. *Guido Carlos Levi*, E. A. S. Meideros, J. S. De Mendonça, M. C. S. De Carvalho, H. A. V. Stefani, H. Pinczowski, *Hospital do Servidor Público Estadual, Sao Paulo, Brazil.*

T.B.P.318 Severe, Acute Trimethroprim- Sulfamethoxazole (T-S) Reaction Mimics Sepsis in AIDS Patients. *Michael P. Johnson*, S. D. Goodwin, Jr., J. W. Shands, *University of Florida School of Medicine, Gainesville, FL, U.S.A.*

T.B.P.319 Hypoglycémie et diabète dûs au mesylate de pentamidine au cours du SIDA. *Christian M. Perronne*, F. Bricaire, C. Leport, J. L. Vildé, D. Assan, R. Assan, *Service des maladies infectieuses, Hôpital Claude-Bernard, Paris, France.*

T.B.P.320 Oral Desensitization to Sulfadiazine and Trimethoprim-Sulfamethoxazole (TMP-SMZ) in 4 Patients with Acquired Immunodeficiency Syndrome. *Jose N. Moreno*, C. M. Maggio, *University of Miami School of Medicine, Miami, FL, U.S.A.*

T.B.P.321 A Method for Rapid Oral Desensitization of Patients Allergic to AZT. *Douglas K. MacFadden, Department of Medicine, University of Toronto, Toronto, ON, Canada.*

T.B.P.322 Recombinant Interferon ßser Protects against Zidovudine-Induced Genetic Damage in AIDS Patients. *Hasnaa M. Shafik*, M. A. Nokta, R. B. Pollard, *University of Ain Shams, Faculty of Medicine, Department of Community Medicine, Cairo, Egypt.*

T.B.P.323 Megaloblastic Changes in the Bone Marrow of AZT Treated AIDS Patients as a Prognostic Marker for Need of Blood Transfusion. *H. W. Reesink*, L. Buys, M. Van den Berg-Wolf, R. Pietersz, J. Ten Veen, *Red Cross Blood Bank, Amsterdam, Netherlands.*

T.B.P.324 The Effects of PCP Prophylactic Agents on Zidovudine-Induced Anemias. *Craig W. Keyes*, P. Rodgers, C. Marte, J. Kelly, J. Wolbert, D. Ribble, *Community Health Project, New York, NY, U.S.A.*

T.B.P.325 Home Transfusion for AIDS Patients on Zidovudine. *Mary Busalacchi*, K. Ivantic, I. Gilson, *Visiting Nurse Association, West Allis, WI, U.S.A.*

T.B.P.326 The Toxicity of Zidovudine in the Treatment of Patients with AIDS-related Complex (ARC) and AIDS. *Drago Stambuk*, N. Mir, D. Hawkins, C. Costello, B. Gazzard, *St. Stephen's Hospital, London, U.K.*

T.B.P.327 Polymyositis during Zidovudine Therapy. *Thomas Sharpton, Kaiser Foundation Hospital, Oakland, CA, U.S.A.*

T.B.P.328 Eosinophilia in HIV Infected Patients under Zidovudine Therapy. *Pierre M. J. T. Dejace*, J. E. Morgan, C. E. O'Neil, G. Valainis, N. E. Hyslop, *Tulane University Medical School, New Orleans, LA, U.S.A.*

T.B.P.329 AZT: Double-Edged Sword. *Ilona L. Pivar*, L. Temoshok, *University of California Medical Center, Berkeley, CA, U.S.A.*

T.B.P.330 Psoriasis in HIV AB Positive Drug Abusers. *Marco Masina*, A. Patrizi, A. M. Costa, E. Ricchi, P. Costigliola, F. Chiodo, *Instituto Clinica Dermatologica, Policlinico S. Orsola, Bologna, Italy.*

T.B.P.331 Phase I Study of Interferon Alpha-2b (Intron), Zidovudine and rGM-CSF in Patients with AIDS-Associated Kaposi's Sarcoma. *Margaret A. Fischl*, R. Uttamchandani, L. Thompson, S. Santiago, S. Gagnon, *University of Miami School of Medicine, Miami, FL, U.S.A.*

T.B.P.332 A New, More Sensitive and Highly Specific Anti HIV-1 Assay Based on Recombinant Proteins. *Urzsula Beckford*, C. Berrisford, R. J. S. Duncan, L. Mackinlay, P. Weston, R. S. Tedder, *Wellcome Diagnostics, Beckenham, U.K.*

Diagnostic Diagnosis

T.B.P.333 Update on Program Standardization among Public Health Laboratories in the U.S.A. Performing Tests for Human Retroviruses. *William J. Hausler*, A. F. DiSalvo, J. M. Joseph, J. P. Getchell, *State Hygienic Laboratory, University of Iowa, Iowa City, IA, U.S.A.*

T.B.P.334 T4A-"Internal Image"-Bearing Antibodies in Sera of Patients with HIV-1 Infection. *Ingolf Schedel*, P. Winkelmann, U. Dreikhausen, J. Flik, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany.*

T.B.P.335 Evaluation of Different Anti-HIV Reagents that Are Available in Mexico. *José-Luis Domínguez*, C. Morales, M. Romero, M. Moreno, M. Orozco, *Centro Nacional de la Transfusión Sanguínea, Mexico City, Mexico.*

T.B.P.336 Which Is the Best Laboratory Marker when Following HIV-Positive Persons? *Myriam Reis*, E. Sprinz, M. Kronfeld, M. Azevedo, C. Seadi, R. Oravec, et al., *Laboratorio Weinmann, Porto Alegre, Brazil.*

T.B.P.337 Comparison of Commercially Available Test for HIV Antibodies Using Zambian Sera. *Nkandu P. Luo*, S. Hira, J. Siyambango, R. Nshimbi, L. Chipuka, Macwacwa, *University Teaching Hospital, Lusaka, Zambia.*

T.B.P.338 Comparison of Two HIV-1 Immunoblot Techniques. *Peter Wanzala*, G. Maitha, *Kenya Medical Research Institute, Nairobi, Kenya.*

T.B.P.339 Laboratory Testing for HIV-1 Antibody Testing in California: Analysis of Current Practices and Improvement Efforts. *K. Michael Peddecord*, A. S. Benenson, L. K. Hofherr, M. S. Ascher, *San Diego State University, San Diego, CA, U.S.A.*

T.B.P.340 Cross-Reactivity between ELISAs for Detection of HIV-1 and HIV-2. *María Belén Bouzas*, G. Muchinik, G. Picchio, F. Simon, I. Mathov, F. Brun Vézinet, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

T.B.P.341 Failure of ELISA and WB Testing to Detect HIV Infected Subjects. *Emilio Mannella*, G. Ippolito, M. Miceli, M. Mirolo, M. Pezzella, P. Angeloni, *Italian Red Cross, Rome, Italy.*

T.B.P.342 Correction of False-Positive Results of ELISA of Immunodeficient State. *Regina V. Svirska*, R. Kukaine, A. Sochnev, A. Burstein, B. Shif, A. Denisova, *August Kirchenstein Institute of Microbiology, Latvian SSR Academy of Sciences, Riga, U.S.S.R.*

T.B.P.343 Serosurvey of Women in a Maternity Ward. *A. Santos-Pinto*, W. Canas Ferreira, E. Prieto, R. Sousa, *Instituto de Higiene e Medicina Tropical, Lisbon, Portugal.*

Donneurs et receveurs de sang et de produits sanguins
Recipients and Donors of Blood and Blood Products

T.B.P.344 Lookback: An Update on the New York Experience. *Suzanne M. Gaynor*, D. Kessler, S. Andrews, P. Berge, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A.*

T.B.P.345 The Italian Hemophilic Register and Natural History of HIV Infection. *Nicola Schinaia*, A. Ghirardini, C. Valdarchi, A. Gringeri, G. Mariani, P. M. Mannucci, *National Institute of Health, Rome, Italy.*

T.B.P.346 Transfusion-Associated (T-A) AIDS Cases in Italy. *Nicola Schinaia*, C. Valdarchi, *National Institute of Health, Rome, Italy.*

T.B.P.347 HIV-1 p24 Antigen Screening of Male Blood Donors in Localities with High HIV-1 Antibody Prevalence. *Michael P. Busch, Irwin Memorial Blood Center, San Francisco, CA, U.S.A.*

T.B.P.348 HIV Infection in Western Blot Indeterminate Blood Donors. *J. Brooks Jackson*, M. Hanson, S. Kwok, S. Stramer, H. H. Balfour, Jr., K. MacDonald, et al., *University of Minnesota, Minneapolis, MN, U.S.A.*

T.B.P.349 Multicenter Evaluation of a Recombinant Based HIV-1/HIV-2 Combination Screening Enzyme Immunoassay. Hugo Troonen*, *H. Hampl, B. Schoen, L. Guertler, F. Avilez, S. Ranger, et al., *Abbott Laboratories, Wiesbaden-Delkenheim, Federal Republic of Germany.*

T.B.P.350 Human Immunodeficiency Virus Antibody Screening of Blood Donors: An International Survey. Roger A. Perrault*, *S. Mankikar, A. Adatia, *The Canadian Red Cross Society, Ottawa, ON, Canada.*

T.B.P.351 Use of Rapid Assays for Antibody to HIV in Blood Donors, Persons Practicing High Risk Behaviors and Suspected AIDS Cases in Ghana. Julius Mingle*, *S. Mitchell, O. Osei-Kwasi, *Noguchi Memorial Institute for Medical Research, Accra, Ghana.*

T.B.P.352 The Gift Relationship Revisited: HIV Seroprevalence of Blood Donors and Other Low-Risk Groups in Africa. Barbara B. Torrey*, *M. Mulligan, P. Way, *Center for International Research, U.S. Census Bureau, Washington, DC, U.S.A.*

T.B.P.353 The Impact of AIDS on Blood Transfusion Services at the University Teaching Hospital, Lusaka. Abraham Mwile, *University Teaching Hospital, Lusaka, Zambia.*

T.B.P.354 HIV Antigen Tests among New Blood Donors. Prakash C. Das*, *A. H. de Vries, R. L. McShine, C. T. Smit Sibinga, *Groningen-Drenthe Red Cross Blood Bank, Groningen, Netherlands.*

T.B.P.355 Indeterminate HTLV-I Western Blot Results in Blood Donors: Absence of Infectivity to Recipients of Blood. Cees L. Van der Poel*, *N. Leslie, H. Reesink, P. Ehlers, E. Bakker, H. Huisman, *Amsterdam, Red Cross Blood Bank, Amsterdam, Netherlands.*

T.B.P.356 Case Control Study in HIV Seropositivity in Hemodialysis Patients. Conceiçao A. Accetturi*, *R. Salomao, R. Barata, J. Salvador, I. Longo, N. F. Mendes, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

T.B.P.357 A Clinical and Serological Follow-up of HIV-2: Positive Patients from Guinea-Bissau (West Africa). Wanda Canas-Ferreira*, *C. Costa, J. Champalimaud, K. Mansinho, A. Santos Pinto, E. Prieto, Instituto de Higiene e Medicina Tropical, Lisbon, Portugal.*

T.B.P.358 Latex Agglutination Testing of Whole Blood for HIV-1 in the Field. B. Biryahwaho*, *S. Musgrave, J. Ndumu, R. Downing, A. Ojiwya, S. Sempala, *Uganda Virus Research Institute, Entebbe, Uganda.*

T.B.P.359 Anti-HIV Lookback Programme of the Canadian Red Cross Society. Sadanand Mankikar*, *V. Hogan, A. Adatia, N. B. Whittemore, *The Canadian Red Cross Society, Ottawa, ON, Canada.*

T.B.P.360 Retrospective Study of Post-Transfusion HIV Infection. Birgit E. Gathof*, *U. Bäcker, G. Gathof, L. Gürtler, J. Eberle, F. Deinhardt, *Bavarian Red Cross Blood Transfusion Service, Munich, Federal Republic of Germany.*

T.B.P.361 Determination of Erythrocyte Adenosine Deaminase Activity in Anti-HIV Seronegative Homosexual Men with Latent HIV Infection. Mario Ferrazzi*, *M. L. De Rinaldis, M. Pezzella, F. Caprilli, A. Bozzi, R. Strom, *Institute for Infectious Diseases, University of Rome "La Sapienza", Policlinico Umberto I, Rome, Italy.*

Manifestations cliniques
Clinical Manifestations

T.B.P.362 Clinical Characterisation of HIV-2 Disease in West Africa. *T. Corrah*, A. Egboga, A. Wilkins, I. Gaye, H. Whittle, B. Greenwood, *Medical Research Council, Fajara, Gambia.*

T.B.P.363 Clinical Evolution of 377 Cases of LAS/ARC (Follow-up Since 6-48 Months). *Sergio Ranieri*, F. Nicolli, D. De Dona, P. Bassi, G. Ballardini, A. Barelli, *S. Maria delle Croci Hospital, Ravenna, Italy.*

T.B.P.364 Clinical and Epidemiological Spectrum of AIDS Disease in Rio de Janeiro, Brazil. *Eleonora P. Quinhoes*, A. B. Sereno, C. Ismael, C. F. Ramos Filho, M. A. Perez, B. G. Weniger, et al. *Hospital Universitario Gaffrée e Guinle, Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

T.B.P.365 AIDS-Associated Glomerulopathy. *Luiz Paulo José Marques*, O. Santos, G. S. Lopes, C. A. Brasilio de Oliveira, A. V. Oliveira, L. S. Riodja, *Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

T.B.P.366 Cervical Lesions and HIV Infections in a Cohort of Prostitutes in Kinshasa, Zaire. *Ann Marie Nelson*, Z. Nsiangana, N. Nzila, M. Laga, B. Edidi, R. Marsella, *Projet SIDA, Kinshasa, Zaire.*

T.B.P.368 Relations entre hépatite B, infections HIVs et syndrome d'immunodéficience acquise. *Antoine Ouattara*, M. Meite, M. Gody, L. K. Manlan, G. De Thé, *Institut Pasteur de Côte d'Ivoire, Abidjan, Ivory Coast.*

T.B.P.369 Lymphadenopathy and HIV Infection. *Eleonora P. Quinhoes*, C. A. Basílio, H. A. Valle, F. Fialho, F. S. Sion, C. A. Morais de Sá, *Gaffreé & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

T.B.P.370 Thymic Pathology in Pediatric AIDS. *M. Alba Greco*, P. Thomas, V. Mahnovski, M. Magid, E. Kahn, V. Anderson, *New York University, Department of Pediatric Pathology, New York, NY, U.S.A.*

T.B.P.371 Delayed Healing of Infectious Syphilitic Lesions in HIV-Infected Zambian Men Receiving Appropriate Penicillin Treatment. *Subhash K. Hira*, D. Mwendasilumba, R. Macauca, P. L. Perine, *University Teaching Hospital, Lusaka, Zambia.*

T.B.P.372 Dermatitis of the Face and Yellow Toe Nail Changes Indicate Progression to AIDS/OI in Patients with HIV Infection. *Linda Morfeldt-Monson*, I. Julander, B. Nilsson, *Karolinska Institute, Roslagstull Hospital, Stockholm, Sweden.*

T.B.P.373 Étude comparative des manifestations dermatologiques des séropositifs HIV-1 et HIV-2. *Assane Kane*, B. Ndiaye, S. M'Boup, M. Guiraud, A. Traore, M. T. Dieng, *Université de Dakar, Faculté de médecine, Dakar, Senegal.*

T.B.P.374 Clinical Manifestations in African Children Perinatally Infected by HIV and Aged 5 Years Old or More. *Philippe Lepage*, P. Van de Perre, D. G. Hitimana, C. Van Goethem, P. Kestelyn, F. Nsengumuremyi, *Department of Pediatrics, Centre hospitalier de Kigali, Kigali, Rwanda.*

T.B.P.375 Gastrointestinal Kaposi's Sarcoma in AIDS: Endoscopic Findings. *Walter Heise*, P. Mostertz, J. Skörde, K. Nehm, G. Grosse, M. L'Age, *Auguste-Viktoria Hospital, 2nd Internal Department, Berlin, Federal Republic of Germany.*

T.B.P.376 Severe Reversible Gastrointestinal Dilatation Associated with HIV-1 Infection. *Rui M. M. Victorino*, M. Lucas, F. Neto, M. C. Moura, *Faculty of Medicine of Lisbon, Lisbon, Portugal.*

T.B.P.377 The Spectrum of Clinical Disease among Filipino AIDS Cases. *Ofelia T. Monzon*, V. Basaca-Sevilla, C. Hayes, J. Capellan, C. Manaloto, M. C. Saniel, *Research Institute for Tropical Medicine, Manila, Philippines.*

T.B.P.378 Intrauterine HIV Exposed Children: Results of a Four-Year Prospective Investigation. *Ilse Grosch-Wörner*, S. Koch, M. Vocks, A. Schäfer, K.-O. Habermehl, M. Mielke, et al., *Rudolf Virchow University Clinic, Standort Charlottenburg Children's Clinic, Berlin, Federal Republic of Germany.*

T.B.P.379 Pneumocystis Carinii Pneumonia (PCP) Presenting as Cystic Apical Lung Lesions While on Aerosolized Pentamidine Prophylaxis. *Bary J. Siegel*, N. Flynn, W. Martin, M. Soehn, S. Pomerantz, *University of California at Davis, Medical Center, Division of General Medicine, Sacramento, CA, U.S.A.*

T.B.P.380 Occurrence of Kaposi's Sarcoma (KS) in Patients Treated with Zidovudine (AZT). *Anne Mathieu-Boué*, F. Boué, P. Malfon, J.-F. Delfraissy, *Hôpital de Bicêtre, Le Kremlin- Bicêtre, France.*

T.B.P.381 Regression of Kaposi's Sarcoma and Improvement of Performance Status by a Combined Interferon-beta ß and Zidovudine Therapy in AIDS Patients. *N. H. Brockmeyer*, L. Mertins, R. Male-betaßa, R. Biniek, M. Goos, *Department of Dermatology, University of Essen, Essen, Federal Republic of Germany.*

T.B.P.382 Encéphalite aiguë spontanément régressive révélatrice d'une infection à HIV-2. *Jean-Philippe Rogez*, S. Ranger, C. Buffet-Janvresse, D. Morcamp, F. Denis, J. Leroy, *Service de Médecine interne, CHG, Elbeuf, France.*

T.B.P.383

T.B.P.384 Physician Experience with HIV Infection in a Low Prevalence Area. *Barry A. Hong*, J. Rice, S. Wightman, W. Seyfried, W. Powderly, L. Ratner, *Washington University School of Medicine, St. Louis, MO, U.S.A.*

Section
C

Mardi 6 juin
Tuesday, June 6

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Session d'affichage
Poster Session

Immunologie de base
Basic Immunology

T.C.P.1 Measurement of Affinity Maturation in HIV-1 Infected Chimpanzees. *Richard T. Coughlin*, P. Bulger, V. G. Masison, D. J. Marciani, J. Eichberg, *Cambridge Bioscience Corp., Worcester, MA, U.S.A.*

T.C.P.2 Type-specific CTL Response to the HHIV-1 Envelope Gene Product. *Karen A. Birch-Limberger*, B. D. Walker, C. Flexner, R. T. Moss, T. J. Schooley, T. J. Paradis, *Massachusetts General Hospital, Boston, MA, U.S.A.*

T.C.P.3 AZT Inhibits LPS-Induced Secretion of IL-1 by Cultured Normal Human Monocytes. *Laurence Weiss*, N. Haeffner-Cavaillon, M. Laude, M. D. Kazatchkine, *Unité d'Immunopathologie, Hôpital Broussais, Paris, France.*

T.C.P.4 Enhancement of Lymphocyte-Mediated, HIV Specific Antibody-Dependent Cellular Cytotoxicity by Biologic Immune Response. *Tsugiya Murayama*, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

T.C.P.5 CD4+ and CD8+ Cytotoxic T Lymphocyte-Mediated Lysis of Macrophages Expressing HIV Antigens. *David J. Torpey*, T. Murayama, P. Gupta, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

T.C.P.6 Differential Kinetics of HIV Infection of Blood Monocytes and Macrophages In Vitro and Effects of Subsequent Functions. *Farhad Kazazi*, J. M. Mathijs, P. Foley, T. C. Sorrell, A. L. Cunningham, *Westmead Hospital, Virology Unit, ICPMR, Westmead, Australia.*

T.C.P.7 Immunotoxins Prepared from Human Monoclonal Antibodies Coupled to Deglycosylated Ricin A Chain Kill HIV-Infected Lines of T Cells and Monocytes. *Susan Zolla-Pazner*, M. A. Till, M. K. Gorny, J. S. Patton, J. W. Uhr, E. S. Vitetta, *New York University Medical Center, Department of Pathology, New York, NY, U.S.A.*

T.C.P.8 Selective Infection of Macrophage Subsets in the Lung by HIV. *Margaret A. Johnson*, L. W. Poulter, *Department of Thoracic Medicine, Royal Free Hospital, London, U.K.*

T.C.P.9 Normal Capacity of Monocytes from AIDS Patients for Uptake and Growth Inhibition of Mycobacterium Avium-Intracellulare. *John Johnson*, H. Shiratsuchi, H. Toba, J. J. Ellner, *Case Western Reserve University, Cleveland VA Medical Center, Cleveland, OH, U.S.A.*

T.C.P.10 Definition of a Subset of CD4+ Lymphocytes Selectively Infected with SIV/Mne using Three-Color Immunofluorescence and PCR. *Edward A. Clark*, J. Gibbon, D. Willford, M. J. Gale, P. Hoffman, W. M. Gallatin, *University of Washington, Regional Primate Research Center, Department of Microbiology, Seattle, WA, U.S.A.*

T.C.P.11 Pilot Study of Anti-LEU3a in HIV-1 Seropositives. *David Wilks*, L. C. Walker, J. A. Habershaw, A. G. Dalgleish, *Clinical Research Centre, Division of Immunological Medicine, Harrow, U.K.*

T.C.P.12 CD8+ Lymphocytes Can Control Acute HIV Infection of CD4+ T Cells. *Christopher M. Walker*, G. Thomson-Honnebier, F. Hsieh, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

T.C.P.13 Antibody-Binding Epitopes of HIV-1 Envelope Glycoproteins. *John E. Krowka*, D. P. Stites, B. Singh, *University of California at San Francisco, Department of Laboratory Medicine, San Francisco, CA, U.S.A.*

T.C.P.14 Mechanisms of Lymphocyte Dysfunction in HIV-Infected Patients. *Anna Vyakarnam*, P. Matear, B. Stanley, I. Weller, P. C. L. Beverley, *Academic Department of Genito-Urinary Medicine, James Pringle House, London, U.K.*

T.C.P.15 Inhibition of CD3 Signalling by gp120 Is Associated with CD4 Modulation and Altered G Protein-Regulated Calcium Gating. *Hardy Kornfeld*, W. W. Cruikshank, S. W. Pyle, D. M. Center, *Boston University School of Medicine, Pulmonary Center, Boston, MA, U.S.A.*

T.C.P.16 Identification of a Potent Synthetic HIV-1 Immunogen Comprising of gag-p24 Tandem-T and B-Cell Epitopes. *Pele Chong*, D. Y. Sia, J. Haynes, M. Sydov, M. Klein, *Connaught Laboratories Ltd., Willowdale, ON, Canada.*

T.C.P.17 HIV Infection of Bone Marrow Stromal Macrophages. *Florence M. Hofman*, J. Zheng, M. Rarrick, P. Gill, A. Mazumder, *University of Southern California, Los Angeles, CA, U.S.A.*

T.C.P.18 Determination of Epitopes Recognized by HIV-Specific CTL. *Scott Koenig*, P. Earl, L. Wood, B. Powell Moss, A. S. Fauci, *National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.19 The Role of HIV-Induced IL 6 Production in B Cell Activation in AIDS. *Elizabeth C. Breen*, J. F. Salazar-Gonzalez, T. Hirano, T. Kishimoto, O. Martinez-Maza, *University of California, Department of Microbiology and Immunology, Los Angeles School of Medicine, Los Angeles, CA, U.S.A.*

T.C.P.20 CD8+ T Cells Can Suppress HIV Replication Via a Soluble Factor. *Jan E. Brinchmann*, G. Gaudernack, E. Thorsby, F. Vartdal, *Institute of Transplantation Immunology, The National Hospital, Oslo, Norway.*

T.C.P.21 Monocytes and Neutrophils from HIV-Infected Individuals Contain Very Low or Undetectable Levels of Provirus as Determined by PCR Analysis. *Gregory T. Spear*, J. L. Moore, A. L. Landay, H. A. Kessler, G. Schochetman, C.-Y. Ou, *Rush Presbyterian-St. Luke's Medical Center, Chicago, IL, U.S.A.*

T.C.P.22 Presence of Anti-HIV Antibodies in Genital Secretions. *Paul M. Martin*, L. Belec, G. Steenman, M. C. Georges-Courbot, A. J. Georges, *Institut Pasteur, Bangui, Central African Republic.*

T.C.P.23 A Cross-Reactive Cytotoxic T Cell Epitope Between HIV-1 and HIV-2. *Douglas F. Nixon*, C. Rizza, J. Gallwey, J. Rothbard, K. Howland, A. J. McMichael, *John Radcliffe Hospital, Institute of Molecular Medicine, Molecular Immunology Group, Oxford, U.K.*

T.C.P.24 Antibodies Which Recognize both Conserved and Variable Regions of HIV-1 gp120 Are Responsible for HIV-Specific ADCC. *Richard A. Koup*, C. Pikora, S. McKenzie, G. Mazzara, D. Panicali, J. Sullivan, *University of Massachusetts Medical Center, Department of Pediatrics, Worcester, MA, U.S.A.*

T.C.P.25 CD8+HNK1+ Cells Suppress the HIV-Specific T Cell Activities. *Brigitte Autran*, P. Joly, J. M. Guillon, F. Plata, C. Mayaud, P. Debrée, et al., *Hôpital Pitié-Salpêtrière, Paris, France.*

T.C.P.26 An HLA-DR+, Light Density, Peripheral Blood Mononuclear Cell Produces Alpha Interferon in Response to HIV. *Charles R. Rinaldo*, J. Toso, G. Rappocciolo, P. Gupta, J. Ferbas, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

T.C.P.27 Antigen-Reactive T Lymphocytes are Present in HIV-Infected Individuals who are Non-Reactive in Conventional Lymphocyte Proliferative Assays. *Steffanie Sabbaj*, P. Adams, C. Orosz, M. Para, R. Fass, C. Whitacre, *Ohio State University, Department of Medical Microbiology and Immunology, Columbus, OH, U.S.A.*

T.C.P.28 The Immunoregulation of Human Immunodeficiency Virus in Human Semen. *Joanne Rhoads*, V. Polonis, D. L. Birx, R. Hendricks, D. S. Burke, R. R. Redfield, et al., *Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S.A.*

T.C.P.29 Relationship between Antibody against the C-Terminal Region of gp120 and Markers of HIV-Specific Immunoregulation. *Victoria Polonis*, H. Husayni, T. H. Lee, M. Essex, D. S. Burke, R. R. Redfield, *Walter Reed Army Institute of Research, Department of Retrovirology, Rockville, MD, U.S.A.*

T.C.P.30 Cytokines Alter Susceptibility of Human Monocytes to Infection by HIV-1. *Donald R. Skillman*, H. E. Gendelman, M. S. Meltzer, *Walter Reed Army Medical Center, Washington, DC, U.S.A.*

T.C.P.31 Function of CD8 Cell Subsets in HIV Infection. *Susan F. Plaeger-Marshall*, M. A. Hausner, V. Gudeman, D. Smith, J. V. Giorgi, *University of California, Los Angeles School of Medicine, Department of Pediatrics, Los Angeles, CA, U.S.A.*

T.C.P.32 Anti-HIV Antibody Directed Cytotoxicity: Cellular and Humoral Defects. *Douglas S. Tyler*, S. D. Stanley, C. L. Nastala, K. C. Stine, D. P. Bolognesi, K. J. Weinhold, *Duke University Medical Center, Department of Surgery, Durham, NC, U.S.A.*

T.C.P.33 Characterization of p17 Protein on Plasma Membrane of HIV-Infected Cells by Monoclonal Antibodies and Epitope Mapping. *Francis W. Ruscetti*, J. Mikovits, M. Baseler, M. Sheu, L. Papsidero, *Frederick Cancer Research Facility, Laboratory of Molecular Immunoregulation, Frederick, MD, U.S.A.*

T.C.P.34 HIV-1 Stimulates Tumor Necrosis Factor-Alpha Release from Human Monocyte/Macrophages (MI). *Eric S. Daar*, J. K. S. Chia, D. Yim, D. D. Ho, *Cedars-Sinai Medical Center and University of California, Los Angeles School of Medicine, Los Angeles, CA, U.S.A.*

T.C.P.35 Comparative Study of NK and ADCC Activity of CD3-,CD2+,CD16+ Cell Lines Obtained from Normal Seronegative and HIV Seropositive Subjects. *Daniel Scott*, F. Vuillier, G. Dighiero, *Institut Pasteur, Unité d'Immunopathologie et Immunohématologie, Paris, France.*

T.C.P.36 Role of FC Receptors in the Binding of HIV to Monocytes. *Loyda Meléndez-Guerrero*, J. K. A. Nicholson, J. S. McDougal, C. D. Dawson, *Emory University, Department of Pathology, Atlanta, GA, U.S.A.*

T.C.P.37 Identification of Common Epitopes of HIV-1 and HIV-2 by Monoclonal Antibodies. *Bernd Zorr*, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany.*

T.C.P.38 Effect of HIV on Antigen-Induced T Cell Proliferation. *Zaruhi Küpcü*, N. Barrett, F. Dorner, R. C. Gallo, M. M. Eibl, J. W. Mannhalter, *Immuno A.G., Department of Immunological Research, Orth/Donau, Austria.*

T.C.P.39 HIV Induced, HIV-Specific In Vitro Antibody Response. *Jean-François Delfraissy*, C. Wallon, F. Boué, J. Dormont, P. Galanaud, F. Barré-Sinoussi, *Hôpital Antoine Béclère, Clamart, France.*

T.C.P.40 Tumor Necrosis Factor Inhibits Activation of B Cells by Human Immunodeficiency Virus (HIV). *Jean-François Delfraissy*, C. Wallon, F. Boué, P. Galanaud, F. Barré-Sinoussi, *Hôpital Antoine Béclère, Clamart, France.*

T.C.P.41 FcE Expression in HIV-1 Infected T Cell Lines. *C. Carini*, M. Chierchi, F. Aiuti, *Allergology and Clinical Immunology, University of Rome "La Sapienza", Rome, Italy.*

T.C.P.42 Prevalence of Anti-nef Postive Sera in HIV Infected Patients: Mapping of the Major Epitopes of nef Protein Using Synthetic Peptides. *Elmostafa Bahraoui*, J. Van Rietschoten, C. Granier, J. C. Gluckman, L. Montagnier, J. M. Sabatier, *Institut Pasteur, Untié d'Oncologie Virale, Paris, France.*

T.C.P.43 Increased Serum Levels of Soluble 1L-2 Receptors (sIL-2R) in HIV Infection. Correlation Studies and Clinical Significance. *Jean-Marie Lang*, G. Coumaros, S. Levy, A. Aleksijevic, L. Lehr, C. Koehl, *Hôpital de Hautepierre, Strasbourg, France.*

T.C.P.44 Low Levels of LFA1+ Cells in HIV Infection. *Corinne Amiel*, B. Gobert, T. May, M. C. Bene, G. Faure, P. Canton, *Department of Infectious Diseases, Nancy, France.*

T.C.P.45 Expression of the T-Cell Receptor Molecule in HIV Infection. *Corinne Amiel*, M. C. Bene, T. May, G. Faure, P. Canton, *Department of Infectious Diseases, Nancy, France.*

T.C.P.46 Most Sera from HIV Infected Individuals Contain HIV Antigen as Immune Complexes. *Parunag G. Nishanian*, K. Huskins, S. Stehn, R. Detels, J. L. Fahey, *University of California, Los Angeles School of Medicine, CHS, Department of Microbiology and Immunology, Los Angeles, CA, U.S.A.*

T.C.P.47 Productive In Vitro HIV Infection of Normal CD8+ Lymphocytes. *Richard W. Bailey*, D. E. Lewis, *Baylor College of Medicine, Houston, TX, U.S.A.*

T.C.P.48 CD4-Derived Synthetic Peptide Protects CD4+ T Cells from HIV-1 Infection. *Orit Shaira-Nahor*, H. Golding, K. L. Vujcic, A. F. Robey, *National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.49 HIV-1 Disease Status and Seroreactivity to gag, pol and env Gene Products. *Phillip P. Shadduck*, T. J. Matthews, T. Grove, C. S. Chiang, C. W. McMillan, G. C. White, *Duke University Medical Center, Durham, NC, U.S.A.*

T.C.P.50 Phenotypic Characterization of the Expanded CD8Leu-7+ Cell Population in Patients with HIV Infection. *Celsa A. Spina*, J. A. McCutchan, D. D. Richman, *University of California at San Diego, School of Medicine and the VA Medical Center, San Diego, CA, U.S.A.*

T.C.P.51 Immunodominant Epitopes of gp120: A Potential Obstacle for Vaccine Development. *Tun-Hou Lee*, W. J. Syu, B. Du, W. R. Lee, R. D. Chang, M. Huang, et al., *Harvard School of Medicine, Department of Cancer Biology, Boston, MA, U.S.A.*

T.C.P.52 Differences among Lymphocyte Subpopulations in HIV Positive or Negative Homosexual and Heterosexual Males as Determined by Multiparameter Flow Cytometry. *Carol T. Schnizlein-Bick*, M. R. Magier, R. B. Jones, K. H. Fife, E. B. Walker, *Indiana University School of Medicine, Departments of Medicine and Infectious Diseases, Indianapolis, IN, U.S.A.*

T.C.P.53 Envelope Glycoproteins of HIV-1 Inhibit Expression of mRNA for IL-2 but not for IL2R in Tetanus-Specific T Cell Cones. *Naoki Oyaizu*, N. Chirmule, W. Hall, V. S. Kalyanaraman, H. Slade, S. Pahwa, *North Shore University Hospital, Manhasset, NY, U.S.A.*

T.C.P.54 Interferon Beta and Interleukin-2 but not Interferon Alpha Augment Natural Killing of HIV-Infected Targets among HIV (+) Subjects. *Keith M. Ramsey*, G. J. Stanton, M. W. Cloyd, *University of Texas Medical Branch, Galveston, TX, U.S.A.*

T.C.P.55 Correlation of ADCC and Neutralization with a Better Clinical Stage in Children Born to HIV-1 Infected Mothers. *Kristina Ljunggren*, V. Moschese, P. A. Broliden, B. Wahren, P. Rossi, M. Jondal, *Karolinska Institute, Department of Immunology, Stockholm, Sweden.*

T.C.P.56 An Analysis of the Expression of CD4 Receptors by Blood Monocytes and T Cells from Normal and HIV-1+ Individuals. *Lionel G. Filion*, C. A. Izaguirre, G. E. Garber, L. Huebsch, *University of Ottawa, Ottawa, ON, Canada.*

T.C.P.57 Augmentation of Monocyte-Mediated Direct Cytotoxicity and ADCC by AIDS Peripheral Blood-Derived Monocytes. *Benjamin Bonavida*, A. Jewett, P. Nishanian, R. Mitsuyasu, *University of California, Los Angeles School of Medicine, Los Angeles, CA, U.S.A.*

T.C.P.58 Monocytes/Macrophages Infected with HIV-1 Produce Acid-Labile Interferon-a. *János Szebeni*, R. M. Friedman, S. M. Wahl, L. M. Wahl, J. N. Weinstein, *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.59 Characterization of Human Monoclonal Antibodies against HIV-1 with Group Specific Neutralizing Activities. *Véronique Boyer*, P. Madaule, S. Souche, D. Zagury, C. Desgranges, *INSERM U271, Lyon, France.*

T.C.P.60 Autoantibodies against Collagen in AIDS: Correlation with Risk Factors and Disease Progression. *Michael D. Grant*, M. S. Weaver, G. W. Hoffmann, *University of British Columbia, Department of Microbiology, Vancouver, BC, Canada.*

T.C.P.61 Potential Extracorporeal Treatments Using a CD8 T-Activator for Patients with AIDS. *Dewey J. Moody*, A. Mizerek-Erhart, L. A. Feeney, S. Finch-Manzagol, H. Hollander, T. B. Okarma, *Applied Immune Sciences, Menlo Park, CA, U.S.A.*

T.C.P.62 Anti-Lymphocyte Antibodies Associated with HIV Infection. *William J. Cronin*, B. D. Dorsett, H. L. Ioachim, *Lenox Hill Hospital, Department of Pathology, New York, NY, U.S.A.*

T.C.P.63 Preferential Loss of LEU 8-, CD45R-, HLA-DR+ CD8 Cells during Culture of Mononuclear Cells from Former Blood Donors Seropositive for HIV-1. *Harry E. Prince, American Red Cross Blood Services, Los Angeles, CA, U.S.A.*

T.C.P.64 Inverse Aberrancies of the Mucosal and Systemic IGA Systems in AIDS. *Susan Jackson*, D. Kotler, *The University of Alabama at Birmingham, Department of Microbiology, Birmingham, AL, U.S.A.*

T.C.P.65 Heightened Complement Sensitivity of AIDS/ARC Lymphocytes Related to Diminished Expression of Decay Accelerating Factor (DAF). *Michael M. Lederman*, S. F. Purvis, E. I. Walter, J. T. Carey, M. E. Medof, *University Hospitals of Cleveland, Cleveland, OH, U.S.A.*

T.C.P.66 Evaluation of Mononuclear Cell Associated HIV Antigens in Infants and Children. *Merlin L. Robb*, J. Baker, L. Toro, J. Vincent, G. Pettett, G. Fischer, et al., *Walter Reed Army Medical Center, Department of Pediatrics, Washington, DC, U.S.A.*

T.C.P.67 Sequential Analysis of HIV-Specific CTL Function in HIV-Infected Patients during AZT Therapy. *Agnès Hoffenbach*, G. Dadaglio, F. Michel, N. Chenciner, P. Sansonetti, F. Plata, *Institut Pasteur, Paris, France.*

T.C.P.68 Complement Deposition on the Surface of HIV-Infected Cells Mediates Binding to Cells Carrying Complement Receptors. *Brigitte Sölder*, T. Schulz, P. Hengster, G. Bitterlich, H. Wachter, M. P. Dierich, *Institute for Hygiene, Innsbruck, Austria.*

T.C.P.69 Functional and Envelope Binding Antibodies to HIV-1 in Seropositive Subjects from Africa and the Americas. *Emily W. Carrow*, D. A. Katzenstein, L. A. Sawyer, R. M. Hendry, E. J. Boone, G. V. Quinnan, et al., *Center for Biologics Evaluation Research, Food and Drug Administration, Laboratory of Retrovirus Research, Division of Virology, Bethesda, MD, U.S.A.*

T.C.P.70 The Transmembrane Protein of HIV-1, gp41, Exists in Virions in the Form of Tetrameric Structures Which Possess Enhanced Immunoreactivities. *Abraham Pinter*, W. J. Honnen, S. A. Tilley, C. Bona, M. K. Gorny, S. Zolla-Pazner, *Public Health Research Institute, New York, NY, U.S.A.*

T.C.P.71 In Vitro Activation of Natural Killer (NK) Cells by Interleukin-2 (IL-2) or Interferon-B (IFN-B) Induces Loss of Cytotoxic Capacity. *Gregory T. Spear*, B. N. Dittel, A. L. Landay, R. A. Bray, *Rush Presbyterian-St. Luke's Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A.*

T.C.P.72 Unique and Cross-Reactive Antigenic Regions within the Transmembrane Proteins of HIV-1/HIV-2 and Their Utility in Diagnosis of Viral Infections. *Sushil G. Devare*, J. Hunt, K. Boardway, R. Gutierrez, G. Dawson, V. Sarin, *Abbott Laboratories, Abbott Park, IL, U.S.A.*

T.C.P.73 Human Antibody Response to HIV-1 Protease According to Disease Stage. *Charles A. B. Boucher*, M. H. De Jager, C. Debouck, F. De Wolf, T. F. W. Wolfs, J. Goudsmit, *Academic Medical Center, Human Retroviral Laboratory, Amsterdam, Netherlands.*

T.C.P.74 Quantitative, not Qualitative, Defects Characterize Responses of Cells from HIV+ Subjects to B Cell Mitogens. *Andrew S. Edelman*, S. Zolla-Pazner, *New York University Medical Center, Department of Pathology, New York, NY, U.S.A.*

T.C.P.75 Human Monoclonal Antibodies (HuMAb) to HIV-1. *Douglas Lake*, T. Kawamura, A. Morice, Y. Masuho, E. Petersen, E. Hersh, *University of Arizona Cancer Center, Tucson, AZ, U.S.A.*

T.C.P.76 Fine Specificity of HIV-Specific Cytotoxic T Lymphocytes in Humans. *Pierre Langlade-Demoyen*, G. Dadaglio, M. Bahraoui, R. Fisher, F. Plata, *Institut Pasteur, Paris, France.*

T.C.P.77 HIV Recombinant p18 Core Protein Inhibits Proliferative Responses by Normal Lymphocytes in Humans and Mice. *Frédérique Michel*, R. Cheynier, G. Lacaud, M. P. Kieny, M. Girard, F. Plata, et al., *Institut Pasteur, Paris, France.*

T.C.P.78 Localization within the HIV-1 LTR of Nucleotides Responsive to CMV-Mediated Transactivation. *Paul A. Luciw*, P. Barry, E. Pratt-Lowe, M. Marthas, N. Duchange, K. Jones, *University of California at Davis, Department of Pathology, Davis, CA, U.S.A.*

T.C.P.79 Lymphokine-Activated Killer Cell Activity in Patients with AIDS. *Chryssa Gryllis*, B. Brenner, R. Margolese, M. Gornitsky, M. Wainberg, *Sir Mortimer Davis Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada.*

Biologie moléculaire
Molecular Biology

T.C.P.80 Analysis of the Mechanism Underlying rev Regulation of HIV Structural Protein Gene Expression. *Marie-Louise Hammarskjöld*, J. Heimer, A. Smith, N. Lewis, W. Andrews, D. Rekosh, *State University of New York at Buffalo, Departments of Microbiology and Oral Biology, Buffalo, NY, U.S.A.*

T.C.P.81 Assay Systems for HIV rev Function Using Chimeric Gene Constructions. *Xiaobin Lu*, M.-L. Hammarskjöld, S. Prasad, I. Sangwan, D. Polisoto, D. Rekosh, *State University of New York at Buffalo, Department of Biological Sciences, Buffalo, NY, U.S.A.*

T.C.P.82 Direct Analysis of Genetic Diversity and Evolution of HIV in Infected Persons Using Polymerase Chain Reaction (PCR). *Chin-Yih Ou*, K. Robbins, J. Jason, C. R. Horsburgh, B. Evatt, G. Schochetman, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

T.C.P.83 Human Chromosome-12 Is Required to Support an Elevated Level of HIV Gene Expression in Human-Hamster Hybrid Cells. *Clyde E. Hart*, J. Galphin, C.-Y. Ou, L. T. Bacheler, J. Wasmuth, S. R. Petteway, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

T.C.P.84 Epitope Mapping of the HIV-1 gag Region by Analysis of gag Gene Deletion Fragments Expressed in E. Coli Defines Eight Antigenic Determinants. *Carol J. Marcus-Sekura*, A. Woerner, P.-F. Zhang, M. Klutch, *Division of Virology, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A.*

T.C.P.85 Active HIV Protease Purified in a Single Step from Escherichia Coli Inclusion Bodies. *Alfredo G. Tomasselli*, J. O. Hui, D. J. Staples, T. K. Sawyer, C.-S. C. Tomich, R. L. Heinrikson, *The Upjohn Company, Kalamazoo, MI, U.S.A.*

T.C.P.86 Analysis of the Expression of HIV-1 Antigens in the Baculovirus System. *David Parker*, R. Weller, S. Ahern, B. Rodgers, *Wellcome Diagnostics, Beckenham, U.K.*

T.C.P.87 Translated Effects of the 5' Untranslated Region of HIV-1 In Vivo: Regulation by tat. *Neil T. Parkin*, C. Rosen, N. Sonenberg, *McGill University, Department of Biochemistry, Montreal, QC, Canada.*

T.C.P.88 Failure of Interferon- and messenger RNA Synthesis in PBMC of HIV-1 Infected Patients at Late Stages. *Rila Voth*, S. Rossol, K. Klein, W. E. G. Müller, S. Brunner, K. H. Meyer zum Büschenfelde, et al., *University of Mainz, First Medical Clinic, Mainz, Federal Republic of Germany.*

T.C.P.89 Acidic Residues within the Amino Terminal Region of HIV-1 tat is Critical for Transactivation. *Jay F. Rappaport*, S. J. Lee, K. Khalili, F. Wong-Staal, *Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.*

T.C.P.90 CD4(81-92) Peptide Analogs Block HIV Infection, HIV-Induced Cytopathicity and Post-Infection Viral Transmission In Vitro, at Micromolar Concentrations. *Dianne M. Rausch*, L. Eiden, K. Hwang, P. Nara, M. Padgett, J. Lifson, *National Institute of Mental Health, Bethesda, MD, U.S.A.*

T.C.P.91 Promotor Activity of 5' LTR Region of a Highly Cytopathic Strain of HIV-1. *Joséphine Sire*, I. Hirsch, V. Zachar, B. Spire, J. C. Chermann, *INSERM U322, Marseille, France.*

T.C.P.92 Detection and Sequencing of Individual Molecules of HIV DNA Amplified by a Modified PCR. *Peter Simmonds*, P. B. Balfe, A. J. Leigh-Brown, J. O. Bishop, *University of Edinburgh, Department of Genetics, Edinburgh, U.K.*

T.C.P.93 Binding of the HIV-1 tat Protein to tar Sequences in Vitro. *Michael A. Skinner*, C. Dingwall, I. Ernsberg, S. Haephy, M. J. Gait, J. Karn, *MRC Laboratory of Molecular Biology, Cambridge, U.K.*

T.C.P.94 Characterization of the Infectivity of HIV Proviruses Containing Mutations in LTR Regulatory Sequences. *Arnold B. Rabson*, J. M. Leonard, C. M. Parrott, A. Buckler-White, M. A. Martin, *NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.95 Analysis of VPX Function in HIV-2 Infected Cells. *Lee Ratner*, W. Hu, N. Vander Heyden, *Washington University, St. Louis, MO, U.S.A.*

T.C.P.96 Highly Efficient Neutralization of HIV with Recombinant CD4-Immunoglobulin Molecules. *Klaus E. Karjalainen*, A. Traunecker, J. Schneider, H. Kiefer, *Basel Institute for Immunology, Basel, Switzerland.*

T.C.P.97 Packaging and Transfer of a Marker Gene by HIV Vector Particles. *François Clavel*, O. Danos, M. Alizon, *LMN, NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.98 Interaction of HIV with Interferon Regulated, Antiviral Enzymes. *Bryan Williams*, R. H. Silverman, D. N. Sengupta, M. Dion, *Toronto Hospital for Sick Children, Toronto, ON, Canada.*

T.C.P.99 HIV-1 Replicates in Human Sperm Mitochondria of HIV-1 Seropositive Individuals. *Omar Bagasra*, W. Lischner, G. Haligen, B. Hains, M. Freund, *University of Medicine and Dentistry of New Jersey, Camden, NJ, U.S.A.*

T.C.P.100 Transmission of SIVmnd in a Semi-Free Range Breeding Colony of Mandrills in Gabon. *Martine Peeters*, E. Delaporte, C. Honoré, R. W. Cooper, P. Bussi, A. L. Dixson, *Centre international de recherches médicales, Franceville, Gabon.*

T.C.P.101 A Colormetric Assay for Transactivation of the HIV-1 LTR. *Edward D. Blair*, M. G. Davis, C. R. Roberts, *The Wellcome Research Laboratories, Beckenham, U.K.*

T.C.P.102 HIV-1 rev Induced Modulation of nef Protein Underlies Regulation of Viral Replication. *Nafees Ahmad*, R. K. Maitra, S. Venkatesan, *National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.103 HIV-1 tat Functions in Xenopus Oocytes in the Presence of Transcription Inhibitors. *Martin Braddock*, A. Chambers, W. Wilson, A. J. Kingsman, S. M. Kingsman, *Department of Biochemistry, University of Oxford, Oxford, U.K.*

T.C.P.104 Genes in the 3'End of HIV Control HIV Replication and Cytopathology. *Cecilia Cheng-Mayer*, M. Quiroga, D. Dina, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

T.C.P.105 Molecular Cloning and Sequencing of a New HIV-2 Isolate (HIV2CAM2). *Michael Tristem*, A. Karpas, F. Hill, *University of Cambridge Clinical School of Medicine, Department of Haematology, Cambridge, U.K.*

T.C.P.106 Stable Expression and Secretion of Recombinant HIV-1 Envelope Protein in Drosophila Schneider Cells. *Hanne R. Johansen*, J. Culp, S. Mai, B. Vickroy, M. Chaiken, S. Comer, et al., *Smith Kline & French Laboratories, Swedeland, PA, U.S.A.*

T.C.P.107 Possible Mode of Insertion into a Lipid Bilayer of N-Terminal Fusogenic Segment of Viral Envelope Proteins. *Isabelle. M. G. Martin*, R. Brasseur, A. Burny, M. Vandenbranden, J.-M. Ruysschaert, *Université Libre de Bruxelles, Brussels, Belgium.*

T.C.P.108 Characterization of Recombinant HIV Reverse Transcriptase: Purification of Homogeneous, Stable P66 by Nature/Denaturation Protocols. *Gary Tarpley*, T. J. McQuade, D. P. Brunner, M. R. Deibel, *The Upjohn Company, Kalamazoo, MI, U.S.A.*

T.C.P.109 An HIV 1 Peptide Library Expressed in Yeast Reveals New Continuous Epitopes. *Pascal Madaule*, J. E. Gairin, J. P. Rossier, *CNRS, Laboratoire de Physiologie Nerveuse, Gif-sur-Yvette, France.*

T.C.P.110 Effect of Hydrocortisone on the Replication of HIV-1 in Different Cell Types. *Hugo Soudeyns*, R. Geleziunas, G. Shyamala, M. A. Wainberg, W. Schneider, *Lady Davis Institute for Medical Research, Montreal, QC, Canada.*

T.C.P.111 Characterization of HIV-1 Clinical Isolates Resistant to Zidovudine. *Ronald Rooke*, M. Tremblay, M. A. Wainberg, *McGill University, Montreal, QC, Canada.*

T.C.P.112 The Effect of HIV Infection on Monocyte Differentiation. *Romas Geleziunas*, F. Boulerice, S. Bour, M. A. Wainberg, *Lady Davis Institute, Montreal, QC, Canada.*

T.C.P.113 Chromosomal Localization of tat-Interacting Cellular Factors. *Peter R. Shank*, M. Newstein, *Division of Biology and Medicine, Brown University, Providence, RI, U.S.A.*

T.C.P.114 The rev Gene Product of the Human Immunodeficiency Virus Affects RNA Localization. *Keith Peden*, M. Emerman, R. Vazeux, *Johns Hopkins University, School of Medicine, Baltimore, MD, U.S.A.*

T.C.P.115 Effect of Mutations in vpx on the Infectivity of Viral Particles of HIV-2. *Keith Peden*, M. Guyader, M. Emerman, L. Montagnier, *Johns Hopkins University, School of Medicine, Baltimore, MD, U.S.A.*

T.C.P.116 Expression in E. coli and Purification in One Step of a Functional Hybrid Protein between a Bacterial Periplasmic Protein (Male) and the T Lymphocyte-Helper Inducer CD-4 Protein (Soluble Part). *Jean-Marie Clément*, S. Szmelcman, O. Schwartz, Y. Henin, L. Montagnier, M. Hofnung, et al., *PMTG, Institut Pasteur, Paris, France.*

T.C.P.117 Constitutive Synthesis of NF-xB-like Nuclear Proteins in Monocytes: An Explanation for HIV Latency? *Nancy L. McCartney-Francis*, M. Norcross, *NIDR/National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.118 Activation of HIV and Interferon Regulatory Elements in Hematopoietic and Epithelial Cells. *Lucie Cohen*, J. F. Leblanc, L. Sportaza, S. Xanthoudakis, J. Hiscott, *Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.*

T.C.P.119 Detection of a Novel DNA Topoisomerase I Activity Associated with a Human Immunodeficiency Virus (HIV) and Other Retrovirus Particles. *Esther Priel*, O. Yosef, S. Segal, M. Aboud, S. D. Showalter, M. Roberts, et al., *National Cancer Institute, Frederick, MD, U.S.A.*

T.C.P.120 Nef Responsive Sequences (NRS) of the HIV-1 LTR Mediate Transcriptional Suppression. *Lee Ratner*, T. M. J. Niederman, *Washington University, St. Louis, MO, U.S.A.*

T.C.P.121 Myristoylation-Dependent Assembly of Infectious HIV-1. *Lee Ratner*, M. L. Bryant, *Washington University, St. Louis, MO, U.S.A.*

T.C.P.122 Biological Significance of HIV-1 Envelope Heterogeneity. *Terry McNearney*, P. Westervelt, B. J. Thielan, D. Trowbridge, J. Garcia, L. Ratner, *Washington University, St. Louis, MO, U.S.A.*

T.C.P.123 HIV Infection of Colonic Mucosa Associated with Colitis. *J.M. Mathijs*, M. Hing, C. Goldschmidt, D. A. Cooper, A. L. Cunningham, *Westmead Hospital, Virology Unit, Westmead, Australia.*

T.C.P.124 Analysis of HIV Sequence Change During Infection. *Andrew J. Leigh Brown*, P. Balfe, *University of Edinburgh, Department of Genetics, Edinburgh, U.K.*

T.C.P.125 Localization of a Domain of Human CD4 Required for HIV-Mediated Syncytium Formation by Comparison with CD4 cDNAs Isolated from the Chimpanzee and Rhesus Monkey. *David Camerini*, B. Seed, *Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A.*

T.C.P.126 Studies of the Function of vpx in HIV-2. *John C. Kappes*, W. D. Decker, S. W. Lee, C. D. Morrow, G. M. Shaw, B. H. Hahn, *University of Alabama at Birmingham, Birmingham, AL, U.S.A.*

T.C.P.127 Comparative Analysis of HIV-1 and HIV-2 Gene Expression. *Suresh K. Arya*, R. C. Gallo, *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

T.C.P.128 Restriction Map Patterns in Selected Clinical Pairs of HIV Isolates. *Mary Anne T. Vahey*, F. McCutchan, J. Mosca, R. Redfield, D. Burke, *Walter Reed Army Institute of Research, Department of Retroviral Research, Rockville, MD, U.S.A.*

T.C.P.129 A Strategy for the Detection of Specifically Spliced mRNAs Encoding HIV-1 Regulatory Genes. *John C. Guatelli*, D. Richman, T. Gingeras, *University of California at San Diego Medical Center, Division of Infectious Diseases, San Diego, CA, U.S.A.*

T.C.P.130 Processing of the gag Polyprotein by Human Immunodeficiency Virus Protease Occurs in a Sequential Manner. *Susan K. Erickson-Viitanen*, J. Manfredi, P. Viitanen, D. Tribe, R. Tritch, R. Swanstrom, et al., *E. I. Dupont de Nemours & Co. Inc., Medical Products Department, Wilmington, DE, U.S.A.*

T.C.P.131 Polymerase Chain Reaction in HIV Infection. *Jean-Jacques Lefrère*, M. Mariotti, S. Berriche, D. Vittecoq, B. Noël, *Institut National de transfusion sanguine, Paris, France.*

T.C.P.132 In Vitro Expression of a Functional HIV-nef Gene Product. *Louise Poulin*, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

T.C.P.133 Two Epstein-Barr Virus Latent Proteins (LMP and EBNA2) Transactivate the HIV-1 LTR. *Marie-Louise Hammarskjöld*, M. C. Simurda, *State University of New York at Buffalo, Departments of Microbiology and Oral Biology, Buffalo, NY, U.S.A.*

T.C.P.134 Infection of Rhesus Macaques with a Molecularly Cloned Simian Immunodeficiency Virus. *Paul A. Luciw*, M. Marthas, B. Banapour, T. McGraw, P. Marx, N. Pedersen, *University of California at Davis, Department of Pathology, Davis, CA, U.S.A.*

Additionnels
Additional

T.C.P.135

T.C.P.136

T.C.P.137 HIV-1 pol Expression Is Dependent on a General "Shifty" Sequence. *Wilma Wilson*, M. Braddock, S. M. Kingsman, A. J. Kingsman, *University of Oxford, Department of Biochemistry, Oxford, U.K.*

T.C.P.138 Molecular Characterization of the Human CD4 Gene. *Zaher Hanna*, E. Cheung, P. Jolicoeur, *Clinical Research Institute of Montreal, Montreal, QC, Canada.*

T.C.P.139 Regulation of HIV-1 Gene Expression by tat, rev and nef. *George N. Pavlakis*, B. K. Felber, C. M. Drysdale, A. Athanassopoulos, S. Schwartz, *National Cancer Institute, Frederick Cancer Research Facility, BRI, Basic Research Program, Frederick, MD, U.S.A.*

T.C.P.140 HIV Infection through Endocytosis Mediated by Fc-Receptors of Macrophages. *Károly Nagy*, A. Valentin, G. Szegedi, *Institute of Isotopes of the Hungarian Academy of Sciences, Budapest, Hungary.*

T.C.P.141 Study of the CD45R and UCHL1 Positive Lymphocyte Subsets in the Blood of HIV-Seropositive (HIV POS) and HIV-Seronegative (HIV NEG) Haemophiliacs. *George Füst*, K. Pálóczi, P. Beverley, E. Ujhelyi, R. Mihalik, G. Králl, *National Institute of Haematology and Blood Transfusion, Budapest, Hungary.*

T.C.P.142 The Immunomodulating and Antiviral Effects of AS101, an Organotellurium Compound. *Ami Vonsover*, Y. Kalechman, M. Oron, F. Shalit, M. Albeck, B. Sredni, *Bar-Ilan University, Ramat Gan, Israel.*

T.C.P.143 A Nucleotide Sequence of Unknown Function Amplified from DNA Polymerase Chain Reaction (PCR) in HIV-Infected Cells. *Wu-Tse Liu*, S.-T. Hu, S.-R. Wang, *National Yang-Ming Medical College, Taipei, Republic of China.*

T.C.P.144 Inhibition of HIV-1 Reproduction by Synthetic Peptides from Region of Proteins Similar to Cell Receptors CD-4 and HLA-DR. *Andrey G. Pokrovsky*, V. Blinov, O. Yastrebova, S. Chapligina, L. Sandachiev, A. Kozhich, et al., *All-Union Research Institute of Molecular Biology, Novosibirsk, U.S.S.R.*

T.C.P.145 5'-Phosphonate Derivatives of 3'-Azido-2', 3'-Dideoxynucleosides: Synthesis and Inhibition of HIV Reproduction in Cell Cultures. *Natalya Tarussova*, M. Kukhanova, A. Khorlin, A. Krayevsky, G. Galegov, M. Kornilova, et al., *Institute of Molecular Biology, USSR Academy of Sciences, Moscow, U.S.S.R.*

T.C.P.146 Reduced In Vitro Growth and Differentiation of Monocytes from Patients with HIV Infection. *Fredrik Müller*, H. Rollag, G. Gaudernack, S. Frland, *University of Oslo, The National Hospital, Oslo, Norway.*

T.C.P.147 The Role of Interleukin-4 (IL-4) in AIDS. *Khorshed M. Pavri, Centre for AIDS Research and Control, Indian Council of Medical Research, Pune, India.*

T.C.P.148 Further Investigations on a Laboratory Model Based on HIV-1 Specific Cytotoxic T Lymphocytes. *Elie N. Arida, National Research Centre, Research Group of Viruses and Tissue Culture, Cairo, Egypt.*

T.C.P.149 Monoclonal Antibodies Raised to Recombinant HIV-1 gag-Proteins Can Identify Immuno-Dominant B Cell Epitopes in AIDS Patients. *Eric Saman*, P. De Baetselier, R. J. De Leys, C. Wauters, H. Van Heuverswyn, *Innogenetics N.V., Antwerp, Belgium.*

T.C.P.150 Human Monoclonal Antibodies to HIV. *Dirk Berzow*, M. Boegel, C. G. Meyer, R. Grunow, R. Von Baehr, H. Schmitz, *Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany.*

Notes



Section
D

Le SIDA et l'individu
AIDS and the Individual

Mardi 6 juin
Tuesday, June 6

Session d'affichage
Poster Session

Adolescents (partie 2)
Adolescents (Part 2)

T.D.P.1 Modifications of Sexual Activities in the Era of AIDS: A Trend Analysis. *Eleanor Tyndale, Vanier College, University of Calgary, Calgary, AB, Canada.*

T.D.P.2 Sexual Behaviour, Contraceptive Use and STD History among Heterosexual College Students. *June M. Reinisch*, S. A. Sanders, M. Ziemba-Davis, C. A. Hill, *The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A.*

T.D.P.3 Short-term Impact of an AIDS Education Curriculum for Adolescents. *Susan M. Blake*, E. Tishman, R. Makinodan, *American Red Cross National Headquarters, Washington, DC, U.S.A.*

T.D.P.4 Sexual Behaviour in High-Risk Adolescents. *Heino F. L. Meyer-Bahlburg*, M. J. Rotheram-Borus, C. Koopman, T. M. Exner, A. A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

T.D.P.5 Condom Behavior in 17, 18 and 19-Year Old Norwegians. *Bente Træen*, J. Rise, P. Kraft, *National Institute of Public Health, Oslo, Norway.*

T.D.P.6 The Impact of Teenagers' Knowledge and Concern of AIDS on Sexual Behavior and Prevention Strategies. *Timothy M. Sankary, AIDS Prevention Center, San Francisco, CA, U.S.A.*

T.D.P.7 Demographic and High Risk Behavior Study of Incarcerated Adolescents. *Robert Morris*, S. Huscroft, J. Roseman, O. Ré, C. Baker, K. Iwakoshi, *University of California at Los Angeles Department of Pediatrics, Los Angeles, CA, U.S.A.*

T.D.P.8 Knowledge, Attitudes and Behaviour of Street-Involved People in Vancouver. *Michael L. Rekart*, L. Manzou, P. Loftus, *STD Control, Ministry of Health, Vancouver, BC, Canada.*

T.D.P.9 HIV-Related Knowledge, Beliefs, and Behaviors among High School Students in the United States. *Laura Kann*, G. Nelson, J. Jones, L. Klobe, * Centers for Disease Control, Division of Adolescent and School Health, Atlanta, GA, U.S.A.*

T.D.P.10 Étudiants et SIDA : intérêt d'une typologie pour une prevention spécifique. *Dominique D. Pérard*, A. L. Lazartigues, H. L. Lisandre, T. P. Pailleux, *Université Paris X, V.F.R. Sciences psychologiques, Nanterre, France.*

T.D.P.11 Adolescent Runaways' Behavioral Risk Factors, Knowledge about AIDS and Attitudes about Condom Use. *Charles Haley*, R. A. Hudson, B. A. Petty, A. C. Freeman, M. A. Krepcho, *Dallas County Health Department, Dallas, TX, U.S.A.*

T.D.P.12 The Relationship of Knowledge and Attitudes towards AIDS to Safe Sex Practices among Runaway and Gay Adolescents. *Mary Jane Rotheram-Borus*, C. Selfridge, C. Koopman, C. Haignere, H. Meyer-Bahlburg, A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

T.D.P.13 Youth in Detention at High Risk for HIV: Knowledge, Attitudes and Behaviours Regarding Condom Usage. *Lydia Temoshok*, J. M. Moulton, R. M. Ellmer, D. M. Sweet, M. Baxter, J. Shalwitz, * University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

Comportement (partie 2)
Behaviour (Part 2)

T.D.P.14 The National Study of Health and Sexual Behaviour. *Virginia S. Cain*, W. Baldwin, *NICHD/National Institutes of Health, Bethesda, MD, U.S.A.*

T.D.P.15 HIV Status Related to Knowledge and Behavioural Change. *Kenneth P. Miller*, Patient Managers, *University of California at San Francisco, Department of Physiological Nursing, San Francisco, CA, U.S.A.*

T.D.P.16 Self Perception of the Risk of Contracting AIDS among University Students. *Francisco H. Aoki*, M. M. Diaz, P. Goodson, S. Vera, J. Diaz, J. L. Pinto e Silva, *State University of Campinas, Campinas, Brazil.*

T.D.P.17 Prevalence of Genital Lesions in an STD Clinic: Sexual Behavior Characteristics. *W. L. Whittington*, B. Jacobs, T. Edward, R. Moxey, N. P. Whittington, A. Nahmias, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.D.P.18 Behavioral Patterns of Bisexual Males in the U.S., 1982. *David E. Kanouse*, J. Lever, W. H. Rogers, S. Carson, R. Hertz, *The RAND Corporation, Santa Monica, CA, U.S.A.*

T.D.P.19 Patterning in the Sequences of Sexual Activity between Men and Its Implications for HIV-1 Transmission. *Peter M. Davies*, A. P. M. Coxon, *Project SIGMA, South Bank Polytechnic, London, U.K.*

T.D.P.20 Factors Associated with Seropositivity to HIV-1 among a Non-Clinic Sample of Gay and Bisexual Men in London. *Peter M. Davies*, A. J. Hunt, A. P. M. Coxon, T. J. McManus, S. Sutherland, *Project SIGMA, South Bank Polytechnic, London, U.K.*

T.D.P.21 Trends in AIDS Knowledge, Attitudes and Behaviours (KAB) in Heterogeneous, High-Risk Groups, Florida. *Spencer Lieb*, R. S. Zimmerman, M. Kuechler, L. M. Langer, J. Sims, J. J. Witte, *Florida Department of Health and Rehabilitative Services, Tallahassee, FL, U.S.A.*

T.D.P.22 Behavioral and Psychosocial Predictors of Compliance in HIV Asymptomatic and Symptomatic Patients in Clinical Trials. *Janie Patrone-Reese*, M. McCann, J. Chidekel, T. Fayne, B. Haliburton, L. Pringle, *University of Miami School of Medicine, Miami, FL, U.S.A.*

T.D.P.23 Male Homosexual Behaviour in the U. K.: 1985-1988. *Thomas J. McManus*, P. Davies, A. M. P. Coxon, *King's College Hospital, London, U.K.*

T.D.P.24 A Review of Studies of Behavioural Response to HIV-Antibody Testing among Gay Men. *Robert R. Stempel*, A. R. Moss, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A.*

T.D.P.25 Attitudes of Dentists and Graduation Students towards AIDS in Belo Horizonte, Brazil. *Dirceu B. Greco*, E. I. Oliveira, M. R. Oliveira, U. H. M. Paulino, M. A. A. Vitoria, I. Adams, *Federal University of Minas Gerais, Immunodeficiency Clinic, Belo Horizonte, Brazil.*

T.D.P.26 A Study to Investigate the Effectiveness of Role Play in HIV Health Education Groups for Drug Abusers. *Mary P. J. Burgess, King's College Hospital, London, U.K.*

T.D.P.27 Perceived Community Norms and Risk Reduction: Behavior Change in a Cohort of Gay Men. *Kevin R. O'Reilly*, D. L. Higgins, C. Galavotti, J. Sheridan, R. Wood, D. Cohn, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.D.P.28 Hypermasculinity as a Predictor of Sexual Risk Behaviours in a Cohort of Gay Men. *Theresa M. Exner*, H. F. L. Meyer-Bahlburg, R. S. Gruen, A. A. Ehrhardt, J. M. Gorman, *New York State Psychiatric Institute, Columbia University, New York, NY, U.S.A.*

T.D.P.29 Behavioral Targets for Possible Immunomodulation Therapy in AIDS Patients. *Robert M. Schmidt*, V. I. Kvitash, *Center for Preventive Medicine and Health Research, Pacific Presbyterian Medical Center and San Francisco University, San Francisco, CA, U.S.A.*

T.D.P.30 Willpower Assessment: A Decision-Making Model for Designing Tailored Targetted and Positive Promotion. *Carol L. Pass*, B. J. Lapointe, *McGill University, Department of Epidemiology, Montreal, QC, Canada.*

T.D.P.31 Factors Associated with Recurrence of Unsafe Sexual Practices in a Cohort of Gay Men Previously Engaging in "Safer" Sexual Practices. *Scott P. Saltzman*, A. M. Stoddard, J. McCusker, K. H. Mayer, *Fenway Community Health Center, Boston, U.S.A.*

T.D.P.32 The Role of Penitentiary Reform and Solidarity Enhancement among Jail Inmates in the Prevention of AIDS in the Dominican Republic. *E. Antonio De Moya*, S. Carías, S. Rosario, E. Guerrero, L. Abreu-Larancuent, R. Garcia-Alvarez, *PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

T.D.P.33 Implications of Health Beliefs for AIDS Prevention Programs: The San Francisco Men's Health Study. *Maria L. Ekstrand*, T. J. Coates, G. Stone, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.D.P.34 Sexual Behaviour of Expatriates in Africa. *Hans Houweling*, P. W. Kok, A. De Grave, S. P. Smits, R. J. Ligthelm, A. Leentvaar, et al., *National Institute of Public Health, Department of Epidemiology, Bilthoven, Netherlands.*

T.D.P.35 Changes in Sexual Practices in the Sydney AIDS Project: 1984-1989. *Brett D. Tindall*, T. Nicholas, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology, Surry Hills, Australia.*

T.D.P.36 Change in Sexual Behavior in Homosexuals at Risk for AIDS. *S. Maurice Adib*, M. Tal, J. G. Joseph, *University of Michigan, Ann Arbor, MI, U.S.A.*

T.D.P.37 Comportement sexuel et risque d'infection à VIH au Sénégal. *Ousmane Diouf*, M. Carballo, I. Ndoye, A. Petitgirard, *Centre National d'éducation pour la santé, Dakar, Senegal.*

T.D.P.38 AIDS Health Promotion Messages. *Iain McLellan*, A. Richardson, *World Health Organization, Global Programme on AIDS, Health Promotion Unit, Geneva, Switzerland.*

T.D.P.39 Behavioral Intentions and Other Factors Influencing Behaviour Change in a Cohort of Gay Men: A Prospective Study. *Christine Galavotti*, K. R. O'Reilly, D. L. Higgins, J. Sheridan, D. L. Cohn, *Centers for Disease Control, Department of Sexually Transmitted Diseases, Atlanta, GA, U.S.A.*

T.D.P.40 AIDS-Related Behavior Change of Gay Men in Richmond, VA, 1985-1988. *Judith B. Bradford*, M. Johnson, *Virginia Commonwealth University, Survey Research Laboratory, Richmond, VA, U.S.A.*

T.D.P.41 Sexual Behaviour Changes among Male Sexual Contacts of Men with HIV Disease: A 3 Year Overview. *Liviana Calzavara*, R. Coates, S. E. Read, J. K. Johnson, V. Farewell, M. Fanning, *University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

T.D.P.42 Psychological and Behavioural Components of Belief of Anti-HIV-1 Status in Healthy Gay Males. *Sharon M. August*, M. H. Antoni, G. Ironson, A. Laperriere, N. Schneiderman, M. A. Fletcher, *University of Miami, Department of Psychology, Coral Gables, FL, U.S.A.*

T.D.P.43 Safe and Unsafe Sexual Practices by Heterosexuals and Homosexual Men: Predicting Intentions and Behaviour. *Malcolm McCamish*, C. Gallois, Y. Kashima, A. Ede, A. Chauvin, *University of Queensland, Queensland AIDS Council, St. Lucia, Australia.*

T.D.P.44 Psychoneuroimmunologic Relationships in Men with ARC. *Lydia Temoshok*, G. F. Solomon, S. Jenkins, D. P. Stites, D. M. Sweet, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

T.D.P.45 Changes in Condom Use among Gay Men: Predictors and Methodological Issues. *Joseph A. Catania*, T. Coates, R. Stall, L. Bye, F. Capell, H. Turner, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

T.D.P.46 Coping of HIV-Infected Men and AIDS Patients. *Claudia Hermann*, P. Leiberich, M. Engeter, T. Harrer, E. Olbrich, Kalden J. R., *AIDS-Center of Federal Health Administration, Berlin, Federal Republic of Germany.*

T.D.P.47 De nouveaux comportements parmi les homosexuels en Europe: les cas de Paris et d'Amsterdam. *Michael Pollak*, Y. Algra, O. Berges, W. A. M. Dröge, H. I. Hannema, G. Pele, *Centre National de la Recherche Scientifique (CNRS), Paris, France.*

Psychologie et sexologie
Psychology and Sexology

T.D.P.48 Psychological Factors Associated with Prognosis in AIDS. *Michelle R. Reillo*, R. M. Brownell, *University of Maryland Medical Systems, State of Maryland AIDS Administration, Baltimore, MD, U.S.A.*

T.D.P.49 Psychosocial Reactions of Men Who Are Carers for HIV-Infected Peers and Men Who Are HIV-Antibody Positive. *Levinia Crooks*, L. Viney, M. Walker, *University of Wollongong, Wollongong, Australia.*

T.D.P.50 Psychological Interventions in the Treatment of Persons with AIDS, ARC and Asymptomatic HIV Infection. *Anne K. Enthus, Metaformation Inc., Montreal, QC, Canada.*

T.D.P.51 Defense Mechanisms and HIV Risk Related Behaviors in Substance Abusers. *Bernard Bihari*, G. Ottomanelli, *SUNY Health Science Center at Brooklyn, King's County Addictive Disease Hospital, Brooklyn, NY, U.S.A.*

T.D.P.52 Processus d'adaptation à la maladie de personnes atteintes du SIDA. *José K. Côté*, M. Fortin, *Université de Montréal, Faculté des sciences infirmières, Montreal, QC, Canada.*

T.D.P.53 Retentissement psychologique de l'infection à VIH sur la relation de couple. *Marie-Ange Gudefin*, S. Tisseron, Y. Edel, *Centre Hospitalier de Villeneuve-Saint-Georges, Villeneuve-Saint-Georges, France.*

T.D.P.54 Difficulties in the Management of AIDS Patients and Infected People in Brazil. *L. Rodrigues*, L. Ervolino, A. Silva, *Divisao Nacional de Doenças Sexualmente Transmissíveis, Ministerio da Saúde, Brasilia, Brazil.*

T.D.P.55 Psychological Correlates of the Transmission and Acceptance of Rumors about AIDS. *Allan J. Kimmel, Fitchburg State College, Behavioral Sciences Department, Fitchburg, MA, U.S.A.*

T.D.P.56 The Stress of Caring: Dimensions of Strain among Informal AIDS Caregivers. *Heather A. Turner, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.D.P.57 Help-Seeking for AIDS-Related Concerns: A Comparison of Gay Men with Various HIV Diagnoses. *Robert B. Hays*, J. Catania, L. McKusick, T. Coates, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

T.D.P.58 Short Term Memory (STM) Capacity Declines as a Function of AIDS Dementia Complex Severity. *John J. Sidtis*, J. G. Keilp, A. E. Sadler, D. Dorfman, L. Wolf, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

T.D.P.59 Evidence of Frank Cognitive Impairment and Depression Appearing Independently of Walter Reed Stage. *William C. Grace**, *E. C. Tramont, C. N. Oster, *Walter Reed Army Medical Center, Washington, DC, U.S.A.*

T.D.P.60 Attributional Style and Depression in HIV-Related Illness. *David B. Freeman**, *G. Evans, W. Van Gorp, J. Rosenbaum, L. George, J. Hamil, *West Los Angeles VA Medical Center, Psychology Service, Los Angeles, CA, U.S.A.*

T.D.P.61 HIV-1 Patients' Self-Reported Complaints of Memory Failure and Their Relationship to Actual Memory Performance. *John G. Keilp**, *A. E. Sadler, A. Wolf, D. Dorfman, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer Center, Department of Neuropsychology, New York, NY, U.S.A.*

T.D.P.62 Quality of Life of Persons with AIDS/ARC. *Donald Ellerman**, *M. D. Smith, *University of Pennsylvania, Philadelphia, PA, U.S.A.*

T.D.P.63 Emotional States in Relation to Immune Function in a Cohort of Male Sexual Contacts of Men with HIV Disease. *Rosemary Barnes**, *L. Calzavara, R. Coates, S. Read, D. MacFadden, K. Johnson, *Women's College Hospital, Toronto, ON, Canada.*

T.D.P.64 Personality Disorders and HIV Infection in Heroine Abusers. *Roberto Muga Bustanante**, *C. Jacas, J. Tor, R. Llistar, J. Pascual, P. Planas, *Hospital German Trias I Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.*

T.D.P.65 HIV Infection and Neuropsychological Status in Asymptomatic Heroin Abusers. *Jordi Tor Aguilera**, *C. Jacas, R. Muga, R. Llistar, P. Pascual, P. Planas, *Hospital Germans Trias I Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.*

T.D.P.66 Psychological Factors Predicting Distress after HIV Testing. *Baruch Fishman**, *S. Perry, L. Jacobsberg, A. Frances, *Cornell University Medical College, Department of Psychiatry, New York, NY, U.S.A.*

T.D.P.67 Psychological and Social Functioning in a Cohort of Homosexual Men at Risk for AIDS. *Susan Caumartin**, *M. Tal, J. C. Joseph, R. Kessler, *University of Michigan, Ann Arbor, MI, U.S.A.*

T.D.P.68 The Psychological Management of a Care Support Unit for Male Prisoners with HIV in England and Wales. *Kay Nooney**, *L. Curran, *H.M. Prison Wandsworth, London, U.K.*

T.D.P.69 Beyond Information-Provision as a Technique for HIV Education: A Study of the Psychological Determinants of Young Offenders' Beliefs about HIV. *David Thornton**, *L. Curran, *Young Offender Psychology Unit, Prison Department, London, U.K.*

T.D.P.70 Psychosocial Adaptation among HIV Positive Patients. *Denise M. Korniewicz, Johns Hopkins University School of Nursing, Baltimore, MD, U.S.A.*

T.D.P.71 Risk of Adult HIV Infection and Childhood Sexual Abuse. *Kenneth H. Mayer**, *S. Zierler, L. Feingold, D. Laufer, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A.*

T.D.P.72 Longitudinal Neuropsychological Study in Asymptomatic Seropositive Subjects. *Huib Van Dis*, M. Van Beuzekom, F. De Wolf, R. A. Coutinho, *University of Amsterdam, Department of Psychology, Amsterdam, Netherlands.*

T.D.P.73 Psychosexual Assessment in AIDS Research: Interviewer Selection, Training and Monitoring. *Rhoda S. Gruen*, M. Calderwood, H. F. L. Meyer-Bahlburg, A. A. Ehrhardt, *New York State Psychiatric Institute, Columbia University HIV Center, New York, NY, U.S.A.*

T.D.P.74 SIDA, sexologie et culture en Afrique centrale. *Brooke G. Schoepf, Projet CONNAISSIDA, Kinshasa, Zaire.*

T.D.P.75 Self-Labeled Sexual Orientation and Sexual Behaviour among Women. *Stephanie A. Sanders*, J. M Reinisch, M. Ziemba-Davis, *The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A.*

T.D.P.76 Safer Sex Practices amongst Homosexual Men: Meaning and Motivation. *Jane Chetwynd*, J. Horn, J. Kelleher, *Christchurch School of Medicine, University of Otago, Christchurch, New Zealand.*

T.D.P.77 Variables Influencing Condom Use among Intravenous Drug Users. *Stephen Magura*, J. L. Shapiro, Q. Siddiqi, D. S. Lipton, *Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

T.D.P.78 Sexual Behaviour Survey of Brazilian Men that Are Clients of Transvestite Prostitutes. *Arletty Pinel, Centro de Referência e Treinamento-AIDS, Sao Paulo, Brazil.*

T.D.P.79 Childhood Gender Nonconformity Predicts HIV-1 Seropositivity in Homosexual Men. *James D. Weinrich*, I. Grant, J. H. Atkinson, D. Richman, S. Spector, J. A. McCutchan, *University of California, at San Diego, Treatment Center, San Diego, CA, U.S.A.*

T.D.P.80 Sex and Drug Practices in the Illicit Sex Industry as Related to the Spread of AIDS. *Joyce I. Wallace*, S. Beatrice, *Foundation for Research on Sexually Transmitted Diseases, Inc., New York, NY, U.S.A.*

T.D.P.81 Condom Use among Heterosexual Male IV Drug Users Is Affected by the Nature of Social Relationships. *J. L. Sotheran*, S. R. Friedman, D. C. Des Jarlais, S. D. Engel, J. Weber, R. Rockwell, et al., *Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

T.D.P.82 HIV Seroprevalence and Its Implications for a Transsexual Population. *Diana Lynne Alan*, J. J. Guinan, L. Mc Callum, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

T.D.P.83 Evaluation of Sexuality in HIV-Infected Patients by the Wartegg Test. *Paulo H. P. Longo*, L. D. Carvalho, C. A. Morais de Sá, *Gaffrée & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

T.D.P.84 AIDS Phobia: A Clinico-Psychoanalytical Study. *Ishwarprasad S. Gilada*, G. V. Bhimani, B. Shah, V. Thakur, *Indian Health Organisation, Bombay, India.*

T.D.P.85 Attitudes and Behavioural Research for AIDS. *Antonio Leon*, L. Guerra, V. Cazco, E. Noboa, O. Cruz, E. Sanchez, *Central University, Ministry of Health, School of Professional Psychology, Quito, Ecuador.*

Les adolescents (partie 3)
Adolescents (Part 3)

T.D.P.86 Le risque de contamination par le VIH dans une population de jeunes en psychiatrie. *Alain Lazartigues*, D. P. Pérard, H. L. Lisandre, T. P. Pailleux, *Clinique Dupré, Fondation Santé des étudiants de France, Sceaux, France.*

T.D.P.87 Targeting AIDS Information at Sexually Active 15-17 Year-Olds. *Barbara J. Jones*, M. Liepold, S. Lunney, *Federal Center for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

T.D.P.88 Peer Education in Adolescent AIDS Prevention: Experimental Phase. *A. Bunde-Birouste*, D. Jayle, D. Guillemot, *Association pour la prévention du SIDA, Paris, France.*

T.D.P.89 Impact of Adolescent Health Messengers' AIDS Prevention Program on Peers and Adult Relatives in the Dominican Republic. *E. Antonio De Moya*, M. Brea de Cabral, E. Guerrero, L. Dominguez, M. Buttler, *PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

T.D.P.90 General and Personalized Knowledge of AIDS among Adolescents. *Cheryl Koopman*, J. Hunter, R. Henderson, M. J. Rotheram-Borus, *New York State Psychiatric Institute, Columbia University, New York, NY, U.S.A.*

T.D.P.91 Influence of Perceived Referent-Group Normative Behavior on Adolescents' Use of Condoms. *Ralph J. Diclemente*, R. DuNah, *University of California at San Francisco, San Francisco, CA, U.S.A.*

T.D.P.92 Differential Effects of AIDS Knowledge and Perceived Susceptibility on the Reduction of High-Risk Sexual Behaviors among College Adolescents. *Ralph J. Diclemente*, K. Forrest, S. Mickler, *University of California at San Francisco, CA, San Francisco, U.S.A.*



Section
E

Mardi 6 juin
Tuesday, June 6

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Session d'affichage
Poster Session

Éducation (partie 1)
Education (Part 1)

T.E.P.1 Reported Likelihood of Sexual Activities with a New Partner in a Survey of Bar Patrons in a Local Gay Community. *David J. Martin*, C.W. Edwards, W. Geiger, *University of California at Los Angeles, School of Medicine, Harbor-UCLA, Los Angeles, Medical Center, Department of Psychiatry, Torrance, CA, U.S.A.*

T.E.P.2 AIDS-Prevention Activities Targeting Homo- and Bisexual Men. *Michael Von Bröckel, Deutsche AIDS-Hilfe, Berlin, Federal Republic of Germany.*

T.E.P.3 Adaptation of Safer-Sex Workshop for Gay and Bisexual Men in Barcelona, Spain. *Daniel A. Wohlfeiler*, C. Frutchey, R. De Blai, A. Procupet, *University of California at Berkeley, School of Public Health, Berkeley, CA, U.S.A.*

T.E.P.4 Sources of Information on AIDS in Zaire and Implications for Program Planning. *Melinda Moore*, N. Lusakulira, S. E. Hassig, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A.*

T.E.P.5 AIDS Education: Using Community Television to Reach Gay Men and Bisexuals. *Michael Sobota, AIDS Committee of Thunder Bay, Thunder Bay, ON, Canada.*

T.E.P.6 Les effets d'une campagne grand public sur les homosexuels français. *Michael Pollak*, P. Bocsson, *CNRS-GSPM, Paris, France.*

T.E.P.7 Tracking Survey of AIDS Knowledge, Attitudes and Behaviors in San Francisco's Black Communities. *Noel A. Day*, A. Houston-Hamilton, D. Taylor, G. Lemp, G. Rutherford, *Polaris Research and Development, San Francisco, CA, U.S.A.*

T.E.P.8 Effective Safe Sex Discussion Groups. *Bill Rowe*, C. Crossman, W. Fisher, *King's College, University of Western Ontario, London, ON, Canada.*

T.E.P.9 Réaction de la société Zaïroise envers le SIDA. *Wa Nkera Rukarangira, Harvard Schook of Public Health, Boston, MA, U.S.A.*

T.E.P.10 Community Based AIDS Prevention and Education: Linking Research, Resources and Community. *Debbie Indyk*, P. Lefkowitz, E. Barrett, R. Belville, D. Rose, *Mount Sinai School of Medicine, New York, NY, U.S.A.*

T.E.P.11 Development of a Unique AIDS Consortium Center to Address HIV/AIDS in the Minority Community in the U.S. *Rudolph E. Jackson*, M. Haynes, P. Griffith, *Morehouse School of Medicine, Atlanta, GA, U.S.A.*

T.E.P.12 Local Action and Research. *Paul Christian Madsen*, I. Bentzen, *AIDS Info/Funen, County of Funen, Odense, Denmark.*

T.E.P.13 Fighting AIDS: An Educational Module for Army Units. *Inon Schenker, School of Public Health and Community Medicine, Hebrew University Medical Faculty, Jerusalem, Israel.*

T.E.P.14 An Assessment of Knowledge, Perceived Risk and Beliefs about Prevention Strategies among New York State Residents. *Carolyn G. Beeker*, M. Zielinski, J. Holmes, *New York State Department of Health AIDS Institute, Albany, NY, U.S.A.*

T.E.P.15 Effectiveness of Fear Appeals in AIDS-Education Posters: Comparison by Race/Ethnicity, Age, and Gender in Three Populations. *Fen Rhodes*, R. J. Wolitski, L. Arguelles, *AIDS Research and Education Project, Long Beach, CA, U.S.A.*

T.E.P.16 Computer-Assisted HIV Education for IVDUs. *Benjamin F. Lewis*, D. J. Ahlgren, A. G. Grace, *Spectrum House, Inc., Westboro, MA, U.S.A.*

T.E.P.17 Promotion of HIV Prevention Outreach Activities Targeting Intravenous Drug Users in the United States. *Imani P. Thompson*, T. S. Jones, K. O'Reilly, *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.E.P.18 Married Homosexual and Bisexual Men: The Development of AIDS Education Strategies and Resources for Healthcare Professionals. *John W. Molenaar, Gay and Married Men's Association, Ministry of Education, Victoria, North Balwyn, Australia.*

T.E.P.19 Direct Approach with Information to Blood Donors at Risk of AIDS Increases the Safety of the Blood Supply. *C. Van der Poel*, H. Reesink, *Red Cross Bloodbank Amsterdam, Amsterdam, Netherlands.*

T.E.P.20 Evaluation of the AIDS Education Programme in N.S.W. Prisons, Australia. *Lisa Conolly*, F. Potter, *N.S.W. Department of Corrective Services, Sydney, Australia.*

T.E.P.21 Knowledge, Attitude and Practice (KAP) of Selected Population Groups towards the Disease AIDS. *Zenaw E. Adam*, A. Yeneabat, D. Fekadu, E. Yacob, A. Helina, T. Mulai, *Department of Community Health, Faculty of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.*

T.E.P.22 CIS-AIDS Zagreb: Telephone Enquiry Service: Two Years' Experience. *Petar Gotovac*, S. Lang, M. Svjetlicic, M. Stritof, Z. Baklaic, M. Vodopija, et al., *Institute of Public Health, Zagreb, Yugoslavia.*

T.E.P.23 La prévention du SIDA, réalisation et évaluation dans l'Océan Indien. *Thierry Troussier*, B. Duffaud, P. Provansal, *Association Réunionnaise Prévention SIDA, Réunion France, St-Denis, France.*

T.E.P.24 Essai d'un didacticiel en prévention du SIDA/MTS auprès d'adolescents. *Richard Cloutier, Département de santé communautaire, Hôpital Général de Montréal, Montreal, QC, Canada.*

T.E.P.25 Live Beyond Your Limits. *Louie Nassaney*, G. R. Kolb, *Louise L. Hay Educational Institute, Santa Monica, CA, U.S.A.*

T.E.P.26 Evaluation of the Italian National AIDS Information Campaign. *Giuseppe Marasca*, V. Bonvini, D. Greco, M. Piazzoli, A. Zampieri, *Istituto Superiore di Sanità, Rome, Italy.*

T.E.P.27 Those Affected by AIDS Treated as Outsiders: Consequence of Misinformation. *Alonso Coronado Luengo*, F. Conde, C. Arredondo, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spain.*

T.E.P.28 Needs of Family Caregivers of Persons with AIDS. *Nancy H. Corby*, G. Wilson, *Long Beach Health Department, Long Beach, CA, U.S.A.*

T.E.P.29 The Male Couple: A Case Study. *Judy G. Krueckl, St.Paul's Hospital, Vancouver, BC, Canada.*

T.E.P.30 AIDS Prevention as Community Intervention. *Viveka Urwitz*, T. Juvall, M. Öhgren, P. Sennerfedlt, *Youth Project Stockholm AIDS Prevention Programme, Stockholm, Sweden.*

T.E.P.31 The HIV Epidemic: Attitudes towards Public Preventive Measures in the Norwegian Population. *Jostein Rise*, P. Kraft, *National Institute of Public Health, AIDS Information Centre, Oslo, Norway.*

T.E.P.32 AIDS in Barbados. *Errol R. Walrond*, M. Hoyos, *University of the West Indies, St. Michael's, Barbados.*

Politiques sociales
Social Policy

T.E.P.33 Community Participation in the Development of a Five- Year Plan on AIDS: New York State's Process and Significant Findings. *Joseph P. Anarella*, C. Bergmann, *AIDS Institute, New York State Department of Health, Albany, NY, U.S.A.*

T.E.P.34 Patients' Preferences for Locus of Care and for Active Treatment: Preliminary Results of a Multi-site Study. *Vincent Mor*, J. A. Fleishman, J. D. Piette, *Brown University, Center for Gerontology and Health Care Research, Providence, RI, U.S.A.*

T.E.P.35 A Feminist View of AIDS: Policy Implications of the Social Construction of a Disease. *Barbara L. A. Herbert, Fenway Community Health Center, Cambridge, MA, U.S.A.*

T.E.P.36 The Social Correlates of AIDS Bigotry: Causes for Concern. *Farrell J. Webb, New York University, Department of Sociology, New York, NY, U.S.A.*

T.E.P.37 L'infection par le VIH: analyse des axes de la politique de santé des pouvoirs publics (pp) en France. *Annie Serfaty*, M. Brodin, C. Alfaro, B. Pissarro, *Faculté Xavier Bichat, Paris, France.*

T.E.P.38 Sexual and Injecting Risk Behavior amongst Drug Users in Birmingham, England. *Hilary R. Kinnell*, R. K. G. Griffiths, *Community Medicine Department, Central Birmingham Health Authority, District Offices, Birmingham, U.K.*

T.E.P.39 AIDS-related Knowledge, Attitudes, and Behavior of Hospital Administrators and Physicians: A Comparative Analysis. *Scott Campbell*, K. Willenbrig, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

T.E.P.40 HIV Counselling for Women Policies and Programs. *Helen Rodriguez-Trias*, A. Dumois, V. Alexander, W. Chavkin, S. Kohn, *New York State Department of Health, AIDS Institute, New York, NY, U.S.A.*

T.E.P.41 Developing Long-Range AIDS Plans in New York City and San Francisco. *Linda L. Udall*, E. L. Rautenberg, G. W. Rutherford, M. Baker, J. W. Amory, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

T.E.P.42 Factors Associated with Willingness to Enter Drug Treatment. *Jeanne E. Kleyn*, R. Fiser, E. Lake, *University of Washington, Seattle, WA, U.S.A.*

T.E.P.43 Current Utilization of Inpatient Alcohol and Drug Treatment Services in a Cohort of IV Drug Users. *Liza Solomon*, R. Frank, D. Vlahov, D. Celentano, S. Cohn, *The ALIVE Study, Johns Hopkins University, Baltimore, MD, U.S.A.*

T.E.P.44 The Soft Underbelly of Research: Administrative and Cost Challenges in a Study of Heterosexual HIV Transmission. *Kenneth H. Mayer*, D. Laufer, L. Feingold, S. Zierler, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A.*

T.E.P.45 New Jersey's Emergency Retrovir Reimbursement Program: Evaluation of Its Effect on Survival Time. *Robert F. Hummel*, R. Conviser, S. Young, E. Bishberg, S. Costa, *New Jersey State Department of Health, Trenton, NJ, U.S.A.*

T.E.P.46 Politique d'intervention municipale de la ville de Montréal relative à la problématique du SIDA. *Léa Cousineau*, L. Doré, R. Blain, *Ville de Montréal, Montreal, QC, Canada.*

T.E.P.47 Recent Changes in Sexual Behavior among Men in Los Angeles. *Kathleen Montgomery*, H. Freeman, C. Lewis, C. Corey, *University of California at Los Angeles, Los Angeles, U.S.A.*

T.E.P.48 Science as a Political Force: The Case of the AIDS Epidemic. *Stephen C. Smith, Human Rights Campaign Fund, Washington, DC, U.S.A.*

T.E.P.49 The Reference and Training Center on AIDS, Sao Paulo, Brazil. *Maria Eugenia Fernandes*, P. R. Texeira, R. Del Bianco, V. Pinto, M. Veda, *Centro de Referência e Treinamento AIDS, Sao Paulo, Brazil.*

T.E.P.50 A Study of National AIDS/HIV Policies and Programmes in the 32 Countries for the European Region. *Brigitte Gredler*, S. Wayling, *World Health Organization, Regional Office for Europe, Copenhagen, Denmark.*

T.E.P.51 Providing Access to Promising Investigational Drugs for AIDS: A Management Model for "Treatment IND". *Deborah G. Katz*, J. Feinberg, M. Myers, E. Gubish, D. Hoth, *AIDS Program, National Institute of Allergy and Infectious Diseases, Rockville, MD, U.S.A.*

T.E.P.52 The Extent and Impact of HIV-related Discrimination in New York City: A Survey of PWAs and Service Providers. *Mitchell Karp, New York City Commission on Human Rights/AIDS Discrimination, New York, NY, U.S.A.*

T.E.P.53 Psychosocial Adaptation and Economic Circumstances of Persons with AIDS or ARC. *Stephen Crystal*, M. Jackson, *Rutgers University, Institute for Health, New Brunswick, NJ, U.S.A.*

Rôle des organismes non-gouvernementaux
The Role of Non-Governmental Organizations

T.E.P.54 Canadian Hemophilia Society: A Planned Response to HIV and AIDS. *Nena M. Nera*, R. O'Neill, *Federal Centre for AIDS, Ottawa, ON, Canada.*

T.E.P.55 Canadian Hemophilia Society: A Collaborative Model Approach with a Non-Governmental Organization (NGO). *Nena M. Nera*, R. J. Shearer, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

T.E.P.56 Role of the University: Education, Research, Policy and Service. *Caryn Berman*, J. A. Cooksey, *University of Illinois at Chicago, Chicago, IL, U.S.A.*

T.E.P.57 Primary Care at a Residence for Persons with AIDS (PWAs): Bailey House, New York City, New York. *Ramon A. Torres*, J. Staats, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A.*

T.E.P.58 AIDS Coalition for Education (ACE): A Broad Organization for the Coordination of AIDS Education, Information and Prevention Efforts. *Peter L. Ralin*, D. Holbrook, M. Peterson, *Denver Disease Control Service, Denver, CO, U.S.A.*

T.E.P.59 Un exemple de collaboration entre une ONG et le programme mondial de lutte contre le SIDA de l'OMS : la formulation clinique dans les pays africains. *Jean E. Malkin*, L. J. Lebas, D. T. Tarantola, L. A. Landi, *Organisation Mondiale de la Santé, Geneva, Switzerland.*

T.E.P.60 A Proposal for a Permanent International Forum of NGOs Working with AIDS. *Walter Almeida*, H. Daniel, S. Ramos, C. D. Guimaraes, R. Cardoso, F. Braune Wiik, *Brazilian Interdisciplinary AIDS Association, Rio de Janeiro, Brazil.*

T.E.P.61 Social Marketing of Condoms and Spermicides in Kinshasa, Zaire. *Tibo Van der Does*, K. Kakera, N. Mivumbi, *Population Services International, Kinshasa, Zaire.*

T.E.P.62 Obtaining Multi-Sectorial Commitments to AIDS Prevention through Leadership Workshops in Developing Countries. *John D. Dupree*, M. Lioy, B. Nirigara, *Academy for Educational Development, Washington, DC, U.S.A.*

T.E.P.63 Role of Voluntary Organizations in Developing Countries in the Battle against AIDS. *Audrey V. Courtneay, Belize Red Cross, Belize, Belize.*

T.E.P.64 ABIA: A Brazilian Strategy for AIDS Prevention Based on Action and Solidarity. *Carmen D. Guimaraes*, W. Almeida, R. Cardoso, H. Daniel, S. Ramos, *Brazilian Interdisciplinary AIDS Association, Rio de Janeiro, Brazil.*

T.E.P.65 Out-Patient Clinic for Social Outcasts in Rio de Janeiro, Brazil. *Maria Inez Linhares Carvalho*, J. M. Tame, L. R. Castello-Branco, N. Feijó, *Banco da Providencia da Arquidiocese do Rio de Janeiro, Rio de Janeiro, Brazil.*

T.E.P.66 Prise en charge des patients infectés par le VIH au sein d'une consultation hospitalière specialisée : Rôle des associations de volontaires. *Jacques Lebas*, O. Baudry, M. C. Meyohas, G. Gonzalez, O. Picard, J. C. Imbert, *Hôpital St-Antoine, Paris, France.*

T.E.P.67 Survey of the Client Structure of the Austrian AIDS Foundation's Counselling Centre in Vienna, July 1987-December 1988. *Judith Hutterer*, R. Brandstaetter, G. Vogt, F. Piribauer, P. Blaas, *Oesterreichische AIDS-Hilfe, Vienna, Austria.*

T.E.P.68 Recherche d'une stratégie de communication efficace contre le SIDA. *Bernard Dagenais, Université Laval, Département d'Information et Communication, Québec, QC, Canada.*

T.E.P.69 A 40-Hour Training Program on AIDS for Public High School Teachers. *Maria Eugenia Fernandes*, A. Pinel, M. A. Nardi, N. Abud, A. C. Issler, E. Inglese, *Centro de Referência e Treinamento AIDS, Sao Paulo, Brazil.*

T.E.P.70 AIDS: New Types of Public Health Programs in West Berlin. *Monika Hachmann*, P. C. Bargstedt, K. Messing, P. Klapps, A. Kohlhoff, *Landesinstitut für Tropenmedizin, Arbeitsgruppe AIDS, Berlin, Federal Republic of Germany.*

T.E.P.71 AIDS Service Organization: Lessons for Strategic Planning and Organizational Design. *Richard Rector*, S. Wayling, R. Grose, *AIDS Health Consultant, Copenhagen, Denmark.*

T.E.P.72 Placing Educational Interventions within the Context of Comprehensive Social Policies to Reduce the Spread of HIV Infection. *Ronny A. Shtarkshall, The Hebrew University, Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel.*

T.E.P.73 AIDS and the Role of Civic Movements: A Communication Bridge in Both Directions. *Héctor Anabitarte*, J. Torres, R. Usieto, B. Mompradé, *Comité Ciudadano Anti-SIDA España, Madrid, Spain.*

T.E.P.74 Successful Community-Based HIV/AIDS Education and Information Programs Targeting Racial and Ethnic Minority Communities in the United States. *Stephen E. Schindler*, M. Murgia, A. E. Gambrell, C. Nowicki, R. D. Johnson, G. S. Bowen, et al., *Centers for Disease Control, Atlanta, GA, U.S.A.*

T.E.P.76 The Stockholm Model: Community Intervention as a Means to Reach 1.6 Million People with AIDS Prevention. *Anna-Karin Asp*, B. Gustafsson, L. Abascal, V. Urwitz, *Stockholm County Council, Stockholm, Sweden.*

Section
F
Droit et éthique
Ethics and Law

Mardi 6 juin
Tuesday, June 6

Session d'affichage
Poster Session

La confidentialité et ses limites
Confidentiality and Its Limits

T.F.P.1 Trial of Chemo-Prophylaxis of HIV-Infection and the Health-Care Worker's Right-to-know Vis-à-vis the Patient's Right to Confidentiality. *Stanley Bauer, The Bronx-Lebanon Hospital Center, Department of Pathology, Bronx, NY, U.S.A.*

T.F.P.2 Confidentiality and AIDS: A Canadian Perspective. *Robert M. MacMillan*, M. E. Barnes, *Assistant Deputy Minister, Community Health, Toronto, ON, Canada.*

T.F.P.3 Confidentialité et SIDA: Utilisation d'un codage irréversible de l'identité. *Xavier Thirion*, R. Sambuc, C. Manuel, J. L. San Marlo, *Laboratoire de Santé Publique, Faculté de Médecine, Marseille, France.*

T.F.P.4 Ethical Theories Applied to Confidentiality in HIV+ Males. *Dena J. Seiden*, *Union Theological Seminary, New York, NY, U.S.A.*

Éthique clinique
Clinical Ethics

T.F.P.5 Perceptions and Attitude of Health Care Workers on Ethical and Social Aspects of AIDS in a Developing Country. *Prabhakar Parimi*, F. A. Orrett, *University of the West Indies, Kingston, Jamaica.*

T.F.P.6 A Model for Facilitating Physicians' Acceptance of Risk when Treating Patients with AIDS. *Walter V. Flegenheimer*, J. Wallack, P. Bialer, *Beth Israel Medical Center, New York, NY, U.S.A.*

T.F.P.7 CHUL Bioethics Committee and the Anti-HIV Screening Test. *Michel R. Morissette*, M.-J. Melançon, *Centre hospitalier de l'Université Laval (DSC), Ste-Foy, QC, Canada.*

T.F.P.8 A Legal or Ethical Duty to Warn: One Last Time. *Richard L. North*, K. Rothenberg, *University of Maryland School of Law, Baltimore, MD, U.S.A.*

T.F.P.9 Ethical Standards in the Context of HIV Infection. *Norbert Specht*, Ian Schäfer, *Deutsche AIDS-Hilfe, Berlin, Federal Republic of Germany.*

T.F.P.10 SIDA : Les droits des malades. *Catherine Manuel*, Y. Charrel, M. P. Larher, P. Enel, J. L. San Marco, *Laboratoire de Santé Publique, Faculté de Médecine, Marseille, France.*

T.F.P.11 Approche éthique du phénomène SIDA : Revue bibliographique. *Catherine Manuel*, P. Enel, J. Charrel, M. P. Lahrer, D. Reviron, X. Thirion, *Laboratoire de Santé publique, Faculté de Médecine, Marseille, France.*

T.F.P.12 Influence of HIV Status on Decision Making for Newborns. *Kathleen E. Powderly*, J. D. Moreno, B. W. Levin, *Columbia University School of Nursing, New York, NY, U.S.A.*

Section
G

Mardi 6 juin
Tuesday, June 6

Implications internationales
International Issues

Session d'affichage
Poster Session

Stratégies et programmes
Strategies and Programmes

T.G.P.1 The International AIDS Activities of the U.S.A. Government. *Kathryn S. Aultman*, J. R. Harris, J. D. Wells, *United States Agency for International Development, Washington, DC, U.S.A.*

T.G.P.2 The Epidemiology of AIDS in the Americas. *Ronald K. St-John*, M. Clifford, F. R. K. Zacarias, *Pan American Health Organization, Washington, DC, U.S.A.*

T.G.P.3 Priorities for HIV Epidemiological Research. *Marc Karam*, B. Nkowane, R. Biritwum, P. Bres, E. Beausoleil, J. Mann, *The World Health Organization, Geneva, Switzerland.*

T.G.P.4 Impact of the HIV Epidemic: Emergency Department Resource Utilization by Patients with Known HIV-1 Infection. *Gabor D. Kelen*, G. Johnson, T. DiGiovanna, K. Loring, K. Sivertson, *The Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

T.G.P.5 The International Working Group on AIDS and IV Drug Use. *Joycelyn Sue Woods*, D. C. Des Jarlais, S. R. Friedman, *Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

T.G.P.6 Serosurveillance of Human Immunodeficiency Virus (HIV) Infection in Tribal Population of Andaman-Nicobar Islands, India. *Pradeep Seth*, M. Mukherjee, I. C. Verma, R. Elango, S. Mathew, *All India Institute of Medical Sciences, New Delhi, India.*

T.G.P.7 Detailed Estimates of the Current and Future Extent of the HIV/AIDS Pandemic in Sub-Saharan Africa. *Paul Sato*, J. Chin, S. Lwanga, E. G. Beausoleil, J. Mann, *World Health Organization, Geneva, Switzerland.*

T.G.P.8 Control of Tranfusion Related Transmission of HIV Infection, Strategies of the EEC's AIDS Programme for Developing Countries. *Johannes C. Van Dam*, T. Amat Cortadillas, L. Fransen, *AIDS Task Force, Brussels, Belgium.*

T.G.P.9 Planning a National Strategy on AIDS and Injection Drug Use: Lessons from the Literature. *Betsy Mackenzie*, K. Elmslie, *Federal Centre for AIDS, Ottawa, ON, Canada.*

T.G.P.10 Medium Term Plan for the Control of AIDS in Cameroon, Africa: October 1988-September 1993. *Roger Salla*, L. Kaptue, *Service de lutte contre le SIDA, Yaounde, Cameroon.*

T.G.P.11 Élaboration d'une stratégie de prévention du SIDA adaptée au milieu de la prostitution organisée à Cotonou, Bénin. *Ronald Verbeke*, B. Monteiro, *Université de Mons, Mons, Belgium.*

T.G.P.12 The Importance of Qualitative Research in Developing Operations Research Protocols: Strategies for Gay and Bi-Sexual Men in the Dominican Republic. *Michael L. E. Ramah*, R. Pareja, *Porter/Novelli, AIDSCOM, Washington, DC, U.S.A.*

T.G.P.13 Contraceptive Social Marketing Principles: Promoting Condom Use in Uganda and Tanzania for AIDS Prevention. *Dace Stone*, D. Levy, S. Saunders, *Academy for Educational Development/Johns Hopkins University, Washington, DC, U.S.A.*

T.G.P.14 Follow-up of Groups at Risk for HIV Infection. *M. Beatriz S. Dias*, J. N. Lima, W. B. Abreu, F. H. Aoki, N. Gonçales, R. J. Pedro, *Hospital de Clinicas, University of Campinas, Grupo de AIDS, Campinas, Brazil.*

T.G.P.15 Education and Law: The Control of Transmissible Diseases through the Control of Gossip, Ignorance, and Discrimination. *Kit Traub, University of Georgia School of Law, Athens, GA, U.S.A.*

T.G.P.16 Training Health Workers in Zambia for HIV Infection. *A. Haworth*, K. Kalumba, M. Kelly, A. Chingono, *University of Zambia School of Medicine, Lusaka, Zambia.*

T.G.P.17 International AIDS Programs at the National Institutes of Health. *Kenneth Bridbord*, M. Hamburg, P. E. Schambra, J. Whitescarver, A. S. Fauci, *Fogarty International Center, National Institutes of Health, Bethesda, MD, U.S.A.*

T.G.P.18 Development of the AIDS Epidemic in South Africa. *Sylvia S. Johnson*, B. D. Schoub, D. Martin, S. F. Lyons, G. N. Padayachee, S. Naidoo, *National Institute for Virology, University of the Witwatersrand, Transvaal, South Africa.*

T.G.P.19 Small Particle Permeability of Used Versus Unused Surgical Rubber Gloves. *Andrew S. Goldstein*, K. Stokes, P. Yoshihara, S. C. Arya, *Epitope, Inc., Beaverton, OR, U.S.A.*

T.G.P.20 A Study on HIV-1 Infection amongst Haemophiliacs in Iran. *Houri Rezvan*, S. Taroyan, S. Jalali, M. Kayhani, *Iranian Blood Transfusion Service, Tehran, Iran.*

T.G.P.21 Adapting Western Experiential Exercises into AIDS Prevention Counselling Training in Developing Countries. *John D. Dupree*, A. Demby, R. Chingono, *Academy for Educational Development, Johns Hopkins University, Washington, DC, U.S.A.*

T.G.P.22 Prevention Counselling: Integrating Concepts and Techniques in all AIDS Prevention Strategies. *Dace Stone*, N. Kaleeba, V. Orias, *Academy for Educational Development, Johns Hopkins University, Washington, DC, U.S.A.*

T.G.P.23 AIDS and Adolescents: A Preliminary Study of Youths' Perception of AIDS as a Disease: Nigerian Experience. *Lola Vivian Adekunle, Department of Preventive and Social Medicine, UCH, Ibadan, Nigeria.*

T.G.P.24 HIV/AIDS-related Travel and Migration Restrictions. *Margaret Duckett*, A. Orkin, *McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

Épidémiologie : VIH-2
Epidemiology: HIV-2

T.G.P.25 Detection of HIV-2 Infection and Ratio to HIV-1 among Hospitalized Patients in Rio de Janeiro, Brazil. *John W. Krebs*, F. S. Sion, A. B. Sereno, R. S. Goncalves, E. P. Quinhoes, B. G. Weniger, et al., *Centers for Disease Control, AIDS Program, AIDS Laboratory Branch, Atlanta, GA, U.S.A.*

T.G.P.26 Problématique de l'infection HIV-2 : exemple du Sénégal. *Souleymane M'Boup*, I. Ndoye, A. Samb, T. Siby, C. B. Boye, L. Sangaré, et al., *Hôpital Le Dantec, Dakar, Senegal.*

T.G.P.27 HIV-2 Link to AIDS. *Isabelle Romieu*, R. Marlink, S. M'Boup, P. J. Kanki, M. Hernandez, M. Essex, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

T.G.P.28 Double HIV-1 and HIV-2 Seropositivity in Guinea. *Catherine Foucault-Fretz*, J. C. Gluckman, J. J. Fournel, K. Kourouma, P. Diallo, K. Diallo, *Blood Transfusion Center, Hôpital de la Pitié-Salpêtrière, Paris, France.*

T.G.P.29 Coinfections HIV-2/HTLV-I dans un groupe de sujets à risque au Sénégal. *Dominique Ricard*, S. M'Boup, F. Denis, M. Essex, *Université de Dakar, Dakar, Senegal.*

T.G.P.30 The Epidemiology of HIV-1 and HIV-2 in the Gambia, West Africa. *Bruce J. Oelman*, H. A. Wilkins, A. Hughes, H. Whittle, K. O. Jaiteh, M. K. Cham, *Epidemiology and Statistics Unit, Banjul, Gambia.*

T.G.P.31 No Evidence of Vertical Transmission of HIV-2 in Bissau. *Anne-Grethe Poulsen*, B. B. Kvinesdal, P. Aaby, K. Frederiksen, K. Mlbak, F. Dias, et al., *Statens Seruminstitut, Copenhagen, Denmark.*

T.G.P.32 Prevalence and Correlates of Retroviral Infections among Prostitutes Working in the Gambia. *Jacques Pépin*, A. Egboga, P. Alonso, I. Gaye, H. Whittle, H. A. Wilkins, et al., *The MRC Laboratories, Banjul, Gambia.*

Notes

Section
H

Mardi 6 juin
Tuesday, June 6

Répercussions économiques du SIDA
The Economic Impact of AIDS

Session d'affichage
Poster Session

Planification/Gestion
Planning/Management

T.H.P.1 The Impact of Caring for AIDS Patients on the Workload of Primary Care Physicians in a Health Maintenance Organization. *Kathryn L. Coltin*, J. Goldberg, *Harvard Community Health Plan, Brookline, NY, U.S.A.*

T.H.P.2 Hospital-Based AIDS Volunteer Program in Health Maintenance Organization (HMO). *Deborah Casado*, J. Stone, *Kaiser Permanente (Department of Social Work Services), San Francisco, CA, U.S.A.*

T.H.P.3 Demographic, Utilization and Reimbursement Data for AIDS Patients in 21 U.S. Cities. *S. Matheny*, C. Hostetter, N. Paquin, D. McMenamin, *Department of Health and Human Services, Rockville, MD, U.S.A.*

T.H.P.4 Development of a Severity Index for Use with Statewide Medicaid AIDS Patient Files. *Barbara J. Turner*, F. Alemi, L. Markson, *Jefferson Medical College, Philadelphia, PA, U.S.A.*

T.H.P.5 Specific and Sensitive Estimates of Acute Care Hospital Stays Associated with HIV in New York. *George T. DiFerdinando*, G. Kaufman, *New York State Department of Health, Albany, NY, U.S.A.*

T.H.P.6 The C-100 Clinic: The Establishment of a Primary Care Program at Charity Hospital at New Orleans, Louisiana. *Ted L. Wisniewski, Louisiana State University Medical Center, New Orleans, LA, U.S.A.*

T.H.P.7 Scatter Bed Versus Cluster Unit Treatment of AIDS Inpatients. *George Fulop*, J. J. Strain, M. C. Fahs, H. S. Sacks, *The Mount Sinai School of Medicine, New York, NY, U.S.A.*

T.H.P.8 The Economic Impact of Early Intervention in HIV Disease. *Peter S. Arno*, D. Shenson, N. F. Siegel, P. Franks, P. R. Lee, *Montefiore Medical Center, Bronx, NY, U.S.A.*

T.H.P.9 Assessing the Cost of AIDS to Both Patients and the Health Care Institution. *Mary A. Pittman-Lindeman*, D. Miller, P. E. Sowa, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

T.H.P.10 Hospital Costs and DRG Reimbursements for HIV Admissions. *Jihad Slim*, D. Heldge, G. Perez, E. S. Johnson, E. Perez, *Saint-Michael's Medical Center, Newark, NJ, U.S.A.*

T.H.P.11 Shifting towards Ambulatory Care of AIDS Patients: Lessons from the PCP Epidemic. *Nirvair Levitt*, J. S. G. Montaner, L. Lawson, R. Sigurnjak, L. Malysh, J. Ruedy, *University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada.*

T.H.P.12 Health Care Costs of Class 4 HIV Care in an HMO Setting. *Elizabeth S. Anderson*, A. Shields, T. Revis, M. Mehring, Y. Chi, R. L. Thompson, *Group Health Cooperative of Puget Sound, Center for Health Promotion, Seattle, WA, U.S.A.*

T.H.P.13 An Interdisciplinary Model of AIDS Care in a Teaching Hospital. *Irene L. Goldstone*, J. Ruedy, A. McLeod, *St. Paul's Hospital, Vancouver, BC, Canada.*

T.H.P.14 Essai d'adaptation d'un cabinet de médecine générale en ville. *Jean-Florian Mettetal*, M. Bary, F. Edelmann, A. Jourdan, *ARCAT-SIDA, Paris, France.*

T.H.P.15 Community-based Pneumo-Clinics as a Model for Cost-effective Lowered Morbidity and Mortality in HIV Disease. *Mark Harrington*, D. Z. Kirschenbaum, *ACT-UP/NY, New York, NY, U.S.A.*

Financement et assurances
Financing and Insurance

T.H.P.16 The "Medicaidization" of AIDS. *Jesse Green*, P. Arno, *New York University Medical Center, Department of Health Policy Research, New York, NY, U.S.A.*

T.H.P.17 Lifetime Patterns of Medicaid Expenditures for Persons with AIDS in California. *Roxanne M. Andrews*, M. Keyes, P. Pine, *Systemetrics/McGraw Hill, Washington, DC, U.S.A.*

T.H.P.18 Consumption of Mental Health and Social Services by PWAs. *Marilyn Cvitanic*, C. L. Bennett, R. L. Bennett, A. Pascal, *RAND/UCLA, Center for Health Policy Study, Santa Monica, CA, U.S.A.*

T.H.P.19 Meeting the Needs? *Jonanthan P. Cooper, The Haemophilia Society, London, U.K.*

T.H.P.20 Access to Insurance and Perceived Discrimination by Homosexual Men. *Nancy E. Kass, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

T.H.P.21 Costs of Hospitalization for AIDS Patients at a Community Hospital in Connecticut. *Robert W. Lyons*, G. M. Madden, R. M. Costanzo, *St. Francis Hospital and Medical Center, University of Connecticut, Hartford, CT, U.S.A.*

T.H.P.22 How Do Persons with Symptomatic HIV Disease Finance Their Care in Texas? *Martin M. Crane*, S. Tortolero, A. Hines, L. Jardine, C. Johnson, *University of Texas, Department of Health Science, Houston, TX, U.S.A.*

T.H.P.23 Health Insurance Status and the Utilization of Health Services in a Cohort of IV Drug Users. *Liza Solomon*, R. Frank, D. Celentano, D. Vlahov, S. Cohn, *The ALIVE Study, Johns Hopkins University, Baltimore, MD, U.S.A.*

T.H.P.24 The Share of AIDS Medical Care Costs Paid by Private Insurance in the U.S.A. *Charles L. Eby, Health Insurance Association of America, Inc., Washington, DC, U.S.A.*

T.H.P.25 The Global Philanthropic Response to AIDS. *Michael S. Seltzer*, S. Moskie, *Executive Director, Funders Concerned About AIDS, New York, NY, U.S.A.*

Additionnels
Additional

T.H.P.27 AIDS Case Management: What Insurance Companies Are Doing. *Charles L. Eby*, C. Jajich-Toth, *Health Insurance Association of America, Inc., Washington, DC, U.S.A.*

T.H.P.28 Statistical Methodology for Study of the AIDS Epidemic. *Donald L. Thomsen, Societal Institute of the Mathematical Sciences, New Canaan, CT, U.S.A.*

T.H.P.29 AIDS in the Workplace: A Worldwide Health Concern Becomes a Business Concern. *Paul A. Ross, Digital Equipment Corporation, Concord, MA, U.S.A.*

Mercredi
Wednesday

le mercredi 7 juin

Etat de la Question

Présidente: *L'Honorable Monique Landry*
Ministre des relations extérieures et du développement international du Canada

Conférenciers:

Les femmes, les enfants et le SIDA - questions touchant les femmes, les enfants et le SIDA dans le monde industrialisé

Catherine Hankins
Directeur
Programme régional de contrôle
MTS-SIDA
Québec, Canada

Le SIDA chez les enfants en Afrique: perspectives et défis

Angela A. Okolo
Maître de conférence
Département de santé de l'enfant
Collège des sciences médicales
University of Benin
Nigéria

Epidémiologie et lutte contre le SIDA chez les consommateurs de drogues

Roel A. Coutinho
Service de santé municipale
Département de la santé publique et de l'environnement
Pays-Bas

Thérapie anti-rétrovirale: le passé, le présent et l'avenir

Samuel Broder
Directeur, National Cancer Institute
Etats-Unis

Pour une approche bio-culturelle du SIDA: impasses et nouvelles pistes

Gilles Bibeau
Professeur et Directeur
Département d'anthropologie
Université de Montréal
Québec, Canada

State-of-the-Art

Chairperson:

The Honourable Monique Landry
Minister for International Relations
and International Development of
Canada

Plenary speakers:

Women, children, and AIDS - issues involving women, children and AIDS in the developed world

Catherine Hankins
Director
Montreal Regional STD-AIDS Control
Quebec, Canada

Childhood AIDS in Africa: perspectives, challenges

Angela A. Okolo
Senior Lecturer
Department of Child Health
College of Medical Sciences
University of Benin
Nigeria

Epidemiology and control of AIDS among drug users

Roel A. Coutinho
Municipal Health Service
Department of Public Health and
Environment
The Netherlands

Anti-retroviral therapy; past, present, and future

Samuel Broder
Director
National Cancer Institute
U.S.A.

For a biocultural approach to AIDS: dead ends and new leads

Gilles Bibeau
Professor and Director
Department of Anthropology
University of Montreal
Quebec, Canada

11:00 - 12:30

Salle
Room **407A**



Section
A

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique **Transmission du VIH dans le milieu des soins de la santé**

Specialty Session **HIV Transmission in the Health Care Setting**

Présidents
Chairpersons
James Curran (U.S.A.)
Julian Gold (Australia)
Catherine Peckman (U.K.)

11:00 **W.A.O.1** Health-Care Workers Exposed to Patients Infected with Human Immunodeficiency Virus (HIV), United States. *Ruthanne Marcus and the Cooperative Needlestick Surveillance Group, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **W.A.O.2** Surveillance Update: Health-Care Workers with AIDS. *Mary E. Chamberland, L. Conley, T. Bush, H. Jaffe, Centers for Disease Control, CID, AIDS, Atlanta, GA, U.S.A.*

11:30 **W.A.O.3** Prevalence of HIV Infection among Persons Employed in Medicine and Health Occupations. *David N. Cowan, Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

11:45 **W.A.O.4** Adherence to Universal Precautions by HCWs in an Inner-City Emergency Department with High HIV-1 Prevalence among Patients. *Gabor D. Kelen, T. DiGiovanna, D. Kalainov, L. Bisson, C. Scott, The Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

12:00 **W.A.O.5** Nosocomial Outbreak of HIV Infection in Elista, USSR. *V.V. Pokrovsky, E. U. Eramova, Laboratory of Immunodeficiency, Central Institute of Epidemiology, Moscow, U.S.S.R.*

11:00 - 12:30

Salle
Room **408BC**



Section
A

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde
Round Table

Transmission hétérosexuelle
Heterosexual Transmission

Présidents
Chairpersons

Frank Plummer (Canada)
Martin Schechter (Canada)

11:00 **W.A.O.6**

Program Content:

- Efficiency of transmission: male-to-female, female-to-male
- STDs as cofactors for index and secondary partner
- Other possible co-factors, including circumcision, menstrual cycle
- Viral factors, e.g. strain virulence, size of inoculum
- Efficacy of condoms, spermicides, other barrier contraceptives
- Methodologic issues in designing and interpreting transmission studies

Panelists:

Marie Laga, Antwerp, Belgium.
Nancy Padian, San Francisco, CA, U.S.A.
Nzilambi Nzila, Zaire.

11:00 - 12:30

Salle / Room **401ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Pharmacologie et toxicité de l'AZT / AZT Pharmacology and Toxicity**

Présidents / Chairpersons
Robert E. Allen (USA)
Fred Aoki (Canada)
David Cooper (Australia)

11:00 **W.B.O.1** Pharmacokinetics of Zidovudine in Early HIV-Infected Homosexual Males. *John Ruedy, J. S. G. Montaner, T. Le, K. Gelmon, M. Fanning, J. Smith, et al., St. Paul's Hospital, University of British Columbia, Multicentre Canadian AZT Trial (MCAT), Vancouver, BC, Canada.*

11:15 **W.B.O.2** A Phase One Study of Zidovudine (AZT) in Infants, Less than Three Months Old, at Risk for HIV Infection. *François D. Boucher*, C. G. Prober*, A. M. Arvin*, J. F. Modlin**, M. Maha***, S. Lafon***, et al., *Stanford University Medical Center, Division of Pediatric I. D., Stanford, CA; **Johns Hopkins University, Baltimore, MD; ***Burroughs-Wellcome Co., Research Triangle Park, NC, U.S.A.*

11:30 **W.B.O.3** Pharmacokinetics of Zidovudine in IDU Related HIV Infection. *Raymond P. Brettle*, G. A. Jones*, J. Bingham*, B. E. M. Spacey**, B. Weatherley**, R. Churchus**, *Department of Infectious Diseases, City Hospital, Edinburgh; **Wellcome Research Laboratories, Beckenham, U.K.*

11:45 **W.B.O.4** Probenecid Inhibits the Metabolic and Renal Clearance of Zidovudine in Human Volunteers. *Mohsen A. Hedaya, W. F. Elmquist, R. J. Sawchuk, University of Minnesota, Department of Pharmaceutics, Minneapolis, MN, U.S.A.*

12:00 **W.B.O.5** Effect of Acetaminophen (ACET) on the Pharmacokinetics of Zidovudine (AZT). *Richard J. Ko*, R. I. Koda*, D. Antoniskis*, M. Shields*, H. Malancon*, J. L. Cohen**, J. M. Leedom*, F. R. Sattler*, et al., *University of Southern California, School of Pharmacy, Los Angeles, CA; **University of Kentucky, Lexington, KY, U.S.A.*

12:15 **W.B.O.6** Long-term Non-Hematological Adverse Effects of AZT and Its Effect on Pre-Treatment Symptomatology. *Mary M. Fanning*, J. Osachoff*, J. S. G. Montaner**, C. Tsoukas***, K. Gelmon****, J. Ruedy*, et al., *University of Toronto, Toronto, ON; **University of British Columbia, Vancouver, BC; ***McGill University, Montreal, QC, Canada; ****St. Paul's Hospital, London, U.K.*

11:00 - 12:30

Salle / Room **403ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session: **Traitement : thrombocytopénie / Therapy: Thrombocytopenia**

Présidents / Chairpersons: Penny J. Ballem (Canada), Eva Marie Coll (Senegal), Roger A. Pradinaud (French Guyana)

11:00 **W.B.O.7** Zidovudine as a Possible Treatment for Thrombocytopenia Associated with AIDS and ARC. *Stephen T. Green, W. C. Love, D. Nathwani, D. J. Goldberg, R. J. Fallon, D. H. Kennedy, Clinical Department of Infectious Diseases, Ruchill Hospital, Glasgow, U.K.*

11:15 **W.B.O.8** The Effect of Zidovudine on Platelet Count in HIV-Associated Thrombocytopenia. *Julio S. G. Montaner*/**, T. Le**, K. Gelmon**, M. Fanning**, J. Falutz**, J. Ruedy**, G. Tsoukas**, G. Wells**, M. O'Shaughnessy**, M. Wainberg**, *St. Paul's Hospital, University of British Columbia; **Multicentre Canadian Azidothymidine Trial (MCAT), Vancouver, BC, Canada.*

11:30 **W.B.O.9** The Effect of Zidovudine on HIV-Associated Thrombopenia. *Matei A. Popesco, H. Jäger, W. Kaboth, AIDS Study Group, Schwabinger Krankenhaus, Munich, Federal Republic of Germany.*

11:45 **W.B.O.10** The Epidemiology of Immune Thrombocytopenia (ITP): Are Increases in ITP in the Population a Manifestation of the HIV Epidemic? *Walter F. Schlech, C. Nesdoly, N. Meagher, J. Turner, D. Dickey, et al., Dalhousie University and Victoria General Hospital, Halifax, NS, Canada.*

12:00 **W.B.O.11** Treatment of Severe HIV-Related Thrombocytopenia in Drug Users. *Massimo Galli*, G. Landonio**, A. M. Nosari**, A. Lazzarin*, L. Voltolin*, F. De Cataldo**, *L. Sacco Hospital, University of Milan, Infectious Diseases Clinic; **Niguarda Hospital, Department of Hematology, Milan, Italy.*

12:15 **W.B.O.12** HIV-1 Associated Thrombocytopenia: Disappointing Long Term Results of Splenectomy. *Sunil Shaunak, D. S. Tyler, J. A. Bartlett, J. D. Iglehart, Duke University Medical Center, Durham, NC, U.S.A.*

11:00 - 12:30

Salle
Room **407B**

Section
B

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Colloque — **Qualité des soins offerts aux personnes atteintes de SIDA**

Symposium — **Quality of Care for Patients with AIDS**

Présidents / Chairpersons — Norbert Gilmore (Canada)
Paul A. Volberding (U.S.A.)

11:00 **W.B.O.13** Quality of Care for Patients with AIDS: Role of Community Physician. <u>B. Willoughby</u>, *Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*

11:15 **W.B.O.14** Hospital Care of AIDS Patients. <u>Nathan Clumeck</u>, *Free University of Brussels, St-Pierre University Hospital, Brussels, Belgium.*

11:30 **W.B.O.15** Outpatient Clinics. <u>Paul Volberding</u>, *San Francisco General Hospital, San Francisco, CA, U.S.A.*

11:45 **W.B.O.16** Home Care Therapy. <u>Jeannie Parker-Martin</u>, *Visiting Nurses and Hospice of San Francisco, San Francisco, CA, U.S.A.*

12:00 **W.B.O.16a** AIDS and US Veterans: A Comprehensive Care Approach in a National Health Care System. <u>Robert Allan</u>, *AIDS Program Office, Department of Veterans Affairs, Washington, DC, U.S.A.*

11:00 - 12:30

Salle
Room **407C**

Section
C

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium

Gènes régulateurs et diversité génomique virale
Regulatory Genes and Viral Genomic Diversity

Présidents / Chairpersons: Lars Olof Kallings, Flossie Wong-Staal

11:00 **W.C.O.1** Genetic Regulation of HIV-1 Expression. *Flossie Wong-Staal, Laboratory of Tumour Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.*

11:15 **W.C.O.2** Feline Immunodeficiency Virus: Genetic Organization and Regulation. *Paul Luciw*, J. Elder**, R. Talbott**, E. Sparger*, N. Pedersen*, *University of California, Davis, CA; **Research Foundation of Scripps Clinic, LaJolla, CA, U.S.A.*

11:30 **W.C.O.3** Viral Mutogenesis. *William Haseltine, Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

11:45 **W.C.O.4** The HIV-Quasispecies: A Necessary Description. *S. Wain-Hobson, Unité de recombinaison et expression génétique, Institut Pasteur, Paris, France.*

11:00 - 12:30

Salle / Room **408A**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Éléments de base en immunologie / Basic Immunology (Part 1)**

Présidents / Chairpersons
Dietmar Fuchs (Austria)
Clifford Lane (U.S.A.)
Rosemarie Pereira (France)

11:00 **W.C.O.5** CD8+ Lymphocytes Are the Critical Cells Mediating Suppression of HIV Release by CD4+ Cells. *Lory D. Wiviott, C. M. Walker, J. A. Levy, University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

11:15 **W.C.O.6** Infection by HIV-1 of Purified NK Cells with a CD3-, CD2+, CD8+, CD16+ Phenotype. *Daniel Scott, V. Favier, F. Vuillier, D. Guetard, L. Montagnier, G. Dighiero, Unité d'Immunopathologie et Immunohématologie, Institut Pasteur, Paris, France.*

11:30 **W.C.O.7** Activation and Infection of T Cells by HIV-1 Infected Antigen Presenting Monocyte/Macrophages. *Dean L. Mann, S. Gartner, M. Popovic, National Cancer Institute-FCRF Laboratory of Viral Carcinogenesis, Frederick, MD, U.S.A.*

11:45 **W.C.O.8** Macrophage-Activating-Factors (MAFs) Alter HIV-1 Production from Primary Mononuclear Phagocytes. *John W. Mellors, M. Ortiz, N. Asato, B. Griffith, M. Landry, J. Ryan, Yale University School of Medicine and Veterans Administration Medical Center, West Haven, CT, U.S.A.*

12:00 **W.C.O.9** Pattern of HIV Replication during In Vitro Maturation of Monocytes into Macrophages. *René Olivier*, F. Chapuis**, T. Jouault**, C. Parravicini***, J. C. Gluckman**, L. Montagnier*, *Institut Pasteur, Unité d'Oncologie Virale; **UER Pitié-Salpêtrière, Paris, France; ***V Catt. Anat. Pat. Università di Milano, Ospedale L. Sacco, Milan, Italy.*

12:15 **W.C.O.10** Adherent Lymphokine-activated Killer Cell (A-LAK) Cytotoxic Activity against HIV-infected Monocytes. *Robert J. Melder*/**, R. Balachandran*, P. Gupta*, C. R. Rinaldo*, T. L. Whiteside*/**, R. B. Herberman*/**, *University of Pittsburgh; **Pittsburgh Cancer Institute, Pittsburgh, PA, U.S.A.*

11:00 - 12:30

Salle / Room **410ABC**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Biologie moléculaire (partie 2) / Molecular Biology (Part 2)**

Présidents / Chairpersons
Jesus V. Benitez Fuentes (Cuba)
M. P. Kieny (France)
Paul Luciw (U.S.A.)

11:00 **W.C.O.11** Inhibitors of HIV-1 Protease Inhibit the Processing of GAG and GAG/POL Polyproteins in Infected T-Cells. *Stephen R. Petteway, D. M. Lambert, T. Meek, G. Dreyer, J. J. Leary, B. Metcalf, Smith Kline & French Laboratories, Departments of Antiinfectives and Chemical Sciences, King of Prussia, PA, U.S.A.*

11:15 **W.C.O.12** Interaction of CD4 with gp120 of the HIV Viruses. *Raymond W. Sweet*, J. Arthos*/**, K. C. Deen*, R. Axel***, J. Hoxie**, et al., *Smith Kline & French Laboratories, King of Prussia; **University of Pennsylvania, Philadelphia, PA; Columbia University, New York, NY, U.S.A.*

11:30 **W.C.O.13** Identification of an Attenuated AIDS-Inducing FeLV that Has a Defect in Envelope Protein Processing. *Julie Overbaugh*, E. A. Hoover**, J. I. Mullins***, M. Poss**, *University of Washington, Seattle, WA; Colorado State University, Fort Collins, CO; ***Harvard School of Public Health, Boston, MA, U.S.A.*

11:45 **W.C.O.14** Single Point Mutations in the HIV Envelope Gene Encoding Extracellular Glycoprotein Affect Viral Tropism and Receptor Binding. *Agnès M. Cordonnier, Y. Rivière, L. Montagnier, M. Emerman, Institut Pasteur, Unité d'Oncologie virale, Paris, France.*

12:00 **W.C.O.15** The Effect of HIV Infection on Monocyte Differentiation. *Romas Geleziunas, F. Boulerice, S. Bour, M.A. Wainberg, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada.*

12:15 **W.C.O.16** Evidence that CD4(81-92) May Constitute a Unique Binding Epitope for HIV Envelope Glycoprotein/CD4 Interaction. *Lee E. Eiden*, V. Kalyanaraman*, J. Lifson**, K. Hwang**, M. Padgett***, D. Rausch***, *Bionetics Research Inc., Rockville, MD; **Genelabs Inc., Redwood City, CA; ***National Institute of Mental Health, Bethesda, MD, U.S.A.*

11:00 - 12:30

Salle / Room **409ABC**



Section **D**

Mercredi 7 juin
Wednesday, June 7

Le SIDA et l'individu
AIDS and the Individual

Séance thématique / Specialty Session **Les femmes / Women**

Présidents / Chairpersons: Kimberly Elmslie (Canada); Helga Rubsamen-Waigmann (Federal Republic of Germany); J. K. W. Mati (Kenya)

11:00 **W.D.O.1** HIV Infection among Women Attending Women's Health Clinics in the United States, 1988-89. Patricia A. Sweeney, *D. Allen, I. Onorato, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **W.D.O.2** Relationship between HIV Awareness, Partner Selection Criteria and Early Relationship Formation in Two Groups of San Francisco Bar Patrons. Leon McKusick, *C. C. Hoff, University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

11:30 **W.D.O.3** AIDS-Related Knowledge, Attitudes, Behaviors and Practices in HIV+ and HIV- Urban Women in Kigali, Rwanda. Susan Allen*/**, *F. Nsengumuremyi**, P. Vandeperre***, A. Serufilira**, M. Carael****, S. Hulley*, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.; **Projet San Francisco, Kigali; ***National AIDS Prevention Program of Rwanda, Kigali, Rwanda; ****World Health Organization Global Programme on AIDS, Geneva, Switzerland.*

11:45 **W.D.O.4** Gender Rules as Barriers to Risk Reduction for Black Women. Mindy T. Fullilove, *R. Fullilove, K. Haynes, S. A. Gross, University of California at San Francisco, Center for AIDS Prevention Studies and the Bayview-Hunter's Point Foundation, San Francisco, CA, U.S.A.*

12:00 **W.D.O.5** Barriers to AIDS Interventions among Sexual Partners of IV Drug Users. Claire E. Sterk*, *S. R. Friedman*, M. Sufian*, D. C. Des Jarlais**, B. Stepherson*, *Narcotic and Drug Research Inc.; **New York State Division of Substance Abuse Services, New York, NY, U.S.A.*

12:15 **W.D.O.6** Contraceptive Utilization and Reproductive Desires in a Group of HIV-Positive Women in Kinshasa. Susan E. Hassig*/**, *L. Piripiri*, A. Doppagne***, M. Moore*/**, W. E. Bertrand*/**, T. D. Kashala*, R. W. Ryder****, *Zaire School of Public Health, Kinshasa, Zaire; **Tulane University, New Orleans, LA, U.S.A.; ***Banque Commerciale du Zaire; ****Projet SIDA, Kinshasa, Zaire.*

11:00 - 12:30

Salle / Room **411A**



Section **E**

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la societé et le comportement
AIDS, Society and Behaviour

Séance thématique **Rôle des ONG dans la lutte mondiale contre le SIDA**

Specialty Session **The Role of NGOs in the Global Response to AIDS**

Présidents / Chairpersons: Walter Almeida (Brazil), Henri Maurel (France), Anne Usher (Canada)

11:00 **W.E.O.1** The Key Role of a National Non-Governmental AIDS Education Program in Canada. *David J. Walters, K. Wardrop, R. Burr, I. Gemmill, Canadian Public Health Association, Ottawa, ON, Canada.*

11:10 **W.E.O.2** Significance of the American Red Cross Role in HIV/AIDS Education. *Carole K. Kauffman, M. Cotton, American Red Cross, National Headquarters, Washington, DC, U.S.A.*

11:20 **W.E.O.3** Swift...and Sure? The U.K. Voluntary Response to AIDS. *Stephanie Malach*, J. Grimshaw**, S. Mansfield*, U. O'Brien*, *London Lighthouse; **Landmark, London, U.K.*

11:30 **W.E.O.4** Role of Non-Governmental Organisations and NGO Networks in the Control of HIV Infection. *Susan E. Lucas, P. Poore, U.K. NGO AIDS Consortium for the Third World, London, U.K.*

11:40 **W.E.O.5** Role of Non-Governmental Organizations in the Struggle against AIDS. Case Study: Uganda Red Cross Society. *Juliet Lubega*, O. Mueller**, J. Senoga*, R. Sebbowa*, *Uganda Red Cross Society, Kampala, Uganda; **League of Red Cross and Red Crescent Societies, Geneva, Switzerland.*

11:50 **W.E.O.6** Developing a Programme of World Health Organization Support for Non-Governmental Organizations in the Framework of National AIDS Control Programmes. *Robert N. Grose, J. M. Mann, World Health Organization, Geneva, Switzerland.*

12:00 **W.E.O.7** Community Organization for HIV Prevention: Programs and Priorities of the Centers for Disease Control. *Gary R. West*, R. N. Kohmescher*, S. E. Schindler*, K. Cahill*, G. S. Bowen*, R. Johnson**, et al., *Centers for Disease Control, Atlanta, GA; **United States Conference of Mayors, District of Columbia, Washington, DC, U.S.A.*

11:00 - 12:30

Salle
Room **411B**



Section
E

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique **La lutte communautaire contre le SIDA dans les années 1990**

Specialty Session **The Community-Based Response to AIDS into the 1990s**

Présidents / Chairpersons: Richard Burzynski (Canada), Peter Wood (Canada)

11:00 **W.E.O.8** Role of Community Based Organisations in the Australian AIDS Response. *Bill H. Whittaker, Australian Federation of AIDS Organisations, Surry Hills, Australia.*

11:15 **W.E.O.9** The Community Based AIDS Response in the 1990's. *Jim Holm, The National AIDS Network, Washington, DC, U.S.A.*

11:30 **W.E.O.10** Innovations in Health Care Delivery for HIV-infected Individuals. *Judith B. Braslow, C. Hostetter, M. Horner, G. Dolecek, J. Hutchings, Health Resources and Services Administration, Public Health Service, Department of Health and Human Services, Rockville, MD, U.S.A.*

11:45 **W.E.O.11** Community Groups into the 1990s. *Mary Mantell Network of Voluntary Organisations in AIDS and HIV (NOVOAH), Reading, U.K.*

12:00 **W.E.O.12** Comparative Study of AIDS Service Organizations. *Ken A. Morrison, The Canadian AIDS Society, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

12:15 **W.E.O.13** Discussant. *Freda Paltiel, Health and Welfare Canada, Ottawa, ON, Canada.*

11:00 - 12:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Mercredi 7 juin
Wednesday, June 7

Colloque / Symposium **Recherche de traitements et de vaccins / Research for Treatments and Vaccines**

Présidents / Chairpersons: Robert J. Levine (U.S.A.), C. Zavariz (Brazil)

11:00 **W.F.O.1** Overview of the Issues. *Robert Levine, Yale School of Medicine, New Haven, CT, U.S.A.*

11:20 **W.F.O.3** Ethical Aspects of the International AIDS Research Agenda, *Nicholas A. Christakis, Cambridge, MA, U.S.A.*

11:30 **W.F.O.4** Vaccine Testing: An Important Legal Question. *Wendy Mariner, Boston University Schools of Public Health and Medicine, Boston, MA, U.S.A.*

11:40 **W.F.O.5** Ethical Points on Placebo and Treatment Controls in HIV Drug Trials. *Benjamin Freedman, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

11:50 **W.F.O.6** The Ethics of Placebo-Controlled Trials of Therapy for HIV Infection. *Kathleen Nolan, The Hastings Center, Briarcliff, NY, U.S.A.*

12:00 **W.F.O.7** Special Problems in IRB Review of Community-Based AIDS Research. *Vanessa Merton*/**, C. Levine**/***, *City University of New York Law School; **Citizens Commission on AIDS for New York City and Northern New Jersey; ***Community Research Initiative, New York, NY, U.S.A.*

12:10 **W.F.O.8** Commentary. *Carole Levine, New York, NY, U.S.A.*

11:00 - 12:30

Salle / Room **406A**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Séance thématique / Specialty Session **Le VIH en pédiatrie / HIV in Pediatrics**

Présidents / Chairpersons: Eusebe Alihonou ( )
Sophie Lallement-LeCoeur (Bukina Fasso)
J. Pizzo (U.S.A.)

11:00 **W.G.O.1** Inability to Demonstrate a Dose-response Effect between Receipt of Mother's Milk and Perinatally-acquired Infection (PI) in a Cohort of 114 Infants Born to HIV(+) Mothers. *Tarande Manzila*, E. Baende*, U. Kabagabo*, E. Paquot**, R. Colebunders*/***, R. Ryder*/***, *Projet SIDA, Kinshasa; **Clinique Ngaliema, Kinshasa, Zaire; ***Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **W.G.O.2** Symptomatic Children with Perinatally Acquired HIV Infection in Puerto Rico: The San Juan City Hospital and University Pediatric Hospital. *Clemente Diaz, E. Jiménez, L. López, R. López-Correa, M. Carrer, J. M. García, et al., University of Puerto Rico School of Medicine, San Juan, Puerto Rico, U.S.A.*

11:30 **W.G.O.3** Complications loco-régionales de la vaccination par le BCG chez des enfants nés de mère positive pour anti-HIV-1 : Étude cas-témoins à Brazzaville (R.P. Congo). *Sophie Lallemant Le Coeur*, D. Cheynier**, M. Lallemant***, S. Nzingoula**, J. Drucker****, B. Larouzé*, et al., *INSERM U13, Hôpital Claude Bernard, Paris, France; **Ministère de la Santé/DSMIES, Brazzaville, Congo; ***ORSTOM (S/URB) Brazzaville/Paris; ****APMP, Paris, France.*

11:45 **W.G.O.4** Cause-Specific Morbidity in the First 18 Months of Life in 477 Infants Born to Seropositive Mothers in Zaire. *Wato Nsa*, T. Manzila*, M. Mvula*, B. Matela*, S. Hassig*, R. Ryder*/**, *Projet SIDA, Kinshasa, Zaire; **Centers for Disease Control, Atlanta, GA, U.S.A.*

12:00 **W.G.O.5** HIV Disease in Infants and Children: 22-Month Prospective Study. *Adel N. A. Malek, K. Mukelabai, N. P. Luo, University Teaching Hospital, Lusaka, Zambia.*

12:15 **W.G.O.6** Clinical Manifestations in African Children Perinatally Infected by HIV and Aged 5 Years Old or More. *Phillipe Lepage*, P. Van de Perre**, C. Van Goethem*, D. G. Hitimana*, F. Nsengumuremyi*, P. Kestelyn*, *Departments of Pediatrics and Ophthalmology, Centre hospitalier de Kigali; **Programme National de Lutte contre le SIDA, Kigali, Rwanda.*

11:00 - 12:30

Salle / Room **406BC**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Colloque / Symposium

Infections parasitaires tropicales : impact du VIH
Tropical Diseases: The Impact of HIV

Présidents / Chairpersons: Hunnington Pamba (Kenya), Pierre Viens (Canada)

11:00 **W.G.O.7** Studies of the Relationship Between Plasmodium Falciparum Malaria and HIV Infection in Africa. *Alan E. Greenberg, AIDS Program and Malaria Branch, Centers for Disease Control, Bethesda, MD, U.S.A.*

11:15 **W.G.O.8** Leishmaniasis and Leprosy. *Warren D. Johnson, Department of Medicine, Cornell University Medical Center, Ithica, NY, U.S.A.*

11:30 **W.G.O.9** Isopora Belli and Other Sporozoa. *Jean Pape, Cornell University Medical Center, Ithaca, NY, U.S.A.*

11:45 **W.G.O.10** Microsporidiosis and ARC. *Ann Cali*, Robert L. Owen**, *Rutgers University, Department of Biological Science, Newark, NJ; **VA Medical Center, San Francisco, CA, U.S.A.*

12:00 **W.G.O.11** HIV: Its Potential to Alter the Epidemiology of Parasitic Diseases. *Warren Johnson, Cornell University Medical Center, Ithica, NY, U.S.A.*

11:00 - 12:30

Salle / Room **404AB**

Section **H**

Mercredi 7 juin
Wednesday, June 7

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique **Rôle des assurances**
Specialty Session **The Role of Insurance**

Présidents / Chairpersons: Jacques Ross (Canada), W. Whittaker (Australia)

11:00	**W.H.O.1**	*Claude Castonguay, Groupe la Laurentienne, Montreal, QC, Canada.*
11:15	**W.H.O.2**	*Kourouma Hamadou, Togo.*
11:30	**W.H.O.3**	*Carl Schramm, U.S.A.*
11:45	**W.H.O.4**	Who Pays for AIDS in the U.K. Life Insurance Industry? *Dai Harris, The Terrence Higgins Trust Legal Centre, London, U.K.*
12:00	**W.H.O.5**	*Bernard Pottier, U.S.A.*

11:00 - 12:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

Mercredi 7 juin
Wednesday, June 7

La Perte et le deuil

Loss and Mourning

11:00 Introduction: *Andy Fabo*

11:11 **W.I.V.1** ***"MILDRED PEARSON: WHEN YOU LOVE A PERSON"***

Vidéo de/Video by:
Yannick Durand
Année/Year: 1988

11:20 **W.I.V.2** ***"THE INAUGURAL DISPLAY OF THE NAMES QUILT"***

Vidéo de/Video by:
David Thompson
Année/Year: 1988

11:36 **W.I.V.3** ***"DANNY"***

Vidéo de/Video by:
Stashu Kybartas
Année/Year: 1987

11:56 **W.I.V.4** ***"A PLAGUE HAS SWEPT MY CITY"***

Vidéo de/Video by:
Emjay Wilson
Année/Year: 1987

11:59 **W.I.V.5** ***"GAB"***

Vidéo de/Video by:
Ann Moriyasu
Année/Year: 1986

→

12:11 **W.I.V.6** *"A"*

Vidéo de/Video by:
Andre Burke
Année/Year: 1986

12:19 **W.I.V.7** *"THIS IS NOT AN AIDS ADVERTISEMENT"*

Vidéo de/Video by:
Isaac Julien
Année/Year: 1987

Vivre la perte d'un être cher. Ces films vont de l'hommage à l'élégie—douleur collective et peine individuelle, douleur vécue dans les familles traditionnelles et dans d'autres qui le sont moins.

Dealing with the loss of a loved one. These tapes range from tributes to elegies, from collective to individual grief and from alternative family to traditional family grieving.

12:45 - 13:45

Salle / Room **409ABC**



Section **I**

Mercredi 7 juin
Wednesday, June 7

Aspects audio-visuels
Audio-Visual Aspects

Sessions du midi / Noon Hour Sessions

L'érotisme, la sexualité sécuritaire et les changements de comportement
Erotica, Safer Sex, and Behavior Change

Présidents / Chairpersons: Kevin Orr (Canada), Alfred Machela (South Africa)

12:45 L'érotisme et les changements de comportement : l'anthropologie comme voyeur/Erotica and Behaviour Change: Anthropologist as Voyeur. *Bernard Arcand, Département d'anthropologie, Université Laval/Department of Anthropology, Laval University, Québec, QC, Canada.*

12:55 Porno ou pablum? - Évaluer l'assistance en préparant des produits sexuels-sécuritaires/Porno or Pablum? - Reading Your Audience in Preparing Safer Sex Material. *Cindy Patton, Directrice de l'éducation communautaire/Manager of Community Education, AIDS Action Committee, Boston, MA, U.S.A.*

13:05 Serre-le ou perds-le : la censure de l'État, la censure de l'institution ou l'auto-censure/Lace Up or Lose It: State Censorship, Institutional Censorship, Self-censorship. *Simon Watney, Président du Comité politique/Chairperson of Policy Committee, Terrence Higgins Trust, London, U.K.*

13:15 Sexe sécuritaire explicite et l'autodétermination d'une communauté/Explicit Safer Sex and Community Self-empowerment. *Gregg Bordowitz, Section de production audio-visuelle, Département d'éducation/Audio-visual production unit, Education Department, GMHC, New York, NY, U.S.A.*

13:25 Travailler avec le langage cinématographique des films porno: Une vision allemande du sexe sécuritaire/Working with the Film Language of Porn: A German View of Safer Sex. *Wieland Speck, Producteur/Filmmaker, Berlin, Federal Republic of Germany.*

→

La pornographie crée d'énormes controverses. Très peu sont indifférents à son existence ou à sa disponibilité. Cette session regroupe différentes perceptions de la construction contemporaine de la pornographie dans un contexte de sexualité sécuritaire. Des exemples de productions récentes de New York et Berlin sont présentés.

Porn has created enormous controversy. Few remain indifferent to its existence or availability. This session combines several views of the contemporary construction of porn within the context of Safer Sex education. Examples of recent works from New York and Berlin are included

Notes

14:00 - 15:30

Salle / Room **407A**



Section **A**

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Études séro-épidémiologiques des femmes enceintes / Seroepidemiological Studies in Childbearing Women**

Présidents / Chairpersons: Alastair J. Clayton (Canada)
George F. Grady (U.S.A.)RF.
Mueke (Kenya)

14:00 **W.A.O.7** Statewide HIV-1 Serologic Survey of Newborns with Resultant Changes in Screening and Delivery System Policy. *Christine M. Grant, R. Altman, D. Brandon, S. Shahied, E. Rappaport, S. Costa, et al., New Jersey State Department of Health, Trenton, NJ, U.S.A.*

14:15 **W.A.O.8** HIV Infection in Adolescent Childbearing Women. *Lloyd F. Novick*, D. Glebatis*, R. Stricof*, D. Berns**, *New York State Department of Health, Center for Community Health; **New York State Department of Health, Wadsworth Center for Laboratories and Research, Albany, NY, U.S.A.*

14:30 **W.A.O.9** Measurement of HIV Seroprevalence in Childbearing Women in London. *Richard S. Tedder*, M. Briggs*, N. Parra*, A. Ades**, M. Helm***, C. Peckham**, *University College and Middlesex School of Medicine; **Institute of Child Health; ***The Hospital for Sick Children, London, U.K.*

14:45 **W.A.O.10** HIV Infection in Pregnant Women and Perinatal Transmission in Sweden. *Ann-Britt Bohlin**, B. Anzén***, M. Arneborn*, M. Böttiger*, M. Forsgren****, K. Lidman***, et al., *Department of Epidemiology, National Bacteriology Laboratory, Stockholm; **Huddinge Hospital, Department of Pediatrics, Huddinge; ***Departments of Obstetrics and Infectious Diseases, Danderyds Hospital, Danderyds; ****Central Microbiology Laboratory, Stockholm, Sweden.*

15:00 **W.A.O.11** HIV-Screening Program at a Los Angeles Prenatal/Family Planning Center. *Laura J. Fehrs, D. Hill, P. Kerndt, T. Rose, C. Henneman, New Mexico Health and Environment Department, Santa Fe, NM, U.S.A.*

15:15 **W.A.O.12** National Surveys of HIV Seroprevalence in Women Delivering Live Children in the United States. *Marguerite Pappaioanou*, R. George*, H. Hannon**, R. Hoff***, A. Willoughby****, A. Novello****, et al., *AIDS Program, Centers for Disease Control; **CEHIC, Centers for Disease Control, Atlanta, GA; ***Massachusetts Department of Health, Boston, MA; ****NICHD, Bethesda, MD, U.S.A.*

14:00 - 15:30

Salle / Room **408BC**



Section **A**

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Incidence et mortalité du SIDA / AIDS Incidence and Mortality**

Présidents / Chairpersons: Dale N. Laurence (U.S.A.), Jaime Sepulveda (Mexico), Kayembe Tshilumba (Zaire)

14:00 **W.A.O.13** Are AIDS Cases among Homosexual Males Leveling? *Ruth L. Berkelman*, J. Karon*, P. Thomas**, P. Kerndt***, G. Rutherford****, J. Stehr-Green*, *Centers for Disease Control, AIDS Program, Atlanta, GA; **New York City Department of Health, New York, NY; ***Los Angeles County Health Department, Los Angeles; ****San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

14:15 **W.A.O.14** Heterosexual AIDS in the Province of Québec. *Robert S. Remis, L. Bédard, R. W. H. Palmer, Bureau régional des maladies infectieuses, Montreal, QC, Canada.*

14:30 **W.A.O.15** Surveillance of Heterosexually Acquired AIDS, U.S.A. *Mary E. Chamberland, L. Conley, J. Buehler, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

14:45 **W.A.O.16** Impact of the HIV Epidemic on Mortality Trends in Men 25-44 Years of Age, United States. *James W. Buehler, R. L. Berkelman, O. J. Devine, F. M. Chevarley, Centers for Disease Control, Center for Infectious Diseases, AIDS, Atlanta, GA, U.S.A.*

15:00 **W.A.O.17** National Surveillance of Perinatally-Acquired AIDS, U.S.A. *Margaret J. Oxtoby, M. Rogers, T. Bush, R. Berkelman, Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

15:15 **W.A.O.18** The Relative Importance of AIDS as a Cause of Death in Pediatric and Young Adult Populations in the U.S. 1980-1987. *Barbara W. Kilbourne, M. F. Rogers, T. J. Bush, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:00 - 15:30

Salle / Room **401ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Manifestations cliniques / Clinical Manifestations**

Présidents / Chairpersons: Katabira (South Africa), Yves Mouton (France), Robert Redfield ( )

14:00 **W.B.O.17** Contrasting Determinants of Susceptibility to Reiter's Syndrome and Psoriasiform Manifestations Associated with HIV Infection. *Lenore J. Brancato, S. Itescu, M. L. Skovron, C. Navarrete, G. Solomon, R. Winchester, Hospital for Joint Diseases, New York University Medical Center, New York, NY, U.S.A.*

14:15 **W.B.O.18** Clinicopathologic and Immunocytochemical Study of the Eye in AIDS: Observations in 25 Cases. *Dominique Hénin*, U. De Girolami*, B. Girard*, R. Vazeux**, P. Le Hoang*, J. J. Hauw*, *Hôpital de la Salpêtrière; **Institut Pasteur, Paris, France.*

14:30 **W.B.O.19** Changing Prevalence of Malignancies in Men at San Francisco General Hospital during the HIV Epidemic. *David M. Heyer*, S. Desmond**, P. Volberding*, J. Kahn*, *San Francisco General Hospital; **University of California at San Francisco, San Francisco, CA, U.S.A.*

14:45 **W.B.O.20** Malignant Lymphomas in HIV-infected Patients: Clinical and Pathological Features. *Dirk Schürmann*, D. Dienemann**, B. Ruf*, G. Jautzke*, A. Langford***, H. D. Pohle*, *Rudolf Virchow University Hospital, Berlin; **University Clinic, Department for Pathology, Steglitz; ***Freie Universität, Clinic for Oral Surgery, Berlin, Federal Republic of Germany.*

15:00 **W.B.O.21** The Value of Lymph Node Biopsy in HIV Infection. *Maria José Forjaz Lacerda, L. Tavares, R. Madureira, Faculty of Medicine/Santa Maria Hospital, Departments of Pathology and Infectious Diseases, Lisbon, Portugal.*

15:15 **W.B.O.22** Increased Capillary Pulmonary Volume during AIDS-related Kaposi Sarcoma (KS). *Thomas Similowski, J. Regnard, A. T. Dinh Xuan, A. Lockhart, Hôpital Cochin, Laboratoire d'Explorations Fonctionnelles Respiratoires, Paris, France.*

14:00 - 15:30

Salle / Room **403ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Hémophilie : histoire clinique et études de cohortes**

Specialty Session **Hemophilia: Natural History/Cohort Studies**

Présidents / Chairpersons
P. Kernoff (U.K.)
Christopher Tsoukas (Canada)
Jack Wilima (Malawi)

14:00 **W.B.O.23** Survival of Patients with Hemophilia-Associated AIDS in the United States. *Jeanette K. Stehr-Green, R. C. Holman, M. A. Mahoney, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:15 **W.B.O.24** Cumulative Risk for AIDS and Other HIV-outcomes in a Cohort of Hemophiliacs in Western Pennsylvania. *Margaret V. Ragni*, L. A. Kingsley**, *University of Pittsburgh School of Medicine, Hemophilia Center of Western Pennsylvania; **Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

14:30 **W.B.O.25** Natural History and Pathogenesis of HIV Infection in Patients with Hemophilia. *John L. Sullivan*, R. Koup*, D. Brettler**, P. Levine**, *University of Massachusetts Medical Center, Department of Pediatrics; Worcester Memorial Hospital, Worcester, MA, U.S.A.*

14:45 **W.B.O.26** Natural History of HIV in Patients of the Bonn Haemophiliac Cohort Study. *Bernd S. Kamps*, D. Niese*, H. H. Brackmann**, C. Maintz*, B. Van Loo**, T. Kamradt***, *Medizinische Universitätsklinik; **Institut für experimentelle Hämatologie, Bonn, Federal Republic of Germany; ***Massachusetts Institute of Technology, Cambridge, MA, U.S.A.*

15:00 **W.B.O.27** Canadian National Hemophilia Study (CNHS): HIV Infection in Hemophilia (HEM) and Other Bleeding Disorders (1985-1989). *Man-Chiu Poon*, S. K. Ali, R. Card, B. Garvey, G. Growe, N. Kobrinsky, et al., *University of Calgary, Foothills Hospital, Calgary, AB; Memorial University, St. John's NF; University of Saskatchewan, Saskatoon, SK; University of Toronto, Toronto, ON; University of British Columbia, Vancouver, BC; University of Manitoba, Winnipeg, MB; Université de Montréal; McGill University, Montreal, QC, Canada.*

15:15 **W.B.O.28** Nine Year Follow-up of a Cohort of 112 Anti-HIV Seropositive Haemophiliacs. *Christine Ann Lee, A. N. Phillips, J. Elford, G. Janossy, P. D. Griffiths, P. B. A. Kernoff, Haemophilia Centre, Royal Free Hospital, London, U.K.*

14:00 - 15:30

Salle / Room **407B**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Colloque — **Infection par le VIH : atteintes à certains organes**

Symposium — **HIV Infection: Organ Specific Involvement**

Présidents / Chairpersons — Julio S. Montaner (Canada), Anthony Pinching (U.K.)

14:00 **W.B.O.29** Clinical Gastrointestinal (GI) Diseases in AIDS. *Donald P. Kotler, St. Luke's Hospital Center, New York, NY, U.S.A.*

14:15 **W.B.O.30** Clinical Bone Marrow Involvement. *Karen Gelmon, St Paul's Hospital, London, U.K.*

14:30 **W.B.O.31** Clinical Central Nervous System Involvement. *Court Pederson, Hvidovre Hospital, Hvidovre, Denmark.*

14:45 **W.B.O.32** Pathology of the Central Nervous System in AIDS. *Jean Michaud, Hôpital Ste-Justine, Département de pathologie, Montréal, QC, U.S.A.*

15:00 **W.B.O.33** The Lungs, The Cause of Death and Bacterial Infections in AIDS: What Autopsy Studies Show. *Larry Nichols, currently at Research Triangle Institute, Research Triangle Park, NC, U.S.A.*

14:00 - 15:30

Salle / Room **407C**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium: **Mise au point de vaccins contre le SIDA / Vaccine Developments in AIDS**

Présidents / Chairpersons: Stanley E. Read (Canada), Geoffrey C. Schild (U.K.)

14:00 **W.C.O.17** Current Trends in HIV Vaccine Preparation. *Marc Girard, Pasteur Vaccins and Institut Pasteur, Paris, France.*

14:15 **W.C.O.18** Development of an HIV Subunit Vaccine. *Scott Putney, Repligen Corporation, Cambridge, MA, U.S.A.*

14:30 **W.C.O.19** Immunisation experimentale anti HIV chez l'homme. *Daniel Zagury, Université Pierre et Marie Curie, Paris, France.*

14:45 **W.C.O.20** Evaluation of a Recombinant HIV-1 Envelope Protein (gp 160) as an Immunogen in Humans. *Clifford Lane, NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

14:00 - 15:30

Salle / Room **408A**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session

Mise au point de médicaments : nouvelle approche pour l'étude des médicaments antiviraux

Drug Development: Novel Study Approach to Anti-Viral Drugs

Présidents / Chairpersons
Louis S. Kucera (U.S.A.)
Brendan Larder (U.K.)
Fernand Turgeon (Canada)

14:00 **W.C.O.21** Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs. *Louis S. Kucera*, N. Iyer*, A. Raben*, E. Modest*, L. Daniel*, C. Piantadosi**, *Bowman Gray School of Medicine, Winston-Salem; **University of North Carolina, Chapel Hill, NC, U.S.A.*

14:15 **W.C.O.22** Generation of Indicator Cell Lines for Fast Assay of HIV-1 and for the Study of Antiviral Drugs. *George N. Pavlakis, B. K. Felber, National Cancer Institute-FCRF, BRI-Basic Research Program, Frederick, MD, U.S.A.*

14:30 **W.C.O.23** Mechanism of Action of Sulphated Polyanions as Inhibitors in HIV Infection In Vitro. *L. Low, A. L. Cunningham, C. Parish, H. Warren, J. M. Mathys, F. Kazazi, Westmead Hospital, Virology Unit, Westmead, Australia.*

14:45 **W.C.O.24** Colchicine Inhibits HIV-1 In Vitro. *Stanley E. Read*, M. Lyons**, H. Li*, J. Zabriskie**, *Toronto Hospital for Sick Children, Toronto, ON, Canada; **Rockefeller University, New York, NY, U.S.A.*

15:00 **W.C.O.25** Structures Necessary for HIV-2 Entry. *David B. Weiner*, W. V. Williams*, J. A. Hoxie*, K. Hubner**, J. A. Berzofsky***, M. I. Greene*, *University of Pennsylvania, Department of Pathology; **Wistar Institute, Philadelphia, PA; ***National Institutes of Health, Bethesda, MD, U.S.A.*

15:15 **W.C.O.26** Identification and Characterization of Complement-Mediated Enhancement of HIV-1 Infection by Mannosidase I and II Inhibitors. *David C. Montefiori, W. E. Robinson, Jr., A. Modliszewski, W. M. Mitchell, Vanderbilt University, Department of Pathology, Nashville, TN, U.S.A.*

14:00 - 15:30

Salle / Room **410ABC**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Modèles animaux (partie 2) / Animal Models (Part 2)**

Présidents / Chairpersons
Zvi Bentuich (Israel)
Ming Huang (Canada)
James I. Mullins (U.S.A.)

14:00 **W.C.O.27** Evaluation by PCR of HIV-1 Status of Chimpanzees Challenged with HIV after Receiving Human HIVIG. *Indira K. Hewlett*, J. Epstein*, C. A. Hawthorne*, J. Eichberg***, A. M. Prince**, *Food and Drug Administration, Bethesda, MD; **New York Blood Center, NY; ***Southwest Foundation, TX, U.S.A.*

14:15 **W.C.O.28**

14:30 **W.C.O.29** Effects of Sperm and Autoimmunity on Murine AIDS (MAIDS). *Zvi H. Bentwich*, Z. Weisman*, A. Meshorer**, J. Rubinstein**, E. Mozes***, *R. Ben Ari Institute of Clinical Immunology, Kaplan Hospital, Hebrew University Medical School; **Experimental Animal Unit; ***Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel.*

➜

14:45 **W.C.O.30** Molecular Cloning and Sequence Analysis of Feline Immunodeficiency Virus (FIV). *Robert A. Olmsted*, A. K. Barnes**, J. K. Yamamoto***, V. M. Hirsch*, R. H. Purcell**, P. R. Johnson*, *Georgetown University, National Institute of Health/Twinbrook II, Rockville; **NIAID, National Institutes of Health, Bethesda, MD; ***University of California at Davis, Davis, CA, U.S.A.*

15:00 **W.C.O.31** T-Cell Killing by the FeLV-FAIDS Immunodeficiency Virus. *Peter R. Donahue*, E. A. Hoover**, C. M. C. De Noronha*, S. L. Quackenbush**, J. Overbaugh*, J. I. Mullins*, *Harvard University School of Public Health, Department of Cancer Biology, Boston, MA; **Colorado State University, Fort Collins, CO, U.S.A.*

15:15 **W.C.O.32** Infection of the New Zealand White Laboratory Rabbit (Oryctolagus Cuniculus) with HIV-1. *Phillip D. Markham*, S. Reina**/***, E. A. Gard*, G. Ford*, A. Buchbinder***, R. C. Gallo*, et al., *Bionetics Research Inc., Rockville, MD, U.S.A.; **Visiting from Institute of Microbiology, Genova, Italy; ***National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A.*

14:00 - 15:30

Salle / Room **409ABC**



Section **D**

Mercredi 7 juin
Wednesday, June 7

Le SIDA et l'individu
AIDS and the Individual

Colloque — **Consommateurs de drogues par voie intraveineuse : réalités changeantes et mythes persistants**

Symposium — **Injection Drug Users: Changing Realities and Persisting Myths**

Présidents / Chairpersons — Don C. Desjarlais (U.S.A.), Bryce Lark (Canada)

14:00 **W.D.O.7** Culturally Conditioned Belief System. *Robert Olin, National Health and Welfare, Stockholm, Sweden.*

14:15 **W.D.O.8** Drug Injecting and Sexual Behaviour. *Giovanni Rezza, Italian Ministry of Health, and WHO Consultant, SBR/GPA, Geneva, Switzerland.*

14:30 **W.D.O.9** Impact of Improved Needle Accessibility on Drug Use Patterns and Demand for Treatment. *Roel A. Coutinho, Municipal Health Service, Amsterdam, The Netherlands.*

14:45 **W.D.O.10** The Prevention Message: AIDS and Initiation into Drug Injection. *Don C. Des Jarlais, Beth Israel Medical Center, New York, NY, U.S.A.*

15:00 **W.D.O.11** AIDS Among Drug Users in Developing Countries: The Thai Experience. *Pratlom Sakuntanaga, Bangkok, Thailand.*

14:00 - 15:30

Salle / Room **411A**



Section **E**

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique / Specialty Session **Le SIDA en milieu de travail / AIDS in the Workplace**

Présidents / Chairpersons: Philippe Engelhard (Senegal), Louise Lamothe (Canada), Paul A. Ross (U.S.A.)

14:00 **W.E.O.14** AIDS and the Workplace: United States Policy and Education Initiatives. *John F. Bunker, The Circle, Inc., McLean, VA, U.S.A.*

14:15 **W.E.O.15** HIV/AIDS: A Psychosocial Task for Managers. *Anita Sandblom, I. Österberg, G. Ramstedt, J. A. Gunnarsson, Personnel and Organisation Department, Stockholm, Sweden.*

14:30 **W.E.O.16** An AIDS Prevention Program Designed for Civil Construction Workers in Rio de Janeiro. *Silvia Ramos*, C. Afonso**, C. Gomes***, M. J. Ramos***, *Brazilian Interdisciplinary AIDS Association (ABIA); **Audiovisual Training Center; ***Social Workers of Civil Construction Companies, Rio de Janeiro, Brazil.*

14:45 **W.E.O.17** AIDS in the Workplace: An African Model from Uganda. *Dace Stone*, J. Kasswara**, D. Weeks***, P. Cohn****, *Academy for Educational Development/Johns Hopkins University, Washington, DC; **Federation of Uganda Employers, Uganda; ***Consultant AIDSCOM, Washington, DC, U.S.A.; ****USAID/Kampala, Uganda.*

15:00 **W.E.O.18** Neuropsychological Impairment of HIV-Infected Persons: Legal Implications for the Workplace. *Mark Barnes, I. John, C. Berti, AIDS Law Clinic, Columbia University School of Law, New York, NY, U.S.A.*

15:15 **W.E.O.19** Regional and Time Differences in the Effects of AIDS-HIV (A-H) Education on Changes in Knowledge and Fears among Worksite Employees. *Harvey Bartnof*/***, D. Verolini**, D. Roth***, *University of California at San Francisco, School of Medicine and AIDS Virus Education Research Institute; **California School of Professional Psychology; ***AIDS Virus Education and Research Institute (AVERI), San Francisco, CA, U.S.A.*

14:00 - 15:30

Salle
Room **411B**



Section
E

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique **Le SIDA dans les médias**
Specialty Session **AIDS in the Media**

Présidents
Chairpersons

John F. James (U.S.A.)
Teresa Gonzales Kury (Mexico)
Keith Speicer (Canada)

14:00 **W.E.O.20** Media AIDS Education: The Boomerang Effect. *Jonathan P. Baggaley, Concordia University, Department of Education, Montreal, QC, Canada.*

14:15 **W.E.O.21** Les médias à l'épreuve du SIDA : analyse thématique et comparaison de la presse française et américaine. *G. Pial, Journal "Libération", Paris, France.*

14:30 **W.E.O.22** Correlation between Large Scale Mass Media Campaigns on AIDS Prevention, and Homosexual and IVDUs Giving Up Risk Practices in Madrid. *P. Estebáñez*, A. Martinez**, C. Manzano**, R. Estébañez**, *Madrid City Council, Health Department; **Journalist, Universidad Complutense, Madrid, Spain.*

14:45 **W.E.O.23** The U.K. National AIDS Health Promotion Programme: Recent Developments. *Mukesh Kapila, K. Wellings, S. Perl, S. Hagard, Health Education Authority, London, U.K.*

15:00 **W.E.O.24** Flagrant Bias and Lack of Representation of Women's Groups and Experts in Media Coverage of Major AIDS Issues. *Chris Norwood, Women and AIDS Studies, New York, NY, U.S.A.*

15:15 **W.E.O.25** Evaluation of the National AIDS Multi-Media Public Information Campaign. *Kenneth R. Williams*, D. D. Dawson**, P. Murdock***, *Centers for Disease Control, Atlanta, GA; **National Center for Health Statistics, Hyattsville, MD; ***Ogilvy & Mather Advertising, Atlanta, GA, U.S.A.*

14:00 - 15:30

Salle
Room **411C**

Section
F

Droit et éthique
Ethics and Law

Mercredi 7 juin
Wednesday, June 7

Colloque — **Prévenir la transmission du VIH : les conflits religieux en matière de santé publique**

Symposium — **Preventing HIV Transmission: Religious Conflicts in Public Health**

Présidents / Chairpersons — Earl Shelp (U.S.A.), Cécile De Sweemer (Senegal)

14:00 **W.F.O.9** The Context. *Earl Shelp, Foundation For Interfaith Research and Ministry, Houston, TX, U.S.A.*

14:10 **W.F.O.10** A Roman Catholic Perspective. *Gregory Baum, Montreal, QC, Canada.*

14:25 **W.F.O.11** A View From Scotland. *Archie McLullich, Glasgow, U.K.*

14:40 **W.F.O.14** AIDS and Indian Ethical Values. *D. V. P. Raja, Madurai Institute of Social Work, Madurai, India.*

14:50 **W.F.O.15** Saving Life As An Overriding Demand: A Jewish Perspective. *W. Gunther Plaut, Toronto, ON, Canada.*

15:05 **W.F.O.16** Commentary. *David Hallman, The United Church of Canada, Toronto, ON, Canada.*

15:15 **W.F.O.17** Commentary. *Cécile De Sweemer, Dakar, Sénégal.*

14:00 - 15:30

Salle / Room **406A**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Séance thématique / Specialty Session **Perspectives mondiales / Global Perspectives**

Présidents / Chairpersons: Manuel Carballo (Switzerland), Margaret Hilson (Canada), A. Taole (Canada)

14:00 **W.G.O.13** AIDS and Restrictions on Immigration and Travel: U.S. Policy and Its Ramifications. Richard K. Edwards*, R. E. D. Whitaker**, *Northeastern University and Pine Manor College; **Boston University and Tufts New England Medical Center, Boston, MA, U.S.A.

14:15 **W.G.O.14** Comparison of National AIDS Strategies in Australia and Canada. Margaret Duckett, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.

14:30 **W.G.O.15** The Epidemiological Surveillance System for AIDS in Brazil: Critical Assessment. Lair Rodrigues*, P. Chequer*, D. Bergamaschi*, E. Castilho**, L. De Paula*, *Ministry of Health, National Division of STD/AIDS, Brasilia; **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil.

14:45 **W.G.O.16** Functional and Dysfunctional AIDS Prevention Programs in Latin America and the Caribbean. Fernando R. K. Zacarias, L. Zessler, G. Mongalo, S. Luelmo, R. St. John, Pan American Health Organization, Washington, DC, U.S.A.; Global Programme on AIDS, World Health Organization, Geneva, Switzerland.

15:00 **W.G.O.17** Strategies of the EEC's AIDS Programme for Developing Countries to Control Sexually Transmitted HIV Infections. Discussion of Programme Implementation and Main Issues. Lieve Fransen, C. J. Van Dam, AIDS Task Force, Brussels, Belgium.

15:15 **W.G.O.18** National AIDS Programmes. Progress Achieved and Opportunities for Further Development. Daniel J. M. Tarantola, J. M. Mann, World Health Organization, Geneva, Switzerland.

14:00 - 15:30

Salle / Room **406BC**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Colloque / Symposium

Transmission hétérosexuelle et rôle des MTS
Heterosexual Transmission and Role of STDs

Présidents / Chairpersons
Theresa Malandi (Kenya)
Marcel Mony-Lobe (Cameroon)
Marc Steben (Canada)

14:00 **W.G.O.19** Health Education among Commercial Sex Workers in Zimbabwe. *David J. Wilson, S. Sibanda, L. Mboyi, S. Msimanga, G. Dube, University of Zimbabwe, Department of Psychology, Harare, Zimbabwe.*

14:15 **W.G.O.20** Surveillance-éducation sanitaire des prostituées au Sénégal. *Tidiane Siby*, I. Thior*, J. L. Sankale*, A. Gueye*, I. N'doye**, S. M'Boup*, et al., *Université de Dakar, Bactériologie/Virologie; **Clinique MST/IHS Dakar, Senegal.*

14:30 **W.G.O.21** Prostitutes as Health Educators for Their Peers in Yaounde: Changes in Knowledge, Attitudes and Practices. *Marcel Monny-Lobe*, D. Nichols**, L. Zekeng***, R. Salla*, L. Kaptue*, *Central Hospital Yaounde; **Family Health International, NC, U.S.A.; ***University Teaching Hospital, Yaounde, Cameroon.*

14:45 **W.G.O.22** Social Characteristics and Sexual Behaviour of Women in the High Risk Behaviour Category. *M. N. Katsivo, L. N. Muthami, Kenya Medical Research Institute, Nairobi, Kenya.*

15:00 **W.G.O.23** AIDS Prevention among Brazilian Prostitutes: A Pilot Project. *Lair G. M. Rodrigues*, T. Mathias**, F. Borges**, F. Delgrange***, *Division of Sexually Transmitted Diseases and AIDS, Brasilia; **Secretaria da Saúde do Estado do Ceará, Fortaleza, Brazil; ***Inter AIDE, France.*

15:15 **W.G.O.24** Sexual Practices and HIV Infection of Female Prostitutes in Nigeria. *Ekanem E. Williams*, N. Hearst**, O. Udofia*, *University of Calabar, Calabar, Nigeria; **Centre for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:00 - 15:30

Salle / Room **404AB**

Section **H**

Mercredi 7 juin
Wednesday, June 7

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique / Specialty Session **Financement et assurances / Financing and Insurance**

Présidents / Chairpersons
Geoffrey Carliner (U.S.A.)
Rod Fraser (Canada)
Guiseppe Marasca (Italy)

14:00 **W.H.O.7** Empire Blue Cross and Blue Shield: The First 7,500 AIDS Cases. *Jon Eisenhandler, A. Padgug, Empire Blue Cross and Blue Shield, New York, NY, U.S.A.*

14:15 **W.H.O.8** Health Insurance Industry Modeling of the HIV Epidemic in the United States. *Charles L. Eby*, J. Dinius**, *Health Insurance Association of America, Inc.; **Aetna Life and Casualty, Washington, DC, U.S.A.*

14:30 **W.H.O.9** Coverage of Selected Drugs Under State Medical Assistance (Medicaid) Programs in the U.S.A. *Benjamin Schatz, National Gay Rights Advocates, San Francisco, CA, U.S.A.*

14:45 **W.H.O.10** Analysis of AZT Assistance Provided by a Private Hospital. *Mark A. Benge, M. Cintron, R. Muniz, T. Watson, St. Clare's Hospital and Health Center, New York, NY, U.S.A.*

15:00 **W.H.O.11** National Survey of State Spending for AIDS Program Activities. *Mona J. Rowe*, C. C. Ryan*, R. M. Keintz*, D. M. Merritt*, J. Richland**, S. Madden**, K. Farrell***, et al., *George Washington University, Intergovernmental Health Policy Project-AIDS Policy Center; **Public Health Foundation; ***National Association of State Budget Officers, Washington, DC, U.S.A.*

15:15 **W.H.O.12** Financing the Medical Cost of the HIV Epidemic in the United States: A Policy Review. *Harvey J. Makadon*, G. R. Seage**, K. E. Thorpe*, H. V. Fineberg*, *Center for Policy and Education, Harvard AIDS Institute, Harvard School of Public Health; **Department of Health and Hospitals, Boston, MA, U.S.A.*

14:00 - 15:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Mercredi 7 juin
Wednesday, June 7

Session vidéo
Video session

Le Militantisme et la résistance culturelle

Activism and Cultural Resistance

14:00		Introduction: *John Greyson*
14:03	**W.I.V.8**	***"THE AIDS EPIDEMIC"***
		Vidéo de/Video by: *John Greyson* Année/Year: 1987
14:08	**W.I.V.9**	***"SNOW JOB"***
		Vidéo de/Video by: *Barbara Hammer* Année/Year: 1986
14:16	**W.I.V.10**	***"WE'RE NOT REPUBLICANS"***
		Vidéo de/Video by: *Bob Huff* Année/Year: 1988
14:30	**W.I.V.11**	***"STIFF SHEETS"***
		Vidéo de/Video by: *John Goss* Année/Year: 1989
14:49	**W.I.V.12**	***"ANOTHER MAN"***
		Vidéo de/Video by: *Youth Against Monsters* Année/Year: 1988

➜

14:54 **W.I.V.13** ***"TESTING THE LIMITS NEW YORK part 1"***

Vidéo de/Video by:
Testing the Limits Collective
Année/Year: 1988

15:20 **W.I.V.14** ***"SPREAD THE WORLD"***

Vidéo de/Video by:
Aboriginal Medical Service
Redfern Co-Operative Ltd.
Année/Year:

Le militantisme artistique et la résistance culturelle face au SIDA ont entraîné une prolifération de films et de vidéos. Cette séance en présente parmi les meilleurs. Des défilés de mode provocateurs aux vidéos musicaux subversifs, de la désobéissance civile à l'analyse critique des médias, les stratégies esthétiques illustrées prouvent qu'il ne faut pas seulement réinventer la politique du SIDA mais aussi le langage du SIDA.

Aesthetic activism and cultural resistance in response to AIDS has meant a proliferation of videos. This session is a sampling of some of the best. From guerrilla fashion shows to subversive music videos, from civil disobedience to media deconstruction, the aesthetic strategies illustrated show that not just the politics of AIDS but the politics of language related to AIDS needs to be reinvented.

16:00 - 17:30

Salle / Room **407A**



Section **A**

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **L'annonce aux partenaires / Partner Notification**

Présidents / Chairpersons: Walter R. Dowdle (U.S.A.)RIbra N'Doye (Senegal) Michael Rekart (Canada)

16:00 **W.A.O.19** Experience of Partner Notification among HIV-Infected Heterosexuals in Brussels. *Nathan Clumeck, V. Arendt, P. Hermans, M. Schoumacher, Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

16:15 **W.A.O.20** Partner Acceptability of Health Department Notification of HIV Exposure, South Carolina. *Jeffrey L. Jones*, R. F. Wykoff**, W. B. Gamble**, S. L. Hollis**, S. T. Longshore**, R. A. Gumm*, *Centers for Disease Control, Division of Field Services, Atlanta, GA; **South Carolina Department of Health and Environmental Control, Columbia and Greenwood, SC, U.S.A.*

16:30 **W.A.O.21** Result and Benefit: Cost Analysis of Provider-Assisted HIV Partner Notification and Referral. *Nancy E. Spencer, C. Raevsky, F. Wolf, Colorado Department of Health, STD/AIDS Section, Denver, CO, U.S.A.*

16:45 **W.A.O.22** Partner Notification for HIV Prevention: Current State Policy in the United States. *Kathleen E. Toomey, K. Cahill, W. Cates, Centers for Disease Control, Division of STDs, Atlanta, GA, U.S.A.*

17:00 **W.A.O.23** Assessment of the Development and Implementation of State AIDS/HIV Partner Notification Programs: Five Case Studies. *Lorraine M. Fishback*, J. W. Flynt**, J. Focht**, L. Baughman**, C. Morgan**, *Office of the Assistant Secretary for Health, Public Health Service, Washington, DC; Macro Systems Inc., Silver Spring, MD, U.S.A.*

17:15 **W.A.O.24** Combatting AIDS with Contact Tracing. *J. Giesecke, Swedish Study Group on Contact Tracing, Environmental Health and Disease Control, Karolinska Hospital, Stockholm, Sweden.*

16:00 - 17:30

Salle / Room **408BC**



Section **A**

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Test de dépistage du VIH/Questions en matière de politiques et de programmes / HIV Testing/Policy and Programme Issues**

Présidents / Chairpersons: Shankar Choudhury (India), Ian Gemmill (Canada), Mervyn Silverman (U.S.A.)

16:00 **W.A.O.25** Mandatory Premarital HIV Antibody Testing: A Twelve-Month Experience. *Chester J. Kelly, B. J. Turnock, Illinois Department of Public Health/AIDS Activity Section, Springfield, IL, U.S.A.*

16:15 **W.A.O.26** HIV Antibody Testing among Adults in the United States. *Ann M. Hardy, D. Dawson, National Center for Health Statistics, Hyattsville, MD, U.S.A.*

16:30 **W.A.O.27** HIV Antibody Status and Behavior Change in Two Cohorts of Gay Men in San Francisco: The San Francisco Men's Health Study (SFMHS) and the AIDS Behavioral Research Project (ABRP). *Thomas J. Coates, M. Ekstrand, S. M. Kegeles, R. D. Stall, University of California at San Francisco, San Francisco, CA, U.S.A.*

16:45 **W.A.O.28** Targeting AIDS Prevention towards HIV-Infected Persons. Do Prevention/Treatment Programs Reduce Transmission and Improve the Quality of Life? *Donald P. Francis*, M. Gorman**, M. Fenstersheib***, A. Esposito***, N. Padian****, W. Henke-Quinn*****, et al., *Centers for Disease Control, Berkeley; **Rand Corporation, Santa Monica; ***Santa Clara County Health Department, San José; ****Long Beach Department of Public Health, Long Beach; *****University of California at San Francisco, San Francisco, CA, U.S.A.*

17:00 **W.A.O.29** HIV Epidemiology in Sweden. *Margareta Böttiger, National Bacteriological Laboratory, Stockholm, Sweden.*

17:15 **W.A.O.30** Risk Factors and HIV Seroprevalence in Screening U.S. Immigration Applicants: 1988. *Timothy M. Sankary, AIDS Prevention Center, San Francisco, CA, U.S.A.*

16:00 - 17:30

Salle / Room **401ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Infections associées au SIDA**
Specialty Session **AIDS Related Infections**

Présidents / Chairpersons
Donald Armstrong (U.S.A.)
Jean Kalilani (Malawi)
Rosemary Soave ( )

16:00 **W.B.O.34** Intravitreal Ganciclovir Administration for CMV Retinitis in 11 AIDS Patients. *Roberto Novati*, R. Pinna**, A. D'Arminio Monforte*, A. Lazzarin*, L. Gagliardi**, G. Bertoni**, *Infectious Diseases Clinic; **Ophthalmology Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

16:15 **W.B.O.35** Monitoring of Cytomegalovirus (CMV) Antigenemia during Treatment of Serious CMV Infection in AIDS Patients. *Herman G. Sprenger, J. Weits, J. T. Anema, J. Schirm, T. H., The Groningen University Hospital, Groningen, Netherlands.*

16:30 **W.B.O.36** Foscarnet Treatment of Cytomegalovirus Retinitis in AIDS. *Mary M. Fanning, S. E. Read, M. F. Benson, A. Rachlis, S. Vas, V. Kouzesek, et al., Toronto General Hospital, Toronto, ON, Canada.*

16:45 **W.B.O.37** Differences among Pulmonary (PT), Extrapulmonary (ET) and Disseminated Tuberculosis (DT) in HIV-Infected Patients. *V. Cárcaba, J. A. Carton, Z. García, J. J. Palacio, J. A. Maradona, J. A. Muñoz, et al., Hospital Universitario de Oviedo, Oviedo, Spain.*

17:00 **W.B.O.38** Intestinal Microsporidiosis as a Cause of Diarrhea in AIDS. *Jan Marc Orenstein*, W. Steinberg*, J. Chiang*, P. Smith**, H. Rotterdam***, D. Kotler****, *George Washington University Medical Center, Washington, DC; **NIDR, National Institutes of Health, Bethesda, MD; ***New York University Medical Center; ****St. Luke's-Roosevelt Hospital, New York, NY, U.S.A.*

17:15 **W.B.O.39** Improved Survival in AIDS Patients with Opportunistic Infections. *Jonathan W. M. Gold, S. W. Campbell, M. Carrow, D. Niedzwiecki, D. Armstrong, Memorial Sloan-Kettering Cancer Institute, New York, NY, U.S.A.*

16:00 - 17:30

Salle / Room **403ABC**

Section **B**

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **Atteintes neuropsychiatriques / Neuropsychiatric Involvement**

Présidents / Chairpersons
M. I. Botez (Canada)
P. Bridges (U.S.A.)
Rolf R. Riedel (Federal Republic of Germany)

16:00 **W.B.O.40** Prevalence and Predictors of Depression in Gay and Bisexual Men during the AIDS Epidemic: The San Francisco Men's Health Study. *Thomas J. Coates*, F. Castro**, M. Ekstrand*, *University of California at San Francisco, San Francisco; **Stanford University, Stanford, CA, U.S.A.*

16:15 **W.B.O.41** Is There Adaptive "Habituation" to Loss in the AIDS Epidemic? *Robert H. Remien, R. Neugebauer, J. Williams, J. Rabkin, J. Gorman, Columbia University, New York State Psychiatric Institute, HIV Center for Clinical and Behavioral Studies, New York, NY, U.S.A.*

16:30 **W.B.O.42** Neurological and Neuropsychological Deficits in 240 HIV-Seropositive Hemophiliacs in WR 2-6. *Rolf R. Riedel*, P. Clarenbach*, P. Bülau**, C. Helmstadter**, C. Bruzki*, K. Wirtz, et al., University Clinic, Department of Neurology, Bonn, Federal Republic of Germany.*

16:45 **W.B.O.43** Slowed Cognitive Processing in HIV+ Patients in Comparison to Psychiatric Controls. *Alex Martin, D. Kampen, A. M. Salazar, J. Williams, W. Law, T. Roller, et al., Walter Reed Army Medical Center, Washington, DC, U.S.A.*

→

17:00 **W.B.O.44** Neuropsychological Change on Longitudinal Assessment: Prevalence and Pattern in HIV Spectrum Disorders. *Lydia Temoshok, M. Drexler, J. P. Canick, D. M. Sweet, H. Hollander, University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

17:15 **W.B.O.45** Further Evidence of Lack of HIV-1 Related Cognitive Impairment during the Asymptomatic Stages: The Multicenter AIDS Cohort Study. *Ola A. Selnes*, J. C. McArthur*, E. N. Miller**, K. Sheridan***, J. T. Becker****, B. Gordon*, et al., *Johns Hopkins Medical Institutions, Baltimore, MD; **University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA; ***Northwestern University, Chicago, IL; ****University of Pittsburgh, Pittsburgh, PA, U.S.A.*

17:30 **W.B.0.45a** Peptide T Phase I Study: Neuropsychiatric Results. *Peter T. Bridge*, F. K. Goodwin*, P. N. R. Heseltine**, E. Eaton**, E. S. Parker**, *National Institute of Mental Health, Bethesda, MD; ** University of Southern California, Los Angeles, CA, U.S.A.*

16:00 - 17:30

Salle
Room **407B**

Section
B

Mercredi 7 juin
Wednesday, June 7

Aspects cliniques
Clinical Aspects of AIDS

Colloque — **Essais cliniques : points de vue des "acteurs"**

Symposium — **Clinical Trials: The "Actors" Perspective**

Présidents / Chairpersons — Mary Fanning (Canada), Jaap Goudsmit (Netherlands)

16:00 **W.B.O.46** Investigators Perspective. *Allan R. Ronald, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.*

16:15 **W.B.O.47** Clinical Trials in AIDS: The Regulatory Perspective. *Ellen C. Cooper, U.S. Food and Drug Administration, Rockville, MD, U.S.A.*

16:30 **W.B.O.48** The Role of the Pharmaceutical Industry in Drug and Vaccine Development. *John C. Petricciani, Pharmaceutical Manufacturers Association, Washington, DC, U.S.A.*

16:45 **W.B.O.49** Patient's Perspective. *Claude Leblanc, Montreal, QC, Canada.*

17:00 **W.B.O.50** The Challenge of Testing Therapies for HIV Infection. *Daniel Hoth, NIAID, National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.S.A.*

17:15 **W.B.O.51** Ethicists and Clinical Trials. *Robert J. Levine, Yale University School of Medicine, New Haven, CT, U.S.A.*

16:00 - 17:30

Salle / Room **407C**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Virologie (partie 3) / Virology (Part 3)**

Présidents / Chairpersons S. Harada (Japan), Scott Putney (U.S.A.)

16:00 **W.C.O.33** Analysis of T Cell Nuclear Factors Which Bind to the Negative Regulatory Elements (NRE) of the HIV LTR. *Bruno Guy, B. Acres, M. P. Kieny, Transgène S.A., Strasbourg, France.*

16:15 **W.C.O.34** Functional Role of HIV-1 VPU. *Eric Cohen, E. Terwilliger, J. Sodroski, W. Haseltine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

16:30 **W.C.O.35** Effects of Mutations in the nef Gene on the Growth of HIV. *Sunyoung Kim*, K. Ikeuchi**, R. Byrn**, J. Groopman**, D. Baltimore*, *Whitehead Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge; **New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

16:45 **W.C.O.36** VPU: A Protein Unique for HIV-1 Is Required for Efficient Virion Maturation and Release. *Thomas Klimkait*, K. Strebel*, J. Orenstein**, M. A. Martin*, *NIAID, National Institutes of Health, Bethesda, MD; **George Washington University Medical School, Washington, DC, U.S.A.*

17:00 **W.C.O.37** Effects of nef Expression on HIV Replication and Cellular Functions. *Cecilia Cheng-Mayer*, P. Iannello*, P. A. Luciw**, J. A. Levy*, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco; **University of California at Davis, Department of Medical Pathology, Davis, CA, U.S.A.*

17:15 **W.C.O.38** In Vitro Generation of Neutralization-Resistant Human Immunodeficiency Virus (HIV). *Shinji Harada*, T. Masuda*, M. Kannagi*, S. Matsushita**, K. Takatsuki**, *Kyoto University, Institute for Virus Research, Kyoto; **Kumamoto University Medical School, Kumamoto, Japan*

16:00 - 17:30

Salle / Room **408A**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique **Éléments de base en immunologie (partie 2)**

Specialty Session **Basic Immunology (Part 2)**

Présidents / Chairpersons
G. L. Ada (U.S.A.)
Jean-Claude Chermann (France)
Rafick Sekaly (Canada)

16:00 **W.C.O.39** Analysis of the Functional Defects of T-Lymphocytes in HIV-Infected Patients. *Giuseppe Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, National Institutes of Health, Bethesda, MD, U.S.A.*

16:15 **W.C.O.40** In Vitro Lymphocyte Proliferative Responses to Recombinant and Synthetic Peptide Antigens of HIV-1. *John F. Krowka*, D. P. Stites*, K. S. Steimer**, N. Duzgunes*, et al., *University of California at San Francisco, Department of Laboratory Medicine, San Francisco; **Chiron Corporation, Emeryville, CA, U.S.A.*

16:30 **W.C.O.41** Determination of Epitopes Recognized by HIV-Specific CTL. *Scott Koenig, P. Earl, L. Wood, D. Powell, B. Moss, A. S. Fauci, et al., LIR, LVD, NIAID, and National Institutes of Health, Bethesda, MD, U.S.A.*

16:45 **W.C.O.42** A Cytotoxic T Lymphocyte Inhibits AIDS Virus Replication in Peripheral Blood Lymphocytes. *Hiroshi Tsubota, C. I. Lord, N. L. Letvin, Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A.*

17:00 **W.C.O.43** Long-Term Culture and Fine Antigen Specificity of HIV-1 Reverse Transcriptase-Specific Cytotoxic T-Lymphocyte (CTL) Clones. *Bruce D. Walker*, K. A. Birch-Limberger*, L. L. Ficher*, R. A. Young**, B. Moss***, R. T. Schooley*, *Harvard Medical School and Massachusetts General Hospital, Boston; **Massachusetts Institute of Technology, Whitehead Institute, Cambridge, MA; ***NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

17:15 **W.C.O.44** Analysis of the Structural and Non-Structural Proteins of HIV-1 Recognized by Primary Cytotoxic T Lymphocytes. *Yves Rivière*, F. Tanneau*, P. Sansonetti*, M.-P. Kieny**, O. López***, L. Montagnier*, *Institut Pasteur, Unité d'oncologie virale, Paris; **Transgène; ***Centre de Transfusion Sanguine, Pitié-Salpêtrière, Paris, France.*

16:00 - 17:30

Salle / Room **410ABC**

Section **C**

Mercredi 7 juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Modèles animaux (partie 3) / Animal Models (Part 3)**

Présidents / Chairpersons
Muthiah Daniel (U.S.A.)
Vanessa M. Hirsch (U.S.A.)
Roger Perreault (Canada)

16:00 **W.C.O.45** Neuropathological Study of SIV-Infected Macaques. Daniel C. Anderson*, H. M. McClure*, J. L. Ribas**, A. Ansari*, P. Fultz*, S. Mirra***, *Emory University, Yerkes Primate Research Center, Atlanta, GA; **Armed Forces Institute of Pathology and Walter Reed Army Institute of Research, Washington, DC; VA Medical Center, Atlanta, GA, U.S.A.

16:15 **W.C.O.46** Clinical, Immunological and Virological Follow-Up of HIV-2 Infected Rhesus Monkeys. Dominique Dormont*/**, J. Livartowski*, S. Chamaret**, D. Guétard**, F. Rouaix*, L. Montagnier*, et al., *Commissariat à l'Énergie Atomique, Centre de recherches de santé des armées, Fontenay-aux-Roses; **Institut Pasteur, Paris, France.

16:30 **W.C.O.47** Monkeys with Simian AIDS Produce an Antibody Directed against a Histone-like Protein on CD4+ T-Cells. Raphael B. Stricker*, P. N. Fultz**, A. M. Haislip*, *University of California at San Francisco, San Francisco, CA; **Emory University, Yerkes Regional Primate Research Center, Atlanta, GA, U.S.A.

16:45 **W.C.O.48** Vaccine Protection against Simian Immunodeficiency Virus Infection. Muthiah Daniel, P. Sehgal, M. Wyand, D. Ringler, N. King, R. Desrosiers, New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, U.S.A.

17:00 **W.C.O.49** Evidence for Progression to Disease in Chimpanzees Chronically Infected with HIV-1? Patricia N. Fultz*, R. Siegel*, H. McClure*, K. Steimer**, D. Dina**, B. Swenson*, et al., *Emory University, Atlanta, GA; **Chiron Corp., Emeryville, CA, U.S.A.

17:15 **W.C.O.50** Genetic Variation of SIV in Experimentally Infected Macaques: Tissue Versus Tissue Culture. Philip R. Johnson*, R. A. Olmsted*, R. H. Purcell**, V. M. Hirsch*, *Georgetown University, National Institutes of Health/Twinbrook II, Rockville; **NIAID, National Institutes of Health, Bethesda, MD, U.S.A.

16:00 - 17:30

Salle
Room **409ABC**



Section
D

Mercredi 7 juin
Wednesday, June 7

Le SIDA et l'individu
AIDS and the Individual

Colloque
Symposium

Les femmes dans les pays industrialisés : questions et options
Women in Developed Countries: Issues and Options

Présidents
Chairpersons

Marjo Meijer (The Netherlands)
Janet Mitchell (U.S.A.)
Elizabeth Reed (Australia)

16:00 **W.D.O.12** Women Injection Drug Users: Issues and Strategies. Yolande Serrano, *Association for Drug Abuse Prevention and Treatment, (ADAPT), Inc., New York, NY, U.S.A.*

16:20 **W.D.O.13** Community Development Model for Interventions with Prostitutes. Julie Bates, *Australian Prostitutes' Collective Inc., Canberra, Australia.*

16:40 **W.D.O.14** On Being HIV-Positive, European, Female, and "Non-Existent". Amanda Heggs, *Copenhagen, Denmark.*

17:00 **W.D.O.15** Psychosocial Factors that Hinder Health Care in HIV-Infected Women. Denise Ribble, *Bellevue Hospital/Community Health Project; New York, NY, USA.*

17:15 **W.D.O.16** Access to Services for Women with AIDS in Poor Minority Communities. Melinda Cuthbert, *Yale University, New Haven, CT, U.S.A.*

16:00 - 17:30

Salle / Room **411B**



Section **E**

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique **Services de pastorale**
Specialty Session **Pastoral Care**

Présidents / Chairpersons: Santo Dharan (Singapore), Munoz Mejia (Colombie), Charles A. Roy

16:10 **W.E.O.26** Pastoral Care in AIDS Management. *Alison D. Rader, M. Malama, I. D. Campbell, T. Chaava, The Salvation Army Chikankata Hospital, Mazabuka, Zambia.*

16:25 **W.E.O.27** An Evangelical Denomination Responds to AIDS. *Reginald F. Finger*, M. Malloy**, *Nazarene Health Care Fellowship Compassionate Ministries/Church of the Nazarene, Kansas City, MO; **Christian Counseling Services, Nashville, TN, U.S.A.*

16:40 **W.E.O.28** Jewish Law, Values and the Social Issues Arising from HIV Disease. *Benjamin Freedman, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada*

16:55 **W.E.O.29** Religious Leaders in Sao Paulo, Brazil Join the AIDS Prevention and Control. *Elisabeth Inglesi, M. E. Fernandes, Centro de Referência e Treinamento AIDS, Sao Paulo, Brazil.*

17:10 **W.E.O.30** Baha'i Concepts towards AIDS Patients and Society. *Farzin Davachi*, N. Davachi**, M. Wingi***, L. Sefu****, M. Mbanga**, *Mama Yemo Hospital, Department of Pediatrics; **National Spiritual Assembly of the Baha'is of Zaire; ***University of Kinshasa, Kinshasa, Zaire.*

17:20 **W.E.O.31** Discussant. *Stephen A. Pieters, Universal Fellowship of Metropolitan Community Churches, Los Angeles, CA, U.S.A.*

16:00 - 17:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Mercredi 7 juin
Wednesday, June 7

Colloque / Symposium

Coercition ou volontarisme? Analyse critique internationale
Coercion or Voluntarism: An International Critical Review

Présidents / Chairpersons: Ronald Bayer (U.S.A.), Margaret Sommerville (Canada)

16:00 **W.F.O.18** USA: A Review. Lawrence O. Gostin, *Harvard University, School of Public Health, Boston, MA, U.S.A.*

16:10 **W.F.O.19** Cuba: A Review. Hector Terry-Molinert, *Ministry of Public Health, Havana, Cuba.*

16:20 **W.F.O.20** Bavaria: Coercion or Voluntarism; An International Critical Review. Hans Jäger, *Stadtkrankenhaus, Münich, Federal Republic of Germany.*

16:30 **W.F.O.21** Sweden: A Review on Compulsive Treatment. Gunnar Agren, *County Council of Stockholm, Stockholm, Sweden.*

16:40 **W.F.O.22** Ethical and Legal Issues of AIDS in South Africa. Gideon J. Knobel, *University of Cape Town, Cape Town, South Africa.*

16:50 **W.F.O.23** A Human Rights Perspective. Justice Michael Kirby, *Court of Appeal, Supreme Court of Australia, Sydney, Australia.*

17:00 **W.F.O.24** Ethical and Policy Issues Posed by the Use of Coercion to Combat the Spread of HIV Infection. Ronald Bayer, *Columbia University School of Public Health, Division of Sociomedical Sciences, New York, NY, U.S.A.*

16:00 - 17:30

Salle / Room **406A**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Séance thématique **Prévalence (partie 3)**
Specialty Session **Prevalence (Part 3)**

Présidents / Chairpersons: Lutz Guertler (Federal Republic of Germany)
Pierre Tousignant (Canada)
Thomas Ogada (Kenya)

16:00 **W.G.O.25** The Use of HIV Surveillance Data for Guiding National AIDS Programme Decisions. *Gary Slutkin, J. Chin, D. Tarantola, J. Mann, World Health Organization, Geneva, Switzerland.*

16:15 **W.G.O.26** Suggestion of a Stabilization of HIV Infection in Selected Populations in Zaire between 1986 and 1989. *BosengeN'Galy*, R. Ryder**/***, M. Kamenga**, B. Kapita****, *National AIDS Programme Coordination Bureau; **Projet SIDA, Kinshasa, Zaire; Centers for Disease Control, Atlanta, GA, U.S.A.; ****Mama Yemo Hospital, Kinshasa, Zaire.*

16:30 **W.G.O.27** Sentinel Site Surveillance for AIDS in Abidjan, Côte d'Ivoire. *Kevin M. De Cock*, A. Porter*, J. Moreau*, L. Diaby*, K. Odehouri*, W. Heyward**, et al., *Projet RETRO-CI, Abidjan, Ivory Coast; **Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

16:45 **W.G.O.28** Les aspects épidémiologiques des affections liées au HIV-1 et 2 en République Centrale Africaine. *Alain J. Georges*, P. Somse**, M. R. Siopathis***, J. A. Vohito****, J. C. Bouquety***, M. D. Vohito***, *Institut Pasteur; **Programme National de Lutte contre le SIDA; ***Centre National Hospitalier; ****Laboratoire National de Santé publique, Bangui, Central African Republic.*

17:00 **W.G.O.29** Comparison of the Age Distribution of Anti-HIV-1 and Anti-HBc in an Urban Population from Malawi. *Lutz Guertler*, N. G. Liomba**, J. Eberle*, H. M. Ntaba**, F. Deinhardt*, T. Rehle***, *University of Munich, Max von Pettenkofer Institute, Munich, Federal Republic of Germany; **Queen Elizabeth Central Hospital, Blantyre, Malawi; ***Gesellschaft für technische Zusammenarbeit, Eschborn, Federal Republic of Germany.*

17:15 **W.G.O.30** HIV, HTLV-1 and HBV Infection in Pregnant Women from an Urban Population in Zaire. *Oscar Kashala*, L. Lomami**, K. Ngalula**, P. Kanki*, M. Kalengayi**, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.; **University of Kinshasa, Kinshasa, Zaire.*

16:00 - 17:30

Salle / Room **406BC**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Atelier / Workshop — **Atelier régional : Afrique occidentale / Regional Workshop: West Africa**

Présidents / Chairpersons — Joshua Adenyi (Nigeria), Ali Guindo (Mali)

16:00 **W.G.O.31** The HIV Problems in West Africa. *Femi Soyinka, Obafemi Awolowo University, Ile-Ife, Nigeria.*

16:15 **W.G.O.32** Poverty, Women and AIDS. *Patrick A. Twumasi, University of Ghana, Department of Sociology, Legon, Ghana.*

16:30 **W.G.O.33** Pediatric AIDS. *Janet Neeguayee, University of Ghana Medical School, Department of Child Health, Accra, Ghana.*

16:45 **W.G.O.34** AIDS and other STDs. *Bila Kapita, Hôpital Mama Yemo, Département de médecine interne, Kinshasa, Zaire.*

17:00 **W.G.O.35** Prostitution and AIDS. *Moussa Seck, Dakar, Senegal.*

17:15 **W.G.O.36** Blood Bank Service and AIDS. *Lamina Diakhote, Centre national de transfusion sanguine, Dakar Fann, Senegal.*

16:00 - 17:30

Salle / Room **411A**

Section **G**

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Colloque / Symposium

Déplacements internationaux et SIDA
International Travel and AIDS: A Perspective

Présidents / Chairpersons: Allan S. Meltzer (Canada)
Daniel Tarantola (Switzerland)

16:00 **W.G.O.37** AIDS and Tourism. *Branford Taitt, Ministry of Health, St. Michael, Barbados.*

16:15 **W.G.O.38** Freedom of International Travel. *Terry Mooney, WHO Global Programme on AIDS, World Health Organization, Geneva, Switzerland.*

16:30 **W.G.O.39** Le SIDA et les voyageurs : Perspectives en sante publique. *Michel Cayemittes, Institut Haitien de l'Enfance, Port-au-Prince, Haiti.*

16:45 **W.G.O.40** SIDA: Conseils aux Voyageurs. *Jean Robert, Hôpital Saint-Luc, Département de Santé communautaire, Montréal, QC, Canada.*

16:00 - 17:30

Salle / Room **404AB**

Section **H**

Mercredi 7 juin
Wednesday, June 7

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique / Specialty Session **Méthodologie des analyses de coûts / Methodology of Cost Studies**

Présidents / Chairpersons: André-Pierre Contandriopoulos (Canada); Hans Jäger (Federal Republic of Germany); Reiner Leidl (Federal Republic of Germany)

16:00 **W.H.O.13** Overview. *Yves Souterand, Paris, France.*

16:15 **W.H.O.14** Use and Costs of Health Care Services of Persons with AIDS in Three Practice Settings in San Francisco, 1986-87. *Anne A. Scitovsky, M. Cline, Palo Alto Medical Foundation/Research Institute, Palo Alto, CA, U.S.A.*

16:30 **W.H.O.15** Forecasting the Medical Care Costs of AIDS in the United States: 1989-1993. *Fred J. Hellinger, National Center for Health Services Research, United States Department of Health and Human Services, Rockville, MD, U.S.A.*

16:45 **W.H.O.16** Scenarios Linking Epidemiology and Economics: Possible Impacts of Drug Treatment of HIV-Infected in the FRG. *Reiner Leidl, Institute for Medical Informatics/GSF, Munich-Neuherberg, Federal Republic of Germany*

17:00 **W.H.O.17** Development and Application of a Model HIV Information System. *Julia Hidalgo, C. Hamidi, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A.*

17:15 **W.H.O.18** Labour Market Productivity. *Sherry Glied, Harvard University, Department of Economics, Cambridge, MA, U.S.A.*

16:00 - 17:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau

Section
I

Session vidéo
Video session

Mercredi 7 juin
Wednesday, June 7

Les clips

Clips

16:00 Introduction: *René Lavoie*

16:15 **W.I.V.15** ***Clips télévisés du monde entier***

Television spots from around the world

Les campagnes de prévention restent le principal moyen d'informer le grand public. Beaucoup d'organismes, gouvernementaux et communautaires, ont essayé d'intervenir en utilisant les techniques médiatiques existantes comme les messages télévisés d'intérêt public ou des clips spécialisés pour les lieux publics.

Ces clips sont réservés ou conservateurs, explicites ou hilarants, réactionnaires ou fascinants. Ils sont juxtaposés à dessein pour amener le public à choisir activement entre la peur et la prise en charge de soi.

Prevention campaigns remain the primary means of getting information to the general public. Many organizations, both government and community-based, have tried to intervene using existing media techniques such as Television Public Service Announcements (PSA's) or community-specific shorts intended for use in public venues.

These clips vary from coy to conservative, explicit to hilarious, reactionary to riveting. They are purposefully juxtaposed to force the audience to actively participate in choosing between promotion of fear or of empowerment.

Notes



Section
A

Mercredi 7 juin
Wednesday, June 7

Épidémiologie et santé publique
Epidemiology and Public Health

Session d'affichage
Poster Session

Prévalence du VIH chez les femmes et les enfants
HIV Prevalence in Women and Children

W.A.P.1 Seroprevalence of HIV Antibodies in Neonates and Children. *Shannon C. Fenn*, W. Bigler, M. Wilder, S. Manoff, J. Patti, J. Witte, et al., *Health and Rehabilitative Services of Florida, Tallahassee, FL, U.S.A.*

W.A.P.2 Routine HIV Antibody Screening in Los Angeles County Prenatal Clinics: A Demonstration Project. *Wendy Cozen*, L. Mascola, S. Bauch, M. Finn, C. Heneman, *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A.*

W.A.P.3 Epidemiology of HIV Infection in Women from Frankfurt Area. *Schlomo Staszewski*, E. Schieck, S. Rehmet, J. Odewald, R. Müller, W. Stille, et al., *Klinikum der J. W. Goethe Universität, Zentrum der immeren Medizim, Frankfurt, Federal Republic of Germany.*

W.A.P.4 Epidemiology and Outcome of HIV Seropositive Children in Madrid Community. *M. D. Gurbindo Gutierrez*, R. Bueno, J. Herrera, M. Moro, F. Omeñaca, J. Ruiz, et al., *Hospital General Gregorio Marañon, Madrid, Spain.*

W.A.P.5 Newborn Screening for HIV Antibody Seropositivity in the South Bronx. *Andrew Wiznia*, I. L. Hand, R. T. Checola, M. H. Kim, L. M. Noble, J. J. Yoon, *Bronx-Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

W.A.P.6 HIV Risk Factor Prevalence among Young Women of Child-Bearing Age Attending Women's Primary Care Clinics. *Robert W. Wood*, N. V. Harris, S. G. Hopkins, E. H. Sohlberg, T. J. Kimball, H. Watts, et al., *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A.*

W.A.P.7 Herpes Simplex, Syphilis and Hep. B: Association with HIV-1 and HTLV-I in Pregnant Haitian Women. *Reginald Boulos*, N. Halsey, A. Ruff, M. Adrien, T. C. W. Quinn, A. Nahmius, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.*

W.A.P.8 HIV Infection in Pregnant Women at a Public Hospital in New Orleans, Louisiana. *Louise McFarland*, H. Dean, B. Trahan, L. Muirhead, *Louisiana Department of Health and Hospitals, New Orleans, LA, U.S.A.*

W.A.P.9 The Seroprevalence of HIV Infection in New York City Children. *Isaac B. Weisfuse*, P. Thomas, M. Oxtoby, S. Back, R. Stevens, D. Berns, et al., *New York City Department of Health, New York, NY, U.S.A.*

W.A.P.10 HIV Infection in Lesbians. Denise J. Ribble*, C. Marte, J. Kelly, C. Keyes, P. Rodgers, J. Wolbert, *Bellevue Hospital, Community Health Project, New York, NY, U.S.A.

W.A.P.11 No Change in HIV Seroprevalence among Parturients and Women Having Induced Abortions in New York City, 1987-1988. Maria Rosario G. Araneta*, P. A. Thomas, L. L. Ramirez, I. B. Weisfuse, S. Schultz, *New York City Department of Health, AIDS Research Unit, New York, NY, U.S.A.

Incidence du SIDA
AIDS Incidence

W.A.P.12 The Evolving Epidemiology of AIDS in New York City: Trends in AIDS Case Surveillance Data. Alan E. Greenberg*, P. A. Thomas, R. H. Hindin, A. W. Greene, E. L. Rautenberg, S. J. Schultz, *AIDS Surveillance Unit, New York City Department of Health; AIDS Center for Disease Control, New York, NY, U.S.A

W.A.P.13 The Epidemiology of AIDS in San Francisco's Elderly Population. Susan F. Payne*, C. Wilson, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.

W.A.P.14 The Epidemiology of AIDS-related Non-Hodgkin's Lymphoma in San Francisco. George F. Lemp*, S. F. Payne, D. P. Neal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.

W.A.P.15 Changing Trends in the AIDS Epidemic in Europe. Angela M. Downs*, R. A. Ancelle-Park, J. B. Brunet, *World Health Organization Collaborating Centre on AIDS, IMET, Paris, France.

W.A.P.16 Four-fold Increase in Tuberculosis/AIDS Patients in New York City, 1985-1988. Eddy Laroche*, M. R. G. Araneta, R. L. Stoneburner, J. J. Adler, *New York City Department of Health, New York, NY, U.S.A.

W.A.P.17 Epidemiology of AIDS-associated Lymphomas: United States. Thomas A. Peterman*, V. Beral, R. L. Berkelman, *Centers for Disease Control, Atlanta, GA, U.S.A.

W.A.P.18 Changing Patterns of Heterosexually-acquired AIDS in Florida. Deborah Holtzman*, N. A. Brandenburg, J. Sims, J. J. Witte, *Department of Health and Rehabilitative Services, AIDS Program, Tallahassee, FL, U.S.A.

W.A.P.19 The Relative Risk of AIDS for the Black and Hispanic Communities in New Jersey. Molly J. Coye*, N. Williams, J. Ryan, *New Jersey State Department of Health, Trenton, NJ, U.S.A.

W.A.P.20 Changes in Mode of Transmission among AIDS Cases in Houston, Texas, U.S.A. Robert L. Falletti*, A. Phelps, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A.

W.A.P.21 Heterosexually Transmitted AIDS in New York State. J. Stan Lehman*, P. Smith, J. Mikl, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.S.A.

W.A.P.22 Hepatitis Delta (HDV) and AIDS in Risk Communities in Argentina. *Oscar Fay*, G. R. Muchinik, J. Biglione, M. B. Bouzas, E. Fernandez, J. Galíndez, et al., *Universidad de Rosario, Centro de Tecnología en Salud Pública, Rosario, Argentina.*

W.A.P.23 Risk of AIDS and HIV Infection in American Indians and Alaska Natives. *George A. Conway*, E. Y. Hooper, M. E. St. Louis, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.A.P.24 Decline in Rate of New AIDS Cases among Homosexual and Bisexual Men in San Francisco. *Christina P. Lindan*, G. W. Rutherford, S. F. Payne, N. Hearst, G. F. Lemp, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.A.P.25 Analyse des tendances des caractéristiques socio-démographiques des cas de SIDA rapportés en France. *Anne Laporte*, B. H. Hubert, A. M. Marciniack, S. C. Cluzan, J. B. Brunet, *Ministère de la Santé, Direction générale, Paris, France.*

W.A.P.26 AIDS in the Department of Veterans' Affairs: Demographics and Epidemiology. *Robert E. Allen*, S. H. Mather, M. R. Peterson, *AIDS Program Office, Veterans Administration, Washington, DC, U.S.A.*

Mortalité liée au SIDA/VIH
AIDS/HIV Related Mortality

W.A.P.27 Impact of AIDS on Mortality in San Francisco: 1979-1986. *George W. Rutherford*, L. D. Saunders, G. F. Lemp, L. Barnhart, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

W.A.P.28 HIV-associated Mortality in England and Wales Is Greater than that Identified by AIDS Surveillance. *Anna McCormick*, *PHLS Communicable Disease Surveillance Centre, London, U.K.*

W.A.P.29 Estimate of HIV-related Deaths in Young Adult Men, United States, 1986. *James W. Buehler*, R. L. Berkelman, O. J. Devine, *Centers for Disease Control, Centre for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

W.A.P.30 Causes of Death in a Large Cohort of I.V. Drug Users (IVDUs) in Milan: An Update. *Massimo Galli*, G. Codini, M. Carito, V. Cruccu, L. Zampini, D. Ciacci, et al., *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy.*

W.A.P.31 Mortality among 1,862 HIV-Infected Persons in a Geographically Dispersed U.S. Population: Preliminary Results. *Andrew L. Dannenberg*, J. McNeil, J. Brundage, *National Heart, Lung, and Blood Institute, Bethesda, MD, U.S.A.*

W.A.P.32 AIDS Mortality among Puerto Rican-born Residents of New York City: 1981-1987. *Ernest Drucker*, B. Menendez-Bergad, S. Blum, R. Perez-Agosto, J. Parga, S. H. Vermund, *Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

W.A.P.33 The Impact of Non-Opportunistic Infections on Mortality in a National Sample of AIDS Hospitalizations. *Barbara J. Turner*, J. K. Ball, *Jefferson Medical College, Philadelphia, PA, U.S.A.*

W.A.P.34 Stabilization of AIDS Mortality in Non-Drug Using Men in New York City (NYC). *Rand L. Stoneburner*, C. Stevens, M. Chiasson, J. Morrison, W. E. Ewing, T. Singh, et al., *New York City Department of Health, New York, NY, U.S.A.*

W.A.P.35 Comparison of U.S. HIV Mortality Trends from Vital Statistics and AIDS Surveillance. *Frances M. Chevarley*, K. D. Kochanek, J. W. Buehler, *National Center for Health Statistics, Hyattsville, MD, U.S.A.*

Transmission homosexuelle
Homosexual Transmission

W.A.P.36 Risk Factors for Transmission and Impact of Knowledge of HIV-AB Seroconversion on Sexual Behavior among Homosexual Men. *Godfried J. P. Van Griensven*, C. Kuiken, E. M. M. De Vroome, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

W.A.P.37 Retrospective Study of Factors Responsible for HIV Transmission in Male Homosexuals. *Anastasia Roumeliotou*, G. Kallinikos, M. Kotsianopoulou, A. Nestoridou, E. Trichopoulou, G. Papaevangelou, *National Center for AIDS, Athens School of Hygiene, Athens, Greece.*

W.A.P.38 Risk Factors for HIV Infection among Male Prostitutes in Atlanta. *Kirk Elifson*, J. Boles, M. Sweat, W. Darrow, *Georgia State University, Department of Sociology, Atlanta, GA, U.S.A.*

W.A.P.39 Relationship of STD History to HIV Seropositivity in a Cohort of Homosexual Men in Dallas, Texas. *Charles E. Haley*, P. Anderson, A. Freeman, A. Petty, *Dallas County Health Department, Dallas, TX, U.S.A.*

W.A.P.40 HIV-1 Discordant Couples in the Baltimore MACS Study. *John G. Palenicek*, R. Fox, N. Odaka, H. Armenian, J. Harris, W. Hardy, et al., *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

W.A.P.41 Failure to Confirm Herpes Simplex Virus Type 2 (HSV-2) Infection as a Risk Factor for HIV-1 Seroconversion among Homosexual Men. *Lawrence A. Kingsley*, J. Armstrong, A. Rahman, M. Ho, C. R. Rinaldo, *University of Pittsburgh, Infectious Diseases and Microbiology, Pittsburgh, PA, U.S.A.*

W.A.P.42 Seroepidemiologic Study of HIV Infection among Homosexual Men Attending a Medical Practice in Montreal. *Robert S. Remis*, M. Najjar, C. Pass, G. Paradis, *Bureau régional des maladies infectieuses, Montreal, QC, Canada.*

W.A.P.43 Risk Factors in Homosexual Transmission of HIV. *Ennio Ricchi*, P. Costigliola, M. Borderi, N. Dentale, M. C. Re, F. Chiodo, *Istituto Malattie Infettive, Università di Bologna, Bologna, Italy.*

W.A.P.44 Epidemiological, Immunological and Behavioural Parameters in a Cohort of Homosexual Men: Sequential Changes Over Six Years. *Brian P. Mulhall*, L. Carter, I. H. Frazer, *Royal Melbourne Hospital, Melbourne, Australia.*

W.A.P.45 The Incidence of Human Immunodeficiency Virus (AIDS) Infection among the Cohorts of Sexually Transmitted (STD) Patients with Different Veneral Disease Histories. *Wayne X. Shandera, Baylor College of Medicine, Ben Taub Hospital, Houston, TX, U.S.A.*

W.A.P.46 Recent HIV Seroconverters (SC) in a San Francisco Cohort of Homosexual/Bisexual Men: Risk Factors for New Infection. *Alan R. Lifson*, P. M. O'Malley, N. A. Hessol, L. S. Doll, L. Cannon, G. W. Rutherford, *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

Transmission verticale
Vertical Transmission

W.A.P.47 Maternal Factors and Neonatal Characteristics Associated with HIV Infection in Infants of Seropositive Women. *Prasanna Nair*, J. Johnson, S. Hines, L. Alger, S. Seiden, *University of Maryland School of Medicine, Baltimore, MD, U.S.A.*

W.A.P.48 Risk Factors (RF) in Symptomatic HIV Seropositive (SP) Children in the San Juan City Hospital (SJCH), Puerto Rico. *Eleanor Jimenez*, M. T. Carrer, L. A. Lopez, I. Perez, C. N. Reyes, *San Juan City Hospital, Rio Piedras, Puerto Rico*

W.A.P.49 Prospective Study of the Vertical Transmission of HIV. *Jack Levy*, S. Sprecher, J. Duchateau, N. Clumeck, J. Ninane, G. Zissis, et al., *Hôpital universitaire Saint-Pierre, Bruxelles, Belgium.*

W.A.P.50 Perinatal Transmission of HIV-1 in Lusaka, Zambia. *Subhash K. Hira*, G. Bhat, J. Kamanga, C. Mwale, N. Luo, P. Perine, et al., *University Teaching Hospital, Lusaka, Zambia.*

W.A.P.51 Perinatally Acquired HIV Infection and the Risk of Vertical Transmission in Rio de Janeiro, Brazil. *Dario J. H. P. Signorini*, N. P. M. Rubini, R. Rocco, W. A. Eyer-Silva, F. S. Sion, C. A. Morais de Sá, *Gaffrée and Guinle University Hospital/University of Rio de Janeiro, Rio de Janeiro, Brazil.*

W.A.P.52 HIV-Isolations in Pregnant Women and Their Offspring. *Anneka C. Ehrnst*, S. Lindgren, A. B. Bohlin, C. Ottenblad, J. Czajkowski, A. Sönnerborg, et al., *Central Microbiological Laboratory, Stockholm, Sweden.*

Progression de l'infection vers la maladie
Progression from Infection to Disease

W.A.P.53 Follow-up of HIV-Infected Homosexuals with Lymphadenopathy Syndrome (LAS). *Thomas Harrer*, K. Messing, E. Meyer, U. Bienzle, J. R. Kalden, *Medizinische Klinik III Universität Erlangen-Nürnberg Erlangen, Federal Republic of Germany.*

W.A.P.54 Risk of AIDS in Patients Presenting with Herpes Zoster, PGL or "Other" Features of ARC. *Subhash K. Hira*, G. Tembo, D. Wadhawan, J. Kamanga, R. Macuacua, P. Perine, *University Teaching Hospital, Lusaka, Zambia.*

W.A.P.55 Incidence of AIDS in Spanish HIV Infected Patients. *José M. Gatell*, D. Podzamczer, B. Clotet, I. Ocaña, C. Estany, J. M. Miro, et al., *Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain.*

W.A.P.56 Natural History of HIV Infection in Women of Child-Rearing Age in Uganda. *E. Mworozi*, S. Kiguli, *Makerere University, Kampala, Uganda.*

W.A.P.57 Deflection of an AIDS Progression Curve in a Gay Cohort. *Martin T. Schecter*, K. J. P. Craib, T. N. Le, B. Willoughby, J. S. G. Montaner, *Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*

W.A.P.58 Progression to AIDS in Cohorts of Seroprevalent and Seroincident Gay Men: Results at 6 Years. *Kevin J. P. Craib*, M. T. Schechter, W. A. McLeod, M. S. Weaver, B. Willoughby, B. Douglas, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*

W.A.P.59 Progression of HIV Disease among Intravenous Drug Abusers (IVDA): A Three-Year Prospective Study. *U. Tirelli*, S. Saracchini, S. Diodato, D. Serraino, P. Martelli, E. Vaccher, *Centro di Riferimento Oncologico, Division of Medical Oncology, Aviano, Italy.*

W.A.P.60 Devenir des sujets infectés par le VIH : Premiers résultats d'une surveillance hospitalière. *François Dabis*, D. Commenges, G. Chêne, J. L. Pellegrin, A. Schmitt, Groupe d'épidémiologie clinique du SIDA on Aquitaine (GECSA), Université Bordeaux 2, Département d'Informatique médicale, Bordeaux, France.*

W.A.P.61 Risk Estimates of AIDS in Hemophiliacs. *Joyce F. Killinger*, P. S. Rosenberg, J. J. Goedert, L. M. Aledort, C. M. Kessler, M. H. Gail, et al., *Research Triangle Institute, Research Triangle Park, NC, U.S.A.*

W.A.P.62 Enhancement Prediction of AIDS in HIV Seropositive Asymptomatic Men: Relative Value of 8 Cellular and Serologic Markers Singly and in Combination. *J. L. Fahey*, J. M. G. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, et al., *University of California at Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA, U.S.A.*

W.A.P.63 Follow-up of a Cohort of Ex-IVDAs Resident in Therapeutical Communities in Italy. *Giuseppe Marasca*, A. Fiume, C. Marchitelli, V. Masini, T. Prestileo, A. Zampieri, et al., *Istituto Superiore di Sanità, Rome, Italy.*

W.A.P.64 AIDS Yearly Incidence in 1984 HIV Seroprevalent Cohort: No Definite Trend 1985-1988. *Barbara R. Visscher*, L. Jacobson, R. Detels, J. Dudley, P. English, J. Chmiel, et al., *University of California at Los Angeles School of Public Health, Los Angeles, CA, U.S.A.*

W.A.P.65 Natural History of HIV-1 Infection Following Pregnancy. *Pratibha Datta*, J. E. Embree, M. Braddick, J. Kreiss, J. Ndinya-Achola, F. A. Plummer, *University of Nairobi, Nairobi, Kenya.*

W.A.P.66 The Prognosis of Asymptomatic HIV Infection: The United States Army Three-Year Experience. *Robert R. Redfield*, J. Brundage, C. Oster, E. Tramont, D. Burke, U.S. Army Retroviral Research Group, *Walter Reed Army Institute of Research, Department of Retroviral Research, Rockville, MD, U.S.A.*

W.A.P.67 Estimation of Maturity of HIV-1 Infection in Subgroups of Seroprevalent Cohort of Homosexual Men. *Alvaro Muñoz*, V. Carey, A. Saah, J. Chmiel, R. Detels, L. Kingsley, et al., *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A.*

W.A.P.68 AIDS-Free Time After HIV-1 Seroconversion in Homosexual Men According to Demographic Subgroups. *Alvaro Muñoz*, S. Bass, A. Saah, J. Chmiel, J. Taylor, L. Kingsley, *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A.*

W.A.P.69 Statistical Models for Assessing Feedback: An Analysis of Immune Function and Social Behaviors in the Multicenter AIDS Cohort Study. *Scott L. Zeger*, K. Y. Liang, L. Park, R. Fox, L. Kingsley, J. Chmiel, et al., *Johns Hopkins School of Public Health, Baltimore, MD, U.S.A.*

W.A.P.70 Survival and Time of Progression to AIDS among Patients at Gaffrée and Guinle University Hospital, Rio de Janeiro, Brazil. *Fernando S. Sion*, W. Eyer-Silva, M. C. Rachid de Lacerda, C. A. Morais de Sá, E. A. Castilho, M. D. C. Guimaraes, *Gaffrée and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

W.A.P.71 Natural History of HIV Infection in a Cohort of Intravenous Drug Users (IVDUs): A Five-Year Prospective Study. *Roberto Muga Bustamante*, J. Tor, R. Melus, C. Ginesta, C. Rey-Joly, M. Foz, *Hospital "Germans Trias I Pujol", Universidad Autonoma de Barcelona, Badalona, Barcelona, Spain.*

W.A.P.72 Problem-Oriented Data Collection for Natural History Studies of HIV-Infected Patients. *Frank W. Stitt*, G. Dickinson, N. G. Klimas, G. Laperriere, *University of Miami, School of Medicine, Miami, FL, U.S.A.*

W.A.P.73 Progression of HIV-1 Disease in a Population of Seropositive Navy and Marine Corps Personnel. *Douglas L. Mayers*, D. B. Wilson, K. F. Wagner, *Infectious Diseases Division, National Naval Medical Center, Bethesda, MD, U.S.A.*

W.A.P.74 Prospective Multicenter Cohort Study in Homosexual Men in the FRG. A 4-Year Follow-up: Epidemiological Results. *Bernhard Schwartländer, AIDS Center, Federal Health Office, Berlin, Federal Republic of Germany.*

W.A.P.75 Natural History of HIV Infection among IV Drug Abusers in Basque Country. *J. Arrizabalaga*, J. A. Iribarren, C. Garde, G. Cilla, P. Etxaniz, D. Zulaica, *Hospital Nuestra Señora de Aránzazu, San Sebastian, Spain.*

Survie des personnes atteintes du SIDA
Survival of the AIDS Patient

W.A.P.76 Degree of HIV-Related CNS Involvement and Long-Term Survival: Preliminary Results. *Frank T. Kenny*, D. K. MacFadden, *Toronto Western Hospital, Toronto, ON, Canada.*

W.A.P.77 Immunologic and Virologic Determinants of Survival in AIDS: Role of Cytomegalovirus, CD4+ and CD8+ Lymphocytes. *Fiala Milan*, L. A. Cone, L. Schwartz, V. Kermani, W. W. Tourtellotte, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A.*

W.A.P.78 Predictors of Survival for AIDS in Barcelona (Spain). *Juan Batalla*, J. M. Gatell, J. A. Caylà, J. M. Jansà, A. Plasencia, N. Parellada, *Institut Municipal de la Salut, Barcelona, Spain.*

W.A.P.79 Predicting In-Hospital Mortality for AIDS Patients: A Validated Model. *Steven A. Grover*, N. Gilmore, J. Falutz, C. Tsoukas, L. Coupal, R. Fakhry, *Montreal General Hospital, Division of Clinical Epidemiology, Montreal, QC, Canada.*

W.A.P.80 Effect of Multiple Disease Manifestations on Length of Survival for AIDS Patients in San Francisco. *Susan F. Payne*, G. F. Lemp, G. W. Rutherford, D. P. Neal, T. Temelso, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

W.A.P.81 Improved Survival of AIDS Patients in Dallas, Texas After 1986. *Charles E. Haley*, V. Reff, A. Freeman, I. Haslund, M. Bierman, *Dallas County Health Department, Dallas, TX, U.S.A.*

W.A.P.82 Increased Survival for PWA. *William E. Lafferty*, D. Glidden, S. Hopkins, J. Harwell, J. Honey, M. Fields, *Washington State Office on HIV/AIDS, Epidemiology Section, Seattle, WA, U.S.A.*

W.A.P.83 Surveillance-based Survival Analysis of Quebec AIDS Patients. *Denis Roy*, R. W. H. Palmer, R. S. Remis, *Bureau régional des maladies infectiuses, Montreal, QC, Canada.*

Prévention par l'annonce au(x) partenaire(s)
Prevention through Partner Notification

W.A.P.84 Syphilis Contact Tracing in a New York City STD Clinic: Implications for HIV Partner Notification. *Suzanne Laussuca*, M. A. Chiasson, W. E. Ewing, S. Schultz, R. L. Stoneburner, *New York City Department Health, AIDS Research Unit, New York, NY, U.S.A.*

W.A.P.85 Sexually Transmitted Disease (STD) Clinic Client Opinions on HIV Partner Notification. *Catherine Raevsky*, N. Spencer, F. Wolf, C. Simms, *Colorado Department of Health, STD/AIDS Section, Denver, CO, U.S.A.*

W.A.P.86 Study of Sexual Contacts of the HIV Seropositive Persons. *Enrique Galbán*, J. Menéndez, R. Gil, H. Terry, *Ministerio de Salud Pública, Havana, Cuba.*

W.A.P.87 Epidemiologic Benefits of Health Department Notification of HIV Exposure. *Randolph F. Wykoff*, J. L. Jones, S. L. Longshore, S. L. Hollis, C. B. Quiller, W. B. Gamble, *South Carolina Department of Health and Environmental Control, Greenwood, SC, U.S.A.*

Prévention de la transmission par contact sexuel et par consommation de drogues
Preventing Transmission by Sexual Contact and Drug Use

W.A.P.88 Ineffectiveness of Education in Intravenous Drug Users to Prevent HIV Sexual Transmission. *Jean-François Delfraissy*, A. Levy, A. Abelhauser, D. Penso, A. Blanc, F. Boué, et al., *Hôpital Antoine Béclère, Clamart, France.*

W.A.P.89 Risk Behaviours of IV Cocaine Users: Implications for Intervention. *Dale D. Chitwood*, C. B. McCoy, M. Comerford, E. J. Trapido, *University of Miami Medical School, Miami, FL, U.S.A.*

W.A.P.90 Trends of Risk Reduction among Initiates into Intravenous Drug Use 1982-1987. *David Vlahov*, J. C. Anthony, D. D. Celentano, L. Solomon, N. Choudhury, W. Mandell, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

W.A.P.91 Self-Efficacy and Community Norms Predict AIDS Risk Reduction among Gay and Bisexual Men in San Francisco: The AIDS Behavioural Research Project. *Leon McKusick*, T. J. Coates, S. Morin, *University of California at San Francisco, Department of Medicine, Division of Internal Medicine, San Francisco, CA, U.S.A.*

W.A.P.92 Sexual Behaviours and Characteristics of 627 Gay and Bisexual Male Participants of the Talking Sex Project: Small Group Educational Interventions for the Prevention of AIDS. *Fred G. Tudiver*, T. Myers, R. Kurtz, E. Jackson, K. Orr, C. Rowe, *Sunnybrook Medical Centre, Toronto, ON, Canada.*

W.A.P.93 Preliminary Analysis of Factors Associated with Compliance and Guidelines for Prevention of Sexual Transmission of HIV in Heterosexual Couples. *Margaret Nichols*, P. Paroski, G. Sampson, J. Leibel, M. J. Kennedy, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.S.A.*

W.A.P.94 Ongoing Impact Evaluation of the Condom Use Promotion/Desensitization Program for Preventing AIDS in the Dominican Republic. *Ernesto Guerrero*, E. De Moya, S. Rosario, PROCETS, *Ministry of Public Health, Santo Domingo, Dominican Republic.*

W.A.P.95 An Evaluation of the Effects of Various Lubricants on Latex Condoms. *Bradley L. Pugh*, M. D. Englert, *Ansell Incorporated, Dothan, AL, U.S.A.*

W.A.P.96 Evaluation of Condom Utilization and Acceptability of Spermicides among Prostitutes in Kinshasa, Zaire. *Nzilambi Nzila*, M. Laga, M. Kivuvu, K. Mokwa, A. T. Manoka, R. Ryder, *Projet SIDA, Kinshasa, Zaire.*

W.A.P.97 AIDS and Condom Use in the Netherlands. *Ernest De Vroome*, T. G. M. Sandfort, M. Paalman, R. A. P. Tielman, *University of Utrecht, Department of Studies on Homosexuality, Utrecht, Netherlands.*

W.A.P.98 The Supply of, and Demand for, Condoms to Prevent HIV Transmission in Developing Countries. *Lenni W. Kangas*, J. R. Harris, J. D. Shelton, *Office of Health, Agency for International Development, Washington, DC, U.S.A.*

W.A.P.99 Persistent Condom Breakage. *Bruce Voeller, Mariposa Foundation, Topanga, CA, U.S.A.*

W.A.P.100 Increasing Condom Accessibility: What Are the Barriers?. *Brenda E. Spencer*, A. Spira, N. Job-Spira, *INSERM U292, Hôpital de Bicêtre, Paris, France.*

W.A.P.101 A Simulated Physiologic Test of Latex Condoms. *Bruce A. Herman*, W. A. Herman, S. M. Retta, J. E. Rinaldi, R. F. Carey, T. W. Athey, *U.S. Food and Drug Administration, Rockville, MD, U.S.A.*

W.A.P.102 Inactivation of HIV-1 in Vaginal and Seminal Secretions by the Spermicide Benzalkonium Chloride. *Mark A. Wainberg*, R. Thomas, *McGill University, Montreal, QC, Canada.*

W.A.P.103 The Relationship between Condom Use and Sex Behavior. *Jon Martin Sundet*, I. K. Kvalem, P. Magnus, J. K. Grnnesby, H. Stigum, L. S. Bakketeig, *National Institute of Public Health, Oslo, Norway.*

W.A.P.104 Needle-Sharing and Bleach Use among Intravenous Drug Users (IVDUs) Seeking to Enter an Acute Detoxification Program. *Sharon G. Hopkins*, M. Carlisle, J. Honey, N. Harris, J. McGough, *Seattle-King County Department of Public Health, Seattle, WA, U.S.A.*

W.A.P.105 Outcomes of an AIDS Prevention Program for Methadone Maintenance Patients. *Stephen Magura*, Q. Siddiqi, J. L. Shapiro, J. I. Grossman, D. S. Lipton, *Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

W.A.P.106 Anthropological and Epidemiological Observations of Changes in Needle Use and Needle Sharing Practices Following Twelve Months of Bleach Distribution. *Margaret M. Connors*, B. F. Lewis, *Spectrum House, Inc., Westboro, MA, U.S.A.*

W.A.P.107 Evidence for Risk Reduction among IVDU in Amsterdam. *Anneke van den Hoek*, H. J. A. Van Haastrecht, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands.*

W.A.P.108 Changes in HIV Risk Behaviour in Drug Injectors Attending Syringe-Exchange Projects in England and Scotland. *Gerry V. Stimson*, M. C. Donoghoe, K. Dolan, *Monitoring Research Group, Goldsmiths' College, London, U.K.*

W.A.P.109 Drug Treatment Centers as the Nucleus for a Prevention-based Case Management System for Intravenous Drug Users. *Jessica Gardom*, T. S. Jones, C. H. Hayden, H. A. Stern, P. O. Poppe, G. S. Bowen, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Prévention : politiques et évaluation des programmes
Prevention: Policy Issues, Program Evaluation

W.A.P.110 CARA: A Tool for AIDS Prevention. *Wilfried Belschner, University of Oldenburg, Department of Psychology and Health, Oldenburg, Federal Republic of Germany.*

W.A.P.111 Short and Long Term Results of an AIDS Prevention Program. *Timothy E. Miller*, C. D. Booraem, J. V. Flowers, A. E. Iversen, *AIDS Response Program, Garden Grove, CA, U.S.A.*

W.A.P.112 Training the Health Care Professional: The AIDS Regional Education and Training Centers Program of the Health Resources and Service Administration (HRSA). *Phyllis B. Heffron*, M. J. Horner, A. Macher, D. Moore, B. Martell, *U.S. Public Health Service, Rockville, MD, U.S.A.*

W.A.P.113 Outcome of HIV Prevention and Counseling at Cook County Hospital, Chicago: A Two-Year Follow-up. *Renslow Sherer*, D. Seibert, N. Cadena, E. Hite, L. Holder, *Cook County Hospital, Chicago, IL, U.S.A.*

W.A.P.114 Applications of Methods and Results from Family Planning Operations Research to AIDS Prevention in Africa. *Maria J. Wawer, Center for Population and Family Health, Columbia University, New York, NY, U.S.A.*

W.A.P.115 Determinants of AIDS Policy Preference of the General Public. *David G. Ostrow*, M. Traugott, *University of Michigan Institute for Social Research, Ann Arbor, MI, U.S.A.*

W.A.P.116 Sexual Behaviour of Young Adults and the Effects of AIDS-Prevention Campaigns in Switzerland. *Françoise H. Dubois-Arber*, P. Zeugin, D. Hausser, P. Lehmann, *Institut universitaire de Médecine sociale et préventive, Lausanne, Switzerland.*

W.A.P.117 Effectiveness of the Swiss AIDS Prevention Campaigns in 1988. *Dominique Hausser*, F. Dubois-Arber, P. Lehmann, F. Gutzwiller, *Institut universitaire de Médecine sociale et préventive, Lausanne, Switzerland.*

W.A.P.118 More than One Type of Education and Testing Program Is Necessary to Reach Selected Target Population in Large Numbers. *Neil Flynn*, A. Sweha, S. Jain, N. Nassar, D. Webb, G. Acuna, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A.*

W.A.P.119 How Can Seroprevalence Survey Data Be Used to Manage HIV Prevention Programs? *Ida M. Onorato*, T. S. Jones, W. R. Forrester, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.A.P.120 A Program to Encourage AIDS Prevention Counselling by Primary Care Physicians. *Jay Wortman*, M. Rekart, M. Gelfer, *College of Family Physicians of Canada, B.C. Chapter, Vancouver, BC, Canada.*

Notes

Section
B
Clinical Aspects of AIDS
Aspects cliniques

Mercredi 7 juin
Wednesday, June 7

Session d'affichage
Poster Session

Cryptococcose
Cryptococcus Infection

W.B.P.1 Fluconazole Therapy of Patients with AIDS and Cryptococcal Meningitis and Failed Conventional Antifungal Therapy. *Robert H. Rubin*, P. A. Robinson, A. K. Knirsch, J. A. Joseph, *Massachusetts General Hospital, Boston, MA, U.S.A.*

W.B.P.2 Itraconazole in the Treatment of Cryptococcal Meningitis in Patients with AIDS. *Jan De Gans*, P. Portegies, G. Tiessens, J. K. M. Eeftinck Schattenkerk, R. J. Van Ketel, *Academisch Medisch Centrum, Department of Neurology, Amsterdam, Netherlands.*

W.B.P.3 Pulmonary Involvement in Cryptococcosis in Patients with AIDS. *Miriam L. Cameron*, J. Bartlett, H. Waskin, H. Gallis, *Duke University Medical Center, Durham, NC, U.S.A.*

W.B.P.4 Prognostic Factors of Cryptococcal Meningitis in AIDS Patients. *Kayembe Kalambayi*, P. Desmet, *University of Kinshasa, Department of Internal Medicine, Kinshasa, Zaire.*

W.B.P.5 Intravenous and Oral Fluconazole (FCZ) for the Treatment of Acute Cryptococcal Meningitis. *Veeraf M. Sanjana*, M. Davidson, M. Mullen, D. Boyle, M. Raviglione, H. Cortes, *Cabrini Medical Center, New York, NY, U.S.A.*

W.B.P.6 Serum Cryptococcal Antigen Screening in the Early Diagnosis of Cryptococcal Infection in Patients with HIV Infection. *Joseph R. Masci*, G. Pierone, P. Nicholas, *Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.S.A.*

W.B.P.7 Response of Cryptococcal Meningitis to Anti-Fungal Therapy in Patients with AIDS. *Kenrad E. Nelson*, G. K. Thager, W. Merz, J. G. Bartlett, *Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A.*

W.B.P.8 Spectrum of Cryptococcus Neoformans Infection in 68 HIV-Infected Patients. *Rebecca A. Clark*, D. Greer, W. Atkinson, G. Valainis, H. Hyslop, *Tulane/Louisiana State University ACTU, New Orleans, LA, U.S.A.*

W.B.P.9 Fluconazole (FLU) Treatment of Persistent Urinary Cryptococcosis (PUC) After Cryptococcal Meningitis (CM). *Samuel A. Bozzette*, R. Larsen, J. Chiu, M. Leal, K. Large, J. A. McCutchan, et al., *University of California at San Diego, San Diego Medical Center, San Diego, CA, U.S.A.*

W.B.P.10 Therapy (Rx) of Cryptococcal Meningitis (CM) and Cryptococcosis (C) in AIDS with Oral Itraconazole. *David W. Denning*, R. M. Tucker, J. R. Hamilton, L. H. Hanson, D. A. Stevens, *Santa Clara Valley Medical Center and Stanford University, San José, CA, U.S.A.*

W.B.P.11 Persistent Cryptococcus Neoformans Prostatic Infection After Successful Treatment of Meningitis. *Robert A. Larsen*, S. Bozzette, J. A. McCutchan, J. Chiu, M. A. Leal, D. D. Richman, *Los Angeles County, University of Southern California, Medical Center, Los Angeles, CA, U.S.A.*

W.B.P.12 Efficacité du fluconazole comparée avec amphotericine B plus 5-flucystosine dans le traitement intensif et de maintien de la cryptococcose méningée associée au SIDA. *Bila Kapita*, M. Kahotwa, B. Colebunders, A. Mungieri, J. Perriens, *Hôpital Mama Yemo, Kinshasa, Zaire.*

W.B.P.13 La fluconazole dans le traitement de la cryptococose méningée chez les patients atteints de SIDA. *Kalambayi Kayembe*, P. Desmet, *Cliniques Universitaires de Kinshasa, Kinshasa, Zaire.*

W.B.P.14 La cryptococcose au Burundi. *Jean-Jacques Floch*, R. Laroche, P. Kadende, E. Ndabaneze, B. Mrfizi, M. Derrner, *Faculté de médecine de Bujumbura, Bujumbura, Burundi.*

W.B.P.15 Cryptococcal Disease and HIV Infection in North Carolina. *Hetty Anne Waskin*, J. A. Bartlett, H. A. Gallis, *Duke University Medical Center, Durham, NC, U.S.A.*

W.B.P.16 Cryptococcal Meningitis in Patients with AIDS. Diagnostic Features and Outcome in 8 Cases. *Giuseppe Ippolito*, G. Antonucci, O. Armignacco, E. Bordi, S. Galgani, L. R. Grillo, *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy.*

W.B.P.17 The Limited Value of Routine Serum Antigen Screening for Cryptococcal Infection. *Mark R. Nelson*, D. E. Smith, D. Hawkins, D. Shanson, C. Reed, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

W.B.P.18 Cryptococcus Neoformans Pulmonary Infection in 17 HIV-Infected Patients. *Rebecca A. Clark*, D. Greer, G. Valainis, N. Hyslop, *Tulane/Louisiana State University ACTU, New Orleans, LA, U.S.A.*

W.B.P.19 Cryptococcosis in AIDS Patients: Clinical and Therapeutic Aspects. *Thomas Weinke*, G. Rögler, C. Ortmann, H. D. Pohle, *Universitätsklinikum Rudolf Virchow, Berlin, Federal Republic of Germany.*

W.B.P.20 Cryptococcal Meningitis in AIDS Patients: Incidence in Rio Grande do Sul (Brasil). *Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

W.B.P.21 Therapeutic Study in 35 Patients with AIDS and Cryptococcal Meningitis. *R. Del Bianco*, R. Scapini, P. S. Prado, G. Brunetti, S. S. T. Leme, M. Mendonça, *Centro de Referência e Treinamento em AIDS, Sao Paulo, Brazil.*

W.B.P.22 Maintenance Therapy with Amphotericin B in AIDS Patients with Cryptococcal Meningitis. *Bonaventura Clotet*, R. Villegas, G. Sirera, M. Dominguez, A. Jou, J. M. Gimeno, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain.*

Infections liées au SIDA : Toxoplasmose
AIDS Related Infection: Toxoplasmosis

W.B.P.23 Toxoplasmose pulmonaire du SIDA. *Ruben Mayorga*, C. Marche, M. Wolff, S. Matheron, D. Salmon, L. Matthiessen, *Hôpital Bichat Claude Bernard, Bretigny/Orge, France.*

W.B.P.24 Long-term Survival of AIDS Patients Successfully Treated for Toxoplasmic Encephalitis. *Diana Antoniskis*, J. M. Nussbaum, B. R. Dannemann, J. A. McCutchan, J. Chiu, J. M. Leedom, et al., *Los Angeles County, University of Southern California, Pasadena, CA, U.S.A.*

W.B.P.25 Toxoplasma Gondii Pneumonia (TGP) in AIDS. *Eric Oksenhendler*, J. Cadranel, A. Datry, C. Sarfati, C. Marche, J. P. Clauvel, *Hôpital Saint-Louis, Paris, France.*

W.B.P.26 Incidence de la toxoplasmose cérébrale au cours du SIDA: Données anatomo-cliniques (Paris 1982-1985). *Adrien G. Saimot*, L. Matthiessen, S. Matheron, C. Le Port, C. Marche, C. Vedrenne, *Hôpital Bichat Claude Bernard, Paris, France.*

W.B.P.27 Cerebral Toxoplasmosis in Danish AIDS Patients. *Else Smith*, C. Pers, L. Matthiesen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

W.B.P.28 Toxoplasmose cérébrale et SIDA en Espagne. *Inmaculada Ocaña*, A. De Luis, I. Ruiz, A. Castro, J. Romero, J. M. Martínez, *Autonomous University of Barcelona, Barcelona, Spain.*

W.B.P.29 Failure of High Doses of Roxithromycin (R) in AIDS Patients with Central Nervous System Toxoplasmosis (CNST). *Jean M. Decazes*, T. Doco-Lecompte, J. Modai, *Saint-Louis Hospital, Paris, France.*

W.B.P.30 Vesical Toxoplasmosis: A New Sign of Parasitic Dissemination in AIDS. *Grégoire Noël*, R. Morriset, M. Grégoire, L. Lamarre, S. Lapointe, *Université de Montréal and Hôtel-Dieu de Montréal, Montreal, QC, Canada.*

W.B.P.31 Therapeutic of Toxoplasmic Encephalitis in AIDS Patients. *Joao S. Mendonça*, I. M. F. Lobo, H. N. Stefani, M. L. N. Biancalana, G. A. Rodrigues, G. C. Levi, *Hospital do Servidor Público Estadual de Sao Paulo, Sao Paulo, Brazil.*

W.B.P.32 In Vitro Secretion of Toxoplasma Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. *Jacques Reynes*, J.-P. Vendrell, J. Ducos, M.-F. Huguet, A. Cannat, A. Serre, *Université Montpellier I, Hôpital Saint-Éloi, Montpellier, France.*

W.B.P.33 The Value of Pyrimethamin/Sulfadoxin (FANSIDAR) in the Prevention of CNS-Toxoplasmosis in AIDS Patients. *Thomas Balzer*, A. Rolfs, G. Höffken, K. M. Deppermann, B. Hamm, E. O. Riecken, *Freie Universität Berlin, Klinikum Steglitz, Medezinische Klinik, Berlin, Federal Republic of Germany.*

W.B.P.34 Treatment of CNS Toxoplasmosis in AIDS Patients: Results of Prospective Studies Using Pyrimethamine and Macrolide Antibiotics. *Bernhard Ruf*, H. D. Pohle, J. R. Iglesias, *Second Department of Internal Medicine, Rudolf Virchow University Hospital, Berlin, Federal Republic of Germany.*

W.B.P.35 Localisations de la toxoplasmose dans le tube digestif : Étude anatomo-clinique. *Ruben Mayorga*, C. Marche, B. Clair, D. Trophilme, J. Frottier, A. G. Saimot, *Hôpital Bichat Claude Bernard, Bretigny/Orge, France.*

Infections liées au SIDA : Diarrhée
AIDS Related Infection: Diarrhea

W.B.P.36 Adénovirus isolé du tube digestif chez 20 patients SIDA. Quelle signification clinique? *Dominique Salmon*, J. Leport, J. Garcia, C. Leport, F. Bricout, J.-L. Vildé, *Hôpital Claude Bernard, Université de Paris, Paris, France.*

W.B.P.37 Blastocystis Hominis Infection in AIDS Patients. *Kenneth V. I. Rolston*, S. J. Rodriguez, *The University of Texas, M. D. Anderson Cancer Center, Houston, TX, U.S.A.*

W.B.P.38 Variable Localization of Intestinal Cryptosporidiosis in AIDS. *Todd D. Heller*, A. R. Tierney, D. P. Kotler, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

W.B.P.39 Colonoscopic Etiological Diagnosis of Diarrhea in AIDS. *Dirce Bonfim de Lima*, E. Jurado da Silva, C. Orazem Favoreto, M. S. Treistman, R. H. Passos, *Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.*

W.B.P.40 Incidence of Infectious Gastroenteritis in Spanish AIDS Patients. *Josep Mallolas*, A. Moreno, J. M. Miro, J. M. Gatell, X. Latorre, E. Soriano, *University of Barcelona, Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain.*

W.B.P.41 Gastrointestinal Multiinfection in AIDS Patient: A Case Report. *Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

W.B.P.42 Rotavirus as a Diarrheal Agent in Adult AIDS Patients. *Jihad Slim*, P. DeLuca, G. Perez, J. Shah, A. DeLuca, *Saint Michael's Medical Center, Newark, NJ, U.S.A.*

W.B.P.43 Efficacité de la somatostatine longue action (SMS 201-995) dans le traitement des diarrhées et dans les cytopénies de deux malades atteints du SIDA. *J.-P. Routy*, J. Latreille, D. Phaneuf, J. A. Neemeh, M. Monte, R. Beaulieu, *Hôpital Hôtel-Dieu, Université de Montréal, Montreal, Qc, Canada.*

W.B.P.44 Gastric Leishmaniasis in an AIDS Patient. *Alain Pesce*, H. Vinti, B. Taillan, M. C. Saint-Paul, P. Marty, Y. Le Fichoux, et al., *Service de médecine interne II, Hôpital de Cimiez, Nice, France.*

W.B.P.45 Successful Use of Hyperimmune Bovine Colostrum to Treat Cryptosporidium Infection in an AIDS Patient. *Beth L. P. Ungar*, D. Ward, R. Fayer, C. Quinn, *Uniformed Services University of the Health Sciences, Bethesda, MD, U.S.A.*

W.B.P.46 A Comparison of Electron Microscopy (E/M) and Light Microscopy (L/M) in the Diagnosis of Cryptosporidial and Blastocystis Infection. *Gerard M. Connolly*, G. Tovey, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

W.B.P.47 Treatment of Cryptosporidial Infection with Recombinant Interleukin-2 (rIL-2). *Gerard M. Connolly*, S. L. Owen, D. A. Hawkins, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

W.B.P.48 Gastrointestinal Cryptosporidiosis in Rio Grande do Sul State: The Highest Incidence. *Eduardo Sprinz*, M. Kronfeld, K. Capobianco, A. Barth, V. Petrillo, *Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

Infections liées au SIDA : Syphilis
AIDS Related Infection: Syphilis

W.B.P.49 Atypical Secondary Syphilis in HIV Seropositive Patients. *Michel Janier*, E. Caumes, F. Janssen, M. Rybojad, A. Dallot, P. Morel, *Hôpital Saint-Louis, Clinique des Maladies sexuellement transmissibles, Paris, France.*

W.B.P.50 Neurosyphilis in HIV-Infected Patients: Evidence of Unreliable Serologic Responses. *Rolf Malessa*, M. Bahro, N. Brockmeyer, R. Biniek, G. Schwendemann, *Aachen University Clinic, Department of Neurology, Aachen, Federal Republic of Germany.*

W.B.P.51 Syphilitic Myelopathy with Human Immunodeficiency Virus: A Treatable Cause of Spinal Cord Disease. *Joseph R. Berger*, G. Hensley, L. Moskowitz, *University of Miami, School of Medicine, Department of Neurology, Miami, FL, U.S.A.*

W.B.P.52 History of and Conventional Tests for Syphilis in HIV-1 Seropositive Homosexual Men in the Baltimore MACS. *Karla Alwood*, R. Fox, E. Hook, J. H. McArthur, D. Starkey, A. Saah, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

W.B.P.53 An Association of Syphilis Episodes and Human Immunodeficiency Virus (HIV) Infection in Sexually Transmitted Disease (STD) Patients in Los Angeles County. *Thanne P. Rose*, W. Ford, P. Kerndt, E. Mohilef, I. Onorato, *Los Angeles Department of Health Services, Los Angeles, CA, U.S.A.*

W.B.P.54 "Seroreversion" of Treponemal Tests during HIV Infection. *Jennifer S. Haas*, G. Bolan, S. A. Larsen, M. J. Clement, A. R. Moss, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.B.P.55 Meningovascular Syphilis in AIDS. *Thierry Saint-Marc*, J. L. Touraine, J. M. Livrozet, J. L. Garnier, F. Meignan, *Hôpital Édouard Herriot, Lyon, France.*

W.B.P.56 Serological and Cerebrospinal Fluid Parameters Related to Syphilis in HIV Asymptomatic Seropositives. *Joseph R. Berger*, M. McCarthy, M. A. Fletcher, N. Klimas, L. Pall, E. Lo, *University of Miami, School of Medicine, Department of Neurology, Miami, FL, U.S.A.*

W.B.P.57 Syphilis Treatment Response in HIV Infected Persons. *Michele S. Zweig*, E. E. Telzak, J. Harrison, R. L. Stoneburner, S. Schultz, *New York City Department of Health, New York, NY, U.S.A.*

W.B.P.58 Retreatment of Syphilis in HIV Positive Patients. *Phillip E. Hay*, J. R. W. Harris, D. Goldmeier, *St. Mary's Hospital Medical School, The Praed Street Clinic, London, U.K.*

W.B.P.59 Failure of Benzathine Penicillin to Eradicate Syphilis in HIV Positive Patients. *Phillip E. Hay*, V. Kitchen, J. R. W. Harris, D. Goldmeier, *St. Mary's Hospital Medical School, The Praed Street Clinic, London, U.K.*

Soins alternatifs, soins traditionnels
Alternative and Traditional Care

W.B.P.60 HIV-Related Primary Medical Care for Intravenous Drug Users (IVDU) in a Methadone Maintenance Treatment Program (MMTP). *Peter A. Selwyn*, A. R. Feingold, A. Iezza, M. Satyadeo, J. F. Shaw, R. Torres, *Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

W.B.P.61 Report on a Statewide Survey to Determine Levels of Outpatient Clinic/Ambulatory Care Services for Persons with HIV Infection. *Christine M. Grant*, S. R. Young, *New Jersey State Department of Health, Trenton, NJ, U.S.A.*

W.B.P.62 A Collaborative Approach to Primary Outpatient-oriented Care of Patients with HIV Infection. *Peter C. Jensen*, K. Bartlett, D. Hadley, *University of California at San Francisco, VA Medical Center, San Francisco, CA, U.S.A.*

W.B.P.63 Comprehensive HIV Case Management Protocols for 26 Northern California Counties. *Patty S. Blomberg*, N. Flynn, *Sacramento AIDS Foundation, University of California at Davis Medical School, Sacramento, CA, U.S.A.*

W.B.P.64 Visiting Physician Service for AIDS Patients in Nassau County. *Bruce D. Agins*, G. Feleke, S. Forlenza, *Nassau County Medical Center, East Meadow, NY, U.S.A.*

W.B.P.65 Home Transfusion: A Safe, Effective Alternative to Traditional Care. *Renée L. Peugeot, Atlanta Home Care, Atlanta, GA, U.S.A.*

W.B.P.66 At-Home Care of Terminal AIDS Patients. *C. Garde*, C. Arrizabalaga, J. Arrizabalaga, J. A. Iribarren, D. Zulaica, *Hospital Nuestra Señora de Aránzazu, San Sebastian, Spain.*

W.B.P.67 A Survey of Complementary AIDS/HIV Therapies and Services. *David G. Ostrow*, M. Heirich, A. Shefner, *University of Michigan, Institute for Social Research, Ann Arbor, MI, U.S.A.*

W.B.P.68 Effect of Cardiovascular Conditioning in HIV Infection. *Craig W. Keyes*, P. Rodgers, J. Wolbert, C. Marte, J. Kelly, D. Ribble, *Bellevue Hospital Center, Community Health Project, New York, NY, U.S.A.*

Diagnostic : Marqueurs et progression de l'infection par le VIH
Diagnosis: Markers of HIV Infection and Progression

W.B.P.69 Clinical Value of a tac-Inhibitory Activity Produced Spontaneously by Adherent Cells of HIV-Infected Subjects. *Vassilis Georgoulias*, A. Ammar, C. Cibert, A. M. Bertoli, P. Meyer, C. Jasmin, *INSERM U268, Oncogenèse appliquée, Hôpital Paul-Brousse, Villejuif, France.*

W.B.P.70 Appearance of p24 Antigen and Decline of T4 Cell Counts as Predictive Markers in AIDS. *M. Elaine Eyster*, J. Goedert, *Pennsylvania State University, College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, U.S.A.*

W.B.P.71 Chicago/Boston Cohorts Study: dp24/gp41 Antibody Response at HIV Seroconversion. *Bernard B. Blaauw*, L. Falk, R. Allen, K. Mayer, G. Dawson, S. Saltzman, et al., *Rush Presbyterian-St. Luke's Hospital, Chicago, IL, U.S.A.*

W.B.P.72 Predictive Value of CD4+ Numbers, Levels of Neopterin and Beta-2 Microglobulin and Risk of Developing *Pneumocystis Carinii* Pneumonia. *Rainer Weber*, J. Brühwiler, B. Ledergerber, M. Vogt, W. Fierz, R. Lüthy, et al., *Medical Polyclinic, Department of Medicine, University Hospital, Zurich, Switzerland.*

W.B.P.73 Human Immunodeficiency Virus (HIV) IgA Serum Antibodies in a Longitudinal Study of HIV Infection and Subsequent Progression of the Disease in Homosexual Men. *Miriam Margalith*, B. Sarov, I. Sarov, C. Rinaldo, A. Saah, E. Levy, et al., *Virology Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.*

W.B.P.74 T-Cell Subset, B2 Microglobulin, and Neopterin Levels in Edinburgh Haemophiliacs. *Christopher A. Ludlam*, C. M. Steel, R. F. G. Cuthbert, D. Beatson, *Department of Haematology, Royal Infirmary of Edinburgh, Edinburgh, U.K.*

W.B.P.75 IFN-alpha Production, Correlation with Circulating IFN-alpha Antigenemia P24 and Serological Profile in HIV-1 Infected Patients at Different Clinical Stages. *Annick Ruffault*, N. Genetet, C. Michelet, O. Guisthau, F. Cartier, B. Fauconnier, *Laboratoire de Virologie, CHU Pontchaillou, Rennes, France.*

W.B.P.76 Comparison of Activation Markers for Progression to AIDS. *Matthew J. Di Franco*, C. Berger, A. Friedman-Kien, R. Edelson, M. McLane, R. Marlink, *Harvard School of Public Health, Boston, MA, U.S.A.*

W.B.P.77 Forecasting Individual Rates of Progression from ARC to AIDS Using Routine Clinical Laboratory Tests. *Robert M. Schmidt*, V. I. Kvitash, *San Francisco University, Center for Preventive Medicine and Health Research, Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A.*

W.B.P.78 Increased Beta 2-Microglobulin Concentrations in Children with AIDS. *Maria Chan*, S. Josephs, J. M. Campos, A. Morales, N. Rifai, *Department of Laboratory Medicine, Children's Hospital, National Medical Center, Washington, DC, U.S.A.*

W.B.P.79 Neopterin as Predictive Marker for Disease Progression in Human Immunodeficiency Virus-1 Infection. *Dietmar Fuchs*, T. J. Spira, A. Hausen, G. Reibnegger, E. R. Werner, H. Wachter, *University of Innsbruck, Innsbruck, Austria.*

W.B.P.80 Persistence of Good E-CR1 Activity Relates to Non-Progression of Immune Dysfunction in HIV Positive Individuals. *Michael Lange*, Y. Inada, E. Buimovici-Klein, W. Ramey, L. Z. Cooper, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

W.B.P.81 Serum B2M in Intravenous Drug Abusers with HIV Infection. *Edward H. Cooper*, M. A. Forbes, S. Sutherland, *University of Leeds, Leeds, U.K.*

W.B.P.82 [1-14c] Arachidonic Acid Release from Human CD4+ Monocytic U 937 and CD4+ T-Lymphocytic CEM Cell Lines in the Early Stage of HIV Infection. *Fernand Dray*, C. A. Renard, D. Guétard, M. Errasfa, B. Vulliez-Le Normand, L. Montagnier, *INSERM, URIA, Institut Pasteur, Paris, France.*

W.B.P.83 Evaluation of Beta-2-Microglobulin and Neopterin as Prognostic Markers in HIV Disease. *Eric Sandström*, A. Carlsson, V. Holmberg, *The Gay Men's Health Clinic, Stockholm, Sweden.*

W.B.P.84 Increased Proliferation of Oral Epithelial Cells in HIV-Infected Patients. *Angelika Langford*, R. O. F. Kunze, I. Ehm, H.-D. Pohle, P. A. Reichart, *Freie Universität Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany.*

W.B.P.85 Measurement of Beta-2-Microglobulin (Beta-2M) by Rate Immunonephelometric Assay in Blood from AIDS Patients. *Hassan Khayam-Bashi*, N. Johnson, K. Chen, J. Wilber, *Clinical Laboratories, San Francisco General Hospital and Department of Laboratory Medicine, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.B.P.86 The Classification of HIV Disease: Correlation of Beta-2 Microglobulin (B-2-M) and Erythrocyte Sedimentation Rate (ESR). *Evelyn J. Fisher*, J. Kilborn, N. Markowitz, L. Saravolatz, *Henry Ford Hospital, Detroit, MI, U.S.A.*

W.B.P.87 Quest for Prognostic Markers in HIV-Infected Haemophiliac Children. *Susan J. Skidmore*, M. D. Williams, S. J. Mawson, F. G. H. Hill, *Regional Virus Laboratory, East Birmingham Hospital, Birmingham, U.K.*

W.B.P.88 Routine Laboratory Tests Which Correlate with HIV-1 Infection Prior to Onset of AIDS. *Joyce I. Wallace*, S. Beatrice, H. S. Sacks, *Foundation for Research on Sexually Transmitted Diseases Inc., New York, NY, U.S.A.*

W.B.P.89 Neopterin Is a Relevant Diagnostic Marker in HIV Infection. *Emil C. Reisinger*, P. Kern, S. Schwander, A. Dörlemann, A. Plettenberg, M. Dietrich, *Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany; University of Innsbruck, Institute for Hygiene, Innsbruck, Austria.*

W.B.P.90 The Use of Serum Oligoclonal Immunoglobulins to Monitor the Course of HIV Infection. *Nicholas Papadopoulos*, R. Costello, *National Institutes of Health, Bethesda, MD, U.S.A.*

W.B.P.91 CSF Neopterin in HIV-1 Infection and as a Function of AIDS Dementia Complex (ADC) Severity. *Bruce J. Brew*, R. Bhalla, M. Schwartz, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.92 Predictive Value of Neopterin, B-2-Microglobulin and Thymidinkinase in HIV Infection. *Frank D. Goebel*, A. Matuschke, B. Heinrich, H. S. Füessl, J. R. Bogner, *Medizimische Poliklinik, Universität München, Munich, Federal Republic of Germany.*

Diagnostic : Le VIH
Diagnosis: HIV

W.B.P.93 Efficient Screening for HIV-1 and HIV-2 Antibodies with a 3rd Generation Assay. *Udo Krupka*, S. Brust, T. Julien, *Behringwerke AG, Marburg, Federal Republic of Germany.*

W.B.P.94 The Use of the N-Terminal Portion of the Transmembrane Proteins for the Early Detection and Discrimination of HIV-1 and HIV-2 Infection. *Rolf Vornhagen*, W. Hinderer, M. Motz, E. Soutschek-Bauer, H. Wolf, H.-H. Sonneborn, et al., *BIOTEST AG, Research Department, Offenbach, Federal Republic of Germany.*

W.B.P.95 A Semiautomated Dot Blot Immunoassay for the Confirmation of HIV Seropositivity. *Kevin M. Knigge*, B. Braun, E. Chan, A. Kapsalis, W. Schulze, J. Stephens, et al., *Abbott Laboratories, Diagnostics Division, Abbott Park, IL, U.S.A.*

W.B.P.96 Improvement of Anti-HIV-2 Reactivity of Vironostika Anti-HTLV-III. *Erik D. Sprengers*, P. Ten Kortenaar, J. A. Hellings, H. J. Theunissen, J. Ariens, R. Van Sprang, *Organon International BV, Oss, Netherlands.*

W.B.P.97 Development of Two Diagnostic Systems for HIV-1 Seroconversion Using Recombinant Antigens. *Jesús V. Benitez Fuentes*, L. I. Novoa, J. A. Machado, J. García, G. Padrón, L. Herrera, et al., *Center of Genetic Engineering and Biotechnology, Havana, Cuba.*

W.B.P.98 Cross Reaction between HIV-1 and HIV-2 or Double Infection? *Felix Mayer*, L. Schmidt, F. Gschnait, J. Hutterer, M. Dierich, F. Banekowich, et al., *Lainz Hospital, Department of Dermatology, Vienna, Austria.*

W.B.P.99 Evaluation of HIV-1 and HIV-2 ELISA Based on Synthetic Peptides of gp41. *Christian Kunz*, F. X. Heinz, U. Parkhede, *University of Vienna, Institute of Virology, Vienna, Austria.*

W.B.P.100 Aptitude d'un test rapide pour HIV-1 et de tests d'agglutination à détecter des anticorps anti-HIV-2 au Sénégal. *Souleymane M'Boup*, J. L. Sankalé, C. M. Kabeya, L. Diakhaté, D. Thiam, S. Mitchell, *Hôpital Le Dantec, Laboratoire de bactériologie, Dakar, Senegal.*

W.B.P.101 Contribution of Synthetic Peptides (SYP) to the Serologic Diagnosis of HIV-1 and HIV-2 Reactivity. *Guadalupe Ercilla*, J. M. Barrera, M. P. Gil, A. Baylo, J. M. Gatell, R. Castillo, *Blood Bank Hospital Clinic, Barcelona, Spain.*

W.B.P.102 Diagnostic Specificity of the Highly Immunoreactive Epitopes of HIV-2. *Mirja Korkolainen*, A. Närvänen, S. Kontio, R. Rescaldani, A. Visconti, M.-L. Huhtala, *Labsystems Research Laboratories, Helsinki, Finland.*

W.B.P.103 Evaluation of a New Combined HIV-1/HIV-2 IgG EIA-Based on Synthetic Peptides. *Siegfried Seidl, Blutenspendedienst Hessen des Deutschen Roten Kreuzes, Frankfurt, Federal Republic of Germany.*

W.B.P.104 Reliable Differentiation between Anti-HIV-1 and Anti-HIV-2 Antibodies Using a Competitive Assay. *Christian G. Meyer*, D. Berzow, H. Schmitz, *Bernhard Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany.*

W.B.P.105 Line Immunoassay for the Simultaneous Detection of Antibodies to HIV-1 and HIV-2 in Human Sera. *Eric Saman*, D. E. Pollet, B. van der Broght, G. Vercauteren, P. Büscher, G. van der Groen, et al., *Innogenetics NV, Antwerp, Belgium.*

W.B.P.106 Efficacy of Abbott Recombinant HIV-1/HIV-2 EIA for Early Detection of HIV-2 and/or HIV-1 Seroconversions. *F. Ferchal*, F. A. Agbalika, P. H. Honderlick, V. B. Barateau, Y. P. Perol, *Hôpital St-Louis, Paris, France.*

W.B.P.107 Detection of HIV-1 and HIV-2 Antibodies in African Sera by the env-9 (gp120-HIV-1) Recombinant Protein. *Martine Peeters*, E. Delaporte, C. Honoré, L. Bedjabaga, S. Ossari, F. Brun-Vézinet, *Centre International de recherches médicales, Franceville, Gabon.*

W.B.P.108 Performances obtenues avec 11 kits ELISA HIV-1 et/ou HIV-2 utilisant virus entiers, antigènes recombinants ou peptides synthétiques et des sérums africains. *Guy Léonard*, G. M. Gershy-Damet, A. Sangare, M. Verdier, S. Ranger, F. Denis, *Laboratoire de virologie, CHU Dupuytren, Limoges, France.*

W.B.P.109 Sensitivity and Discriminatory Value of Synthetic Peptide Assays for HIV-1 and 2 Infections. *Joep M. A. Lange*, A. Vahlne, C. Boucher, F. Barin, U. Parkhede, J. Goudsmit, *University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.*

W.B.P.110 Comparative Performance of Cyclic Versus Linear Peptides in an ELISA for HIV-1- and HIV-2- Specific Antibodies. *Martial Lacroix*, R. Chalifour, M. D. Stern, G. Dionne, *IAF BioChem International Inc., Laval, QC, Canada.*

W.B.P.111 A Peptide-Based Microtiter ELISA Kit for the Detection of Antibodies to HIV-1 and HIV-2. *Martial Lacroix*, C. L. Penney, R. J. Dwyer, M. D. Stern, F. Bellini, G. Dionne, et al., *IAF BioChem International Inc., Laval, QC, Canada.*

W.B.P.112 Serologic Classification of US Patient Sera Dually Reactive for HIV-1 and HIV-2. *Chou-Pong Pau*, R. George, S. Wolinsky, G. Schochetman, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.B.P.113 Evaluation of HIV-1 and HIV-2 Peptide ELISA Tests in Sera from Abidjan, Côte d'Ivoire. *William L. Heyward*, M. Rayfield, J. Krebs, K. De Cock, K. Odehouri, G. Schochetman, et al., *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.B.P.114 Evaluation of Pharmacia HIV-1 and -2 Combi IgG EIA, a Synthetic Peptide EIA. *Lena Grillner*, U. Parkhede, P. O. Persson, E. Sandström, *Karolinska Hospital, Department of Clinical Microbiology, Stockholm, Sweden.*

Techniques nouvelles et améliorées
New and Improved Techniques

W.B.P.115 Detection of HIV-1 Antibodies Using Synthetic Peptides. *Zulma Peixinho*, N. Mendes, H. Hernandez, I. Longo, C. Nakaie, A. Paiva, *Escola Paulista de Medicina, Sao Paulo, Brazil.*

W.B.P.116 Detection of Anti-HIV, Core and Envelope IgG, in HIV-Infected and Tropical Diseased Patients from Brazil. *Arthur Timmerman*, N. Hammerschlak, *Hospital Albert Einstein, Sao Paulo, Brazil.*

W.B.P.117 Comparison of Cambridge Biosciences Recombigen HIV Latex Agglutination Assay with Three Commercial ELISA Assays. *Mario Tamburini*, R. G. Downing, B. Biryahwaho, *World Health Organization, AIDS Control Program, Entebbe, Uganda.*

W.B.P.118 The Determination of Additional Serological Markers Concerning HIV Infection Using Recombinant Viral Antigens of All HIV-1 Reading Frames. *Rolf Vornhagen*, M. Motz, E. Soutschek-Bauer, W. Pichler, H. Wolf, H.-H. Sonneborn, et al., *BIOTEST AG, Research Department, Offenbach, Federal Republic of Germany.*

W.B.P.119 Anti-HTLV-I TAX ELISA for Detection of Infection in Standard HTLV-I ELISA Negative Intravenous Drug Users (IVDUs). *Jordan B. Glaser*, B. J. Poiesz, M. Sliwkowski, H. Simpkins, J. J. Sninsky, G. D. Ehrlich, et al., *The Staten Island Hospital, Staten Island, NY, U.S.A.*

W.B.P.120 Clinical Evaluation of Testpack HIV-1/HIV-2 Rapid Assay for the Detection of Antibody to HIV-1 and HIV-2 Using Recombinant DNA Derived HIV-1 and HIV-2 Proteins. *Rachelle A. Weiss*, X. Alcalde, J. M. Staller, L. A. Prozorovsky, K. M. Knigge, R. M. Pennington, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.121 Testpack HIV: Rapid Assays Capable of Detecting Antibodies to HIV Present in Serum, Plasma and Whole Blood. *Rachelle A. Weiss*, R. M. Pennington, K. M. Knigge, J. M. Staller, L. A. Prozorovsky, A. Martorano, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.122 Unique Immunoreactivity of a Normal Human Serum with Recombinant HTLV-I env Gene Products. *James W. Shih*, J. Genesca, T. Frenkl, R. Terry, D. Buonagurio, M. Longiaru, et al., *National Institutes of Health, Department of Transfusion Medicine, Bethesda, MD, U.S.A.*

W.B.P.123 Improved In Situ Detection of HIV Nucleic Acid with Fluorescent Probes and Laser Excitation. *Richard M. Donovan*, L. Hart, P. F. Bradey, W. R. Peterson, E. Goldstein, *University of California at Davis, Department of Medical Microbiology, Davis, CA, U.S.A.*

W.B.P.124 Detection of HIV in Hematopoietic Cells from Patients with AIDS and AIDS-Related Complex (ARC). *Nora C. J. Sun*, M.-Y. Hsu, A. Conrad, P. Shapshak, G. Beall, D. Imagawa, *Harbor-University of California at Los Angeles Medical Center, Torrance, CA, U.S.A.*

W.B.P.125 Seroconversion Followed by Recombinant and Synthetic Peptide Based Anti-HIV Analysis. *Edgar Lauritzen*, C. Petersen, G. L. Vejlsgaard, B. . Lindhardt, F. Black, P. Horal, *Statens Seruminstitut, Rubella Department/HIV Laboratory, Copenhagen, Denmark.*

W.B.P.126 HIV-1 Pol Synthetic Peptides. *Erik D. Sprengers*, J. J. Schalken, J. A. Hellings, R. Van Sprang, *Organon International BV, Oss, Netherlands.*

W.B.P.127 Investigation of Recombigen (TM) HIV EIA (Cambridge BioScience Corp.). *Carol J. Major*, B. McLaughlin, M. V. O'Shaughnessy, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada.*

W.B.P.128 Production and Characterization of Monoclonal Antibodies against HTLV-I Core Proteins. *Paul H. Yoshihara*, S. Williams, M. Benelli, S. Majewski, A. S. Goldstein, D. Logan, *Epitope Inc., Beaverton, OR, U.S.A.*

W.B.P.129 Early Seroconversion Detected by Anti-HIV Recombinant ELISA. *Agneta B. Samuelson*, M. V. Sydow, L. Grillner, H. Gaines, M. Forsgren, O. Strannegard, *Central Microbiological Laboratory of Stockholm County Council, Stockholm, Sweden.*

W.B.P.130 Detection of Anti-tax Antibody in HTLV-I Western Blots. *Mark C. Connelly*, M. B. Tadler, C. A. O'Connell, *E. I. DuPont de Nemours Co., Medical Products Department, Glasgow, DE, U.S.A.*

W.B.P.131 Detection of HIV-1 Antibodies in Immunometric ELISA Based on Labeled Synthetic Peptide. *Alexander T. Kozhich*, V. S. Ivanov, Z. K. Suvorova, *Shemyakin Institute of Bioorganic Chemistry, USSR Academy of Sciences, Moscow, U.S.S.R.*

W.B.P.132 Vironostika HIV Core Assay: An Anti-p24/p55 Specific Test Using Viral Antigen and Monoclonal Antibodies. *John J. Schaiken*, W. Keur, A. Jacobs, P. Vodegel, J. A. Hellings, *Organon International BV, Oss, Netherlands.*

W.B.P.133 A Screening Assay for Antibodies for HIV-1 Using Recombinant Antigens. *Ping Wu*, D. R. Keehn, D. J. Liu, J. M. Pawlowski, M. A. Roser, J. A. Staser, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.134 Characterization of Full-Length Recombinant HIV-1 p41 and p24 for Use in the Improved Abbott HIV-1 Enzyme Immunoassay. *Kevin V. Rote*, R. Holzman, G. Robey, B. Braun, S. Knicker, J. Severin, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.135 Detection of Antibodies to HIV-1 by a Passive Hemagglutination Assay (Retrocell HIV-1). *James W. Scheffel*, A. Kapsalis, D. Wiesner, C. Krenc, D. Traylor, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.136 Detection of IgM and IgA Antibodies to HIV-1 after Removal of IgG by Protein G. *Barbara Weiblen*, R. Schumacher, R. Hoff, *Massachusetts Department of Public Health, Jamaica Plain, MA, U.S.A.*

W.B.P.137 Structural Characterization of Recombinant HIV-1 Proteins p24 and p41 by HPLC Protease V8 Mapping and Mass Spectrometry. *Olivia S. Martin*, A. Buko, K. Rote, S. Dorwin, H. Whatley, G. Robey, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.138 A Filter Immunoplaque Assay for the Detection and Enumeration of Human HIV-1 Antibody-Secreting Cells. *Jean-Pierre Vendrell*, J. Favero, M.-F. Huguet, H. Rabesandratana, A. Serre, A. Cannat, *Université Montpellier I, Hôpital Lapeyronie, Montpellier, France.*

W.B.P.139 Characterization and Clinical Significance of HIV p24 Antibody. *Brian J. McRae*, R. Thys, R. Fico, L. Falk, J.-P. Allain, *Abbott Laboratories, North Chicago, IL, U.S.A.*

W.B.P.140 Evaluation of the Wellcozyme Recombinant Enzyme Immunoassay. *Philip H. Cunningham*, A. Imrie, A. Cooper, *St. Vincent's Hospital, Center for Immunology, Sydney, Australia.*

W.B.P.141 HIV-1 Seropositive Individuals Recognize Different Epitopes of p17: Potential for Staging Disease Progression. *Paul H. Naylor*, A. L. Goldstein, G. Sinnadorai, P. H. Sarin, S. S. Wang, *The George Washington University, Washington, DC, U.S.A.*

W.B.P.142 Detection of HIV-1 Antibodies in Urines of Asymptomatic and ARC/AIDS Patients. *Toby Gottfried*, A. G. Govindarajan, J. Kung, A. Friedman-Kien, Y. Cao, H. Urnovitz, et al., *Calypte Biomedical Company, Berkeley, CA, U.S.A.*

W.B.P.143 Simple, Easy to Use HIV-1 Recombinant Antigen Based Blood Antibody Test. *Howard B. Urnovitz*, I. Mitra, A. G. Govindarajan, T. Gottfried, V. Haight, T. Weiss, *Calypte Biomedical Company, Berkeley, CA, U.S.A.*

W.B.P.144 Proliferative Response to Soluble and Microplate-Adsorbed gp41 Synthetic Peptide in HIV+ Versus Normal Subjects. *Clara Gabiano*, A. Biglino, E. Palomba, A. Pugliese, H. Del Venthal, P. A. Tovo, *Istituto Clinica Pediatrica, Università diTorino, Turin, Italy.*

W.B.P.145 Direct Detection of HIV-DNA in Peripheral Blood Mononuclear Cells from Asymptomatic Patients: Comparison of Three Different Probes. *Inmaculada Castillo*, J. Bartolome, M. G. Martínez, J. C. Porres, V. Carreño, *Hepatology Unit, Fundación Jiménez Díaz, Madrid, Spain.*

W.B.P.146 Detection of Anti-nef Antibodies in Sera of at Risk Individuals. *Paola Verani*, F. Titti, S. Butto, G. Rezza, A. Lazzarin, G. B. Rossi, *Istituto Superiore di Sanità, Rome, Italy.*

W.B.P.147 Clinical and Theoretical Applications of New Procedures for HIV Reverse Transcriptase and HIV Reverse Transcriptase Antibody Quantitation. *J. Simon Gronowitz*, M. Neumüller, C. F. R. Källander, R. Bhikhabhai, J. Albert, E.-M. Fenyö, et al., *Department of Medical Virology, University of Uppsala, Uppsala, Sweden.*

W.B.P.148 Passive Agglutination with Recombinant env Antigen to Detect Antibodies to Human Immunodeficiency Virus. *Andrée L. Proulx*, C. R. Riggin, *Cambridge Bioscience Corporation, Worcester, MA, U.S.A.*

W.B.P.149 Chemiluminescent Detection of HIV-Infected Cells Using In-situ Hybridization Assay Technique. *Irena Bronstein*, J. H. Kerschner, J. C. Voyta, E. G. Jablonski, *Quest Systems Inc., Bedford, MA, U.S.A.*

Tests diagnostiques
Diagnostic Tests

W.B.P.150 Indirect Immunofluorescence to Detect Anti-HIV Antibody. *T. Scott Croxson*, V. J. Shah, C. L. Strand, H. Polensky, P. Holland, R. Randell, *Beth Israel Medical Center, New York, NY, U.S.A.*

W.B.P.151 Sérologie VIH et infection à plasmodium falciparum. *Bernard Carme*, N. Copin, M. Rosenheim, P. Mpelé, M. Biendo, F. Yala, et al., *Centre hospitalier et universitaire de Brazzaville, Brazzaville, Congo.*

W.B.P.152 HTLV-I Antibody Reactivity Removed from Sera with High Antibody Titers to Malaria by Adsorption with Plasmodium fFalciparum Infected Red Blood Cells. *Curtis G. Hayes*, J. Burans, R. Oberst, *U.S. Naval Medical Research Unit No. 2, San Francisco, CA, U.S.A.*

W.B.P.153 Evaluation of HIV-1 Antibody Testing Strategy in a Mixed Low Risk/High Risk Population. *Jean C. Downie*, R. Howard, B. Bowcock, A. Cunningham, *ICPMR Westmead Hospital, Westmead, Australia.*

W.B.P.154 Significance of an Indeterminate HIV Western Blot (WBi). *Juan Genesca*, J. Shih, B. Jett, I. Hewlett, J. Epstein, H. Alter, *Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, U.S.A.*

W.B.P.155 Western-blot quantitatif: Intérêt dans la surveillance des patients HIV-séropositifs. *J. M. L. Puel*, D. Schiavini, *Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France.*

W.B.P.156 Field Evaluation for the Detection of HIV-1 Specific IgG Antibodies (HIV-AB) in Saliva: A Cost-Effective and Accurate Alternative to Blood Testing. *Frieda Behets*, B. Edidi, L. Atikala, T. C. Quinn, C. Brown, *Projet SIDA, Kinshasa, Zaire.*

W.B.P.157 Application of Virus Culture and PCR for HIV Detection in Blood Donors with Persistent Anti-p24 Reactivity in Western Blot. *Cees L. van der Poel*, J. Huisman, M. Wester, H. W. Reesnick, M. Tersmette, S. Bruisten, *Red Cross Blood Bank, Amsterdam, Netherlands.*

W.B.P.158 Anti-nef Antibodies in Blood Donors with Persistent Anti-p24 Reactivity in HIV Western Blot and Characterization with Recombinant p24 in Bidimensional Blot and ELISA. *Cees L. van der Poel*, S. Gadelle, H. Reesnick, *Red Cross Blood Bank, Amsterdam, Netherlands.*

W.B.P.159 Detection of HIV-1 Specific Antibodies and Neutralizing Activity (NT Act.) in the Urine of Seropositive Persons. *Yunzhen Cao*, M. Mirabile, X. L. Li, D. D. Ho, D. Dietrich, A. E. Friedman-Kien, *New York University Medical Center, New York, NY, U.S.A*

W.B.P.160 Comparison of Western Blot (WB) Interpretive Criteria for HIV-1 Antibody. *Charles A. Schable*, J. George, S. Phillips, G. Schochetman, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

W.B.P.161 The Use of Recombinant HIV ELISA Kits as a Secondary Supplemental Test for Confirmation of HIV Infection. *Michael V. O'Shaughnessy*, D. Lepine, S. Frenette, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

W.B.P.162 Laboratory Identification of Recent HIV Seroconversion: The Utility of Early Repeat Specimens and Coordination with the Counselling Team. *Judith C. Wilber*, B. Louie, E. Soncuya, A. Back, A. Brickman, A. Lifson, et al., *San Francisco Department of Public Health Laboratory, San Francisco, CA, U.S.A.*

W.B.P.163 The D-Mannose-Specific Lectin from Gerardia savaglia Blocks Binding of HIV-1 to H9 Cells In Vitro. *Werner E. G. Muller*, P. Reuter, K. Renneisen, H. C. Schroder, *Institut für Physiologische Chemie, Universität Duesbergweg, Duisberg, Federal Republic of Germany.*

W.B.P.164 Early Serologic Evidence of Infection with Human Immunodeficiency Virus-Type 1 (HIV-1). *John P. Phair*, J. Crisler, J. Huprikar, L. Tsung, D. Hart, J. Chmiel, *Northwestern University Medical School, Chicago, IL, U.S.A.*

W.B.P.165 Is there a Long "Silent" Period before Anti-HIV-1 Serum Antibodies, Appearance in HIV-1 Infection? *Juan A. Pineda*, M. Leal, I. Aguado, C. Rey, Y. Torres, E. Lissen, *Virgen del Rocío Hospital, University of Seville, Seville, Spain.*

W.B.P.166 Comparison of False Positive Reactions in Direct Binding Anti-HIV ELISA Using Cell Lysate or Recombinant Antigens. *John Craske*, R. Abbott, M. Collier, V. Martlew, E. Love, D. Lee, *Public Health Laboratory, Withington Hospital, Manchester, U.K.*

W.B.P.167 Negative Results of In Vitro Tests for HIV-1 Antibody Production by Peripheral Blood Cells in 12 Cases of Isolated gag-Encoded Protein Positivity. *Jacques Ducos*, J.-P. Vendrell, J. Reynes, M.-F. Huguet, A. Cannat, A. Serre, *Université Montpellier I, Hôpital Laperyonie, Montpellier, France.*

W.B.P.168 Comparison of Indirect Immunofluorescence and Western Blot Tests for Detection of Antibody to Human Immunodeficiency Virus. *Angulo G. Barriga*, L. V. M. Peredo, T. N. Castillo, L. R. Herrera, *Hospital de Infectología, Centro Médico La Raza, Mexico City, Mexico.*

W.B.P.169 Resolution of Indeterminate HIV Western Blot Results by Additional Testing. *James R. Carlson*, J. L. Yee, *University of California at Davis, Davis, CA, U.S.A.*

W.B.P.170 Prognostic Value of Repeated Western Blot Analysis. *Bernd S. Kamps*, D. Niese, H. H. Brackmann, T. Kamradt, P. Euler, B. Van Loo, *Medizinische Universitätsklinik, Bonn, Federal Republic of Germany.*

W.B.P.171 Sensitivity of a New Recombinant Inhibition Type ELISA System for the Detection of HIV-1 Antibodies. *Cees L. van der Poel*, N. Lelie, H. Reesink, A. Plaisier, E. Bakker, T. Moshe-Sterk, *Red Cross Blood Bank, Amsterdam, Netherlands.*

W.B.P.172 Performance of a Dot Immunoblot Kit for HIV Antibody Testing. *Christopher H. Sherlock*, D. Cook, M. O'Shaughnessy, P. Gill, *University of British Columbia and Provincial Laboratory, Vancouver, BC, Canada.*

W.B.P.173 Use of Agglutination Assays as Supplemental Tests for Antibody to HIV. *Jackton A. Nyamongo*, P. Tukei, S. Mitchell, E. Muniu, *National Public Health Laboratory Services, Nairobi, Kenya.*

W.B.P.174 Performance Appraisal of Laboratories Testing Dried Blood Spot Specimens for Blinded HIV Seroprevalence Surveys in the United States. *Harry W. Hannon*, S. Lewis, S. McGee, R. George, M. Pappaioanou, *Center for Environmental Health and Injury Control, Centers for Disease Control, Atlanta, GA. U.S.A.*

W.B.P.175 Assessment of Dried Blood Spot Quality Control and Performance Evaluation Materials for National HIV Seroprevalence Surveys. *Susan A. McGee*, H. Hannon, S. Lewis, *Center for Environmental Health and Injury Control, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.B.P.176 Chronic HIV Infection with Delayed Appearance of Antibodies by Usual Techniques and a Case of Seroreversion. *Bernadette J. McLaughlin*, C. Major, C. Swantee, J. Brunton, S. Read, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada.*

W.B.P.177 Reducing False Reactive Results When Testing for Antibodies to HIV-1. *Wolf Prensky*, M. E. Ganguly, M. Lifshitz, J. H. Brassel, D. Solanki, Y. Li, *St. Clare's Hospital and Health Center, New York, NY, U.S.A.*

W.B.P.178 Interpretation and Follow-up of Indeterminate Western Blot (WB) Test Results. *Radka Argirova*, E. Bodjeva, V. Ivanova, D. Beshkov, O. Troshev, *Bulgaria Medical Academy, Central AIDS Laboratory, Institute for Infectious and Parasitic Diseases, Sofia, Bulgaria.*

W.B.P.179 Evaluation of Twelve Commercial Kits for Screening of HIV-1 Antibodies in Mexico. *Carmen Soler*, C. Mosqueira, C. Morales, J. L. Valdespino, J. Sepúlveda, *Instituto de Investigaciones Biomédicas Universidad Nacional de Mexico, Mexico City, Mexico.*

Psychiatrie/Neuropsychologie
Psychiatry/Neuropsychology

W.B.P.180 Neuropsychological Function in Physically Asymptomatic HIV Seropositive and Seronegative Gay/Bisexual Men. *Samuel Perry*, D. Belsky-Barr, R. Swanda, W. Barr, L. Jacobsberg, *Cornell University Medical Center, New York, NY, U.S.A.*

W.B.P.181 Immunological and Psychological Predictors of Disease Progression in Gay Males at Risk for AIDS. *Mary A. Fletcher*, G. Ironson, A. Laperriere, J. Simoneau, N. Klimas, N. Schneiderman, *University of Miami School of Medicine, Miami, FL, U.S.A.*

W.B.P.182 A Comparison of Neuropsychological Testing and Mental Status Exam in AIDS Patients. *Joyce S. Kobayashi*, R. Heaton, L. Thompson, I. Norton, D. Cohn, *University of Colorado Health Sciences Center, Denver, CO, U.S.A.*

W.B.P.183 Neuropsychological Impact of AIDS on the Developing Brain. *Hugh L. Coffman*, B. L. Kammerer, G. A. Gioia, *Harvard Medical School, The Children's Hospital, Boston, MA, U.S.A.*

W.B.P.184 Neuropsychological Change on Longitudinal Assessment: Prevalence and Pattern in HIV Spectrum Disorders. *Lydia Temoshok*, M. Drexler, J. P. Canick, D. M. Sweet, H. Hollander, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

W.B.P.185 Mood State, Neuropsychology, and Self-Reported Cognitive Deficits in HIV Infection. *Mary V. Herns*, S. Newman, R. McAllister, I. Weller, M. Harrison, *University College and Middlesex School of Medicine, London, U.K.*

W.B.P.186 Neuropsychiatric Disturbances in HIV-Infected Patients. *Silvano Cairoli*, A. P. Verri, G. Barbarini, A. Parisi, G. D'Avola, P. G. Cerutti, *Third Department of Neurology, IRCCS C. Mondino, University of Pavia, Pavia, Italy.*

W.B.P.187 Psychometric Evaluations in Zidovudine-Treated Patients: Standardized Test Procedures Demonstrate Measurable Psychosocial Improvement. *Hans Jäger*, G. Franke, *AIDS Study Group, Schwabinger Krankenhaus, Munich, Federal Republic of Germany.*

W.B.P.188 Peptide T Phase I Study: Neuropsychiatric Results. *T. Peter Bridge*, F. K. Goodwin, P. N. R. Heseltine, E. Eaton, E. S. Parker, *National Institute of Mental Health, Intramural Research Program, National Institutes of Health, Rockville, MD, U.S.A.*

W.B.P.189 The Use of Medroxyprogesterone as Pharmacologic Treatment of Hypersexuality in Male Patients with HIV-1 Infection. *Frederick W. Schaerf*, T. Koenig, B. Wisner-Carlson, F. Berlin, *Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

W.B.P.190 Norepinephrine Response and Immune Functioning in HIV+ Subjects. *Mahendra Kumar*, R. Morgan, M. A. Fletcher, A. M. Kumar, J. Szapocznik, C. Eisdorfer, *University of Miami, School of Medicine, Department of Psychiatry, Miami, FL, U.S.A.*

W.B.P.191 Response to Antidepressant Therapy in Depressed Persons with Advanced HIV Infection. *Francisco Fernandez*, J. K. Levy, P. W. A. Mansell, *St. Luke's Episcopal Hospital and Baylor College of Medicine, Houston, TX, U.S.A.*

W.B.P.192 Neuropsychological Manifestations of HIV Infection in Gay Men. *Yaakov Stern*, M. Sano, S. Goldstein, D. Mindry, M. Richards, G. Todak, et al., *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A.*

W.B.P.193 The Use of the Mini Mental Status Exam as a Cognitive Screen in Patients with AIDS. *James W. Dilley*, A. Boccellari, A. Davis, *San Francisco General Hospital, University of California at San Francisco, School of Medicine, Department of Psychiatry, San Francisco, CA, U.S.A.*

W.B.P.194 Trytophan Levels Are Unrelated to Disturbances of Mood in HIV-1 Infected Patients. *John G. Keilp*, B. J. Brew, M. Heyes, A. E. Sadler, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer Center (Neuropsychology), New York, NY, U.S.A.*

W.B.P.195 Neuropsychological and Immunological Abnormalities in Advanced HIV Infection. *Francisco Fernandez*, J. K. Levy, F. P. Pirozzolo, *St. Luke's Episcopal Hospital and Baylor College of Medicine, Houston, TX, U.S.A.*

W.B.P.196 A Brief Screening Test Battery for Cognitive Deficits in HIV Infection. *Stephen K. C. Woo*, J. Hunter, P. Wang, A. Simor, G. Wortzman, A. Bury, et al., *Mount Sinai Hospital, Department of Psychiatry, Toronto, ON, Canada.*

W.B.P.197 Drug Use History in Gay Men with AIDS and Its Relation to Neuropsychological Findings. *James W. Dilley*, D. San Giovanni, A. Boccellari, A. Davis, *San Francisco General Hospital, University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

W.B.P.198 Relationship between Neuropsychological and Immune Variables in HIV-Positive Asymptomatic Men. *James W. Dilley*, A. Boccellari, A. Davis, A. Moss, P. Bacchetti, M. Young, *San Francisco General Hospital, University of California at San Francisco, School of Medicine, Department of Psychiatry, San Francisco, CA, U.S.A.*

W.B.P.199 Cognitive Dysfunction and Psychosocial Factors in Symptomatic Seropositive Men. *Jonathan P. Canick*, L. Temoshok, D. M. Sweet, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A.*

W.B.P.200 Early Diagnosis of HIV Infection in Infants. *Antonella d'Arminio Monforte*, R. Novati, P. Marchisio, N. Zanchetta, A. Lazzarin, R. Tornaghi, et al., *L. Sacco Hospital, Infectious Diseases Clinic, University of Milan, Milan, Italy.*

Enquêtes
Surveys

W.B.P.201 Impact of HIV Diagnosis on Mood: St. Stephen's Cohort Study. *Danitza Jadresic*, M. Riccio, D. Hawkins, B. Wilson, C. Thompson, *John Hunter Clinic, St. Stephen's Hospital, London, U.K.*

W.B.P.202 A VA Hospital Specialized Psychiatry Program for Patients with HIV Disease: A Review of the First 50 Referrals. *Douglas G. Vanderburg, San Francisco Veterans Administration Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.B.P.203 Request of Mental Health-Care Worker Intervention by Physicians Attending HIV+ or AIDS Patients: The Importance of an Integrated and Multidisciplinary Approach. *Gisela Cardoso*, M. Tostes, A. Queiroz, A. Navarro, M. Zornitta, *Federal University of Rio de Janeiro, Hospital Universitario C.F.F., Rio de Janeiro, Brazil.*

W.B.P.204 Personality, Behaviour and Cognitive Changes in AIDS as Rated by Patients and Their Carers and as Related to Neuropychological Test Results. *Agnes E. Kocsis*, J. A. Church, S. F. Vearnals, J. Green, *St. Mary's Hospital, Paterson Wing, Psychology Department, London, U.K.*

W.B.P.205 Competency Consultation to HIV Patients: A Liaison Psychiatry Perspective. *Henry W. Weisman*, L. Perton, P. Agnelli, *Queen's Hospital Affiliation, Long Island Jewish Medical Center, New York, NY, U.S.A.*

W.B.P.206 Positivité à l'HIV en psychiatrie : Observation sur 18 mois. *Marco M. Zamperetti*, G. F. Goldwurm, I. Fernandez, V. Sassoli, *Ospedale Cà Granda Niguarda, Milan, Italy.*

W.B.P.207 Étude de la demande psychothérapeutique chez 100 patients atteints de SIDA. *Yves Edel*, O. Ouvry, F. Rognier-Aeberhard, N. Marchand-Gonod, J. Rodriguez, *Groupe Hospitalier Pitié-Salpêtrière, Paris, France.*

W.B.P.208 Classification des troubles psychiatriques selon le DSM III-r en cours de SIDA. *Marco M. Zamperetti*, I. Schlact, D. Ferrazzi, *Ospedale Cà Granda Niguarda, Milan, Italy.*

W.B.P.209 HIV Seroprevalence Study of Involuntarily Hospitalized Mentally Ill Homeless from the Streets of Manhattan, New York. *Maureen Empfield*, A. Weinstock, F. Cournos, H. Schrage, I. Meyer, E. Schoenbaum, et al., *Creedmoor Psychiatric Center, Queens Village, NY, U.S.A.*

W.B.P.210 Psychiatric Diagnoses among Volunteers for HIV Testing. *Lawrence B. Jacobsberg*, S. Perry, B. Fishman, A. Frances, J. Ryan, K. Fogel, *Cornell University Medical College, New York, NY, U.S.A.*

W.B.P.211 Psychiatric Diagnoses and Treatment Outcome in an AIDS Specialty Center. *Jennifer F. Havens*, E. Finkelstein, M. Viederman, J. Jacobs, *New York Hospital, Cornell Medical Center, New York, NY, U.S.A.*

W.B.P.212 Psychosocial Status of 192 Patients with HIV Infection and AIDS. *Michael B. King, Institute of Psychiatry, London, U.K.*

W.B.P.213 Analysis of Initial Psychiatric Referrals from a Hospital HIV Service. *Cleto Di Giovanni*, P. F. Goyer, *National Naval Medical Center, Reston, VA; Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

W.B.P.214 A Comparison of Suicidal Behaviors in Patients in an AIDS-Related Psychiatric Clinic and in a General Psychiatry Clinic. *Mary Alice O'Dowd*, F. P. McKegney, C. Natali, J. Harkavy, G. Asnis, *Montefiore Medical Center, Bronx, NY, U.S.A.*

W.B.P.215 Psychiatric History among Homosexuals and Drug Addicts Infected with Human Immunodeficiency Virus. *Costanzo Gala*, S. Martini, A. Pergami, M. Rossini, R. Russo, A. Lazzarin, *University of Milan Medical School, Department of Psychiatry, Milan, Italy.*

W.B.P.216 A Comparison of Psychiatric Consultations in AIDS and Non-AIDS Patients. *Mary Alice O'Dowd*, F. P. McKegney, *Montefiore Medical Center, Bronx, NY, U.S.A.*

W.B.P.217 Establishment of an HIV-Related Psychiatric Clinic in an Area of High Substance Abuse. *Mary Alice O'Dowd*, C. Natali, F. P. McKegney, *Montefiore Medical Center, Bronx, NY, U.S.A.*

W.B.P.218 Effect of Neuropsychiatric Signs and Symptoms on Homeless Persons with AIDS in a Group Residence. *Joanne Staats*, G. Hough, D. Dornan, *AIDS Resource Center, New York, NY, U.S.A.*

W.B.P.219 Locus of Control, Social Supports and Depression among HIV-Infected Subjects. *Costanzo Gala*, S. Martini, A. Pergami, M. Rossini, R. Russo, F. Durbano, *University of Milan Medical School, Department of Psychiatry, Milan, Italy.*

W.B.P.220 Frequency of Psychiatric Disorders in Hospitalized AIDS Patients: Comparison to a General Hospital Population. *Frederick W. Schaerf*, T. Koenig, B. Wisner-Carlson, *Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

Psychiatrie/Études de prévalence
Psychiatry Prevalence Studies

W.B.P.221 Handedness and Immune System Function in Gay/Bisexual Men. *James T. Becker*, L. Kingsley, S. Bass, P. Satz, M. A. Dew, L. Penkower, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.*

W.B.P.222 Psychoneuroimmunologic Studies of Gay Men with HIV Infection. *Jack M. Gorman*. Williams, Y. Stern, R. Mayeux, R. Goetz, R. Kertzner, et al., *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

W.B.P.223 Psychiatric Disorder and HIV Infection: A Controlled, Longitudinal Study. *J. Hampton Atkinson*, I. Grant, R. K. Heaton, J. Weinrich, J. A. McCutchan, *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A.*

W.B.P.224 Neuropsychological and Psychosocial Function in Two Cohorts of Gay Men: Relation to Stage of HIV-1 Infection. *Andrew J. Saykin*, R. S. Janssen, G. C. Sprehn, T. J. Spira, L. Cannon, J. E. Kaplan, et al., *University of Pennsylvania, Philadelphia, PA, U.S.A.*

W.B.P.225 The Effect of HIV Antibody Status on U.S. Military Applicant Aptitude Test Scores. *David R. Arday*, J. F. Brundage, L. I. Gardner, M. Goldenbaum, F. Wann, S. Wright, *HQ U.S. Army Forces Command, Fort McPherson, GA, U.S.A.*

W.B.P.226 A Longitudinal Analysis of Perception of Physical Health and Symptoms of Depression in Gay/Bisexual Men. *James T. Becker*, S. Zeger, M. A. Dew, R. Karim, L. Kingsley, P. Satz, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.*

W.B.P.227 Neuropsychiatric Features of AIDS: A Comparison with Multiple Sclerosis. *Frederick W. Schaerf*, R. Morriss, J. Brandt, J. McArthur, M. Folstein, *Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

W.B.P.228 Psychiatric Findings in HIV-Seropositive Persons in a Mandatory HIV Screening Program. *James R. Rundell*, G. R. Brown, S. L. Paolucci, *Uniformed Services University of the Health Sciences, School of Medicine, Bethseda, MD, U.S.A.*

W.B.P.229 Auditory Event Related Potentials (ERPs) in the Clinical Examination of HIV-Infected Drug Users. *Ann Chiswick*, V. Egan, G. Goodwin, R. St. Clair, R. Brettle, *Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, U.K.*

W.B.P.230 Discriminating Depression from Cognitive Impairment in HIV Illness. *Igor Grant*, R. Olshen, J. H. Atkinson, R. K. Heaton, J. Weinrich, J. A. McCutchan, et al., *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A.*

W.B.P.231 Preliminary Findings on a Screening Symptom Checklist for HIV Dementia. *James W. Dilley*, A. Boccellari, A. Davis, A. Moss, P. Bachetti, B. Wagner, *University of California at San Francisco, AIDS Health Project, San Francisco, CA, U.S.A.*

W.B.P.232 Correlation of P300 Auditory Evoked Potentials (AEPs) and Tests of Cognitive Function in HIV-Positive Drug Users. *Vincent G. Egan*, A. Chiswick, G. Goodwin, D. St. Clair, R. Brettle, *Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, U.K.*

W.B.P.233 Relating Depression to Neuropsychological Impairment. *J. Hampton Atkinson*, R. K. Heaton, I. Grant, J. Weinrich, J. A. McCutchan, *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A.*

W.B.P.234 The Development of a Brief Screening Battery to Detect Cognitive Defects in Patients with AIDS. *James W. Dilley*, A. Boccellari, A. Davis, *University of California at San Francisco, AIDS Health Project, San Francisco, CA, U.S.A.*

W.B.P.235 Neuropsychological Functioning in HIV Infection. *Uta Schick*, C. Perro, D. Naber, F. D. Goebel, *Psychiatrische Klinik der Universität München, Munich, Federal Republic of Germany.*

W.B.P.236 Qualitative Aspects of Depressed Mood and Neuropsychological Function in HIV-1+/- Gay and Bisexual Men. *James T. Becker*, F. W. Schaerf, L. Kingsley, R. Fox, M. A. Dew, *University of Pittsburgh, School of Medicine, Pittsburgh, PA, U.S.A.*

Soins
Care

W.B.P.237 Evaluation of Training for Physicians at the National Reference Centers in Brazil. *José F. Rodrigues*, L. Rodrigues, *University of Brasilia, Brasilia, Brazil.*

W.B.P.238 A Comprehensive Approach to Community Hospital Care of AIDS Patients. *Laurie Andrews*, J. Klimek, *Hartford Hospital, Hartford, CT, U.S.A.*

W.B.P.239 Inverse Correlation of Complement-Mediated, Antibody-Dependent Enhancing Titers with Stage of Disease in Individuals Infected with HIV-1. *William M. Mitchell*, D. C. Montefiori, W. E. Robinson, A. Modliszewski, L. B. Lefkowitz, *Department of Pathology, Vanderbilt University, Nashville, TN, U.S.A.*

W.B.P.240 Impediments to IVDA Enrollment in ACTG Clinical Trials. *Patrick G. Fairchild*, C. Jaffarian, S. Cheeseman, C. Bova, K. Tolson, N. Blacklow, et al., *University of Massachusetts Medical School, Worcester, MA, U.S.A.*

W.B.P.241 The Role of the Government of Canada in the Nature and Direction of Clinical Research in the Management of HIV Disease in Canada. *Sabih R. Khan*, N. N. Joshi, *Drugs Directorate, Health Protection Branch, Health and Welfare Canada, Vanier, ON, Canada.*

W.B.P.242 Thermographic Imaging of HIV Patients. *Ray P. Clark*, M. R. Goff, M. Youle, B. Gazzard, *Clinical Research Center, Harrow, U.K.*

W.B.P.243 Art Therapy with People with AIDS. *Eva I. Sansom, Casey House Hospice, Toronto, ON, Canada.*

W.B.P.244 Maintenance of Hope in an HIV Sample. *Robert H. Remien*, J. G. Rabkin, J. B. W. Williams, R. Neugebauer, *New York State Psychiatric Institute, New York, NY, U.S.A.*

W.B.P.245 A Rehabilitation Program for Clients with HIV Associated Conditions. *Patricia Gentile*, K. Marshall, M. Bennett, P. Laqueur, H. Alexander, I. Davis, *Department of Ambulatory Care, Woodhull Medical and Mental Health Center, Brooklyn, NY, U.S.A.*

W.B.P.246 Compliance of HIV-Infected Intravenous Drug Users in Clinical Trials. *Sarah H. Cheeseman*, P. Fairchild, M. Glode, K. Tolson, C. Jaffarian, N. Blacklow, et al., *University of Massachusetts Medical School, Worcester, MA, U.S.A.*

W.B.P.247 Insuring Quality of Data in Community-Based Clinical Trials. *Donald I. Abrams*, T. F. Mitchell, C. C. Child, Z. Weingart, *San Francisco County Community Consortium, San Francisco, CA, U.S.A.*

W.B.P.248 Évaluation de la charge de travail infirmier : Comparaison entre patients hospitalisés infectés et non infectés par le VIH. *Christian Chidiac*, D. Chaussoy, G. Beaucaire, O. Leroy, E. Senneville, Y. Mouton, *Service des maladies infectieuses, Centre hospitalier G. Dron, Tourcoing, France.*

W.B.P.249 AIDS Treatment Registry (ATR) of New York. *Iris Long*, M. Cowing, J. Eigo, R. Huff, *AIDS Treatment Registry Inc., Brooklyn, NY, U.S.A.*

W.B.P.250 ATR: A Regional Model for Establishing a Community-Based, Computerized Registry of AIDS/HIV Clinical Drug Trials. *James Eigo*, M. Cowing, I. Long, *AIDS Treatment Registry, Inc., New York, NY, U.S.A.*

W.B.P.251 Program Directors' Attitudes towards Residents' Care of Persons with AIDS. *Rodney A. Hayward*, R. K. Kravitz, M. K. Shapiro, *University of Michigan Hospitals, Ann Arbor, MI, U.S.A.*

W.B.P.252 Impact of Serum p24 HIV Antigen Screening on Patient Eligibility for Antiviral Clinical Trials. *Margo E. Heath-Chiozzi*, G. Pearlstein, H. Eigenrauch, C. Crumpacker, D. Cotton, *Beth Israel Hospital, Harvard AIDS Clinical Trials Unit, Boston, MA, U.S.A.*

W.B.P.253 New Developments in a Model Program of AIDS Hospice Care. *Bruce A. Priebe, Visiting Nurses and Hospice of San Francisco, San Francisco, CA, U.S.A.*

W.B.P.254 A Brief Health Status Instrument for Use in AIDS Clinical Trials. *Albert W. Wu*, H. R. Rubin, W. C. Mathews, W. D. Hardy, I. Grant, D. D. Richman, et al., *University of California at San Francisco, San Francisco, CA, U.S.A.*

W.B.P.255 Neuropsychological Test Performance in HIV-1 Seropositive Patients On and Off Azidothymidine (AZT). *John J. Sidtis*, A. E. Sadler, J. G. Keilp, B. J. Brew, H. A. Aronow, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.256 Test-Re-Test Performance on Neuropsychological Tests in a Group of HIV-1 Seropositive Patients. *Abigail E. Sadler*, J. G. Keilp, H. Thaler, B. J. Brew, R. W. Price, J. J. Sidtis, et al., *Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY, U.S.A.*

W.B.P.257 New Modalities for Clinical Trials: A Synthesis of Pharmacology and Health Care. *Mark Harrington*, J. Eigo, D. Z. Kirschenbaum, I. Long, *ACT-UP/NY, New York, NY, U.S.A.*

W.B.P.258 Co-Morbid Events in First HIV Identified Hospitalizations, New York State (NYS), 1984-86. *George T. DiFerdinando*, K. Arthur, G. Kaufman, *New York State Department of Health, Albany, NY, U.S.A.*

W.B.P.259 Neuropsychological Performance as a Function of AIDS Dementia Complex (ADC) Severity. *Abigail E. Sadler*, J. G. Keilp, D. Dorfman, B. J. Brew, R. W. Price, J. J. Sidtis, et al., *Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY, U.S.A.*

W.B.P.260 The Organization of AIDS Services at Cook County Hospital, Chicago. *Renslow Sherer*, S. Kathpalia, R. Sable, M. Cohen, L. Gath, A. Hamb, et al., *Cook County Hospital, Chicago, IL, U.S.A.*

W.B.P.261 Clinic for HIV-Related Concerns: One Model of Outpatient Psychiatric Care. *Stephen K. C. Woo, Mount Sinai Hospital, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.*

W.B.P.262 Principles of Rehabilitation of Patients with Immunodeficiencies. *R. I. Sepiashvili, Immunological Center, Kutaisi, U.S.S.R.*

W.B.P.263 Sacramento Cares: One Community's Response to Providing Comprehensive Medical Care to People with HIV-Related Disorders. *Neil M. Flynn*, J. Riley, S. Pomerantz, S. Grant, M. Wolf, L. McCandless, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A.*

W.B.P.264 Referral Patterns in a Comprehensive AIDS Clinic. *Shirley J. Lee, The New York Hospital, Cornell Medical Center, New York, NY, U.S.A.*

W.B.P.265 Clinical Care as Part of Integrated AIDS Management in a Zambian Rural Community. *Clement M. Chela*, I. D. Campbell, Z. Siankanga, *The Salvation Army Chikankata Hospital, Mazabuka, Zambia.*

W.B.P.266 Study of a Series of 121 Consecutive AIDS Patients. *Mário B. Corrêa-Lima*, M. A. Silva, C. E. Brandao-Mello, C. T. C. Leite, L. R. Haddad, M. A. Fonseca, *Hospital Universitário Gaffrée e Guinle, Universidade do Rio de Janeiro, Rio de Janeiro, Brazil.*

W.B.P.267 AIDS Issues for Rural Hospitals in U.S. Frontier Areas. *Vicky L. Carwein*, D. Berry, *University of Nevada at Las Vegas, Las Vegas, NV, U.S.A.*

W.B.P.268 Seroprevalence of HIV, Herpes Viruses and Immunologic Abnormalities in a Group of IV Drug Abusers. *Constance T. Pachucki*, D. Schaaff, J. Lentino, M. Schaefer, W. Dorus, *Edward Hines Jr. Veterans Administration Hospital, School of Infectious Diseases, Hines, IL, U.S.A.*

W.B.P.269 Psychosocial Issues Associated with Human Immunodeficiency Virus (HIV) Infection in a City Hospital: Experience of the Multidisciplinary Patient Care Meeting. *Tony W. Cheung*, H. Weissman, A. Montreuil, *Queens Hospital Center, Long Island Jewish Medical Center, Jamaica, NY, U.S.A.*

W.B.P.270 Triage System for Potential Research Subjects into Active AIDS Clinical Trials. *Paul A. Volberding*, V. DeGenova, J. Mills, R. Holland, D. Feigal, M. Nash, *University of California at San Francisco, San Francisco, CA, U.S.A.*

W.B.P.271 Assessment of the Needs of an HIV Acute/Chronic Level Care Unit. *Rochelle Scheib*, S. Marks, O. Bradley, B. Morgan, A. Desroches, J. Baer, et al., *Tufts University, Lemuel Shattuck Hospital, Department of Public Health, Boston, MA, U.S.A.*

W.B.P.272 The Role of the Pharmacist in the HIV Team. *Sarah Fitt*, R. J. Bunn, T. J. McManus, J. Moxuam, *Dulwich Hospital, London, U.K.*

W.B.P.273 Causes of Hospitalizations Following AIDS Diagnosis in a Population-Based Cohort. *David W. Fleming*, S. Modesitt, R. Klockner, D. Bennett, S. Hulman, *Oregon Health Division, Portland, OR, U.S.A.*

W.B.P.274 Tuberculin Skin Testing in HIV-Infected Persons. *Gale G. Cromwell, University of Maryland Medical System, Baltimore, MD, U.S.A.*

Immunomodulateurs
Immunomodulators

W.B.P.275 Cellular Pharmacology and Clinical Pharmacokinetics of 2',3'-Dideoxyadenosine and 2',3'-Dideoxyinosine. *Neil R. Hartman*, R. Yarchoan, G. S. Ahluwalia, J. A. Kelley, S. Broder, D. G. Johns, *National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A.*

W.B.P.276 Immunostimulation comme un support chez SIDA-malades et chez HIV-seropositif. *Waclaw Kornaszewski*, Z. Lurhuma, K. Lutete, M. Mbula, A. Skotnicki, *Université de Kinshasa, Kinshasa, Zaire.*

W.B.P.277 Diethyldithiocarbamate Inhibits the Progression of HIV Infection: Results of a Prospective Randomized Clinical Study. *Manfred Dietrich, Bernhard Nocht Institute for Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany.*

W.B.P.278 Treatment of HIV-Infected Patients with D-Penicillamin: Tentative Clinical and Immunological Results. *Gert Höffken*, B. Bieniek, W.-D. Ludwig, H. Lode, M. Mielke, B. Zorr, *Freie Universität Berlin, Klinikum Steglitz, Med. Klinik, Berlin, Federal Republic of Germany.*

W.B.P.279 Recovery of Delayed-Type Hypersensitivity (DTH) in Patients with AIDS Related Complex (ARC) in Randomized Trial of IMREG-1. *Milan Fiala*, L. A. Cone, J. Sayre, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A.*

W.B.P.280 Effect of Isoprinosine on HIV-Antigenaemia. *Lars Teglbjaerg*, S. Kroon, T. Moestrup, B. G. Hansson, B. F. Vestergaard, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

W.B.P.281 Induction of T Lymphocyte-related Functions by Imuthiol through Down Regulation of Prostaglandin Secretion by Monocytes/Macrophages. *Djavad Mossalayi*, A. H. Dalloul, J. M. Bertho, P. Debré, *Hôpital de la Pitié-Salpêtrière, Paris, France.*

W.B.P.282 A Multicenter Randomized Double-Blind Placebo Controlled Dose-Response Trial of LF 1695 in p24-Antigen Seropositive Patients. *René Roué*, J. L. Kienzler, D. Dormon, H. Fleury, J. M. Lang, Y. Mouton, et al., *Hôpital militaire Bégin, Saint-Mandé, France.*

W.B.P.283 AS 101: A New Immunomodulating Compound in the Treatment of AIDS. *Jean-Philippe Laporte*, J. Lebas, M. C. Meyohas, G. Gonzales, B. Sredni, A. Najman, et al., *Hôpital St-Antoine, Paris, France.*

W.B.P.284 Enhancement of T-Cell Growth in HIV+ Patients Treated with Dithocarb (IMUTHIOL): Evidence for Monocyte Involvement. *Ali H. Dalloul*, M. Kirstetter, P. Debré, M. D. Mossalayi, *CHU Pitié-Salpêtrière, Paris, France.*

W.B.P.285 Survival Rate in AIDS Patients Following Transfusion Therapy with CR1 Enriched Erythrocytes. *Judith Sulzberger*, Y. Inada, G. McKinley, H. Ikegami, A. Senderowicz, M. Lange, et al., *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

W.B.P.286 Peptide T Phase I Study: Immuno/Virologic Results. *Peter Heseltine*, F. K. Goodwin, T. P. Bridge, J. Martin, J. M. Leedom, *University of Southern California Medical Center, General Hospital, Los Angeles, CA, U.S.A.*

W.B.P.287 Dose Response Study of Daily Diethyldithiocarbamate (DTC) in Patients with ARC/AIDS. *Eskild A. Peterson*, E. Hersh, D. Fish, C. Kaplan, R. Gorman, M. Darragh, *University of Arizona, College of Medicine, Tucson, AZ, U.S.A.*

W.B.P.288 The Effect of Isoprinosine R (Inosine Pranobex) in Patients with Low Risk for Developing AIDS. *Mark O. Loveless*, D. S. Robins, *Oregon Health HIV Sciences University, Portland, OR, U.S.A.*

W.B.P.289 Effect of Oral Dextran Sulfate on the Mouse Intestine. *Frank S. Rhame*, C. L. Wells, S. L. Erlandsen, *University of Minnesota, Minneapolis, MN, U.S.A.*

W.B.P.290 Immunological Data from an Isoprinosine (Imunovir) Double-Blind Placebo Controlled Study. *Birn Seberg*, E. Dickmeiss, P. Skinhj, *University Hospital, Rigshospitalet, Department of Infectious Diseases and Tissue typing Laboratory, Copenhagen, Denmark.*

W.B.P.291 Intravenous Immunoglobulins in Adults with ARC and WR5: A Double-Blind Longitudinal Trial. *Matthias Schrappe-Bächer*, H. Rasokat, S. Degenhardt, G. Fätkenheuer, B. Salzberger, ARC-IVIG Study Group Cologne/Berne, *University of Cologne, Department of Internal Medicine II, Cologne, Federal Republic of Germany.*

W.B.P.292 Clinical Efficacy of Two Kinds of Kampo Medicine on HIV- Infected Patients. *Michio Fujimaki*, S. Ikematsu, M. Hada, K. Mori, H. Takahashi, M. Inagaki, *Tokyo Medical College, Department of Clinical Pathology, Tokyo, Japan.*

W.B.P.293 The Effect of the Polyene Macrolide Antibiotic Amphotericin B and Its Methylated Derivative (AME) on Human Immunodeficiency Virus and Phagocytosis in Macrophage Cultures. *Molly J. Coye*, D. Pontani, D. Sun, B. Wolf, P. Bryant, S. Shahied, et al., *New Jersey State Department of Health, Trenton, NJ, U.S.A.*

W.B.P.294 Activation of Methionine-Enkephalin (MEK): Enhancement of Cytotoxic T-Cells in HIV+ Patients. *Nicholas P. Plotnikoff*, G. C. Miller, J. Wybran, *University of Illinois at Chicago, Chicago, IL, U.S.A.*

W.B.P.295 Therapeutic Effect of Intravenous Immunoglobulines (IVIG) in HIV Infected Hemophiliac Children and Adolescents. *Norbert Wagner*, R. Bialek, H. Radinger, M. Becker, *University of Bonn, Department of Pediatrics, Bonn, Federal Republic of Germany.*

W.B.P.296 Long-term Administration of Dithiocarb in HIV-Seropositive Subjects. *Jean-Marie Lang*, M. Kirstetter, J. M. Livrozet, J. L. Touraine, *Hôpital de Hautepierre, Strasbourg, France.*

W.B.P.297 Side Effects of Imuthiol (Dithiocarb, DTC, Diethyldithiocarbamate) in the Therapy of Early Stage HIV-1 Infection. *Emil C. Reisinger*, A. Gottesleben, G. Götze, S. Schwander, A. Dörlemann, M. Dietrich, *Hamburg Tropical Institute, Hamburg, Federal Republic of Germany; and University of Innsbruck Institute for Hygiene, Innsbruck, Austria.*

W.B.P.298 Clinical Evaluation of Glycyrrhizin on HIV-Infected Asymptomatic Hemophiliac Patients in Japan. *Nobuko Ikegami*, K. Yoshioka, K. Akatani, *Osaka National Hospital, Clinical Research Institute, Osaka, Japan.*

W.B.P.299 Intravenous Versus Oral Application of Pentosan-Polysulfate (HOE/BAY 946). *Malte Peters*, B. Ruf, H.-D. Pohle, *Rudolf Virchow University Hospital, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

W.B.P.300 Two-Year Clinical Trial with Pentosan-Polysulfate (HOE/BAY 946) in HIV-Infected Patients. *Bernhard Ruf*, M. Peters, D. Schürmann, H. Rubsamen-Waigmann, H.-D. Pohle, *Rudolf Virchow University Hospital, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

W.B.P.301 Clinical Influence of Imuthiol (Sodium Dithiocarb) in HIV-Infected Patients: A Review of 4 Controlled Studies and Long-term Influence. *Jean Caraux*, International AIDS Imuthiol Study Group, *Institut Mérieux, Lyon, France.*

W.B.P.302 Two-Month Double-Blind Placebo-Controlled Trial of Cyclosporin in HIV-Asymptomatic Subjects. *Jean-Pierre Aboulker*, J. M. Andrieu, J. A. Gastaud, P. Debré, B. Milpied-Homsi, *Institut national de la santé et de la recherche médicale, Villejuif, France.*

W.B.P.303 Acute Response to Ampligen Infusions in HIV-Infected People. *George J. Pazin*, X.-L. Huang, D. K. McMahon, J. A. Armstrong, C. R. Rinaldo, M. Ho, et al., *University of Pittsburgh, School of Medicine and Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

W.B.P.304 Failure of Isoprinosine in Prevention of ARC to AIDS. *Daniel Barbaro*, H. Fragua, *University of Texas Southwestern Medical School, Dallas, TX, U.S.A.*

W.B.P.305 Neopterin and T-Helper/Neopterin Ratio in the Monitoring of Long-term Treatment of HIV-Infected Patients by ImuthiolR (sodium dithiocarb, DTC). *Myriam Kirsetter*, A. Burkel, A. Felten, *Hôpital St-Antoine, Paris, France.*

W.B.P.306 Timomoduline and Lithium Carbonate for HIV Patients. *Gregorio Buchovsky*, B. Popescu, C. Levin, J. Corrales, M. Baez, G. Esbivel, *Hospital Escuela General, San Martin, Corrientes, Argentina.*

W.B.P.307 Case Report of Disulfiram as First Line Therapy in Seropositive Patients Attending a Community Clinic. *Iris L. Davis*, J. Leibel, P. Paroski, A. Morgan, B. Norris, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.S.A.*

W.B.P.308 Immunologic and Virologic Parameters in 100 HIV-Infected Patients (PTS) Treated with Isoprinosine (ISO) or Placebo (PLB) as Part of a Multicenter Phase III Clinical Trial. *Marcelo B. Sztein*, R. S. Schulof, D. Mai, G. L. Simon, D. M. Parenti, J. Courtless, et al., *The George Washington University Medical Center, Washington, DC, U.S.A.*

W.B.P.309 Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A Phase-I Trial in Neutropenic AIDS Patients. *Susan E. Krown*, K. O'Boyle, J. W. M. Gold, N. Flomenberg, W. Anselmo, E. Bonnem, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.310 Reestablishment of a Normal Immunoregulatory Mechanism in HIV-Infected Patients with Immune Thrombocytopenic Purpura (ITP). *Harry W. Snyder*, F. R. Jones, *IMRE Corp., Seattle, WA, U.S.A.*

W.B.P.311 Amelioration of Deteriorated Polymorphonuclear Leukocyte (PMN) Phagocytic Function of Hemophiliacs with HIV Infection by Administration of Long-term Polysaccharide Immunopotentiator (Lentinan). *Juzo Matsuda*, K. Gohchi, T. Kinoshita, T. Abe, *Teikyo University School of Medicine, Department of Medicine, Tokyo, Japan.*

W.B.P.312 An Open Label Dose-Ranging Trial of AL 721 in PGL and ARC. *Donna Mildvan*, D. Armstrong, D. Antoniskis, H. Sacks, H. Balfour, J. Buzas, et al., *Beth Israel Medical Center, New York, NY, U.S.A.*

W.B.P.313 Inosine Pranobex Therapy in HIV Seropositive Patients at Risk of Developing AIDS. *Robert Murphy*, J. Von Roenn, J. Pottage, L. Williams, C. Benson, H. Kessler, et al., *Northwestern University Medical School, Section of Infectious Diseases, Chicago, IL, U.S.A.*

W.B.P.314 Effect of Passive Immunization in Patients with ARC and AIDS. *Abraham Karpas*, F. Hill, M. Youle, J. Gray, J. K. Oates, B. G. Gazzard, *University of Cambridge Clinical School of Medicine, Department of Haematology, Cambridge, U.K.*

W.B.P.315 A Phase I/II Dose Ranging Trial of Oral Dextran Sulfate in HIV p24 Antigen Positive Individuals (ACTG 060): Results of a Safety and Efficacy Trial. *Donald I. Abrams*, C. Petinelli, M. Power, V. B. Kubacki, M. H. Grieco, W. K. Henry, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

W.B.P.316 Effet du MMI sur les malades atteints du SIDA. *Z. Lurhuma*, A. Shafik, M. Diese, J. Wane, K. Tshiamala, B. Bimamisana, *Kinshasa, Zaire.*

Thérapie et évaluation clinique : Tests contrôlés
Therapy and Clinical Evaluation: Controlled Trials

W.B.P.317 Use of Zidovudine in Injection Drug Use (IDU) Related HIV Infection: Drug Compliance and Clinical Attendance. *Frances M. Cowan*, M. E. Jones, P. J. Flegg, L. R. MacCallum, R. P. Brettle, J. A. Gray, et al., *City Hospital, Department of Infectious Diseases, Edinburgh, U.K.*

W.B.P.318 Effectiveness of Low-Dose Combination Therapy with Azidothymidine (Zidovudine) and Acyclovir in AIDS and ARC Patients. *Peter Walger*, P. Baumgart, G. Wilke, M. V. Eiff, U. Kupfer, K.-G. Dorst, *Medizinische Poliklinik, Universität Münster, Münster, Federal Republic of Germany.*

W.B.P.319 Allogeneic Bone Marrow Transplantation (BMT) Plus Azidothymidine (AZT) in an AIDS Patient with Non-Hodgkin's Lymphoma (NHL). *Albert D. Donnenberg*, H. K. Holland, J. J. Rossi, J. A. Zaia, G. W. Santos, R. Saral, *The Johns Hopkins University Oncology Center, Baltimore, MD, U.S.A.*

W.B.P.320 AS 101 in Association with AZT in AIDS Patients: A Phase I Pilot Study. *Jean-Philippe Laporte*, J. Frottier, D. Dormont, J.-C. Imbert, M. Albeck, A. Najman, et al., *Hôpital St-Antoine, Paris, France.*

W.B.P.321 Effect of Combination of Zidovudine and Interferon-Alpha Compared with Zidovudine and Acyclovir on HIV-Antigenaemia in Asymptomatic Patients. *Rainer Weber*, A. Bonetti, R. Lüthy, R. Putzi, B. Spacey, W. Siegenthaler, et al., *Medical Polyclinic, Department of Medicine, University Hospital, Zurich, Switzerland.*

W.B.P.322 Zidovudine vs. Alpha Interferon vs. the Combination in Patients with Early HIV Infection. *Kathryn M. Zunich*, V. Davey, J. A. Metcalf, H. Masur, A. S. Fauci, H. C. Lane, et al., *National Institutes of Health, Rockville, MD, U.S.A.*

W.B.P.323 An Open-Label Study of the Safety and Efficacy of Co-Administration of Zidovudine and Recombinant-IFN-Beta. *Michael J. Borucki*, R. B. Pollard, *University of Texas, Medical Branch, Virology Research, Galveston, TX, U.S.A.*

W.B.P.324 Effect of a Combined Dextran Sulfate/Zidovudine Therapy Compared to Zidovudine Monotherapy in AIDS. *N. H. Brockmeyer*, L. Mertins, M. Goos, *Department of Dermatology, University of Essen, Essen, Federal Republic of Germany.*

W.B.P.325 The Safety of Zidovudine and Interleukin-2 in Asymptomatic HIV Infected Patients. *John A. Bartlett*, K. D. Blankenship, M. Greenberg, D. S. Tyler, K. J. Weinhold, *Duke University Medical Center, Durham, NC, U.S.A.*

W.B.P.326 Combined Treatment with Zidovudine and Lymphoblast Interferon Alpha in Patients with HIV-Related Kaposi's Sarcoma. *Reinhard Baumann*, Swiss Clinical Task Force on AIDS, *University Hospital, Zürich, Switzerland.*

W.B.P.327 Long-term (18-Month) Treatment of Severe HIV Infection with an Alternating Regimen of AZT and 2',3'-Dideoxycytidine (ddC). *Robert Yarchoan*, J. M. Pluda, R. V. Thomas, C. F. Perno, N. McAtee, S. Broder, *National Cancer Institute, Bethesda, MD, U.S.A.*

W.B.P.328 Daily Subcutaneous Recombinant Granulocyte-Macrophage Colony Stimulating Factor Improves the Neutropenia Induced by Azidothymidine in Patients with AIDS/ARC: Follow-up. *James D. Levine*, J. D. Allan, J. H. Tessitore, N. Falcone, R. Israel, J. E. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

W.B.P.329 The Use of an Alternating Regimen of AZT and Subcutaneous (SC) GM-CSF in Patients with Severe HIV Infection and Leukopenia. *James M. Pluda*, R. Yarchoan, N. McAtee, R. Thomas, D. Oette, S. Broder, *National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A.*

W.B.P.330 Augmentation of Non-MHC Restricted Cellular Cytotoxicities in Patients Receiving Zidovudine Plus Interleukin-2. *Kent J. Weinhold*, D. S. Tyler, A. A. Austin, H. K. Lyerly, D. P. Bolognesi, J. A. Bartlett, et al., *Duke University Medical Center, Durham, NC, U.S.A.*

W.B.P.331 Zidovudine (AZT) Treatment of the AIDS Dementia Complex (ADC): Results of a Placebo-Controlled, Multicentered Therapeutic Trial. *Richard W. Price*, M. A. Koch, J. J. Sidtis, J. Feinberg, A. Collier, C. Kennedy, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.332 Study Compliance among Asymptomatic HIV Seropositives (ASX HIV+) Being Treated with Azidothymidine (AZT). *Paul B. Jacobsen*, C. Vassalos, D. Brown, K. Gorfinkle, G. Philogene, B. Polsky, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.333 Survival of Patients with HIV Disease Treated with Zidovudine (AZT). *David H. Shepp*, M. Kaplan, C. Muggeo, M. Smith, M. Lesser, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A.*

W.B.P.334 Reduction of Zidovudine Side Effects by an Intermittent Therapy Scheme. *Schlomo Staszewski*, J. Odewald, A. Gottstein, E. B. Helm, W. Stille, *Klinikum der J.W.-Goethe-Universität, Frankfurt, Federal Republic of Germany.*

W.B.P.335 A Phase I/II Trial of the Contamination of Zidovudine and Interleukin-2 in the Treatment of HIV-Related Kaposi's Sarcoma. *Joseph A. Kovacs*, R. Davey, M. Polis, K. Zunich, A. S. Fauci, H. C. Lane, et al., *National Institutes of Health, Bethesda, MD, U.S.A.*

W.B.P.336 Zidovudine Use in Intravenous Drug Users. *Jihad Slim*, G. Perez, C. Forrester, G. Tonnesen, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.S.A.*

W.B.P.337 Outcomes of Treatment with AZT of Patients with AIDS and Symptomatic HIV Infection (ARC). *Patricia Cox*, G. N. Beall, C. Styer, M. Martin, *Harbor-UCLA Medical Center, Torrance, CA, U.S.A.*

W.B.P.338 AZT Therapy in Infected People: Efficacy and Side Effects. *Francesco Chiodo*, P. Costigliola, E. Ricchi, M. Borderi, R. Manfredi, A. Guariento, et al., *Istituto Malattie Infettive, Università di Bologna, Bologna, Italy.*

W.B.P.339 Zidovudine Treatment of HIV Infection: Clinical and Immunological Evaluation. *M. Eulalia Valencia*, M. C. G. Rodriguez, P. Lavilla, V. Pintado, A. Gil, J. J. Vazquez, *Hospital La Paz, Servicio de Medicina Interna, Madrid, Spain.*

W.B.P.340 Zidovudine (AZT) Treatment in AIDS and ARC. *Enzo Raise*, V. Vannini, M. L. Schiattone, L. Pulsatelli, G. Gualandi, A. Cicognani, et al., *C.A. Pizzardi Hospital, Department of Infectious Diseases and Immunopathology Unit, C.A. Pizzardi Hospital, Bologna, Italy.*

W.B.P.341 Neurological and Immunological Evaluation of a Patient Treated with AZT with Acute HIV Infection and Encephalopathy. *Robert Zangerle*, P. Pohl, S. Felber, P. Fritsch, *University of Innsbruck, Department of Dermatology, Innsbruck, Austria.*

W.B.P.342 Follow-up and Treatment of 58 HIV-Infected Patients in Greece. *Antonios I. Papadopoulos*, G. D. Stergiou, G. M. Ploumidis, A. N. Roumeliotou, S. A. Georgopolou, G. I. Papaevangelou, *First IKA Hospital Athens, Melissia, Greece.*

W.B.P.343 Update on AZT Therapy in an Inner-City Population. *Jonathan E. Samuels*, J. Hendrix, M. Hilton, V. Sloan, C. B. Small, *North Central Bronx Hospital, Bronx, NY, U.S.A.*

W.B.P.344 Devenir de 365 malades atteints d'ARC ou de SIDA et traités par AZT pendant 4 à 18 mois. *Eric Dournon*, S. Matheron, W. Rozenbaum, C. Michon, C. Perronne, *Hôpital Raymond-Poincaré, Garches, France.*

W.B.P.345 Experience with Zidovudine in a City Hospital AIDS Clinic. *Laurel A. Miller*, K. Peterson, A. Davidson, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A.*

W.B.P.346 Effects of Zidovudine Different Dose Regimens on Clinical, Immunological and Virological Indices of ARC Patients for One Year. *Piera Cuneo-Crovari*, G. Cassola, P. Crovari, B. Guida, G. C. Icardi, N. Piersantelli, *University of Genoa, Institute of Hygiene and Preventive Medicine, Genoa, Italy.*

W.B.P.347 Benefits of AZT when Started at Increasing Times after AIDS/PCP Diagnosis. *Steven M. Pounders*, S. D. Nightingale, V. Orcutt, S. Collins, J. D. Jockusch, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.*

W.B.P.348 Progression of HIV-Infected Hemophiliacs under AZT Treatment: One Year Follow-up Study. *Titika Mandalaki*, A. Karafoulidou, A. Gialeraki, J. Economidou, P. Maknis, A. Potamianou, et al., *Laikon Hospital, Athens, Greece.*

W.B.P.349 Zidovudine (AZT) in HIV-Positive Haemophiliacs. *Seng Gee Lim*, C. A. Lee, M. Hales, P. L. F. Giangrande, P. B. A. Kernoff, *Haemophilia Centre and Haemostasis Unit, Academic Department of Haematology, Royal Free Hospital, London, U.K.*

W.B.P.350 Zidovudine Therapy in Homosexual/Bisexual Patients with AIDS-Related Complex (ARC) in Australia. *Cheryl Elaine Swanson*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, Sydney, Australia.*

W.B.P.351 Cessation of Zidovudine (AZT) Therapy Leads to Increased Frequency of Viral Isolation. *Mark A. Wainberg*, M. Fanning, J. Gill, K. Gelmon, J. S. G. Montaner, M. O'Shaughnessy, et al., *McGill University, Montreal, QC, Canada.*

W.B.P.352 Improvement of Survival in AIDS Patients with Zidovudine Therapy. *Claudio Arici*, M. Rizzi, M. G. Finazzi, E. Minola, *Ospedali Riuniti di Bergamo, Department of Infectious Diseases, Bergamo, Italy.*

W.B.P.353 Efficacy of AZT at a Municipal Hospital Clinic. *Jonathan Cohn*, A. McMeeking, H. Schlamm, M. Vogler, S. Allen, R. Holzman, *New York University, Bellevue Hospital, New York, NY, U.S.A.*

W.B.P.354 The Effect of Zidovudine (AZT) on Survival of AIDS Patients in San Francisco. *George F. Lemp*, S. F. Payne, D. P. Neal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

W.B.P.355 Zidovudine (AZT), Preventive Treatment of AIDS in HIV Seropositive Patients? *Jean-Marc Tourani*, M. Stern, M. Volstein, W. Lowenstein, J. M. Andrieu, *Laennec Hospital, Paris, France.*

W.B.P.356 Open Trial of the Long-term Safety of Zidovudine: Interim Analysis. *Linda Houle*, J. D. Peake, M. J. F. Fletcher, Canadian Zidovudine Collaboration Group, *Burroughs Wellcome Inc., Kirkland, QC, Canada.*

W.B.P.357 Disease Status and HIV Isolate Replication in 31 Haemophiliacs Including 11 AZT Treated Patients. *Elio Boeri*, P. G. Mori, E. Franchini, T. Lanza, G. Ferrari, O. E. Varnier, *G. Gaslini Institute, Department of Hematology and Oncology, Genoa, Italy.*

W.B.P.358 Major Opportunistic Infections in AIDS Patients after Eight to One Hundred Fifty Weeks of Zidovudine Therapy. *Dennis M. Causey*, J. M. Leedom, H. Melancon, *University of Southern California, Los Angeles, CA, U.S.A.*

W.B.P.359 Essai clinique du traitement des patients SIDA par la zidovudine. *Bila Kapita*, M. Minlangu, R. Ryder, M. Nyst, E. Chalhoub, *Hôpital Mama Yemo, Kinshasa, Zaire.*

W.B.P.360 Zidovudine Delays Development of AIDS for Patients with 4C-2, 3 and 4A HIV Disease. *Anita R. Rachlis*, M. Bonner, M. Fletcher, L. Houle, *Sunnybrook Medical Centre, University of Toronto, Toronto, ON, Canada.*

W.B.P.361 Treatment with Retrovir in Different Stages of the HIV Infection. *Elio Manzillo*, G. Maio, C. M. Izzo, S. Buonocore, G. Manzillo, *D. Cotugno Hospital, Naples, Italy.*

W.B.P.362 Efficacy and Tolerance of Zidovudine in Patients with Asymptomatic HIV Infection or with PGL. *Pietro Tullio-Cataldo*, A. Chirianni, S. Noce, G. Bonadies, L. Picciotto, M. Piazza, *University of Naples, Clinic of Infectious Diseases, Naples, Italy.*

W.B.P.363 Long-term Assessment of Toxicity and Clinical Outcome in Treatment of HIV Infection with Zidovudine. *Toby S. Dyner*, W. Lang, J. Geaga, J. Bender, *AIDS Clinical Research Project, Children's Hospital of San Francisco, San Francisco, CA, U.S.A.*

W.B.P.364 Zidovudine Treatment in 100 Consecutive Patients with AIDS or AIDS-Related Complex. *Alain T. Sobel*, F. Roudot, M. L. Hargous, B. Cassinat, I. Rekacewicz, F. Lyonnet, et al., *Hôpital Henri-Mondor, Créteil, France.*

W.B.P.365 Correlation between p24 Antigenaemia and CD4+/Neopterin Ratio in AZT-Treated Patients. *Paolo Crocchiolo*, A. Lizioli, M. Panzeri, C. Filippi, I. Arcidiacono, M. L. Nardella, *Ospedale Maggiore, Infectious Diseases Department, Lodi, Italy.*

W.B.P.366 Suivi clinique et biologique de 108 malades traités par zidovudine sur une période de 12 à 18 mois. *J. P. Cassuto*, C. Boillot, A. Pesce, J. F. Quaranta, H. Vinti, B. Taillan, *Hôpital de Cimiez, Service de médecine interne II, Nice, France.*

W.B.P.367 AZT Therapy in Intravenous Drug Users (IVDUs) and Their Sexual Partners. *Alice Spears*, S. Landesman, R. Shafer, K. Chirgwin, J. De Hovitz, *Kings County Hospital, Brooklyn, NY, U.S.A.*

W.B.P.368 Treatment of Symptomless HIV Seropositive Subjects by Azidothymidine (AZT). A Control Study in 56 Patients. *Daniel Vittecoq*, J. J. Lefrère, P. Lambin, J. F. Mettetal, C. Rouzioux, *Hôpital Necker, Service d'Immmunologie, Paris, France.*

W.B.P.369 An Intermittent Zidovudine Regimen: Toxicity and Efficacy. *Neil J. Bodsworth*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, University of New South Wales, Surry Hills, Australia.*

W.B.P.370 Long-term Safety and Efficacy of Zidovudine in Large Cohorts of IV Drug Abusers: 20-Month Experience with 200 Asymptomatic, 500 ARC and 400 AIDS Patients. *Stefano Vella*, F. Menniti Ippolito, M. G. Agresti, P. Pezzotti, *National Institute of Health, Rome, Italy.*

W.B.P.371 Use of Zidovudine (AZT) in Injection Drug Use (IDU) Related HIV Infection: Clinical Outcome. *Frances M. Cowan*, M. E. Jones, P. J. Flegg, L. R. MacCallum, R. P. Brettle, J. A. Gray, et al., *City Hospital, Department of Infectious Diseases, Edinburgh, U.K.*

W.B.P.372 Zidovudine in ARC and AIDS Patients: Clinical, Immunological and Virological Efficacy. *Gerd Höffken*, M. Petri, K. M. Deppermann, W. D. Ludwig, M. Mielke, B. Zorr, et al., *Freie Universität Berlin, Klinikum Steglitz, Med. Klinik, Berlin, Federal Republic of Germany.*

W.B.P.373 Compliance with Zidovudine Therapy in an Inner-City HIV-Infected Population. *Ivetta Y. Williams*, J. Noel-Connor, W. El-Sadr, *Harlem Hospital Center, Infectious Disease Section, New York, NY, U.S.A.*

W.B.P.374 Interferon (IFN) Alpha+ AZT in AIDS-Associated Kaposi's Sarcoma (KS): Final Results of a Phase I Trial. *Susan E. Krown*, D. Bundow, B. Gansbacher, J. Gold, N. Flomenberg, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.B.P.375 Outpatient Transfusion Therapy for Retrovir-Associated Anemia. *Susan Weiss*, E. Visser, P. Rodgers, A. McMeeking, H. Schlamm, *AIDS Program, Bellevue Hospital Center, New York, NY, U.S.A.*

W.B.P.376 Self Care Nursing for AIDS/ARC Via Computer Networks. *Stefan J. Ripich*, P. F. Brennan, *Case Western Reserve University, Cleveland, OH, U.S.A.*

W.B.P.377 Complementary Therapies at Casey House Hospice: A Model for Traditional/Alternative Interaction. *William E. Berinati*, *Casey House Hospice Inc., Toronto, ON, Canada.*

W.B.P.378 Problems in an AIDS Hospice Setting. *Jeff A. Bloom*, J. Flannery, *Casey House Hospice Inc., Toronto, ON, Canada.*

W.B.P.379 Development of a Day Facility for People with AIDS/HIV Infections. *Ann Kelly, St. Stephen's Hospital, London, U.K.*

W.B.P.380 Fonctions du psychiatre dans un hôpital de jour pour patients HIV+. *Françoise Linard*, D. Sylvestre, *INSERM U158, Hôpital Claude Bernard, Paris, France.*

W.B.P.381 Implantable Infusion Ports in Patients with AIDS. *B. Lynn Johnston*, Y. Lynch, T. Marrie, *Dalhousie University, Halifax, NS, Canada.*

W.B.P.382 Follow-up of Infants Born to HIV-Infected Mothers in Argentina. *Mercedes C. Weissenbacher*, B. Massa, M. Gomez Carrillo, N. Fernandez, M. Balbaryski, M. Boxaca, et al., *Departamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.*

W.B.P.383 The Impact of AIDS on Families of Haemophiliacs in Wales. *Jacqueline Y. Beese, University of Wales, College of Medicine, Cardiff, U.K.*

Notes

Section
C

Mercredi 7 Juin
Wednesday, June 7

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Session d'affichage
Poster Session

Modèles animaux
Animal Models

W.C.P.1 Aerosol Delivery of Pentamidine to the Deep Lung: A Model of Isotopic Quantitation in Baboons. *P. Choutet*, C. Jubault, J. L. Baulieu, E. Lemarie, A. Le Pape, P. Diot, *Centre hospitalier universitaire, Tours, France.*

W.C.P.2 SIVagm and SIVmnd Might Be Nonpathogenic In Vivo. *Yoshihiro Ohta*, K. Ishikawa, H. Tsujimoto, R. Mukai, S. Honjo, M. Hayami, et al., *University of Tokyo, Institute of Medical Science, Tokyo, Japan.*

W.C.P.3 Persistent HIV-2 Infections of Rhesus, Macaques, Baboons and Mangabeys. *Isabelle Nicol*, G. Flamminio-Zola, P. Dubouch, I. Desportes, J. Bernard, D. Zagury, *Université Paris VI, Physiologie cellulaire, Paris, France.*

W.C.P.4 A Rabbit Model of HTLV-I Infection: Seroconversion Patterns and Detection of Virus by PCR. *Michael D. Lairmore*, G. C. Cockerell, T. M. Hartley, B. K. De, J. Rovnak, I. Miyoshi, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

W.C.P.5 CD8+ and CD4+ Responses to HIV-1 Antigens in Mice Immunized with Vaccinia Virus (VV) Recombinants. *Frédérique Michel*, A. Hoffenbach, N. Chenciner, M. P. Kieny, S. Wain-Hobson, F. Plata, et al., *Institut Pasteur, Paris, France.*

W.C.P.6 Macrophages from LP-BM5 Infected Mice Induce Murine AIDS. *Janis K. Lazdins*, R. M. Cozens, J. D. Gangemi, *CIBA-GEIGY Ltd., Basel, Switzerland.*

W.C.P.7 Intercomparison of Different SIV Isolates in Rhesus and Cynomolgus Macaques. *Peter Kitchin*, M. P. Cranage, E. J. Stott, A. Baskerville, *World Health Organization AIDS Collaborating Centre, NIBSC, South Mimms, U.K.*

W.C.P.8 Strain Specificity of Lymphocyte Proliferative Responses in Experimental Animals Immunized with Recombinant HIV-1 gp120 Antigens. *Peggy A. Wentworth*, B. Doe, N. Haigwood, J. Shuster, C. Scandella, K. Steimer, *Chiron Corp., Emeryville, CA, U.S.A.*

W.C.P.9 The Significance of Premature Stop Codons in env of SIV. *Dawn P. Wooley*, T. Kodama, Y. Naidu, H. Kestler, Y. Li, R. Desrosiers, *Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A.*

W.C.P.10 Construction and Characterization of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of SIVmne. *Shiu-Lok Hu*, B. M. Travis, K. Abrams, J. Chinn, W. R. Morton, R. Benveniste, *Oncogen, Seattle, WA, U.S.A.*

W.C.P.11 FIV-AIDS Model for Testing Novel Vaccine Approaches for Human AIDS. *Janet K. Yamamoto*, T. Okuda, *School of Veterinary Medicine, Department of Medicine, Davis, CA, U.S.A.*

W.C.P.12 Evolution of the Envelope Gene of SIVmac-BK28. *Paul F. Edmonson*, M. Murphey-Corb, V. Hirsch, J. I. Mullins, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.*

W.C.P.13 Isolation and Preliminary Characterization of a Neurotropic Strain of Feline Leukemia Virus. *Peter W. Gasper*, L. R. Whalen, J. Overbaugh, D. W. Wheeler, S. W. Dow, M. L. Poss, *Pathology Department, Colorado State University, Fort Collins, CO, U.S.A.*

W.C.P.14 In Situ Immunoassaying Suggests Central Neuroendocrine Involvement in Infant Feline AIDS (FAIDS). *Manuel J. Torres-Anjel*, B. Ray, J. C. Elliott, J. G. Tshikuka, *University of Missouri at Columbia, Columbia, MO, U.S.A.*

W.C.P.15 In Vivo Analysis of the Minimal Infectious Dose of an Acutely Lethal Pool of SIV (SIV/SMM/PBj-14). *Harold M. McClure*, D. C. Anderson, A. Ansari, P. Fultz, *Emory University, Atlanta, GA, U.S.A.*

W.C.P.16 HIV-1 Infection in a Continuous Rabbit Macrophage Line. *Henrietta Kuluga*, D. Recker, E. Gugel, T. J. Kindt, *NIHM, St. Elizabeth's Hospital, Washington, DC, U.S.A.*

W.C.P.17 Regulation of the Visna Virus LTR in Macrophages Involves Cellular Factors Which Bind Sequences Containing AP-1 Sites. *Dana H. Gabuzda*, J. Hess, A. Dela Torre, J. Small, J. Clements, *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

W.C.P.18 Infection with Simian Immunodeficiency Virus (SIV) Via Conjunctival and Oral Mucosae in a Newborn Rhesus Macaque. *Myra B. Jennings*, N. Lerche, S. Tillery, J. Yee, L. Antipa, P. Chesney, *University of California at Davis, Davis, CA, U.S.A.*

W.C.P.19 Therapy of MAIDS (LP-BM5 Infection of C57BL-6 Mice) with Diethyldithiocarbamate (DTC). *Carole Funk*, D. Mosier, E. Petersen, E. Hersh, *University of Arizona, Tucson, AZ, U.S.A.*

W.C.P.20 Molecular Construction of a Chimeric HIV/Akv MuLV Proviral Clone. *Livia Pedroza-Martins*, F. Plata, S. Wain-Hobson, N. Chenciner, R. Cheynier, S. Delassus, et al., *Institut Pasteur, Paris, France.*

W.C.P.21 Pathology of Feline Immunodeficiency Virus (FIV) Infection. *Akihiro Konno*, T. Ishida, S. Matsumura, T. Washizu, I. Tomoda, *Nippon Veterinary and Zootechnical College, Musashino, Japan.*

W.C.P.22 Un modèle expérimental du SIDA chez la souris, qui élicite des infections et des angiosarcomes (AS). *Manon F. Dubé*, P. Madarnas, M. Rola-Pleszczynski, V. N. Nigam, *Université de Sherbrooke, Faculté de médecine, CHUS, Sherbrooke, QC, Canada.*

W.C.P.23 Adaptation of Human Immunodeficiency Virus Serologic Tests to the Simian Immunodeficiency Virus Model. *JoAnn L. Yee*, M. B. Jennings, N. W. Lerche, J. R. Carlson, *University of California at Davis, Davis, CA, U.S.A.*

W.C.P.24 Enhancement of Antiviral Therapy in HIV Infection Using Blood-Brain Barrier (BBB) Modification with Insulin: Animal Data and Clinical Considerations. *Steven G. Ayre*, B. Skaletski, A. D. Mosnaim, *Chicago Medical School, Antioch, IL, U.S.A.*

W.C.P.25 Lack of Vertical Transmission of SIVagm in a Breeding Colony of Cercopithecus Aethiops. *Birgit Bak Kvinesdal*, L. S. Bruun, C. M. Nielsen, *Statens Seruminstitut, Rubella Department/HIV Laboratory, Copenhagen, Denmark.*

W.C.P.26 Experimental HIV-2 Infection of Old World Monkeys. *Blesila A. Castro*, J. W. Eichberg, N. W Lerche, J. A. Levy, *University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

W.C.P.27 Mechanism of Downregulation of CD4 Expression by Plastic Adherent Human Macrophages In Vitro. *J. M. Mathijs*, F. Kazazi, P. Malafiej, P. Foley, A. L. Cunningham, *Virology Unit, Westmead Hospital, Westmead, Australia.*

W.C.P.28 Culture Requirements for HIV-1 Isolation from Infected Chimpanzees. *Paolo A. Piazza*, K. E. Kobb, J. W. Eichberg, *Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A.*

W.C.P.29 Primary Retroviral Infection Versus Chronic Viremia: Differential Response to Therapy. *Ruth M. Ruprecht*, S. Mullaney, J. Andersen, *Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

W.C.P.30 Pathology of Early Lesions in SIV Encephalitis. *Leroy R. Sharer*, L. G. Epstein, J. Michaels, M. Murphey-Corb, L. N. Martin, G. B. Baskin, *New Jersey Medical School Department of Pathology, Newark, NJ, U.S.A.*

W.C.P.31 HIV-1 Antigenemia in Athymic "Nude" Mice. *Neal T. Wetherall*, A. Erling, *Vanderbilt University, Medical Center, Department of Pathology, Nashville, TN, U.S.A.*

W.C.P.32 Langerhans Cells in Rhesus Monkey Oral Mucosa Before and After Infection with Simian Retrovirus Serotype-1 (SRV-1). *Christoph H. F. Hammerle*, M. Schidt, A. Lackner, G. Armitage, M. Wirthlin, J. Greenspan, et al., *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.S.A.*

W.C.P.33 Inoculation of Baboons and Macaques with Virus Produced from SIV/Mne Molecular Clone. *William R. Morton*, L. Kuller, E. A. Clark, M. J. Gale, K. Foy, J. Overbaugh, et al., *Regional Primate Research Center, University of Washington, Seattle, WA, U.S.A.*

W.C.P.34 Mutational Analysis of the Cytoplasmic Domain of SIV Transmembrane Protein. *Lisa A. Chakrabarti*, P. Tiollais, P. Sonigo, *UREG Institut Pasteur, Paris, France.*

W.C.P.35 Infection of Rhesus Macaques with Molecularly-Cloned HIV-2. *Phillip D. Markham*, G. Franchini, E. Gard, S. Kueberuwa, K. Fargnoli, M. Robert-Guroff, et al., *Bionetics Research, Inc., Rockville, MD, U.S.A.*

W.C.P.36 Clinical and Immunologic Staging of Feline Immunodeficiency Virus (FIV) Infection. *Takuo Ishida*, A. Taniguchi, T. Washizu, T. Kobayashi, I. Tomoda, *Nippon Veterinary and Zootechnical College, Musashino, Japan.*

W.C.P.37 Establishment of FIV-Producing Cell Lines from FIV Seropositive Cats. *Joe Chiba*, S. Nagata, S. Tamura, T. Kobayashi, T. Ishida, T. Kurata, *Department of Pathology, National Institute of Health, Tokyo, Japan.*

W.C.P.38 Serologic Variables at Diagnosis with Kaposi's Sarcoma (KS) Predictors of Shortened Survival. *Paul A. Volberding*, A. Moss, P. Bacchetti, E. Winger, R. Edison, P. Cusik, et al., *AIDS Activities Division, San Francisco General Hospital, San Francisco, CA, U.S.A.*

W.C.P.39 Human Recombinant IL-2 Induces Cytotoxic LGL from FeLV Infected IL-2 Immunosuppressed Cats. *Hilda R. Holcombe*, M. Tompkins, W. Tompkins, *North Carolina State University, College of Veterinary Medecine, Raleigh, NC, U.S.A.*

W.C.P.40 Isolation and Partial Characterization of an HIV-1 Related Virus Occurring Naturally in Chimpanzees in Gabon. *Martine Peeters*, R. W. Cooper, C. Honoré, T. Huet, P. Bussi, E. Delaporte, *Centre international de recherches médicales (CIRM), Franceville, Gabon.*

W.C.P.41 HIV-1 Infection in the Rabbit. *Thomas J. Kindt*, H. Kulaga, M. E. Truckenmiller, D. Recker, T. M. Folks, *NIAID, Laboratory of Immunogenetics, National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.42 P24 Antigen in the CSF and Serum of Patients with Non-Hodgkin's Lymphoma Treated with Standard Chemotherapy with or without GM-CSF. *James O. Kahn*, L. A. Kaplan, S. Crowe, P. Volberding, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

W.C.P.43 HIV-1 Infection of Human Fetal Central Nervous System Tissue. *Ruy Soeiro*, K. Tanaka, W. Cihak, S. Udem, A. Rubinstein, W. D. Lyman, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

W.C.P.44 Natural Antibody Perception of Amino Acid Divergence within an HIV-1 Neutralization Epitope. *Jaap Goudsmit*, G. Zwart, M. Bakker, L. Epstein, C. Kuiken, F. De Wolf, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

W.C.P.45 HIV-1 Brain Infection: Distribution of Infection and Clinical Correlates. *Richard W. Price*, K. C. Cronin, M. Rosenblum, B. J. Brew, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.C.P.46 Differences in Risk for AIDS and AIDS Mortality in 49 Individuals Infected with Low- and High-Virulent HIV Variants. *Matthijs Tersmette*, J. M. A. Lange, R. E. Y. De Goede, J. G. Huisman, J. Goudsmit, F. Miedema, *Central Laboratory Blood Transfusion Service, Deparment of Clinical (Viro) Immunology, Amsterdam, Netherlands.*

Oncologie
Oncology

W.C.P.47 Co-Factors in the Development of Kaposi's Sarcoma (KS): HHV-6 Infection. *Gaetano Giraldo*, E. Beth-Giraldo, D. Serwadda, E. Katongole-Mbidde, F. Romano, R. C. Gallo, *Istituto Nazionale Tumori "Fond. Pascale", Naples, Italy.*

W.C.P.48 AIDS Kaposi's Sarcoma (KS) Derived Cells Express Cytokines with a Potential Role in the Pathogenesis of KS Lesions. *Barbara Ensoli*, S. Nakamura, S. Z. Salahuddin, F. Wong-Staal, R. C. Gallo, *Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.*

W.C.P.49 Miscellaneous Carcinomas Developing in Patients with HIV Infection. *Mark U. Rarick*, D. Sharma, P. S. Gill, L. Bernstein, M. Bernstein-Singer, A. M. Levine, *University of Southern California, Los Angeles, CA, U.S.A.*

W.C.P.50 49 Unusual HIV-Related Malignant Tumors. *Umberto Tirelli*, E. Vaccher, A. Sinicco, S. Sabbatani, M. Giudici, S. Monfardini, et al., *Centro di Riferimento Oncologico, Division of Medical Oncology, Aviano, Italy.*

W.C.P.51 HIV-HPV Infection and Penile Carcinomas (PC) in Uganda. *Franco M. Buonaguro*, E. Beth-Giraldo, M. L. Tornesello, E. Katongole-Mbidde, M. Monaco, G. Giraldo, *National Cancer Institute, "Fond. G. Pascale", Naples, Italy.*

W.C.P.52 Kaposi's Sarcoma-like Cell Line from Simian AIDS with Subcutaneous and Retroperitoneal Fibromatosis Associated with Type D Retrovirus (SRV-2) Infection. *Cheng C. Tsai*, J. Sligh, M. D. Woon, S. T. Roodman, *St. Louis University School of Medicine, St. Louis, MO, U.S.A.*

W.C.P.53 Cervical Neoplasia in HIV-Infected Women. *Wolfgang Friedmann*, A. Schäfer, B. Schwartländer, *Free University of Berlin, Deparment of Obstetrics and Gynecology, Berlin, Federal Republic of Germany.*

W.C.P.54 Characteristics of In Vitro Culture of KS-Derived Cells. *Peter Biberfeld*, S. Nakamura, Z. S. Salahuddin, B. Ensoli, R. C. Gallo, *Immunopathology Laboratory, Department of Pathology, Karolinska Hospital, Stockholm, Sweden.*

Pathogenèse
Pathogenesis

W.C.P.55 Vacuolar Myelopathy: HIV-1 Expression Correlates with Extent of Clinical and Pathologic Disease. *Barbara Weiser*, N. Peress, D. Eilbott, D. LaNeve, R. Seidman, H. Burger, *State University of New York at Stony Brook, Division of Infectious Diseases, Stony Brook, NY, U.S.A.*

W.C.P.56 HIV-1 Antigenic Variants with Distinct Biological Properties Emerge at the Decline of the Homologous Antibody. *Jean-Jacques De Jong*, M. Tersmette, W. Krone, R. Meloen, F. Miedema, J. Goudsmit, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

W.C.P.57 Early Appearance of Crossreactive Antibodies Specific for a Common Epitope in gp41 and HLA Class II Antigens Can Interfere with Normal Immune Functions in AIDS Patients. *Hana Golding*, G. M. Shearer, K. Hillman, J. Manischewitz, B. Golding, *Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A.*

W.C.P.58 HIV-Infected Humans, but not Chimpanzees, Have Cytoxic T Lymphocytes That Lyse Uninfected CD4+ Cells. *Patricia A. Moron*, J. M. Zarling, J. A. Ledbetter, J. Sias, P. Fultz, J. Eichberg, *Oncogen, Seattle, WA, U.S.A.*

W.C.P.59 Induction of Human Immunodeficiency Virus from Chronically Infected Clones by Cytokines and Pharmacological Agents Requires Protein Kinase C Activation. *Audrey Kinter*, W. Maury, G. Poli, A. S. Fauci, T. M. Folks, *National Institutes of Health, Rockville, MD, U.S.A.*

W.C.P.60 Morphological Changes of the Vacuolar Myelopathy in AIDS. *Juan Artigas*, F. Niedobitek, G. Grosse, G. Bonk, W. Heise, *Department of Pathology, Auguste-Viktoria-Krankenhaus, Berlin, Federal Republic of Germany.*

W.C.P.61 HIV-1 Infection of Human Fetal Central Nervous System Organotypic Cultures. *William D. Lyman*, M. Tricoche, Y. Kress, W. Hatch, F. C. Chiu, R. Soeiro, *Albert Einstein College of Medicine, Department of Pathology, Bronx, NY, U.S.A.*

W.C.P.62 Use of Polymerase Chain Reaction (PCR) to Detect the Presence of HIV-1 DNA in Subpopulations of Peripheral Blood Mononuclear Cells (PBMCS) in Infected Individuals. *Steven M. Schnittman*, M. C. Psallidopoulos, H. C. Lane, M. Baseler, N. P. Salzman, A. S. Fauci, *NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.63 HIV Infection Alters the Interaction of Macrophages with Toxoplasma and Leishmania. *D. Chester Kalter*, H. Gendelman, J. Orenstein, M. S. Meltzer, S. Reed, *H. M. Jackson Foundation, Bethesda, MD, U.S.A.*

W.C.P.64 Infection of Human Fetal Brain Macrophages and Mixed Neural Cells in Tissue Culture by HIV-1. *Kei Numazaki*, H. Goldman, X. Q. Bai, I. Wong, M. A. Wainberg, *McGill University, Montreal Children's Hospital Research Institute, Montreal, QC, Canada.*

W.C.P.65 General Decrease of Leukocyte Viability of AIDS Patients in Serum-Free Medium. *Denise Guétard*, V. Favier, M. Hardefelt, M. Adams, L. Montagnier, *Institut Pasteur, Paris, France.*

W.C.P.66 Mechanisms of HIV Infections in Macrophages. *Bernd Zorr*, T. Kaunath, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany.*

W.C.P.67 CNS and Lymph Node Changes in HIV Infection. *Peter Biberfeld*, C. V. Parravicini, A. L. Petrén, M. Ekman, A. Porwit, R. C. Gallo, *Immunopathology Laboratory, Deparment of Pathology, Karolinska Hospital, Stockholm, Sweden.*

W.C.P.68 Cytomegalovirus (CMV) Induction of Tumor Necrosis Factor (TNF) Secretion by Human Monocytes/Macrophages May Contribute to Tissue Inflammation in AIDS Patients. *Phillip D. Smith*, C. L. Lamerson, S. S. Saini, L. M. Wahl, S. M. Wahl, *National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.69 Altered Brain Metabolites in AIDS Dementia as Measured by Magnetic Resonance Spectroscopy. *Peter C. Jensen*, B. Hubesch, R. Parks, R. Deicken, P. Krell, M. Weiner, et al., *VA Medical Center, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.C.P.70 Induction of HIV-1 from Latently Infected CNS Derived Cells. *Mark Laughlin*, M. Laughlin, J. M. Harouse, F. Gonzales-Scarano, *University of Pennsylvania, Medical Center, Philadelphia, PA, U.S.A.*

W.C.P.71 In Vivo Activation of Alveolar Macrophages and Lymphocytes in Spontaneous Interstitial Lung Disease Due to the Visna-Maedi Virus in Sheep. *Geneviève Cordier*, J. L. Cadoré, G. Cozon, J. F. Mornex, *Hôpital Édouard Herriot, INSERM U80, CNRS, UCBL, Lyon, France.*

W.C.P.72 Morbidité systémique et expression rétrovirale (infection productive) chez le porteur HIV. *Jacques Leibowitch*, D. Mathez, D. Cesari, C. Belilovsky, I. Gorin, J. Deleuze, et al., *Hôpital Raymond Poincaré, Garches, France.*

W.C.P.73 Altered IgG-Subclass Distribution in Lymph Node Cells and Serum of Patients with HIV Infection. *Fredrik Müller*, S. Frland, P. Brandtzaeg, *University of Oslo, Rikshospitalet, Oslo, Norway.*

W.C.P.74 The Effect of HIV on Membrane Lipids of Lymphocytes. *Ami Klein*, P. Gordon, S. Ramcharitar, L. Mercure, A. Malkin, M. Wainberg, *Department of Clinical Biochemistry, Sunnybrook Medical Center, Toronto, ON, Canada.*

W.C.P.75 Simian Immunodeficiency Virus Bone Marrow Hematopoietic Progenitor Cell Growth. *Mamoru Watanabe*, D. J. Ringler, N. L. Letvin, P. A. DeLong, *Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A.*

W.C.P.76 Infection of Glial Cells Expressing the CD4 Molecule. *Janet M. Harouse*, F. Gonzalez-Scarano, M. A. Laughlin, H. Friedman, B. Godfrey, J. Hastings, *University of Pennsylvania, Department of Neurology, Microbiology and Medicine, School of Medicine, Philadelphia, PA, U.S.A.*

W.C.P.77 Role of Endotoxin in Modulation of HIV Expression in a Monocytic Cell Line. *Jean-Michel Molina*, H. Chhay, C. Amirault, C. Dinarello, J. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

W.C.P.78 Production de TNF et d'IL-1ß par les cellules de la lignée monocytaire infectées par le VIH. *Jean-Michel Molina*, D. Scadden, R. Ferriani, R. Byrn, C. Dinarello, J. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

W.C.P.79 HIV-2 Envelope Glycoproteins and Cell Fusion. *Mark J. Mulligan*, P. Kumar, H. Hui, D. Ritter, B. Hahn, R. Compans, *University of Alabama at Birmingham, Department of Microbiology, Birmingham, AL, U.S.A.*

W.C.P.80 CMV Is not a Cofactor in the Progression of HIV Infection. *Lawrence W. Drew*, H. Brodie, W. R. Byrne, C. Graham, A. Kadakia, M. T. Williams, *Mount Zion Hospital and Medical Center, San Francisco, CA, U.S.A.*

W.C.P.81 Aberrant Circadian Physiologic, Immune and Endocrine Rhythms in HIV-Infected Individuals. *Frank S. Rhame*, R. Sothern, L. Sackett-Lundeen, C. Suarez, W. Hrushesky, E. Haus, *University of Minnesota, Minneapolis, MN, U.S.A.*

W.C.P.82 Regulation of Cytokine Receptor Expression by HIV. *Allan S. Lau*, M. Dion, J. F. Livesey, *Hospital for Sick Children, Division of Infectious Diseases, Toronto, ON, Canada.*

W.C.P.83 Enhanced Production of Tumor Necrosis Factor in Symptomatic HIV Infections. *Allan S. Lau*, S. E. Read, S. Der, *Hospital for Sick Children, Division of Infectious Diseases, Toronto, ON, Canada.*

W.C.P.84 Analysis of Brain from AIDS Patients for HIV-1 DNA Sequences Using the Polymerase Chain Reaction (PCR). *Hakan Gadler*, B. H. Hahn, G. M. Shaw, B. J. Brew, M. Rosenblum, R. W. Price, *Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY, U.S.A.*

W.C.P.85 Effects of Tumor Necrosis Factor (TNF-a), Gamma Interferon and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) on HIV Replication in HIV-Infected Human Myelomonocytic Cell Lines. *Eduardo Cortes*, J. P. Koeffler, J. Q. Zhao, R. T. Mitsuyasu, *University of California at Los Angeles, Los Angeles, CA, U.S.A.*

W.C.P.86 Presence of HIV-1 in the Sperms of HIV-1 Seropositive Individuals by DNA-Hybridization and Immunogold Methods. *Omar Bagasra*, M. Freund, D. Condoluci, B. Heins, J. Weidman, J. Comida, *University of Medicine and Dentistry of New Jersey, Camden, NJ, U.S.A.*

W.C.P.87 Presence of Tumor Necrosis Factor in the Cerebral Spinal Fluid (CSF) of AIDS Patients with HIV Encephalopathy. *Victor L. Perez*, R. Janssen, T. Spira, A. S. Fauci, R. Dubois, T. M. Folks, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

W.C.P.88 Detection of Unintegrated Viral DNA in HIV-1 Infection: Use of a Rapid and Easy PCR Method. *Suzanne Jurriaans*, J. Geelen, L. Epstein, M. Clement, J. Lange, J. Goudsmit, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

W.C.P.89 Serum Capacity to Inhibit Reverse Transcriptase In Vitro Distinguishes HIV-1 Infection from HIV-2 or SIV Infection. *Jaap Goudsmit*, T. Wolfs, J. Geelen, H. Schellekens, F. Barin, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

W.C.P.90 Expression of a Potential HIV Receptor on Human Gastrointestinal Epithelial Cells (GIECs). *Mary Pat Moyer*, R. I. Huot, D. A. Wideman, D. W. Martin, *University of Texas Health Science Center at San Antonio, Department of Surgery, San Antonio, TX, U.S.A.*

W.C.P.91 Cell-Specific Control of HIV Production in Chronically Infected Glial Cells. *Volker Erfle*, W. Mellert, H. Festl, A. Kleinschmidt, N. Müller-Lantzsch, *GSF-Abteilung für Molekulare Zellpathologie, Neuherberg-Munich, Federal Republic of Germany.*

W.C.P.92 Neutralizing and Enhancing Antibodies in Different Stages of HIV Infection. *Eszter Ujhelyic*, F. Tóth, B. Szabó, A. Horváth, G. Füst, D. Bánhegyi, et al., *National Institute of Hematology and Blood Transfusion, Budapest, Hungary.*

W.C.P.93 Low Plasma Cysteine and Elevated Glutamate Levels in HIV-1+ Patients May Contribute to Loss of T-cell Functions. *Wulf Dröge*, H.-P. Eck, H. Frey, *The German Cancer Research Center, Institute of Immunology and Genetics, Heidelberg, Federal Republic of Germany.*

W.C.P.94 Identification of Phenotypic Ultrastructures of Lymphocytes Reacting with Auto-Antibodies in AIDS. *Drasko D. Pekovic*, S. Garzon, H. Strykovski, N. Lapointe, D. Ajdukovic, *Biomedco Canada Inc., Montreal, QC, Canada.*

W.C.P.95 Longitudinal Study of HIV Antibody Responses of Infants Born to Seropositive Women in Zaire. *David A. Katzenstein*, R. M. Hendry, W. Nsa, C. Ryder, C. Brown, T. C. Quinn, et al., *Laboratory of Retrovirus Research, Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A.*

W.C.P.96 Neutralizing Antibodies in Seropositive Subjects from Africa, South and North America against 4 Divergent Strains of HIV. *David A. Katzenstein*, L. Vujcic, A. Latif, B. Galvao, N. Halsey, G. V. Quinnan, et al., *Laboratory of Retrovirus Research, Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A.*

W.C.P.97 Specific Defect in Tissue Factor Expression in Monocytes from AIDS Patients. *Janet L. Lathey*, J. M. Agosti, L. Corey, T. S. Edgington, M. B. A. Oldstone, J. A. Nelson, *Research Institute of Scripps Clinic, La Jolla, CA, U.S.A.*

W.C.P.98 Antibodies to gp41 Peptide (HIVIS, aa 583-599) do not Correlate Significantly with Protection from Disease in HIV Infection. *Rachanee Cheingsong-Popov*, K. Caun, C. Panagiotidi, J. Blomberg, J. Weber, *Royal Postgraduate Medical School, Hammersmith Hospital, Department of Medicine, London, U.K.*

W.C.P.99 Autoimmunity against Neutrophils and Thrombocytes in Different Stages of HIV Infection. *Robert J. L. Klaassen*, J. W. Mulder, A. B. J. Vlekke, J. M. A. Lange, A. E. G. von dem Borne, *Central Laboratory of the Blood Transfusion Service, Amsterdam, Netherlands.*

W.C.P.100 HIV Target Cells in Testes and Epididymides from AIDS Patients. *Axel Ellrodt*, R. Vazeux, D. Hénin, M. Hachouel, C. Katlama, M. Auroux, et al., *INSERM U56, CHU de Bicêtre, Bicêtre, France.*

W.C.P.101

W.C.P.102 Novel Sporozoite Lectin in Cryptosporidium Parvum. *Donald Thea*, M. E. A. Pereira, C. Sterling, G. T. K. Keusch, *New England Medical Center Hospitals, Boston, MA, U.S.A.*

W.C.P.103 A Possible Block of VIP Dependent Neuronal Survival by gp120 in AIDS Dementia Complex. *Junko Kimura-Kuroda*, K. Yasui, T. Iwasaki, *Tokyo Metropolitan Institute for Neurosciences, Department of Microbiology, Fuchu-city, Japan.*

W.C.P.104 The Early Steps of T Lymphocyte Activation and Inhibition by HIV-2, STLV-III, and Different Strains of HIV-1. *Bo Hofmann*, P. Nishanian, P. Insixiengmay, J. L. Fahey, *University of California at Los Angeles, School of Medicine, Department of Microbiology/Immunology, Los Angeles, CA, U.S.A.*

W.C.P.105 Viral Antigen Stimulation of the Secretion of Human Monokines Capable of Regulating HIV-1 Expression. *Kathleen Clouse*, I. Washington, P. B. Robbins, B. Fernie, J. M. Ostrove, A. S. Fauci, *Georgetown University, Department of Microbiology, Washington, DC, U.S.A.*

W.C.P.106 Efficient HIV Isolation from Healthy Seropositive Individuals Using Normal Monocyte Targets: Implications for HIV Cell Tropism. *Guido Poli*, F. E. Massari, S. M. Schnittman, H. C. Lane, A. S. Fauci, *National Institutes of Health, Rockville, MD, U.S.A.*

W.C.P.107 TNF-a Can Induce the Expression of HIV from Chronically Infected Cells in an Autocrine Fashion. *Guido Poli*, J. Justement, A. Kinter, K. Clouse, T. M. Folks, A. S. Fauci, et al., *National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.108 Qualitative Differences in HIV-1 and HIV-2 Infections of a Panel of CD4+ T-Cell Clones. *Guido Poli*, E. Duh, A. Rabson, F. Clavel, A. S. Fauci, *National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.109 GM-CSF Inhibition of Susceptibility of M-CSF Treated Human Monocytes to In Vitro Infection with HIV. *Ferdinand Massari*, G. Poli, A. S. Fauci, *National Institutes of Health, Rockville, MD, U.S.A.*

W.C.P.110 Thymus Involvement in AIDS Pathogenesis: In Vitro Studies of Thymus Infection. *Anita De Rossi*, M. L. Calabro, D. Bernardi, M. Danozzo, L. Chieco-Bianchi, *University of Padua, Institute of Oncology, Padua, Italy.*

W.C.P.111 Inhibition of HIV-1 Replication with Reverse Transcriptase Inhibiting (RTI) Antibody in Lymphocyte Cultures. *Tomohiko Takasaki*, D. Imagawa, M. Lee, H. Kusakabe, K. Sugita, P. Nishanian, et al., *Harbor-University of California at Los Angeles Medical Center, Torrance, CA, U.S.A.*

W.C.P.112 Virologic Markers of Central Nervous System HIV Infection in HIV Seropositive Homosexual Men without Neurological Symptoms. *Robert W. Coombs*, A. C. Collier, K. Chloupka, J. Dragavon, H. H. Handsfield, L. Corey, *University of Washington, Virology Office, Children's Hospital, Seattle, WA, U.S.A.*

W.C.P.113 In Vitro Interactions of HIV with Neurons, Astrocytes and Microglial Cells. *Marc Tardieu*, C. Hery, O. Boesplug, S. Peudenier, R. M. Valeux, L. Montagnier, et al., *INSERM U56, Université de Paris Sud, Le Kremlin-Bicêtre, France.*

W.C.P.114 Raised Levels of Circulating Tumour Necrosis Factor Cachectin in Patients with AIDS: Pathogenetic Implications. *C. P. J. Maury*, J. Lähdevirta, A. M. Teppo, H. Repo, *Fourth Department of Medicine, University of Helsinki, Helsinki, Finland.*

W.C.P.115 Anaemia and Lymphopenia in HIV Infection: Relation to Serum Levels of Tumour Necrosis Factor- . *C. P. J. Maury*, A. M. Teppo, *Fourth Department of Medicine, University of Helsinki, Helsinki, Finland.*

W.C.P.116 Replication of HIV-1 and Insertion and Deletion Mutants in Human Cell Lines. *Volker Heisig*, G. Jahn, D. Zagury, *IMMI, Hamburg, Federal Republic of Germany.*

W.C.P.117 Immunohistochemical Analysis of Germinal Centers in Rectal Biopsies of Patients with HIV-1 Infection. *Paul Racz*, K. Tenner-Racz, H. Schmidt, M. G. Hartmann, M. Popovic, *Institute for Tropical Diseases, Hamburg, Federal Republic of Germany.*

W.C.P.118 Evidence for Intrafollicular Virus Replication in Germinal Centers of Lymph Nodes of Cats Infected with FeIV. *Klara Tenner-Racz*, F. Noronha, H. Schmidt, P. Racz, *A.K. St. Georg, Hamburg, Federal Republic of Germany.*

W.C.P.119 Establishment of a Cell Line Chronically Infected but not Producing HIV-1 from an Asymptomatic Seropositive Subject. *Fausto F. Titti*, M. Federico, A. Borsetti, L. Ceccarelli, P. Verani, G. B. Rossi, *Istituto Superiore di Sanità, Rome, Italy.*

W.C.P.120 Increased Production of Arachidonic Acid Metabolites (Prostaglandin E2 and Thromboxane B2) by Monocytes from Drug Addicts (IVDA) Infected with Human Immunodeficiency Virus. *Eduardo P. Fernandez-Cruz*, J. M. Zabay, N. Longo, G. Gomez, J. Rosello, I. Ramis, et al., *Hospital General Gregorio Marañon Complutense University, Madrid, Spain.*

W.C.P.121 Ras Oncongene Co-Transfection Induces Transactivation of the HIV-LTR Through NF-KB Binding Site. *Fernando Arenzana-Seisdedos*, N. Israël, F. Bachelerie, U. Hazan, F. Dautry, J. L. Virelizier, *Institut Pasteur, Paris, France.*

W.C.P.122 Cytokine Modulation of HIV-Reproduction in Monocytes/Macrophages. *Thomas Kaunath*, B. Zorr, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany.*

W.C.P.123 HIV-Associated Changes in Transmembrane Signal Transduction in Macrophages. *Sudhir Gupta*, B. Vayuvegula, *University of California at Irvine, Irvine, CA, U.S.A.*

W.C.P.124 Prevalence and Significance of Antibodies to nef (p27) in HIV-1 Infection. *Rachanee Cheingsong-Popov*, C. Panagiotidi, S. Bowcock, J. Weber, *Royal Postgraduate Medical School, Hammersmith Hospital, Department of Medicine, London, U.K.*

W.C.P.125 Human Herpesvirus 6 (HHV-6) as a Potential Cofactor in AIDS. *Paolo Lusso*, B. Ensoli, F. Negro, S. DeRocco, P. Markham, R. Gallo, et al., *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.126 Mise en évidence de séquences virales HIV chez des sujets Martiniquais à western blot indéterminés. *L. D'Auriol*, C. Neisson-Vernat, F. Barré-Sinoussi, D. Cales-Quist, F. Galibert, N. Monplaisir, *Centre Hayem, Hôpital Saint-Louis, Paris, France.*

W.C.P.127 HIV Encephalitis in Adults and Children. *Rosemay Vazeux*, M. C. Cumont, L. Montagnier, *Institut Pasteur, Paris, France.*

W.C.P.128 Blocking of Infectivity and Immunosuppression by an HIV Envelope-Derived Synthetic Peptide. *W. John Morrow*, T. Kieber, J. Krowka, L. Wing, A. Whalley, L. Berquist, *IDEC Pharmaceuticals Corp., La Jolla, CA, U.S.A.*

W.C.P.129

W.C.P.130 Hypothesis: AIDS Is an Autoimmune Disease Caused by HIV Plus Allogeneic Cells. *Geoffrey W. Hoffmann*, M. D. Grant, *University of British Columbia, Department of Microbiology, Vancouver, BC, Canada.*

W.C.P.131 Quantitation and Modulation of HIV p24 Antigen Content in Intestinal Mucosa. *Safak Reka*, A. Borcich, D. P. Kotler, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

W.C.P.132 Creation of a New Target Cell Type for HIV-1. *Mary Jane Potash*, D. J. Volsky, *St. Luke's-Roosevelt Hospital, Columbia University, New York, NY, U.S.A.*

W.C.P.133 HIV DNA Is Present in a High Percentage of Peripheral Blood Mononuclear Cells in Infected Individuals. *Karen Hsia*, E. LeBlanc, S. A. Spector, *University of California at San Diego, Medical Center, San Diego, CA, U.S.A.*

W.C.P.134 Plasma-Associated Human Immunodeficiency Virus Type-1 (HIV) Is a Marker of Progression of HIV Infection. *Robert W. Coombs*, A. C. Collier, K. Chaloupka, L. Corey, *University of Washington, Children's Hospital, Seattle, WA, U.S.A.*

W.C.P.135 Blocking of Antibody-Enhanced HIV-1 Infection by Recombinant Soluble CD4 (rCD4). *Michael Zeira*, R. A. Byrn, J. E. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A.*

W.C.P.136 HIV-2 Seroconversion in Senegal, West Africa. *Phyllis J. Kanki*, S. Maayan, S. M'Boup, R. Marlink, K. Travers, M. Essex, et al., *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

W.C.P.137 Stress Mediated Induction of HIV Expression from a Chronically Infected Promonocytic Cell Line. *Sharilyn Stanley*, T. M. Folks, A. S. Fauci, *National Institutes of Health, Bethesda, MD, U.S.A.*

W.C.P.138 Anti-Histone H2B Antibodies in HIV-Seropositive Individuals. *W. John Morrow*, A. S. Whalley, C. Leahy, J. Rosenberg, R. B. Stricker, J. A. McCutchan, *IDEC Pharmaceuticals Corp., La Jolla, CA, U.S.A.*

W.C.P.139 Mise en évidence de séquences virales HTLV-I chez des malades neurologiques séronégatifs à W.B. indéterminés. *Nicole Monplaisir*, L. d'Auriol, M. Ouka, F. Galibert, G. Buisson, J. C. Vernant, *Centre départemental de transfusion sanguine, Fort-de-France, Martinique.*

W.C.P.140 Lymphocyte Subpopulations in Mediterranean Kaposi's Sarcoma. *Angelos Hatzakis*, O. Georgopoulou, D. Ferentinou, H. Polychronaki, H. Vassilopoulou-Kada, J. Stratigos, et al., *Athens University Medical School, Athens, Greece.*

Additionnels
Additional

W.C.P.141 Experimental Infection of Cynomolgus Monkeys with HIV-2. *Per Putkonen*, B. Böttiger, K. Warstedt, R. Thorstensson, J. Albert, G. Biberfeld, *National Bacteriological Laboratory, Department of Immunology, Stockholm, Sweden.*

W.C.P.142 Effect of Whole Body Hyperthermia on Cats Infected with Feline Leukemia Virus. *Dennis W. Macy*, P. W. Gasper, S. A. Oulton, N. S. Zeider, E. L. Gillette, R. J. Scott, M. L. McGee, *Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO, U.S.A.*

W.C.P.143 Experimental Infection of Specific Pathogen-Free (SPF) Cats with U.K. Isolates of Feline Immunodeficiency Virus (FIV). *Cherida D. Hopper*, D. A. Harbour, T. J. Gruffydd-Jones, *University of Bristol, Langford, U.K.*

W.C.P.144 A Mouse Model for Investigating HIV-1 Replication. *Barney S. Graham*, N. Wetherall, *Vanderbilt University, Division of Infectious Diseases, Nashville, TN, U.S.A.*

W.C.P.145 Analysis of Guinea Pig Dermal Hypersensitivity to HIV Whole Virus Immunogen. *Michael S. Ascher*, H. Sheppard, *California Department of Health Services, Viral and Rickettsial Disease Laboratary, Berkeley, CA, U.S.A.*

W.C.P.146 Growth Characteristics of Simian Kaposi's Sarcoma in Nude Mice. *Cheng Tsai*, J. C. Sligh, M. D. Woon, *St. Louis University School of Medicine, St. Louis, MO, U.S.A.*

W.C.P.147 Development of a Study Set on the Pathololgy of Simian Retroviral Diseases. *Jorge L. Ribas*, G. Baskin, N. W. King, H. M. McClure, L. J. Lowenstine, M. L. Axthelm, et al., *Walter Reed Army Institute of Research, Division of Retrovirology, Washington, DC, U.S.A.*

W.C.P.148 Biochemical and Biomechanic Substantiation of AIDS Laser Therapy and Trials of Elaboration of Laser-Metabolic Antiviral and Anticancer Trap. *V. Vasilionkaitis, Lithuanian Cancer Research Institute, Vilnius, U.S.S.R.*

Notes



Section
D
Le SIDA et l'individu
AIDS and the Individual

Mercredi 7 Juin
Wednesday, June 7

Session d'affichage
Poster Session

Counseling
Counselling

W.D.P.1 HIV Partner Notification within an Anonymous Testing System. *Evelyn M. Blankenship*, J. M. Owen-O'Dowd, D. H. Jolly, W. J. Petz, R. A. Meriwether, *Division of Health Services, AIDS Control Program, Raleigh, NC, U.S.A.*

W.D.P.2 Intensive HIV Counselling Following Serostatus Notification Associated with a Low Divorce Rate in 122 Serodiscordant Zairian Married Couples. *Kashama Mbuyi*, M. Jingu, M. Mbu, N. Nzila, R. Ryder, *Projet SIDA, Kinshasa, Zaire.*

W.D.P.3 Recently Acquired Sexually Transmitted Diseases (STD) in Homosexuals with HIV Infection. *Johannes R. Bogner*, U. Kronawitter, B. Heinrich, A. Matuschke, H. Fuessl, F. D. Goebel, *Medizinische Poliklinik, Universität München, Munich, Federal Republic of Germany.*

W.D.P.4 Discussing the "Do Not Resuscitate" Issue with AIDS Patients. *Inez Madera*, L. Laviena, P. J. De Caprariis, M. Stehney, J. Stiles, *Sunset Park, Family Health Center of the Lutheran Medical Center, Brooklyn, NY, U.S.A.*

W.D.P.5 AIDS Risk Assessment (ARA) and Counselling Behaviors of Primary Physicians in Community Medical Centers. *Lila Laux*, J. Coverdale, J. Aruffo, J. Thornby, C. Vallbona, *Baylor College of Medicine, Houston, TX, U.S.A.*

W.D.P.6 AIDS Risk Behaviors and AIDS Beliefs in HIV Seroconverters. *Robert W. Wood*, C. Dunphy, L. Krueger, *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A.*

W.D.P.7 Management of Psychological Distress: A Hospital Based "Mutual Aid" Support Group for HIV Seropositive Men. *Jonathan L. Jacobs*, G. Ilaria, P. Reid, S. Miller, V. Lebowitz, *Cornell University Medical College, New York, NY, U.S.A.*

W.D.P.8 The Need for Counselling HIV-1 Tested Individuals in a Rural Community in Uganda. *Anthony Lwegaba*, W. Naamara, M. Wawer, D. Konde-Lule, D. Serwadda, S. Musgrave, *AIDS Control Program, Ministry of Health, Entebbe, Uganda.*

W.D.P.9 Psychological Issues Presented by Self-Identified Bisexual Men with HIV Conditions. *Les L. Gallo-Silver*, A. McCabe, R. Moynihan, V. Raveis, C. Kletecka, J. Segal, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.D.P.10 Psychological Issues Presented by Transfusion Associated HIV-Infected Adults and Their Families. *Les L. Gallo-Silver*, S. Wise-Campbell, R. Moynihan, J. M. W. Gold, V. Raveis, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

W.D.P.11 A Review of HIV Counselling in an Inner-City University Hospital. *Marguerite Barbacci*, W. Wilson, R. Chiasson, *Johns Hopkins University Hospital, Baltimore, MD, U.S.A.*

W.D.P.12 Counselling Training-Current Needs: An Evaluation of AIDS Counselling Training Courses Looking at Change and Content. *Lorraine Sherr*, A. MacCreamer, J. Green, *St. Mary's Hospital, London, U.K.*

W.D.P.13 HIV-precipitated Life Crises: Life Enhancing and Constricting Resolutions. *Karl Zener, Walter Reed Army Medical Center, Washington, DC, U.S.A.*

W.D.P.14 Evaluation of Psychotherapeutic Program in HIV Seropositive Subjects. *Elisa Salame*, L. Rossi, G. Ornelas, J. Sepulveda, *Centro de Información Sobre SIDA-Sur, Mexico City, Mexico.*

W.D.P.15 HIV Counseling and Testing in New York State (NYS) Sexually Transmitted Disease (STD) Clinics. *George T. DiFerdinando, Jr.*, H. G. Chang, D. Morse, D. Murphy, E. Tobey, *New York State Department of Health, Albany, NY, U.S.A.*

W.D.P.16 Helping HIV+ Mothers After the Birth of Their Babies: A Counselling Out-Patient Clinic. *Françoise Weil-Halpern*, S. Blanche, F. Veber, M. Debré, A. M. Duliège, C. Griscelli, *Hôpital des Enfants Malades, Paris, France.*

W.D.P.17 Evaluation of a Meditation and Hypnosis-Based Stress Management Program for Men with HIV. *Paul J. Kelly, Psychology Department, Toronto General Hospital, Toronto, ON, Canada.*

W.D.P.18 The Effects on Parents of Hospitalisation of AIDS Patients. *John F. Quirk*, F. M. Pearce, *University College and Middlesex School of Medicine, Academic Department of Genito-Urinary Medicine, London, U.K.*

W.D.P.19 Counselling HIV Asymptomatic Patients for AZT MRC/INSERM Drug Trial. *Riva Miller*, R. Bor, C. A. Lee, S. C. Lim, M. Johnson, *Haemophilia Centre, Royal Free Hospital, London, U.K.*

W.D.P.20 Lack of Impact of HIV Counselling on Women with STD Checkups to Alter the Likelihood of Subsequent STD Visits. *Gregory W. Hammond*, R. Malazdrewicz, R. Tate, V. Bhayana, K. Elmslie, *University of Manitoba, Cadham Provincial Laboratory, Winnipeg, MB, Canada.*

Minorités
Minorities

W.D.P.21 Racial/Ethnic Differences in Cohorts of Gay/Bisexual Men and Recovering Addicts: Implications for AIDS Prevention Strategies. *Johanne E. Mantell*, A. T. Di Vittis, H. B. Spivack, *Gay Men's Health Crisis Center, Department of Education, New York, NY, U.S.A.*

W.D.P.22 Sources of AIDS Information among Heterosexuals: Asian, Black, Latino and White College Students. *Susan D. Cochran*, V. M. Mays, S. Rothspan, *California State University at Northridge, Department of Psychology, Northridge, CA, U.S.A.*

W.D.P.23 Prevention of HIV Infection in the Mentally Impaired, Featuring West Berlin. *Monika Hachmann*, C. Matthey, E. Dieck, K. Messing, *Arbeitsgruppe AIDS beim Landesinstitut für Tropenmedizin, Berlin, Federal Republic of Germany.*

W.D.P.24 Racial and Ethnic Differences in HIV Seroprevalence in Selected United States Populations. *Marta Gwinn*, R. Selik, D. Allen, L. Petersen, M. St. Louis, T. Dondero, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.D.P.25 Recruitment, Retention and Compliance of Minority Patients and Drug Abusers in a VA Cooperative Study. *Michael Simberkoff*, J. Hamilton, P. Hartigan, G. Drusano, *New York VA Medical Center, New York University, School of Medicine, New York, NY, U.S.A.*

W.D.P.26 Native American Youth and AIDS: AIDS Knowledge and Risk Behavior among Native American Students Entering College. *Kathleen E. Toomey*, K. Tsouhlarakis, G. Lounsberry, L. Fox, *Division of Sexually Transmitted Diseases, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.D.P.27 Close Encounters of an Unsafe Kind: Risky Sexual Behaviors and Predictors among Black Gay and Bisexual Men. *John L. Peterson*, R. F. Fullilove, J. A. Catania, T. J. Coates, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

W.D.P.28 Demographic Profiles of San Francisco Bay Area Black and Latin AIDS Deaths, 1985-1986. *Katherine Haynes*, G. T. S. Chu, N. M. Riordan, D. Tokugawa, R. Fullilove, *MIRA, University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

W.D.P.29 Comparison of the Knowledge, Attitudes, and AIDS-Risk Behavior of Black and White College Students in the Southeastern United States. *Janet S. St. Lawrence*, S. Betts, *Jackson State University, Jackson, MS, U.S.A.*

W.D.P.30 AIDS: Knowledge, Attitudes and Sexual Practices among Hispanics in Chicago: Results of a 1988 City-wide Survey. *Aida L. Giachello*, O. Aguillon, J. Probst, *University of Illinois at Chicago, College of Social Work, Chicago, IL, U.S.A.*

W.D.P.31 Psycho-Social Aspects of Male Prostitution in Washington, DC. *Cudore L. Snell*, A. B. S. Jones, *Howard University, Washington, DC, U.S.A.*

W.D.P.32 Pulling Coyote's Tail: American Indian Sexuality and AIDS Education and Prevention in a Cross-Cultural Setting. *Terry Tafoya*, R. Rowell, L. Beaulieu, A. Green Rush, *National Native American AIDS Prevention Centre, Oakland, CA, U.S.A.*

W.D.P.33 AIDS among Hispanics in the United States. *Alice Kroliczak, Koba Institute, Washington, DC, U.S.A.*

W.D.P.34 HIV Seroprevalence and Its Implications for a Transsexual Population. *Diana L. Alan*, J. Guinan, L. McCallum, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

W.D.P.35 Minority Patient Populations' Knowledge about AIDS. *John Aruffo*, J. Coverdale, C. Vallbona, *Baylor College of Medicine, Department of Psychiatry, Houston, TX, U.S.A.*

W.D.P.36 HIV-Risk Related Sexual Practices among Asian Young Adults. *Vickie M. Mays*, S. D. Cochran, L. Leung, *University of California at Los Angeles, Los Angeles, CA, U.S.A.*

W.D.P.37 Effects of a Spanish-Language Community Intervention in Southwest Texas on Reported HIV Infection Knowledge, Attitudes and Behavior. *Christine Galavotti*, C. Amezcua, A. Ramirez, A. McAlister, R. McCuan, C. Reed, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Les femmes (partie 1)
Women (Part 1)

W.D.P.38 Psychological Aspects of the HIV Infected Women in Rio de Janeiro, Brazil. *Paulo H. P. Longo*, J. L. L. Hanan, L. D. Carvalho Neto, C. A. Morais de Sá, *Gaffrée and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

W.D.P.39 Evaluation of the WPC-333 Female Condom Barrier. *Mary Ann Leeper*, M. Conrardy, J. Henderson, *Wisconsin Pharmacal, Chicago, IL, U.S.A.*

W.D.P.40 Differences in Stage of Presentation and Presenting Symptoms between Women and Men in a Primary Care AIDS Clinic. *Denise J. Ribble*, C. Marte, A. Farber, J. Kelly, C. Keyes, J. Wolbert, *Bellevue Hospital, Community Health Project, New York, NY, U.S.A.*

W.D.P.41 Male Clients of Female Prostitutes in Birmingham, England: A Bridge for Transmission of HIV. *Hilary R. Kinnell*, R. K. G. Griffiths, *Community Medicine Department Central Birmingham Health Authority, Birmingham, U.K.*

W.D.P.42 Educational Needs Assessment for Women at Risk for HIV Through Intravenous Drug Use. *Ann B. Williams, Columbia University, New York, NY, U.S.A.*

W.D.P.43 AIDS Outreach/Pregnant Women and Children. *Patti L. Juliana*, J. H. L. Lowinson, S. Weiner, L. Finnegan, G. Weissman, K. Lewis, et al., *The Albert Einstein College of Medicine, Division of Substance Abuse, Bronx, NY, U.S.A.*

W.D.P.44 HIV/AIDS Public Information Campaign Targetting Women at Risk and Sexually Active Adults. *Kenneth R. Williams*, F. Kroger, M. Shepard, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.D.P.45 Barriers to Comprehending Risk Reduction Messages among High Risk Black and Latina Women. *Rani B. Eversley, University of California at San Francisco, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

W.D.P.46 AIDS Risk among Women with Multiple Sexual Partners: HIV Risk Screening Data from a Family Planning Population. *Rani B. Eversley*, A. Newstetter, *University of California at San Francisco, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

W.D.P.47 Attitudes to and Awareness of AIDS among South African Women. *Dennis Sifris*, S. D. Miller, *HIV Clinic, Johannesburg Hospital, Johannesburg, South Africa.*

W.D.P.48 National Surveillance of AIDS in Women, 1981-1988: A Report from the Centers for Disease Control. *Tedd V. Ellerbrock*, M. E. Chamberland, T. J. Bush, M. F. Rogers, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.D.P.49 Comparison of Black and White Women Tested for Human Immunodeficiency Virus. *Bonnie Coats*, S. H. Simpson, *University of Florida, Gainesville, FL, U.S.A.*

W.D.P.50 Comparing Estimates of HIV Seroprevalence in U.S. Women: Childbearing Women and Military Recruit Applicants. *Shari C. Wasser*, M. Gwinn, M. Pappaioanou, A. Novello, A. Willoughby, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.D.P.51 Unsafe Sexual Behavior and High Risk Partners: Change over Time in a Prospective Study of Women at Risk for AIDS. *Judith B. Cohen*, L. E. Dorfman, T. J. Kelly, M. Rila, D. R. Garcia, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, AWARE, San Francisco, CA, U.S.A.*

W.D.P.52 Emerging Patterns of Drug Use, Sexual Behavior, HIV Infection and STDs in High Risk San Francisco Areas from 1986-1989. *Catherine Lyons*, J. B. Cohen, G. J. Lockett, P. A. McConnell, L. R. Sanchez, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, AWARE, San Francisco, CA, U.S.A.*

W.D.P.53 Behavior Changes to Reduce HIV Transmission Risk in a Prospective Study of Seropositive Women. *Lauren E. Poole*, J. B. Cohen, C. A. Lyons, T. J. Kelly, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A.*

W.D.P.54 Epidemiological Infectiological and Immunological Results from the HIV-Ambulance of the Department of Obstetrics and Gynecology. *Klaus Friese*, S. Rossol, R. Voth, G. Hess, K. H. Meyer zum Büchenfelde, G Knapstein, *University of Mainz, Department of Gynecology and Obstetrics, Mainz, Federal Republic of Germany.*

W.D.P.55 HIV Infection in Heterosexual Women in Copenhagen. *Else Smith*, S. Kroon, J. Gerstoft, B. Kvinesdal, L. Mathiesen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

W.D.P.56 Importance of IVDA as a Risk Factor for HIV Infection in Women of Buenos Aires City. *Jorge A. Benetucci*, S. Multare, L. Martinez Peralta, J. Macias, M. Calello, M. Weissenbacher, *Hospital Muñiz, Buenos Aires, Argentina.*

W.D.P.57 Working with High Risk Women in a National AIDS Prevention Program: The U.S., Puerto Rico and Mexico. *Barbara J. Sowder*, G. Weissman, D. Hunt, V. Brown, L. Argueles, *NOVA Research Company, Bethesda, MD, U.S.A.*

W.D.P.58 Influence of HIV Infection on Pregnancy Decisions. *Ann Sunderland*, S. Holman, G. Moroso, M. Berthaud, H. Mendez, S. Landesman, *State University of New York at Brooklyn, Health Science Center, Brooklyn, NY, U.S.A.*

W.D.P.59 AIDS in Women: Canadian Surveillance Program. *Kimberly D. Elmslie*, P. Nault, *Federal Centre for AIDS, Ottawa, ON, Canada.*

W.D.P.60 A Survey of AIDS-Related Knowledge, Attitudes, Beliefs and Behaviours among Women in New York City. *Angelita B. Balanon*, J. Fordyce, R. Stoneburner, E. Rautenberg, *AIDS Research Unit, New York City Department of Health, New York, NY, U.S.A.*

Consommateurs de drogues par voie intraveineuse (partie 1)
I.V. Drug Users (Part 1)

W.D.P.61 Crack Use and Risk for AIDS among Black Adolescents. *Robert E. Fullilove*, M. T. Fullilove, B. P. Bowser, S. A. Gross, *University of California at San Francisco Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

W.D.P.62 Relationship between HIV Risk Behaviours, Knowledge and Serostatus of Sydney Intravenous Drug Users, 1987. *Alex D. Wodak*, J. Wolk, A. Morlet, J. Gold, *St. Vincent's Hospital, Sydney, Australia.*

W.D.P.63 The Effect of a Needle and Syringe Exchange on a Methadone Maintenance Unit. *Alex D. Wodak*, J. S. Wolk, J. J. Guinan, *St. Vincent's Hospital, Sydney, Australia.*

W.D.P.64 HIV Risk Behaviours of Intravenous Drug Users Presenting to the Albion Street (AIDS) Centre, Sydney, Australia. *Julian Gold*, A. Morlet, J. J. Guinan, S. Darke, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

W.D.P.65 A HIV-Prevention Syringe Exchange Program in Lund, Sweden. Two Years of Observations of the Attenders. *Kerstin Tunving*, B. Andersson, B. Ljungberg, B. Christensson, *University of Lund, Department of Psychiatry and Neurochemistry, Lund, Sweden.*

W.D.P.66 Risk Taking and Risk Reduction among IV Drug Users in 4 U.S. Cities. *Wayne W. Wiebel*, N. L. Altman, D. Chene, R. B. Fritz, *University of Illinois at Chicago, Chicago, IL, U.S.A.*

W.D.P.67 Cessation of Alcohol and Drug Use Disorders in an HIV Sample. *Robert H. Remien*, J. G. Rabkin, J. B. W. Williams, J. G. Gorman, A. A. Ehrhardt, *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A.*

W.D.P.68 Demographic, Behavioral and Clinical Features of HIV Infection in New York City Intravenous Drug Users (IVDUs). *Lawrence S. Brown*, A. Chu, T. Nemoto, B. J. Primm, *Addiction Research and Treatment Corp., Brooklyn, NY, U.S.A.*

W.D.P.69 Needle Sharing among IVDUs where Needles Are Available without Prescription. *David W. Fleming*, B. Sibthorpe, R. McAlister, R. Klockner, J. Gould, *Oregon Health Division, Portland, OR, U.S.A.*

W.D.P.70 Sexual Risk for HIV Transmission in a Gay Male Substance-Abusing Population. *Ronald D. Stall*, J. P. Paul, F. Davis, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, U.S.A.*

W.D.P.71 Absence of Antibody to HIV in Long-Term, Socially Rehabilitated Methadone Maintenance Patients. *David M. Novick*, H. Joseph, T. S. Croxson, E. A. Salsitz, G. Wang, B. L. Richman, et al., *Beth Israel Medical Center, New York, NY, U.S.A.*

W.D.P.72 HIV Status and Risk Behavior in Participating and Non-Participating IV Drug Patients in an HIV Testing/Education Program. *Melodie R. Schaefer*, W. Dorus, C. Pachucki, J. Lentino, D. Schaaff, *Hines Hospital, Loyola University, Hines, IL, U.S.A.*

W.D.P.73 Do Male Intravenous Drug Abusers Give Consistent Responses to Behavioral Questions? *Nicholas H. Wright*, P. Akarasewi, W. Pokapanichwong, S. Vanichseni, K. Choopanya, *Department of Environmental and Community Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, U.S.A.*

W.D.P.74 Predicting Needle-Sharing Behavior of IVDUs in Treatment. *William J. Woods*, A. Abramowitz, J. Guydish, W. Clark, N. Hearst, R. Kiefer, *University of California at San Francisco, San Francisco, CA, U.S.A.*

W.D.P.75 Human Immunodeficiency Virus in Drug Users and Increased Consultation in General Practice. *Carol A. Skidmore*, J. J. K. Roberts, J. R. Robertson, *Edinburgh Drug Addiction Study, Edinburgh, U.K.*

W.D.P.76 HIV Status and Changes in Risk Behaviour among Arrested and Detained Intravenous Drug Abusers in Stockholm 1987-88. *Robert Olin*, K. Käll, *Department of Social Medicine, Karolinska Institute/Kronan Health Centre, Sweden.*

W.D.P.77 Observance et compliance du traitement par zidovudine (AZT) chez les toxicomanes IV infectés par le VIH. *Michael J.P. Finaud*, P. Rambaua, P. Casanova, *Hôpital de la Conception, Service des maladies infectieuses, Marseille, France.*

W.D.P.78 Reducing HIV Transmission by Providing Methadone Treatment to Intravenous Drug Users in Jail. *Herman Joseph*, S. Magura, A. Rosenblum, J. Jeffers, J. Perez, M. Wishart, *New York State Division of Substance Abuse Services, New York, NY, U.S.A.*

W.D.P.79 IVDU and AIDS: More Resistance to Changing Their Sexual than Their Needle Sharing Practices. *Sunita Jain*, N. Flynn, V. Bailey, A. Sweha, D. Ding, W. Sloan, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A.*

W.D.P.80 Use of a Fingerstick Paper-Absorbed Method (PAM) Blood Sample for HIV Serosurveys in Intravenous Drug Users (IVDU). *Kathlenn A. Steger*, B. Comella, J. Forbes, R. McLoughlin, R. A. Hoff, D. E. Craven, *Boston City Hospital, Boston, MA, U.S.A.*

W.D.P.81 Experience with an Anonymous Drop-In HIV Testing Program for Intravenous Drug Users (IVUD) and Their Contacts. *Brianne Comella*, F. Feltch, L. Kunches, J. Harris, K. Steger, D. Craven, *Project TRUST, Boston City Hospital, Boston, MA, U.S.A.*

W.D.P.82 Drug Use and Sexual Behavior in Male Patients at an STD Clinic: Implications for AIDS Prevention. *Paul M. Gibson*, R. Kohn, G. Bolan, *Division of STD Control, Department of Public Health, San Francisco, CA, U.S.A.*

W.D.P.83 Prevention of AIDS in IV Drug Users and Its Consequences on the Epidemic in an Interacting Heterosexual Population. *Mary E. Halloran*, C. J. Struchiner, *Harvard School of Public Health, Department of Population Sciences, Boston, MA, U.S.A.*

W.D.P.84 Role of HIV Infection in Alteration of Pulmonary Function in Intravenous Heroin Addicts (IHA). *Valeriano Foresti*, A. Villa, G. Guareschi, E. Parisio, N. Scolari, A. M. Pediconi, *Fatebenefratelli Hospital, Milan, Italy.*

Additionnels
Additional

W.D.P.85 Sexual Behaviors of Intravenous Drug Users. *Andrew J. Saxon*, D. A. Calsyn, S. Whittaker, G. Freeman, Jr., *Seattle VA Medical Center, University of Washington, Seattle, WA, U.S.A.*

W.D.P.86 Preventive and Counselling Activities of Drug Abuse Centers for HIV-Infected and Non-Infected Drug Addicts. *Eva-Maria Fahrner*, J. Schumann, U. Niemeck, *Institute for Therapy Research, Munich, Federal Republic of Germany.*

W.D.P.87 The Use of Condoms by Prostitutes in Yaounde, Cameroon. *Marcel Monny-Lobe*, D. Nichols, L. Zekeng, R. Salla, L. Kaptue, *Central Hospital Yaounde, Yaounde, Cameroon.*

W.D.P.88 Free Condoms for 15-25 Year Olds: A Pilot Project in Stockholm County, Sweden. *Viveka Urwitz*, L. Mobrandt, *Youth Project, Stockholm AIDS Prevention Programme, Stockholm, Sweden.*

W.D.P.89 Barriers to Continued Condom Use. *Mary-Louise McLaws*, B. Oldenburg, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemology and Clinical Research, Surry Hills, Australia.*

W.D.P.90 Les femmes Africaines devant le SIDA au Zaire. *Wa Nkera Rukarangira*, E. Walu, N. Payanzo, B. G. Schoepf, *Projet CONNAISSIDA, Kinshasa, Zaire.*

W.D.P.91 Self-Reported Sexual Behavior in a Cohort of Homosexual Men: Cross-sectional Analysis at 6 Years. *Brian Willoughby*, M. T. Schechter, B. Douglas, K. J. P. Craib, P. Constance, W. A. McLeod, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*



Section
E

Mercredi 7 juin
Wednesday, June 7

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Session d'affichage
Poster Session

Éducation (partie 2)
Education (Part 2)

W.E.P.1 Structure of Americans' Knowledge Regarding Transmission of HIV Infection: Implications for Targeted Education. *Varda Soskolne*, D. J. Schnell, S. O. Aral, G. S. Bowen, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.E.P.2 AIDS Activism: A Means for Productive Change to Promote Clinical Research and Drug Development. *William R. Bahlman, Lavender Hill Education Project, ACT UP, New York, NY, U.S.A.*

W.E.P.3 SIDA, sexologie et culture en Afrique Centrale. *Brooke G. Schoepf*, W. N. Rukarangira, N. Payanzo, E. Walu, *Projet CONNAISSIDA, Kinshasa, Zaire.*

W.E.P.4 La société sénégalaise face au SIDA. *Martial Barry*, A. Sy, I. Sarr, L. Fall, O. Toure, M. Ba, *Unité de Recherches Épidémiologiques et Statistiques DAST, Ministère du Plan, Dakar, Senegal.*

W.E.P.5 L'information et la prévention du SIDA: Analyse comparative de deux programmes nationaux d'éducation pour la santé en Afrique Centrale et de l'Ouest. *Anne Petitgirard*, S. Chaze, O. Diouf, P. Somse, *Organisation Mondiale de la Santé, GPA/NPS, Geneva, Switzerland.*

W.E.P.6 Computer Simulation as an Aid to Rational Problem Awareness. *José Gonzalez*, M. Myrtveit, L. Vavik, *Aust-Agder Central Hospital, Arendal, Norway.*

W.E.P.7 AIDS Prevention through Outreach Education in Public Sex Environments. *David L. Beckstein*, R. Gunn-Mota, *Santa Cruz AIDS Project, Santa Cruz, CA, U.S.A.*

W.E.P.8 A Multidimensional Approach to Promote Awareness of AIDS in the Gambia. *Sekou Dibba, Medical and Health Department, Banjul, Gambia.*

W.E.P.9 Takin' It to the Streets: The Dynamics of Community Outreach to Combat AIDS. *Patrick Biernacki*, R. S. Broadhead, *Youth Environment Study, Inc., San Francisco, CA, U.S.A.*

W.E.P.10 AIDS Education and Outreach in Toronto Bath Houses. *Bob Tivey, City of Toronto, Department of Public Health, Toronto, ON, Canada.*

W.E.P.11 "MTS BUSTERS": Réactions et pénétration de la population-cible à une intervention novatrice dans les bars. *Réjean Thomas*, J. Lagüe, R. Bastien, J. L. Denis, *Département de santé communautaire de l'hôpital Charles Lemoyne, Greenfield Park, QC, Canada.*

W.E.P.12 Integrating AIDS Education Research into a Drug Treatment Programme. *Judith Phalen*, B. F. Lewis, C. Morrison, J. McCusker, G. Cameron, *Spectrum House Inc., Westboro, MA, U.S.A.*

W.E.P.13 The Use of Indigenous Workers for AIDS Outreach Education/Prevention. *Rebecca S. Ashery, National Institute on Drug Abuse, Rockville, MD, U.S.A.*

W.E.P.14 An Information, Education Workshop to Increase Condom Use among Male Bar Workers in Bangkok. *Werasit Sittitrai*, R. E. Roddy, *Institute of Population Studies, Bangkok, Thailand.*

W.E.P.15 Education Strategies for Health Care Workers and Prisoners in Wales. *Alan Michael George*, C. Griffiths, *The Welsh Office, Cardiff, U.K.*

W.E.P.16 Les services à domicile: La personne d'abord. *Céline Bureau*, A. Duranceau, R. Fortier, C. Gagnon, J. Lachance, *CLSC Métro, Montreal, QC, Canada.*

W.E.P.17 Evaluation of an Educational Program. *Sigrid Michel, Soziopädagogisches Institut, Prien, Federal Republic of Germany.*

W.E.P.18 School and Community Partnership in AIDS Education. *Mark J. Askew, Sydney Catholic Education Office, Sydney, Australia.*

W.E.P.19 Knowledge and Attitudes of Italian Youth about AIDS. *Annalaura Carducci*, M. Frasca, G. Matteelli, A. Calamusa, M. Bendinelli, C. M. Avio, *University of Pisa, Department of Biomedicine, Pisa, Italy.*

W.E.P.20 Preparing Teachers for Adolescent AIDS Prevention Education: Year Two of the Massachusetts Team Training Design. *Gerald W. Davoli*, K. Cranston, S. Rosenfeld, *Massachusetts Department of Education, Quincy, MA, U.S.A.*

W.E.P.21 Pediatric AIDS Sourcebook. *Dorothy J. Allbritten, National Association of Children's Hospitals and Related Institutions, Alexandria, VA, U.S.A.*

W.E.P.22 Knowledge and Attitude to AIDS Shown by Ugandan School Children, Based on a Nationwide Poster Competition. *Olaf Mueller*, J. Lubega, J. Senoga, *League of Red Cross and Red Crescent Societies, Berlin, Federal Republic of Germany.*

W.E.P.23 AIDS Information in French Schools: An Experience and a Sociological View. *François Deniaud*, M. Kalamaridès, S. Crespin, C. Livrozet, D. Moreaux, A. Delamater, et al., *Institut Pasteur, Paris, France.*

W.E.P.24 An HIV/AIDS Education and Training Program for Law Enforcement Officers. *William Mindell*, B. Yaffe, M. Federico, D. Hancock, *City of Toronto Department of Public Health, Toronto, ON, Canada.*

W.E.P.25 Implementing a Mandated Curriculum. *Marion Bacon*, W. McConnell, L. Hyne, A. Craven, *TV Ontario, Toronto, ON, Canada.*

W.E.P.26 AIDS Graduate Education: Eight Semesters, Experience in Teaching an Advanced, Interdisciplinary Course on AIDS. *Robert M. Schmidt, Center for Preventive Medicine and Health Research, San Francisco University and Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A.*

W.E.P.27 World AIDS Day: The Launching of an Extended AIDS Prevention Project. *D. Jayle, F. Aeberhard, J. Lebas, D. Rayon, C. Reynaud, Association pour la Prévention du SIDA, Paris, France.*

W.E.P.28 World AIDS Day: South Africa. *Ruben Sher*, G. Christie, M. Zazayokwe, G. N. Padayachee, *School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.*

W.E.P.29 Readability Analysis of AIDS Brochures and Pamphlets from the U.S.A. *James A. Wells*, R. A. Sell, P. DeFilippes, *Project HOPE, Center for Health Affairs, Washington, DC, U.S.A.*

W.E.P.30 Trends in Condom Promotion Strategies for HIV Prevention: Practical Concepts for Consideration. *Susan G. Saunders*, W. A. Smith, M. L. Ramah, *Academy for Educational Development, Washington, DC, U.S.A.*

W.E.P.31 AIDS Information at the National Center for Health Statistics. *Ann M. Hardy*, R. Wilson, *National Center for Health Statistics, Hyattsville, MD, U.S.A.*

W.E.P.32 Docaids: Un système documentaire VIH-SIDA. *Mark R. Vanderveken*, J. A. Bury, D. Jayle, D. Pluskwa, A. Spoiden, M. A. Bertrand, *Université Catholique de Louvain, Brussels, Belgium.*

W.E.P.33 Evaluation of Prevention Components in the MTPs of Costa Rica, Panama, Trinidad and Tobago, and Uruguay. *Lydia S. Bond*, D. Longshore, R. St. John, F. Zacarias, *Pan American Health Organization, World Health Organization, Washington, DC, U.S.A.*

W.E.P.34 Effecting Attitude and Behavior Change in Regard to HIV Infection. *Ann W. Auleb*, E. Dundas, *San Francisco State University, San Francisco, CA, U.S.A.*

W.E.P.35 Avoiding AIDS: Preventing AIDS While Preserving Sex. *Ronny A. Shtarkshall*, E. Bargai, *The Hebrew University and Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel.*

W.E.P.36 AIDS Education for Adolescents: Who Responds?. *Larry K. Brown*, V. J. Barone, G. K. Fritz, *Rhode Island Hospital, Brown University, Providence, RI, U.S.A.*

W.E.P.37 Stratégies pour un programme pour mineurs internés. *Irani Camargo*, G. A. Cecchini, V. M. Casillas, S. A. Paiva, M. E. L. Fernandes, N. Abbud, *Fundaçao Estadual do Bem Estar do Menor, Sao Paulo, Brazil.*

W.E.P.38 Parental Viewpoints on AIDS Education in the Public Schools of Copenhagen. *Merete M. Lindholm, The School Department of Copenhagen, Copenhagen, Denmark.*

W.E.P.39 Researching Relevant AIDS Education Material for Young People. *Anna O'Sullivan*, P. A. Gillies, *University of Nottingham, Nottingham, U.K.*

W.E.P.40 AIDS Education for Youth: A Randomised Controlled Trial. *Pamela A. Gillies*, K. Bellingham, *University of Nottingham, Nottingham, U.K.*

W.E.P.41 Reconciling Costs, Risk Targetting, and Probable Long-term Outcomes in Information, Education, Communities (IEC) Strategies for Preventing HIV Infections among Women. *Chloe O'Gara*, J. Shelton, R. Landis, *U.S. Government, Agency for International Development, Office of Education, Bureau for Science and Technology, Washington, DC, U.S.A.*

W.E.P.42 An Instructional Program on AIDS Awareness and Prevention in the High School. *Murray C. Newell*, F. Caron, *École secondaire Lemoyne d'Iberville, Longueuil, QC, Canada.*

W.E.P.43 Implementation of a Mandated HIV/AIDS Curriculum in the Public Schools of Washington State. *Gary L. Livingston*, P. Baldwin, A. Downer, *State of Washington, Office on HIV/AIDS, Spokane, WA, U.S.A.*

W.E.P.44 Les appartements de relais thérapeutique et social : accueil post-hospitalier et réinsertion sociale. *Jean Javanni*, J. P. Cordonnier, H. Maurel, A. Michel, A. Sobel, *Aparts, Paris, France.*

W.E.P.45 Health Education for AIDS Prevention among Students. *Carlo Alberto Perucci*, P. Borgia, D. Abeni, G. Todini, *Regional Epidemiologic Unit of Latium Region, Rome, Italy.*

W.E.P.46 "Does AIDS Hurt?": Educating Young Children About AIDS. *Marcia J. Quackenbush*, S. Villarreal, *University of California AIDS Health Project, San Francisco, CA, U.S.A.*

W.E.P.47 School Based AIDS Education in a National Perspective: The Implementation and Preliminary Evaluation of the Israeli Module. *Inon, I. Schenker, Hebrew University Medical Faculty, School of Public Health and Community Medicine, Jerusalem, Israel.*

W.E.P.48 Sex Education Materials to Prevent STD and AIDS in Adolescents. *Matilde De Tafur*, C. De Martin, R. Martinez, *Fundación para el Desarrollo Humano y Social "CRESALC COLOMBIA", Bogotá, Colombia.*

W.E.P.49 A National Strategy Designed to Reduce Barriers Hindering the Implementation of Effective HIV Education for Youth: First Year's Achievements. *Carlton Duncan*, J. Jones, L. Daily, D. Poehler, L. Kann, L. Kolbe, *Division of Adolescent and School Health, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.E.P.50 A National Strategy for the Diffusion of Programs on School Health Education to Prevent the Spread of HIV. *Lisa A. Daily*, J. Jones, W. Jubb, J. Martindale, A. Sheffield, L. Kolbe, *Division of Adolescent and School Health, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.E.P.51 Comparative KAP Studies and STD in Two Different Socio-Economic Groups. *Edward A. Oyewo*, J. Bamgbose, A. Adetugbo, A. Durosinmi, F. Soyinka, *Obafemi Awolowo University, Ile Ife, Nigeria.*

W.E.P.52 Un exemple de collaboration entre médecin et journaliste. *Frank Fontenay*, J. F. Mettetal, F. Edelmann, *ARCAT-SIDA, Paris, France.*

W.E.P.53 Comparison of AIDS Knowledge Levels and Behaviors in Sexually Transmitted Disease (STD) Clinic Patients and Alternative Testing Site (ATS) Clients. *John Moye*, J. Day, B. Dillon, L. Kunches, L. Mofenson, *Massachusetts Department of Public Health, Boston, MA, U.S.A.*

W.E.P.54 Proposed Model of Medical Workshop on AIDS in Africa. *Paolo Crocchiolo*, H. A. Attas, O. J. Khatib, N. Schinaia, A. Othman, H. M. Chwaya, *World Health Organization, Global Programme on AIDS, Geneva, Switzerland.*

W.E.P.55 Proposed Model of Medical Workshop on AIDS in Africa. *Paolo Crocchiolo*, H. A. Attas, O. J. Khatib, N. Schinaia, A. Othman, H. M. Chwaya, et al., *Ospedale Maggiore, Milan, Italy.*

W.E.P.56 Cross-Cultural Obstacles to AIDS Education in the Southern African Context. *Grania M. Christie*, M. Zazayokwe, R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa.*

W.E.P.57 Directions for the Future: A Review of Worldwide AIDS Programs. *Kathryn Carovano*, G. MacDonald, M. Helquist, *Johns Hopkins University, Academy for Educational Development, Washington, DC, U.S.A.*

W.E.P.58 Reported Behavior Change in AIDS Risk Groups. *Christine Galavotti*, A. McAlister, P. Shoemaker, P. Zbylot, D. Vacalis, C. Reed, *Centers for Disease Control, Atlanta, GA, U.S.A.*

W.E.P.59 A Community-wide Survey of AIDS Knowledge, Attitudes, and Preferred Information Sources. *Richard J. Wolitski*, F. Rhodes, N. H. Corby, *AIDS Research and Education Project, Long Beach, CA, U.S.A.*

W.E.P.60 How to Educate 26,000 Health Care Workers in 6 Months. *Barbara Lamberto*, D. M. Evans, *Kaiser Permanente Medical Center, San Francisco, CA, U.S.A.*

W.E.P.61 The Judicious Use of Humor in a Condom Promotion Campaign. *Ann E. Downer*, B. Kelleigh, N. Welch, T. Purdue, *University of Washington, AIDS Education and Training Center, Seattle, WA, U.S.A.*

W.E.P.62 SIDAIDS: A Computerized Telephone AIDS Information and Counselling Service (Telematic). *Margaret Duckett*, P. Billon, L. Champoux, T. Baribeau, R. Descout, *Visiting Scholar, McGill University, Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

W.E.P.63 AIDS Prevention Campaign in Healthy City Project of Lódz. *Tadeusz Górski*, H. Kamieniak, E. Korczynski, *Sanitary-Epidemiological Station, Lódz, Poland.*

W.E.P.64 Extending the Role of AIDS Hotlines in AIDS Prevention Programs in Developed and Developing Countries. *Susan G. Saunders*, M. Helquist, J. Stein, K. Carovano, E. De la Vega, B. Duke, *Academy for Educational Development, Washington, DC, U.S.A.*

W.E.P.65 Knowledge and Perceived Risk of AIDS among the Adult Population of Kinshasa, Zaire. *Susan E. Hassig*, J. T. Bertrand, M. Bakutuvwidi, L. N. Kinavwidi, D. Balowa, C. Chirwisa, *Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, U.S.A.*

W.E.P.66 Secondary School Students as AIDS Health Promoters for an Illiterate Rural West African Village Population. *Diane E. Bennett*, A. Demby, P. Kamara, *Global Programme on AIDS, Health Promotion Unit, Geneva, Switzerland.*

W.E.P.67 AIDS Education in Prisons: A Model. *Loree V. Rose, Educational Consultant/Private Practice, Vancouver, BC, Canada.*

W.E.P.68 Risk Reduction after Outreach Intervention among Intravenous Drug Users. *Meryl Sufian*, S. R. Friedman, A. Neaigus, D. Goldsmith, D. C. Des Jarlais, F. L. Graves, *Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

W.E.P.69 Niveau de connaissance du SIDA dans une population exposée. *Abdelkrim Soulimane*, M. Taleb, S. Sadok, *Service d'Epidémiologie et de Médecine préventive, Sidi-Bel-Abbes, Algeria.*

W.E.P.70 Community Response to the AIDS Epidemic in Four U.S Cities: New York, San Francisco, Los Angeles and Miami. *Embry M. Howell*, R. Andrews, R. McClung, B. Preston, M. Keyes, *SysteMetrics, McGraw-Hill, Washington, DC, U.S.A.*

W.E.P.71 Impact of Pilot Interventions to Reduce the Spread of HIV Infection among High Risk Women in Africa. *Douglas J. Nichols*, M. Monny-Lobe, B. Koumare, A. Neequaye, R. De Buysscher, K. Jesencky, S. Weir, *Family Health International, Durham, NC, U.S.A.*

W.E.P.72 Social and Cultural Constraints in the Control of AIDS and HIV Infection in Sub-Saharan Africa. *Valentino M. Lema, University of Nairobi, Nairobi, Kenya.*

W.E.P.73 The AIDS-Related Knowledge, Attitudes, and Behaviors of Internists and Surgeons: A Comparative Analysis. *Keith Henry*, S. Campbell, S. Eyer, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

W.E.P.74 AIDS and Family Planning in Adolescents. *Hani El Tonsi*, S. Hafez, *El Menia University, Faculty of Medicine, Egypt.*

W.E.P.75 A Study of Knowledge, Attitudes and Beliefs about AIDS among Fourth Year Medical Students of Tanta University, Egypt. *Ibrahim Mohamad Shoaib, Faculty of Medicine, Tanta University, Tanta, Egypt.*

W.E.P.76 Attitudes sur le SIDA et comportement sexuel entre le personnel de la santé à Lisbonne: Une étude exploratoire. *Louise Cunha Teles*, F. Amaro, A. Dantas, *Fundaçao Nossa Senhora do Bom Sucesso, Lisbon, Portugal.*

Section
F
Droit et éthique
Ethics and Law

Mercredi 7 juin
Wednesday, June 7

Session d'affichage
Poster Session

Recherche de traitements et de vaccins
Research for Treatments and Vaccines

W.F.P.1 The Study Giveth, The Study Taketh Away: The Emotional Cost of Stopping an HIV Treatment Trial. *Sheila R. Enders*, N. Flynn, S. Jain, B. Siegel, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A.*

W.F.P.2 Ethical and Clinical Concerns in HIV Research Design. *Robert Kertzner*, G. Todak, J. McKinnon, J. Gorman, A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

W.F.P.3 Ehtical and Legal Issues in Clinical Trials for HIV-Infected Children. *Henry S. Sacks*, J. Martin, *Mount Sinai Medical Center, New York, NY, U.S.A.*

W.F.P.4 Les problèmes éthiques posés par la vaccination anti-HIV. *Patricia Enel*, J. Charrel, M. P. Larher, D. Reviron, C. Manuel, J. L. San Marco, *Laboratoire de Santé Publique, Faculté de Médecine, Marseille, France.*

Prévenir la transmission du VIH : les conflits religieux en matière de santé publique
Preventing HIV Transmission: Religious Conflicts in Public Health

W.F.P.5 Meeting the Moral Challenge of High-Risk Lifestyles: AIDS and Education. *Patricia Illingworth, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

W.F.P.6 The Ethics of Increasing Access to Sterile Syringes as an Approach to Reducing Perinatal HIV Transmission. *Kathleen Nolan, The Hastings Center, Briarcliff Manor, NY, U.S.A.*

W.F.P.7 Promoting a Safer Sex. *Maria E. Paalman*, A. Meyer, *Dutch Foundation for STD Control, Utrecht, Netherlands.*

W.F.P.8 Female Prostitution in Glasgow: Historical Studies. *Stephen T. Green*, D. J. Goldberg, F. A. Green, *Infectious Diseases Unit, Ruchill Hospital, Glasgow, U.K.*

Additionnels
Additional

W.F.P.9 Justesse et justice du traitement du SIDA. *Ruth Murbach, Département des sciences juridiques, Université du Quebec à Montréal, Montreal, QC, Canada.*

W.F.P.10 Practical and Ethical Inadequacies of Partner Restriction as a Method of AIDS Prevention. *Curtis Cole*, L. Spiegel, L. Baker, *New York Blood Center, New York, NY, U.S.A.*

Section
G

Mercredi 7 juin
Wednesday, June 7

Implications internationales
International Issues

Session d'affichage
Poster Session

Aspects cliniques (partie 1)
Clinical Features (Part 1)

W.G.P.1 HIV, HBV, Delta-Agent and T-Pallidium Infections in Two Rural African Areas. *Fausto De Lalla*, G. Rizzardini, P. L. Zeli, E. Rinaldi, D. Santoro, G. Verga, *Ospedale Santa Anna, Divisione Malattie Infettive, Como, Italy.*

W.G.P.2 Marqueurs des rétrovirus HIV et HTLV-I et du virus de l'hépatite B chez les lépreux au Congo. *François Denis*, A. Itoua-N'Gaporo, E. Sassou-Guesseau, G. Léonard, M. Verdier, M. Mounier, *Laboratoire de Virologie, Limoges, France.*

W.G.P.3 A Two-Year Experience in HIV-positive Patients in Hospital de Clinicas de Porto Alegre (Brazil). *Eduardo Sprinz*, M. Kronfeld, M. Motta, *Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

W.G.P.4 A Survey for Unrecognized HIV Infection in a Special STD Clinic in Kuwait. *Rashed Alowaish*, K. Behbehani, *Ministry of Public Health, Safat, Kuwait.*

W.G.P.5 About Monitoring of HIV-Spread in a Developing Country. *Reinhard Bornemann*, C. Richter, F. Bschor, *Institut für Rechtsmedizin, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

W.G.P.6 AIDS-associated Endemic Infectious Diseases in Mexico. *Lourdes Garcia*, R. A. Morales, M. Palacios, E. Bravo, J. L. Valdespino, J. Sepulveda, et al., *General Directorate of Epidemiology, Mexico City, Mexico.*

W.G.P.7 The Impact of HIV Infection on Child Survival in Africa. *Linda A. Valleroy*, J. R. Harris, P. O. Way, *United States Agency for International Development, Washington, DC, U.S.A.*

W.G.P.8 The Natural History of HIV Infection in Twin Pairs Born to HIV+ Women in Kinshasa, Zaire. *Susan E. Hassig*, W. Nsa, T. Manzila, M. Kashamuka, R. Ryder, *Projet SIDA, Tulane University, Kinshasa, Zaire; New Orleans, LA, U.S.A.*

W.G.P.9 Correlation of Hypergammaglobulinemia with Asymptomatic and Symptomatic HIV Infection in a Cohort of African Infants. *Margaret J. Oxtoby*, R. Ryder, W. Nsa, T. Manzila, S. Hassig, F. Behets, et al., *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A.*

W.G.P.10 Infection par HIV-1 dans les 5 maternités de Brazzaville (R.P. Congo): Facteurs de risque maternel et caractéristiques des nouveau-nés *Marc Lallemant*, S. Lallemant-Le Coeur, G. Jourdain, P. Mpele, C. Rouzioux, B. Larouze, et al., *Orstom (Santé/Urbanisation) Commission scientifique 5, Paris, France.*

W.G.P.11 Update on the Transition from Homosexual to Heterosexual AIDS in Trinidad and Tobago. *Farley Cleghorn*, K. Battoo, C. Diaz, M. Francis, B. Hull, C. Bartholomew, *The Caribbean Epidemiology Centre, Port-of-Spain, Trinidad.*

W.G.P.12 Clinical Manifestations of AIDS in Quito, Ecuador. *Roy A. Ringenberg*, R. Sempértegui, J. Moreno, *Ministry of Public Health, Quito, Ecuador.*

W.G.P.13 A Model for AIDS Outpatient Care. *Luiz Loures*, L. Rodrigues, W. Pinto, D. Cardo, D. Greco, F. Rangel, et al., *National Division of STD/AIDS, Ministry of Health, Brasilia, Brazil.*

W.G.P.14 Theory and Method to Develop a Revised Case Definition of AIDS from Empirical Clinical Data. *Bruce G. Weniger*, M. A. Perez, C. Ismael, E. P. Quinhoes, C. F. Ramos Filho, L. A. Loures, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

W.G.P.15 Evaluation of HIV Antibody Tests in Brazil. *Jairo Ivo-Dos-Santos*, D. L. Campos, J. C. Couto-Fernandez, R. M. Passos, L. A. Dias-Carneiro, B. Galvao-Castro, *WHO Collaborating Centre on AIDS, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil.*

Facteurs de risque liés aux MTS (partie 1)
STD Risk Factors (Part 1)

W.G.P.16 Prevalence of HIV Seropositivity among STD Patients in Freetown, Sierra Leone. *Andrew Kosia*, T. K. Kargbo, I. D. Thorlie, N. M. Mansaray, E. J. Mackiu, J. M. Kanu, *Virus Reference Laboratory, Connaught Hospital, Freetown, Sierra Leone.*

W.G.P.17 Targeting Travellers for AIDS Prevention Education. *Ona A. Pela, University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Camden, NJ, U.S.A.*

W.G.P.18 HIV Infection in Heterosexuals from Buenos Aires City Consulting for Venereal Disease. *Martha C. Boxaca*, L. Belli, R. Casoo, M. Gomez Carrillo, O. Libonatti, M. Weissenbacher, et al., *Departamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.*

W.G.P.19 Case Control Study of HIV Positivity among Male Intravenous Drug Addicts in Bangkok. *Nicholas H. Wright*, S. Vanichseni, P. Akarasewi, W. Pokapanichwong, D. Taylor, K. Choopanya, *Department of Environmental and Community Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, U.S.A.*

W.G.P.20 Sexual Behavior and Perceived Risk for AIDS among Bank Employees and Spouses in Kinshasa. *Melinda Moore*, A. Doppagne, S. E. Hassig, L. Piripiri, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A.*

W.G.P.21 Anti-HIV Antibodies in Male and Female Streetwalkers in Buenos Aires City. *Salvador Multare*, M. Zarate, M. Boxaca, L. Martinez Peralta, M. Weissenbacher, *Hospital F. J. Muñiz, Buenos Aires, Argentina.*

W.G.P.22 Comparison of New HIV-2 Isolates by Southern Blot and PCR. *Bette Korber*, P. Kanki, F. Barin, S. M'Boup, M. Essex, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.*

W.G.P.23 Tendency of Anti-HIV Antibodies in Masculine Homosexuals during the last Five in Guadalajara, Jalisco. *Eduardo Vazquez-Valls*, B. M. Torres-Mendoza, M. L. Jauregui-Rios, *Instituto de Patología Infecciosa y Experimental de la Universidad de Guadalajara, Guadalajara, Mexico.*

W.G.P.24 HIV Transmission among Heterosexual Couples in Mexico. *Jaime Sepulveda*, C. Avila, M. Hernandez, E. Dickenson, A. Nazar, P. J. Kanki, *Dirección General de Epidemiología, Mexico City, Mexico.*

W.G.P.25 Male Bisexuality and AIDS. Present Status and Perspectives in Mexico. *Lourdes Garcia*, J. A. Izazola, J. L. Valdespino, C. Magis, C. Ornelas, J. Sepúlveda, et al., *General Directorate of Epidemiology, Mexico City, Mexico.*

W.G.P.26 HTLV-I Seroprevalence Is Increased among Those Living at Low Altitude in Jamaica. *Edward L. Murphy*, E. Maloney, J. P. Figueroa, W. N. Gibbs, M. Holding-Cobham, B. Cranston, et al., *San Francisco General Hospital, San Francisco, CA, U.S.A.*

Épidémiologie
Epidemiology

W.G.P.27 HIV Seroprevalence Survey among High Risk Females at Mombasa, Kenya. *Kishorchandra Mandaliya*, G. Mbugua, G. S. Gachihi, S. Adaw, F. M. Mueke, E. Mupate, *Kenya Ministry of Health, Coast General Hospital, Mombasa, Kenya.*

W.G.P.28 Prevalence of HIV-1 Antibodies in STD Patients. *Hailu Kefene*, D. Bekure, M. Seifu, D. Zewdie, T. Kebede, *Armed Forces Hospital, Addis Ababa, Ethiopia.*

W.G.P.29 HIV-1 Prevalence in Nairobi Sentinel Populations. *Jackoniah O. Ndinya-Achola*, P. Datta, P. Waiyaki,*

W.G.P.30 [illegible] *Patrick C. K. Li*, E. K. Yeoh, W. Y. Lam, F. Y. Leung, Y. F. Ho, Y. H. Lee, et al., *Queen Elizabeth Hospital, Hong Kong.*

W.G.P.31 Approche communautaire de la lutte contre le SIDA en Haïti. *Gabriel A. Thimothe, Programme National de Lutte contre le SIDA, Port-au-Prince, Haiti.*

W.G.P.32 The Family and Care-Giving in Uganda. *E. Maxine Ankrah*, M. Lubega, S. Nkumbi, *Makerere University, Kampala, Uganda.*

Notes

Section
H

Mercredi 7 juin
Wednesday, June 7

Répercussions économiques du SIDA
The Economic Impact of AIDS

Session d'affichage
Poster Session

Pays en voie de développement
Developing Countries

W.H.P.1 Costs of Treating AIDS Patients in Africa. *Marty Makinen*, H. Wong, *ABT Associates Inc., Washington, DC, U.S.A.*

W.H.P.2 Health-Care Cost of AIDS at a Hospital in Canary Islands. *Portela Armas*, P. Jimenez, J. M. Martin, E. Gomez, J. Antolin, A. Acosta, et al., *Hospital Nuestra Señora del Pino, Las Palmas, Spain.*

W.H.P.3 Direct Medical Costs of AIDS in Latin America and the Caribbean: More Cost-Effective Models. *Yamil H. Kouri*, F. Zacarias, D. Shepard, *Harvard, Institute for International Development, Cambridge, MA, U.S.A.*

W.H.P.4 Comparative Costs of AIDS Care in Public and Private Settings. *Yamil H. Kouri*, D. S. Shepard, R. Risek, J. E. Risek, S. Smith, S. Verjee, *Harvard Institute for International Development, Cambridge, MA, U.S.A.*

W.H.P.5 Economic Analysis of AIDS in Puerto Rico. *José I. Alameda-Lozada*, A. González-Martinez, *University of Puerto Rico at Mayaguez, Mayaguez, Puerto Rico.*

W.H.P.6 The Economic and Social Implications of AIDS in an African Setting. *Farzin Davachi*, N. Mayemba, L. Kabongo, K. Ndoko, B. N'Galy, *Department of Pediatrics, Mama Yemo Hospital, Kinshasa, Zaire.*

Méthodologie des coûts
Costing Methodology

W.H.P.7 HIV Case Management Utilizing Information Systems. *Sylvia A. Moreno*, J. Jockush, T. Emanuele, M. T. Karpf, *Parkland Memorial Hospital, Dallas, TX, U.S.A.*

W.H.P.8 Direct Costs and Financing of HIV-Hospital and Community-Based Treatment. *Julia Hidalgo, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A.*

W.H.P.9 Socio-Economic Models to Assess the Economic Impact of HIV Infection. *Joan Kahn, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

W.H.P.10 HIV Infected Hospital Patients in New York State (NYS): The Creation of Longitudinal Information from a Hospital Discharge Data System. *Lloyd F. Novick*, G. I. Kaufman, J. C. Grabau, Y. Han, E. Schmidt, *New York State Department of Health, Center for Community Health, Albany, NY, U.S.A.*

Modèlisation mathématique et prévisions
Mathematical Modelling and Prediction

W.H.P.11 Temporal Changes in Financing of HIV Treatment. *Julia Hidalgo, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A.*

W.H.P.12 A Production Function Approach to Estimating the Aggregate Macroeconomic Impact of AIDS on Central African Economies. *Mead Over*, R. Bulatao, D. Jamison, L. Lau, *The World Bank, Washington, DC, U.S.A.*

W.H.P.13 A Medium-Run Model for the Analysis of the Economic Impact of AIDS in Sub-Saharan Africa. *Gerard Kambou*, S. Devarajan, M. Over, *Northeastern University, Department of Economics, Boston, MA, U.S.A.*

W.H.P.14 The Sociocultural and Economic Impact of AIDS on Society. *Frans M. van den Boom*, H. C. Jager, D. P. Reinking, *The Netherlands Institute of Mental Health, Utrecht, Netherlands.*

W.H.P.15 Decline of AIDS Incidence in Kenya. *L. N. Muthami*, N. N. Agata, G. S. Gachihi, G. G. Mbugua, T. N. Mulandi, *Kenya Medical Research Institute, Nairobi, Kenya.*

W.H.P.16 The Use of Random Graphs in Modelling the Transmission Dynamics of HIV Infection. *Philippe Blanchard*, G. F. Bolz, T. Krüger, *Fakultät für Physik, Universität Bielefeld, Federal Republic of Germany.*

W.H.P.17 A Model for Evaluation of Unknown Number of HIV-Infected Persons. *Anders Blaxhult*, M. Böttiger, *National Bacteriological Laboratory, Stockholm, Sweden.*

W.H.P.18 HIV Carriers: Non-Infectious Initial Interval Slows Up Spread of Virus. *José J. Gonzalez*, P. Davidsen, C. E. Moe, M. G. Koch, *AUST-AGDER Central Hospital, Arendal, Norway.*

W.H.P.19 Short Term Prediction of HIV Infection and AIDS: A Critique of the Cox Report. *Malcolm S. Rees, Harrison Department, Radcliffe Infirmary, Oxford, U.K.*

W.H.P.20 Particular Features of a Lentivirus Epidemic and Their Dynamic Consequences, Such as Transients, Crescents, and a 10 Years' Moratorium for the Detection of Errors. *Michael G. Koch*, J. J. González, D. Dörner, P. Davidsen, J. L'age-Stehr, U. van Welck, *Vårdcentralen, Karlsborg, Sweden.*

W.H.P.21 Proportion of New AIDS Case Reports Attributable to the 1987 CDC Revised Surveillance Case Definition: Canada - United States Differences. *Colin L. Soskolne, University of Alberta, Edmonton, AB, Canada.*

W.H.P.22 Changing Trends in the AIDS Epidemic in Europe. *Angela M. Downs*, R. A. Ancelle-Park, J. B. Brunet, *WHO Collaborating Centre on AIDS, IMET, Paris, France.*

W.H.P.23 Comparison of Epidemiological Data from the AIDS Epidemic in the USA and the FRG. *Bernhard Schwartländer*, R. Schlittgen, J. Dobberstein, M. A. Koch, *AIDS Center, Federal Health Office, Berlin, Federal Republic of Germany.*

W.H.P.24 It Takes Two to Tango but One Infects: Effects of Non-Disclosure on the Under-Estimation of the Perceived Risk of HIV Infection. *Ronny A. Shtarkshall*, T. Awerbuch, *The Hebrew University, Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel.*

W.H.P.25 Deterministic Model of the U.S.A. AIDS Epidemic. *Bruce R. Buzby*, J. W. Ramey, *University of Connecticut Business School, Brookfield, CT, U.S.A.*

W.H.P.26 Utilizing Commercially Available PC Software for the Analysis and Management of Clinical Trials HIV Data. *S. Rae, Mackay, III*, L. Corey, J. Benedetti, *ACTU, University of Washington, Seattle, WA, U.S.A.*

Jeudi
Thursday

le jeudi 8 juin

Synthèse des plénières

Présidents:

L'Honorable Elinor Caplan
Ministre de la santé de l'Ontario
Canada

Claude Evin
Ministre de la solidarité, de la santé et de la protection sociale
France

Conférenciers:

Structure et pathogénèse du VIH

Marie-Paule Kieny
Directrice scientifique associée
Division de la virologie et de l'immunologie
TRANSGENE
France

L'épidémiologie de l'infection par le VIH: progrès récents et questions à résoudre

Peter Piot
Professeur et Chef du Département de microbiologie
Institut de médecine tropicale
Belgique

Perspectives et embûches de la vaccination contre le VIH

Dani P. Bolognesi
Professeur James B. Duke
Département de Chirurgie
Duke University Medical Centre
Etats-Unis

Infection par le VIH dans le contexte d'une épidémiologie changeante des maladies transmissibles sexuellement

King K. Holmes
Professeur et vice-président
Département de Médecine
University of Washington
Etats-Unis

Prévention: peut-on mobiliser ce qui a été appris?

June E. Osborn
Doyen
Ecole de santé publique
University of Michigan
Etats-Unis

"Synthesis"

Chairpersons:

The Honourable Elinor Caplan
Minister of Health of Ontario
Canada

The Minister of Health Claude Evin
Minister of Solidarity, Health and
Social Protection
France

Plenary Speakers:

Structure and pathogenesis of HIV

Marie-Paule Kieny
Associate Scientific Director
Virology and Immunology Division
TRANSGENE
France

The epidemiology of HIV infection: recent advances and remaining questions

Peter Piot
Professor and Head
Department of Microbiology
Institute of Tropical Medicine
Belgium

Prospects and pitfalls of vaccination against HIV

Dani P. Bolognesi
James B. Duke Professor
Department of Surgery
Duke University Medical Centre
U.S.A.

HIV infection in the context of changing epidemiologic patterns of sexually transmitted diseases

King K. Holmes
Professor and Vice-Chairman
Department of Medicine
University of Washington
U.S.A.

Prevention: can we mobilize what has been learned?

June E. Osborn
Dean
School of Public Health
University of Michigan
U.S.A.

11:00 - 12:30

Salle
Room **407A**



Section
A

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde
Round Table

Surveillance de l'épidémie de VIH
Monitoring the HIV Epidemic

Présidents
Chairpersons

James Chin (Switzerland)
Timothy Dondero (U.S.A.)

11:00 **Th.A.O.1**

Program Content:

- Needs and Uses of Serosurveillance
- Choice of sentinel populations
- Blinded versus non-blinded studies
  -methodologic aspects
  -legal and ethical considerations
- Interpretation of data of non-representative populations
- Serosurveys using probability samples

Panelists:

O. Noel Gill, London, U.K.
Steve Lwanga, Geneva, Switzerland.
Lloyd Novick, Albany, NY, U.S.A.

11:00 - 12:30

Salle / Room **408A**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde / Round Table — **Modélisation mathématique / Mathematical Modelling**

Présidents / Chairpersons — Roy M. Anderson (U.K.), Ron Brookmeyer (U.S.A.)

11:00 **Th.A.O.2**

Program Content:

- Short-term prediction and back calculation
- Incubation period and infectivity
- Models of transmission dynamics
- Demographic impact
- Data needs and access to data bases
- Research needs

Panelists:

Carlos Castillo-Chavez, Ithaca, NY, U.S.A.
James Curran, Atlanta, GA, U.S.A.
John Koran, Atlanta, GA, U.S.A.
G. Medley, London, U.K.
Andrew Moss, San Francisco, CA, U.S.A.

11:00 - 12:30

Salle / Room **408BC**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Transmission périnatale / Perinatal Transmission**

Présidents / Chairpersons: R. G. Choto (Zimbabwe), Peter Piot (Belgium), Pauline A. Thomas (U.S.A.)

11:00 **Th.A.O.3** Vertical Transmission of HIV Infection: European Collaborative Study Update. *Catherine Peckham, A. E. Ades, M. L. Newell, European Collaborative Study, Institute of Child Health, London, U.K.*

11:15 **Th.A.O.4** HIV Antibody Negative Children with Positive Virology: Observations from the European Collaborative Study. *Marie-Louise Newell, C. S. Peckham, A. E. Ades, European Collaborative Study, Department of Paediatric Epidemiology, Institute of Child Health, London, U.K.*

11:30 **Th.A.O.5** Breast Feeding and HIV-1 Transmission. *Subhash K. Hira*, U. Mangrola*, C. Mwale*, N. Mwansa*, C. Chintu*, P. Perine**, et al., *University Teaching Hospital, Lusaka, Zambia; **Uniformed Services University of Health Sciences, Bethesda, MD, U.S.A.*

11:45 **Th.A.O.6** High Perinatal HIV Rates with Prematurity or Low Anti-gp120. *James J. Goedert*, H. Mendez**, A. Willoughby*, S. H. Landesman*, *National Cancer Institute, Rockville, MD; **State University of New York Health Science Center, Brooklyn, NY, U.S.A.*

12:00 **Th.A.O.7** Early Predictors and Rate of Perinatal HIV Disease. *Pauline A. Thomas, The New York City Perinatal HIV Transmission Study Group, Director, AIDS and HIV Surveillance, New York City Department of Health, New York, NY, U.S.A.*

12:15 **Th.A.O.8** Maternal Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus-1 (HIV-1). *Gwendolyn B. Scott, C. Hutto, C. Mitchell, W. P. Parks, University of Miami, School of Medicine, Department of Pediatrics, Miami, FL, U.S.A.*

11:00 - 12:30

Salle / Room **401ABC**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique — **Thérapie : la ribavirine et les autres médicaments anti-VIH**

Specialty Session — **Therapy: Ribavirin and Other Anti-HIV Drugs**

Présidents / Chairpersons — Clyde Crumpacker (U.S.A.), Anita Rachlis (Canada)

11:00 **Th.B.O.1** Phase I Trial of Oral Ribavirin in High Risk Patients for AIDS. Richard B. Roberts*, R. Makuch**, K. Jurica*, *Cornell University Medical College, New York, NY; **Yale University, School of Medicine, New Haven, CT, U.S.A.

11:15 **Th.B.O.2** Phase I/II Trial of Ribavirin + Isoprinosine in Asymptomatic HIV Viremic Gay Men. Richard S. Schulof*, G. L. Simon*, D. M. Parenti*, M. B. Sztein*, W. A. Meyer**, H. Paxton**, et al., *The George Washington University Medical Center, Washington, DC; **Maryland Medical Laboratory, Baltimore, MD, U.S.A.

11:30 **Th.B.O.3** 2', 3' Dideoxycytidine (DDC) in the Treatment of Patients with AIDS and ARC. Michael S. Gottlieb*, J. Galpin*, J. Thompkins*, D. E. Wilson**, L. Donatacci**, W. Soo**, *Porton Medical Group, Sherman Oaks, CA; **Hoffmann-La Roche, Nutley, NJ, U.S.A.

11:45 **Th.B.O.4** Escalating Dose Phase I Study of Intravenous and Oral 2', 3'-Dideoxyinosine (ddI) in Patients with AIDS or ARC. Robert Yarchoan, R. V. Thomas, J. M. Pluda, N. R. Hartman, D. G. Johns, S. Broder, et al., National Cancer Institute, Bethesda, MD, U.S.A.

12:00 **Th.B.O.5** Pharmacokinetic Studies of Recombinant Soluble CD4 in Patients with AIDS and AIDS Related Complex. James O. Kahn*, A. J. Davis**, L. A. Kaplan*, J. Groopman**, S. Sherwin***, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA; **New England Deaconess Hospital, Harvard Medical School, Boston, MA; ***Genentech Inc., South San Francisco, CA, U.S.A.

12:15 **Th.B.O.6** Escalating Dose Tolerance of Recombinant Soluble CD4 in Humans. Robert T. Schooley*, D. D. Ho**, P. Gaut**, M. R. Tierney*, J. Schindler***, S. Henochowicz****, et al., *Massachusetts General Hospital, Boston, MA; **Cedars-Sinai Medical Center, Los Angeles, CA; ***Biogen, Inc., Cambridge, MA; ****NIAID, AIDS Program, Bethesda, MD, U.S.A.

11:00 - 12:30

Salle / Room **404AB**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Test de dépistage par réaction en chaîne des polymérases**

Specialty Session **PCR Diagnostic Test**

Présidents / Chairpersons
Pedro Cahn (Argentina)
François Catalan (France)
Denis Phaneuf (Canada)

11:00 **Th.B.O.7** A Method for Quantitating Relative Amounts of HIV Proviral Sequences in PBMCS by the Polymerase Chain Reaction (PCR). *Shirley Y. Kwok, D. Kellogg, J. J. Sninsky, Cetus Corp., Department of Infectious Diseases, Emeryville, CA, U.S.A.*

11:15 **Th.B.O.8** Comparison of PCR Analysis and Culture in the Detection of HIV-1 Infection in Hemophiliacs. *J. Brooks Jackson*, K. Sannerud*, S. Kwok**, J. Sninsky**, J. Hopsicker*, H. H. Balfour, *University of Minnesota, Minneapolis, MN; **Cetus Corp., Emeryville, CA, U.S.A.*

11:30 **Th.B.O.9** Evaluation of the Polymerase Chain Reaction (PCR) in a Well-Characterized Cohort of Homosexual and Bisexual Men: PCR-Positive, HIV-Antibody Negative Results Are Rare. *Alan R. Lifson*, M. Stanley**, P. M. O'Malley*, J. Pane**, G. W. Rutherford*, P. Sohmer**, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco; **Pathology Institute, Berkeley, CA, U.S.A.*

11:45 **Th.B.O.10** Detection of HIV-1 DNA in Peripheral Blood by Polymerase Chain Reaction (PCR) and Non-Radioactive Oligonucleotide Probes. *Karl E. Adler*, L. J. Bechtel**, B. Conway**, J. C. Kaplan**, M. S. Hirsch**, *Dupont Medical Products, Billerica; **Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A.*

12:00 **Th.B.O.11** Simultaneous Detection of HTLV-I in AIDS Patients by PCR. *Barun K. De, A. Srinivasan, Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

12:15 **Th.B.O.12** A Microtiter-Based DNA Sandwich Assay for the Detection of HIV-1 in Clinical Samples. *George H. Keller, D. P. Huang, L. Jagodzinski, C. Overholt, D. Petersen, M. Manak, Biotech Research Laboratories, Inc., Rockville, MD, U.S.A.*

11:00 - 12:30

Salle
Room **407B**

Section
B

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Colloque **Infections respiratoires chez les consommateurs de drogues par voie intraveineuse**

Symposium **Respiratory Infection in IV Drug Users**

Présidents Jerome Ernst (U.S.A.)
Chairpersons G. Visco (Italy)

11:00 **Th.B.O.13** Pneumonies bacteriennes et Virales au Cours du SIDA chez les utilisateurs de drogue par voie intraveineuse (IVDU). *Yves Mouton, Service régional des maladies infectieuses, Centre Hospitalier, Tourcoing, France.*

11:15 **Th.B.O.14** Fungal Pneumonia. *Giuseppe Visco, Università di Roma, Rome Italy.*

11:30 **Th.B.O.15** Mycobacterial Infections in HIV-Infected IV Drug Addicts. *W. Stille, Klinikum der Johann Wolfgang Goethe-Universität, Zentrum der Inneren Medizin, Frankfurt, Federal Republic of Germany.*

11:45 **Th.B.O.16** PCP and Drug Abusers: The Bronx Lebanon Experience. *Jerome Ernst, The Bronx-Lebanon Hospital Center, Division of Pulmonary and Infectious Diseases, Bronx, NY, U.S.A.*

11:00 - 12:30

Salle / Room **403ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session: **Éléments de base en immunologie / Basic Immunology (Part 3)**

Présidents / Chairpersons: Jean-Claude Gluckman (France), José Menezes (Canada), John Sullivan (U.S.A.)

11:00 **Th.C.O.1** Selective Signaling Defect Via the CD3/TCR Complex in T Cells from HIV-Infected Men. *R. Gruters, C. J. M. van Noesel, F. G. Terpstra, P. T. A. Schellekens, R. A. W. van Lier, F. Miedema, Central Laboratory, Netherlands Red Cross Blood Transfusion Service and the University of Amsterdam, Laboratory of Experimental and Clinical Immunology, Amsterdam, Netherlands.*

11:15 **Th.C.O.2** Chemically Induced CD4 Mutants Provide Evidence for Additional Sites Involved in HIV-1 Infection and Syncytia. *Hana Golding*, K. Hillman*, J. Manischewitz*, R. Seeman*, J. Hooley**, *LDV, DV, CBER, FDA; **NIAID, Bethesda, MD, U.S.A.*

11:30 **Th.C.O.3** Human Monoclonal Antibodies to Variant and Conserved Epitopes of HIV Envelope Glycoproteins. *James E. Robinson, D. Holton, S. Pancheco, J. Liu, H. McMurdo, Louisiana State University Medical School, Department of Pediatrics, New Orleans, LA, U.S.A.*

11:45 **Th.C.O.4** A Hybridoma Producing Human Monoclonal IgG Neutralizes the HIVIIIb Isolate *In Vitro*. *Takashi Kawamura*, D. Lake**, E. Robinson***, E. Petersen**, W. Mitchell***, E. Hersh**, *Teijin Institute for Biomedical Research, Tokyo, Japan; **University of Arizona Department of Hematology and Oncology, Tucson, AZ; ***Department of Pathology, Vanderbilt University, Nashville, TN, U.S.A.*

→

12:00 **Th.C.O.5** Detection of Anti-CD4 Autoantibodies in the Sera of HIV-Infected Patients Using Recombinant Soluble CD4 Molecules. *Vida Chams, T. Jouault, E. Fenouillet, J.-C. Gluckman, D. Klatzmann, Hôpital de la Pitié-Salpêtrière, Laboratoire de Biologie et Génétique des déficits immunitaires, CERVI, Paris, France.*

12:15 **Th.C.O.6** Antibody Response to the HIV-1 Regulatory Gene Products nef, vif and vpr in HIV-1 Infected Seronegative Individuals. *Jean-Claude Ameisen*, B. Guy**, M. Loche***, S. Chamaret****, Y. Mouton*****, A. Capron*, et al., *CIBP Institut Pasteur, Lille; **Transgène SA, Strasbourg, France; ***Université de Genève, Geneva, Switzerland; *****CHU Tourcoing, Tourcoing, France.*

11:00 - 12:30

Salle / Room **407C**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium

Aspects pathologiques de l'infection par le VIH
Pathological Aspects of HIV Infection

Présidents / Chairpersons: Jean Latreille (Canada); Paul Racz (Federal Republic of Germany)

11:00 **Th.C.O.7** Distinct Histologic Lymph Node Changes following HIV Infection in Adults. *N. L. Harris, Massachusetts General Hospital, Boston, MA, U.S.A.*

11:15 **Th.C.O.8** Detection of HIV in Lymph Nodes. *Paul Racz, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Federal Republic of Germany.*

11:30 **Th.C.O.9** In situ Hybridization for Detection of HIV Genome. *Peter Biberfeld, Karolinska Institute, Stockholm, Sweden.*

11:45 **Th.C.O.10** Biological Functions of Human Monoclonal Antibodies to HIV. *S. Zolla-Pazner, VA Medical Center, New York, NY, U.S.A.*

11:00 - 12:30

Salle / Room **410ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session

Mise au point de médicaments : utilisation des molécules CD-4

Drug development: Use of CD4 Molecules in AIDS Therapy

Présidents / Chairpersons: Sam Broder (U.S.A.); Volker Erfle (Federal Republic of Germany); Sabih R. Khan (Canada)

11:00 **Th.C.O.11** Retroviral Vectors Expressing Soluble CD4: A Potential Gene Therapy for AIDS. *Richard A. Morgan*, D. J. Looney***, D. D. Muenchau*, F. Wong-Staal**, R. C. Gallo**, W. F. Anderson*, *Laboratory of Molecular Hematology, National Heart, Lung, and Blood Institute and **Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda; ***Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

11:15 **Th.C.O.12** Specific Anti-HIV Activities of a Recombinant Human CD4-*Pseudomonas* Exotoxin Hybrid Toxin. *Edward A. Berger*, V. K. Chaudhary**, K. A. Clouse***, D. J. FitzGerald**, I. Pastan**, B. Moss*, *Laboratory of Viral Diseases, NIAID; **Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD; ***Georgetown University, Washington, DC, U.S.A.*

11:30 **Th.C.O.13** Inhibition of the Infectivity of HIV-1 and HIV-2 by Soluble rCD4: Differential Sensitivity to Soluble rCD4. *Hiroaki Mitsuya*, S. Hayashi*, D. L. Looney**, S. M. Chamow***, F. Wong-Staal**, S. Broder*, *The Clinical Oncology Program; **Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD; ***Genentech, Inc., South San Francisco, CA, U.S.A.*

→

11:45 **Th.C.O.14** The Development of Immunotoxins Specific for HIV-Infected Cells. *Mark A. Till*, V. Ghetie*, T. Gregory**, J. W. Uhr*, D. Capon**, E. S. Vitetta*, *University of Texas, Southwestern Medical Center at Dallas, Department of Microbiology, Dallas, TX; **Genentech, Inc., South San Francisco, CA, U.S.A.*

12:00 **Th.C.O.15** Designing CD4 Immunoadhesins for AIDS Therapy. *Daniel J. Capon*, S. Chamow*, J. Mordenti*, H. Mitsuya**, R. Byrn***, C. Lucas*, et al., *Genentech, Inc., South San Francisco, CA; **The Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; New England Deaconess Hospital, Harvard Medical School, Division of Hematology-Oncology, Boston, MA, U.S.A.*

12:15 **Th.C.O.16** Effect of Recombinant Soluble CD4 in Rhesus Monkeys Infected with Simian Immunodeficiency Virus of Macaques. *Norman L. Letvin*, M. Watanabe*, K. A. Reimann*, T. Liu**, R. A. Fisher**, P. A. DeLong*, *Harvard Medical School, New England Regional Primate Research Center, Southborough; **Biogen Research Corp., Cambridge, MA, U.S.A.*

11:00 - 12:30

Salle / Room **409ABC**



Section **D**

Jeudi 8 juin
Thursday, June 8

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Consommateurs de drogues par voie intraveineuse (partie 1)**

Specialty Session **Injection Drug Users (Part 1)**

Présidents / Chairpersons
Robert G. Covell (U.K.)
François Lamothe (Canada)
V. Pushyachind (Thailand)

11:00 **Th.D.O.1** What Thai Intravenous Drug Abusers Say about Their Beliefs and Behavior: Report of a Series of Focus Group Discussions. *Waranee Pokapanichwong*, D. Douglas**, N. Wright***, S. Vanichseni****, K. Choopanya****, *Cornell University, Ithaca, NY, U.S.A.; **Prog. Approp. Tech. Hlth.; ***Division of Epidemiology, Ministry of Public Health; ****Bangkok Metropolitan Administration, Bangkok, Thailand.*

11:15 **Th.D.O.2** Temporal Pattern of Cocaine Use and AIDS in Intravenous Drug Users in Methadone Maintenance (MM). *Diana Hartel, E. E. Schoenbaum, P. A. Selwyn, E. Drucker, W. Wasserman, G. H. Friedland, et al., Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

11:30 **Th.D.O.3** Effects of Changes in Drugs Injected on Drug Using Environments and on Risk Reduction among IV Users. *Samuel R. Friedman*, C. Sterk*, M. Sufian*, D. C. Des Jarlais**, *Narcotic & Drug Research, Inc.; **New York State Division of Substance Abuse, New York, NY, U.S.A.*

11:45 **Th.D.O.4** Endocarditis, Subcutaneous Abscesses, and Other Bacterial Infections in Intravenous Drug Users and Their Association with Skin-Cleaning at Drug Injection Sites. *John K. Watters*/**, F. Herb*, P. Case**, D. Pettiti*, *University of California at San Francisco; **Urban Health Study, San Francisco, CA, U.S.A.*

12:00 **Th.D.O.5** Methadone Maintenance and Behavior Change in Seropositive Drug Abusers: The San Francisco General Hospital Program for AIDS Counseling and Education (PACE). *James L. Sorensen, S. L. Batki, D. R. Gibson, R. Dumontet, S. Purnell, San Francisco General Hospital, University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

12:15 **Th.D.O.6** Intravenous Drug Users and Maintenance of Behaviour Change. *Don C. Des Jarlais*, S. Tross**, A. Abdul-Quader**, A. Kouzi**, S. R. Friedman**, *New York State Division of Substance Abuse Services; **Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

11:00 - 12:30

Salle / Room **411A**



Section **D**

Jeudi 8 juin
Thursday, June 8

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Prostitution**
Specialty Session **Prostitution**

Présidents / Chairpersons: Judith B. Cohen (U.S.A.), Pamela Gillies (U.K.), Ibra Ndoye (Senegal)

11:00 **Th.D.O.7** The Impact of an Educational Program on HIV Infection among Prostitutes. *James R. Foreit*, A. Tejada**, J. Alarcon**, J. Piscoya**, L. Varela*, *The Population Council; **Universidad Nacional Mayor de San Marcos, Lima, Peru.*

11:15 **Th.D.O.8** Young Male Prostitutes: Safe and Unsafe Sex and AIDS Knowledge. *Richard R. Pleak, H. F. L. Meyer-Bahlburg, HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A.*

11:30 **Th.D.O.9** Women Working as Prostitutes: Participatory/Consensus-Based Planning for Provision of Mobile Prevention, Risk Reduction, and Seroprevalence Activities. *Clay P. Stephens, B. J. Hayes, R. Adams, M. Gross, Massachusetts Department of Public Health, AIDS Office, Boston, MA, U.S.A.*

11:45 **Th.D.O.10** The Agglutinating Approach to Joint STD/AIDS Prevention and Control in Female Sex Workers in the Dominican Republic. *Ernesto Guerrero, S. Rosario, E. A. De Moya, C. Vólquez, R. Alcántara, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

12:00 **Th.D.O.11** Evaluation of Key Messages to Increase the Use of Condoms in Sex Workers. A Quasi-Experimental Study. *José Luís Valdespino*, J. A. Izazola*, J. Sepúlveda*, M. Ramah**, M. L. Garcia*, et al., *Ministry of Health, General Directorate of Epidemiology; **AIDSCOM, Mexico City, Mexico.*

12:15 **Th.D.O.12** The Development of Micro-Enterprises as Work Alternatives for Female Sex Workers in the Dominican Republic. *Ernesto Guerrero, M. C. Abenia, S. Rosario, E. A. De Moya, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic.*

11:00 - 12:30

Salle
Room **411B**



Section
E

Jeudi 8 juin
Thursday, June 8

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Atelier — **Innovations en matière de prévention et d'éducation au sujet du SIDA**

Workshop — **Innovations in AIDS Education and Prevention**

Présidents / Chairpersons — Rebecca Asmery (U.S.A.)
Weraist Sittitrai (Thailand)
Anne V. Whyte (Canada)

11:00 **Th.E.O.1** Innovative AIDS Education for Adolescents: Strategies for Behavior Change. *Beverlie Conant Sloane, M. Dyer Chamberlain, K. Berry, R. Van Treuren, Dartmouth College, Department of Health Education, Hanover, NH, U.S.A.*

11:10 **Th.E.O.2** Developments of the National AIDS Telephone Help Line in the Netherlands, 1985-1988. *Monique A. C. M. Middelhoff, J. L. Roosjen, [illegible]ch National Committee on AIDS Control (NCAB), Amsterdam, Netherlands.*

11:20 **Th.E.O.3** Equipping Kinshasa Public Buses with a Cassette Playback System Is Effective in an AIDS Prevention Campaign. *Kitoto K. Kalombo*, B. N'Galy*, B. France**, T. Eke***, R. Eiger**, N. Nzuzi****, *Coordination Bureau, National AIDS Progamme, Kinshasa, Zaire; **Population Services International, Washington, DC, U.S.A.; ***Human Sciences Research Center; ****GAPPS Agency, Kinshasa, Zaire.*

11:30 **Th.E.O.4** AIDS Street Nurses. *Michael L. Rekart, M. McCarthy, C. Farrow, STD Control, British Columbia Ministry of Health, Vancouver, BC, Canada.*

11:40 **Th.E.O.5** The Futures Workshop as a Method for Mobilization and Coordination in AIDS Prevention. *Viveka Urwitz, T. Juvall, M. Öhgren, P. Sennerfeldt, Youth Project, Stockholm AIDS Prevention Programme, Stockholm, Sweden.*

11:50 **Th.E.O.6** Bleachman: A Super-Hero Teaches AIDS Prevention. *Les G. Pappas, San Francisco AIDS Foundation, San Francisco, CA, U.S.A.*

12:00 **Th.E.O.6a** Incorporating AIDS Education into Family Planning. *Luis R. Varela, The Population Council, New York, NY, U.S.A.*

11:00 - 12:30

Salle
Room **406A**

Section
G & B

Jeudi 8 juin
Thursday, June 8

Implications internationales/
Aspects cliniques
International Issues/
Clinical Aspects of AIDS

Séance thématique **SIDA et tuberculose**
Speciality Session **AIDS and Tuberculosis**

Présidents / Chairpersons: Ngaly Bosenge (U.S.A.), D. Kochi (Switzerland), Grégoire Noël (Canada)

11:00 **Th.G.O.1** AIDS and Tuberculosis (TB) in the USA. *M. Miles Braun, W. Heyward, C. Ciesielski, R. Berkelman, R. Byers, A. Bloch, Centers for Disease Control, Atlanta, GA, U.S.A.*

11:15 **Th.G.O.2** Effect of Tuberculosis as a New AIDS Definition Criteria on Surveillance Data. *Jordi Casabona, T. Salas, A. Bosch, A. Segura, Epidemiology Section, Generalitat de Catalunya, AIDS Program, Barcelona, Spain.*

11:30 **Th.G.O.3** Tuberculosis and AIDS: Our Experience. *Jorge A. Benetucci, L. Astarloa, J. Gonzalez Montaner, E. Abbate, J. H. Da Bouza, et al., Hospital Francisco J. Muñiz, Buenos Aires, Argentina.*

11:45 **Th.G.O.4** The Impact of Human Immunodeficiency Virus (HIV) on Tuberculosis in Zambia: A Cross-Sectional Study. *Alison M. Elliott*, N. Luo*, G. Tembo*, G. Steenbergen**, P. Nunn***, K. McAdam***, et al., *University Teaching Hospital; **Ministry of Health, Lusaka, Zambia; ***London School of Hygiene and Tropical Medicine, London, U.K.*

12:00 **Th.G.O.5** A Study of HIV Infection in Association with Tuberculosis Patients Seen in Infectious Diseases Hospital (I.D.H.), Nairobi. *Daniel K. Kibuga*, S. N. Gathua*, P. P. Nunn**, *Infectious Diseases Hospital, Nairobi, Kenya; **London School of Tropical Medicine and Hygiene, London, U.K.*

12:15 **Th.G.O.6** Association of Tuberculosis and HIV Infection in Zimbabwe. *William G. W. Legg, M. Mahart, S. Houston, P. Neill, C. S. Ray, E. Marowa, Harare City Health Department, Harare, Zimbabwe.*

11:00 - 12:30

Salle / Room **406BC**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Colloque / Symposium

Recherches sur la sexualité humaine
Human Sexuality Research

Présidents / Chairpersons: Gilles Bibeau (Canada)
Edward S. Herold (Canada)

11:00 **Th.G.O.7** Reliability and Validity Issues in the Assessment of Sexual Behaviour. *Joseph A. Catania, Center for AIDS Prevention Research, University of California at San Francisco, San Francisco, CA, U.S.A.*

11:15 **Th.G.O.8** Sexuality Research in Zaire. *Namagosi Lusakulira, Kinshasa, Zaire.*

11:30 **Th.G.O.9** Sexuality Research in Thailand. *Werasit Sittitrai, Institute of Population Studies, Chulalongkorn University, Bangkok, Thailand.*

11:45 **Th.G.O.10** Sexuality Research in Brazil. *Arletty Pinel, Centro de Referência e Treinamento-AIDS, Sao Paulo, Brazil.*

12:00 **Th.G.O.11** Research on Human Sexuality in Sub Saharan Africa. *Lawrence Adeokun, Global Programme on AIDS, World Health Organization, Geneva, Switzerland.*

11:00 - 12:30

Salle / Room **411C**

Section **H**

Jeudi 8 juin
Thursday, June 8

Répercussions économiques du SIDA
The Economic Impact of AIDS

Séance thématique / Speciality Session: **Affectation des ressources et processus décisionnels** / **Resource Allocation and Decision-Making**

Présidents / Chairpersons: Pierre-Marc Johnson (Canada); Denise Laberge-Ferron (Canada); Phillip Lee (U.S.A.)

11:00 **Th.H.O.1** Resource Allocation by Donor Countries: to High Prevalence or Low prevalence? *Edward Elmendorf, The World Bank, New York, NY, U.S.A.*

11:15 **Th.H.O.2** Allocation de ressources decisions politiques et contraintes. *Pierre-Marc Johnson, Faculté de droit et Centre de médecine, éthique et droit, Montréal, QC, Canada.*

11:30 **Th.H.O.3** Data Gaps in Modeling AIDS Service Utilization and Costs. *Linda Bilheimer, Mathematica Policy Research, Inc., Washington, DC, U.S.A.*

11:45 **Th.H.O.4** Comparative Evaluation of the Use of NGO's for Resource Allocation. *Steven Manning, AIDS Committee of Toronto, Toronto, ON, Canada.*

12:00 **Th.H.O.5** The Financial Impact of Integrated Care Delivery. *Cliff Morrison, The AIDS Health Service Program, University of California at San Francisco, CA, U.S.A.*

11:00 - 12:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

Jeudi 8 juin
Thursday, June 8

Programme international-espagnol

Spanish International Programme

11:00 Introduction: *Dr. Guy Lonergan*

11:03 **Th.I.V.1** ***"PUPPETS AGAINST AIDS"***

Vidéo de/Video by:
Gary Friedman, African Research and Educational Puppetry Programme
Année/Year: 1989

11:08 **Th.I.V.2** ***"SIDA UN PROBLEMA DE TODOS"***

Vidéo de/Video by:
Daniel Villalobos
Année/Year: 1988

11:38 **Th.I.V.3** ***"OJOS QUE NO VEN"***

Vidéo de/Video by:
Latino AIDS Project Instituto Familiar de la Raza
Année/Year: 1987

Trois voies pour l'éducation communautaire et l'éducation des jeunes. D'Afrique du Sud, un film vidéo qui dépeint l'emploi de marionnettes géantes pour décrire le SIDA. Du Chili, un film gouvernemental d'information sur le SIDA et sur la transmission du VIH mettant en scène des jeunes et un médecin. Des États-Unis, la transposition du SIDA sur le petit écran dans des téléromans explorant les relations sociales au sein de la communauté latino-américaine.

Three alternatives to community and youth education. From southern Africa, a video depicting the use of oversized puppets to describe AIDS. From Chile, a state informational video on AIDS and HIV transmission with youth and a doctor. From the United States, the dramatization of AIDS by the use of soap opera/ tele novella exploring the social intricacies of the latino community.

12:45 - 13:45

Salle / Room **409ABC**



Section I

Jeudi 8 juin
Thursday, June 8

Aspects audio-visuels
Audio-Visual Aspects

Sessions du midi / Noon Hour Sessions

La musique, les performances et les changements sociaux
Music, Performance and Social Change

Chairpersons / Présidents: Rita Arauz (Nicaragua), Doumbi Fakoly (Senegal)

12:45 Personnes atteintes, l'infection du VIH et l'autodétermination/PWAs and Music, HIV Infection and Self-empowerment. *Michael Callen, Musicien, Coalition des personnes atteintes du SIDA/Musician, People with AIDS Coalition, New York, NY, U.S.A.*

12:55 Chanson, danse-dramatique et art dans les travaux d'éducation communautaire: Un exemple de la Zambie/Song, Dance-drama and Art in Health Education Work: A Zambian Example. *Chandra Mouli, Projet d'éducation communautaire du Copperbelt/Copperbelt Health Education Project, Kitme, Zambia.*

13:05 Musique rap, danse et changement social chez les jeunes/Rap-Music, Dance and Social Change in Youth. *Kevin Hicks, Quincy Delight III, Musiciens/Musicians, Los Angeles, CA, U.S.A.*

13:15 Moyens d'éducation officiels et populaires sur le SIDA à Trinidad et dans les autres îles des Caraïbes/Formalised and Popular Mediums to Educate on AIDS in Trinidad and Other Caribbean Territories. *Godfrey Sealy, Acteur/Performer, Port of Spain, Trinidad.*

13:25 Putain sécuritaire : activisme, droits des prostitué(e)s et SIDA/Safe Sex Slut: Performance, Activism, Prostitutes' Rights and AIDS. *Carol Leigh, and Scarlot Harlot, Activistes des droits des prostitué(e)s/Prostitutes' rights activists, Oakland, CA, U.S.A.*

13:35 La musique et le message : un exemple du Gabon/Music and Message: An Example from Gabon. *Helaron Nguema, Musicien/Musician, Libreville, Gabon.*

➜

La musique est un moyen de changement. Les thèmes peuvent rester les mêmes, mais les rythmes changeront. Cette session regroupe des extraits de pièces musicales utilisées lors des campagnes d'éducation sur le SIDA dans différentes parties du monde. Appréciez-en le rythme.

Music as means of change. The themes might stay the same but the rhythm changes. This session consists of music and performance in AIDS education from various parts of the world. Bring your lunch and enjoy the rhythms.

14:00 - 15:30

Salle
Room **407A**



Section
A

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde
Round Table

Rôle du dépistage et du counseling dans la prévention du SIDA
The Role of HIV Testing and Counselling in AIDS Prevention

Présidents
Chairpersons

Hunter H. Handsfield (U.S.A.)
Sirkka-Lisa Valle (Finland)

14:00 **Th.A.O.9**

Program Content:

- Review of data on the influence of testing and counselling on behavioural change
- Differential approach and effect in different populations (e.g. men, STD clinic patients, IVDU's)
- Role of testing and counselling in HIV prevention in the developing world
- Further research on the efficacy of HIV testing and counselling, including possible methodologic approaches and pitfalls

Panelists:

Stephen Bowen, Atlanta, GA, U.S.A.
Edward W. Hook, III, Baltimore, MD, U.S.A.
Gloria Ornelas-Hall, Mexico, Mexico.

14:00 - 15:30

Salle / Room **408A**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Questions de méthodologie / Methodologic Issues**

Présidents / Chairpersons
Akwasi Aidoo (South Africa)
Michael Alary (Canada)
James J. Goedert (U.S.A.)

14:00 **Th.A.O.10** HIV Screening in Low Prevalence Populations: Short-Term Seroconversion Experience of EIA+/WB- Individuals. *Robert T. Pero, J. G. McNeil, D. S. Burke, The Walter Reed Research Group, Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

14:15 **Th.A.O.11** Incidence of Pediatric AIDS in the United States: Predictions from Seroprevalence Data. *Marta Gwinn*, M. Rogers*, R. Berkelman*, A. Willoughby**, A. Novello**, M. Pappaioanou*, *Centers for Disease Control, Atlanta, GA; **NICHD, Bethesda, MD, U.S.A.*

14:30 **Th.A.O.12** Relationship between Cumulative Incidence of AIDS and Prevalence of HIV in Women of Reproductive Age in the United States. *Marguerite Pappaioanou*, J. Buehler*, M. Gwinn*, J. Karon*, A. Wright**, A. Novello**, *Centers for Disease Control, AIDS Program, Atlanta, GA; **NICHD, Bethesda, MD, U.S.A.*

14:45 **Th.A.O.13** Evaluating the Feasibility of the National Household Seroprevalence Survey (NHSS). *Geraldine M. McQuillan, T. Ezzati, J. Massey, Centers for Disease Control, National Center for Health Statistics, Hyattsville, MD, U.S.A.*

15:00 **Th.A.O.14** Application of Lot Quality Assurance (LQA) Sampling to HIV and AIDS Sentinel Surveillance. *S. Lwanga, J. Chin, J. Mann, World Health Organization, Geneva, Switzerland.*

15:15 **Th.A.O.15** Methodological Considerations for Assessing the Impact of Condom, Spermicide and Oral Contraceptive Use on HIV Transmission. *Ruby T. Senie, D. Kleinbaum, E. D. Eaker, N. C. Lee, H. B. Peterson, Centers for Disease Control, Atlanta, GA, U.S.A.*

14:00 - 15:30

Salle / Room **408BC**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session: **Transmission sexuelle du VIH (partie 3) / Sexual Transmission of HIV (Part 3)**

Présidents / Chairpersons: Fred Mahlu (Tanzania), Carlos Vega (Canada), James Waley (U.S.A.)

14:00 **Th.A.O.16** Evaluation of the Role of Nitrite Inhalants in HIV Transmission: Confounding or Effect Modification? *George R. Seage*, K. H. Mayer**, C. R. Horsburgh***, S. H. Holmberg***, G. A. Lamb*, *Boston Department of Health & Hospitals; **Fenway Community Health Center, Boston, MA; ***Centers for Disease Control, Atlanta, GA, U.S.A.*

14:15 **Th.A.O.17** The Role of Ulcerative Genital Diseases in Promoting Acquisition of HIV-1 by Homosexual Men. *Mark J. Van Raden*, R. A. Kaslow*, L. Kingsley**, R. Detels***, J. Narer****, R. Murphy*****, et al., *NIAID, Bethesda, MD; **NIAID, Pittsburgh, PA; ***NIAID, Los Angeles, CA; ****NIAID, Baltimore, MD; *****NIAID, Chicago, IL, U.S.A.*

14:30 **Th.A.O.18** Syphilis Is Strongly Associated with HIV Infection in Baltimore STD Clinic Patients Independent of Risk Group. *Robert O. Cannon*, T. C. Quinn*/**, A. Rompalo*/***, D. Glasser***, S. L. Groseclose***, E. W. Hook*/***, *Johns Hopkins University, Baltimore; **NIAID, Bethesda; ***Baltimore City Health Department, Baltimore, MD, U.S.A.*

14:45 **Th.A.O.19** Serological Evaluation of Sexual Partners, Children, and Household Contacts of HIV Infected Persons in Yaounde, Cameroon. *Marcel Monny-Lobe*, J.-G. Tsagadigui*, L. Zekeng**, R. Salla*, L. Kaptue*, *Central Hospital Yaounde; **University Teaching Hospital, Yaounde, Cameroon.*

15:00 **Th.A.O.20** Heterosexual Transmission of HIV: A European Study. II: Female-to-Male Transmission. *Isabelle De Vincenzi, R. Ancelle-Park, Centre collaborateur, Organisation Mondiale de la Santé-SIDA Europe, IMET, Hôpital Claude Bernard, Paris, France.*

15:15 **Th.A.O.21** High Prevalence and Incidence of HIV and Other Sexually Transmitted Diseases (STD) among 801 Kinshasa Prostitutes. *Marie Laga*, N. Nzila**, A. T. Manoka**, M. Kivuvu**, P. Piot*, R. Ryder**/***, et al., *Institute of Tropical Medicine, Antwerp, Belgium; **Projet SIDA, Kinshasa, Zaire; ***Centers for Disease Control, Atlanta, GA, U.S.A.*

14:00 - 15:30

Salle / Room **401ABC**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Neurologie**
Specialty Session **Neurology**

Présidents / Chairpersons
Youssouph Guisse (Senegal)
Robert M. Levy (U.S.A.)
Arrigo A. Moglia (Italy)

14:00 **Th.B.O.19** Autoantibodies in HIV-Related Peripheral Neuropathy. *Raphael B. Stricker*, D. Dale**, A. M. Wesley**, S. Mahawar**, University of California at San Francisco, *Department of Medicine and **Department of Neurology, San Francisco, CA, U.S.A.*

14:15 **Th.B.O.20** Electrophysiological Investigation of Central and Peripheral Nervous System in HIV Infected Patients. *Arrigo Moglia*/***, C. Zandrini*, E. Alfonsi*, G. Sandrini*, S. Bergonzoli*, W. Calderon**, *Department of Clinical Neurophysiology and **Third Department of Neurology, IRCCS C. Mondino; ***University of Pavia, Department of Infectious Diseases, Pavia, Italy.*

14:30 **Th.B.O.21** Study of Nerve Biopsies in 36 Patients with HIV Infection. *Jean-Jacques Hauw, M.-P. Chaunu, H. Ratinahirana, D. Hénin, M. Raphael, J.-M. Léger, Hôpital de la Salpêtrière, Laboratoire de Neuropathologie, Paris, France.*

14:45 **Th.B.O.22** Morphological Features of HIV-Encephalitis. *Juan Artigas*, F. Niedobitek*, G. Grosse*, K. Freund*, W. Heise**, Auguste-Viktoria-Krankenhaus, *Department of Pathology and **Department of Medicine, Berlin, Federal Republic of Germany.*

15:00 **Th.B.O.23** MR Imaging of Intracranial Manifestations of AIDS: Unenhanced and GD-DTPA Enhanced Studies. *Hans Henkes*, W. Schörner*, R. Jochens*, J. Iglesias**, B. Ruf***, R. Felix*, *Free University Berlin, Rudolf Virchow University Clinic, Department of Radiology; **Department of Neuropathology; ***Department of Internal Medicine II, Berlin, Federal Republic of Germany.*

15:15 **Th.B.O.24** The Interval between Equivocal and Definite Neurological Signs and Symptoms in the AIDS Dementia Complex (ADC). *John J. Sidtis, H. T. Thaler, B. J. Brew, A. E. Sadler, J. G. Keilp, R. W. Price, et al., Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

14:00 - 15:30

Salle / Room **404AB**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Les lymphokines**
Specialty Session **Lymphokines**

Présidents / Chairpersons
Scott Hamer (U.S.A.)
Andre Lefesvre (France)
Femni Soyinka (Nigeria)

14:00 **Th.B.O.25** Differences in Immune Activation Parameters during and after HIV Seroconversion: Serum ß-2 Microglobulin Neopterin and Soluble IL-2R. *Bo Hofmann, W. Cumberland, R. Detels, J. L. Fahey, University of California at Los Angeles, Schools of Medicine and Public Health, Department of Microbiology/Immunology, Los Angeles, CA, U.S.A.*

14:15 **Th.B.O.26** 2'-5'A Synthetase and Blastogenesis as Measures of Response to Azidothymidine (AZT). *Stanley E. Read, M. Fanning, J. Osachoff, R. Coates, University of Toronto, Hospital for Sick Children, Toronto, ON, Canada.*

14:30 **Th.B.O.27** Power of Serum Beta-2-Microglobulin and Serum Neopterin in Detecting Advanced HIV-Disease. *Johannes Brühwiler*, B. Ledergerber*, H. Joller-Jemelka**, P. J. Grob**, R. Lüthy*, *University Hospital, Department of Medicine, Division of Infectious Diseases; **Division of Clinical Immunology, Zurich, Switzerland.*

14:45 **Th.B.O.28** Interferon (IFN), Beta-2 Microglobulin (ß2-m) and Neopterin (Neo) in AIDS-Associated Kaposi's Sarcoma (KS). *Susan E. Krown, R. Bhalla, D. Niedzwiecki, D. Bundow, Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

15:00 **Th.B.O.29** High Interferon Levels Predict Subsequent Development of AIDS. *Robert E. Anderson*, J. Merritt**, R. Hamilton**, S. Shiboski***, W. Winkelstein***, *ViRx, Inc., San Francisco, CA; **The Upjohn Company, Kalamazoo, MI; ***University of California, Berkeley, CA, U.S.A.*

15:15 **Th.B.O.30** Tumor Necrosis Factor (TNF) in the Plasma of Africans Infected with HIV. *Steven M. Holland*, R. L. Colebunders**, H. L. Francis**, Khondi**, B. Kapita**, T. C. Quinn***, et al., *Johns Hopkins Hospital, Division of Infectious Diseases, Baltimore, MD, U.S.A.; **Projet SIDA, Kinshasa, Zaire; ***NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

14:00 - 15:30

Salle / Room **407B**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Colloque / Symposium

Les problèmes associés au VIH en hémophilie : aujourd'hui et demain

HIV Related Issues in Hemophilia: Today and Tomorrow

Présidents / Chairpersons: Gershom Growe (Canada), Sinbaga Smith (Switzerland)

14:00 **Th.B.O.31** The First and Second Epidemics. *Bruce Evatt, AIDS Program, Centres for Disease Control, Atlanta, GA, U.S.A.*

14:15 **Th.B.O.32** Virucidal Methods for Clotting Factor Concentrates: Are They Effective. *Pierre Manucci, University of Milano, Milan, Italy.*

14:30 **Th.B.O.33** Natural History of HIV Infection in Hemophilia. *Chris M. Tsoukas, Montreal General Hospital, Division of Clinical Immunology, Montreal, QC, Canada.*

14:45 **Th.B.O.34** Rates, Markers and Cofactors of HIV-Infection and AIDS in Hemophiliacs. *James Goedert, National Institutes of Health, Viral Epidemiology Section, Bethesda, MD, U.S.A.*

15:00 **Th.B.O.35** Hemophilia: Special Management Issues. *Christine A. Lee, Hemophilia and Hemostasis Unit, Royal Free Hospital, London, U.K.*

15:15 **Th.B.O.36** Concentrates: Meeting the Demand. *Louis M. Aledort, Mount Sinai School of Medicine, New York, NY, U.S.A.*

14:00 - 15:30

Salle / Room **403ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique — **Mise au point de médicaments : utiliation de l'AZT et d'autres oligonucléotides dans le traitement du SIDA**

Specialty Session — **Drug Development: Use of AZT and Other Oligonucleotides in AIDS Therapy**

Présidents / Chairpersons — Aly Guido (Malawi)
Jean-Claude Péchère (Switzerland)
Robert Yarchoam (U.S.A.)

14:00 **Th.C.O.17** Differential Modulation of HIV Replication and AZT Activity in Monocyte/Macrophages by GM-CSF, M-CSF, and G-CSF. *Carlo-Federico Perno, R. Yarchoan, D. A. Cooney, H. Mitsuya, D. G. Johns, S. Broder, National Cancer Institute, Bethesda, MD, U.S.A.*

14:15 **Th.C.O.18** Inhibition of HIV Replication by Novel Phospholipid Derivatives of AZT and Other Antiretroviral Nucleosides *In Vitro*. *Karl Y. Hostetler*/**, D. D. Richman**, *Vical Inc., San Diego; **University of California at San Diego, and the VA Medical Center, San Diego, CA, U.S.A.*

14:30 **Th.C.O.19** Inhibition of HIV Expression: Enhancement of Activity of Phosphorothioate Oligodeoxynucleotides by Chemical Modification. *Makoto Matsukura*, K. Mori**, G. Zon***, J. S. Cohen**, S. Broder*, *National Cancer Institute, National Institutes of Health, Clinical Oncology Program and **Medicine Branch, Bethesda, MD; ***Applied Biosystems Inc., Foster City, CA, U.S.A.*

14:45 **Th.C.O.20** 5-Halogeno-3'-Fluoro-2',3'-dideoxyuridines Are Potent Inhibitors of Retrovirus Replication *In Vitro*. *Jan M. Balzarini*, A. Van Aerschot*, R. Pauwels*, M. Baba*, D. Schols*, C. Roelants**, *Rega Institute for Medical Research; **Laboratory of Hematology, Leuven, Belgium.*

15:00 **Th.C.O.21** Conformational Preference of Anti-HIV Nucleosides and Drug Design. *C. K. Chu*, P. Van Roey**, R. F. Schinazi***, E. W. Taylor*, *University of Georgia, College of Pharmacy, Athens, GA; **Medical Foundation of Buffalo, Buffalo, NY; ***Emory University School of Medicine/VA Medical Center, Atlanta, GA, U.S.A.*

15:15 **Th.C.O.22** Synthesis and *In Vitro* Function of Ribozymes Targeted to HIV-1 Specific RNA Sequences. *John A. Zaia*, J. Rossi**, P. Chang**, D. Stephens*, P. Ladne*, E. Cantin**, *City of Hope Medical Center; **Beckman Research Institute of the City of Hope, Duarte, CA, U.S.A.*

14:00 - 15:30

Salle / Room **407C**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique **Virologie**
Specialty Session **Virology (Part 4)**

Présidents / Chairpersons: Michael John Gill (Canada), Kondou Odehouri (Cotonou), Giovanni B. Rossi (Italy)

14:00 **Th.C.O.23** Establishment of Human Astrocytoma Cell Clone Constitutively Expressing the HIV-NEF Protein. *Françoise Bachelerie, N. Israël, J. L. Virelizier, Institut Pasteur, Laboratoire d'Immunologie virale, Paris, France.*

14:15 **Th.C.O.24** Two West-African Isolates of HIV-2 with Marked Tropism for Macrophages, One of Which is Highly Divergent and Genetically Equidistant between HIV-2ROD and SIVMAC. *Helga Rübsamen-Waigmann*, M. Adamski*, R. Esser*, C. Meichsner**, H. Kühnel*, R. Dietrich*, *Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus; **Hoechst AG, Frankfurt am Main, Federal Republic of Germany.*

14:30 **Th.C.O.25** Characterization of a Biological Variant of HIV-1, Defective in the Ability to Modulate CD4. *James A. Hoxie*, E. P. Reddy**, M. Inoue**, P. Durda***, M. Spiritos*, B. S. Haggarty*, et al., *Hospital of the University of Pennsylvania; **Wistar Institute of Anatomy and Biology, Philadelphia, PA; ***E. I. Du Pont de Nemours & Co., North Billerica, MA, U.S.A.*

14:45 **Th.C.O.26** Murine Monoclonal Antibodies to a Synthetic Peptide of HIV-1 Have Neutralizing and Fusion Blocking Activities. *Paul J. Durda*, K. Weinhold**, T. Matthews**, M. Rayner*, L. Bacheler*, R. Pomerantz***, *E. I. Du Pont de Nemours & Co., Medical Products Department, North Billerica, MA, and Wilmington, DE; **Duke University, School of Medicine, Durham, NC; ***Massachusetts General Hospital, Infectious Diseases Unit, Boston, MA, U.S.A.*

15:00 **Th.C.O.27** Inhibition of HIV Production by Infected Cells Using Monoclonal Antibodies to CD4. *Françoise Rey, P. Corbeau, G. Donker, J.-C. Chermann, Unité de Recherches INSERM sur les Rétrovirus et Maladies associées (U.322), Campus de Luminy, Marseille, France.*

15:15 **Th.C.O.28** HIV Isolates from Asymptomatic Men Are Biologically and Genetically Different from Those Isolated from AIDS Patients. *Phalguni Gupta, R. Balachandran, P. Thampatty, C. Rinaldo, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

14:00 - 15:30

Salle / Room **410ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Vaccins : étude de l'immunisation à l'aide des glycoprotéines du VIH / Vaccines: Immunization Study Using HIV Glycoproteins**

Présidents / Chairpersons: J. Eichberg (U.S.A.), Peter Gill (Canada), Daniel Zagury (France)

14:00 **Th.C.O.29** Epitopes Recognized by the Neutralizing Antibodies of an HIV-1 Infected Individual. *Albert T. Profy*, P. Salinas*, L. Eckler*, P. Nara**, T. Matthews***, A. Langlois***, et al., *Repligen Corp., Cambridge, MA; **National Cancer Institute, Frederick, MD; ***Duke University Medical School, Durham, NC, U.S.A.*

14:15 **Th.C.O.30** Neutralization of In Vivo HIV-1 Infectivity Mediated by In Vitro Neutralizing Antibody. *Emilio A. Emini*, J. Eichberg**, P. L. Nara***, J. A. Lewis*, S. Matsushita****, S. D. Putney*****, et al., *Merck, Sharp and Dohme Research Laboratories, West Point, PA; **Southwest Foundation for Biomedical Resarch, San Antonio, TX; ***National Cancer Institute/Frederick Cancer Research Facility, Frederick, MD, U.S.A.; ****Kumamoto University Medical School, Kumamoto, Japan; *****Repligen Corp., Cambridge, MA, U.S.A.*

14:30 **Th.C.O.31** Studies of Hypervariable Region Deletion Mutants of HIV-1 gp120. *Nancy L. Haigwood, G. K. Moore, K. A. Mann, P. T. Pruyne, P. V. Skiles, K. S. Steimer, et al., Chiron Corp., Emeryville, CA, U.S.A.*

14:45 **Th.C.O.32** Antibody Dependent Cellular Cytotoxicity (ADCC) Following Vaccination with a Recombinant HIV-1 gp160 Vaccine. *Geoffrey J. Gorse, F. Newman, R. B. Belshe, AIDS Vaccine Program, NIAID, Bethesda, MD; Marshall University School of Medicine, Department of Medicine, Huntington, WV, U.S.A.*

15:00 **Th.C.O.33** Safety and Immunogenicity of HIV-1 Recombinant gp160 Vaccine Candidate in Normal Volunteers. *Raphael Dolin*, B. Graham**, S. Greenberg**, C. Tackett**, R. Belshe**, M. Clements**, et al., *University of Rochester School of Medicine, Rochester, NY; **NIAID, AIDS Vaccine Evaluation Group; ***MicroGeneSys, Inc., West Haven, CT, U.S.A.*

15:15 **Th.C.O.34** T Cell Responses to HIV in Humans Immunized with Recombinant Vaccinia Virus Containing HIV Envelope. *Elizabeth L. Cooney*, J. Zarling**, S. L. Hu**, A. Watson**, L. Corey*, P. Greenberg*, *University of Washington, School of Medicine; **Oncogen, Seattle, WA, U.S.A.*

14:00 - 15:30

Salle / Room **409ABC**



Section **D**

Jeudi 8 juin
Thursday, June 8

Le SIDA et l'individu
AIDS and the Individual

Séance thématique **Consommateurs de drogues par voie intraveineuse (partie 2)**

Specialty Session **Injection Drug Users (Part 2)**

Présidents / Chairpersons
Ernst Buning (Netherlands)
Praphan Phanuphak (Thailand)
Derstilng Tunving (Sweden)

14:00 **Th.D.O.13** Drug Use Trends among Participants in the Tacoma Syringe Exchange. <u>Hollis C. Hagan</u>*, *D. C. Des Jarlais***, *D. Purchase***, *T. Reid**, *S. R. Friedman*****, **Tacoma Pierce County Health Department, Tacoma, WA; ***New York State Division of Substance Abuse Services, New York, NY; ****Point Defiance AIDS Project, Tacoma, WA; *****Narcotic and Drug Research, Inc., New York, NY, U.S.A.*

14:15 **Th.D.O.14** The Prevalence of High Risk Sexual Behaviour in Male Homosexual IV Drug Users. <u>Diane K. Lewis</u>*, *J. K. Watters**/***, *P. Case****, **University of California at Santa Cruz, Santa Cruz; ***University of California at San Francisco; ****Urban Health Study, San Francisco, CA, U.S.A.*

14:30 **Th.D.O.15** Reducing HIV Transmission among Recovering Female Drug Users. <u>Robert F. Schilling</u>*, *N. El-Bassel**, *K. Gordon***, *S. Nichols****, **Columbia University School of Social Work, New York; ***Albert Einstein Medical College, Bronx; ****Beth Israel Medical Center, New York, NY, U.S.A.*

14:45 **Th.D.O.16** Impact of AIDS on Morbidity and Mortality among Intravenous Drug Users in a Methadone Maintenance Treatment Program (MMTP). <u>Peter A. Selwyn</u>, *D. Hartel, W. Wasserman, E. Drucker, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

15:00 **Th.D.O.17** HIV in Prisons: A Description and Evaluation of a Project Designed Specifically for Work with IVDAs in Prison. <u>Ragnar Kvarness</u>, *S. Svensen, R. Ervik, M. Skogstad, F. Jensen, Oslo City Health and Environment Department, Oslo, Norway.*

15:15 **Th.D.O.18** AIDS Prevention through the Criminal Justice System (CJS): Referral of Intravenous Drug Abusers (IVDAs) to Drug Abuse Treatment. <u>Robert J. Battjes</u>, *C. G. Leukefeld, R. W. Pickens, National Institute on Drug Abuse, Rockville, MD, U.S.A.*

14:00 - 15:30

Salle
Room **411A**



Section
D

Jeudi 8 juin
Thursday, June 8

Le SIDA et l'individu
AIDS and the Individual

Colloque — **Les femmes des pays en voie de développement : Où commencer? Que faire?**

Symposium — **Women in Developing Countries: Where Do We Start? What Can We Do?**

Présidents / Chairpersons — Maxine Ankrah (Uganda)
Phyllis Onyabgo (Kenya)
J. Willson-Smille (Jamaica)

14:00 **Th.D.O.19** AIDS and the African Woman: Reproductive Issues. *Eustace Muhondwa, Nuhimbili Medical Centre, University of Dar es Salaam, Dar es Salaam, Tanzania.*

14:20 **Th.D.O.20** Women with AIDS: Issues in Patient Care. *Susan Allen, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

14:40 **Th.D.O.21** Women as Care-Givers. *Noerine Kaleeba, TASO, Kampala, Uganda.*

15:00 **Th.D.O.22** The Research Agenda for African Women. *Fatia Mahmud, Bethesda, MD, U.S.A.*

15:15 **Th.D.O.23** Educational Interventions for Women. *Rebecca Nyonyintono, Kampala, Uganda.*

14:00 - 15:30

Salle / Room **411B**



Section **E**

Jeudi 8 juin
Thursday, June 8

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique — **Politiques sociales: expériences et critiques**

Specialty Session — **Public Policy: Experiences and Critiques**

Présidents / Chairpersons — L. Malo (Canada)
Andrew Mouraviekf-Apostol (Switzerland)
J. P. Okias (Gabon)

14:00 **Th.E.O.7** Une stratégie d'information par rapport à l'action des pouvoirs publics français. *Frédéric Edelmann, J. F. Mettetal, F. Fontenay, ARCAT-SIDA, CIVIS, Paris, France.*

14:15 **Th.E.O.8**

14:30 **Th.E.O.9** Report of the Child Welfare League of America Task Force on Children and HIV Infection. *Burt J. Annin, D. Pressma, V. Anderson, R. M. Horowitz, L. J. Emery, et al., Child Welfare League of America, Washington, DC, U.S.A.*

14:45 **Th.E.O.10** AIDS as a Challenge and an Innovation in Health Care and Health Policy. *Knud Josephsen, Danish Positive Group, Birkerod, Denmark.*

15:00 **Th.E.O.11** AIDS and Social Politics. *Arne Grnningsæter, Norwegian Association of Social Workers, Oslo, Norway.*

15:15 **Th.E.O.12** State AIDS Legislative and Policy Trends: 1983-1988. *Caitlin Ryan, George Washington University, Washington, DC, U.S.A.*

14:00 - 15:30

Salle
Room **411C**

Section
G

Jeudi 8 juin
Thursday, June 8

Implications internationales
International issues

Séance thématique **Les femmes à risque**
Specialty Session **Women at Risk**

Présidents B. A. Ousmane (Senegal)
Chairpersons A. Malek (Zambia)

14:00 **Th.G.O.13** Heterosexual Transmission of Human Immunodeficiency virus: The Past and the Future. *J. O. Ndinya-Achola, University of Nairobi, Department of Medical Microbiology, Nairobi, Kenya.*

14:15 **Th.G.O.14** Population Attributable risk of Sexually Transmitted Diseases (STDs) to HIV Infection. *Seth Berkeley, Uganda Ministry of Health and the Task Force for Child Survival, Kampala, Uganda.*

14:30 **Th.G.O.15** Research Needs and Priorities. *Ahmad Latif, University of Zimbabwe Medical School, Department of Medicine, Harare, Zimbabwe.*

14:45 **Th.G.O.16** A Description of a National STD Control Program. *Subhash Hira, University Teaching Hospital, Lusaka, Zambia.*

15:00 **Th.G.O.17** Programmatic Implications. *André Meheus, Programme des MST, Organisation Mondiale de la Santé, Geneva, Switzerland.*

14:00 - 15:30

Salle / Room **406BC**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Atelier / Workshop — **Atelier régional : Antilles** / **Regional Workshop: Caribbean**

Présidents / Chairpersons — Edwige Abede (Kenya), A. Edward Almendorf (U.S.A.)

14:00 **Th.G.O.19** The WHO's Concept of National AIDS Programme Management. *Daniel Tarantola, Global Programme on AIDS, World Health Organization, Geneva, Switzerland.*

14:15 **Th.G.O.20** A Non-Governmental Independent Perspective. *Meechai Viravaidhya, Harvard Institute of International Development, Cambridge, MA, U.S.A.*

14:00 - 15:30

Salle / Room **404AB**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Colloque / Symposium: **Défis posés par la gestion de programmes** / **Challenge of Programme Management**

Présidents / Chairpersons: Joshi Jones (U.K.), Fathia Mahmud (U.S.A.), Rejean Thomas (Canada)

14:00 **Th.G.O.25** Prospective Studies on HIV Infection of Prostitutes in the Philippines. *Curtis G. Hayes*, C. Manaloto*, L. Padre*, V. Basaca-Sevilla**, A. Andrada***, G. Espinosa***, et al., *U.S. Naval Medical Research Unit No. 2; **Philippine Department of Health, Manila; ***The City Health Office, Olongapo, Philippines.*

14:15 **Th.G.O.26** Statut sérologique d'une population de prostituées doublement exposées aux HIV-1 et HIV-2 au Burkina Faso. *Lasanna Sangare*, P. Kanki***, R. Soudré**, H. Tiendrebéogo**, S. M'Boup*, M. Essex***, et al., *Hôpital le Dantec, Dakar, Senegal; **Hôpital Yalgado Ouédrago, Ouagadougou, Burkina Faso; ***Harvard School of Public Health, Boston, MA, U.S.A.*

14:30 **Th.G.O.27** Male Circumcision in Eastern and Southern Africa: Association with HIV Seroprevalence. *Stephen Moses*, F. A. Plummer**, A. R. Ronald***, J. O. Ndinya-Achola**, *International Development Research Centre (IDRC); **University of Nairobi, Nairobi, Kenya; ***University of Manitoba, Winnipeg, MB, Canada.*

14:45 **Th.G.O.28** Factors Associated with Prevalent HIV-1 Infection in Pregnant Women in Malawi. *Alfred J. Saah, J. Chiphangwi, E. Ndovi, G. Dallabetta, P. Miotti, N. G. Liomba, The Queen Elizabeth Central Hospital, Blantyre, Malawi; The Johns Hopkins School of Hygiene and Public Health, Baltimore, MA, U.S.A.*

15:00 **Th.G.O.29** Condom Use and Knowledge in General Population, Female Prostitutes and Gay and Bisexual Men. *José Antonio Izazola, L. Pineda, J. L. Valdespino, J. Sepulveda, Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.*

15:15 **Th.G.O.30** Comparison between High Risk Practices in Female Prostitutes and Gay and Bisexual Men. *José Antonio Izazola, C. Romero, J. L. Valdespino, J. Sepulveda, Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.*

14:00 - 15:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section I

Session vidéo
Video session

Jeudi 8 juin
Thursday, June 8

Le personnel soignant

Care givers

14:00 Introduction: *James Miller*

14:04 **Th.I.V.4** ***"WITH LOVING ARMS"***

Vidéo de/Video by:
Child Welfare League of America
Année/Year: 1989

14:22 **Th.I.V.5** ***"FINDING OUR WAY TOGETHER"***

Vidéo de/Video by:
Mark Dworkin, John Mitsud, American Red Cross
Année/Year: 1989

14:50 **Th.I.V.6** ***"NURSING AND AIDS—COMMUNITY CARE"***

Vidéo de/Video by:

Année/Year: 1988

15:00 **Th.I.V.7** ***"THE INSIDE STORY"***

Vidéo de/Video by:
Lynn Coward, Royal Victoria Hospital
Année/Year:

Les intervenants sociaux ont besoin de formation, de conseils et de soutien dans l'aide qu'ils apportent aux personnes atteintes du SIDA. Ces films évoquent le rôle des parents d'accueil, des familles, de la communauté homosexuelle et lesbienne, de tous ceux qui dispensent des soins palliatifs, des infirmiers et infirmières et de divers bénévoles qui racontent comment ils ont vécu la réaction de la société au SIDA.

Care providers need training, guidance and support when caring for people with AIDS. These videos depict the role of foster parents, families, the gay and lesbian community, palliative care workers, nurses and various volunteers telling their stories about society's response to AIDS.

16:00 - 17:30

Salle / Room **407A**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Histoire clinique de l'infection au VIH : progression vers l'infection / Natural History of HIV Infection: Progression in Disease**

Présidents / Chairpersons: Francisco Diaz (Guinea), Richard A. Kaslow (U.S.A.), Alain Pompidou (France)

16:00 **Th.A.O.22** Time-to-AIDS in 816 Seroconverters. *Robert J. Biggar, J. J. Goedert, W. A. Blattner, Seroconverters' Working Group, National Cancer Institute, Bethesda, MD, U.S.A.*

16:15 **Th.A.O.23** HTLV-I/II Co-Infection Is Significantly Associated with Risk for Progression to AIDS among HIV+ Intravenous Drug Abusers. *Stanley H. Weiss*, J. French**, B. Holland*, M. A. Parker*, A. Lin-Greenberg***, R. Altman**, et al., *UMDNJ, New Jersey Medical School, Department of Preventive Medicine, Newark; **New Jersey Department of Health, Trenton; ***Jersey City Medical Center, Jersey City, NJ, U.S.A.*

16:30 **Th.A.O.24** Clinical Progression of HIV-related Disease in Intravenous Drug Users (IVDU) in a Prospective Cohort Study: 1985-1989. *Peter A. Selwyn, D. Hartel, E. E. Schoenbaum, R. S. Klein, G. H. Friedland, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

16:45 **Th.A.O.25** Progression to Disease in Women with Known Duration of HIV Infection. *Aggrey Anzala, *F. Plummer, I. Wamola, J. Ndinya-Achola, J. Kreiss, P. Waiyaki, *University of Nairobi, Kenya Medical Research Institute, Nairobi, Kenya; University of Manitoba, Winnipeg, MB, Canada; University of Washington, Seattle, WA, U.S.A.*

17:00 **Th.A.O.26** The Effect of Age on HIV Progression in Hemophiliacs. *James J. Goedert, M. E. Eyster, J. E. Drummond, M. W. Hilgartner, J. L. Bray, A. R. Cohen, et al., National Cancer Institute for the Multicenter Study of AIDS in Hemophiliacs, Rockville, MD, U.S.A.*

17:15 **Th.A.O.27** The Natural History of HIV Infection in a Cohort of Male Sexual Contacts of Men with HIV Disease. *Randall A. Coates, J. K. Johnson, S. E. Read, J. Raboud, L. M. Calzavara, V. Farewell, et al., University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada*

16:00 - 17:30

Salle / Room **408BC**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Table ronde / Round Table

Infection par le VIH et travailleurs de la santé : questions actuelles
HIV Infection and the Health Care Worker: Contemporary Issues

Présidents / Chairpersons: Robert J. Pratt (U.K.), Walter F. Schlech III (Canada)

16:00 **Th.A.O.28**

Program Content:

- Universal precautions
- Occupational risks
- Screening issues
- Attitude and practices of health care workers concerning HIV infection
- Occupational risk in the developing world
- The HIV-infected health care worker

Panelists:

David M. Bell, Atlanta, GA, U.S.A.
J. Louise Geberding, San Francisco, CA, U.S.A.
Fred M. Gordin, Washington, DC, U.S.A.
Bosenji Ngaly, Kinshasa, Zaire.

16:00 - 17:30

Salle / Room **409ABC**



Section **A**

Jeudi 8 juin
Thursday, June 8

Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique / Specialty Session **Autres rétrovirus : le HTLV-I / Other Retroviruses: HTLV-I**

Présidents / Chairpersons: William A. Blatner (U.S.A.), Guy de Thé (France), Gloria Echeverria de Perez (Venezuela)

16:00 **Th.A.O.29** HTLV-I and HTLV-II Infection in U.S. Blood Donors. *Helen Lee*, J. Burczak*, V. Laitila*, J. Leete*, J. Schrode*, C. Fang**, *Abbott Laboratories, North Chicago, IL; **American Red Cross, Rockville, MD, U.S.A.*

16:15 **Th.A.O.30** Antibodies to HIV-1 and HTLV-I in Haiti. *Robert Elie*, R. Chout**, A. Lassegue*, J. Dorlette*, D. César*, *Laboratoire d'investigations biologiques, Port-au-Prince, Haiti; **Hôpital du Lamentin, Lamentin, Martinique.*

16:30 **Th.A.O.31** HTLV-I-Associated Myelopathy (HAM/TSP) Is Associated with Blood Transfusion. *Robert S. Janssen*, M. Osame*, A. Igata*, H. Kubota*, H. Nishitani***, R. Khabbaz**, *Centers for Disease Control, Atlanta, GA, U.S.A.; **Kagoshima University, Kagoshima; ***Utano National Sanatorium Hospital, Kyoto, Japan.*

16:45 **Th.A.O.32** HTLV-I Infection Correlates with Increased Age in Intravenous Drug Users. *C. Robert Horsburgh*, D. Hartel**, R. F. Khabbaz***, M. Lairmore***, R. S. Klein**, G. H. Friedland**, *AIDS Program, Centers for Disease Control, Atlanta, GA; **Montefiore Medical Center, Bronx, NY; ***Division of Viral Diseases, Centers for Disease Control, Atlanta, GA, U.S.A.*

17:00 **Th.A.O.33** Significance of Positive and Indeterminate HTLV-I Serologic Results in Blood Donors. *Rima F. Khabbaz*, M. Lairmore*, H. Lee**, S. Critchley***, B. De*, G. Shulman***, *Centers for Disease Control, Atlanta, GA; **Abbott Laboratories, Chicago, IL; ***American Red Cross, Atlanta Region, Atlanta, GA, U.S.A.*

17:15 **Th.A.O.34** Prevalence of Human T-Lymphotropic Virus Type 1 in Applicants for the United States Armed Forces. *Donald R. Fipps*, W. Hann**, S. Alexander***, J. Damato****, J. Brundage****, D. Burke****, *William Beaumont Army Medical Center, El Paso, TX; **Bowling Green State University, Bowling Green, OH; ***BioTech Research Laboratories, Rockville, MD; ****Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

16:00 - 17:30

Salle / Room **401ABC**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **SIDA et nutrition**
Specialty Session **Nutrition and AIDS**

Présidents / Chairpersons: Peter Henning-Althoff (Fed. Rep. of Germany)
Moses S. Kapembwa (Uganda)
Ranjit Kumar

16:00 **Th.B.O.37** Effect of Home Total Parenteral Nutrition upon Body Cell Mass in AIDS. *Donald P. Kotler, A. R. Tierney, J. A. Culpepper-Morgan, J. Wang, R. N. Pierson, St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

16:15 **Th.B.O.38** Increased Resting Energy Expenditure in HIV-Infected Men. *Miriam J. T. Hommes*, J. A. Romijn*, M. H. Godfried*, E. Endert**, S. A. Danner*, H. P. Sauerwein**, *Department of Internal Medicine; **Department of Endocrinology, Academic Medical Centre, Amsterdam, Netherlands.*

16:30 **Th.B.O.39** Human Immunodeficiency Virus Infection in Malnourished Children at Kenyatta National Hospital, Nairobi, Kenya. *Martin Luta, G. Anabwani, M. Braddick, Department of Paediatrics, University of Nairobi, Nairobi, Kenya.*

16:45 **Th.B.O.40** Nutritional Abnormalities in Early HIV-1 Infection: I. Plasma Vitamin Levels. *Richard Beach*/**, E. Mantero-Atienza*/**, F. Van Riel*/**, R. Morgan*/**, M. K. Fordyce-Baum*/**, *University of Miami School of Medicine, Department of Epidemiology; **University of Miami, School of Medicine, The Biopsychosocial Center on AIDS, Miami, FL, U.S.A.*

17:00 **Th.B.O.41** Ileal Absorptive Function in Acquired Immunodeficiency Syndrome (AIDS). *Moses S. Kapembwa, C. Bridges, A. E. A. Joseph, S. C. Fleming, G. E. Griffin, St. George's Hospital Medical School, London, U.K.*

17:15 **Th.B.O.42** Imbalance of the Amino Acids Pattern in Patients with AIDS: Special Treatment with Adapted Amino Acid Solution? *Peter-Henning Althoff, E. Schifferdecker, H. Förster, B. Michels, P. Hunold, S. Klauke, et al., University Hospital, Frankfurt, Federal Republic of Germany.*

16:00 - 17:30

Salle
Room **404AB**

Section
B

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique **Immunomodulateurs**
Specialty Session **Immunomodulators**

Présidents
Chairpersons

Arthur A. Gotlieb (U.S.A.)
Carlo A. Isaquirre (Canada)
Court Pederson (Denmark)

16:00 **Th.B.O.43** A Placebo-Controlled Trial of Interferon Alfa-2b in Asymptomatic HIV Infection. *Victoria Davey, J. A. Kovacs, B. Herpin, J. A. Metcalf, A. S. Fauci, H. C. Lane, et al., Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, U.S.A.*

16:15 **Th.B.O.44** Immunization with Inactivated, Envelope-Depleted HIB Immunogen in HIV Infected Men with ARC: Preliminary Report of Exploratory Studies in Progress. *Alexandra M. Levine*, B. E. Henderson*, S. Groshen*, R. Peters**, H. W. Shepard***, J. Salk****, et al., *University of Southern California, School of Medicine, Los Angeles; **Immune Response Corp., La Jolla; ***Department of Health Services, Berkeley; ****Salk Institute, La Jolla, CA, U.S.A.*

16:30 **Th.B.O.45** Intramuscular Poly-ICLC Administration in AIDS: Preliminary Findings. *Andres M. Salazar*, J. Morales**, H. B. Levy***, P. Sarin****, L. Toro*, C. Hawkes*, et al., *Uniformed Services University of Health Sciences, Bethesda, MD and Walter Reed Army Medical Center, Washington, DC; **Ashford Presbyterian Hospital, San Juan, Puerto Rico; ***NIAID, National Institutes of Health; ****National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

16:45 **Th.B.O.46** Isoprinosine Reduced Clinical Progression in HIV Infected Patients in a Double Blind Placebo Controlled Study. *Court Pedersen, E. Sandström, C. Sand Petersen, J. Gerstoft, G. Norkrans, K. Christensen, Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

17:00 **Th.B.O.47** Follow-Up Morbidity among ARC Patients on Post-Trial IMREG-1 Treatment. *Marise S. Gottlieb, R. A. Zackin, A. A. Gottlieb, IMREG-1 Trial Investigators; IMREG Inc., and IMREG-1 Trial Sites at Boston, MA, Cleveland, OH, New Orleans, LA, New York, NY, Philadelphia, PA, Rancho Mirage, CA, U.S.A.*

17:15 **Th.B.O.48** The Anti-HIV Drugs Castanospermine (CSP) and Dextran Sulfate (DS) also Allow the Growth of In Vivo Infected CD4+ T Cells. *Carlos A. Izaguirre, J. Drouin, University of Ottawa, Ottawa, ON, Canada*

16:00 - 17:30

Salle / Room **407B**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Colloque — **Pharmacologie des médicaments anti-SIDA**

Symposium — **Pharmacology of Anti-AIDS Drugs**

Présidents / Chairpersons — Raymond Beaulieu (Canada), Paul Lietman (U.S.A.)

16:00 **Th.B.O.49** Pharmacological Principles applied in AIDS. *John Ruedy, St. Paul's Hospital, Vancouver, BC, Canada.*

16:15 **Th.B.O.50** Pharmacokinetics of AZT. *David Barry, The Wellcome Research Laboratories, Burroughs Wellcome Company, Research Triangle Park, NC, U.S.A.*

16:30 **Th.B.O.51** Intracellular Metabolism of anti HIV Nucleosides. *M.G.H. Hitchock, Bristol Myers, Wallingford, CT, U.S.A.*

16:45 **Th.B.O.52** Pharmacological Interaction of Drugs in AIDS. *Terry Blasky, Stanford University, CA, U.S.A.*

16:00 - 17:30

Salle / Room **408A**

Section **B**

Jeudi 8 juin
Thursday, June 8

Aspects cliniques
Clinical Aspects of AIDS

Séance thématique / Specialty Session **VIH-2 et autres rétrovirus / HIV-2 and Other Retroviruses**

Présidents / Chairpersons: Urzula Beckford (U.K.), Andrew Hughes (Gambia), Martial Lacroix (Canada)

16:00 **Th.B.O.54** Detection of HIV-2 Antibodies with a Novel HIV-2 Transmembrane Synthetic Peptide in a Line Immunoassay. *Martine Peeters*, D. Pollet**, C. Honoré*, F. Brun-Vézinet***, E. Delaporte*, H. Van Heuverswijn**, *Centre International de recherches médicales, Franceville, Gabon; **Innogenetics, Antwerp, Belgium; ***Hôpital Claude Bernard, Paris, France.*

16:15 **Th.B.O.55** Comparaison des performances d'un réactif ELISA utilisant un peptide recombinant pour la détection des infections à HIV-2. *F. Catalan*, A. Milovanovic*, T. D. Ly*, K. Odehouri**, J. Moreau**, A. Kadiot**, *Institut Alfred Fournier, Paris, France; **Service des Maladies infectieuses, CHU de Trechville, Abidjan, Ivory Coast.*

16:30 **Th.B.O.56** A Novel Enzyme Immunoassay to Detect Antibodies to Both HIV-1 and HIV-2. *Urzsula Beckford, C. A. Roberts, R. J. S. Duncan, S. Paye, Wellcome Diagnostics, Beckenham, Kent, U.K.*

16:45 **Th.B.O.57** Comparison of Serologic Assays for Transforming Retroviruses. *Chester R. Roberts, C. Romines, J. Damato, D. Burke, Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

17:00 **Th.B.O.58** Serologic Evidence of Retroviral Infection in Intravenous Drug Abusers (IVDAs). *David L. Nichols*, W. Wiebel**, B. Stevko**, A. Landay*, *Rush Medical Center, Department of Immunology; **AIDS Project, University of Illinois at Chicago, School of Public Health, Chicago, IL, U.S.A.*

17:15 **Th.B.O.59** Relative Specificity of Two EIAs for Antibodies to HTLV-I. *Chyang T. Fang*, R. Akins*, P. Le*, L. Porter*, J. Leete**, H. Lee**, *American Red Cross Blood Services, Rockville, MD; **Abbott Laboratories, Abbott Park, IL, U.S.A.*

16:00 - 17:30

Salle / Room **403ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique **Oncologie**
Specialty Session **Oncology**

Présidents / Chairpersons: Janet Neeguayee (Ghana), Christine Rougioux (France), John L. Ziegler (U.S.A.)

16:00 **Th.C.O.35** The Immunoglobulins (Igs) Expressed by AIDS-Associated B Cell Lymphomas (AL) Contain Shared Idiotopes (SIds) and Are Reactive with HIV Antigens. *Richard A. Miller*, S. Hart*, L. Wing*, M. Samoszuk**, B. Herndier***, M. McGrath***, *IDEC Pharmaceuticals Corp., Mountain View; **University of California at Irvine, Irvine; ***University of California at San Francisco, San Francisco, CA, U.S.A.*

16:15 **Th.C.O.36** Anal HPV Infection and Cytologic Abnormalities in HIV-Infected Individuals. *Joel Palefsky, J. Gonzales, H. Hollander, R. Greenblatt, University of California at San Francisco, San Francisco, CA, U.S.A.*

16:30 **Th.C.O.37** A Common Cell Surface Immunoglobulin Idiotype in High-Grade Lymphomas and in Prelymphomatous Reactive Lymph Nodes in HIV-Infected Individuals. *Brian G. Herndier*, F. Khayam-Bashi*, L. Kaplan*, R. Miller**, T. Meeker***, M. S. McGrath*, *University of California at San Francisco and San Francisco General Hospital, San Francisco; **IDEC Pharmaceuticals, Mountain View; ***UCSF/Veterans Administration Medical Center, San Francisco, CA, U.S.A.*

16:45 **Th.C.O.38** Presence of Epstein-Barr Virus by In-situ Hybridization in Non-Hodgkin's Lymphomas of AIDS Patients. *Jeannette Guarner, C. Del Rio, L. E. Hendrix, E. R. Unger, Emory University Hospital, Department of Anatomic Pathology, Atlanta, GA, U.S.A.*

17:00 **Th.C.O.39** Differences between Burkitt's and Non-Burkitt's High Grade Lymphomas (HGL) Associated with HIV Infection. *Jean-Marie Andrieu, M. Raphael, M. Gentilini, J. M. Tourani, B. Dupont, M. Armengaud, Laennec Hospital, Paris, France.*

17:15 **Th.C.O.40** HIV-Related Tumors: A Report of 435 Cases from GICAT (Gruppo Italiano Cooperativo AIDS & Tumori). *Umberto Tirelli, E. Vaccher, A. Lazzarin, G. Rezza, F. Gavosto, S. Monfardini, et al., Centro di Riferimento Oncologico, Division of Medical Oncology, Aviano, Italy.*

16:00 - 17:30

Salle / Room **407C**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Colloque / Symposium

Le rôle des macrophages et des lymphocytes comme réservoirs du VIH-1

Role of Macrophages and Lymphocytes as Reservoirs of HIV-1

Présidents / Chairpersons: Anthony S. Fauci (U.S.A.), Mark A. Wainberg (Canada)

16:00 **Th.C.O.41** Entry of HIV into Cells. *J. Steven McDougall, Centers for Disease Control, Atlanta, GA, U.S.A.*

16:15 **Th.C.O.42** Role of Macrophages in Pathogenesis of HIV. *S. Gartner, New Mexico State University, Primate Research Institute, Alamogardo, NM, U.S.A.*

16:30 **Th.C.O.43** Surface Recognition Structure of HIV. *Angus Dalgleish, MRC Clinical Research Centre, Harrow, U.K.*

16:40 **Th.C.O.44** Cytokine Induction of HIV Expression. *Anthony S. Fauci, NIAID, National Institutes of Health, Bethesda, MD, U.S.A.*

16:00 - 17:30

Salle / Room **410ABC**

Section **C**

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Séance thématique / Specialty Session **Vaccins : utilisation d'un modèle animal pour l'étude des vaccins anti-VIH**
Vaccines: Use of Animal Model to Study Anti-HIV Vaccines

Présidents / Chairpersons: Dani Bolognesi (U.S.A.), Marc Girard (France), Lise Thibodeau (Canada)

16:00 **Th.C.O.45** Immunization of Rhesus Macaques with Inactivated SIV Fails to Protect against Mucosal or IV Challenge. *M. B. Gardner, N. Pedersen, C. V. Hanson, C. Miller, A. Gettie, M. Jennings, et al., University of California at Davis, Davis, CA, U.S.A.*

16:15 **Th.C.O.46** HIV Immunization and Challenge of HIV Seropositive and Seronegative Chimpanzees. *C. J. Gibbs*, C. Mora*, R. Peters**, F. C. Jensen**, D. J. Carlo**, J. Salk***, *National Institutes of Health, Bethesda, MD; **The Immune Response Corp.; ***The Salk Institute, San Diego, CA, U.S.A.*

16:30 **Th.C.O.47** Immunogenicity of Potential HIV Vaccines in Chimpanzees. *Marc P. Girard*, M.-P. Kieny**, J. P. Lecocq**, M. Yagello***, J. C. Gluckman***, F. Barré-Sinoussi ****, et al., *Pasteur Vaccins, Marnes-la-Coquette; **Transgène, Strasbourg; ***CHU Pitié-Salpêtrière; ****Institut Pasteur, Paris, France.*

16:45 **Th.C.O.48** Simian Immunity to HIV-1 Candidate Vaccines. *Peter W. Neumann*, M. V. O'Shaughnessy*, G. Smith**, M. Cochran**, *Health and Welfare Canada, Federal Centre for AIDS, Ottawa, ON, Canada; **MicroGeneSys Inc., West Haven, CT, U.S.A.*

17:00 **Th.C.O.49** Vaccination with Live Retroviruses: The Nature of the Protective Immune Response. *Ruth M. Ruprecht, R. Hom, S. Mullaney, M. A. Gama-Sosa, R. Finberg, Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

17:15 **Th.C.O.50** Development of an HIV Subunit Vaccine. *Scott D. Putney*, K. Javaherian*, A. Profy*, J. Rusche*, T. Matthews**, D. Bolognesi**, *Repligen Corp., Cambridge, MA; Duke University Medical School, Durham, NC, U.S.A.*

16:00 - 17:30

Salle / Room **411B**



Section **E**

Jeudi 8 juin
Thursday, June 8

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Séance thématique / Specialty Session **Dimensions sociales du SIDA / Social Dimensions of AIDS**

Présidents / Chairpersons
Ann Derval-Murray (Ireland)
Manuel Lujan (Peru)
Sylvie C. Tourigny (Canada)

16:10 **Th.E.O.13** Some Sociological Aspects of AIDS: An Indian Profile. *Swaminathan Sundararaman, S. Solomon, R. Thara, S. Rajkumar, Subha, University of Madras, Madras Medical College, Madras, India.*

16:25 **Th.E.O.14** Approche socio-démographique d'une population de malades du SIDA héberges dans les appartements thérapeutiques à Paris et sa banlieue. *Jean Javanni, J. P. Cordonnier, H. Maurel, A. Michel, A. Sobel, Aparts, Paris, France.*

16:40 **Th.E.O.15** Social Organization as a Determinant in HIV Transmission. *John Kreniseke, HIV Center for Clinical and Behavioral Studies, New York, NY, U.S.A.*

16:45 **Th.E.O.16** Sociological Analysis of AIDS Prevention among Homosexual Men. *Robert A. P. Tielman, University of Utrecht, Utercht, Netherlands.*

17:10 **Th.E.O.17** Risk Perception, Risk-Taking and Risk Management among Intravenous Drug Users: Implications for AIDS Prevention. *Margaret M. Connors, Spectrum House, Inc., Westboro, MA, U.S.A.*

17:20 **Th.E.O.18** De campagnes générales à des approches communautaires. *Michel Perreault, CERMES (Centre de recherche Médecine, Maladie et Sciences Sociales), Paris, France.*

16:00 - 17:30

Salle / Room **411C**

Section **F**

Droit et éthique
Ethics and Law

Jeudi 8 juin
Thursday, June 8

Colloque / Symposium **Discrimination et droits de la personne / Discrimination and Human Rights**

Présidents / Chairpersons Raj Anand (Canada)
Susan S. Connor (U.S.A.)

16:00 **Th.F.O.1** Discrimination: The Issues. Raj Anand, *Ontario Human Rights Commission, Toronto, ON, Canada.*

16:15 **Th.F.O.2** Legal Services for Persons with AIDS (PWAs) of Predominantly Heterosexual, Poor, Minority Background. Alice Herb, *D. LaGamma, Montefiore Medical Center, Bronx, NY, U.S.A.*

16:25 **Th.F.O.3** Anti-Discrimination Law and AIDS-Related Discrimination: A Philosophical Analysis. Todd Ducharme*, *J. Hathaway***, **University of Alberta, Faculty of Law, Edmonton, AB; ***Osgoode Hall Law School, Toronto, ON, Canada.*

16:35 **Th.F.O.4** AIDS in the U.S. Workplace: The Evolution of AIDS Litigation, Legislation, and Regulation. Verla S. Neslund, *G. W. Matthews, Office of the General Counsel, Centers for Disease Control, Atlanta, GA, U.S.A.*

16:45 **Th.F.O.6** VIH et toxicomanie : aspects éthiques. Pierre Espinoza*, *L. Letellier**, *P. David***, **Hôpital de Fresnes (EHPNF), Fresnes; Hôpital de Bicêtre, Bicêtre, France.*

16:55 **Th.F.O.7** Discrimination Reflected in the Language and Diagnoses on Target HIV Client by Physicians. Robert W. Norton*, *J. Schwartzbaum***, *J. Wheat***, **Memphis State University; ***University of Tennessee, Memphis, TN, U.S.A.*

17:05 **Th.F.O.8** Commentary. Susan Scholle-Connor, *Pan American World Health Organization. Washington, DC, U.S.A.*

16:00 - 17:30

Salle / Room **406A**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International issues

Séance thématique / Specialty Session **Aspects cliniques / Clinical**

Présidents / Chairpersons: Raymond Duperval (Canada), Larry Gelmon (Canada), Bernardin Niragira (U.S.A.)

16:00 **Th.G.O.31** Rôle du Centre de lutte contre les MTS dans la prévention de l'infection à VIH. "L'expérience du Sénégal". *Ibra I. N'doye*, S. M'Boup**, M. T. A. Sy***, F. Van der Veen*, E. Siby**, I. Thior**, *Bureau National MST; **Université Cheikh Anta Diop; ***Programme National MST, Ministère de la Santé, DHPS, Dakar, Senegal.*

16:15 **Th.G.O.32** Pathology of HIV Infection in Zaire. *Ann Marie Nelson*/**/***; M. Kayembe*, N. Ilunga*, P. Angriti***, M. M. Kalengayi*, *University Hospital of Kinshasa; **Projet SIDA, Kinshasa, Zaire; ***Armed Forces Institute of Pathology, Washington, DC, U.S.A.*

16:30 **Th.G.O.33** Clinical Findings in 201 Symptomatic Children with AIDS. *Farzin Davachi*, L. Kabongo*, N. Mayemba*, K. Ndoko*, K. Ngoie*, B. N'Galy**, *Department of Pediatrics, Mama Yemo Hospital; **Ministry of Health, Kinshasa, Zaire.*

16:45 **Th.G.O.34** Validation of a Case Definition for Perinatally-acquired AIDS in Africa. *Wato Nsa*, T. Manzila*, U. Kabagabo*, M. Mvula*, R. Ryder*/**, *Projet SIDA, Kinshasa, Zaire; **Centers for Disease Control, Atlanta, GA, U.S.A.*

17:00 **Th.G.O.35** Clinical Findings among HIV-Infected Individuals Attending the Dermato-Venereology Clinics. *Roy D. Mugerwa, P. Nsubuga, N. Sewankambo, E. Katabira, Makerere University, Kampala, Uganda.*

17:15 **Th.G.O.36** Evaluation of Clinical Illness and Timing of Seroconversion in Sexually Transmitted Acute HIV-1 Infection. *D. William Cameron*, L. J. D'Costa*, G. M. Maitha*, A. R. Ronald**, J. O. Ndinya-Achola*, F. A. Plummer**, *University of Nairobi, Nairobi City Commission, Nairobi, Kenya; **University of Manitoba, Winnipeg, MB, Canada.*

16:00 - 17:30

Salle / Room **406C**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Atelier / Workshop — **Atelier régional : Amérique Latine / Regional Workshop: Latin America**

Présidents / Chairpersons — Pedro Cahn (Argentina), J. L. Valdespino (Mexico)

16:00 **Th.G.O.37** Mexican Experience on Interrelationship between Epidemiology and Education on AIDS. *José-Luis Valdespino, Mexico City, Mexico.*

16:15 **Th.G.O.38** Clinical-Epidemiological Characteristics of AIDS Cases in Argentina. *Pedro Cahn, Buenos Aires, Argentina.*

16:30 **Th.G.O.39** Development of AIDS Programmes for Hispanic Communities in the USA. *Arletty Pinel, Sao Paulo, Brazil.*

16:45 **Th.G.O.40** AIDS Educational programmes in Sao Paulo, Brazil. *Maria Eugenia Lemos Fernandes, Sao Paulo, Brazil.*

17:00 **Th.G.O.41** AIDS in Prostitutes: Experience in the Dominican Republic. *Ernesto Guerrero*, Santo Domingo, Dominican Republic.

16:00 - 17:30

Salle / Room **406B**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Atelier / Workshop — **Atelier régional : Antilles / Regional Workshop: Caribbean**

Présidents / Chairpersons — Yamil H. Kouri (U.S.A.), Jai P. Narain (Trinidad)

16:00 **Th.G.O.42** AIDS: A Caribbean Perpective. *Jai P. Narain, Caribbean Epidemiology Centre (CAREC), Port of Spain, Trinidad.*

16:10 **Th.G.O.43** Epidemiology of AIDS in the Bahamas, August 1985 - March 1989. *Kenneth Ofusu-Barko, Community Health Services Department, Ministry of Health, Nassau, Bahamas.*

16:20 **Th.G.O.44** AIDS in the Dominican Republic: Interventions Among Persons with High-Risk Behaviour. *Ernesto Guerrero, CARE PWR, Santo Domingo, Dominican Republic.*

16:30 **Th.G.O.45** Situation epidemiologique du SIDA en Guyane Française. *Patricia Vienne, D.D.A.S.S. de Cayenne - Médecin inspecteur de la santé, Guyana.*

16:40 **Th.G.O.46** Strategies for Prevention and Control of AIDS in Haiti. *Gabriel Timothée, CARE PWR Haiti, Port-au-Prince, Haiti.*

16:50 **Th.G.O.47** AIDS Educational Strategies and Ethnic Diversity in Suriname. *Ruben Del Prado, National AIDS Program, Bureau of Public Health, Paramaribo, Suriname.*

17:00 **Th.G.O.48** Challenges in Dealing with the AIDS Epidemic in Trinidad and Tobago. *Beulah Duke, AIDS Programme, Eric Williams Medical Complex, Mount Hope, Trinidad and Tobago.*

16:00 - 17:30

Salle / Room **411A**

Section **G**

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Séance thématique **Le SIDA chez l'enfant**
Specialty Session **Pediatric AIDS**

Présidents / Chairpersons
Diane Ashley (Canada)
Locko Mafouta (Congo)
Donald Sutherland (Uganda)

16:00 **Th.G.O.49** Mortality Associated with HIV and Diarrhea in Haitian Children. *Jean W. Pape, L. Oriol, S. Madhavan, Jr., W. D. Johnson, Cornell University Medical College, New York, NY, U.S.A.*

16:15 **Th.G.O.50** Pediatric AIDS in Brazil: Description and Analysis of Trends. *Denise Bergamaschi*, P. Chequer*, L. Rodrigues*, E. Castilho**, *Ministry of Health, National Division of STD/AIDS, Brasilia; **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil.*

16:30 **Th.G.O.51** The Effect of HIV-1 and HTLV-I Infections on Birthweight in a Population without IV Drug Abuse. *Elisabeth Holt*, R. Boulos**, N. Halsey*, J. Brutus**, U. Auguste**, H. Davis**, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.; **Centers for Health and Development, Port-au-Prince, Haiti; ***National Cancer Institute, Bethesda, MD, U.S.A.*

16:45 **Th.G.O.52** Morbidity and Mortality in Infants of HIV-1 Infected Mothers. *Pratibha P. Datta*, J. E. Embree**, M. Braddick***, J. Kreiss****, J. O. Ndinya-Achola*, F. A. Plummer*/**, *University of Nairobi, Nairobi, Kenya; **University of Manitoba, Winnipeg, MB, Canada; ***Middlesex Hospital, London, U.K.; ****University of Washington, Seattle, WA, U.S.A.*

17:00 **Th.G.O.53** HIV Infection as a Risk Factor for Poor Obstetrical Outcome. *Marleen Temmerman*/***, N. Mirza*, F. Plummer*/**, J. O. Ndinya-Achola*, I. Wamola*, P. Piot***, et al., *University of Nairobi, Nairobi, Kenya; **University of Manitoba, Winnipeg, MB, Canada; ***Institute of Tropical Medicine, Department of Microbiology, Antwerp, Belgium.*

17:15 **Th.G.O.54** Survie des enfants nés de mère positive pour HIV-1 : Étude prospective à Brazzaville (R. P. Congo). *Marc Lallemant*, S. Lallemant Le Coeur**, D. Cheynier***, S. Nzingoula***, M. Sinet**, B. Larouzé**, et al., *ORSTOM, Brazzaville/Paris; **INSERM U13, Paris, France; ***Ministère de la Santé/DSMIES, Brazzaville, R.P. Congo.*

16:00 - 17:30

Cinéma de l'ONF, Complexe Guy Favreau

NFB Cinema, Complexe Guy Favreau



Section
I

Session vidéo
Video session

La Prévention

Prevention

16:00 Introduction: *Ken Morrison*

16:05 **Th.I.V.8** ***"THE BEST DEFENSE"***

Vidéo de/Video by:
Deborah Shames
Année/Year: 1988

16:10 **Th.I.V.9** ***"WORK SAFE PLAY SAFE"***

Vidéo de/Video by:
Jessica Douglas Henry
Année/Year: 1988

16:30 **Th.I.V.10** ***"SOMETHING FIERCE"***

Vidéo de/Video by:
GMHC
Année/Year: 1989

16:50 **Th.I.V.11** ***"ON GUARD"***

Vidéo de/Video by:
Deborah Shames
Année/Year: 1988

17:13 **Th.I.V.12** ***"AIDS-WISE, NO LIES"***

Vidéo de/Video by:
David Current, Anne Ruthledge
Année/Year: 1988

➜

La prévention reste le noyau fondamental de toute intervention contre le SIDA. Puisant dans le déluge de films vidéos proposés, cette séance présente un aperçu général des techniques de prévention mises en oeuvre pour de nombreux groupes cibles : toxicomanes, travailleurs du secteur de la santé et des services sociaux, personnels paramédicaux, prostituées, homosexuels et jeunes.

The nucleus of AIDS work remains prevention. From the deluge of videos submitted on the subject, this session provides an overview of prevention techniques for many target groups: drug users, health care workers, paramedics, prostitutes, gay men and youth.



Session d'affichage
Poster Session

Autres rétrovirus : HTLV-I et HTLV-II
Other Retroviruses: HTLV-I and HTLV-II

Th.A.P.1 Prevalence of HTLV-I/HIV-1 Infection among Male Intravenous Abusers and Their Sexual Partners in Chicago. *Joseph R. Lentino*, C. T. Pachucki, D. Schaaff, M. Schaefer, D. Schroer, W. Dorus, *Hines Veterans Administration Hospital, Hines, IL, U.S.A.*

Th.A.P.2 Screening for HTLV-I Antibodies among Finnish Blood Donors, Hemophiliacs and HIV-suspected. *Pauli O. Leinikki*, E. Mattila, J. Koistinen, J. Leikola, H. Brummer-Korvenkontio, M. L. Kantanen, *National Public Health Institute, Helsinki, Finland.*

Th.A.P.3 HTLV-I en France métropolitaine. *Jean-Marie Lemaire*, J. Coste, A. M. Couroucé, *GRSNTS, Centre régional de Transfusion sanguine, Montpellier, France.*

Th.A.P.4 Prevalence of HTLV-I Antibodies in HIV-1 Infected Patients in a Minority Community in the Bronx, N.Y. *Stanley Bauer*, L. Amaral, J. Ernst, *The Bronx-Lebanon Hospital Center, Department of Pathology, Bronx, NY, U.S.A.*

Th.A.P.5 HTLV-I Seroprevalence in Patients with HIV and Neurologic Disease, Other Risk Groups, and Blood Donors in Zimbabwe. *Stan Houston*, C. Thornton, J. Emmanuel, H. Smith, A. Latif, *University of Zimbabwe, Harare, Zimbabwe.*

Th.A.P.6 HIV-1 and HTLV-I Infections in Intravenous Drug Users (IVDU) in Detroit: 1985-1989. *Louis D. Saravolatz*, A. Ognjan, N. Markowitz, D. Pohlod, H. Lee, B. Belian, et al., *Henry Ford Hospital, Detroit, MI, U.S.A.*

Th.A.P.7 HTLV-I Antibodies in the Solomon Islands. *Daniel B. Hardy*, J. R. Carlson, J. L. Yee, M. Y. K. Armstong, *University of California at Davis, Medical Center, Sacramento, CA, U.S.A.*

Th.A.P.8 Lack of HTLV-I Infection in Non-I.V. Drug Using HIV Seropositive Men in Los Angeles. *David M. Aboulafia*, R. T. Mitsuyasu, D. J. Slamon, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.*

Th.A.P.9 HIV-1 and HTLV-I Seroprevalence in Critically Ill Resuscitated Emergency Department Patients. *Louis D. Saravolatz*, C. Lewandowski, A. Ognjan, E. Rivers, D. Pohlod, B. Belian, *Henry Ford Hospital, Detroit, MI, U.S.A.*

Th.A.P.10 HIV-1 and HTLV-I Infections in Intravenous Drug Users (IVDU) in Detroit 1985-1989. *Louis D. Saravolatz*, A. Ognjan, N. Markowitz, D. Pohlod, H. Lee, B. Belian, et al., *Henry Ford Hospital, Detroit, MI, U.S.A.*

Th.A.P.11 Prevalence of HTLV-I Antibody in Selected Women in the Los Angeles Area. *Suraiya Rasheed*, S. S. Barker, P. S. Gill, *University of Southern California, School of Medicine, Los Angeles, CA, U.S.A.*

Th.A.P.12 HTLV-I Infection in an Inner-City Emergency Department Population. *Gabor D. Kelen*, T. DiGiovanna, L. Lofy, K. Sivertson, T. Quinn, *The Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

Th.A.P.13 Anti-HTLV-I in New York Blood Donors (1985-1986). *Patricia E. Taylor*, C. E. Stevens, H. Lee, *The New York Blood Center, Laboratory of Epidemiology, New York, NY, U.S.A.*

Th.A.P.14 Determinants of HTLV-I Seroprevalence in Miyazaki Prefecture, Japan. *Sherri O. Stuver*, N. Tachibana, F. Romano, N. Mueller, *Harvard School of Public Health, Department of Epidemiology, Boston, MA, U.S.A.*

Th.A.P.15 Seroprevalence of HTLV-I in a Parturient Population at Risk for HIV-1 Infection. *Keith Krasinski*, W. Borkowsky, A. Fidelia, D. Bebenroth, T. Moore, *New York University Medical Center, New York, NY, U.S.A.*

Th.A.P.16 Seroprevalence of HTLV-I in Patients Attending Sexually Transmitted Diseases (STD) Clinics in the United States. *Rima F. Khabbaz*, J. Douglas, R. Spiegel, M. St. Louis, W. Whittington, M. Lairmore, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.17 Risk of Development of HTLV-I-associated Myelopathy (HAM/TSP) among Persons Infected with HTLV-I. *Jonathan E. Kaplan*, M. Osame, A. Igata, H. Kubota, H. Nishitani, R. Janssen, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.18 HTLV-I/II Seroprevalence and HIV/HTLV Coinfection among IV Drug Abusers (DA) in the U.S. *Kenneth P. Cantor*, S. H. Weiss, J. Goedert, R. Battjes, *National Cancer Institute, Bethesda, MD, U.S.A.*

Th.A.P.19 HTLV-I and HIV-1 Infection in Intravenous Drug Abusers of Barcelona. *Jordi Tor Aguilera*, V. Soriano, R. Muga, A. Ribera, B. Clotet, M. Foz, *Hospital "Germans Trias I Pujol," Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.*

Th.A.P.20 HTLV-I Antibodies among Prison Inmates in Maryland. *David Vlahov*, E. Taylor, C. Wisniewski, C. Tanner, W. Mehaffey, H. Lee, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

Th.A.P.21 High Rate of Confirmed HTLV-II Infection among Intravenous Drug Abusers (IVDA) from New Orleans. *Helen Lee*, P. Swanson, V. Shorty, J. Zack, J. Rosenblatt, I. Chen, *Abbott Laboratories, North Chicago, IL, U.S.A.*

Th.A.P.22 HTLV-I Infection in Spain. *Vincent Soriano*, E. Abella, J. Tor, A. Flores, B. Clotet, A. Ribera, * University of Barcelona, Hospital "Germans Trias I Pujol", Badalona, Barcelona, Spain.*

Th.A.P.23 Co-Infection with HIV, HTLV-I and HBV in Trinidad and Tobago. *Courtenay Bartholomew*, F. Cleghorn, B. Hull, K. Battoo, C. Diaz, W. Blattner, *Faculty of Medical Sciences, University of the West Indies, Port of Spain, Trinidad.*

Th.A.P.24 HTLV-I in Intravenous Drug Addicts (IVDA) and Gay Men in San Francisco. *Ellen G. Feigal*, E. Murphy, J. Drummond, P. Bacchetti, R. Chaisson, J. S. Greenspan, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

Th.A.P.25 Counseling and Follow-up of Individuals Positive for HTLV-I Antibody. *Harvey Dosik*, M. Kohen, L. Williams, K. Hershman, E. Silberman, M. Goldstein, *Interfaith Medical Center, Brooklyn, NY, U.S.A.*

Th.A.P.26 Seroprevalence of HTLV-I Antibody in a Black Brooklyn Community. *Harvey Dosik*, L. Williams, M. Goldstein, E. Silberman, P. Levine, R. Maloof, *Interfaith Medical Center, Brooklyn, NY, U.S.A.*

Th.A.P.27 Prevalence of HTLV-I in Greek Blood Donors. *Vassilis Georgoulias*, A. Derivianaki, E. Malliaraki-Pinetidou, *University of Crete, School of Medicine and AIDS Reference Center of Crete, Iraklion, Crete, Greece.*

Th.A.P.28 Seroprevalence of HTLV-I among U.S. Marines Stationed in a Hyperendemic Area. *Stephanie K. Brodine*, E. C. Oldfield, A. L. Corwin, R. J. Thomas, A. B. Ryan, J. Holmberg, et al., *Naval Hospital, Infectious Diseases Division, San Diego, CA, U.S.A.*

Th.A.P.29 Investigations on the Presence of HTLV-I Infection in Intravenous Drug Abusers and Homosexuals in the Federal Republic of Germany. *Andreas Beck*, I. Ehm, G. Pauli, B. Thiele, B. Karbowiak, M. A. Koch, *AIDS-Zentrum, Berlin, Federal Republic of Germany.*

Th.A.P.30 Co-infections HIV-1/HTLV-I en Martinique. *Claudine Neisson-Vernant*, R. Demeleumesster, N. Monplaisir, R. Chout, G. Sobesky, D. Cales-Quist, *Centre hospitalier régional universitaire La Meynard, Fort de France, Martinique.*

Th.A.P.31 Serological Confirmation of HTLV-I Infection in Blood Donors. *David W. Anderson*, T. H. Lee, M. Lairmore, C. Saxinger, V. S. Kalyanaraman, D. Slamon, et al., Food and Drug Administration, Division of Blood and Blood Products, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A.*

Th.A.P.32 Antibody to HTLV-I/II among Blood Donors in Four Cities of the United States. *James W. Mosley*, Transfusion Safety Study Group, *University of Southern California at Los Angeles, CA, U.S.A.*

Th.A.P.33 Recall Bias and Memory Failure: An Empiric Demonstration in Persons with Acquired Immune Deficiency Syndrome. *Karen Gelmon*, M. T. Schechter, S. B. Sheps, R. Hershler, K. J. P. Craib, *Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada.*

Th.A.P.34 HIV Tests or Testees? *Sirkka-Liisa Valle*, S. Sarna, *University Central Hospital, Department of STDs, Helsinki, Finland.*

Th.A.P.35 Calculating HIV Incidence Rates from Seroprevalence Data. *David C. Sokal*, B. Shelton, L. Kupper, *Family Health International, Research Triangle Park, NC, U.S.A.*

Th.A.P.36 Significance of Mean Age of Anti-HIV Positive Persons Identified in Test Programs. *Gert G. Frosner*, *Max von Pettenkofer-Institut, University of Munich, Munich, Federal Republic of Germany.*

Th.A.P.37 Sample Sizes for Needles in a Haystack: The Case of HIV Seroprevalence Surveys in Canada. *John W. Frank*, R. A. Coates, J. M. Garbutt, R. Brant, *University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

Th.A.P.38 Voluntary HIV Studies Can Underestimate Seroprevalence. *Michael L. Rekart*, D. Cook, *STD Control, Ministry of Health, Vancouver, BC, Canada.*

Th.A.P.39 Research or Surveillance? Anonymous Seroprevalence Studies: The Quebec Experience. *Catherine A. Hankins*, N. Lapointe, C. Laberge, D. Roy, K. Elmslie, S. Gendron, *DSC, Hôpital Général de Montréal and McGill University, Montreal, QC, Canada.*

Th.A.P.40 Evaluation of Dried Blood Filter Paper Samples, Collected by Finger Stick as an Alternative to Venipuncture for HIV Seroprevalence in High Risk Adults. *Haynes W. Sheppard*, J. Wiley, M. Ascher, *California Public Health Foundation, Berkeley, CA, U.S.A.*

Th.A.P.41 Designing Observational Studies and Field Trials of Treatments and Preventions against HIV Infection and AIDS. *Mary E. Halloran*, C. J. Struchiner, J. M. Robins, *Harvard School of Public Health, Department of Population Sciences, Boston, MA, U.S.A.*

Th.A.P.42 Validation of Sexual Histories of Homosexual Male Couples. *George R. Seage*, K. H. Mayer, C. R. Horsburgh, B. Cai, G. A. Lamb, *Boston Department of Health and Hospitals, Boston, MA, U.S.A.*

Th.A.P.43 Statistical Considerations of Misclassification of Patients at Baseline in Two AIDS Clinical Trials. *Alan B. Forsythe*, J. D. Elashoff, W. J. Dixon, *Viratek Inc., University of California at Los Angeles, School of Medicine, Costa Mesa, CA, U.S.A.*

Infection par le VIH chez les travailleurs de la santé
HIV Infection among Health Care Workers

Th.A.P.44 Guidelines for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Health-Care and Public Safety Workers. *Edward L. Baker*, R. J. Mullan, M. J. Scally, P. W. Strine, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.45 Zidovudine Prophylaxis for Persons with Accidental Percutaneous Blood Exposure: A Decision Analysis. *David N. Rose*, H. S. Sacks, *Mount Sinai School of Medicine, New York, NY, U.S.A.*

Th.A.P.46 National Surveillance Program: Occupational Exposure to Human Immunodeficiency Virus (HIV-1) Infection in Canada. *Kimberly D. Elmslie*, L. Mulligan, M. V. O'Shaughnessy, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

Th.A.P.47 Blood Exposures during Surgical Procedures. *Adelisa Panlilio*, C. Perlino, C. Parrish, D. Foy, P. Lowry, D. Bell, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.48 Report of a Possible Laboratory Acquired HIV Infection. *Charles E. Haley*, V. J. Reff, F. K. Murphy, *Dallas County Health Department, Dallas, TX, U.S.A.*

Th.A.P.49 The Risk of Exposure to Human Immunodeficiency Virus among Health Care Workers (HCW) at a Southern U.S. Urban Hospital. *George F. Risi*, R. Gaumer, S. Weeks, J. Leete, C. Sanders, *Louisiana State University Medical Center, New Orleans, LA, U.S.A.*

Modélisation mathématique et prévisions
Mathematical Modelling and Prediction

Th.A.P.50 Census Data and Forecasting U.S. AIDS Cases. *John Pickering*, J. E. Robbin, L. E. Lieb, G. W. Rutherford, N. E. Woodbury, M. J. W. Van de Laar, et al., *University of Georgia, Department of Entomology, Athens, GA, U.S.A.*

Th.A.P.51 Behaviorally Based Modeling of the Spread of HIV. *Tim Brown, University of Hawaii at Manoa, Honolulu, HI, U.S.A.*

Th.A.P.52 A Dynamic Model of HIV Transmission and AIDS in San Francisco. *Herbert W. Hethcote, University of Iowa, IA, U.S.A.*

Th.A.P.53 HIV Carriers: Increasing Infectivity with Progression to AIDS Has Important Implications for the AIDS Epidemic among Heterosexuals. *José J. Gonzalez*, C. E. Moe, P. Davidsen, M. G. Koch, *AUST-AGDER Central Hospital, Arendal, Norway.*

Th.A.P.54 A Multiple Risk Group Model to Estimate and Project the Spread of HIV. *Philip C. Cooley*, S. Christopher, D. Hamill, C. Van der Horst, *Research Triangle Institute, Research Triangle Park, NC, U.S.A.*

Th.A.P.55 HIV Dynamics in Linked Risk Groups, a Multigroup Transmission Model. *Hans Van Druten*, J. C. Jager, M. J. J. C. Poos, R. A. Coutinho, E. J. Ruitenberg, *University of Nijmegen, Nijmegen, Netherlands.*

Th.A.P.56 Enhanced Computer Model of HIV Transmission Via Needle Sharing. *David J. Ahlgren*, A. C. Stein, B. F. Lewis, *Trinity College, Department of Engineering and Computer Science, Hartford, CT, U.S.A.*

Th.A.P.57 Impact of Sexual Behaviour Change on the AIDS Epidemic. *Steve P. Blythe, Strathclyde University, Glasgow, U.K.*

Th.A.P.58 Modelling of Immune System Dynamics in HIV Pathogenesis: Issues in Immunomodulation. *Rupert E. D. Whitaker, Boston University/Tufts, New England Medical Center Hospitals, Boston, MA, U.S.A.*

Th.A.P.59 The Potential for Spread of HIV in the Heterosexual Population in Norway, a Simulation Model Study. *Hein Stigum*, J. K. Grnnesby, P. Magnus, J. M. Sundet, L. S. Bakketeig, *National Institute of Public Health, Oslo, Norway.*

Th.A.P.60 Evidence for a 16-18 Year Mean Time between HIV Viral Infection and AIDS Onset. *Wilson Greatbatch*, W. S. Holmes, *Greatbatch GEN-AID, Ltd., Clarence, NY, U.S.A.*

Th.A.P.61 Incubation Time for AIDS in Transfusion-Associated Cases: An Estimation from the French Dataset. *Dominique Costagliola*, A. Laporte, A.-J. Valleron, *INSERM U 263, Université Paris VII, Paris, France.*

Th.A.P.62 Heterogeneity in the Incubation Time of AIDS: A Stochastic Serial Compartment Model. *Firoze Mauji*, N. Nagelkerke, F. A. Plummer, *Kenya Medical Research Institute, Nairobi, Kenya.*

Th.A.P.63 Modelling Progression of HIV Infection. *Victor G. De Gruttola*, N. Lange, *Harvard University School of Public Health, Boston, MA, U.S.A.*

Th.A.P.64 "Structured" and "Selective" Mixing Formulations of Heterogenous Contact to Study HIV Transmission. *James S. Koopman*, J. A. Jacquez, C. P. Simon, *University of Michigan School of Public Health, Ann Arbor, MI, U.S.A.*

Th.A.P.65 Simulating the Epidemic Dynamics of HIV-Infection Using Stochastic Processes over Random Graphs. *Georg F. Bolz*, P. Blanchard, T. Krüger, *Universität Bielefeld, Fakultät für Physik, Bielefeld, Federal Republic of Germany.*

Th.A.P.66 A Risk Based Heterosexual Model of the Spread of HIV. *James M. Hyman*, E. A. Stanley, S. A. Colgate, S. P. Layne, *Los Alamos National Laboratory, Los Alamos, NM, U.S.A.*

Th.A.P.67 Challenges in Modeling HIV Infection in Low Seroprevalence Populations. *John K. Watters, University of California at San Francisco, Urban Health Study, San Francisco, CA, U.S.A.*

Th.A.P.68 Estimating Intravenous Drug User (IVDU) Population from AIDS Statistics in San Francisco. *Patrick Biernacki*, M. Aldrich, J. Mandel, *Youth Environment Study, Inc., San Francisco, CA, U.S.A.*

Th.A.P.69 AIDS in the Nordic Countries: Forecasts. *Bo Eriksson, Nordic School of Public Health, Guttenburg, Sweden.*

Th.A.P.70 Effects of Modeling Heterogeneity of Drug Use Behavior. *Joanna E. Siegel*, M. C. Weinstein, D. S. Shepard, J. K. Watters, H. V. Fineberg, *Harvard School of Public Health, Boston, MA, U.S.A.*

Th.A.P.71 A Heterosexual Model for the Spread of HIV and the Demographic Impact of the AIDS Epidemic. *Elizabeth Ann Stanley*, S. T. Seitz, P. O. Way, T. F. Curry, J. M. Hyman, P. D. Johnson, et al., *Los Alamos National Laboratory, Los Alamos, NM, U.S.A.*

Th.A.P.72 Estimation of the Effect of AZT on Time-to-AIDS in HIV-Infected Subjects from Observational Data. *James Robins, Harvard School of Public Health, Boston, MA, U.S.A.*

Th.A.P.73 Simulation of HIV Transmission in a Structured Community of Intravenous Drug Users. *Denton R. Peterson*, K. Willard, M. Altmann, *University of Minnesota, Laboratory of Medicine and Pathology, Division of Health Computer Science, Minneapolis, MN, U.S.A.*

Th.A.P.74 Reverse Extrapolation as a Method for Estimating HIV Seroprevalence. *Colin L. Soskolne*, J. R. McGregor, A. N. Jaroni, *University of Alberta, Edmonton, AB, Canada.*

Th.A.P.75 The Prediction of the Numbers of AIDS Cases in the UK, and the Estimation of the Incubation Period of AIDS. *Graham F. Medley*, R. M. Anderson, *Imperial College, Department of Biology, London, U.K.*

Th.A.P.76 Projecting Local AIDS Incidence Using Both Surveillance and Seroprevalence Measures. *Laura J. Fehrs*, T. Byers, J. LeTourneau, H. F. Hull, J. Wilson, *New Mexico Health and Environment Department, Santa Fe, NM, U.S.A.*

Th.A.P.77 Reliability of Estimates Based on Backcalculation. *Mitchell H. Gail*, P. S. Rosenberg, R. J. Biggar, J. J. Goedert, R. Brookmeyer, *National Cancer Institute, Bethesda, MD, U.S.A.*

Th.A.P.78 A Review of Some Techniques for Backward Estimating the Prevalence of HIV from AIDS Case Incidence. *Philip C. Cooley*, S. Reade-Christopher, D. Hamill, C. Van der Horst, *Research Triangle Institute, Chapel Hill, NC, U.S.A.*

Th.A.P.79 Projecting Proportions of AIDS Cases Over Time. *John M. Karon*, O. J. Devine, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.80 The AIDS Epidemic in Mexico. *Alejandro Mohar*, V. DeGruttola, J. L. Valdespino, L. García, J. Sepúlveda, *Harvard School of Public Health, Boston, MA, U.S.A.*

Th.A.P.81 Modelling of the AIDS Epidemic in Mexico. *Isabelle Romieu*, S. Sanderg, T. Awerbuch, A. Mohar, J. L. Valdespino, J. Sepúlveda, et al., *Harvard University School of Public Health, Boston, MA, U.S.A.*

Th.A.P.82 Limitations of Official Forecasts Used in Planning Future AIDS Service Needs. *Jesse Green*, M. Leigh, N. Wintfeld, *New York University Medical Center, Department of Health Policy Research, New York, NY, U.S.A.*

Th.A.P.83 Genetic Epidemiology of AIDS. *Leslie G. Louie*, S. Desmond, K. Gilles, B. Newman, M. C. King, *Epidemiology, School of Public Health, University of California at Berkeley, Berkeley, CA, U.S.A.*

Th.A.P.84 Evaluation of the Immunological Staging System in a Population Based Cohort. *Rachel A. Royce*, W. Winkelstein, R. Anderson, W. Lang, *University of California at Berkeley, Epidemiology, School of Public Health, Berkeley, CA, U.S.A.*

Th.A.P.85 Time from First HIV Infection to Persistent Antigenemia. *Joan S. Chmiel*, A. Muñoz, J. Phair, K. Macdonell, V. Carey, L. Tsung, *Northwestern University Medical School, Biometry Section, Chicago, IL, U.S.A.*

Th.A.P.86 Long-term HIV Infection Without Clinical Illness or Immunodeficiency: Homosexual Men Who Have not "Progressed". *Alan R. Lifson*, S. P. Buchbinder, H. W. Sheppard, J. Wilber, N. A. Hessol, G. W. Rutherford, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A.*

Th.A.P.87 Defining the Interval Between Human Immunodeficiency Virus (HIV) Infection and the Appearance of HIV Antibody. *Robert C. Horsburgh*, C. Y. Ou, J. M. Jason, S. D. Holmberg, T. M. Longini, H. W. Jaffe, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.88 Occurrence of Indeterminant Western Blot (IWB) Tests and Lack of Transmission of IWB in Persons at Low Risk for HIV Infection, Huntington, WV, U.S.A., 1986-1988. *Robert B. Belshe*, A. Schindzielorz, *Marshall University School of Medicine, Huntington, WV, U.S.A.*

Th.A.P.89 International Registry of Seroconverters. *Robert J. Biggar, Seroconverters' Registry Group, National Cancer Institute, Bethesda, MD, U.S.A.*

Th.A.P.90 Lack of Correlation Between Neutralizing Antibody Titers and CD4+ Decline in the San Francisco Men's Health Study. *Haynes W. Sheppard*, C. Hanson, L. Miksza, R. Royce, *California Public Health Foundation, Berkeley, CA, U.S.A.*

Th.A.P.91 The Effect of Hepatitis B Virus Vaccination on T-Cell Subsets in HIV-1 Seropositive Men in the Baltimore MACS. *Nancy J. Odaka*, J. Margolick, R. Fox, A. Muñoz, *Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

Th.A.P.92 Increased Rate of HIV-1 Isolation among Infected Homosexuals with Low CD4 Count. *Homayoon Farzadegan*, D. Imagawa, W. Hardy, M. Lee, C. Grovit, P. Gupta, et al., *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

Th.A.P.93 Increased "Viral Burden" in Late Stages of HIV Infection. *Donald S. Burke*, R. Redfield, A. Fowler, C. Oster, *Walter Reed Retroviral Research Group, Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

Th.A.P.94 Graphical Description of Hematological Changes after HIV-1 Seroconversion in Homosexual Men. *Alvaro Muñoz*, J. Margolick, J. Phair, J. V. Giorgi, C. Rinaldo, *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A.*

Th.A.P.95 Serologic Evidence of Epstein-Barr Virus (EBV) Reactivation Before and After HIV-1 Seroconversion. *Abid Rahman*, L. A. Kingsley, C. R. Rinaldo, R. Atchison, M. Ho, M. K. Breinig, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

Th.A.P.96 Clinical Pattern and Course of HIV-Infection in 29 Patients with Seroconversion. *Hans-Reinhard Brodt*, S. Staszewski, G. Kindervater, A. Gottstein, A. Helm, *Universitätsklinik Frankfurt, Zentrum der inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

Th.A.P.97 Immunologic Abnormalities in Anti-HIV-1 Negative (-) and Anti-HTLV-I/II Negative and Positive (+) IV Drug Abusers (IVDA) on Methadone. *Nancy C. Klimas*, N. Blaney, R. Morgan, J. Simoneau, M. A. Fletcher, *University of Miami School of Medicine, Miami, FL, U.S.A.*

Th.A.P.98 Mycobacterial Infections in Massachusetts AIDS Patients. *Laureen M. Kunches*, L. Makarewicz, J. Day, B. Heinze-Lacey, S. Oddleifson, L. Mofenson, et al., *Massachusetts Department of Public Health, Boston, MA, U.S.A.*

Th.A.P.99 Ajustement de modèles chronologiques avec rupture sur une fonction discriminante. *Bernard Prum*, D. B. Picard, W. Rozenbaum, D. Garbanzadeh, C. Guihenneuc, *Université de Paris V, Paris, France.*

Th.A.P.100 Do Clinical Herpes Simplex Virus (HSV) and Varicella-Zoster (VZV) Infections Accelerate HIV-1-Induced Immunodeficiency? *Richard A. Kaslow*, M. J. VanRaden, M. A. Deloria, S. Zeger, J. Dudley, K. Alwood, et al., *National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.S.A.*

Th.A.P.101 Lack of Association of T-Cell Subsets with Continuing Intravenous Drug Use and High Risk Heterosexual Sex, Independent of HIV Infection and Disease. *Gerald H. Friedland*, E. E. Schoenbaum, D. Hartel, K. Davenny, R. Klein, P. Selwyn, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.A.P.102 Progression of HIV Disease in Intravenous Drug Users. *Robert Gorter*, K. Kocurek, B. Brodie, P. Bachetti, E. Ross, A. R. Moss, *University of California at San Francisco, San Francisco, CA, U.S.A.*

Th.A.P.103 A Retrospective Follow-up Study of Morbidity among HIV Infected Young Adults Prior to a Diagnosis of HIV Infection: A True Natural History. *Philip O. Renzullo*, J. G. McNeil, J. F. Brundage, *Walter Reed Army Institute of Research, Washington, DC, U.S.A.*

Th.A.P.104 HIV Infection Increases the Frequency and Severity of Papillomavirus Induced Cervical Cytologic Abnormalities. *Anat R. Feingold*, S. H. Vermund, R. D. Burk, K. F. Kelley, L. K. Schrager, R. S. Klein, et al., *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.A.P.105 Early HIV-1 Influence on Malignancies. *Eva A. Operskalski*, Transfusion Safety Study Group, University of Southern California, Los Angeles, CA, U.S.A.*

Additionnels
Additional

Th.A.P.106

Th.A.P.107 Psoriasis as a Cause of False-Positive HIV Western Blots: Detection of gag-Specific Antibodies in Virtually All Cases. *Jörg Schüpbach*, A. Baumgartner, L. Bruckner-Tuderman, *Swiss National Center of Retroviruses, University of Zurich, Zurich, Switzerland.*

Th.A.P.108 Double-postifs Western-Blot VIH-1 et VIH-2 discriminés à l'aide de peptides synthétiques. *Jean-François Delagneau*, A. Sanjuan, M.-C. Cot, *Diagnostics Pasteur, Marnes-la-Coquette, France.*

Th.A.P.109 PCR Subtyping of HIV Infections Exhibiting Reactive Serologic Responses to HIV-1 and -2. *Mark A. Rayfield*, C. Y. Ou, J. Krebs, K. Odehouri, W. M. Heyward, G. Schochetman, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.A.P.110 Confirmation and Virus Typing Using PCR Analysis of HTLV-1 ELISA Reactive Samples. *John J. Sninsky*, J. Lipka, D. Kellogg, N. McKinney, S. Fong, S. Kwok, et al., *Cetus Corp., Emeryville, CA, U.S.A.*

Th.A.P.111 Detection of HIV-1 from Needles Discarded by I.V. Drug Users in Zurich and Basel Using Polymerase Chain Reaction Assessment of In Vitro Infectivity. *Ines Raineri*, H. P. Senn, C. Scheidegger, R. Hornung, R. Luethy, M. Vogt, *University Hospital, Division of Infectious Diseases, Zurich, Switzerland.*

Th.A.P.112 A Comparison of IFA and EIA in Determining HTLV-I Seroprevalence in the Ivory Coast. *Michel Canavaggio*, M. Verdier, E. Anderson, A. Sangare, F Denis, W. Glusic, *Abbott Laboratories, North Chicago, IL, U.S.A.*

Th.A.P.113 Antibodies to HIV-1 gp 120 env Epitopes Correlate with Uninfected Status of the Children Born to Seropositive Mothers. *Paolo L. Rossi*, V. Moschese, P. A. Broliden, K. Ljunggren, M. Jondal, B. Wahren, et al., *Department of Immunology, Karolinska Institute, Stockholm, Sweden.*

Th.A.P.114 Strain-Specific DNA Probes to Study the Epidemiology of HIV Infection. *Chin-Yih Ou*, R. L. Robbins, J. L. Moore, Y. Villamarzo, Jr., C. P. Horsburgh, G. Schochetman, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A.*

Th.A.P.115 The Establishment of a Routine Surveillance System for Detecting Prevalence of HIV Infection in Scotland. *David J. Goldberg*, J. Emslie, C. Guthrie, D. Reid, *Communicable Diseases (Scotland) Unit, Ruchill Hospital, Glasgow, U.K.*

Th.A.P.116 Are Seronegative High Risk Subjects HIV-infected? *Jean-Jacques Lefrère*, D. Vittecoq, B. Noël, S. Chamaret, M. Nariotti, P. Lambin, et al., *Institut national de transfusion sanguine, Paris, France.*

Th.A.P.117 Comparison of the Sensitivity of Various Enzyme and Substrate Systems for Western Blot Assay. *Shirley Y. W. Sum*, S. L. Yap, L. Chan, *Diagnostic Biotechnology, Singapore.*

Th.A.P.118 A Rapid and Sensitive HTLV-I Antibody Screening Method with High Specificity. *David J. Waters*, J. T. Drummond, G. L. Warner, W. A. Blattner, G. B. Braman, R. M. Thorn, *NCI-Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A.*

Th.A.P.119 Seroconversion: Antibody Profiles to HTLV I. *Helen Lee*, A. Mann, J. Gibbs, M. Perol, G. Tegtmeier, F. Ferchal, et al., *Abbott Laboratories, North Chicago, IL, U.S.A.*

Th.A.P.120 Epidemiology of AIDS in the Bahamas. *M. Perry Gomez*, K. Ofuso-Barko, R. Bain, *Princess Margaret Hospital, Nassau, Bahamas.*

Notes

Section
B
Aspects cliniques
Clinical Aspects of AIDS

Jeudi 8 juin
Thursday, June 8

Session d'affichage
Poster Session

Hémophilie
Hemophilia

Th.B.P.1 Lymphocytes Cytochemistry Behavior in Hemophilic Patients with HIV Infection. *Gabriella Gamba*, S. Testa, L. Ponchio, R. Invernizzi, F. P. Di Fazio, G. B. Ippoliti, *Clinica Medica 2, IRCCS Policlinico S. Matteo, Università degli Studi, Pavia, Italy.*

Th.B.P.2 Antiphospholipid Antibodies and HIV Infection in Hemophilia. *Sofia Testa*, L. Ponchio, N. Montani, C. M. Montecucco, G. Cascone, G. Gamba, *Clinica Medica 2, IRCCS Policlinico S. Matteo, Università degli Studi, Pavia, Italy.*

Th.B.P.3 Absence of HIV-2 Infection in Hemophilia in Buenos Aires. *María Belén Bouzas*, F. Simon, G. Muchinik, G. Picchio, F. Brun Vézinet, I. Mathov, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.B.P.4 HIV Infection and Chagas' Disease in Hemophiliacs in Argentina. *María Belén Bouzas*, R. Corral, G. Muchinik, S. Grinstein, R. Campestri, R. Pérez Bianco, et al., *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.B.P.5 Response to Hepatitis B Immunization in Hemophiliac Children: Relationship to Human Immunodeficiency Type I (HIV-1) Virus Infection. *Wendy Chan*, M. Petric, E. Wang, G. Koren, S. Read, V. Blanchette, *Hospital for Sick Children, Toronto, ON, Canada.*

Th.B.P.6 Beneficial Effect of an Ultrapure Factor VIII Concentrate on Hypergammaglobulinemia in HIV-Positive Hemophiliacs. *Sam Schulman*, H. Johnsson, *Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.*

Th.B.P.7 Hemophilia, Septic Arthritis and Human Immunodeficiency Virus. *Peter Jarzem*, C. Tsoukas, D. Burke, H. Strawczynski, G. Growe, M. C. Poon, *Montreal General Hospital, McGill University, Montreal, QC, Canada.*

Th.B.P.8 Longitudinal Analyses of HIV-Specific Antibody Responses in Hemophiliacs with Long-term HIV Infection. *Abraham Pinter*, P. Flomenberg, W. Honnen, K. Revesz, M. Hilgartner, J. Conway, et al., *Public Health Research Institute, New York, NY, U.S.A.*

Histoire clinique de l'hémophilie
Hemophilia: Natural History

Th.B.P.9 Étude prospective d'un groupe de 28 jeunes hémophiles infectés par le virus VIH. *Joëlle Tricoire*, A. Robert, J. Puel, C. Gayet, B. Boneu, C. Régnier, *Hôpital Purpan, Toulouse, France.*

Th.B.P.10 Immunological and Virological Findings in Paradoxical HIV-1 Seronegative Multitransfused Haemophiliacs (1983-1989). *Anne-Marie Berthier*, S. Chamaret, J. C. Ameison, F. Laure, Groupe Rennais de recherche sur le SIDA, L. Montagnier, *Rey-Leroux Haemophiliac Center, Liffre-la-Bouexière, France.*

Th.B.P.11 Évolutivité de l'infection au virus de l'immunodéficience humaine chez 69 hémophiles séropositifs. *Françoise Ferrer Le Coeur*, M.-C. Meyohas, P. Hivert, M. Eliaszewicz, J. Lebas, J. Frottier, *Centre National de Transfusion sanguine (CNTS), Hôpital Saint-Antoine, Paris, France.*

Th.B.P.12 Progression of HIV-Infection in 46 Hemophilic Patients. *Ulrike Brunkhorst*, B. Tschechne, M. Barthels, I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany.*

Th.B.P.13 Clinical Signs and Death Causes in HIV+ Hemophiliacs (hem) with Progressing Disease. *Guillermo Muchinik*, R. Pérez Bianco, A. Anselmo, M. De Tezanos Pinto, M. B. Bouzas, E. Rickard, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.B.P.14 Hemophiliac Population of Costa Rica from 1979 to 1989. *Kirsten A. Visona*, L. Taylor, C. Montero, R. Cordero, M. C. Astua, A. Roy, et al., *Louisiana State University, International Center for Medical Research and Training, San José, Costa Rica.*

Th.B.P.15 An Immunological Follow-up in Hemophilic Non-Converters after Treatment with an HIV-Contaminated Batch. *Sam Schulman*, E. Berntorp, *Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.*

Th.B.P.16 Natural History of HIV Infection in Large Hemophilia Cohort: Follow-up since 1983: 1988/89 Update. *Gaetano Giraldo*, E. Beth-Giraldo, E. Miraglia, R. De Biasi, A. Rocino, F. Martucci, *Istituto Nazionale Tumori «Fond. Pascale», Naples, Italy.*

Th.B.P.17 Natural History of HIV Infection in a Group of Hemophiliacs with Known Year of Seroconversion. *Anastasia Karafoulidou*, A. Gialeraki, A. Hatzakis, J. Economidou, K. Psarra, C. Markakis, et al., *Laikon Hospital, Athens, Greece.*

Th.B.P.18 HIV-1 Infection in Children with Hemophilia A and B. A Report from the Canadian Pediatric Hemophilia AIDS Study Group. *Victor S. Blanchette, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.*

Th.B.P.19 Hemophiliac Age Affects Immune Functions in HIV-infected Patients. *W. Abe Andes*, K. Wulff, C. Lemoine, C. Daul, J. Morgan, R. D. DeShazo, et al., *Tulane University School of Medicine, New Orleans, LA, U.S.A.*

Th.B.P.20 A Prospective Study of HIV Infection in Children with Hemophilia. *Kaiser Ali*, R. Card, D. Garvey, G. Growe, N. Kobrinsky, C. Tsoukas, et al., *Janeway Child Health Center, St. John's, NF, Canada.*

Hémophilie : autres virus
Hemophilia: Other Viruses

Th.B.P.21 Contamination d'un jeune hémophile par le virus VIH-2. *Joëlle Tricoire*, A. Robert, J. Puel, F. Brun-Vézinet, C. Gayet, C. Régnier, *Hôpital Purpan, Toulouse, France.*

Th.B.P.22 Pre-existing Cytomegalovirus Infection Increases the Progression towards AIDS in a Cohort of Haemophiliacs. *Paul D. Griffiths*, A. Webster, C. Lee, J. E. Grundy, V. C. Emery, P. Kernoff, *Royal Free Hospital School of Medicine, London, U.K.*

Th.B.P.23 High Burden of Epstein-Barr Virus in HIV-Infected Hemophiliac Patients. *Ciro V. Sumaya*, R. Martinez, R. Parmley, J. Drake, Y. Ench, *University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX, U.S.A.*

Th.B.P.24 HTLV-I in Hemophiliacs. *María Belén Bouzas*, I. Mathov, G. Muchinik, R. Campestri, R. Pérez Bianco, G. Vercauteren, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.B.P.25 Significance of Viral Superinfections by HTLV-I, EBV and CMV for Immunological Disorder in HIV-Infected Hemophiliacs. *Susumu Okubo*, K. Yasunaga, *Kansai Medical University, Osaka, Japan.*

Hémophilie : aspects psycho-sociaux
Hemophilia: Psycho-Social

Th.B.P.26 Living with HIV: A Weekend Retreat for Teenagers and Young Adults with Hemophilia. *Jacqueline Martin*, L. Lindner, J. Neil, *Hemophilia Assessment Clinic, The Arthritis Society, Vancouver, BC, Canada.*

Th.B.P.27 Responding to the Palliative Care Needs of Persons with Hemophilia and AIDS. *Nena M. Nera*, R. J. Shearer, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

Th.B.P.28 Psychosocial Management of HIV Infection among Hemophiliacs in Western Canada. *Wilma M. McClure*, L. Lindner, J. McDonald, C. Bell, N. Schwetz, J. Akabutu, et al., *Northern Alberta Comprehensive Hemophilia Centre, University of Alberta, Edmonton, AB, Canada.*

Th.B.P.29 AIDS and Hemophilia: Creating Unique Family Dynamics. *Charles M. Roy, Montreal Children's Hospital, Social Service Department, Montreal, QC, Canada.*

Th.B.P.30 Condom Usage Reported by Female Sexual Partners of Asymptomatic HIV Seropositive Hemophilic Men. *William A. Price*, T. Merigan, T. Peterman, *Research Triangle Institute, Research Triangle Park, NC, U.S.A.*

Th.B.P.31 Psychosocial and Neuropsychological Status of Haemophiliacs and Gay Men with HIV Infection: A Controlled Investigation. *José Catalan*, I. Klimes, A. Bond, A. Garrod, A. Day, C. Rizza, *Oxford University Department of Psychiatry, Headington, Oxford, U.K.*

Th.B.P.32 Risk Factors for Psychiatric Distress among Hemophiliacs Infected with HIV. *Mary-Amanda Dew*, M. V. Ragni, P. Nimorwicz, *University of Pittsburgh, School of Medicine, Pittsburgh, PA, U.S.A.*

Th.B.P.33 Prediction of Safer Sex Practices and Psychosocial Distress in Adults with Hemophilia at Risk for AIDS. *Kathy L. Parish*, J. Mandel, J. Thomas, E. Gomperts, *Children's Hospital of Los Angeles, Behavioral Science Section, Los Angeles, CA, U.S.A.*

Th.B.P.34 Guidelines for Dealing with Pregnancy in Seropositive Hemophiliacs and Their Spouses. *Elissa M. Kraus*, D. B. Brettler, A. Forsberg, *Worcester Memorial Hospital, Worcester, MA, U.S.A.*

Th.B.P.35 A Team Response to HIV/AIDS Care in Persons with Hemophilia. *Nena M. Nera*, R. O'Neill, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

Maladies mycobactériennes
Mycobacterial Diseases

Th.B.P.36 Tuberculosis in AIDS Patients in Rio Grande do Sul: A New Epidemic? *Eduardo Sprinz*, M. Kronfeld, *Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

Th.B.P.37 Pulmonary Tuberculosis and AIDS: Bacteriological Results. *Eduardo Barroso Werneck*, R. Silva, A. M. M. Costa, N. L. Boechat, A. L. Kritski, *Institute of Physiology and Pneumology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.*

Th.B.P.38 Thoracic X-Ray Aspects of Tuberculosis in AIDS. *Helio K. Yamashita*, C. A. Accetturi, S. A. Ribeiro, J. N. Stávale, A. M. Kambara, *Escola Paulista de Medicina, Department of Imaging Diagnosis, Sao Paulo, Brazil.*

Th.B.P.39 Gastrointestinal Tuberculosis in AIDS Patients: The Rio Grande do Sul Experience. *Eduardo Sprinz*, M. Kronfeld, *Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

Th.B.P.40 Tuberculosis and AIDS. *Maria Lucia Biancalana*, W. S. Mendes, G. A. Rodrigues, H. N. Stefani, G. C. Levi, J. S. Mendonça, *Hospital do Servidor Publico Estadual, Sao Paulo, Brazil.*

Th.B.P.41 Drug-Resistant Tuberculosis in AIDS and ARC. *Mario C. Raviglione*, A. Pablos-Mendez, R. C. Battan, *Department of Medicine, Cabrini Medical Center, New York, NY, U.S.A.*

Th.B.P.42 Mycobacterium Kansasii Infection in HIV Infected Patients: A 5-Year Review. *Gregory T. Valainis*, L. Cardona, D. Greer, *Tulane University Medical Center, New Orleans, LA, U.S.A.*

Th.B.P.43 Tuberculosis in HIV Patients: Correlation between Natural History, Clinical Presentation and Immunological Status. *Stéphane De Wit*, M. Gerard, B. Sommereijns, N. Clumeck, *St-Pierre University Hospital, Division of Infectious Diseases, Brussels, Belgium.*

Th.B.P.44 Surveillance for HIV/AIDS-Related Tuberculosis (TB) in the United States (U.S.). *Carol A. Ciesielski*, J. Buehler, A. Bloch, R. Berkelman, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.B.P.45 Incidence Diagnosis and Treatment of Mycobacteriosis in AIDS. *Walter Heise*, J. Skörde, K. Nehm, K. Arasteh, R. Habermann, M. L'Age, *Auguste-Viktoria-Hospital, II Internal Medicine Department, Berlin, Federal Republic of Germany.*

Th.B.P.46 Evidence of Another Epidemic: Tuberculosis and HIV in a NYC Community Hospital. *Marie I. Ciacco, St. Clare's Hospital and Health Center, New York, NY, U.S.A.*

Th.B.P.47 Influence of Geographic Distribution on Atypical Mycobacteriosis and Isospora Belli in Rio Grande do Sul (Brazil). *Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.*

Th.B.P.48 Factors Influencing Mortality in Disseminated M. Avium (MAI) Infection in Acquired Immunodeficiency Syndrome (AIDS). *Sadhana S. Sathe*, Z. Kaminski, R. Kapila, P. Kloser, L. Reichman, P. Gasione, *University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ, U.S.A.*

Th.B.P.49 Mycobacterium Kansasii Infection in 15 Patients with Class IV HIV Infection: Clinical and Mycobacteriologic Features. *Renslow Sherer*, S. Blair, K. Muller, F. Kocka, P. Muthuswamy, *Cook County Hospital, Chicago, IL, U.S.A.*

Th.B.P.50 Seroprevalence of HIV Infection in 183 Consecutive Patients with Tuberculosis (TB) at a New York City Hospital. *Robert W. Shafer*, K. D. Chirgwin, A. E. Glatt, M. A. Dahdouh, S. H. Landesman, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

Th.B.P.51 Tuberculosis as AIDS-Associated, Pulmonary Complication. *Nicoló Piersantelli*, B. Guida, *Divisione Malattie Infettive, Opsedale Galliera, Genoa, Italy.*

Th.B.P.52 Tuberculosis in HIV-Infected Individuals in the Province of British Columbia (1983-1988). *Steve Blackie*, S. Vedal, L. M. Lawson, J. Ruedy, J. S. G. Montaner, *St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.*

Th.B.P.53 Fever, Weight Loss, Anemia, Splenomegaly and Abdominal Lymphadenopathy Are Highly Predictive of Disseminated Mycobacteriosis in Patients Who Are HIV Antibody Positive. *Lawrence A. Cone*, D. R. Woodard, D. Wade, N. Curry, W. Boughton, M. Fiala, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A.*

Th.B.P.54 Mycobacterioses and AIDS: Therapeutic Approaches. *Dirk Schürmann*, B. Ruf, H. Mauch, H.-D. Pohle, *Second Department of Internal Medicine, Rudolf Virchow University Hospital Freie Universität Berlin, Berlin, Federal Republic of Germany.*

Th.B.P.55 Detection of Antimycobacterial Antibodies in HIV Infection. *Claire-Michèle Farber*, J. De Bruyn, J. C. Yernault, J. P. Van Vooren, *Hôpital Érasme, Université Libre de Bruxelles, Department of Immunology, Brussels, Belgium.*

Th.B.P.56 Clinical Immunological and Prognostic Aspects of Tuberculosis (TB) in HIV Patients. *Giuseppe Visco*, P. Narciso, G. C. Leoni, P. Sette, F. Spinazzola, V. Tozzi, et al., *"L. Spallanzani" Hospital, Department of Infectious Diseases, Rome, Italy.*

Th.B.P.57 Tuberculose et SIDA en Espagne. *Inmaculada Ocaña*, A. De Luis, I. Ruiz, N. Martí, R. Vidal, J. M. Martínez-Vázquez, *Autonomous University of Barcelona, Barcelona, Spain.*

Th.B.P.58 Generalized Infection with an Unidentified Acid-Fast Micro-organism (AFB). *Nicolas Mach*, H. R. Chang, J. D. Piguet, F. Portaels, R. Auckenthaler, B. Hirschel, et al., *Institut de pathologie, Centre médical universitaire, Geneva, Switzerland.*

Th.B.P.59 Tuberculosis and AIDS in Frankfurt. *Ruth Müller*, K. Koller-Campert, A. Jakschik, R. Brodt, G. Schulze-Werninghaus, E. B. Helm, *Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

Th.B.P.60 MNT Infection in 63 of 328 AIDS Patients in Frankfurt. *Karin Koller-Lampert*, R. Brodt, A. Staszewski, A. Jakschik, E. B. Helm, *Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

Th.B.P.61 Aminoglycoside Antibiotics Have Potential Value in the Treatment of Mycobacterium Avium Complex (MAC) Disease in AIDS Patients. *Pattisapu R. J. Gangadharam*, L. Kesavalu, V. K. Perumal, K. Parikh, N. Ghori, *National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, U.S.A.*

Th.B.P.62 Plasmids Influence Virulence of Mycobacterium Avium Complex (MAC) Strains in AIDS Patients. *Pattisapu R. J. Gangadharam*, V. K. Perumal, J. H. Crawford, J. H. Bates, *National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, U.S.A.*

Th.B.P.63 Incidence of Acquired Immunodeficiency Syndrome (AIDS) in Outpatients with Tuberculosis. *Sandra A. Ribeiro*, S. M. G. P. Togeiro, C. A. Accetturi, H. K. Yamashita, *Department of Preventive Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.*

Th.B.P.64 Tuberculose et SIDA : Faits cliniques observés en milieu hospitalier parisien, implications épidémiologiques. *Françoise Papillon*, J. Chrétien, *Clinique de Pneumophtisiologie, Université Paris V, Hôpital Laennec, Paris, France.*

Th.B.P.65 Tuberculosis in AIDS Patients. *J. A. Iribarren*, J. Arrizabalaga, C. Garde, I. Muñoz-Baroja, E. Pérez-Trallero, D. Zulaica, *Hospital Nuestra Señora de Aránzazu, San Sebastian, Spain.*

Th.B.P.66 Association between Tuberculosis and AIDS in Rio de Janeiro, Brazil. *Carlos Alberto Morais de Sá*, W. Eyer-Silva, R. Severo, M. Guimaraes-Dias, D. P. Oliveira, F. S. Sion, et al., *Gaffrée and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

Th.B.P.67 The Clinical Impact of Mycobacterial Infections in HIV-infected Persons. *Kristi L. Boldt*, L. Miedzinski, G. Taylor, G. A. Evans, S. Chomyc, *University of Alberta, Edmonton, AB, Canada.*

Th.B.P.68 Poor Compliance Is the Major Obstacle in Controlling the HIV-Associated Tuberculosis (TB) Outbreak. *Karen Brudney*, J. Dobkin, *Harlem Hospital, Columbia University, New York, NY, U.S.A.*

Th.B.P.69 Successful Antituberculosis Treatment with Various Drug Regimens in Patients with HIV Infection. *J. A. Carton*, V. Cárcaba, J. A. Maradona, R. Llorente, J. Moris, A. Colmeiro, et al., *Hospital Universitario de Oviedo, Oviedo, Spain.*

Th.B.P.70 Natural History of M. Leprae and HIV Co-infection. *Claude Pean*, J. W. Pape, M. M. Deschamps, M. Dambreville, W. D. Johnson, *Institut Cardinal Léger contre la lèpre, Fame Pereo, Cornell University, New York, NY, U.S.A.*

Th.B.P.71 Mycobacterium Avium-Intracellulare Infection Limited to the Skin and Lymph Nodes in Patients with AIDS. *Daniel J. Barbaro*, B. M. Coldiron, V. L. Orcutt, *University of Texas Southwestern Medical School, Dallas, TX, U.S.A.*

Th.B.P.72 Mycobacterial Infection in AIDS Patients. *Andrea Antinori*, F. Damiano, M. Fantoni, G. Ventura, F. Ardito, C. Archibusacci, et al., *Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.*

Th.B.P.73 Epidemiological and Environmental Features of Mycobacteria Other than Tuberculosis in Germany. *Malte Peters*, B. Ruf, D. Schürmann, K.-H. Schröder, H. Mauch, H.-D. Pohle, *Rudolf Virchow University Hospital, Freie Universität Berlin, Berlin, Federal Republic of Germany.*

Th.B.P.74 Tuberculosis and AIDS: Rio de Janeiro, Brazil. *Afranio Lineu Kritski*, A. Matida, B. Galvao-Castro, *Institute of Physiology and Pneumology of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.*

Immunologie : méthodologie/divers
Immunology: Methodology/Miscellaneous

Th.B.P.75 HIV Infection Alters Immune Response to Cigarette Smoking. *Rachel A. Royce*, W. Winkelstein, Jr., *University of California at Berkeley, Department of Epidemiology, School of Public Health, Berkeley, CA, U.S.A.*

Th.B.P.76 Non-Specific Pneumonitis (NSP) in HIV Seropositive Adults. *Francesco M. Gritti*, V. Poletti, L. Spiga, S. Sabbatani, A. Grillo, *Ospedale Maggiore, Bologna, Italy.*

Th.B.P.77 Expression of Cell Surface "Activation" Antigens in Bronchoalveolar Lavage (BAL) T-Cells from HIV-Infected Patients Undergoing Pneumonitis. *Francisco J. Aspa Marco*, M. L. Jimenez Gonzalez-Adleo, A. Gonzalez, I. Santos-Gil, F. Sanchez Madrid, M. Lopez-Botet, *Hospital de la Princesa, Madrid, Spain.*

Th.B.P.78 Mechanisms Underlying the Functional Impairment of Pulmonary NK Cells from Patients with HIV Infection. *Carlo Agostini*, R. Zambello, V. Poletti, L. Trentin, L. Spiga, G. Semenzato, et al., *Clinica Medica ed Immunologia Clinica, Istituto di Medicina Clinica, Padua, Italy.*

Th.B.P.79 Alveolar Macrophages from Patients with HIV Infections Spontaneously Release Tumor Necrosis Factor. *Carlo Agostini*, L. Trentin, V. Poletti, R. Zambello, L. Spiga, G. Semenzato, et al., *University of Padua, Clinica Medica ed Immunologia Clinica, Istituto di Medicina Clinica, Padua, Italy.*

Th.B.P.80 CD4 Lymphocyte Counts and Serum p24 Antigen of No Diagnostic Value in Monitoring HIV-infected Patients with Pulmonary Symptoms. *Marianne K. Orholm*, T. L. Neilsen, J. D. Lundren, *Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.*

Th.B.P.81 Immunological Subtyping of Leucocytes Obtained from Bronchoalveolar Lavage (BAL) and Peripheral Blood in HIV-Infected Patients with Pneumonia. *Martin Kurt Kaegi*, W. Fierz, C. Kronauer, R. Speich, E. Russi, P. Grob, *University Hospital, Clinical Immunology, Zurich, Switzerland.*

Th.B.P.82 Cutaneous Delayed Hypersensitivity in Drug Addicts. *Antonio Villa*, V. Cruccu, C. Grondonna, G. Guareschi, A. M. Pediconi, F. Confalonieri, *Fatebenefratelli Hospital, Milan, Italy.*

Th.B.P.83 Increased Production of Soluble IL 2 Receptor in Patients with HIV Infection. *Yasuko Yokota*, K. Kitamura, K. Matsuda, R. Mitsuyasu, J.-C. Chermann, M. Honda, *Department of Cellular Immunology, National Institute of Health and Department of Immunology, Tokyo, Japan.*

Th.B.P.84 Changes in CD16 Receptor Expression on the Neutrophils of HIV-Infected Individuals. *J. George Bekesi*, P. Boros, J. P. Roboz, J. C. Unkeless, *Mount Sinai School of Medicine, New York, NY, U.S.A.*

Th.B.P.85 Adenosine Deaminase Isoenzyme in Retrovirus Infected Diseases. *Mitchel Mitsuo Yokoyama*, I. Tsuboi, *Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan.*

Th.B.P.86 CD4+/Neopterin Ration Correlates with p24 Antigenaemia in HIV-infected Patients. *Paolo Crocchiolo*, A. Lizioli, G. Bedarida, F. D'Agostino, G. Cambié, C. Filippi, *Ospedale Maggiore, Infectious Diseases Department, Lodi, Italy.*

Th.B.P.87 Lymphocyte Reactivity to Anti-CD3 as a Prognostic Marker in HIV-1 Infected Homosexual Men. *Marijke T. L. Roos*, F. Miedema, F. de Wolf, J. Lange, P. T. A. Schellekens, *Central Laboratory of Blood Transfusion Service, Department of Clinical (Viro) Immunology, Amsterdam, Netherlands.*

Th.B.P.88 Neutrophil Radical Release and Lipid Peroxidation in HIV Infected Patients. *Connie Jarstrand*, G. Carlin, A. Sönnerborg, B. Åkerlund, *Huddinge Hospital, Huddinge, Sweden.*

Th.B.P.89 Impairment of Polymorphonucleocyte (PMN) Chemotactic and Bactericidal Function in HIV-Infected Children. *Emmanuel Roilides*, S. Mertins, J. Eddy, D. Venzon, T. Walsh, P. Pizzo, et al., *National Cancer Institute, Bethesda, MD, U.S.A.*

Th.B.P.90 Oxidative Burst Activity and Cell Surface Antigen Expression of Monocytes from Asymptomatic HIV-infected Individuals (AHI). *Alan L. Landay*, H. Kessler, C. Benson, J. Phair, L. R. Rothberg, G. Spear, et al., *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A.*

Th.B.P.91 Stratification of HLA Alloantigen Presenting Cell Function in Patients with AIDS. *Alan L. Landay*, M. Clerici, H. Kessler, G. Shearer, *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A.*

Th.B.P.92 In Situ Demonstration of IL2 Production in Lymph Nodes of HIV-1 Positive Patients with PGL. *Michel Peuchmaur*, D. Emilie, M. C. Crevon, J. F. Delfraissy, G. Lemaigre, P. Galanaud, *INSERM Unité 131, Clamart, France.*

Th.B.P.93 Variability in Isotype-Specific Immunoglobulin (Ig) Secreting Cells in Asymptomatic HIV Infection. *André J. Nahmias*, T. Spira, F. Lee, C. Reimer, L. Bozeman, S. Nesheim, *Emory University School of Medicine, Atlanta, GA, U.S.A.*

Th.B.P.94 Impaired IgM Production and Mitogen-Induced Suppression of Immunoglobulins by Mononuclear Cells from AIDS Patients. *Edward Janoff*, P. D. Smith, S. M. Wahl, *Veterans Administration Medical Center, Minneapolis, MN, U.S.A.*

Th.B.P.95 Increased Spontaneous Release of CD8 Antigen from CD8+ Cells Reflects the Clinical Progression of HIV-1 Infected Individuals. *J. George Bekesi*, F. N. Chu, P. H. Tsang, J. P. Toboz, J. I. Wallace, *The Mount Sinai School of Medicine, New York, NY, U.S.A.*

Th.B.P.96 HIV and Bone Marrow Progenitors Proliferation. *Enrica Tamburrini*, F. Pallavicini, A. Antinori, A. Candido, *Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy.*

Th.B.P.97 Studies on the In Vitro Secretion of HIV-1 Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. *Arlette Serre*, P. Corbeau, J.-P. Vendrell, J. Ducos, J. Reynes, M.-F. Huguet, et al., *Université Montpellier 1, Hôpital Lapeyronie, Montpellier, France.*

Th.B.P.98 Enhanced TNF Production in Peripheral Blood Mononuclear Cells of HIV-1 Infected Patients. *Siegbert Rossol*, R. Voth, S. Brunner, K. Klein, M. Büttner, W. E. G. Müller, et al., *University of Mainz, 1 Med. Klinik, Mainz, Federal Republic of Germany.*

Th.B.P.99 Normal and HIV-associated Fungicidal Activity of Monocytes. *Enrica Tamburrini*, A. Antinori, G. Morace, S. Manzara, L. Ortona, *Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy.*

Th.B.P.100 Augmentation de la production de radicaux libres de l'oxygène par les phagocytes circulants des malades infectés par le virus HIV-1. *Dominique A. Vuitton*, J.-M. Didier, J. Vuillier, M. A. Bertrand, C. Drobacheff, Cellule «SIDA» du CHU-Franche-Comté, *Service de médecine interne et immunologie clinique, Besançon, France.*

Th.B.P.101 Refractoriness of B Cells to Regulation by LGL in HIV Infection. *Gloria Echeverría de Pérez*, L. Deibis, R. Ramirez, Z. Rios, M. De Marquez, I. Blanca, et al., *Clinical Immunology, National Center, Central University, Caracas, Venezuela.*

Th.B.P.102 Activated T-Cells (TC) and Human Immunodeficiency Virus (HIV) Progression. *R. Neal Boswell*, T. Freeman, N. Boswell, R. Hensley, C. Butzin, *Wilford Hall, USAF Medical Center, San Antonio, TX, U.S.A.*

Th.B.P.103 Decreased Lymphocyte Proliferation Towards Pokeweed Mitogen Appears as a Very Early Marker in HIV Infection. *P. Henrivaux*, K. Huygen, Y. Fairon, *CHU Sart Tilman, Internal Medicine/Hematology, State University of Liège, Liège, Belgium.*

Th.B.P.104 In Vitro B-Cell Differentiation in Normals, rGP160 Vaccinated Volunteers, and HIV+ Subjects. *James M. Reuben*, L. Liang, S. Li, S. Greenberg, G. Smith, R. Couch, *University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A.*

Th.B.P.105 Usefulness of Lymphoblastic Transformation Test (L.T.T.) in Asymptomatic Patients (II and III Status of CDC Classification). *Claude Beuscart*, A. Coget, B. Sivery, O. Leroy, Y. Mouton, A. Fourrier, *Service régional des maladies infectieuses, Centre hospitalier Tourcoing, Tourcoing, France.*

Th.B.P.106 Impact of 3'-Azido-3'-Deoxythymidine (AZT) on the In Vitro Immunoglobulin Secretion in a Pokeweed Nitrogen-Driven Cell System. *Finn T. Black*, P. Tauris, C. M. Peterson, B. Moller, *Department of Medicine and Infectious Diseases, University of Aarhus, Aarhus, Denmark.*

Th.B.P.107 Inhibition of Lymphocyte Proliferation Induced by Microbial Antigens in HIV-Infected Individuals. *Rui M. M. Victorino*, V. A. J. Maria, L. A. Pinto, *Faculty of Medicine of Lisbon, Lisbon, Portugal.*

Th.B.P.108 Estimation of Best Absolute CD4 Count from Multiple Pairings in Two-Color Flow Cytometry. *Joyce C. Niland*, Transfusion Safety Study Group, *City of Hope National Medical Center, Department of Biostatistics, Duarte, CA, U.S.A.*

Th.B.P.109 Identification of Multiple HIV-1 Core Proteins on Western Blot by a Monoclonal Antibody. *Chi-Ming Liang*, S. Henry, J. S. Epstein, *Division of Blood and Blood Products, Food and Drug Administration, Bethesda, MD, U.S.A.*

Th.B.P.110 Evaluation of Sensitivity and Specificity of Synthetic Peptide and Recombinant Based Anti-HIV-1 and -2 EIA. *Peter W. Joller*, H. I. Joller-Jemelka, *ANAWA Laboratories Inc., Wangen, Switzerland.*

Th.B.P.111 Development of a Method for Correlating the Presence of HIV Antigen and Provirus. *David B. Paul*, M. Bankowski, M. Kuhns, A. McNamara, A. L. Landay, G. T. Spear, *Rush University, Chicago, IL, U.S.A.*

Th.B.P.112 Human Immunodeficiency Virus (HIV) Expression and Antigenic Stability of HIV-Infected Cells for Use in Flow Cytometric Immunofluorescence Assay (FIFA). *Julie M. Sligh*, S. T. Roodman, A. P. Knutsen, C. C. Tsai, *St. Louis University School of Medicine, Department of Pathology, St. Louis, MO, U.S.A.*

Th.B.P.113 Immunodosage type ELISA des antigènes membranaires CD4 et CD8 de lymphocytes provenant de sujets sains ou infectés par le virus HIV. *Dominique Carrière*, C. Fontaine, H. Rabesandratana, A. Serre, J. P. Vendrell, M. Andary, et al., *Sanofi Recherches, Montpellier, France.*

Th.B.P.114 Simple Laboratory Tests as Markers for the Various Clinical Manifestations of HIV Infection. *Dirceu B. Greco*, U. H. M. Paulino, I. Adams, M. A. A. Vitoria, C. L. Praça, C. C. Castro, et al., *Federal University of Minas Gerais, Immunodeficiency Clinic, Minas Gerais, Brazil.*

Th.B.P.115 Comparison of the Simultaneous Administration of Intradermal (ID) and Merieux Multitest CMI (MM) Skin Test Methods in HIV-1 Seropositive Patients. *Douglas L. Mayers*, W. L. Ebbeling, D. L. Goodman, K. F. Wagner, *Infectious Diseases Division, National Naval Medical Center, Bethesda, MD, U.S.A.*

Th.B.P.116 Phenotypic Analysis of Lymphocyte Subsets in the Diffuse Infiltrative Lymphocytosis Syndrome Associated with HIV Infection. *Silviu Itescu*, L. Brancato, J. Dalton, R. Perdue, R. Winchester, *Hospital for Joint Diseases, New York University Medical Center, New York, NY, U.S.A.*

Th.B.P.117 Antibodies to Sulfamethoxazole (SMX) in Normal, Allergic, HIV-Infected, and AIDS Patients. *Timothy J. Sullivan*, R. Davidson, R. Budens, S. Nightingale, *University of Texas, Southwestern Medical Center, Dallas, TX, U.S.A.*

Th.B.P.118 HIV-Infected Subjects Respond to Polio Vaccination Booster According to T4 Cell Count. *Nurit Vardinon*, R. Handsher, V. Zackut, M. Burke, A. Hasner, I. Yust, *Tel Aviv Medical Center, Tel Aviv, Israel.*

Th.B.P.119 The Effect of Vaccination against Hepatitis B on the CD4+ Cell Count in Anti-HIV Positive Men. *Klaus Gutfreund*, D. Cheatham-Speth, S. Rossol, R. Voth, R. Clemens, G. Hess, *University of Mainz, Mainz, Federal Republic of Germany.*

Th.B.P.120 Immunologic Aspects of Multiple Simultaneous Vaccinations in HIV Seropositive Subjects. *Joanne Rhoads*, D. L. Birx, R. R. Redfield, D. S. Burke, *Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

Th.B.P.121 Correlation between Histological Changes in Lymph Nodes and Alterations of Cellular Immunity in Drug Addicts at Risk for AIDS. *Eduardo P. Fernandez-Cruz*, J. M. Zabay, J. Tardio, B. Gonzalez, J. Escalona, J. Menarguez, *Hospital General Gregorio Marañon, Complutense University, Madrid, Spain.*

Immunologie : Protéines plasmatiques/Immunité humorale
Immunology: Plasma Proteins/Humoral Immunity

Th.B.P.122 Serum Interferon alpha in Anti HIV-1 Positive Patients Is Different from In Vitro Produced Interferon alpha. *Rike Voth*, S. Rossol, H. P. Laubenstein, M. Büttner, W. E. G. Müller, H. G. Schröder, et al., *University of Mainz, 1 Medizinische Klinik, Mainz, Federal Republic of Germany.*

Th.B.P.123 Serum Immunoglobulin Profile in HIV Infection. *Luis Tavares*, J. Botas, H. Feliciano, C. Carvalho, F. Antunes, J. D. Paiva, et al., *Department of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal.*

Th.B.P.124 Évaluation des antigènes phénoglycolipidique et sulfolipidique de mycobacterium tuberculosis pour le diagnostic sérologique de tuberculose chez les malades ARC et SIDA. *H. C. Berlie*, P. Cruaud, F. Papa, H. David, G. L. Daguet, *Hôpital Saint-Antoine, Paris, France.*

Th.B.P.125 The Composition of Circulating Immune Complexes (CIC) in HIV-Infected Individuals by Clq- and C3d-Binding ELISA. *Thomas A. Schwartzer*, G. Nahass, D. J. Gocke, *Robert Wood Johnson Medical School, New Brunswick, NJ, U.S.A.*

Th.B.P.126 Autoreactivity in Patients Infected with HIV. *R. Neal Boswell*, C. Andrzejewski, J. Benton, S. Valtier, D. Lucey, *Wilford Hall, USAF Medical Center, San Antonio, TX, U.S.A.*

Th.B.P.127 Complement Activation in HIV Infection Occurs through the Classical Pathway and Reflects Disease Severity. *Mark Peakman*, G. Senaldi, T. McManus, E. T. Davies, D. E. H. Tee, D. Vergani, et al., *Department of Immunology, King's College School of Medicine, London, U.K.*

Th.B.P.128 Serum IgD Levels in the Course of HIV Infection. *Jill-Patrice Cassuto*, M. Vivinus, J. F. Quaranta, C. Casasnovas, M. De Matteis, P. Dellamonica, *Médecine interne II, Hématologie, Hôpital de Cimiez, CHRU Nice, Nice, France.*

Th.B.P.129 Monoclonal Gammopathies in HIV Infection. *Jill-Patrice Cassuto*, M. Vivinus, J. F. Quaranta, C. Casasnovas, P. Ferrari, P. Dellamonica, *Médecine interne II, Hématologie, Hôpital de Cimiez, CHRU Nice, Nice, France.*

Th.B.P.130 Adenosine Deaminase (ADA) Levels in Tears of AIDS Patients and AIDS Carriers. *Kotaro Eto*, I. Tsuboi, Y. Saneyoshi, H. Yoshioka, M. M. Yokoyama, *Department of Immunology, Kurume University of Medicine, Fukuoka, Japan.*

Th.B.P.131 Bullous Pemphigoid (BP) Type Antibodies in HIV-Infected Patients. *Sabine Kinloch de Loes*, L. Didierjean, J.-H. Saurat, *Hôpital cantonal, Clinique de dermatologie, Geneva, Switzerland.*

Th.B.P.132 Comparison of the Immunoglobulins (IG) Profile between White Patients (PTS) Infected in Africa (WA), White PTS Infected in Europe (WW) and Black PTS Infected in Africa (AA). *B. Vandercam*, D. Zenagui, M. Cahill, M. Omar, P. Fernez, F. Zech, *Department of Internal Medicine, St-Luc University Hospital, Brussels, Belgium.*

Th.B.P.133 Antibodies to Endogenous Interferon- in Controls and HIV-Infected Persons in Different Disease States. *Peter W. Joller*, H. I. Joller-Jemelka, *ANAWA Laboratories Inc., Wangen, Switzerland.*

Th.B.P.134 Complement Levels and Circulating Immune Complexes in a Controlled, Longitudinal Multicenter Study on Effects of Intravenous Immunoglobulin (IVIG) in Adults with ARC/WR5. *Peter J. Späth*, G. Mauff, *Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland.*

Th.B.P.135 Serum IgE Levels Vary with Absolute CD4A Lymphocyte Counts in HIV-Positive Persons. *Daniel R. Lucey*, R. Zajac, G. Melcher, C. Butzin, R. N. Boswell, *HIV Unit, Wilford Hall Medical Center, SGHMMI, Lackland AFB, San Antonio, TX, U.S.A.*

Th.B.P.136 Plasma Fibronectin (PFN) Levels in Patients with HIV Infection. *Donato Torre*, C. Sampietro, M. Issi, G. Ferraro, A. Bascialla, *Division of Infectious Diseases, Varese Regional Hospital, Varese, Italy.*

Th.B.P.137 Serum and Salivary Immunoglobulins to Candida in HIV Positive Individuals. *David Wray*, D. H. Felix, *University of Edinburgh, Department of Oral Medicine and Oral Pathology, Edinburgh, U.K.*

Th.B.P.138 Serum Prolactin Levels in Patients with Human Immunodeficiency Virus (HIV) Infection. *Robert P. Nelson*, D. N. Wright, D. H. Russell, D. K. Ledford, R. F. Lockey, R. A. Good, *All Children's Hospital, University of South Florida College of Medicine, St. Petersburg, FL, U.S.A.*

Th.B.P.139 Activation of the Alternative Complement Pathway (AP) in Different Stages of HIV Infection. *Eszter Ujhelyi*, T. Hidvégi, M. Kirschfink, G. Füst, D. Bánhegyi, I. Zimony, et al., *National Institute of Haematology and Blood Transfusion, Budapest, Hungary.*

Th.B.P.140 Granulocyte-associated Immunoglobulins in Asymptomatic HIV-Infected Subjects. *Jean-Jacques Lefrère*, J. C. Cartron, J. L. C. Celton, P. R. Rouger, *Institut National de transfusion sanguine, Paris, France.*

Th.B.P.141 Anticardiolipin Antibody (ACA) in Patients with Human Immunodeficiency Virus (HIV) Infection. *Ramon A. Arroyo*, R. N. Boswell, R. Brey, J. Higgs, N. Harris, *Wilford Hall USAF Medical Center, Lackland AFB, TX, U.S.A.*

Th.B.P.142 CD4+ Lymphocyte Autoantibodies as Indicators of Disease Progression in HIV Infection. *Volker Daniel*, R. Weimer, K. Schimpf, G. Opelz, *Department of Transplantation-Immunology, Institute of Immunology, Heidelberg, Federal Republic of Germany.*

Th.B.P.143 Predictive Value of IgE in HIV Disease. *Françoise Labrousse*, D. Israel-Biet, J. M. Tourani, H. Sors, J. M. Andrieu, P. Even, *Hôpital Laennec (Biochimie), Paris, France.*

Immunologie : molécules CD4 et autres marqueurs
Immunology: CD4 and Other Markers

Th.B.P.144 The Relationship of CD-8 Lymphocyte Counts to AIDS Progression in HIV Seropositive Men. *Robert E. Anderson*, W. Lang, S. Shiboski, N. Jewell, M. Busch, W. Winkelstein, *ViRx, Inc., San Francisco, CA, U.S.A.*

Th.B.P.145 A Follow-up of Immune Parameters in HIV-infected Patients Treated with Low Dose Azidothymidine (AZT). *Philippe Henrivaux*, K. Huygen, Y. Fairon, *Hôpital Universitaire du Sart Tilman, Service de Médecine Interne-Hématologie, Liège, Belgium.*

Th.B.P.146 An Update on the Lymphocyte Immunophenotyping Quality Assurance Program in Support of the Army HIV Studies. *William J. Rickman*, M. L. J. Waxdal, C. Monical, J. D. Damato, D. S. Burke, *Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

Th.B.P.147 Sous-populations de lymphocytes T CD4+ CD45R+(2H4+) et CD4+CDW29+(4B4+) chez 70 patients avec infection VIH. *Christiane Caudie*, F. Barbier, F. Touraine, J. M. Livrozet, C. P. Quincy, J. L. Touraine, *Laboratoire d'immunobiologie, Hôpital Neurologique, Lyon, France.*

Th.B.P.148 CD4 and Total Lymphocyte Count (TLC) in Patients with Antibodies to HIV. Predicting Value, Clinical Significance and Long-term Follow-up Variance. *Bonaventura Clotet*, A. Jou, J. Tor, G. Sirera, M. Dominguez, J. M. Gimeno, et al., *Badalona Hospital "Germans Trias i Pujol", Barcelona, Spain.*

Th.B.P.149 Consistency of Routine CD4+, CD8+ Peripheral Lymphocyte Measurements. *Jean-Pierre Aboulker*, B. Autran, F. Touraine, N. Tubiana, J. D. Bignon, *INSERM U21, Villejuif, France.*

Th.B.P.150 Immunological Features in HIV-1 Positive Patients: Clinical Correlation. *G. Luzi*, I. Mezzaroma, C. Papetti, A. M. Pesce, E. Pinter, M. Cherchi, et al., *Department of Allergy and Clinical Immunology, University of Rome, Rome, Italy.*

Th.B.P.151 Immunological Parameters of HIV-1 and HIV-2 Seropositives. *Bernard M. Le Guenno*, J. L. Sarthou, *Institut Pasteur de Dakar, Dakar, Senegal.*

Th.B.P.152 A Longitudinal Study of Lymphocyte Surface Markers in a Population of 200 HIV +ve Intravenous Drug Abusers. *James A. Whitelaw*, G. Bird, R. Brettle, L. MacCallum, P. Flegg, R. Robertson, *Blood Transfusion Service, Edinburgh, U.K.*

Th.B.P.153 Relations between Distribution Patterns of Leu8- Subsets among CD4- and CD8- T-Lymphocytes in the Peripheral Blood. *Bernhard Thiele*, R. O. F. Kunze, R. Krasser, P. Trinkler, I. Ehm, G. Pauli, *AIDS-Zentrum, Robert-Koch Institut, Berlin, Federal Republic of Germany.*

Th.B.P.154 Prediction of CD4-CD8 Ratios from Serum Parameters. *Bernhard Thiele*, R. O. F. Kunze, R. Krasser, P. Trinkler, G. Pauli, A. Beck, *AIDS-Zentrum Robert-Koch Institut, Berlin, Federal Republic of Germany.*

Th.B.P.155 Correlation of In Vivo Cellular Immune Function with CD4 Number and Disease Progression in HIV Seropositive Patients. *Deborah L. Birx*, J. Rhoads, E. Tramont, C. Oster, D. Burke, R. Redfield, *Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A.*

Th.B.P.156 HIV-2 Infection and Immunodeficiency. *Anne-Grethe Poulsen*, I. Lisse, P. Aaby, B. B. Kvinesdal, K. Molbak, F. Dias, et al., *Statens Seruminstitut, Copenhagen, Denmark.*

Th.B.P.157 Blood and Cerebrospinal Fluid (CSF) Lymphocyte Phenotyping and HIV-1 p24 Antigen (AG) Detection in HIV-1 Infected (HIV+) Zairians with and without Neurologic Symptoms. *Christopher Brown*, T. Quinn, N. Lubaki, J. Perriens, *Projet SIDA, Kinshasa, Zaire.*

Th.B.P.158 Évolution des différentes sous-populations CD4 et CD8 au cours de l'infection par le virus HIV-1. *Marcella Arras*, S. Piras, A. Pintus, S. Piro, E. Sulis, L. Contu, *Cattedra di Genetica Medica, Università di Cagliari, Cagliari, Sardinia, Italy.*

Th.B.P.159 Immunologic Abnormalities of Seropositive and Negative Gay Men. *Mary A. Fletcher*, N. G. Klimas, G. Ironson, A. Laperriere, N. Schneiderman, *University of Miami School of Medicine, Miami, FL, U.S.A.*

Th.B.P.160 Depletion of CD16 NK Cells in HIV Infection Due to a Selective Decline in the CD16+ CD8+ Compartment. *Christian Doinel*, I. Mansour, P. Bourin, J. J. Lefrère, M. C. Meyohas, C. Salmon, et al., *Institut National de transfusion sanguine, Paris, France.*

Th.B.P.161 AIDS Predictors. *Ruben Sher, School of Pathology, University of Witwatersrand, Johannesburg, South Africa.*

Th.B.P.162 Dichotomy of Two CD8+ Lymphocyte Subsets in HIV-Infected Patients: Depletion of CD8+ CD3- and Expansion of CD8+ CD3+ Subsets. *Christian Doinel*, I. Mansour, P. Bourin, H. Roquin, J. J. Lefrère, P. Rouger, *Institut National de transfusion sanguine, Paris, France.*

Th.B.P.163 Comparison of T4 Count, CD4%, and T4/T8 Ratio with Correlation to Clinical Stage of HIV-1. *Joseph L. Malone*, K. F. Wagner, D. L. Mayers, B. B. Hendrick, E. T. Coffin, D. B. Wilson, *Naval Hospital, San Diego and National Naval Medical Center, Bethesda, MD, U.S.A.*

Th.B.P.164 A Longitudinal Study of Lymphocyte Surface Markers in a Population of 200 HIV+ Intravenous Drug Abusers (IVDA). *James A. Whitelaw*, A. G. Bird, R. P. Brettle, J. R. Robertson, J. R. MacCallum, P. J. Flegg, *HIV Immunology Laboratory, Blood Transfusion Service, Royal Infirmary, Edinburgh, U.K.*

Th.B.P.165 Blood and Cerebrospinal Fluid (CSF) Lymphocyte Phenotyping (LP) and HIV-1 p24 Antigen (AG) Detection in HIV-1 Infected (HIV+) Zairians with (N+) and without (N-) Neurologic Signs. *Christopher C. Brown*, T. Quinn, M. Lubaki, J. Perriens, *Projet SIDA, Kinshasa, Zaire.*

Th.B.P.166 T and B Lymphocyte Subset Distributions within Clinical Stages of HIV-1 Infected Patients. *Maryse Levacher*, S. Tallet, F. Hulstaert, J. Lowder, J. J. Pocidalo, *Hôpital Claude-Bernard, Paris, France.*

Th.B.P.167 Appeareance of T-Cells of Intrathymic Phenotype (CD3+ CD4+ CD8+) in the Peripheral Blood of a Patient with AIDS. *Michael Baseler*, W. Urba, C. Budzyn, R. Stevens, J. Kasper, M. Psallidopoulos, et al., *PRI, Frederick, MD, U.S.A.*

Th.B.P.168 Kinetics of Activated T Lymphocytes (CD3/DR+), NK Cells (Leu7+/2-) and "Unstained Cells" in the Course of HIV Infection. *Johannes R. Bogner*, A. Matuschke, B. Heinrich, H. S. Füeßl, F.-D. Goebel, *Medizinische Poliklinik, Universität München, Munich, Federal Republic of Germany.*

Immunologie : réactions immunitaires
Immunology: Antibody Responses

Th.B.P.169 Densitometric Analysis of HIV-1 Serology on Immunoblotting: Prognostic Interest. *Jacques Ritter*, S. Escaich, P. Chevallier, C. Trepo, M. Sepetjan, *Laboratoire de santé publique, Lyon, France.*

Th.B.P.170 Correlation of Clinical Diagnosis of HIV Infection with the Results of ELISA, Karpas Cell Test and Western Blot for Anti-HIV Antibodies. *Dirceu B. Greco, Federal University of Minas Gerais, Immunodeficiency Clinic, Minas Gerais, Brazil.*

Th.B.P.171 Secretory and Systemic Immunity in HIV-Infected Individuals. *Di Sun*, P. Furth, D. Archibald, *University of Maryland Dental School, Baltimore, MD, U.S.A.*

Th.B.P.172 IgG Subclass Antibodies against Synthetic Peptides of HIV-1 Proteins in HIV-1 Infected Individuals. *Bernhard Schwartländer*, B. Bek, R. O. F. Kunze, G. Pauli, *AIDS-Zentrum, Bundesgesundheitsamt, Berlin, Federal Republic of Germany.*

Th.B.P.173 Indeterminate HTLV-I Immunoblot Reactivity in Low and High HTLV-I Seroprevalence Groups: Probability of Resolution of Indeterminate Immunoblot Results by Radioimmunoprecipitation Assay. *Trudie M. Hartley*, R. F. Khabbaz, R. O. Cannon, J. E. Kaplan, M. D. Lairmore, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

Th.B.P.174 Salivary IgA to HIV in Patients with or at Risk of AIDS. *Károly Nagy*, A. Voevodin, E. Drexler, *Institute of Isotopes of the Hungarian Academy of Sciences, Budapest, Hungary.*

Th.B.P.175 Class-Specific Antibodies to Human Immunodeficiency Virus-1 (HIV) in Small Intestinal Fluids from AIDS Patients. *Edward Janoff*, P. D. Smith, S. M. Wahl, *Veterans Administration Medical Center, Minneapolis, MN, U.S.A.*

Th.B.P.176 Antibodies to Human Immunodeficiency Virus in Seroconverters with a Rapid Test. *Céleste Chenet-Monte*, C. H. Riggin, *Cambridge Bioscience Corp., Worcester, MA, U.S.A.*

Th.B.P.177 Differing Sensitivity of Three HIV-1 Antigen-Capture Assays to the Presence of HIV-1 Antibody. *James E. Drummond*, D. J. Waters, L. O. Arthur, J. W. Bess, W. A. Blattner, *NCI-Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A.*

Th.B.P.178 Distribution of Anti-nef Antibodies in 26 HIV Seronegative Stable Sexual Partners of HIV Seropositive Patients: Epidemiological Correlation. *Yves Mouton*, B. Sivery, J. C. Ameisen, M. Maniez, C. Beuscart, A. Capron, *Service régional des maladies infectieuses, Centre hospitalier, Tourcoing, France.*

Th.B.P.179 Western Blot and PCR Reactivity Patterns in Individuals at High Risk for HIV Exposure. *Richard T. Davey*, J. Metcalf, M. Easter, V. Vasudevachari, M. Psallidopoulos, H. C. Lane, et al., *National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.S.A.*

Th.B.P.180 Positive HIV Western-Blot Reactions in Serum Samples from LED Patients Non-Infected by HIV. *Nicolas Dolivo*, P. Burgisser, P. C. Frei, *Centre hospitalier universitaire Vaudois, Division of Immunology/Allergy, Lausanne, Switzerland.*

Th.B.P.181 HIV-Antigen, Various Antibodies and T4 Cell Counts as Markers of Clinical Progression in HIV Infection. *Andrea Kleinschmidt*, A. Matuschke, D. Schuster, S. Schewe, W. Mellert, G. G. Frösner, *GSB-Abteilung für Molekulare Zellpathologie, Neuherberg, Federal Republic of Germany.*

Th.B.P.182 Correlation between HIV-1 p24 Antigenemia, Anti-p24 Antibody and Neutralizing Antibody Response in All Stages of HIV-1 Infection. *J. George Bekesi*, P. H. Tsang, F. N. Chu, P. Mason, Y. Sei, J. I. Wallace, et al., *The Mount Sinai School of Medicine, New York, NY, U.S.A.*

Th.B.P.183 Prospective Multicenter Cohort Study in Homosexual Men in FRG. Observation of Immunological Parameters in a 4-Year Follow-up. *Bernhard Schwartländer*, J. Koch, G. Pauli, *AIDS-Center, Federal Health Office, Berlin, Federal Republic of Germany.*

Th.B.P.184 Relation of Antigenaemia, Loss of Antibodies to Human Immunodeficiency Virus Reverse Transcriptase (RT) and Impairment of Cellular Immunity to Development of AIDS in Drug Addicts. *Eduardo P. Fernadez-Cruz*, M. Garcia-Montes, N. Longo, B. Gonzalez, A. Fernandez, J. M. Zabay, *Hospital General Gregario Marañon, Complutense University, Madrid, Spain.*

Th.B.P.185 Neutralizing Antibodies in HIV Patients: A 3-Year Follow-up. *Michael Gesemann*, N. Brockmeyer, O. Thraenhart, *Institute for Medical Virology and Immunology, University of Essen, Medical School, Essen, Federal Republic of Germany.*

Th.B.P.186 Prevalence of HIV-1 p24 Antigen (AG) in Different Populations at Risk for HIV-1 Infection in Zaire: A Comparison of Three Commercial AG Assays. *Christopher Brown*, L. Stibu, R. Kline, R. Ryder, A. Nelson, T. C. Quinn, et al., *Projet SIDA, Kinshasa, Zaire.*

Th.B.P.187 HIV Antigenemia in Various Clinical Stages of HIV Infection in African Patients. *Philippe Lepage, Department of Pediatrics, Centre hospitalier de Kigali, Kigali, Rwanda.*

Neurologie : généralités
Neurology: General

Th.B.P.188 The Spectrum of Altered Mentation in AIDS and ARC. *Renée Malouf*, G. Jacquette, J. Dobkin, J. C. M. Brust, *Harlem Hospital Center, Columbia University, New York, NY, U.S.A.*

Th.B.P.189 Acquired Immunodeficiency Syndrome: Neurologic Complication in 44 Cases. *M. P. Sohler*, A. C. O. Favoretto, C. André, C. A. Peixoto, S. A. Novis Pereira, *Universidade Federal do Rio de Janeiro, Hospital Universitário Neurology, Rio de Janeiro, Brazil.*

Th.B.P.190 Orthostatic Hypotension (OH) in HIV+ Patients May Represent Generalized Autonomic Nervous System (ANS) Dysfunction. *Jeffrey Allen Cohen*, L. Miller, L. Polish, *University of Colorado School of Medicine, Denver General Hospital, Denver, CO, U.S.A.*

Th.B.P.191 Possible Pathogenetic Role of Immune Complexes in HIV-Related Autonomic Neuropathy. *Franco Confalonieri*, A. Villa, V. Cruccu, V. Foresti, E. Parisio, N. Scolari, *Fatebenefratelli Hospital, Milan, Italy.*

Th.B.P.192 Two Years Neurological Follow-up Study in HIV-Positive Hemophiliacs: Do Any Prognostic Data Exist? *Rolf R. Riedel*, P. Clarenbach, P. Bülau, C. Helmstadter, C. Bruzki, K. Wirtz, et al., *University Clinic, Department of Neurology, Bonn, Federal Republic of Germany.*

Th.B.P.193 Incidence of the AIDS Dementia Complex as the First Manifestation of AIDS: A Prospective Study. *Josep Abos Navarro*, F. Graus Ribas, J. Alom Poveda, J. Miro Meda, J. Gatell, E. Tolosa Sarro, *Hospital Clinic I Provincial, University of Barcelona, Barcelona, Spain.*

Th.B.P.194 Myelopathy as Presentation of AIDS: Treatment with AZT. *Clara Schiantarelli*, L. Caggese, I. Schlacht, M. Gasparini, P. L. Oreste, M. R. Villa, *Niguarda Ca' Granda Hospital, Milan, Italy.*

Th.B.P.195 Neuropsychological Follow-up of Subjects on AZT Licensing Trial: San Diego Cohort. *Jacqueline Day*, I. Grant, J. H. Atkinson, L. Brysk, J. McCutchan, R. K. Heaton, et al., *University of California at San Diego and San Diego State University, San Diego, CA, U.S.A.*

Th.B.P.196 Peripheral Neuropathies and HIV Infection: Spectrum and Natural History. *Dominique Hénin*, J.-M. Léger, F. Bolgert, M. Rosenheim, P. Bouche, M. Chaunu, et al., *Service de Neurologie, Hôpital de la Salpêtrière, Paris, France.*

Th.B.P.197 A System for Staging the AIDS Dementia Complex: Correlations with Neurological and Neuropsychological Assessments. *Richard W. Price*, B. J. Brew, J. J. Sidtis, A. Sadler, J. Kielp, W. Wolf, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.198 Pharmacokinetic Analysis of the Enhanced Distribution of Zidovudine into Rabbit Cerebrospinal Fluid Caused by Probencid. *Ronald J. Sawchuk*, M. A. Hedaya, *University of Minnesota, MN, U.S.A.*

Th.B.P.199 Transfusion-Related HTLV-I Neurological Disease: A Putative Marker of Disease Activity and Response Therapy. *Bruce J. Brew*, W. Hardy, B. Poiesz, G. Ehrlich, M. Larimore, R. W. Price, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.200 Neuropsychological Follow-up of 1,787 Participants in the Multicenter AIDS Cohort Study. *Barbara R. Visscher*, E. Miller, P. Satz, J. McArthur, O. Selnes, B. Cohen, et al., *School of Public Health, University of California at Los Angeles, Los Angeles, CA, U.S.A.*

Th.B.P.201 The Epidemiology of AIDS-Related Neurological Diseases. *Mary J. Wilson*, G. F. Lemp, D. Neal, A. Vlamis, D. D. Ferguson, G. W. Rutherford, *California Department of Health Services, San Francisco, CA, U.S.A.*

Th.B.P.202 Neuropsychological Follow-up in Patients Who Have Progressed to AIDS: The Multicenter AIDS Cohort Study (MACS). *Ola A. Selnes*, E. N. Miller, J. C. McArthur, B. Cohen, J. T. Becker, A. Saah, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

Th.B.P.203 Neurological Involvement in Group IV HIV+ Patients: Neurophysiological and Clinical Data. *Massimo Di Pietro*, P. Paci, F. Mazzotta, F. Pinto, A. Grippo, M. G. Colao, et al., *Ospedale Careggi, Divisione Malattie Infettive, Florence, Italy.*

Th.B.P.204 Effect of Mannitol IV Infusion on Distribution of Zidovudine between Plasma and Cerebrospinal Fluid in Rabbits. *Yanfeng Wang*, M. A. Hedaya, R. J. Sawchuk, *University of Minnesota, Minneapolis, MN, U.S.A.*

Th.B.P.205 Cranial Neuropathies in AIDS Patients. *Edwin M. Lewis*, S. Mahawar, A. M. Wesely, D. E. Bredesen, *University of California at San Francisco, San Francisco, CA, U.S.A.*

Th.B.P.206 Neurologic Abnormalities among HIV-1 Seropositive Intravenous Drug Users. *Walter Royal*, M. Updike, D. R. Cornblath, O. A. Selnes, L. Solomon, D. Vlahov, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

Th.B.P.207 Subclinical Neuropsychological and Peripheral Abnormalities in HIV+ Patients. *Pedro E. Cahn*, C. Mangone, H. Pérez, A. Casiro, C. Dellepiane, G. Muchinik, et al., *Infectología, Hospital Fernández, Buenos Aires, Argentina.*

Th.B.P.208 Multivariate Statistical Determination of Incidence and Character of Cognitive Impairments in HIV Patients. *Pim Brouwers*, E. Mohr, M. Hendricks, J. Claus, M. Young, P. Pierce, *National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A.*

Th.B.P.209 Peripheral Facial Palsy as a Predictive Indicator of HIV Infection in Central Africa. *Laurent Belec*, P. M. V. Martin, E. Vuillecard, D. Di Costanzo, E. Schuller, A. J. Georges, *Institut Pasteur, Bangui, Central African Republic.*

Th.B.P.210 Declining Incidence of AIDS Dementia Complex and HIV-1 Antigen Detection in the Cerebrospinal Fluid following Systematic Zidovudine Treatment. *Peter Portegies*, J. De Gans, M. M. A. Derix, S. A. Danner, J. M. A. Lange, J. Goudsmit, *University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.*

Th.B.P.211 A Case Definition of AIDS Dementia Complex for Use in African Patients. *Joseph H. Perriens*, M. Mussa, M. Luabeya, K. Kayembe, R. Colebunders, B. Kapita, *Projet SIDA, Kinshasa, Zaire.*

Th.B.P.212 Neurophysiological Manifestations of HIV Infection: A Prospective Study. *Jean-Philippe Chave*, F. Thuillard, G. Assal, M. P. Glauser, *Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.*

Th.B.P.213 CNS Lesions in AIDS: Analysis of 44 Patients. *Roberto Luzzati*, E. Concia, L. Bontempini, M. Malena, R. Mazzi, D. Bassetti, *Institute of Infectious Diseases, University of Verona, Civil Hospital, Verona, Italy.*

Th.B.P.214 Guillain-Barre Syndrome in HIV Infection: Experience from an African Center. *Charles A. Thornton*, A. S. Latif, *University of Zimbabwe School of Medicine, Department of Medicine, Avondale, Zimbabwe.*

Th.B.P.215 Long-term Effects of Treatment with Zidovudine on Neuropsychological Functions in Subjects with ADC. *Ivar Reinvang*, S. S. Frland, A. J. Lundervold, * Department Psychosomatic Medicine, Rikshospitalet, Oslo, Norway.*

Th.B.P.216 Prevalence, Treatment, and Costs of Mental Disorders among Persons with AIDS. *Julia Hidalgo*, F. Schaerf, D. B. Larson, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A.*

Th.B.P.217 Neurological Disturbances Associated with HIV Infection: Experience at an African Center. *Charles A. Thornton*, A. S. Latif, S. Houston, *University of Zimbabwe School of Medicine, Department of Medicine, Avondale, Zimbabwe.*

Th.B.P.218 Effects of Azidothymidine on Neuropsychological Performance in Asymptomatic and Symptomatic HIV-1 Infection: The Multicenter AIDS Cohort Study. *Justin C. McArthur*, E. N. Miller, O. A. Selnes, J. Becker, B. A. Cohen, D. Starky, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

Th.B.P.219 Natural History of Central Nervous System (CNS) Impairment in HIV Infection. *Christine Katlama*, P. Duneton, F. Chieze, H. Agut, P. Brunet, M. Gentilini, *Department de santé publique, Parasitologie, Médecine tropicale, Hôpital de la Salpêtrière, Paris, France.*

Th.B.P.220 Neurological Manifestations in HIV Infection. Analysis of 217 Patients. *Giuseppe Visco*, S. Galgani, G. Piazza, G. Antonucci, O. Armignacco, P. Narciso, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy.*

Th.B.P.221 Neuropsychiatric Findings in HIV-infected Patients at an Infectious Disease Clinic in Kinshasa, Zaire. *Mesu'a-Kabwa Luabeya*, K. Kayembe, M. Mussa, K. A. L. Kayembe, K. A. Izzia, T. D. Kashala, *Tulane University SPHTM, New Orleans, LA, U.S.A.*

Neurologie : études sur le LCR
Neurology: CSF Studies

Th.B.P.222 Markers of HIV Infection in the CNS. *Sonja Zerjav*, D. Jevtovic, B. Brmbolic, V. Suvakovic, M. Sasic, *Institute for Infectious and Tropical Diseases, Virological Laboratory, Belgrade, Yugoslavia.*

Th.B.P.223 Cytokines and Immunoglobulins (Ig) in Cerebrospinal Fluid (CSF) of Anti-HIV-1 Positive, Anti-HTLV-I Negative Asymptomatic Men. *Nancy C. Klimas*, J. Berger, S. Spector, H. Friedman, M. Ashman, M. A. Fletcher, *University of Miami School of Medicine, Department of Medicine, Miami, FL, U.S.A.*

Th.B.P.224 Serotonin Metabolite Deficiency in HIV Infection and AIDS. *Carolyn B. Britton*, S. Kranzler, A. Naini, L. Côté, *HIV Center, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A.*

Th.B.P.225 Intrathecal Synthesis of Free Light Chains in Human Immunodeficiency Virus Type I Infected Patients. *Paolo Gallo*, S. Pagni, M. G. Piccinno, A. De Rossi, L. Chieco-Bianchi, B. Tavolato, *Institute of Neurology, University of Padua, Padua, Italy.*

Th.B.P.226 Activation of the Cellular Immune System in the CNS of HIV-1 Infected Individuals. *Anders B. Sönnerborg*, L. V. Von Stedingk, L. O. Hansson, Ö. Strannegard, *Department of Virology, Central Microbiological Laboratory, Stockholm, Sweden.*

Th.B.P.227 Lack of Relationship between Tryptophan and Neurological Disease in HIV-1 Infected Individuals. *Bruce J. Brew*, M. Heyes, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.228 Cerebrospinal Fluid Findings in Two Patients with Human Immunodeficiency Virus. *R. Alvarado*, R. Andrade-Arzabe, M. A. Pacheco, V. Bartos, R. De La Vega, J. Auza, *San Gabriel Hospital, La Paz, Bolivia.*

Th.B.P.229 Longitudinal CSF Cell and Protein Levels in 258 HIV-Infected US Air Force Personnel. *Douglas W. Marshall*, R. L. Brey, C. A. Butzin, R. A. Zajac, R. N. Boswell, *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A.*

Th.B.P.230 Intrathecal Production of IgG in a Longitudinal Study of 258 HIV-Infected US Air Force Personnel. *Douglas W. Marshall*, R. L. Brey, C. A. Butzin, D. R. Lucey, R. N. Boswell, *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A.*

Th.B.P.231 Intrathecal Antibody Production Assayed by Recombinant Antigens, Purified gp120 and RIPA. *Thomas Weber*, W. Lüke, W. Lüer, J. Mous, D. Stüber, H. Döbeli, et al., *Neurologische Klinik, Universität Göttingen, Göttingen, Federal Republic of Germany.*

Th.B.P.232 Quinolinic Acid Concentrations Are Increased in Plasma and Cerebrospinal Fluid in AIDS and Correlates with AIDS Dementia Complex. *Melvyn P. Heyes*, B. J. Brew, S. P. Markey, A. Martin, R. W. Price, D. Rubinow, et al., *National Institute of Mental Health, Bethesda, MD, U.S.A.*

Th.B.P.233 CSF ß2 Microglobulin as a Marker of the Presence and Severity of AIDS Dementia Complex. *Bruce J. Brew*, R. Bhalla, M. Paul, M. Schwartz, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.234 Adenosine Deaminase (ADA) Values in Cerebrospinal Fluid of Asymptomatic HIV-Infected Patients. *Bonaventura Clotet*, G. Sirera, C. Pastor, J. Romeu, C. Tural, A. Jou, et al., *Hospital "Germans Trias i Pujol", Badalona, Barcelona, Spain.*

Th.B.P.235 Detection of HIV Markers in Cerebrospinal Fluid. *Henri Agut*, A. Devillechabrolle, C. Katlama, P. Duneton, E. Schuller, J. M. Huraux, et al., *Laboratoire de virologie, CERVI, Hôpital Pitié-Salpêtrière, Paris, France.*

Th.B.P.236 Cerebrospinal Fluid and Blood Markers in HIV Seropositive Individuals with and without Neurologic Complications. *Wallace W. Tourtellotte*, E. J. Singer, K. Syndulko, P. J. Ruane, R. Mitsuyasu, *Veterans Administration Medical Center Wadsworth, University of California at Los Angeles, Los Angeles, CA, U.S.A.*

Th.B.P.237 Serotonin Metabolite Deficiency in HIV Infection and AIDS. *Carolyn B. Britton*, S. Kranzler, A. Naini, L. Côté, *HIV Center, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A.*

Th.B.P.238 Increasing CSF Abnormalities in HIV-Infected Individuals with Declining Systemic Immune Status. *Justin C. McArthur*, J. H. McArthur, C. Herman, H. Farzadegan, J. Margolick, A. Saah, *Johns Hopkins Hospital Medical Institutions, Baltimore, MD, U.S.A.*

Th.B.P.239 Antibody Dependent Cellular Cytotoxicity (ADCC) in Blood and Cerebrospinal Fluid (CSF) of HIV-1 Infected Zairian Patients. *Christopher Brown*, J. Perriens, N. Lubaki, A. Fauci, T. C. Quinn, *Projet SIDA, Kinshasa, Zaire.*

Th.B.P.240 Immunophenotyping in Asymptomatic and Neurologically Symptomatic Anti-HIV-1 Positive, Anti-HTLV-I Negative Men. *Nancy G. Klimas*, J. Berger, L. LaVoie, M. A. Fletcher, *University of Miami School of Medicine, Department Medicine, Miami, FL, U.S.A.*

Th.B.P.241 CRF, ß-Endorphin and ACTH Are Significantly Decreased in Cerebrospinal Fluid of AIDS Patients. *Catherine Rougeot*, J. Lebas, A. Sobel, S. Everaere, F. Dray, *Institut Pasteur, Paris, France.*

Th.B.P.242 Brain Radiological, Neurological and Neuropsychological Follow-up in Relation to Intrathecal Immune Response in HIV Infection. *Irina Elovaara*, E. Poutiainen, R. Raininko, L. Valanne, A. Virta, J. Lähdevirta, *University of Helsinki, Department of Virology, Helsinki, Finland.*

Th.B.P.243 CSF Changes in Different Stages of HIV Infection. *Lorenzo Minoli*, R. Brustia, R. Maserati, M. Furione, D. Franciotta, G. L. Melzi d'Eril, *University of Pavia, Department of Infectious Diseases, Pavia, Italy.*

Th.B.P.244 Neopterin and ß2-Microglobulin in Cerebrospinal Fluid in HIV Infection. *Frank D. Goebel*, J. R. Bogner, B. Junge-Hülsing, A. Matuschke, B. Heinrich, K. Einhäupl, *Med. Poliklinik Universität München, Munich, Federal Republic of Germany.*

Th.B.P.245 The CSF-HIV Markers in the Different Stages of Infection. *Raffaele Pristerá*, O. Moling, E. Kafmann, A. Castegna, M. Marchesi, L. Grimaldi, et al., *Bolzano General Hospital, Infectious Diseases Department, Bolzano, Italy.*

Th.B.P.246 Cerebrospinal Fluid Analysis in Opportunistic Brain Infections. *Wilfried Lüer*, S. Poser, G. Rögler, H.-D. Pohle, K. Felgenhauer, *Georg-August Universität, Department of Neurology, Göttingen, Federal Republic of Germany.*

Th.B.P.247 Modifications biologiques du LCR au cours de l'infection par le VIH. *Thierry Saint-Marc*, A. Vergne, C. Caudie, F. Touraine, J. M. Livrozet, C. Quincy, et al., *Hôpital Édouard-Herriot, Lyon, France.*

Neurologie : visualisation et aspects pathologiques
Neurology: Imaging and Pathological Studies

Th.B.P.248 Productive Infection by HIV of Human Central Nervous System (CNS) Tissues. *Herbert Budka, University of Vienna, Neurological Institute, Vienna, Austria.*

Th.B.P.249 Clinical-Pathological Features of HTLV-I Associated Myelopathy (HAM) in AIDS. *Bruce J. Brew*, M. R. Rosenblum, H. A. Aronow, W. Hardy, K. Cronin, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.250 Can HIV-1 Alone Induce a Subacute Encephalitis? A Morphometric and Immunocytochemical Study. *Dominique Hénin*, I. Reux, R. Vazeux, V. Sazdovitch, C. Katlama, J.-J. Hauw, *Laboratoire de Neuropathologie, Hôpital de la Salpêtrière, Paris, France.*

Th.B.P.251 Intérêt de l'étude ultrastructurale lors des neuropathies périphériques associées á l'HIV. *Jean-Paul Brion*, M. Mezin, P. Leclercq, J. P. Stahl, P. Stoebner, M. Micoud, *Centre Hospitalier régional et universitaire de Grenoble, Grenoble, France.*

Th.B.P.252 Early Astrocyte Involvement in Neuro-AIDS. *Domenica Taruscio*, F. Malchiodi Albedi, S. Pauluzzi, G. Stagni, D. Francisci, G. Donelli, *Laboratorio di Ultrastrutture, Istituto Superiore di Sanità, Rome, Italy.*

Th.B.P.253 Étude par résonance magnétique des atteintes cérébrales au cours du SIDA de l'adulte: Confrontations autopsiques. *Pierre M. Trotot*, C. Sandoz-Tronca, R. Levillain, R. Vazeux, L. Mathiesen, F. Gray, et al., *Institut Pasteur, Paris, France.*

Th.B.P.254 Apport de l'IRM au diagnostic précoce des complications encéphaliques du SIDA. *Pierre M. Trotot*, C. Sandoz-Tronca, M. Thibierge, A. E. Cabée, R. Lavayssière, J. M. Bigot, et al., *Institut Pasteur, Paris, France.*

Th.B.P.255 Single Photon Emission Computed Tomography (SPECT) Findings in HIV Infection: Preliminary Results. *Giuseppe Visco*, F. Pigorini, F. M. Pau, S. Galgani, P. Narciso, M. A. Rosci, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy.*

Th.B.P.256 Brain Magnetic Resonance Imaging (MRI) Findings in HIV Infection. *Giuseppe Visco*, V. Tozzi, R. Ciciani, S. Galgani, M. A. Rosci, V. Volpini, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy.*

Th.B.P.257 Cerebral Atrophy in HIV-Infected Patients: Relationship to Neurological and Neuropsychological Measures. *Howard Aronow*, J. G. Kielp, B. J. Brew, R. W. Price, J. J. Sidtis, A. E. Sadler, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.*

Th.B.P.258 Autoradiographic Analysis of AIDS Brain Lesions with an Omega 3 (Peripheral Type Benzodiazepine) Binding Site Radioligand. *Jean-Jacques Hauw*, P. Cornu, V. Sazdovitch, M. Grilia, C. Duyckaerts, D. Hénin, *Hôpital de la Salpêtrière, Laboratoire de Neuropathologie, Paris, France.*

Th.B.P.259 Cerebral Metabolic (PET), Neuropsychologic and Neurologic Abnormalities in Patients with AIDS. *Wilfred G. Van Gorp*, M. Mandelkern, J. Ropchan, G. Evans, W. Blahd, F. Flynn, et al., *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A.*

Th.B.P.260 HM-PAO Spect and GD-DTPA Enhances MR Imaging in CNS-Manifestations of AIDS. *Michael Cordes*, H. Henkes, J. Hunger, R. Jochens, W. Heise, R. Felix, *Universitätsklinik Rudolf Virchow, Department of Radiology, Berlin, Federal Republic of Germany.*

Neurologie : Atteintes neurologiques du VIH asymptomatique
Neurology: Neurological Involvement in Asymptomatic HIV

Th.B.P.261 Absence of Neurological Disease Early in HIV Infection. *Karen Marder*, K. Bell, G. Dooneief, J. Gorman, G. Todak, R. Mayeux, *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A.*

Th.B.P.262 Neuropsychological Change in CDC II, III and IV Persons after 6 to 12 Months: Evidence for Decline. *Igor Grant*, R. K. Heaton, T. Jernigan, J. Hesselink, J. H. Atkinson, J. Weinrich, et al., *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A.*

Th.B.P.263 T4 Lymphocyte Counts and the Presence of Abnormalities on Neurological Examination in Asymptomatic HIV Seropositive Subjects. *Joseph R. Berger*, M. McCarthy, L. Resnick, M. A. Fletcher, N. Klimas, L. Pall, et al., *University of Miami School of Medicine, Department of Neurology, Miami, FL, U.S.A.*

Th.B.P.264 Neurologic Findings in Early HIV Infection. *Michael Coats*, A. M. Salazar, A. Martin, B. Jabbari, C. Geyer, D. Burke, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A.*

Th.B.P.265 Major Dysfunction and Cognitive Disturbances in 50 Clinically Asymptomatic HIV-Infected Patients with Normal MRT-Scans. *Gabriele Arendt*, H. Hefter, C. Elsing, H.-J. Freund, *University of Düsseldorf, Department of Neurology, Düsseldorf, Federal Republic of Germany.*

Th.B.P.266 Choice Reaction Time Measures and Cognitive Dysfunction in Persons with HIV Infection. *Michael Perdices*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, Surry Hills, Australia.*

Th.B.P.267 Incidence of Mild Neuropsychiatric Abnormalities in HIV-Infected Patients in Kinshasa, Zaire. *Mesu'a-Kabwa Luabeya*, K. Kayembe, M. Mussa, K. A. L. Kayembe, K. Izzia, W. E. Bertrand, *Tulane University SPHTM, New Orleans, LA, U.S.A.*

Th.B.P.268 Uncommon Neurologic Manifestations in HIV-1 Infected Patients without AIDS. *Alejo Erice*, J. Fortún, J. M. Hermida, R. Nash, L. Buzón, *Hospital Ramón y Cajal, University of Alcalá Medical School, Madrid, Spain.*

Th.B.P.269 Neuropsychometric Function in Early HIV Positive Patients Compared with a Matched HIV Negative Population. *David B. Clifford*, J. P. Miller, W. Seyfried, M. Glicksman, R. Jacoby, *Washington University School of Medicine, St. Louis, MO, U.S.A.*

Th.B.P.270 Central Nervous System Findings and Neurologic (N) Correlates of HIV Infection in Men with CDC Group II/III HIV Disease. *Ann C. Collier*, C. Marra, B. Coombs, W. Cohen, K. Claypoole, H. Handsfield, et al., *University of Washington, Harborview Medical Center, Seattle, WA, U.S.A.*

Th.B.P.271 Neuropsychological Abnormalities among Asymptomatic IV Drug Users: No Relationship with HIV-1 Serostatus. *Ola A. Selnes*, T. V. Proctor, W. R. Royal, C. Herman, D. Vlahov, J. C. McArthur, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A.*

Neurologie : Divers (dépistage, psychologie, physiologie, électrophorèse)
Neurology: Miscellaneous (Testing, Psychology, Physiology, Electrophoresis)

Th.B.P.272 Neurophysiological Diagnosis of AIDS Dementia Complex: Electroencephalographic Study on 271 HIV-Positive Subjects. *Maurizio Strosselli*, A. Parisi, G. Barbarini, L. Minoli, E. G. Rondanelli, *University of Pavia, Department of Infectious Diseases, Pavia, Italy.*

Th.B.P.273 EEG Background Slowing Appears in HIV-Infected Patients in the Absence of Metabolic Derangements or Other Cerebral Involvement. *Michael J. Borucki*, K. Norcross-Nechay, S. J. Borucki, R. B. Pollard, *The University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX, U.S.A.*

Th.B.P.274 The Neurophysiology of Sleep Destruction in Patients with CNS-Manifestations of AIDS. *Klaus Terstegge*, H. Henkes, B. Ruf, G. Scholz, S. Kubicki, *Free University Berlin, Department of Clinical Neurophysiology, Rudolf Virchow Clinic, Berlin, Federal Republic of Germany.*

Th.B.P.275 Comparison of EEG Findings in HIV-Infected and Non-Infected Patients in Out-Patient and In-Patient Follow-ups. *Ralf Schnurbus*, J. Könneke, W. Scheuler, S. Kubicki, W. Girke, U. Bienzle, et al., *Free University Berlin, Department of Neurology, Klinikum Rudolf Virchow, Berlin, Federal Republic of Germany.*

Th.B.P.276 Quantitative Vibration Threshold Testing (QVTT) and Computer-based Neurobehavioral Testing (NES) of Persons Infected with HIV. *Alfred Franzblau*, R. E. Letz, D. Hershman, P. Mason, J. Wallace, J. G. Bekesi, *Mount Sinai Medical Center, New York, NY, U.S.A.*

Th.B.P.277 Neurotoxicity Battery for Phase I HIV Drug Assessment: Initial Applications. *Elizabeth S. Parker*, T. P. Bridge, L. Ingraham, E. Eaton, P. N. R. Heseltine, *Center for Neuropsychology, Newport Beach, CA, U.S.A.*

Th.B.P.278 Cognitive Abnormalities as a Function of HIV-1 Clinical Status and Use of Azidothymidine (AZT): The Multicenter AIDS Cohort Study (MACS). *Eric N. Miller*, O. A. Selnes, B. Cohen, J. Becker, L. Park, B. Visscher, et al., *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A.*

Th.B.P.279 Decision-Making Speed in Early Human Immunodeficiency Virus (HIV) Infection. *Howard E. Edelstein*, E. Martin, L. Robertson, *VA Medical Center, Martinez, CA, U.S.A.*

Th.B.P.280 Abnormalities of EEG and Otoneurologic Tests in Asymptomatic HIV Infected Homosexuals: A Prospective Controlled Study. *Igor Koralnik*, A. Beaumanoir, R. Hausler, A. Kohler, R. Delacoux, B. Hirschel, et al., *Hôpital Cantonal Universitaire de Genève, Geneva, Switzerland.*

Th.B.P.281 EEG Findings and Cognitive Performance in 82 HIV-Infected Patients. *Lorenzo Minoli*, A. Parisi, G. Bono, E. Sinforiani, M. Turla, G. Nappi, *IRCCS S. Matteo, Department of Infectious Diseases, Pavia, Italy.*

Th.B.P.282 Étude en imagerie par résonnance magnétique nucléaire (IRM) et corrélation anatomoclinique, lors d'atteintes neurologiques du SIDA. *Jean-Paul Brion*, P. Leclercq, J. P. Stahl, M. Micoud, T. Tomasi, J. F. Lebas, *Centre hospitalier régional et universitaire de Grenoble, Grenoble, France.*

Th.B.P.283 Prospective Evaluation of an Algorithm for the Diagnosis of AIDS-Related Neurologic Illness: Experience with Over 200 Patients. *Robert M. Levy*, S. Grohmann, B. Cohen, J. Von Roenn, R. Murphy, *Northwestern University Medical School, Chicago, IL, U.S.A.*

Th.B.P.284 Patterns of Neuropsychological Dysfunction in a Select Group of HIV+ Individuals in Comparison to Psychiatric Controls. *Alex Martin*, A. M. Salazar, D. Kampen, J. Williams, W. Law, C. Gomez, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A.*

Th.B.P.285 Current Perception Threshold in HIV-Positive Patients. *Jefferson J. Katims*, D. N. Taylor, J. I. Wallace, J. G. Bekesi, J. C. Masdeu, *Cabrini Medical Center, New York, NY, U.S.A.*

Th.B.P.286 Neuropsychological Evidence for Early Involvement of the Basal Ganglia Region in a Subgroup of HIV+ Individuals. *Alex Martin*, D. Kampen, A. M. Salazar, J. Williams, W. Law, T. Roller, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A.*

Th.B.P.287 Prospective Neurological and Neurophysiological Assessment in a Cohort of Homosexual Men. *Ruth H. McAllister*, M. J. G. Harrison, G. B. Griffin, C. J. Fowler, S. P. Newman, M. V. Herns, et al., *University College and Middlesex School of Medicine, London, U.K.*

Th.B.P.288 Changes in Performance on the Trail-Making Test before and after HIV-1 Seroconversion and Diagnosis of AIDS: The Multicenter AIDS Cohort Study. *Eric N. Miller*, O. A. Selnes, B. Visscher, J. C. McArthur, P. Satz, J. Dudley, *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A.*

Th.B.P.289 Neuropsychological Performance in HIV-1 Immunocompromised Patients. *Wilfred G. Van Gorp*, E. Miller, P. Satz, B. Visscher, *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A.*

Th.B.P.290 Antisaccadic Eye Movement Abnormalities in Asymptomatic HIV Seropositive Individuals. *Jon N. Currie*, B. M. Ramsden, J. M. Lynch, C. L. McArthur, E. M. Benson, M. Perdices, et al., *Mental Health Research Institute of Victoria, Melbourne, Australia.*

Th.B.P.291 Sequential Autonomic Function Tests in HIV Infection. *Gordon R. Scott*, D. J. Ewing, A. Piaggesi, *Edinburgh Royal Infirmary, Edinburgh, U.K.*

Th.B.P.292 Neuro-Performance Measurement and Memory Profiles of Disability in HIV Seropositive Individuals. *Wallace W. Tourtellotte*, K. Syndulko, E. Singer, P. Ruane, B. Fahy-Chandon, G. V. Kondraske, *Veterans' Administration Medical Center Wadsworth, University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.*

Th.B.P.293 Latency of P300 and Pattern Visual-Evoked Potential Are not Sensitive to Early HIV-Related Neurologic Disease. *Wallace W. Tourtellotte*, K. Syndulko, E. Singer, P. Ruane, B. Chandon, *Veterans' Administration Medical Center Wadsworth, University of California at Los Angeles, Los Angeles, CA, U.S.A.*

Th.B.P.294 Computerized Screening for HIV-Related Cognitive Decline: Cross-Sectional Analyses and One-Year Follow-up. *Eric N. Miller*, P. Satz, W. Van Gorp, B. Visscher, J. Dudley, *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A.*

Th.B.P.295 Event-Related Potential Measures of Dementia in HIV Disease. *Christine L. Ollo*, R. Johnson, J. Grafman, L. Govoni, D. Rubinow, P. Bridge, *National Institute for Mental Health, Bethesda, MD, U.S.A.*

Th.B.P.296 Clinical Validation of a Bedside Antisaccadic Test for the Assessment of AIDS Dementia. *Elizabeth M. Benson*, J. N. Currie, B. M. Ramsden, J. M. Lynch, C. L. McArthur, D. A. Cooper, *Monash University Medical School, Alfred Hospital, Melbourne, Australia.*

Th.B.P.297 Multimodality Evoked Potentials in HIV Infected Subjects: A Longitudinal Study. *Costanzo Gala*, A. Ducati, R. Donati, L. Vianello, M. Mansi, S. Martini, *University of Milan Medical School, Department of Psychiatry, Milan, Italy.*

Th.B.P.298 Body Composition in Asymptomatic HIV-Positive Men. *Christopher Oliver*, J. Gold, B. J. Allen, N. Blagojevic, A. Rose, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

Th.B.P.299 Nutritional Status in AIDS Patients. *Daniel Scevola*, G. Barbarini, A. Zambelli, G. Bottari, *University of Pavia, Institute of Infectious Diseases, Pavia, Italy.*

Th.B.P.300 Less Diarrhea Seen in HIV-Positive Patients on Low-Fat Elemental Diet. *Alison B. King*, G. McMillan, J. St. Arnaud, T. T. Ward, *Norwich Eaton Pharmaceuticals, Inc., a division of Procter and Gamble, Norwich, CT, U.S.A.*

Th.B.P.301 Identification des besoins d'information en nutrition en relation avec l'infection par le VIH. *Michèle Cossette, CLSC Centre-Ville, Montreal, QC, Canada.*

Th.B.P.302 AIDS Nutrition Network (ANN). *William F. Horn*, D. F. Moore, S. L. Matheny, *San Jose State University, Nutrition Services Consulting, HRSA, PHS, DHHS, San Jose, CA, U.S.A.*

Th.B.P.303 Evaluation of the Zinc Taste Test (ZTT) in AIDS Patients. *Sandra M. Johnson*, B. S. Peters, G. Johnson, G. M. Hems, A. J. Pinching, *St. Mary's Hospital, London, U.K.*

Th.B.P.304 Garlic as an Antimicrobial and Immune Modulator in AIDS. *Tariq H. Abdullah*, D. V. Kirkpatrick, L. Williams, J. Carter, *Akbar Research Foundation, Panama City, FL, U.S.A.*

Th.B.P.305 Protein Turnover and Substrate Cycling in AIDS Patients. *T. Peter Stein*, D. Condoluci, C. Nutinsky, C. E. Bodwell, *University of Medicine and Dentistry of New Jersey, Newark, NJ, U.S.A.*

Th.B.P.306 Early Predictors of Nutritional Status in HIV Infection. *Richard S. Beach*, E. Mantero-Atienza, F. Van Riel, R. Morgan, M. K. Fordyce-Baum, *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S.A.*

Th.B.P.307 Dietary Intake in HIV Infection: Relative Caloric Deficiency in Patients with AIDS. *Rowan T. Chlebowski*, M. Grosvenor, S. Kruger, L. Bulcavage, K. Beck, G. Beall, *Harbor-UCLA Medical Center, Torrance, CA, U.S.A.*

Th.B.P.308 Dietary Intervention in ARC Patients. *Paul Khal, S. Golden, B. Sears, Medica, Homestead, FL, U.S.A.*

Th.B.P.309 Megestrol Acetate in the Treatment of HIV-Related Cachexia. *Jamie H. Von Roenn*, R. Murphy, L. Williams, S. Weitzman, *Northwestern University, Chicago, IL, U.S.A.*

Th.B.P.310 Nutritional Abnormalities in Early HIV-1. Infection II: Trace Elements. *Marianna K. Fordyce-Baum*, E. Mantero-Atienza, F. Van Riel, R. Morgan, R. S. Beach, *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S.A.*

Th.B.P.311 Plasma Nutritional Changes Antedate AIDS in Hemophiliacs. *W. Abe Andes*, R. Warrier, J. I. Lybanon, R. Sharma, *Tulane University School of Medicine, New Orleans, LA, U.S.A.*

Th.B.P.312 Effect of Enteral Nutritional Therapy upon Body Cell Mass in AIDS. *Robert Ferraro*, D. P. Kotler, P. Cuff, A. R. Tierney, S. Heymsfield, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A.*

Th.B.P.313 Low Vitamin B6 Levels and Immune Dysregulation in HIV-1 Infection. *Emilio Mantero-Atienza*, R. Beach, F. Van Riel, M. A. Fletcher, R. Morgan, C. Eisdorfer, et al., *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S.A.*

Th.B.P.314 Nutritional Knowledge, Health Beliefs, and Practices in the HIV Infected Patient. *Emilio Mantero-Atienza*, M. Fordyce-Baum, F. Van Riel, R. Beach, *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S.A.*

Th.B.P.315 The Role of Zinc in HIV-Induced Immunosuppression. *Julian M. Falutz*, C. M. Tsoukas, G. Deutsch, *Montreal General Hospital, McGill University, Montreal, QC, Canada.*

Th.B.P.316 Functional Correlates of Decreased Serum Zinc in Human Immunodeficiency Virus (HIV) Disease. *Julian M. Falutz*, C. M. Tsoukas, G. Deutsch, *Montreal General Hospital, McGill University, Montreal, QC, Canada.*

Th.B.P.317 Exocrine Pancreatic Function in Human Immunodeficiency (HIV) Infection in London and Kampala Patients. *Moses S. Kapembwa*, S. C. Fleming, N. Sewankambo, G. E. Griffin, K. Caun, A. J. Pinching, et al., *St. George's Hospital Medical School, London, U.K.*

Th.B.P.318 Nutritional Status Parameters Associated with Psychosocial Well-Being Seen in AIDS/ARC Clients at an Outpatient Clinic in San Francisco. *Bonnie Broderick*, J. K. Nesset, *Better Health Programs, San Francisco, CA, U.S.A.*

SIDA buccal Oral AIDS

Th.B.P.319 Single-Dose Therapy for Esophageal Candidiasis with Fluconazole: A Pilot Study. *Jean-Philippe Chave*, P. Vernazza, D. Margalith, M. P. Glauser, *Centre Hospitalier Universitaire Vaudois, Division of Infectious Diseases, Lausanne, Switzerland.*

Th.B.P.320 Sites and Relative Prevalence of Hairy Leukoplakia, Pseudomembranous Candidiasis and Erythematous Candidiasis. *Deborah Greenspan*, G. Overby, D. W. Feigal, L. MacPhail, S. Miyasaki, J. S. Greenspan, *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.S.A.*

Th.B.P.321 Oral Findings in Patients with Asymptomatic HIV Disease. *Engelbert Schulten*, R. W. Ten Kate, I. Van der Waal, *Free University Hospital, Department of Oral Pathology, Amsterdam, Netherlands.*

Th.B.P.322 Single-Dose Therapy for Oral Candidiasis with Fluconazole in HIV-Infected Adults. *Angela Cajot*, Swiss Group for Clinical Studies on AIDS, *Centre Hospitalier Universitaire Vaudois, Division of Infectious Diseases, Lausanne, Switzerland.*

Th.B.P.323 The Identification and Tracking of Candida Albicans Isolates from Oral Lesions in HIV-Seropositive Individuals. *Shelley H. Miyasaki*, I. Polacheck, J. Hicks, D. Greenspan, J. S. Greenspan, *University of California at San Francisco, Oral AIDS Center, San Francisco, CA, U.S.A.*

Th.B.P.324 Oral Mucosal Lesions in Infants of HIV+ve and HIV-ve Mothers. *Peter Wanzala*, P. Datta, M. Temmerman, J. J. Pindborg, H. Kariuki, N. Kisumbi, *Kenya Medical Research Institute, Nairobi, Kenya.*

Th.B.P.325 Oral Mucosal Lesions and Lymphadenopathy in HIV-1 Seropositive Patients. *Peter Wanzala*, F. Manji, F. Plummer, J. J. Pindborg, *Kenya Medical Research Institute, Nairobi, Kenya.*

Th.B.P.326 Erythematous Candidiasis: Early Clinical Manifestations in HIV-Reactive Patients. *Pedro E. Cahn*, Z. Casariego, H. Perez, A. Casiro, N. Grinberg, G. Muchinik, et al., *Hospital Fernández, Infectología, Buenos Aires, Argentina.*

Th.B.P.327 Hairy Leukoplakia in Spanish HIV-Infected Patients: An Early Marker of HIV-Disease Progression. *Daniel Podzamczer*, F. Bolao, X. Pagerols, A. Romeu, F. Gudiol, *Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.*

Th.B.P.328 Itraconazole vs. Ketoconazole in the Treatment of Mucocutaneous Candidosis. *Don E. Smith*, M. Allan, G. M. Connelly, J. Migley, B. G. Gazzard, *St. Stephen's Hospital, London, U.K.*

Th.B.P.329 Oral Candidiasis (OC) Determined by a Quantitative Method: Correlation to Marker of the Immunologic System. *Andreas Plettenberg*, E. Reisinger, U. Lenzner, M. Ernst, P. Kern, W. Meigel, *Allgemeines Krankenhaus St-Georg, Dermatologie, Hamburg, Federal Republic of Germany.*

Th.B.P.330 Oral Melanotic Macules in Patients Infected with HIV-1. *Giuseppe Ficarra*, E. Shillitoe, K. Adler-Storthz, D. Gaglioti, R. Riccardi, M. Di Pietro, *University of Florence, Division of Maxillofacial Surgery, Florence, Italy.*

Th.B.P.331 Local Destruction of Labial Surface of Mandibular Teeth by Direct Application of Cocaine in Drug Users with AIDS. *Arthur M. Quart*, C. B. Small, R. S. Klein, *North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.B.P.332 Immunohistochemical Studies of Oral Scratches in HIV-Infected Patients. *Angelika Langford*, R. O. F. Kunze, S. Schmelzer, H.-D. Pohle, P. A. Reichard, *Freie Universität Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany.*

Th.B.P.333 Recurrent Oral Aphthae in HIV-Infected Homosexual Males. *Francina I. Lozada-Nur*, M. Huang, S. Silverman, *University of California at San Francisco, School of Dentistry, San Francisco, CA, U.S.A.*

Th.B.P.334 Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV-Positive Patients. *Gudrun Just*, M. Schnellbach, C. Böttinger, G. Gentschew, E. B. Helm, W. Stille, *Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany.*

Th.B.P.335 Carriage of Oral Candida Albicans: Correlations with HIV Infections and Cellular Immunity in Heroin Abusers. *Roberto Muga Bustamante*, J. Tor, R. Melús, C. Ginestá, C. Rey-Joly, M. Foz, *Hospital "Germans Trias I Pujol", Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.*

Th.B.P.336 Tumeurs lymphoïdes du cavum au cours de l'infection par le VIH. *Marc Pulik*, E. Oksenhendler, H. Lida, A. Gaulier, M. F. D'Agay, J. P. Clauvel, *Hopital V. Dupouy, Argenteuil, France.*

Th.B.P.337 Oral Pathology in HIV Infected Patients. *Rita de Cassia Bertazzoli*, A. C. Rissi, R. C. Rissi, M. P. Lima, S. B. Bellucci, *Centro Corsini, Campinas, Sao Paulo, Brazil.*

Th.B.P.338 Correlation of HIV in Gingival Crevicular Fluid with HIV in Serum. *James R. Winkler*, P. A. Murray, C. K. French, J. A. Lippke, K. K. Vaccaro, *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.S.A.*

Th.B.P.339 An Immunohistochemical and Ultrastructural Study of Oral Hairy Leukoplakia in HIV-Positive Patients. *Nicola Mongiardo*, V. Manca, F. Pellegrino, G. Lami, L. D'Andrea, B. De Rienzo, *University of Modena, Department of Infectious Diseases, Modena, Italy.*

Th.B.P.340 Oral Kaposi's Sarcoma: The Sequence of Appearance with Respect to Other AIDS Complications. *Caroline L. Dodd*, D. Greenspan, G. Overby, D. W. Feigal, H. Hollander, J. S. Greenspan, et al., *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.S.A.*

Th.B.P.341 Clinical Aspects and Treatment of Oral/Oropharyngeal Kaposi's Sarcoma. *Sol Silverman*, G. Ficarra, F. Lozada-Nur, A. M. Berson, J. M. Quivey, C. A. Migliorati, et al., *University of California at San Francisco, San Francisco, CA, U.S.A.*

Th.B.P.342 Oral Hyperpigmentation Associated with HIV Infection. *Angelika Langford*, R. O. F. Kunze, A. Groth, H. Gelderblom, H.-D. Pohle, *Freie Universität Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany.*

Th.B.P.343 Oral Leukoplakia: Clinical Behavior and Treatment Results. *Giuseppe Ficarra*, D. Gaglioti, M. Di Pietro, P. Paci, A. Ravina, *University of Florence, Division of Maxillofacial Surgery, Florence, Italy.*

Th.B.P.344 Salivary SLgA and HIV Infection. *Alessandro Sinicco*, D. Moniaci, D. Greco, R. Raiteri, G. Marietti, *Institute of Infectious Diseases, "Amadeo Di Savoia" Hospital, University of Turin, Turin, Italy.*

Th.B.P.345 Occurrence of Oral Pathology among Different Risk Groups of HIV Infected Patients. *Stéphane De Wit*, I. Loeb, F. Prieels, N. Clumeck, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium.*

Th.B.P.346 Oral Manifestations of HIV Infection in Abidjan, Côte d'Ivoire. *Sopiato Likimani*, K. DeCock, T. L. Green, R. Colebunders, J. S. Greespan, K. Odehouri, et al., *World Health Organization, Center for Disease Control, Abidjan, Ivory Coast.*

Th.B.P.347 Natural History of HIV-Associated Salivary Gland Disease. *Morten Schidt*, D. Greenspan, C. Dodd, D. Chernoff, D. Wara, P. Leggott, et al., *University of California at San Francisco, Oral AIDS Center, San Francisco, CA, U.S.A.*

Th.B.P.348 Treatment of HIV+ Patients with Oropharyngeal and/or Oesophageal Candidiasis: The Results of a D.B. Study. *Roberto Esposito*, C. Uberti Foppa, M. Cernuschi, *Clinic of Infectious Diseases of the University of Milan, Milan, Italy.*

Th.B.P.349 Carbon Dioxide Laser Treatment of Oral Kaposi's Sarcoma. *Roel J. Hadderingh*, F. W. Van der Meulen, *University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.*

Th.B.P.350 Predominant Microflora of HIV-Related Periodontitis. *Mario Andriolo*, T. E. Rams, D. Feik, S. N. Abel, T. M. McGivern, J. Slots, *St. Clare's Hospital and Health Center, New York, NY, U.S.A.*

Th.B.P.351 In Situ Characterization of the Inflammatory Infiltrate in HIV Associated Periodontitis. *Michael Stern*, P. A. Murray, J. R. Winkler, C. Williams, J. S. Greenspan, *University of California at San Francisco, Oral AIDS Center, San Francisco, CA, U.S.A.*

Th.B.P.352 Periodontal Disease in Heterosexual Patients with AIDS. *Arthur M. Quart*, C. B. Small, R. S. Klein, *North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.B.P.353 Salivary Inhibition of HIV-1 Infectivity in Seronegative Men, Women, and Children and Seropositive Men. *Philip C. Fox*, A. Wolff, C.-K. Yeh, J. C. Atkinson, B. J. Baum, *CIPCB, National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S.A.*

Th.B.P.354 Disinfection/Sterilization Protocols Recommended by Impression Manufacturers. *James A. Cottone*, P. Dinyarian, *University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A.*

Th.B.P.355 Fluconazole for Oropharyngeal Candidiasis in Anti-HIV Positive Haemophiliacs. *Seng Gee Lim*, C. A. Lee, M. Hales, M. O'Doherty, M. Winter, P. B. A. Kernoff, *Haemophilia Centre and Haemostasis Unit, Academic Department of Haematology, Royal Free Hospital, London, U.K.*

Th.B.P.356 Oral Bacterial Flora: Role in the Infectivity of HIV. *D. Ajdukovic*, Q. L. Liu, S. Garzon, D. Mayrand, D. D. Pekovic, *Institut Armand-Frappier, Laval, QC, Canada.*

Th.B.P.357

Immunologie
Immunology

Th.B.P.358 Serum Beta-2 Microglobulin and CD4 Lymphocyte Count in HIV Infection. *Julian Gold*, J. J. Guinan, A. Morlet, L. Virtue, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.*

Th.B.P.359 Evolution of the CD4 4B4 and CD4 2H4 Lymphocyte Subsets During HIV Infection. *B. Vanderçam*, D. Zenagui, M. Canill, F. Zech, M. Omar, P. Fernez, et al., *Department of Internal Medicine, St-Luc University Hospital, Brussels, Belgium.*

Th.B.P.360 Intra Laboratory Evaluation of a Cryoprotected Doubled Labeled Preparation for Flow Cytometry. *Francis Mandy*, M. Bergeron, B. McCulloch, M. V. O'Shaughnessy, *Bureau of Laboratories and Research Services, Health and Welfare Canada, Ottawa, ON, Canada.*

Th.B.P.361 A Rapid Verification of Monocyte Enrichment/Depletion Technique Utilizing Flow Cytometry. *Francis Mandy*, A. Sherring, V. M. O'Shaughnessy, *Bureau of Laboratories and Research Services, Health and Welfare Canada, Ottawa, ON, Canada.*

Th.B.P.362 Leukoagglutination in Patients with Hemophilia. *Guillermo Muchinik*, N. Riera, M. Felippo, E. Rickard, R. Pérez Bianco, M. M. de E. De Bracco, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.B.P.363 Intra Blood-Brain-Barrier Total IgG Synthesis in Patients with Human Immunodeficiency Virus Infection. *Armando Sena*, V. Sena, F. Maltez, A. Sousa, A. Morgado, R. Proença, *Faculdade de Ciências Médicas, Lisbon, Portugal.*

Th.B.P.364 Incidence of Autoantibodies in HIV Infection. *Pierre Dellamonica*, J. F. Quaranta, M. De Matteis, C. Casasnovas, M. Vivinus, J. P. Cassuto, *Service de maladies infectieuses et tropicales, Hôpital de l'Archet, Nice, France.*

Th.B.P.365 Lymphocytes CD4+, beta-2 microglobuline et néoptérine dans le LCR et le sang au cours de l'infection par VIH. *Christiane Caudie*, A. Vergne, J. Brun, F. Touraine, J. M. Livrozet, C. Quincy, et al., *Laboratoire d'immunobiologie, Hôpital Neurologique, Lyon, France.*

Th.B.P.366 Study of Predisposing Factors on the Susceptibility of Individuals to Infection by HIV. *D. Ajdukovic*, Q. L. Liu, R. Turcotte, D. D. Pekovic, G. Lamoureux, *Institut Armand-Frappier, Laval, QC, Canada.*

Th.B.P.367 Raised beta ß-2-Microglobulin Levels in Asymptomatic Phase of the HIV-1 Infection. *Vlastimil Mayer*, P. Uherová, H. Schmidtmayerová, O. Feldes, M. Mikulecky, V. Zachar, *Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia.*

Th.B.P.368 HIV-1 IgG Antibodies in Breast Milk: Detection Methods and Correlation with Serum Markers. *Andrea J. Ruff*, H. Farzadegan, J. Marzouka, R. Buolos, A. Saah, N. Halsey et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.*

Th.B.P.369 Comparison of Eight Anti-HIV Enzymeimmunoassays, 3 HIV Antigen Assays and Two Western Blots on a Seroconverter Panel. *Allison A. Imrie*, D. A. Cooper, *Center for Immunology, St. Vincent's Hospital, Sydney, Australia.*

Th.B.P.370 Detection of HIV Antigen and HIV Core Antibody During Seroconversion. *Allison A. Imrie*, D. A. Cooper, G. Doherty, *Center for Immunology, St. Vincent's Hospital, Sydney, Australia.*

Th.B.P.371 Sensitive Detection of HIV-1 Antibody with a Peptide-Based ELISA in Two Seroconversion Panels. *Martial Lacroix*, R. J. Dwyer, M. Fauvel, *IAF BioChem International Inc., Laval, QC, Canada.*

Th.B.P.372 Immunocompetent Cells in Livers of Children with AIDS. *M. Alba Greco*, P. A. Thomas, E. Kahn, M. Magid, V. Mahnovski, V. Anderson, *New York University, Department of Pediatric Pathology, New York, NY, U.S.A.*

Th.B.P.373 Serial Immunologic Studies as an Indicator of Progression to AIDS in a Cohort of Male Sexual Partners of Men with HIV Disease. *Stanley E. Read*, R. Coates, V. Farewell, M. Klein, D. MacFadden, L. Calzavara, et al., *Hospital for Sick Children, Toronto, ON, Canada.*

Neurologie
Neurology

Th.B.P.374 Neurological Manifestations in Patients with Human Immunodeficiency Virus Infection. *Beng T. Goh*, S. Estreich, G. E. Forster, C. Kennard, M. Swash, *The London Hospital, London, U.K.*

Th.B.P.375 AIDS-Related Neurological Illness in Two U.S. Cities: A Comparison of Similar Populations. *Rober M. Levy*, S. Grohmann, D. Bredesen, M. Rosenblum, B. Cohen, J. Von Roenn, et al., *Northwestern University Medical School, Chicago, IL, U.S.A.*

Th.B.P.376 Impaired Motor Performance of HIV-1 Infected Patients Is not Due to Simple Fatigue. *John G. Keilp*, A. E. Sadler, L. Wolf, B. J. Brew, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer Center, Department of Neuropsychology, New York, NY, U.S.A.*

Th.B.P.377 Expressions neuropyschiatriques du SIDA au Sénégal. *L. D'Almeida*, A. G. Diop, C. A Povo, *Centre Hospitalier Universitaire de Fann, Dakar, Senegal.*

Nutrition
Nutrition

Th.B.P.378 Nutritional Factors Associated with AIDS. *Sally A. Zumwalt*, R. M. Schmidt, *Pacific Presbyterian Medical Center, Center for Preventive Medicine and Health Research, University of San Francisco, San Francisco, CA, U.S.A.*

Th.B.P.379 The Challenge of Nutritional Care of Patients with AIDS. *Sonia A. Chrysomilides*, *St. Paul's Hospital, Vancouver, BC, Canada.*

Th.B.P.380 Nutritional Aspects of AIDS Patients in an Inner City Clinic. *Jihad Slim*, C. Forrester, S. Koller, G. Perez, E. Perez, *Saint Michael's Medical Center, Newark, NJ, U.S.A.*

Th.B.P.381 Dietary Intervention in Kaposi's Sarcoma Patients. *Barry Sears*, P. Kahl, S. Golden, *BioSyn, Marblehead, MA, U.S.A.*

Section
C

Jeudi 8 juin
Thursday, June 8

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Session d'affichage
Poster Session

Virologie
Virology

Th.C.P.1 Role des glycannes dans l'interaction entre la glycoprotéine d'enveloppe du VIH et son récepteur cellulaire CD4. Caractérisation enzymatique. *E. Fenouillet*, B. Clerget-Raslain, J. C. Gluckman, D. Guétard, L. Montagnier, E. Bahraoui, *Hôpital de la Pitié-Salpêtrière, Paris, France.*

Th.C.P.2 High Level Expression of Native Reverse Transcriptase and Mutants Affecting the Enzyme Activity. *Erwin Soutschek*, M. Motz, R. Wagmen, H. Wolf, *Max von Pettenkofer Institute, Ludwig Maximilian University, Munich, Federal Republic of Germany.*

Th.C.P.3 HTLV-I Binds not only to Human T Lymphocytes, but also to B Cells and Monocytes. *Subhash Dhawan*, P. Casali, H. Z. Streicher, L. M. Wahl, A. L. Notkins, *National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S.A.*

Th.C.P.4 Protease Activation during HIV Infection in a CD4 Positive Cell Line. *Giuseppe Piedimonte*, P. G. Petronini, D. Guétard, V. Favier, A. G. Borghetti, L. Montagnier, *Università di Parma, Instituto di Patologia Generale, Parma, Italy.*

Th.C.P.5 Concomitant Infection with Human T Cell Lymphotropic Virus II (HTLV-II) and HIV-1. *William W. Hall*, M. H. Kaplan, M. Coronesi, S. Z. Salahuddin, N. Oyaizu, K. Nagashima, et al., *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A.*

Th.C.P.6 Envelope Cross-Reactivity between HIV-1 and HIV-2. *Blenda Böttiger*, A. Karlsson, A. Naucler, P.-Å. Andreasson, C. Mendes Costa, G. Biberfeld, *National Bacteriological Laboratory, Department of Immunology, Stockholm, Sweden.*

Th.C.P.7 Prospective Study of Newborns to HIV Seropositive Mothers: Prognostic Value of Antigenemia and Antibodies Western-Blot Analysis. *Christine Rouzioux*, M. J. Mayaux, C. Jacomet, S. Blanche, C. Griscelli, French HIV Infection in Newborns Collaborative Study Group, *Laboratoire de microbiologie, Hôpital Necker, Paris, France.*

Th.C.P.8 Three-Dimensional Electron Microscopy of HIV-Infected Macrophages (In Vitro and In Vivo). *Christophe R. Bron*, J. Jendis, J. Fleury, P. Gremillet, D. Launay, *Swiss National Center of Retroviruses, University of Zurich, Zurich, Switzerland.*

Th.C.P.9 The HIV-1 Production in Peripheral Blood Mononuclear Cells is Inhibited by Anti-ß2 Microglobulin Monoclonal Antibodies. *Pierre Corbeau*, C. Devaux, J. Boucraut, F. Rey, F. Kourilsky, J. C. Chermann, *Unité de Recherches sur les Rétrovirus et Maladies associées, Marseille, France.*

Th.C.P.10 HIV-1 Proteinase Inhibition by Cerulenin. *Myra O. McClure*, L. H. Pearl, T. F. Schulz, K. Moelling, M.-T. Knoop, *Institute for Cancer Research, London, U.K.*

Th.C.P.11 Isolation of HIV-2 Strains with Different Neutralization Patterns. *Thomas F. Schulz*, D. Whitby, H. Whittle, R. A. Weiss, *Chester Beatty Laboratories, Institute for Cancer Research, London, U.K.*

Th.C.P.12 Inhibition of Envelope Oligosaccharide Processing Diminishes HIV-1 Infectivity. *Douglas Dedera*, N. Vander Heyden, L. Ratner, *Washington University, St. Louis, MO, U.S.A.*

Th.C.P.13 1,25(OH)2 Vitamin D3 (1,25D) Enhances HIV-1 Replication in a Monocyte Cell Line. *Paul R. Skolnik*, M. Wang, T. Rota, S. Krane, M. Hirsch, *New England Medical Center, Tufts University, Division of Infectious Diseases, Boston, MA, U.S.A.*

Th.C.P.14 Stimulation of HIV Expression in B Lymphocytes by B Cell Growth Factor. *Phalguni Gupta*, P. Thampatty, R. Balachandran, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A.*

Th.C.P.15 Cellular Control but not Entry Down-Regulate HIV-1 Expression in Neural Cells. *Yaffa Mizrachi*, F. Sinangil, D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A.*

Th.C.P.16 Latent/Induced Expression of HIV-1 in Glial Cells. *Helen Kim*, M. Shahabuddin, Y. Mizrachi, D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A.*

Th.C.P.17 Differences among HIV Isolates in Cellular Entry and Fusogenicity as Measured by Fluorescence Dequenching Technique. *Faruk Sinangil*, Y. Mizrachi, D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A.*

Th.C.P.18 The Role of the vpu Gene in HIV-1 Life Cycle. *Zene Matsuda*, M. Matsuda, M. Essex, T. H. Lee, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

Th.C.P.19 Molecular Interactions between HHV-6 and HIV-1 in Coinfected CD4+ T-Cells Lead to Increased HIV-1 Gene Expression. *Barbara Ensoli*, P. Lusso, F. Schachter, J. Rappaport, S. Josephs, F. Wong-Staal, et al., *Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

Th.C.P.20 Induction of Human Immunodeficiency Virus Expression by Ultraviolet Light. *Reza M. Sadaie*, E. Tschachler, K. Valerie, M. Rosenberg, G. N. Pavlakis, F. Wong-Staal, et al., *Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.*

Th.C.P.21 Isolation of HIV in a HIV-1-HIV-2 Dual Seroconverted Child Infected by Blood Transfusion in 1984 in France: Characterization with PCR. *Christine Rouzioux*, M. Burgard, V. Courgnaud, C. Brechot, C. Gazengel, P. Bercite, et al., *Hôpital Necker, Laboratoire de microbiologie, Paris, France.*

Th.C.P.22 Binding Characteristics of HIV-1 and HIV-2: Differences in Binding Inhibition by Soluble CD4 and Dextran Sulfate. *David J. Looney*, H. Mitsuya, G. Franchini, S. Broder, R. Redfield, F. Wong-Staal, *Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S.A.*

Th.C.P.23 Characterization of nef Genes from SIV and HIV-2. *Harry W. Kestler*, Y. Li, M. D. Daniel, C. V. Butler, R. C. Desrosiers, *New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, U.S.A.*

Th.C.P.24 In Situ Hybridization Analysis of HIV RNA Induction in U1 Cells Treated with Phorbol Ester. *Maurice J. Rosenstraus*, H. Russo, W. Maltzman, B. Sellers, A. Saunders, J. Laurance, *Enzo Biochem Inc., New York, NY, U.S.A.*

Th.C.P.25 Non-Radioactive Immunoprecipitation Assay as Confirmatory Test for Antibodies to HTLV-1 Virus. *Chang-Chih Tai*, S. Alexander, E. Lillehoj, R. C. Ting, *Biotech Research Laboratories Inc., Rockville, MD, U.S.A.*

Th.C.P.26 Purification of HIV in an Aqueous Two-Phase System Retains the Infectious Titer and Gives a High Yield of gp120. *Lena Hammar*, G. Gilljam, *National Veterinary Institute, Department of Virology, Uppsala, Sweden.*

Th.C.P.27 Complementation of HIV-1 rev mutants by rex Protein of HTLV-1 but not by rex of BLV. *Barbara K. Felber*, D. Derse, A. Athanassopoulos, G. N. Pavlakis, *National Cancer Institute, Frederick Cancer Research Facility, BRI-Basic Research Program, Frederick, MD, U.S.A.*

Th.C.P.28 Analysis of Unintegrated Viral DNA and Cytopathic Effect (CPE) Induced by HIV. *Takao Masuda*, S. Harada, *Kyoto University, Institute for Virus Research, Kyoto, Japan.*

Th.C.P.29 Interferons (IFN) and Bacterial Lipopolysaccharide (LPS) Prevent HIV Infection in Macrophages by Blocking Provirus Formation. *Richard S. Kornbluth*, P. S. Oh, J. R. Munis, P. H. Cleveland, D. D. Richman, *University of California at San Diego, and the Veterans Administration Medical Center, La Jolla, CA, U.S.A.*

Th.C.P.30 Characterization of HTLV-1 Cell Lines Derived from U.S. Patients with Spastic Paraparesis. *Michael D. Lairmore*, B. K. De, R. Khabbaz, R. Janssen, J. Kaplan, T. Folks, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

Th.C.P.31 Generation of Hybrid Immunodeficiency Viruses. *Alagarsamy Srinivasan*, S. Kalyanaraman, S. M. Desai, S. G. Devare, J. Jannoun-Nasr, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

Th.C.P.32 Factors Influencing Homologous Recombination between HIV DNAs in Cultured Human Cells. *Alagarsamy Srinivasan*, S. Kalyanaraman, R. Jannoun-Nasr, R. Baine, J. Benson, D. Swan, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

Th.C.P.33 Localization of the Defect in HIV Proviral DNA by Homologous Recombination. *Alagarsamy Srinivasan*, S. Kalyanaraman, D. Butler, R. Jannoun-Nasr, D. York, B. De, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A.*

Th.C.P.34 Human Antibodies to HIV-1 gp160 Inhibit Attachment to CD4. *Nicole K. T. Back*, C. Thiriart, L. Van Der Hoek, C. Bruck, J. Goudsmit, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

Th.C.P.35 Distinction between HIV-1 and HIV-2 Infection Using Antibody Response to Accessory Gene Products. *Jaap Goudsmit*, T. Dekker, C. Boucher, A. De Ronde, C. Debouck, F. Barin, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands.*

Th.C.P.36 Expression of Eight Human Immunodeficiency Virus Genes in Escherichia Coli for Use in Diagnostic Tests. *Sushil G. Devare*, S. Desai, J. Casey, R. Aneja, D. Kramer, K. Rupprecht, et al., *Abbott Laboratories, Abbott Park, IL, U.S.A.*

Th.C.P.37 Discrimination of HIV-2 Infection by Western Blot and Radioimmunoprecipitation Analysis (RIPA). *Timothy J. Holzer*, R. G. Allen, C. A. Heynen, M. M. Kennedy, D. A. Paul, G. J. Dawson, *Abbott Laboratories, North Chicago, IL, U.S.A.*

Th.C.P.38 Pseudotypes of Human Immunodeficiency Virus (HIV) with the Envelope Antigens of Vesicular Stomatitis Virus (VSV) or Herpes. *Steve Chen*, Z. Zhu, A. S. Huang, *The Children's Hospital, Division of Infectious Diseases, Boston, MA, U.S.A.*

Th.C.P.39 HIV Positive Sera Identified with Synthetic Peptide Analogs of env, gag, tat, and nef. *Dale A. McPhee*, S. Cumming, B. Kemp, R. Doherty, *Fairfield Hospital, NHMRC Special Unit for AIDS Virology, Fairfield Hospital, Fairfield, Australia.*

Th.C.P.40 HIV-1 Infection on Human Monocytes is Inhibited by Antisera to HIV-1 or by LPS Activation of the Cells. *David A. Katzenstein*, S. A. Grace, E. W. Carrow, P. Vial, D. S. Webb, G. V. Quinnan, *Food and Drug Administration, Laboratory of Retrovirus Research, Division of Virology, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A.*

Th.C.P.41 Growth Kinetics of HIV in HTLV-I Transformed Cells. *Rosemary E. Kiernan*, D. A. McPhee, J. A. Marshall, R. R. Doherty, *NHMRC Special Unit for AIDS Virology, Fairfield Hospital, Fairfield, Australia.*

Th.C.P.42 Monoclonal Antibody Identifies a Conserved Epitope of the HIV-1, HIV-2 and HTLV-I Core Proteins. *Chi-Ming Liang*, S. Henry, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A.*

Th.C.P.43 Role of Oligosaccharides on the Processing and Maturation of Glycoproteins from Human T-Cell Lymphotropic Retroviruses. *Ranajit Pal*, G. M. Hoke, R. C. Gallo, M. G. Sarngadharan, *Bionetics Research, Inc., Rockville, MD, U.S.A.*

Th.C.P.44 Mapping of the Immunoreactive Epitopes of the HIV-1 Endonuclease Protein by Means of Recombinant Proteins. *Cristina Vinga-Martins*, N. Mueller-Lantzsch, *Klinikum des Universität des Saarlandes, Institut für Medizinische Mikrobiologie und Hygiene, Homburg/Saar, Federal Republic of Germany.*

Th.C.P.45 A Human Monoclonal Antibody against Envelope Glycoprotein of HIV-1 Enhances HIV-1 Infection In Vitro. *W. Edward Robinson*, D. Lake, D. C. Montefiori, Y. Masuho, T. Kawamura, W. M. Mitchell, et al., *Vanderbilt University Medical Center, Department of Pathology, Nashville, TN, U.S.A.*

Th.C.P.46 Correlation Study Involving the Detection of HIV-1 in Samples from AIDS Patients Using Co-Culture, p24 ELISA, and TAS- and PCR Mediated Hybridization Assays. *Thomas R. Gingeras*, J. Guatelli, D. Richman, G. R. Davis, *The Salk Institute Biotechnology/Industrial Associates, Inc., La Jolla, CA, U.S.A.*

Th.C.P.47 Expanded Host Range of HIV Acquired through Modification of gp120. *Deborah Seto*, C. Cheng-Mayer, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.48 Replication of HIV-1 in a Variety of Animal Fibroblast Cells Using Phenotypically Mixed Viral Particles. *Martine Canivet*, A. Hoffman, D. Hardy, J. Sernatinger, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.49 The Antibody Response to Immunodeficiency Virus: Neutralization vs. Enhancement. *Jacques Homsy*, M. Meyer, C. Cheng-Mayer, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.50 Are There Multiple Strains of HIV in an Infected Individual? *Li-Zhen Pan*, J. A. Levy, C. Cheng-Mayer, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.51 Parameters Involved in the Cell Fusion Induced by the Human Immunodeficiency Virus. *Shen-Bei Tang*, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.52 Growth of HIV-1 and T Cell Subsets in Sequential Blood Samples Taken from a HHV-6 Patient before, during, and after Infection. *Paul M. Feorino*, D. Warfield, K. Sanderlin, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.C.P.53 Gold-Linked Immuno Assay (GLIA): A Method in Viral Diagnosis. *Carola Grewe*, H. R. Gelderblom, *Robert Koch Institute, Berlin, Federal Republic of Germany.*

Th.C.P.54 Characterization of Proteins Associated with Two Novel Retroviruses Isolated from AIDS-Associated Lymphoma Tissue. *Valerie L. Ng*, F. Khayam-Bashi, J. Marsh, M. S. McGrath, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A.*

Th.C.P.55 Diagnosis of HIV-2 or HIV-1/HIV-2 Double Infection with Synthetic Peptides as an Additional Confirmatory Assay. *Cees L. Van der Poel*, N. Lelie, H. Reesink, M. Cot, H. Huisman, *Red Cross Blood Bank, Amsterdam, Netherlands.*

Th.C.P.56 Superinfection with Infectious HIV-1 of Defective HIV-1 Producing Cell Clones. *Kazuyoshi Ikuta*, M. Yunoki, H. Imai, S. Miyake, K. Hirai, S. Kato, *Osaka University, Osaka, Japan.*

Th.C.P.57 Association of Human Herpes Virus 6 (HHV6) and HIV Infections in Africa. *Daniel A. Scott*, N. T. Constantine, *US Naval Medical Research Unit No. 3, WHO Collaborating Centre for AIDS, Cairo, Egypt.*

Th.C.P.58 SIVsmm: A Possible Progenitor of HIV-2 and SIVmac. *Yen Li*, Y. M. Naidu, H. W. Kestler, P. Fultz, M. D. Daniel, R. C. Desrosiers, *Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A.*

Th.C.P.59 Mapping of Seven HIV-1 Anti-p24 Monoclonals Using a Series of Overlapping Peptides. *R. Bridget Ferns*, J. C. Partridge, R. S. Tedder, R. P. Spence, *University College and Middlesex Medical School, Department of Medical Microbiology and Virology, London, U.K.*

Th.C.P.60 Lectin Binding Pattern of HIV Envelope Glycoprotein. *John-Erik S. Hansen*, C. M. Nielsen, C. Nielsen, P. Heegaard, L. Mathiesen, J. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

Th.C.P.61 Inhibition of Syncytium Formation with Lectins. *John-Erik S. Hansen*, C. M. Nielsen, C. Nielsen, P. Heegaard, L. Mathiesen, J. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark.*

Th.C.P.62 Electron Microscopic Evidence for Coinfection and Replication of Herpesvirus and HIV-1 in the Same Human T-Cell. *David Raben*, L. Kucera, E. Leake, N. Iyer, Q. Myrvik, *Bowman Gray School of Medicine, Baptist Hospital, Winston-Salem, MA, U.S.A.*

Th.C.P.63 Co-Infection of a Human T-Lymphocyte Cell Line with HIV-1 and a Newly Identified Virus-like Infectious Agent (VLIA). *Dennis M. Wong*, J. B. Benish, S. C. Lo, *Armed Forces Institute of Pathology, Washington, DC, U.S.A.*

Th.C.P.64 Chemical Inducers of Cell Differentiation Inhibit HIV Replication In Vitro. *Dimitri Viza*, A. Aranda-Anzaldo, D. Ablashi, S. Z. Salahuddin, J. Vich, *Université de Paris V, Faculté de médecine, Paris, France.*

Th.C.P.65 Brain and Blood HIV-1 Isolates from the Same Individual Have Different Biological Properties. *Carol D. Weiss*, C. Cheng-Mayer, D. Seto, J. A. Levy, *University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.66 Inhibition of the Maturation of HIV Structural Proteins by Renin Peptide Inhibitor. *Sylvie Marchetto*, D. Nisato, J. C. Chermann, *INSERM U322, Marseille, France.*

Th.C.P.67 HIV Down-Regulates Its Receptor by Two Different Mechanisms. *Patrick Salmon*, R. Olivier, Y. Rivière, L. Montagnier, J.-C. Gluckman, D. Klatzmann, *Hôpital de la Pitié-Salpêtrière, CERVI, Paris, France.*

Th.C.P.68 Productive HIV-1 Infection of Hepatocellular Carcinoma Cell (HCC) Lines In Vitro. *Yunzhen Cao*, A. E. Friedman-Kien, Y. X. Huang, X. L. Li, M. Mirabile, D. Zucker-Franklin, et al., *New York University Medical Center, New York, NY, U.S.A.*

Th.C.P.69 Quantification and Cellular Distribution of HIV Proviral DNA in Buffy Coats from HIV Seropositive Haemophiliacs. *Peter Simmonds*, J. F. Peutherer, A. J. Leigh-Brown, J. O. Bishop, C. A. Ludlam, *University of Edinburgh, Department of Genetics, Edinburgh, U.K.*

Th.C.P.70 HIV-1 DNA Sequences Detected by PCR in Seronegative, yet Anti-nef Positive, Individuals. *Françoise Laure*, V. Courgnaud, S. Chamaret, M. Raphaël, L. Montagnier, C. Brechot, *CHU Necker, Paris, France.*

Th.C.P.71 Sequence Analysis of a Highly Cytopathic Strain of HIV-1: Correlation between Biological and Genomic Variability. *B. Spire*, J. Sire, C. Neuveut, J. C. Chermann, *INSERM U322, Marseille, France.*

Th.C.P.72 Susceptibility to HIV-1 Infection of a Human B-lymphoblastoid Cell Line, DG75, Transfected with Subgenomic DNA Fragments. *Natan Goldblum*, S. Daefler, T. Llana, D. Ablashi, S. Josephs, Z. Salahuddin, *Hebrew University, Jerusalem, Israel.*

Th.C.P.73 Processing of gag and pol Polypeptides as In Vitro Model for Protease Inhibition Studies in Eucaryotic Target Cells. *Erwim Soutschek*, R. Wagmen, M. Motz, H. Wozf, *Max von Pettenkofer Institute, Ludwig Maximilian University, Munich, Federal Republic of Germany.*

Th.C.P.74 Biological and Molecular Pattern of Different HIV Isolates from Zidovudine (AZT) Treated and Untreated AIDS Patients. *Alfredo A. García-Saíz*, A. Bernal, L. Muñoz, S. Sanchez-Palomino, J. M. Rojas, R. Nájera, *Instituto de Salud Carlos III, Majadahonda, Spain.*

Th.C.P.75 Identification d'épitopes séquentiels des protéines majeures de core des virus HIV-1 et HIV-2. *Blandine Janvier*, P. Archinard, B. Mandrand, F. Barin, *CHRU Bretonneau, Service de Virologie, URA CNRS, Tours, France.*

Th.C.P.76 Differential Susceptibility to AZT of HIV-1 Variants Grown in EBV-Transformed B Cell Lines. *Michel Tremblay*, M. A. Wainberg, *Lady Davis Institute, Montreal, QC, Canada*

Th.C.P.77 Molecular Characterization of Two Non-Infectious HIV-1 Isolates. *Stéphane Bour*, F. B. Boulerice, A. V. Lvovich, M. A. Wainberg, *Jewish General Hospital, McGill University, Montreal, QC, Canada*

Th.C.P.78 Intérêt de peptides synthétiques dans l'étude de virus apparentés au VIH : L'exemple des virus simiens. *Marie-Camille Cot*, M. Bissonnier, M. Jennings, M. C. Georges-Courbot, V. Boucher, F. Barré-Sinoussi, *Diagnostics Pasteur, Marnes-la-Coquette, France.*

Th.C.P.79 Dideoxynucleosides Prevent Formation of HIV-1 Provirus during Single Infection of Macrophages. *James R. Munis*, R. S. Kornbluth, D. D. Richman, *Veterans Administration Medical Center, Infectious Diseases, San Diego, CA, U.S.A.*

Th.C.P.80 Quantification of gp160 from HIV by a "Capture" ELISA. *Lennart S. Akerblom*, T. Fridberger, M. Villacres, *Swedish University of Agriculture Science, Department of Veterinary Microbiology, Section of Virology, Uppsala, Sweden.*

Th.C.P.81 Sequencing of PCR-amplified HIV-1 Related Sequences Found in the DNA of Insects from Central Africa. *Maurice L. J. Moncany*, L. Montagnier, J. L. Becker, *Unité d'Oncologie virale, Institut Pasteur, Paris, France.*

Th.C.P.82 Improved Assays for DNA Polymerizing Enzymes, by the Use of 5-125 I-Iododeoxyuridine Triphosphate, Illustrated by Direct Quantification of HIV-RT Antibody (AB). *J. Simon Gronowitz*, M. Neumüller, A. R. Karlström, C. F. R. Källander, *University of Uppsala, Department of Medical Virology, Uppsala, Sweden.*

Th.C.P.83 Multiple Sclerosis and Retrovirus: Screening with Retroviral Probes of a cDNA Library Constructed with Poly A+ RNA from Active Lesions. *Suzie Lefebvre*, J. F. Bureau, S. Chirinian, M. Brahic, *Institut Pasteur, Unité des virus lents, Paris, France.*

Th.C.P.84 A Single-Tube, One-Step Purification and Assay for the Analyses of Reverse Transcriptase Activity (RT) in Crude Specimens and Some Applications with Reference to HIV. *J. Simon Gronowitz*, M. Neumüller, R. Bhikhabhai, T. Unge, C. F. R. Källander, *University of Uppsala, Department of Medical Virology, Uppsala, Sweden.*

Th.C.P.85 Characterization of an HIV-2 Related Virus with a Smaller Sized Envelope Precursor. *Bernard Krust*, M. A. Rey, A. G. Laurent, D. Guétard, L. Montagnier, A. G. Hovanessian, *Institut Pasteur, Unité d'Oncologie virale, Paris, France.*

Th.C.P.86 New Tests Using Synthetic Peptides in the Diagnosis and Typing of HIV Infections in Humans. *Jacques Martin*, S. Bettinger, D. Adda, P. K. Tsaï, C. Richardson, G. Somme, *CLONATEC, Paris, France.*

Th.C.P.87 Infection and Replication of HIV-1 in Human Broncho-Alveolar and Peripheral Blood Monocytes-Macrophages. *Marie Suzan*, D. Salaun, G. Pautrat, J. C. Chermann, *Unité de Recherches sur les rétrovirus, Marseille, France.*

Th.C.P.88 Zidovudine Serum Levels and Half-Life in Patients on Chronic Maintenance Hemodialysis. *Hans-Jürgen Stellbrink*, R. Averdunk, *Universitätskrankenhaus Eppendorf, Hamburg, Federal Republic of Germany.*

Th.C.P.89 Expression of Viral and Cellular Genes in Cells Infected by the Human Immunodeficiency Virus, HIV-1 and the Simian Immunodeficiency Virus, SIV/Mne. *Michael G. Katze*, W. R. Morton, R. E. Benveniste, K. Foy, L. Corey, M. Agy, *University of Washington, Department of Microbiology, Primate Research Center, Seattle, WA, U.S.A.*

Th.C.P.90 Identification of HIV-1 Packaging Signals. *Andrew M. L. Lever*, H. Gottlinger, W. Haseltine, J. Sodroski, *Dana-Farber Cancer Institute, Boston, MA, U.S.A.*

Th.C.P.91 Differential Inhibition of HIV Variant Induced Syncytium Formation by Seropositive Pediatric Sera. *Arye Rubinstein*, E. Steinhauer, R. Sangsakphisarn, O. Cahill, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.C.P.92 HIV-1 Infection of Human Monocyte Cultures: Implications for Silent Infection. *Antonio Valentin*, J. Albert, E. M. Fenyö, B. Åsjö, *Karolinska Institute, Department of Virology, Stockholm, Sweden.*

Th.C.P.93 Effect of Calcium Channel Blocker on HIV-1 Expression in Lymphoid Cells. *Mary A. Harbison*, S. Kim, D. Baltimore, S. Hammer, *New England Deaconess Hospital, Infectious Diseases Section, Boston, MA, U.S.A.*

Th.C.P.94 A Rapid and Sensitive Plaque Assay of HIV-1 on C8166 Cells. *Kenneth McIntosh*, Z. Zhu, S. Chen, R. A. Weiss, *Children's Hospital, Boston, MA, U.S.A.*

Th.C.P.95 Processing and Assembly of HIV-1 Core Antigens Expressed by Recombinant Vaccinia Virus. *Shui-Lok Hu*, B. M. Travis, P. Sridhar, T. Dykers, J. Garrigues, *Oncogen, Seattle, WA, U.S.A.*

Th.C.P.96 Characterization of HIV-1 Proteins Expressed by Vaccinia Virus and E. Coli. *Atsushi A. Yasuda*, A. Kojima, T. Okamoto, J. Chiba, T. Sata, T. Kurata, *Nippon Zeon Co., Ltd., Kawasaki-Shi, Japan.*

Th.C.P.97 HIV-1 Specific Antibodies in Cerebrospinal Fluid Mediate Cellular Cytotoxicity and Neutralization. *Francesca Chiodi*, K. Ljunggren, P. A. Broliden, G. Norkrans, M. Jondal, E. M. Fenyö, *Karolinska Institute, Department of Virology, Stockholm, Sweden.*

Th.C.P.98 In vitro, une heure d'exposition à une micromole d'AZT protégée des lymphocytes de l'infection HIV pendant plus de quarante-huit heures. *Dominique Mathez*, D. Paul, J. Leibowitch, *Hôpital Raymond Poincaré, Garches, France.*

Th.C.P.99 Detection of the nef Cellular Protein by Synthetic Monoclonal Antibody from HIV Infected Subjects. *Mario Pezzella*, A. M. Anastasi, N. Vonesch, S. Marcolini, E. Sturchio, R. D. DeSantis, *University of Rome "La Sapienza", Institute of Infectious Diseases, Policlinico Umberto I, Rome, Italy.*

Th.C.P.100 Quantifying HIV Infectivity. *Scott P. Layne*, J. L. Spouge, M. Dembo, *University of California, Los Alamos National Laboratory, Los Alamos, NM, U.S.A.*

Th.C.P.101 Host Cell Tropism of HIV Strains: Comparison of Replication in Peripheral Blood Lymphocytes and Monocyte-Derived Macrophages. *Ronald G. Collman*, H. Friedman, S. Douglas, R. Walker, N. Hassan, B. Godfrey, et al., *University of Pennsylvania Medical Center, Philadelphia, PA, U.S.A.*

Th.C.P.102 Specificity of Murine Antibodies towards Epitopes of HIV-1. *Rula F. R. Khuzaie*, A. Bernatowicz, S. Pingel, H. J. Streckert, *Ruhr University, Department of Medical Microbiology and Virology, Bochum, Federal Republic of Germany.*

Th.C.P.103 Single Amino Acid Substitutions Identify Amino Acids Critical for RNASE H Activity and Replication of HIV. *Francois Clavel*, R. Repaske, T. D. Maudru, *National Institutes of Health, Bethesda, MD, U.S.A.*

Th.C.P.104 HIV Detection in Plasma of Patients with Retrovir. *Wei Lu*, A. Venet, J. M. Andrieu, D. Israël-Biet, J. M. Tourani, M. Stern, et al., *Hôpital Laënnec, Paris, France.*

Th.C.P.105 HTLV-I Antibody Screening in IV Drug Misusers, Haemophiliacs, Homosexuals and Blood Donors in Edinburgh, Scotland. *Sheila M. Burns*, F. D. Hargreaves, P. L. Yap, A. Jordan, J. Tosswell, G. Leadbetter, et al., *Regional Virus Laboratory, City Hospital, Edinburgh, U.K.*

Th.C.P.106 The Killing Effect of 65C Temperature on HIV-1 in Dried Blood: Decontamination of Lab Instruments/Equipment. *Homayoon Farzadegan*, W. Hardy, K. Qatsha, B. Tepper, P. Goldenbaum, A. Saah, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

Th.C.P.107 Fusions of Simian Immunodeficiency Virus (SIVmac) with Liposomes and Erythrocyte Ghosts. *Charles E. Larsen*, D. R. Alford, L. Young, K. D. Lee, T. McGraw, N. Düzgünes, *University of California, Cancer Research Institute, San Francisco, CA, U.S.A.*

Th.C.P.108 Monoclonal Antibodies to HTLV-I and HTLV-II gag Proteins. *Cathy L. Heffner-Barrett*, A. J. Bodner, S. Alexander, Z. Salahuddin, M. Lipsky, A. Corrigan, *Biotech Research Laboratories Inc., Rockville, MD, U.S.A.*

Th.C.P.109 Additional Characterization of Unusual Human Immunodeficiency Isolates from Two Cameroonians (ANT 70 and ANT 70 NA). *Robert J. De Leys*, B. Vanderborght, L. Brys, M. Vanden Haeselvede, H. Van Heuverswyn, *Innogenetics N.V., Antwerp, Belgium.*

Th.C.P.110 Expression of the gag/pol Gene Products of Human Immunodeficiency Virus by Recombinant Vaccinia Virus Vector. *Tatsuo Shioda*, K. Hirose, H. Sawada, H. Shibuta, *University of Tokyo, Institute of Medical Science, Tokyo, Japan.*

Th.C.P.111 Detection of HIV Genome in Seronegative Homosexual Men. *Mario Pezzella*, E. S. Sturchio, P. C. F. Cordiali-Fei, N. V. Vonesch, E. G. Gentili, F. C. Caprilli, *University of Rome "La Sapienza", Institute of Infectious Diseases, Policlinico Umberto I, Rome, Italy.*

Th.C.P.112 A Method for Quantitating Infectious HIV Particles. *Enok Tjta*, B. Grinde, *National Institute of Public Health, Department of Virology, Oslo, Norway.*

Th.C.P.113 Diminutive Utilization of CD4 Entry Pathway for Infection by Putative Neuropathic HIV-1 Isolates. *Rita Anand*, S. Nayyar, *National Institute of Mental Health, St. Elizabeth's Research Hospital, Washington, DC, U.S.A.*

Th.C.P.114 Viral Gene Expression Assessed by PCR in HIV-1 Infected H9 Cells. *Indira K. Hewlett*, M. Ruta, S. J. Geyer, C. A. Hawthorne, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A.*

Th.C.P.115 Purification and Analysis of the HTLV-I Envelope Glycoprotein gp46 Using an Anti-Carboxyl-Terminal Synthetic Peptide Serum. *Erik Lillehoj*, N. Nguyen, C. Tai, S. Alexander, *Biotech Research Laboratories, Rockville, MD, U.S.A.*

Th.C.P.116 Biological Heterogeneity among HIV-1 Isolates. *Barbara E. Moore*, A. R. Hart, M. W. Cloyd, *University of Texas, Medical Branch, Department of Microbiology, Galveston, TX, U.S.A.*

Th.C.P.117 Clonal Heterogeneity of HIV-1 Isolates in U-937 Cells. *François Boulerice*, S. Bour, R. Geleziunas, M. A. Wainberg, *Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.*

Th.C.P.118 A Rapid, Direct Assay for Reverse Transcriptase Activity in HIV-Infected Cell Culture Supernatants. *Sharon J. Geyer*, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Retrovirology, Bethesda, MD, U.S.A.*

Th.C.P.119 Simultaneous Detection of HIV-1 and HTLV-I Infections by Co-Amplification Using PCR. *Martin Ruta*, I. K. Hewlett, C. A. Hawthorne, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A.*

Th.C.P.120 Variability of HIV-1: Computer Analysis of Data Base. *Hirofumi Doi, Division of Biological Information Science, IIAS-SIS, Fujitsu Ltd., Ohta-ku, Japan.*

Th.C.P.121 Development of a Novel Quantitative Assay to Study Membrane Fusion Mediated by gp120/gp41. *M. Bud Nelson*, Y.-H. Zhang, D. Rekosh, M.-L. Hammarskjöld, *State University of New York at Buffalo, Departments of Biochemistry and Microbiology, Buffalo, NY, U.S.A.*

Th.C.P.122 Expression and Characterization of HIV-1 Envelope Proteins Synthesized from a SV40 Vector. *Björn P. Hammarskjöld*, M.-L. Hammarskjöld, D. Rekosh, M. B. Nelson, *State University of New York at Buffalo, Departments of Biochemistry and Microbiology, Buffalo, NY, U.S.A.*

Th.C.P.123 Purified Reverse Transcriptase (RT) from HIV-1, HIV-2 and EIAV Share Structural and Immunologic Properties. *Anthony L. DeVico*, T. Copeland, S. Oroszlan, R. Montelaro, R. Gallo, M. G. Sarngadharan, *Bionetics Research, Inc., Rockville, MD, U.S.A.*

Th.C.P.124 Cloning, Preliminary Characterisation and Expression of Gene Fragments of a European HIV-2 Isolate (ANT 53). *David Parker*, M. Vanden Haesevelde, B. Vanderborght, A. Driver, M. Jarvill, P. E. Highfield, *Wellcome Diagnostics, Beckenham, U.K.*

Th.C.P.125 Kinetics of Appearance and Specificity of Neutralizing Antibodies in Patients with Primary HIV Infection. *Jan Albert*, K. Ljunggren, K. Nagy, B. Abrahamsson, E. M. Fenyö, *National Bacteriological Laboratory, Stockholm, Sweden.*

Th.C.P.126 Evaluation of Three Methods for HIV Detection in Culture in Haemophilia-A Patients. *Selma Rebus*, D. Beatson, J. Stewart, C. M. Steel, R. J. G. Cuthbert, C. A. Ludlam, et al., *University of Edinburgh, Department of Bacteriology, Edinburgh, U.K.*

Th.C.P.127 Recognition of Antibodies in HIV-1 Positive Sera by Peptides Derived from Different Viral Proteins. *Otakar Mach*, M. Reinis, J. Kamínková, Z. Vacek, J. Vandasová, V. Krchnák, *Institute of Molecular Genetics, Prague, Czechoslovakia.*

Th.C.P.128 Measurement of Antibody to HIV-1 Reverse Transcriptase. *Clive Loveday*, H. Williams, R. S. Tedder, I. V. D. Weller, J. N. Weber, *University College and Middlesex School of Medicine, Department of Virology, London, U.K.*

Th.C.P.129 Complement Receptor Type 2 (CR-2) Is a Receptor for In Vitro Complement-Mediated, Antibody-Dependent Enhancement (C'-ADE) of HIV-1 Infection. *W. Edward Robinson*, D. C. Montefiori, W. M. Mitchell, *Vanderbilt University Medical Center, Department of Pathology, Nashville, TN, U.S.A.*

Th.C.P.130 Processing of the HIV-1 gag-pol Precursor Protein. *Velissarios Karacostas*, B. Moss, *Howard Hughes Medical Institute, Laboratory of Viral Diseases, National Institutes of Health, NIAID, Bethesda, MD, U.S.A.*

Th.C.P.131 Double Reactive Sera for HIV-1 and HIV-2 Antibodies and HIV Variant Strain from West Africa. *François Simon*, S. Mas, M. C. Dazza, V. Courgnaud, S. Matheron, F. Brun-Vézinet, *Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France.*

Th.C.P.132 Frequent Isolation and Molecular Identification of Human T-Cell Leukemia Virus Type-2 (HTLV-II) in Three U.S. Population Centers. *Ira Gore*, T. L. Snyder, W. D. Decker, B. H. Hahn, E. S. Parks, S. H. Weiss, et al., *University of Alabama at Birmingham, Birmingham, AL, U.S.A.*

Th.C.P.133 Quantitative HIV Blood Cultures. *Robert H. Redfield*, A. Fowler, C. Oster, O. S. Burke, *Walter Reed Army Institute of Research, Department of Retroviral Research, Rockville, MD, U.S.A.*

Th.C.P.134 A Host-Range Mutant of HIV Which Can Infect Fibroblast-like Cells Derived from Human Brain. *Yasuhiro Takeuchi*, H. Hoshino, *Gunma University School of Medicine, Department of Hygiene, Maebashi, Japan.*

Th.C.P.135 Infection of Mesenchymal Cells with HIV-1 In Vitro. *Volker Erfle*, W. Mellert, A. Kleinschmidt, H. Festl, J. Schmidt, A. Willer, *GSF-Abteilung für Molekulare Zellpathologie, Neuherberg-Munich, Federal Republic of Germany.*

Th.C.P.136

Th.C.P.137 Comparison Between Immunocytofluorographic Analysis (ICF) and In Situ Hybridization (ISH) in Detection of HIV Infection of Monocyte-Macrophages. *Suzanne M. Crowe*, T. Elbeik, N. McManus, P. Lekas, M. McGrath, J. Mills, *Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Fairfield, Australia.*

Th.C.P.138 Quantitation of HIV-1 in Plasma and Peripheral Blood Mononuclear Cells (PBMC) of Seropositive Persons. *David D. Ho*, M. Alam, T. Moudgil, S. Liu, *University of California at Los Angeles, School of Medecine and Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.*

Th.C.P.139 The Binding Of HBsAg to Human T4 Lymphocytes Indicates the Possibility of the Antigen to Function as Oligopeptide Antagonist to HIV Primary Infection of T4 Lymphocytes. *Lakew Gebreselassie, National Research Institute of Health, Addis Ababa, Ethiopia.*

Th.C.P.140 Analysis of a Functional HIV-2 Gene. *Sylvie Paulous*, M. Emermen, A. Cordonnier, *Institut Pasteur, Paris, France.*

Additionnels
Additional

Th.C.P.141 Human Monoclonal Antibody Against HIV. *Kimitaka Sagawa*, K. Sakata, K. Katagiri, H. Natori, M. M. Yokoyama, *Kurume University, School of Medicine, Department of Immunology, Kurume, Japan.*

Th.C.P.142 Characterization of Monoclonal Antibodies Reactive with Different Proteins of HIV-1-NDK Strain. *Christian Devaux*, V. Robert, M. Tatsumi, J. C. Chermann, *Unité de Recherches sur les Rétrovirus et Maladies associées, Marseille, France.*

Th.C.P.143 Decreasing Production of IgG, IgM, and IgA Antibodies against Pneumocystis Carinii Antigens in AIDS Patients Measured by ELISA and Western Blot. *Peder B. Nielsen*, A. G. Poulsen, C. Koch, B. Hofmann, M. Mojon, *Department of Clinical Microbiology, Copenhagen, Denmark.*

Th.C.P.144 B-Cell System Activation and HIV-1 Infection. *Alberto Amadori*, R. Zamarchi, E. Francavilla, A. Barelli, A. Borri, L. Chieco-Bianchi, *University of Padua, Institute of Oncology, Padua, Italy.*

Th.C.P.145 Fine Structure of Inside the Viral Envelope of the HIV-1. *Ichiro Takahashi*, A. M. Ladhoff, M. Takama, D. Scholz, *Central Laboratory for Electron Microscopy, Teikyo University, School of Medicine, Itabashi-Ku, Japan.*

Th.C.P.146 Some Observations on the Latent HIV Infection Period. *Mario Pezzella*, E. Mannella, M. A. Rosci, M. Mirolo, M. Miceli, N. Vonesch, *University of Rome, Institute of Infectious Diseases, Policlinico Umberto I, Rome, Italy.*

Th.C.P.147 HIV-1 Does not Replicate in Human Vaginal Epithelial Cells. *James C. Sunstrum*, C. Meriwether, J. Sobel, *Wayne State University, Detroit, MI, U.S.A.*

Th.C.P.148 Excretion of Human Immunodeficiency Virus in Body Fluids. *Mark Cordery*, Y. Barrett, S. O'Shea, J. E. Banatvala, C. Bradbeer, *St. Thomas' Hospital, Department of Virology, London, U.K.*

Th.C.P.149 Molecular Characterization of a Defective Human Immunodeficiency Virus. *Masahiro Inoue*, J. A. Hoxie, E. P. Reddy, *The Wistar Institute, Philadelphia, PA. U.S.A.*

Th.C.P.150 HIV: Early Virus-Cell Interactions. *Carola Grewe*, A. Beck, H. R. Gelderblom, *Robert Koch Institut, Berlin, Federal Republic of Germany.*



Section
D

Jeudi 8 juin
Thursday, June 8

Le SIDA et l'individu
AIDS and the Individual

Session d'affichage
Poster Session

Les femmes (partie 2)
Women (Part 2)

Th.D.P.1 HIV Antibody and High Risk Behaviours among Non-Intravenous Drug Using Women Obtaining Abortions in the South Bronx, New York City. *Mayris P. Webber*, E. E. Schoenbaum, L. S. Stern, E. Drucker, H. Gayle, *Montefiore Medical Center, AIDS Research Department, Epidemiology and Social Medicine, Bronx, NY, U.S.A.*

Th.D.P.2 HIV Infection in Women: Effect of Counselling on Risk-Associated Behavior. *Charles C. J. Carpenter*, S. Danforth, *Brown University, The Miriam Hospital, Providence, RI, U.S.A.*

Th.D.P.3 Glasgow Street Prostitutes: A Study of Sexual Behaviour and Injected Drug Usage. *Stephen T. Green*, D. J. Goldberg, A. Thomson, D. H. Kennedy, J. A. Emslie, *Infectious Diseases Unit, Ruchill Hospital, Glasgow, U.K.*

Th.D.P.4 Sexual Partner Notification: Attitudes and Actions of HIV-Infected Women. *Stanley H. Weiss*, J. L. Chervenak, *University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Preventive Medicine, Newark, NJ, U.S.A.*

Th.D.P.5 Perception of AIDS Risk among Women Sexual Partners of IV Drug Users in San Francisco. *Laurie A. Wermuth*, J. Ham, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

Th.D.P.6 An Ethnographic Study of High Risk Sexual Behaviour in 96 Women Using IV Heroin, Cocaine and Crack in the South Bronx. *Ernest Drucker*, D. Worth, K. Eric, B. Chabon, A. Pivnick, K. Cochrane, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.D.P.7 The Women's Center: A Model Peer Support Program for High Risk IV Drug-and Crack-Using Women in the Bronx. *Ernest Drucker*, K. Eric, D. Worth, B. Chabon, A. Pivnick, K. Cochrane, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.D.P.8 Discrimination against HIV Positive Women by Abortion Clinics in New York City. *Katherine M. Franke, New York City Commission on Human Rights, AIDS Discrimination Division, New York, NY, U.S.A.*

Th.D.P.9 Differences between Symptomatic HIV+ Female and Male Patients. *Patricia J. Kelly*, V. Graham, L. Hall, A. Kitchens, A. Bastien, J. DeHovitz, *King's County Hospital Center, Brooklyn, NY, U.S.A.*

Th.D.P.10 Selected Gynecological Issues in Women with HIV Infection. *Jean R. Anderson*, J. Horn, R. King, J. Keller, B. Herbert, M. Barbacci, *The Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.*

Th.D.P.11 College Women's Sexual Behavioural Intent and Perception of Risk of HIV Infection for Self and Peers. *Donna L. Richter*, F. Sy, T. Theocharis, D. Summers, J. Hussey, *University of South Carolina, School of Public Health, Columbia, SC, U.S.A.*

Th.D.P.12 Female Sex Partners of IV Drug Users: A Study of Socio-Psychological Characteristics and Needs. *Lourdes Argüelles*, A. M. Rivero, C. J. Reback, N. H. Corby, *University of California at Los Angeles, School of Social Welfare, Los Angeles, CA, U.S.A.*

Th.D.P.13 Gender Differences in "Maturing Out" of Intravenous Drug Use. *Patrick Biernacki*, J. S. Mandel, M. R. Aldrich, *Youth Environment Study, Inc., San Francisco, CA, U.S.A.*

Th.D.P.14 Access and Utilization of Services for Women with AIDS in Poor Minority Communities. *Melinda A. Cuthbert, Yale University, New Haven, CT, U.S.A.*

Th.D.P.15 Female Family Members as Mediators of Utilization of Health and Social Services. *Stephen Crystal*, N. Schiller, E. Dejowski, S. Hansell, C. Merzel, P. Beck, *Rutgers University, Institute for Health, New Brunswick, NJ, U.S.A.*

Th.D.P.16 HIV Infection among Females Entering New York State Prisons. *Perry F. Smith*, J. Mikl, B. Truman, E. Lord, R. Broaddus, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.S.A.*

Th.D.P.17 Determinants of Sexual Risk Reduction in Female IV Drug Users Recruited from the Street. *Susan Tross*, A. Abdul-Quader, D. C. Des Jarlais, A. Kouzi, S. R. Friedman, E. McCoy, *Narcotic and Drug Research Inc., New York, NY, U.S.A.*

Th.D.P.18 Differences in HIV/AIDS Counselling for Women and for Men. *Judith Hutterer*, P. Blaas, C. Oberauer, M. Ogris, B. Pec, M. Stögerer, et al., *Austrian AIDS Foundation, Vienna, Austria.*

Th.D.P.19 Pratiques de risque et SIDA parmi les prostituées espagnoles. *Ricardo R. Usieto*, J. Sastre, J. Torres, H. Anabitarte, R. De Andres, J. Menor, *Université Internationale Menendez Pelayo, Madrid, Spain.*

Th.D.P.20 STD Patients' and Prostitutes' Knowledge on AIDS: Modification of Sexual Practices and Education Needs. *F. Soyinka*, M. Z. Hossain, O. Onayemi, *Obafemi Awolowo University, Ile Ife, Nigeria.*

Th.D.P.21 "Twilight Phenomena": A Project Concerning Men as Buyers of the Services of Prostitutes as a Risk Factor. *Elizabeth Pettersson*, J. Larsson, G. Mellberg, B. Pettersson, B. Svennecke, S. Ungerfelt, *The Prostitution Group, Gothenburg Social Services, Gothenburg, Sweden.*

Th.D.P.22 HIV Infection and Prostitution in Yaounde, Cameroon. *Marcel Monny-Lobe*, D. Nichols, L. Zekeng, R. Salla, L. Kaptue, *Central Hospital of Yaounde, Yaounde, Cameroon.*

Th.D.P.23 HIV Infection in Prostitutes: the Potential of HIV Transmission. *Klaus Friese*, S. Rossol, C. Klein, G. Hess, K. H. Meyer zum Büschenfelde, G. Knapstein, *University of Mainz, Department of Gynecology and Obstetrics, Mainz, Federal Republic of Germany.*

Th.D.P.24 A Descriptive Analysis of Patients Attending the Women's HIV Clinic at the Johns Hopkins Hospital. *Janet Horn*, J. Anderson, J. Atkinson, K. Alwood, S. Cohn, R. Chaisson, *Sinai Hospital of Baltimore, Johns Hopkins Hospital, Baltimore, MD, U.S.A.*

Th.D.P.25 AIDS and Women: Change in Sexual Behaviour. *Francisco S. Sy*, D. Richter, T. Theocharis, J. Hussey, D. Summers, *University of South Carolina, School of Public Health, Columbia, SC, U.S.A.*

Th.D.P.26 Serosurvey of Women of Childbearing Age in Texas, USA. *Christie M. Reed*, E. G. Thompson, L. Suarez, K. B. Buchanan, B. L. Therrell, *Texas Department of Health, AIDS Division, Austin, TX, U.S.A.*

Th.D.P.27 The Women and AIDS Resource Network (WARN). *Saint Cyr-Delpe, Women and AIDS Resource Network, Brooklyn, NY, U.S.A.*

Th.D.P.28 Medical-Psychological Counselling for Women. *Monika Fröschl*, B. Dorn, G. Hutner, O. Braun-Falco, *Dermatological Department of Ludwig-Maximilians University, Munich, Federal Republic of Germany.*

Th.D.P.29 An AIDS Prevention Program Consisting of Education, Confidential Testing, and Condom/Spermicide Distribution in Rwanda: Does It Change Behavior? *Susan Allen*, A. Serufilira, P. Vandeperre, F. Nsengumuremyi, J. Tice, et al., University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

Consommateurs de drogues par voie intraveineuse (partie 2)
IV Drug Users (Part 2)

Th.D.P.30 Risk-Taking Behaviour of Intravenous Drug Users. *Frederick R. Snyder*, M. H. Myers, *NOVA Research Company, Bethesda, MD, U.S.A.*

Th.D.P.31 Risk Factors for HIV Seropositivity among IV Drug Abusers (IVDA) in France: Evidence of a Change in Behaviour. *Philippe Chossegros*, P. Barlet, J. Ritter, V. Fayol, C. Trepo, M. Sepetjan, *INSERM U271, Lyon, France.*

Th.D.P.32 The Impact of Law and Policy on Needle Exchange Programmes in Canada. *Anne Duffie*, A. Orkin, *McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada.*

Th.D.P.33 Increasing Crack Use among Drug Users in an AIDS Epicenter: San Francisco. *Joseph R. Guydish*, A. Abramowitz, W. Woods, W. Clark, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

Th.D.P.34 Sharing Needles: Risk Reduction among Intravenous Drug Users in San Francisco. *Joseph R. Guydish*, A. Abramowitz, W. Woods, J. Newmeyer, W. Clark, J. Sorenson, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A.*

Th.D.P.35 Modification du comportement des toxicomanes IV. *Pierre Espinoza*, V. Lebouc, I. Roustang, J. Polo de Voto, I. Bouchard, P. Balian, *Hôpital de Fresnes (EHPNF), Fresnes, France.*

Th.D.P.36 A HIV-Prevention Syringe Exchange Program in Lund, Sweden: Two Years of Observations of the Attenders. *Kerstin Tunving*, B. Ljungberg, B. Andersson, B. Christensson, E. Johnsson, *University of Lund, Department of Psychiatry and Neurochemistry, Lund, Sweden.*

Th.D.P.37 An AIDS Intervention Program for the Black Out-of-Treatment Intravenous Drug User. *Charles E. Haley*, J. Valentine, A. Thomas, M. Krepcho, D. Johnson, A. Freeman, *Dallas County Health Department, Dallas, TX, U.S.A.*

Th.D.P.38 The Needle and Syringe Exchange Pilot Program in New York City. *Kevin J. Mahoney*, M. Zweig, C. Eaton, S. Schultz, S. Joseph, *New York City Department of Health, New York, NY, U.S.A.*

Th.D.P.39 Risk of AIDS in Seroconverter Drug Injectors: A Comparison with Other Risk Groups. *Giovanni Rezza*, F. Menniti-Ippolito, A. Lazzarin, G. Angarano, A. Sinicco, U. Tirelli, *AIDS Unit, Department of Social Medicine, Ministry of Health, Rome, Italy.*

Th.D.P.40 AIDS Incidence and Risk Factors for Disease Progression in a Cohort of Seroconverter Drug Injectors. *Giovanni Rezza*, F. Menniti-Ippolito, A. Lazzarin, A. Sinicco, G. Angarano, U. Tirelli, et al., *AIDS unit, Department of Social Medicine, Ministry of Health, Rome, Italy.*

Th.D.P.41 HIV Infection in Intravenous Drug Addicts. *Walentyna Mazurkiewicz*, A. Stapinki, B. Ochelska, T. Gluska, Z. Selibórska, *Medical Academy, Institute of Venereology, Warsaw, Poland.*

Th.D.P.42 Risk Behavior and Attitudes among Recovering IV Drug Users. *Robert F. Schilling*, N. El-Bassel, S. P. Schiuke, G. Botvin, M. Orlandi, S. Nichols, *Columbia University, School of Social Work, New York, NY, U.S.A.*

Th.D.P.43 AIDS Beliefs and Behavior Change in Minority IV Drug Users. *Mildred S. Braunstein*, M. D. Anderson, G. A. D. Smereck, *Personalized Nursing Corp., Detroit, MI, U.S.A.*

Th.D.P.44 Cocaine Use and Sexually Transmitted Diseases Including HIV. *Howard L. Minkoff*, S. McCalla, I. Delke, R. Stevens, M. Salwen, J. Feldman, *State University of New York, Health Science Center at Brooklyn, Department of Obstetrics and Gynecology, Brooklyn, NY, U.S.A.*

Th.D.P.45 The Epidemiology of AIDS among New York State Prison Inmates. *Dale L. Morse*, B. Truman, J. Mikl, P. Smith, R. Broaddus, B. Maguire, *New York State Department of Health, Albany, NY, U.S.A.*

Th.D.P.46 HIV Infection among IV Drug Abusers in Buenos Aires, Argentina. *Pedro E. Cahn*, H. Perez, A. Casiro, N. Vallejo, D. Wolk, G. Muchinik, *Departamento de Infectología, Hospital Fernandez, Buenos Aires, Argentina.*

Th.D.P.47 Sexual Activities of IV Drug Users with Multiple Sex Partners. *H. Virgina McCoy*, E. J. Trapido, J. A. Inciardi, D. C. McBride, C. Y. McKay, *Florida International University, North Miami, FL, U.S.A.*

Th.D.P.48 Mobility, Risk Cities, Risk Behavior, and HIV Status of IV Drug Users. *Clyde B. McCoy*, D. D. Chitwood, J. B. Page, *University of Miami School of Medicine, Miami, FL, U.S.A.*

Th.D.P.49 Generational Differences in HIV Risk Behaviors and Sero-Prevalence Rates among IV Drug Users. *Duane C. McBride*, J. A. Inciardi, C. B. McCoy, D. D. Chitwood, H. V. McCoy, *Andrews University, Behavioral Sciences Department, Berrien Springs, MI, U.S.A.*

Th.D.P.50 IVDU Characteristics Associated with Needle Sharing. *Wallace Mandell*, D. Vlahov, S. Cohn, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A.*

Th.D.P.51 Cocaine, Marijuana and Alcohol as Risk Factors for HIV Infection in Homosexual Men: A Pilot Study. *Allen J. McCutchan*, S. Loue, L. Brysk, P. Spechko, J. Weinrich, C. Molgaard, *University of California at San Diego, San Diego Medical Center, San Diego, CA, U.S.A.*

Th.D.P.52 AIDS-Related Knowledge, Attitudes and Behaviours in IDUs Attending a Toronto Treatment Facility. *Margaret E. Millson*, R. Coates, P. Devenyi, T. Franklin, J. Rankin, *University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada.*

Th.D.P.53 Mode of HIV Transmission among Seroconverted Intravenous Drug Users (IVDUs): 1987 and 1988 Cohort Study. *Lawrence S. Brown*, T. Nemoto, B. J. Primm, K. Foster, A. Chu, *Addiction Research and Treatment Corporation, Brooklyn, NY, U.S.A.*

Th.D.P.54 Inpatient Group Work with Inner-City Minority Drug-Using AIDS/ARC Patients: It Can Be Done. *Rachel A. Pousson*, V. Graham, A. Kitchens, *King's County Hospital AIDS Team, Brooklyn, NY, U.S.A.*

Th.D.P.55 The Disinfectant Potential of Vinegar Solutions Used by Glasgow IDUs to Prepare Heroin for Injection. *David J. Goldberg*, N. Flynn, S. T. Green, S. Jain, H. Watson, E. Keddie, *CD(S)U Ruchill Hospital, Glasgow, U.K.*

Th.D.P.56 Seroprevalence and Demographic Results of Intravenous Drug Users among Individuals at Risk for HIV Infection in a Community-based Study in Winnipeg, Manitoba, Canada. *Gregory W. Hammond*, D. Buchanan, R. Malazdrewicz, R. Tate, L. Selka, V. Bhayana, *Cadham Provincial Laboratory, University of Manitoba, Winnipeg, MB, Canada.*

Th.D.P.57 Information on HIV-1 Transmission and Sexual Behaviour in Couples of Intravenous Drug Abusers (IDAs). *Jordi Tor Aguilera*, C. Ginesta, R. Muga, B. Clotet, C. Rey-Joly, M. Foz, *Hospital Germans Trias I Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain.*

Th.D.P.58 HIV Seroprevalence in Two Methadone Drug Treatment Programs in Los Angeles County, 1988. *Peter R. Kerndt*, W. Ford, I. Strantz, J. Keasler, T. Rose, *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A.*

Th.D.P.59 Low HIV Seroconversion and Change in High Risk Behaviour in Intravenous Drug Users (IVDUs) from 1985-88 in the Bronx, N.Y.C. *Diana Hartel*, E. E. Schoenbaum, P. A. Selwyn, R. S. Klein, G. H. Friedland, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.D.P.60 Social, Sexual and Drug Use Profile of HIV (+) and HIV (-) Women with PID. *Bente Hoegsberg*, T. Dotson, O. Abulafia, S. Tross, D. DesJalans, S. Landesman, et al., *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A.*

Th.D.P.61 Access to IV Drug Users (IVDUs) through Combined Efforts of a Public Health Department and Indigenous Outreach Workers. *Frances Feeney*, T. Brewster, A. Davidson, S. Koester, G. Burke, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A.*

Th.D.P.62 Modification of Needle Use in Out-of-Treatment Intravenous Drug Users. *Harvey W. Feldman*, P. Biernacki, T. Knapp, E. Margolis, *Youth Environment Study Inc., San Francisco, CA, U.S.A.*

Th.D.P.63 Risk Behaviour Is Common among Drug Users despite Knowledge of Transmission Routes, Access to Sterile Syringes and HIV Antibody Testing. *Anne Eskild*, I. Lundin Kvalem, B. Nilsen, *Department of Epidemiology, National Institute of Public Health, Oslo, Norway.*

Th.D.P.64 Predictors of Attempted Sexual Behaviour Change in a Street Sample of Active Male IV Drug Users in New York City. *Abu Abdul-Quader*, S. Tross, D. C. Des Jarlais, A. C. Kouzi, S. R. Friedman, E. McCoy, *Narcotic and Drug Research Inc., New York, NY, U.S.A.*

Th.D.P.65 Street Outreach Strategies for Intravenous Drug and Crack Users, Their Sexual Partners and Addicted Prostitutes at Risk for HIV. *Yolanda Serrano*, D. Goldsmith, *Association for Drug Abuse Prevention and Treatment, Brooklyn, NY, U.S.A.*

Th.D.P.66 Organizing Intravenous Drug Users against AIDS. *Yolanda Serrano*, S. R. Friedman, L. Torres, M. Sufian, P. Nelson, F. Tardalo, *Association for Drug Abuse Prevention and Treatment, Brooklyn, NY, U.S.A.*

Th.D.P.67 Long-term Follow-up of a Cohort of Drug Abusers of the Area of Reggio Emilia (North Italy). *Sergio Gafà*, M. G. Giudici, F. Vezzani, A. Tuzza, G. F. Calonghi, *Divisione Malattie Infettive, Arcispedale S. Maria Nuova, Modena, Italy.*

Th.D.P.68 A Study Comparing Non-HIV-Related Deaths among HIV Seropositive IVDAs with Deaths among Seronegative IVDAs: The HIV Prevalence and the Sero-Conversion Rate among IVDAs. *Christian Sohlberg*, P. Kittelson, F. Jensen, P. Magnus, *Oslo City Health and Environment Department, Oslo, Norway.*

Th.D.P.69 Methadone Maintenance in HIV Infected IV Drug Addicts: Medical and Psychological Effects. *Peter Walger*, P. Baumgart, G. Wilke, U. Kupfer, K. G. Dorst, M. V. Eiff, *Medizinische Poliklinik, Universität Münster, Münster, Federal Republic of Germany.*

Th.D.P.70 The Use of Sterile Syringes among IVDUs That Had Gone through Detoxicating Treatment at Home Directed by a Center of Health Promotion in Madrid. *Pilar Estebanez*, J. C. Martinez Barrios, P. Vitores, R. Wall, *Madrid City Council, Health Department, Madrid, Spain.*

Th.D.P.71 Survey of the Methadone Treatment Programme of the Outpatient Clinic of the Vienna Psychiatric University Hospital. *Judith Hutterer*, O. Presslich, V. Pfersmann, D. Pfersmann, E. Hollerer, K. Gutierrez-Lobos, *Austrian AIDS Foundation, Vienna, Austria.*

Th.D.P.72 AIDS-related Behaviour and Attitudes among IV Drug Users in Greece. *A. Kokkevi*, S. Alevizou, C. Stefanis, *Athens University Medical School, Department of Psychiatry, Athens, Greece.*

Th.D.P.73 Street-Based Needle Exchange Programs: The Next Step in HIV Prevention. *Research Prevention Group Point, Independent Community-Based Research Group, San Francisco, CA, U.S.A.*

Th.D.P.74 Historical Account of the Tacoma Syringe Exchange. *David Purchase*, H. Hagan, D. C. Des Jarlais, T. Reid, *Point Defiance AIDS Project, Tacoma, WA, U.S.A.*

Th.D.P.75 AIDS Education and the Transition from Non-Injecting Drug Use to Injecting Drug Use. *Don C. Des Jarlais*, C. Casriel, S. R. Friedman, A. Rosenblum, E. Rodriguez, E. Khouri, *New York State Division of Substance Abuse Services, New York, NY, U.S.A.*

Th.D.P.76 The Effects of AIDS Education on the Knowledge and Attitudes towards AIDS by Substance Abusers in a Drug Detoxification Setting. *John Weber*, L. Dengelegi, S. Torquato, S. Yancovitz, A. Kolakathis, *Beth Israel Medical Center, New York, NY, U.S.A.*

Th.D.P.77 Needle Sharing Patterns of Intravenous Drug Users. *Donald A. Calsyn*, A. J. Saxon, S. Whittaker, G. Freeman, *Seattle Veterans Administration Medical Center and University of Washington, Seattle, WA, U.S.A.*

Th.D.P.78 Use of Clinical Criteria to Predict HIV Antibody Status among Intravenous Drug Users (IVDU) in a Prospective Cohort Study. *Peter A. Selwyn*, D. Hartel, E. E. Schoenbaum, R. S. Klein, D. Buono, G. H. Friedland, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.D.P.79 Clinical Symptoms and Medical Histories of a Cohort of IV Drug Users: Correlation with HIV Seroprevalence. *Kenrad E. Nelson*, D. Vlahov, L. Solomon, A. Lindsay, N. Chowdhury, *Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A.*

Th.D.P.80 Risk Factors for Transmission and Changes in Risk Behaviour among IV Drug Addicts (IVDAs) in Geneva. *Claude F. Robert*, B. Hirschel, J. J. Deglon, *University Hospital, Division of Infectious Diseases, Geneva, Switzerland.*

Th.D.P.81 The Use of a Minimal Behavioural Intervention as Part of a Risk Reduction Strategy among Intravenous Drug Users. *Anna Stallard*, M. G. T. Dow, *Counselling Clinic, Psychology Department, Ruchill Hospital, Glasgow, U.K.*

Th.D.P.82 A Comparative Analysis of HIV Infection among IV Drug Users in Treatment and on the Street. *Clyde B. McCoy*, D. D. Chitwood, J. B. Page, *University of Miami School of Medicine, Miami, FL, U.S.A.*

Th.D.P.83 Comparison of Sexual Behaviors among White IVDU and Non-IVDU (NIVDU) Heterosexuals in Southeastern New England. *Kenneth H. Mayer*, S. Zierler, L. Feingold, D. Laufer, C. Carpenter, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A.*

Th.D.P.84 Psychoeducational Group Approach to AIDS Prevention with Drug Abusers in Residential Treatment: Impact 6 Months after Intervention. *James L. Sorensen*, D. R. Gibson, C. Heitzmann, R. Dumontet, M. Costantini, I. Melese-D'Hospital, et al., *University of California at San Francisco, General Hospital, San Francisco, CA, U.S.A.*

Th.D.P.85 AIDS and Substance Use Education and Prevention: A Community-Based Approach. *Diane M. Riley*, M. McCrimmon, K. Sheyka, *Municipality of Metropolitan Toronto, Toronto, ON, Canada.*

Th.D.P.86 Management of HIV-Infected Female IVDAs. *Axel Schäfer*, W. Heckmann, M. Eck, B. Schwartländer, Friedmann, *Freie Universität Berlin, Department of Obstetrics and Gynecology, Berlin, Federal Republic of Germany.*

Th.D.P.87

Additionnels
Additional

Th.D.P.88 Changes in the Sexual Behavior of HIV-Infected Patients Participating in a Group Process. *Luisa Rossi*, L. Garcia, E. Salame, *Centro de Informacion Sobre SIDA-Sur, Mexico City, Mexico.*

Th.D.P.89 Counselling and Education on AIDS. *Eleonora Quinhoes*, M. C. Rachid de Lacerda, J. L. L. Hanan, P. H. Longo, E. M. M. Moura, *Gaffrée Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil.*

Th.D.P.90 HIV-AIDS Counselling: A Collaborative Project. *Gweneth Gowanlock*, J. Findlay, M. Carballo, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada.*

Th.D.P.91 AIDS Prevention in the Legalized Sex Industry. *Cheryl M. Overs*, A. P. Hunter, *Prostitutes Collective of Victoria, St. Kilda, Melbourne, Australia.*

Th.D.P.92 Survey of Physicians' Needs. *Marg Hulin*, M. Grondin, *City of Toronto, Department of Public Health, Toronto, ON, Canada.*



Section
E

Jeudi 8 juin
Thursday, June 8

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Session d'affichage
Poster Session

Tendances démographiques, tendances de la fertilité
Demography and Fertility Patterns

Th.E.P.1 Contraceptive Utilization In and Out of the Marital Setting: Implications for the Transmission of HIV in Kinshasa. *Susan E. Hassig*, A. Doppagne, M. Moore, L. Piripiri, R. W. Ryder, W. E. Bertrand, *Tulane University, New Orleans, LA, U.S.A., Zaire School of Public Health.*

Th.E.P.2 Modelling the Spread of HIV/AIDS and Its Demographic Impact: A Review of Approaches. *Larry Heligman*, A. Palloni, *United Nations, Population Division, New York, NY, U.S.A.*

Th.E.P.3 Risk Factors for HIV-2 Infection. *Phyllis Kanki*, B. De Zalduando, T. Siby, R. Marlink, M. Essex, S. M'Boup, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A.*

Th.E.P.4 Determinants of Contraceptive Practices among Intravenous Drug Users in New York City. *Anthony C.Kouzi*, D. C. Des Jarlais, S. F. Friedman, S. Tross, A. Abdul-Quader, *Narcotic and Drug Research Inc., New York, NY, U.S.A.*

Th.E.P.5 Characteristics of Men in the National Mortality Followback Survey Who Died of AIDS. *Eve Powell-Griner*, K. Trent, *National Center for Health Statistics, Hyattsville, MD, U.S.A.*

Dépistage
Testing

Th.E.P.6 Aptitude d'un test rapide pour HIV et de tests d'agglutination à détecter des anticorps anti-HIV-2 au Sénégal. *Souleymane M'Boup*, J. L. Sankale, C. M. Kabeya, L. Diakhate, D. Thiam, S. Mitchell, *Université Cheikh Anta Diop, Bactériologie-Virologie, Dakar, Senegal.*

Th.E.P.7 Centre de dépistage anonyme volontaire et gratuit de Médecins du Monde, Paris, France. *Françoise Aeberhard*, J. Lebas, B. Masse, A. Bedossa, M. C. Coignet, *Médecins du Monde, ONG France, Paris, France.*

Th.E.P.8 Estimating the Percentages of High Risk Groups Which Have Been Tested and Counseled for HIV by 1988. *Franklyn N. Judson*, J. M. Douglas, A. Davidson, *Denver Public Health, University of Colorado, Denver, CO, U.S.A.*

Th.E.P.9 Emotional Impact of Voluntary HIV Antibody Testing. *Samuel W. Perry*, L. Jacobsberg, B. Fishman, A. Frances, A. Novick, R. Rein, *Cornell Medical Center, New York, NY, U.S.A.*

Th.E.P.10 HIV Antibody Testing by Canadian General Practitioners and Family Physicians. *Thomas J. Elmslie*, J. Shearman, N. Busing, *University of Ottawa, Ottawa, ON, Canada.*

Th.E.P.11 Telephone Screening of Men at Risk of HIV Infection. *Charles E. Lewis*, H. Freeman, K. Montgomery, *University of California at Los Angeles, Department of Medicine, Los Angeles, CA, U.S.A.*

Th.E.P.12 Campagne de promotion pour le dépistage volontaire, anonyme et gratuit a Lyon-France. *Bruno Dubessy*, R. Lozat, J. M. Livrozet, J. L. Estournel, *Médecins du Monde, Lyon, France.*

Th.E.P.13 Anonymity Sought in HIV Antibody Testing. *James W. Dilley*, J. M. Moulton, B. E. Havassy, *University of California at San Francisco, School of Medicine, Department of Psychiatry, AIDS Health Project, San Francisco, CA, U.S.A.*

Th.E.P.14 Assessing the Ethical and Policy Implications of Testing Surgical Patients for HIV Antibody in the USA. *A. Gene Copello, Vanderbilt University, Nashville, TN, U.S.A.*

Th.E.P.15 Preliminary Evaluation of an Admission, HIV Antibody, Voluntary Screening Program in a Large Private Hospital. *Richard L. Harris*, E. Boisaubin, P. Salyer, D. Semands, *The Methodist Hospital, Baylor College of Medicine, Houston, TX, U.S.A.*

Th.E.P.16 Évolution des motifs de prescription de sérologie VIH en médecine générale en Aquitaine, France, 1981-1988. *Roger Salamon*, S. Maurice, G. Poumerol, C. Vivares, F. Dabis, B. Tilly, *Département d'informatique médicale, Université Bordeaux 2, Bordeaux, France.*

Th.E.P.17 Caractéristiques des consultants d'un centre de dépistage anonyme et gratuit de l'infection par le VIH, Bordeaux, 1988. *Jean-Paul Jost*, G. Mamane, A. Chaslerie, A. M. Frossard, M. Géniaux, R. Salamon, *Service de Dermatologie, Hôpital Pellegrin-Tripode, Bordeaux, France.*

Th.E.P.18 Characteristics of Patients Submitted to HIV Serology in a Clinic for Sexually Transmitted Diseases of Downtown Montreal. *Michel Alary*, J. Castel, C. Olivier, S. Côté, M. Marchand, *Département de Santé communautaire, Hôpital du Saint-Sacrement, Québec, QC, Canada.*

Th.E.P.19 Altérations socio-économiques et comportementales des personnes infectées par HIV. *Janete L. L. Hanan*, E. M. M. Moura, C. A. Morais de Sá, *Centro Brasileiro de Cooperaçao e Intercâmbio de Serviços Sociais, Rio de Janeiro, Brazil.*

Th.E.P.20 Funk and Epidemiology: Viral Dialectics in the Soul Music of Prince. *Mark Harrington*, D. Barr, R. Vazquez, R. Deagle, *ACT UP/NY, New York, NY, U.S.A.*

Th.E.P.21 Study of the Prevalence in an HIV Testing Center. *Danielle Sondag-Thull*, J. Defourny, M. Krings, D. Mauchard, J. F. Bachelet, *Université de Liège, Liège, Belgium.*

Th.E.P.22 Prevalence of Anti-HIV Antibodies in Phthisics: Sorocaba (Sao Paulo): Brazil. *Vilma Lucia Carmona Gonçalves*, R. M. P. Dos Anjos, M. C. O. Gomes, T. Ramos, *Conjunto Hospitalar de Sorocaba, Grupo de Vigilancia Epidemiologica, Sorocaba, Brazil.*

Th.E.P.23 Social Acceptability of HIV Screening among Pregnant Women. *Jean-Paul Moatti*, C. Le Gales, R. Henrion, E. Papiernik, *INSERM U240, Fontenay-aux-Roses, France.*

Th.E.P.24 Psychosocial Predictors of People Who Fail to Return for Their HIV Test Results. *Joseph A. Catania*, M. Kegeles, T. Coates, *University of California, San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.*

Th.E.P.25 A Confidential Public Health HIV Testing Clinic as an Acceptable Alternative to Anonymous Testing. *Michael L. Rekart*, D. Cook, W. Black, *STD Control, Ministry of Health, Vancouver, BC, Canada.*

Th.E.P.26 Factors Affecting the Decision to Refuse HIV Testing among Haitian Immigrants in Montreal. *Alix Adrien*, C. A. Hankins, Y. Tousignant, J. F. Boivin, *Département de santé communautaire de l'Hôpital Général de Montréal, Montreal, QC, Canada.*

Th.E.P.27 Anxiety and Attitudes to HIV Testing in an Ante-Natal Clinic. *Lorraine Sherr*, C. Victor, A. Stevens, *St. Mary's Hospital, London, U.K.*

Th.E.P.28 HIV Testing and Counselling Practices in the U.S.A.: A Descriptive National Study. *Felissa L. Cohen, University of Illinois, College of Nursing, Chicago, IL, U.S.A.*

Th.E.P.29 Impact of Experience with AIDS on HIV Testing Patterns: An Analysis of Minnesota and U.S. Hospitals. *Scott Campbell*, J. R. Thurn, M. Maki, K. Willenbring, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A.*

Th.E.P.30 Characteristics and Responses of Men Seeking HIV Antibody Test Results. *David G. Ostrow*, J. Joseph, E. Beltran, J. Chmiel, J. Phair, *University of Michigan, Institute for Social Research, Ann Arbor, MI, U.S.A.*

Th.E.P.31 Premarital Screening for Antibodies to HIV-1 in the U.S. *Carol R. White*, L. Petersen, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.E.P.32 The Effect of Mandatory AIDS Education on Voluntary HIV Testing in Prisons. *Jon K. Andrus*, D. Fleming, C. Knox, R. McAlister, J. Horan, L. Foster, *Centers for Disease Control, Atlanta, GA, U.S.A.*

Th.E.P.33 A Report on a Newly Developed AIDS Intervention Programme in Montreal. *Marlene Yuen-Boyer*, F. Bates, C. Paquin, G. Schoel, *CLSC Métro, Montreal, QC, Canada.*

Anthropologie
Anthropology

Th.E.P.34 Sexuality and HIV Transmission in Kagera Region, Tanzania. *George K. Lwihula, Faculty of Medicine, Dar es Salaam, Tanzania.*

Th.E.P.35 Sexualité et connaissance du SIDA chez les lycéens et jeunes femmes de Dakar et banlieue. *Y. Mb. Guisse*, P. D'Almeida, *Université de Dakar, IFAM Cheikh Anta Diop, Dakar, Senegal.D*

Th.E.P.36 The Role of IV Drug Withdrawal Symptoms and Symptom Anticipation in AIDS Risk Reduction. *Margaret M. Connors, Spectrum House, Inc., Westboro, MA, U.S.A.*

Th.E.P.37 A Cross-Cultural Perspective on AIDS-Risk-Related Sexual Behaviors as Depicted in Art throughout History. *June M. Reinisch*, M. Ziemba-Davis, S. A. Sanders, *The Kinsey Institute for Research in Sex, Gender, and Reproduction, Bloomington, IN, U.S.A.*

Th.E.P.38 Traditional Healers and AIDS among the Yorubas in Nigeria. *M. K. Jinadu*, B. Ajuwon, D. A. Jaiyeoba, *Obafemi Awolowo University, Ile-Ife, Nigeria.*

Th.E.P.39 AIDS Knowledge, Attitude and Practice in a Deprived Urban Area of Nairobi, Kenya. *Doris M. W. Kinuthia*, V. Orinda, J. P. Brady, J. S. Meme, *Department of Pediatrics, University of Nairobi, Nairobi, Kenya.*

Th.E.P.40 SIDA: Représentations et pratiques populaires en Afrique centrale. *Brooke G. Schoepf*, C. Schoepf, *Woods Hole, MA, U.S.A.*

Rôle de la religion
Role of Religion

Th.E.P.41 Religious Organizations Respond to a Community Affected by HIV. *Rodney J. De Martini*, C. Hartquist, A. Rose, *Archdiocese of San Francisco, Office of AIDS Education, San Francisco, CA, U.S.A.*

Th.E.P.42 Involving the Religious Community: A Statewide Model. *Thaddeus A. Bennett*, D. Wood, C. Carnahan, *AIDS Ministries Program, Episcopal Diocese of Connecticut, Hartford, CT, U.S.A.*

Th.E.P.43 Religion as a Tool in Preventing the Spread of HIV in Uganda. *Muhammed Musagara*, F. Namaganda, *AIDS Control Program, Entebbe, Uganda.*

Th.E.P.44 How Organized Religion Impacts on the AIDS Pandemic in Prevention, Education, and Prejudice. *Henry J. Yeager, The Dwight Foundation, New York, NY, U.S.A.*

Th.E.P.45 Mobilization of Volunteers for Control of the HIV Epidemic. *Charles F. Clark, Tampa Veterans Administration Hospital, Tampa, FL, U.S.A.*

Sociologie du SIDA
Sociology of AIDS

Th.E.P.46 Comportement sexuel et attitudes relativement au SIDA dans la ville de Lisbonne: Une étude éxploratoire. *Fausto Amaro*, L. Teles, A. Dantas, *Fundaçao Nossa Senhora do Bom Sucesso, Lisbon, Portugal.*

Th.E.P.47 Where Are People in England and Wales Dying from AIDS? *Ann R. Kennedy*, G. A. Ellam, J. D. H. Porter, *Communicable Disease Surveillance Centre, Public Health Laboratory Service, London, U.K.*

Th.E.P.48 Pratiques de risque et SIDA parmi les homosexuels-bisexuels espagnols. *Ricardo R. Usieto*, J. Sastre, H. Anabitarte, J. Torres, R. De Andres, M. C. Contreras, *Université Internationale Menendez Pelayo, Madrid, Spain.*

Th.E.P.49 AIDS Treatment Deficits: An Ethnographic Study of the Management of the AIDS Epidemic, the Ontario Case. *George W. Smith, Ontario Institute for Studies in Education/AIDS ACTION NOW!, Toronto, ON, Canada.*

Th.E.P.50 AIDS as an Emergent Field: Lessons from a Comparison with Perinatal Medicine and Geriatrics. *Debbie Indyk, Mt. Sinai School of Medicine, New York, NY, U.S.A.*

Th.E.P.51 The Impact of AIDS on the Homosexual Clone Community in New York City. *Martin P. Levine, Bloomfield College, Department of Sociology, Bloomfield, CT, U.S.A.*

Th.E.P.52 Connaissance, attitudes et croyances sur le SIDA à Bangui (R.C.A.). *Alain Jean Georges*, G. Gresenguet, P. Somse, L. Belec, S. Chaze, J. P. Danagoro, *Institut Pasteur, Bangui, Central African Republic.*

Th.E.P.53 AIDS as a Challenge to Physicians' Professional Identity. *Kathryn M. Taylor*, J. K. Eakin, M. J. Kelner, *University of Toronto, Department of Behavioural Sciences, Toronto, ON, Canada.*

Th.E.P.54 A Model Comparing Condom Use vs. Partner Reduction Strategies. *Ira L. Reiss*, R. K. Leik, *University of Minnesota, Department of Sociology, Minneapolis, MN, U.S.A.*

Th.E.P.55 AIDS in an Aging Society: Ethical and Psychosocial Considerations. *Robert M. Schmidt*, R. H. Kenen, *Center for Preventive Medicine and Health Research, San Francisco University and Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A.*

Th.E.P.56 Health Professionals' Views of Social Distance from Persons with AIDS and Other Conditions. *Felissa L. Cohen*, R. Mudro, *University of Illinois, College of Nursing, Chicago, IL, U.S.A.*

Th.E.P.57 Guardianship Status and Supportive Relationships as Co-Determinants of Enrollment of HIV-Positive Children in a Placebo-Controlled Study. *Katherine E. Steinberg*, T. Calvelli, J. Kashkin, A. Willoughby, L. Bernstein, A. Rubinstein, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.E.P.58 Perinatal Study Compliance of HIV-Infected Women: Significance of Risk Factors as a Determinant. *Cecilia Douglas*, T. Cabat, C. Bueti, T. Calvetti, A. Rubinstein, A. Willoughby, *Albert Einstein College of Medicine, Bronx, NY, U.S.A.*

Th.E.P.59 Changes in Sexual Behavior of a Cohort of Female Health Care Workers during the AIDS Era. *Charles T. Leach*, S. Viker, T. Kuhls, N. Parris, J. Cherry, P. Christenson, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.*

Th.E.P.60 Social Aspects of AIDS: An Analysis of Attitudes and Awareness. *S. Shanmuganandan*, P. T. K. Subramanian, *Department of Geography, Madurai Kamaraj University, Madurai, India.*

Les arts
Arts

Th.E.P.61 Our Lady of AIDS: The Talismanic Design of André Durand's Plague Icon "Votive Offering". *James L. Miller, University of Western Ontario, London, ON, Canada.*

Th.E.P.62 Back to Basics: Use of Popular Theatre in AIDS Awareness Campaign. *Rodreck S. Mupedziswa, University of Zimbabwe, School of Social Work, Harare, Zimbabwe.*

Th.E.P.63 Private/Public Sector Cooperation in AIDS Education. *Ann E. Downer*, C. Bishop, P. Hillard, C. Granat, *University of Washington, AIDS Education and Training Center, Seattle, WA, U.S.A.*

Th.E.P.64 1989 Partnership in Caring Calendar. *Diane McMenamin*, C. Hostetter, *Department of Health and Human Services, Rockville, MD, U.S.A.*

Th.E.P.65 The Rural Theatre Project: AIDS Education in the Villages of Trinidad and Tobago. *Michael Helquist*, O. Besly, R. John, C. Almedal, *Academy for Educational Development, Washington, DC, U.S.A.*

Th.E.P.66 Physician-Patient Relationships in AIDS Dramas. *Howard C. Rubin*, G. Nakajima, *Mount Sinai School of Medicine, New York, NY, U.S.A.*

La communauté (partie 2)
Community (Part 2)

Th.E.P.67 The "Fundación SIDA de Puerto Rico" Experience. *José Toro-Alfonso*, M. Rodríguez, A. Nigaglioni, A. Meaux, *Fundación SIDA de Puerto Rico, Inc., San Juan, Puerto Rico.*

Th.E.P.68 Le Comité SIDA Aide Montréal et ses activités. *Lise L. Lanctôt, Comité SIDA Aide Montréal, Montreal, QC, Canada.*

Th.E.P.69 HIV Related Services: A Model for Community Service Provision. *Nicholas A. Rango, New York State Department of Health, AIDS Institute, Albany, NY, U.S.A.*

Th.E.P.70 Contributions of the International Gay Community to AIDS Research. *Lawrence A. Falk*, W. A. Verick, *Committee for a Nobel Endeavor, Chicago, IL, U.S.A.*

Th.E.P.71 London Lighthouse: A Continuum of Care. *Christopher Spence*, H. MacGregor, S. Malach, S. J. Mansfield, U. O'Brien, M. Pipes, et al., *London Lighthouse, London, U.K.*

Th.E.P.72 Créer un milieu de vie: Une approche architecturale novatrice. *Céline Germain*, R. Morisset, J. Coutoudon, *Corporation Félix-Hubert-D'Hérelle, Montreal, QC, Canada.*

Éducation (partie 3)
Education (Part 3)

Th.E.P.73 The Stop-AIDS Model for Community Change: Acceptability in a Low-Incidence Area for AIDS. *Carolyn G. Beeker*, T. Rose, *New York State Department of Health, AIDS Institute, Albany, NY, U.S.A.*

Th.E.P.74 Educational Intervention in a Cohort of Homo/Bisexual Men towards a Change in High Risk Behavior for HIV Infection: An Assessment of the Process. *Carlos F. Caceres*, F. Mariscal, E. De La Vega, E. Gotuzzo, M. Ramah, *Instituto de Medicina Tropical Alexander Von Humboldt, U. P. Cayetano Heredia, Lima, Peru.*

Th.E.P.75 Resources for Educating about Married Homesexual and Bisexual Men: A Facilitator's Kit in Action. *John W. Molenaar, Gay and Married Men's Association, Ministry of Education, Box Hill, Australia.*

Th.E.P.76 STD Patients' and Prostitutes' Knowledge on AIDS: Modification of Sexual Practices and Education Needs. *Femi Soyinka*, M. Z. Hossain, O. Onayemi, *Obafemi Awolowo University, Ile-Ife, Nigeria.*

Section
F
Droit et éthique
Ethics and Law

Jeudi 8 juin
Thursday, June 8

Session d'affichage
Poster Session

Discrimination et droits de la personne
Discrimination and Human Rights

Th.F.P.1 AIDS and Ethics. *Guido Carlos Levi*, A. O. L. Barros, *Hospital do Servidor Publico Estadual, Sao Paulo, Brazil.*

Th.F.P.2 L'éthique dans les groupes communautaires. *Isabelle Sourdif, Comité SIDA Aide Montréal (CSAM), Montreal, QC, Canada.*

Th.F.P.3 State/Local Strategies to Prevent and Resolve HIV-related Discrimination: Five Case Studies. *Anne M. Guthrie*, L. Sherwood-Fabre, R. J. Steele, S. E. Karsten, B. F. Lorenz, J. L. Ritter, *Office of the Assistant Secretary for Health, U.S. Public Health Service, Washington, DC, U.S.A.*

Th.F.P.4 Equality Rights for People with AIDS: Mandatory Reporting of HIV Infection and Contact Tracing in Ontario. *William F. Flanagan, Columbia University School of Law, New York, NY, U.S.A.*

Th.F.P.5 Governments' Duty to Provide Financial Assistance and Compensation to Persons Who Have Become Infected with HIV through Blood Transfusions and Blood Products. *Jacques J. M. Shore, Heenan Blaikie, Montreal, QC, Canada.*

Th.F.P.6 Providing High Quality, Low Cost Legal Services to People with AIDS: A Discrimination Law Project. *Mark Barnes*, D. M. Greenberg, *Columbia University School of Law, AIDS Law Clinic, New York, NY, U.S.A.*

Th.F.P.7 AIDS Policies of Canadian Universities. *Donald C. Savage*, M. Blanchette, *Canadian Association of University Teachers, Ottawa, ON, Canada.*

Th.F.P.8 Forum for Civil and Human Rights Bodies Active in AIDS Work. *The B.C. Civil Liberties Association, Vancouver, BC, Canada.*

Th.F.P.9 HIV-Antibody Testing: Is Consent the Legal Issue? *Dai Harris, The Terrence Higgins Trust Legal Centre, London, U.K.*

Th.F.P.10 A Bill of Rights for Persons with AIDS. *Herbert R. Spiers*, C. Taylor, *New York University, New York, NY, U.S.A.*

Th.F.P.11 Catastrophic Rights. *John Dixon, The B.C. Civil Liberties Association, Vancouver, BC, Canada.*

Th.F.P.12 The Influence of AIDS on Individual Rights and the Dignity of People. *Carmen Arredondo Miguel*, F. Conde, A. Coronado, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spain.*

Th.F.P.13 Development of Community-Based Legal Services for Persons with HIV Infection. *Clint Hockenberry*, M. Zavos, *AIDS Legal Referral Panel, San Francisco, CA, U.S.A.*

Th.F.P.14 Legal Needs Assessment of HIV-Infected Men and Women. *Brian R. Saltzman*, D. C. Perlman, J. Clayton, P. Colligan-Levine, C. Lane, L. Comeau, et al., *Beth Israel Medical Center, New York, NY, U.S.A.*

Th.F.P.15 HIV Antibody Testing of "Canada World Youth" (CWY) Applicants. *R. Morisset*, D. J. Roy, J. Jobin, J. Joubert, *Hôtel-Dieu de Montréal, Clinical Research Institute of Montreal, Canada World Youth, Montreal, QC, Canada.*

Section
G

Jeudi 8 juin
Thursday, June 8

Implications internationales
International Issues

Session d'affichage
Poster Session

Aspects cliniques (partie 2)
Clinical Features (Part 2)

Th.G.P.1 HIV and HTLV-I Infection among Homosexual and Bisexual Men in Kingston, Jamaica. *Edward L. Murphy*, W. N. Gibbs, J. P. Figueroa, B. Bain, L. Lagrenade, B. Cranston, et al., *San Francisco General Hospital, San Francisco, CA, U.S.A.*

Th.G.P.2 Risk Factors for HTLV-I Infection in Pregnant Haitian Women. *Andrea J. Ruff*, E. Holt, S. Wiktor, R. Boulos, W. Blattner, N. Halsey, et al., *Johns Hopkins University School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.*

Th.G.P.3 HIV Infection among Prostitutes and Transvestites in Brazil. *Francisco H. Aoki*, J. N. Lima, W. B. Abreu, D. T. Monteiro, M. H. P. Pavan, R. J. Pedro, *Hospital de Clinicas, Unicamp, Grupo de AIDS, Campinas, Brazil.*

Th.G.P.4 Merchant Seamen: A Risk Population for HIV Infection? *Mónica Cornejo*, R. Jerez, D. Casanova, *University of Valparaíso, Viña Del Mar, Chile.*

Th.G.P.5 Preventive Intervention for HIV in STD Clinics in Zambia. *Subhash K. Hira*, P. Matondo, *University Teaching Hospital, Lusaka, Zambia.*

Facteurs de risque liés aux MTS (partie 2)
STD Risk Factors (Part 2)

Th.G.P.6 Detection of HIV-1 from Filter Paper by Polymerase Chain Reaction (PCR). *Shlomit Orgad*, B. Korber, R. Marlink, M. Kanki, M. Essex, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.*

Th.G.P.7 Liaison entre la densité optique en ELISA et le résultat du Western Blot chez les donneurs de sang de Brazzaville (Congo). *Michel Rosenheim*, P. M'Pele, A. Itoua-Ngaporo, N. Copin, F. Yala, M. Gentilini, *Département de Parasitologie, Médecine tropicale, et Santé publique, Hôpital de la Salpêtrière, Paris, France.*

Th.G.P.8 Rapid Method for Detection of HIV-1 and HIV-2 Infections: Evaluation of Sensitivity and Specificity. *Daniel Zulaica*, G. Cilla, E. Perez-Trallero, *Hospital Nuestra Señora de Aránzazu, Servicio de Microbiología, San Sebastián, Spain.*

Th.G.P.9 Modified Western Blot Assays for HIV Infection. *Sunil K. Arora*, S. Sehgal, *Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.*

Th.G.P.10 FDA Reform: An Activist Perspective on the Need for Legal and Regulatory Change. *Mark Harrington*, J. Eigo, M. McCarthy, I. Long, D. Z. Kirschenbaum, *ACT-UP/NY, New York, NY, U.S.A.*

Th.G.P.11 Blinded by Science: DHPG and the Conflict between "Clean Data" and Humane Health Care. *Mark Harrington*, K. Wiley, J. Eigo, *ACT-UP/NY, New York, NY, U.S.A.*

Th.G.P.12 National Institutes of Health/NIAID-WHO AIDS Research and Reference Reagent Program. *Susan A. Stern*, L. Muul, G. Milman, *National Institutes of Health-NIAID AIDS Reagent Program, Rockville, MD, U.S.A.*

Th.G.P.13 Phase-I Study of Recombinant Peptide Corresponding to the gp41 Transmembrane Protein of the HIV-1 Virus Coupled to Ficoll. *Manfred Dietrich*, S. Schwander, D. Hanson, B. Letwin, J. Schindler, *Bernhard-Nocht Institute for Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany.*

Th.G.P.14 African HIV Education Mobilized through a Public-Private Workshop. *Lester N. Wright*, H. Elder, R. Hart, *Oregon Health Division, Portland, OR, U.S.A.*

Th.G.P.15 The Role of Female Prostitution in the Heterosexual AIDS Epidemic in South Africa. *Barry David Schoub*, D. Martin, A. N. Smith, S. F. Lyons, G. N. Padayachee, S. Naidoo, *National Institute for Virology, Sandringham, Transaal, South Africa.*

Épidémiologie
Epidemiology

Th.G.P.16 Attitudes Explaining Desertion and Non-Use of Condoms in Gay Men in Mexico. *Jose-Antonio Izazola*, R. Basañez, J. L. Valdespino, M. Ramah, J. Sepúlveda, *Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.*

Th.G.P.17 HIV Infection in Pregnant Women and Their Infants in Argentina. *Arnaldo D. Casiro*, F. Uranga Imaz, A. Capdevila, E. Rickard, L. Astarloa, P. Cahn, et al., *Hospital Fernandez, Infectología, Buenos Aires, Argentina.*

Th.G.P.18 Lessons from AIDS Surveillance and Prevention in Uganda. *Ikwaras S. Okware*, S. F. Berkley, W. Naamara, W. D. Sutherland, *Uganda National AIDS Control Programme, Entebbe, Uganda.*

Th.G.P.19 AIDS and African Women. *E. Maxine Ankrah, Makerere University, Kampala, Uganda.*

Th.G.P.20 Connaissances, attitudes et comportement à l'egard du SIDA de la population Rwandaise. *G. Muligande*, N. Ndibisheye, D. Nzaramba, P. Lehman, M. Carsel, *Sociological and Behavioural Research, Global Program on AIDS, World Health Organization, Geneva, Switzerland.*

Th.G.P.21 Heterosexual Transmission of HIV Infection in Hemophiliacs. *Ema Rickard*, G. Muchinik, M. Manca, R. Campestri, R. Pérez Bianco, M. De Tezanos Pinto, *IIHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina.*

Th.G.P.22 HIV in Mozambique. A General Overview. *Fernando V. De La Cruz*, J. A. X. Barreto, C. A. D. Palha de Sousa, L. Barquet, A. J. R. Cabral, J. F. L. Schwalbach, *Instituto Nacional da Saúde, Immunology Laboratory, Maputo, Mozambique.*

Th.G.P.23 Les pratiques et moeurs sexuelles au Sénégal. Contribution à la connaissance du SIDA. *Y. N. Guisse*, L. D'Almeida, E. Bienvenu, *IFAM Cheikh Anta Diop, Dakar, Senegal.*

Th.G.P.24 Incidence of HIV Infection among Female Infertile Patients. *Selvamani Samundi Sankari*, L. Anantha Subramanian, R. B. Asthagiri, S. Solomon, S. Subramanian, C. Saikumar, *Madras University Madras Medical College, Government K. G. Hospital, Madras, India.*

Th.G.P.25 Hijras: A Cult Susceptibility for AIDS. *Ishwarprasad S. Gilada, Indian Health Organization, J. J. Hospital, Bombay, India.*

Th.G.P.26 Epidemiological Findings of HIV Infection among Women in Sao Paulo, Brazil. *Ana Carolina I. Ferreira*, J. L. Grandi, M. E. Fernandes, C. Accetturi, W. Pinto, *Reference and Training for AIDS, Sao Paulo, Brazil.*

Th.G.P.27 Epidemiological Features of Pediatric AIDS in the Caribbean. *Jai P. Narain*, S. Mahabir, J. Hospedales, D. Bassett, *Caribbean Epidemiology Center, Port-of-Spain, Trinidad.*

Th.G.P.28 Increasing Problem of Heterosexually-Acquired AIDS in the English-Speaking Caribbean and Suriname. *Jai P. Narain*, J. Mahabir, J. Hospedales, D. Bassett, *Caribbean Epidemiology Center, Port-of-Spain, Trinidad.*

Th.G.P.29 Modification of High Risk Heterosexual Behaviour after Education and Counselling in Nairobi. *D. William Cameron,*, L. J. D'Costa, A. M. Maingi, J. O. Ndinya-Achola, A. R. Ronald, F. A. Plummer, *Ottawa General Hospital, Ottawa, ON, Canada.*

Th.G.P.30 Transmission of HIV in Mansa, Zambia. *Peter L. Perine*, S. K. Hira, G. J. Bhat, K. Mukelabai, N. N. Pearsall, C. Chishemba, et al, *Uniformed Services University of the Health Sciences, Bethesda, MD, U.S.A.*

Notes

Section
H

Jeudi 8 juin
Thursday, June 8

Répercussions économiques du SIDA
The Economic Impact of AIDS

Session d'affichage
Poster Session

Affectation des ressources
Resource Allocation

Th.H.P.1 Affectation des ressources monétaires (CSAM). *Lise Lanctôt, Comité SIDA Aide Montréal, Montreal, QC, Canada.*

Th.H.P.2 The Economic Impact of AIDS: A Patient Perspective. *Lois A. Jackson*, M. M. Fanning, *Toronto General Hospital, CCRW, Toronto, ON, Canada.*

Th.H.P.3 Distribution and Characteristics of AIDS Hospitalizations in the U.S., 1986-87. *Judy K. Ball*, B. J. Turner, *U.S. DHHS, National Center for Health Services Research, Rockville, MD, U.S.A.*

Th.H.P.4 The Economic Impact of AIDS on the Health Care System in Switzerland. *Maurice R. H. Pedergnana, University of St. Gallen, St. Gallen, Switzerland.*

Th.H.P.5 Hospital Utilization and Hospital Expenditures for Patients with HIV Diagnoses: United States, 1984-1987. *Mary Moien*, L. J. Kozak, *National Center for Health Statistics, Hyattsville, MD, U.S.A.*

Th.H.P.6 Impact and Distribution of Hospitalized HIV Disease in a Low-Incidence Area of Canada. *Geoffrey D. Taylor*, L. J. Miedzinski, *University of Alberta, Edmonton, AB, Canada.*

Th.H.P.7 A Systemic Approach to AIDS Economic and (Social) Development Impact Analysis. *Samuel Bounya-Épée, University of Yaounde, Department of Economics, Yaounde, Cameroon.*

Th.H.P.8 The Canadian AIDS Research Contribution: A Critique. *Allan R. Ronald, University of Manitoba, Department of Internal Medicine, Winnipeg, MB, Canada.*

Th.H.P.9 Labor Productivity Losses to Nevada's and the American Economy Resulting from Premature Death Due to AIDS. *Vicky L. Carwein*, C. G. Ray, *Department of Nursing, University of Nevada at Las Vegas, Las Vegas, NV, U.S.A.*

Th.H.P.10 Study on Consumption of Care of HIV-Positive Patients. *Harriet E. Malmquist*, B. R. Nilsson, K. Lidman, *National Swedish Board of Health and Welfare, Stockholm, Sweden.*

Th.H.P.11 Medical Consumption of HIV Patients Outside Hospitals in France: An Analysis in Terms of Gravity Level. *Annie Triomphe*, Y. A. Flori, G. Brucker, P. Gutbrau, *Université Paris I, Panthéon-Sorbonne, Laboratoire d'Économie sociale, Paris, France.*

Th.H.P.12 A Comprehensive and Cost-Effective Approach to the Management of AIDS Patients in an Outpatient Facility: The Results of a Patient Survey. *Raúl Benitez*, J. Sotomayer, *San Juan AIDS Institute, Hato Rey, Puerto Rico.*

Th.H.P.13 Enlisting the Support of Traditional Healers in AIDS Education Campaign. *E. Sivile*, B. U. Chirwa, *Ministry of Health, Lusaka, Zambia.*

Th.H.P.14

Pays en voie de développement - divers
Developing Countries - Miscellaneous

Th.H.P.15 The Fear of AIDS in Young Women. *George Iatrakis*, G. Sakellaropoulos, G. Kourounis, E. Argyroudis, *Department of Obstetrics and Gynecology, Athens, Greece.*

Th.H.P.16 Étude du temps moyen de survie des patients atteints de SIDA à Kinshasa, Zaïre. *Kalambayi Kayembe*, M. P. Mulumba, K. Tonduangu, *Cliniques Universitaires Kinshasa, Kinshasa, Zaire.*

Th.H.P.17 Incidence d'infection HIV-1 dans les prostituées de Callao, Perou. Étude de cohorte. *Jorge Alarcón*, O. Palacios, A. Tejada, I. Phillips, L. Varela, *Universidad Nacional Mayor de San Marcos, Lima, Peru.*

Th.H.P.18 Utilisation d'un test rapide au latex pour prévenir la transmission du HIV par transfusion dans les soins de santé primaires à Kinshasa. *Marie-Madeleine Gerniers*, M. Kabeya, M. Kasali, P. Pauwels, J. Perriens, *Projet Santé pour Tous-Kinshasa, Kinshasa, Zaire.*

Th.H.P.19 Peak Prevalence of HIV in Namibian Teenagers. *Gersimos Lecatsas*, J. J. Joubert, C. H. J. Schutte, M. B. Taylor, C. Swanevelder, *Medical University of South Africa, Pretoria, South Africa.*

Th.H.P.20 AIDS and Migration in Jalisco, Mexico: Their Relation with Risk Factors. *David Diaz-Santana*, A. Celis, *Consejo Estatal para la Prevención del SIDA en Jalisco, Guadalajara, Mexico.*

Th.H.P.21 HTLV-I Infection in Sexually Active and HIV-1 Infected Subjects in the Philippines. *Ofelia T. Monzon*, F. J. E. Paladin, S. S. Mohammad, C. Lazo, J. M. Capellan, *Research Institute for Tropical Medicine, Manila, Philippines.*

Th.H.P.22 Mode de contamination des enfants à Pointe-Noire (Congo). *Joëlle Nicolas-Randegger*, L. B. Brunet, N. Mboungou-Kimpolo, J. D. Balende, A. Wilson, *Hôpital Robert-Debré, Unité d'Immunohématologie, Paris, France.*

Th.H.P.23 HIV Infection in Heterosexual Population: Paradox or Concealment of Information? *Pedro E. Cahn*, H. M. Perez, A. D. Casiro, N. S. Grinberg, G. Muchinik, M. B. Bouzas, *Servicio de Infectologa, Hospital Fernandez, Buenos Aires, Argentina.*

Th.H.P.24 Typology, Behavior, Bisexuality and HIV Infection of Homosexual Men of Costa Rica, 1985-1988. *Leonardo J. Mata*, E. Ramírez, J. Badilla, E. Mata, *Instituto de Investigaciones en Salud, University of Costa Rica, San Pedro, Costa Rica.*

Th.H.P.25 HIV-1 and HIV-2 Serological Study Carried out on Blood Donors from Guinea Bissau. *Sergio Sabbatani*, M. Ghidinelli, A. M. Visintainer, B. Biasioli, P. J. Mendez, F. Diaz, *Ospedale Maggiore, Bologna, Italy.*

Th.H.P.26 AIDS Surveillance in Sichuan, China. *Dongyou Yan*, L. Chen, B. Lu, P. Deng, *Health and Anti-Epidemic Center of Sichuan Province, Chengdu, China.*

Th.H.P.27 Prevention of Transfusion-associated HIV Transmission in Kinshasa, Zaire. *Helmut Jaeger*, K. Nseka, J. Perriens, C. Kabeya, R. Ryder, T. Rehle, et al., *Deutsche Gesellschaft für Technische Zusammenarbeit, Eschborn, Federal Republic of Germany.*

Th.H.P.28 AIDS in Egypt: An Epidemiological Study. *Samir Mohamed Wassif*, A. B. Mobarak, A. S. Rashid, O. M. Wassif, *Faculty of Medicine, Zagazig University, Zagazig, Egypt.*

Th.H.P.29 AIDS Education for Commercial Sex Workers in Honduras. *Barbara Janowitz*, M. Coello, P. Bailey, K. Clarke, *Family Health International, Research Triangle Park, NC, U.S.A.*

Th.H.P.30 AIDS Prevention and Its Countercurrents in Asia. *Shahul Hameed Ebrahim*, D. Hilsorst, *Bicol Christian College of Medicine, Legaspi City, Philippines.*

Vendredi
Friday

le vendredi 9 juin

Perspectives d'Avenir

Présidente: *Thérèse Lavoie-Roux*
Ministre de la santé et des services sociaux du Québec

Conférenciers: *Simone Veil*
Présidente du Groupe libéral, démocratique et réformateur
Parlement Européen
France

Robert Gallo
Chef
Laboratory of Tumor Cell Biology
Etats-Unis

Luc Montagnier
Département de Virologie
Unité d'oncologie virale
Institut Pasteur
France

Alastair Clayton
Directeur général
Centre fédéral sur le SIDA
Canada

Richard A. Morisset
Président, Comité du programme de la Conférence
Professeur titulaire
Département de microbiologie et immunologie
Université de Montréal
Québec, Canada

Future Prospects

Friday June 9

Chairperson

Thérèse Lavoie-Roux
Minister of Health and Social Services
of Quebec

Plenary Speakers:

Simone Veil
Président
Groupe libéral, démocratique et
réformateur
Parlement Européen
France

Robert Gallo
Chief
Laboratory of Tumor Cell Biology
U.S.A.

Luc Montagnier
Department of Virology
Viral Oncology Unit
Institut Pasteur
France

Alastair Clayton
Director General
Federal Centre for AIDS
Canada

Richard A. Morisset
Chairman, Conference Programme
Committee
Professsor, Microbiology and
Immunology
University of Montreal
Quebec, Canada

Cérémonie de clôture

le vendredi 9 juin

Président:

Ivan Head
Président de la Conférence
Président du Centre de recherches pour le développement international

Conférenciers:

L'Honorable Perrin Beatty
Ministre de Santé et bien-être social
Canada

Mohammed Abdelmoumène
Directeur général adjoint
Organisation mondiale de la santé

John Ziegler
Président
VIe Conférence internationale sur le SIDA
San Francisco

Lars Olof Kallings
Président
International AIDS Society
Ministère de la santé et des affaires sociales
Suède

Message de

Danielle Mitterrand
Présidente, FONDATION FRANCE-LIBERTÉS

Randy Shilts
Correspondant national
San Francisco Chronicle
Etats-Unis

Closing Ceremony

Friday June 9

Chairman:

Ivan Head
Conference Chairman
President, International Development Research Centre

Plenary Speakers:

The Honourable Perrin Beatty
Minister of Health and Welfare Canada

Mohammed Abdelmoumene
Deputy Director-General
World Health Organization

John Ziegler
Chairman
VI International Conference on AIDS
San Francisco

Lars Olof Kallings
President
International AIDS Society
Ministry of Health and Social Affairs
Sweden

Message from

Danielle Mitterrand
President
FONDATION FRANCE-LIBERTÉS

Randy Shilts
National Correspondent
San Francisco Chronicle
U.S.A.

A

Abdul-Quader, Abu
Th.D.P.64
Abdullah, Tariq H.
Th.B.P.304
Abos Navarro, Josep
Th.B.P.193
Aboulafia, David M.
Th.A.P.8
Aboulker, Jean-Pierre
W.B.P.302, Th.B.P.149
Abrams, Donald I.
W.B.P.247, W.B.P.315
Accetturi, Conceiçao A.
M.B.P.266, T.B.P.356
Achour, Ammar
M.C.P.30
Adam, Zenan E.
T.E.P.21
Adekunle, Lola Vivian
T.G.P.23
Adeniyi-Jones, Samuel R.
T.C.P.136
Adeokun, Lawrence A.
M.G.O.18, Th.G.O.11
Adib, S. Maurice
T.D.P.36
Adler, Karl E.
Th.B.O.10
Adrien, Alix
M.D.P.33, M.E.P.10, Th.E.P.26
Adrien, Mario
T.G.O.20
Aeberhard, Françoise
Th.E.P.7
Afessa, Bekele
M.B.P.201
Aggleton, Peter J.
T.E.O.12
Agins, Bruce D.
W.B.P.64
Agius, Gérard
M.A.O.14, M.C.P.28
Agosti, Jan M.
M.C.P.101
Agostini, Carlo
Th.B.P.78, Th.B.P.79
Agrawal, Krishna C.
M.C.P.64
Agrawal, Sudhir
M.C.P.80
Agren, Gunnar
W.F.O.21
Agut, Henri
Th.B.P.235
Ahlgren, David J.
T.A.O.38, Th.A.P.56
Ahmad, Nafees
T.C.P.102
Aidoo, Akwasi
M.F.O.4
Ajdukovic, D.
Th.B.P.356, Th.B.P.366
Akao, Masafumi
M.A.P.42
Akerblom, Lennart S.
M.C.P.10, Th.C.P.80
Akil, Bisher
M.B.P.286, T.B.P.286
Alameda-Lozada, José I.
W.H.P.5
Alan,, Diana Lynne
T.D.P.82, W.D.P.34
Alarcón, Jorge
Th.H.P.17
Alary, Michel
M.A.O.21, Th.E.P.18
Albert, Jan
Th.C.P.125
Aledort, Louis M.
Th.B.O.36
Alexander, Linda L.
M.D.P.17
Alger, L.
M.B.P.12
Ali, Kaiser
Th.B.P.20
Allan, Davis J.
T.B.P.303
Allbritten, Dorothy J.
W.E.P.21
Allen, David M.
T.A.O.10
Allen, Robert E.
W.A.P.26, W.B.O.16
Allen, Susan
Th.D.O.20
Allerton, Micheal W.
W.E.P.54
Almeida, Manuel José M.
M.G.P.2
Almeida, Matos, M.G.
M.B.P.82
Almeida, Walter
T.E.P.60
Alowaish, Rashed
W.G.P.4
Althoff, Peter-Henning
Th.B.O.42
Alvarado, R.
Th.B.P.228
Alwood, Karla
W.B.P.52
Amadori, Alberto
Th.C.P.144
Amaro, Fausto
Th.E.P.46
Ameisen, Jean-Claude
Th.C.O.6
Amiel, Corinne
T.C.P.44, T.C.P.45
Ampel, Neil M.
M.B.P.46
Anabitarte, Héctor
T.E.P.73
Anand, Raj
Th.F.O.1
Anand, Rita
Th.C.P.113
Anarella, Joseph P.
T.E.P.33
Ancelle-Park, Rosemary
W.A.P.15
Anderson, Daniel C.
W.C.O.45
Anderson, David W.
Th.A.P.31
Anderson, Elizabeth S.
T.H.O.2, T.H.P.12
Anderson, Jean R.
Th.D.P.10
Anderson, Robert E.
T.B.P.85, Th.B.O.29, Th.B.P.144
Anderson, Roy
Th.A.O.2
Andes, W. Abe
Th.B.P.19, Th.B.P.311
Andiman, Warren A.
T.B.P.228
Andrada-Serpa, Maria-José
M.A.P.53
Andreasson, Per-Ake
M.G.P.16
Andrews, Laurie
W.B.P.238
Andrews, Roxanne M.
T.H.P.17
Andrieu, Jean-Marie
Th.C.O.39
Andriolo, Mario Jr.
Th.B.P.350
Andrulis, Dennis P.
M.H.P.18
Andrus, Jon K.
Th.E.P.32
Angeloff, Luben G.
M.C.P.140
Ankrah, E. Maxine
M.G.O.15, W.G.P.32, Th.G.P.19
Annas, George J.
M.F.O.15
Annin, Burt J.
M.E.P.71, Th.E.O.9
Antinori, Andrea
M.B.P.229, Th.B.P.72
Antoniskis, Diana
M.B.P.45, W.B.P.24
Anumudu, Nicolas
M.E.O.29
Anzala, Aggrey
Th.A.O.25

Aoki, Francisco H.
T.D.P.16, Th.G.P.3
Apisook, Chantawipa
T.G.O.15
Aral, Sevgi O.
T.D.O.11
Araneta, Maria Rosario G.
W.A.P.11
Arastéh, Keikawus
T.B.P.28
Archibald, David W.
M.C.P.37, T.B.P.238
Arday, David R.
W.B.P.225
Arendt, Gabriele
Th.B.P.265
Arenzana-Seisdedos, Fernando
W.C.P.121
Argirova, Radka
W.B.P.178
Argüelles, Lourdes
Th.D.P.12
Arici, Claudio
W.B.P.352
Arico, Maurizio
T.B.P.264
Arida, Elie N.
T.C.P.148
Armas, Portela
W.H.P.2
Armbruster, Christine
M.B.P.213
Arno, Peter S.
T.H.P.8
Arnold, Wendy
T.D.O.26, T.G.O.10
Aronow, Howard
Th.B.P.257
Arora, Sunil K.
Th.G.P.9
Arras, John D.
T.F.O.19
Arras, Marcella
Th.B.P.158
Arredondo Miguel, Carmen
M.E.P.22, Th.F.P.12
Arrizabalaga, J.
T.B.P.278, W.A.P.75
Arroyo,, Ramon A.
Th.B.P.141
Arsenian, Sergey G.
T.B.P.91
Artigas, Juan
M.B.P.95, W.C.P.60, Th.B.O.22
Aruffo, John
W.D.P.35
Arya, Suresh K.
T.C.P.127
Ascher, Michael S.
W.C.P.145
Ashery, Rebecca S.
W.E.P.13
Askew, Mark J.
W.E.P.18
Asma, L.D.
M.G.O.12
Asp, Anna-Karin
T.E.P.76
Aspa Marco, Francisco J.
M.B.P.212, M.B.P.214, Th.B.P.77
Atkinson, Amy R.
T.B.P.101
Atkinson, J. Hampton
W.B.P.223, W.B.P.233
Atkinson, William
T.A.P.50
August, Sharon M.
T.D.P.42
Auleb, Ann W.
W.E.P.34
Aultman, Kathryn S.
T.G.P.1
Autran, Brigitte
M.B.P.42, T.C.P.25
Avonts, Dirk
M.A.P.66, M.D.P.67
Ayehunie, Seyoum
M.A.P.79
Ayre, Steven G.
W.C.P.24
Ayres, Laura
M.A.P.82, M.A.P.86
Ayroza, Galvao
T.A.P.17

B

B.C. Civil Liberties Ass.,
Th.F.P.8
Baba, Masanori
M.C.P.75
Bach, Michael C.
M.B.P.247
Bachelerie, Françoise
Th.C.O.23
Back, Nicole K. T.
Th.C.P.34
Bacon, Marion
W.E.P.25
Badi, Nsanga
T.B.P.205
Bagasra, Omar
T.C.P.99
Baggaley, Jonathan P.
W.E.O.20
Bahlman, William R.
W.E.P.2
Bahraoui, Elmostafa
T.C.P.42
Bailey, Richard W.
T.C.P.47
Baker, Edward L.
Th.A.P.44
Balanon, Angelita B.
W.D.P.60
Ball, Judy K.
M.H.O.8, Th.H.P.3
Ballem, Penny J.
M.B.P.143, T.B.P.270
Balotta, Claudia
M.B.P.267
Balthazar, J. Hector
M.E.O.24
Balzarini, Jan M.
M.C.P.76, Th.C.O.20
Balzer, Thomas
W.B.P.33
Banarjee, Kaylan
T.G.O.22
Bangura, Hassan
M.E.O.6a
Bánhegyi, Dénes
T.B.P.302
Bankowski, Matthew J.
T.B.P.80
Barbacci, Marguerite
M.B.P.5, M.B.P.10, W.D.P.11
Barbarini, Giorgio
T.A.P.56
Barbaro, Daniel J.
W.B.P.304, Th.B.P.71
Bariu, Francis
T.G.O.1
Barlow, David
M.A.P.58
Barnes, Mark
W.E.O.18, Th.F.P.6
Barnes, Rosemary
T.D.P.63
Barnes, Sandra E.
T.B.P.237
Barré-Sinoussi, François
T.C.O.41
Barrera, José
M.A.P.104
Barreto, Jorge A. X.
M.B.P.373
Barriga, Angulo G.
W.B.P.168
Barry, David
Th.B.O.50
Barry, Martial
W.E.P.4
Bartholomew, Courtenay
M.B.P.296, M.G.O.30, Th.A.P.23
Bartlett, John A.
W.B.P.325
Bartnof, Harvey S.
M.D.P.85, W.E.O.19
Barton, Simon E.
M.B.P.115

Baruchel, Sylvain S.
T.B.P.261
Baseler, Michael
Th.B.P.167
Bastien, Arnaud
M.E.P.12
Batalla, Juan
W.A.P.78
Bates, Julie
W.D.O.13
Batra, K. K.
M.B.P.345
Battegay, Manuel M.
M.A.P.88
Battjes, Robert J.
T.A.P.39, T.A.P.40, Th.D.O.18
Bauer, Pierre G.
M.B.P.136
Bauer, Stanley
T.F.P.1, Th.A.P.4
Baughman, Robert P.
T.B.P.9
Baum, Gregory
W.F.O.10
Baumann, Reinhard
W.B.P.326
Bayer, Ronald
W.F.O.24
Beach, Richard S.
Th.B.O.40, Th.B.P.306
Beaucaire, Gilles
T.B.P.282, T.B.P.288
Becherer, Paul R.
M.A.P.45
Beck, Andreas
Th.A.P.29
Becker, James T.
W.B.P.221, W.B.P.226, W.B.P.236
Beckford, Urzsula
T.B.P.332, Th.B.O.56
Beckstein, David L.
W.E.P.7
Beeker, Carolyn G.
T.E.P.14, Th.E.P.73
Beery, William L.
M.E.P.27
Beese, Jackie
M.B.O.8
Beese, Jacqueline Y.
W.B.P.383
Begley, Kim
T.D.O.30
Behets, Frieda
M.G.O.3, W.B.P.156
Bekesi, J. George
Th.B.P.84, Th.B.P.95, Th.B.P.182
Belec, Laurent
Th.B.P.209
Belleau, Bernard
T.C.O.1
Belman, Anita L.
T.B.P.174
Belschner, Wilfried
W.A.P.110
Belshe, Robert B.
Th.A.P.88
Ben-Porath, Edna
T.A.P.81
Benetucci, Jorge A.
W.D.P.56, Th.G.O.3
Benge, Mark A.
W.H.O.10
Benitez Fuentes, Jesús V.
W.B.P.97
Benitez, Raúl
Th.H.P.12
Bennett, Charles L.
M.B.P.376, M.H.O.17, M.H.P.17
Bennett, Diane E.
W.E.P.66
Bennett, Thaddeus A.
Th.E.P.42
Benson, Elizabeth M.
Th.B.P.296
Bentwich, Zvi H.
W.C.O.29, W.C.P.129
Bergamaschi, Denise
Th.G.O.50
Berger, Edward A.
Th.C.O.12
Berger, Joseph R.
M.A.P.90, W.B.P.51, W.B.P.56, Th.B.P.263
Berinati, William E.
W.B.P.377
Berkeley, Seth
Th.G.O.14
Berkelman, Ruth L.
W.A.O.13
Berlie, H. C.
Th.B.P.124
Berman, Caryn
T.E.P.56
Bernal, Antonio
M.B.P.235
Bernard, Edward M.
T.B.P.53
Bernard, Evelyne
M.B.P.252
Berrebi, Alain
M.B.P.25, M.B.P.26
Bertazzoli, Rita de Cassia
Th.B.P.337
Berthelot, Pierre
M.E.P.41
Berthier, Anne-Marie
Th.B.P.10
Berzow, Dirk D.
T.C.P.150
Bess, Jr., Julian W.
M.C.P.38
Bettinger, Stéphane
T.B.P.128
Beuscart, Claude
Th.B.P.105
Bez, Gabriel
M.H.P.15
Biancalana, Maria Lucia
Th.B.P.40
Biberfeld, Peter
W.C.P.54, W.C.P.67, Th.C.O.9
Biernacki, Patrick
W.E.P.9, Th.A.P.68, Th.D.P.13
Biggar, Robert J.
Th.A.O.22, Th.A.P.89
Biglino, Alberto
M.B.P.353
Bihari, Bernard
M.C.P.59, M.C.P.62, T.D.P.51
Bilello, John A.
M.C.P.53
Bilheimer, Linda
Th.H.O.3
Birch-Limberger, Karen A.
T.C.P.2
Birx, Deborah L.
Th.B.P.155
Biryahwaho, B.
T.B.P.358
Bisset, Catherine M.
M.A.P.47
Blaauw, Bernard B.
W.B.P.71
Black, Finn T.
Th.B.P.106
Black, John R.
T.B.P.30
Blackie, Steve
Th.B.P.52
Blair, Edward D.
T.C.P.101
Blake, Susan M.
M.E.P.33, T.D.P.3
Blakeney, Barbara
M.E.P.48
Blanc, Sylvie
T.B.P.231
Blanchard, Philippe
W.H.P.16
Blanche, S.
M.B.O.3
Blanchette, Victor S.
Th.B.P.18
Blankenship, Evelyn M.
W.D.P.1
Blasky, Terry
Th.B.O.52

Blattner, William A.
M.C.O.7
Blaxhult, Anders
W.H.P.17
Blini, Mirella
M.B.P.227
Blomberg, Patty S.
W.B.P.63
Bloom, Jeff A.
W.B.P.378
Blough, Herbert
M.C.P.106
Blower, Sally M.
T.A.O.40
Blythe, Steve P.
Th.A.P.57
Bobo, John W.
T.D.O.9
Boccon-Gibod, Liliane A.
T.B.P.155
Bodsworth, Neil J.
M.B.P.222, W.B.P.369
Boeri, Elio
W.B.P.357
Bogner, Johannes R.
M.B.P.64, W.D.P.3, Th.B.P.168
Bohlin, Ann-Britt
W.A.O.10
Boldt, Kristi L.
Th.B.P.67
Bolz, Georg F.
Th.A.P.65
Bonavida, Benjamin
T.C.P.57
Bond, Lydia S.
W.E.P.33
Bonfim de Lima, Dirce
M.B.P.231, W.B.P.39
Bor, Robert
M.E.O.13
Borghi, Vanni
T.B.P.235
Borleffs, Jan C. C.
M.H.P.8
Bornemann, Reinhard
T.A.P.28, W.G.P.5
Borucki, Michael J.
W.B.P.323, Th.B.P.273
Boshell, Jorge
M.G.O.6
Boswell, R. Neal
Th.B.P.102, Th.B.P.126
Botas, Julio
M.A.P.77
Böttiger, Blenda
Th.C.P.6
Böttiger, Margareta
W.A.O.29
Bouchard, Andrée
M.D.P.41
Bouchard, Isabelle
M.A.P.24
Boucher, Charles A. B.
T.C.P.73
Boucher, François D.
W.B.O.2
Boucher, Marc
M.B.P.17
Boudinot, Douglas F.
M.C.P.98
Boulay, Fabrice
M.H.O.12, M.H.P.19
Boulerice, François
Th.C.P.117
Boulos, Reginald
T.G.O.19, W.A.P.7
Boulton, Mary
M.D.P.15
Bounya-Épéé, Samuel
Th.H.P.7
Bour, Stephan
Th.C.P.77
Bouzas, María Belén
T.A.P.108, T.B.P.340, Th.B.P.3, Th.B.P.4, Th.B.P.24
Boxaca, Martha C.
W.G.P.18
Boyer, Véronique
T.C.P.59
Bozzette, Samuel A.
T.B.P.8, T.B.P.12, W.B.P.9
Bradbeer, Caroline S.
M.B.P.58
Braddock, Martin
T.C.P.103
Bradford, Judith B.
T.D.P.40
Brajtburg, Janina M.
M.C.P.141
Brancato, Lenore J.
W.B.O.17
Brandao-Mello, Carlos Eduardo
M.B.P.112, M.B.P.223
Brankovan, Vera
M.C.P.128
Braslow, Judith B.
W.E.O.10
Braun, M. Miles
M.G.P.24, Th.G.O.1
Braunstein, Mildred S.
Th.D.P.43
Breen, Elizabeth C.
T.C.P.19
Bremer, James W.
T.B.P.121
Brettle, Raymond P.
T.A.P.51, W.B.O.3
Brew, Bruce J.
T.B.P.299, W.B.P.91, Th.B.P.199, Th.B.P.227, Th.B.P.233, Th.B.P.249
Bridbord, Kenneth
T.G.P.17
Bridge, T. Peter
W.B.O.45a
Brinchmann, Jan E.
T.C.P.20
Brion, Jean-Paul
Th.B.P.251, Th.B.P.282
Britton, Carolyn B.
Th.B.P.224, Th.B.P.237
Brockmeyer, N. H.
M.B.P.335, T.B.P.381, W.B.P.50, W.B.P.324
Broderick, Bonnie
Th.B.P.318
Brodine, Stephanie K.
Th.A.P.28
Brodt, Hans-Reinhard
M.A.P.103, Th.A.P.96
Bron, Christophe R.
Th.C.P.8
Bronson, Joanne J.
M.C.P.74
Bronstein, Irena
W.B.P.149
Brouwers, Pim
T.B.P.179, Th.B.P.208
Brown, Christopher C.
T.B.P.107, Th.B.P.165, Th.B.P.186, Th.B.P.239
Brown, Larry K.
W.E.P.36
Brown, Lawrence S.
T.A.P.49, W.D.P.68, Th.D.P.53
Brown, Tim
Th.A.P.51
Bru, Francisco
T.A.P.22
Brudney, Karen
Th.B.P.68
Brühwiler, Johannes
Th.B.O.27
Brundage, John F.
M.A.O.6
Bruneau, Julie
T.A.P.59
Brunkhorst, Ulrike
M.B.P.280, Th.B.P.12
Brutus, Jean-Robert
T.D.O.32
Bschor, Friedrich
T.A.P.60
Buchbinder, Susan P.
M.B.P.224
Buchovsky, Gregorio
W.B.P.306

Budka, Herbert
Th.B.P.248
Buehler, James W.
W.A.O.16, W.A.P.29
Bunde-Birouste, A.
T.D.P.88
Buning, Ernst C.
T.A.P.82
Bunker, John F.
W.E.O.14
Buonaguro, Franco M.
W.C.P.51
Burchett, Sandra K.
T.B.P.234
Burckhardt, Johann J.
M.A.P.43
Bureau, Céline
W.E.P.16
Burgess, Mary P. J.
T.D.P.26
Burke, Donald S.
Th.A.P.93
Burke, Michael
T.A.P.2
Burns, Sheila M.
T.B.P.5, Th.C.P.105
Burrell, Peter G.
M.A.P.28, M.E.P.7
Busalacchi, Mary
T.B.P.325
Busch, Michael P.
M.A.O.10, M.B.P.150, M.B.P.172, T.B.P.347
Buzby, Bruce R.
W.H.P.25
Bymes, John J.
M.C.P.99

C

Caceres, Carlos F.
Th.E.P.74
Cahill, Kathy
M.A.P.55, M.A.P.75
Cahn, Pedro E.
Th.G.O.38, Th.B.P.207, Th.B.P.326, Th.D.P.46, Th.H.P.23
Cain, Virginia S.
T.D.P.14
Cairoli, Silvano
W.B.P.186
Cajot, Angela
Th.B.P.322
Calabrese, Leonard H.
M.B.P.261
Cali, Ann
W.G.O.10
Calsyn, Donald A.
Th.D.P.77
Calvelli, Theresa A.
T.B.P.184, T.B.P.233
Calzavara, Liviana
T.A.P.69, T.D.P.41
Camargo, Irani
W.E.P.37
Camerini, David
T.C.P.125, W.C.O.15
Cameron, D. William
T.A.P.91, Th.G.O.36, Th.G.P.29
Cameron, Miriam L.
W.B.P.3
Campagnolo, Iona
M.G.O.12a
Campbell, Scott
M.D.O.16, M.D.P.56, T.E.P.39, Th.E.P.29
Camus, Françoise
T.B.O.2
Canas-Ferreira, Wanda
T.B.P.357
Canavaggio, Michel
Th.A.P.112
Canick, Jonathan P.
W.B.P.199
Canivet, Martine
Th.C.P.48
Cannon, Robert O.
Th.A.O.18
Cantor, Kenneth P.
Th.A.P.18
Cao, Yunzhen
W.B.P.159, Th.C.P.68
Capon, Daniel J.
Th.C.O.15
Caraux, Jean
W.B.P.301
Cárcaba, V.
T.B.P.274, W.B.O.37
Cardoso, Gisela
W.B.P.203
Carducci, Annalaura A.
W.E.P.19
Caredda, Francesco
M.B.P.216
Cargill, V. A.
M.E.O.19
Cargnel, Antonietta
M.B.P.215, M.B.P.361
Carini, C.
T.C.P.41
Carlson, James R.
W.B.P.169
Carme, Bernard
M.B.P.91, T.B.P.19, W.B.P.151
Carminati, Guido
M.B.P.50
Carmona Gonçalves, Vilma Lucia
Th.E.P.22
Carosi, Giampiero
M.A.P.78, M.B.P.16
Carovano, Katheryn
W.E.P.57
Carpenter, Charles C. J.
T.B.P.95, Th.D.P.2
Carr, Susan E.
M.B.P.310
Carrick, Richard V.
M.E.P.63
Carrière, Dominique
Th.B.P.113
Carrow, Emily W.
T.C.P.69
Carter, Susan R.
M.B.P.305
Carton, J. A.
Th.B.P.69
Carvalho Neto, Lahire D.
M.E.O.17
Carvalho, Maria Inez Linhares
T.E.P.65
Carwein, Vicky L.
W.B.P.267, Th.H.P.9
Casabona, Jordi
M.A.P.52, M.B.P.137, T.A.P.114, Th.G.O.2
Casado, Concepcion
T.B.P.92
Casado, Deborah
T.H.P.2
Casariego, Zulema
M.B.O.16
Casiro, Arnaldo D.
Th.G.P.17
Casoli, Claudio
M.B.P.358
Cassuto, Jill-Patrice
W.B.P.366, Th.B.P.128, Th.B.P.129
Castilho, Euclides A.
M.G.P.1, M.G.P.6
Castillo, Inmaculada
M.B.P.221, M.B.P.242, M.B.P.246, T.B.P.216, W.B.P.145
Castonguay, Claude
W.H.O.1
Castro, Blesila A.
W.C.P.26
Catalan, F.
T.B.P.120, Th.B.O.55
Catalan, José
Th.B.P.31
Catania, Joseph A.
M.D.P.4, T.D.P.45, Th.E.P.24, Th.G.O.7
Caubel, Patrick
M.B.P.55
Cauda, Roberto
M.C.O.32
Caudie, Christiane
Th.B.P.147, Th.B.P.365

Caumartin, Susan
T.D.P.67
Causey, Dennis M.
M.B.P.83, M.B.P.379, W.B.P.358
Cavelier, Annick
M.A.O.24
Cayemittes, Michel
W.G.O.39
Caylà, Joan-Arthur
T.A.O.3
Celentano, David D.
T.A.P.44
Cellini, Mauro
M.B.P.228
Cendoroglo, Miguel Neto
M.B.P.279
Chachkes, Ester
M.E.P.67
Chaison, Richard
M.B.O.30
Chakrabarti, Lisa A.
W.C.P.34
Chakroun, Mohamed
M.B.P.226
Chamberland, Mary E.
W.A.O.2, W.A.O.15
Chamness, Barbara A.
M.E.O.2, M.E.P.39
Chams, Vida
Th.C.O.5
Chan, Maria
W.B.P.78
Chan, Wendy
Th.B.P.5
Chandwani, Sulachni
M.B.P.20
Chateauvert, Michel
M.E.O.28
Chavanet, Pascal
M.B.P.88, T.B.P.304
Chave, Jean-Philippe
Th.B.P.212, Th.B.P.319
Chaves, Ricardo L.
M.B.P.44
Cheeseman, Sarah H.
W.B.P.246
Cheingsong-Popov, Rachanee
W.C.P.98, W.C.P.124
Chela, Clement M.
W.B.P.265
Chen, Steve
Th.C.P.38
Chenet-Monte, Céleste
M.B.P.168, Th.B.P.176
Cheng-Mayer, Cecilia
T.C.P.104, W.C.O.37
Chequer, Pedro
M.G.O.26, T.B.O.12
Chernoff, David N.
M.B.P.193
Chetwynd, Jane
T.D.P.76
Cheung, Tony W.
M.B.P.198, M.B.P.297, W.B.P.269
Chevallier, Philippe
M.G.P.7
Chevarley, Frances M.
W.A.P.35
Chiasson, Mary Ann
T.A.P.112
Chiba, Joe
W.C.P.37
Chidiac, Christian
W.B.P.248
Chief, Ajisefinni S. O.
M.C.P.150
Chimfwembe, Evelyn C.
T.B.P.144
Chin, James
T.B.O.18
Chiodi, Francesca
Th.C.P.97
Chiodo, Francesco
W.B.P.338
Chirgwin, Keith
M.B.P.57
Chiswick, Ann
W.B.P.229
Chitwood, Dale D.
M.A.P.38, W.A.P.89
Chiu, Joseph
M.B.P.300
Chlebowski, Rowan T.
Th.B.P.307
Chmiel, Joan S.
Th.A.P.85
Chong, Pele
T.C.P.16
Chossegros, Philippe
Th.D.P.31
Chou, Ting-Chao
M.C.P.110
Choudhury, Shankar
T.G.O.27
Chout, Roger
T.A.P.12
Choutet, P.
W.C.P.1
Chow, Jean
M.B.P.371, T.B.P.156
Chrétien, Michel
M.F.O.8
Christakis, Nicholas A.
W.F.O.2
Christie, Grania M.
M.D.P.48, M.E.P.28, W.E.P.56
Chrysomilides, Sonia A.
Th.B.P.379
Chu, C. K.
M.C.P.115, Th.C.O.21
Chun, Peter K.
T.B.P.125
Church, John A.
M.D.P.92
Church, Joseph A.
T.B.P.213
Ciacco, Marie I.
Th.B.P.46
Ciesielski, Carol A.
Th.B.P.44
Clark, Charles F.
Th.E.P.45
Clark, Edward A.
T.C.P.10
Clark, Elizabeth
M.E.P.51
Clark, Rebecca A.
W.B.P.8, W.B.P.18
Clavel, François
T.C.P.97, Th.C.P.103
Clavreul, Geneviève M.
M.E.P.24
Cleghorn, Farley
W.G.P.11
Clement, Jean-Marie
T.C.P.116
Clifford, David B.
Th.B.P.269
Closen, Michael L.
T.F.O.1
Clotet, Bonaventura
M.B.P.103, M.B.P.240, M.B.P.245, M.B.P.251, T.B.P.308, W.B.P.22, Th.B.P.148, Th.B.P.234
Clouse, Kathleen
W.C.P.105
Cloutier, Richard
T.E.P.24
Clumeck, Nathan
M.B.P.253, M.B.P.271, M.B.P.272, W.A.O.19, W.B.O.14
Coates, Anthony R. M.
M.C.P.40
Coates, Randall A.
M.A.P.97, M.A.P.113, Th.A.O.27
Coates, Thomas J.
M.A.O.49, W.A.O.27, W.B.O.40
Coats, Bonnie
W.D.P.49
Coats, Michael
Th.B.P.264
Cochran, Nancy A.
M.C.P.72
Cochran, Susan D.
W.D.P.22
Coen, Massimo
M.B.P.94

Coffman, Hugh L.
W.B.P.183
Cohen, Eric A.
T.C.O.49, W.C.O.34
Cohen, Felissa L.
Th.E.P.28, Th.E.P.56
Cohen, Jeffrey Allen
Th.B.P.190
Cohen, Judith B.
W.D.P.51
Cohen, Lucie
T.C.P.118
Cohen, Sarale
T.B.P.183
Cohen, Stuart H.
M.C.P.50
Cohn, David L.
M.A.P.76, T.A.P.52, T.D.O.6
Cohn, Jonathan
W.B.P.353
Cole, Curtis
W.F.P.10
Cole, Nanette L.
T.A.P.73
Colgate, Stirling A.
T.A.O.39
Coll, A. M.
M.B.P.183, M.B.P.195
Collier, Ann C.
M.C.P.11, Th.B.P.270
Collman, Ronald G.
Th.C.P.101
Colomo-Gomez, Concepcion
M.A.O.41
Coltin, Kathryn L.
M.H.O.14, T.H.P.1
Comella, Brianne
W.D.P.81
Comenford, Mary
T.A.P.46
Conant Sloane, Beverlie
Th.E.O.1
Conant, Marcus A.
T.B.P.290
Cone, Lawrence A.
M.B.P.204, Th.B.P.53
Confalonieri, Franco
Th.B.P.191
Conley, Lois J.
T.A.P.85
Conlon, Christopher P.
M.B.P.236
Conly, John M.
M.H.P.16
Connelly, Mark C.
W.B.P.130
Conner, Edward M.
T.B.P.162
Connolly, Gerard M.
W.B.P.46, W.B.P.47
Connor, Susan S.
M.F.O.19, Th.F.O.8
Connors, Margaret M.
W.A.P.106, Th.E.O.17, Th.E.P.36
Conolly, Lisa
T.E.P.20
Conte, John E.
T.B.P.25, T.B.P.72
Conway, George A.
T.A.P.61, W.A.P.23
Cooley, Philip C.
Th.A.P.54, Th.A.P.78
Cooley, Timothy P.
T.B.P.297
Coombs, Robert W.
W.C.P.112, W.C.P.134
Cooney, Elizabeth L.
Th.C.O.34
Cooper, Edward H.
W.B.P.81
Cooper, Ellen C.
M.C.P.61, W.B.O.47
Cooper, Ellen R.
T.B.P.150
Cooper, Jonanthan P.
T.H.P.19
Copello, Gene A.
Th.E.P.14
Corbeau, Pierre
Th.C.P.9
Corby, Nancy H.
T.A.P.42, T.E.P.28
Cordery, Mark
Th.C.P.148
Cordes, Michael
Th.B.P.260
Cordier, Geneviève
W.C.P.71
Cordonnier, Agnès M.
W.C.O.14
Cornejo, Mónica
Th.G.P.4
Coronado Luengo, Alonso
T.E.P.27
Corrah, T.
T.B.P.362
Corrêa-Lima, Mário B.
W.B.P.266
Cortes, Eduardo
W.C.P.85
Cortes, Eduardo J. B.
M.G.P.12, M.G.P.13, M.G.P.14, M.G.P.15, M.G.P.20
Cory, Joan M.
T.B.P.84
Cossette, Michèle
Th.B.P.301
Costagliola, Dominique
Th.A.P.61
Costigliola, Paolo
T.A.O.19
Cot, Marie-Camille
Th.C.P.78
Côté, José K.
T.D.P.52
Cotton, Terry M.
M.E.P.53
Cottone, James A.
M.D.P.82, Th.B.P.354
Coughlin, Richard T.
T.C.P.1
Coulaud, Jean-Pierre
T.B.P.27
Courgnaud, Valérie
M.B.P.1
Courouce, Anne-Marie
M.A.P.33, M.A.P.85
Courtneay, Audrey V.
T.E.P.63
Cousineau, Léa
T.E.P.46
Coutinho, Roel A.
W.D.O.9
Cowan, David N.
M.A.P.1, W.A.O.3
Cowan, Frances M.
M.B.P.3, W.B.P.317, W.B.P.371
Cowan, Morton J.
T.B.P.227
Cox, Patricia
W.B.P.337
Coye, Molly J.
T.A.P.79, W.A.P.19, W.B.P.293
Cozen, Wendy
W.A.P.2
Craib, Kevin J. P.
W.A.P.58
Crandles, Sheila
M.E.O.16
Crane, Martin M.
T.H.P.22
Craske, John
W.B.P.166
Creagh-Kirk, Terri H.
M.B.O.45
Crocchiolo, Paolo
W.B.P.365, W.E.P.55, Th.B.P.86
Cromwell, Gale G.
W.B.P.274
Cronin, William J.
M.B.P.191, M.B.P.274, T.C.P.62
Crooks, Levinia
T.D.P.49
Crowe, Suzanne M.
M.C.P.109, Th.C.P.137
Croxson, T. Scott
W.B.P.150
Crumpacker, Clyde S.
T.B.P.296

Crysler, Carl
M.C.P.127
Crystal, Stephen
T.E.P.53, Th.D.P.15
Cullen, Bryan R.
T.C.O.9
Cuneo-Crovari, Piera
W.B.P.346
Cunha Teles, Louise
W.E.P.76
Cunningham, Ineke
M.E.P.19
Cunningham, Philip H.
W.B.P.140
Curran, William
M.F.O.7
Currie, Jon N.
Th.B.P.290
Cuthbert, Melinda A.
T.E.O.17, W.D.O.16, Th.H.O.4
Cvitanic, Marilyn
T.H.P.18
Cynamon, Marcie L.
M.D.O.6
Cyr, W. Howard
M.A.P.114

D

D'Almeida, L.
Th.B.P.377
D'Angelo, Lawrence J.
M.D.P.10
D'Arminio Monforte, Antonella
W.B.P.200
D'Auriol, L.
W.C.P.126
Daar, Eric S.
T.C.P.34
Dabis, François
W.A.P.60
Dagenais, Bernard
T.E.P.68
Daily, Lisa A.
W.E.P.50
Dalgleish, Angus
Th.C.O.43
Dalloul, Ali H.
W.B.P.284
Daniel, Muthiah
W.C.O.48
Daniel, Volker
Th.B.P.142
Danila, Richard N.
M.A.P.70, M.A.P.72
Dannenberg, Andrew L.
W.A.P.31
Danner, Sven A.
M.B.P.283
Das, Prakash C.
M.B.P.153, T.B.P.131, T.B.P.354
Dascal, André
M.B.P.359, T.B.P.97
Dassey, David E.
M.H.O.18
Datry, Annick
T.B.P.13
Datta, Pratibha P.
M.G.O.20, W.A.P.65, Th.G.O.52
Dattel, Bonnie J.
M.B.P.33, T.B.P.198
Davachi, Farzin
T.B.P.188, W.E.O.30, W.H.P.6, Th.G.O.33
Davenny, Katherine
M.B.P.8
Davey, Richard T.
Th.B.P.179
Davey, Victoria
Th.B.O.43
Davidson, Bruce L.
M.A.O.39
Davidson, Susan J.
T.A.O.14
Davies, Peter M.
T.D.P.19, T.D.P.20
Davis, Iris L.
W.B.P.307
Davis, Jeffrey P.
M.A.P.22
Davoli, Gerald W.
W.E.P.20
Day, Jacqueline
Th.B.P.195
Day, Noel A.
M.E.O.34, T.E.P.7
Dazza, Marie-Christine
M.B.P.348
De Caprariis, Pascal J.
M.D.P.62
De Cock, Kevin M.
W.G.O.27
De Gans, Jan
M.B.P.121, M.B.P.134, W.B.P.2
De Gruttola, Victor G.
Th.A.P.63
De Jong, Jean-Jacques
W.C.P.56
De La Cruz, Fernando V.
Th.G.P.22
De Lalla, Fausto
W.G.P.1
De Leys, Robert J.
Th.C.P.109
De Maria, Andrea
T.B.P.252
De Martini, Rodney J.
Th.E.P.41
De Moya, E. Antonio
T.D.P.32, T.D.P.89
De Rossi, Anita
T.B.P.244, W.C.P.110
De Sweemer, Cécile
M.F.O.17, W.F.O.17
De Tafur, Matilde
W.E.P.48
De Thé, Guy
T.B.P.158
De Vincenzi, Isabelle
T.A.P.98, Th.A.O.20
De Vroome, Ernest
W.A.P.97
De Wit, Stéphane
M.B.P.356, Th.B.P.43, Th.B.P.345
De Wolf, Frank
M.A.O.47
De, Barun K.
Th.B.O.11
DeVico, Anthony L.
Th.C.P.123
Debouck, Christine M.
T.C.O.11
Decazes, Jean M.
T.B.P.26, W.B.P.29
Decker, Scott R.
M.C.P.126
Dedera, Douglas
T.C.O.46, Th.C.P.12
Dejace, Pierre M. J. T.
T.B.P.328
Dejarlais, Don C.
W.D.O.10
Del Bianco, R.
W.B.P.21
Del Bianco, Rosana
M.B.P.40
Del Prado, Ruben
Th.G.O.47
Del Rio, Carlos
M.B.P.290
Delagneau, Jean-François
Th.A.P.108
Delaney, Martin
T.E.O.11
Delaporte, Eric
M.A.O.16
Delfraissy, Jean-François
M.B.P.2, M.B.P.34, T.C.P.39, T.C.P.40, W.A.P.88
Della Negra de Paula, Marinella
T.B.P.194, T.B.P.196, T.B.P.199
Dellamonica, Pierre
M.A.P.37, T.B.P.33, Th.B.P.364
Deniaud, François
W.E.P.23

Denis, François
W.G.P.2
Denning, David W.,
W.B.P.10
Dennis, Macy W.
W.C.P.142
Denny, Thomas N.
M.B.P.19
Des Jarlais, Don C.
T.A.O.20, Th.D.O.6, Th.D.P.75
Deschamps, Marie-Marcelle
M.B.P.6
Desmond, Gerald M.
T.H.O.13
Desportes, Isabelle
M.C.P.119
Devare, Sushil G.
T.C.P.72, Th.C.P.36
Devash, Yair
M.C.P.25
Devaux, Christian
Th.C.P.142
Devine, Owen J.
T.A.P.63
Dew, Mary-Amanda
Th.B.P.32
Dhawan, Subhash
Th.C.P.3
Di Franco, Matthew J.
W.B.P.76
Di Giovanni, Cleto
W.B.P.213
Di John, David
T.B.P.262
Di Maria, Hugo
M.B.O.5
Di Pietro, Massimo
T.B.P.100, Th.B.P.203
DiFerdinando, George T. Jr.
M.A.P.71, T.H.P.5, W.B.P.258, W.D.P.15
Diakhote, Lamina
W.G.O.36
Dianzani, Ferdinando
M.C.P.39
Dias, M. Beatriz S.
T.G.P.14
Diaz, Clemente
W.G.O.2
Díaz-Mitoma, Francisco
M.A.P.87
Diaz-Santana, David
Th.H.P.20
Dibba, Sekou
W.E.P.8
Dickens, Bernard
T.F.O.17
Diclemente, Ralph J.
T.D.P.91, T.D.P.92
Didiez, Nelson
M.E.O.11
Dieterich, Douglas T.
M.B.P.116
Dietrich, Manfred
W.B.P.277
Dilley, James W.
W.B.P.193, W.B.P.197, W.B.P.198, W.B.P.231, W.B.P.234, Th.E.P.13
Diouf, Ousmane
M.E.O.7, T.D.P.37
Diquet, Bertrand
M.B.P.343
Dixon, John
Th.F.P.11
Dobkin, Jay F.
M.B.P.71
Dodd, Caroline L.
Th.B.P.340
Dodd, Roger Y.
M.A.P.29
Doerr, H. W.
T.A.P.10
Doi, Hirofumi
Th.C.P.120
Doinel, Christian
M.A.P.106, Th.B.P.160, Th.B.P.162
Dolin, Raphael
Th.C.O.33
Dolivo, Nicolas
Th.B.P.180
Doll, Lynda S.
M.D.O.2, M.D.P.23
Dollard-Pavlis, Sheila H.
M.B.P.306
Domínguez, José-Luis
T.B.P.335
Donahue, James G.
M.B.P.161
Donahue, Peter R.
W.C.O.31
Dondero, Timothy J.
M.A.O.4, Th.A.O.1
Donegan, Elizabeth A.
T.A.P.106
Donnenberg, Albert D.
T.B.P.285, W.B.P.319
Donovan, Richard M.
W.B.P.123
Dörlemann, Alois
T.B.P.39
Dormont, Dominique
W.C.O.46
Dornan, Douglas H.
M.E.P.68
Dosik, Harvey
Th.A.P.25, Th.A.P.26
Douglas, Bruce
T.A.O.34
Douglas, Cecilia
Th.E.P.58
Doumon, Eric
W.B.P.344
Douville, Helene
M.B.O.34
Dowell, Scott E.
M.B.P.233
Downer, Ann E.
W.E.P.61, Th.E.P.63
Downie, Jean C.
W.B.P.153
Downing, More
Th.D.P.73
Downs, Angela M.
M.A.O.7, W.H.P.22
Drager, Nick
M.H.O.2
Dray, Fernand
W.B.P.82
Drew, W. Lawrence
M.H.P.25, W.C.P.80
Driscoll, John S.
M.C.P.107
Dröge, Wulf
W.C.P.93
Drucker, Ernest
W.A.P.32, Th.D.P.6, Th.D.P.7
Drummond, James E.
Th.B.P.177
Drusano, George L.
M.C.P.94
Dubé, Manon F.
W.C.P.22
Dubessy, Bruno
Th.E.P.12
Dubois-Arber, Françoise H.
W.A.P.116
Ducharme, Todd
Th.F.O.3
Duckett, Margaret
M.H.O.1, T.G.P.24, W.E.P.62, W.G.O.14
Ducos, Jacques
W.B.P.167
Duffhues, Josee C.
M.E.P.14
Duffie, Anne
M.F.P.12, Th.D.P.32
Duke, Beulah
Th.G.O.48
Duke, Sharen I.
M.D.P.45
Duliège, Anne-Marie S.
T.B.P.170
Dumpson, James R.
M.E.O.23
Duncan, Carlton
W.E.P.49
Duncanson, Frederick P.
M.B.P.189, T.B.P.37
Dupree, John D.
T.E.P.62, T.G.P.21

Durbin, Meg A.
M.D.P.6, M.H.P.12
Durda, Paul J.
Th.C.O.26
Dussaix, Elisabeth
T.A.P.92
Duval, Bernard
M.E.P.76
Dyner, Toby S.
W.B.P.363

E

Earl, Patricia L.
T.C.O.34
Eberle, Josef
M.B.P.148
Ebrahim, Shahul Hameed
Th.H.P.30
Eby, Charles L.
T.H.P.24, T.H.P.26, T.H.P.27, W.H.O.8, W.H.O.9
Echeverría de Pérez, Gloria
Th.B.P.101
Edel, Yves
W.B.P.207
Edelman, Andrew S.
T.C.P.74
Edelmann, Frederic
Th.E.O.7
Edelstein, Howard E.
Th.B.P.279
Edlin, Brian R.
M.C.P.116
Edmonson, Paul F.
W.C.P.12
Edwards, Richard K.
W.G.O.13
Egan, Vincent G.
W.B.P.232
Ehrnst, Anneka C.
W.A.P.52
Eichberg, Jorg W.
M.C.O.26, T.C.O.26
Eiden, Lee E.
W.C.O.16
Eigo, James
W.B.P.250
Eisenhandler, Jon
W.H.O.7
Eitelbach, Florian
M.B.P.11, M.B.P.18
Ekstrand, Maria L.
M.D.P.31, T.D.O.8, T.D.P.33
El Tonsi, Hani
W.E.P.74
Eliaszewicz, Muriel
M.B.O.36, M.B.P.32, T.B.P.71
Elie, Robert
Th.A.O.30
Elifson, Kirk
W.A.P.38
Ellenberg, Susan S.
M.C.P.45
Ellerbrock, Tedd V.
W.D.P.48
Ellerman, Donald
T.D.P.62
Elliott, Alison M.
Th.G.O.4
Ellrodt, Axel
W.C.P.100
Elmendorf, Edward
Th.H.O.1
Elmslie, Kimberly D.
W.D.P.59, Th.A.P.46
Elmslie, Thomas J.
Th.E.P.10
Elovaara, Irina
Th.B.P.242
Elsing, C.
M.B.P.100, T.B.P.17
Emanuele, Tom E.
M.B.P.307, M.B.P.311
Embree, Joanne E.
M.G.O.23, M.G.P.27
Emini, Emilio A.
Th.C.O.30
Empfield, Maureen
W.B.P.209
Ena, Javier
M.B.P.107
Enders, Sheila R.
W.F.P.1
Enel, Patricia
T.F.O.7, W.F.P.4
Engel, Jeffrey P.
M.B.P.51
Engel, Robert R.
T.A.O.6
Enochs, Micheal D.
M.A.P.73
Ensoli, Barbara
W.C.P.48, Th.C.P.19
Enthus, Anne K.
T.D.P.50
Epstein, Jay
M.B.P.333
Epstein, Joel B.
M.B.O.21
Ercilla, Guadalupe
W.B.P.101
Erfle, Volker
M.C.P.33, W.C.P.91, Th.C.P.135
Erice, Alejo
Th.B.P.268
Erickson, Beth
M.A.P.68
Erickson-Viitanen, Susan K.
T.C.P.130
Eriksson, Bertil F, H.
M.C.P.54
Eriksson, Bo
Th.A.P.69
Ernst, Jerome A.
M.A.P.10, T.B.P.55, Th.B.O.16
Errante, Isabella
T.A.P.111
Eskild, Anne
M.A.P.91, Th.D.P.63
Español, Teresa
T.B.P.214
Espinoza, Pierre
M.A.O.40, M.A.P.25, Th.D.P.35, Th.F.O.6
Esposito, Roberto
Th.B.P.348
Essex, Myron
T.C.O.23
Essien, Etim M.
M.B.P.156, M.B.P.158
Estebanez, Pilar
W.E.O.22
Eto, Kotaro
Th.B.P.130
Evans, Patricia E.
T.H.O.5
Evatt, Bruce
Th.B.O.31
Eversley, Rani B.
W.D.P.45, W.D.P.46
Exner, Theresa M.
M.D.P.38, T.D.P.28
Eyster, M. Elaine
T.B.P.82, W.B.P.70

F

Fabricius, Eva-Maria
M.B.P.52
Fahey, J. L.
W.A.P.62
Fahmer, Eva-Maria
W.D.P.86
Fahs, Marianne
M.H.O.9
Fairchild, Patrick G.
W.B.P.240
Falk, Lawrence A.
Th.E.P.70
Falkenbach, Albrecht
M.B.P.265, M.B.P.270
Falutz, Julian M.
Th.B.P.315, Th.B.P.316
Fang, Chyang T.
Th.B.O.59
Fanning, Mary M.
M.B.P.349, M.B.P.367, W.B.O.6, W.B.O.36
Farber, Claire-Michèle
Th.B.P.55

Farewell, Vernon
T.A.O.33
Farzadegan, Homayoon
T.B.P.98, Th.A.P.92, Th.C.P.106
Fauci, Anthony S.
Th.C.O.44
Fauvel, Micheline
T.B.P.217, T.B.P.243
Favero, Martin S.
T.A.P.26
Fay, Oscar
M.G.O.29, M.G.P.29, W.A.P.22
Fedeli, Franco
M.B.P.113
Federico, Maurizio M.
M.C.P.105
Feeney, Frances
Th.D.P.61
Fehrs, Laura J.
W.A.O.11, Th.A.P.76
Feigal, David W.
M.B.O.19, M.A.P.31, T.A.P.76
Feigal, Ellen G.
Th.A.P.24
Feinberg, Judith
T.B.O.28
Feingold, Anat R.
Th.A.P.104
Feizi, Ten
M.C.O.4
Felber, Barbara K.
T.C.O.50, Th.C.P.27
Feldblum, Paul J.
M.A.O.37
Feldman, Douglas A.
M.E.O.35
Feldman, Harvey W.
Th.D.P.62
Fenger, Terry W.
M.C.P.23
Fenn, Shannon C.
W.A.P.1
Fenouillet, E.
Th.C.P.1
Fenyö, Eva M.
M.C.O.9
Feorino, Paul M.
Th.C.P.52
Ferchal, F.
W.B.P.106
Fernádez-Cruz, Eduardo P.
W.C.P.120, Th.B.P.121, Th.B.P.184
Fernandes, Maria Eugenia Lemos
T.E.P.49, T.E.P.69, Th.G.O.40
Fernandez, Francisco
W.B.P.191, W.B.P.195
Fernandez, M. Isabel
M.E.P.8, M.E.P.15
Fems, R. Bridget
Th.C.P.59
Ferraro, Robert
Th.B.P.312
Ferrazzi, Mario
T.B.P.361
Ferreira, Ana Carolina I.
M.B.P.108, Th.G.P.26
Ferrer Le Coeur, Françoise
Th.B.P.11
Fiala, Milan
W.B.P.279
Ficarra, Giuseppe
Th.B.P.330, Th.B.P.343
Fierz, Walter
T.B.P.86
Filion, Lionel G.
T.C.P.56
Finaud, Michaël, J. P.
M.B.P.39, M.B.P.130, W.D.P.77
Fineberg, Harvey
M.H.O.3
Finger, Reginald F.
W.E.O.27
Fipps, Donald R.
Th.A.O.34
Fisch, Alain
M.D.P.68
Fischl, Margaret A.
M.B.P.329, T.B.O.13, T.B.P.331
Fish, Falk
M.B.O.25
Fishback, Lorraine M.
W.A.O.23
Fisher, Evelyn J.
W.B.P.86
Fishman, Baruch
T.D.P.66
Fitt, Sarah
W.B.P.272
Flamholc, Leo
T.B.P.58
Flanagan, William F.
Th.F.P.4
Flaskerud, Jacquelyn H.
T.D.O.17
Flegenheimer, Walter V.
T.F.P.6
Flegg, Peter J.
M.A.P.92, M.A.P.105, T.B.P.271
Fleishman, John A.
M.E.P.69
Fleming, David W.
M.A.O.22, M.H.P.9, W.B.P.273, W.D.P.69
Fletcher, Mary A.
M.B.P.144, W.B.P.181, Th.B.P.159
Fleury, Hervé J. A.
M.G.P.21, T.B.P.115, T.B.P.245
Floch, Jean-Jacques
W.B.P.14
Flynn, Neil M.
W.A.P.118, W.B.P.263
Fontelos, Pablo
T.B.P.164
Fontenay, Frank
W.E.P.52
Ford, Wesley L.
M.A.P.74
Fordyce, James E.
M.D.P.44
Fordyce-Baum, Marianna K.
Th.B.P.310
Foreit, James R.
Th.D.O.7
Foresti, Valeriano
M.B.P.206, W.D.P.84
Forjaz Lacerda, Maria José
W.B.O.21
Forsberg, Ann D.
T.A.P.109
Forsythe, Alan B.
Th.A.P.43
Fortney, Judith A.
T.G.O.21
Fortuny, Claudia
T.B.P.202
Foster, Geoff
M.E.P.50
Foucault-Fretz, Catherine
T.G.P.28
Fouchard, Jan
M.D.P.55
Foung, Steven K.H.
M.B.P.173
Fowler, Arnold K.
T.B.P.112
Fox, Philip C.
Th.B.P.353
Francis, Donald P.
M.A.O.19, W.A.O.28
Frank, John W.
Th.A.P.37
Franke, Katherine M.
T.E.P.52
Fransen, Lieve
W.G.O.17
Franzblau, Alfred
Th.B.P.276
Frederick, Toni
T.B.P.161
Freedberg, Kenneth A.
T.B.P.68
Freedman, Benjamin
W.E.O.28, W.F.O.5

Frenkel, Lawrence D.
T.B.P.169
Fridland, Arnold
M.C.P.120
Friedland, Gerald H.
Th.A.P.101
Friedman, Samuel R.
T.A.O.12, Th.D.O.3
Friedman-Kien, Alvin E.
M.B.P.36
Friedmann, Wolfgang
W.C.P.53
Friese, Klaus
W.D.P.54, Th.D.P.23
Fröschl, Monika
M.B.P.187, M.B.P.365, Th.D.P.28
Frösner, Gert G.
T.A.P.64, Th.A.P.36
Frost, Andra R.
T.B.P.230
Fuchs, Dietmar
W.B.P.79
Fujimaki, Michio
W.B.P.292
Fullilove, Mindy T.
M.E.P.9, W.D.O.4
Fullilove, Robert E.
W.D.P.61
Fullwood, Catlin P.
M.E.P.11
Fulop, George
T.H.P.7
Fultz, Patricia N.
M.C.O.13, W.C.O.49
Funk, Carole
W.C.P.19
Füst, George
T.C.P.141
Futterman, Donna
T.B.P.258

G

Gabiano, Clara,
W.B.P.144
Gabuzda, Dana H.
W.C.P.17
Gadler, Hakan
W.C.P.84
Gafà, Sergio
M.B.P.65, M.B.P.363, T.B.P.74, Th.D.P.67
Gaifuba, Jonathan K.
M.E.O.8
Gail, Mitchell H.
Th.A.P.77
Gaïto, Michel
T.E.O.9
Gala, Costanzo
W.B.P.215, W.B.P.219, Th.B.P.297
Galavotti, Christine
T.D.P.39, W.D.P.37, W.E.P.58
Galbán, Enrique
W.A.P.86
Galli, Massimo
M.B.P.354, T.B.P.212, W.A.P.30, W.B.O.11
Gallo, Paolo
Th.B.P.225
Gallo, Robert C.
T.C.O.10
Gallo-Silver, Les L.
W.D.P.9, W.D.P.10
Gallop, Ruth M.
M.D.P.58
Gamba, Gabriella
Th.B.P.1
Gangadharam, Pattisapu R.J.
M.B.P.190, Th.B.P.61, Th.B.P.62
Gangemi, J. David
M.C.P.81
Garcia, Lourdes
M.D.P.69, W.G.P.6, W.G.P.25
García-Polo, Iluminada
T.B.P.293
García-Sáiz, Alfredo A.
Th.C.P.74
Garde, C.
W.B.P.66
Gardner, Lytt I.
M.A.P.3
Gardner, M. B.
Th.C.O.45
Gardom, Jessica
W.A.P.109
Garib, Jorge
W.H.P.3
Garland, Frank C.
M.A.P.11
Garner, Jane
M.A.P.107
Garris, Ivelisse
M.G.O.25
Garrison, Leslie
M.C.P.12, T.B.P.123
Gartner, S.
Th.C.O.42
Gasper, Peter W.
W.C.P.13
Gatell, J. M.
T.B.P.294
Gatell, José M.
M.B.O.37, W.A.P.55
Gathof, Birgit E.
T.B.P.360
Gayle, Helene D.
M.A.P.9, M.D.O.7
Gayle, Jacob A.
M.E.O.20
Gaynor, Suzanne M.
M.B.P.141, M.B.P.142, M.B.P.152, T.B.P.344
Gebreselassie, Lakew
Th.C.P.139
Geleziunas, Romas
T.C.P.112
Gelmon, Karen
W.B.O.30, Th.A.P.33
Gemmill, Robert H.
M.E.P.74
Gendelman, Howard E.
M.C.O.20
Genesca, Juan
W.B.P.154
Gentile, Patricia
W.B.P.245
Gentsch, Jon R.
T.B.P.87
George, Alan Michael
W.E.P.15
George, James R.
M.B.P.163, T.B.P.119
Georges, Alain Jean
T.B.P.191, W.G.O.28, Th.E.P.52
Georgoulias, Vassilis
M.A.P.80, W.B.P.69, Th.A.P.27
Gerberding, Julie Louise
M.D.O.14, M.E.P.26
Gerbert, Barbara
M.D.P.52, M.D.P.53, T.D.O.33
Germain, Céline
M.E.P.75, Th.E.P.72
Gerna, Giuseppe
M.B.O.31
Gerniers, Marie-Madeleine
Th.H.P.18
Gershon, Robyn R. M.
M.D.P.70
Gershy-Damet, Guy-Michel
M.G.P.25
Gesemann, Michael
Th.B.P.185
Geyer, Sharon J.
Th.C.P.118
Gharakhanian, Shahin
M.B.P.368
Ghetie, Victor
M.C.P.129
Giachello, Aida L.
W.D.P.30
Giaquinto, Carlo
M.B.P.14, M.B.P.324, T.B.P.165
Gibbs, C. J.
Th.C.O.46
Gibson, David R.
T.A.O.22

Gibson, Paul M.
W.D.P.82
Giesecke, J.
W.A.O.24
Gil Aguado, Antonio
M.C.P.71
Gilada, Ishwarprasad S.
T.D.P.84, Th.G.P.25
Gill, M. John
M.B.P.165, M.B.P.241
Gill, O. Noel
T.A.P.4
Gill, Parkash S.
M.B.P.366
Gillies, Pamela A.
W.E.P.40
Gilmore, Norbert
M.F.O.13a
Gilmour, Jacqueline E. M.
M.C.P.34
Gilson, Ian
M.B.P.186
Gingeras, Thomas R.
Th.C.P.46
Ginsberg, Michele M.
M.A.P.62
Giordano, Michael
M.G.P.3
Giorgi, Janis V.
M.C.P.24
Giovanetti, Anna
M.A.O.11
Gir, Elucir
M.D.P.61, M.D.P.87
Giraldo, Gaetano
W.C.P.47, Th.B.P.16
Girard, Marc P.
W.C.O.17, Th.C.O.47
Girard, Pierre-Marie
T.B.P.23, T.B.P.49
Gjerset, George F.
M.B.P.145
Glaser, Jordan B.
M.B.P.37, T.A.P.32, W.B.P.119
Gleason-Morgan, Deborah
T.B.P.260
Glenn, H. Patrick
M.F.P.7, T.F.O.4
Glied, Sherry
W.H.O.18
Glück, Dorothee
M.A.P.40
Gluck, Michael E.
M.H.P.13
Gluckman, Jean-Claude
M.C.O.3, M.C.P.31
Gnaore, Emmanuel
T.B.O.8
Godes, Jan R.
M.E.P.6
Godin, Norman J.
M.C.P.149
Goebel, Frank D.
W.B.P.92, Th.B.P.244
Goedert, James J.
Th.A.O.6, Th.A.O.26, Th.B.O.34
Goeffray, Anne
M.B.P.255
Goh, Beng T.
Th.B.P.374
Gold, Jonathan W. M.
W.B.O.39
Gold, Julian
M.D.O.12, T.B.P.298, W.D.P.64, Th.B.P.358
Goldberg, David J.
Th.A.P.115, Th.D.P.55
Goldblum, Natan
Th.C.P.72
Golding, Hana
W.C.P.57, Th.C.O.2
Goldstein, Allan L.
M.C.P.13
Goldstein, Andrew S.
T.G.P.19
Goldstone, Irene L.
M.B.O.7, T.H.P.13
Gomatos, Peter John
M.C.O.15
Gomez, M. Perry
Th.A.P.120
Gonzalez, José J.
W.E.P.6, W.H.P.18, Th.A.P.53
Gonzalez-Canali, Gustavo
T.B.P.279
Gordin, Fred M.
M.B.P.104
Gore, Ira
Th.C.P.132
Gorman, Jack M.
W.B.P.222
Gorse, Geoffrey J.
Th.C.O.32
Górski, Tadeusz
W.E.P.63
Gorter, Robert
Th.A.P.102
Gostin, Larry O.
M.F.O.6, W.F.O.18
Gosting, Larry H.
T.B.P.124
Gotovac, Petar
T.E.P.22
Gottfried, Toby
W.B.P.142
Gottlieb, Marise S.
Th.B.O.47
Gottlieb, Michael S.
Th.B.O.3
Goudeau, Alain M.
M.A.P.15
Goudsmit, Jaap
W.C.P.44, W.C.P.89, Th.C.P.35
Gowanlock, Gweneth
Th.D.P.90
Grace, John W.
T.F.O.5
Grace, William C.
T.D.P.59
Grade, Margaret M.
M.D.P.42
Graham, Barney S.
M.C.P.19, W.C.P.144
Grandi, Joao Luis
M.E.P.31
Grant, Christine M.
T.A.P.78, W.A.O.7, W.B.P.61
Grant, Igor
W.B.P.230, Th.B.P.262
Grant, Michael D.
T.C.P.60
Grant, Peter J.
T.D.O.7
Gravier, Bruno
T.D.O.2
Gray, Graciela
T.B.P.152
Greatbatch, Wilson
Th.A.P.60
Greco, Dirceu B.
T.D.P.25, Th.B.P.114, Th.B.P.170
Greco, M. Alba
T.B.P.370, Th.B.P.372
Gredler, Brigitte
T.E.P.50
Green, Jesse
M.H.O.10, M.H.P.5, T.H.P.16, Th.A.P.82
Green, Miriam
T.E.O.6
Green, Stephen T.
W.B.O.7, W.F.P.8, Th.D.P.3
Greenberg, Alan E.
W.A.P.12, W.G.O.7
Greenblatt, Ruth M.
T.D.O.25
Greenhalgh, John B.
M.A.P.60
Greenspan, Deborah
M.B.O.20, Th.B.P.320
Greer, Pedro Jr.
M.A.O.28
Gregersen, Jens-Peter
M.C.P.44
Gregg, Robert A.
T.B.P.232
Grewe, Carola
Th.C.P.53, Th.C.P.150

Griffiths, Paul D.
Th.B.P.22
Grillner, Lena
W.B.P.114
Griscelli, Claude
T.B.O.20
Gritti, Francesco M.
M.B.P.96, Th.B.P.76
Gronowitz, J. Simon
W.B.P.147, Th.C.P.82, Th.C.P.84
Grosch-Wörner, Ilse
T.B.P.378
Grose, Robert N.
W.E.O.6
Grover, Steven A.
M.H.O.7, W.A.P.79
Gruen, Rhoda S.
T.D.P.73
Gruters, R.
Th.C.O.1
Gryllis, Chryssa
T.C.P.79
Gmningsæter, Arne
Th.E.O.11
Guarner, Jeannette
M.B.P.62, Th.C.O.38
Guatelli, John C.
T.C.P.129
Gudefin, Marie-Ange
T.D.P.53
Guedj, Roger
M.C.P.93
Guerrero, Ernesto
W.A.P.94, Th.D.O.10, Th.D.O.12, Th.G.O.41, Th.G.O.44
Guertler, Lutz
W.G.O.29
Guetard, Denise
W.C.P.65
Guimaraes, Carmen D.
T.E.P.64
Guimares, Rogerio Fiaro
M.E.O.4
Guinan, James
M.A.P.65
Guisse, Y. Mb.
M.D.P.18, Th.E.P.35
Guisse, Y. N.
Th.G.P.23
Gupta, Anil
T.B.P.254
Gupta, Phalguni
M.C.P.133, T.B.P.114, Th.C.O.28, Th.C.P.14
Gupta, Sudhir
W.C.P.123
Gurbindo, Gutierrez M. D.
M.B.P.277, T.B.P.215, W.A.P.4
Gutfreund, Klaus
Th.B.P.119
Guthrie, Anne M.
M.F.P.13, Th.F.P.3
Guy, Bruno
W.C.O.33
Guydish, Joseph R.
Th.D.P.33, Th.D.P.34
Gwinn, Marta
W.D.P.24, Th.A.O.11

H

Haas, Jennifer S.
W.B.P.54
Haase, David A.
T.B.P.42
Hachmann, Monika
T.E.P.70, W.D.P.23
Hadderingh, Roel J.
M.B.P.203, Th.B.P.349
Hadler, James L.
T.A.O.8
Hagan, Hollis C.
Th.D.O.13
Hague, Rosemary A.
T.B.P.246
Hahn, Beatrice H.
T.C.O.20
Haigwood, Nancy L.
Th.C.O.31
Haley, Charles E.
M.A.P.120, M.D.P.29, T.A.P.21, T.D.P.11, W.A.P.39, W.A.P.81, Th.A.P.48, Th.D.P.37
Hall, William W.
Th.C.P.5
Hallman, David
W.F.O.16
Halloran, Mary E.
W.D.P.83, Th.A.P.41
Halsey, Neal A.
T.A.O.18
Hamblin, Julie C.
M.F.P.10
Hambraeus, Lars
M.E.P.32
Hamerschlak, Nelson
M.B.P.167
Hamidi, Cyrus
T.A.P.68, T.A.P.77
Hamilton, John
T.B.P.118
Hammar, Lena
M.C.P.26, Th.C.P.26
Hammarskjöld, Björn P.
Th.C.P.122
Hammarskjöld, Marie-Louise
T.C.P.80, T.C.P.133
Hammer, Glenn S.
T.B.P.29
Hammerle, Christoph H. F.
W.C.P.32
Hammett, Theodore M.
M.F.P.4
Hammond, Gregory W.
W.D.P.20, Th.D.P.56
Hampl, Hartmut
T.G.O.5
Hanan, Janete L.L.
Th.E.P.19
Handsfield, H. Hunter
M.A.P.61, Th.A.O.9
Handzel, Zeev T.
M.A.P.59
Hankins, Catherine A.
M.A.P.23, Th.A.P.39
Hanna, Zaher
T.C.P.138
Hannen, Tom
T.H.O.6
Hannon, Harry W.
W.B.P.174
Hansen, John-Erik S.
Th.C.P.60, Th.C.P.61
Hanson, L Celine
T.B.P.266
Harada, Shinji
W.C.O.38
Harbison, Mary A.
Th.C.P.93
Harding, Timothy
T.D.O.1
Hardy, Ann M.
W.A.O.26, W.E.P.31
Hardy, Daniel B.
Th.A.P.7
Hardy, Iain R.
M.G.P.18
Hardy, W. David
T.B.P.46
Harelimana, Fidele
M.B.P.188
Harouse, Janet M.
W.C.P.76
Harper, Mary, E.
T.C.P.18
Harrer, Thomas
M.C.P.56, W.A.P.53
Harrington, Mark
T.H.P.15, W.B.P.257, Th.E.P.20, Th.G.P.10, Th.G.P.11
Harris, Dai
T.F.O.2, W.H.O.4, Th.F.P.9
Harris, N.L.
Th.C.O.7
Harris, Richard L.
Th.E.P.15
Harrison, Janet S.
M.D.P.24
Hart, Clyde E.
T.C.P.83

Hart, Graham J.
T.A.O.9
Hartel, Diana
Th.D.O.2, Th.D.P.59
Hartgers, Christina
T.A.O.21
Hartley, Trudie M.
Th.B.P.173
Hartman, Neil R.
W.B.P.275
Haseltine, William
W.C.O.3
Hassan, Rashidah Lorraine
M.E.O.21
Hassig, Susan E.
T.B.P.204, T.H.O.9, W.D.O.6, W.E.P.65, W.G.P.8, Th.E.P.1
Hatzakis, Angelos
M.A.P.89, M.A.P.109, W.C.P.140
Hausler, William J.
T.B.P.333
Hausser, Dominique
W.A.P.117
Hauw, Jean-Jacques
Th.B.O.21, Th.B.P.258
Havens, Jennifer F.
W.B.P.211
Haworth, A.
T.G.P.16
Hay, Phillip E.
W.B.P.58, W.B.P.59
Hayami, Masanori
M.C.O.5, M.C.O.25, T.C.O.25
Hayes, Curtis G.
W.B.P.152, Th.G.O.25
Haynes, Katherine
W.D.P.28
Hays, Robert B.
T.D.O.19, T.D.P.57
Hayward, Rodney A.
W.B.P.251
Hearn, Thomas L.
T.B.P.141
Hearst, Norman G.
T.A.O.7
Heath-Chiozzi, Margo E.
T.B.P.7, W.B.P.252
Hébert, Martin
T.F.O.8
Hedaya, Mohsen A.
M.B.P.339, W.B.O.4
Hedderman, Michael
M.E.P.65
Hedge, Barbara
T.D.O.18
Heffner-Barrett, Cathy L.
Th.C.P.108
Heffron, Phyllis B.
W.A.P.112
Heggs, Amanda
M.E.O.1, W.D.O.14
Heinze-Lacey, Beverly
T.A.O.2
Heise, Walter
M.B.P.120, T.B.P.375, Th.B.P.45
Heisig, Volker
W.C.P.116
Helgadottir, Hildur
M.B.P.321
Heligman, Larry
Th.E.P.2
Heller, Todd D.
W.B.P.38
Hellinger, Fred J.
W.H.O.15
Helquist, Michael
Th.E.P.65
Henderson, David K.
M.D.P.73, M.D.P.88
Hendrix, Craig W.
M.C.P.85
Hénin, Dominique
W.B.O.18, Th.B.P.196, Th.B.P.250
Henkes, Hans
Th.B.O.23
Henrivaux, Philippe
M.B.P.340, Th.B.P.103, Th.B.P.145
Henry, Keith
M.D.P.57, M.D.P.89, W.E.P.73
Herb, Alice
Th.F.O.2
Herbert, Barbara L. A.
T.E.P.35
Herbert, Daniel
T.E.O.5
Herek, Gregory M.
M.E.P.3
Herman, Bruce A.
W.A.P.101
Hermann, Claudia
T.D.P.46
Hernandez, Sandra R.
M.H.P.7
Hernandez-Sampelayo, Teresa
T.B.P.172
Hemdier, Brian G.
Th.C.O.37
Hems, Mary V.
W.B.P.185
Heseltine, Peter
W.B.P.286
Hesselton, Ruthann M.
M.C.P.17
Hessol, Nancy A.
M.A.O.27, M.A.P.111
Hethcote, Herbert W.
Th.A.P.52
Hewlett, Indira K.
M.A.O.33, W.C.O.27, Th.C.P.114
Heyer, David M.
W.B.O.19
Heyes, Melvyn P.
Th.B.P.232
Heymann, David
T.A.O.41
Heyward, William L.
W.B.P.113
Hidalgo, Julia
W.H.O.17, W.H.P.8, W.H.P.11, Th.B.P.216
Higgins, Donna L.
M.D.P.32
Hilberg, Charles F.
M.B.O.26
Hill, Deirdre A.
M.A.P.12
Hiller, Klaus F.
M.B.P.60
Hindin, Rita H.
T.A.P.70, T.A.P.71
Hingson, Ralph W.
T.D.O.24
Hira, Subhash K.
M.G.O.22, T.B.P.371, W.A.P.50, W.A.P.54, Th.A.O.5, Th.G.O.16, Th.G.P.5
Hirsch, Vanessa M.
T.C.O.43
Hittleman, Joan
M.B.O.42, T.B.P.180
Ho, David D.
Th.C.P.138
Ho, Hsu-Tso
M.C.P.96
Hockenberry, Clint
T.F.O.6, Th.F.P.13
Hoegsberg, Bente
Th.D.P.60
Hoff, Rodney
T.B.P.130
Hoffenbach, Agnès
T.C.P.67, T.C.P.76
Höffken, Gert
W.B.P.278, W.B.P.372
Hoffmann, Geoffrey W.
W.C.P.130
Hofman, Florence M.
T.C.P.17
Hofmann, Bo
W.C.P.104, Th.B.O.25
Holcombe, Hilda R.
W.C.P.39
Holland, Steven M.
Th.B.O.30
Hollander, Harry
M.B.O.50

Hollinger, F. Blaine
T.B.P.117, T.B.P.122, T.B.P.148
Holm, Jim
W.E.O.9
Holmberg, Scott D.
M.A.O.46
Holt, Elisabeth
Th.G.O.51
Holton, Donna
M.A.P.110
Holtzman, Deborah
W.A.P.18
Holzemer, Stephen P.
M.B.P.301, M.B.P.303
Holzer, Timothy J.
Th.C.P.37
Hommes, Mirjam J.T.
Th.B.O.38
Homsy, Jacques
T.C.O.21, Th.C.P.49
Hong, Barry A.
M.B.P.383, T.B.P.384
Hooykaas, Crista
T.A.P.14
Hopewell, Phil
M.B.O.12
Hopkins, Karen
M.E.O.15
Hopkins, Sharon G.
M.H.O.15, T.A.P.72, W.A.P.104
Hopper, Cheridad
W.C.P.143
Horal, Peter
T.C.O.37
Horn, Janet
Th.D.P.24
Horn, William F.
Th.B.P.302
Horsburgh, C. Robert, Jr.
Th.A.O.32, Th.A.P.87
Horton, Jacqueline A.
M.A.P.2
Hostetler, Karl Y.
Th.C.O.18
Hostetter, C.
M.E.P.49
Hoth, Daniel
W.B.O.50
Houle, Linda
W.B.P.356
Houston, Stan
Th.A.P.5
Houweling, Hans
T.D.P.34
Hovanessian, Ara G.
T.C.O.5
Howell, Embry M.
W.E.P.70
Hoxie, James A.
Th.C.O.25
Hoy, Jennifer F.
M.B.P.124, T.B.P.311
Hsia, Karen
W.C.P.133
Hu, Dale J.
M.E.P.4
Hu, Shiu-Lok
W.C.P.10, Th.C.P.95
Huang, Karen H. C.
M.D.O.5
Huang, Ming
M.C.O.11, W.C.O.28
Huebsch, Lothar
T.B.P.306
Hughes, Andrew S. B.
M.G.O.5
Hulin, Marg
Th.D.P.92
Hummel, Robert F.
T.E.P.45
Huscroft, Susan
M.D.P.5
Husdal, Arne N.
T.E.O.8
Hutterer, Judith
T.E.P.67, Th.D.P.18, Th.D.P.71
Hyman, James M.
Th.A.P.66
Hymes, James P.
T.E.O.10
Hynes, Patrick
T.D.O.4

I

Iatrakis, George
Th.H.P.15
Ikegami, Nobuko
W.B.P.298
Ikeuchi, Kenji
T.C.O.18
Ikuta, Kazuyoshi
Th.C.P.56
Illingworth, Patricia
W.F.P.5
Imrie, Allison A.
Th.B.P.369, Th.B.P.370
Indyk, Debbie
T.E.P.10, Th.E.P.50
Inglesi, Elisabeth
W.E.O.29
Inoue, Masahiro
Th.C.P.149
Iosub, Silvia
T.B.P.147, T.B.P.168, T.B.P.265
Ippolito, Giuseppe
M.A.P.8, M.D.P.72, M.E.P.61, M.G.P.9, W.B.P.16
Iribarren, J. A.
Th.B.P.65
Ishida, Takuo
W.C.P.36
Ismael, Carla
M.B.P.109, M.B.P.291
Itescu, Silviu
Th.B.P.116
Ivanus, Lidia
M.B.O.10
Ivo-Dos-Santos, Jairo
T.B.P.99, W.G.P.15
Izaguirre, Carlos A.
Th.B.O.48
Izazola, José-Antonio
T.G.O.8, Th.G.O.29, Th.G.O.30, Th.G.P.16

J

Jackson, J. Brooks
T.B.P.348, Th.B.O.8
Jackson, Lois A.
Th.H.P.2
Jackson, Rudolph E.
T.E.P.11
Jackson, Susan
T.C.P.64
Jacob, K. S.
M.B.P.381
Jacobs, Jonathan
M.B.P.322, M.E.P.64, T.B.P.300, W.D.P.7
Jacobs, Raymond M.
T.D.O.15
Jacobsberg, Lawrence B.
W.B.P.210
Jacobsen, Paul B.
W.B.P.332
Jacobson, Kathleen L.
M.D.P.75
Jacobson, Mark A.
M.B.P.123, M.B.P.166, M.C.P.111, T.B.P.312
Jacobson, Susan J.
M.B.P.205
Jadresic, Danitza
W.B.P.201
Jaeger, Helmut
Th.H.P.27
Jäger, Hans
W.B.P.187, W.F.O.20
Jain, Sunita
W.D.P.79
James, Gillian
M.E.P.5
James, William S.
M.C.P.77
Janier, Michel
W.B.P.49
Janoff, Edward
Th.B.P.94, Th.B.P.175

Janowitz, Barbara
Th.H.P.29
Janssen, Robert S.
M.A.O.31, Th.A.O.31
Janvier, Blandine
Th.C.P.75
Jarstrand, Connie
Th.B.P.88
Jarzem, Peter
Th.B.P.7
Javaherian, Kashi
M.C.P.6
Javanni, Jean
W.E.P.44, Th.E.O.14
Jayle, D.
W.E.P.27
Jeffrey, Kelly A.
M.D.P.21
Jennings, Myra B.
W.C.P.18
Jensen, Brigitte Nybo
T.B.P.59
Jensen, Peter C.
W.B.P.62, W.C.P.69
Jestin, Christine M.
M.H.P.11
Jimenez, Eleanor
W.A.P.48
Jinadu, M. K.
Th.E.P.38
Johansen, Hanne R.
T.C.P.106
Johnson, John L.
T.C.P.9
Johnson, John P.
T.B.P.210, T.B.P.220
Johnson, Margaret A.
T.C.P.8
Johnson, Michael P.
T.B.P.318
Johnson, Philip R.
W.C.O.50
Johnson, Pierre-Marc
Th.H.O.2
Johnson, Sandra M.
Th.B.P.303
Johnson, Sylvia S.
T.G.P.18
Johnson, Victoria Anne
M.C.P.97
Johnson, Warren D.
W.G.O.8, W.G.O.11
Johnston, B. Lynn
W.B.P.381
Johnston, Margaret I.
M.C.P.123
Joller, Peter W.
Th.B.P.110, Th.B.P.133
Jonckheer, Tijl
T.B.P.197
Jones, Barbara J.
T.D.P.87
Jones, Donna S.
M.A.P.35
Jones, Jeffrey L.
W.A.O.20
Jonkheer, Tijl
T.B.P.251
Jonsen, Albert
T.F.O.12
Joseph, Herman
W.D.P.78
Josephsen, Knud
Th.E.O.10
Joshi, Sadhna
M.C.P.145
Joshi, Vijay V.
T.B.P.259
Jost, Jean-Paul
Th.E.P.17
Joy, Dan M.
M.D.P.28
Judson, Franklyn N.
M.A.P.54, T.A.P.83, Th.E.P.8
Juliana, Patti L.
W.D.P.43
Jullien, Anne-Marie
M.B.P.151
Jurriaans, Suzanne
W.C.P.88
Just, Gudrun
Th.B.P.334
Juszczyk, Jacek R.
T.A.P.7

K

Kägi, Martin Kurt
Th.B.P.81
Kahn, James O.
W.C.P.42, Th.B.O.5
Kahn, Joan
W.H.P.9
Kairam, Ram
M.B.O.44
Kalambayi, Kayembe
W.B.P.4
Kaleeba, Noerine
M.G.O.34, Th.D.O.21
Kales, Christopher P.
M.B.P.70, M.B.P.77
Kalombo, Kitoto K.
Th.E.O.3
Kalter, D. Chester
W.C.P.63
Kalyanaraman, V. S.
M.C.P.1
Kambou, Gerard
T.H.O.17, W.H.P.13
Kamenga, Munkolenkole M.
M.G.O.17, T.D.O.35
Kamps, Bernd S.
M.A.O.12, T.A.P.107, W.B.O.26, W.B.P.170
Kane, Assane
T.B.P.373
Kangas, Lenni W.
W.A.P.98
Kanki, Phyllis J.
M.A.O.15, T.G.O.3, W.C.P.136, Th.E.P.3
Kann, Laura
T.D.P.9
Kanouse, David E.
T.D.P.18
Kantor, Elizabeth
T.D.O.5
Kapembwa, Moses S.
Th.B.O.41, Th.B.P.317
Kapila, Mukesh
M.E.P.46, W.E.O.23
Kapita, Bila
W.B.P.12, W.B.P.359, W.G.O.34
Kaplan, Jonathan E.
Th.A.P.17
Kaplan, Lawrence D.
M.B.P.288, T.B.P.284
Kaplan, Marcy E.
M.B.P.313, M.B.P.317
Kaplan, Mark H.
M.B.P.4, T.B.P.35
Kappes, John C.
T.C.P.126
Kaptue, Lazare N.
M.B.P.99
Karabulut, Nigahus
M.B.P.69
Karacostas, Velissarios
Th.C.P.130
Karafoulidou, Anastasia
Th.B.P.17
Karam, Marc
T.G.P.3
Karjalainen, Klaus E.
T.C.P.96
Karon, John M.
T.A.O.37, Th.A.P.79
Karp, Mitchell
Th.D.P.8
Karpas, Abraham
M.C.O.18, W.B.P.314
Kashala, Oscar
W.G.O.30
Kaslow, Richard A.
M.A.P.101, Th.A.P.100
Kass, Nancy E.
T.H.P.20
Katabira, E. T.
T.B.O.11
Katims, Jefferson J.
Th.B.P.285

Katlama, Christine
M.B.P.117, M.B.P.119, Th.B.P.219
Katner, Harold P.
M.D.P.59
Katner, Harold, P.
M.D.P.16
Katsivo, M. N.
W.G.O.22
Katz, Deborah G.
T.E.P.51
Katze, Michael G.
Th.C.P.89
Katzenstein, David A.
W.C.P.95, W.C.P.96, Th.C.P.40
Kauffman, Carole K.
W.E.O.2
Kaunath, Thomas
W.C.P.122
Kawamura, Takashi
Th.C.O.4
Kay, John W. D.
M.B.P.170
Kayembe, Kalambayi
W.B.P.13, Th.H.P.16
Kazazi, Farhad
T.C.P.6
Keefer, Michael C.
M.C.P.8
Kefene, Hailu
W.G.P.28
Kegeles, Susan M.
M.D.P.3
Keilp, John G.
T.D.P.61, W.B.P.194, Th.B.P.376
Kelen, Gabor D.
T.G.P.4, W.A.O.4, Th.A.P.12
Keller, George H.
Th.B.O.12
Kelley, Patrick W.
M.A.P.4
Kelly, Ann
M.B.P.308, W.B.P.379
Kelly, Chester J.
W.A.O.25
Kelly, Jeffrey A.
M.D.P.22
Kelly, Patricia J.
Th.D.P.9
Kelly, Paul J.
W.D.P.17
Kelner, Merrijoy
M.D.P.74
Kemeny, Margaret E.
T.D.O.23
Kengeya-Kayondo, Jane Frances
T.A.P.11
Kennedy, Ann R.
Th.E.P.47
Kenny, Colin
M.A.P.57
Kenny, Frank T.
W.A.P.76
Kensil, Charlotte R.
M.C.P.2
Keogh, Pauline M.
T.E.O.3
Kerndt, Peter R.
Th.D.P.58
Kertzner, Robert
W.F.P.2
Kessler, Ronald C.
M.A.O.48
Kestelyn, Philippe G.
T.B.P.203
Kestens, Luc
T.B.P.135
Kestler III, Harry W.
Th.C.P.23
Keyes, Craig W.
T.B.P.51, T.B.P.324, W.B.P.68
Khabbaz, Rima F.
Th.A.O.33, Th.A.P.16
Khal, Paul
Th.B.P.308
Khan, Sabih R.
W.B.P.241
Khayam-Bashi, Hassan
W.B.P.85
Khuzaie, Rula F.R.
Th.C.P.102
Kibuga, Daniel K.
Th.G.O.5
Kiernan, Rosemary E.
Th.C.P.41
Kilbourne, Barbara W.
W.A.O.18
Killinger, Joyce F.
W.A.P.61
Kim, Helen
Th.C.P.16
Kim, Sunyoung
W.C.O.35
Kimani, V.
M.G.O.11
Kimmel, Allan J.
T.D.P.55
Kimura, Satoshi
M.B.P.63
Kimura-Kuroda, Junko
W.C.P.103
Kindt, Thomas J.
W.C.P.41
King, Alison B.
Th.B.P.300
King, Michael B.
T.F.O.3, W.B.P.212
Kingsley, Lawrence A.
W.A.P.41
Kinloch de Loes, Sabine
Th.B.P.131
Kinnell, Hilary R.
T.E.P.38, W.D.P.41
Kinney, Evlin L.
M.B.P.282, M.B.P.284
Kinter, Audrey
W.C.P.59
Kinuthia, D. M. W.
Th.E.P.39
Kipke, Michele D.
T.D.O.27
Kirby, Justice Michael
M.F.O.1, W.F.O.23
Kirsch, Gorm D.
M.B.P.304
Kirsetter, Myriam
W.B.P.305
Kitchen, Valerie S.
M.B.P.244
Kitchin, Peter
W.C.P.7
Klaassen, Robert J. L.
W.C.P.99
Klein, Ami
W.C.P.74
Kleinman, A.
M.G.O.7
Kleinschmidt, Andrea
Th.B.P.181
Kletter, Ron
M.B.P.24
Kleyn, Jeanne E.
T.E.P.42
Klimas, Nancy G.
Th.A.P.97, Th.B.P.223, Th.B.P.240
Klimkait, Thomas
W.C.O.36
Kline, Richard L.
T.B.P.126, T.B.P.127
Klotman, Mary E.
T.C.O.13
Knechten, Heribert
T.B.P.291
Knigge, Kevin M.
W.B.P.95
Knight, Susan
T.B.P.110
Knobel, Gideon J.
W.F.O.22
Knox, Michael D.
M.D.P.60
Knutsen, Alan P.
T.B.P.253
Ko, Richard J.
W.B.O.5
Kobayashi, Joyce S.
W.B.P.182
Koblin, Beryl A.
T.A.P.29

Koch, Michael G.
W.H.P.20
Koch, Thomas K.
T.B.P.177
Kochen, Michael M.
M.D.P.66
Kocsis, Agnes E.
W.B.P.204
Koenig, Scott
W.C.O.41
Koff, Wayne C.
M.C.P.3
Kohn, Robert
M.D.P.30
Koistinen, Jukka
M.B.P.159
Kokkevi, A.
Th.D.P.72
Koller-Lampert, Karin
Th.B.P.60
Konde-Lule, Joseph K.
M.G.O.13
Kong, Lilly I.
T.C.O.19
Konno, Akihiro
W.C.P.21
Koopman, Cheryl
T.D.P.90
Koopman, James S.
Th.A.P.64
Kopolo, Olive
M.B.O.9
Köppen, Stefan
M.B.P.331
Koralnik, Igor
Th.B.P.280
Korber, Bette
W.G.P.22
Korkolainen, Mirja
W.B.P.102
Kornaszewski, Waclaw
W.B.P.276
Kornbluth, Richard S.
Th.C.P.29
Kornfeld, Hardy
T.C.P.15
Korniewicz, Denise M.
M.H.P.27, T.D.P.70
Kosia, Andrew
W.G.P.16
Kotler, Donald P.
M.B.P.135, W.B.O.29, Th.B.O.37
Kotloff, Karen L.
T.A.P.16, T.B.P.263
Koucher, Bernard
M.F.O.14
Koup, Richard A.
T.C.P.24
Kouri, Yamil
T.H.O.10, W.H.P.4
Kourouma, Hamadou
W.H.O.2
Kouzi, Anthony C.
Th.E.P.4
Kovacs, Joseph A.
W.B.P.335
Kowalski, Alex
M.E.O.25
Kozhich, Alexander T.
W.B.P.131
Krämer, Alexander
M.A.O.45
Krasinski, Keith
Th.A.P.15
Kraus, Elissa M.
Th.B.P.34
Krebs, John W.
T.G.P.25
Kreiss, Joan
M.A.O.36, M.B.P.53
Kreniseke, John
Th.E.O.15
Kreuz, Wolfhart
T.B.P.218, T.B.P.257
Krieger, Monica S.
T.B.P.129
Kritski, Afranio Lineu
Th.B.P.37, Th.B.P.74
Kroliczak, Alice
W.D.P.33
Kronfeld, Matias
M.B.P.102, W.B.P.20, W.B.P.41, Th.B.P.47
Krowka, John F.
T.C.P.13, W.C.O.40
Krown, Susan E.
W.B.P.309, W.B.P.374, Th.B.O.28
Krueckl, Judy G.
T.E.P.29
Krupka, Udo
W.B.P.93
Krust, Bernard
Th.C.P.85
Krvavac, Sukrija
M.C.P.138
Krystossek, Heinz
M.B.P.125
Kucera, Louis S.
W.C.O.21
Kulaga, Henrietta
W.C.P.16
Kumar, Mahendra
W.B.P.190
Kunches, Laureen M.
Th.A.P.98
Kunsch, Charles
M.C.O.31
Kunz, Christian
W.B.P.99
Küpcü, Zaruhi
T.C.P.38
Kvarness, Ragnar
Th.D.O.17
Kvinesdal, Birgit Bak
W.C.P.25
Kwok, Shirley Y.
Th.B.O.7

L

LaCharité, Christopher
M.D.P.81
LaLota, Marlene
M.A.P.6
Labrousse, Françoise
Th.B.P.143
Lachance, Colette
M.E.P.45
Lacouture, Yves
T.B.P.89
Lacroix, Martial
W.B.P.110, W.B.P.111, Th.B.P.371
Lafferty, William E.
W.A.P.82
Laga, Marie
Th.A.O.21
Lai, Patrick K.
M.C.P.118
Lairmore, Michael D.
W.C.P.4, Th.C.P.30
Lake, Douglas
T.C.P.75
Lake-Bakaar, G.
M.B.P.218
Lallemant, Marc
W.G.P.10, W.G.O.54
Lallemant Le Coeur, Sophie
W.G.O.3
Lambert, John S.
M.C.P.130
Lamberto, Barbara
W.E.P.60
Lanctôt, Lise
Th.E.P.68, Th.H.P.1
Landay, Alan L.
T.B.P.224, Th.B.P.90, Th.B.P.91
Landesman, Sheldon
T.F.O.20
Landis, Suzanne E.
M.A.O.23, M.D.P.20
Landonio, Giuseppe
T.B.P.272
Landry, Yves
M.A.P.39
Lane, Clifford
W.C.O.20
Lang, Jean-Marie
T.C.P.43, W.B.P.296
Lang, Onnie S.
T.B.O.5

Lang, Sabine
T.C.O.45
Lang, William
M.A.P.99
Lange, Joep M. A.
M.B.O.23, M.B.P.352, W.B.P.109
Lange, Michael
W.B.P.80
Lange, W. Robert
T.A.P.13
Langford, Angelika
W.B.P.84, Th.B.P.332, Th.B.P.342
Lapointe, Bernard
T.E.O.7
Laporte, Anne
W.A.P.25
Laporte, Jean-Philippe
W.B.P.283, W.B.P.320
Laqueur, Peter A.
M.B.P.314
Larder, Brendan A.
T.C.O.7
Laroche, Eddy
W.A.P.16
Larsen, Charles E.
Th.C.P.107
Larsen, Robert A.
W.B.P.11
Lassegue, Alix
M.A.O.29
Lathey, Janet L.
W.C.P.97
Latif, Ahmed S.
M.B.P.289, Th.G.O.15
Lau, Allan S.
W.C.P.82, W.C.P.83
Laubenstein, Linda J.
M.E.P.23
Laughlin, Mark A.
W.C.P.70
Lauré, Françoise
Th.C.P.70
Laurence, Jeffrey
T.B.O.34
Lauritzen, Edgar
W.B.P.125
Laussucq, Suzanne
W.A.P.84
Lautenberger, James A.
M.B.O.22
Laux, Lila
W.D.P.5
Laverda, Anna Maria
T.B.P.178, T.B.P.186
Lavoie, Michel
M.D.P.11
Lawrence, David W.
T.A.P.33
Layne, Scott P.
Th.C.P.100
Lazartigues, Alain A.
T.D.P.86
Lazdins, Janis K.
W.C.P.6
Lazzarin, Adriano
M.B.P.336, M.B.P.351
Le Gales, Catherine
M.H.O.5
Le Guenno, Bernard M.
Th.B.P.151
Leach, Charles T.
M.B.P.110, Th.E.P.59
Lebas, Jacques
T.E.P.66
Lecatsas, Gersimos
Th.H.P.19
Lee, Christine Ann
M.A.P.41, M.A.P.96, W.B.O.28, Th.B.O.35
Lee, Helen
Th.A.O.29, Th.A.P.21, Th.A.P.119
Lee, Shirley J.
W.B.P.264
Lee, Stephanie L.
T.B.P.116
Lee, Tun-Hou
T.C.P.51
Leeper, Mary Ann
W.D.P.39
Lefebvre, Suzie
Th.C.P.83
Lefkowitz, Mathew
M.B.P.202
Lefrère, Jean-Jacques
M.A.P.102, T.C.P.131, Th.A.P.116, Th.B.P.140
Legg, William G. W.
Th.G.O.6
Lehman, J. Stan
W.A.P.21
Leibowitch, Jacques
W.C.P.72
Leidl, Reiner
W.H.O.16
Leigh Brown, Andrew J.
T.C.P.124
Leinikki, Pauli O.
Th.A.P.2
Leite, Jane Te Luzia
M.E.P.66
Leitman, Paul
Th.B.O.51
Lema, Valentino M.
W.E.P.72
Lemaire, Jean-Marie
Th.A.P.3
Lemp, George F.
W.A.P.14, W.B.P.354
Lentino, Joseph R.
Th.A.P.1
Leon, Antonio
T.D.P.85
Leonard, Guy
W.B.P.108
Leoro-Monroy, Galo
M.G.P.19
Leoung, Gifford S.
T.B.O.3, T.B.P.76, T.B.P.78
Lepage, Philippe
T.B.P.374, W.G.O.6, Th.B.P.187
Letellier de St-Just, Louis
M.F.O.5
Leturcq, Didier J.
M.C.P.67
Letvin, Norman L.
Th.C.O.16
Levacher, Maryse
M.B.P.347, Th.B.P.166
Lever, Andrew M. L.
Th.C.P.90
Levi, Guido Carlos
T.B.P.317, Th.F.P.1
Levine, Alexandra M.
Th.B.O.44
Levine, Carol
M.E.P.29, T.F.O.13, W.F.O.8
Levine, James D.
W.B.P.328
Levine, Martin P.
Th.E.P.51
Levine, Robert J.
W.B.O.51, W.F.O.1
Levitt, Nirvair
T.H.P.11
Levy, Jack
W.A.P.49
Levy, Jay A.
M.C.O.1
Levy, Robert M.
Th.B.P.283, Th.B.P.375
Lewi, David Salomao
M.B.P.263
Lewis, Benjamin F.
T.A.P.35, T.E.P.16, W.E.P.12
Lewis, Diane K.
Th.D.O.14
Lewis, Dorothy E.
M.C.P.20, M.C.P.124
Lewis, Edwin M.
Th.B.P.205
Li, Patrick C. K.
W.G.P.30
Li, Yen
Th.C.P.58
Liang, Chi-Ming
Th.B.P.109, Th.C.P.42
Lieb, Loren E.
M.B.P.68, T.A.P.67
Lieb, Spencer
T.D.P.21

Liekweg, Richard J.
M.H.P.10
Liesnard, Corrinne A.
M.B.P.357
Lifschitz, Marta
T.B.P.175
Lifson, Alan R.
W.A.P.46, Th.A.P.86, Th.B.O.9
Lightfoote, Marilyn M.
T.C.O.2
Likimani, Sopiato
Th.B.P.346
Lillehoj, Erik
Th.C.P.115
Lim, Seng Gee
T.B.P.275, W.B.P.349, Th.B.P.355
Linard, Françoise
W.B.P.380
Lindan, Christina P.
W.A.P.24
Lindholm, Merete M.
W.E.P.38
Linsk, Nathan L.
M.D.P.63
Lipshultz, Steven E.
T.B.P.146
Lisa, Joseph F.
M.F.P.11
Lischner, Harold W.
T.B.P.225
Litterst, Charles
M.C.P.122
Liu, Wu-Tse
T.C.P.143
Livingston, Gary L.
W.E.P.43
Livrozet, Jean-Michel
T.B.P.47
Ljunggren, Kristina
T.C.P.55
Lloyd, Gary A.
T.E.O.4
Lockwood, Don E.
T.B.P.102
Lombardo, Joseph M.
M.A.P.16
Lomvardias, Stylianos
M.B.P.177
Long, Iris
W.B.P.249
Longini, Ira M. Jr
T.A.O.36
Longo, Paulo H. P.
T.D.P.83, W.D.P.38
Looney, David J.
M.C.O.21, Th.C.P.22
Lorentsen, Kevin J.
T.B.P.295
Louie, Leslie G.
Th.A.P.83
Loures, Luiz
W.G.P.13
Loveday, Clive
Th.C.P.128
Loveless, Mark O.
W.B.P.288
Low, L.
W.C.O.23
Lozada-Nur, Francina I.
Th.B.P.333
Lu, Wei
Th.C.P.104
Lu, Xiaobin
T.C.P.81
Luabeya, Mesu'a-Kabwa
Th.B.P.221, Th.B.P.267
Luban, Naomi L. C.
T.B.P.157, T.B.P.241
Lubega, Juliet
W.E.O.5
Lucas, Susan, E.
W.E.O.4
Lucey, Daniel R.
Th.B.P.135
Luciw, Paul A.
T.C.P.78, T.C.P.134, W.C.O.2
Ludlam, Christopher A.
W.B.P.74
Lüer, Wilfried
Th.B.P.246
Lujan, Manuel E.
M.E.P.20
Luna, Cajetan G.
M.D.O.9
Lundgren, Bettina
T.B.P.6
Lundgren, Jens D.
T.B.P.32
Luo, Nkandu P.
M.B.P.149, T.B.P.337
Lurhuma, Z.
W.B.P.316
Lusakulira, Namagosi
Th.G.O.8
Lusso, Paolo
W.C.P.125
Luta, Martin
Th.B.O.39
Luzi, Giuseppe
T.A.P.103, Th.B.P.150
Luzuriaga, Katherine F.
T.B.P.209
Luzzati, Roberto
M.B.P.171, M.B.P.217, Th.B.P.213
Lwanga, S.
Th.A.O.14
Lwegaba, Anthony
W.D.P.8
Lwihula, George K.
Th.E.P.34
Ly, T. D.
T.B.P.113
Lyman, William D.
W.C.P.61
Lyons, Catherine
W.D.P.52
Lyons, Robert W.
T.H.P.21
Lyons, Susan F.
M.A.P.83

M

M'Boup, Souleymane
M.E.O.10, M.A.P.19, T.B.P.105, T.G.P.26, W.B.P.100
Ma, Pearl
M.B.O.32, M.B.P.38
Maboshe, Mwendaweli N.
M.A.O.42
MacDonald, Kristine L.
T.A.O.26, T.A.P.43
MacFadden, Douglas K.
T.B.P.321
MacKenzie, Malcom R.
T.C.O.39
MacMillan, Robert M.
T.F.P.2
Mach, Nicolas
Th.B.P.58
Mach, Otakar
Th.C.P.127
Machela, Alfred
T.G.O.14
Mackay, S. Rae, III
W.H.P.26
Mackenzie, Betsy
T.G.P.9
Macklin, Ruth
T.F.O.22
Madaule, Pascal
T.C.P.109
Madden, Gayle M.
T.A.P.23
Maddon, Paul
T.C.O.8
Madera, Inez
W.D.P.4
Madsen, Paul Christian
T.E.P.12
Magis, Carlos L.
T.A.P.8
Magura, Stephen
M.A.P.20, T.D.P.77, W.A.P.105
Mahmud, Fatia
Th.D.O.22
Mahoney, Kevin J.
Th.D.P.38
Maison, Belinda
M.E.O.3

Major, Carol J.
T.B.P.145, W.B.P.127
Makadon, Harvey J.
M.D.P.84, W.H.O.12
Makinen, Marty
W.H.P.1
Malach, Stephanie
W.E.O.3
Malau, Clement
T.G.O.24
Malek, Adel N. A.
M.B.P.372, W.G.O.5
Malkin, Jean E.
T.E.P.59
Malkin, Jean-Elie
M.G.P.26
Mallolas, Josep
W.B.P.40
Malmquist, Harriet E.
Th.H.P.10
Malone, Joseph L.
Th.B.P.163
Malouf, Renée
Th.B.P.188
Manak, Mark M.
M.C.P.9
Mancini, Maryline
M.C.P.4
Mancuso, Salvatrice
M.B.P.248
Mandalaki, Titika
W.B.P.348
Mandaliya, Kishorchandra
W.G.P.27
Mandell, Wallace
Th.D.P.50
Mandy, Francis
Th.B.P.360, Th.B.P.361
Mankikar, Sadanand
M.B.P.157, T.B.P.359
Mann, Dean L.
W.C.O.7
Mannella, Emilio
M.A.P.36, T.B.P.341
Manning, Nicholas P.
M.E.P.54, M.E.P.55
Mannucci, Pier
M.A.P.44
Mantell, Johanne E.
W.D.P.21
Mantell, Mary
W.E.O.11
Mantero-Atienza, Emilio
Th.B.P.313, Th.B.P.314
Manucci, Pierre
Th.B.O.32
Manuel, Catherine
M.F.P.9, T.F.P.10, T.F.P.11
Manzila, Tarande
W.G.O.1
Manzillo, Elio
W.B.P.361
Marasca, Giuseppe
M.D.P.37, T.E.P.26, W.A.P.63
Marchetto, Sylvie S.
Th.C.P.66
Marcus, Joseph C.
T.B.P.185
Marcus, Ruthanne
T.A.P.27, W.A.O.1
Marcus-Sekura, Carol J.
T.C.P.84
Marder, Karen
Th.B.P.261
Margalith, Miriam
W.B.P.73
Margo, Glen E.
M.D.O.4
Margolick, Joseph B.
M.A.P.98
Marichal, Bernard J.
M.C.P.139
Mariner, Wendy
W.F.O.4
Markham, Phillip D.
W.C.O.32, W.C.P.35
Marlink, Richard G.
M.A.O.13, M.B.P.200
Marmor, Michael
T.A.P.24
Marone, Piero
M.B.P.75
Marques, Luiz Paulo José
M.B.P.74, M.B.P.281, T.B.P.365
Marshall, Douglas W.
Th.B.P.229, Th.B.P.230
Marshall, T. David
T.F.O.9
Marte, Carola
M.B.P.276
Martin, Alex
W.B.O.43, Th.B.P.284, Th.B.P.286
Martin, David J.
T.E.P.1
Martin, Isabelle, M. G.
T.C.P.107
Martin, Jacqueline
Th.B.P.26
Martin, Jacques
Th.C.P.86
Martin, Jean
M.F.O.13
Martin, Malcolm
T.C.O.24
Martin, Olivia S.
W.B.P.137
Martin, Paul M.
T.C.P.22
Martin, Steven R.
T.B.P.249
Martinez-Barrios, Juan Carlos
Th.D.P.70
Masci, Joseph R.
W.B.P.6
Mascola, Laurene
T.A.P.65
Masina, Marco
T.B.P.330
Mason, Gregory R.
T.B.P.3
Massari, Ferdinand
W.C.P.109
Massari, Véronique
M.D.P.51, M.H.O.13
Masterson, Andrew
T.A.O.5
Masuda, Takao
Th.C.P.28
Masur, Henry
T.B.O.23
Mata, Leonardo J.
Th.H.P.24
Matheny, S.
T.H.P.3
Matheron, Sophie
M.B.P.225, M.B.P.249, T.B.P.195
Mathes, Lawrence E.
M.C.P.69
Mathez, Dominique
M.B.P.350, Th.C.P.98
Mathieu-Boué, Anne
T.B.P.310, T.B.P.380
Mathijs, J. M.
T.C.P.123, W.C.P.27
Matsuda, Juzo
W.B.P.311
Matsuda, Zene
Th.C.P.18
Matsukura, Makoto
Th.C.O.19
Matsushita, Shuzo
M.C.P.5
Matthews, Gene W.
M.F.P.6
Mauji, Firoze
Th.A.P.62
Maury, C. P. J.
W.C.P.114, W.C.P.115
Maxeiner, Horst-Günter
T.A.P.9
Mayer, Felix
W.B.P.98
Mayer, Kenneth H.
M.A.P.108, T.A.P.96, T.A.P.97, T.D.P.71, T.E.P.44, Th.D.P.83
Mayer, Vlastimil
Th.B.P.367
Mayers, Douglas L.
W.A.P.73, Th.B.P.115

Mayers, Marguerite M. *T.B.P.173*
Mayhew, Miriam *M.E.P.47*
Maynard, Pat *M.B.O.11*
Mayorga, Ruben *W.B.P.23, W.B.P.35*
Mays, Vickie M. *W.D.P.36*
Mazurkiewicz, Walentyna *Th.D.P.41*
Mbuyi, Kashama *W.D.P.2*
McAllister, Ruth H. *Th.B.P.287*
McArthur, Julie H. *M.B.O.35*
McArthur, Justin C. *Th.B.P.218, Th.B.P.238*
McBride, Duane C. *Th.D.P.49*
McCamish, Malcolm *T.D.P.43*
McCarthy, Michael C. *M.G.P.5*
McCartney-Francis, Nancy L. *T.C.P.117*
McClure, Harold M. *T.C.O.42, W.C.P.15*
McClure, Myra O. *M.C.P.91, Th.C.P.10*
McClure, Wilma M. *Th.B.P.28*
McCormick, Anna *W.A.P.28*
McCormick, Wayne C. *M.E.P.70*
McCoy, Clyde B. *Th.D.P.48, Th.D.P.82*
McCoy, Virgina H. *Th.D.P.47*
McCray, Eugene *M.A.O.20*
McCutchan, Allen J. *Th.D.P.51*
McCutchan, J. Allen *M.B.P.325*
McDonald, John R. *M.E.P.37*
McDougall, J. Steven *Th.C.O.41*
McFarland, Louise *W.A.P.8*
McGee, Juli S. *M.C.P.15*
McGee, Susan A. *W.B.P.175*
McGuigan, Chris *M.C.P.70*
McIntosh, Kenneth *Th.C.P.94*
McKiman, David J. *T.D.O.10*
McKusick, Leon *W.A.P.91, W.D.O.2*
McLaughlin, Bernadette *T.A.P.6, W.B.P.176*
McLaws, Mary-Louise *W.D.P.89*
McLellan, Iain *T.D.P.38*
McLullich, Archie *W.F.O.11*
McMahon, Deborah *M.B.P.355*
McManus, Thomas J. *T.D.P.23*
McMenamin, Diane M. *Th.E.P.64*
McNearney, Terry *T.C.P.122*
McNeil, John G. *M.A.O.1*
McPhee, Dale A. *T.C.O.35, Th.C.P.39*
McQuillan, Geraldine M. *Th.A.O.13*
McRae, Brian J. *W.B.P.139*
McSharry, James J. *T.B.P.88*
Medley, Graham F. *Th.A.P.75*
Meheus, André *Th.G.O.17*
Mehryar, A. H. *T.G.O.7*
Meisenhelder, Janice Bell *M.D.P.54*
Melder, Robert J. *W.C.O.10*
Meléndez, Guerrero Loyda *T.C.P.36*
Meliço-Silvestre, Antonio *M.A.P.18*
Mellado, Maria José *M.B.P.369, T.B.P.255*
Mellors, John W. *W.C.O.8*
Menares, Juan *M.D.P.40*
Mendes, Nelson *M.G.P.8*
Mendez, Hermann *T.B.P.240*
Mendez, Theresa C. *T.D.O.31*
Mendonça, Joao S. *W.B.P.31*
Mercure, Louis *M.C.P.112*
Merigan, Tom *T.B.O.14*
Merrill, Joseph M. *M.D.O.15*
Merton, Vanessa *W.F.O.7*
Metroka, Craig E. *M.B.P.126, M.B.P.192, T.B.O.4*
Mettetal, Jean-Florian *T.H.P.14*
Meyer, Andreas *T.B.P.40*
Meyer, Christian G. *W.B.P.104*
Meyer-Bahlburg, Heino F. L. *T.D.O.22, T.D.P.4*
Meyerhans, Andreas *T.C.O.28*
Mezzelani, Paolo *T.A.P.30*
Mhalu, Fred S. *T.G.O.11*
Michaud, Jean *W.B.O.32*
Michejda, Christopher J. *Th.C.P.136*
Michel, André *M.D.P.91*
Michel, Frédérique *T.C.P.77, W.C.P.5*
Michel, Sigrid *W.E.P.17*
Middelhoff, Monique *Th.E.O.2*
Midthun, Karen *M.C.P.14*
Miedzinski, Lilly J. *T.B.P.38*
Mijch, Anne M. *T.B.P.44*
Mikovits, Judy A. *M.C.O.16*
Milan, Fiala *W.A.P.77*
Mildvan, Donna *W.B.P.312*
Miles, Steven A. *M.C.P.52, M.C.P.100*
Miller, Eric N. *Th.B.P.278, Th.B.P.288, Th.B.P.294*
Miller, James L. *Th.E.P.61*
Miller, Kenneth P. *T.D.P.15*
Miller, Laurel A. *T.B.P.43, W.B.P.345*
Miller, Richard A. *Th.C.O.35*
Miller, Riva *M.B.P.155, W.D.P.19*
Miller, Steven D. *T.B.P.60*

Miller, Timothy E.
W.A.P.111
Miller, Veronica E.
M.C.O.29
Millson, Margaret E.
Th.D.P.52
Mindell, William
W.E.P.24
Mingle, Julius
T.B.P.351
Minkoff, Howard L.
Th.D.P.44
Minoli, Lorenzo
M.B.P.114, M.B.P.258, M.B.P.298, Th.B.P.243, Th.B.P.281
Mitchell, Sheila W.
T.B.P.133
Mitchell, William M.
W.B.P.239
Mitsuya, Hiroaki
M.C.P.135, Th.C.O.13
Miyasaki, Shelley H.
Th.B.P.323
Mizrachi, Yaffa
Th.C.P.15
Mizukami, Tamio
M.C.P.89
Moatti, Jean-Paul
T.D.O.20, Th.E.P.23
Mofenson, Lynne M.
M.A.P.14
Moglia, Arrigo
Th.B.O.20
Mohar, Alejandro
Th.A.P.80
Moien, Mary
Th.H.P.5
Mok, Jacqueline Y. Q.
T.B.P.211
Molenaar, John W.
T.E.P.18, Th.E.P.75
Molina, Jean-Michel
W.C.P.77, W.C.P.78
Moncany, Maurice L. J.
Th.C.P.81
Mongiardo, Nicola
Th.B.P.339
Monnig, Regina L.
M.B.P.320
Monny-Lobe, Marcel
W.D.P.87, W.G.O.21, Th.A.O.19, Th.D.P.22
Monplaisir, Nicole
W.C.P.139
Montagnier, Luc
M.C.O.14
Montaner, Julio S. G.
M.B.O.15, T.B.O.29, T.B.P.54, W.B.O.8
Montano, B. Lily
T.A.P.62
Montefiori, David C.
M.C.P.136, W.C.O.26
Montella, Francesco
M.B.P.199
Montgomery, A. Bruce
T.B.O.26
Montgomery, Kathleen E.
T.E.P.47, Th.E.P.11
Monzon, Ofelia T.
T.B.P.377, Th.H.P.21
Moody, Dewey J.
T.C.P.61
Moon, Martha W.
T.B.P.70
Mooney, Terry
W.G.O.38
Moore, Barbara E.
Th.C.P.116
Moore, Melinda
M.D.O.3, M.D.O.17, M.D.P.13, M.D.P.49, M.G.O.16, T.E.P.4, W.G.P.20
Moore, Melinda K.
M.D.P.14
Mor, Vincent
T.E.P.34
Morais de Sá, Carlos Alberto
M.B.P.257, Th.B.P.66
Morales, Edward S.
T.D.O.12
Moran, John S.
T.A.O.24
Moran, Patricia A.
W.C.P.58
Mordaunt, John
M.E.O.27
Moreno, Jose N.
T.B.P.320
Moreno, Sylvia A.
W.H.P.7
Morfeldt-Manson, R. Linda
T.B.P.372
Morgan, Richard A.
Th.C.O.11
Morisset, R.
Th.F.P.15
Morissette, Michel R.
T.F.P.7
Morlat, Philippe
M.B.P.254, T.A.P.25
Morris, Robert
T.D.P.7
Morris, Scott K.
M.B.P.237
Morrison, Cliff
Th.H.O.5
Morrison, Ken A.
W.E.O.12
Morrow, John W.
W.C.P.128, W.C.P.138
Morse, Dale L.
M.A.P.27, Th.D.P.45
Morse, Gene D.
M.B.P.342
Morton, William R.
W.C.P.33
Mosca, Joseph D.
T.C.O.14
Moses, Stephen
Th.G.O.27
Mosier, Donald E.
T.C.O.44
Mosley, James W.
Th.A.P.32
Moss, Andrew R.
T.A.O.11, T.A.O.31
Moss, Gregory B.
T.A.P.88
Moss, Howard A.
T.B.P.248
Mossalayi, Djavad
W.B.P.281
Mouton, Yves
Th.B.O.13, Th.B.P.178
Moye, John
M.A.O.25, W.E.P.53
Moyer, Mary Pat
W.C.P.90
Mposo, Ntumbanzondo
T.H.O.8
Muchinik, Guillermo
T.B.P.140, Th.B.P.13, Th.B.P.362
Mueller, N.
Th.A.P.14
Mueller, Olaf
W.E.P.22
Muga Bustamante, Roberto
T.D.P.64, W.A.P.71, Th.B.P.335
Mugerwa, Roy D.
Th.G.O.35
Muggiasca, Maria-Luisa
M.B.P.56, T.B.P.201
Muhondwa, Eustace
Th.D.O.19
Mulhall, Brian P.
W.A.P.44
Muligande, G.
Th.G.P.20
Müller, Fredrik
T.C.P.146, W.C.P.73
Müller, Ruth
Th.B.P.59
Muller, Werner E. G.
W.B.P.163
Mulligan, Mark J.
W.C.P.79
Mullins, James I.
M.C.O.12
Multare, Salvador
W.G.P.21

Mundy, Thomas M.
T.B.P.167
Munis, James R.
Th.C.P.79
Muñoz, Alvaro
W.A.P.67, W.A.P.68, Th.A.P.94
Mupedziswa, Rodreck S.
Th.E.P.62
Murayama, Tsugiya
T.C.P.4
Murbach, Ruth
W.F.P.9
Murphy, Edward L.
W.G.P.26, Th.G.P.1
Murphy, Robert
W.B.P.313
Musagara, Muhammed
Th.E.P.43
Muthami, L.N
W.H.P.15
Mwendapole, Rosemary M.
M.G.P.28
Mwile, Abraham
T.B.P.353
Mworozi, Edison A.
M.G.O.19, T.B.P.189, W.A.P.56
Myers, Gerald
M.C.O.24

N

N'Galy, Bosenge
M.F.O.16, W.G.O.26
Nagy, Károly
T.C.P.140, Th.B.P.174
Näher, Helmut
M.B.O.18
Nahmias, André J.
M.B.P.346, T.A.P.119, T.B.P.223, Th.B.P.93
Nair, Prasanna
W.A.P.47
Nara, Peter L.
T.C.O.22
Narain, Jai P.
Th.G.O.42, Th.G.P.27, Th.G.P.28
Narkunas, John P.
T.A.P.15
Nassaney, Louie
T.E.P.25
Nathanson, Vivienne
M.F.O.11
Navarette, Maria-Soledad
T.B.P.307
Navia, Manuel A.
M.C.O.23
Naylor, Paul H.
W.B.P.141
Ndinya-Achola, Jackoniah O.
W.G.P.29, Th.G.O.13
Ndoye, Ibra I.
Th.G.O.31
Neeguayee, Janet
W.G.O.33
Neihart, Robert E.
M.B.P.80
Neisson-Vernant, Claudine
Th.A.P.30
Nelson, Ann Marie
T.B.P.366, Th.G.O.32
Nelson, Kenrad E.
M.A.O.9, M.A.P.34, T.A.P.58, W.B.P.7, Th.D.P.79
Nelson, M. Bud
Th.C.P.121
Nelson, Mark R.
M.B.P.209, W.B.P.17
Nelson, Robert P.
Th.B.P.138
Nera, Nena M.
M.D.P.46, T.E.P.54, T.E.P.55, Th.B.P.27, Th.B.P.35
Neslund, Verla S.
Th.F.O.4
Neumann, Peter W.
Th.C.O.48
Newell, Marie-Louise
Th.A.O.4
Newell, Mark E.
M.B.P.122
Newell, Murray C.
W.E.P.42
Newsome, Glenn S.
M.B.P.208
Ng, Timothy
M.H.P.1
Ng, Valerie L.
Th.C.P.54
Ngugi, Elizabeth
M.G.O.32
Nichols, David L.
Th.B.O.58
Nichols, Douglas J.
W.E.P.71
Nichols, Larry C.
T.B.P.22, W.B.O.33
Nichols, Margaret
T.A.P.104, W.A.P.93
Nicol, Isabelle
W.C.P.3
Nicolas-Randegger, Joëlle
Th.H.P.22
Nicolau, Claude
M.C.P.102
Nicolosi, Alfredo
T.A.P.41
Niedrig, Matthias
T.C.P.65
Nielsen, Peder B.
Th.C.P.143
Nielsen, Thyge Lynghj
M.B.P.259, T.B.P.24
Niese, Detlef
T.A.P.110
Nightingale, Stephen D.
T.B.P.56, T.B.P.77
Niland, Joyce C.
Th.B.P.108
Nishanian, Parunag G.
T.C.P.46
Nixon, Douglas F.
T.C.P.23
Noël, Grégoire
W.B.P.30
Nokta, Mostafa A.
M.B.P.341
Nolan, Kathleen
W.F.O.6, W.F.P.6
Nooney, Kay
T.D.P.68
Norbeck, Daniel
M.C.P.65
North, Marie-Louise
M.A.P.118
North, Richard L.
M.F.P.2, T.F.P.8
Norton, Robert W.
Th.F.O.7
Norwood, Chris
M.E.P.40, W.E.O.24
Novati, Roberto
W.B.O.34
Novella, Antonia
M.H.P.20
Novick, David M.
M.B.P.243, T.A.P.48, W.D.P.71
Novick, Lloyd F.
W.A.O.8, W.H.P.10
Nozyce, Molly
M.B.O.41
Nsa, Wato
W.G.O.4, Th.G.O.34
Numazaki, Kei
W.C.P.64
Nussbaum, Joseph
M.B.O.49
Nyamongo, Jackton A.
W.B.P.173
Nyonyintono, Rebecca
Th.D.O.23
Nzila, Nzilambi
T.A.P.90, W.A.P.96

O

O'Brien, William A.
T.C.O.16
O'Doherty, Michael J.
T.B.P.67, T.B.P.79

O'Dowd, Mary Alice
W.B.P.214, W.B.P.216, W.B.P.217
O'Gara, Chloe
W.E.P.41
O'Reilly, Kevin R.
T.D.P.27
O'Shaughnessy, Michael V.
M.G.O.2, T.B.O.33, T.B.P.106, T.B.P.314, W.B.P.161
O'Sullivan, Anna
W.E.P.39
O'Sullivan, Mary J.
M.B.P.23
Ocaña, Inmaculada
M.B.P.67, M.B.P.98, M.B.P.260, T.B.P.289, W.B.P.28, Th.B.P.57
Ochsendorf, Falk R.
M.B.P.180, M.B.P.275
Odaka, Nancy J.
Th.A.P.91
Oddleifson, Stephanie
T.A.P.74
Odehouri, Koudou
T.B.O.10
Oelman, Bruce J.
M.D.P.12, T.G.P.30
Ofusu-Barko, Kenneth
Th.G.O.43
Ohi, Gen
M.E.P.18
Ohlsson-Wilhelm, Betsy M.
T.B.P.83, T.B.P.313
Ohnota, Hideki
M.C.P.108
Ohta, Yoshihiro
M.C.O.6, W.C.P.2
Oksenhendler, Eric
M.B.P.295, T.B.P.273, T.B.P.280, W.B.P.25
Okubo, Susumu
Th.B.P.25
Okware, Ikwaras S.
Th.G.P.18
Olgiati, Marco
T.A.P.34
Olin, Robert
W.D.O.7, W.D.P.76
Oliver, Christopher
Th.B.P.298
Olivier, Clément
T.F.O.16
Ollo, Christine L.
Th.B.P.295
Olmsted, Robert A.
W.C.O.30
Olvier, René
W.C.O.9
Omar, Bagasra
W.C.P.86
Ong, Kenneth R.
M.C.P.142
Ono, Katsuhiko
M.C.P.144
Onorato, Ida M.
M.A.P.5, W.A.P.119
Onyango, Philista
T.F.O.21
Operskalski, Eva A.
Th.A.P.105
Opravil, Milos
T.B.P.50
Orenstein, Jan Marc
W.B.O.38
Oreste, Pierluigi
M.B.P.294
Orgad, Shlomit
Th.G.P.6
Orholm, Marianne K.
Th.B.P.80
Orkin, Andrew
M.G.P.30
Oroszlan, Stephen
M.C.P.66
Orrett, Fitzroy A.
M.D.P.47
Ortiz de LejaRazu, Rául
M.A.P.21
Osborn, June
M.F.O.10
Osmond, Dennis
M.A.P.100
Ostrow, David G.
W.A.P.115, W.B.P.67, Th.E.P.30
Otake, Toru
M.C.P.79
Otis, Joanne
M.D.P.27
Ou, Chin-Yih
T.C.P.82, Th.A.P.114
Ouattara, Antoine
T.B.P.368
Over, Mead
M.G.O.31, T.H.O.15, W.H.P.12
Overbaugh, Julie
W.C.O.13
Overs, Cheryl M.
M.F.P.8, Th.D.P.91
Oxtoby, Margaret J.
W.A.O.17, W.G.P.9
Oyaizu, Naoki
T.C.P.53
Oyewo, Edward A.
W.E.P.51

P

Paalman, Maria E.
W.F.P.7
Pachucki, Constance T.
W.B.P.268
Padian, Nancy S.
T.A.O.16, T.A.P.93, T.A.P.94
Pagels, William R.
T.B.P.137, T.B.P.138
Pal, Ranajit
Th.C.P.43
Palefsky, Joel
Th.C.O.36
Palenicek, John G.
W.A.P.40
Palha de Sousa, Cesar A. D.
M.B.P.327
Palmer, William A.
M.E.P.36, M.E.P.43
Paltiel, Freda
W.E.O.13
Pan, Li-Zhen
Th.C.P.50
Panicali, Dennis L.
M.C.P.16, M.C.P.47
Panlilio, Adelisa
Th.A.P.47
Panmoung, Wattana
T.B.P.221
Pantaleo, Giuseppe
W.C.O.39
Papadopoulos, Antonios I.
W.B.P.342
Papadopoulos, Nicholas
W.B.P.90
Pape, Jean
W.G.O.9
Pape, Jean W.
Th.G.O.49
Papillon, Françoise
Th.B.P.64
Pappaioanou, Marguerite
W.A.O.12, Th.A.O.12
Pappas, Les G.
Th.E.O.6
Parimi, Prabhakar
T.F.P.5
Parish, Kathy L.
Th.B.P.33
Park, Lawrence
W.A.P.69
Parker, David
T.C.P.86, Th.C.P.124
Parker, Elizabeth S.
Th.B.P.277
Parker-Martin, Jeannee
W.B.O.16
Parkin, Neil T.
T.C.P.87
Parks, James M.
M.B.P.78
Pass, Carol L.
T.D.P.30
Paterlini, Patricia
M.B.O.6

Patron-reese, Janie
T.D.P.22
Pattanayak, S.
T.G.O.28
Patten, John T.
M.E.O.14
Pau, Chou-Pong
W.B.P.112
Paul, David B.
Th.B.P.111
Paul, Morris O.
M.B.P.101
Paulous, Sylvie
Th.C.P.140
Paulson, Yana J.
T.B.P.61
Pauza, C. David
M.C.O.19
Pavlakis, George N.
T.C.P.139, W.C.O.22
Pavri, Khorshed M.
T.C.P.147, T.G.O.26
Payne, Susan F.
M.D.P.26, W.A.P.13, W.A.P.80
Pazin, George J.
M.B.P.338, W.B.P.303
Peakman, Mark
Th.B.P.127
Pean, Claude
Th.B.P.70
Pearson, Andrew P.
M.C.P.132
Peckham, Catherine
M.B.O.1, T.B.O.17, Th.A.O.3
Peddecord, K. Michael
T.B.P.339
Peden, Keith
T.C.P.114, T.C.P.115
Pedergnana, Maurice R. H.
Th.H.P.4
Pedersen, Court
T.A.O.30, W.B.O.31, Th.B.O.46
Pedro, Rogerio J.
M.B.P.93
Pedroza-Martins, Livia
W.C.P.20
Peeters, Martine
T.C.P.100, W.B.P.107, W.C.P.40, Th.B.O.54
Pegge, John V.
T.E.O.15
Peixinho, Zulma
W.B.P.115
Pekovic, Drasko D.
W.C.P.94
Pela, Ona A.
W.G.P.17
Pepin, Jacques
T.G.P.32
Perales, Cesar A.
T.E.O.1
Pérard, Dominique D.
T.D.P.10
Perdices, Michael
Th.B.P.266
Pereira, Rosemarie
M.C.O.30
Perez Rguez, Gustavo
T.B.P.193
Perez, Alvarez Lucia
T.B.P.229
Perez, Victor L.
W.C.P.87
Perine, Peter L.
Th.G.P.30
Perlman, David C.
M.B.P.90
Perno, Carlo-Federico
M.C.P.49, Th.C.O.17
Pero, Robert T.
Th.A.O.10
Perrault, Roger A.
T.B.P.350
Perreault, Michel
Th.E.O.18
Perriens, Joseph H.
M.B.O.17, M.B.O.38, Th.B.P.211
Perroni, Luigi
T.A.P.113
Perronne, Christian M.
M.B.P.179, T.B.P.319
Perry, Samuel W.
W.B.P.180, Th.E.P.9
Pert, Candace B.
M.C.P.92
Perucci, Carlo Alberto
T.A.P.5, W.E.P.45
Pesce, Alain
W.B.P.44
Peterman, Thomas A.
M.A.O.30, W.A.P.17
Peters, Barry S.
M.B.P.239, M.B.P.326
Peters, Malte
W.B.P.299, Th.B.P.73
Petersen, Heidi M.
T.A.P.100
Petersen, Lyle R.
M.A.O.5, M.A.P.32
Peterson, Denton R.
Th.A.P.73
Peterson, Eskild A.
W.B.P.287
Peterson, John L.
W.D.P.27
Peterson, Marvelu R.
M.F.O.2
Peterson, Peggy L.
M.D.P.39
Petitgirard, Anne
W.E.P.5
Petricciani, J.
W.B.O.48
Pettersson, Elisabeth
Th.D.P.21
Petteway, Stephen R.
W.C.O.11
Peuchmaur, Michel
Th.B.P.92
Peugeot, Renée L.
W.B.P.65
Pezzella, Mario
Th.C.P.99, Th.C.P.111, Th.C.P.146
Phair, John P.
M.A.O.44, M.B.P.380, W.B.P.164
Phanuphak, Praphan
M.D.P.50, T.G.O.25
Phelps, Ann F.
W.A.P.20
Pial, G.
W.E.O.21
Pialoux, Gilles
M.B.P.362
Piazza, Paolo A.
W.C.P.28
Pichuantes, Sergio
M.C.P.84
Pickering, John
Th.A.P.50
Piedimonte, Giuseppe
Th.C.P.4
Pierone, Gerald
T.B.O.6, T.B.P.48
Piersantelli, Nicoló
Th.B.P.51
Pieters, Stephen A.
W.E.O.31
Pileri, Stefano
M.B.P.256
Pincus Strom, Diane
M.E.P.62
Pineda, Juan A.
W.B.P.165
Pinel, Arletty
M.G.O.8, T.D.P.78, Th.G.O.10, Th.G.O.39
Pinter, Abraham
T.C.P.70, Th.B.P.8
Piot, Didier F.
M.B.P.377
Piot, Peter
M.A.O.32, T.G.O.2
Piotrow, Phyllis T.
M.E.O.12
Pittman-Lindeman, Mary A.
T.H.O.4, T.H.P.9
Pivar, Iiona L.
T.B.P.329

Pizzo, Philip A.
T.B.P.247
Plaeger-Marshall, Susan F.
T.C.P.31
Plascencia, Rosalina
T.G.O.16
Platt, Denise
M.E.P.56
Plaut, Rabbi Gunther
W.F.O.15
Pleak, Richard R.
Th.D.O.8
Plettenberg, Andreas
M.B.P.234, Th.B.P.329
Plotnikoff, Nicholas P.
W.B.P.294
Pluda, James M.
W.B.P.329
Plummer, Francis A.
T.A.O.25, T.A.P.87
Poblete, Rita
M.B.P.287
Podzamczer, Daniel
M.B.P.43, M.B.P.176, Th.B.P.327
Pohlman, Hans
M.B.P.35
Pokapanichwong, Waranee
Th.D.O.1
Pokrovsky, Andrey G.
T.C.P.144
Pokrovsky, V. V.
W.A.O.5
Poli, Guido
W.C.P.106, W.C.P.107, W.C.P.108
Polis, Michael A.
M.B.P.128
Pollak, Michael
T.A.P.19, T.D.P.47, T.E.O.13, T.E.P.6
Polonis, Victoria
T.C.P.29
Polsky, Bruce
M.C.P.131
Pompidou, Alain
M.F.O.9, T.B.O.15
Poole, Lauren E.
W.D.P.53
Poon, Man-Chiu
W.B.O.27
Popesco, Matei A.
W.B.O.9
Portegies, Peter
Th.B.P.210
Potash, Mary Jane
W.C.P.132
Potter, Bill D.
M.H.P.23
Pottier, Bernard
W.H.O.5
Poulin, Louise
T.C.P.132
Poulsen, Anne-Grethe
T.G.P.31, Th.B.P.156
Pounders, Steven M.
W.B.P.347
Pousson, Rachel A.
M.E.P.52, Th.D.P.54
Powderly, Kathleen E.
T.F.P.12
Powel-Griner, Eve E.
Th.E.P.5
Praats, Christ'l
M.A.P.49
Pradinaud, Roger A.
M.B.P.181
Prensky, Wolf
W.B.P.177
Price, Richard W.
W.B.P.331, W.C.P.45, Th.B.P.197
Price, William A.
Th.B.P.30
Priebe, Bruce A.
W.B.P.253
Priel, Esther
T.C.P.119
Prieto, Cecilia
T.B.P.236
Prince, Harry E.
T.C.P.63
Pristerá, Raffaele
Th.B.P.245
Profy, Albert T.
Th.C.O.29
Prose, Neil S.
T.B.P.149
Proulx, Andrée L.
W.B.P.148
Prum, Bernard
Th.A.P.99
Psallidopoulos, Miltiades
M.C.O.10
Puel, Jacqueline M.L.
M.A.P.46, T.B.P.90, T.B.P.219, T.B.P.222, T.B.P.242, W.B.P.155
Pugh, Bradley L.
W.A.P.95
Pulik, Marc
M.B.P.197, Th.B.P.336
Purchase, David
Th.D.P.74
Purifoy, Dorothy J.
T.C.O.4
Putkonen, Per
W.C.P.141
Putney, Scott D.
W.C.O.18, Th.C.O.50

Q

Quackenbush, Marcia J.
M.B.P.318, M.E.P.59, W.E.P.46
Qualtiere, Louis F.
M.C.P.147, T.B.P.111
Quart, Arthur M.
Th.B.P.331, Th.B.P.352
Queener, Sherry F.
M.B.O.13
Quinhoes, Eleonora P.
M.B.P.182, T.B.P.364, T.B.P.369, Th.D.P.89
Quirk, John F.
W.D.P.18
Quirk, Mark E.
M.D.P.8

R

Raben, David
Th.C.P.62
Rabson, Arnold B.
M.C.P.95, T.C.O.12, T.C.P.94
Rachlis, Anita R.
W.B.P.360
Rácz, Paul
W.C.P.117, Th.C.O.8
Rader, Alison D.
W.E.O.26
Radford, Joyce L.
M.D.O.8
Raevsky, Catherine
W.A.P.85
Ragni, Margaret V.
W.B.O.24
Rahman, Abid
Th.A.P.95
Raineri, Ines
Th.A.P.111
Raise, Enzo
M.A.P.94, W.B.P.340
Raja, D.V.P.
W.F.O.14
Ralin, Peter L.
T.E.P.58
Ramah, Michael L. E.
T.G.P.12
Ramos Filho, Celso F.
T.B.O.7
Ramos, Silvia
W.E.O.16
Ramsey, Keith M.
T.C.P.54
Rango, Nicholas A.
M.H.O.16, Th.E.P.69
Ranieri, Sergio
T.B.P.363
Rappaport, Jay, F.
T.C.O.31, T.C.P.89

Rarick, Mark U.
M.B.O.48, W.C.P.49
Rasheed, Suraiya
Th.A.P.11
Ratner, Lee
M.C.P.90, T.C.P.95, T.C.P.120, T.C.P.121
Rausch, Dianne M.
T.C.P.90
Rautenberg, Ellen
M.A.O.43
Raviglione, Mario C.
M.B.P.72, M.B.P.89, Th.B.P.41
Rawal, Bhupat
M.B.P.169
Rayfield, Mark A.
Th.A.P.109
Read, Stanley E.
M.B.P.315, W.C.O.24, Th.B.O.26, Th.B.P.373
Rebus, Selma
Th.C.P.126
Rector, Richard
T.E.P.71
Reddy, Mohan M.
M.B.P.360
Redfield, Robert R.
T.B.O.22, W.A.P.66, Th.C.P.133
Reed, Christie M.
Th.D.P.26
Reed, David E.
T.B.P.287
Rees, Malcolm S.
W.H.P.19
Reesink, H. W.
T.B.P.323
Regeniter, A.
M.B.P.105
Rehmet, Sybille
T.B.P.200
Reid, Stewart
M.B.O.33
Reining, Priscilla
T.A.P.86
Reinisch, June M.
T.D.P.2, Th.E.P.37
Reinvang, Ivar
Th.B.P.215
Reis, Myriam
T.B.P.336
Reisbeck, Günter
T.D.O.34
Reisinger, Emil C.
W.B.P.89, W.B.P.297
Reiss, Ira L.
Th.E.P.54
Reiter, William M.
T.B.P.315
Reka, Safak
M.C.O.27, W.C.P.131
Rekart, Michael L.
M.A.P.115, T.A.P.84, T.D.P.8, Th.A.P.38, Th.E.O.4, Th.E.P.25
Remien, Robert H.
T.B.P.192, W.B.O.41, W.B.P.244, W.D.P.67
Remington, Jack S.
M.B.O.28
REMIS, Robert S.
T.A.O.1, W.A.O.14, W.A.P.42
René, E.
M.H.P.4
Renzullo, Philip O.
M.A.O.3, Th.A.P.103
Representative WHO (Geneva),
M.F.O.12
Resnick, Lionel
M.C.P.86, M.C.P.87
Reuben, James M.
Th.B.P.104
Rey, Françoise
Th.C.O.27
Rey, Marie-Anne
T.C.O.36
Reynes, Jacques
W.B.P.32
Rezvan, Houri
T.G.P.20
Rezza, Giovanni
W.D.O.8, Th.D.P.39, Th.D.P.40
Rhame, Frank S.
W.B.P.289, W.C.P.81
Rhoads, Joanne
T.C.P.28, Th.B.P.120
Rhodes, Fen
T.E.P.15
Rhodes, Tim J.
M.D.O.18
Ribas, Jorge L.
W.C.P.147
Ribble, Denise J.
W.D.O.15, W.A.P.10, W.D.P.40
Ribeiro, Sandra A.
Th.B.P.63
Ricard, Dominique
T.G.P.29
Ricchi, Ennio
M.B.P.118, W.A.P.43
Rich, Kenneth C.
T.B.P.206
Richardson, Mark
M.C.P.35
Richman, Douglas
T.B.O.16
Richter, Donna L.
Th.D.P.11
Rickard, Ema
T.B.P.139, Th.G.P.21
Rickman, William J.
Th.B.P.146
Riedel, Rolf R.
W.B.O.42, Th.B.P.192
Riley, Diane M.
M.E.P.25, Th.D.P.85
Rinaldo, Charles R.
T.C.P.26
Ringenberg, Roy A.
M.G.O.28, W.G.P.12
Ripich, Stefan J.
W.B.P.376
Rise, Jostein
T.E.P.31
Risi, George F.
Th.A.P.49
Ritter, Jacques
Th.B.P.169
Rivière, Yves
W.C.O.44
Rizzi, Marco
M.A.P.95
Robb, Merlin L.
T.C.P.66
Robert, Claude F.
Th.D.P.80
Robert, Jean
T.F.O.15, W.G.O.40
Roberts, Chester R.
Th.B.O.57
Roberts, James W.
M.B.P.273
Roberts, Michael
T.C.P.135
Roberts, Richard B.
M.C.P.88, Th.B.O.1
Robins, James
Th.A.P.72
Robinson, James E.
Th.C.O.3
Robinson, W. Edward
Th.C.P.45, Th.C.P.129
Rodrigues, José F.
W.B.P.237
Rodrigues, Lair G. M.
T.D.O.28, T.D.P.54, W.G.O.15, W.G.O.23
Rodriguez, Kassandra
T.B.P.69
Rodriguez-Trias, Helen
T.E.P.40
Rogers, Martha F.
M.B.O.4, T.B.O.19
Rogez, Jean Philippe
T.B.P.382
Roilides, Emmanuel
Th.B.P.89
Roland, Michelle E.
M.D.P.76

Rolston, Kenneth V. I.
M.B.P.66, M.B.P.129, W.B.P.37
Romaguera, J.
M.B.P.27
Romieu, Isabelle
T.G.P.27, Th.A.P.81
Ronald, Allan R.
W.B.O.46, Th.H.P.8
Rooke, Ronald
T.C.P.111
Roos, Marijke T. L.
Th.B.P.87
Rose, David N.
Th.A.P.45
Rose, Loree V.
W.E.P.67
Rose, Thanne P.
W.B.P.53
Rosenberg, Philip S.
T.A.O.35
Rosendahl, Carla
T.B.P.163
Rosenheim, Michel
M.A.P.119, Th.G.P.7
Rosenstraus, Maurice J.
Th.C.P.24
Rosenthal, Eric
T.E.O.16
Rosenthal, Jonathan H.
M.B.P.84
Rosenthal, Kenneth L.
M.C.P.21
Ross, Lawrence A.
T.B.P.267
Ross, Paul A.
T.H.P.29
Rossi, Luisa
Th.D.P.88
Rossi, Paolo L.
Th.A.P.113
Rossol, Siegbert
M.B.P.220, Th.B.P.98
Rote, Kevin V.
W.B.P.134
Rotheram-Borus, Mary Jane
T.D.P.12
Rotterdam, Heidrun
M.B.P.127, M.B.P.293
Roué, René
T.B.P.309, W.B.P.282
Rougeot, Catherine
Th.B.P.241
Roumeliotou, Anastasia
W.A.P.37
Routy, J.-P.
T.B.P.277, T.B.P.305, W.B.P.43
Roux, Patricia
T.B.P.1, T.B.P.4
Rouzioux, Christine
T.B.O.32, Th.C.P.7, Th.C.P.21
Rowe, Bill
T.E.P.8
Rowe, Ian F.
M.B.P.262
Rowe, Mona J.
M.F.O.3, W.H.O.11
Rowell, Ronald M.
T.D.O.13
Rowley, Jane T. F.
T.H.O.16
Roy, Charles M.
Th.B.P.29
Roy, David J.
T.F.O.10
Roy, Denis
W.A.P.83
Roy, Sophie
T.C.O.27
Royal, Walter
Th.B.P.206
Royce, Rachel A.
Th.A.P.84, Th.B.P.75
Rozenbaum, Willy
M.B.P.132, T.B.O.25, T.B.P.283
Rubin, Howard C.
M.E.P.72, Th.E.P.66
Rubin, Robert H.
W.B.P.1
Rubini, Norma P. M.
T.B.P.190
Rubinstein, Arye
M.B.P.7, Th.C.P.91
Rübsamen-Waigmann, Helga
Th.C.O.24
Ruedy, John
M.B.O.47, W.B.O.1, Th.B.O.49
Ruf, Bernhard
T.B.P.21, W.B.P.34, W.B.P.300
Ruff, Andrea J.
T.B.P.256, Th.B.P.368, Th.G.P.2
Ruffault, Annick
W.B.P.75
Rugg, Deborah L.
M.E.P.30
Rukarangira, Wa Nkera
M.E.O.33, W.D.P.90
Rumi, Mariagrazia
M.C.P.43
Rundell, James R.
W.B.P.228
Ruprecht, Ruth M.
M.C.P.51, W.C.P.29, Th.C.O.49
Ruscetti, Francis W.
T.C.P.33
Rust, Michael G.
M.B.P.210
Ruta, Martin
Th.C.P.119
Rutherford, George W.
T.A.O.32, W.A.P.27
Ryan, Caitlin
Th.E.O.12
Ryder, Robert W.
M.A.O.35, M.B.P.31, T.B.P.181
Ryder, Robin
M.G.O.21

S

Saah, Alfred J.
T.A.O.29, Th.G.O.28
Saalfield, Catherine G.
M.E.P.21
Sabbaj, Steffanie
T.C.P.27
Sabbatani, Sercio
Th.H.P.25
Sabbatier, René
M.F.O.20
Sacchi, Giuseppe
T.B.P.269
Sacharski, Eileen
T.B.P.154
Sacks, Henry S.
W.F.P.3
Sadaie, Reza M.
Th.C.P.20
Sadler, Abigail E.
W.B.P.256, W.B.P.259
Safrin, Sharon
M.B.P.48, M.B.P.54
Sagawa, Kimitaka
Th.C.P.141
Saimot, Adrien G.
W.B.P.26
Saint Cyre-Delpe,
Th.D.P.27
Saint-Marc, Thierry
W.B.P.55, Th.B.P.247
Sakuntanaga, Pratlom
W.D.O.11
Salame, Elisa
W.D.P.14
Salamon, Roger
Th.E.P.16
Salas, Ana
M.B.P.97
Salazar, Andres M.
Th.B.O.45
Sall, Richard K.
M.B.P.49
Salla, Roger
T.G.P.10
Salmaso, Stefania
T.A.P.38

Salmon, Dominique
W.B.P.36
Salmon, Patrick
Th.C.P.67
Saltzman, Brian R.
M.B.P.87, Th.F.P.14
Saltzman, Scott P.
T.D.P.31
Saman, Eric
T.C.P.149, W.B.P.105
Sampson, James M.
T.B.P.36
Samson, Johanne
T.B.P.151
Samson, Susan
M.A.P.30
Samuels, Jonathan E.
T.B.P.52, W.B.P.343
Samuelson, Agneta B.
W.B.P.129
Samundi Sankari, Selvamani
Th.G.P.24
Sanchez, Gerardo F.
M.G.P.17
Sandblom, Anita
W.E.O.15
Sande, Merle
M.B.O.29
Sanders, Stephanie A.
T.D.O.21, T.D.P.75
Sandström, Eric
W.B.P.83
Sangare, Lasanna
Th.G.O.26
Sanjana, Veeraf M.
W.B.P.5
Sankale, J.-L.
T.G.O.4
Sankary, Timothy M.
T.D.P.6, W.A.O.30
Sansom, Eva I.
W.B.P.243
Santos-Ferreira, Maria Odette
M.A.P.84
Santos-Pinto, A.
T.B.P.343
Sanusi, Sahid
M.B.P.238
Saracco, Alberto
M.A.P.48, T.A.P.99
Saravolatz, Louis D.
Th.A.P.9, Th.A.P.10
Sarver, N.
M.C.P.58
Sathe, Sadhana S.
Th.B.P.48
Sato, Paul
T.G.P.7
Satzinger, Walter
M.E.P.57
Saunders, Susan G.
W.E.P.30, W.E.P.64
Sauvageon-Martre, Hélène
M.B.P.323, M.C.P.57
Savage, Donald C.
Th.F.P.7
Sawchuk, Ronald J.
Th.B.P.198
Sawyer, Leigh A.
T.B.P.281
Saxinger, Carl
M.A.O.17
Saxon, Andrew J.
W.D.P.85
Saykin, Andrew J.
W.B.P.224
Scalia, Vito
M.B.P.174
Scevola, Daniel
M.B.P.232, Th.B.P.299
Schable, Charles A.
W.B.P.160
Schaefer, Melodie R.
W.D.P.72
Schaeffler, Barbara A.
M.G.O.4
Schaerf, Frederick W.
W.B.P.189, W.B.P.220, W.B.P.227
Schäfer, Axel
M.B.P.21, Th.D.P.86
Schäffer, Ian
M.E.O.26
Schaiken, John J.
W.B.P.132
Schalla, William O.
T.B.P.143
Schatz, Benjamin H.
M.F.P.1, T.E.O.14
Schecter, Martin T.
W.A.O.6, W.A.P.57
Schedel, Ingolf
T.B.P.334
Scheffel, James W.
W.B.P.135
Scheib, Rochelle
W.B.P.271
Schenker, Inon, I.
T.E.P.13, W.E.P.47
Schiantarelli, Clara
M.A.P.63, Th.B.P.194
Schick, Uta
W.B.P.235
Schiff, Robert
M.B.O.27
Schilling, Robert F.
Th.D.O.15, Th.D.P.42
Schinaia, Nicola
T.B.P.345, T.B.P.346
Schinazi, Raymond F.
M.C.P.55
Schindler, Stephen E.
T.E.P.74
Schidt, Morten
Th.B.P.347
Schlech, Walter F.
M.D.P.79, T.B.P.268, W.B.O.10, Th.A.O.28
Schlenzig, Celia A.
T.B.P.301
Schmidt, Robert M.
T.D.P.29, W.B.P.77, W.E.P.26, Th.E.P.55
Schneeberger, Claudie
M.B.P.316
Schneider, D. Jean
T.A.P.66
Schnittman, Steven M.
W.C.P.62
Schnizlein-Bick, Carol T.
T.C.P.52
Schnurbus, Ralf
Th.B.P.275
Schochetman, Gerald
T.B.O.36
Schoepf, Brooke G.
W.E.P.3, Th.E.P.40
Schöfer, Helmut
M.B.P.111, T.B.P.316
Schooley, Robert T.
Th.B.O.6
Schoub, Barry David
Th.G.P.15
Schramm, Carl
W.H.O.3
Schrappe-Bächer, Matthias
W.B.P.291
Schull, Diane E.
M.B.P.302
Schulman, Sam
Th.B.P.6, Th.B.P.15
Schulof, Richard S.
Th.B.O.2
Schulten, Engelbert
Th.B.P.321
Schultz, Alan M.
M.C.P.27
Schulz, Susan Lloyd
M.D.P.43
Schulz, Thomas F.
Th.C.P.11
Schüpbach, Jörg
T.B.P.226, Th.A.P.107
Schürmann, Dirk
W.B.O.20, Th.B.P.54
Schwartländer, Bernhard
W.A.P.74, W.H.P.23, Th.B.P.172, Th.B.P.183
Schwartz, Olivier
M.C.P.104
Schwartzer, Thomas A.
Th.B.P.125
Schwarz, Gabriele
M.E.P.38

Scitovsky, Anne A.
M.H.P.2, W.H.O.14
Scolaro, Michael J.
T.B.O.1, T.B.P.276
Scott, Daniel
T.C.P.35, W.C.O.6
Scott, Daniel A.
Th.C.P.57
Scott, Gordon R.
Th.B.P.291
Scott, Gwendolyn B.
M.B.O.40, T.B.O.21, T.B.P.153, T.B.P.166, Th.A.O.8
Scribailo, Steven
M.E.O.18
Seage, George R.
Th.A.O.16, Th.A.P.42
Sealy, Godfrey
M.E.O.5
Sears, Barry
Th.B.P.381
Seck, Moussa
M.E.O.32, W.G.O.35
Seiden, Dena J.
T.F.P.4
Seidl, Siegfried
W.B.P.103
Seidlin, Mindell
T.A.O.17
Seigneurin, Jean-Marie
M.B.P.61
Seki, Jun-ichi
M.C.P.121
Selik, Richard M.
T.A.O.4, T.A.P.37
Selnes, Ola A.
W.B.O.45, Th.B.P.202, Th.B.P.271
Seltzer, Michael S.
T.H.P.25
Selwyn, Peter A.
W.B.P.60, Th.A.O.24, Th.D.O.16, Th.D.P.78
Sena, Armando
Th.B.P.363
Senie, Ruby T.
Th.A.O.15
Sepiashvili, R. I.
W.B.P.262
Sepkowitz, Kent
M.B.P.207
Septimus, Anita
M.E.P.34
Sepulveda, Jaime
M.G.O.1, T.G.O.9, W.G.P.24
Serfaty, Annie
T.E.P.37
Serraino, Diego
M.A.O.38
Serrano, Yolanda
W.D.O.12, Th.D.P.66
Serre, Arlette
Th.B.P.97
Serwadda, David
M.G.O.14
Sestak, Phil
M.A.O.26
Seth, Pradeep
T.G.P.6
Seto, Deborah
Th.C.P.47
Seyrer, Yann
M.D.P.36
Shadduck, Phillip P.
T.C.P.49
Shafer, Robert W.
Th.B.P.50
Shafik, Hasnaa M.
T.B.P.322
Shah, Pramod M.
M.B.P.76
Shaira-Nahor, Orit
T.C.P.48
Shandera, Wayne X.
W.A.P.45
Shank, Peter R.
T.C.P.113
Shanmuganandan, S.
M.D.P.90, M.G.P.31, Th.E.P.60
Shannon, William M.
M.C.P.125
Shao, John
M.G.O.33
Sharer, Leroy R.
W.C.P.30
Sharp, Erica S.
M.A.P.17
Sharp, Victoria L.
T.B.P.18
Sharpton, Thomas
T.B.P.327
Shaunak, Sunil
W.B.O.12
Shelp, Earl
W.F.O.9
Shepard, Donald S.
T.H.O.12
Shepp, David H.
W.B.P.333
Sheppard, Haynes W.
Th.A.P.40, Th.A.P.90
Sher, Ruben
W.E.P.28, Th.B.P.161
Sherer, Renslow
M.B.P.47, W.A.P.113, W.B.P.260, Th.B.P.49
Sherlock, Christopher H.
W.B.P.172
Sherr, Lorraine
W.D.P.12, Th.E.P.27
Shiboski, Stephen C.
T.A.P.95
Shih, James W.
W.B.P.122
Shimizu, Hiroyuki
M.C.P.134
Shin, Diana M.
M.D.P.77
Shioda, Tatsuo
Th.C.P.110
Shneck, Mary
M.B.P.29
Shoaib, Ibrahim M.
W.E.P.75
Shockley, Robert K.
T.B.P.136
Shore, Jacques J. M.
Th.F.P.5
Shtarkshall, Ronny A.
T.E.P.72, W.E.P.35, W.H.P.24
Sia, Dwo Yuan
M.C.P.41
Siby, Tidiane
M.A.P.117, W.G.O.20
Sidtis, John J.
T.D.P.58, W.B.P.255, Th.B.O.24
Siegel, Bary J.
T.B.P.379
Siegel, Joanna E.
Th.A.P.70
Sifris, Dennis
W.D.P.47
Signorini, Dario J.H.P.
W.A.P.51
Silverman, Sol, Jr.
Th.B.P.341
Simader, R.
M.B.P.374
Simberkoff, Michael
W.D.P.25
Similowski, Thomas
W.B.O.22
Simmonds, Peter
T.C.P.92, Th.C.P.69
Simon, François
T.B.P.109, Th.C.P.131
Simonds, Anita
T.B.P.65
Simpson, David M.
M.B.P.330
Sinangil, Faruk
Th.C.P.17
Singh, Surinder
M.D.P.86, M.H.P.3
Singlas, Eric
M.B.P.344
Sinicco, Alessandro
M.B.P.194, M.B.P.219, Th.B.P.344

Sion, Fernando S.
T.A.P.117, W.A.P.70
Sioufi, Habib A.
M.B.P.138
Sire, Joséphine
T.C.P.91
Sittitrai, Werasit
M.D.P.19, W.E.P.14, Th.G.O.9
Sivile, E.
Th.H.P.13
Skahan, Kenneth J.
M.B.P.73
Skidmore, Carol A.
T.A.P.31, W.D.P.75
Skidmore, Susan J.
W.B.P.87
Skillman, Donald R.
T.C.P.30
Skinner, Michael A.
T.C.O.29, T.C.P.93
Skolnik, Paul R.
Th.C.P.13
Skoutelis, Athanasios
M.B.P.86, T.B.P.31
Sligh, Julie M.
Th.B.P.112
Slikkerveer, L.
M.G.O.9
Slim, Jihad
T.B.P.2, T.B.P.15, T.H.P.10, W.B.P.42, W.B.P.336, Th.B.P.380
Slutkin, Gary
W.G.O.25
Smith, Alan
T.C.O.6
Smith, Camilla M.
M.C.P.73
Smith, Don E.
M.B.P.175, T.B.O.30, T.B.P.64, T.B.P.66, Th.B.P.328
Smith, Donald G.
M.B.P.312
Smith, Else
M.B.P.79, W.B.P.27, W.D.P.55
Smith, George W.
Th.E.P.49
Smith, James R.
M.B.P.292
Smith, James W.
M.C.P.46
Smith, Marilyn S.
M.C.P.82
Smith, Mark
M.H.O.6
Smith, Perry F.
T.A.P.80, Th.D.P.16
Smith, Phillip D.
W.C.P.68
Smith, Stephen C.
M.F.P.5, T.E.P.48
Snart, Ronald S.
T.C.O.15
Snee, Thomas H.
M.B.P.309
Snell, Cudore L.
W.D.P.31
Sninsky, John J.
Th.A.P.110
Snyder, Frederick R.
Th.D.P.30
Snyder, Harry W.
W.B.P.310
Sobel, Alain T.
W.B.P.364
Sobota, Michael
T.E.P.5
Sodroski, Joseph G.
M.C.O.22
Seberg, Bjm B.S.
W.B.P.290
Soeiro, Ruy
W.C.P.43
Sohlberg, Christian
Th.D.P.68
Sohler, M. P.
Th.B.P.189
Sojo, Diana J.
M.B.P.59
Sokal, David C.
Th.A.P.35
Sölder, Brigitte
T.C.P.12, T.C.P.68
Soler, Carmen
W.B.P.179
Solinger, Alan M.
M.B.P.178
Solomon, Liza
T.E.P.43, T.H.P.23
Somerville, Margaret A.
T.F.O.11
Sondag-Thull, Danielle
Th.E.P.21
Sonigo, Pierre
T.C.O.40
Sönnerborg, Anders B.
T.B.P.81, Th.B.P.226
Sorensen, James L.
Th.D.O.5, Th.D.P.84
Soriano, Vincent
M.A.P.81, Th.A.P.22
Soskolne, Colin L.
W.H.P.21, Th.A.P.74
Soskolne, Varda
W.E.P.1
Sotheran, J. L.
T.D.P.81
Soto, Julio C.
M.D.P.64
Soudeyns, Hugo
T.C.P.110
Soulimane, Abdelkrim
W.E.P.69
Sourdif, Isabelle
Th.F.P.2
Souterand, Yves
W.H.O.13
Soutschek, Erwin
Th.C.P.2, Th.C.P.73
Sowder, Barbara J.
W.D.P.57
Soyinka, F.
Th.D.P.20, Th.E.P.76
Soyinka, Femi
W.G.O.31
Späth, Peter J.
Th.B.P.134
Spear, Gregory T.
T.C.P.21, T.C.P.71
Spears, Alice
W.B.P.367
Specht, Norbert
T.F.P.9
Spence, Christopher
Th.E.P.71
Spencer, Brenda E.
W.A.P.100
Spencer, Nancy E.
W.A.O.21
Sperling, Rhoda S.
M.A.P.56
Spiers, Herbert R.
Th.F.P.10
Spina, Celsa A.
T.C.P.50
Spire, B.
Th.C.P.71
Sprenger, Herman G.
W.B.O.35
Sprengers, Erik D.
W.B.P.96, W.B.P.126
Sprinz, Eduardo
W.B.P.48, W.G.P.3, Th.B.P.36, Th.B.P.39
Srinivasan, Alagarsamy
Th.C.P.31, Th.C.P.32, Th.C.P.33
Ssebbenja, Peter
M.E.O.6, T.G.O.13
St-John, Ronald K.
T.G.P.2
St. Lawrence, Janet S.
W.D.P.29
St. Louis, Michael E.
M.A.O.2, M.D.P.1
Staats, Joanne
W.B.P.218
Stall, Ronald D.
W.D.P.70
Stallard, Anna
Th.D.P.81
Stambuk, Drago
M.B.P.264, T.B.P.326

Stanley, Elizabeth Ann
Th.A.P.71
Stanley, Samuel D.
M.C.O.17
Stanley, Sharilyn
W.C.P.137
Staszewski, Schlomo
T.A.O.15, T.B.P.73, W.A.P.3, W.B.P.334
Steffe, Erika M.
M.B.P.337, M.C.P.113
Steffen, Robert
M.D.P.25
Steger, Kathy A.
W.D.P.80
Stehr-Green, Jeanette K.
T.A.O.27, W.B.O.23
Stein, Barry S.
T.C.O.38
Stein, Robert E.
M.F.O.18
Stein, T. Peter
Th.B.P.305
Steinberg, Katherine E.
Th.E.P.57
Stellbrink, Hans-Jürgen
Th.C.P.88
Stempel, Robert R.
T.D.P.24
Stephens, Clay P.
Th.D.O.9
Sterk, Claire E.
W.D.O.5
Stern, Adam C.
M.H.P.6, T.H.O.3
Stern, Michael
Th.B.P.351
Stern, Susan A.
Th.G.P.12
Stern, Yaakov
W.B.P.192
Sterrano, Yolanda
Th.D.P.65
Sterzycki, Roman Z.
M.C.P.114
Stevens, Cladd E.
M.A.P.93
Stevens, Roy W.
M.A.O.18, T.A.P.53
Stewart, James L.
T.B.P.93
Stigum, Hein
Th.A.P.59
Stille, W.
Th.B.O.15
Stimson, Gerry V.
W.A.P.108
Stitt, Frank W.
W.A.P.72
Stone, Dace
T.G.P.13, T.G.P.22, W.E.O.17
Stoneburner, Rand L.
W.A.P.34
Stramer, Susan L.
M.B.P.140, M.B.P.164
Strapinski, A.
M.A.P.69
Strebel, Klaus
T.C.O.47
Stricker, Raphael B.
W.C.O.47, Th.B.O.19
Strosselli, Maurizio
Th.B.P.272
Struchiner, Claudio
M.G.P.4
Strunin, Lee
M.D.P.71
Stuart, Ann
M.E.P.35
Stuart, Marla L.
Th.A.P.106
Sufian, Meryl
W.E.P.68
Sulis, Efisio
T.B.P.292
Sullam, Paul M.
M.B.P.375
Sullivan, John L.
M.C.O.2, W.B.O.25
Sullivan, Timothy J.
Th.B.P.117
Sulzberger, Judith
W.B.P.285
Sum, Shirley Y. W.
Th.A.P.117
Sumaya, Ciro V.
Th.B.P.23
Sun, Di
Th.B.P.171
Sun, Nora C.J.
W.B.P.124
Sundararaman, Swaminathan
Th.E.O.13
Sunderland, Ann
W.D.P.58
Sundet, Jon Martin
W.A.P.103
Sunkara, Prasad S.
M.C.P.117
Sunstrum, James C.
M.B.P.147, Th.C.P.147
Surick, Ilona W.
T.A.P.89
Susser, Phyllis L.
M.E.P.42
Sutherland, Sheena
T.A.P.55
Suzan, Marie
Th.C.P.87
Svirska, Regina V.
T.B.P.342
Swales, Thomas P.
T.B.P.182
Swanson, Cheryl Elaine
W.B.P.350
Sweeney, Patricia A.
W.D.O.1
Sweet, Raymond W.
W.C.O.12
Swenson, Cheryl L.
M.C.P.68
Sy, Francisco S.
M.D.P.80, Th.D.P.25
Szebeni, János
M.C.P.42, T.C.P.58
Sztein, Marcelo B.
W.B.P.308

T

Tafoya, Terry
W.D.P.32
Tai, Chang-Chih
Th.C.P.25
Taillan, Bruno
M.B.P.250
Taitt, Branford
W.G.O.37
Takahashi, Ichiro
Th.C.P.145
Takasaki, Tomohiko
W.C.P.111
Takeda, Augusta K.
T.B.P.132
Takeuchi, Yasuhiro
Th.C.P.134
Tam, Janice Y.
M.B.P.334
Tamburini, Mario
W.B.P.117
Tamburrini, Enrica
M.B.P.230, Th.B.P.96, Th.B.P.99
Tang, Shen-Bei
Th.C.P.51
Tapia, Roberto C.
T.H.O.11
Tarantola, Daniel J. M.
W.G.O.18, Th.G.O.19
Tardieu, Marc
M.B.O.39, W.C.P.113
Tarpley, Gary
T.C.P.108
Tartaglione, Teresa
M.B.P.332
Taruscio, Domenica
Th.B.P.252
Tarussova, Natalya
T.C.P.145
Tavares, Luis
Th.B.P.123
Taylor, Clark L.
M.H.P.24
Taylor, Geoffrey D.
Th.H.P.6

Taylor, Kathryn M.
M.D.P.78, Th.E.P.53
Taylor, Patricia E.
Th.A.P.13
Taylor, Roger
T.B.P.142
Tedder, Richard S.
W.A.O.9
Teglbjærg, Lars L. S.
T.B.P.103, W.B.P.280
Telzak, Edward E.
M.A.O.34
Tembo, George S.
M.G.P.23
Temmerman, Marleen
Th.G.O.53
Temoshok, Lydia
T.D.O.29, T.D.P.13, T.D.P.44, W.B.O.44
Temu, Dorothy
T.F.O.21
Tenner-Racz, Klara
W.C.P.118
Terry-Molinet, Hector
W.F.O.19
Tersmette, Matthijs
M.C.O.8, W.C.P.46
Terstegge, Klaus
Th.B.P.274
Testa, Sofia
Th.B.P.2
Tetanye, Ekoe
T.A.P.1
Thea, Donald
W.C.P.102
Thibodeau, Lise
M.C.P.29
Thiele, Bernhard
Th.B.P.153, Th.B.P.154
Thimothe, Gabriel A.
W.G.P.31
Thirion, Xavier
T.F.P.3
Thomas, Pauline A.
Th.A.O.7
Thomas, Réjean
W.E.P.11
Thomas, Simon H. L.
T.B.P.57
Thomas, Steven G.
T.D.O.3
Thompkins, Jennifer E.
M.B.P.328
Thompson, Ian L.
M.B.P.278
Thompson, Imani P.
T.E.P.17
Thomsen, Donald L.
T.H.P.28
Thornton, Charles A.
Th.B.P.214, Th.B.P.217
Thornton, David
T.D.P.69
Thorstensson, Rigmor
T.B.P.104
Thum, Joseph R.
M.B.P.85, M.D.O.13
Tielman, Robert A.P.
M.D.P.34, Th.E.O.16
Till, Mark A.
Th.C.O.14
Timmerman, Arthur
W.B.P.116
Timothée, Gabriel
Th.G.O.46
Tindall, Brett D.
T.D.P.35
Tirelli, Umberto
M.C.P.103, W.A.P.59, W.C.P.50, Th.C.O.40
Titti, Fausto F.
W.C.P.119
Tivey, Bob
W.E.P.10
Tjtta, Enok
Th.C.P.112
To Be Announced,
T.H.O.14, W.B.O.50
Toma, Emil
M.B.O.14, T.B.O.31
Tomasselli, Alfredo G.
T.C.P.85
Toomey, Kathleen E.
W.A.O.22, W.D.P.26
Tor Aguilera, Jordi
T.D.P.65, Th.A.P.19, Th.D.P.57
Toro-Alfonso, José R.
Th.E.P.67
Torpey, David J.
T.C.P.5
Torre, Donato
Th.B.P.136
Torres, José
M.H.P.21
Torres, Ramon A.
M.A.P.51, T.B.P.75, T.E.P.57
Torres-Anjel, Manuel J.
W.C.P.14
Torres-Mendoza, Blanca
M.G.P.10
Torrey, Barbara B.
T.B.P.352
Tourani, Jean-Marc
W.B.P.355
Tourette-Turgis, Catherine
T.E.O.2
Tourtellotte, Wallace W.
Th.B.P.236, Th.B.P.292, Th.B.P.293
Tousignant, Yves
M.D.P.65
Træen, Bente
T.D.P.5
Traore, Bougary
T.B.P.41
Traub, Kit
T.G.P.15
Travis, William D.
T.B.P.16
Tremblay, Michel
Th.C.P.76
Tricoire, Joëlle
T.B.P.187, Th.B.P.9, Th.B.P.21
Triomphe, Annie
Th.H.P.11
Tripathy, Srikanth Prasad
M.B.P.139
Tristem, Michael
T.C.P.105
Troonen, Hugo
T.B.P.349
Tross, Susan
Th.D.P.17
Trotot, Pierre M.
M.B.P.41, M.B.P.196, Th.B.P.253, Th.B.P.254
Troussier, Thierry
T.E.P.23
Troutman, Adewale
M.D.O.11
Truman, Benedict I.
T.A.P.54
Tsai, Cheng C.
W.C.P.52, W.C.P.146
Tschechne, Barbara
M.B.P.299, M.C.P.143
Tsoukas, Chris M.
Th.B.O.33
Tsubota, Hiroshi
W.C.O.42
Tudiver, Fred G.
W.A.P.92
Tukei, Peter M.
T.B.P.134
Tullio Cataldo, Pietro
T.A.P.115, W.B.P.362
Tunving, Kerstin
W.D.P.65, Th.D.P.36
Turner, Barbara J.
M.H.O.11, T.H.P.4, W.A.P.33
Turner, Heather A.
T.D.P.56
Twumasi, Patrick A.
W.G.O.32
Tyler, Douglas S.
T.C.O.33, T.C.P.32
Tyndale, Eleanor
T.D.P.1
Tyson, Pat
M.E.P.73

U

Udall, Linda M.
T.E.P.41
Ujhelyi, Eszter
M.C.P.146, T.B.P.96, W.C.P.92, Th.B.P.139
Unadkat, Jashvant D.
M.B.P.13, M.B.P.15, M.B.P.22
Ungar, Beth L. P.
W.B.P.45
Upton, Kim
T.D.O.16
Uribe, Patricia Estela
M.D.P.7
Urnovitz, Howard B.
W.B.P.143
Urwitz, Viveka
T.E.P.30, W.D.P.88, Th.E.O.5
Usieto, Ricardo R.
Th.D.P.19, Th.E.P.48
Ussery, Fred M.
M.C.P.60

V

Vahey, Mary Anne T.
T.C.P.128
Valainis, Gregory T.
Th.B.P.42
Valdespino, José-Luis
M.G.O.27, Th.D.O.11, Th.G.O.37
Valencia, M. Eulalia
M.B.P.370, W.B.P.339
Valentin, Antonio
T.C.O.3, Th.C.P.92
Valentine, Fred
M.C.P.18
Valle, Sirkka-Liisa
T.A.P.18, Th.A.P.34
Valleron, A. J.
T.A.P.75
Valleroy, Linda A.
W.G.P.7
Van Dam, Johannes C.
T.G.P.8
Van Devanter, Nancy L.
M.E.P.1
Van Dis, Huib
T.D.P.72
Van Druten, Hans
Th.A.P.55
Van Gorp, Wilfred G.
T.D.P.60, Th.B.P.259, Th.B.P.289
Van Griensvèn, Godfried J. P.
M.A.P.112, T.A.P.20, W.A.P.36
Van Haastrecht, Harry J. A.
T.A.P.36
Van Raden, Mark J.
Th.A.O.17
Van den Boom, Frans M.
M.B.P.382, W.H.P.14
Van den Hoek, Anneke
T.A.O.13, W.A.P.107
Van der Does, Tibo
T.E.P.61
Van der Poel, Cees L.
M.B.P.162, T.B.P.355, T.E.P.19, W.B.P.157, W.B.P.158, W.B.P.171, Th.C.P.55
Van der Veen, Fred
T.A.P.3
Vanderburg, Douglas G.
W.B.P.202
Vandercam, B.
Th.B.P.132, Th.B.P.359
Vanderveken, Mark R.
W.E.P.32
Vanichseni, Suphak
T.G.O.23
Vardinon, Nurit
Th.B.P.118
Varela, Luis R.
Th.E.O.6a
Vasilionkaitis, V.
W.C.P.148
Vaslin, Bruno
M.C.P.7
Vazeux, Rosemay
W.C.P.127
Vazquez-Valls, Eduardo
M.F.P.3, W.G.P.23
Velandia, Manuel
T.G.O.17
Vella, S.
M.B.P.92
Vella, Stefano
M.B.O.46, W.B.P.370
Vendrell, Jean-Pierre
M.B.P.131, W.B.P.138
Verani, Paola
W.B.P.146
Verbeke, Ronald
M.E.O.36, T.G.P.11
Vercauteren, Gaby
T.B.P.94, T.B.P.108
Verdier, Mireille
T.B.O.9
Vernazza, Pietro L.
M.B.P.364
Victorino, Rui M. M.
T.B.P.376, Th.B.P.107
Vienne, Patricia
Th.G.O.45
Viglianti, Gregory A.
T.C.O.30
Vignon, Dominique
M.B.P.154
Villa, Antonio
Th.B.P.82
Villette, Jean-Marie
M.B.P.269
Vincent, Judy
T.B.P.176
Vinga-Martins, Cristina
Th.C.P.44
Vinti, Henri
T.B.P.20
Virani, Nzeera A.
T.B.P.11
Viravaidhya, Meechai
Th.G.O.20
Visco, Giuseppe
M.B.P.106, Th.B.O.14, Th.B.P.56, Th.B.P.220, Th.B.P.255, Th.B.P.256
Visona, Kirsten A.
Th.B.P.14
Visscher, Barbara R.
W.A.P.64, Th.B.P.200
Vitkovic, Ljubisa
M.C.O.28
Vittecoq, Daniel
W.B.P.368
Viza, Dimitri
Th.C.P.64
Vlahov, David
M.A.P.26, T.A.P.45, W.A.P.90, Th.A.P.20
Vocks-Hauck, Mechthild
T.B.P.250
Voeller, Bruce
W.A.P.99
Vogler, Mary A.
T.A.P.101
Vogt, Markus W.
M.C.P.83
Vohito, M. Dieudonné
M.B.P.185
Volberding, Paul A.
W.B.O.15, W.B.P.270, W.C.P.38
Volonterio, Alberto
M.B.P.133
Von Bröckel, Michael
T.E.P.2
Von Roenn, Jamie H.
Th.B.P.309
Von Salisch, Maria
M.D.P.9
Von Zeipel, M. G. Claes
M.E.P.2
Vonsover, Ami
T.C.P.142
Vornhagen, Rolf
W.B.P.94, W.B.P.118
Voth, Rike
Th.B.P.122

Voth, Rila
T.C.P.88
Vuitton, Dominique A.
Th.B.P.100
Vyakarnam, Anna
T.C.P.14

W

Wachter, Robert M.
T.B.O.27
Wagner, Norbert
W.B.P.295
Wain-Hobson, Simon
W.C.O.4
Wainberg, Mark A.
M.C.P.63, T.B.O.35, W.A.P.102, W.B.P.351
Waivers, Leo E.
M.H.P.14
Walger, Peter
W.B.P.318
Walker, Bruce D.
W.C.O.43
Walker, Christopher M.
T.C.O.32
Wallace, Joyce I.
M.B.P.184, T.D.P.80, W.B.P.88
Walrond, Errol R.
T.E.P.32
Walter, Emmanuel B.
T.B.P.207
Walters, David J.
W.E.O.1
Walzer, Peter
Th.D.P.69
Wang, Yanfeng
Th.B.P.204
Wanzala, Peter
T.B.P.338, Th.B.P.324, Th.B.P.325
Ward, Douglas J.
M.B.P.378
Ward, John W.
M.A.O.8, T.A.P.105
Warren, Rueben C.
M.E.O.22
Warwick, Ian
M.D.P.2
Waskin, Hetty Anne
W.B.P.15
Wasser, Shari C.
W.D.P.50
Wassif, Samir Mohamed
Th.H.P.28
Watanabe, Kazuhito
M.C.P.148
Watanabe, Mamoru
W.C.P.75
Waters, David J.
Th.A.P.118
Watson-Williams, E. John
T.G.O.12
Watters, John K.
Th.A.P.67, Th.D.O.4
Watts, Douglas M.
M.G.P.22
Watts, Heather
M.B.P.9
Wawer, Maria J.
W.A.P.114
Waweru, Samuel E. N.
M.B.P.160
Way, Peter O.
M.G.P.11
Webb, Farrell J.
T.E.P.36
Webber, Mayris P.
Th.D.P.1
Weber, Günter
T.B.P.14
Weber, John
Th.D.P.76
Weber, Rainer
W.B.P.72, W.B.P.321
Weber, Thomas
Th.B.P.231
Webster, Claudia L.
M.E.P.16
Weeramunda, J.
M.E.O.31
Weiblen, Barbara
W.B.P.136
Weil-Halpern, Françoise
W.D.P.16
Weiner, David B.
W.C.O.25
Weiner, Marc
M.E.P.13
Weiner, Susan M.
M.B.P.30
Weinhold, Kent J.
M.C.P.22, W.B.P.330
Weinke, Thomas
M.B.P.211, W.B.P.19
Weinrich, James D.
T.D.P.79
Weiser, Barbara
W.C.P.55
Weisfuse, Isaac B.
M.A.P.67, W.A.P.9
Weisman, Henry W.
W.B.P.205
Weisman, Joel D.
T.B.P.62, T.B.P.63
Weiss, Carol D.
Th.C.P.65
Weiss, Laurence
T.C.P.3
Weiss, Rachelle A.
W.B.P.120, W.B.P.121
Weiss, Stanley H.
Th.A.O.23, Th.D.P.4
Weiss, Susan
W.B.P.375
Weissenbacher, Mercedes C.
M.D.O.10, W.B.P.382
Wells, Carole J.
T.B.P.34
Wells, James A.
M.D.O.1, W.E.P.29
Welsh, Gregory M.
T.B.P.239
Weniger, Bruce G.
W.G.P.14
Wentworth, Peggy A.
W.C.P.8
Wermuth, Laurie A.
Th.D.P.5
West, Gary R.
W.E.O.7
Westblom, T. Ulf
M.C.P.32
Wetherall, Neal T.
W.C.P.31
Whitaker, Rupert E. D.
Th.A.P.58
White, Carol R.
Th.E.P.31
White, Nick D.
M.H.P.22
Whitelaw, James A.
Th.B.P.164
Whittaker, Bill H.
W.E.O.8
Whittington, W. L.
T.A.P.118, T.D.P.17
Widman, Mindy
M.E.P.60
Wiebel, Wayne W.
M.A.P.50, W.D.P.66
Wieland, Ulrike
M.B.O.24
Wiik, Flavio Braune
M.E.O.9
Wilber, Judith C.
W.B.P.162
Wilks, David
T.C.P.11
Williams, Alan E.
M.B.P.146
Williams, Ann B.
W.D.P.42
Williams, Bryan
T.C.P.98
Williams, Ekanem E.
W.G.O.24
Williams, Ivetta Y.
W.B.P.373
Williams, Kenneth R.
W.D.P.44, W.E.O.25
Williamson, Donald E.
M.A.P.7
Willoughby, Anne D.
M.B.O.2, T.F.O.18

Willoughby, Brian
W.B.O.13, W.D.P.92
Wilson, David J.
W.G.O.19
Wilson, Mary J.
M.A.P.64, Th.B.P.201
Wilson, Wilma
T.C.P.137
Winkler, James R.
Th.B.P.338
Winslow, Dean L.
T.B.P.45
Wintergest, Uwe
T.B.P.208
Wisniewski, Ted L.
T.H.P.6
Wittek, Alec E.
M.C.P.36
Wiviott, Lory D.
W.C.O.5
Wiznia, Andrew
T.B.P.159, T.B.P.160, W.A.P.5
Wodak, Alex D.
W.D.P.62, W.D.P.63
Wohlfeiler, Daniel A.
T.E.P.3
Wolbert, Jerry
M.B.P.319
Wolfe, Hannah
T.A.P.47
Wolitski, Richard J.
W.E.P.59
Wolters, Pamela L.
M.B.O.43
Wong, Dennis M.
Th.C.P.63
Wong, Holly
T.H.O.7
Wong-Staal, Flossie
W.C.O.1
Woo, Stephen
M.E.P.58
Woo, Stephen K. C.
W.B.P.196, W.B.P.261
Wood, Robert D.
M.B.P.285, T.B.P.10
Wood, Robert W.
M.D.P.35, M.E.P.17, T.A.P.57, W.A.P.6, W.D.P.6
Woods, Joycelyn Sue
T.G.P.5
Woods, William J.
W.D.P.74
Wooley, Dawn P.
W.C.P.9
Wortman, Jay
T.D.O.14, W.A.P.120
Wray, David
Th.B.P.137
Wright, Lester N.
Th.G.P.14
Wright, Nicholas H.
W.D.P.73, W.G.P.19
Wu, Albert W.
W.B.P.254
Wu, Ping
W.B.P.133
Wykoff, Randolph F.
W.A.P.87

Y

Yamamoto, Janet K.
W.C.P.11
Yamashita, Helio K.
Th.B.P.38
Yan, Dongyou
Th.H.P.26
Yarchoan, Robert
M.C.P.137, W.B.P.327, Th.B.O.4
Yasuda, Atsushi
Th.C.P.96
Yeager, Henry J.
M.E.P.44, Th.E.P.44
Yee, JoAnn L.
W.C.P.23
Yelin, Edward
T.H.O.1
Yeoh, E. K.
T.A.P.120
Yokota, Yasuko
Th.B.P.83
Yokoyama, Mitchel Mitsuo
Th.B.P.85
Yoshihara, Paul H.
W.B.P.128
Youle, M.
W.B.P.242
Youle, Mike
M.B.P.81
Young, Mary A.
M.B.P.268
Yu, Xiao-Fang
T.C.O.17
Yuen-Boyer, Marlene
Th.E.P.33

Z

Zacarias, Fernando R. K.
T.B.O.24, W.G.O.16
Zagury, Daniel
M.C.P.48, W.C.O.19
Zaia, John A.
Th.C.O.22
Zajac, Robert A.
M.A.P.13
Zamperetti, Marco
M.B.P.384
Zamperetti, Marco M.
W.B.P.206, W.B.P.208
Zanetti, Alessandro
T.A.P.116
Zangerle, Robert
W.B.P.341
Zazayokwe, Musa
M.G.O.10
Zbitnew, Audrey
M.H.P.26
Zeira, Michael
W.C.P.135
Zener, Karl
W.D.P.13
Zerjav, Sonja
Th.B.P.222
Zewdie, Debrework
T.A.P.102
Zimmerman, Rick S.
M.D.P.83
Zolla-Pazner, Susan
T.C.P.7, Th.C.O.10
Zorr, Bernd
T.C.P.37, W.C.P.66
Zorrilla, Carmen D.
M.B.P.28
Zowall, Hanna
M.H.O.4
Zucker-Franklin, Dorothea
M.C.P.78
Zulaica, Daniel D.
T.A.O.23, Th.G.P.8
Zumwalt, Sally A.
Th.B.P.378
Zunich, Kathryn M.
W.B.P.322
Zweig, Michele S.
W.B.P.57

Aboriginal Medical Service
W.I.V.14
Balser, Michael and Andy Fabo
T.I.V.4
Blais, Robert
T.I.V.10
British Medical Association
Foundation for AIDS
M.I.V.1
Burke, Andre
W.I.V.6
Carlomusto, Maggenti
M.I.V.9
Child Welfare League of
America
Th.I.V.4
Coward, Lynn
Th.I.V.7
Current, David and Anne
Ruthledge
Th.I.V.12
Douglas Henry, Jessica
Th.I.V.9
Durand, Yannick
W.I.V.1
Dworkin, Mark, and John
Mitsud
Th.I.V.5
Edan Programs
T.I.V.1
Friedman, Gary
Th.I.V.1
GMHC
M.I.V.4
GMHC
T.I.V.5
GMHC
Th.I.V.10
Goss, John
W.I.V.11
Greyson, John
W.I.V.8
Grunberg, Slawomir
T.I.V.7
Hammer, Barbara
W.I.V.9
Harlot, Scarlot
M.I.V.7
Hollibaugh, Amber
T.I.V.8
Huff, Bob
W.I.V.10
Jayle, Didier (Dr.)
T.I.V.9
Johanssen, Nicke
T.I.V.3
Julien, Isaac
W.I.V.7
Kalin, Tom
M.I.V.5
Kybartas, Stashu
W.I.V.3
Latino AIDS Project
Th.I.V.3
Levin, Seth
M.I.V.10
Marshall, Stuart
T.I.V.2
Moriyasu, Ann
W.I.V.5
Muska, Suzan
M.I.V.2
OMS/WHO
T.I.V.12
Pretibhe Parmar
M.I.V.6
Rogers, G.T.
T.I.V.6
Rouleau, Fabrice
T.I.V.13
Shames, Deborah
Th.I.V.11
Shames, Deborah
Th.I.V.8
Sobell, Nina
M.I.V.8
Testing the Limits Collective
W.I.V.13
Thompson, David
W.I.V.2
Tuff, David
M.I.V.3
Van De Velde, Quentin
T.I.V.14
Villalobos, Daniel
Th.I.V.2
Wardrop, ACSP, CTC., Kate
M.I.V.11
Wilson, Emjay
W.I.V.4
Youth Against Monsters
W.I.V.12

Notes

Notes

C